Clinical	O
and	O
physiological	O
data	O
,	O
serum	O
concentrations	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
quantitative	O
cultures	O
of	O
lower	O
respiratory	O
tract	O
specimens	O
were	O
obtained	O
from	O
46	O
patients	O
with	O
ARDS	O
and	O
20	O
with	O
severe	O
pneumonia	O
within	O
24	O
hours	O
of	O
the	O
onset	O
of	O
the	O
disease	O
and	O
from	O
10	O
control	O
subjects	O
with	O
no	O
inflammatory	O
lung	O
disease	O
.	O

For	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
the	O
observed	O
differences	O
were	O
not	O
statistically	O
significant	O
between	O
patients	O
with	O
ARDS	O
(	O
IL	O
-	O
1beta	O
:	O
34	O
(	O
65	O
)	O
pg	O
/	O
ml	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
:	O
712	O
(	O
1058	O
)	O
pg	O
/	O
ml	O
),	O
those	O
with	O
severe	O
pneumonia	O
(	O
IL	O
-	O
1beta	O
:	O
3	O
(	O
4	O
)	O
pg	O
/	O
ml	O
,	O
p	O
=	O
0	O
.	O
071	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
:	O
834	O
(	O
1165	O
)	O
pg	O
/	O
ml	O
,	O
p	O
=	O
1	O
.	O
0	O
),	O
and	O
controls	O
(	O
IL	O
-	O
1beta	O
:	O
6	O
(	O
11	O
)	O
pg	O
/	O
ml	O
,	O
p	O
=	O
0	O
.	O
359	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
:	O
94	O
(	O
110	O
)	O
pg	O
/	O
ml	O
,	O
p	O
=	O
0	O
.	O
262	O
).	O

TITLE	O
:	O
The	O
Q	O
-	O
base	O
of	O
asparaginyl	O
-	O
tRNA	B-FUNC
is	O
dispensable	O
for	O
efficient	O
-	O
1	O
ribosomal	O
frameshifting	O
in	O
eukaryotes	O
.	O

Asparaginyl	O
-	O
tRNA	B-FUNC
,	O
which	O
decodes	O
the	O
A	O
-	O
site	O
codon	O
AAC	O
,	O
has	O
the	O
modified	O
base	O
Q	O
at	O
the	O
wobble	O
position	O
of	O
the	O
anticodon	O
(	O
5	O
'	O
QUU	O
3	O
')	O
and	O
it	O
has	O
been	O
speculated	O
that	O
Q	O
may	O
be	O
required	O
for	O
frameshifting	O
.	O

Growth	O
in	O
horse	O
serum	O
,	O
which	O
contains	O
no	O
free	O
queuine	O
,	O
eliminates	O
Q	O
from	O
the	O
cellular	O
tRNA	B-FUNC
population	O
upon	O
repeated	O
passage	O
.	O

We	O
confirmed	O
that	O
the	O
cells	O
cultured	O
in	O
horse	O
serum	O
were	O
devoid	O
of	O
Q	O
by	O
purifying	O
tRNAs	O
and	O
assessing	O
their	O
Q	O
-	O
content	O
by	O
tRNA	B-FUNC
transglycosylase	O
assays	O
and	O
coupled	O
HPLC	O
-	O
mass	O
spectroscopy	O
.	O

These	O
findings	O
were	O
recapitulated	O
in	O
an	O
in	O
vitro	O
system	O
using	O
rabbit	O
reticulocyte	O
lysates	O
that	O
had	O
been	O
largely	O
depleted	O
of	O
endogenous	O
tRNAs	O
and	O
resupplemented	O
with	O
Q	O
-	O
free	O
or	O
Q	O
-	O
containing	O
tRNA	B-FUNC
populations	O
.	O

Thus	O
Q	O
-	O
base	O
is	O
not	O
required	O
for	O
frameshifting	O
at	O
the	O
IBV	O
signal	O
and	O
some	O
other	O
explanation	O
is	O
required	O
to	O
account	O
for	O
the	O
slipperiness	O
of	O
eukaryotic	O
asparaginyl	O
-	O
tRNA	B-FUNC
.	O

Biochemical	O
analyses	O
of	O
RNA	O
-	O
binding	B-FUNC
properties	O
were	O
performed	O
on	O
full	O
-	O
length	O
and	O
partial	O
N	O
protein	O
segments	O
to	O
define	O
the	O
RNA	O
-	O
binding	B-FUNC
domain	O
.	O

The	O
full	O
-	O
length	O
N	O
protein	O
and	O
the	O
GST	O
-	O
N	O
protein	O
fusion	O
product	O
had	O
similar	O
binding	B-FUNC
activities	O
with	O
a	O
dissociation	O
constant	O
(	O
K	O
(	O
d	O
))	O
of	O
14	O
nM	O
when	O
the	O
MHV	O
5	O
'-	O
leader	O
sequence	O
was	O
used	O
as	O
ligand	B-FUNC
.	O

The	O
smallest	O
N	O
protein	O
fragment	O
which	O
retained	O
RNA	O
-	O
binding	B-FUNC
activity	O
was	O
a	O
55	O
aa	O
segment	O
containing	O
residues	O
177	O
-	O
231	O
which	O
bound	O
viral	O
RNA	O
with	O
a	O
K	O
(	O
d	O
)	O
of	O
32	O
nM	O
.	O
A	O
consensus	O
viral	O
sequence	O
recognized	O
by	O
the	O
N	O
protein	O
was	O
inferred	O
from	O
these	O
studies	O
;	O
AAUCYAAAC	O
was	O
identified	O
to	O
be	O
the	O
potential	O
minimum	O
ligand	B-FUNC
for	O
the	O
N	O
protein	O
.	O

Although	O
the	O
core	O
UCYAA	O
sequence	O
is	O
often	O
tandemly	O
repeated	O
in	O
viral	O
genomes	O
,	O
ligands	O
containing	O
one	O
or	O
more	O
repeats	O
of	O
UCYAA	O
showed	O
no	O
difference	O
in	O
binding	B-FUNC
to	O
the	O
N	O
protein	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
cleavage	O
activity	O
of	O
the	O
first	O
papain	O
-	O
like	O
proteinase	B-FUNC
domain	O
encoded	O
by	O
open	O
reading	O
frame	O
1a	O
of	O
the	O
coronavirus	O
Avian	O
infectious	O
bronchitis	O
virus	O
and	O
characterization	O
of	O
the	O
cleavage	O
products	O
.	O

Previously	O
we	O
identified	O
the	O
first	O
cleavage	O
event	O
as	O
proteolysis	O
at	O
the	O
Gly	O
(	O
673	O
)-	O
Gly	O
(	O
674	O
)	O
dipeptide	O
bond	O
mediated	O
by	O
the	O
first	O
papain	O
-	O
like	O
proteinase	B-FUNC
domain	O
(	O
PLPD	O
-	O
1	O
)	O
to	O
release	O
an	O
87	O
-	O
kDa	O
mature	O
protein	O
.	O

By	O
using	O
a	O
region	O
-	O
specific	O
antiserum	O
raised	O
against	O
the	O
IBV	O
sequence	O
encoded	O
by	O
nucleotides	O
8865	O
to	O
9786	O
,	O
we	O
also	O
demonstrated	O
that	O
a	O
33	O
-	O
kDa	O
protein	O
,	O
representing	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLP	O
),	O
was	O
specifically	O
immunoprecipitated	O
from	O
the	O
virus	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
virus	O
,	O
the	O
mutants	O
were	O
unable	O
to	O
bind	B-FUNC
to	O
porcine	O
submandibulary	O
mucin	O
,	O
a	O
substrate	O
rich	O
in	O
sialic	O
acid	O
.	O

Each	O
of	O
the	O
mutants	O
was	O
found	O
to	O
contain	O
a	O
single	O
point	O
mutation	O
in	O
the	O
S	O
protein	O
(	O
Cys155Phe	O
,	O
Met195Val	O
,	O
Arg196Ser	O
,	O
Asp208Asn	O
or	O
Leu209Pro	O
),	O
indicating	O
that	O
these	O
amino	O
acids	O
are	O
affecting	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
site	O
.	O

In	O
four	O
of	O
the	O
HAD	O
mutants	O
a	O
nearby	O
antigenic	O
site	O
is	O
affected	O
in	O
addition	O
to	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
site	O
,	O
as	O
indicated	O
by	O
reactivity	O
with	O
monoclonal	O
antibodies	O
.	O

An	O
alternative	O
function	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
-	O
accessory	O
binding	B-FUNC
to	O
intestinal	O
tissues	O
-	O
is	O
also	O
discussed	O
.	O

TITLE	O
:	O
Neutralization	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
:	O
preparation	O
of	O
monoclonal	O
antibody	B-FUNC
that	O
shows	O
cell	O
tropism	O
in	O
neutralizing	O
activity	O
after	O
viral	O
absorption	O
into	O
the	O
cells	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
of	O
feline	O
macro	O
-	O
phages	O
is	O
enhanced	O
by	O
mouse	O
anti	O
-	O
FIPV	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
).	O

Myeloperoxidase	B-FUNC
activity	I-FUNC
reached	O
micromolar	O
levels	O
in	O
the	O
lavage	O
fluid	O
when	O
corrected	O
for	O
dilution	O
,	O
and	O
was	O
significantly	O
higher	O
in	O
the	O
plasma	O
of	O
the	O
sepsis	O
patients	O
who	O
subsequently	O
died	O
.	O

The	O
techniques	O
used	O
included	O
lung	O
rest	B-FUNC
,	O
pulmonary	O
physiotherapy	O
,	O
diuresis	O
to	O
dry	O
weight	O
using	O
hemofiltration	O
if	O
needed	O
,	O
minimal	O
anticoagulation	O
,	O
and	O
optimal	O
systemic	O
oxygen	O
delivery	O
.	O

Indirect	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
,	O
immunodot	O
assay	O
,	O
and	O
immunoprecipitation	O
were	O
used	O
to	O
select	O
hybridomas	O
that	O
produced	O
anti	O
-	O
BRV	O
MAbs	O
.	O

Two	O
clones	O
,	O
8B4	O
(	O
immunoglobulin	B-FUNC
G2a	O
[	O
IgG2a	O
])	O
and	O
2B11	O
(	O
IgG1	O
),	O
were	O
found	O
suitable	O
for	O
use	O
in	O
an	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detecting	O
BRV	O
in	O
bovine	O
fecal	O
samples	O
.	O

Antigens	O
from	O
all	O
three	O
transgenic	O
plant	O
lines	O
induced	O
TGEV	O
-	O
specific	O
immune	O
responses	O
in	O
pigs	O
as	O
determined	O
by	O
virus	O
neutralization	O
and	O
ELISA	O
,	O
and	O
the	O
resultant	O
antibody	B-FUNC
titers	O
for	O
all	O
three	O
constructs	O
were	O
similar	O
.	O

Dual	O
-	O
labeling	O
experiments	O
demonstrated	O
colocalization	O
of	O
the	O
majority	O
of	O
p1a	O
-	O
22	O
in	O
replication	O
complexes	O
with	O
the	O
helicase	O
,	O
nucleocapsid	O
,	O
and	O
3C	O
-	O
like	O
proteinase	B-FUNC
,	O
as	O
well	O
as	O
with	O
p1a	O
-	O
10	O
,	O
-	O
12	O
,	O
and	O
-	O
15	O
.	O

Quantification	O
of	O
PMNs	O
by	O
morphometry	O
showed	O
that	O
there	O
were	O
constantly	O
less	O
granulocytes	O
in	O
the	O
lungs	O
of	O
the	O
animals	O
treated	O
with	O
the	O
anti	O
-	O
CD18	O
antibody	B-FUNC
(	O
p	O
<	O
0	O
.	O
001	O
).	O

In	O
this	O
particular	O
model	O
of	O
ARDS	O
the	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
CD11	O
-	O
CD18	O
complex	O
had	O
a	O
beneficial	O
effect	O
,	O
reducing	O
PMN	O
infiltration	O
and	O
oxygen	O
radical	O
release	O
in	O
the	O
lungs	O
,	O
preventing	O
alveolocapillary	O
membrane	O
damage	O
,	O
improving	O
gas	O
exchange	O
and	O
,	O
finally	O
,	O
significantly	O
reducing	O
mortality	O
.	O

There	O
was	O
no	O
variation	O
in	O
the	O
isotype	O
-	O
specific	O
BCV	O
antibody	B-FUNC
titres	O
between	O
healthy	O
quarters	O
of	O
the	O
same	O
udder	O
,	O
but	O
subclinical	O
mastitis	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
IgA	O
antibodies	O
and	O
weak	O
false	O
IgM	O
positive	O
reactions	O
in	O
undiluted	O
milk	O
.	O

The	O
antibody	B-FUNC
responses	O
to	O
BCV	O
were	O
followed	O
in	O
milk	O
and	O
serum	O
from	O
six	O
dairy	O
cows	O
and	O
in	O
serum	O
from	O
four	O
calves	O
for	O
a	O
period	O
of	O
1	O
year	O
after	O
an	O
outbreak	O
of	O
winter	O
dysentery	O
(	O
WD	O
).	O

TITLE	O
:	O
Characterization	O
of	O
protection	O
against	O
coronavirus	O
infection	O
by	O
noninternal	O
image	O
antiidiotypic	O
antibody	B-FUNC
.	O

Serologic	O
(	O
viral	O
neutralization	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
[	O
ELISA	O
])	O
assays	O
and	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
.	O

The	O
virus	O
neutralization	O
assay	O
was	O
performed	O
by	O
inoculating	O
24	O
-	O
to	O
-	O
25	O
-	O
day	O
-	O
old	O
turkey	O
embryos	O
via	O
the	O
amniotic	O
route	O
and	O
by	O
assessing	O
the	O
embryo	O
infectivity	O
on	O
the	O
basis	O
of	O
gross	O
intestinal	O
lesions	O
and	O
intestinal	O
maltase	B-FUNC
activity	I-FUNC
at	O
72	O
hr	O
postinoculation	O
.	O

Sensitivity	O
of	O
this	O
test	O
was	O
compared	O
with	O
embryo	O
lesions	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Serum	O
concentrations	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
and	O
macrophage	O
inflammatory	O
protein	O
2	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
binding	B-FUNC
site	O
in	O
the	O
amino	O
region	O
of	O
N	O
was	O
either	O
not	O
present	O
or	O
only	O
partially	O
present	O
in	O
the	O
first	O
91	O
residues	O
because	O
no	O
interaction	O
with	O
RNA	O
was	O
observed	O
with	O
the	O
polypeptide	O
incorporating	O
these	O
residues	O
.	O

The	O
proinflammatory	O
cytokines	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
),	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
)	O
have	O
been	O
shown	O
to	O
play	O
key	O
roles	O
in	O
several	O
respiratory	O
disease	O
conditions	O
.	O

The	O
third	O
part	O
summarises	O
studies	O
that	O
were	O
recently	O
undertaken	O
in	O
the	O
authors	O
'	O
laboratory	O
to	O
investigate	O
the	O
relationship	O
between	O
respiratory	O
disease	O
in	O
pigs	O
and	O
bioactive	O
lung	O
lavage	O
levels	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
during	O
single	O
and	O
combined	O
infections	O
with	O
the	O
above	O
viruses	O
.	O

After	O
combined	O
inoculation	O
with	O
PRCV	O
followed	O
by	O
bacterial	O
lipopolysaccharide	O
,	O
both	O
clinical	O
respiratory	O
disease	O
and	O
TNF	O
-	O
alpha	O
/	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
production	O
were	O
markedly	O
more	O
severe	O
than	O
those	O
associated	O
with	O
the	O
respective	O
single	O
inoculations	O
.	O

Starting	O
from	O
literature	O
data	O
and	O
the	O
SARs	O
developed	O
in	O
this	O
work	O
,	O
a	O
putative	O
binding	B-FUNC
mode	O
of	O
styrylquinoline	O
inhibitors	O
to	O
HIV	O
-	O
1	O
IN	O
was	O
derived	O
.	O

CNI	O
-	O
1493	O
,	O
which	O
attenuates	O
mediator	O
production	O
through	O
p38	B-FUNC
MAP	O
kinase	O
inhibition	O
,	O
was	O
administered	O
intraperitoneally	O
to	O
mice	O
while	O
control	O
animals	O
received	O
saline	O
.	O

Serum	O
hepatic	O
enzymes	O
and	O
hepatic	O
neutrophil	O
infiltration	O
by	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
were	O
measured	O
as	O
indicators	O
of	O
hepatic	O
insult	O
.	O

Serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	B-FUNC
)	O
protein	O
(	O
ELISA	O
),	O
hepatic	O
TNF	B-FUNC
mRNA	O
(	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
),	O
and	O
hepatic	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
were	O
also	O
determined	O
.	O

A	O
significant	O
increase	O
in	O
hepatic	O
enzymes	O
and	O
MPO	B-FUNC
activity	O
was	O
induced	O
by	O
AP	O
and	O
mirrored	O
by	O
intraperitoneal	O
elastase	O
.	O

Elastase	O
-	O
treated	O
animals	O
with	O
mediator	O
production	O
inhibited	O
(	O
CNI	O
-	O
1493	O
)	O
had	O
attenuated	O
hepatic	O
enzymes	O
,	O
MPO	B-FUNC
activity	O
,	O
TNF	O
protein	O
,	O
and	O
TNF	O
mRNA	O
.	O

In	O
the	O
subgroup	O
of	O
four	O
trials	O
where	O
a	O
high	O
volume	O
strategy	O
(	O
HVS	B-FUNC
)	O
was	O
used	O
,	O
HFOV	O
results	O
in	O
more	O
favourable	O
pulmonary	O
outcomes	O
.	O

Of	O
the	O
four	O
trials	O
in	O
the	O
subgroup	O
using	O
surfactant	O
routinely	O
,	O
three	O
also	O
used	O
the	O
HVS	B-FUNC
.	O

The	O
trends	O
in	O
results	O
were	O
similar	O
with	O
surfactant	O
to	O
those	O
for	O
the	O
HVS	B-FUNC
subgroup	O
analysis	O
.	O

In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	B-FUNC
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	O
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
PVL	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

The	O
overall	O
meta	O
-	O
analyses	O
is	O
dominated	O
by	O
the	O
large	O
HIFI	O
study	O
which	O
did	O
not	O
use	O
the	O
HVS	B-FUNC
recommended	O
on	O
the	O
basis	O
of	O
animal	O
studies	O
,	O
and	O
in	O
which	O
surfactant	O
was	O
not	O
available	O
.	O

Immunoprecipitation	O
of	O
UV	O
-	O
cross	O
-	O
linked	O
proteins	O
identified	O
the	O
73	O
-	O
kDa	O
protein	O
as	O
the	O
cytoplasmic	O
poly	O
(	O
A	O
)-	O
binding	B-FUNC
protein	O
(	O
PABP	O
).	O

RNAs	O
with	O
shortened	O
poly	O
(	O
A	O
)	O
tails	O
exhibited	O
less	O
in	O
vitro	O
PABP	O
binding	B-FUNC
,	O
suggesting	O
that	O
decreased	O
interactions	O
with	O
the	O
protein	O
may	O
affect	O
RNA	O
replication	O
.	O

A	O
clinicopathologic	O
study	O
using	O
immunohistochemical	O
staining	O
and	O
viral	O
genome	O
detection	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
with	O
this	O
autopsied	O
case	O
.	O

The	O
CL	O
antigen	O
,	O
combined	O
with	O
an	O
oil	O
adjuvant	O
,	O
was	O
tested	O
for	O
protective	O
and	O
antibody	B-FUNC
-	O
inducing	O
activities	O
in	O
cattle	O
.	O

The	O
groups	O
immunized	O
with	O
the	O
CL	O
antigen	O
having	O
an	O
HA	O
titer	O
of	O
4000	O
or	O
16	O
000	O
produced	O
hemagglutination	O
inhibition	O
(	O
HI	O
)	O
antibody	B-FUNC
titers	O
of	O
>	O
320	O
and	O
serum	O
neutralizing	O
(	O
SN	O
)	O
antibody	B-FUNC
titers	O
of	O
>	O
1280	O
.	O

In	O
the	O
groups	O
immunized	O
with	O
CL	O
antigen	O
at	O
an	O
HA	O
titer	O
of	O
1000	O
or	O
250	O
,	O
HI	O
antibody	B-FUNC
titers	O
were	O
40	O
to	O
160	O
and	O
SN	O
titers	O
were	O
80	O
to	O
640	O
.	O

These	O
results	O
indicate	O
that	O
CL	O
antigen	O
with	O
high	O
HA	O
titer	O
induces	O
antibody	B-FUNC
production	O
in	O
cattle	O
that	O
provides	O
effective	O
protection	O
against	O
winter	O
dysentery	O
.	O

Rising	O
anti	O
-	O
FCoV	O
antibody	B-FUNC
titres	O
did	O
not	O
indicate	O
that	O
the	O
cat	O
would	O
develop	O
FIP	O
.	O

ORF1b	O
encodes	O
homologues	O
of	O
the	O
'	O
SDD	O
'	O
polymerase	O
,	O
which	O
among	O
(+)-	O
RNA	O
viruses	O
is	O
unique	O
to	O
nidoviruses	O
,	O
as	O
well	O
as	O
metal	O
-	O
ion	O
-	O
binding	B-FUNC
and	O
helicase	O
domains	O
.	O

The	O
sequence	O
of	O
a	O
tight	O
-	O
binding	B-FUNC
,	O
mAb	O
-	O
selected	O
peptide	O
suggested	O
the	O
location	O
of	O
a	O
discontinuous	O
epitope	O
within	O
the	O
N	O
-	O
terminal	O
S1	O
subunit	O
.	O

Several	O
tightly	O
binding	B-FUNC
phage	O
were	O
amplified	O
and	O
used	O
directly	O
as	O
immunogens	O
in	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	O
.	O

Orally	O
immunized	O
BALB	O
/	O
c	O
mice	O
showed	O
that	O
987P	O
fimbriated	O
Salmonella	O
serovar	O
Typhimurium	O
CS3263	O
(	O
aroA	O
asd	O
)	O
with	O
pCS151	O
(	O
fas	O
(+)	O
asd	O
(+))	O
elicited	O
a	O
significantly	O
higher	O
level	O
of	O
987P	O
-	O
specific	O
systemic	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
and	O
mucosal	O
IgA	O
than	O
serovar	O
Typhimurium	O
CS3263	O
with	O
pCS152	O
(	O
fasD	O
mutant	O
,	O
asd	O
(+))	O
expressing	O
987P	O
periplasmic	O
antigen	O
.	O

Samples	O
of	O
blood	O
and	O
respiratory	O
tract	O
secretions	O
were	O
sent	O
to	O
central	O
laboratories	O
for	O
antibody	B-FUNC
testing	O
,	O
culture	O
,	O
DNA	O
testing	O
,	O
and	O
histopathological	O
analyses	O
.	O

Sera	B-FUNC
against	O
Australia	O
T	O
,	O
China	O
Ch5	O
,	O
Singapore	O
P4	O
,	O
USA	O
M41	O
and	O
China	O
T3	O
isolates	O
were	O
used	O
to	O
study	O
the	O
conservation	O
and	O
localization	O
of	O
the	O
antigenic	O
region	O
on	O
the	O
IBV	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
in	O
preweaning	O
pigs	O
with	O
diarrhoea	O
.	O

Although	O
the	O
condition	O
is	O
well	O
described	O
in	O
adults	O
,	O
particularly	O
trauma	O
patients	O
,	O
little	O
is	O
known	O
about	O
ACS	B-FUNC
in	O
children	O
.	O

Three	O
girls	O
,	O
ages	O
4	O
,	O
5	O
,	O
and	O
5	O
years	O
,	O
were	O
treated	O
for	O
ACS	B-FUNC
by	O
silo	O
decompression	O
.	O

The	O
third	O
presented	O
with	O
shock	O
of	O
unknown	O
etiology	O
,	O
and	O
ACS	B-FUNC
developed	O
acutely	O
with	O
a	O
bladder	O
pressure	O
of	O
26	O
mm	O
Hg	O
.	O

TITLE	O
:	O
Further	O
characterization	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
3C	O
-	O
like	O
proteinase	B-FUNC
and	O
determination	O
of	O
a	O
new	O
cleavage	O
site	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
a	O
trypsin	O
-	O
like	O
proteinase	B-FUNC
(	O
3C	O
-	O
like	O
proteinase	B-FUNC
)	O
by	O
ORF	O
1a	O
,	O
which	O
has	O
been	O
demonstrated	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
proteolytic	O
processing	O
of	O
gene	O
1	O
-	O
encoded	O
polyproteins	O
.	O

Deletion	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
proteinase	B-FUNC
shows	O
that	O
a	O
significant	O
amount	O
of	O
the	O
enzymatic	O
activity	O
is	O
maintained	O
upon	O
deletion	O
of	O
up	O
to	O
67	O
amino	O
acids	O
,	O
suggesting	O
that	O
the	O
extreme	O
C	O
-	O
terminal	O
region	O
may	O
be	O
dispensable	O
for	O
the	O
proteolytic	O
activity	O
of	O
the	O
proteinase	B-FUNC
.	O

Analysis	O
of	O
the	O
autoprocessing	O
kinetics	O
in	O
vitro	O
reveals	O
that	O
proteolysis	O
at	O
the	O
Q	O
(	O
2779	O
)-	O
S	O
(	O
2780	O
)	O
site	O
is	O
the	O
first	O
cleavage	O
event	O
mediated	O
by	O
this	O
proteinase	B-FUNC
.	O

The	O
occurrence	O
of	O
both	O
cleavage	O
events	O
in	O
intact	O
cells	O
is	O
potentially	O
rapid	O
and	O
efficient	O
,	O
as	O
no	O
intermediate	O
cleavage	O
products	O
covering	O
the	O
proteinase	B-FUNC
were	O
detected	O
in	O
either	O
IBV	O
-	O
infected	O
or	O
transfected	O
cells	O
.	O

Immunofluorescence	O
microscopy	O
and	O
subcellular	O
fractionation	O
studies	O
further	O
show	O
differential	O
subcellular	O
localization	O
of	O
the	O
proteinase	B-FUNC
in	O
IBV	O
-	O
infected	O
cells	O
and	O
in	O
cells	O
expressing	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
alone	O
,	O
indicating	O
that	O
additional	O
roles	O
in	O
viral	O
replication	O
might	O
be	O
played	O
by	O
this	O
protein	O
.	O

Finally	O
,	O
a	O
Q	O
-	O
A	O
(	O
Q	O
(	O
3379	O
)-	O
A	O
(	O
3380	O
))	O
dipeptide	O
bond	O
encoded	O
by	O
nucleotides	O
10	O
,	O
663	O
to	O
10	O
,	O
668	O
was	O
demonstrated	O
to	O
be	O
a	O
cleavage	O
site	O
of	O
the	O
proteinase	B-FUNC
.	O

Degenerate	O
primers	O
CK4	O
and	O
CK2	O
,	O
utilized	O
previously	O
in	O
our	O
laboratory	O
,	O
were	O
selected	O
for	O
DACS	B-FUNC
because	O
they	O
successfully	O
amplify	O
a	O
wide	O
range	O
of	O
serotypes	O
represented	O
by	O
various	O
reference	O
strains	O
and	O
field	O
isolates	O
and	O
the	O
resulting	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
product	O
contains	O
diagnostically	O
relevant	O
S	O
-	O
1	O
sequences	O
that	O
can	O
be	O
used	O
to	O
identify	O
the	O
serotype	O
of	O
IBV	O
.	O

Reference	O
strains	O
Massachusetts	O
(	O
Mass	O
)	O
41	O
,	O
Connecticut	O
(	O
Conn	O
),	O
Arkansas	O
(	O
Ark	O
)	O
DPI	O
,	O
JMK	O
,	O
and	O
DE	O
/	O
072	O
/	O
92	O
were	O
initially	O
tested	O
by	O
DACS	B-FUNC
to	O
establish	O
the	O
feasibility	O
of	O
the	O
procedure	O
.	O

The	O
DACS	B-FUNC
procedure	O
provided	O
high	O
-	O
quality	O
and	O
reproducible	O
S	O
-	O
1	O
sequence	O
for	O
all	O
IBV	O
serotypes	O
tested	O
,	O
including	O
variant	O
serotypes	O
that	O
had	O
not	O
been	O
sequenced	O
previously	O
.	O

In	O
the	O
unknown	O
panel	O
,	O
the	O
nucleotide	O
identities	O
of	O
the	O
DACS	B-FUNC
S	O
-	O
1	O
sequences	O
of	O
field	O
isolates	O
of	O
serotypes	O
previously	O
identified	O
by	O
virus	O
neutralization	O
were	O
also	O
found	O
to	O
be	O
very	O
high	O
(>	O
or	O
=	O
95	O
.	O
5	O
%)	O
after	O
alignment	O
with	O
database	O
sequences	O
.	O

DACS	B-FUNC
of	O
IBV	O
S	O
-	O
1	O
RT	O
-	O
PCR	O
products	O
will	O
enable	O
researchers	O
to	O
rapidly	O
identify	O
field	O
strains	O
,	O
including	O
new	O
,	O
previously	O
unrecognized	O
variant	O
virus	O
serotypes	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examined	O
whether	O
exposure	O
of	O
pigs	O
to	O
both	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
and	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
can	O
potentiate	O
respiratory	O
disease	O
and	O
lung	O
secretion	O
of	O
tumour	O
necrosis	O
factor	O
-	O
a	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
).	O

Clinical	O
signs	O
,	O
virus	O
replication	O
and	O
(	O
histo	O
)	O
pathological	O
changes	O
in	O
the	O
lungs	O
,	O
percentage	O
of	O
neutrophils	O
and	O
bioactive	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
in	O
broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
were	O
examined	O
.	O

IL	B-FUNC
-	I-FUNC
1	I-FUNC
levels	O
(	O
106	O
-	O
1631	O
U	O
/	O
ml	O
versus	O
28	O
-	O
654	O
U	O
/	O
ml	O
after	O
LPS	O
only	O
)	O
were	O
also	O
increased	O
,	O
but	O
persisted	O
for	O
longer	O
after	O
clinical	O
recovery	O
than	O
TNF	O
-	O
alpha	O
.	O

Production	O
of	O
TNF	O
-	O
alpha	O
,	O
but	O
not	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
was	O
also	O
dependent	O
on	O
the	O
time	O
interval	O
between	O
inoculations	O
and	O
was	O
tightly	O
correlated	O
with	O
disease	O
.	O

The	O
putative	O
functional	O
site	O
for	O
acetylesterase	B-FUNC
activity	I-FUNC
was	O
present	O
in	O
the	O
HE	O
protein	O
as	O
Phe	O
-	O
Gly	O
-	O
Asp	O
-	O
Ser	O
(	O
FGDS	O
),	O
suggesting	O
that	O
the	O
SDAV	O
HE	O
protein	O
might	O
have	O
retained	O
the	O
esterase	B-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
case	O
of	O
multiple	O
organ	O
dysfunction	O
syndrome	O
with	O
acute	O
respiratory	O
failure	O
due	O
to	O
alveolar	O
haemorrhage	O
associated	O
with	O
antiphospholipid	O
antibodies	O
in	O
a	O
42	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
medical	O
history	O
of	O
antinuclear	O
antibody	B-FUNC
-	O
negative	O
systemic	O
lupus	O
erythematosus	O
and	O
antiphospholipid	O
syndrome	O
.	O

Detailed	O
immunophenotyping	O
,	O
in	O
situ	O
hybridization	O
for	O
EBV	O
early	O
RNA	O
-	O
1	O
(	O
EBER1	O
)	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analyses	O
for	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
heavy	O
chain	O
and	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)-	O
gamma	O
gene	O
rearrangements	O
were	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tissue	O
from	O
all	O
patients	O
.	O

The	O
binding	B-FUNC
of	O
srr7	O
and	O
srr11	O
to	O
both	O
MHVR1	O
and	O
MHVR2	O
was	O
revealed	O
lower	O
by	O
two	O
-	O
to	O
fourfold	O
relative	O
to	O
the	O
wt	O
binding	B-FUNC
.	O

Infection	O
of	O
the	O
human	O
astrocytic	O
cell	O
line	O
U	O
-	O
373MG	O
by	O
the	O
OC43	O
strain	O
of	O
human	O
coronavirus	O
caused	O
an	O
upregulation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
mRNA	O
expression	O
.	O

Pulmonary	O
artery	O
pressure	O
(	O
PAP	B-FUNC
)	O
and	O
pulmonary	O
capillary	O
wedge	O
pressure	O
(	O
PCWP	O
)	O
were	O
monitored	O
.	O

In	O
the	O
host	O
infected	O
by	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
LPS	O
),	O
the	O
expression	O
and	O
release	O
of	O
proinflammatory	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNFalpha	O
)	O
rapidly	O
increases	O
,	O
and	O
this	O
cytokine	O
production	O
is	O
regulated	O
by	O
agents	O
elevating	O
cyclic	O
AMP	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
evidence	O
that	O
terbutaline	O
,	O
a	O
beta2	O
-	O
agonist	O
,	O
inhibits	O
TNFalpha	O
production	O
and	O
enhances	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
release	O
in	O
the	O
anesthetized	O
rat	O
treated	O
with	O
LPS	O
.	O

Hospital	O
admissions	O
for	O
acute	O
respiratory	O
illnesses	O
were	O
identified	O
,	O
and	O
cell	O
culture	O
for	O
rhinovirus	O
and	O
serologic	O
assays	O
on	O
paired	O
sera	B-FUNC
for	O
coronaviruses	O
229E	O
and	O
OC43	O
were	O
performed	O
.	O

To	O
date	O
,	O
no	O
well	O
-	O
controlled	O
study	O
has	O
been	O
completed	O
analyzing	O
the	O
relative	O
merits	O
of	O
the	O
two	O
most	O
commonly	O
used	O
therapies	O
,	O
namely	O
plasmapheresis	O
or	O
intravenously	O
administered	O
immunoglobulin	B-FUNC
.	O

The	O
purified	O
recombinant	O
protein	O
had	O
in	O
vitro	O
ATPase	B-FUNC
activity	I-FUNC
that	O
was	O
strongly	O
stimulated	O
by	O
poly	O
(	O
U	O
),	O
poly	O
(	O
dT	O
),	O
poly	O
(	O
C	O
),	O
and	O
poly	O
(	O
dA	O
),	O
but	O
not	O
by	O
poly	O
(	O
G	O
).	O

The	O
DNA	B-FUNC
helicase	I-FUNC
activity	I-FUNC
of	O
the	O
enzyme	O
preferentially	O
unwound	O
5	O
'-	O
oligopyrimidine	O
-	O
tailed	O
,	O
partial	O
-	O
duplex	O
substrates	O
and	O
required	O
a	O
tail	O
length	O
of	O
at	O
least	O
10	O
nucleotides	O
for	O
effective	O
unwinding	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
p38	B-FUNC
mitogen	O
activate	O
kinase	O
attenuates	O
the	O
severity	O
of	O
pancreatitis	O
-	O
induced	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

Pathogen	O
-	O
free	O
Sprague	O
-	O
Dawley	O
rats	O
weighing	O
225	O
-	O
250	O
g	O
.	O
Sterile	O
,	O
endotoxin	O
-	O
and	O
cytokine	O
-	O
free	O
pancreatic	O
ascites	O
tested	O
for	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
TNF	O
-	O
alpha	O
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
obtained	O
from	O
rats	O
18	O
hrs	O
after	O
the	O
induction	O
of	O
severe	O
,	O
acute	O
pancreatitis	O
.	O

Healthy	O
animals	O
administered	O
intravenous	O
ascites	O
were	O
randomized	O
to	O
receive	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
the	O
p38	B-FUNC
mitogen	O
activated	O
kinase	B-FUNC
inhibitor	I-FUNC
CNI	O
-	O
1493	O
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
investigate	O
the	O
ability	O
of	O
an	O
oil	O
adjuvanted	O
vaccine	O
containing	O
bovine	O
coronavirus	O
antigen	O
to	O
enhance	O
lactogenic	O
immunity	O
in	O
the	O
calf	O
,	O
pregnant	O
cows	O
and	O
heifers	O
were	O
vaccinated	O
and	O
specific	O
virus	O
neutralising	O
antibody	B-FUNC
levels	O
determined	O
in	O
serum	O
,	O
colostrum	O
and	O
milk	O
.	O

TITLE	O
:	O
Identification	O
of	O
mouse	O
hepatitis	O
virus	O
papain	O
-	O
like	O
proteinase	B-FUNC
2	O
activity	O
.	O

To	O
date	O
,	O
two	O
of	O
the	O
MHV	O
replicase	O
-	O
encoded	O
proteinases	O
,	O
papain	O
-	O
like	O
proteinase	B-FUNC
1	O
(	O
PLP1	O
)	O
and	O
the	O
poliovirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
),	O
have	O
been	O
shown	O
to	O
process	O
the	O
replicase	O
polyprotein	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
activity	O
of	O
the	O
third	O
MHV	O
proteinase	B-FUNC
domain	O
,	O
PLP2	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
enzymatic	O
activity	O
of	O
the	O
PLP2	O
domain	O
and	O
to	O
demonstrate	O
that	O
three	O
distinct	O
viral	O
proteinase	B-FUNC
activities	O
process	O
the	O
MHV	O
replicase	O
polyprotein	O
.	O

Infection	O
is	O
resolved	O
within	O
fourteen	O
days	O
with	O
a	O
rise	O
in	O
antibody	B-FUNC
titres	O
.	O

Identification	O
is	O
either	O
by	O
monoclonal	O
antibody	B-FUNC
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
or	O
polymerase	O
chain	O
reaction	O
.	O

The	O
viraemic	O
period	O
in	O
vaccinated	O
slaughter	O
ostriches	O
is	O
between	O
nine	O
and	O
eleven	O
days	O
and	O
there	O
are	O
no	O
indications	O
of	O
a	O
carrier	O
state	O
or	O
presence	O
of	O
the	O
virus	O
in	O
the	O
meat	O
or	O
any	O
other	O
tissues	O
after	O
this	O
period	O
,	O
with	O
peak	O
immunoglobulin	B-FUNC
G	O
response	O
reached	O
on	O
day	O
fourteen	O
post	O
infection	O
.	O

Adenovirus	O
DNA	O
was	O
detected	O
in	O
one	O
of	O
the	O
20	O
nasopharyngeal	O
swabs	O
of	O
healthy	O
controls	O
;	O
the	O
rest	B-FUNC
of	O
the	O
control	O
samples	O
were	O
negative	O
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
446	O
serum	O
samples	O
from	O
88	O
herds	O
in	O
Korea	O
were	O
examined	O
for	O
antibody	B-FUNC
to	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
using	O
blocking	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

By	O
ELISA	O
,	O
237	O
out	O
of	O
446	O
sera	B-FUNC
tested	O
(	O
53	O
.	O
1	O
%)	O
and	O
54	O
out	O
of	O
88	O
sampled	O
herds	O
(	O
61	O
.	O
3	O
%)	O
were	O
positive	O
against	O
PRCV	O
.	O

Of	O
446	O
sera	B-FUNC
from	O
88	O
herd	O
tested	O
,	O
185	O
(	O
41	O
.	O
5	O
%)	O
serum	O
samples	O
from	O
22	O
(	O
25	O
%)	O
herds	O
were	O
seronegative	O
against	O
PRCV	O
and	O
transmissible	O
gastroenteritis	O
virus	O
infection	O
.	O

TITLE	O
:	O
Down	O
-	O
regulation	O
of	O
Bgp1	O
(	O
a	O
)	O
viral	O
receptor	O
by	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
is	O
related	O
to	O
the	O
antiviral	O
state	O
and	O
resistance	O
to	O
mouse	O
hepatitis	O
virus	O
3	O
infection	O
.	O

ABSTRACT	O
:	O
Together	O
with	O
the	O
evidence	O
that	O
the	O
reduced	O
virus	O
growth	O
and	O
the	O
antiviral	O
state	O
induced	O
by	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
occurring	O
only	O
in	O
macrophages	O
from	O
resistant	O
animals	O
,	O
correlated	O
with	O
the	O
decrease	O
of	O
MHV3	O
binding	B-FUNC
to	O
macrophage	O
membrane	O
proteins	O
,	O
we	O
show	O
here	O
the	O
expression	O
of	O
cellular	O
and	O
viral	O
genes	O
in	O
resistant	O
(	O
A	O
/	O
J	O
)	O
and	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
mouse	O
macrophages	O
after	O
IFN	O
-	O
gamma	O
activation	O
/	O
infection	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
identified	O
the	O
upregulation	O
of	O
Fas	O
ligand	B-FUNC
(	O
FasL	O
)	O
and	O
granzyme	O
B	O
mRNAs	O
within	O
the	O
infected	O
retinas	O
.	O

These	O
cattle	O
were	O
immunologically	O
naive	O
to	O
both	O
infectious	O
agents	O
at	O
the	O
onset	O
of	O
the	O
epizootics	O
,	O
but	O
those	O
that	O
died	O
after	O
day	O
7	O
had	O
rising	O
antibody	B-FUNC
titers	O
against	O
RBCV	O
and	O
Pasteurella	O
haemolytica	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
hnRNP	O
A1	O
,	O
the	O
mutant	O
protein	O
failed	O
to	O
bind	B-FUNC
a	O
250	O
kDa	O
cellular	O
protein	O
,	O
suggesting	O
that	O
the	O
recruitment	O
of	O
cellular	O
proteins	O
by	O
hnRNP	O
A1	O
is	O
important	O
for	O
MHV	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
titers	O
against	O
bovine	O
coronavirus	O
and	O
shedding	O
of	O
the	O
virus	O
via	O
the	O
respiratory	O
tract	O
in	O
feedlot	O
cattle	O
.	O

Serum	O
samples	O
were	O
obtained	O
at	O
time	O
of	O
arrival	O
and	O
again	O
28	O
days	O
after	O
arrival	O
;	O
sera	B-FUNC
were	O
analyzed	O
for	O
antibodies	O
to	O
BCV	O
,	O
using	O
an	O
antibody	B-FUNC
-	O
detection	O
ELISA	O
.	O

Cattle	O
shedding	O
BCV	O
from	O
the	O
nasal	O
cavity	O
and	O
developing	O
an	O
antibody	B-FUNC
response	O
against	O
BCV	O
were	O
1	O
.	O
6	O
times	O
more	O
likely	O
to	O
require	O
treatment	O
for	O
respiratory	O
tract	O
disease	O
than	O
cattle	O
that	O
did	O
not	O
shed	O
the	O
virus	O
or	O
develop	O
an	O
immune	O
response	O
against	O
BCV	O
.	O

RESULTS	O
:	O
Cattle	O
shedding	O
BCV	O
from	O
the	O
nasal	O
cavity	O
and	O
developing	O
an	O
antibody	B-FUNC
response	O
against	O
BCV	O
were	O
1	O
.	O
6	O
times	O
more	O
likely	O
to	O
require	O
treatment	O
for	O
respiratory	O
tract	O
disease	O
than	O
cattle	O
that	O
did	O
not	O
shed	O
the	O
virus	O
or	O
develop	O
an	O
immune	O
response	O
against	O
BCV	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
titers	O
for	O
antibodies	O
against	O
canine	O
herpesvirus	O
-	O
1	O
in	O
North	O
American	O
river	O
otters	O
,	O
and	O
it	O
suggests	O
a	O
low	O
prevalence	O
of	O
antibody	B-FUNC
titers	O
against	O
most	O
canine	O
viruses	O
in	O
otter	O
populations	O
in	O
northern	O
and	O
eastern	O
New	O
York	O
.	O

Addition	O
of	O
anti	O
-	O
interferon	O
antibody	B-FUNC
to	O
MHV	O
-	O
infected	O
cells	O
did	O
not	O
inhibit	O
28S	O
rRNA	O
cleavage	O
.	O

To	O
identify	O
new	O
receptor	O
-	O
ligand	B-FUNC
interactions	O
that	O
might	O
be	O
used	O
to	O
redirect	O
vectors	O
to	O
the	O
apical	O
surface	O
,	O
we	O
investigated	O
the	O
process	O
of	O
infection	O
of	O
airway	O
epithelial	O
cells	O
by	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
a	O
common	O
cause	O
of	O
respiratory	O
tract	O
infections	O
.	O

The	O
spike	O
glycoprotein	O
that	O
mediates	O
HCoV	O
-	O
229E	O
binding	B-FUNC
and	O
fusion	O
to	O
CD13	O
is	O
a	O
candidate	O
for	O
pseudotyping	O
retroviral	O
envelopes	O
or	O
modifying	O
other	O
viral	O
vectors	O
.	O

A	O
recombinant	O
form	O
of	O
nsp10	O
,	O
MBP	O
-	O
nsp10	O
,	O
was	O
produced	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
the	O
maltose	O
-	O
binding	B-FUNC
protein	O
.	O

The	O
protein	O
was	O
partially	O
purified	O
by	O
affinity	O
chromatography	O
and	O
shown	O
to	O
have	O
ATPase	B-FUNC
activity	I-FUNC
that	O
was	O
strongly	O
stimulated	O
by	O
poly	O
(	O
dT	O
),	O
poly	O
(	O
U	O
),	O
and	O
poly	O
(	O
dA	O
)	O
but	O
not	O
by	O
poly	O
(	O
G	O
).	O

TITLE	O
:	O
Detection	O
of	O
antibody	B-FUNC
to	O
turkey	O
coronavirus	O
by	O
antibody	B-FUNC
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
utilizing	O
infectious	O
bronchitis	O
virus	O
antigen	O
.	O

The	O
performance	O
of	O
the	O
ELISA	O
system	O
was	O
evaluated	O
with	O
45	O
normal	O
turkey	O
sera	B-FUNC
and	O
325	O
turkey	O
sera	B-FUNC
from	O
the	O
field	O
and	O
the	O
cutoff	O
point	O
was	O
determined	O
.	O

Serum	O
samples	O
of	O
turkeys	O
experimentally	O
infected	O
with	O
TCV	O
collected	O
sequentially	O
from	O
1	O
to	O
63	O
days	O
postinfection	O
were	O
applied	O
to	O
the	O
established	O
antibody	B-FUNC
-	O
capture	O
ELISA	O
using	O
IBV	O
antigens	O
.	O

The	O
day	O
of	O
hatch	O
mean	O
antibody	B-FUNC
titer	O
to	O
IBV	O
was	O
12	O
,	O
668	O
+/-	O

TITLE	O
:	O
Comparison	O
of	O
virus	O
isolation	O
,	O
immunohistochemistry	O
,	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
procedures	O
for	O
detection	O
of	O
turkey	O
coronavirus	O
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
and	O
two	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)-	O
based	O
immunohistochemical	O
procedures	O
were	O
developed	O
for	O
detection	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
in	O
tissues	O
and	O
intestinal	O
contents	O
/	O
dropping	O
samples	O
.	O

The	O
RT	O
-	O
PCR	O
,	O
MAb	O
-	O
based	O
fluorescent	O
antibody	B-FUNC
(	O
FA	O
),	O
and	O
MAb	O
-	O
based	O
immunoperoxidase	O
(	O
IP	O
)	O
procedures	O
were	O
compared	O
with	O
virus	O
isolation	O
(	O
VI	O
)	O
for	O
detection	O
of	O
TCV	O
in	O
experimentally	O
infected	O
turkeys	O
.	O

ABSTRACT	O
:	O
Fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
2	O
(	O
FGF2	O
)	O
is	O
an	O
excellent	O
candidate	O
to	O
regulate	O
remyelination	O
based	O
on	O
its	O
proposed	O
actions	O
in	O
oligodendrocyte	O
lineage	O
cell	O
development	O
in	O
conjunction	O
with	O
its	O
involvement	O
in	O
CNS	O
regeneration	O
.	O

In	O
normal	O
and	O
lesioned	O
white	O
matter	O
,	O
oligodendrocyte	O
lineage	O
cells	O
,	O
including	O
progenitors	O
and	O
mature	O
cells	O
,	O
were	O
found	O
to	O
express	O
multiple	O
FGFR	B-FUNC
types	O
(	O
FGFR1	O
,	O
FGFR2	O
,	O
and	O
/	O
or	O
FGFR3	O
).	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
66	O
-	O
year	O
-	O
old	O
caucasian	O
woman	O
suffering	O
from	O
polymyositis	O
with	O
the	O
anti	O
-	O
Jo	O
-	O
1	O
antibody	B-FUNC
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
patient	O
suffering	O
from	O
polymyositis	O
with	O
the	O
anti	O
-	O
Jo	O
-	O
1	O
antibody	B-FUNC
who	O
survived	O
such	O
a	O
complication	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
course	O
of	O
the	O
energy	O
balance	O
in	O
relation	O
to	O
leptin	O
and	O
the	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
receptors	O
(	O
sTNF	O
-	O
R	O
)	O
55	O
and	O
75	O
,	O
plasma	O
glucose	O
,	O
and	O
serum	O
insulin	O
in	O
patients	O
with	O
severe	O
COPD	O
during	O
the	O
first	O
7	O
d	O
of	O
hospitalization	O
for	O
an	O
acute	O
exacerbation	O
(	O
n	O
=	O
17	O
,	O
11	O
men	O
,	O
age	O
mean	O
[	O
SD	O
]	O
66	O
[	O
10	O
]	O
yr	O
,	O
FEV	O
(	O
1	O
)	O
36	O
[	O
12	O
]	O
%	O
pred	O
).	O

Cardiorespiratory	O
parameters	O
were	O
measured	O
using	O
a	O
Swan	O
-	O
Ganz	O
catheter	O
,	O
the	O
pressure	O
-	O
volume	O
(	O
PV	O
)	O
curve	O
was	O
measured	O
using	O
the	O
gross	O
syringe	O
method	O
,	O
and	O
fast	B-FUNC
spiral	O
computed	O
tomography	O
(	O
CT	O
)	O
was	O
performed	O
.	O

TITLE	O
:	O
Pulmonary	O
capillary	O
endothelium	O
-	O
bound	O
angiotensin	O
-	O
converting	O
enzyme	B-FUNC
activity	I-FUNC
in	O
acute	O
lung	O
injury	O
.	O

Applying	O
indicator	O
-	O
dilution	O
techniques	O
,	O
we	O
measured	O
single	O
-	O
pass	O
transpulmonary	O
hydrolysis	O
of	O
the	O
synthetic	O
ACE	O
substrate	O
(	O
3	O
)	O
H	O
-	O
benzoyl	O
-	O
Phe	O
-	O
Ala	O
-	O
Pro	O
(	O
BPAP	O
)	O
in	O
33	O
mechanically	O
ventilated	O
,	O
critically	O
ill	O
patients	O
with	O
a	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
ranging	O
from	O
0	O
(	O
no	O
lung	O
injury	O
)	O
to	O
3	O
.	O
7	O
(	O
severe	O
lung	O
injury	O
)	O
and	O
calculated	O
the	O
kinetic	O
parameter	O
A	O
(	O
max	O
)/	O
K	O
(	O
m	O
).	O

Both	O
parameters	O
decreased	O
early	O
during	O
the	O
ALI	O
continuum	O
and	O
were	O
inversely	O
related	O
to	O
APACHE	O
II	O
score	O
and	O
LIS	B-FUNC
.	O

TITLE	O
:	O
Immunoprophylactic	O
effect	O
of	O
chicken	O
egg	O
yolk	O
immunoglobulin	B-FUNC
(	O
Ig	O
Y	O
)	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
piglets	O
.	O

The	O
method	O
that	O
we	O
have	O
designed	O
to	O
generate	O
an	O
infectious	O
cDNA	O
construct	O
of	O
TGEV	O
could	O
theoretically	O
be	O
used	O
to	O
precisely	O
reconstruct	O
microbial	O
or	O
eukaryotic	O
genomes	O
approaching	O
several	O
million	O
base	B-FUNC
pairs	I-FUNC
in	O
length	O
.	O

Hantavirus	O
-	O
specific	O
antibodies	O
were	O
detected	O
in	O
patient	O
sera	B-FUNC
,	O
and	O
virus	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Identification	O
of	O
nucleocapsid	O
binding	B-FUNC
sites	O
within	O
coronavirus	O
-	O
defective	O
genomes	O
.	O

As	O
a	O
step	O
toward	O
understanding	O
how	O
N	O
interacts	O
with	O
viral	O
RNAs	O
,	O
we	O
mapped	O
high	O
-	O
efficiency	O
N	O
-	O
binding	B-FUNC
sites	O
within	O
BCV	O
-	O
and	O
MHV	O
-	O
defective	O
genomes	O
.	O

For	O
comparative	O
purposes	O
N	O
-	O
binding	B-FUNC
sites	O
were	O
also	O
mapped	O
for	O
the	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)-	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
MIDI	O
-	O
C	O
.	O
Binding	B-FUNC
efficiencies	O
similar	O
to	O
those	O
for	O
Drep	O
were	O
measured	O
for	O
RNA	O
transcripts	O
of	O
a	O
region	O
encompassing	O
the	O
MHV	O
packaging	O
signal	O
(	O
nts	O
3949	O
-	O
4524	O
),	O
as	O
well	O
as	O
a	O
region	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
MHV	O
N	O
ORF	O
(	O
nts	O
4837	O
-	O
5197	O
)	O
within	O
MIDI	O
-	O
C	O
.	O
Binding	B-FUNC
to	O
the	O
full	O
-	O
length	O
MIDI	O
-	O
C	O
transcript	O
(	O
approximately	O
5500	O
nts	O
)	O
and	O
to	O
an	O
approximately	O
1	O
-	O
kb	O
transcript	O
from	O
the	O
gene	O
1a	O
region	O
(	O
nts	O
935	O
-	O
1986	O
)	O
of	O
MIDI	O
-	O
C	O
that	O
excluded	O
the	O
packaging	O
signal	O
were	O
both	O
significantly	O
higher	O
than	O
that	O
measured	O
for	O
the	O
smaller	O
transcripts	O
.	O

The	O
data	O
clearly	O
demonstrate	O
that	O
N	O
binds	B-FUNC
coronavirus	O
RNAs	O
more	O
efficiently	O
than	O
nonviral	O
RNAs	O
.	O

ABSTRACT	O
:	O
The	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
5B19	O
.	O
2	O
,	O
which	O
has	O
virus	O
-	O
neutralizing	O
and	O
fusion	O
inhibition	O
activities	O
,	O
binds	B-FUNC
to	O
an	O
epitope	O
(	O
S2A	O
)	O
consisting	O
of	O
nine	O
hydrophobic	O
amino	O
acids	O
in	O
the	O
S2	O
subunit	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Co	O
-	O
immunoprecipitation	O
analyses	O
demonstrated	O
that	O
while	O
the	O
binding	B-FUNC
of	O
virus	O
to	O
the	O
receptor	O
was	O
blocked	O
by	O
anti	O
-	O
S1	O
MAbs	O
,	O
it	O
was	O
not	O
blocked	O
by	O
the	O
S2A	O
antiserum	O
,	O
indicating	O
that	O
S2A	O
was	O
not	O
involved	O
in	O
receptor	O
-	O
binding	B-FUNC
.	O

Indirect	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
procedures	O
and	O
virus	O
neutralization	O
assays	O
demonstrated	O
a	O
close	O
antigenic	O
relationship	O
with	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
mammalian	O
group	O
2	O
coronaviruses	O
).	O

Using	O
previously	O
described	O
BCV	O
primers	O
,	O
the	O
N	O
protein	O
gene	O
of	O
isolate	O
NC99	O
was	O
amplified	O
by	O
a	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
.	O

Serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
(	O
MIP	O
-	O
2	O
)	O
levels	O
are	O
markedly	O
increased	O
1	O
h	O
and	O
beyond	O
after	O
cryo	O
compared	O
with	O
partial	O
hepatectomy	O
where	O
no	O
elevation	O
occurs	O
.	O

Animals	O
underwent	O
35	O
%	O
hepatic	O
resection	O
or	O
a	O
similar	O
volume	O
hepatic	O
cryo	O
and	O
were	O
sacrificed	O
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
.	O
Pulmonary	O
histologic	O
features	O
were	O
assessed	O
using	O
hematoxylin	O
and	O
eosin	O
and	O
immunoperoxidase	O
staining	O
with	O
a	O
macrophage	O
-	O
specific	O
antibody	B-FUNC
(	O
anti	O
-	O
lysozyme	O
,	O
1	O
:	O
200	O
dilution	O
,	O
Dako	O
,	O
Carpinteria	O
,	O
CA	O
).	O

Three	O
recombinant	O
viruses	O
were	O
tested	O
by	O
oral	O
immunization	O
of	O
pigs	O
and	O
both	O
antibody	B-FUNC
response	O
and	O
virus	O
shedding	O
were	O
monitored	O
.	O

One	O
assay	O
used	O
p	O
-	O
nitrophenyl	O
acetate	O
(	O
PNPA	O
)	O
as	O
substrate	O
and	O
detected	O
serine	O
-	O
esterase	B-FUNC
activity	I-FUNC
;	O
the	O
second	O
assay	O
monitored	O
AE	O
function	O
with	O
bovine	O
submaxillary	O
mucin	O
(	O
BSM	O
)	O
as	O
substrate	O
.	O

TITLE	O
:	O
Sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
affects	O
sedimentation	O
behavior	O
of	O
virions	O
and	O
solubilized	O
glycoproteins	O
.	O

This	O
high	O
density	O
was	O
observed	O
only	O
when	O
TGEV	O
with	O
a	O
functional	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
was	O
analyzed	O
.	O

Mutants	O
of	O
TGEV	O
that	O
lacked	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
due	O
to	O
a	O
point	O
mutation	O
in	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
site	O
of	O
the	O
S	O
protein	O
were	O
mainly	O
recovered	O
at	O
a	O
lower	O
-	O
density	O
position	O
on	O
the	O
sucrose	O
gradient	O
(	O
1	O
.	O
18	O
to	O
1	O
.	O
19	O
g	O
/	O
cm	O
(	O
3	O
)).	O

These	O
results	O
suggest	O
that	O
binding	B-FUNC
of	O
sialoglycoproteins	O
to	O
the	O
virion	O
surface	O
is	O
responsible	O
for	O
the	O
sedimentation	O
behavior	O
of	O
TGEV	O
.	O

In	O
the	O
case	O
of	O
systemic	O
immunodeficiencies	O
such	O
as	O
the	O
antibody	B-FUNC
deficiency	O
syndrome	O
,	O
HIV	O
infection	O
or	O
immunosuppressive	O
therapy	O
,	O
the	O
indication	O
for	O
antibiotic	O
treatment	O
is	O
more	O
liberally	O
established	O
.	O

For	O
scoring	O
the	O
severity	O
of	O
respiratory	O
failure	O
,	O
the	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
according	O
to	O
Murray	O
and	O
the	O
SOFA	O
score	O
lung	O
(	O
sepsis	O
-	O
related	O
organ	O
failure	O
assessment	O
)	O
according	O
to	O
Vincent	O
were	O
evaluated	O
.	O

The	O
LIS	B-FUNC
at	O
time	O
of	O
recruitment	O
into	O
the	O
study	O
was	O
2	O
.	O
2	O
(+/-	O

TITLE	O
:	O
The	O
membrane	O
M	O
protein	O
carboxy	O
terminus	O
binds	B-FUNC
to	O
transmissible	O
gastroenteritis	O
coronavirus	O
core	O
and	O
contributes	O
to	O
core	O
stability	O
.	O

A	O
specific	O
ionic	O
interaction	O
between	O
the	O
M	O
protein	O
carboxy	O
terminus	O
and	O
the	O
nucleocapsid	O
was	O
demonstrated	O
using	O
three	O
complementary	O
approaches	O
:	O
(	O
i	O
)	O
a	O
binding	B-FUNC
assay	O
performed	O
between	O
a	O
collection	O
of	O
M	O
protein	O
amino	O
acid	O
substitution	O
or	O
deletion	O
mutants	O
and	O
purified	O
nucleocapsids	O
that	O
led	O
to	O
the	O
identification	O
of	O
a	O
16	O
-	O
amino	O
-	O
acid	O
(	O
aa	O
)	O
domain	O
(	O
aa	O
237	O
to	O
252	O
)	O
as	O
being	O
responsible	O
for	O
binding	B-FUNC
the	O
M	O
protein	O
to	O
the	O
nucleocapsid	O
;	O
(	O
ii	O
)	O
the	O
specific	O
inhibition	O
of	O
this	O
binding	B-FUNC
by	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
binding	B-FUNC
to	O
a	O
carboxy	O
-	O
terminal	O
M	O
protein	O
domain	O
close	O
to	O
the	O
indicated	O
peptide	O
but	O
not	O
by	O
MAbs	O
specific	O
for	O
the	O
M	O
protein	O
amino	O
terminus	O
;	O
and	O
(	O
iii	O
)	O
a	O
26	O
-	O
residue	O
peptide	O
,	O
including	O
the	O
predicted	O
sequence	O
(	O
aa	O
237	O
to	O
252	O
),	O
which	O
specifically	O
inhibited	O
the	O
binding	B-FUNC
.	O

Direct	O
binding	B-FUNC
of	O
the	O
M	O
protein	O
to	O
the	O
nucleoprotein	O
was	O
predicted	O
,	O
since	O
degradation	O
of	O
the	O
exposed	O
RNA	O
by	O
RNase	O
treatment	O
did	O
not	O
affect	O
the	O
binding	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
specific	O
endothelial	O
cell	O
product	O
von	O
Willebrand	O
factor	O
antigen	O
(	O
vWf	O
:	O
Ag	O
)	O
was	O
measured	O
in	O
plasma	O
and	O
lung	O
function	O
tests	O
were	O
carried	O
out	O
and	O
the	O
following	O
lung	O
injury	O
parameters	O
measured	O
:	O
P	O
(	O
a	O
)	O
O2	O
/	O
F	O
(	O
i	O
)	O
O2	O
ratio	O
,	O
static	O
respiratory	O
compliance	O
and	O
Murray	O
'	O
s	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
in	O
a	O
follow	O
-	O
up	O
study	O
of	O
36	O
severely	O
traumatized	O
patients	O
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
initial	O
vWf	O
:	O
Ag	O
concentration	O
and	O
ISS	O
,	O
APACHE	O
II	O
,	O
LIS	B-FUNC
.	O

ABSTRACT	O
:	O
Evaluate	O
the	O
safety	O
of	O
filgrastim	O
(	O
recombinant	O
methionyl	O
human	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
)	O
administration	O
,	O
combined	O
with	O
standard	O
therapy	O
,	O
in	O
patients	O
with	O
pneumonia	O
and	O
either	O
septic	O
shock	O
or	O
severe	O
sepsis	O
who	O
were	O
receiving	O
mechanical	O
ventilation	O
.	O

Our	O
final	O
diagnosis	O
was	O
ARDS	O
induced	O
by	O
fulminant	O
influenza	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
68	O
(	O
H3	O
N2	O
))	O
virus	O
pneumonia	O
,	O
because	O
the	O
antibody	B-FUNC
titers	O
of	O
H3	O
N2	O
influenza	O
of	O
paired	O
sera	B-FUNC
showed	O
a	O
128	O
-	O
fold	O
increase	O
.	O

TITLE	O
:	O
Effect	O
of	O
liquid	O
paraffin	O
on	O
antibody	B-FUNC
responses	O
and	O
local	O
adverse	O
reactions	O
of	O
bivalent	O
oil	O
adjuvanted	O
vaccines	O
containing	O
newcastle	O
disease	O
virus	O
and	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Effects	O
of	O
liquid	O
paraffin	O
on	O
antibody	B-FUNC
responses	O
and	O
local	O
adverse	O
reactions	O
after	O
intramuscular	O
injection	O
of	O
oil	O
adjuvanted	O
vaccines	O
containing	O
Newcastle	O
disease	O
(	O
ND	O
)	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
virus	O
were	O
investigated	O
in	O
chickens	O
.	O

These	O
vaccines	O
induced	O
sustained	O
antibody	B-FUNC
responses	O
against	O
ND	O
and	O
IB	O
.	O

Antibody	B-FUNC
titer	O
to	O
IBV	O
suggested	O
that	O
the	O
laying	O
chickens	O
were	O
infected	O
with	O
IBV	O
repeatedly	O
during	O
the	O
experiment	O
on	O
both	O
farms	O
.	O

These	O
four	O
isolates	O
were	O
further	O
characterized	O
by	O
the	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
techniques	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
to	O
respiratory	O
coronavirus	O
infections	O
of	O
cattle	O
during	O
shipping	O
fever	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
responses	O
against	O
respiratory	O
bovine	O
coronavirus	O
(	O
RBCV	O
)	O
infections	O
were	O
monitored	O
in	O
cattle	O
from	O
the	O
onset	O
of	O
a	O
naturally	O
occurring	O
severe	O
shipping	O
fever	O
(	O
SF	O
)	O
epizootic	O
to	O
complete	O
recovery	O
of	O
affected	O
cattle	O
or	O
fatal	O
outcomes	O
.	O

The	O
HE	O
and	O
S	O
glycoproteins	O
were	O
recognized	O
earliest	O
by	O
the	O
bovine	O
immune	O
system	O
while	O
the	O
N	O
protein	O
induced	O
antibody	B-FUNC
responses	O
during	O
the	O
later	O
stage	O
of	O
initial	O
infection	O
and	O
the	O
early	O
stage	O
of	O
reinfection	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
the	O
impact	O
of	O
the	O
helicase	O
domain	O
upon	O
protease	O
inhibitor	O
binding	B-FUNC
is	O
substantial	O
.	O

Twenty	O
-	O
six	O
organ	O
donors	O
prospectively	O
satisfying	O
clinical	O
criteria	O
for	O
lung	O
donation	O
underwent	O
bronchoalveolar	O
lavage	O
and	O
lung	O
biopsy	O
to	O
determine	O
the	O
effect	O
of	O
neutrophil	O
infiltration	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
expression	O
in	O
the	O
donor	O
lung	O
on	O
graft	O
function	O
and	O
survival	O
in	O
26	O
respective	O
recipients	O
after	O
lung	O
transplantation	O
.	O

The	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
signal	O
in	O
the	O
donor	O
lung	O
correlated	O
with	O
the	O
percent	O
neutrophils	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
before	O
implantation	O
(	O
42	O
.	O
4	O
+/-	O
7	O
.	O
24	O
[	O
mean	O
+/-	O

An	O
increased	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
donor	O
BALF	O
was	O
associated	O
with	O
the	O
development	O
of	O
severe	O
early	O
graft	O
dysfunction	O
(	O
p	O
=	O
0	O
.	O
027	O
)	O
and	O
with	O
early	O
recipient	O
mortality	O
(	O
p	O
=	O
0	O
.	O
0034	O
).	O

Use	O
of	O
donor	O
lungs	O
with	O
high	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
after	O
lung	O
transplantation	O
.	O

Among	O
the	O
collection	O
of	O
variants	O
,	O
mutations	O
were	O
identified	O
in	O
regions	O
encoding	O
both	O
the	O
receptor	O
-	O
binding	B-FUNC
(	O
S1	O
)	O
and	O
fusion	O
-	O
inducing	O
(	O
S2	O
)	O
subunits	O
of	O
the	O
spike	O
protein	O
.	O

TITLE	O
:	O
Virus	O
-	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
expressed	O
in	O
milk	O
of	O
transgenic	O
mice	O
provides	O
full	O
protection	O
against	O
virus	O
-	O
induced	O
encephalitis	O
.	O

Milk	O
from	O
these	O
transgenic	O
mice	O
contained	O
up	O
to	O
0	O
.	O
7	O
mg	O
of	O
recombinant	O
antibody	B-FUNC
/	O
ml	O
.	O

This	O
demonstrates	O
that	O
a	O
single	O
neutralizing	O
antibody	B-FUNC
expressed	O
in	O
the	O
milk	O
of	O
transgenic	O
mice	O
is	O
sufficient	O
to	O
completely	O
protect	O
suckling	O
offspring	O
against	O
MHV	O
-	O
JHM	O
-	O
induced	O
encephalitis	O
.	O

For	O
the	O
prototype	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
has	O
been	O
shown	O
to	O
be	O
able	O
to	O
bind	B-FUNC
in	O
vitro	O
to	O
the	O
negative	O
strand	O
of	O
the	O
intergenic	O
sequence	O
,	O
a	O
cis	O
-	O
acting	O
element	O
found	O
in	O
the	O
leader	O
RNA	O
and	O
preceding	O
each	O
downstream	O
ORF	O
in	O
the	O
genome	O
.	O

To	O
test	O
this	O
hypothesis	O
genetically	O
,	O
we	O
initially	O
constructed	O
MHV	O
mutants	O
with	O
a	O
very	O
high	O
-	O
affinity	O
hnRNP	O
A1	O
binding	B-FUNC
site	O
inserted	O
in	O
place	O
of	O
,	O
or	O
adjacent	O
to	O
,	O
an	O
intergenic	O
sequence	O
in	O
the	O
MHV	O
genome	O
.	O

This	O
inserted	O
hnRNP	O
A1	O
binding	B-FUNC
site	O
was	O
not	O
able	O
to	O
functionally	O
replace	O
,	O
or	O
enhance	O
transcription	O
from	O
,	O
the	O
intergenic	O
sequence	O
.	O

This	O
replacement	O
resulted	O
in	O
the	O
loss	O
of	O
the	O
CTAAACTT	O
leader	O
RNA	O
-	O
binding	B-FUNC
site	O
and	O
ATG	O
start	O
codon	O
for	O
the	O
ORF	O
-	O
3A	O
gene	O
but	O
it	O
did	O
not	O
affect	O
the	O
ORF	O
-	O
3B	O
gene	O
.	O

The	O
results	O
of	O
in	O
situ	O
hybridization	O
for	O
the	O
detection	O
of	O
TGEV	O
were	O
compared	O
with	O
virus	O
isolation	O
(	O
VI	O
),	O
a	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
FAT	O
),	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
).	O

TITLE	O
:	O
Infectivity	O
-	O
neutralizing	O
and	O
hemagglutinin	O
-	O
inhibiting	O
antibody	B-FUNC
responses	O
to	O
respiratory	O
coronavirus	O
infections	O
of	O
cattle	O
in	O
pathogenesis	O
of	O
shipping	O
fever	O
pneumonia	O
.	O

An	O
increase	O
in	O
serum	O
IN	O
antibody	B-FUNC
after	O
day	O
7	O
led	O
to	O
reduction	O
of	O
virus	O
shedding	O
in	O
nasal	O
secretions	O
by	O
the	O
majority	O
of	O
the	O
cattle	O
between	O
days	O
7	O
and	O
14	O
.	O

A	O
substantial	O
rise	O
in	O
the	O
serum	O
HAI	O
antibody	B-FUNC
was	O
observed	O
during	O
the	O
initial	O
phase	O
among	O
the	O
sick	O
but	O
not	O
the	O
clinically	O
normal	O
cattle	O
which	O
were	O
infected	O
with	O
RBCV	O
.	O

The	O
RBCV	O
-	O
neutralizing	O
activity	O
is	O
associated	O
with	O
serum	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
particularly	O
the	O
IgG2	O
subclass	O
,	O
while	O
RBCV	O
-	O
specific	O
HAI	O
antibody	B-FUNC
is	O
related	O
to	O
both	O
serum	O
IgG	O
and	O
IgM	O
fractions	O
.	O

TITLE	O
:	O
Mitochondrial	O
aconitase	O
binds	B-FUNC
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
.	O

Antibody	B-FUNC
raised	O
against	O
purified	O
mitochondrial	O
aconitase	O
recognizes	O
the	O
RNA	O
-	O
protein	O
complex	O
and	O
the	O
90	O
-	O
kDa	O
protein	O
,	O
which	O
can	O
be	O
released	O
from	O
the	O
complex	O
by	O
RNase	O
digestion	O
.	O

Furthermore	O
,	O
UV	O
cross	O
-	O
linking	O
studies	O
indicate	O
that	O
highly	O
purified	O
mitochondrial	O
aconitase	O
binds	B-FUNC
specifically	O
to	O
the	O
MHV	O
3	O
'	O
protein	O
-	O
binding	B-FUNC
element	O
.	O

Increasing	O
the	O
intracellular	O
level	O
of	O
mitochondrial	O
aconitase	O
by	O
iron	O
supplementation	O
resulted	O
in	O
increased	O
RNA	O
-	O
binding	B-FUNC
activity	O
in	O
cell	O
extracts	O
and	O
increased	O
virus	O
production	O
as	O
well	O
as	O
viral	O
protein	O
synthesis	O
at	O
early	O
hours	O
of	O
infection	O
.	O

These	O
results	O
are	O
particularly	O
interesting	O
in	O
terms	O
of	O
identification	O
of	O
an	O
RNA	O
target	O
for	O
mitochondrial	O
aconitase	O
,	O
which	O
has	O
a	O
cytoplasmic	O
homolog	O
,	O
cytoplasmic	O
aconitase	O
,	O
also	O
known	O
as	O
iron	O
regulatory	O
protein	O
1	O
,	O
a	O
well	O
-	O
recognized	O
RNA	O
-	O
binding	B-FUNC
protein	O
.	O

The	O
binding	B-FUNC
properties	O
of	O
mitochondrial	O
aconitase	O
and	O
the	O
functional	O
relevance	O
of	O
RNA	B-FUNC
binding	I-FUNC
appear	O
to	O
parallel	O
those	O
of	O
cytoplasmic	O
aconitase	O
.	O

Serum	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
assayed	O
at	O
1	O
and	O
4	O
hours	O
after	O
the	O
injury	O
stimuli	O
.	O

However	O
,	O
evaluation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
demonstrated	O
a	O
substantial	O
increase	O
after	O
H	O
/	O
R	O
,	O
EL	O
,	O
and	O
H	O
/	O
R	O
+	O
EL	O
compared	O
with	O
baseline	O
and	O
at	O
1	O
hour	O
.	O

It	O
would	O
appear	O
that	O
serum	O
TNF	O
-	O
alpha	O
has	O
little	O
impact	O
on	O
the	O
pathogenesis	O
of	O
ALI	O
after	O
EL	O
,	O
whereas	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
may	O
be	O
more	O
important	O
.	O

Sera	B-FUNC
from	O
15	O
.	O
8	O
%	O
of	O
the	O
open	O
population	O
and	O
40	O
.	O
8	O
%	O
of	O
kennelled	O
dogs	O
were	O
positive	O
for	O
CCV	O
antibodies	O
.	O

The	O
high	O
prevalence	O
of	O
virus	O
specific	O
T	O
cells	O
correlates	O
with	O
ex	O
vivo	O
cytolytic	O
activity	O
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
and	O
efficient	O
reduction	O
in	O
virus	O
.	O

Retention	O
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
envelope	O
protein	O
in	O
the	O
pre	O
-	O
Golgi	O
compartments	O
and	O
physical	B-FUNC
interaction	I-FUNC
between	O
the	O
envelope	O
and	O
membrane	O
proteins	O
.	O

ABSTRACT	O
:	O
One	O
missing	O
link	O
in	O
the	O
coronavirus	O
assembly	O
is	O
the	O
physical	B-FUNC
interaction	I-FUNC
between	O
two	O
crucial	O
structural	O
proteins	O
,	O
the	O
membrane	O
(	O
M	O
)	O
and	O
envelope	O
(	O
E	O
)	O
proteins	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
L	O
-	O
arginine	O
[	O
correction	O
of	O
F	O
-	O
arginine	O
]	O
and	O
phosphodiesterase	B-FUNC
inhibitor	O
(	O
dipyridamole	O
)	O
to	O
wean	O
from	O
inhaled	O
nitric	O
oxide	O
.	O

Exogeous	O
NO	O
may	O
lead	O
to	O
down	O
regulation	O
of	O
endogenous	O
NO	O
production	O
,	O
and	O
further	O
lead	O
to	O
rapid	O
hydrolization	O
of	O
cyclic	O
guanosine	O
3	O
',	O
5	O
'	O
monophosphate	O
(	O
cGMP	O
),	O
the	O
smooth	O
muscle	O
relaxant	O
,	O
by	O
the	O
enzyme	O
phosphodiesterase	B-FUNC
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
and	O
E	O
.	O
coli	O
K99	O
.	O

For	O
both	O
microorganisms	O
,	O
a	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
has	O
been	O
shown	O
to	O
be	O
an	O
essential	O
pathogenicity	O
factor	O
.	O

Here	O
we	O
demonstrate	O
with	O
haemagglutination	O
and	O
haemagglutination	O
-	O
inhibition	O
assays	O
that	O
TGEV	O
and	O
E	O
.	O
coli	O
K99	O
differ	O
in	O
their	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activities	O
with	O
respect	O
to	O
the	O
type	O
and	O
amount	O
of	O
sialic	O
acid	O
residues	O
required	O
on	O
the	O
erythrocytes	O
surface	O
as	O
well	O
as	O
with	O
respect	O
to	O
the	O
type	O
of	O
sialoglycoconjugate	O
preferentially	O
recognized	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
and	O
expressed	O
in	O
the	O
baculovirus	O
expression	O
system	O
.	O

Hemagglutinating	O
antibodies	O
were	O
detected	O
in	O
sera	B-FUNC
of	O
convalescent	O
birds	O
at	O
12	O
DPI	O
.	O

TITLE	O
:	O
The	O
exacerbating	O
effect	O
of	O
infectious	O
bronchitis	O
virus	O
infection	O
on	O
the	O
infectious	O
bursal	O
disease	O
virus	O
-	O
induced	O
suppression	O
of	O
opsonization	O
by	O
Escherichia	O
coil	O
antibody	B-FUNC
in	O
chickens	O
.	O

To	O
understand	O
the	O
host	O
factors	O
that	O
may	O
contribute	O
to	O
the	O
E	O
.	O
coli	O
infection	O
,	O
we	O
investigated	O
macrophage	O
-	O
mediated	O
E	O
.	O
coli	O
phagocytosis	O
,	O
intracellular	O
bacterial	O
killing	O
,	O
and	O
development	O
of	O
opsonizing	O
antibody	B-FUNC
in	O
previously	O
uninfected	O
chickens	O
and	O
in	O
those	O
infected	O
with	O
IBV	O
,	O
IBDV	O
,	O
and	O
IBDV	O
plus	O
IBV	O
.	O

These	O
results	O
indicate	O
that	O
although	O
IBDV	O
alone	O
has	O
the	O
potential	O
to	O
markedly	O
reduce	O
opsonizing	O
ability	O
of	O
antibody	B-FUNC
,	O
this	O
effect	O
is	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
exacerbated	O
by	O
IBV	O
infection	O
.	O

By	O
immunoprecipitation	O
of	O
UV	O
-	O
cross	O
-	O
linked	O
cellular	O
proteins	O
and	O
in	O
vitro	O
binding	B-FUNC
of	O
the	O
recombinant	O
protein	O
,	O
we	O
have	O
identified	O
the	O
major	O
RNA	O
-	O
binding	B-FUNC
protein	O
species	O
as	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
A1	O
(	O
hnRNP	O
A1	O
).	O

A	O
strong	O
hnRNP	O
A1	O
-	O
binding	B-FUNC
site	O
was	O
located	O
90	O
to	O
170	O
nucleotides	O
from	O
the	O
3	O
'	O
end	O
of	O
MHV	O
RNA	O
,	O
and	O
a	O
weak	O
binding	B-FUNC
site	O
was	O
mapped	O
at	O
nucleotides	O
260	O
to	O
350	O
from	O
the	O
3	O
'	O
end	O
.	O

These	O
binding	B-FUNC
sites	O
are	O
complementary	O
to	O
the	O
sites	O
on	O
the	O
negative	O
-	O
strand	O
RNA	O
that	O
bind	B-FUNC
another	O
cellular	O
protein	O
,	O
polypyrimidine	O
tract	O
-	O
binding	B-FUNC
protein	O
(	O
PTB	O
).	O

Mutations	O
that	O
affect	O
PTB	O
binding	B-FUNC
to	O
the	O
negative	O
strand	O
of	O
the	O
3	O
'-	O
UTR	O
also	O
inhibited	O
hnRNP	O
A1	O
binding	B-FUNC
on	O
the	O
positive	O
strand	O
,	O
indicating	O
a	O
possible	O
relationship	O
between	O
these	O
two	O
proteins	O
.	O

Defective	O
-	O
interfering	O
RNAs	O
containing	O
a	O
mutated	O
hnRNP	O
A1	O
-	O
binding	B-FUNC
site	O
have	O
reduced	O
RNA	O
transcription	O
and	O
replication	O
activities	O
.	O

To	O
determine	O
the	O
involvement	O
of	O
individual	O
MMPs	O
in	O
the	O
development	O
of	O
lung	O
injury	O
,	O
mice	O
genetically	O
deficient	O
in	O
gelatinase	O
B	O
(	O
MMP	O
-	O
9	O
)	O
and	O
stromelysin	O
1	O
(	O
MMP	O
-	O
3	O
)	O
were	O
acutely	O
injured	O
with	O
immunoglobulin	B-FUNC
G	O
immune	O
complexes	O
and	O
the	O
intensity	O
of	O
the	O
lung	O
injury	O
was	O
compared	O
with	O
genetically	O
identical	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
with	O
normal	O
MMP	O
activities	O
.	O

ABSTRACT	O
:	O
Chicks	O
hatched	O
with	O
high	O
levels	O
of	O
maternal	O
antibody	B-FUNC
had	O
excellent	O
protection	O
(>	O
95	O
%)	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
challenge	O
at	O
1	O
day	O
of	O
age	O
,	O
but	O
not	O
at	O
7	O
days	O
(<	O
30	O
%).	O

This	O
protection	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
correlated	O
with	O
levels	O
of	O
local	O
respiratory	O
antibody	B-FUNC
and	O
not	O
with	O
serum	O
antibody	B-FUNC
.	O

A	O
high	O
percentage	O
of	O
both	O
maternal	O
antibody	B-FUNC
-	O
positive	O
(	O
Mab	O
+)	O
and	O
maternal	O
antibody	B-FUNC
-	O
negative	O
(	O
Mab	O
-)	O
chicks	O
failed	O
to	O
produce	O
IBV	O
antibody	B-FUNC
when	O
vaccinated	O
at	O
1	O
day	O
of	O
age	O
by	O
the	O
intraocular	O
route	O
.	O

Mab	O
+	O
chicks	O
experienced	O
a	O
more	O
rapid	O
decline	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
maternal	O
antibody	B-FUNC
after	O
1	O
-	O
day	O
-	O
of	O
-	O
age	O
vaccination	O
compared	O
to	O
their	O
unvaccinated	O
counterparts	O
.	O

A	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
blocking	O
ELISA	O
that	O
measured	O
antibody	B-FUNC
levels	O
specific	O
to	O
S1	O
glycoprotein	O
of	O
IBV	O
correlated	O
well	O
with	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

The	O
serum	O
IgM	O
antibody	B-FUNC
responses	O
came	O
earlier	O
in	O
most	O
of	O
the	O
calves	O
than	O
in	O
the	O
cows	O
.	O

Very	O
long	O
-	O
lasting	O
IgA	O
antibody	B-FUNC
responses	O
were	O
detected	O
both	O
systemically	O
and	O
locally	O
.	O

TITLE	O
:	O
Use	O
of	O
a	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
for	O
monitoring	O
the	O
shedding	O
of	O
feline	O
coronavirus	O
by	O
healthy	O
cats	O
.	O

Viral	O
RNA	O
was	O
detected	O
in	O
faeces	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
plasma	O
antiviral	O
antibodies	O
by	O
immunofluorescence	O
.	O

There	O
was	O
a	O
correlation	O
between	O
shedding	O
and	O
antibody	B-FUNC
titre	O
but	O
the	O
cats	O
could	O
remain	O
seropositive	O
for	O
some	O
time	O
after	O
they	O
had	O
ceased	O
shedding	O
virus	O
.	O

An	O
IBV	O
monoclonal	O
antibody	B-FUNC
neutralization	O
-	O
resistant	O
mutant	O
(	O
NR	O
18	O
)	O
had	O
an	O
unusual	O
substitution	O
of	O
Ile	O
for	O
Arg	O
at	O
the	O
fourth	O
position	O
,	O
giving	O
the	O
sequence	O
Arg	O
-	O
Arg	O
-	O
Ser	O
-	O
Ile	O
-	O
Arg	O
,	O
which	O
likely	O
prevents	O
cleavage	O
and	O
,	O
thus	O
,	O
destroys	O
the	O
conformationally	O
dependent	O
monoclonal	O
antibody	B-FUNC
binding	B-FUNC
epitope	O
.	O

Adult	O
rats	O
(	O
body	O
weight	O
285	O
to	O
315	O
g	O
,	O
n	O
=	O
45	O
)	O
were	O
allocated	O
randomly	O
to	O
either	O
a	O
negative	O
control	O
group	O
(	O
N	O
-	O
Control	O
,	O
n	O
=	O
9	O
)	O
with	O
only	O
sham	O
laparotomy	O
,	O
or	O
groups	O
(	O
n	O
=	O
9	O
each	O
)	O
for	O
induction	O
of	O
I	O
/	O
R	O
by	O
occlusion	O
of	O
superior	O
mesenteric	O
artery	O
,	O
followed	O
by	O
treatment	O
with	O
(	O
1	O
)	O
surfactant	O
at	O
100	O
mg	O
/	O
kg	O
(	O
Surf	O
),	O
(	O
2	O
)	O
iNO	O
at	O
20	O
ppm	O
(	O
NO	O
),	O
(	O
3	O
)	O
both	O
surfactant	O
and	O
iNO	O
(	O
SNO	B-FUNC
),	O
or	O
(	O
4	O
)	O
no	O
surfactant	O
no	O
iNO	O
(	O
a	O
positive	O
control	O
,	O
P	O
-	O
Control	O
).	O

After	O
120	O
minutes	O
of	O
treatment	O
,	O
the	O
SNO	B-FUNC
group	O
had	O
the	O
highest	O
PaO2	O
and	O
Cdyn	O
values	O
,	O
close	O
to	O
that	O
of	O
the	O
N	O
-	O
Control	O
group	O
.	O

The	O
lungs	O
of	O
the	O
SNO	B-FUNC
group	O
had	O
significantly	O
alleviated	O
edema	O
and	O
neutrophil	O
infiltration	O
compared	O
with	O
the	O
P	O
-	O
Control	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
testing	O
against	O
canine	O
coronavirus	O
by	O
immunoperoxidase	O
plaque	O
staining	O
.	O

The	O
IP	O
test	O
did	O
not	O
react	O
with	O
sera	B-FUNC
from	O
either	O
15	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
dogs	O
or	O
7	O
SPF	O
dogs	O
immunized	O
with	O
a	O
multivalent	O
vaccine	O
,	O
including	O
canine	O
parvovirus	O
type	O
2	O
,	O
canine	O
distemper	O
virus	O
,	O
canine	O
adenovirus	O
type	O
2	O
,	O
and	O
canine	O
parainfluenza	O
virus	O
.	O

To	O
compare	O
the	O
IP	O
test	O
with	O
the	O
neutralizing	O
test	O
(	O
NT	O
),	O
sera	B-FUNC
from	O
240	O
healthy	O
dogs	O
and	O
from	O
3	O
experimentally	O
CCV	O
-	O
infected	O
dogs	O
were	O
examined	O
.	O

All	O
60	O
sera	B-FUNC
positive	O
for	O
NT	O
antibody	B-FUNC
were	O
positive	O
for	O
IP	O
antibody	B-FUNC
,	O
and	O
all	O
180	O
sera	B-FUNC
negative	O
for	O
NT	O
antibody	B-FUNC
were	O
negative	O
for	O
IP	O
antibody	B-FUNC
in	O
the	O
healthy	O
dogs	O
.	O

2	O
.	O
1	O
%	O
of	O
48	O
sera	B-FUNC
and	O
20	O
.	O
3	O
%	O
of	O
74	O
sera	B-FUNC
,	O
which	O
were	O
all	O
negative	O
for	O
NT	O
antibody	B-FUNC
,	O
were	O
positive	O
for	O
IP	O
antibody	B-FUNC
in	O
the	O
dogs	O
of	O
under	O
one	O
year	O
of	O
age	O
and	O
at	O
least	O
one	O
year	O
of	O
age	O
,	O
respectively	O
.	O

TITLE	O
:	O
Murine	O
cytomegalovirus	O
is	O
regulated	O
by	O
a	O
discrete	O
subset	O
of	O
natural	O
killer	O
cells	O
reactive	O
with	O
monoclonal	O
antibody	B-FUNC
to	O
Ly49H	O
.	O

Each	O
virus	O
vigorously	O
induced	O
an	O
NK	O
cell	O
infiltrate	O
into	O
the	O
peritoneal	O
cavity	O
and	O
liver	O
,	O
causing	O
some	O
redistributions	O
of	O
NK	O
cell	O
subsets	O
defined	O
by	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
directed	O
against	O
Ly49A	O
,	O
C	O
/	O
I	O
,	O
D	O
,	O
and	O
G2	O
.	O

S	O
glycoprotein	O
binds	B-FUNC
to	O
specific	O
receptors	O
on	O
the	O
apical	O
membranes	O
of	O
enterocytes	O
,	O
and	O
can	O
undergo	O
a	O
temperature	O
-	O
dependent	O
,	O
receptor	O
-	O
mediated	O
conformational	O
change	O
that	O
leads	O
to	O
fusion	O
of	O
the	O
viral	O
envelope	O
with	O
host	O
membranes	O
to	O
initiate	O
infection	O
.	O

In	O
two	O
patients	O
,	O
antibody	B-FUNC
-	O
mediated	O
rejection	O
either	O
was	O
the	O
immediate	O
cause	O
of	O
death	O
(	O
hyperacute	O
rejection	O
,	O
one	O
patient	O
)	O
or	O
preceded	O
a	O
fatal	O
case	O
of	O
pneumonia	O
(	O
accelerated	O
antibody	B-FUNC
-	O
mediated	O
rejection	O
,	O
one	O
patient	O
).	O

In	O
experiment	O
2	O
,	O
2	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	O
containing	O
antibody	B-FUNC
titers	O
of	O
1	O
:	O
512	O
,	O
1	O
:	O
128	O
and	O
1	O
:	O
32	O
,	O
and	O
UCC	O
were	O
inoculated	O
with	O
PED	O
virus	O
,	O
and	O
survival	O
rates	O
after	O
challenge	O
were	O
100	O
,	O
75	O
,	O
50	O
and	O
0	O
%,	O
respectively	O
.	O

The	O
intergenic	O
sequence	O
is	O
the	O
presumed	O
crossover	O
region	O
(	O
fusion	O
site	O
)	O
for	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
during	O
discontinuous	O
transcription	O
,	O
a	O
process	O
leading	O
to	O
sgmRNAs	O
that	O
are	O
both	O
5	O
'	O
and	O
3	O
'	O
coterminal	O
.	O

We	O
learned	O
that	O
(	O
i	O
)	O
mutations	O
that	O
were	O
predicted	O
to	O
unfold	O
the	O
stem	O
-	O
loop	O
in	O
various	O
ways	O
did	O
not	O
switch	O
RdRp	B-FUNC
crossover	O
to	O
the	O
upstream	O
canonical	O
site	O
,	O
(	O
ii	O
)	O
a	O
totally	O
nonconforming	O
downstream	O
motif	O
resulted	O
in	O
no	O
measurable	O
transcription	O
from	O
either	O
site	O
,	O
(	O
iii	O
)	O
the	O
canonical	O
upstream	O
site	O
does	O
not	O
function	O
ectopically	O
to	O
lend	O
competence	O
to	O
the	O
downstream	O
noncanonical	O
site	O
,	O
and	O
(	O
iv	O
)	O
altering	O
flanking	O
sequences	O
downstream	O
of	O
the	O
downstream	O
noncanonical	O
motif	O
in	O
ways	O
that	O
diminish	O
sequence	O
similarity	O
with	O
the	O
virus	O
genome	O
5	O
'	O
end	O
caused	O
a	O
dramatic	O
switch	O
to	O
the	O
upstream	O
canonical	O
site	O
.	O

ABSTRACT	O
:	O
Western	O
blot	O
experiments	O
showed	O
that	O
sera	B-FUNC
from	O
mice	O
infected	O
with	O
the	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
contained	O
autoantibodies	O
(	O
autoAb	O
)	O
that	O
bound	O
to	O
a	O
40	O
-	O
kDa	O
protein	O
present	O
in	O
liver	O
and	O
kidney	O
extracts	O
.	O

TITLE	O
:	O
Shed	O
L	O
-	O
selectin	B-FUNC
(	O
sCD62L	O
)	O
load	O
in	O
trauma	O
patients	O
.	O

ABSTRACT	O
:	O
Low	O
circulating	O
plasma	O
concentrations	O
of	O
the	O
leukocyte	O
adhesion	O
molecule	O
L	O
-	O
selectin	B-FUNC
(	O
sCD62L	O
)	O
were	O
found	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
subsequent	O
lung	O
failure	O
and	O
case	O
fatality	O
after	O
severe	O
trauma	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
robustness	O
of	O
soluble	O
L	O
-	O
selectin	B-FUNC
,	O
correcting	O
for	O
a	O
broad	O
spectrum	O
of	O
physiological	O
variables	O
.	O

Plasma	O
samples	O
were	O
obtained	O
on	O
hospital	O
presentation	O
,	O
and	O
circulating	O
soluble	O
L	O
-	O
selectin	B-FUNC
was	O
measured	O
with	O
a	O
commercially	O
available	O
ELISA	O
kit	B-FUNC
.	O

L	O
-	O
Selectin	B-FUNC
levels	O
did	O
not	O
differ	O
between	O
survivors	O
and	O
nonsurvivors	O
.	O

Lower	O
L	O
-	O
selectin	B-FUNC
levels	O
indicated	O
patients	O
at	O
risk	O
for	O
lung	O
injury	O
with	O
a	O
relative	O
odds	O
estimated	O
at	O
4	O
.	O
43	O
(	O
P	O
=	O
0	O
.	O
017	O
).	O

The	O
results	O
of	O
this	O
study	O
highlight	O
the	O
independent	O
predictive	O
value	O
of	O
initially	O
decreased	O
soluble	O
L	O
-	O
selectin	B-FUNC
levels	O
for	O
the	O
identification	O
of	O
patients	O
susceptible	O
to	O
subsequent	O
respiratory	O
complications	O
after	O
severe	O
trauma	O
.	O

In	O
the	O
mouse	O
,	O
splice	O
variants	O
of	O
CEACAM1	O
have	O
either	O
two	O
or	O
four	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
domains	O
linked	O
through	O
a	O
transmembrane	O
domain	O
to	O
either	O
a	O
short	O
or	O
a	O
long	O
cytoplasmic	O
tail	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
either	O
virus	O
-	O
specific	O
CD4	O
(+)	O
or	O
CD8	O
(+)	O
T	O
cells	O
are	O
able	O
to	O
mediate	O
demyelination	O
and	O
also	O
that	O
the	O
antibody	B-FUNC
response	O
is	O
crucial	O
for	O
clearing	O
infectious	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
Fas	O
/	O
Fas	O
ligand	B-FUNC
(	O
FasL	O
)	O
system	O
has	O
been	O
implicated	O
in	O
alveolar	O
epithelial	O
cell	O
apoptosis	O
during	O
pulmonary	O
fibrosis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
specific	O
antibody	B-FUNC
titre	O
against	O
all	O
three	O
antigens	O
in	O
the	O
serum	O
of	O
the	O
vaccinated	O
animals	O
(	O
even	O
in	O
the	O
presence	O
of	O
pre	O
-	O
existing	O
antibody	B-FUNC
)	O
which	O
was	O
accompanied	O
by	O
increased	O
levels	O
of	O
protective	O
antibodies	O
to	O
rotavirus	O
,	O
coronavirus	O
and	O
E	O
coli	O
F5	O
(	O
K99	O
)	O
in	O
their	O
colostrum	O
and	O
milk	O
for	O
at	O
least	O
28	O
days	O
.	O

MHV	O
N	O
protein	O
binds	B-FUNC
to	O
all	O
MHV	O
mRNAs	O
,	O
whereas	O
envelope	O
M	O
protein	O
interacts	O
only	O
with	O
mRNA	O
1	O
.	O

ABSTRACT	O
:	O
Toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
is	O
a	O
rare	O
severe	O
acute	O
exfoliative	O
drug	O
-	O
induced	O
skin	O
disorder	O
which	O
has	O
recently	O
been	O
ascribed	O
to	O
alterations	O
in	O
the	O
control	O
of	O
keratinocyte	O
apoptosis	O
,	O
mediated	O
by	O
an	O
interaction	O
between	O
the	O
cell	O
surface	O
death	O
receptor	O
Fas	O
and	O
its	O
respective	O
ligand	B-FUNC
.	O

A	O
therapeutic	O
approach	O
with	O
intravenous	O
immunoglobulins	O
(	O
IVIG	O
)	O
associated	O
with	O
pulse	O
methylprednisolone	O
,	O
based	O
on	O
the	O
inhibition	O
of	O
Fas	O
-	O
mediated	O
keratinocyte	O
death	O
by	O
naturally	O
occurring	O
Fas	O
-	O
blocking	O
antibodies	O
included	O
in	O
human	O
immunoglobulin	B-FUNC
preparations	O
,	O
has	O
produced	O
good	O
preliminary	O
results	O
.	O

Three	O
new	O
potential	O
sequence	O
motifs	O
with	O
homology	O
to	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
polymerase	O
-	O
associated	O
nucleocapsid	O
phosphoprotein	O
of	O
rinderpest	O
virus	O
,	O
the	O
Bowman	O
-	O
Birk	O
type	O
of	O
proteinase	B-FUNC
inhibitors	O
,	O
and	O
the	O
metallothionein	O
superfamily	O
of	O
cysteine	O
rich	O
chelating	O
proteins	O
have	O
been	O
identified	O
.	O

Substitution	O
of	O
two	O
amino	O
acids	O
that	O
inserted	O
an	O
N	O
-	O
glycosylation	O
site	O
at	O
amino	O
acid	O
291	O
also	O
resulted	O
in	O
a	O
mutant	O
hAPN	O
that	O
lacked	O
receptor	B-FUNC
activity	I-FUNC
because	O
it	O
failed	O
to	O
bind	B-FUNC
HCoV	O
-	O
229E	O
.	O

Single	O
amino	O
acid	O
revertants	O
that	O
removed	O
this	O
sequon	O
at	O
amino	O
acids	O
291	O
to	O
293	O
but	O
had	O
one	O
or	O
five	O
pAPN	O
amino	O
acid	O
substitution	O
(	O
s	O
)	O
in	O
this	O
region	O
all	O
regained	O
HCoV	O
-	O
229E	O
binding	B-FUNC
and	O
receptor	O
activities	O
.	O

This	O
sequon	O
is	O
within	O
the	O
region	O
that	O
determines	O
receptor	B-FUNC
activity	I-FUNC
for	O
porcine	O
and	O
feline	O
coronaviruses	O
.	O

Mutant	O
hAPN	O
lacking	O
the	O
sequon	O
at	O
amino	O
acids	O
818	O
to	O
820	O
maintained	O
HCoV	O
-	O
229E	O
receptor	B-FUNC
activity	I-FUNC
but	O
did	O
not	O
gain	O
receptor	B-FUNC
activity	I-FUNC
for	O
porcine	O
or	O
feline	O
coronaviruses	O
.	O

Paired	O
serum	O
samples	O
obtained	O
were	O
tested	O
for	O
antibodies	O
to	O
BCV	O
,	O
using	O
antibody	B-FUNC
-	O
detection	O
ELISA	O
.	O

Following	O
MHV	O
infection	O
,	O
chemokines	O
including	O
CXC	O
chemokine	O
ligand	B-FUNC
(	O
CXCL	O
)	O
10	O
(	O
IFN	O
inducible	O
protein	O
10	O
kDa	O
),	O
CXCL9	O
(	O
monokine	O
induced	O
by	O
IFN	O
-	O
gamma	O
),	O
and	O
CC	O
chemokine	O
ligand	B-FUNC
5	O
(	O
RANTES	O
)	O
are	O
expressed	O
during	O
both	O
acute	O
and	O
chronic	O
stages	O
of	O
disease	O
suggesting	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
exacerbation	O
.	O

Treatment	O
with	O
anti	O
-	O
CXCL10	O
reduced	O
CD4	O
+	O
T	O
lymphocyte	O
and	O
macrophage	O
invasion	O
,	O
diminished	O
expression	O
of	O
IFN	O
-	O
gamma	O
and	O
CC	O
chemokine	O
ligand	B-FUNC
5	O
,	O
inhibited	O
progression	O
of	O
demyelination	O
,	O
and	O
increased	O
remyelination	O
.	O

TITLE	O
:	O
Infectious	O
bronchitis	O
serology	O
in	O
broilers	O
and	O
broiler	O
breeders	O
:	O
correlations	O
between	O
antibody	B-FUNC
titers	O
and	O
performance	O
in	O
vaccinated	O
flocks	O
.	O

The	O
antibody	B-FUNC
patterns	O
in	O
the	O
broiler	O
breeders	O
indicated	O
frequent	O
field	O
infections	O
breaking	O
through	O
vaccinal	O
immunity	O
.	O

Significant	O
correlations	O
measured	O
between	O
antibody	B-FUNC
titers	O
and	O
production	O
parameters	O
within	O
and	O
between	O
the	O
generations	O
strongly	O
suggested	O
negative	O
effects	O
of	O
IBV	O
infections	O
on	O
laying	O
percentage	O
in	O
the	O
breeders	O
and	O
on	O
mortality	O
and	O
daily	O
weight	O
gain	O
in	O
the	O
broilers	O
.	O

We	O
concluded	O
that	O
IBV	O
vaccination	O
strategies	O
should	O
aim	O
at	O
high	O
and	O
uniform	O
antibody	B-FUNC
titers	O
in	O
the	O
broiler	O
breeders	O
.	O

Following	O
a	O
1	O
month	O
rest	B-FUNC
,	O
untreated	O
and	O
inoculated	O
animals	O
were	O
again	O
tested	O
on	O
their	O
respective	O
air	O
versus	O
odor	O
discrimination	O
task	O
.	O

This	O
new	O
serotype	O
of	O
IBV	O
appears	O
to	O
be	O
evolving	O
very	O
fast	B-FUNC
compared	O
with	O
other	O
serotypes	O
of	O
IBV	O
.	O

Immunoglobulin	B-FUNC
G2a	O
was	O
predominant	O
among	O
these	O
antibodies	O
,	O
which	O
was	O
indicative	O
of	O
Th1	O
type	O
cell	O
activation	O
in	O
pcDNA	O
/	O
N	O
immunized	O
mice	O
.	O

In	O
addition	O
,	O
Ig	O
gradually	O
increased	O
from	O
7	O
to	O
21	O
d	O
PI	O
and	O
remained	O
at	O
80	O
immunofluroescent	O
antibody	B-FUNC
assay	O
(	O
IFA	O
)	O
titers	O
or	O
more	O
thereafter	O
.	O

In	O
Experiment	O
3	O
,	O
the	O
IgG	O
isotype	O
antibody	B-FUNC
response	O
to	O
TCV	O
was	O
markedly	O
increased	O
after	O
21	O
d	O
PI	O
and	O
remained	O
high	O
until	O
63	O
d	O
PI	O
.	O

The	O
IgA	O
isotype	O
antibody	B-FUNC
response	O
to	O
TCV	O
was	O
very	O
low	O
as	O
detected	O
at	O
7	O
(	O
0	O
.	O
13	O
),	O
14	O
(	O
0	O
.	O
20	O
),	O
and	O
21	O
(	O
0	O
.	O
17	O
)	O
d	O
PI	O
.	O

In	O
cells	O
infected	O
with	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
three	O
proteins	O
of	O
100	O
,	O
39	O
,	O
and	O
35	O
kDa	O
,	O
respectively	O
,	O
were	O
previously	O
identified	O
as	O
mature	O
cleavage	O
products	O
released	O
from	O
the	O
1b	O
region	O
of	O
the	O
1a	O
/	O
1b	O
polyprotein	O
by	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

TITLE	O
:	O
Antibody	B-FUNC
is	O
required	O
for	O
clearance	O
of	O
infectious	O
murine	O
hepatitis	O
virus	O
A59	O
from	O
the	O
central	O
nervous	O
system	O
,	O
but	O
not	O
the	O
liver	O
.	O

TITLE	O
:	O
Neutralisation	O
and	O
binding	B-FUNC
of	O
VHS	O
virus	O
by	O
monovalent	O
antibody	B-FUNC
fragments	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
the	O
cloning	O
and	O
characterisation	O
of	O
the	O
heavy	O
and	O
light	O
chain	O
variable	O
domain	O
genes	O
encoding	O
three	O
monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
that	O
bind	B-FUNC
viral	O
haemorrhagic	O
septicaemia	O
virus	O
(	O
VHSV	O
).	O

To	O
further	O
study	O
the	O
mechanism	O
of	O
neutralisation	O
,	O
Fab	O
fragments	O
as	O
well	O
as	O
a	O
series	O
of	O
recombinant	O
bacterial	O
single	O
chain	O
antibody	B-FUNC
(	O
scAb	O
)	O
fragments	O
were	O
generated	O
from	O
the	O
three	O
anti	O
-	O
VHSV	O
Mabs	O
and	O
their	O
variable	O
domain	O
genes	O
,	O
respectively	O
.	O

These	O
investigations	O
,	O
together	O
with	O
computer	O
assisted	O
molecular	O
analysis	O
of	O
the	O
theoretical	O
influence	O
of	O
each	O
mutation	O
on	O
antigen	B-FUNC
binding	I-FUNC
,	O
led	O
to	O
the	O
identification	O
of	O
a	O
single	O
mutation	O
at	O
position	O
35a	O
in	O
the	O
VH	O
domain	O
as	O
having	O
the	O
most	O
marked	O
impact	O
on	O
viral	O
neutralisation	O
.	O

In	O
the	O
subgroup	O
of	O
six	O
trials	O
where	O
a	O
high	O
volume	O
strategy	O
(	O
HVS	B-FUNC
)	O
was	O
used	O
for	O
HFOV	O
,	O
this	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
CLD	O
in	O
survivors	O
at	O
28	O
-	O
30	O
days	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
53	O
(	O
0	O
.	O
36	O
,	O
0	O
.	O
76	O
)],	O
of	O
'	O
death	O
or	O
CLD	O
at	O
28	O
-	O
30	O
days	O
'	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
56	O
(	O
0	O
.	O
40	O
,	O
0	O
.	O
77	O
)	O
and	O
oxygen	O
use	O
at	O
36	O
-	O
37	O
weeks	O
postmenstrual	O
age	O
or	O
discharge	O
[	O
five	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
72	O
(	O
0	O
.	O
56	O
,	O
0	O
.	O
93	O
)].	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
characterized	O
two	O
host	O
protein	B-FUNC
binding	I-FUNC
elements	O
located	O
within	O
the	O
3	O
'-	O
terminal	O
166	O
nucleotides	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
genome	O
and	O
assessed	O
their	O
functions	O
in	O
defective	O
-	O
interfering	O
(	O
DI	O
)	O
RNA	O
replication	O
.	O

To	O
determine	O
the	O
role	O
of	O
RNA	O
secondary	O
structures	O
within	O
these	O
two	O
host	O
protein	B-FUNC
binding	I-FUNC
elements	O
in	O
viral	O
replication	O
,	O
we	O
explored	O
the	O
secondary	O
structure	O
of	O
the	O
3	O
'-	O
terminal	O
166	O
nucleotides	O
of	O
the	O
MHV	O
strain	O
JHM	O
genome	O
using	O
limited	O
RNase	O
digestion	O
assays	O
.	O

Three	O
stem	O
structures	O
were	O
chosen	O
as	O
targets	O
for	O
the	O
introduction	O
of	O
transversion	O
mutations	O
designed	O
to	O
destroy	O
base	B-FUNC
pairing	I-FUNC
structures	O
.	O

Mutations	O
predicted	O
to	O
destroy	O
the	O
base	B-FUNC
pairing	I-FUNC
of	O
nucleotides	O
142	O
to	O
136	O
with	O
nucleotides	O
68	O
to	O
74	O
exhibited	O
a	O
deleterious	O
effect	O
on	O
DIssE	O
replication	O
.	O

The	O
upstream	O
side	O
of	O
this	O
conserved	O
stem	O
-	O
loop	O
is	O
contained	O
within	O
a	O
host	O
protein	B-FUNC
binding	I-FUNC
element	O
(	O
nucleotides	O
166	O
to	O
129	O
).	O

We	O
have	O
previously	O
demonstrated	O
significantly	O
raised	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
levels	O
in	O
the	O
lungs	O
of	O
at	O
-	O
risk	O
patients	O
that	O
progress	O
to	O
ARDS	O
,	O
and	O
identified	O
the	O
alveolar	O
macrophage	O
as	O
an	O
important	O
source	O
of	O
this	O
chemokine	O
.	O

We	O
wished	O
to	O
extend	O
this	O
study	O
in	O
a	O
well	O
-	O
defined	O
group	O
of	O
patients	O
with	O
major	O
trauma	O
,	O
and	O
to	O
investigate	O
potential	O
mechanisms	O
for	O
rapid	O
intrapulmonary	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
generation	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
other	O
proinflammatory	O
mediator	O
expression	O
was	O
measured	O
by	O
ELISA	O
,	O
northern	O
blotting	O
or	O
multi	O
-	O
probe	O
RNase	O
protection	O
assay	O
.	O

In	O
patients	O
with	O
major	O
trauma	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
that	O
progressed	O
to	O
ARDS	O
compared	O
to	O
those	O
that	O
did	O
not	O
(	O
n	O
=	O
56	O
,	O
P	O
=	O
0	O
.	O
0001	O
).	O

High	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
negatively	O
correlated	O
with	O
PaO2	O
/	O
FiO2	O
(	O
r	O
=	O
-	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
human	O
monocyte	O
derived	O
macrophages	O
hypoxia	O
rapidly	O
upregulated	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
protein	O
(	O
within	O
2	O
hours	O
)	O
and	O
mRNA	O
expression	O
(	O
within	O
30	O
mins	O
).	O

Acute	O
hypoxia	O
also	O
increased	O
rabbit	O
alveolar	O
macrophage	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
expression	O
.	O

Rapidly	O
raised	O
intrapulmonary	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
are	O
associated	O
with	O
ARDS	O
progression	O
in	O
patients	O
with	O
major	O
trauma	O
.	O

Acute	O
hypoxia	O
may	O
represent	O
one	O
of	O
potentially	O
several	O
proinflammatory	O
stimuli	O
responsible	O
for	O
rapid	O
intrapulmonary	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
generation	O
in	O
patients	O
at	O
-	O
risk	O
of	O
ARDS	O
.	O

Mean	O
systemic	O
arterial	O
pressure	O
,	O
mean	O
pulmonary	O
arterial	O
pressure	O
,	O
arterial	O
oxygen	O
tension	O
(	O
PO2	O
),	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
and	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	O
pressure	O
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
.	O

It	O
reduced	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
peripheral	O
neutropenia	O
and	O
increased	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

RESULTS	O
:	O
Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	O
pressure	O
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
.	O

It	O
reduced	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
peripheral	O
neutropenia	O
and	O
increased	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

Intestinal	O
contents	O
or	O
intestines	O
from	O
affected	O
turkey	O
poults	O
and	O
inoculated	O
turkey	O
embryos	O
contained	O
coronaviruses	O
as	O
revealed	O
by	O
electron	O
microscopy	O
or	O
were	O
positive	O
for	O
turkey	O
coronavirus	O
by	O
immunofluorescent	O
antibody	B-FUNC
assay	O
.	O

In	O
Experiment	O
2	O
,	O
treatment	O
differences	O
in	O
growth	O
responses	O
,	O
lymphoid	O
organ	O
development	O
,	O
and	O
primary	O
antibody	B-FUNC
titers	O
to	O
SRBC	O
did	O
not	O
occur	O
.	O

We	O
found	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
antibody	B-FUNC
production	O
in	O
response	O
to	O
attenuated	O
IBV	O
between	O
0	O
and	O
25	O
IU	O
/	O
kg	O
of	O
supplemented	O
VE	O
and	O
no	O
further	O
increase	O
at	O
higher	O
levels	O
.	O

Antibody	B-FUNC
levels	O
to	O
SRBC	O
were	O
higher	O
in	O
birds	O
supplemented	O
with	O
50	O
IU	O
of	O
VE	O
/	O
kg	O
compared	O
to	O
those	O
supplemented	O
with	O
0	O
or	O
200	O
IU	O
/	O
kg	O
of	O
VE	O
.	O

TITLE	O
:	O
Pulmonary	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
and	O
Flt	O
-	O
1	O
in	O
fetuses	O
,	O
in	O
acute	O
and	O
chronic	O
lung	O
disease	O
,	O
and	O
in	O
persistent	O
pulmonary	O
hypertension	O
of	O
the	O
newborn	O
.	O

TITLE	O
:	O
Nanostructured	O
materials	O
designed	O
for	O
cell	O
binding	B-FUNC
and	O
transduction	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
-	O
functionalization	O
of	O
shell	O
cross	O
-	O
linked	O
(	O
SCK	O
)	O
nanoparticles	O
with	O
the	O
oligomeric	O
peptide	O
sequence	O
YGRKKRRQRRR	O
,	O
the	O
protein	O
transduction	O
domain	O
(	O
PTD	B-FUNC
)	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
TAT	O
protein	O
,	O
is	O
described	O
,	O
and	O
the	O
cell	O
binding	B-FUNC
interactions	O
these	O
nanobioconjugates	O
exhibit	O
are	O
demonstrated	O
.	O

Finally	O
,	O
cleavage	O
from	O
the	O
solid	O
support	O
was	O
performed	O
,	O
which	O
also	O
facilitated	O
deprotection	O
of	O
the	O
peptide	O
side	O
chain	O
functionalities	O
as	O
well	O
as	O
hydrolysis	O
of	O
the	O
poly	O
(	O
epsilon	O
-	O
caprolactone	O
)	O
segments	O
composing	O
the	O
SCK	O
core	O
domain	O
,	O
to	O
yield	O
PTD	B-FUNC
-	O
derivatized	O
nanocage	O
structures	O
(	O
PTD	B-FUNC
-	O
nanocage	O
).	O

The	O
fluorescent	O
PTD	B-FUNC
-	O
nanocage	O
bioconjugates	O
were	O
found	O
to	O
interact	O
with	O
CHO	B-FUNC
cells	O
and	O
HeLa	O
cells	O
,	O
whereas	O
the	O
analogous	O
structure	O
lacking	O
the	O
PTD	B-FUNC
component	O
did	O
not	O
.	O

TITLE	O
:	O
Adverse	O
effects	O
of	O
feline	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
during	O
DNA	O
vaccination	O
against	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

Again	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
did	O
not	O
meet	O
expectations	O
-	O
on	O
the	O
contrary	O
,	O
it	O
enhanced	O
susceptibility	O
to	O
FIPV	O
challenge	O
.	O

We	O
investigated	O
whether	O
methylprednisolone	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
could	O
inhibit	O
increase	O
of	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
activity	O
in	O
the	O
lung	O
and	O
lead	O
to	O
protection	O
against	O
a	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
rabbits	O
.	O

for	O
2	O
h	O
)	O
provoked	O
pulmonary	O
hemorrhage	O
and	O
edema	O
,	O
protein	O
leakage	O
and	O
massive	O
neutrophil	O
infiltration	O
,	O
resulted	O
in	O
severe	O
hypoxemia	O
and	O
impaired	O
lung	O
compliance	O
,	O
accompanying	O
the	O
increase	O
of	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
activity	O
and	O
interleukin	O
-	O
8	O
,	O
and	O
degradation	O
of	O
surfactant	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

for	O
6	O
h	O
)	O
did	O
not	O
improve	O
the	O
above	O
described	O
lung	O
injury	O
induced	O
by	O
oleic	O
acid	O
,	O
nor	O
did	O
it	O
suppress	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
activity	O
and	O
degradation	O
of	O
surfactant	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
while	O
it	O
strongly	O
reduced	O
interleukin	O
-	O
8	O
levels	O
in	O
both	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

We	O
conclude	O
that	O
methylprednisolone	O
did	O
not	O
attenuate	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
this	O
can	O
be	O
explained	O
partly	O
by	O
its	O
failure	O
to	O
reduce	O
the	O
increase	O
of	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
activity	O
and	O
the	O
surfactant	O
degradation	O
in	O
the	O
lung	O
,	O
which	O
might	O
also	O
account	O
for	O
its	O
clinical	O
ineffectiveness	O
against	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Four	O
hundred	O
twenty	O
-	O
five	O
sera	B-FUNC
were	O
tested	O
for	O
evidence	O
of	O
exposure	O
to	O
canine	O
coronavirus	O
by	O
means	O
of	O
an	O
indirect	O
fluorescent	O
antibody	B-FUNC
procedure	O
.	O

Stool	O
and	O
serum	O
samples	O
were	O
analysed	O
for	O
RV	O
and	O
bovine	O
CV	O
antigen	O
and	O
antibody	B-FUNC
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

We	O
determined	O
the	O
influence	O
of	O
trauma	O
severity	O
for	O
endothelium	O
activation	O
/	O
injury	O
by	O
measurement	O
of	O
specific	O
endothelial	O
cell	O
markers	O
--	O
soluble	O
E	O
-	O
selectin	B-FUNC
(	O
sES	O
)	O
and	O
von	O
Willebrand	O
factor	O
antigen	O
(	O
vWF	O
:	O
Ag	O
).	O

Plasma	O
vWF	O
:	O
Ag	O
concentration	O
seems	O
to	O
be	O
an	O
important	O
,	O
early	O
marker	O
of	O
trauma	O
severity	O
,	O
while	O
serum	O
sE	O
-	O
selectin	B-FUNC
level	O
may	O
serve	O
as	O
prognostic	O
factor	O
in	O
immediate	O
postinjury	O
period	O
course	O
.	O

These	O
effects	O
were	O
dependent	O
on	O
the	O
concentration	O
of	O
soMHVR	O
in	O
the	O
culture	O
and	O
were	O
specifically	O
blocked	O
by	O
the	O
anti	O
-	O
MHVR	O
monoclonal	O
antibody	B-FUNC
CC1	O
.	O

These	O
results	O
indicated	O
that	O
the	O
binding	B-FUNC
of	O
soMHVR	O
to	O
the	O
S	O
protein	O
expressed	O
on	O
the	O
DBT	O
cell	O
surface	O
potentiates	O
the	O
fusion	O
of	O
MHV	O
-	O
infected	O
DBT	O
cells	O
with	O
nonpermissive	O
BHK	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
binding	B-FUNC
of	O
soMHVR	O
to	O
the	O
S	O
protein	O
converts	O
the	O
S	O
protein	O
to	O
a	O
fusion	O
-	O
active	O
form	O
competent	O
to	O
mediate	O
cell	O
-	O
cell	O
fusion	O
,	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
fusion	O
of	O
virus	O
and	O
cell	O
membranes	O
.	O

The	O
relevant	O
sequences	O
contributing	O
to	O
TRS	B-FUNC
activity	O
have	O
been	O
studied	O
by	O
extending	O
the	O
CS	O
5	O
'	O
upstream	O
and	O
3	O
'	O
downstream	O
.	O

An	O
optimized	O
TRS	B-FUNC
has	O
been	O
designed	O
comprising	O
88	O
nt	O
from	O
the	O
N	O
gene	O
TRS	B-FUNC
,	O
the	O
CS	O
,	O
and	O
3	O
nt	O
3	O
'	O
to	O
the	O
M	O
gene	O
CS	O
.	O

The	O
expression	O
of	O
a	O
reporter	O
gene	O
(	O
beta	O
-	O
glucuronidase	O
)	O
by	O
using	O
the	O
selected	O
TRS	B-FUNC
led	O
to	O
the	O
production	O
of	O
2	O
to	O
8	O
microg	O
of	O
protein	O
per	O
10	O
(	O
6	O
)	O
cells	O
.	O

Replicon	O
constructs	O
were	O
constructed	O
that	O
lacked	O
either	O
the	O
ORF	O
3B	O
and	O
E	O
genes	O
or	O
the	O
ORF	O
3B	O
,	O
E	O
,	O
and	O
M	O
genes	O
[	O
TGEV	O
-	O
Rep	B-FUNC
(	O
AvrII	O
)	O
and	O
TGEV	O
-	O
Rep	B-FUNC
(	O
EcoNI	O
),	O
respectively	O
].	O

A	O
one	O
-	O
step	O
reverse	O
transcription	O
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
targeting	O
a	O
730	O
-	O
base	B-FUNC
pair	I-FUNC
fragment	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
BCV	O
and	O
a	O
nested	O
PCR	O
targeting	O
a	O
407	O
-	O
base	B-FUNC
pair	I-FUNC
fragment	O
of	O
the	O
N	O
gene	O
were	O
used	O
in	O
an	O
attempt	O
to	O
detect	O
TOCV	O
from	O
North	O
Carolina	O
,	O
Indiana	O
,	O
and	O
a	O
prototype	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
.	O

These	O
primers	O
amplified	O
a	O
1082	O
-	O
base	B-FUNC
pair	I-FUNC
region	O
spanning	O
portions	O
of	O
the	O
membrane	O
glycoprotein	O
(	O
M	O
)	O
and	O
N	O
protein	O
genes	O
of	O
IBV	O
and	O
TCV	O
.	O

All	O
flocks	O
were	O
tested	O
for	O
TCV	O
by	O
an	O
indirect	O
fluorescent	O
antibody	B-FUNC
assay	O
.	O

The	O
esterases	B-FUNC
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strains	O
S	O
and	O
JHM	O
and	O
puffinosis	O
virus	O
(	O
PV	O
)	O
specifically	O
hydrolysed	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
4	O
-	O
O	O
-	O
acetylneuraminic	O
acid	O
(	O
Neu4	O
,	O
5Ac2	O
)	O
as	O
well	O
as	O
the	O
synthetic	O
substrates	O
p	O
-	O
nitrophenyl	O
acetate	O
,	O
4	O
-	O
methylumbelliferyl	O
acetate	O
and	O
fluorescein	O
diacetate	O
.	O

The	O
K	O
(	O
m	O
)	O
values	O
of	O
the	O
MHV	O
-	O
like	O
esterases	B-FUNC
for	O
the	O
latter	O
substrates	O
were	O
two	O
-	O
to	O
tenfold	O
lower	O
than	O
those	O
of	O
the	O
sialate	O
-	O
9	O
-	O
O	O
-	O
acetylesterases	O
of	O
influenza	O
C	O
viruses	O
.	O

De	O
-	O
O	O
-	O
acetylation	O
of	O
the	O
glycoproteins	O
by	O
alkaline	O
treatment	O
or	O
incubation	O
with	O
the	O
viral	O
esterases	B-FUNC
resulted	O
in	O
a	O
complete	O
loss	O
of	O
recognition	O
,	O
indicating	O
a	O
specific	O
interaction	O
of	O
MHV	O
-	O
like	O
coronaviruses	O
with	O
Neu4	O
,	O
5Ac2	O
.	O

At	O
6	O
h	O
post	O
-	O
inoculation	O
(	O
hpi	B-FUNC
),	O
the	O
mean	O
score	O
of	O
the	O
villous	O
height	O
/	O
crypt	O
depth	O
(	O
VH	O
/	O
CD	O
)	O
ratio	O
of	O
pigs	O
inoculated	O
with	O
the	O
Purdue	O
or	O
Miller	O
strain	O
was	O
significantly	O
less	O
than	O
that	O
of	O
pigs	O
inoculated	O
with	O
the	O
Korean	O
strain	O
or	O
uninfected	O
control	O
pigs	O
.	O

In	O
-	O
situ	O
hybridization	O
showed	O
significant	O
differences	O
between	O
the	O
Korean	O
and	O
American	O
strains	O
in	O
terms	O
of	O
the	O
amount	O
of	O
TGEV	O
nucleic	O
acid	O
at	O
6	O
,	O
12	O
and	O
60	O
hpi	B-FUNC
.	O

Because	O
anti	O
-	O
JO1	O
antibody	B-FUNC
is	O
considered	O
to	O
be	O
a	O
marker	O
of	O
interstitial	O
lung	O
disease	O
in	O
polymyositis	O
/	O
dermatomyositis	O
,	O
close	O
pulmonary	O
follow	O
-	O
up	O
of	O
anti	O
-	O
JO1	O
-	O
positive	O
patients	O
with	O
polymyositis	O
is	O
therefore	O
required	O
for	O
early	O
detection	O
of	O
subclinical	O
impairment	O
.	O

TITLE	O
:	O
Isotype	O
-	O
specific	O
antibody	B-FUNC
-	O
secreting	O
cells	O
in	O
systemic	O
and	O
mucosal	O
associated	O
lymphoid	O
tissues	O
and	O
antibody	B-FUNC
responses	O
in	O
serum	O
of	O
conventional	O
pigs	O
inoculated	O
with	O
PEDV	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
)	O
has	O
been	O
developed	O
to	O
detect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)-	O
specific	O
antibody	B-FUNC
secreting	O
cells	O
(	O
ASC	O
)	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
(	O
duodenum	O
and	O
ileum	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
)	O
and	O
systemic	O
locations	O
(	O
spleen	O
and	O
blood	O
)	O
of	O
conventional	O
pigs	O
so	O
as	O
to	O
characterise	O
the	O
mucosal	O
and	O
systemic	O
antibody	B-FUNC
response	O
generated	O
by	O
the	O
infection	O
with	O
PEDV	O
.	O

Memory	O
antibody	B-FUNC
response	O
to	O
the	O
PEDV	O
was	O
also	O
studied	O
by	O
secondary	O
in	O
vitro	O
stimulation	O
of	O
the	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
isolated	O
from	O
mesenteric	O
lymph	O
nodes	O
,	O
spleen	O
and	O
blood	O
.	O

Mp	O
-	O
associated	O
HPS	O
was	O
diagnosed	O
in	O
this	O
case	O
by	O
clinical	O
and	O
laboratory	O
findings	O
,	O
including	O
a	O
bone	O
marrow	O
aspiration	O
specimen	O
and	O
serum	O
Mp	O
antibody	B-FUNC
titer	O
.	O

Treatment	O
with	O
CY	O
mainly	O
induced	O
B	O
cell	O
deficiency	O
as	O
indicated	O
by	O
significant	O
reductions	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
antibody	B-FUNC
responses	O
to	O
sheep	O
erythrocytes	O
7	O
days	O
after	O
injection	O
.	O

Turkeys	O
treated	O
with	O
CY	O
had	O
1	O
-	O
2	O
fold	O
higher	O
immunofluorescent	O
antibody	B-FUNC
assay	O
(	O
IFA	O
)	O
scores	O
for	O
TCV	O
antigens	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
intestine	O
than	O
untreated	O
turkeys	O
at	O
9	O
or	O
14	O
days	O
PI	O
.	O

TITLE	O
:	O
Regulation	O
of	O
pulmonary	O
and	O
hepatic	O
cytochrome	B-FUNC
P4501A	O
expression	O
in	O
the	O
rat	O
by	O
hyperoxia	O
:	O
implications	O
for	O
hyperoxic	O
lung	O
injury	O
.	O

Cytochrome	B-FUNC
P4501A	O
enzymes	O
have	O
been	O
implicated	O
in	O
hyperoxic	O
lung	O
injury	O
.	O

Thus	O
,	O
to	O
develop	O
and	O
express	O
protein	O
fragment	O
from	O
S	O
gene	O
and	O
to	O
use	O
the	O
protein	O
as	O
a	O
coating	O
antigen	O
for	O
antibody	B-FUNC
detection	O
against	O
IBV	O
are	O
the	O
purposes	O
of	O
this	O
experiment	O
.	O

The	O
expressed	O
S	O
-	O
fg	O
protein	O
was	O
used	O
as	O
a	O
coating	O
antigen	O
for	O
developing	O
an	O
ELISA	O
(	O
S	O
-	O
fg	O
ELISA	O
)	O
for	O
serum	O
antibody	B-FUNC
detection	O
in	O
anti	O
-	O
IBV	O
antisera	O
from	O
different	O
IBV	O
serotypes	O
and	O
in	O
field	O
sera	B-FUNC
.	O

The	O
results	O
show	O
that	O
the	O
S	O
-	O
fg	O
fusion	O
protein	O
is	O
highly	O
cross	O
-	O
reactive	O
among	O
different	O
IBV	O
serotypes	O
,	O
and	O
the	O
S	O
-	O
fg	O
ELISA	O
is	O
found	O
to	O
be	O
a	O
convenient	O
,	O
economical	O
,	O
and	O
efficient	O
method	O
for	O
antibody	B-FUNC
detection	O
against	O
IBV	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
an	O
intraperitoneal	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
persists	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)-	O
deficient	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
and	O
results	O
in	O
subacute	O
fatal	O
peritonitis	O
,	O
which	O
bears	O
a	O
resemblance	O
to	O
feline	O
infectious	O
peritonitis	O
.	O

The	O
serum	O
alanine	B-FUNC
aminotransferase	I-FUNC
activity	I-FUNC
of	O
infected	O
BALB	O
-	O
GKO	O
mice	O
were	O
higher	O
than	O
that	O
of	O
B6	O
-	O
GKO	O
mice	O
and	O
was	O
paralleled	O
with	O
the	O
severity	O
of	O
the	O
pathological	O
changes	O
and	O
viral	O
titers	O
in	O
infected	O
mice	O
.	O

TITLE	O
:	O
Mucosal	O
and	O
systemic	O
isotype	O
-	O
specific	O
antibody	B-FUNC
responses	O
and	O
protection	O
in	O
conventional	O
pigs	O
exposed	O
to	O
virulent	O
or	O
attenuated	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

Isotype	O
-	O
specific	O
antibody	B-FUNC
responses	O
in	O
serum	O
were	O
investigated	O
by	O
ELISA	O
.	O

The	O
ASC	O
and	O
serum	O
antibody	B-FUNC
responses	O
after	O
the	O
challenge	O
corresponded	O
to	O
a	O
secondary	O
immune	O
response	O
in	O
the	O
groups	O
inoculated	O
with	O
attenuated	O
virus	O
,	O
whereas	O
a	O
primary	O
response	O
was	O
evident	O
in	O
the	O
control	O
group	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
association	O
between	O
antibody	B-FUNC
(	O
Ab	O
)	O
production	O
and	O
disease	O
resistance	O
.	O

Antibody	B-FUNC
titer	O
to	O
IBV	O
,	O
delayed	O
-	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
response	O
against	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
),	O
the	O
absolute	O
number	O
and	O
percentage	O
of	O
leukocyte	O
subpopulations	O
,	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)-	O
like	O
cytokine	O
production	O
by	O
splenocytes	O
were	O
evaluated	O
at	O
5	O
-	O
6	O
weeks	O
of	O
age	O
.	O

While	O
antibody	B-FUNC
response	O
to	O
IBV	O
in	O
juvenile	O
chicks	O
was	O
unaffected	O
by	O
the	O
in	O
ovo	O
lead	O
exposure	O
,	O
IFN	O
-	O
gamma	O
-	O
like	O
cytokine	O
production	O
by	O
splenocytes	O
was	O
significantly	O
depressed	O
following	O
lead	O
exposure	O
at	O
both	O
developmental	O
stages	O
.	O

TITLE	O
:	O
Recruitment	O
kinetics	O
and	O
composition	O
of	O
antibody	B-FUNC
-	O
secreting	O
cells	O
within	O
the	O
central	O
nervous	O
system	O
following	O
viral	O
encephalomyelitis	O
.	O

Molecular	O
masses	O
of	O
the	O
IgE	O
-	O
binding	B-FUNC
proteins	O
and	O
cross	O
-	O
reactivity	O
among	O
the	O
P	O
.	O
acerifolia	O
pollen	O
and	O
different	O
food	O
extracts	O
were	O
also	O
determined	O
.	O

Once	O
on	O
the	O
surface	O
of	O
infected	O
cells	O
and	O
virions	O
,	O
peripheral	O
S1	O
fragments	O
bind	B-FUNC
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
(	O
CEACAM	O
)	O
receptors	O
,	O
and	O
this	O
triggers	O
membrane	O
fusion	O
reactions	O
mediated	O
by	O
integral	O
membrane	O
S2	O
fragments	O
.	O

We	O
discovered	O
that	O
soluble	O
S1	O
fragments	O
were	O
dimers	O
and	O
that	O
CEACAM	O
binding	B-FUNC
was	O
entirely	O
dependent	O
on	O
this	O
quaternary	O
structure	O
.	O

However	O
,	O
two	O
differentially	O
tagged	O
CEACAMs	O
could	O
not	O
co	O
-	O
precipitate	O
with	O
the	O
S	O
dimers	O
,	O
suggesting	O
that	O
binding	B-FUNC
sites	O
were	O
closely	O
juxtaposed	O
in	O
the	O
dimer	O
(	O
steric	O
hindrance	O
)	O
or	O
that	O
a	O
single	O
CEACAM	O
generated	O
global	O
conformational	O
changes	O
that	O
precluded	O
additional	O
interactions	O
(	O
negative	O
cooperativity	O
).	O

CEACAM	O
binding	B-FUNC
did	O
indeed	O
alter	O
S1	O
conformations	O
,	O
generating	O
alternative	O
disulfide	O
linkages	O
that	O
were	O
revealed	O
on	O
SDS	O
gels	O
.	O

iNO	O
had	O
no	O
adverse	O
effects	O
on	O
surfactant	O
phospholipids	O
and	O
lung	O
fluid	O
balance	O
,	O
but	O
attenuated	O
expression	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
beta2	O
integrin	O
CD11b	O
,	O
and	O
interleukin	O
-	O
8	O
mRNA	O
in	O
the	O
lungs	O
by	O
22	O
%,	O
44	O
%,	O
and	O
25	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

iNO	O
had	O
no	O
adverse	O
effects	O
on	O
surfactant	O
phospholipids	O
and	O
lung	O
fluid	O
balance	O
,	O
but	O
attenuated	O
expression	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
beta2	O
integrin	O
CD11b	O
,	O
and	O
interleukin	O
-	O
8	O
mRNA	O
in	O
the	O
lungs	O
by	O
22	O
%,	O
44	O
%,	O
and	O
25	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
MHV	O
was	O
not	O
detected	O
at	O
diagnostic	O
laboratories	O
by	O
use	O
of	O
viral	O
isolation	O
or	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
of	O
tissues	O
from	O
MHV	O
-	O
seropositive	O
animals	O
.	O

Liver	O
Dialysis	O
employs	O
hemodiabsorption	O
(	O
dialysis	O
of	O
blood	O
against	O
powdered	O
sorbents	O
including	O
charcoal	O
and	O
cation	O
exchanger	B-FUNC
)	O
to	O
remove	O
selectively	O
numerous	O
small	O
-	O
molecular	O
-	O
weight	O
toxins	O
of	O
hepatic	O
failure	O
.	O

Sorbent	O
columns	O
of	O
charcoal	O
and	O
an	O
anion	O
exchanger	B-FUNC
remove	O
hepatic	O
toxins	O
from	O
the	O
albumin	O
dialysate	O
,	O
and	O
a	O
second	O
dialyzer	O
removes	O
water	O
-	O
soluble	O
toxins	O
,	O
such	O
as	O
ammonium	O
.	O

2	O
.	O
ExPLIs	O
markedly	O
inhibited	O
LPS	O
and	O
LTA	O
induced	O
production	O
and	O
mRNA	O
expression	O
of	O
the	O
neutrophile	O
attracting	O
chemokines	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
Gro	O
-	O
alpha	O
and	O
ENA	O
-	O
78	O
,	O
as	O
well	O
as	O
of	O
the	O
adhesion	O
molecules	O
ICAM	O
-	O
1	O
and	O
E	O
-	O
selectin	B-FUNC
.	O

Concomitantly	O
,	O
ExPLIs	O
inhibited	O
the	O
LPS	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	O
but	O
not	O
its	O
activation	O
by	O
TNF	O
-	O
alpha	O
or	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
.	O

TITLE	O
:	O
Field	O
validation	O
of	O
a	O
commercial	O
blocking	O
ELISA	O
to	O
differentiate	O
antibody	B-FUNC
to	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
respiratory	O
coronavirus	O
and	O
to	O
identify	O
TGEV	O
-	O
infected	O
swine	O
herds	O
.	O

Nine	O
sera	B-FUNC
from	O
uninfected	O
pigs	O
,	O
34	O
sera	B-FUNC
from	O
16	O
pigs	O
experimentally	O
infected	O
with	O
TGEV	O
,	O
and	O
sera	B-FUNC
from	O
10	O
pigs	O
experimentally	O
infected	O
with	O
PRCV	O
were	O
evaluated	O
using	O
both	O
the	O
TGEV	O
/	O
PRCV	O
blocking	O
ELISA	O
and	O
a	O
virus	O
neutralization	O
(	O
VN	O
)	O
assay	O
.	O

Sera	B-FUNC
from	O
100	O
commercial	O
swine	O
herds	O
(	O
1	O
,	O
783	O
sera	B-FUNC
;	O
median	O
15	O
per	O
herd	O
)	O
were	O
similarly	O
evaluated	O
using	O
both	O
tests	O
.	O

When	O
sera	B-FUNC
from	O
specific	O
age	O
groups	O
were	O
compared	O
,	O
the	O
ELISA	O
identified	O
a	O
greater	O
proportion	O
(	O
0	O
.	O
83	O
)	O
of	O
pigs	O
in	O
herds	O
with	O
TGEV	O
antibody	B-FUNC
when	O
suckling	O
piglets	O
were	O
used	O
.	O

In	O
repeatability	O
experiments	O
,	O
the	O
ELISA	O
gave	O
consistent	O
results	O
when	O
the	O
same	O
sera	B-FUNC
were	O
evaluated	O
on	O
different	O
days	O
(	O
kappa	O
0	O
.	O
889	O
)	O
and	O
when	O
sera	B-FUNC
were	O
evaluated	O
before	O
and	O
after	O
heating	O
(	O
kappa	O
0	O
.	O
888	O
).	O

Its	O
N	O
-	O
terminal	O
domain	O
has	O
a	O
uniquely	O
folded	O
CC	O
'	O
loop	O
that	O
encompasses	O
key	O
virus	O
-	O
binding	B-FUNC
residues	O
.	O

We	O
discuss	O
the	O
structural	O
basis	O
of	O
virus	O
receptor	O
activities	O
of	O
murine	O
CEACAM1	O
proteins	O
,	O
binding	B-FUNC
of	O
Neisseria	O
to	O
human	O
CEACAM1	O
,	O
and	O
other	O
homophilic	O
and	O
heterophilic	O
interactions	O
of	O
CEA	O
family	O
members	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
was	O
positive	O
for	O
a	O
respiratory	O
virus	O
in	O
56	O
(	O
65	O
%)	O
of	O
the	O
86	O
illnesses	O
.	O

The	O
infant	O
was	O
diagnosed	O
with	O
congenital	O
Guillain	O
-	O
Barr	O
syndrome	O
,	O
was	O
treated	O
with	O
intravenous	O
immunoglobulin	B-FUNC
and	O
showed	O
clinical	O
improvement	O
within	O
48	O
hours	O
of	O
treatment	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
experimental	O
virus	O
infection	O
may	O
induce	O
host	O
responses	O
that	O
provoke	O
enhanced	O
immunoglobulin	B-FUNC
E	O
(	O
IgE	O
)	O
synthesis	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
replication	O
-	O
induced	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
promotes	O
interleukin	O
-	O
6	O
production	O
and	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O

ABSTRACT	O
:	O
Analyses	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
in	O
a	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
infected	O
macrophage	O
-	O
derived	O
J774	O
.	O
1	O
cell	O
line	O
showed	O
activation	O
of	O
two	O
MAPKs	O
,	O
p38	B-FUNC
MAPK	B-FUNC
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
),	O
but	O
not	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
).	O

Several	O
other	O
MHV	O
-	O
permissive	O
cell	O
lines	O
also	O
showed	O
activation	O
of	O
both	O
p38	B-FUNC
MAPK	B-FUNC
and	O
JNK	B-FUNC
,	O
which	O
indicated	O
that	O
the	O
MHV	O
-	O
induced	O
stress	O
-	O
kinase	O
activation	O
was	O
not	O
restricted	O
to	O
any	O
particular	O
cell	O
type	O
.	O

The	O
upstream	O
kinase	O
responsible	O
for	O
activating	O
MHV	O
-	O
induced	O
p38	B-FUNC
MAPK	B-FUNC
was	O
the	O
MAPK	B-FUNC
kinase	O
3	O
.	O

Furthermore	O
,	O
MHV	O
production	O
was	O
suppressed	O
in	O
SB	O
203580	O
-	O
treated	O
cells	O
,	O
demonstrating	O
that	O
activated	O
p38	B-FUNC
MAPK	B-FUNC
played	O
a	O
role	O
in	O
MHV	O
replication	O
.	O

Interestingly	O
,	O
there	O
was	O
a	O
transient	O
increase	O
in	O
the	O
amount	O
of	O
phosphorylation	O
of	O
the	O
translation	O
initiation	O
factor	O
4E	O
(	O
eIF4E	O
)	O
in	O
infected	O
cells	O
,	O
and	O
this	O
eIF4E	O
phosphorylation	O
was	O
p38	B-FUNC
MAPK	B-FUNC
dependent	O
;	O
it	O
is	O
known	O
that	O
phosphorylated	O
eIF4E	O
enhances	O
translation	O
rates	O
of	O
cap	O
-	O
containing	O
mRNAs	O
.	O

MHV	O
utilized	O
this	O
p38	B-FUNC
MAPK	B-FUNC
-	O
dependent	O
increase	O
in	O
eIF4E	O
phosphorylation	O
to	O
promote	O
virus	O
-	O
specific	O
protein	O
synthesis	O
and	O
subsequent	O
progeny	O
virus	O
production	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
to	O
cell	O
surface	O
sialoglycoproteins	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
glycoprotein	O
S	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
has	O
two	O
binding	B-FUNC
activities	O
.	O

(	O
i	O
)	O
Binding	B-FUNC
to	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
is	O
essential	O
for	O
the	O
initiation	O
of	O
infection	O
.	O

(	O
ii	O
)	O
Binding	B-FUNC
to	O
sialic	O
acid	O
residues	O
on	O
glycoproteins	O
is	O
dispensable	O
for	O
the	O
infection	O
of	O
cultured	O
cells	O
but	O
is	O
required	O
for	O
enteropathogenicity	O
.	O

By	O
comparing	O
parental	O
TGEV	O
with	O
mutant	O
viruses	O
deficient	O
in	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
,	O
we	O
determined	O
the	O
contributions	O
of	O
both	O
binding	B-FUNC
activities	O
to	O
the	O
attachment	O
of	O
TGEV	O
to	O
cultured	O
cells	O
.	O

In	O
the	O
presence	O
of	O
a	O
functional	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
,	O
the	O
amount	O
of	O
virus	O
bound	O
to	O
two	O
different	O
porcine	O
cell	O
lines	O
was	O
increased	O
sixfold	O
compared	O
to	O
the	O
binding	B-FUNC
of	O
the	O
mutant	O
viruses	O
.	O

On	O
the	O
other	O
hand	O
,	O
binding	B-FUNC
to	O
the	O
sialic	O
acid	O
residues	O
of	O
the	O
high	O
-	O
molecular	O
-	O
mass	O
glycoprotein	O
was	O
observed	O
regardless	O
of	O
whether	O
the	O
cellular	O
proteins	O
had	O
been	O
separated	O
under	O
reducing	O
or	O
nonreducing	O
conditions	O
.	O

We	O
propose	O
that	O
binding	B-FUNC
to	O
a	O
surface	O
sialoglycoprotein	O
is	O
required	O
for	O
TGEV	O
as	O
a	O
primary	O
attachment	O
site	O
to	O
initiate	O
infection	O
of	O
intestinal	O
cells	O
.	O

Furthermore	O
,	O
increased	O
accumulation	O
of	O
the	O
16	O
-	O
kDa	O
protein	O
upon	O
stimulation	O
with	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
was	O
observed	O
,	O
providing	O
preliminary	O
evidence	O
that	O
the	O
protein	O
might	O
be	O
involved	O
in	O
the	O
growth	O
factor	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
Abdominal	O
Compartment	O
Syndrome	O
(	O
ACS	B-FUNC
)	O
has	O
multiple	O
causes	O
,	O
and	O
decompressive	O
laparotomy	O
has	O
been	O
the	O
most	O
frequent	O
modality	O
to	O
prevent	O
worsening	O
cardiovascular	O
,	O
respiratory	O
,	O
and	O
renal	O
function	O
.	O

Nine	O
of	O
13	O
(	O
69	O
%)	O
study	O
patients	O
developed	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
that	O
progressed	O
to	O
abdominal	O
compartment	O
syndrome	O
in	O
4	O
(	O
31	O
%).	O

Five	O
patients	O
underwent	O
PD	O
successfully	O
,	O
and	O
their	O
IAH	B-FUNC
did	O
not	O
progress	O
to	O
ACS	B-FUNC
.	O

A	O
breed	O
x	O
time	O
interaction	O
existed	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
for	O
plasma	O
prolactin	B-FUNC
,	O
LH	O
,	O
insulin	O
,	O
glucagon	O
,	O
cortisol	O
,	O
triiodothyronine	O
and	O
glucose	O
concentrations	O
.	O

The	O
breed	O
x	O
time	O
interaction	O
tended	O
to	O
affect	O
(	O
p	O
=	O
0	O
.	O
14	O
)	O
growth	B-FUNC
hormone	I-FUNC
and	O
influenced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
respiration	O
rates	O
.	O

Ergotamine	O
reduced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
plasma	O
LH	O
and	O
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
growth	B-FUNC
hormone	I-FUNC
concentrations	O
in	O
Brahman	O
.	O

This	O
result	O
strengthens	O
a	O
functional	O
role	O
for	O
the	O
N	O
-	O
terminal	O
domain	O
in	O
recombination	O
in	O
addition	O
to	O
its	O
arm	O
-	O
type	O
DNA	O
-	O
binding	B-FUNC
activity	O
.	O

Sinusitis	O
was	O
also	O
associated	O
with	O
pasteurella	O
cultured	O
from	O
the	O
sinus	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
antibody	B-FUNC
to	O
avian	O
pneumovirus	O
(	O
APV	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
avian	O
coronaviruses	O
as	O
detected	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
(	O
P	O
<	O
0	O
.	O
05	O
);	O
there	O
was	O
no	O
association	O
between	O
disease	O
and	O
APV	O
as	O
detected	O
by	O
PCR	O
.	O

The	O
objectives	O
of	O
this	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
cohort	O
study	O
were	O
to	O
describe	O
the	O
use	O
of	O
the	O
score	O
of	O
neonatal	O
acute	O
physiology	O
(	O
SNAP	B-FUNC
)	O
as	O
a	O
measure	O
of	O
illness	O
severity	O
in	O
mechanically	O
ventilated	O
term	O
infants	O
,	O
to	O
compare	O
the	O
SNAP	B-FUNC
scores	O
of	O
the	O
different	O
diagnostic	O
groups	O
,	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
individual	O
SNAP	B-FUNC
items	O
to	O
the	O
overall	O
SNAP	B-FUNC
severity	O
category	O
,	O
and	O
to	O
assess	O
SNAP	B-FUNC
as	O
a	O
predictor	O
of	O
mortality	O
and	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
resource	O
utilization	O
(	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
and	O
duration	O
of	O
ventilation	O
(	O
LOV	O
)).	O

Highest	O
mean	O
(	O
SD	O
)	O
SNAP	B-FUNC
scores	O
occurred	O
in	O
infants	O
ventilated	O
for	O
meconium	O
aspiration	O
(	O
18	O
(	O
9	O
)),	O
and	O
perinatal	O
asphyxia	O
(	O
17	O
(	O
9	O
)),	O
compared	O
with	O
pulmonary	O
hypertension	O
(	O
14	O
(	O
6	O
))	O
and	O
respiratory	O
distress	O
syndrome	O
(	O
13	O
(	O
5	O
)).	O

The	O
individual	O
SNAP	B-FUNC
items	O
that	O
contributed	O
most	O
to	O
SNAP	B-FUNC
moderate	O
and	O
severe	O
categories	O
were	O
blood	O
gas	O
items	O
,	O
creatinine	O
,	O
urine	O
output	O
,	O
blood	O
glucose	O
,	O
and	O
seizures	O
.	O

SNAP	B-FUNC
alone	O
was	O
not	O
a	O
good	O
predictor	O
of	O
NICU	O
resource	O
utilization	O
(	O
LOS	O
,	O
LOV	O
)	O
in	O
term	O
infants	O
.	O

SNAP	B-FUNC
is	O
a	O
useful	O
measure	O
of	O
severity	O
of	O
illness	O
in	O
sick	O
term	O
neonates	O
admitted	O
to	O
a	O
tertiary	O
NICU	O
.	O

The	O
cELISA	O
utilized	O
a	O
recombinant	O
baculovirus	O
(	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
)-	O
expressed	O
TCV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
biotin	O
-	O
labeled	O
TCV	O
N	O
protein	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
.	O

Sensitivity	O
and	O
specificity	O
of	O
the	O
cELISA	O
for	O
detection	O
of	O
TCV	O
antibodies	O
were	O
determined	O
by	O
comparison	O
with	O
the	O
indirect	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
IFAT	O
)	O
with	O
1269	O
reference	O
,	O
experimentally	O
derived	O
,	O
and	O
field	O
-	O
origin	O
sera	B-FUNC
.	O

Sera	B-FUNC
with	O
discordant	O
cELISA	O
and	O
IFAT	O
results	O
were	O
further	O
evaluated	O
by	O
western	O
immunoblot	O
analyses	O
.	O

Thirty	O
-	O
eight	O
of	O
those	O
isolates	O
were	O
recognized	O
as	O
Mass	O
serotype	O
viruses	O
based	O
on	O
their	O
reactivity	O
to	O
Mass	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
(	O
Mab	O
)	O
and	O
neutralization	O
by	O
Mass	O
-	O
specific	O
chicken	O
serum	O
.	O

Intestinal	O
sections	O
were	O
prepared	O
from	O
turkey	O
embryos	O
infected	O
with	O
different	O
TCV	O
isolates	O
and	O
reacted	O
with	O
polyclonal	O
or	O
monoclonal	O
antibodies	O
to	O
TCV	O
,	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
reovirus	O
,	O
rotavirus	O
,	O
adenovirus	O
,	O
or	O
enterovirus	O
in	O
immunofluorescent	O
antibody	B-FUNC
staining	O
.	O

The	O
role	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
in	O
the	O
symptoms	O
and	O
pathology	O
of	O
porcine	O
pleuropneumonia	O
has	O
recently	O
been	O
proven	O
by	O
use	O
of	O
an	O
adenovirus	O
vector	O
expressing	O
the	O
anti	O
-	O
inflammatory	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

In	O
the	O
authors	O
'	O
laboratory	O
,	O
studies	O
were	O
undertaken	O
to	O
investigate	O
the	O
relationship	O
between	O
viral	O
respiratory	O
disease	O
and	O
bioactive	O
lung	O
lavage	O
levels	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Disease	O
and	O
lung	O
pathology	O
were	O
tightly	O
associated	O
with	O
the	O
simultaneous	O
production	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Mycoplasma	O
infection	O
was	O
diagnosed	O
by	O
repeated	O
antibody	B-FUNC
determination	O
(	O
complement	O
fixation	O
test	O
)	O
and	O
confirmed	O
using	O
the	O
polymerase	O
chain	O
reaction	O
to	O
detect	O
the	O
pathogen	O
from	O
a	O
tracheal	O
aspirate	O
.	O

Ricin	B-FUNC
intoxication	O
can	O
manifest	O
as	O
gastrointestinal	O
hemorrhage	O
after	O
ingestion	O
,	O
severe	O
muscle	O
necrosis	O
after	O
intramuscular	O
injection	O
,	O
and	O
acute	O
pulmonary	O
disease	O
after	O
inhalation	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
kinetics	O
and	O
magnitudes	O
of	O
specific	O
IgA	O
antibody	B-FUNC
responses	O
in	O
intestines	O
of	O
turkey	O
poults	O
infected	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
).	O

Intestinal	O
segment	O
cultures	O
were	O
administered	O
for	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
and	O
the	O
IgA	O
antibody	B-FUNC
responses	O
were	O
analyzed	O
at	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
or	O
9	O
weeks	O
post	O
-	O
infection	O
(	O
PI	O
)	O
in	O
two	O
different	O
experiments	O
.	O

The	O
kinetics	O
of	O
virus	O
-	O
specific	O
IgA	O
antibody	B-FUNC
responses	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
were	O
similar	O
:	O
gradually	O
increased	O
from	O
1	O
week	O
PI	O
,	O
reached	O
the	O
peak	O
at	O
3	O
or	O
4	O
weeks	O
PI	O
,	O
and	O
declined	O
afterward	O
.	O

The	O
virus	O
-	O
specific	O
IgA	O
antibody	B-FUNC
responses	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
showed	O
negative	O
correlation	O
with	O
duration	O
of	O
TCV	O
antigen	O
in	O
the	O
corresponding	O
locations	O
of	O
intestine	O
with	O
Spearman	O
'	O
s	O
correlation	O
coefficient	O
of	O
-	O
0	O
.	O
85	O
(	O
p	O
=	O
0	O
.	O
034	O
),	O
-	O
0	O
.	O
74	O
(	O
p	O
=	O
0	O
.	O
096	O
),	O
and	O
-	O
0	O
.	O
75	O
(	O
p	O
=	O
0	O
.	O
084	O
),	O
respectively	O
.	O

Moreover	O
,	O
the	O
virus	O
-	O
specific	O
IgA	O
antibody	B-FUNC
responses	O
in	O
serum	O
were	O
positively	O
correlated	O
with	O
that	O
of	O
duodenum	O
(	O
coefficient	O
=	O
0	O
.	O
829	O
,	O
p	O
=	O
0	O
.	O
042	O
),	O
jejunum	O
(	O
coefficient	O
=	O
0	O
.	O
829	O
,	O
p	O
=	O
0	O
.	O
042	O
),	O
and	O
ileum	O
(	O
coefficient	O
=	O
0	O
.	O
771	O
,	O
p	O
=	O
0	O
.	O
072	O
)	O
segment	O
cultures	O
,	O
suggesting	O
that	O
the	O
induction	O
of	O
specific	O
IgA	O
response	O
in	O
serum	O
was	O
predictive	O
of	O
an	O
IgA	O
response	O
in	O
intestine	O
.	O

TITLE	O
:	O
Structure	O
of	O
coronavirus	O
main	O
proteinase	B-FUNC
reveals	O
combination	O
of	O
a	O
chymotrypsin	O
fold	O
with	O
an	O
extra	O
alpha	O
-	O
helical	O
domain	O
.	O

ABSTRACT	O
:	O
The	O
key	O
enzyme	O
in	O
coronavirus	O
polyprotein	O
processing	O
is	O
the	O
viral	O
main	O
proteinase	B-FUNC
,	O
M	O
(	O
pro	O
),	O
a	O
protein	O
with	O
extremely	O
low	O
sequence	O
similarity	O
to	O
other	O
viral	O
and	O
cellular	O
proteinases	O
.	O

Molecular	O
modelling	O
and	O
mutagenesis	O
data	O
implicate	O
the	O
loop	O
in	O
substrate	O
binding	B-FUNC
and	O
elucidate	O
S1	O
and	O
S2	O
subsites	O
suitable	O
to	O
accommodate	O
the	O
side	O
chains	O
of	O
the	O
P1	O
glutamine	O
and	O
P2	O
leucine	O
residues	O
of	O
M	O
(	O
pro	O
)	O
substrates	O
.	O

Paired	O
sera	B-FUNC
were	O
collected	O
at	O
arrival	O
and	O
21	O
DPA	O
and	O
tested	O
for	O
antibodies	O
to	O
BCV	O
using	O
an	O
indirect	O
ELISA	O
.	O

Eleven	O
percent	O
of	O
cattle	O
had	O
antibody	B-FUNC
titers	O
against	O
BCV	O
at	O
0	O
DPA	O
and	O
91	O
%	O
of	O
cattle	O
seroconverted	O
to	O
BCV	O
by	O
21	O
DPA	O
.	O

The	O
BCV	O
fecal	O
and	O
nasal	O
shedding	O
detected	O
by	O
ELISA	O
and	O
RT	O
-	O
PCR	O
were	O
statistically	O
correlated	O
with	O
ELISA	O
antibody	B-FUNC
seroconversion	O
(	O
P	O
<	O
0	O
.	O
0001	O
);	O
however	O
,	O
BCV	O
fecal	O
and	O
nasal	O
shedding	O
were	O
not	O
significantly	O
related	O
to	O
clinical	O
signs	O
.	O

Lung	O
injury	O
,	O
quantitated	O
by	O
measuring	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
(	O
an	O
indicator	O
of	O
neutrophil	O
sequestration	O
),	O
alveolar	O
-	O
capillary	O
permeability	O
,	O
and	O
alveolar	O
membrane	O
thickness	O
was	O
less	O
severe	O
in	O
GM	O
-	O
CSF	O
-/-	O
than	O
in	O
GM	O
-	O
CSF	O
+/+	O
mice	O
.	O

In	O
this	O
series	O
of	O
3	O
patients	O
,	O
etanercept	O
(	O
Enbrel	O
;	O
Immunex	O
,	O
Seattle	O
,	O
WA	O
),	O
a	O
soluble	O
,	O
dimeric	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
-	O
binding	B-FUNC
protein	O
,	O
was	O
administered	O
to	O
3	O
consecutive	O
pediatric	O
allogeneic	O
BMT	O
recipients	O
with	O
IPS	O
.	O

A	O
pool	O
of	O
Elisa	O
positive	O
sera	B-FUNC
were	O
also	O
tested	O
to	O
clearly	O
identify	O
the	O
binding	B-FUNC
profiles	O
of	O
CCoV	O
proteins	O
.	O

Endogenous	O
immunoglobulin	B-FUNC
production	O
was	O
also	O
suppressed	O
until	O
120	O
days	O
after	O
the	O
accident	O
.	O

These	O
results	O
suggest	O
that	O
fast	B-FUNC
neutrons	O
in	O
doses	O
higher	O
than	O
8	O
to	O
10	O
Gy	O
cause	O
complete	O
abrogation	O
of	O
the	O
human	O
immune	O
system	O
,	O
which	O
may	O
lead	O
to	O
fatal	O
outcome	O
even	O
if	O
autologous	O
hematopoiesis	O
recovers	O
.	O

TITLE	O
:	O
Alveolar	O
macrophage	O
activation	O
after	O
trauma	O
-	O
hemorrhage	O
and	O
sepsis	O
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-FUNC
/	O
ERK	B-FUNC
mechanisms	O
.	O

We	O
hypothesized	O
that	O
alveolar	O
macrophage	O
(	O
AMPhi	O
)	O
chemokine	O
and	O
cytokine	O
release	O
after	O
hemorrhage	O
and	O
sepsis	O
is	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-FUNC
.	O

Lung	O
tissues	O
were	O
analyzed	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
and	O
wet	O
/	O
dry	O
weight	O
ratio	O
.	O

In	O
control	O
animals	O
,	O
AMPhi	O
were	O
stimulated	O
with	O
LPS	O
with	O
or	O
without	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-FUNC
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
or	O
the	O
upstream	O
MAPK	B-FUNC
significantly	O
decreased	O
LPS	O
-	O
stimulated	O
AMPhi	O
activation	O
.	O

Prospective	O
randomized	O
trials	O
show	O
that	O
maintaining	O
gut	O
integrity	O
is	O
equally	O
as	O
important	O
as	O
placing	O
the	O
pancreas	O
at	O
rest	B-FUNC
while	O
inflammation	O
within	O
the	O
gland	O
resolves	O
.	O

This	O
conserved	O
multifunctional	O
protein	O
is	O
also	O
efficient	O
in	O
inducing	O
NDV	O
-	O
specific	O
antibody	B-FUNC
in	O
chickens	O
.	O

At	O
24	O
,	O
48	O
,	O
72	O
,	O
and	O
120	O
hr	O
postinfection	O
(	O
HPI	B-FUNC
),	O
bursa	O
,	O
lung	O
,	O
spleen	O
,	O
heart	O
,	O
and	O
thymus	O
were	O
collected	O
,	O
fixed	O
in	O
10	O
%	O
neutral	O
buffered	O
formalin	O
,	O
and	O
paraffin	O
embedded	O
.	O

TITLE	O
:	O
Absence	O
of	O
fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
2	O
promotes	O
oligodendroglial	O
repopulation	O
of	O
demyelinated	O
white	O
matter	O
.	O

ABSTRACT	O
:	O
This	O
study	O
takes	O
advantage	O
of	O
fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
2	O
(	O
FGF2	O
)	O
knock	O
-	O
out	O
mice	O
to	O
determine	O
the	O
contribution	O
of	O
FGF2	O
to	O
the	O
regeneration	O
of	O
oligodendrocytes	O
in	O
the	O
adult	O
CNS	O
.	O

INTERVENTIONS	O
Pulmonary	O
(	O
with	O
muscle	O
as	O
control	O
)	O
leukocyte	O
accumulation	O
was	O
assessed	O
by	O
uptake	O
of	O
technetium	O
-	O
99m	O
-	O
labeled	O
chemotactic	O
peptide	O
(	O
fMLFK	O
)	O
and	O
confirmed	O
by	O
measurement	O
of	O
myeloperoxidase	B-FUNC
activity	I-FUNC
.	O

Lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
18FDG	O
,	O
and	O
peripheral	O
white	O
blood	O
cells	O
all	O
significantly	O
increased	O
in	O
both	O
mild	O
and	O
severe	O
pancreatitis	O
,	O
but	O
lung	O
fMLFK	O
only	O
increased	O
in	O
severe	O
pancreatitis	O
.	O

Many	O
interstitial	O
infiltrating	O
cells	O
were	O
positive	O
for	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
but	O
their	O
number	O
diminished	O
after	O
treatment	O
.	O

These	O
cells	O
,	O
but	O
not	O
conventional	O
CD4	O
or	O
CD8	O
alpha	O
beta	O
T	O
cells	O
,	O
were	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
of	O
MHV	O
-	O
infected	O
nude	O
mice	O
and	O
their	O
depletion	O
with	O
neutralizing	O
antibody	B-FUNC
resulted	O
in	O
an	O
80	O
%	O
reduction	O
in	O
demyelination	O
.	O

The	O
method	O
has	O
the	O
potential	O
to	O
be	O
used	O
to	O
construct	O
viral	O
,	O
microbial	O
,	O
or	O
eukaryotic	O
genomes	O
approaching	O
several	O
million	O
base	B-FUNC
pairs	I-FUNC
in	O
length	O
and	O
used	O
to	O
insert	O
restriction	O
sites	O
at	O
any	O
given	O
nucleotide	O
in	O
a	O
microbial	O
genome	O
.	O

TITLE	O
:	O
Amyloid	O
associated	O
with	O
elastin	B-FUNC
-	O
staining	O
laminar	O
aggregates	O
in	O
the	O
lungs	O
of	O
patients	O
diagnosed	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
ordered	O
nature	O
of	O
the	O
ELS	O
,	O
as	O
indicated	O
by	O
both	O
elastin	B-FUNC
and	O
amyloid	O
stains	O
,	O
together	O
with	O
little	O
morphological	O
evidence	O
of	O
inflammation	O
or	O
edema	O
,	O
suggests	O
that	O
this	O
cohort	O
of	O
ARDS	O
may	O
represent	O
another	O
form	O
of	O
conformational	O
disease	O
.	O

However	O
,	O
since	O
antibodies	O
against	O
these	O
viruses	O
,	O
HAV	O
and	O
B19	O
,	O
are	O
constantly	O
present	O
in	O
large	O
plasma	O
pools	O
,	O
it	O
is	O
conceivable	O
that	O
antibody	B-FUNC
binding	B-FUNC
will	O
lead	O
to	O
an	O
increase	O
in	O
size	O
of	O
the	O
viruses	O
due	O
to	O
a	O
corona	O
of	O
antibodies	O
on	O
the	O
virus	O
surfaces	O
.	O

In	O
this	O
study	O
,	O
antibody	B-FUNC
-	O
coated	O
viruses	O
and	O
free	O
virions	O
were	O
subjected	O
to	O
nanofiltration	O
to	O
determine	O
whether	O
the	O
antibody	B-FUNC
-	O
mediated	O
increase	O
in	O
size	O
contributes	O
to	O
the	O
elimination	O
of	O
viruses	O
which	O
are	O
otherwise	O
too	O
small	O
to	O
be	O
retained	O
by	O
filters	O
of	O
a	O
given	O
nominal	O
pore	O
diameter	O
.	O

Antibody	B-FUNC
-	O
coated	O
BEV	O
was	O
eliminated	O
to	O
below	O
detection	O
limit	O
by	O
the	O
50	O
-	O
nm	O
filters	O
(	O
logarithmic	O
reduction	O
factors	O
[	O
LRF	O
]	O
>	O
or	O
=	O
5	O
),	O
while	O
free	O
BEV	O
virions	O
passed	O
without	O
restraint	O
through	O
the	O
same	O
filters	O
.	O

Similarly	O
,	O
antibody	B-FUNC
-	O
coated	O
BPV	O
was	O
completely	O
retained	O
by	O
the	O
20	O
-	O
nm	O
filters	O
(	O
LRF	O
>	O
or	O
=	O
5	O
).	O

RESULTS	O
:	O
Antibody	B-FUNC
-	O
coated	O
BEV	O
was	O
eliminated	O
to	O
below	O
detection	O
limit	O
by	O
the	O
50	O
-	O
nm	O
filters	O
(	O
logarithmic	O
reduction	O
factors	O
[	O
LRF	O
]	O
>	O
or	O
=	O
5	O
),	O
while	O
free	O
BEV	O
virions	O
passed	O
without	O
restraint	O
through	O
the	O
same	O
filters	O
.	O

Furthermore	O
,	O
since	O
sera	B-FUNC
from	O
mice	O
immunized	O
with	O
a	O
purified	O
fraction	O
of	O
the	O
rat	O
liver	O
enzyme	O
do	O
react	O
with	O
its	O
homologous	O
protein	O
,	O
this	O
antiserum	O
can	O
be	O
used	O
as	O
a	O
positive	O
control	O
avoiding	O
the	O
manipulation	O
of	O
samples	O
from	O
MHV	O
-	O
infected	O
animals	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
requiring	O
endotracheal	O
intubation	O
and	O
erythrocytopheresis	O
are	O
at	O
increased	O
risk	O
for	O
neurologic	O
morbidity	O
.	O

This	O
study	O
examines	O
patients	O
with	O
sickle	O
cell	O
disease	O
who	O
developed	O
severe	O
episodes	O
of	O
ACS	B-FUNC
,	O
leading	O
to	O
endotracheal	O
intubation	O
,	O
ventilatory	O
support	O
for	O
respiratory	O
failure	O
,	O
and	O
erythrocytapheresis	O
.	O

Five	O
consecutive	O
patients	O
,	O
aged	O
3	O
to	O
9	O
years	O
,	O
were	O
identified	O
with	O
severe	O
ACS	B-FUNC
.	O

Children	O
with	O
severe	O
ACS	B-FUNC
should	O
have	O
a	O
magnetic	O
resonance	O
image	O
of	O
the	O
brain	O
,	O
neurologic	O
examination	O
by	O
a	O
neurologist	O
,	O
and	O
cognitive	O
testing	O
to	O
detect	O
the	O
presence	O
of	O
neurologic	O
morbidity	O
.	O

TITLE	O
:	O
Use	O
of	O
TaqMan	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
serologic	O
testing	O
to	O
eliminate	O
an	O
enzootic	O
infection	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Because	O
the	O
application	O
of	O
exogenous	O
surfactant	O
has	O
been	O
proposed	O
as	O
a	O
treatment	O
for	O
ARDS	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
surfactant	O
on	O
ventilation	O
-	O
induced	O
release	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
6	O
-	O
keto	O
-	O
PGF	O
(	O
1	O
alpha	O
)	O
(	O
the	O
stable	O
metabolite	O
of	O
prostacyclin	O
)	O
in	O
isolated	O
perfused	O
mouse	O
lungs	O
ventilated	O
with	O
high	O
end	O
-	O
inspiratory	O
pressures	O
.	O

Exogenous	O
surfactant	O
increased	O
the	O
ventilation	O
-	O
induced	O
liberation	O
of	O
TNF	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
into	O
the	O
perfusate	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
release	O
of	O
6	O
-	O
keto	O
-	O
PGF	O
(	O
1	O
alpha	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
soMHVR	O
induces	O
the	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
,	O
as	O
shown	O
by	O
the	O
proteinase	B-FUNC
digestion	O
test	O
.	O

A	O
cl	O
-	O
2	O
mutant	O
,	O
srr7	O
,	O
of	O
the	O
MHV	O
JHM	O
virus	O
(	O
JHMV	O
)	O
was	O
digested	O
with	O
proteinase	B-FUNC
K	O
after	O
treatment	O
with	O
soMHVR	O
,	O
and	O
the	O
resultant	O
S	O
protein	O
was	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
10G	O
,	O
specific	O
for	O
the	O
membrane	O
-	O
anchored	O
S2	O
subunit	O
.	O

Coimmunoprecipitation	O
indicated	O
that	O
the	O
direct	O
binding	B-FUNC
of	O
soMHVR	O
to	O
srr7	O
S	O
protein	O
induced	O
these	O
conformational	O
changes	O
;	O
this	O
was	O
also	O
suggested	O
by	O
the	O
inhibition	O
of	O
the	O
changes	O
following	O
pretreatment	O
of	O
soMHVR	O
with	O
anti	O
-	O
MHVR	O
MAb	O
CC1	O
.	O

The	O
implications	O
of	O
this	O
proteinase	B-FUNC
-	O
resistant	O
fraction	O
are	O
discussed	O
.	O

The	O
geometric	O
mean	O
of	O
the	O
hemagglutination	O
inhibition	O
antibody	B-FUNC
titer	O
was	O
34	O
.	O
2	O
before	O
vaccination	O
in	O
test	O
cows	O
.	O

A	O
high	O
antibody	B-FUNC
titer	O
persisted	O
at	O
396	O
.	O
0	O
;	O
241	O
.	O
0	O
;	O
and	O
201	O
.	O
5	O
,	O
at	O
3	O
,	O
6	O
,	O
and	O
9	O
months	O
after	O
the	O
2nd	O
injection	O
,	O
respectively	O
.	O

This	O
confirms	O
the	O
safety	O
and	O
high	O
antibody	B-FUNC
-	O
response	O
induced	O
by	O
this	O
prototype	O
vaccine	O
.	O

ABSTRACT	O
:	O
Reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCRs	O
)	O
were	O
used	O
to	O
examine	O
RNA	O
extracted	O
from	O
mouth	O
/	O
nasal	O
swabs	O
from	O
pheasants	O
exhibiting	O
signs	O
of	O
respiratory	O
disease	O
.	O

In	O
acute	O
infections	O
,	O
we	O
need	O
two	O
sera	B-FUNC
samples	O
given	O
in	O
2	O
weeks	O
period	O
with	O
4	O
-	O
fold	O
rise	O
or	O
fall	O
in	O
titers	O
.	O

TITLE	O
:	O
Severe	O
acute	O
pancreatitis	O
is	O
related	O
to	O
increased	O
early	O
urinary	O
levels	O
of	O
the	O
activation	O
Peptide	O
of	O
pancreatic	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
).	O

Urinary	O
samples	O
were	O
taken	O
on	O
admission	O
and	O
at	O
6	O
-	O
hour	O
intervals	O
for	O
48	O
h	O
,	O
then	O
every	O
12	O
h	O
up	O
to	O
72	O
h	O
,	O
and	O
finally	O
daily	O
for	O
at	O
least	O
5	O
days	O
for	O
measurement	O
of	O
the	O
activation	O
peptide	O
of	O
sPLA	O
(	O
2	O
)-	O
I	O
(	O
pro	O
-	O
phosphatase	B-FUNC
A	O
(	O
2	O
);	O
PROP	O
)	O
and	O
trypsinogen	O
activation	O
peptide	O
.	O

Analyses	O
of	O
the	O
subcellular	O
distribution	O
of	O
cytochrome	B-FUNC
c	I-FUNC
,	O
procaspase	O
-	O
9	O
,	O
and	O
Apaf	O
-	O
1	O
suggested	O
an	O
aberrant	O
apoptosome	O
formation	O
in	O
the	O
vicinity	O
of	O
the	O
mitochondria	O
,	O
which	O
could	O
be	O
a	O
cell	O
type	O
-	O
specific	O
event	O
.	O

TITLE	O
:	O
Polypyrimidine	O
-	O
tract	O
-	O
binding	B-FUNC
protein	O
affects	O
transcription	O
but	O
not	O
translation	O
of	O
mouse	O
hepatitis	O
virus	O
RNA	O
.	O

ABSTRACT	O
:	O
Polypyrimidine	O
-	O
tract	O
-	O
binding	B-FUNC
protein	O
(	O
PTB	O
)	O
has	O
been	O
shown	O
to	O
bind	B-FUNC
specifically	O
to	O
the	O
5	O
'	O
ends	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
and	O
its	O
complementary	O
strand	O
.	O

JHMV	O
infection	O
of	O
antibody	B-FUNC
-	O
deficient	O
mice	O
confirmed	O
a	O
primary	O
role	O
of	O
cellular	O
immunity	O
and	O
a	O
redundant	O
role	O
for	O
humoral	O
immunity	O
during	O
acute	O
infection	O
.	O

Reactivation	O
in	O
antibody	B-FUNC
-	O
deficient	O
mice	O
is	O
not	O
associated	O
with	O
increased	O
T	O
-	O
cell	O
infiltration	O
,	O
but	O
is	O
prevented	O
via	O
transfer	O
of	O
neutralizing	O
antibody	B-FUNC
.	O

A	O
vital	O
role	O
for	O
humoral	O
immunity	O
during	O
persistence	O
is	O
supported	O
by	O
the	O
accumulation	O
and	O
retention	O
of	O
virus	O
-	O
specific	O
antibody	B-FUNC
secreting	O
cells	O
following	O
clearance	O
of	O
infectious	O
virus	O
.	O

Later	O
,	O
in	O
vivo	O
expression	O
was	O
demonstrated	O
by	O
the	O
detection	O
of	O
IBV	O
-	O
specific	O
serum	O
immunoglobulin	B-FUNC
G	O
and	O
neutralization	O
antibodies	O
in	O
the	O
sera	B-FUNC
of	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
S1	O
.	O

Serum	O
IBV	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
antibody	B-FUNC
geometric	O
mean	O
titers	O
(	O
GMTs	O
)	O
after	O
vaccination	O
with	O
the	O
combinations	O
of	O
live	O
attenuated	O
strains	O
were	O
low	O
,	O
ranging	O
from	O
184	O
to	O
1	O
,	O
354	O
,	O
prior	O
to	O
NIBV	O
challenge	O
at	O
10	O
wk	O
of	O
age	O
.	O

ABSTRACT	O
:	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
are	O
thought	O
to	O
be	O
important	O
cytokines	O
for	O
T	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O

Mice	O
deficient	O
in	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	O
-	O
2Ralpha	O
,	O
and	O
IL	O
-	O
2Rbeta	O
are	O
each	O
characterized	O
by	O
a	O
rapid	O
lethal	O
autoimmune	O
lymphoproliferative	O
disorder	O
that	O
complicates	O
their	O
use	O
in	O
studies	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
these	O
cytokines	O
and	O
receptors	O
for	O
immune	O
responses	O
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
these	O
mice	O
were	O
used	O
to	O
investigate	O
the	O
extent	O
by	O
which	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
are	O
essential	O
for	O
T	O
cell	O
immunity	O
in	O
vivo	O
.	O

Thus	O
,	O
although	O
T	O
effector	O
function	O
is	O
somewhat	O
impaired	O
,	O
T	O
cell	O
immunity	O
is	O
largely	O
functional	O
in	O
the	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-	O
induced	O
signaling	O
through	O
IL	O
-	O
2Rbeta	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
binds	B-FUNC
to	O
viral	O
murine	O
CEACAM	O
receptor	O
glycoproteins	O
and	O
causes	O
membrane	O
fusion	O
.	O

On	O
virions	O
,	O
the	O
180	O
-	O
kDa	O
S	O
glycoprotein	O
of	O
the	O
MHV	O
-	O
A59	O
strain	O
can	O
be	O
cleaved	O
by	O
trypsin	O
to	O
form	O
the	O
90	O
-	O
kDa	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	B-FUNC
subunit	O
(	O
S1	O
)	O
and	O
the	O
90	O
-	O
kDa	O
membrane	O
-	O
anchored	O
fusion	O
subunit	O
(	O
S2	O
).	O

Receptor	B-FUNC
binding	I-FUNC
induced	O
a	O
profound	O
,	O
apparently	O
irreversible	O
conformational	O
change	O
in	O
S	O
on	O
the	O
viral	O
envelope	O
that	O
allowed	O
S2	O
,	O
but	O
not	O
S1	O
,	O
to	O
be	O
degraded	O
by	O
trypsin	O
at	O
4	O
degrees	O
C	O
.	O
Various	O
murine	O
CEACAM	O
proteins	O
triggered	O
conformational	O
changes	O
in	O
S	O
on	O
recombinant	O
MHV	O
strains	O
expressing	O
S	O
glycoproteins	O
of	O
MHV	O
-	O
A59	O
or	O
MHV	O
-	O
4	O
(	O
MHV	O
-	O
JHM	O
)	O
with	O
the	O
same	O
specificities	O
as	O
seen	O
for	O
virus	O
neutralization	O
and	O
virus	O
-	O
receptor	O
activities	O
.	O

A	O
novel	O
120	O
-	O
kDa	O
subunit	O
was	O
formed	O
following	O
incubation	O
of	O
the	O
receptor	O
-	O
triggered	O
S	O
(	O
A59	O
)	O
H716D	O
virions	O
with	O
trypsin	O
at	O
4	O
degrees	O
C	O
.	O
The	O
data	O
show	O
that	O
unlike	O
class	O
1	O
fusion	O
glycoproteins	O
of	O
other	O
enveloped	O
viruses	O
,	O
the	O
murine	O
coronavirus	O
S	O
protein	O
can	O
be	O
triggered	O
to	O
a	O
membrane	O
-	O
binding	B-FUNC
conformation	O
at	O
37	O
degrees	O
C	O
either	O
by	O
soluble	O
receptor	O
at	O
neutral	O
pH	O
or	O
by	O
alkaline	O
pH	O
alone	O
,	O
without	O
requiring	O
previous	O
activation	O
by	O
cleavage	O
between	O
S1	O
and	O
S2	O
.	O

We	O
have	O
used	O
two	O
assays	O
,	O
one	O
an	O
in	O
vitro	O
liposome	O
binding	B-FUNC
assay	O
and	O
the	O
other	O
a	O
tissue	O
culture	O
replication	O
assay	O
.	O

The	O
liposome	O
binding	B-FUNC
assay	O
shows	O
that	O
interaction	O
of	O
the	O
receptor	O
with	O
spikes	O
on	O
virions	O
at	O
37	O
degrees	O
C	O
causes	O
a	O
conformational	O
change	O
that	O
makes	O
the	O
virions	O
hydrophobic	O
so	O
that	O
they	O
bind	B-FUNC
to	O
liposomes	O
(	O
B	O
.	O
D	O
.	O
Zelus	O
,	O
J	O
.	O
H	O
.	O
Schickli	O
,	O
D	O
.	O
M	O
.	O
Blau	O
,	O
S	O
.	O
R	O
.	O
Weiss	O
,	O
and	O
K	O
.	O
V	O
.	O
Holmes	O
,	O
J	O
.	O
Virol	O
.	O

These	O
data	O
suggest	O
that	O
the	O
RBD	O
domain	O
and	O
the	O
rest	B-FUNC
of	O
the	O
spike	O
must	O
coevolve	O
to	O
optimize	O
function	O
in	O
viral	O
entry	O
and	O
spread	O
.	O

ABSTRACT	O
:	O
Gill	O
-	O
associated	O
virus	O
(	O
GAV	O
),	O
a	O
positive	O
-	O
stranded	O
RNA	O
virus	O
of	O
prawns	O
,	O
is	O
the	O
prototype	O
of	O
newly	O
recognized	O
taxa	O
(	O
genus	O
Okavirus	O
,	O
family	O
Roniviridae	O
)	O
within	O
the	O
order	O
NIDOVIRALES	O
:	O
In	O
this	O
study	O
,	O
a	O
putative	O
GAV	O
cysteine	O
proteinase	B-FUNC
(	O
3C	O
-	O
like	O
proteinase	B-FUNC
[	O
3CL	O
(	O
pro	O
)]),	O
which	O
is	O
predicted	O
to	O
be	O
the	O
key	O
enzyme	O
involved	O
in	O
processing	O
of	O
the	O
GAV	O
replicase	O
polyprotein	O
precursors	O
,	O
pp1a	O
and	O
pp1ab	O
,	O
was	O
characterized	O
.	O

Treatment	O
of	O
sensitive	O
Balb	O
/	O
cJ	O
mice	O
with	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
antibody	B-FUNC
could	O
increase	O
the	O
STAT1	O
alpha	O
/	O
beta	O
ratio	O
to	O
<	O
1	O
.	O
0	O
in	O
spleens	O
,	O
predicting	O
enhanced	O
rates	O
of	O
survival	O
.	O

Soluble	O
L	O
-	O
selectin	B-FUNC
(	O
sL	O
-	O
selectin	B-FUNC
)	O
level	O
on	O
Day	O
1	O
in	O
the	O
DIC	O
patients	O
who	O
died	O
was	O
markedly	O
lower	O
than	O
those	O
in	O
the	O
non	O
-	O
DIC	O
patients	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
endogenous	O
PDGF	B-FUNC
and	O
FGF2	O
activity	O
in	O
these	O
glial	O
cultures	O
isolated	O
from	O
demyelinated	O
CNS	O
tissue	O
.	O

These	O
findings	O
correlate	O
well	O
with	O
our	O
previous	O
demonstration	O
of	O
increased	O
in	O
vivo	O
expression	O
of	O
PDGF	B-FUNC
and	O
FGF2	O
ligand	B-FUNC
and	O
corresponding	O
receptors	O
in	O
MHV	O
-	O
A59	O
lesions	O
.	O

Binding	B-FUNC
of	O
S	O
(	O
547	O
)	O
to	O
hAPN	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
hAPN	O
monoclonal	O
antibody	B-FUNC
that	O
inhibits	O
binding	B-FUNC
of	O
virus	O
to	O
hAPN	O
and	O
blocks	O
virus	O
infection	O
of	O
human	O
cells	O
and	O
was	O
also	O
blocked	O
by	O
polyclonal	O
anti	O
-	O
HCoV	O
-	O
229E	O
antibody	B-FUNC
.	O

S	O
proteins	O
that	O
contain	O
the	O
N	O
-	O
terminal	O
268	O
or	O
417	O
amino	O
acids	O
did	O
not	O
bind	B-FUNC
to	O
hAPN	O
-	O
3T3	O
cells	O
.	O

Antibody	B-FUNC
to	O
the	O
region	O
from	O
amino	O
acid	O
417	O
to	O
the	O
C	O
terminus	O
of	O
S	O
blocked	O
binding	B-FUNC
of	O
S	O
(	O
547	O
)	O
to	O
hAPN	O
-	O
3T3	O
cells	O
.	O

Thus	O
,	O
the	O
data	O
suggest	O
that	O
the	O
domain	O
of	O
the	O
spike	O
protein	O
between	O
amino	O
acids	O
417	O
and	O
547	O
is	O
required	O
for	O
the	O
binding	B-FUNC
of	O
HCoV	O
-	O
229E	O
to	O
its	O
hAPN	O
receptor	O
.	O

Provision	O
of	O
supplemental	O
oxygen	O
,	O
lung	O
rest	B-FUNC
,	O
and	O
supportive	O
care	O
are	O
the	O
fundamentals	O
of	O
therapy	O
.	O

A	O
method	O
based	O
on	O
xylene	O
deparaffinization	O
followed	O
by	O
proteinase	B-FUNC
K	O
digestion	O
yielded	O
RNA	O
of	O
a	O
suitable	O
quality	O
for	O
reliable	O
and	O
consistent	O
multiplex	O
RT	O
-	O
nPCR	O
analyses	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
series	O
of	O
potent	O
,	O
selective	O
HIV	O
-	O
1	O
N	O
-	O
acylthiocarbamate	O
(	O
ATC	O
)	O
nonnucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTIs	O
)	O
is	O
described	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
liquid	O
-	O
phase	O
blocking	O
(	O
LPB	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
chicken	O
and	O
rabbit	O
affinity	O
purified	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
has	O
been	O
developed	O
to	O
detect	O
and	O
estimate	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
concentration	O
directly	O
in	O
infected	O
allantoic	O
fluid	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
principle	O
of	O
binding	B-FUNC
of	O
specific	O
IgG	O
to	O
the	O
test	O
IBV	O
antigen	O
and	O
the	O
assay	O
of	O
unbound	O
IgG	O
on	O
an	O
antigen	O
-	O
coated	O
ELISA	O
plate	O
.	O

Following	O
stimulation	O
with	O
MHV	O
-	O
A59	O
,	O
it	O
was	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
that	O
HNF4alpha	O
binds	B-FUNC
the	O
HNF4	O
cis	O
-	O
element	O
in	O
the	O
fgl2	O
promoter	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
the	O
increased	O
antibody	B-FUNC
-	O
titer	O
to	O
M	O
.	O
pneumoniae	O
later	O
.	O

Phosphoenolpyruvate	O
(	O
PEP	O
)	O
is	O
an	O
endogenous	O
substance	O
that	O
is	O
one	O
of	O
the	O
ATP	O
precursors	O
and	O
can	O
cross	O
some	O
cell	O
membranes	O
via	O
anion	O
exchanger	B-FUNC
.	O

In	O
contrast	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
receptor	O
antagonist	O
(	O
IL	B-FUNC
-	I-FUNC
1ra	I-FUNC
)	O
were	O
the	O
most	O
abundant	O
cytokines	O
in	O
the	O
PF	O
and	O
plasma	O
,	O
and	O
the	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
also	O
elevated	O
in	O
both	O
compartments	O
.	O

ABSTRACT	O
:	O
Mannan	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
is	O
a	O
glycoprotein	O
and	O
a	O
member	O
of	O
the	O
C	O
-	O
type	O
lectin	O
super	O
family	O
,	O
the	O
collectin	O
family	O
,	O
and	O
the	O
acute	O
phase	O
protein	O
family	O
.	O

The	O
MBL	O
exerts	O
its	O
function	O
by	O
directly	O
binding	B-FUNC
to	O
microbial	O
surfaces	O
through	O
its	O
carbohydrate	O
recognition	O
domains	O
,	O
followed	O
by	O
direct	O
opsonization	O
or	O
complement	O
activation	O
via	O
MBL	O
-	O
associated	O
serine	O
proteases	O
(	O
MASP	O
)-	O
1	O
and	O
-	O
2	O
.	O

The	O
results	O
showed	O
that	O
the	O
acute	O
phase	O
MBL	O
response	O
to	O
infection	O
with	O
IBV	O
was	O
,	O
to	O
a	O
degree	O
(	O
P	O
<	O
0	O
.	O
0068	O
),	O
dependent	O
on	O
whether	O
the	O
chickens	O
were	O
inoculated	O
after	O
12	O
h	O
of	O
rest	B-FUNC
(	O
dark	O
)	O
or	O
after	O
12	O
h	O
of	O
activity	O
(	O
light	O
).	O

The	O
acute	O
phase	O
response	O
in	O
chickens	O
challenged	O
after	O
12	O
h	O
of	O
activity	O
peaked	O
after	O
4	O
.	O
6	O
d	O
with	O
an	O
increase	O
of	O
24	O
%,	O
whereas	O
the	O
acute	O
phase	O
response	O
in	O
chickens	O
challenged	O
after	O
12	O
h	O
of	O
rest	B-FUNC
peaked	O
after	O
3	O
.	O
1	O
d	O
with	O
an	O
increase	O
of	O
51	O
%.	O

The	O
specific	O
antibody	B-FUNC
titer	O
against	O
IBV	O
was	O
also	O
tested	O
,	O
and	O
a	O
difference	O
(	O
P	O
<	O
0	O
.	O
0091	O
)	O
between	O
the	O
two	O
experimental	O
groups	O
was	O
found	O
with	O
peak	O
titer	O
values	O
of	O
6	O
,	O
816	O
and	O
4	O
,	O
349	O
.	O

Thus	O
,	O
an	O
inverse	O
relation	O
exists	O
between	O
the	O
MBL	O
response	O
and	O
the	O
IBV	O
specific	O
antibody	B-FUNC
response	O
.	O

The	O
complement	O
activation	O
was	O
directly	O
associated	O
with	O
the	O
concentration	O
of	O
MBL	O
in	O
serum	O
,	O
indicating	O
neutralization	O
of	O
the	O
virus	O
before	O
the	O
humoral	O
antibody	B-FUNC
response	O
took	O
over	O
.	O

We	O
found	O
that	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
in	O
this	O
setting	O
was	O
dependent	O
on	O
the	O
activation	O
of	O
p38	B-FUNC
and	O
Akt	O
kinases	O
.	O

Diminished	O
activation	O
of	O
NF	O
-	O
kappaB	O
or	O
Akt	O
,	O
but	O
not	O
p38	B-FUNC
,	O
in	O
the	O
early	O
postintubation	O
period	O
was	O
associated	O
with	O
less	O
time	O
on	O
the	O
ventilator	O
and	O
improved	O
survival	O
in	O
critically	O
ill	O
patients	O
with	O
ALI	O
.	O

TITLE	O
:	O
CC	O
chemokine	O
ligand	B-FUNC
3	O
(	O
CCL3	O
)	O
regulates	O
CD8	O
(+)-	O
T	O
-	O
cell	O
effector	O
function	O
and	O
migration	O
following	O
viral	O
infection	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
contributions	O
of	O
the	O
CC	O
chemokine	O
ligand	B-FUNC
3	O
(	O
CCL3	O
)	O
to	O
the	O
differentiation	O
and	O
migration	O
of	O
effector	O
T	O
cells	O
in	O
response	O
to	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
were	O
analyzed	O
.	O

Expression	O
levels	O
driven	O
by	O
this	O
TRS	B-FUNC
were	O
higher	O
than	O
those	O
of	O
an	O
expression	O
cassette	O
under	O
the	O
control	O
of	O
regulating	O
sequences	O
engineered	O
with	O
the	O
N	O
gene	O
TRS	B-FUNC
.	O

As	O
a	O
consequence	O
,	O
a	O
major	O
species	O
of	O
subgenomic	O
mRNA	O
was	O
generated	O
from	O
a	O
TRS	B-FUNC
with	O
the	O
noncanonical	O
core	O
sequence	O
5	O
'-	O
CUAAAA	O
-	O
3	O
'.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
:	O
receptor	B-FUNC
binding	I-FUNC
domain	O
and	O
neutralization	O
by	O
soluble	O
receptor	O
at	O
37	O
degrees	O
C	O
.	O
ABSTRACT	O
:	O
Truncated	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
spike	O
glycoproteins	O
containing	O
amino	O
acids	O
407	O
to	O
547	O
bound	O
to	O
purified	O
,	O
soluble	O
virus	O
receptor	O
,	O
human	O
aminopeptidase	O
N	O
(	O
hAPN	O
).	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
an	O
intraperitoneal	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
acute	O
hepatic	O
failure	O
accompanying	O
extremely	O
elevated	O
viral	O
growth	O
in	O
the	O
liver	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
deficient	O
BALB	O
/	O
c	O
(	O
BALB	O
-	O
GKO	O
),	O
but	O
not	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
.	O

Specific	O
antibody	B-FUNC
production	O
in	O
sera	B-FUNC
collected	O
at	O
7	O
days	O
p	O
.	O
i	O
.	O
did	O
not	O
correlate	O
with	O
protection	O
.	O

TITLE	O
:	O
Pulmonary	O
expression	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
in	O
sepsis	O
.	O

TITLE	O
:	O
Control	O
of	O
central	O
nervous	O
system	O
viral	O
persistence	O
by	O
neutralizing	O
antibody	B-FUNC
.	O

Neutralizing	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
but	O
not	O
IgA	O
anti	O
-	O
spike	O
Ab	O
suppressed	O
virus	O
recrudescence	O
,	O
reduced	O
viral	O
antigen	O
in	O
most	O
cell	O
types	O
except	O
oligodendroglia	O
,	O
and	O
was	O
associated	O
with	O
reduced	O
demyelination	O
.	O

Cortisol	O
supports	O
vascular	O
tone	O
and	O
endothelial	O
integrity	O
,	O
modulates	O
a	O
large	O
number	O
of	O
proinflammatory	O
cytokines	O
,	O
and	O
suppresses	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
),	O
cyclo	O
-	O
oxygenase	B-FUNC
,	O
and	O
nitric	O
oxide	O
synthase	O
.	O

This	O
is	O
consistent	O
with	O
the	O
lower	O
levels	O
of	O
hepatocellular	O
necrosis	O
and	O
serum	O
ALT	B-FUNC
and	O
the	O
decreased	O
titers	O
of	O
MHV	O
-	O
2	O
virus	O
in	O
the	O
liver	O
tissues	O
(	O
48	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
72	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

From	O
October	O
2000	O
through	O
April	O
2001	O
,	O
we	O
tested	O
1803	O
respiratory	O
samples	O
for	O
HCoV	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

Indirect	O
fluorescence	O
antibody	B-FUNC
tests	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
made	O
with	O
the	O
new	O
isolate	O
have	O
been	O
used	O
to	O
demonstrate	O
a	O
virus	O
-	O
specific	O
serologic	O
response	O
.	O

We	O
identified	O
HLA	O
-	O
A2	O
binding	B-FUNC
HPV16	O
E7	O
variant	O
peptides	O
from	O
human	O
,	O
bacterial	O
,	O
or	O
viral	O
origin	O
which	O
are	O
able	O
to	O
drive	O
CD8	O
(+)-	O
T	O
-	O
cell	O
responses	O
directed	O
against	O
wild	O
-	O
type	O
HPV16	O
E7	O
amino	O
acid	O
11	O
to	O
19	O
/	O
20	O
(	O
E7	O
(	O
11	O
-	O
19	O
/	O
20	O
))	O
epitope	O
YMLDLQPET	O
(	O
T	O
)	O
in	O
vitro	O
.	O

CD8	O
(+)	O
T	O
cells	O
reacting	O
to	O
the	O
HLA	O
-	O
A2	O
-	O
presented	O
peptide	O
from	O
HPV16	O
E7	O
(	O
11	O
-	O
19	O
(	O
20	O
))	O
recognized	O
also	O
the	O
HLA	O
-	O
A2	O
binding	B-FUNC
peptide	O
TMLDIQPED	O
(	O
amino	O
acids	O
52	O
to	O
60	O
)	O
from	O
the	O
human	O
coronavirus	O
OC43	O
NS2	O
gene	O
product	O
.	O

Calves	O
that	O
were	O
seronegative	O
or	O
had	O
low	O
antibody	B-FUNC
titers	O
against	O
BoTV	O
(<	O
or	O
=	O
1	O
:	O
10	O
hemagglutination	O
inhibition	O
units	O
)	O
at	O
arrival	O
seroconverted	O
to	O
BoTV	O
(>	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
);	O
these	O
calves	O
were	O
more	O
likely	O
to	O
shed	O
virus	O
than	O
calves	O
that	O
were	O
seropositive	O
against	O
BoTV	O
at	O
arrival	O
.	O

The	O
purified	O
recombinant	O
protein	O
was	O
then	O
evaluated	O
for	O
its	O
antigenicity	O
and	O
reliability	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
CCoV	O
antibodies	O
in	O
dog	O
sera	B-FUNC
.	O

We	O
defined	O
the	O
clinical	O
presentation	O
and	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
and	O
investigated	O
the	O
causal	O
agents	O
by	O
chest	O
radiography	O
and	O
laboratory	O
testing	O
of	O
nasopharyngeal	O
aspirates	O
and	O
sera	B-FUNC
samples	O
.	O

By	O
use	O
of	O
serological	O
and	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
specific	O
for	O
this	O
virus	O
,	O
45	O
of	O
50	O
patients	O
with	O
SARS	O
,	O
but	O
no	O
controls	O
,	O
had	O
evidence	O
of	O
infection	O
with	O
this	O
virus	O
.	O

Coagulopathy	O
was	O
attenuated	O
,	O
and	O
plasma	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
-	O
1	O
levels	O
were	O
significantly	O
lower	O
in	O
the	O
treated	O
animals	O
.	O

We	O
tested	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
obtained	O
from	O
HSCT	O
recipients	O
with	O
acute	O
pulmonary	O
infiltrates	O
for	O
HRV	O
(	O
n	O
=	O
122	O
)	O
and	O
coronavirus	O
(	O
n	O
=	O
46	O
)	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

From	O
November	O
1999	O
to	O
May	O
2001	O
,	O
259	O
specimens	O
from	O
53	O
calves	O
(<	O
or	O
=	O
6	O
months	O
old	O
),	O
27	O
young	O
adults	O
(	O
52	O
years	O
),	O
125	O
adults	O
(>	O
or	O
=	O
2	O
years	O
),	O
and	O
54	O
animals	O
of	O
unknown	O
age	O
were	O
examined	O
by	O
an	O
antigen	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
developed	O
to	O
detect	O
BoTV	O
.	O

TITLE	O
:	O
Coronavirus	O
main	O
proteinase	B-FUNC
(	O
3CLpro	O
)	O
structure	O
:	O
basis	O
for	O
design	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

The	O
viral	O
main	O
proteinase	B-FUNC
(	O
Mpro	O
,	O
also	O
called	O
3CLpro	O
),	O
which	O
controls	O
the	O
activities	O
of	O
the	O
coronavirus	O
replication	O
complex	O
,	O
is	O
an	O
attractive	O
target	O
for	O
therapy	O
.	O

The	O
structures	O
reveal	O
a	O
remarkable	O
degree	O
of	O
conservation	O
of	O
the	O
substrate	O
-	O
binding	B-FUNC
sites	O
,	O
which	O
is	O
further	O
supported	O
by	O
recombinant	O
SARS	O
-	O
CoV	O
Mpro	O
-	O
mediated	O
cleavage	O
of	O
a	O
TGEV	O
Mpro	O
substrate	O
.	O

TITLE	O
:	O
Effect	O
of	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
on	O
bleomycin	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
pulmonary	O
fibrosis	O
.	O

We	O
investigated	O
whether	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
25	O
microg	O
x	O
kg	O
(-	O
1	O
)	O
x	O
day	O
(-	O
1	O
),	O
4	O
days	O
)	O
enhanced	O
endotracheal	O
bleomycin	O
-	O
induced	O
(	O
5	O
mg	O
/	O
kg	O
)	O
acute	O
lung	O
injury	O
and	O
fibrosis	O
in	O
rats	O
.	O

We	O
compared	O
the	O
effects	O
of	O
alveolar	O
instillation	O
of	O
bleomycin	O
in	O
rats	O
treated	O
with	O
either	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
or	O
saline	O
.	O

Mortality	O
was	O
25	O
%	O
with	O
bleomycin	O
only	O
and	O
50	O
%	O
with	O
bleomycin	O
+	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
.	O

Granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
increased	O
alveolar	O
neutrophil	O
recruitment	O
,	O
pulmonary	O
edema	O
,	O
and	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
on	O
day	O
4	O
.	O

Lung	O
static	O
compliance	O
on	O
day	O
15	O
was	O
severely	O
decreased	O
with	O
bleomycin	O
alone	O
and	O
showed	O
a	O
further	O
significant	O
decrease	O
when	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
was	O
added	O
(	O
controls	O
,	O
3	O
.	O
85	O
+/-	O

Granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
enhances	O
bleomycin	O
-	O
induced	O
lung	O
toxicity	O
by	O
a	O
mechanism	O
that	O
probably	O
involves	O
neutrophils	O
.	O

The	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
were	O
lower	O
and	O
interleukin	O
-	O
10	O
was	O
higher	O
in	O
the	O
albumin	O
-	O
treated	O
groups	O
than	O
in	O
the	O
Ringer	O
'	O
s	O
lactate	O
group	O
.	O

We	O
have	O
used	O
convalescent	O
sera	B-FUNC
from	O
several	O
SARS	O
patients	O
to	O
detect	O
proteins	O
in	O
the	O
culture	O
supernatants	O
from	O
cells	O
exposed	O
to	O
lavage	O
another	O
SARS	O
patient	O
.	O

Quantitative	O
reverse	O
-	O
transcriptase	B-FUNC
(	O
RT	O
)	O
PCR	O
of	O
nasopharyngeal	O
aspirates	O
in	O
14	O
patients	O
(	O
four	O
with	O
ARDS	O
)	O
showed	O
peak	O
viral	O
load	O
at	O
day	O
10	O
,	O
and	O
at	O
day	O
15	O
a	O
load	O
lower	O
than	O
at	O
admission	O
.	O

Evidence	O
of	O
infection	O
with	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
human	O
metapneumovirus	O
was	O
sought	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
and	O
serology	O
.	O

Reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proven	O
useful	O
for	O
detection	O
of	O
Sendai	O
virus	O
and	O
PVM	O
immunodeficient	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

The	O
fnRT	O
-	O
PCR	O
assays	O
detected	O
as	O
little	O
as	O
10	O
fg	O
of	O
Sendai	O
virus	O
RNA	O
and	O
one	O
picogram	O
of	O
PVM	O
RNA	O
,	O
respectively	O
,	O
andthe	O
Sendai	O
virus	O
fnRT	O
-	O
PCR	O
assay	O
had	O
comparable	O
sensitivity	O
when	O
directly	O
compared	O
with	O
the	O
mouse	O
antibody	B-FUNC
production	O
test	O
.	O

TITLE	O
:	O
Possible	O
mechanisms	O
underlying	O
development	O
of	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
:	O
roles	O
of	O
anti	O
-	O
major	O
histocompatibility	O
complex	O
class	O
II	O
DR	O
antibody	B-FUNC
.	O

Moreover	O
,	O
MHC	O
class	O
II	O
DR	O
-	O
expressing	O
PMNs	O
were	O
also	O
proved	O
to	O
express	O
a	O
high	O
-	O
affinity	O
receptor	O
for	O
immunoglobulin	B-FUNC
E	O
(	O
IgE	O
)	O
(	O
FcepsilonRI	O
)	O
and	O
to	O
produce	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
and	O
interleukin	O
-	O
18	O
following	O
a	O
challenge	O
with	O
an	O
anti	O
-	O
MHC	O
class	O
II	O
DR	O
monoclonal	O
Ab	O
(	O
MoAb	O
)	O
or	O
anti	O
-	O
DR	O
antiserum	O
.	O

TITLE	O
:	O
Putative	O
hAPN	O
receptor	B-FUNC
binding	I-FUNC
sites	O
in	O
SARS_CoV	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
information	O
of	O
ligand	B-FUNC
-	O
receptor	B-FUNC
binding	I-FUNC
between	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
CD13	O
,	O
identify	O
the	O
possible	O
interacting	O
domains	O
or	O
motifs	O
related	O
to	O
binding	B-FUNC
sites	O
,	O
and	O
provide	O
clues	O
for	O
studying	O
the	O
functions	O
of	O
SARS	O
proteins	O
and	O
designing	O
anti	O
-	O
SARS	O
drugs	O
and	O
vaccines	O
.	O

Possible	O
binding	B-FUNC
sites	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
CD13	O
have	O
been	O
mapped	O
out	O
by	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

The	O
binding	B-FUNC
for	O
one	O
protein	O
-	O
protein	O
interaction	O
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
.	O

This	O
study	O
also	O
provides	O
a	O
possible	O
strategy	O
for	O
mapping	O
the	O
possible	O
binding	B-FUNC
receptors	O
of	O
the	O
proteins	O
in	O
a	O
genome	O
.	O

RESULTS	O
:	O
Possible	O
binding	B-FUNC
sites	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
CD13	O
have	O
been	O
mapped	O
out	O
by	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

TITLE	O
:	O
A	O
3D	O
model	O
of	O
SARS_CoV	O
3CL	O
proteinase	B-FUNC
and	O
its	O
inhibitors	O
design	O
by	O
virtual	O
screening	O
.	O

Bioinformatics	O
analyses	O
were	O
performed	O
to	O
search	O
the	O
homologous	O
proteins	O
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
from	O
the	O
GenBank	O
and	O
PDB	O
database	O
.	O

A	O
3D	O
model	O
of	O
the	O
proteinase	B-FUNC
was	O
constructed	O
by	O
using	O
homology	O
modeling	O
technique	O
.	O

Sequence	O
alignment	O
indicated	O
that	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
was	O
extremely	O
homologous	O
to	O
TGEV	O
Mpro	O
,	O
especially	O
the	O
substrate	O
-	O
binding	B-FUNC
pocket	O
(	O
active	O
site	O
).	O

Accordingly	O
,	O
a	O
3D	O
model	O
for	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
was	O
constructed	O
based	O
on	O
the	O
crystal	O
structure	O
of	O
TGEV	O
Mpro	O
.	O

The	O
3D	O
model	O
adopts	O
a	O
similar	O
fold	O
of	O
the	O
TGEV	O
Mpro	O
,	O
its	O
structure	O
and	O
binding	B-FUNC
pocket	O
feature	O
are	O
almost	O
as	O
same	O
as	O
that	O
of	O
TGEV	O
Mpro	O
.	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	B-FUNC
inhibitors	O
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	B-FUNC
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
.	O

Screening	O
the	O
known	O
proteinase	B-FUNC
inhibitors	O
may	O
be	O
an	O
appreciated	O
shortcut	O
to	O
discover	O
anti	O
-	O
SARS	O
drugs	O
.	O

RESULTS	O
:	O
Sequence	O
alignment	O
indicated	O
that	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
was	O
extremely	O
homologous	O
to	O
TGEV	O
Mpro	O
,	O
especially	O
the	O
substrate	O
-	O
binding	B-FUNC
pocket	O
(	O
active	O
site	O
).	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	B-FUNC
inhibitors	O
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	B-FUNC
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
pure	B-FUNC
sample	O
of	O
SARS	O
small	O
envelope	O
E	O
protein	O
(	O
SARS	O
E	O
protein	O
),	O
study	O
its	O
properties	O
and	O
analyze	O
its	O
possible	O
functions	O
.	O

The	O
pure	B-FUNC
sample	O
of	O
SARS	O
E	O
protein	O
was	O
obtained	O
.	O

RESULTS	O
:	O
The	O
pure	B-FUNC
sample	O
of	O
SARS	O
E	O
protein	O
was	O
obtained	O
.	O

FAV	O
antibody	B-FUNC
ELISA	O
confirmed	O
that	O
maternal	O
antibody	B-FUNC
directed	O
against	O
inclusion	O
body	O
hepatitis	O
(	O
serotype	O
8	O
)	O
had	O
decayed	O
in	O
control	O
birds	O
and	O
that	O
FAV	O
specific	O
serum	O
IgG	O
responses	O
were	O
produced	O
in	O
vaccinated	O
birds	O
at	O
the	O
time	O
of	O
challenge	O
.	O

Further	O
,	O
an	O
S1	O
specific	O
antibody	B-FUNC
response	O
was	O
detected	O
prior	O
to	O
challenge	O
.	O

This	O
review	O
mainly	O
focuses	O
upon	O
the	O
pathogenic	O
contribution	O
of	O
NE	O
to	O
these	O
neutrophil	O
-	O
predominant	O
inflammatory	O
lung	O
diseases	O
,	O
and	O
evaluates	O
the	O
experimental	O
and	O
clinical	O
efficacies	O
of	O
the	O
two	O
-	O
types	O
of	O
appropriate	O
small	O
molecular	O
weight	O
human	O
neutrophil	O
elastase	O
(	O
HNE	O
)	O
inhibitors	O
:	O
acyl	O
-	O
enzyme	B-FUNC
inhibitors	I-FUNC
and	O
transition	O
-	O
state	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
replicase	O
polyprotein	O
of	O
murine	O
coronavirus	O
is	O
extensively	O
processed	O
by	O
three	O
proteinases	O
,	O
two	O
papain	O
-	O
like	O
proteinases	O
(	O
PLPs	O
),	O
termed	O
PLP1	O
and	O
PLP2	O
,	O
and	O
a	O
picornavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
).	O

Even	O
young	O
patients	O
can	O
enter	O
a	O
stage	O
of	O
respiratory	O
compromise	O
rather	O
fast	B-FUNC
.	O

The	O
amino	O
terminal	O
half	O
of	O
the	O
S	O
glycoprotein	O
gene	O
including	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
,	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Within	O
1	O
h	O
of	O
CEES	O
infusion	O
at	O
4	O
mg	O
/	O
kg	O
,	O
high	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
ceramides	O
,	O
and	O
nuclear	O
factor	O
kappaB	O
accumulated	O
in	O
lung	O
and	O
alveolar	O
macrophages	O
.	O

PTX	O
would	O
feature	O
a	O
possible	O
antiviral	O
activity	O
along	O
with	O
a	O
well	O
-	O
known	O
cytokine	O
-	O
modulating	O
activity	O
not	O
as	O
immunosuppressant	O
as	O
that	O
of	O
the	O
corticoids	O
,	O
down	O
-	O
regulating	O
proinflammatory	O
cytokines	O
but	O
leaving	O
functional	O
the	O
rest	B-FUNC
of	O
the	O
immune	O
response	O
.	O

TGEV	O
virions	O
were	O
purified	O
by	O
three	O
different	O
techniques	O
,	O
including	O
an	O
immunopurification	O
using	O
an	O
M	O
protein	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
.	O

Additional	O
cannulae	O
placed	O
at	O
the	O
initiation	O
of	O
venovenous	O
ECMO	O
could	O
be	O
beneficial	O
in	O
achieving	O
flow	O
rates	O
necessary	O
for	O
adequate	O
oxygenation	O
and	O
lung	O
rest	B-FUNC
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
temporal	O
profile	O
of	O
serum	O
antibody	B-FUNC
against	O
coronavirus	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
to	O
evaluate	O
the	O
reliability	O
of	O
indirect	O
immuno	O
-	O
fluorescence	O
assay	O
(	O
IFA	O
)	O
in	O
the	O
diagnosis	O
of	O
SARS	O
.	O

IFA	O
was	O
used	O
to	O
detect	O
the	O
serum	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
.	O

Differential	O
cell	O
counts	O
were	O
performed	O
and	O
supernatant	O
was	O
assayed	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
,	O
IFN	O
-	O
gamma	O
,	O
and	O
eosinophilic	O
cationic	O
protein	O
(	O
ECP	O
).	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
increased	O
in	O
both	O
the	O
upper	O
and	O
lower	O
respiratory	O
tracts	O
in	O
both	O
EVW	O
and	O
control	O
subjects	O
with	O
colds	O
,	O
the	O
largest	O
change	O
being	O
seen	O
on	O
day	O
4	O
in	O
the	O
sputum	O
of	O
those	O
with	O
EVW	O
(	O
mean	O
difference	O
from	O
baseline	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
2	O
.	O
5	O
(	O
0	O
.	O
55	O
-	O
4	O
.	O
46	O
)	O
ng	O
/	O
mL	O
).	O

Only	O
modest	O
changes	O
were	O
seen	O
in	O
IFN	O
-	O
gamma	O
and	O
no	O
changes	O
were	O
seen	O
in	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
or	O
ECP	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
is	O
likely	O
to	O
be	O
an	O
important	O
chemokine	O
in	O
this	O
process	O
.	O

At	O
24	O
-	O
60	O
h	O
post	O
-	O
inoculation	O
(	O
hpi	B-FUNC
),	O
the	O
villous	O
height	O
/	O
crypt	O
depth	O
(	O
VH	O
/	O
CD	O
)	O
ratio	O
of	O
infected	O
pigs	O
was	O
significantly	O
less	O
than	O
that	O
of	O
control	O
pigs	O
.	O

The	O
further	O
experiments	O
demonstrated	O
that	O
N1	O
peptide	O
-	O
induced	O
polyclonal	O
antibodies	O
had	O
a	O
high	O
affinity	O
to	O
bind	B-FUNC
to	O
E	O
.	O
coli	O
expressed	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
it	O
was	O
confirmed	O
that	O
N1	O
peptide	O
-	O
specific	O
IgG	O
antibodies	O
were	O
detectable	O
in	O
the	O
sera	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
antibody	B-FUNC
responses	O
suggest	O
that	O
N	O
protein	O
of	O
SARS	O
is	O
immunodominant	O
and	O
plays	O
an	O
important	O
role	O
in	O
viral	O
pathogenesis	O
.	O

CONCLUSIONS	O
:	O
The	O
antibody	B-FUNC
responses	O
suggest	O
that	O
N	O
protein	O
of	O
SARS	O
is	O
immunodominant	O
and	O
plays	O
an	O
important	O
role	O
in	O
viral	O
pathogenesis	O
.	O

The	O
identification	O
of	O
the	O
mAb	O
against	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
Cov	O
was	O
performed	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
(	O
IFA	O
),	O
and	O
Western	O
immunoblotting	O
.	O

Of	O
the	O
4	O
strains	O
,	O
2	O
were	O
identified	O
as	O
the	O
immunoglobulin	B-FUNC
G1	O
(	O
IgG1	O
)	O
isotype	O
,	O
1	O
IgG2a	O
,	O
and	O
the	O
other	O
IgG2b	O
,	O
with	O
affinity	O
constants	O
(	O
Ka	O
)	O
of	O
2	O
of	O
the	O
strains	O
being	O
4	O
.	O
14	O
x	O
10	O
(-	O
9	O
)	O
M	O
and	O
3	O
.	O
19	O
x	O
10	O
(-	O
9	O
)	O
M	O
respectively	O
.	O

Of	O
the	O
4	O
strains	O
,	O
2	O
were	O
identified	O
as	O
the	O
immunoglobulin	B-FUNC
G1	O
(	O
IgG1	O
)	O
isotype	O
,	O
1	O
IgG2a	O
,	O
and	O
the	O
other	O
IgG2b	O
,	O
with	O
affinity	O
constants	O
(	O
Ka	O
)	O
of	O
2	O
of	O
the	O
strains	O
being	O
4	O
.	O
14	O
x	O
10	O
(-	O
9	O
)	O
M	O
and	O
3	O
.	O
19	O
x	O
10	O
(-	O
9	O
)	O
M	O
respectively	O
.	O

The	O
high	O
aPL	O
antibody	B-FUNC
levels	O
in	O
serum	O
possibly	O
triggered	O
by	O
sepsis	O
were	O
associated	O
with	O
high	O
aPL	O
antibody	B-FUNC
levels	O
in	O
BALF	O
,	O
which	O
can	O
be	O
explained	O
by	O
high	O
capillary	O
-	O
alveolar	O
permeability	O
.	O

Mice	O
immunized	O
orally	O
with	O
the	O
Salmonella	O
pgtE	O
vaccine	O
expressing	O
chimeric	O
fimbriae	O
from	O
the	O
spiC	O
promoter	O
elicited	O
significantly	O
higher	O
systemic	O
and	O
mucosal	O
antibody	B-FUNC
titers	O
against	O
the	O
TGEV	O
epitopes	O
compared	O
to	O
the	O
parental	O
vaccine	O
.	O

ABSTRACT	O
:	O
Acute	O
Chest	O
Syndrome	O
(	O
ACS	B-FUNC
)	O
describes	O
a	O
syndrome	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
a	O
chest	O
X	O
-	O
ray	O
,	O
fever	O
,	O
and	O
respiratory	O
symptoms	O
and	O
is	O
the	O
leading	O
cause	O
of	O
death	O
and	O
hospitalization	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

Six	O
out	O
of	O
the	O
21	O
patients	O
developed	O
one	O
episode	O
of	O
ACS	B-FUNC
(	O
two	O
patients	O
had	O
positive	O
blood	O
cultures	O
,	O
for	O
Mycoplasma	O
pneumoniae	O
and	O
Haemophilus	O
influenzae	O
respectively	O
).	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
therapeutic	O
efficacy	O
of	O
red	O
cell	O
-	O
exchange	O
during	O
ACS	B-FUNC
.	O

During	O
follow	O
up	O
(	O
14	O
-	O
32	O
months	O
),	O
none	O
of	O
the	O
6	O
patients	O
developed	O
viral	O
complications	O
related	O
to	O
transfusion	O
therapy	O
,	O
alloimmunization	O
or	O
recurrence	O
of	O
ACS	B-FUNC
.	O

In	O
conclusion	O
,	O
in	O
regard	O
to	O
the	O
pre	O
-	O
and	O
post	O
-	O
red	O
cell	O
-	O
exchange	O
clinical	O
and	O
laboratory	O
data	O
,	O
we	O
can	O
say	O
that	O
red	O
cell	O
-	O
exchange	O
provides	O
a	O
dramatic	O
resolution	O
of	O
the	O
episode	O
of	O
ACS	B-FUNC
,	O
minimizes	O
the	O
development	O
of	O
iron	O
overload	O
,	O
and	O
rapidly	O
decreases	O
HbS	O
and	O
hematocrit	O
levels	O
.	O

In	O
light	O
of	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
ACS	B-FUNC
episodes	O
are	O
secondary	O
to	O
pulmonary	O
damage	O
and	O
to	O
a	O
gradual	O
worsening	O
related	O
to	O
age	O
,	O
and	O
that	O
there	O
is	O
some	O
evidence	O
that	O
individuals	O
affected	O
by	O
SCD	O
in	O
the	O
third	O
to	O
fourth	O
decade	O
of	O
life	O
are	O
more	O
susceptible	O
to	O
ACS	B-FUNC
and	O
/	O
or	O
other	O
severe	O
disease	O
-	O
related	O
complications	O
,	O
needing	O
repeated	O
and	O
strict	O
clinical	O
follow	O
up	O
.	O

Gefitinib	O
acts	O
by	O
inhibition	O
of	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
tyrosine	O
kinase	O
.	O

The	O
180	O
-	O
kDa	O
oligomeric	O
S	O
protein	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
is	O
posttranslationally	O
cleaved	O
into	O
an	O
S1	O
receptor	B-FUNC
binding	I-FUNC
unit	O
and	O
an	O
S2	O
membrane	O
fusion	O
unit	O
.	O

The	O
factor	O
HNF4	O
binds	B-FUNC
to	O
mfgl2	O
promoter	O
and	O
serves	O
as	O
an	O
essential	O
transcription	O
factor	O
for	O
mfgl2	O
/	O
fibroleukin	O
expression	O
in	O
response	O
to	O
MHV	O
-	O
3	O
N	O
protein	O
.	O

RESULTS	O
:	O
The	O
level	O
of	O
serum	O
IL	O
was	O
increased	O
to	O
a	O
great	O
extent	O
in	O
the	O
35	O
SARS	O
patients	O
,	O
and	O
the	O
levels	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
were	O
242	O
.	O
53	O
(	O
92	O
.	O
69	O
)	O
pg	O
/	O
ml	O
,	O
77	O
.	O
43	O
(	O
63	O
.	O
37	O
)	O
pg	O
/	O
ml	O
and	O
65	O
.	O
94	O
(	O
43	O
.	O
21	O
)	O
pg	O
/	O
ml	O
,	O
respectively	O
.	O

TITLE	O
:	O
Binding	B-FUNC
mechanism	O
of	O
coronavirus	O
main	O
proteinase	B-FUNC
with	O
ligands	O
and	O
its	O
implication	O
to	O
drug	O
design	O
against	O
SARS	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
stimulate	O
the	O
development	O
of	O
drugs	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
based	O
on	O
the	O
atomic	O
coordinates	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
determined	O
recently	O
[	O
Science	O
13	O
(	O
May	O
)	O
(	O
2003	O
)	O
(	O
online	O
)],	O
studies	O
of	O
docking	O
KZ7088	O
(	O
a	O
derivative	O
of	O
AG7088	O
)	O
and	O
the	O
AVLQSGFR	O
octapeptide	O
to	O
the	O
enzyme	O
were	O
conducted	O
.	O

Also	O
,	O
a	O
clear	O
definition	O
of	O
the	O
binding	B-FUNC
pocket	O
for	O
KZ7088	O
has	O
been	O
presented	O
.	O

The	O
course	O
and	O
dosage	O
of	O
glucocorticoid	O
,	O
counts	O
of	O
CD	O
(	O
4	O
)(+),	O
CD	O
(	O
8	O
)(+)	O
and	O
CD	O
(	O
3	O
)(+),	O
electrolytes	O
,	O
blood	O
routine	O
,	O
and	O
sera	B-FUNC
albumin	O
before	O
and	O
after	O
the	O
treatment	O
were	O
analysed	O
.	O

Glucocorticoid	O
increased	O
the	O
level	O
of	O
blood	O
glucose	O
(	O
P	O
=	O
0	O
.	O
01	O
),	O
decreased	O
the	O
level	O
of	O
sera	B-FUNC
albumin	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
its	O
large	O
dosage	O
decreased	O
the	O
counts	O
of	O
CD	O
(	O
4	O
)(+),	O
CD	O
(	O
8	O
)(+)	O
and	O
CD	O
(	O
3	O
)(+).	O

A	O
large	O
dose	O
of	O
glucocorticoid	O
may	O
aggravate	O
the	O
suppression	O
and	O
make	O
the	O
body	O
in	O
an	O
active	O
metabolic	O
state	O
(	O
the	O
increase	O
of	O
blood	O
glucose	O
and	O
the	O
decrease	O
of	O
sera	B-FUNC
albumin	O
).	O

Noninvasive	O
ventilation	O
relieves	O
dyspnea	O
and	O
SpO	O
(	O
2	O
)	O
in	O
patients	O
with	O
critical	O
SARS	O
,	O
and	O
should	O
also	O
be	O
employed	O
in	O
those	O
with	O
SpO	O
(	O
2	O
)	O
of	O
90	O
%	O
-	O
93	O
%	O
at	O
rest	B-FUNC
under	O
O	O
(	O
2	O
)	O
inhalation	O
5	O
L	O
/	O
min	O
.	O

Blood	O
glucose	O
,	O
serum	O
albumin	O
,	O
blood	O
lymphocyte	O
counts	O
,	O
and	O
serum	O
alanine	O
transminase	O
(	O
ALT	B-FUNC
)	O
were	O
checked	O
on	O
the	O
first	O
admission	O
day	O
in	O
ICU	O
and	O
on	O
the	O
12th	O
day	O
after	O
nutrition	O
therapy	O
was	O
started	O
.	O

For	O
each	O
sample	O
,	O
RNA	O
was	O
extracted	O
using	O
commercial	O
kit	B-FUNC
and	O
7	O
Nest	O
RT	O
-	O
PCR	O
using	O
a	O
14	O
-	O
pair	O
different	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
special	O
primers	O
were	O
carried	O
out	O
simultaneously	O
.	O

The	O
IgG	O
antibody	B-FUNC
was	O
detected	O
in	O
22	O
out	O
of	O
34	O
(	O
64	O
.	O
7	O
%)	O
patients	O
and	O
the	O
average	O
time	O
for	O
the	O
occurrence	O
of	O
antibody	B-FUNC
was	O
(	O
18	O
.	O
2	O
+/-	O

Serum	O
antibody	B-FUNC
was	O
not	O
detected	O
until	O
on	O
the	O
9th	O
day	O
of	O
the	O
course	O
of	O
illness	O
;	O
CT	O
is	O
a	O
more	O
sensitive	O
method	O
for	O
detection	O
of	O
the	O
abnormal	O
chest	O
radiographs	O
than	O
regular	O
X	O
-	O
ray	O
test	O
.	O

TITLE	O
:	O
[	O
Primary	O
investigation	O
on	O
the	O
changing	O
mode	O
of	O
plasma	O
specific	O
IgG	O
antibody	B-FUNC
in	O
SARS	O
patients	O
and	O
their	O
physicians	O
and	O
nurses	O
].	O

Plasma	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
was	O
not	O
detected	O
in	O
normal	O
subjects	O
and	O
the	O
clinical	O
personnel	O
.	O

RESULTS	O
:	O
Plasma	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
was	O
not	O
detected	O
in	O
normal	O
subjects	O
and	O
the	O
clinical	O
personnel	O
.	O

CONCLUSIONS	O
:	O
The	O
specificity	O
and	O
sensitivity	O
of	O
ELISA	O
to	O
detect	O
plasma	O
anti	O
-	O
SARS	O
IgG	O
antibody	B-FUNC
were	O
satisfactory	O
.	O

TITLE	O
:	O
[	O
Modeling	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
and	O
conformational	O
flexibility	O
of	O
the	O
active	O
site	O
].	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
3CL	O
proteinase	B-FUNC
is	O
the	O
key	O
enzyme	O
for	O
virus	O
replication	O
which	O
may	O
serve	O
as	O
the	O
target	O
for	O
drug	O
discovery	O
against	O
SARS	O
.	O

A	O
3D	O
structure	O
model	O
has	O
been	O
built	O
for	O
SARS	O
coronavirus	O
3CL	O
proteinase	B-FUNC
by	O
comparative	O
protein	O
modeling	O
.	O

A	O
homodimer	O
model	O
of	O
the	O
proteinase	B-FUNC
was	O
also	O
built	O
.	O

ABSTRACT	O
:	O
SARS	O
virus	O
is	O
a	O
recently	O
found	O
coronavirus	O
,	O
which	O
cause	O
human	O
atypical	O
pneumonia	O
through	O
the	O
binding	B-FUNC
of	O
its	O
spike	O
protein	O
to	O
the	O
receptor	O
on	O
human	O
cells	O
.	O

The	O
antiviral	O
activity	O
may	O
be	O
mediated	O
in	O
part	O
by	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
,	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
,	O
and	O
Mx	O
protein	O
,	O
which	O
inhibit	O
viral	O
replication	O
or	O
degrade	O
viral	O
components	O
,	O
because	O
limitin	O
induced	O
their	O
mRNA	O
expression	O
and	O
enzyme	B-FUNC
activity	I-FUNC
.	O

We	O
provide	O
the	O
first	O
quantitative	O
analysis	O
of	O
the	O
polynucleic	O
acid	O
binding	B-FUNC
and	O
NTPase	O
activities	O
of	O
a	O
Nidovirus	O
helicase	O
,	O
using	O
a	O
high	O
throughput	O
phosphate	O
release	O
assay	O
that	O
will	O
be	O
readily	O
adaptable	O
to	O
the	O
future	O
testing	O
of	O
helicase	O
inhibitors	O
.	O

We	O
found	O
a	O
large	O
variation	O
in	O
the	O
apparent	O
strength	O
of	O
binding	B-FUNC
of	O
different	O
homopolynucleotides	O
,	O
with	O
dT24	O
binding	B-FUNC
over	O
10	O
times	O
more	O
strongly	O
than	O
dA24	O
as	O
observed	O
by	O
the	O
apparent	O
Km	O
.	O

Direct	O
sequencing	O
followed	O
by	O
phylogenetic	O
analysis	O
on	O
that	O
region	O
allowed	O
us	O
to	O
type	O
those	O
field	O
isolates	O
that	O
were	O
not	O
typable	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
).	O

Together	O
with	O
RT	O
-	O
PCR	O
and	O
RFLP	O
,	O
this	O
method	O
will	O
serve	O
as	O
a	O
fast	B-FUNC
typing	O
method	O
for	O
IBV	O
diagnosis	O
.	O

The	O
serum	O
levels	O
of	O
creatine	O
kinase	O
(	O
CK	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
aspartate	O
transaminase	O
(	O
AST	O
),	O
troponin	O
I	O
(	O
TnI	O
),	O
creatine	O
kinase	O
-	O
MB	O
(	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
)	O
and	O
myoglobin	O
(	O
MYO	O
)	O
were	O
measured	O
.	O

The	O
positive	O
rates	O
of	O
TnI	O
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
and	O
MYO	O
in	O
patients	O
were	O
higher	O
than	O
those	O
in	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Thirteen	O
of	O
all	O
the	O
patients	O
were	O
physicians	O
and	O
the	O
rest	B-FUNC
were	O
nurses	O
.	O

Abnormal	O
liver	O
function	O
was	O
found	O
in	O
27	O
cases	O
(	O
mostly	O
with	O
elevated	O
serum	O
ALT	B-FUNC
),	O
with	O
70	O
%	O
occurred	O
at	O
the	O
3rd	O
or	O
4th	O
week	O
.	O

RESULTS	O
:	O
Thirteen	O
of	O
all	O
the	O
patients	O
were	O
physicians	O
and	O
the	O
rest	B-FUNC
were	O
nurses	O
.	O

ABSTRACT	O
:	O
The	O
heterodimeric	O
integration	O
host	O
factor	O
(	O
IHF	O
)	O
is	O
a	O
site	O
-	O
specific	O
DNA	O
-	O
binding	B-FUNC
and	O
DNA	O
-	O
bending	O
protein	O
from	O
Escherichia	O
coli	O
.	O

IHF	O
'	O
s	O
ability	O
for	O
concerted	O
binding	B-FUNC
and	O
bending	O
of	O
DNA	O
is	O
key	O
to	O
its	O
biological	O
function	O
.	O

DNA	B-FUNC
binding	I-FUNC
and	O
DNA	O
bending	O
assays	O
revealed	O
that	O
purified	O
wild	O
-	O
type	O
IHF	O
and	O
scIHF2	O
behave	O
very	O
similarly	O
.	O

Among	O
the	O
96	O
cases	O
,	O
26	O
cases	O
(	O
27	O
%)	O
had	O
diarrhea	O
,	O
17	O
(	O
18	O
%)	O
had	O
nausea	O
,	O
6	O
(	O
6	O
%)	O
had	O
vomiting	O
,	O
16	O
(	O
17	O
%)	O
had	O
bellyache	O
,	O
and	O
8	O
(	O
8	O
%)	O
had	O
ALT	B-FUNC
elevation	O
.	O

RESULTS	O
:	O
Among	O
the	O
96	O
cases	O
,	O
26	O
cases	O
(	O
27	O
%)	O
had	O
diarrhea	O
,	O
17	O
(	O
18	O
%)	O
had	O
nausea	O
,	O
6	O
(	O
6	O
%)	O
had	O
vomiting	O
,	O
16	O
(	O
17	O
%)	O
had	O
bellyache	O
,	O
and	O
8	O
(	O
8	O
%)	O
had	O
ALT	B-FUNC
elevation	O
.	O

MARS	O
therapy	O
was	O
associated	O
with	O
marked	O
reduction	O
of	O
albumin	O
bound	O
toxins	O
and	O
water	O
soluble	O
toxins	O
,	O
together	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
INF	O
-	O
gamma	O
.	O

RESULTS	O
:	O
MARS	O
therapy	O
was	O
associated	O
with	O
marked	O
reduction	O
of	O
albumin	O
bound	O
toxins	O
and	O
water	O
soluble	O
toxins	O
,	O
together	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
INF	O
-	O
gamma	O
.	O

The	O
serum	O
samples	O
were	O
taken	O
from	O
46	O
patients	O
to	O
detect	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
endotoxin	O
and	O
hepatitis	O
related	O
viral	O
inclusions	O
.	O

When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	O
ALT	B-FUNC
and	O
(	O
or	O
)	O
AST	O
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

Abnormal	O
liver	O
function	O
mainly	O
resulted	O
from	O
ALT	B-FUNC
elevation	O
(	O
70	O
.	O
7	O
%),	O
then	O
both	O
ALT	B-FUNC
and	O
AST	O
elevation	O
(	O
22	O
.	O
4	O
%).	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ALT	B-FUNC
/	O
AST	O
elevation	O
rates	O
between	O
severe	O
and	O
mild	O
clinical	O
type	O
(	O
chi2	O
=	O
19	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
levels	O
of	O
some	O
factors	O
,	O
such	O
as	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
patients	O
with	O
elevated	O
ALT	B-FUNC
,	O
were	O
higher	O
than	O
those	O
in	O
ALT	B-FUNC
normal	O
patients	O
(	O
t	O
>	O
or	O
=	O
2	O
.	O
36	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

Infiltration	O
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	B-FUNC
activity	I-FUNC
)	O
was	O
associated	O
with	O
enhanced	O
lipid	O
peroxidation	O
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	O
).	O

Immunohistochemical	O
examination	O
demonstrated	O
a	O
marked	O
increase	O
in	O
immunoreactivity	O
for	O
intracellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
P	O
-	O
selectin	B-FUNC
and	O
E	O
-	O
selectin	B-FUNC
in	O
the	O
pancreas	O
and	O
lung	O
of	O
cerulein	O
-	O
treated	O
mice	O
.	O

They	O
are	O
of	O
positive	O
polarity	O
and	O
are	O
translated	O
to	O
produce	O
the	O
viral	O
proteins	O
needed	O
for	O
the	O
assembly	O
of	O
an	O
active	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
.	O

The	O
MARS	O
therapy	O
was	O
associated	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
INF	O
-	O
gamma	O
,	O
together	O
with	O
marked	O
reduction	O
of	O
other	O
non	O
-	O
water	O
-	O
soluble	O
albumin	O
bound	O
toxins	O
and	O
water	O
-	O
soluble	O
toxins	O
,	O
these	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	O
encephalopathy	O
,	O
deranged	O
hemodynamic	O
situation	O
and	O
as	O
well	O
as	O
renal	O
and	O
respiratory	O
function	O
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
improved	O
outcome	O
:	O
nine	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
,	O
the	O
overall	O
survival	O
of	O
24	O
patients	O
was	O
37	O
.	O
5	O
%.	O

RESULTS	O
:	O
The	O
MARS	O
therapy	O
was	O
associated	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
INF	O
-	O
gamma	O
,	O
together	O
with	O
marked	O
reduction	O
of	O
other	O
non	O
-	O
water	O
-	O
soluble	O
albumin	O
bound	O
toxins	O
and	O
water	O
-	O
soluble	O
toxins	O
,	O
these	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	O
encephalopathy	O
,	O
deranged	O
hemodynamic	O
situation	O
and	O
as	O
well	O
as	O
renal	O
and	O
respiratory	O
function	O
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
improved	O
outcome	O
:	O
nine	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
,	O
the	O
overall	O
survival	O
of	O
24	O
patients	O
was	O
37	O
.	O
5	O
%.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
impact	O
of	O
aerosolised	O
prostacyclin	O
(	O
PGI2	O
)	O
and	O
iloprost	O
in	O
the	O
absence	O
or	O
presence	O
of	O
subthreshold	O
intravascular	O
doses	O
of	O
the	O
dual	O
-	O
selective	O
phosphodiesterase	B-FUNC
-	O
3	O
/	O
4	O
inhibitor	O
zardaverine	O
was	O
investigated	O
in	O
an	O
experimental	O
model	O
of	O
acute	O
respiratory	O
failure	O
.	O

In	O
conclusion	O
,	O
combined	O
use	O
of	O
aerosolised	O
iloprost	O
and	O
subthreshold	O
systemic	O
phosphodiesterase	B-FUNC
-	O
3	O
/	O
4	O
inhibitor	O
may	O
result	O
in	O
selective	O
intrapulmonary	O
vasodilation	O
,	O
a	O
reduction	O
in	O
oedema	O
formation	O
and	O
an	O
improvement	O
in	O
ventilation	O
-	O
perfusion	O
matching	O
in	O
acute	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responsiveness	O
during	O
immunization	O
and	O
challenge	O
of	O
genetically	O
modified	O
antibody	B-FUNC
responder	O
mice	O
with	O
murine	O
hepatitis	O
virus	O
3	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
some	O
immunological	O
patterns	O
involved	O
in	O
natural	O
and	O
acquired	O
resistance	O
against	O
MHV3	O
using	O
the	O
original	O
model	O
of	O
genetically	O
modified	O
lines	O
of	O
mice	O
selected	O
for	O
high	O
(	O
HIII	O
)	O
and	O
low	O
(	O
LIII	O
)	O
antibody	B-FUNC
responsiveness	O
.	O

As	O
previously	O
shown	O
,	O
a	O
lower	O
pre	O
-	O
existing	O
anti	O
-	O
MHV	O
antibody	B-FUNC
level	O
was	O
found	O
in	O
susceptible	O
HIII	O
mice	O
as	O
compared	O
to	O
resistant	O
LIII	O
mice	O
.	O

The	O
present	O
data	O
show	O
that	O
both	O
lines	O
had	O
the	O
potential	O
to	O
synthesize	O
antibodies	O
and	O
that	O
the	O
resistance	O
acquired	O
by	O
the	O
susceptible	O
HIII	O
mice	O
paralleled	O
the	O
antibody	B-FUNC
synthesis	O
.	O

When	O
compared	O
to	O
uvMHV3	O
,	O
a	O
single	O
immunization	O
with	O
a	O
related	O
infectious	O
MHV	O
strain	O
induced	O
a	O
higher	O
antibody	B-FUNC
synthesis	O
and	O
led	O
the	O
HIII	O
mice	O
to	O
resist	O
the	O
MHV3	O
challenge	O
.	O

The	O
resistance	O
and	O
the	O
survival	O
time	O
of	O
these	O
animals	O
increased	O
with	O
the	O
level	O
of	O
antibody	B-FUNC
administered	O
.	O

TITLE	O
:	O
Protective	O
role	O
of	O
heme	O
oxygenase	B-FUNC
-	O
1	O
induction	O
in	O
carbon	O
tetrachloride	O
-	O
induced	O
hepatotoxicity	O
.	O

Heme	O
oxygenase	B-FUNC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
(	O
EC	O
1	O
.	O
14	O
.	O
99	O
.	O
3	O
),	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
heme	O
catabolism	O
,	O
is	O
known	O
to	O
be	O
induced	O
by	O
oxidative	O
stress	O
and	O
to	O
confer	O
protection	O
against	O
oxidative	O
tissue	O
injuries	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
HO	O
-	O
1	O
induction	O
in	O
a	O
rat	O
model	O
of	O
CCl	B-FUNC
(	O
4	O
)-	O
induced	O
acute	O
liver	O
injury	O
.	O

Following	O
CCl	B-FUNC
(	O
4	O
)	O
treatment	O
,	O
hepatic	O
HO	O
-	O
1	O
expression	O
was	O
markedly	O
increased	O
both	O
at	O
transcriptional	O
and	O
protein	O
levels	O
in	O
hepatocytes	O
,	O
especially	O
around	O
the	O
central	O
vein	O
.	O

HO	O
-	O
1	O
induction	O
was	O
mediated	O
in	O
part	O
through	O
a	O
rapid	O
increase	O
in	O
microsomal	O
free	O
heme	O
concentration	O
presumably	O
derived	O
from	O
hepatic	O
cytochrome	B-FUNC
P450	I-FUNC
.	O

Inhibition	O
of	O
HO	O
activity	O
by	O
tin	O
-	O
mesoporphyrin	O
(	O
Sn	O
-	O
MP	O
),	O
which	O
resulted	O
in	O
a	O
sustained	O
increase	O
in	O
microsomal	O
free	O
heme	O
concentration	O
,	O
exacerbated	O
liver	O
injury	O
,	O
as	O
judged	O
by	O
the	O
sustained	O
increase	O
in	O
serum	O
ALT	B-FUNC
activity	O
,	O
extensive	O
hepatocytes	O
injuries	O
,	O
a	O
more	O
pronounced	O
expression	O
of	O
hepatic	O
TNF	O
-	O
alpha	O
mRNA	O
and	O
an	O
enhanced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

These	O
findings	O
indicate	O
that	O
induction	O
of	O
HO	O
-	O
1	O
is	O
an	O
adaptive	O
response	O
to	O
CCl	B-FUNC
(	O
4	O
)	O
treatment	O
,	O
and	O
it	O
may	O
be	O
critical	O
in	O
the	O
recovery	O
of	O
hepatocytes	O
from	O
injury	O
.	O

ABSTRACT	O
:	O
An	O
epidemic	O
of	O
a	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
caused	O
by	O
a	O
new	O
coronavirus	O
has	O
spread	O
from	O
the	O
Guangdong	O
province	O
to	O
the	O
rest	B-FUNC
of	O
China	O
and	O
to	O
the	O
world	O
,	O
with	O
a	O
puzzling	O
contagion	O
behavior	O
.	O

Serum	O
was	O
analyzed	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
procalcitonin	O
.	O
and	O
measurements	O
:	O
EBC	O
NO	O
(	O
2	O
)(-)	O
correlated	O
well	O
with	O
VT	O
(	O
milliliters	O
per	O
kilogram	O
of	O
BW	O
;	O
r	O
=	O
0	O
.	O
79	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
expiratory	O
minute	O
volume	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
but	O
not	O
with	O
other	O
ventilatory	O
parameters	O
or	O
parameters	O
of	O
pulmonary	O
(	O
EBC	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
EBC	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
or	O
systemic	O
(	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
procalcitonin	O
)	O
inflammation	O
.	O

Here	O
we	O
demonstrate	O
that	O
two	O
closely	O
related	O
virus	O
variants	O
,	O
both	O
of	O
which	O
cause	O
acute	O
encephalitis	O
in	O
susceptible	O
strains	O
of	O
mice	O
,	O
cause	O
markedly	O
different	O
diseases	O
if	O
mice	O
are	O
protected	O
with	O
a	O
suboptimal	O
amount	O
of	O
an	O
anti	O
-	O
JHM	O
neutralizing	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
synthesis	O
is	O
mediated	O
by	O
a	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
on	O
membrane	O
-	O
bound	O
replication	O
complexes	O
in	O
the	O
host	O
cell	O
cytoplasm	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
putative	O
MHV	O
RdRp	B-FUNC
(	O
Pol	O
)	O
is	O
targeted	O
to	O
and	O
retained	O
on	O
cellular	O
membranes	O
.	O

Expression	O
of	O
Gpol	O
deletion	O
mutants	O
established	O
that	O
the	O
conserved	O
enzymatic	O
domains	O
of	O
Pol	O
were	O
dispensable	O
for	O
replication	O
complex	O
association	O
,	O
but	O
a	O
38	O
-	O
amino	O
-	O
acid	O
domain	O
in	O
the	O
RdRp	B-FUNC
unique	O
region	O
of	O
Pol	O
was	O
required	O
.	O

ABSTRACT	O
:	O
Heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
has	O
previously	O
been	O
shown	O
to	O
bind	B-FUNC
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
at	O
the	O
3	O
'	O
end	O
of	O
both	O
plus	O
and	O
minus	O
strands	O
and	O
modulate	O
MHV	O
RNA	O
synthesis	O
.	O

These	O
proteins	O
displayed	O
MHV	O
RNA	O
-	O
binding	B-FUNC
affinity	O
and	O
specificity	O
similar	O
to	O
those	O
of	O
hnRNP	O
A1	O
.	O

Among	O
the	O
10	O
index	O
cases	O
,	O
only	O
the	O
super	O
spreader	O
and	O
another	O
one	O
index	O
case	O
transmitted	O
the	O
virus	O
to	O
their	O
contacts	O
but	O
the	O
rest	B-FUNC
of	O
index	O
cases	O
did	O
not	O
cause	O
any	O
secondary	O
infection	O
.	O

Among	O
the	O
10	O
index	O
cases	O
,	O
only	O
the	O
super	O
spreader	O
and	O
another	O
one	O
index	O
case	O
transmitted	O
the	O
virus	O
to	O
their	O
contacts	O
but	O
the	O
rest	B-FUNC
of	O
index	O
cases	O
did	O
not	O
cause	O
any	O
secondary	O
infection	O
.	O

Diagnosis	O
was	O
made	O
on	O
the	O
basis	O
of	O
viral	O
culture	O
and	O
electron	O
microscopy	O
findings	O
that	O
exhibited	O
typical	O
crown	O
-	O
like	O
particles	O
and	O
through	O
amplification	O
of	O
the	O
viral	O
genome	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

In	O
an	O
in	O
vitro	O
screening	O
performed	O
at	O
NCI	O
,	O
several	O
compounds	O
emerged	O
as	O
potent	O
antiproliferative	O
agents	O
at	O
concentrations	O
ranging	O
between	O
10	O
and	O
100	O
microM	O
.	O
Interestingly	O
,	O
some	O
of	O
these	O
compounds	O
proved	O
active	O
also	O
against	O
bovine	O
and	O
murine	O
DHFR	B-FUNC
(	O
Farmaco	O
53	O
(	O
1998	O
)	O
480	O
).	O

Enfuvirtide	O
and	O
C34	O
,	O
another	O
anti	O
HIV	O
-	O
1	O
peptide	O
,	O
exert	O
their	O
inhibitory	O
activity	O
by	O
binding	B-FUNC
to	O
a	O
leucine	O
/	O
isoleucine	O
zipper	O
-	O
like	O
sequence	O
in	O
gp41	O
,	O
thus	O
inhibiting	O
a	O
conformational	O
change	O
of	O
gp41	O
required	O
for	O
its	O
activation	O
.	O

Serum	O
coronavirus	O
nucleic	O
acid	O
was	O
positive	O
in	O
3	O
patients	O
,	O
coronavirus	O
antibody	B-FUNC
positive	O
in	O
two	O
and	O
both	O
were	O
positive	O
in	O
one	O
.	O

The	O
clinical	O
course	O
,	O
laboratory	O
data	O
,	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
titers	O
,	O
and	O
results	O
of	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
were	O
studied	O
.	O

Rather	O
,	O
twelve	O
nucleobases	O
forming	O
six	O
base	B-FUNC
pairs	I-FUNC
joined	O
by	O
mutually	O
exclusive	O
hydrogen	O
bonding	O
patterns	O
are	O
possible	O
within	O
the	O
geometry	O
of	O
the	O
Watson	O
-	O
Crick	O
pair	O
(	O
Fig	O
.	O
1	O
).	O

TITLE	O
:	O
Fas	O
ligand	B-FUNC
-	O
induced	O
murine	O
pulmonary	O
inflammation	O
is	O
reduced	O
by	O
a	O
stable	O
decoy	O
receptor	O
3	O
analogue	O
.	O

ABSTRACT	O
:	O
Fas	O
ligand	B-FUNC
(	O
FasL	O
)-	O
induced	O
lung	O
inflammation	O
has	O
recently	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
disease	O
syndrome	O
(	O
ARDS	O
).	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
beta	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
p70	O
,	O
interferon	O
gamma	O
(	O
IFN	O
gamma	O
),	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
alpha	O
)	O
were	O
determined	O
by	O
quantitative	O
ELISA	O
during	O
the	O
course	O
of	O
disease	O
respectively	O
.	O

Along	O
with	O
the	O
course	O
of	O
disease	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentration	O
kept	O
going	O
up	O
and	O
75	O
%	O
(	O
18	O
/	O
24	O
)	O
patients	O
reached	O
a	O
peak	O
median	O
concentration	O
of	O
149	O
.	O
65	O
ng	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
third	O
and	O
fourth	O
weeks	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
came	O
back	O
to	O
normal	O
control	O
levels	O
one	O
month	O
after	O
discharged	O
from	O
hospital	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
alpha	O
probably	O
play	O
important	O
roles	O
in	O
mediating	O
strong	O
inflammatory	O
response	O
,	O
which	O
are	O
thought	O
to	O
be	O
responsible	O
for	O
lung	O
injury	O
in	O
SARS	O
patients	O
.	O

RESULTS	O
:	O
All	O
SARS	O
patients	O
had	O
remarkably	O
increased	O
plasma	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
(	O
median	O
31	O
.	O
23	O
ng	O
/	O
L	O
)	O
at	O
the	O
onset	O
of	O
disease	O
compared	O
with	O
those	O
of	O
normal	O
controls	O
(	O
6	O
.	O
28	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Viral	O
RNA	O
may	O
persist	O
for	O
some	O
time	O
in	O
patients	O
who	O
seroconvert	O
,	O
and	O
some	O
patients	O
may	O
lack	O
an	O
antibody	B-FUNC
response	O
(	O
immunoglobulin	B-FUNC
G	O
)	O
to	O
SARS	O
-	O
CoV	O
<	O
21	O
days	O
after	O
illness	O
onset	O
.	O

An	O
upsurge	O
of	O
antibody	B-FUNC
response	O
was	O
associated	O
with	O
the	O
aggravation	O
of	O
respiratory	O
failure	O
.	O

All	O
patients	O
had	O
fever	O
(	O
5	O
/	O
5	O
),	O
3	O
chills	O
or	O
rigor	O
,	O
4	O
cough	O
;	O
2	O
with	O
decreased	O
lymphocyte	O
,	O
2	O
decreased	O
platelet	O
,	O
3	O
elevated	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
4	O
hypoalbuminemia	O
,	O
5	O
abnormal	O
chest	O
radiographs	O
.	O

We	O
used	O
a	O
Bayesian	O
phylogenetic	O
inference	O
approach	O
with	O
sliding	O
window	O
analyses	O
of	O
three	O
SARS	O
-	O
CoV	O
proteins	O
:	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	B-FUNC
),	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
).	O

Conservation	O
of	O
RDRP	B-FUNC
allowed	O
us	O
to	O
use	O
a	O
set	O
of	O
Arteriviridae	O
taxa	O
to	O
root	O
the	O
Coronaviridae	O
phylogeny	O
.	O

A	O
systematic	O
search	O
for	O
perinatal	O
transmission	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
including	O
serial	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assays	O
,	O
viral	O
cultures	O
,	O
and	O
paired	O
serologic	O
titers	O
,	O
failed	O
to	O
detect	O
the	O
virus	O
in	O
any	O
of	O
the	O
infants	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

Heart	O
rate	O
,	O
oxygen	O
saturation	O
,	O
temperature	O
,	O
and	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
levels	O
were	O
recorded	O
daily	O
.	O

Admission	O
radiographic	O
score	O
was	O
correlated	O
with	O
admission	O
AST	O
level	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
=.	O
003	O
);	O
treatment	O
radiographic	O
score	O
,	O
with	O
treatment	O
ALT	B-FUNC
and	O
AST	O
levels	O
(	O
r	O
=	O
0	O
.	O
43	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
0	O
.	O
42	O
,	O
P	O
=.	O
019	O
);	O
and	O
time	O
to	O
maximal	O
radiographic	O
score	O
,	O
with	O
AST	O
level	O
at	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
45	O
,	O
P	O
=.	O
006	O
),	O
admission	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
55	O
,	O
P	O
<.	O
001	O
),	O
treatment	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
<.	O
001	O
),	O
and	O
admission	O
ALT	B-FUNC
and	O
AST	O
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
44	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
=.	O
001	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
observed	O
in	O
serum	O
levels	O
of	O
interleukins	O
(	O
ILs	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
mean	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
16	I-FUNC
and	O
TNF	O
-	O
alpha	O
in	O
SARS	O
patients	O
were	O
higher	O
than	O
those	O
of	O
the	O
control	O
group	O
for	O
every	O
length	O
of	O
the	O
clinical	O
courses	O
investigated	O
,	O
and	O
were	O
especially	O
high	O
in	O
remission	O
and	O
recovery	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

SARS	O
patients	O
experienced	O
higher	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
compared	O
with	O
the	O
controls	O
in	O
initial	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
returned	O
to	O
normal	O
levels	O
in	O
peak	O
stage	O
and	O
in	O
remission	O
and	O
recovery	O
stage	O
.	O

Therefore	O
,	O
a	O
target	O
of	O
interest	O
could	O
be	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
zinc	O
finger	O
HIV	O
-	O
1	O
RNA	O
-	O
binding	B-FUNC
nucleocapsid	O
protein	O
p7	O
(	O
NCp7	O
).	O

Through	O
suggested	O
zinc	O
ejection	O
from	O
HIV	O
-	O
1	O
genomic	O
RNA	O
psi	O
-	O
element	O
-	O
binding	B-FUNC
and	O
HIV	O
-	O
1	O
-	O
RNA	O
-	O
duplex	O
packaging	O
NCp7	O
by	O
BN	O
,	O
thus	O
rendering	O
NCp7	O
functionally	O
obsolete	O
,	O
it	O
is	O
deduced	O
that	O
HIV	O
-	O
1	O
replication	O
and	O
effective	O
infectious	O
virion	O
encapsidation	O
could	O
be	O
inhibited	O
by	O
BN	O
.	O

TITLE	O
:	O
Putative	O
caveolin	O
-	O
binding	B-FUNC
sites	O
in	O
SARS	O
-	O
CoV	O
proteins	O
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
information	O
of	O
protein	O
-	O
protein	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
proteins	O
and	O
caveolin	O
-	O
1	O
,	O
identify	O
the	O
possible	O
caveolin	O
-	O
binding	B-FUNC
sites	O
in	O
SARS	O
-	O
CoV	O
proteins	O
.	O

On	O
the	O
basis	O
of	O
three	O
related	O
caveolin	O
-	O
binding	B-FUNC
motifs	O
,	O
amino	O
acid	O
motif	O
search	O
was	O
employed	O
to	O
predict	O
the	O
possible	O
caveolin	O
-	O
1	O
related	O
interaction	O
domains	O
in	O
the	O
SARS	O
-	O
CoV	O
proteins	O
.	O

Thirty	O
six	O
caveolin	O
-	O
binding	B-FUNC
motifs	O
in	O
the	O
SARS	O
-	O
CoV	O
proteins	O
have	O
been	O
mapped	O
out	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

RESULTS	O
:	O
Thirty	O
six	O
caveolin	O
-	O
binding	B-FUNC
motifs	O
in	O
the	O
SARS	O
-	O
CoV	O
proteins	O
have	O
been	O
mapped	O
out	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

These	O
caveolin	O
-	O
binding	B-FUNC
sites	O
located	O
in	O
replicase	O
1AB	O
,	O
spike	O
protein	O
,	O
orf3	O
protein	O
,	O
and	O
M	O
protein	O
,	O
respectively	O
.	O

During	O
the	O
recovery	O
,	O
follow	O
-	O
up	O
stages	O
and	O
in	O
the	O
front	O
healthy	O
crowd	O
,	O
the	O
positive	O
ratios	O
of	O
IgG	O
were	O
all	O
higher	O
than	O
those	O
of	O
IgM	O
.	O
The	O
changeable	O
tendency	O
SARS	O
antibody	B-FUNC
is	O
more	O
different	O
than	O
that	O
of	O
other	O
infectious	O
diseases	O
.	O

During	O
the	O
recovery	O
,	O
follow	O
-	O
up	O
stages	O
and	O
in	O
the	O
front	O
healthy	O
crowd	O
,	O
the	O
positive	O
ratios	O
of	O
IgG	O
were	O
all	O
higher	O
than	O
those	O
of	O
IgM	O
.	O
CONCLUSIONS	O
:	O
The	O
changeable	O
tendency	O
SARS	O
antibody	B-FUNC
is	O
more	O
different	O
than	O
that	O
of	O
other	O
infectious	O
diseases	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
to	O
brush	O
border	O
membrane	O
sialoglycoproteins	O
.	O

A	O
nonenteropathogenic	O
mutant	O
virus	O
that	O
lacked	O
a	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
was	O
unable	O
to	O
bind	B-FUNC
to	O
MGP	O
and	O
to	O
attach	O
to	O
goblet	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
the	O
presence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
-	O
specific	O
antibodies	O
in	O
the	O
sera	B-FUNC
from	O
non	O
-	O
SARS	O
children	O
.	O

Indirect	O
immunofluorescent	O
assay	O
and	O
double	O
-	O
antigen	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
were	O
used	O
to	O
detect	O
the	O
virus	O
-	O
specific	O
antibodies	O
in	O
sera	B-FUNC
of	O
1	O
,	O
060	O
non	O
-	O
SARS	O
children	O
in	O
Guangzhou	O
.	O

No	O
SARS	O
coronavirus	O
-	O
specific	O
antibody	B-FUNC
are	O
present	O
in	O
the	O
sera	B-FUNC
of	O
non	O
-	O
SARS	O
children	O
.	O

The	O
linear	O
decrease	O
of	O
the	O
enzymatic	O
-	O
specific	O
activity	O
with	O
the	O
decrease	O
of	O
enzyme	O
concentration	O
revealed	O
that	O
only	O
the	O
dimeric	O
form	O
is	O
active	O
and	O
the	O
dimeric	O
interface	O
could	O
be	O
targeted	O
for	O
structural	O
-	O
based	O
drug	O
design	O
against	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

By	O
using	O
a	O
high	O
pressure	O
liquid	O
chromatography	O
assay	O
,	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
was	O
shown	O
to	O
cut	O
the	O
11	O
peptides	O
covering	O
all	O
of	O
the	O
11	O
cleavage	O
sites	O
on	O
the	O
viral	O
polyprotein	O
with	O
different	O
efficiency	O
.	O

This	O
study	O
provides	O
a	O
basic	O
understanding	O
of	O
the	O
enzyme	O
catalysis	O
and	O
a	O
full	O
substrate	O
specificity	O
spectrum	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
,	O
which	O
are	O
helpful	O
for	O
structural	O
-	O
based	O
inhibitor	O
design	O
against	O
SARS	O
and	O
other	O
coronavirus	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
IgG	O
antibody	B-FUNC
to	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
animal	O
traders	O
--	O
Guangdong	O
Province	O
,	O
China	O
,	O
2003	O
.	O

This	O
report	O
summarizes	O
results	O
of	O
an	O
investigation	O
conducted	O
by	O
public	O
health	O
authorities	O
in	O
Guangdong	O
Province	O
,	O
which	O
compared	O
the	O
seroprevalence	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
in	O
animal	O
traders	O
(	O
i	O
.	O
e	O
.,	O
workers	O
in	O
live	O
animal	O
markets	O
)	O
with	O
that	O
of	O
persons	O
in	O
control	O
groups	O
.	O

TITLE	O
:	O
Establishment	O
of	O
persistent	O
avian	O
infectious	O
bronchitis	O
virus	O
infection	O
in	O
antibody	B-FUNC
-	O
free	O
and	O
antibody	B-FUNC
-	O
positive	O
chickens	O
.	O

Nevertheless	O
,	O
whether	O
chickens	O
can	O
maintain	O
persistent	O
IBV	O
infection	O
in	O
the	O
absence	O
of	O
reinfection	O
from	O
exogenous	O
sources	O
or	O
the	O
presence	O
of	O
antibody	B-FUNC
in	O
the	O
host	O
can	O
modulate	O
virus	O
persistence	O
remains	O
unclear	O
.	O

In	O
the	O
first	O
of	O
two	O
experiments	O
,	O
intranasal	O
exposure	O
of	O
6	O
-	O
wk	O
-	O
old	O
antibody	B-FUNC
-	O
free	O
chickens	O
to	O
IBV	O
vaccine	O
virus	O
resulted	O
in	O
intermittent	O
shedding	O
of	O
the	O
virus	O
from	O
both	O
trachea	O
and	O
cloaca	O
of	O
individual	O
birds	O
for	O
up	O
to	O
63	O
days	O
.	O

In	O
the	O
second	O
experiment	O
,	O
IBV	O
exposure	O
of	O
1	O
-	O
day	O
-	O
old	O
maternal	O
antibody	B-FUNC
-	O
positive	O
chicks	O
led	O
to	O
periodic	O
virus	O
shedding	O
from	O
the	O
trachea	O
and	O
cloaca	O
in	O
all	O
chickens	O
until	O
77	O
days	O
;	O
however	O
,	O
internal	O
organs	O
(	O
lungs	O
and	O
kidneys	O
)	O
of	O
only	O
one	O
of	O
seven	O
birds	O
(	O
killed	O
at	O
175	O
DPI	O
)	O
were	O
virus	O
positive	O
,	O
suggesting	O
that	O
presence	O
of	O
antibody	B-FUNC
at	O
the	O
time	O
of	O
infection	O
protects	O
internal	O
organs	O
from	O
IBV	O
infection	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	O
bronchitis	O
virus	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
identification	O
of	O
a	O
quasispecies	O
in	O
the	O
Beaudette	O
strain	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
diagnostic	O
test	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
with	O
the	O
use	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technology	O
.	O

Two	O
primers	O
that	O
amplify	O
a	O
383	O
-	O
base	B-FUNC
pair	I-FUNC
product	O
between	O
nucleotide	O
positions	O
703	O
and	O
1086	O
relative	O
to	O
the	O
start	O
codon	O
for	O
the	O
S1	O
gene	O
of	O
the	O
Massachusetts	O
41	O
virus	O
were	O
designed	O
and	O
used	O
to	O
amplify	O
the	O
Beaudette	O
,	O
Massachusetts	O
41	O
,	O
Florida	O
18288	O
,	O
Connecticut	O
,	O
Iowa	O
97	O
,	O
Arkansas	O
DPI	O
,	O
CA	O
/	O
NE95	O
/	O
99	O
,	O
DE	O
/	O
072	O
/	O
92	O
,	O
and	O
GA	O
/	O
0470	O
/	O
98	O
strains	O
of	O
IBV	O
.	O

For	O
RRT	O
-	O
PCR	O
by	O
FRET	O
,	O
an	O
anchor	O
probe	O
conjugated	O
to	O
fluorescein	O
and	O
a	O
detection	O
probe	O
conjugated	O
to	O
a	O
red	O
fluorophore	O
were	O
designed	O
to	O
anneal	O
to	O
a	O
hypervariable	O
region	O
within	O
the	O
383	O
-	O
base	B-FUNC
pair	I-FUNC
product	O
.	O

Serology	O
indicated	O
the	O
infecting	O
virus	O
was	O
most	O
closely	O
related	O
to	O
type	O
I	O
FCoV	O
.	O
Antibody	B-FUNC
levels	O
in	O
the	O
majority	O
of	O
animals	O
were	O
low	O
,	O
even	O
in	O
those	O
actively	O
infected	O
.	O

The	O
cleavage	O
sites	O
of	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
and	O
papain	O
-	O
like	O
proteinase	B-FUNC
are	O
highly	O
conserved	O
.	O

Based	O
on	O
the	O
method	O
of	O
traditional	O
positional	O
weight	O
matrix	O
trained	O
by	O
the	O
peptides	O
around	O
cleavage	O
sites	O
,	O
the	O
present	O
method	O
also	O
sufficiently	O
considers	O
the	O
length	O
conservation	O
of	O
non	O
-	O
structural	O
proteins	O
cleaved	O
by	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
and	O
papain	O
-	O
like	O
proteinase	B-FUNC
to	O
reduce	O
the	O
false	O
positive	O
prediction	O
rate	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
false	O
-	O
positive	O
of	O
serological	O
diagnostic	O
testing	O
for	O
coronavirus	O
antibody	B-FUNC
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
),	O
66	O
normal	O
individual	O
and	O
31	O
SLE	O
with	O
non	O
-	O
SARS	O
patients	O
were	O
detected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-FUNC
and	O
RNA	O
by	O
enzymelinked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
result	O
showed	O
2	O
/	O
66	O
cases	O
(	O
3	O
.	O
0	O
%)	O
were	O
positive	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
antibody	B-FUNC
and	O
66	O
cases	O
were	O
negative	O
of	O
SARS	O
-	O
CoV	O
-	O
IgM	O
antibody	B-FUNC
in	O
the	O
66	O
cases	O
healthy	O
controls	O
;	O
in	O
31	O
cases	O
with	O
SLE	O
,	O
positive	O
rates	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
were	O
58	O
.	O
1	O
%	O
(	O
18	O
/	O
31	O
)	O
and	O
29	O
%	O
(	O
9	O
/	O
31	O
),	O
respectively	O
,	O
in	O
which	O
7	O
cases	O
(	O
22	O
.	O
6	O
%)	O
were	O
positive	O
of	O
both	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
.	O

The	O
ELISA	O
kit	B-FUNC
coated	O
by	O
non	O
-	O
purification	O
antigen	O
may	O
induce	O
the	O
false	O
-	O
positive	O
of	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
in	O
patients	O
with	O
SLE	O
.	O

This	O
result	O
suggested	O
that	O
the	O
specificity	O
of	O
ELISA	O
tests	O
for	O
SARS	O
was	O
excellent	O
and	O
has	O
low	O
false	O
-	O
positive	O
rates	O
when	O
using	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
tests	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
development	O
of	O
IgG	O
and	O
IgM	O
against	O
SARS	O
CoV	O
and	O
characteristics	O
of	O
changes	O
of	O
antibody	B-FUNC
titers	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
search	O
the	O
opportunity	O
for	O
collecting	O
specific	O
anti	O
-	O
serum	O
from	O
convalescent	O
patients	O
with	O
SARS	O
.	O

The	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-FUNC
levels	O
in	O
156	O
SARS	O
patients	O
were	O
measured	O
with	O
ELISA	O
.	O

It	O
was	O
concluded	O
that	O
not	O
all	O
SARS	O
patients	O
could	O
produce	O
the	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-FUNC
.	O

In	O
order	O
to	O
obtain	O
effective	O
anti	O
-	O
serum	O
,	O
the	O
titers	O
of	O
antibody	B-FUNC
must	O
be	O
tested	O
just	O
before	O
collection	O
of	O
convalescent	O
serum	O
,	O
and	O
it	O
ensures	O
the	O
therapeutic	O
effect	O
and	O
provides	O
a	O
measurable	O
index	O
for	O
clinical	O
transfusion	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
RdRp	B-FUNC
and	O
HEL	O
domains	O
were	O
extended	O
to	O
include	O
arterivirus	O
and	O
ronivirus	O
homologs	O
.	O

We	O
showed	O
previously	O
that	O
these	O
persistently	O
infected	O
mice	O
did	O
not	O
mount	O
a	O
measurable	O
serum	O
anti	O
-	O
MHV	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

These	O
findings	O
indicate	O
a	O
key	O
role	O
for	O
the	O
anti	O
-	O
MHV	O
antibody	B-FUNC
response	O
in	O
suppressing	O
virus	O
replication	O
,	O
thereby	O
minimizing	O
the	O
emergence	O
and	O
competitive	O
advantage	O
of	O
CTL	O
escape	O
mutants	O
.	O

Prior	O
treatment	O
of	O
cells	O
with	O
the	O
lysosomotropic	O
agents	O
NH	O
(	O
4	O
)	O
Cl	O
and	O
chloroquine	O
as	O
well	O
as	O
the	O
vacuolar	O
proton	B-FUNC
pump	I-FUNC
-	O
ATPase	O
inhibitor	O
bafilomycin	O
A1	O
,	O
all	O
of	O
which	O
block	O
the	O
acidification	O
of	O
the	O
endosome	O
,	O
prevented	O
oligodendrocytes	O
from	O
succumbing	O
to	O
apoptosis	O
induced	O
by	O
MHV	O
mutant	O
OBLV60	O
,	O
which	O
enters	O
cells	O
via	O
endocytosis	O
,	O
indicating	O
that	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
cell	O
membranes	O
triggers	O
the	O
apoptotic	O
cascade	O
.	O

This	O
series	O
of	O
crystal	O
structures	O
,	O
which	O
is	O
the	O
first	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
any	O
protein	O
from	O
the	O
SARS	O
virus	O
,	O
reveal	O
substantial	O
pH	O
-	O
dependent	O
conformational	O
changes	O
,	O
and	O
an	O
unexpected	O
mode	O
of	O
inhibitor	O
binding	B-FUNC
,	O
providing	O
a	O
structural	O
basis	O
for	O
rational	O
drug	O
design	O
.	O

TITLE	O
:	O
Identifying	O
inhibitors	O
of	O
the	O
SARS	O
coronavirus	O
proteinase	B-FUNC
.	O

On	O
multivariate	O
Cox	O
regression	O
,	O
age	O
older	O
than	O
60	O
years	O
(	O
relative	O
risk	O
,	O
5	O
.	O
10	O
[	O
CI	O
,	O
2	O
.	O
30	O
to	O
11	O
.	O
31	O
];	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
lactate	O
dehydrogenase	O
level	O
greater	O
than	O
3	O
.	O
8	O
micro	O
kat	B-FUNC
/	O
L	O
at	O
presentation	O
(	O
relative	O
risk	O
,	O
2	O
.	O
20	O
[	O
CI	O
,	O
1	O
.	O
03	O
to	O
4	O
.	O
71	O
];	O
P	O
=	O
0	O
.	O
04	O
)	O
were	O
independent	O
predictors	O
of	O
mortality	O
.	O

In	O
recovery	O
phase	O
,	O
the	O
rest	B-FUNC
heart	O
rates	O
in	O
64	O
%	O
of	O
patients	O
with	O
SARS	O
exceeded	O
90	O
bpm	O
,	O
and	O
the	O
heart	O
rates	O
after	O
mild	O
exercises	O
in	O
72	O
.	O
1	O
%	O
of	O
patients	O
with	O
SARS	O
exceeded	O
100	O
bpm	O
.	O

RESULTS	O
:	O
In	O
recovery	O
phase	O
,	O
the	O
rest	B-FUNC
heart	O
rates	O
in	O
64	O
%	O
of	O
patients	O
with	O
SARS	O
exceeded	O
90	O
bpm	O
,	O
and	O
the	O
heart	O
rates	O
after	O
mild	O
exercises	O
in	O
72	O
.	O
1	O
%	O
of	O
patients	O
with	O
SARS	O
exceeded	O
100	O
bpm	O
.	O

GR	O
of	O
peripheral	O
leukocytes	O
in	O
the	O
patients	O
were	O
determined	O
by	O
radioligand	O
binding	B-FUNC
assay	O
using	O
((	O
3	O
)	O
H	O
)	O
dexamethasone	O
as	O
ligand	B-FUNC
.	O

TITLE	O
:	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
employing	O
a	O
recombinant	O
antigen	O
for	O
detection	O
of	O
protective	O
antibody	B-FUNC
against	O
swine	O
erysipelas	O
.	O

Interference	O
with	O
the	O
production	O
of	O
antibody	B-FUNC
against	O
live	O
vaccine	O
by	O
maternal	O
antibody	B-FUNC
or	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
infection	O
1	O
week	O
after	O
vaccination	O
was	O
also	O
clearly	O
detected	O
.	O

These	O
results	O
indicate	O
that	O
the	O
SpaA416	O
ELISA	O
is	O
an	O
effective	O
method	O
not	O
only	O
for	O
evaluating	O
pigs	O
for	O
the	O
presence	O
of	O
protective	O
antibody	B-FUNC
levels	O
resulting	O
from	O
vaccination	O
or	O
maternal	O
antibody	B-FUNC
but	O
also	O
for	O
detecting	O
antibody	B-FUNC
produced	O
by	O
natural	O
infection	O
.	O

Immunity	O
assay	O
with	O
BALB	O
/	O
C	O
mice	O
showed	O
that	O
expression	O
products	O
of	O
transgenic	O
potato	O
with	O
S1	O
gene	O
of	O
IBV	O
were	O
immunogenic	O
,	O
and	O
ELISA	O
antibody	B-FUNC
titer	O
reached	O
1	O
:	O
20	O
to	O
1	O
:	O
40	O
and	O
1	O
:	O
80	O
to	O
1	O
:	O
160	O
with	O
doses	O
of	O
0	O
.	O
5	O
g	O
and	O
1	O
g	O
,	O
respectively	O
.	O

TITLE	O
:	O
Changes	O
in	O
some	O
acute	O
phase	O
protein	O
and	O
immunoglobulin	B-FUNC
concentrations	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
or	O
exposed	O
to	O
feline	O
coronavirus	O
infection	O
.	O

A	O
large	O
component	O
of	O
the	O
variance	O
(	O
91	O
.	O
7	O
%)	O
was	O
accounted	O
for	O
by	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
MIP	O
-	O
1	O
alpha	O
,	O
and	O
RANTES	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
the	O
monoclonal	O
antibody	B-FUNC
against	O
nucleocapsid	O
antigen	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
autopsy	O
tissues	O
from	O
SARS	O
patients	O
].	O

TITLE	O
:	O
[	O
The	O
quantitative	O
detection	O
of	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
titer	O
in	O
medical	O
personnel	O
closely	O
contacted	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
].	O

The	O
serum	O
anti	O
-	O
coronavirus	O
IgG	O
antibody	B-FUNC
titer	O
in	O
patients	O
recovered	O
from	O
SARS	O
was	O
0	O
.	O
07	O
+/-	O

The	O
antibody	B-FUNC
titer	O
in	O
medical	O
personnel	O
was	O
-	O
1	O
.	O
18	O
+/-	O

In	O
the	O
healthy	O
persons	O
,	O
the	O
antibody	B-FUNC
titer	O
of	O
serum	O
samples	O
obtained	O
from	O
Beijing	O
in	O
May	O
,	O
2003	O
was	O
-	O
1	O
.	O
61	O
+/-	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
antibody	B-FUNC
titer	O
between	O
patients	O
of	O
bacterial	O
pneumonia	O
and	O
patients	O
of	O
atypical	O
pneumonia	O
,	O
which	O
was	O
-	O
1	O
.	O
99	O
+/-	O

Close	O
contact	O
with	O
SARS	O
patients	O
can	O
cause	O
the	O
serum	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
titer	O
to	O
increase	O
significantly	O
in	O
medical	O
personnel	O
,	O
a	O
phenomenon	O
deserves	O
further	O
study	O
.	O

RESULTS	O
:	O
The	O
serum	O
anti	O
-	O
coronavirus	O
IgG	O
antibody	B-FUNC
titer	O
in	O
patients	O
recovered	O
from	O
SARS	O
was	O
0	O
.	O
07	O
+/-	O
0	O
.	O
13	O
,	O
which	O
was	O
significantly	O
higher	O
as	O
compared	O
with	O
those	O
in	O
other	O
groups	O
.	O

CONCLUSIONS	O
:	O
Close	O
contact	O
with	O
SARS	O
patients	O
can	O
cause	O
the	O
serum	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
titer	O
to	O
increase	O
significantly	O
in	O
medical	O
personnel	O
,	O
a	O
phenomenon	O
deserves	O
further	O
study	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
observed	O
in	O
serum	O
levels	O
of	O
interleukins	O
(	O
ILs	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
,	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
in	O
8	O
-	O
14	O
days	O
group	O
and	O
in	O
over	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
than	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
mean	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
16	I-FUNC
and	O
TNF	O
-	O
alpha	O
in	O
all	O
groups	O
of	O
SARS	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
,	O
but	O
it	O
was	O
the	O
highest	O
in	O
over	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

SARS	O
patients	O
experienced	O
higher	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
as	O
compared	O
to	O
controls	O
in	O
3	O
-	O
7	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
it	O
returned	O
to	O
normal	O
levels	O
in	O
8	O
-	O
14	O
day	O
group	O
and	O
the	O
over	O
14	O
day	O
group	O
.	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
in	O
SARS	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
groups	O
of	O
SARS	O
patients	O
(	O
P	O
<	O
0	O
.	O
05	O
);	O
The	O
mean	O
concentration	O
of	O
TGF	O
-	O
beta1	O
in	O
all	O
groups	O
of	O
SARS	O
patients	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
.	O

Concurrently	O
,	O
the	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
decreased	O
gradually	O
and	O
the	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
level	O
in	O
SARS	O
patients	O
was	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
the	O
whole	O
disease	O
course	O
.	O

ABSTRACT	O
:	O
The	O
widespread	O
threat	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
human	O
life	O
has	O
spawned	O
challenges	O
to	O
develop	O
fast	B-FUNC
and	O
accurate	O
analytical	O
methods	O
for	O
its	O
early	O
diagnosis	O
and	O
to	O
create	O
a	O
safe	O
antiviral	O
vaccine	O
for	O
preventive	O
use	O
.	O

Consequently	O
,	O
we	O
thoroughly	O
investigated	O
the	O
immunoreactivities	O
with	O
patient	O
sera	B-FUNC
of	O
a	O
series	O
of	O
synthesized	O
peptides	O
from	O
SARS	O
-	O
coronavirus	O
structural	O
proteins	O
.	O

The	O
immunoreactivities	O
of	O
the	O
peptides	O
with	O
SARS	O
patient	O
sera	B-FUNC
were	O
determined	O
by	O
ELISA	O
.	O

N385	O
had	O
the	O
highest	O
affinity	O
for	O
forming	O
peptide	O
-	O
antibody	B-FUNC
complexes	O
with	O
SARS	O
serum	O
.	O

Generally	O
,	O
affected	O
tissues	O
had	O
lower	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
-	O
p40	O
mRNA	O
and	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
mRNA	O
.	O

ABSTRACT	O
:	O
The	O
Type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
of	O
feline	O
macrophages	O
is	O
enhanced	O
by	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
to	O
the	O
S	O
protein	O
of	O
FIPV	O
.	O

This	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
activity	O
increased	O
with	O
the	O
MAb	O
that	O
showed	O
a	O
neutralizing	O
activity	O
with	O
feline	O
kidney	O
cells	O
,	O
suggesting	O
that	O
there	O
was	O
a	O
distinct	O
correlation	O
between	O
ADE	O
activity	O
and	O
the	O
neutralizing	O
activity	O
.	O

Finally	O
,	O
anti	O
-	O
ACE2	O
but	O
not	O
anti	O
-	O
ACE1	O
antibody	B-FUNC
blocked	O
viral	O
replication	O
on	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
[	O
Reliability	O
of	O
detecting	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
for	O
diagnosis	O
of	O
SARS	O
].	O

The	O
ACs	B-FUNC
of	O
T	O
lymphocytes	O
including	O
CD4	O
and	O
CD8	O
subsets	O
in	O
different	O
phases	O
were	O
as	O
below	O
:	O
III	O
>	O
II	O
>	O
I	O
.	O
The	O
ACs	B-FUNC
of	O
subsets	O
involved	O
in	O
activation	O
such	O
as	O
CD3	O
+	O
HLA	O
-	O
DR	O
+/	O
lym	O
,	O
CD3	O
+	O
CD25	O
+/	O
lym	O
,	O
CD28	O
+	O
CD4	O
+/	O
CD4	O
,	O
CD28	O
+	O
CD8	O
+/	O
CD8	O
,	O
and	O
CD38	O
+	O
CD4	O
+/	O
CD4	O
all	O
were	O
highest	O
in	O
group	O
III	O
.	O

Together	O
with	O
data	O
for	O
inhibition	O
of	O
binding	B-FUNC
by	O
antibodies	O
developed	O
against	O
peptides	O
from	O
S	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
is	O
located	O
between	O
amino	O
acid	O
residues	O
303	O
and	O
537	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
of	O
SARS	O
-	O
CoV	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
replication	O
and	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
SARS	O
therapy	O
.	O

To	O
provide	O
insights	O
into	O
the	O
structure	O
and	O
function	O
of	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
,	O
we	O
have	O
located	O
its	O
conserved	O
motifs	O
that	O
are	O
shared	O
by	O
all	O
RdRps	O
,	O
and	O
built	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
the	O
catalytic	O
domain	O
.	O

We	O
predict	O
important	O
structural	O
attributes	O
of	O
potential	O
anti	O
-	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
nucleotide	O
analog	O
inhibitors	O
:	O
hydrogen	O
-	O
bonding	O
capability	O
for	O
the	O
2	O
'	O
and	O
3	O
'	O
groups	O
of	O
the	O
sugar	O
ring	O
and	O
C3	O
'	O
endo	O
sugar	O
puckering	O
,	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
binding	B-FUNC
pocket	O
for	O
non	O
-	O
nucleoside	O
analog	O
inhibitors	O
similar	O
to	O
those	O
observed	O
in	O
hepatitis	O
C	O
virus	O
RdRp	B-FUNC
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
reverse	O
transcriptase	B-FUNC
.	O

On	O
effusion	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
Rivalta	O
'	O
s	O
test	O
,	O
a	O
test	O
that	O
distinguishes	O
between	O
exudates	O
and	O
transudates	O
(	O
0	O
.	O
86	O
and	O
0	O
.	O
97	O
),	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
detection	O
(	O
0	O
.	O
90	O
and	O
0	O
.	O
79	O
),	O
and	O
immunofluorescence	O
staining	O
of	O
coronavirus	O
antigen	O
in	O
macrophages	O
(	O
1	O
.	O
00	O
and	O
0	O
.	O
57	O
)	O
were	O
investigated	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
presence	O
of	O
anti	O
-	O
coronavirus	O
antibodies	O
were	O
0	O
.	O
44	O
and	O
0	O
.	O
90	O
,	O
respectively	O
,	O
antibody	B-FUNC
concentrations	O
(	O
1	O
:	O
1	O
,	O
600	O
)	O
were	O
0	O
.	O
94	O
and	O
0	O
.	O
88	O
.	O

presence	O
of	O
immune	O
complexes	O
measured	O
by	O
a	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
were	O
0	O
.	O
67	O
and	O
0	O
.	O
84	O
,	O
and	O
detection	O
of	O
viral	O
RNA	O
by	O
serum	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
0	O
.	O
90	O
and	O
0	O
.	O
47	O
.	O

TITLE	O
:	O
Characterization	O
of	O
N	O
protein	B-FUNC
self	I-FUNC
-	I-FUNC
association	I-FUNC
in	O
coronavirus	O
ribonucleoprotein	O
complexes	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
binds	B-FUNC
to	O
the	O
large	O
,	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	O
viral	O
genomic	O
RNA	O
to	O
form	O
a	O
helical	O
nucleocapsid	O
structure	O
in	O
mature	O
virions	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
),	O
and	O
in	O
situ	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
lung	O
sections	O
was	O
performed	O
using	O
SARS	O
coronavirus	O
-	O
specific	O
primers	O
.	O

TITLE	O
:	O
A	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
the	O
diagnosis	O
of	O
turkey	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
This	O
study	O
reports	O
on	O
the	O
development	O
of	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
specific	O
detection	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
).	O

The	O
vaccinated	O
animals	O
all	O
had	O
antibody	B-FUNC
responses	O
against	O
spike	O
protein	O
S1	O
fragment	O
and	O
T	O
-	O
cell	O
responses	O
against	O
the	O
nucleocapsid	O
protein	O
.	O

All	O
vaccinated	O
animals	O
showed	O
strong	O
neutralising	O
antibody	B-FUNC
responses	O
to	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

TITLE	O
:	O
A	O
193	O
-	O
amino	O
acid	O
fragment	O
of	O
the	O
SARS	O
coronavirus	O
S	O
protein	O
efficiently	O
binds	B-FUNC
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

Smaller	O
S	O
protein	O
fragments	O
,	O
expressing	O
residues	O
327	O
-	O
510	O
or	O
318	O
-	O
490	O
,	O
did	O
not	O
detectably	O
bind	B-FUNC
ACE2	O
.	O

This	O
event	O
occurred	O
near	O
a	O
region	O
that	O
has	O
been	O
implicated	O
to	O
be	O
the	O
human	O
receptor	B-FUNC
binding	I-FUNC
site	O
and	O
may	O
have	O
been	O
directly	O
responsible	O
for	O
the	O
switch	O
of	O
host	O
of	O
the	O
SARS	O
coronavirus	O
from	O
animals	O
to	O
humans	O
.	O

The	O
MHVR	O
comprising	O
the	O
N	O
-	O
terminal	O
and	O
fourth	O
domains	O
[	O
R1	O
(	O
1	O
,	O
4	O
)]	O
displays	O
these	O
two	O
activities	O
,	O
and	O
the	O
N	O
domain	O
is	O
thought	O
to	O
be	O
critical	O
for	O
binding	B-FUNC
to	O
MHV	O
.	O

All	O
three	O
types	O
of	O
soMHVR	O
similarly	O
bound	O
to	O
MHV	O
,	O
as	O
examined	O
by	O
a	O
solid	O
-	O
phase	O
binding	B-FUNC
assay	O
and	O
neutralized	O
MHV	O
infectivity	O
.	O

The	O
inability	O
of	O
expressed	O
R1	O
(	O
1	O
)	O
to	O
work	O
as	O
a	O
receptor	O
was	O
due	O
to	O
the	O
inaccessibility	O
of	O
virions	O
to	O
R1	O
(	O
1	O
);	O
however	O
,	O
these	O
were	O
accessible	O
using	O
the	O
MHVR	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
CC1	O
.	O

In	O
this	O
work	O
,	O
the	O
M	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
as	O
fusion	O
protein	O
with	O
maltose	O
binding	B-FUNC
protein	O
at	O
N	O
-	O
terminus	O
and	O
MxeGyrA	O
intein	O
CBD	O
at	O
C	O
-	O
terminus	O
.	O

The	O
large	O
spike	O
glycoprotein	O
(	O
S	O
)	O
comprises	O
a	O
carboxy	O
-	O
terminal	O
S2	O
subunit	O
(	O
approximately	O
625	O
amino	O
acid	O
residues	O
),	O
which	O
anchors	O
S	O
in	O
the	O
virus	O
envelope	O
,	O
and	O
an	O
amino	O
-	O
terminal	O
S1	O
subunit	O
(	O
approximately	O
520	O
residues	O
),	O
believed	O
to	O
largely	O
form	O
the	O
distal	O
bulbous	O
part	O
of	O
S	O
.	O
The	O
S1	O
subunit	O
(	O
purified	O
from	O
IBV	O
virus	O
,	O
expressed	O
using	O
baculovirus	O
or	O
expressed	O
in	O
birds	O
from	O
a	O
fowlpoxvirus	O
vector	O
)	O
induced	O
virus	O
neutralizing	O
antibody	B-FUNC
.	O

Differences	O
in	O
S1	O
of	O
2	O
to	O
3	O
%	O
(	O
10	O
to	O
15	O
amino	O
acids	O
)	O
can	O
change	O
serotype	O
,	O
suggesting	O
that	O
a	O
small	O
number	O
of	O
epitopes	O
are	O
immunodominant	O
with	O
respect	O
to	O
neutralizing	O
antibody	B-FUNC
.	O

Serum	O
antibody	B-FUNC
levels	O
do	O
not	O
correlate	O
with	O
protection	O
,	O
although	O
local	O
antibody	B-FUNC
is	O
believed	O
to	O
play	O
a	O
role	O
.	O

All	O
index	O
patients	O
met	O
the	O
criteria	O
of	O
the	O
World	O
Health	O
Organization	O
for	O
a	O
probable	O
case	O
of	O
SARS	O
,	O
and	O
index	O
or	O
secondary	O
cases	O
were	O
confirmed	O
to	O
be	O
positive	O
for	O
SARS	O
-	O
CoV	O
on	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
or	O
serologic	O
testing	O
.	O

Using	O
twelve	O
gene	O
prediction	O
methods	O
to	O
predict	O
coronavirus	O
known	O
genes	O
,	O
we	O
select	O
four	O
better	O
methods	O
including	O
Heuristic	O
models	O
,	O
Gene	O
Identification	O
,	O
ZCURVE_CoV	O
and	O
ORF	O
FINDER	O
to	O
predict	O
SARS	O
-	O
CoV	O
(	O
BJ01	O
),	O
and	O
use	O
ATGpr	O
for	O
analyzing	O
probability	O
of	O
initiation	O
codon	O
and	O
Kozak	O
rule	O
,	O
search	O
transcription	O
regulating	O
sequence	O
(	O
TRS	B-FUNC
)	O
in	O
order	O
to	O
improve	O
the	O
accuracy	O
of	O
predicted	O
genes	O
.	O

A	O
virus	O
overlay	O
protein	B-FUNC
binding	I-FUNC
assay	O
(	O
VOPBA	O
)	O
was	O
used	O
to	O
identify	O
PEDV	O
binding	B-FUNC
protein	O
in	O
permissive	O
cells	O
.	O

The	O
binding	B-FUNC
ability	O
of	O
PEDV	O
to	O
porcine	O
APN	O
(	O
pAPN	O
)	O
and	O
the	O
effects	O
of	O
pAPN	O
on	O
infectivity	O
of	O
PEDV	O
in	O
Vero	O
cells	O
were	O
also	O
investigated	O
.	O

TITLE	O
:	O
Mitochondrial	O
HSP70	O
,	O
HSP40	O
,	O
and	O
HSP60	O
bind	B-FUNC
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
Murine	O
hepatitis	O
virus	O
genome	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
mitochondrial	O
-	O
aconitase	O
binds	B-FUNC
specifically	O
to	O
the	O
3	O
'	O
terminal	O
42	O
nucleotides	O
of	O
the	O
Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
along	O
with	O
three	O
additional	O
proteins	O
of	O
70	O
,	O
58	O
and	O
40	O
kDa	O
to	O
form	O
a	O
stable	O
RNA	O
-	O
protein	O
complex	O
.	O

A	O
series	O
of	O
co	O
-	O
immunoprecipitation	O
assays	O
have	O
established	O
that	O
these	O
four	O
MHV	O
RNA	B-FUNC
binding	I-FUNC
proteins	O
are	O
associated	O
,	O
even	O
in	O
the	O
absence	O
of	O
MHV	O
RNA	O
.	O

TITLE	O
:	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
controls	O
viral	O
infection	O
in	O
the	O
central	O
nervous	O
system	O
:	O
evidence	O
for	O
a	O
role	O
in	O
innate	O
immune	O
response	O
through	O
recruitment	O
and	O
activation	O
of	O
natural	O
killer	O
cells	O
.	O

Herein	O
,	O
we	O
evaluated	O
the	O
contributions	O
of	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
(	O
CXCL10	O
)	O
in	O
promoting	O
innate	O
defense	O
mechanisms	O
following	O
coronavirus	O
infection	O
of	O
the	O
CNS	O
.	O

This	O
process	O
is	O
regulated	O
by	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
preceding	O
each	O
mRNA	O
,	O
including	O
a	O
highly	O
conserved	O
core	O
sequence	O
(	O
CS	O
)	O
with	O
high	O
identity	O
to	O
sequences	O
present	O
in	O
the	O
virus	O
genome	O
and	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
leader	O
(	O
TRS	B-FUNC
-	O
L	O
).	O

This	O
template	O
switch	O
takes	O
place	O
after	O
copying	O
the	O
CS	O
sequence	O
and	O
was	O
predicted	O
in	O
silico	O
based	O
on	O
high	O
base	O
-	O
pairing	O
score	O
between	O
the	O
nascent	O
negative	O
RNA	O
strand	O
and	O
the	O
TRS	B-FUNC
-	O
L	O
and	O
minimum	O
DeltaG	O
.	O

Forty	O
-	O
six	O
clinical	O
specimens	O
were	O
analyzed	O
by	O
this	O
method	O
,	O
and	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
by	O
conventional	O
,	O
single	O
-	O
round	O
,	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
performed	O
in	O
parallel	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
inflammatory	O
cytokine	O
profile	O
in	O
children	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
investigate	O
whether	O
monoclonal	O
antibody	B-FUNC
to	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
could	O
be	O
considered	O
for	O
treatment	O
of	O
these	O
patients	O
.	O

Plasma	O
inflammatory	O
cytokine	O
concentrations	O
(	O
interleukin	O
[	O
IL	O
]-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	O
-	O
12p70	O
,	O
and	O
TNF	O
-	O
alpha	O
)	O
were	O
monitored	O
longitudinally	O
on	O
admission	O
,	O
immediately	O
before	O
corticosteroids	O
,	O
and	O
1	O
to	O
2	O
days	O
and	O
7	O
to	O
10	O
days	O
after	O
the	O
drug	O
treatment	O
in	O
a	O
cohort	O
of	O
pediatric	O
patients	O
(	O
n	O
=	O
8	O
)	O
with	O
virologic	O
confirmed	O
SARS	O
-	O
associated	O
coronavirus	O
infection	O
.	O

In	O
contrast	O
,	O
the	O
plasma	O
concentrations	O
of	O
other	O
key	O
proinflammatory	O
cytokines	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
,	O
were	O
not	O
overtly	O
increased	O
in	O
any	O
of	O
the	O
patients	O
throughout	O
the	O
course	O
of	O
illness	O
.	O

In	O
addition	O
,	O
plasma	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
concentration	O
was	O
significantly	O
lower	O
1	O
to	O
2	O
days	O
and	O
7	O
to	O
10	O
days	O
after	O
corticosteroid	O
treatment	O
,	O
compared	O
with	O
the	O
immediate	O
pretreatment	O
level	O
.	O

Similarly	O
,	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
were	O
significantly	O
decreased	O
7	O
to	O
10	O
days	O
after	O
the	O
drug	O
treatment	O
.	O

Other	O
key	O
proinflammatory	O
cytokines	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
,	O
showed	O
only	O
mildly	O
elevated	O
levels	O
at	O
the	O
initial	O
phase	O
of	O
the	O
illness	O
.	O

Similarly	O
,	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
were	O
significantly	O
decreased	O
7	O
to	O
10	O
days	O
after	O
the	O
drug	O
treatment	O
.	O

Serum	O
ALT	B-FUNC
,	O
AST	O
,	O
LDH	O
and	O
CK	O
were	O
elevated	O
in	O
45	O
.	O
2	O
%,	O
29	O
.	O
4	O
%,	O
42	O
.	O
1	O
%,	O
and	O
18	O
.	O
3	O
%	O
of	O
the	O
patients	O
respectively	O
.	O

TITLE	O
:	O
Antigenicity	O
and	O
receptor	O
-	O
binding	B-FUNC
ability	O
of	O
recombinant	O
SARS	O
coronavirus	O
spike	O
protein	O
.	O

Among	O
these	O
proteins	O
,	O
spike	O
(	O
S	O
)	O
protein	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
specific	O
cellular	O
receptors	O
and	O
is	O
a	O
major	O
antigenic	O
determinant	O
,	O
which	O
induces	O
neutralizing	O
antibody	B-FUNC
.	O

In	O
order	O
to	O
analyze	O
the	O
antigenicity	O
and	O
receptor	O
-	O
binding	B-FUNC
ability	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
we	O
expressed	O
the	O
S	O
protein	O
in	O
Escherichia	O
coli	O
using	O
a	O
pET	O
expression	O
vector	O
.	O

The	O
S	O
protein	O
was	O
recognized	O
by	O
sera	B-FUNC
from	O
SARS	O
patients	O
by	O
ELISA	O
and	O
Western	O
blot	O
,	O
which	O
indicated	O
that	O
recombinant	O
S	O
protein	O
retained	O
its	O
antigenicity	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
recombinant	O
S	O
protein	O
exhibited	O
the	O
antigenicity	O
and	O
receptor	O
-	O
binding	B-FUNC
ability	O
,	O
and	O
it	O
could	O
be	O
a	O
good	O
candidate	O
for	O
further	O
developing	O
SARS	O
vaccine	O
and	O
anti	O
-	O
SARS	O
therapy	O
.	O

SARS	O
-	O
CoV	O
was	O
detected	O
by	O
means	O
of	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
at	O
least	O
one	O
specimen	O
in	O
59	O
(	O
54	O
.	O
1	O
%)	O
of	O
109	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
therapeutic	O
effectiveness	O
of	O
monoclonal	O
TNF	O
antibody	B-FUNC
(	O
infliximab	O
)	O
in	O
acute	O
edematous	O
and	O
severe	O
necrotizing	O
pancreatitis	O
models	O
in	O
rats	O
.	O

Serum	O
amylase	B-FUNC
activity	I-FUNC
,	O
pancreatic	O
histopathology	O
,	O
myeloperoxidase	O
enzyme	B-FUNC
activity	I-FUNC
(	O
MPO	B-FUNC
),	O
and	O
pulmonary	O
changes	O
were	O
assessed	O
.	O

Infliximab	O
treatment	O
significantly	O
decreased	O
serum	O
amylase	B-FUNC
activity	I-FUNC
(	O
11939	O
+/-	O

It	O
also	O
suppressed	O
neutrophil	O
infiltration	O
and	O
MPO	B-FUNC
activity	O
of	O
the	O
pancreatic	O
tissue	O
.	O

Chimeric	O
TNF	O
antibody	B-FUNC
,	O
infliximab	O
,	O
should	O
be	O
evaluated	O
for	O
treatment	O
of	O
acute	O
pancreatitis	O
.	O

The	O
recombination	O
event	O
was	O
assessed	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
combination	O
of	O
specific	O
primers	O
designed	O
to	O
flank	O
a	O
known	O
recombination	O
hot	O
spot	O
of	O
the	O
viral	O
genomic	O
sequence	O
that	O
codes	O
for	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
envelope	O
protein	O
.	O

Concentrations	O
of	O
surfactant	O
protein	O
(	O
SP	O
)-	O
A	O
and	O
SP	O
-	O
D	O
in	O
sera	B-FUNC
reflected	O
the	O
clinical	O
features	O
.	O

Negatively	O
charged	O
ridges	O
surrounding	O
the	O
channel	O
may	O
provide	O
a	O
possible	O
binding	B-FUNC
site	O
for	O
the	O
positively	O
charged	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
S	O
-	O
glycoprotein	O
,	O
which	O
we	O
recently	O
identified	O
[	O
Biochem	O
.	O

Several	O
distinct	O
patches	O
of	O
hydrophobic	O
residues	O
at	O
the	O
ACE2	O
surface	O
were	O
noted	O
at	O
close	O
proximity	O
to	O
the	O
charged	O
ridges	O
that	O
could	O
contribute	O
to	O
binding	B-FUNC
.	O

Antibody	B-FUNC
titers	O
increased	O
up	O
to	O
70	O
days	O
,	O
and	O
high	O
antibody	B-FUNC
titers	O
were	O
maintained	O
at	O
least	O
for	O
another	O
3	O
months	O
.	O

CD45RO	O
antibody	B-FUNC
was	O
used	O
for	O
pre	O
-	O
embedding	O
immunoelectron	O
microscopy	O
.	O

Furthermore	O
mice	O
with	O
gp33	O
-	O
41	O
-	O
specific	O
CD8	O
(+)	O
cells	O
exhibited	O
much	O
reduced	O
levels	O
of	O
viral	O
antigen	O
in	O
the	O
brain	O
as	O
measured	O
by	O
immunohistochemistry	O
using	O
an	O
antibody	B-FUNC
directed	O
against	O
viral	O
nucleocapsid	O
.	O

6	O
-	O
His	O
-	O
tagged	O
recombinant	O
fragment	O
at	O
N	O
-	O
terminal	O
residues	O
249	O
to	O
667	O
of	O
SARS	O
-	O
CoV	O
S1	O
protein	O
including	O
S	O
-	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
.	O

The	O
results	O
indicated	O
that	O
N	O
was	O
recognized	O
in	O
most	O
of	O
the	O
sera	B-FUNC
.	O

There	O
were	O
4	O
groups	O
:	O
Control	O
(	O
C	O
);	O
NO	O
,	O
iNO	O
at	O
1	O
,	O
10	O
,	O
20	O
and	O
40	O
x	O
10	O
(-	O
6	O
)	O
each	O
for	O
60	O
min	O
at	O
30	O
min	O
interval	O
of	O
disconnection	O
;	O
Surf	O
,	O
intratracheal	O
instillation	O
of	O
porcine	O
lung	O
surfactant	O
phospholipids	O
(	O
100	O
mg	O
/	O
kg	O
);	O
SNO	B-FUNC
,	O
both	O
iNO	O
and	O
surfactant	O
as	O
in	O
the	O
NO	O
and	O
Surf	O
groups	O
;	O
and	O
a	O
normal	O
group	O
(	O
N	O
),	O
which	O
did	O
not	O
undergo	O
meconium	O
aspiration	O
but	O
received	O
sham	O
deliveries	O
of	O
normal	O
saline	O
.	O

In	O
the	O
SNO	B-FUNC
,	O
values	O
for	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
improved	O
from	O
(	O
185	O
+/-	O
39	O
)	O
mmHg	O
at	O
baseline	O
to	O
(	O
301	O
+/-	O

Cdyn	O
and	O
Raw	O
were	O
only	O
improved	O
for	O
short	O
time	O
in	O
the	O
Surf	O
,	O
NO	O
and	O
SNO	B-FUNC
groups	O
.	O

The	O
response	O
of	O
iNO	O
in	O
NO	O
group	O
was	O
relatively	O
transient	O
compared	O
to	O
the	O
SNO	B-FUNC
group	O
.	O

TITLE	O
:	O
DNA	O
vaccine	O
of	O
SARS	O
-	O
Cov	O
S	O
gene	O
induces	O
antibody	B-FUNC
response	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
fragments	O
of	O
the	O
truncated	O
S	O
protein	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
and	O
analyzed	O
with	O
pooled	O
sera	B-FUNC
of	O
convalescence	O
phase	O
of	O
SARS	O
patients	O
.	O

The	O
mouse	O
serum	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
was	O
measured	O
by	O
ELISA	O
with	O
E	O
.	O
coli	O
expressed	O
truncated	O
S	O
protein	O
or	O
SARS	O
-	O
CoV	O
lysate	O
as	O
diagnostic	O
antigen	O
.	O

The	O
results	O
showed	O
that	O
all	O
the	O
three	O
fragments	O
of	O
S	O
protein	O
expressed	O
by	O
E	O
.	O
coli	O
was	O
able	O
to	O
react	O
with	O
sera	B-FUNC
of	O
SARS	O
patients	O
and	O
the	O
S	O
gene	O
DNA	O
candidate	O
vaccine	O
could	O
induce	O
the	O
production	O
of	O
specific	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
efficiently	O
in	O
mice	O
with	O
seroconversion	O
ratio	O
of	O
75	O
%	O
after	O
3	O
times	O
of	O
immunization	O
.	O

SARS	O
associated	O
coronavirus	O
specific	O
RNA	O
fragment	O
was	O
found	O
positive	O
by	O
RT	O
-	O
PCR	O
in	O
1	O
case	O
;	O
1	O
case	O
was	O
positive	O
for	O
both	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
the	O
virus	O
;	O
1	O
case	O
was	O
positive	O
for	O
only	O
IgM	O
antibody	B-FUNC
and	O
another	O
2	O
cases	O
were	O
positive	O
for	O
only	O
IgG	O
antibody	B-FUNC
.	O

The	O
purified	O
N	O
protein	O
was	O
recognized	O
by	O
antibody	B-FUNC
to	O
TCoV	O
in	O
Western	O
blotting	O
assay	O
.	O

These	O
results	O
indicated	O
that	O
the	O
expressed	O
N	O
protein	O
is	O
a	O
superior	O
source	O
of	O
TCoV	O
antigen	O
for	O
development	O
of	O
antibody	B-FUNC
-	O
capture	O
ELISA	O
for	O
detection	O
of	O
antibodies	O
to	O
TCoV	O
.	O

After	O
the	O
rats	O
were	O
killed	O
,	O
lung	O
tissue	O
was	O
sampled	O
to	O
measured	O
expression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
),	O
nitrotyrosine	O
(	O
NT	O
),	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
malondialdehyde	O
(	O
MDA	O
),	O
wet	O
-	O
to	O
-	O
dry	O
lung	O
weight	O
ratio	O
(	O
W	O
/	O
D	O
),	O
and	O
pulmonary	O
permeability	O
index	O
(	O
PPI	O
).	O

Compared	O
with	O
the	O
endotoxemic	O
group	O
,	O
both	O
the	O
pretreatment	O
and	O
simultaneously	O
treatment	O
groups	O
,	O
significantly	O
improved	O
PaO2	O
,	O
pH	O
,	O
MAP	O
and	O
5th	O
hour	O
survival	O
rate	O
of	O
rats	O
,	O
and	O
attenuated	O
endotoxin	O
-	O
induced	O
increased	O
iNOSmRNA	O
,	O
NT	O
expression	O
,	O
MPO	B-FUNC
activity	O
and	O
MDA	O
level	O
in	O
lung	O
tissue	O
,	O
and	O
decreased	O
pulmonary	O
microvascular	O
permeability	O
,	O
TNF	O
-	O
alpha	O
,	O
NO	O
in	O
plasma	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
endotoxemic	O
group	O
,	O
both	O
the	O
pretreatment	O
and	O
simultaneously	O
treatment	O
groups	O
,	O
significantly	O
improved	O
PaO2	O
,	O
pH	O
,	O
MAP	O
and	O
5th	O
hour	O
survival	O
rate	O
of	O
rats	O
,	O
and	O
attenuated	O
endotoxin	O
-	O
induced	O
increased	O
iNOSmRNA	O
,	O
NT	O
expression	O
,	O
MPO	B-FUNC
activity	O
and	O
MDA	O
level	O
in	O
lung	O
tissue	O
,	O
and	O
decreased	O
pulmonary	O
microvascular	O
permeability	O
,	O
TNF	O
-	O
alpha	O
,	O
NO	O
in	O
plasma	O
.	O

Paired	O
serum	O
samples	O
were	O
taken	O
in	O
herds	O
during	O
outbreaks	O
of	O
severe	O
respiratory	O
diseases	O
(	O
acute	O
sera	B-FUNC
)	O
and	O
3	O
weeks	O
after	O
(	O
convalescent	O
sera	B-FUNC
).	O

Based	O
on	O
seroconversion	O
to	O
BRSV	O
and	O
clinical	O
picture	O
,	O
67	O
pairs	O
of	O
sera	B-FUNC
were	O
selected	O
from	O
calves	O
with	O
a	O
BRSV	O
-	O
associated	O
PRDS	O
for	O
circulating	O
MC	O
tryptase	O
determination	O
.	O

12	O
.	O
4	O
microg	O
/	O
l	O
)	O
compared	O
to	O
convalescent	O
sera	B-FUNC
(	O
8	O
.	O
4	O
+/-	O

Herein	O
we	O
show	O
that	O
this	O
process	O
of	O
bystander	O
T	O
-	O
cell	O
-	O
mediated	O
demyelination	O
is	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)-	O
dependent	O
.	O

Serologic	O
test	O
was	O
performed	O
for	O
15	O
cases	O
and	O
8	O
were	O
positive	O
for	O
SARS	O
virus	O
-	O
IgG	O
and	O
6	O
for	O
IgM	O
antibody	B-FUNC
.	O

The	O
radiologic	O
changes	O
developed	O
fast	B-FUNC
,	O
in	O
some	O
cases	O
the	O
changes	O
progressed	O
from	O
one	O
side	O
to	O
both	O
sides	O
.	O

Elevated	O
ALT	B-FUNC
was	O
found	O
in	O
3	O
cases	O
and	O
elevated	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
in	O
2	O
cases	O
.	O

Treatment	O
included	O
isolation	O
,	O
good	O
ventilation	O
of	O
the	O
ward	O
,	O
bed	O
rest	B-FUNC
,	O
supportive	O
regimens	O
,	O
low	O
volume	O
oxygen	O
inhalation	O
,	O
use	O
of	O
Chinese	O
traditional	O
medicine	O
,	O
antibiotics	O
to	O
prevent	O
bacterial	O
infection	O
,	O
and	O
anti	O
-	O
inflammation	O
therapy	O
.	O

TITLE	O
:	O
ACE2	O
X	O
-	O
ray	O
structures	O
reveal	O
a	O
large	O
hinge	O
-	O
bending	O
motion	O
important	O
for	O
inhibitor	O
binding	B-FUNC
and	O
catalysis	O
.	O

ABSTRACT	O
:	O
The	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
related	O
carboxypeptidase	O
,	O
ACE2	O
,	O
is	O
a	O
type	O
I	O
integral	O
membrane	O
protein	O
of	O
805	O
amino	O
acids	O
that	O
contains	O
one	O
HEXXH	O
+	O
E	O
zinc	O
-	O
binding	B-FUNC
consensus	O
sequence	O
.	O

At	O
first	O
,	O
Western	O
blotting	O
with	O
the	O
convalescent	O
sera	B-FUNC
from	O
SARS	O
patients	O
demonstrated	O
that	O
there	O
were	O
various	O
structural	O
proteins	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
cultured	O
supernatant	O
of	O
virus	O
infected	O
-	O
Vero	O
E6	O
cells	O
and	O
that	O
nucleocaspid	O
(	O
N	O
)	O
protein	O
had	O
a	O
prominent	O
immunogenicity	O
to	O
the	O
convalescent	O
sera	B-FUNC
from	O
the	O
patients	O
with	O
SARS	O
,	O
while	O
the	O
immune	O
response	O
of	O
spike	O
(	O
S	O
)	O
protein	O
probably	O
binding	B-FUNC
with	O
membrane	O
(	O
M	O
)	O
glycoprotein	O
was	O
much	O
weaker	O
.	O

Glycosylation	O
modification	O
in	O
S	O
protein	O
was	O
also	O
analyzed	O
and	O
four	O
glycosylation	O
sites	O
were	O
discovered	O
by	O
comparing	O
the	O
mass	O
spectra	O
before	O
and	O
after	O
deglycosylation	O
of	O
the	O
peptides	O
with	O
PNGase	B-FUNC
F	I-FUNC
digestion	O
.	O

However	O
,	O
administration	O
of	O
anti	O
-	O
IP	O
-	O
10	O
serum	O
caused	O
no	O
difference	O
in	O
clinical	O
signs	O
,	O
inflammation	O
,	O
demyelination	O
,	O
virus	O
persistence	O
or	O
anti	O
-	O
virus	O
antibody	B-FUNC
response	O
in	O
TMEV	O
infection	O
,	O
while	O
levels	O
of	O
virus	O
specific	O
and	O
autoreactive	O
lymphoproliferation	O
increased	O
.	O

ABSTRACT	O
:	O
We	O
have	O
expressed	O
a	O
series	O
of	O
truncated	O
spike	O
(	O
S	O
)	O
glycoproteins	O
of	O
SARS	O
-	O
CoV	O
and	O
found	O
that	O
the	O
N	O
-	O
terminus	O
14	O
-	O
502	O
residuals	O
were	O
sufficient	O
to	O
bind	B-FUNC
to	O
SARS	O
-	O
CoV	O
susceptible	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Frequent	O
detection	O
of	O
human	O
coronaviruses	O
in	O
clinical	O
specimens	O
from	O
patients	O
with	O
respiratory	O
tract	O
infection	O
by	O
use	O
of	O
a	O
novel	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

RT	O
-	O
PCR	O
showed	O
evidence	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
the	O
liver	O
tissues	O
,	O
but	O
not	O
in	O
the	O
sera	B-FUNC
of	O
all	O
3	O
patients	O
.	O

ABSTRACT	O
:	O
Upregulation	O
of	O
the	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
receptors	O
I	O
and	O
II	O
(	O
sTNFRI	O
/	O
RII	O
)	O
and	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	B-FUNC
-	I-FUNC
1RA	I-FUNC
),	O
by	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
G	O
-	O
CSF	O
)	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
lung	O
injury	O
.	O

Concentrations	O
of	O
G	O
-	O
CSF	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
sTNFRI	O
and	O
sTNFRII	O
,	O
IL	B-FUNC
-	I-FUNC
1RA	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
BALF	O
as	O
well	O
as	O
in	O
serum	O
were	O
determined	O
by	O
ELISA	O
.	O

Results	O
in	O
patients	O
with	O
ARDS	O
and	O
ALI	O
exhibited	O
significant	O
positive	O
correlations	O
in	O
BALF	O
of	O
G	O
-	O
CSF	O
levels	O
with	O
that	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
sTNFRII	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
1RA	I-FUNC
and	O
of	O
G	O
-	O
CSF	O
levels	O
in	O
serum	O
with	O
that	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
1RA	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	O
antibody	B-FUNC
,	O
feline	O
immunodeficiency	O
virus	O
antibody	B-FUNC
,	O
and	O
feline	O
leukemia	O
virus	O
antigen	O
in	O
ascites	O
from	O
cats	O
with	O
effusive	O
feline	O
infectious	O
peritonitis	O
.	O

We	O
show	O
that	O
nsp9	O
binds	B-FUNC
RNA	O
and	O
interacts	O
with	O
nsp8	O
,	O
activities	O
that	O
may	O
be	O
essential	O
for	O
its	O
function	O
(	O
s	O
).	O

Thus	O
,	O
we	O
postulate	O
that	O
the	O
LTH	O
is	O
a	O
key	O
structural	O
element	O
in	O
the	O
discontinuous	O
subgenomic	O
RNA	O
synthesis	O
and	O
is	O
likely	O
critical	O
for	O
leader	O
TRS	B-FUNC
function	O
.	O

After	O
purification	O
,	O
the	O
recombinant	O
protein	O
was	O
identified	O
by	O
anti	O
-	O
SARS	O
positive	O
sera	B-FUNC
from	O
recovered	O
SARS	O
patients	O
.	O

The	O
sera	B-FUNC
from	O
health	O
donors	O
,	O
which	O
were	O
collected	O
before	O
the	O
out	O
-	O
break	O
of	O
SARS	O
,	O
were	O
used	O
as	O
negative	O
control	O
in	O
the	O
study	O
.	O

The	O
recombinant	O
N	O
-	O
terminal	O
protein	O
of	O
SARS	O
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	O
antibody	B-FUNC
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	O
response	O
to	O
SARS	O
virus	O
.	O

The	O
recombinant	O
S1	O
protein	O
could	O
react	O
with	O
three	O
antibody	B-FUNC
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

Since	O
replication	O
of	O
HcoVs	O
depends	O
on	O
extensive	O
proteolytic	O
processing	O
,	O
the	O
main	O
proteinase	B-FUNC
,	O
3CLpro	O
,	O
is	O
an	O
attractive	O
drug	O
target	O
for	O
anti	O
-	O
SARS	O
agents	O
.	O

Previously	O
,	O
we	O
found	O
that	O
MHV	O
-	O
JHM	O
neurovirulence	O
was	O
marked	O
by	O
diminished	O
expression	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
mRNA	O
and	O
a	O
reduced	O
presence	O
of	O
CD8	O
T	O
cells	O
in	O
the	O
CNS	O
concomitant	O
with	O
heightened	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)-	O
1	O
transcript	O
levels	O
and	O
greater	O
macrophage	O
infiltration	O
relative	O
to	O
MHV	O
-	O
A59	O
infection	O
.	O

Thus	O
,	O
demyelination	O
determinants	O
exist	O
within	O
genomic	O
regions	O
on	O
both	O
sides	O
of	O
the	O
hypervariable	O
region	O
,	O
downstream	O
from	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
the	O
S1	O
part	O
of	O
the	O
MHV	O
spike	O
glycoprotein	O
gene	O
.	O

TITLE	O
:	O
Geldanamycin	O
,	O
a	O
ligand	B-FUNC
of	O
heat	O
shock	O
protein	O
90	O
,	O
inhibits	O
the	O
replication	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Geldanamycin	O
(	O
GA	O
)	O
is	O
an	O
antibiotic	O
targeting	O
the	O
ADP	O
/	O
ATP	B-FUNC
binding	I-FUNC
site	O
of	O
heat	O
shock	O
protein	O
90	O
(	O
Hsp90	O
).	O

We	O
have	O
identified	O
eight	O
recombinant	O
human	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
(	O
scFvs	O
)	O
against	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
SARS	O
-	O
CoV	O
from	O
two	O
nonimmune	O
human	O
antibody	B-FUNC
libraries	O
.	O

In	O
addition	O
,	O
mice	O
immunized	O
with	O
plasmids	O
encoding	O
S1	O
fragment	O
developed	O
a	O
Th1	O
-	O
mediated	O
antibody	B-FUNC
isotype	O
switching	O
.	O

These	O
various	O
cholesterol	O
levels	O
had	O
no	O
effect	O
on	O
the	O
binding	B-FUNC
of	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
to	O
cellular	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
(	O
CEACAM	O
)	O
receptors	O
,	O
rather	O
they	O
correlated	O
directly	O
with	O
S	O
-	O
protein	O
-	O
mediated	O
membrane	O
fusion	O
activities	O
.	O

We	O
considered	O
whether	O
cholesterol	O
was	O
indirectly	O
involved	O
in	O
membrane	O
fusion	O
by	O
condensing	O
CEACAMs	O
into	O
""""	O
lipid	O
raft	O
""""	O
membrane	O
microdomains	O
,	O
thereby	O
creating	O
opportunities	O
for	O
simultaneous	O
binding	B-FUNC
of	O
multiple	O
S	O
proteins	O
that	O
subsequently	O
cooperate	O
in	O
the	O
receptor	O
-	O
triggered	O
membrane	O
fusion	O
process	O
.	O

TITLE	O
:	O
Infectious	O
salmon	O
anemia	O
virus	O
specifically	O
binds	B-FUNC
to	O
and	O
hydrolyzes	O
4	O
-	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
ISAV	O
specifically	O
binds	B-FUNC
to	O
glycoproteins	O
containing	O
4	O
-	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

The	O
S1	O
glycoprotein	O
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

We	O
demonstrate	O
that	O
array	O
-	O
based	O
resequencing	O
-	O
by	O
-	O
hybridization	O
is	O
a	O
fast	B-FUNC
,	O
reliable	O
,	O
and	O
economical	O
alternative	O
to	O
capillary	O
sequencing	O
for	O
obtaining	O
SARS	O
-	O
CoV	O
genomic	O
sequence	O
on	O
a	O
population	O
scale	O
,	O
making	O
this	O
an	O
ideal	O
platform	O
for	O
the	O
global	O
monitoring	O
of	O
SARS	O
-	O
CoV	O
and	O
other	O
small	O
-	O
genome	O
pathogens	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
replicative	O
protein	O
nsp9	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
subunit	O
unique	O
in	O
the	O
RNA	O
virus	O
world	O
.	O

We	O
show	O
that	O
SARS	O
-	O
CoV	O
nsp9	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
protein	O
displaying	O
a	O
previously	O
unreported	O
,	O
oligosaccharide	O
/	O
oligonucleotide	O
fold	O
-	O
like	O
fold	O
.	O

Numbers	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
interleukin	O
(	O
IL	O
)-	O
2	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
secreting	O
cells	O
induced	O
by	O
T	O
cell	O
activators	O
were	O
below	O
normal	O
in	O
many	O
or	O
most	O
patients	O
before	O
and	O
during	O
treatment	O
with	O
corticosteroids	O
and	O
ribavirin	O
but	O
returned	O
essentially	O
to	O
normal	O
after	O
completion	O
of	O
treatment	O
.	O

SAC	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
secreting	O
cells	O
were	O
deficient	O
before	O
,	O
during	O
and	O
long	O
after	O
treatment	O
.	O

Numbers	O
of	O
cells	O
induced	O
to	O
produce	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
by	O
T	O
cell	O
or	O
monocyte	O
activators	O
were	O
higher	O
than	O
normal	O
in	O
many	O
early	O
SARS	O
patients	O
and	O
were	O
still	O
increased	O
in	O
some	O
during	O
and	O
after	O
treatment	O
.	O

Stored	O
serum	O
specimens	O
of	O
the	O
patients	O
were	O
detected	O
for	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
Co	O
-	O
V	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

TITLE	O
:	O
Recombinant	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
immunochromatographic	O
tests	O
for	O
detection	O
of	O
immunoglobulin	B-FUNC
G	O
antibodies	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
SARS	O
patients	O
.	O

The	O
ELISA	O
detected	O
IgG	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
in	O
all	O
74	O
convalescent	O
-	O
phase	O
samples	O
from	O
SARS	O
patients	O
while	O
weakly	O
cross	O
-	O
reacting	O
to	O
only	O
1	O
of	O
the	O
210	O
control	O
sera	B-FUNC
from	O
healthy	O
donors	O
.	O

This	O
finding	O
thus	O
led	O
to	O
a	O
kit	B-FUNC
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
of	O
100	O
,	O
99	O
.	O
5	O
,	O
and	O
99	O
.	O
6	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Normal	O
piglets	O
weaned	O
onto	O
soy	O
-	O
or	O
egg	O
-	O
based	O
diets	O
generated	O
antibody	B-FUNC
responses	O
to	O
fed	O
protein	O
.	O

However	O
,	O
TGEV	O
infection	O
did	O
enhance	O
the	O
primary	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
)	O
and	O
IgG1	O
,	O
but	O
not	O
IgG2	O
,	O
antibody	B-FUNC
responses	O
to	O
injected	O
soy	O
in	O
comparison	O
to	O
those	O
of	O
uninfected	O
animals	O
.	O

Paradoxically	O
,	O
TGEV	O
-	O
infected	O
animals	O
showed	O
an	O
enhanced	O
primary	O
IgG1	O
antibody	B-FUNC
response	O
to	O
injected	O
soy	O
at	O
4	O
weeks	O
of	O
age	O
,	O
but	O
they	O
subsequently	O
showed	O
a	O
reduced	O
secondary	O
response	O
after	O
an	O
intraperitoneal	O
challenge	O
at	O
9	O
weeks	O
of	O
age	O
in	O
comparison	O
to	O
uninfected	O
animals	O
.	O

TITLE	O
:	O
Profiles	O
of	O
antibody	B-FUNC
responses	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
recombinant	O
proteins	O
and	O
their	O
potential	O
use	O
as	O
diagnostic	O
markers	O
.	O

For	O
determination	O
of	O
which	O
of	O
the	O
viral	O
proteins	O
encoded	O
by	O
the	O
SARS	O
-	O
CoV	O
genome	O
may	O
be	O
exploited	O
as	O
diagnostic	O
antigens	O
for	O
serological	O
assays	O
,	O
the	O
viral	O
proteins	O
were	O
expressed	O
individually	O
in	O
mammalian	O
and	O
/	O
or	O
bacterial	O
cells	O
and	O
tested	O
for	O
reactivity	O
with	O
sera	B-FUNC
from	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
by	O
Western	O
blot	O
analysis	O
.	O

A	O
total	O
of	O
81	O
sera	B-FUNC
,	O
including	O
67	O
from	O
convalescent	O
patients	O
and	O
seven	O
pairs	O
from	O
two	O
time	O
points	O
of	O
infection	O
,	O
were	O
analyzed	O
,	O
and	O
all	O
showed	O
immunoreactivity	O
towards	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
).	O

The	O
immunoreactivities	O
to	O
these	O
recombinant	O
viral	O
proteins	O
are	O
highly	O
specific	O
,	O
as	O
sera	B-FUNC
from	O
100	O
healthy	O
donors	O
did	O
not	O
react	O
with	O
any	O
of	O
them	O
.	O

The	O
results	O
of	O
our	O
Western	O
blot	O
assay	O
and	O
IFA	O
for	O
the	O
detection	O
of	O
SARS	O
coronavirus	O
-	O
positive	O
sera	B-FUNC
were	O
the	O
same	O
.	O

A	O
panel	O
of	O
S	O
protein	O
-	O
derived	O
peptides	O
was	O
tested	O
for	O
their	O
binding	B-FUNC
affinity	O
to	O
HLA	O
-	O
A	O
*	O
0201	O
molecules	O
.	O

SARS	O
-	O
CoV	O
protein	O
-	O
derived	O
peptide	O
-	O
1	O
(	O
SSp	O
-	O
1	O
RLNEVAKNL	O
),	O
induced	O
peptide	O
-	O
specific	O
CTLs	O
both	O
in	O
vivo	O
(	O
transgenic	O
mice	O
)	O
and	O
in	O
vitro	O
(	O
human	O
PBLs	O
),	O
which	O
specifically	O
released	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
upon	O
stimulation	O
with	O
SSp	O
-	O
1	O
-	O
pulsed	O
autologous	O
dendritic	O
cells	O
(	O
DCs	O
)	O
or	O
T2	O
cells	O
.	O

TITLE	O
:	O
Prior	O
infection	O
and	O
passive	O
transfer	O
of	O
neutralizing	O
antibody	B-FUNC
prevent	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
.	O

Mice	O
developed	O
a	O
neutralizing	O
antibody	B-FUNC
response	O
and	O
were	O
protected	O
from	O
reinfection	O
28	O
days	O
following	O
primary	O
infection	O
.	O

Angiotensin	O
converting	O
enzyme	B-FUNC
inhibitors	I-FUNC
and	O
angiotensin	O
II	O
receptor	O
antagonists	O
should	O
be	O
discontinued	O
due	O
to	O
fetotoxicity	O
.	O

Seroconversion	O
for	O
SARS	O
-	O
CoV	O
using	O
immunofluorescence	O
on	O
infected	O
cells	O
is	O
an	O
excellent	O
method	O
of	O
confirming	O
the	O
diagnosis	O
,	O
but	O
antibody	B-FUNC
responses	O
only	O
appear	O
around	O
day	O
10	O
of	O
the	O
illness	O
.	O

The	O
purified	O
recombinant	O
proteins	O
of	O
350	O
and	O
366	O
amino	O
acids	O
in	O
length	O
,	O
respectively	O
,	O
were	O
employed	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
detection	O
of	O
CCoV	O
type	O
I	O
antibodies	O
in	O
dog	O
sera	B-FUNC
.	O

Only	O
the	O
sera	B-FUNC
-	O
positive	O
for	O
CCoV	O
type	O
I	O
strongly	O
reacted	O
with	O
both	O
the	O
proteins	O
,	O
whereas	O
the	O
sera	B-FUNC
-	O
positive	O
for	O
CCoV	O
type	O
II	O
showed	O
low	O
reactivity	O
in	O
the	O
ELISA	O
test	O
.	O

The	O
rats	O
were	O
killed	O
24	O
hours	O
after	O
injury	O
and	O
some	O
parameters	O
of	O
lung	O
injury	O
were	O
evaluated	O
--	O
i	O
.	O
e	O
.,	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
),	O
lung	O
tissue	O
myeloperoxidase	O
levels	O
(	O
MPO	B-FUNC
)	O
and	O
wet	O
/	O
dry	O
ratios	O
of	O
lung	O
tissue	O
.	O

This	O
effect	O
was	O
attenuated	O
by	O
treatment	O
with	O
N	O
-	O
acetylcysteine	O
(	O
MPO	B-FUNC
43	O
-	O
9	O
microg	O
/	O
mL	O
,	O
BAL	O
protein	O
605	O
-	O
198	O
microg	O
/	O
mL	O
).	O

RESULTS	O
:	O
Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	B-FUNC
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	O
protein	O
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

This	O
effect	O
was	O
attenuated	O
by	O
treatment	O
with	O
N	O
-	O
acetylcysteine	O
(	O
MPO	B-FUNC
43	O
-	O
9	O
microg	O
/	O
mL	O
,	O
BAL	O
protein	O
605	O
-	O
198	O
microg	O
/	O
mL	O
).	O

Here	O
,	O
we	O
show	O
that	O
a	O
DNA	O
vaccine	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
the	O
SARS	O
-	O
CoV	O
induces	O
T	O
cell	O
and	O
neutralizing	O
antibody	B-FUNC
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	O
,	O
in	O
a	O
mouse	O
model	O
.	O

Moreover	O
,	O
antibody	B-FUNC
responses	O
in	O
mice	O
vaccinated	O
with	O
an	O
expression	O
vector	O
encoding	O
a	O
form	O
of	O
S	O
that	O
includes	O
its	O
transmembrane	O
domain	O
elicited	O
neutralizing	O
antibodies	O
.	O

The	O
ability	O
to	O
detect	O
MHV	O
-	O
Y	O
transmission	O
to	O
sentinel	O
mice	O
exposed	O
directly	O
to	O
infected	O
mice	O
or	O
to	O
soil	O
bedding	O
from	O
infected	O
mice	O
was	O
compared	O
with	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
-	O
based	O
detection	O
of	O
viral	O
RNA	O
in	O
the	O
feces	O
.	O

Corticosteroid	O
reduced	O
significantly	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
and	O
IP	O
-	O
10	O
concentrations	O
from	O
5	O
to	O
8	O
days	O
after	O
treatment	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
).	O

Together	O
,	O
the	O
elevation	O
of	O
Th1	O
cytokine	O
IFN	O
-	O
gamma	O
,	O
inflammatory	O
cytokines	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
chemokines	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
and	O
IP	O
-	O
10	O
confirmed	O
the	O
activation	O
of	O
Th1	O
cell	O
-	O
mediated	O
immunity	O
and	O
hyperinnate	O
inflammatory	O
response	O
in	O
SARS	O
through	O
the	O
accumulation	O
of	O
monocytes	O
/	O
macrophages	O
and	O
neutrophils	O
.	O

Attempts	O
at	O
virus	O
isolation	O
were	O
unsuccessful	O
;	O
however	O
,	O
viral	O
RNA	O
was	O
detected	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
blood	O
of	O
both	O
species	O
during	O
the	O
first	O
week	O
after	O
inoculation	O
,	O
and	O
in	O
chicken	O
organs	O
at	O
2	O
weeks	O
after	O
inoculation	O
.	O

Of	O
417	O
patients	O
with	O
clinical	O
SARS	O
from	O
whom	O
paired	O
serum	O
samples	O
were	O
available	O
,	O
92	O
%	O
had	O
an	O
antibody	B-FUNC
response	O
.	O

After	O
its	O
causative	O
agent	O
,	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
confirmed	O
,	O
laboratory	O
methods	O
,	O
including	O
virus	O
isolation	O
,	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
serologic	O
methods	O
,	O
have	O
been	O
quickly	O
developed	O
.	O

Cerebrospinal	O
fluid	O
tested	O
positive	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

ELISA	O
was	O
used	O
to	O
detect	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
.	O
Reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
detect	O
SARS	O
CoV	O
RNA	O
.	O

Of	O
36	O
patients	O
with	O
probable	O
SARS	O
CoV	O
infection	O
,	O
30	O
(	O
83	O
.	O
3	O
%)	O
were	O
positive	O
for	O
IgG	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
;	O
in	O
contrast	O
,	O
only	O
3	O
of	O
48	O
patients	O
with	O
suspected	O
SARS	O
CoV	O
infection	O
,	O
0	O
of	O
112	O
patients	O
with	O
fever	O
but	O
without	O
SARS	O
,	O
and	O
0	O
of	O
96	O
healthy	O
control	O
individuals	O
were	O
positive	O
for	O
it	O
.	O

IgG	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
was	O
first	O
detected	O
between	O
day	O
5	O
and	O
day	O
47	O
after	O
onset	O
of	O
illness	O
(	O
mean	O
+/-	O

RESULTS	O
:	O
Of	O
36	O
patients	O
with	O
probable	O
SARS	O
CoV	O
infection	O
,	O
30	O
(	O
83	O
.	O
3	O
%)	O
were	O
positive	O
for	O
IgG	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
;	O
in	O
contrast	O
,	O
only	O
3	O
of	O
48	O
patients	O
with	O
suspected	O
SARS	O
CoV	O
infection	O
,	O
0	O
of	O
112	O
patients	O
with	O
fever	O
but	O
without	O
SARS	O
,	O
and	O
0	O
of	O
96	O
healthy	O
control	O
individuals	O
were	O
positive	O
for	O
it	O
.	O

CONCLUSIONS	O
:	O
Detection	O
of	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
is	O
useful	O
in	O
the	O
diagnosis	O
of	O
SARS	O
;	O
however	O
,	O
at	O
the	O
incubation	O
and	O
initial	O
phases	O
of	O
the	O
illness	O
,	O
serological	O
assay	O
is	O
of	O
little	O
value	O
,	O
because	O
of	O
late	O
seroconversion	O
in	O
most	O
patients	O
.	O

Many	O
biological	O
functions	O
involve	O
formation	O
of	O
protein	O
-	O
protein	O
complexes	O
;	O
in	O
which	O
the	O
protein	O
molecules	O
behave	O
dynamically	O
in	O
the	O
course	O
of	O
binding	B-FUNC
.	O

TITLE	O
:	O
Antibody	B-FUNC
targeting	O
of	O
the	O
CC	O
chemokine	O
ligand	B-FUNC
5	O
results	O
in	O
diminished	O
leukocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
and	O
reduced	O
neurologic	O
disease	O
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

The	O
CC	O
chemokine	O
ligand	B-FUNC
(	O
CCL	B-FUNC
)	O
5	O
is	O
localized	O
in	O
white	O
matter	O
tracts	O
undergoing	O
demyelination	O
,	O
suggesting	O
that	O
this	O
chemokine	O
participates	O
in	O
the	O
pathogenesis	O
of	O
disease	O
by	O
attracting	O
inflammatory	O
cells	O
into	O
the	O
CNS	O
.	O

We	O
examined	O
the	O
effects	O
of	O
pioglitazone	O
,	O
a	O
synthetic	O
ligand	B-FUNC
of	O
PPAR	O
-	O
gamma	O
,	O
against	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

Lung	O
injury	O
was	O
quantified	O
in	O
terms	O
of	O
lung	O
microvascular	O
permeability	O
(	O
Evans	O
blue	O
dye	O
extravasation	O
),	O
tissue	O
lipid	O
peroxidation	O
(	O
thiobarbituric	O
acid	O
reactive	O
substances	O
),	O
and	O
tissue	O
polymorphonuclear	O
leukocyte	O
accumulation	O
(	O
myeloperoxidase	B-FUNC
activity	I-FUNC
).	O

The	O
protective	O
effects	O
of	O
pioglitazone	O
treatment	O
were	O
correlated	O
with	O
the	O
reduction	O
by	O
79	O
%	O
of	O
the	O
increase	O
of	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
P	O
=	O
0	O
.	O
045	O
)	O
and	O
the	O
reduction	O
by	O
58	O
%	O
of	O
myeloperoxidase	B-FUNC
activity	I-FUNC
increase	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

To	O
understand	O
the	O
functional	O
role	O
of	O
the	O
extra	O
domain	O
and	O
to	O
characterize	O
the	O
enzyme	O
-	O
substrate	O
interactions	O
by	O
use	O
of	O
the	O
dynamic	O
light	O
scattering	O
,	O
circular	O
dichroism	O
,	O
and	O
NMR	O
spectroscopy	O
,	O
we	O
1	O
)	O
dissected	O
the	O
full	O
-	O
length	O
SARS	O
3CL	O
protease	O
into	O
two	O
distinct	O
folds	O
and	O
subsequently	O
investigated	O
their	O
structural	O
and	O
dimerization	O
properties	O
and	O
2	O
)	O
studied	O
the	O
structural	O
and	O
binding	B-FUNC
interactions	O
of	O
three	O
substrate	O
peptides	O
with	O
the	O
entire	O
enzyme	O
and	O
its	O
two	O
dissected	O
folds	O
.	O

TITLE	O
:	O
Host	O
-	O
dependent	O
type	O
1	O
cytokine	O
responses	O
driven	O
by	O
inactivated	O
viruses	O
may	O
fail	O
to	O
default	O
in	O
the	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
or	O
IFN	O
-	O
alpha	O
/	O
beta	O
.	O

Also	O
inactivated	O
preparations	O
of	O
viruses	O
from	O
the	O
paramyxo	O
-	O
(	O
Newcastle	O
disease	O
virus	O
),	O
rhabdo	O
-	O
(	O
rabies	O
virus	O
),	O
corona	O
-	O
(	O
infectious	O
bronchitis	O
virus	O
)	O
and	O
reovirus	O
(	O
avian	O
reovirus	O
)	O
families	O
led	O
to	O
IgG2a	O
antibody	B-FUNC
responses	O
;	O
however	O
,	O
the	O
genetic	O
background	O
of	O
the	O
host	O
did	O
result	O
in	O
considerable	O
variation	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
the	O
leading	O
cause	O
of	O
death	O
in	O
sickle	O
cell	O
disease	O
.	O

Severe	O
ACS	B-FUNC
often	O
develops	O
in	O
the	O
course	O
of	O
a	O
vasoocclusive	O
crisis	O
(	O
VOC	O
),	O
and	O
frequently	O
involves	O
pulmonary	O
fat	O
embolism	O
.	O

The	O
data	O
indicate	O
that	O
measurement	O
of	O
sPLA2	O
can	O
be	O
useful	O
in	O
alerting	O
the	O
clinician	O
to	O
patients	O
with	O
impending	O
ACS	B-FUNC
,	O
and	O
suggest	O
that	O
instituting	O
early	O
therapies	O
based	O
on	O
sPLA2	O
levels	O
,	O
including	O
inhibition	O
of	O
sPLA2	O
activity	O
,	O
may	O
be	O
useful	O
to	O
prevent	O
or	O
reduce	O
the	O
clinical	O
morbidity	O
of	O
ACS	B-FUNC
in	O
sickle	O
cell	O
disease	O
.	O

A	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
detection	O
kit	B-FUNC
developed	O
by	O
C	O
.	O
Drosten	O
(	O
Bernhard	O
Nocht	O
Institute	O
,	O
BNI	O
)	O
was	O
used	O
to	O
amplify	O
SARS	O
-	O
CoV	O
sequences	O
from	O
blood	O
donor	O
samples	O
.	O

At	O
the	O
prefusion	O
intermediate	O
state	O
,	O
CP	O
-	O
1	O
could	O
bind	B-FUNC
to	O
the	O
HR1	O
region	O
and	O
interfere	O
with	O
the	O
conformational	O
changes	O
,	O
resulting	O
in	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
fusion	O
with	O
the	O
target	O
cells	O
.	O

Antisera	O
collected	O
1	O
week	O
after	O
the	O
second	O
immunization	O
were	O
analyzed	O
by	O
ELISA	O
and	O
tested	O
for	O
antibody	B-FUNC
specificity	O
against	O
SARS	O
-	O
CoV	O
by	O
immunofluorescent	O
confocal	O
microscopy	O
.	O

In	O
the	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
section	O
,	O
the	O
new	O
recommendation	O
is	O
to	O
determine	O
,	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
,	O
whether	O
to	O
administer	O
monoclonal	O
antibody	B-FUNC
(	O
palivizumab	O
)	O
to	O
certain	O
infants	O
and	O
children	O
aged	O
<	O
24	O
months	O
who	O
were	O
born	O
prematurely	O
and	O
are	O
at	O
high	O
risk	O
for	O
RSV	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
widespread	O
threat	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
human	O
health	O
has	O
made	O
urgent	O
the	O
development	O
of	O
fast	B-FUNC
and	O
accurate	O
analytical	O
methods	O
for	O
its	O
early	O
diagnosis	O
and	O
a	O
safe	O
and	O
efficient	O
antiviral	O
vaccine	O
for	O
preventive	O
use	O
.	O

The	O
full	O
-	O
length	O
protein	O
and	O
two	O
other	O
fragments	O
reacted	O
with	O
all	O
52	O
sera	B-FUNC
tested	O
.	O

EP2	O
and	O
EP4	O
possessed	O
linear	O
epitopes	O
,	O
whereas	O
EP1	O
and	O
EP2	O
were	O
able	O
to	O
form	O
conformational	O
epitopes	O
that	O
could	O
react	O
with	O
most	O
(>	O
80	O
%)	O
of	O
the	O
tested	O
sera	B-FUNC
.	O

EP3	O
and	O
EP4	O
also	O
formed	O
conformational	O
epitopes	O
,	O
and	O
antibodies	O
against	O
these	O
epitopes	O
existed	O
in	O
all	O
52	O
of	O
the	O
sera	B-FUNC
tested	O
.	O

The	O
N	O
protein	O
is	O
a	O
potential	O
diagnostic	O
antigen	O
and	O
vaccine	O
candidate	O
for	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
The	O
full	O
-	O
length	O
protein	O
and	O
two	O
other	O
fragments	O
reacted	O
with	O
all	O
52	O
sera	B-FUNC
tested	O
.	O

TITLE	O
:	O
[	O
Serum	O
levels	O
of	O
luteinizing	O
hormone	O
,	O
testosterone	O
and	O
prolactin	B-FUNC
in	O
patients	O
with	O
septic	O
shock	O
].	O

We	O
studied	O
serum	O
level	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
),	O
testosterone	O
(	O
T	O
)	O
and	O
prolactin	B-FUNC
(	O
PRL	O
)	O
in	O
20	O
patients	O
with	O
septic	O
shock	O
and	O
in	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
20	O
).	O

During	O
the	O
period	O
of	O
SARS	O
epidemic	O
,	O
detection	O
rate	O
of	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
in	O
people	O
with	O
symptoms	O
of	O
acute	O
respiratory	O
infection	O
was	O
higher	O
(	O
30	O
.	O
70	O
%)	O
than	O
that	O
in	O
those	O
without	O
such	O
symptoms	O
(	O
20	O
.	O
08	O
%).	O

Prevalence	O
of	O
symptoms	O
of	O
acute	O
upper	O
respiratory	O
infection	O
in	O
people	O
with	O
positive	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
was	O
higher	O
(	O
49	O
.	O
28	O
%)	O
than	O
that	O
in	O
those	O
with	O
negative	O
antibody	B-FUNC
(	O
30	O
.	O
35	O
%).	O

TITLE	O
:	O
3C	O
-	O
like	O
proteinase	B-FUNC
from	O
SARS	O
coronavirus	O
catalyzes	O
substrate	O
hydrolysis	O
by	O
a	O
general	O
base	O
mechanism	O
.	O

ABSTRACT	O
:	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
enzyme	O
for	O
drug	O
design	O
against	O
SARS	O
.	O

Since	O
SARS	O
3CL	O
proteinase	B-FUNC
belongs	O
to	O
the	O
cysteine	O
protease	O
family	O
(	O
family	O
C3	O
in	O
clan	O
CB	O
)	O
with	O
a	O
chymotrypsin	O
fold	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
catalytic	O
mechanism	O
of	O
SARS	O
3CL	O
proteinase	B-FUNC
to	O
determine	O
whether	O
the	O
proteolysis	O
proceeds	O
through	O
a	O
general	O
base	O
catalysis	O
mechanism	O
like	O
chymotrypsin	O
or	O
an	O
ion	O
pair	O
mechanism	O
like	O
papain	O
.	O

From	O
the	O
pH	O
dependency	O
of	O
catalytic	B-FUNC
activity	I-FUNC
,	O
the	O
pK	O
(	O
a	O
)'	O
s	O
for	O
His41	O
and	O
Cys145	O
in	O
the	O
wild	O
-	O
type	O
enzyme	O
were	O
estimated	O
to	O
be	O
6	O
.	O
38	O
and	O
8	O
.	O
34	O
,	O
while	O
the	O
pK	O
(	O
a	O
)'	O
s	O
for	O
His41	O
and	O
Ser145	O
in	O
the	O
C145S	O
mutant	O
were	O
estimated	O
to	O
be	O
6	O
.	O
15	O
and	O
9	O
.	O
09	O
,	O
respectively	O
.	O

S	O
(	O
1190	O
)	O
binds	B-FUNC
to	O
the	O
surface	O
of	O
Vero	O
E6	O
cells	O
,	O
a	O
cell	O
permissive	O
to	O
infection	O
,	O
as	O
demonstrated	O
by	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
,	O
suggesting	O
that	O
S	O
(	O
1190	O
)	O
maintains	O
the	O
biologic	O
activity	O
present	O
in	O
native	O
S	O
glycoprotein	O
.	O

This	O
interaction	O
is	O
blocked	O
with	O
serum	O
obtained	O
from	O
recovering	O
SARS	O
patients	O
,	O
indicating	O
that	O
the	O
binding	B-FUNC
is	O
specific	O
.	O

In	O
an	O
effort	O
to	O
map	O
the	O
ligand	B-FUNC
-	O
binding	B-FUNC
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
,	O
carboxy	O
-	O
and	O
amino	O
-	O
terminal	O
truncations	O
of	O
the	O
S	O
(	O
1190	O
)	O
glycoprotein	O
were	O
constructed	O
.	O

Amino	O
acids	O
270	O
to	O
510	O
were	O
the	O
minimal	O
receptor	O
-	O
binding	B-FUNC
region	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

We	O
speculate	O
that	O
amino	O
acids	O
1	O
to	O
510	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
represent	O
a	O
unique	O
domain	O
containing	O
the	O
receptor	O
-	O
binding	B-FUNC
site	O
(	O
amino	O
acids	O
270	O
to	O
510	O
),	O
analogous	O
to	O
the	O
S1	O
subunit	O
of	O
other	O
coronavirus	O
S	O
glycoproteins	O
.	O

TITLE	O
:	O
Exploring	O
the	O
binding	B-FUNC
mechanism	O
of	O
the	O
main	O
proteinase	B-FUNC
in	O
SARS	O
-	O
associated	O
coronavirus	O
and	O
its	O
implication	O
to	O
anti	O
-	O
SARS	O
drug	O
design	O
.	O

ABSTRACT	O
:	O
The	O
main	O
proteinase	B-FUNC
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
an	O
important	O
role	O
in	O
viral	O
transcription	O
and	O
replication	O
,	O
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
.	O

The	O
important	O
thing	O
is	O
to	O
understand	O
its	O
binding	B-FUNC
mechanism	O
with	O
possible	O
ligands	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
noncanonical	O
interactions	O
,	O
potential	O
inhibitors	O
,	O
and	O
binding	B-FUNC
pockets	O
in	O
the	O
main	O
proteinase	B-FUNC
of	O
SARS	O
-	O
CoV	O
based	O
on	O
its	O
recently	O
determined	O
crystal	O
structure	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
similar	O
structure	O
patterns	O
exist	O
in	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-FUNC
with	O
Poliovirus	O
3c	O
Proteinase	B-FUNC
,	O
Rhinovirus	O
3c	O
Protease	O
,	O
Nsp4	O
Proteinase	B-FUNC
From	O
Equine	O
Arteritis	O
Virus	O
,	O
Hepatitis	O
C	O
Virus	O
Ns3	O
Protease	O
,	O
Hepatitis	O
A	O
Virus	O
3c	O
Protease	O
,	O
and	O
Dengue	O
Virus	O
Ns3	O
Protease	O
.	O

ABSTRACT	O
:	O
Induction	O
of	O
effective	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
and	O
/	O
or	O
a	O
specific	O
antibody	B-FUNC
against	O
conserved	O
viral	O
proteins	O
may	O
be	O
essential	O
to	O
the	O
development	O
of	O
a	O
safe	O
and	O
effective	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
vaccine	O
.	O

We	O
found	O
that	O
the	O
DNA	O
vaccination	O
induced	O
both	O
N	O
protein	O
-	O
specific	O
antibody	B-FUNC
and	O
specific	O
CTL	O
activity	O
to	O
the	O
target	O
.	O

When	O
C3H	O
/	O
He	O
mice	O
were	O
immunized	O
by	O
three	O
separate	O
injections	O
,	O
high	O
antibody	B-FUNC
titre	O
(	O
1	O
:	O
3200	O
-	O
1	O
:	O
6400	O
,	O
average	O
titre	O
is	O
1	O
:	O
4580	O
)	O
and	O
high	O
CTL	O
activity	O
(	O
67	O
.	O
4	O
+/-	O
8	O
.	O
4	O
%	O
(	O
E	O
:	O
T	O
=	O
25	O
:	O
1	O
),	O
69	O
.	O
6	O
+/-	O
6	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
50	O
:	O
1	O
)	O
and	O
71	O
.	O
8	O
+/-	O
6	O
.	O
2	O
%	O
(	O
E	O
:	O
T	O
=	O
100	O
:	O
1	O
))	O
were	O
observed	O
.	O

In	O
the	O
case	O
of	O
two	O
vaccine	O
injections	O
,	O
CTL	O
activity	O
was	O
also	O
high	O
(	O
56	O
.	O
6	O
+/-	O
12	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
25	O
:	O
1	O
),	O
57	O
.	O
4	O
+/-	O
11	O
.	O
7	O
%	O
(	O
E	O
:	O
T	O
=	O
50	O
:	O
1	O
)	O
and	O
63	O
.	O
0	O
+/-	O
6	O
.	O
3	O
%	O
(	O
E	O
:	O
T	O
=	O
100	O
:	O
1	O
))	O
However	O
,	O
antibody	B-FUNC
titres	O
were	O
much	O
lower	O
(	O
1	O
:	O
200	O
-	O
1	O
:	O
3200	O
,	O
average	O
titre	O
is	O
1	O
:	O
980	O
).	O

TITLE	O
:	O
Intravenous	O
immunoglobulin	B-FUNC
G	O
is	O
remarkably	O
beneficial	O
in	O
chronic	O
immune	O
dysschwannian	O
/	O
dysneuronal	O
polyneuropathy	O
,	O
diabetes	O
-	O
2	O
neuropathy	O
,	O
and	O
potentially	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

However	O
,	O
81	O
%	O
of	O
my	O
48	O
recently	O
-	O
summarized	O
type	O
-	O
2	O
diabetes	O
patients	O
with	O
polyneuropathy	O
,	O
adequately	O
-	O
treated	O
with	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
,	O
off	O
-	O
label	O
,	O
were	O
relieved	O
,	O
sometimes	O
completely	O
,	O
of	O
various	O
motor	O
and	O
sensory	O
symptoms	O
,	O
including	O
pain	O
,	O
thereby	O
resembling	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	O
.	O

Spinal	O
fluid	O
protein	O
in	O
them	O
is	O
often	O
elevated	O
,	O
higher	O
values	O
seeming	O
to	O
auger	O
a	O
better	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
response	O
.	O

Possible	O
molecular	O
mechanisms	O
of	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
benefit	O
are	O
discussed	O
.	O

I	O
propose	O
that	O
a	O
)	O
there	O
is	O
a	O
higher	O
incidence	O
of	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	O
-	O
like	O
neuropathy	O
in	O
type	O
-	O
2	O
diabetes	O
patients	O
and	O
in	O
patients	O
with	O
a	O
strong	O
family	O
history	O
of	O
type	O
-	O
2	O
diabetes	O
,	O
and	O
b	O
)	O
the	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
-	O
treatable	O
neuropathy	O
in	O
type	O
-	O
2	O
diabetes	O
can	O
be	O
brought	O
on	O
by	O
the	O
genetico	O
-	O
diabetoid	O
-	O
2	O
state	O
.	O

Intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
is	O
herein	O
suggested	O
as	O
a	O
treatment	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
a	O
recent	O
,	O
and	O
feared	O
-	O
repetitive	O
,	O
pandemic	O
with	O
many	O
fatalities	O
caused	O
by	O
a	O
highly	O
-	O
contagious	O
mutant	O
coronavirus	O
,	O
for	O
which	O
there	O
is	O
no	O
definitive	O
treatment	O
.	O

Intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
might	O
:	O
a	O
)	O
combat	O
a	O
dysimmune	O
component	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
including	O
the	O
reactive	O
cytokine	O
-	O
chemokine	O
storm	O
against	O
respiratory	O
tissues	O
;	O
b	O
)	O
contain	O
some	O
antibodies	O
effective	O
against	O
the	O
coronavirus	O
non	O
-	O
specific	O
components	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
;	O
c	O
)	O
block	O
host	O
-	O
cell	O
receptors	O
for	O
the	O
virus	O
;	O
and	O
d	O
)	O
counteract	O
secondary	O
infections	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
response	O
and	O
viraemia	O
during	O
the	O
course	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
infection	O
.	O

Cells	O
infected	O
with	O
MVA	O
/	O
Sor	B-FUNC
MVA	O
/	O
S	O
-	O
HA	O
synthesized	O
a	O
200	O
-	O
kDa	O
protein	O
,	O
which	O
was	O
recognized	O
by	O
antibody	B-FUNC
raised	O
against	O
a	O
synthetic	O
peptide	O
of	O
SARS	O
-	O
CoV	O
S	O
or	O
the	O
epitope	O
tag	O
in	O
Western	O
blot	O
analyses	O
.	O

The	O
attenuated	O
nature	O
of	O
MVA	O
and	O
the	O
ability	O
of	O
MVA	O
/	O
S	O
to	O
induce	O
neutralizing	O
antibody	B-FUNC
that	O
protects	O
mice	O
support	O
further	O
development	O
of	O
this	O
candidate	O
vaccine	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
-	O
induced	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
response	O
of	O
pediatric	O
vs	O
.	O
adult	O
peritoneal	O
macrophages	O
(	O
PMs	O
).	O

IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
TNFalpha	O
production	O
were	O
determined	O
by	O
ELISA	O
.	O

There	O
was	O
no	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
in	O
IL	O
-	O
1beta	O
-	O
stimulated	O
adult	O
PMs	O
.	O

Similarly	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
production	O
was	O
greater	O
in	O
pediatric	O
PMs	O
compared	O
with	O
adults	O
(	O
532	O
+/-	O
3	O
vs	O
.	O
444	O
+/-	O
52	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

There	O
was	O
no	O
difference	O
in	O
IL	O
-	O
1beta	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
production	O
in	O
children	O
compared	O
with	O
adults	O
.	O

The	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
:	O
TNFalpha	O
ratio	O
after	O
IL	O
-	O
1beta	O
stimulation	O
was	O
0	O
.	O
306	O
+/-	O
0	O
.	O
056	O
in	O
pediatric	O
macrophages	O
and	O
0	O
.	O
020	O
+/-	O
0	O
.	O
015	O
in	O
adult	O
macrophages	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
exaggerated	O
anti	O
-	O
inflammatory	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
response	O
in	O
children	O
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
observed	O
differences	O
in	O
ALI	O
between	O
children	O
and	O
adults	O
.	O

ACS	B-FUNC
evolving	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
complication	O
.	O

It	O
was	O
found	O
that	O
bifunctional	O
aryl	O
boronic	O
acid	O
compounds	O
were	O
particularly	O
effective	O
at	O
inhibiting	O
the	O
protease	O
,	O
with	O
inhibition	O
constants	O
as	O
strong	O
as	O
40	O
nM	O
.	O
Isothermal	O
titration	O
microcalorimetric	O
experiments	O
indicate	O
that	O
these	O
inhibitors	O
bind	B-FUNC
reversibly	O
to	O
3CL	O
(	O
pro	O
)	O
in	O
an	O
enthalpically	O
favorable	O
fashion	O
,	O
implying	O
that	O
they	O
establish	O
strong	O
interactions	O
with	O
the	O
protease	O
molecule	O
,	O
thus	O
defining	O
attractive	O
molecular	O
scaffolds	O
for	O
further	O
optimization	O
.	O

Loose	O
stools	O
or	O
diarrhea	O
,	O
hemophagocytosis	O
syndrome	O
,	O
and	O
high	O
serum	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
a	O
associated	O
with	O
lung	O
lesions	O
were	O
found	O
in	O
all	O
10	O
patients	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
an	O
indirect	O
immunofluorescence	O
assay	O
based	O
on	O
virus	O
-	O
infected	O
cells	O
for	O
detecting	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
antibody	B-FUNC
.	O

All	O
confirmed	O
SARS	O
cases	O
demonstrated	O
seroconversion	O
or	O
fourfold	O
rise	O
in	O
IgG	O
antibody	B-FUNC
titer	O
;	O
no	O
control	O
was	O
positive	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
main	O
proteinase	B-FUNC
is	O
a	O
key	O
enzyme	O
in	O
viral	O
polyprotein	O
processing	O
.	O

To	O
allow	O
structure	O
-	O
based	O
design	O
of	O
drugs	O
directed	O
at	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-FUNC
,	O
we	O
predicted	O
its	O
binding	B-FUNC
pockets	O
and	O
affinities	O
with	O
existing	O
HIV	O
,	O
psychotic	O
and	O
parasite	O
drugs	O
(	O
lopinavir	O
,	O
ritonavir	O
,	O
niclosamide	O
and	O
promazine	O
),	O
which	O
show	O
signs	O
of	O
inhibiting	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
.	O
Our	O
results	O
suggest	O
that	O
these	O
drugs	O
and	O
another	O
two	O
HIV	O
inhibitors	O
(	O
PNU	O
and	O
UC2	O
)	O
could	O
be	O
used	O
as	O
templates	O
for	O
designing	O
SARS	O
-	O
CoV	O
proteinase	B-FUNC
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
commercially	O
available	O
in	O
-	O
practice	O
test	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibodies	O
(	O
FCoV	O
Immunocomb	O
,	O
Biogal	O
Galed	O
Laboratories	O
)	O
was	O
evaluated	O
by	O
comparison	O
with	O
the	O
gold	O
standard	O
FCoV	O
immunofluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
test	O
.	O

A	O
strong	O
positive	O
result	O
would	O
be	O
useful	O
in	O
the	O
diagnosis	O
of	O
FIP	O
(	O
in	O
conjunction	O
with	O
other	O
biochemical	O
and	O
cytological	O
testing	O
),	O
but	O
positive	O
results	O
would	O
be	O
of	O
limited	O
value	O
in	O
monitoring	O
FCoV	O
infection	O
in	O
healthy	O
cats	O
as	O
the	O
antibody	B-FUNC
titre	O
could	O
not	O
be	O
reliably	O
compared	O
with	O
those	O
obtained	O
with	O
IFA	O
.	O

The	O
kit	B-FUNC
also	O
appeared	O
to	O
work	O
efficiently	O
with	O
ascites	O
samples	O
(	O
n	O
=	O
6	O
)	O
but	O
too	O
few	O
samples	O
were	O
analysed	O
to	O
draw	O
firm	O
conclusions	O
.	O

The	O
most	O
noteworthy	O
changes	O
were	O
in	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interferon	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
levels	O
.	O

We	O
have	O
proposed	O
the	O
binding	B-FUNC
regions	O
of	O
HR1	O
and	O
HR2	O
of	O
other	O
coronaviruses	O
and	O
a	O
structure	O
model	O
of	O
their	O
fusion	O
core	O
based	O
on	O
our	O
mouse	O
hepatitis	O
virus	O
fusion	O
core	O
structure	O
and	O
sequence	O
alignment	O
.	O

Medical	O
examination	O
was	O
also	O
carried	O
out	O
for	O
313	O
people	O
who	O
had	O
close	O
contact	O
with	O
the	O
29	O
antibody	B-FUNC
positive	O
health	O
care	O
professionals	O
,	O
but	O
no	O
clinical	O
SARS	O
was	O
found	O
.	O

Medical	O
examination	O
was	O
also	O
carried	O
out	O
for	O
313	O
people	O
who	O
had	O
close	O
contact	O
with	O
the	O
29	O
antibody	B-FUNC
positive	O
health	O
care	O
professionals	O
,	O
but	O
no	O
clinical	O
SARS	O
was	O
found	O
.	O

(	O
1	O
)	O
During	O
inhalation	O
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	O
,	O
blood	O
arterial	O
oxygen	O
partial	O
pressure	O
fell	O
gradually	O
,	O
and	O
eventually	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
serum	O
rises	O
significantly	O
after	O
inhalation	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	O
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	O
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	O
,	O
edema	O
and	O
atelectasis	O
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	O
in	O
other	O
organs	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
During	O
inhalation	O
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	O
,	O
blood	O
arterial	O
oxygen	O
partial	O
pressure	O
fell	O
gradually	O
,	O
and	O
eventually	O
met	O
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
serum	O
rises	O
significantly	O
after	O
inhalation	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	O
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	O
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	O
,	O
edema	O
and	O
atelectasis	O
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	O
in	O
other	O
organs	O
.	O

Samples	O
were	O
analyzed	O
by	O
a	O
reverse	O
transcriptase	B-FUNC
PCR	O
assay	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
two	O
second	O
-	O
generation	O
,	O
replicase	O
(	O
R	O
)	O
gene	O
-	O
based	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
kits	O
--	O
the	O
RealArt	O
HPA	O
coronavirus	O
LC	O
kit	B-FUNC
(	O
Artus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
the	O
LightCycler	O
SARS	O
-	O
CoV	O
quantification	O
kit	B-FUNC
(	O
Roche	O
,	O
Penzberg	O
,	O
Germany	O
)--	O
and	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
.	O

The	O
linear	O
range	O
for	O
the	O
Artus	O
RealArt	O
HPA	O
-	O
Coronavirus	O
assay	O
(	O
Artus	O
assay	O
)	O
was	O
1	O
x	O
10	O
(	O
2	O
)	O
to	O
1	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
ml	O
,	O
and	O
that	O
for	O
the	O
Roche	O
LightCycler	O
SARS	O
CoV	O
Quantification	O
kit	B-FUNC
(	O
Roche	O
assay	O
)	O
was	O
1	O
x	O
10	O
(	O
4	O
)	O
to	O
2	O
x	O
10	O
(	O
8	O
)	O
copies	O
/	O
ml	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
evaluation	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
antibody	B-FUNC
tests	O
for	O
serodiagnosis	O
of	O
SARS	O
-	O
CoV	O
pneumonia	O
and	O
compare	O
the	O
sensitivities	O
and	O
specificities	O
of	O
this	O
ELISA	O
for	O
detection	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
IgM	O
,	O
IgA	O
,	O
and	O
their	O
combinations	O
with	O
serum	O
samples	O
from	O
149	O
healthy	O
blood	O
donors	O
who	O
donated	O
blood	O
3	O
years	O
ago	O
as	O
controls	O
and	O
106	O
SARS	O
-	O
CoV	O
pneumonia	O
patients	O
in	O
Hong	O
Kong	O
.	O

Alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

ALT	B-FUNC
,	O
AST	O
,	O
GGT	O
and	O
LDH	O
were	O
always	O
4	O
to	O
9	O
times	O
of	O
normal	O
.	O

The	O
ratio	O
of	O
abnormality	O
of	O
ALT	B-FUNC
,	O
AST	O
and	O
PAB	O
were	O
more	O
than	O
80	O
.	O
0	O
percent	O
,	O
the	O
ratio	O
of	O
abnormality	O
of	O
ALB	O
was	O
42	O
.	O
7	O
percent	O
,	O
and	O
less	O
than	O
30	O
.	O
0	O
percent	O
for	O
other	O
indexes	O
.	O

Anti	O
-	O
P2	O
antibodies	O
and	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
could	O
specifically	O
detect	O
the	O
recombinant	O
SARS	O
protein	O
3a	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
Vero	O
E6	O
cells	O
.	O

Interferon	O
-	O
alpha	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
by	O
contrast	O
,	O
were	O
less	O
effective	O
.	O

To	O
detect	O
false	O
negative	O
results	O
due	O
to	O
PCR	O
inhibitors	O
or	O
faulty	O
RNA	O
extraction	O
,	O
we	O
have	O
further	O
modified	O
this	O
one	O
step	O
RT	O
-	O
PCR	O
assay	O
for	O
simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
18S	O
ribosomal	B-FUNC
RNA	I-FUNC
(	O
rRNA	O
)	O
as	O
an	O
internal	O
positive	O
control	O
.	O

Proliferation	O
of	O
polyclonal	O
plasma	O
cells	O
of	O
recipient	O
-	O
type	O
that	O
was	O
documented	O
postmortem	O
,	O
was	O
most	O
likely	O
responsible	O
for	O
excessive	O
antibody	B-FUNC
formation	O
.	O

Antibody	B-FUNC
prevalence	O
was	O
greater	O
in	O
adults	O
for	O
FIV	O
and	O
FECV	O
/	O
FIPV	O
,	O
and	O
being	O
a	O
female	O
of	O
high	O
social	O
rank	O
was	O
a	O
risk	O
factor	O
for	O
FIV	O
.	O

The	O
lower	O
prevalence	O
of	O
CDV	O
antibody	B-FUNC
-	O
positive	O
hyenas	O
near	O
human	O
habitation	O
suggests	O
that	O
reservoirs	O
for	O
CDV	O
other	O
than	O
domestic	O
dogs	O
are	O
present	O
in	O
the	O
Serengeti	O
ecosystem	O
.	O

Individual	O
bobcats	O
with	O
positive	O
FCV	O
antibody	B-FUNC
titers	O
had	O
patterns	O
of	O
movement	O
that	O
intercepted	O
park	O
inholdings	O
where	O
domestic	O
cats	O
lived	O
.	O

We	O
employed	O
online	O
database	O
analysis	O
to	O
compare	O
the	O
differences	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
homologous	O
T	O
epitopes	O
of	O
HCoV	O
-	O
229e	O
and	O
SARS	O
-	O
CoV	O
.	O
The	O
identified	O
T	O
-	O
cell	O
epitope	O
peptides	O
were	O
synthesized	O
,	O
and	O
their	O
binding	B-FUNC
affinities	O
for	O
HLA	O
-	O
A2	O
were	O
validated	O
and	O
compared	O
in	O
the	O
T2	O
cell	O
system	O
.	O

HLA	O
-	O
A2	O
typing	O
by	O
indirect	O
immunofluorescent	O
antibody	B-FUNC
staining	O
showed	O
that	O
51	O
.	O
6	O
%	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
were	O
HLA	O
-	O
A2	O
positive	O
.	O

Online	O
database	O
analysis	O
and	O
the	O
T2	O
cell	O
binding	B-FUNC
test	O
disclosed	O
that	O
the	O
number	O
of	O
HLA	O
-	O
A2	O
-	O
restricted	O
immunogenic	O
epitopes	O
of	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
decreased	O
or	O
even	O
lost	O
in	O
comparison	O
with	O
the	O
homologous	O
sequences	O
of	O
the	O
S	O
protein	O
of	O
HCoV	O
-	O
229e	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
enzymatic	O
activities	O
of	O
a	O
recombinant	O
form	O
of	O
the	O
SARS	O
-	O
CoV	O
helicase	O
(	O
nonstructural	O
protein	O
[	O
nsp	O
]	O
13	O
),	O
a	O
superfamily	O
1	O
helicase	O
with	O
an	O
N	O
-	O
terminal	O
zinc	O
-	O
binding	B-FUNC
domain	O
.	O

Furthermore	O
,	O
we	O
established	O
an	O
RNA	O
5	O
'-	O
triphosphatase	B-FUNC
activity	I-FUNC
for	O
the	O
SARS	O
-	O
CoV	O
nsp13	O
helicase	O
which	O
may	O
be	O
involved	O
in	O
the	O
formation	O
of	O
the	O
5	O
'	O
cap	O
structure	O
of	O
viral	O
RNAs	O
.	O

Although	O
myeloid	O
dendritic	O
cells	O
were	O
able	O
to	O
interact	O
with	O
S	O
and	O
to	O
bind	B-FUNC
virus	O
,	O
these	O
cells	O
could	O
not	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
these	O
cells	O
were	O
able	O
to	O
transfer	O
the	O
virus	O
to	O
susceptible	O
target	O
cells	O
through	O
a	O
synapse	O
-	O
like	O
structure	O
.	O

MHV	O
infection	O
in	O
quiescent	O
17Cl	O
-	O
1	O
cells	O
prevented	O
normal	O
increases	O
in	O
Cdk4	O
,	O
Cdk6	O
,	O
cyclin	B-FUNC
D1	O
,	O
and	O
cyclin	B-FUNC
D3	O
levels	O
after	O
serum	O
stimulation	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
reduction	O
in	O
the	O
amounts	O
of	O
G	O
(	O
1	O
)	O
cyclin	B-FUNC
-	O
Cdk	B-FUNC
complexes	O
in	O
MHV	O
-	O
infected	O
cells	O
led	O
to	O
a	O
reduction	O
in	O
Cdk	B-FUNC
activities	O
and	O
insufficient	O
hyperphosphorylation	O
of	O
pRb	O
,	O
resulting	O
in	O
inhibition	O
of	O
the	O
cell	O
cycle	O
in	O
the	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
phase	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
murine	O
monoclonal	O
antibody	B-FUNC
specific	O
for	O
SARS	O
-	O
CoV	O
nucleoprotein	O
,	O
and	O
probes	O
specific	O
for	O
a	O
SARS	O
-	O
CoV	O
RNA	O
polymerase	O
gene	O
fragment	O
,	O
for	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
,	O
respectively	O
,	O
to	O
detect	O
SARS	O
-	O
CoV	O
systematically	O
in	O
tissues	O
from	O
patients	O
who	O
died	O
of	O
SARS	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
SARS	O
CoV	O
nucleocapsid	O
protein	O
.	O

The	O
protein	O
consists	O
of	O
a	O
five	O
-	O
stranded	O
beta	O
sheet	O
with	O
a	O
folding	O
topology	O
distinct	O
from	O
other	O
RNA	O
-	O
binding	B-FUNC
proteins	O
.	O

Single	O
-	O
stranded	O
RNAs	O
bind	B-FUNC
to	O
the	O
protein	O
surface	O
at	O
the	O
junction	O
between	O
a	O
flexible	O
,	O
positively	O
charged	O
beta	O
hairpin	O
and	O
the	O
core	O
structure	O
.	O

NMR	O
-	O
based	O
screening	O
was	O
used	O
to	O
identify	O
low	O
molecular	O
weight	O
compounds	O
that	O
bind	B-FUNC
to	O
this	O
site	O
.	O

This	O
protease	O
easily	O
dissociated	O
into	O
inactive	O
monomer	O
and	O
the	O
deduced	O
Kd	O
of	O
the	O
dimer	O
was	O
100	O
microM	O
.	O
In	O
order	O
to	O
detect	O
enzyme	B-FUNC
activity	I-FUNC
,	O
the	O
assay	O
needed	O
to	O
be	O
performed	O
at	O
micromolar	O
enzyme	O
concentration	O
.	O

ABSTRACT	O
:	O
Pharmacophore	O
modeling	O
can	O
provide	O
valuable	O
insight	O
into	O
ligand	B-FUNC
-	O
receptor	O
interactions	O
.	O

TITLE	O
:	O
[	O
Determination	O
and	O
comparison	O
of	O
anti	O
-	O
SARS	O
antibody	B-FUNC
in	O
children	O
and	O
adults	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
positive	O
rate	O
of	O
anti	O
-	O
SARS	O
antibody	B-FUNC
in	O
children	O
and	O
adults	O
without	O
SARS	O
,	O
197	O
paediatric	O
patients	O
under	O
14	O
years	O
old	O
from	O
inpatient	O
and	O
outpatient	O
department	O
of	O
our	O
hospital	O
,	O
156	O
healthy	O
children	O
pupils	O
from	O
primary	O
school	O
,	O
453	O
adult	O
patients	O
over	O
18	O
years	O
old	O
from	O
inpatient	O
and	O
outpatient	O
department	O
of	O
our	O
hospital	O
and	O
other	O
502	O
healthy	O
adult	O
blood	O
donors	O
were	O
selected	O
.	O

The	O
results	O
showed	O
that	O
both	O
the	O
positive	O
rates	O
of	O
IgG	O
antibody	B-FUNC
in	O
paediatric	O
patients	O
and	O
healthy	O
children	O
were	O
about	O
2	O
%	O
(	O
4	O
/	O
197	O
and	O
3	O
/	O
156	O
),	O
while	O
the	O
positive	O
rates	O
in	O
adult	O
patients	O
and	O
healthy	O
adults	O
were	O
about	O
0	O
.	O
2	O
%	O
(	O
1	O
/	O
453	O
and	O
1	O
/	O
502	O
).	O

It	O
is	O
concluded	O
that	O
the	O
anti	O
-	O
SARS	O
IgG	O
antibody	B-FUNC
positive	O
rate	O
in	O
children	O
was	O
obvious	O
higher	O
than	O
that	O
in	O
adults	O
.	O

Here	O
we	O
report	O
that	O
by	O
using	O
in	O
vitro	O
bio	O
-	O
engineering	O
techniques	O
,	O
SARS	O
-	O
CoV	O
HR1	O
and	O
HR2	O
bind	B-FUNC
to	O
each	O
other	O
and	O
form	O
a	O
typical	O
6	O
-	O
helix	O
bundle	O
.	O

ABSTRACT	O
:	O
A	O
TaqMan	O
fluorogenic	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
the	O
detection	O
and	O
quantitation	O
of	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
RNA	O
in	O
the	O
faeces	O
of	O
naturally	O
or	O
experimentally	O
infected	O
dogs	O
.	O

Reverse	O
-	O
transcriptase	B-FUNC
PCR	O
was	O
done	O
on	O
2134	O
specimens	O
of	O
different	O
types	O
.	O

Inhibitors	O
binding	B-FUNC
to	O
HR	O
regions	O
of	O
fusion	O
proteins	O
have	O
been	O
shown	O
to	O
be	O
efficacious	O
against	O
many	O
viruses	O
,	O
notably	O
HIV	O
.	O

Liver	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
and	O
lactic	O
dehydrogenase	O
(	O
LDH	O
)	O
were	O
analyzed	O
in	O
these	O
patients	O
.	O

Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	B-FUNC
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	B-FUNC
activity	I-FUNC
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

RESULTS	O
:	O
Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	B-FUNC
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	B-FUNC
activity	I-FUNC
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

Specific	O
antibody	B-FUNC
responses	O
to	O
the	O
purified	O
recombinant	O
N	O
protein	O
after	O
10	O
,	O
20	O
,	O
and	O
30	O
days	O
of	O
disease	O
onset	O
were	O
observed	O
in	O
13	O
of	O
16	O
(	O
81	O
.	O
3	O
%),	O
16	O
of	O
16	O
(	O
100	O
%)	O
and	O
16	O
of	O
16	O
(	O
100	O
%)	O
SARS	O
patients	O
sera	B-FUNC
,	O
respectively	O
.	O

Comparison	O
of	O
detection	O
results	O
with	O
a	O
commercially	O
available	O
diagnostic	O
kit	B-FUNC
coated	O
with	O
a	O
mixture	O
of	O
SARS	O
-	O
CoV	O
viral	O
proteins	O
showed	O
9	O
of	O
16	O
(	O
56	O
.	O
3	O
%),	O
13	O
of	O
16	O
(	O
81	O
.	O
3	O
%),	O
and	O
15	O
of	O
16	O
(	O
93	O
.	O
7	O
%)	O
positive	O
responses	O
,	O
respectively	O
.	O

None	O
of	O
131	O
control	O
sera	B-FUNC
gave	O
positive	O
reaction	O
in	O
either	O
assay	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
a	O
potential	O
usefulness	O
of	O
a	O
newly	O
developed	O
SF	O
test	O
utilizing	O
an	O
SF	O
specific	O
monoclonal	O
antibody	B-FUNC
(	O
IF	O
-	O
43	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
antibody	B-FUNC
responses	O
against	O
SARS	O
coronaviral	O
nucleocapsid	O
or	O
spike	O
proteins	O
by	O
immunoblotting	O
or	O
ELISA	O
.	O

Although	O
effective	O
in	O
experimental	O
studies	O
no	O
clear	O
recommendation	O
can	O
be	O
made	O
in	O
view	O
to	O
the	O
use	O
of	O
other	O
vasodilators	O
such	O
as	O
phosphodiesterase	B-FUNC
inhibitors	O
or	O
endothelin	O
antagonists	O
.	O

TITLE	O
:	O
[	O
Development	O
and	O
evaluation	O
of	O
the	O
kit	B-FUNC
for	O
detection	O
of	O
SARS	O
-	O
associated	O
Coronavirus	O
RNA	O
].	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
diagnostic	O
kit	B-FUNC
for	O
detection	O
of	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)-	O
related	O
coronavirus	O
RNA	O
based	O
on	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
and	O
to	O
estimate	O
its	O
specificity	O
and	O
sensitivity	O
.	O

The	O
specificity	O
of	O
the	O
kit	B-FUNC
was	O
determined	O
using	O
animal	O
coronaviruses	O
and	O
other	O
bacterial	O
and	O
viral	O
strains	O
,	O
causing	O
acute	O
respiratory	O
and	O
intestinal	O
infections	O
,	O
and	O
was	O
shown	O
to	O
be	O
100	O
%.	O

The	O
sensitivity	O
of	O
the	O
kit	B-FUNC
in	O
different	O
clinical	O
samples	O
was	O
2	O
.	O
2	O
x	O
10	O
(	O
3	O
)	O
genome	O
equivalents	O
of	O
recombinant	O
SARS	O
RNA	O
in	O
1	O
ml	O
of	O
the	O
specimen	O
.	O

The	O
kit	B-FUNC
was	O
evaluated	O
in	O
the	O
Institute	O
of	O
Microbiology	O
and	O
Epidemiology	O
of	O
Beijing	O
(	O
China	O
)	O
using	O
SARS	O
-	O
cov	O
viral	O
suspension	O
and	O
clinical	O
samples	O
from	O
patients	O
with	O
suspected	O
SARS	O
.	O

It	O
was	O
shown	O
that	O
kit	B-FUNC
was	O
able	O
to	O
detect	O
10	O
TCID	O
/	O
50	O
ml	O
of	O
SARS	O
-	O
Cov	O
virus	O
.	O

Testing	O
of	O
clinical	O
samples	O
from	O
patients	O
with	O
suspected	O
SARS	O
showed	O
that	O
diagnostic	O
sensitivity	O
of	O
the	O
kit	B-FUNC
was	O
95	O
%.	O

The	O
kit	B-FUNC
contains	O
reagents	O
for	O
RNA	O
isolation	O
and	O
purification	O
,	O
cDNA	O
synthesis	O
by	O
reverse	O
transcription	O
of	O
RNA	O
,	O
for	O
PCR	O
and	O
for	O
electrophoretic	O
analysis	O
of	O
amplified	O
products	O
.	O

The	O
kit	B-FUNC
also	O
contains	O
recombinant	O
positive	O
and	O
internal	O
control	O
samples	O
allowing	O
to	O
control	O
efficiency	O
of	O
analysis	O
and	O
showed	O
good	O
analytical	O
and	O
diagnostic	O
characteristics	O
.	O

Furthermore	O
,	O
several	O
studies	O
indicate	O
that	O
virus	O
proliferation	O
can	O
be	O
arrested	O
using	O
specific	O
proteinase	B-FUNC
inhibitors	O
supporting	O
the	O
belief	O
that	O
proteinases	O
are	O
indeed	O
important	O
during	O
infection	O
.	O

Prompted	O
by	O
this	O
,	O
we	O
set	O
out	O
to	O
analyse	O
and	O
predict	O
cleavage	O
by	O
the	O
coronavirus	O
main	O
proteinase	B-FUNC
using	O
computational	O
methods	O
.	O

We	O
retrieved	O
sequence	O
data	O
on	O
seven	O
fully	O
sequenced	O
coronaviruses	O
and	O
identified	O
the	O
main	O
3CL	O
proteinase	B-FUNC
cleavage	O
sites	O
in	O
polyproteins	O
using	O
alignments	O
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	O
such	O
as	O
the	O
cystic	B-FUNC
fibrosis	I-FUNC
transmembrane	I-FUNC
conductance	I-FUNC
regulator	I-FUNC
(	O
CFTR	O
),	O
transcription	O
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	B-FUNC
pathway	O
.	O

Furthermore	O
,	O
the	O
method	O
might	O
assist	O
in	O
design	O
of	O
proteinase	B-FUNC
inhibitors	O
for	O
treatment	O
of	O
SARS	O
and	O
possible	O
future	O
diseases	O
caused	O
by	O
coronaviruses	O
.	O

It	O
is	O
made	O
available	O
for	O
public	O
use	O
at	O
our	O
website	O
:	O
http	O
://	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
NetCorona	O
/.	O
RESULTS	O
:	O
We	O
retrieved	O
sequence	O
data	O
on	O
seven	O
fully	O
sequenced	O
coronaviruses	O
and	O
identified	O
the	O
main	O
3CL	O
proteinase	B-FUNC
cleavage	O
sites	O
in	O
polyproteins	O
using	O
alignments	O
.	O

Here	O
,	O
we	O
provide	O
evidences	O
that	O
RNAi	O
targeting	O
at	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	B-FUNC
)	O
using	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	O
plasmids	O
can	O
specifically	O
inhibit	O
expression	O
of	O
extraneous	O
coronavirus	O
RDRP	B-FUNC
in	O
293	O
and	O
HeLa	O
cells	O
.	O

Several	O
putative	O
functional	O
domains	O
such	O
as	O
a	O
papain	O
-	O
like	O
proteinase	B-FUNC
(	O
PL	O
(	O
pro	O
)),	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
and	O
RNA	O
helicase	O
encoded	O
by	O
the	O
replicase	O
gene	O
are	O
important	O
for	O
virus	O
replication	O
.	O

All	O
the	O
coronavirus	O
5	O
'-	O
termini	O
and	O
PL	O
(	O
pro	O
)	O
domains	O
were	O
divergent	O
,	O
unlike	O
the	O
M	O
(	O
pro	O
)	O
and	O
the	O
RdRp	B-FUNC
domains	O
that	O
were	O
highly	O
conserved	O
with	O
28	O
%	O
and	O
48	O
%	O
conserved	O
residues	O
,	O
respectively	O
.	O

The	O
IBV	O
M	O
(	O
pro	O
)	O
and	O
RdRp	B-FUNC
domains	O
were	O
highly	O
conserved	O
with	O
82	O
.	O
7	O
%	O
and	O
92	O
.	O
7	O
%	O
conserved	O
residues	O
,	O
respectively	O
.	O

Among	O
six	O
fusion	O
peptides	O
,	O
S5	O
reacted	O
with	O
monoclonal	O
antibody	B-FUNC
D3C5	O
and	O
S2	O
reacted	O
with	O
monoclonal	O
antibody	B-FUNC
D3D1	O
against	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
epitopes	O
recognized	O
by	O
monoclonal	O
antibodies	O
D3C5	O
and	O
D3D1	O
are	O
linear	O
,	O
and	O
correspond	O
to	O
447	O
-	O
458	O
and	O
789	O
-	O
799	O
amino	O
acids	O
of	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
respectively	O
.	O

TITLE	O
:	O
Sensitive	O
and	O
specific	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
capture	O
enzyme	O
immunoassay	O
for	O
detection	O
of	O
nucleocapsid	O
antigen	O
in	O
sera	B-FUNC
from	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
abundantly	O
expressed	O
in	O
infected	O
-	O
cell	O
culture	O
filtrate	O
as	O
demonstrable	O
by	O
Western	O
blotting	O
using	O
convalescent	O
-	O
phase	O
sera	B-FUNC
from	O
patients	O
with	O
SARS	O
.	O

Using	O
a	O
panel	O
of	O
sera	B-FUNC
collected	O
at	O
different	O
points	O
in	O
time	O
,	O
the	O
amount	O
of	O
circulating	O
N	O
antigen	O
was	O
found	O
to	O
peak	O
6	O
to	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

TITLE	O
:	O
Altered	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
expression	O
in	O
different	O
leukocytes	O
with	O
increment	O
of	O
immunosuppressive	O
mediators	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Patients	O
with	O
SARS	O
had	O
significantly	O
higher	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
in	O
early	O
stage	O
,	O
and	O
higher	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
levels	O
(	O
p	O
=	O
0	O
.	O
039	O
)	O
in	O
late	O
stage	O
than	O
normal	O
controls	O
.	O

Blood	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
nitrite	O
/	O
nitrate	O
levels	O
were	O
not	O
significantly	O
elevated	O
.	O

The	O
fusion	O
protein	O
could	O
react	O
with	O
all	O
the	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
but	O
not	O
with	O
the	O
sera	B-FUNC
from	O
healthy	O
donors	O
.	O

The	O
fusion	O
protein	O
could	O
react	O
with	O
all	O
the	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
but	O
not	O
with	O
the	O
sera	B-FUNC
from	O
healthy	O
donors	O
.	O

TITLE	O
:	O
Phosphorylation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
its	O
downstream	O
targets	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
cells	O
.	O

Phosphorylation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
was	O
significantly	O
up	O
-	O
regulated	O
at	O
18	O
h	O
.	O
p	O
.	O
i	O
.	O

The	O
downstream	O
targets	O
of	O
p38	B-FUNC
MAPK	B-FUNC
,	O
MAPKAPK	O
-	O
2	O
,	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
were	O
phosphorylated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

The	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	O
of	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Using	O
antibody	B-FUNC
specific	O
for	O
the	O
C	O
terminus	O
of	O
U274	O
,	O
we	O
show	O
U274	O
to	O
be	O
expressed	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
and	O
,	O
in	O
addition	O
to	O
the	O
full	O
-	O
length	O
protein	O
,	O
two	O
other	O
processed	O
forms	O
were	O
also	O
detected	O
.	O

In	O
some	O
animals	O
,	O
however	O
,	O
only	O
one	O
determinant	O
(	O
Leu	O
803	O
to	O
Ala	O
828	O
)	O
was	O
able	O
to	O
induce	O
the	O
antisera	O
with	O
the	O
binding	B-FUNC
ability	O
to	O
the	O
native	O
S	O
protein	O
and	O
the	O
neutralizing	O
activity	O
to	O
the	O
SARS	O
-	O
CoV	O
pseudovirus	O
.	O

However	O
,	O
most	O
of	O
the	O
diagnostic	O
methods	O
available	O
today	O
,	O
such	O
as	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
require	O
a	O
second	O
detection	O
method	O
for	O
confirmation	O
because	O
they	O
detect	O
a	O
single	O
sequence	O
region	O
of	O
the	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
major	O
surface	O
antigen	O
of	O
the	O
virus	O
and	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
the	O
generation	O
of	O
neutralizing	O
antibody	B-FUNC
.	O

Tested	O
were	O
19	O
clinically	O
approved	O
compounds	O
from	O
several	O
major	O
antiviral	O
pharmacologic	O
classes	O
:	O
nucleoside	O
analogs	O
,	O
interferons	O
,	O
protease	O
inhibitors	O
,	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
,	O
and	O
neuraminidase	O
inhibitors	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
reaction	O
of	O
GST	O
-	O
N	O
to	O
anti	O
-	O
SARS	O
-	O
CoV	O
sera	B-FUNC
was	O
positive	O
.	O

TITLE	O
:	O
SARS	O
corona	O
virus	O
peptides	O
recognized	O
by	O
antibodies	O
in	O
the	O
sera	B-FUNC
of	O
convalescent	O
cases	O
.	O

We	O
probed	O
these	O
membranes	O
with	O
four	O
pairs	O
of	O
acute	O
and	O
convalescent	O
sera	B-FUNC
from	O
recovered	O
SARS	O
cases	O
.	O

We	O
found	O
that	O
convalescent	O
sera	B-FUNC
with	O
high	O
neutralizing	O
activity	O
recognized	O
exclusively	O
only	O
a	O
limited	O
number	O
of	O
peptides	O
on	O
the	O
membranes	O
.	O

The	O
expression	O
of	O
S	O
with	O
the	O
two	O
other	O
putative	O
virion	O
envelope	O
proteins	O
,	O
the	O
matrix	O
M	O
and	O
small	O
envelope	O
E	O
proteins	O
,	O
did	O
not	O
augment	O
the	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

A	O
catalytic	O
cleft	O
containing	O
the	O
substrate	O
binding	B-FUNC
sites	O
S1	O
and	O
S2	O
between	O
domains	O
I	O
and	O
II	O
are	O
also	O
observed	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
response	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
targets	O
the	O
viral	O
nucleocapsid	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
provided	O
an	O
opportunity	O
to	O
study	O
the	O
antibody	B-FUNC
response	O
of	O
infected	O
individuals	O
to	O
the	O
causative	O
virus	O
,	O
SARS	O
coronavirus	O
.	O

Prophylactic	O
administration	O
of	O
the	O
monoclonal	O
antibody	B-FUNC
at	O
10	O
mg	O
/	O
kg	O
reduced	O
replication	O
of	O
SARS	O
coronavirus	O
in	O
the	O
lungs	O
of	O
infected	O
ferrets	O
by	O
3	O
.	O
3	O
logs	O
(	O
95	O
%	O
CI	O
2	O
.	O
6	O
-	O
4	O
.	O
0	O
logs	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
completely	O
prevented	O
the	O
development	O
of	O
SARS	O
coronavirus	O
-	O
induced	O
macroscopic	O
lung	O
pathology	O
(	O
p	O
=	O
0	O
.	O
013	O
),	O
and	O
abolished	O
shedding	O
of	O
virus	O
in	O
pharyngeal	O
secretions	O
.	O

The	O
data	O
generated	O
in	O
this	O
animal	O
model	O
show	O
that	O
administration	O
of	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
might	O
offer	O
a	O
feasible	O
and	O
effective	O
prophylaxis	O
for	O
the	O
control	O
of	O
human	O
SARS	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
replicase	O
gene	O
-	O
encoded	O
nonstructural	O
protein	O
13	O
(	O
nsp13	O
)	O
contains	O
an	O
N	O
-	O
terminal	O
zinc	O
-	O
binding	B-FUNC
domain	O
and	O
a	O
C	O
-	O
terminal	O
superfamily	O
1	O
helicase	O
domain	O
.	O

A	O
histidine	O
-	O
tagged	O
form	O
of	O
nsp13	O
,	O
which	O
was	O
expressed	O
in	O
insect	O
cells	O
and	O
purified	O
,	O
is	O
reported	O
to	O
unwind	O
efficiently	O
both	O
partial	O
-	O
duplex	O
RNA	O
and	O
DNA	O
of	O
up	O
to	O
several	O
hundred	O
base	B-FUNC
pairs	I-FUNC
.	O

TITLE	O
:	O
Microwave	O
or	O
autoclave	O
treatments	O
destroy	O
the	O
infectivity	O
of	O
infectious	O
bronchitis	O
virus	O
and	O
avian	O
pneumovirus	O
but	O
allow	O
detection	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

However	O
,	O
both	O
IBV	O
and	O
APV	O
could	O
be	O
detected	O
by	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
after	O
autoclaving	O
and	O
as	O
long	O
as	O
5	O
min	O
microwave	O
treatment	O
(	O
Newcastle	O
disease	O
virus	O
and	O
avian	O
influenza	O
viruses	O
were	O
not	O
tested	O
).	O

The	O
cDNA	O
derived	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
was	O
cloned	O
and	O
sequenced	O
.	O

TITLE	O
:	O
Seroprevalence	O
of	O
antibody	B-FUNC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
among	O
health	O
care	O
workers	O
in	O
SARS	O
and	O
non	O
-	O
SARS	O
medical	O
wards	O
.	O

ABSTRACT	O
:	O
The	O
seroprevalence	O
of	O
antibody	B-FUNC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
cohorts	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
with	O
subclinical	O
infection	O
in	O
SARS	O
and	O
non	O
-	O
SARS	O
medical	O
wards	O
was	O
2	O
.	O
3	O
%	O
(	O
3	O
of	O
131	O
HCWs	O
)	O
and	O
0	O
%	O
(	O
0	O
of	O
192	O
HCWs	O
),	O
respectively	O
.	O

Horse	O
polyclonal	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
was	O
bound	O
onto	O
the	O
PZ	O
crystal	O
surface	O
in	O
an	O
ordered	O
orientation	O
through	O
protein	O
A	O
.	O
The	O
antigen	O
sample	O
was	O
atomized	O
into	O
aerosol	O
by	O
an	O
ultrasonator	O
,	O
by	O
which	O
the	O
antibody	B-FUNC
on	O
the	O
crystal	O
could	O
specifically	O
adsorb	O
SARS	O
antigen	O
and	O
the	O
changed	O
mass	O
of	O
crystal	O
would	O
lead	O
a	O
frequency	O
shift	O
.	O

The	O
results	O
can	O
be	O
summarized	O
as	O
follows	O
:	O
(	O
1	O
)	O
higher	O
dosages	O
of	O
vaccine	O
induced	O
higher	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
titer	O
;	O
(	O
2	O
)	O
the	O
level	O
of	O
neutralizing	O
antibodies	O
induced	O
by	O
the	O
inoculation	O
with	O
aluminum	O
hydroxide	O
adjuvant	O
was	O
slightly	O
higher	O
than	O
that	O
without	O
adjuvant	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

TITLE	O
:	O
[	O
Comparison	O
among	O
four	O
kits	O
in	O
detection	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
].	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
sensitivity	O
and	O
specificity	O
of	O
four	O
kits	O
for	O
detection	O
of	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
IgG	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
detected	O
in	O
99	O
serial	O
sera	B-FUNC
from	O
18	O
SARS	O
patients	O
and	O
in	O
123	O
negative	O
reference	O
sera	B-FUNC
,	O
using	O
two	O
enzyme	O
linked	O
immunosorbent	O
assays	O
(	O
EIA	O
No	O
.	O
A	O
and	O
No	O
.	O
B	O
)	O
and	O
two	O
indirect	O
immunofluorescence	O
assays	O
(	O
Australian	O
IFA	O
and	O
Euroimmun	O
IFA	O
).	O

Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
not	O
detected	O
in	O
sera	B-FUNC
collected	O
from	O
SARS	O
patients	O
at	O
the	O
first	O
week	O
after	O
onset	O
by	O
any	O
of	O
the	O
four	O
kits	O
,	O
however	O
,	O
it	O
was	O
detectable	O
in	O
sera	B-FUNC
obtained	O
at	O
the	O
second	O
week	O
of	O
illness	O
by	O
EIA	O
No	O
.	O
B	O
,	O
and	O
two	O
IFA	O
,	O
but	O
not	O
by	O
EIA	O
No	O
.	O
A	O
,	O
with	O
the	O
positive	O
rates	O
of	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
),	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
42	O
.	O
9	O
%	O
(	O
3	O
/	O
7	O
),	O
respectively	O
.	O

The	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
first	O
determined	O
in	O
sera	B-FUNC
on	O
the	O
9th	O
day	O
by	O
Euroimmun	O
IFA	O
,	O
12th	O
day	O
by	O
EIA	O
No	O
.	O
B	O
,	O
13th	O
day	O
by	O
Australian	O
IFA	O
,	O
and	O
16th	O
day	O
by	O
EIA	O
No	O
.	O
A	O
.	O
The	O
positive	O
rates	O
of	O
antibody	B-FUNC
on	O
the	O
3rd	O
week	O
after	O
onset	O
were	O
84	O
.	O
2	O
%	O
(	O
16	O
/	O
19	O
),	O
94	O
.	O
7	O
%	O
(	O
18	O
/	O
19	O
),	O
78	O
.	O
9	O
%	O
(	O
15	O
/	O
19	O
)	O
and	O
52	O
.	O
6	O
%	O
(	O
10	O
/	O
19	O
)	O
respectively	O
.	O

Through	O
detection	O
of	O
123	O
negative	O
reference	O
sera	B-FUNC
,	O
the	O
specificity	O
of	O
EIA	O
No	O
.	O
A	O
and	O
two	O
IFA	O
was	O
100	O
%,	O
with	O
exception	O
of	O
94	O
.	O
9	O
%	O
for	O
EIA	O
No	O
.	O
B	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
two	O
IFAs	O
were	O
relatively	O
higher	O
than	O
that	O
of	O
the	O
two	O
EIAs	O
.	O

RESULTS	O
:	O
Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
was	O
not	O
detected	O
in	O
sera	B-FUNC
collected	O
from	O
SARS	O
patients	O
at	O
the	O
first	O
week	O
after	O
onset	O
by	O
any	O
of	O
the	O
four	O
kits	O
,	O
however	O
,	O
it	O
was	O
detectable	O
in	O
sera	B-FUNC
obtained	O
at	O
the	O
second	O
week	O
of	O
illness	O
by	O
EIA	O
No	O
.	O
B	O
,	O
and	O
two	O
IFA	O
,	O
but	O
not	O
by	O
EIA	O
No	O
.	O
A	O
,	O
with	O
the	O
positive	O
rates	O
of	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
),	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
42	O
.	O
9	O
%	O
(	O
3	O
/	O
7	O
),	O
respectively	O
.	O

Through	O
detection	O
of	O
123	O
negative	O
reference	O
sera	B-FUNC
,	O
the	O
specificity	O
of	O
EIA	O
No	O
.	O
A	O
and	O
two	O
IFA	O
was	O
100	O
%,	O
with	O
exception	O
of	O
94	O
.	O
9	O
%	O
for	O
EIA	O
No	O
.	O
B	O
.	O
CONCLUSIONS	O
:	O
The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
two	O
IFAs	O
were	O
relatively	O
higher	O
than	O
that	O
of	O
the	O
two	O
EIAs	O
.	O

These	O
results	O
demonstrate	O
that	O
there	O
is	O
a	O
relatively	O
broad	O
spectrum	O
of	O
variations	O
in	O
the	O
APN	O
domain	O
critical	O
for	O
coronavirus	O
binding	B-FUNC
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
there	O
is	O
a	O
relatively	O
broad	O
spectrum	O
of	O
variations	O
in	O
the	O
APN	O
domain	O
critical	O
for	O
coronavirus	O
binding	B-FUNC
.	O

Two	O
organic	O
NO	O
donor	O
compounds	O
,	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
(	O
SNAP	B-FUNC
)	O
and	O
sodium	O
nitroprusside	O
(	O
SNP	O
),	O
were	O
tested	O
in	O
a	O
broad	O
range	O
of	O
concentrations	O
.	O

The	O
survival	O
rate	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
was	O
greatly	O
increased	O
by	O
the	O
treatment	O
with	O
SNAP	B-FUNC
,	O
and	O
the	O
concentration	O
of	O
this	O
compound	O
needed	O
to	O
inhibit	O
the	O
viral	O
cytopathic	O
effect	O
to	O
50	O
%	O
was	O
222	O
microM	O
,	O
with	O
a	O
selectivity	O
index	O
of	O
3	O
.	O

CONCLUSIONS	O
:	O
The	O
survival	O
rate	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
was	O
greatly	O
increased	O
by	O
the	O
treatment	O
with	O
SNAP	B-FUNC
,	O
and	O
the	O
concentration	O
of	O
this	O
compound	O
needed	O
to	O
inhibit	O
the	O
viral	O
cytopathic	O
effect	O
to	O
50	O
%	O
was	O
222	O
microM	O
,	O
with	O
a	O
selectivity	O
index	O
of	O
3	O
.	O

Monoclonal	O
antibody	B-FUNC
reagents	O
that	O
recognise	O
specific	O
antigens	O
on	O
SARS	O
-	O
CoV	O
are	O
needed	O
urgently	O
.	O

In	O
this	O
report	O
,	O
the	O
development	O
and	O
immunochemical	O
characterisation	O
of	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
SARS	O
-	O
CoV	O
is	O
presented	O
,	O
based	O
upon	O
their	O
specificity	O
,	O
binding	B-FUNC
requirements	O
,	O
and	O
biological	O
activity	O
.	O

Antibody	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
,	O
but	O
not	O
normal	O
human	O
serum	O
,	O
is	O
also	O
shown	O
to	O
specifically	O
compete	O
off	O
binding	B-FUNC
of	O
mAbs	O
to	O
whole	O
SARS	O
-	O
CoV	O
.	O
These	O
studies	O
highlight	O
the	O
importance	O
of	O
using	O
standardised	O
assays	O
and	O
reagents	O
.	O

TITLE	O
:	O
[	O
Protective	O
effect	O
of	O
specific	O
antibody	B-FUNC
in	O
serum	O
of	O
convalescent	O
patient	O
with	O
SARS	O
].	O

The	O
A	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
in	O
serum	O
of	O
convalescent	O
patients	O
tended	O
to	O
elevate	O
in	O
half	O
an	O
year	O
after	O
SARS	O
onset	O
.	O

CONCLUSIONS	O
:	O
The	O
A	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
in	O
serum	O
of	O
convalescent	O
patients	O
tended	O
to	O
elevate	O
in	O
half	O
an	O
year	O
after	O
SARS	O
onset	O
.	O

Promising	O
treatments	O
have	O
been	O
identified	O
,	O
including	O
interferons	O
,	O
an	O
anti	O
-	O
spike	O
monoclonal	O
antibody	B-FUNC
,	O
and	O
fusion	O
inhibitors	O
.	O

TITLE	O
:	O
Longitudinal	O
profile	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
IgM	O
,	O
and	O
IgA	O
antibodies	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
protein	O
in	O
patients	O
with	O
pneumonia	O
due	O
to	O
the	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
By	O
using	O
a	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
serum	O
specimens	O
serially	O
collected	O
(	O
from	O
day	O
0	O
to	O
day	O
240	O
after	O
symptom	O
onset	O
)	O
from	O
patients	O
with	O
pneumonia	O
due	O
to	O
SARS	O
-	O
CoV	O
,	O
we	O
analyzed	O
the	O
longitudinal	O
profiles	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
IgM	O
,	O
and	O
IgA	O
antibodies	O
against	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
patients	O
with	O
pneumonia	O
due	O
to	O
SARS	O
-	O
CoV	O
.	O
For	O
IgG	O
,	O
the	O
median	O
optical	O
density	O
at	O
450	O
nm	O
(	O
OD450	O
)	O
turned	O
positive	O
at	O
day	O
17	O
and	O
a	O
biphasic	O
response	O
was	O
observed	O
.	O

At	O
day	O
240	O
,	O
36	O
%	O
of	O
the	O
patients	O
were	O
still	O
positive	O
for	O
anti	O
-	O
nucleocapsid	O
protein	O
IgA	O
antibody	B-FUNC
.	O

Further	O
studies	O
should	O
be	O
performed	O
to	O
see	O
whether	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
antibody	B-FUNC
positivity	O
has	O
any	O
prognostic	O
significance	O
.	O

By	O
use	O
of	O
an	O
immunofluorescent	O
(	O
IF	O
)	O
test	O
as	O
the	O
""""	O
gold	O
standard	O
""","	O
both	O
the	O
ELISA	O
and	O
the	O
immunochromatographic	O
test	O
were	O
able	O
to	O
detect	O
immunoglobulin	B-FUNC
G	O
antibodies	O
to	O
SARS	O
not	O
only	O
from	O
late	O
-	O
convalescent	O
-	O
stage	O
samples	O
(>	O
21	O
days	O
from	O
the	O
onset	O
of	O
clinical	O
symptoms	O
),	O
as	O
previously	O
established	O
,	O
but	O
also	O
from	O
early	O
-	O
acute	O
-	O
phase	O
samples	O
(	O
1	O
to	O
10	O
days	O
from	O
onset	O
).	O

The	O
combination	O
of	O
these	O
gel	O
-	O
base	O
and	O
non	O
-	O
gel	O
methods	O
provides	O
fast	B-FUNC
and	O
complimentary	O
approaches	O
to	O
SARS	O
-	O
CoV	O
proteome	O
and	O
can	O
be	O
widely	O
used	O
in	O
the	O
analysis	O
of	O
other	O
viruses	O
.	O

Measurement	O
of	O
serum	O
RNA	O
by	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
technique	O
has	O
a	O
detection	O
rate	O
of	O
75	O
%-	O
80	O
%	O
in	O
the	O
first	O
week	O
of	O
the	O
illness	O
.	O

The	O
detection	O
of	O
S	O
-	O
protein	O
by	O
immunoassays	O
was	O
difficult	O
using	O
human	O
convalescent	O
sera	B-FUNC
,	O
suggesting	O
that	O
the	O
protein	O
may	O
not	O
elicit	O
strong	O
humoral	O
immune	O
response	O
in	O
virus	O
-	O
infected	O
patients	O
.	O

Pseudoviruses	O
infected	O
Vero	O
E6	O
cells	O
in	O
a	O
pH	O
-	O
independent	O
manner	O
and	O
the	O
infection	O
could	O
be	O
specifically	O
inhibited	O
by	O
convalescent	O
sera	B-FUNC
.	O

The	O
high	O
-	O
throughput	O
capacity	O
of	O
this	O
procedure	O
and	O
the	O
safety	O
of	O
using	O
SARS	O
pseudoviruses	O
should	O
make	O
possible	O
large	O
-	O
scale	O
analyses	O
of	O
neutralizing	O
antibody	B-FUNC
responses	O
against	O
SARS	O
-	O
CoV	O
.	O

The	O
prevalence	O
of	O
positive	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
nasopharyngeal	O
secretions	O
and	O
stool	O
samples	O
was	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
was	O
useful	O
in	O
diagnosing	O
SARS	O
in	O
older	O
patients	O
,	O
but	O
the	O
role	O
of	O
serological	O
tests	O
in	O
individual	O
elderly	O
is	O
limited	O
.	O

In	O
this	O
study	O
,	O
sera	B-FUNC
were	O
collected	O
from	O
healthy	O
donors	O
,	O
patients	O
with	O
SARS	O
,	O
patients	O
with	O
severe	O
SARS	O
,	O
and	O
patients	O
with	O
SARS	O
in	O
convalescence	O
.	O

The	O
serum	O
concentrations	O
of	O
interleukin	O
-	O
1	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
tumor	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
and	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
).	O

The	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
was	O
increased	O
in	O
SARS	O
patients	O
and	O
was	O
significantly	O
elevated	O
in	O
severe	O
SARS	O
patients	O
,	O
but	O
the	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentrations	O
were	O
similar	O
in	O
convalescent	O
patients	O
and	O
control	O
subjects	O
,	O
suggesting	O
that	O
there	O
was	O
a	O
positive	O
relationship	O
between	O
the	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
and	O
SARS	O
severity	O
.	O

The	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TGF	O
-	O
beta	O
were	O
decreased	O
in	O
SARS	O
patients	O
and	O
significantly	O
reduced	O
in	O
severe	O
SARS	O
patients	O
,	O
but	O
they	O
were	O
comparable	O
in	O
convalescent	O
SARS	O
patients	O
and	O
control	O
subjects	O
,	O
suggesting	O
that	O
there	O
was	O
a	O
negative	O
relationship	O
between	O
the	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TGF	O
-	O
beta	O
concentrations	O
and	O
SARS	O
severity	O
.	O

The	O
concentrations	O
of	O
IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
showed	O
significant	O
changes	O
only	O
in	O
convalescent	O
SARS	O
patients	O
.	O

The	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
levels	O
were	O
decreased	O
,	O
while	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
increased	O
,	O
and	O
the	O
differences	O
between	O
convalescent	O
SARS	O
patients	O
and	O
other	O
patient	O
groups	O
were	O
statistically	O
significant	O
.	O

To	O
find	O
disease	O
-	O
specific	O
B	O
cell	O
epitopes	O
,	O
phage	O
-	O
displayed	O
random	O
peptide	O
libraries	O
were	O
panned	O
on	O
serum	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
antibodies	O
from	O
patients	O
with	O
SARS	O
.	O

Synthetic	O
peptide	B-FUNC
binding	I-FUNC
and	O
competitive	O
-	O
inhibition	O
assays	O
further	O
confirmed	O
that	O
patients	O
with	O
SARS	O
generated	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
.	O
Immunopositive	O
phage	O
clones	O
and	O
epitope	O
-	O
based	O
peptide	O
antigens	O
demonstrated	O
clinical	O
diagnostic	O
potential	O
by	O
reacting	O
with	O
serum	O
from	O
patients	O
with	O
SARS	O
.	O

Antibody	B-FUNC
-	O
response	O
kinetics	O
were	O
evaluated	O
in	O
4	O
patients	O
with	O
SARS	O
,	O
and	O
production	O
of	O
IgM	O
,	O
IgG	O
,	O
and	O
IgA	O
were	O
documented	O
as	O
part	O
of	O
the	O
immune	O
response	O
.	O

TITLE	O
:	O
Structural	O
organization	O
of	O
the	O
genome	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
Strain	O
SoD	B-FUNC
)	O
isolated	O
on	O
the	O
territory	O
of	O
the	O
Russian	O
Federation	O
.	O

ABSTRACT	O
:	O
Complete	O
nucleotide	O
cDNA	O
sequence	O
(	O
29715	O
nucleotides	O
)	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
strain	O
SoD	B-FUNC
)	O
isolated	O
for	O
the	O
first	O
time	O
in	O
the	O
territory	O
of	O
the	O
Russian	O
Federation	O
was	O
determined	O
.	O

ABSTRACT	O
:	O
This	O
study	O
established	O
a	O
modified	O
alkaline	O
phosphatase	B-FUNC
-	O
labelled	O
avidin	O
-	O
biotin	O
-	O
complex	O
(	O
ABC	O
-	O
AP	O
)	O
method	O
for	O
diagnosis	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
Mycoplasma	O
pulmonis	O
infection	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
wax	O
-	O
embedded	O
sections	O
,	O
murine	O
antibody	B-FUNC
-	O
positive	O
serum	O
being	O
used	O
as	O
the	O
primary	O
reagent	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
binds	B-FUNC
to	O
CD13	O
in	O
rafts	O
and	O
enters	O
the	O
cell	O
through	O
caveolae	O
.	O

The	O
incubation	O
of	O
living	O
fibroblasts	O
with	O
an	O
anti	O
-	O
CD13	O
antibody	B-FUNC
on	O
ice	O
gave	O
punctate	O
labeling	O
that	O
was	O
evenly	O
distributed	O
on	O
the	O
cell	O
surface	O
,	O
but	O
raising	O
the	O
temperature	O
to	O
37	O
degrees	O
C	O
before	O
fixation	O
caused	O
aggregation	O
of	O
the	O
labeling	O
.	O

The	O
HCoV	O
-	O
229E	O
virus	O
particle	O
showed	O
a	O
binding	B-FUNC
and	O
redistribution	O
pattern	O
that	O
was	O
similar	O
to	O
that	O
caused	O
by	O
the	O
anti	O
-	O
CD13	O
antibody	B-FUNC
:	O
the	O
virus	O
bound	O
to	O
the	O
cell	O
evenly	O
when	O
incubated	O
on	O
ice	O
but	O
became	O
colocalized	O
with	O
caveolin	O
-	O
1	O
at	O
37	O
degrees	O
C	O
;	O
importantly	O
,	O
the	O
virus	O
also	O
caused	O
sequestration	O
of	O
CD13	O
to	O
the	O
caveolin	O
-	O
1	O
-	O
positive	O
area	O
.	O

The	O
results	O
indicate	O
that	O
HCoV	O
-	O
229E	O
first	O
binds	B-FUNC
to	O
CD13	O
in	O
the	O
Triton	O
X	O
-	O
100	O
-	O
resistant	O
microdomain	O
,	O
then	O
clusters	O
CD13	O
by	O
cross	O
-	O
linking	O
,	O
and	O
thereby	O
reaches	O
the	O
caveolar	O
region	O
before	O
entering	O
cells	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
against	O
SARS	O
-	O
coronavirus	O
and	O
its	O
nucleocaspid	O
in	O
SARS	O
patients	O
.	O

An	O
understanding	O
of	O
the	O
antibody	B-FUNC
responses	O
to	O
the	O
viral	O
components	O
is	O
very	O
important	O
for	O
diagnosis	O
and	O
vaccine	O
development	O
.	O

Serial	O
serum	O
samples	O
from	O
14	O
SARS	O
patients	O
were	O
isolated	O
from	O
7	O
to	O
210	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
and	O
were	O
tested	O
for	O
anti	O
-	O
viral	O
IgG	O
and	O
IgM	O
by	O
indirect	O
immunofluorescence	O
tests	O
(	O
IFA	O
),	O
anti	O
-	O
nucleocaspid	O
antibody	B-FUNC
by	O
ELISA	O
tests	O
and	O
viral	O
neutralization	O
.	O

Anti	O
-	O
viral	O
antibody	B-FUNC
(	O
IgM	O
)	O
was	O
detected	O
maximally	O
at	O
30	O
days	O
,	O
later	O
than	O
that	O
for	O
the	O
IgG	O
class	O
.	O

IgM	O
antibody	B-FUNC
declined	O
and	O
became	O
undetectable	O
between	O
60	O
to	O
180	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
.	O

Anti	O
-	O
viral	O
IgM	O
antibodies	O
disappeared	O
earlier	O
than	O
IgG	O
.	O
Viral	O
neutralization	O
was	O
demonstrated	O
in	O
the	O
sera	B-FUNC
from	O
the	O
convalescent	O
patients	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
sera	B-FUNC
from	O
all	O
of	O
the	O
patients	O
with	O
SARS	O
symptoms	O
.	O

ABSTRACT	O
:	O
Sera	B-FUNC
from	O
38	O
free	O
-	O
ranging	O
spotted	O
hyenas	O
(	O
Crocuta	O
crocuta	O
)	O
in	O
the	O
Serengeti	O
ecosystem	O
,	O
Tanzania	O
,	O
were	O
screened	O
for	O
exposure	O
to	O
coronavirus	O
of	O
antigenic	O
group	O
1	O
.	O

An	O
immunofluorescence	O
assay	O
indicated	O
high	O
levels	O
of	O
exposure	O
to	O
coronavirus	O
among	O
Serengeti	O
hyenas	O
:	O
95	O
%	O
when	O
considering	O
sera	B-FUNC
with	O
titer	O
levels	O
of	O
>	O
or	O
=	O
1	O
:	O
10	O
and	O
74	O
%	O
when	O
considering	O
sera	B-FUNC
with	O
titer	O
levels	O
of	O
>	O
or	O
=	O
1	O
:	O
40	O
.	O

In	O
this	O
report	O
,	O
the	O
sensitivity	O
of	O
the	O
viral	O
plaque	O
assay	O
,	O
mouse	O
antibody	B-FUNC
production	O
test	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
detection	O
of	O
MHV	O
-	O
A59	O
and	O
MMVp	O
,	O
two	O
of	O
the	O
most	O
prevalent	O
pathogenic	O
viruses	O
in	O
experimental	O
mouse	O
facilities	O
,	O
was	O
compared	O
.	O

For	O
detection	O
of	O
MMVp	O
,	O
the	O
PCR	O
(	O
10	O
(-	O
10	O
)	O
dilution	O
)	O
proved	O
to	O
be	O
10	O
(	O
6	O
)	O
times	O
more	O
sensitive	O
than	O
the	O
viral	O
plaque	O
assay	O
(	O
10	O
(-	O
4	O
)	O
dilution	O
)	O
and	O
the	O
mouse	O
antibody	B-FUNC
production	O
test	O
on	O
day	O
28	O
(	O
10	O
(-	O
4	O
)	O
dilution	O
)	O
which	O
were	O
equally	O
sensitive	O
.	O

Evidence	O
of	O
perinatal	O
transmission	O
of	O
virus	O
was	O
assessed	O
with	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
on	O
cord	O
blood	O
,	O
placenta	O
tissue	O
,	O
and	O
subsequent	O
follow	O
-	O
up	O
of	O
the	O
neonate	O
on	O
serology	O
.	O

ABSTRACT	O
:	O
Three	O
single	O
chain	O
antibodies	O
(	O
scFv	O
)	O
against	O
the	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
isolated	O
by	O
phage	O
display	O
from	O
an	O
scFv	O
antibody	B-FUNC
library	O
.	O

Two	O
of	O
them	O
,	O
B10	O
and	O
C20	O
,	O
could	O
recognize	O
non	O
-	O
overlapping	O
epitopes	O
of	O
the	O
E	O
protein	O
according	O
to	O
the	O
two	O
-	O
site	O
binding	B-FUNC
test	O
result	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
coronavirus	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
.	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	O
-	O
CoV	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

Corresponding	O
tyrosine	O
residues	O
are	O
present	O
in	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
S	O
proteins	O
of	O
other	O
animal	O
CoV	O
but	O
not	O
in	O
the	O
tail	O
portion	O
of	O
the	O
S	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
.	O
Changing	O
the	O
SEPV	O
tetrapeptide	O
in	O
the	O
cytoplasmic	O
tail	O
to	O
YEPI	O
resulted	O
in	O
intracellular	O
retention	O
of	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
As	O
the	O
S	O
proteins	O
of	O
CoV	O
have	O
receptor	B-FUNC
binding	I-FUNC
and	O
fusion	O
activities	O
and	O
are	O
the	O
main	O
target	O
of	O
neutralizing	O
antibodies	O
,	O
the	O
differences	O
in	O
the	O
transport	O
behavior	O
of	O
the	O
S	O
proteins	O
suggest	O
different	O
strategies	O
in	O
the	O
virus	O
host	O
interactions	O
between	O
SARS	O
-	O
CoV	O
and	O
other	O
coronaviruses	O
.	O

Developments	O
in	O
the	O
dissection	O
of	O
the	O
human	O
immune	O
response	O
to	O
SARS	O
indicate	O
that	O
serological	O
tests	O
on	O
convalescent	O
sera	B-FUNC
are	O
essential	O
to	O
confirm	O
SARS	O
infection	O
,	O
given	O
the	O
sub	O
-	O
optimal	O
predictive	O
value	O
of	O
molecular	O
detection	O
tests	O
performed	O
during	O
acute	O
SARS	O
illness	O
.	O

Serial	O
serum	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
and	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
levels	O
were	O
retrospectively	O
analyzed	O
and	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
was	O
also	O
evaluated	O
to	O
correlate	O
with	O
the	O
progression	O
of	O
this	O
disease	O
.	O

Thus	O
,	O
21	O
amino	O
acid	O
substitutions	O
and	O
a	O
7	O
-	O
amino	O
-	O
acid	O
insert	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
S	O
glycoprotein	O
of	O
MHV	O
/	O
BHK	O
confer	O
the	O
ability	O
to	O
bind	B-FUNC
and	O
in	O
some	O
cases	O
infect	O
cells	O
of	O
nonmurine	O
species	O
.	O

With	O
descending	O
in	O
infectious	O
generation	O
,	O
cases	O
treated	O
with	O
methylprednisolone	O
,	O
human	O
gamma	O
-	O
immunoglobulin	B-FUNC
,	O
interferon	O
-	O
alpha	O
,	O
and	O
antiviral	O
drugs	O
(	O
oral	O
ribavirin	O
or	O
oseltamivir	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
duration	O
of	O
their	O
use	O
also	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ELISA	O
indicated	O
that	O
sera	B-FUNC
from	O
SARS	O
patients	O
have	O
significant	O
positive	O
reactions	O
with	O
synthesized	O
peptides	O
derived	O
from	O
the	O
3a	O
protein	O
.	O

Its	O
deletion	O
abolished	O
S	O
-	O
mediated	O
cell	O
membrane	O
fusion	O
but	O
retained	O
the	O
SU	O
-	O
receptor	O
-	O
binding	B-FUNC
function	O
indicating	O
the	O
possibility	O
for	O
a	O
role	O
in	O
post	O
-	O
receptor	B-FUNC
binding	I-FUNC
steps	O
of	O
the	O
virus	O
entry	O
mechanism	O
.	O

We	O
observed	O
that	O
the	O
UV	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
virion	O
elicited	O
a	O
high	O
level	O
of	O
humoral	O
immunity	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
long	O
-	O
term	O
antibody	B-FUNC
secreting	O
and	O
memory	O
B	O
cells	O
.	O

Notably	O
,	O
the	O
SARS	O
-	O
CoV	O
virion	O
itself	O
was	O
able	O
to	O
induce	O
long	O
-	O
term	O
antibody	B-FUNC
production	O
even	O
without	O
an	O
adjuvant	O
.	O

Furthermore	O
,	O
the	O
UV	O
-	O
inactivated	O
virion	O
induced	O
regional	O
lymph	O
node	O
T	O
-	O
cell	O
proliferation	O
and	O
significant	O
levels	O
of	O
cytokine	O
production	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
,	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
)	O
upon	O
restimulation	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
virion	O
in	O
vitro	O
.	O

We	O
found	O
that	O
85	O
.	O
9	O
%	O
of	O
serum	O
samples	O
contained	O
NAbs	O
against	O
SARS	O
-	O
CoV	O
and	O
that	O
most	O
of	O
the	O
NAb	O
activities	O
could	O
be	O
attributed	O
to	O
immunoglobulin	B-FUNC
G	O
.	O
The	O
NAbs	O
became	O
detectable	O
first	O
at	O
5	O
-	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
their	O
levels	O
peaked	O
at	O
20	O
-	O
30	O
days	O
and	O
then	O
were	O
sustained	O
for	O
>	O
150	O
days	O
.	O

APC	O
regulates	O
the	O
coagulation	O
system	O
by	O
inactivating	O
the	O
activated	O
form	O
of	O
factors	O
V	O
and	O
VIII	O
in	O
the	O
presence	O
of	O
protein	O
S	O
.	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
plays	O
critical	O
roles	O
in	O
the	O
development	O
of	O
disseminated	O
intravascular	O
coagulation	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
shock	O
in	O
sepsis	O
by	O
inducing	O
endothelial	O
cell	O
damage	O
through	O
activation	O
of	O
neutrophils	O
.	O

Thus	O
,	O
binding	B-FUNC
of	O
autoAb	O
to	O
insolubilized	O
FAH	O
could	O
be	O
inhibited	O
by	O
MHV	O
depending	O
on	O
the	O
mouse	O
serum	O
or	O
the	O
experimental	O
protocol	O
used	O
.	O

TITLE	O
:	O
The	O
CC	O
chemokine	O
ligand	B-FUNC
3	O
regulates	O
CD11c	O
+	O
CD11b	O
+	O
CD8alpha	O
-	O
dendritic	O
cell	O
maturation	O
and	O
activation	O
following	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
:	O
implications	O
for	O
a	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Diminished	O
CD8alpha	O
-	O
DC	O
activation	O
correlated	O
with	O
reduced	O
IFN	O
-	O
gamma	O
expression	O
by	O
virus	O
-	O
specific	O
T	O
cells	O
accompanied	O
by	O
increased	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
suggesting	O
that	O
CCL3	O
contributes	O
to	O
an	O
effective	O
host	O
response	O
to	O
viral	O
infection	O
by	O
enhancing	O
the	O
T	O
cell	O
activation	O
potential	O
of	O
DC	O
.	O

A	O
72	O
-	O
year	O
-	O
old	O
African	O
American	O
man	O
developed	O
an	O
acute	O
confusional	O
state	O
(	O
ACS	B-FUNC
)	O
one	O
month	O
after	O
receiving	O
celecoxib	O
for	O
osteoarthritis	O
of	O
his	O
knee	O
joints	O
.	O

There	O
was	O
no	O
other	O
identifiable	O
cause	O
of	O
ACS	B-FUNC
such	O
as	O
any	O
recognized	O
cause	O
of	O
metabolic	O
encephalopathy	O
,	O
meningoencephalitis	O
,	O
cerebrovascular	O
accident	O
,	O
or	O
drug	O
intoxication	O
.	O

Although	O
acute	O
methemoglobinemia	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
several	O
drugs	O
,	O
including	O
sulfonamides	O
,	O
as	O
of	O
August	O
13	O
,	O
2004	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
severe	O
methemoglobinemia	O
manifesting	O
as	O
ACS	B-FUNC
with	O
celecoxib	O
therapy	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
titres	O
to	O
selected	O
pathogens	O
(	O
canine	O
adenovirus	O
[	O
CAV	O
-	O
2	O
],	O
feline	O
herpesvirus	O
[	O
FHV	O
],	O
phocine	O
herpesvirus	O
[	O
PHV	O
-	O
1	O
],	O
canine	O
distemper	O
virus	O
,	O
dolphin	O
morbillivirus	O
[	O
DMV	O
],	O
phocine	O
distemper	O
virus	O
[	O
PDV	O
],	O
parainfluenza	O
virus	O
type	O
3	O
[	O
PI3	O
],	O
rabies	O
virus	O
,	O
dolphin	O
rhabdovirus	O
[	O
DRV	O
],	O
canine	O
coronavirus	O
,	O
feline	O
coronavirus	O
,	O
feline	O
leukaemia	O
virus	O
,	O
Borrelia	O
burgdorferi	O
and	O
Toxoplasma	O
gondii	O
)	O
were	O
determined	O
in	O
whole	O
blood	O
or	O
serum	O
samples	O
from	O
selected	O
free	O
-	O
ranging	O
terrestrial	O
carnivores	O
and	O
marine	O
mammals	O
,	O
including	O
cougars	O
(	O
Fellis	O
concolor	O
),	O
lynxes	O
(	O
Fellis	O
lynx	O
),	O
American	O
badgers	O
(	O
Taxidea	O
taxus	O
),	O
fishers	O
(	O
Martes	O
pennanti	O
),	O
wolverines	O
(	O
Gulo	O
gulo	O
),	O
wolves	O
(	O
Canis	O
lupus	O
),	O
black	O
bears	O
(	O
Ursus	O
americanus	O
),	O
grizzly	O
bears	O
(	O
Ursus	O
arctos	O
),	O
polar	O
bears	O
(	O
Ursus	O
maritimus	O
),	O
walruses	O
(	O
Odobenus	O
rosmarus	O
)	O
and	O
belugas	O
(	O
Delphinapterus	O
leucas	O
),	O
which	O
had	O
been	O
collected	O
at	O
several	O
locations	O
in	O
Canada	O
between	O
1984	O
and	O
2001	O
.	O

Then	O
the	O
high	O
rate	O
of	O
antibody	B-FUNC
was	O
maintained	O
for	O
more	O
than	O
6	O
months	O
.	O

CONCLUSIONS	O
:	O
More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	O
could	O
produce	O
IgG	O
antibody	B-FUNC
when	O
they	O
were	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Detecting	O
SARS	O
-	O
CoV	O
IgG	O
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

Enzyme	O
-	O
linked	O
immunoassay	O
kit	B-FUNC
for	O
SARS	O
coronavirus	O
antibodies	O
developed	O
by	O
HuaDa	O
Biological	O
Company	O
was	O
applied	O
to	O
detect	O
specific	O
serum	O
IgG	O
from	O
SARS	O
patients	O
and	O
the	O
production	O
of	O
SARS	O
specific	O
antibodies	O
among	O
patients	O
of	O
different	O
age	O
groups	O
,	O
sex	O
and	O
with	O
or	O
without	O
steroid	O
treatment	O
were	O
statistically	O
compared	O
.	O

CONCLUSIONS	O
:	O
The	O
sensitivity	O
of	O
the	O
SARS	O
specific	O
IgG	O
kit	B-FUNC
utilized	O
needs	O
to	O
be	O
further	O
improved	O
.	O

The	O
damage	O
of	O
several	O
organs	O
was	O
common	O
,	O
including	O
the	O
elevated	O
ALT	B-FUNC
or	O
AST	O
in	O
20	O
patients	O
(	O
37	O
.	O
7	O
%),	O
elevated	O
BUN	O
or	O
SCR	O
in	O
6	O
patients	O
(	O
11	O
.	O
3	O
%)	O
and	O
elevated	O
LDH	O
or	O
CK	O
or	O
HBDH	O
in	O
23	O
patients	O
(	O
43	O
.	O
4	O
%).	O

The	O
damage	O
of	O
several	O
organs	O
was	O
common	O
,	O
including	O
the	O
elevated	O
ALT	B-FUNC
or	O
AST	O
in	O
20	O
patients	O
(	O
37	O
.	O
7	O
%),	O
elevated	O
BUN	O
or	O
SCR	O
in	O
6	O
patients	O
(	O
11	O
.	O
3	O
%)	O
and	O
elevated	O
LDH	O
or	O
CK	O
or	O
HBDH	O
in	O
23	O
patients	O
(	O
43	O
.	O
4	O
%).	O

Indirect	O
immunofluorescence	O
test	O
showed	O
a	O
specific	O
antigen	O
-	O
antibody	B-FUNC
reactivity	O
between	O
the	O
coronavirus	O
and	O
convalescent	O
-	O
phase	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Indirect	O
immunofluorescence	O
test	O
showed	O
a	O
specific	O
antigen	O
-	O
antibody	B-FUNC
reactivity	O
between	O
the	O
coronavirus	O
and	O
convalescent	O
-	O
phase	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

The	O
SARS	O
incidence	O
among	O
EMTs	O
was	O
assessed	O
by	O
investigating	O
probable	O
SARS	O
(	O
P	O
-	O
SARS	O
)	O
and	O
by	O
surveying	O
the	O
seroprevalence	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-FUNC
.	O

The	O
system	O
includes	O
a	O
laser	O
-	O
induced	O
fluorescence	O
microfluidic	O
chip	O
analyzer	O
,	O
a	O
glass	O
microchip	O
for	O
both	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
capillary	O
electrophoresis	O
,	O
a	O
chip	O
thermal	O
cycler	O
based	O
on	O
dual	O
Peltier	O
thermoelectric	O
elements	O
,	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
SARS	O
diagnostic	O
kit	B-FUNC
,	O
and	O
a	O
DNA	O
electrophoretic	O
sizing	O
kit	B-FUNC
.	O

Chandipura	O
viral	O
antigen	O
and	O
RNA	O
were	O
detected	O
in	O
brain	O
tissue	O
of	O
a	O
deceased	O
child	O
by	O
immunofluorescent	O
antibody	B-FUNC
test	O
and	O
PCR	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
activation	O
of	O
the	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
signaling	O
pathway	O
and	O
the	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
partially	O
inhibited	O
its	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	O
.	O

Phosphorylation	O
of	O
a	O
serine	O
residue	O
on	O
Akt	O
was	O
detected	O
at	O
least	O
8	O
h	O
postinfection	O
(	O
hpi	B-FUNC
),	O
which	O
declined	O
after	O
18	O
hpi	B-FUNC
.	O

A	O
downstream	O
target	O
of	O
Akt	O
,	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	B-FUNC
-	O
3beta	O
),	O
was	O
slightly	O
phosphorylated	O
,	O
indicating	O
that	O
the	O
level	O
of	O
activation	O
of	O
Akt	O
was	O
very	O
low	O
.	O

PKCzeta	B-FUNC
,	O
which	O
is	O
downstream	O
of	O
the	O
PI3K	B-FUNC
pathway	O
,	O
was	O
also	O
phosphorylated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
aquaporin	B-FUNC
-	O
1	O
(	O
AQP1	O
)	O
expression	O
in	O
a	O
murine	O
model	O
of	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
A	O
murine	O
model	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
was	O
used	O
to	O
evaluate	O
whether	O
aquaporin	B-FUNC
-	O
1	O
(	O
AQP1	O
)	O
is	O
involved	O
in	O
lung	O
inflammation	O
and	O
lung	O
edema	O
formation	O
.	O

Intratracheal	O
instillation	O
of	O
LPS	O
produced	O
a	O
severe	O
lung	O
injury	O
at	O
2	O
days	O
,	O
characterized	O
by	O
elevation	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
the	O
BAL	O
fluid	O
,	O
and	O
by	O
histological	O
changes	O
consistent	O
with	O
increased	O
lung	O
vascular	O
permeability	O
and	O
neutrophil	O
infiltration	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
not	O
only	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
fusion	O
,	O
but	O
also	O
a	O
major	O
Ag	O
among	O
the	O
SARS	O
-	O
CoV	O
proteins	O
that	O
induces	O
protective	O
Ab	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
highly	O
immunogenic	O
during	O
infection	O
and	O
immunizations	O
,	O
and	O
contains	O
five	O
linear	O
immunodominant	O
sites	O
(	O
sites	O
I	O
to	O
V	O
)	O
as	O
determined	O
by	O
Pepscan	O
analysis	O
with	O
a	O
set	O
of	O
synthetic	O
peptides	O
overlapping	O
the	O
entire	O
S	O
protein	O
sequence	O
against	O
the	O
convalescent	O
sera	B-FUNC
from	O
SARS	O
patients	O
and	O
antisera	O
from	O
small	O
animals	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Site	O
IV	O
located	O
in	O
the	O
middle	O
region	O
of	O
the	O
S	O
protein	O
(	O
residues	O
528	O
-	O
635	O
)	O
is	O
a	O
major	O
immunodominant	O
epitope	O
.	O

We	O
explored	O
the	O
possible	O
contribution	O
of	O
contaminated	O
hospital	O
surfaces	O
to	O
SARS	O
transmission	O
by	O
swabbing	O
surfaces	O
in	O
2	O
hospitals	O
and	O
testing	O
the	O
swab	O
samples	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
viral	O
culture	O
.	O

SARS	O
-	O
CoV	O
antibody	B-FUNC
binding	B-FUNC
assays	O
indicated	O
that	O
SARS	O
specific	O
antibodies	O
inhibited	O
SARS	O
-	O
CoV	O
viral	O
replication	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
tightly	O
binds	B-FUNC
to	O
human	O
cyclophilin	B-FUNC
A	O
.	O
ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
SARS	O
infection	O
.	O

Protein	O
-	O
protein	O
interaction	O
analysis	O
using	O
bioinformatics	O
tools	O
indicated	O
that	O
SARS_NP	O
may	O
bind	B-FUNC
to	O
human	O
cyclophilin	B-FUNC
A	O
(	O
hCypA	O
),	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
technology	O
revealed	O
this	O
binding	B-FUNC
with	O
the	O
equilibrium	O
dissociation	O
constant	O
ranging	O
from	O
6	O
to	O
160nM	O
.	O
The	O
probable	O
binding	B-FUNC
sites	O
of	O
these	O
two	O
proteins	O
were	O
detected	O
by	O
modeling	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
SARS_NP	O
-	O
hCypA	O
complex	O
,	O
from	O
which	O
the	O
important	O
interaction	O
residue	O
pairs	O
between	O
the	O
proteins	O
were	O
deduced	O
.	O

Mutagenesis	O
experiments	O
were	O
carried	O
out	O
for	O
validating	O
the	O
binding	B-FUNC
model	O
,	O
whose	O
correctness	O
was	O
assessed	O
by	O
the	O
observed	O
effects	O
on	O
the	O
binding	B-FUNC
affinities	O
between	O
the	O
proteins	O
.	O

Several	O
old	O
drugs	O
that	O
bind	B-FUNC
to	O
SARS	O
3CLpro	O
active	O
site	O
were	O
selected	O
and	O
in	O
silico	O
derivatized	O
to	O
generate	O
covalent	O
irreversible	O
inhibitors	O
with	O
enhanced	O
affinity	O
.	O

Mutational	O
analysis	O
of	O
the	O
3CLpro	O
demonstrated	O
the	O
importance	O
of	O
His41	O
,	O
Cys145	O
,	O
and	O
Glu166	O
in	O
the	O
substrate	O
-	O
binding	B-FUNC
subsite	O
S1	O
for	O
keeping	O
the	O
proteolytic	O
activity	O
.	O

Therefore	O
,	O
this	O
study	O
not	O
only	O
established	O
the	O
quantifiable	O
and	O
reliable	O
assay	O
for	O
the	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
measurement	O
of	O
the	O
3CLpro	O
activity	O
,	O
but	O
also	O
characterized	O
the	O
molecular	B-FUNC
interaction	I-FUNC
of	O
the	O
SARS	O
-	O
CoV	O
3CLpro	O
with	O
the	O
substrates	O
.	O

We	O
performed	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
on	O
89	O
sera	B-FUNC
collected	O
from	O
28	O
SARS	O
patients	O
,	O
72	O
sera	B-FUNC
from	O
51	O
control	O
patients	O
with	O
various	O
viral	O
or	O
bacterial	O
infections	O
,	O
and	O
10	O
sera	B-FUNC
from	O
apparently	O
healthy	O
individuals	O
.	O

When	O
we	O
monitored	O
the	O
SAA	O
concentrations	O
longitudinally	O
in	O
45	O
sera	B-FUNC
from	O
four	O
SARS	O
patients	O
,	O
we	O
found	O
a	O
good	O
correlation	O
of	O
SAA	O
concentration	O
with	O
the	O
extent	O
of	O
pneumonia	O
as	O
assessed	O
by	O
a	O
serial	O
chest	O
x	O
-	O
ray	O
opacity	O
score	O
.	O

TITLE	O
:	O
[	O
Construction	O
of	O
phage	O
antibody	B-FUNC
library	O
for	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
coronavirus	O
].	O

ABSTRACT	O
:	O
To	O
construct	O
the	O
phage	O
antibody	B-FUNC
library	O
for	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
coronavirus	O
.	O

Phage	O
antibody	B-FUNC
library	O
for	O
human	O
Fab	O
fragment	O
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

RESULTS	O
:	O
The	O
antibody	B-FUNC
library	O
of	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	O
conronavirus	O
was	O
constructed	O
.	O

CONCLUSIONS	O
:	O
Phage	O
antibody	B-FUNC
library	O
for	O
human	O
Fab	O
fragment	O
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	O
cycle	O
progression	O
demonstrated	O
that	O
p28	O
expression	O
resulted	O
in	O
an	O
accumulation	O
of	O
hypophosphorylated	O
retinoblastoma	O
protein	O
(	O
pRb	O
),	O
tumor	O
suppressor	O
p53	O
,	O
and	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
(	O
Cdk	B-FUNC
)	O
inhibitor	O
p21	O
(	O
Cip1	O
).	O

The	O
increased	O
amount	O
of	O
p21	O
(	O
Cip1	O
)	O
suppresses	O
cyclin	B-FUNC
E	O
/	O
Cdk2	O
activity	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
pRb	O
hyperphosphorylation	O
.	O

Simulations	O
were	O
performed	O
in	O
five	O
grades	O
of	O
ARDS	O
in	O
the	O
presence	O
of	O
pure	B-FUNC
alveolar	O
or	O
combined	O
alveolar	O
-	O
small	O
airway	O
closure	O
as	O
well	O
complete	O
or	O
incomplete	O
lung	O
volume	O
recruitability	O
.	O

By	O
using	O
proteomic	O
technology	O
,	O
truncated	O
forms	O
of	O
alpha	O
(	O
1	O
)-	O
antitrypsin	O
(	O
TF	O
-	O
alpha	O
(	O
1	O
)-	O
AT	O
)	O
were	O
found	O
to	O
increase	O
significantly	O
and	O
consistently	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
compared	O
to	O
control	O
subjects	O
.	O

The	O
technique	O
of	O
ECLS	O
included	O
veno	O
-	O
venous	O
or	O
veno	O
-	O
arterial	O
vascular	O
access	O
,	O
lung	O
""""	O
rest	B-FUNC
""""	O
at	O
low	O
FiO2	O
and	O
inspiratory	O
pressure	O
,	O
minimal	O
anticoagulation	O
,	O
and	O
optimization	O
of	O
systemic	O
oxygen	O
delivery	O
.	O

Three	O
months	O
after	O
the	O
discharge	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
assay	O
were	O
used	O
to	O
detect	O
the	O
serum	O
IgG	O
.	O
Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
was	O
used	O
to	O
detect	O
the	O
damage	O
of	O
the	O
head	O
of	O
femur	O
and	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
was	O
used	O
to	O
detect	O
osteoporosis	O
at	O
the	O
left	O
heel	O
.	O

Analysis	O
of	O
the	O
antibody	B-FUNC
specificity	O
revealed	O
that	O
the	O
mouse	O
antisera	O
contained	O
a	O
mixture	O
of	O
antibodies	O
specifically	O
against	O
the	O
structure	O
proteins	O
of	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
mouse	O
antisera	O
conferred	O
higher	O
amount	O
of	O
antibodies	O
against	O
protein	O
N	O
,	O
polypeptide	O
S4	O
and	O
S2	O
than	O
those	O
of	O
proteins	O
M	O
and	O
3CL	O
.	O

Furthermore	O
,	O
the	O
anti	O
-	O
S1	O
and	O
S2	O
Abs	O
were	O
proved	O
to	O
be	O
capable	O
of	O
binding	B-FUNC
to	O
SARS	O
CoV	O
under	O
electron	O
microscope	O
observation	O
.	O

While	O
previous	O
studies	O
demonstrated	O
that	O
effector	O
and	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
are	O
critical	O
in	O
controlling	O
acute	O
IBV	O
infection	O
and	O
disease	O
in	O
chickens	O
,	O
here	O
chicken	O
anti	O
-	O
IBV	O
antibody	B-FUNC
(	O
IgG	O
)	O
secreting	O
cells	O
(	O
ASC	O
)	O
in	O
both	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
spleens	O
collected	O
following	O
IBV	O
Gray	O
infection	O
were	O
evaluated	O
using	O
an	O
ELISPOT	O
assay	O
.	O

The	O
higher	O
concentration	O
of	O
about	O
20	O
ASC	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
spleens	O
may	O
,	O
at	O
least	O
partially	O
,	O
account	O
for	O
the	O
presence	O
of	O
antibody	B-FUNC
in	O
the	O
serum	O
although	O
bone	O
marrow	O
ASC	O
were	O
not	O
determined	O
.	O

In	O
vitro	O
stimulation	O
of	O
PBMC	O
and	O
splenocytes	O
with	O
IBV	O
antigen	O
demonstrated	O
that	O
memory	O
B	O
cells	O
can	O
be	O
activated	O
to	O
secrete	O
antibody	B-FUNC
by	O
3	O
weeks	O
p	O
.	O
i	O
.	O

Evaluation	O
of	O
sera	B-FUNC
from	O
healthy	O
controls	O
(	O
n	O
=	O
60	O
)	O
resulted	O
in	O
two	O
weakly	O
positive	O
ELISA	O
results	O
with	O
the	O
remainder	O
being	O
negative	O
while	O
the	O
S2	O
protein	O
WB	O
demonstrated	O
three	O
positive	O
results	O
from	O
the	O
20	O
controls	O
with	O
a	O
history	O
of	O
SARS	O
contact	O
and	O
no	O
positive	O
results	O
in	O
40	O
noncontact	O
controls	O
.	O

We	O
describe	O
here	O
the	O
screening	O
of	O
Chinese	O
herbal	O
medicine	O
-	O
based	O
,	O
novel	O
small	O
molecules	O
that	O
bind	B-FUNC
avidly	O
with	O
the	O
surface	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
thus	O
can	O
interfere	O
with	O
the	O
entry	O
of	O
the	O
virus	O
to	O
its	O
host	O
cells	O
.	O

The	O
recombinant	O
esterases	B-FUNC
were	O
shown	O
to	O
specifically	O
de	O
-	O
O	O
-	O
acetylate	O
sialic	O
acids	O
on	O
glycoconjugates	O
.	O

ABSTRACT	O
:	O
To	O
measure	O
antibody	B-FUNC
titers	O
against	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
determine	O
frequency	O
of	O
BCV	O
in	O
nasal	O
swab	O
specimens	O
,	O
and	O
compare	O
calves	O
treated	O
for	O
bovine	O
respiratory	O
tract	O
disease	O
(	O
BRD	O
)	O
between	O
those	O
given	O
an	O
intranasally	O
administered	O
vaccine	O
and	O
control	O
calves	O
.	O

Intranasal	O
BCV	O
antigen	O
concentration	O
and	O
antibody	B-FUNC
titer	O
against	O
BCV	O
were	O
measured	O
on	O
entry	O
to	O
a	O
feedlot	O
.	O

Intranasal	O
BCV	O
(	O
125	O
/	O
407	O
[	O
31	O
%])	O
and	O
serum	O
antibody	B-FUNC
titers	O
>	O
or	O
=	O
20	O
against	O
BCV	O
(	O
246	O
/	O
396	O
[	O
62	O
%])	O
were	O
identified	O
in	O
calves	O
entering	O
the	O
feedlot	O
.	O

Univariate	O
analysis	O
revealed	O
that	O
control	O
calves	O
with	O
intranasal	O
BRD	O
on	O
entry	O
to	O
the	O
feedlot	O
and	O
those	O
with	O
antibody	B-FUNC
titer	O
<	O
20	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
treated	O
for	O
BRD	O
.	O

RESULTS	O
:	O
Intranasal	O
BCV	O
(	O
125	O
/	O
407	O
[	O
31	O
%])	O
and	O
serum	O
antibody	B-FUNC
titers	O
>	O
or	O
=	O
20	O
against	O
BCV	O
(	O
246	O
/	O
396	O
[	O
62	O
%])	O
were	O
identified	O
in	O
calves	O
entering	O
the	O
feedlot	O
.	O

Univariate	O
analysis	O
revealed	O
that	O
control	O
calves	O
with	O
intranasal	O
BRD	O
on	O
entry	O
to	O
the	O
feedlot	O
and	O
those	O
with	O
antibody	B-FUNC
titer	O
<	O
20	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
treated	O
for	O
BRD	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
World	O
Summit	O
2004	O
-	O
SRI	O
Conference	O
19	O
-	O
21	O
July	O
2004	O
,	O
Philadelphia	O
,	O
PA	O
,	O
USA	O
.	O

Of	O
particular	O
note	O
,	O
The	O
academics	O
presented	O
cutting	O
-	O
edge	O
science	O
in	O
the	O
antibody	B-FUNC
discovery	O
and	O
development	O
area	O
.	O

Business	O
representatives	O
from	O
various	O
therapeutic	O
antibody	B-FUNC
companies	O
discussed	O
in	O
detail	O
various	O
aspects	O
and	O
challenges	O
of	O
building	O
a	O
viable	O
therapeutic	O
antibody	B-FUNC
company	O
.	O

TITLE	O
:	O
Temporal	O
relationship	O
of	O
viral	O
load	O
,	O
ribavirin	O
,	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
clinical	O
progression	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

We	O
report	O
that	O
ribavirin	O
was	O
not	O
effective	O
in	O
reducing	O
the	O
SARS	O
coronavirus	O
load	O
in	O
3	O
of	O
8	O
probable	O
cases	O
studied	O
and	O
that	O
elevated	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
subsequent	O
to	O
the	O
peak	O
viral	O
load	O
were	O
found	O
in	O
8	O
and	O
6	O
cases	O
,	O
respectively	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
induces	O
highly	O
potent	O
neutralizing	O
antibodies	O
:	O
implication	O
for	O
developing	O
subunit	O
vaccine	O
.	O

The	O
S1	O
contains	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
that	O
can	O
specifically	O
bind	B-FUNC
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
receptor	O
on	O
target	O
cells	O
.	O

Here	O
we	O
show	O
that	O
a	O
recombinant	O
fusion	O
protein	O
(	O
designated	O
RBD	O
-	O
Fc	O
)	O
containing	O
193	O
-	O
amino	O
acid	O
RBD	O
(	O
residues	O
318	O
-	O
510	O
)	O
and	O
a	O
human	O
IgG1	O
Fc	O
fragment	O
can	O
induce	O
highly	O
potent	O
antibody	B-FUNC
responses	O
in	O
the	O
immunized	O
rabbits	O
.	O

Rabbit	O
antisera	O
effectively	O
blocked	O
binding	B-FUNC
of	O
S1	O
,	O
which	O
contains	O
RBD	O
,	O
to	O
ACE2	O
.	O

This	O
suggests	O
that	O
RBD	O
can	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
and	O
has	O
potential	O
to	O
be	O
developed	O
as	O
an	O
effective	O
and	O
safe	O
subunit	O
vaccine	O
for	O
prevention	O
of	O
SARS	O
.	O

TITLE	O
:	O
Interferon	O
-	O
beta	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
synergistically	O
inhibit	O
the	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Recent	O
studies	O
have	O
shown	O
that	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
synergizes	O
with	O
IFN	O
-	O
alpha	O
/	O
beta	O
to	O
inhibit	O
the	O
replication	O
of	O
both	O
RNA	O
and	O
DNA	O
viruses	O
.	O

Furthermore	O
,	O
by	O
yeast	O
two	O
-	O
hybrid	O
and	O
coimmunoprecipitation	O
analyses	O
,	O
we	O
demonstrate	O
that	O
p28	O
specifically	O
binds	B-FUNC
to	O
p10	O
and	O
p15	O
,	O
two	O
coronavirus	O
replicase	O
proteins	O
of	O
unknown	O
function	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
peptide	O
-	O
based	O
enzyme	O
immunoassay	O
for	O
anti	O
-	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
High	O
throughput	O
assays	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
detection	O
are	O
need	O
for	O
large	O
-	O
scale	O
epidemiologic	O
studies	O
.	O

The	O
performance	O
of	O
a	O
microplate	O
enzyme	O
immunoassay	O
,	O
DETECT	O
-	O
SARS	O
was	O
evaluated	O
for	O
the	O
detection	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
.	O

When	O
the	O
host	O
produces	O
antibodies	O
against	O
these	O
viral	O
antigens	O
,	O
the	O
antibodies	O
also	O
bind	B-FUNC
to	O
the	O
host	O
'	O
s	O
own	O
ACTH	O
,	O
which	O
limits	O
the	O
host	O
'	O
s	O
stress	O
response	O
by	O
interfering	O
with	O
ACTH	O
'	O
s	O
ability	O
to	O
stimulate	O
the	O
secretion	O
of	O
corticosteroids	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
identified	O
as	O
a	O
novel	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
main	O
proteinase	B-FUNC
of	O
SARS	O
-	O
CoV	O
,	O
3CLpro	O
,	O
is	O
an	O
attractive	O
target	O
for	O
therapeutics	O
against	O
SARS	O
owing	O
to	O
its	O
fundamental	O
role	O
in	O
viral	O
replication	O
.	O

A	O
quenched	O
fluorescence	O
resonance	O
energy	O
transfer	O
assay	O
was	O
developed	O
for	O
3CLpro	O
to	O
screen	O
the	O
proteinase	B-FUNC
against	O
50	O
,	O
000	O
drug	O
-	O
like	O
small	O
molecules	O
on	O
a	O
fully	O
automated	O
system	O
.	O

She	O
developed	O
fever	O
on	O
April	O
21	O
and	O
respiratory	O
distress	O
on	O
April	O
25	O
,	O
and	O
received	O
ribavirin	O
,	O
intravenous	O
immunoglobulin	B-FUNC
,	O
and	O
steroid	O
.	O

In	O
this	O
structure	O
-	O
activity	O
relation	O
study	O
,	O
the	O
molecules	O
with	O
the	O
highest	O
predicted	O
binding	B-FUNC
scores	O
were	O
identified	O
and	O
assayed	O
for	O
ACE2	O
enzymatic	O
inhibitory	O
activity	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	O
fusion	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
determine	O
highly	O
immunogenic	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
epitope	O
peptides	O
capable	O
of	O
inducing	O
long	O
-	O
lasting	O
immunity	O
,	O
we	O
first	O
screened	O
immunoglobulin	B-FUNC
-	O
G	O
(	O
IgG	O
)	O
antibodies	O
reactive	O
to	O
197	O
different	O
overlapping	O
15	O
-	O
mers	O
from	O
the	O
SARS	O
-	O
CoV	O
proteins	O
in	O
the	O
sera	B-FUNC
of	O
three	O
infected	O
patients	O
.	O

Forty	O
-	O
two	O
peptides	O
among	O
them	O
were	O
reactive	O
to	O
the	O
sera	B-FUNC
from	O
all	O
three	O
patients	O
.	O

Consequently	O
,	O
we	O
tested	O
for	O
the	O
reactivity	O
of	O
these	O
42	O
peptides	O
to	O
patients	O
'	O
sera	B-FUNC
(	O
n	O
=	O
45	O
)	O
at	O
6	O
-	O
month	O
post	O
-	O
infection	O
.	O

The	O
significantly	O
higher	O
levels	O
of	O
IgG	O
antibodies	O
specific	O
to	O
three	O
(	O
S791	O
,	O
M207	O
and	O
N161	O
)	O
of	O
42	O
peptides	O
were	O
detectable	O
in	O
the	O
post	O
-	O
infection	O
sera	B-FUNC
from	O
23	O
(	O
51	O
%),	O
27	O
(	O
60	O
%)	O
and	O
19	O
(	O
42	O
%)	O
of	O
45	O
patients	O
,	O
respectively	O
.	O

We	O
have	O
identified	O
a	O
different	O
human	O
cellular	O
glycoprotein	O
that	O
can	O
serve	O
as	O
an	O
alternative	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
human	O
lung	O
cDNA	O
library	O
in	O
vesicular	O
stomatitis	O
virus	O
G	O
pseudotyped	O
retrovirus	O
was	O
transduced	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
and	O
the	O
cells	O
were	O
sorted	O
for	O
binding	B-FUNC
of	O
soluble	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoproteins	O
,	O
S	O
(	O
590	O
)	O
and	O
S	O
(	O
1180	O
).	O

TITLE	O
:	O
SARS	O
antibody	B-FUNC
test	O
for	O
serosurveillance	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
prevalence	O
in	O
all	O
Hong	O
Kong	O
patient	O
contacts	O
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
1	O
,	O
068	O
asymptomatic	O
close	O
contacts	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
(	O
SARS	O
)	O
from	O
the	O
2003	O
epidemic	O
in	O
Hong	O
Kong	O
were	O
serologically	O
tested	O
,	O
and	O
2	O
(	O
0	O
.	O
19	O
%)	O
were	O
positive	O
for	O
SARS	O
coronavirus	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
.	O

The	O
70	O
patients	O
exposed	O
to	O
the	O
SARS	O
outbreak	O
were	O
isolated	O
from	O
the	O
rest	B-FUNC
of	O
the	O
hospital	O
.	O

ABSTRACT	O
:	O
The	O
cleavage	O
mechanism	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
M	O
(	O
pro	O
)	O
or	O
3CL	O
(	O
pro	O
))	O
for	O
the	O
octapeptide	O
AVLQSGFR	O
is	O
studied	O
using	O
molecular	O
mechanics	O
(	O
MM	O
)	O
and	O
quantum	O
mechanics	O
(	O
QM	O
).	O

We	O
believe	O
our	O
experience	O
warrants	O
an	O
increased	O
vigilance	O
against	O
stroke	O
and	O
other	O
thrombotic	O
complications	O
among	O
critically	O
-	O
ill	O
SARS	O
patients	O
in	O
future	O
outbreaks	O
,	O
especially	O
if	O
treatment	O
such	O
as	O
intravenous	O
immunoglobulin	B-FUNC
,	O
that	O
increases	O
pro	O
-	O
thrombotic	O
tendency	O
,	O
is	O
contemplated	O
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
RNA	O
and	O
antibody	B-FUNC
from	O
convalescent	O
-	O
phase	O
SARS	O
patients	O
discharged	O
from	O
hospital	O
.	O

Toroviruses	O
and	O
group	O
2	O
coronaviruses	O
bind	B-FUNC
to	O
O	O
-	O
acetylated	O
Sias	O
,	O
presumably	O
via	O
their	O
spike	O
proteins	O
(	O
S	O
),	O
whereas	O
other	O
glycoproteins	O
,	O
the	O
hemagglutinin	O
-	O
esterases	B-FUNC
(	O
HE	O
),	O
destroy	O
Sia	O
receptors	O
by	O
de	O
-	O
O	O
-	O
acetylation	O
.	O

As	O
for	O
orthomyxovirus	O
reassortants	O
,	O
the	O
fitness	O
of	O
nidovirus	O
recombinant	O
offspring	O
probably	O
depends	O
both	O
on	O
antigenic	O
properties	O
and	O
on	O
compatibility	O
of	O
receptor	O
-	O
binding	B-FUNC
and	O
receptor	O
-	O
destroying	O
activities	O
.	O

SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
SARS	O
3CL	O
(	O
pro	O
))	O
plays	O
key	O
roles	O
in	O
viral	O
replication	O
and	O
transcription	O
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
discovery	O
.	O

Isothermal	O
titration	O
calorimeter	O
determinations	O
indicate	O
that	O
the	O
equilibrium	O
dissociation	O
constant	O
(	O
K	O
(	O
d	O
))	O
of	O
the	O
N	O
-	O
terminal	O
deleted	O
proteinase	B-FUNC
dimer	O
(	O
262	O
microm	O
)	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
full	O
-	O
length	O
proteinase	B-FUNC
dimer	O
(	O
227	O
microm	O
).	O

Molecular	O
dynamics	O
and	O
docking	O
simulations	O
demonstrate	O
the	O
N	O
-	O
terminal	O
deleted	O
proteinase	B-FUNC
dimer	O
adopts	O
a	O
state	O
different	O
from	O
that	O
of	O
the	O
full	O
-	O
length	O
proteinase	B-FUNC
dimer	O
,	O
which	O
increases	O
the	O
angle	O
between	O
the	O
two	O
protomers	O
and	O
reduces	O
the	O
binding	B-FUNC
pocket	O
that	O
is	O
not	O
beneficial	O
to	O
the	O
substrate	O
binding	B-FUNC
.	O

Mn	O
(	O
2	O
+)	O
at	O
2	O
to	O
10	O
mM	O
was	O
needed	O
for	O
optimal	O
endoribonuclease	B-FUNC
activity	I-FUNC
,	O
but	O
Mg	O
(	O
2	O
+)	O
and	O
several	O
other	O
divalent	O
metals	O
were	O
capable	O
of	O
supporting	O
only	O
a	O
low	O
level	O
of	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
a	O
major	O
viral	O
protein	O
recognized	O
by	O
acute	O
and	O
early	O
convalescent	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

Therefore	O
the	O
exact	O
binding	B-FUNC
sequence	O
to	O
HR2	O
from	O
the	O
HR1	O
is	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
defined	O
the	O
region	O
of	O
HR1	O
that	O
binds	B-FUNC
to	O
HR2	O
by	O
a	O
series	O
of	O
biochemical	O
and	O
biophysical	O
measures	O
.	O

Subsequently	O
the	O
defined	O
HR1	O
(	O
902	O
-	O
952	O
)	O
and	O
HR2	O
(	O
1145	O
-	O
1184	O
)	O
chains	O
,	O
which	O
are	O
different	O
from	O
previously	O
defined	O
binding	B-FUNC
regions	O
,	O
were	O
linked	O
together	O
by	O
a	O
flexible	O
linker	O
to	O
form	O
a	O
single	O
-	O
chain	O
construct	O
,	O
2	O
-	O
Helix	O
.	O

ABSTRACT	O
:	O
The	O
CC	O
chemokine	O
ligand	B-FUNC
2	O
(	O
CCL2	O
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
)	O
is	O
important	O
in	O
coordinating	O
the	O
immune	O
response	O
following	O
microbial	O
infection	O
by	O
regulating	O
T	O
cell	O
polarization	O
as	O
well	O
as	O
leukocyte	O
migration	O
and	O
accumulation	O
within	O
infected	O
tissues	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
CCR2	O
,	O
but	O
not	O
CCL2	O
,	O
is	O
important	O
in	O
host	O
defense	O
following	O
viral	O
infection	O
of	O
the	O
CNS	O
,	O
and	O
CCR2	O
ligand	B-FUNC
(	O
s	O
),	O
other	O
than	O
CCL2	O
,	O
participates	O
in	O
generating	O
a	O
protective	O
response	O
.	O

TITLE	O
:	O
[	O
Severe	O
pulmonary	O
complications	O
of	O
massive	O
intoxication	O
with	O
calcium	B-FUNC
channel	I-FUNC
blockers	O
and	O
isosorbide	O
mononitrate	O
--	O
a	O
case	O
report	O
].	O

Surfactant	O
secretion	O
in	O
epithelial	O
type	O
II	O
cells	O
is	O
inhibited	O
by	O
calcium	B-FUNC
channel	I-FUNC
blockers	O
and	O
it	O
predisposes	O
to	O
develop	O
ARDS	O
.	O

ABSTRACT	O
:	O
To	O
promote	O
viral	O
entry	O
,	O
replication	O
,	O
release	O
,	O
and	O
spread	O
to	O
neighboring	O
cells	O
,	O
many	O
cytolytic	O
animal	O
viruses	O
encode	O
proteins	O
responsible	O
for	O
modification	O
of	O
host	O
cell	O
membrane	O
permeability	O
and	O
for	O
formation	O
of	O
ion	B-FUNC
channels	I-FUNC
in	O
host	O
cell	O
membranes	O
during	O
their	O
life	O
cycles	O
.	O

The	O
consensus	O
transcription	O
-	O
regulating	O
sequence	O
(	O
TRS	B-FUNC
)	O
of	O
IBV	O
,	O
CT	O
(	O
T	O
/	O
G	O
)	O
AACAA	O
,	O
was	O
highly	O
conserved	O
in	O
TCoV	O
genome	O
at	O
the	O
levels	O
of	O
nucleotide	O
sequence	O
and	O
location	O
in	O
regarding	O
to	O
the	O
initiation	O
codon	O
of	O
individual	O
genes	O
.	O

To	O
attempt	O
to	O
determine	O
the	O
clinical	O
efficacy	O
of	O
pentaglobin	O
,	O
an	O
IgM	O
-	O
enriched	O
immunoglobulin	B-FUNC
preparation	O
,	O
on	O
12	O
severe	O
SARS	O
patients	O
who	O
continued	O
to	O
deteriorate	O
despite	O
corticosteroid	O
and	O
ribavirin	O
therapy	O
.	O

p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
and	O
its	O
downstream	O
targets	O
are	O
activated	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
infected	O
Vero	O
E6	O
cells	O
and	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
enhances	O
the	O
cytopathic	O
effects	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
addition	O
to	O
phosphorylation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
in	O
virus	O
-	O
infected	O
cells	O
,	O
other	O
MAPKs	O
,	O
i	O
.	O
e	O
.,	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
1	O
/	O
2	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
),	O
were	O
phosphorylated	O
.	O

Two	O
major	O
immunodominant	O
epitopes	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
362	O
to	O
412	O
)	O
and	O
middle	O
region	O
(	O
aa	O
153	O
to	O
178	O
)	O
reacted	O
with	O
more	O
than	O
75	O
%	O
of	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
elicits	O
high	O
titers	O
of	O
spike	O
protein	O
-	O
specific	O
antibodies	O
that	O
block	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
inactivated	O
by	O
beta	O
-	O
propiolactone	O
elicited	O
high	O
titers	O
of	O
antibodies	O
in	O
the	O
immunized	O
mice	O
and	O
rabbits	O
that	O
recognize	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
especially	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
region	O
.	O

The	O
rSCoVN	O
protein	O
had	O
a	O
high	O
specificity	O
against	O
mouse	O
-	O
anti	O
-	O
SARS	O
-	O
CoVN	O
-	O
mAb	O
and	O
SARS	O
positive	O
sera	B-FUNC
,	O
but	O
had	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	O
.	O

The	O
rSCoVN	O
protein	O
has	O
a	O
high	O
specificity	O
against	O
SARS	O
-	O
CoVN	O
-	O
mAb	O
and	O
SARS	O
positive	O
sera	B-FUNC
,	O
but	O
has	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	O
.	O

Serum	O
total	O
protein	O
(	O
TP	O
),	O
albumin	O
(	O
Alb	O
),	O
total	O
cholesterol	O
(	O
TC	O
),	O
triglyceride	O
(	O
TG	O
),	O
calcium	O
(	O
Ca	O
),	O
ferrum	O
(	O
Fe	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
creatine	O
kinase	O
(	O
CK	O
),	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
between	O
SARS	O
and	O
other	O
viral	O
pneumonias	O
were	O
examined	O
by	O
Roche	O
Diagnostics	O
assay	O
,	O
HITACHI7600	O
automatic	O
analyzer	O
.	O

Compared	O
with	O
healthy	O
person	O
,	O
the	O
levels	O
of	O
serum	O
TC	O
,	O
Fe	O
,	O
Ca	O
,	O
Alb	O
were	O
significantly	O
lowered	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
activity	O
of	O
LDH	O
,	O
CK	O
,	O
ALT	B-FUNC
,	O
AST	O
were	O
elevated	O
,	O
the	O
increase	O
of	O
CK	O
and	O
the	O
decrease	O
of	O
Fe	O
were	O
the	O
most	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
the	O
changes	O
of	O
TP	O
and	O
TG	O
were	O
not	O
obvious	O
.	O

In	O
the	O
other	O
viral	O
pneumonias	O
patients	O
,	O
ALT	B-FUNC
,	O
AST	O
,	O
LDH	O
were	O
elevated	O
slightly	O
than	O
those	O
of	O
healthy	O
person	O
,	O
while	O
Fe	O
,	O
Ca	O
,	O
Alb	O
,	O
TC	O
,	O
CK	O
were	O
a	O
little	O
reduced	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

In	O
convalescent	O
stage	O
,	O
all	O
the	O
tests	O
were	O
returned	O
to	O
normal	O
ranges	O
except	O
ALT	B-FUNC
,	O
AST	O
were	O
still	O
elevated	O
in	O
SARS	O
patients	O
.	O

RESULTS	O
:	O
Compared	O
with	O
healthy	O
person	O
,	O
the	O
levels	O
of	O
serum	O
TC	O
,	O
Fe	O
,	O
Ca	O
,	O
Alb	O
were	O
significantly	O
lowered	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
activity	O
of	O
LDH	O
,	O
CK	O
,	O
ALT	B-FUNC
,	O
AST	O
were	O
elevated	O
,	O
the	O
increase	O
of	O
CK	O
and	O
the	O
decrease	O
of	O
Fe	O
were	O
the	O
most	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
the	O
changes	O
of	O
TP	O
and	O
TG	O
were	O
not	O
obvious	O
.	O

In	O
convalescent	O
stage	O
,	O
all	O
the	O
tests	O
were	O
returned	O
to	O
normal	O
ranges	O
except	O
ALT	B-FUNC
,	O
AST	O
were	O
still	O
elevated	O
in	O
SARS	O
patients	O
.	O

Three	O
methods	O
,	O
including	O
DR	O
Chip	O
and	O
two	O
F	O
-	O
PCR	O
kit	B-FUNC
from	O
Zhongshan	O
College	O
Da	O
'	O
an	O
gene	O
stock	O
company	O
and	O
Shanghai	O
Fortune	O
industrial	O
joint	O
-	O
stock	O
Co	O
,	O
Ltd	O
,	O
were	O
used	O
,	O
and	O
the	O
results	O
were	O
all	O
negative	O
for	O
all	O
specimens	O
,	O
except	O
one	O
cDNA	O
specimen	O
,	O
which	O
was	O
obtained	O
from	O
one	O
SARS	O
suspect	O
patient	O
,	O
virus	O
could	O
be	O
amplified	O
by	O
F	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Three	O
methods	O
,	O
including	O
DR	O
Chip	O
and	O
two	O
F	O
-	O
PCR	O
kit	B-FUNC
from	O
Zhongshan	O
College	O
Da	O
'	O
an	O
gene	O
stock	O
company	O
and	O
Shanghai	O
Fortune	O
industrial	O
joint	O
-	O
stock	O
Co	O
,	O
Ltd	O
,	O
were	O
used	O
,	O
and	O
the	O
results	O
were	O
all	O
negative	O
for	O
all	O
specimens	O
,	O
except	O
one	O
cDNA	O
specimen	O
,	O
which	O
was	O
obtained	O
from	O
one	O
SARS	O
suspect	O
patient	O
,	O
virus	O
could	O
be	O
amplified	O
by	O
F	O
-	O
PCR	O
.	O

TITLE	O
:	O
Specific	O
immunoglobulin	B-FUNC
g	O
antibody	B-FUNC
detected	O
in	O
umbilical	O
blood	O
and	O
amniotic	O
fluid	O
from	O
a	O
pregnant	O
woman	O
infected	O
by	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Specific	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
was	O
detected	O
in	O
maternal	O
blood	O
,	O
umbilical	O
blood	O
,	O
and	O
amniotic	O
fluid	O
from	O
a	O
pregnant	O
SARS	O
patient	O
.	O

ABSTRACT	O
:	O
Several	O
cellular	O
proteins	O
,	O
including	O
several	O
heterogeneous	O
nuclear	O
ribonucleoproteins	O
(	O
hnRNPs	O
),	O
have	O
been	O
shown	O
to	O
function	O
as	O
regulatory	O
factors	O
for	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
synthesis	O
as	O
a	O
result	O
of	O
their	O
binding	B-FUNC
to	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
of	O
the	O
viral	O
RNA	O
.	O

Here	O
,	O
we	O
identified	O
another	O
cellular	O
protein	O
,	O
p70	O
,	O
which	O
has	O
been	O
shown	O
by	O
UV	O
cross	O
-	O
linking	O
to	O
bind	B-FUNC
both	O
the	O
positive	O
-	O
and	O
negative	O
-	O
strand	O
UTRs	O
of	O
MHV	O
RNA	O
specifically	O
.	O

The	O
bacterially	O
expressed	O
SYNCRIP	O
was	O
also	O
able	O
to	O
bind	B-FUNC
to	O
the	O
5	O
'-	O
UTR	O
of	O
both	O
strands	O
.	O

The	O
SYNCRIP	O
-	O
binding	B-FUNC
site	O
was	O
mapped	O
to	O
the	O
leader	O
sequence	O
of	O
the	O
5	O
'-	O
UTR	O
,	O
requiring	O
the	O
UCUAA	O
repeat	O
sequence	O
.	O

This	O
study	O
identified	O
an	O
additional	O
cellular	O
hnRNP	O
as	O
an	O
MHV	O
RNA	O
-	O
binding	B-FUNC
protein	O
potentially	O
involved	O
in	O
viral	O
RNA	O
synthesis	O
.	O

Viral	O
envelope	O
proteins	O
bind	B-FUNC
these	O
receptors	O
,	O
and	O
,	O
in	O
an	O
incompletely	O
understood	O
process	O
,	O
facilitate	O
fusion	O
of	O
the	O
cellular	O
and	O
viral	O
membranes	O
so	O
as	O
to	O
introduce	O
the	O
viral	O
core	O
into	O
the	O
cytoplasm	O
.	O

ABSTRACT	O
:	O
After	O
severe	O
trauma	O
,	O
decreased	O
plasma	O
concentrations	O
of	O
the	O
soluble	O
adhesion	O
molecule	O
L	O
-	O
selectin	B-FUNC
(	O
sCD62L	O
)	O
have	O
been	O
linked	O
to	O
an	O
increased	O
incidence	O
of	O
lung	O
failure	O
and	O
multiorgan	O
dysfunction	O
syndrome	O
(	O
MODS	O
).	O

Early	O
decreased	O
soluble	O
L	O
-	O
selectin	B-FUNC
concentrations	O
after	O
multiple	O
trauma	O
may	O
signal	O
an	O
increased	O
likelihood	O
of	O
lung	O
injury	O
and	O
ARDS	O
.	O

The	O
findings	O
of	O
this	O
metaanalysis	O
warrant	O
a	O
large	O
cohort	O
study	O
to	O
develop	O
selectin	B-FUNC
-	O
based	O
models	O
targeting	O
the	O
risk	O
of	O
inflammatory	O
complications	O
.	O

Pathologic	O
changes	O
in	O
response	O
to	O
viral	O
infection	O
might	O
be	O
reflected	O
in	O
proteomic	O
patterns	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Mutation	O
at	O
these	O
two	O
positions	O
reduces	O
the	O
association	O
affinity	O
between	O
subunits	O
,	O
and	O
the	O
Glu	O
-	O
290	O
mutants	O
had	O
diminished	O
enzyme	B-FUNC
activity	I-FUNC
.	O

We	O
used	O
Cox	O
proportional	O
hazard	O
modelling	O
to	O
analyze	O
potential	O
predictors	O
of	O
survival	O
recorded	O
at	O
the	O
time	O
of	O
presentation	O
,	O
including	O
viral	O
load	O
from	O
nasopharyngeal	O
specimens	O
(	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
[	O
PCR	O
]	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
).	O

To	O
determine	O
the	O
role	O
of	O
LIX	O
in	O
the	O
induction	O
of	O
ALI	O
,	O
we	O
used	O
both	O
exogenous	O
LIX	O
and	O
a	O
LIX	O
blocking	O
antibody	B-FUNC
.	O

Exogenous	O
LIX	O
alone	O
elicited	O
a	O
neutrophil	O
influx	O
in	O
the	O
lungs	O
,	O
and	O
the	O
anti	O
-	O
LIX	O
antibody	B-FUNC
attenuated	O
the	O
LPS	O
-	O
induced	O
neutrophil	O
accumulation	O
in	O
the	O
lungs	O
.	O

Serum	O
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	O
coronavirus	O
antibody	B-FUNC
.	O

Serum	O
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	O
coronavirus	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Identification	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replicase	O
products	O
and	O
characterization	O
of	O
papain	O
-	O
like	O
protease	B-FUNC
activity	I-FUNC
.	O

BALF	O
from	O
ARDS	O
patients	O
induced	O
41	O
%	O
greater	O
procollagen	O
I	O
promoter	O
activation	O
than	O
that	O
from	O
negative	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
TGF	O
-	O
beta1	O
blocking	O
antibody	B-FUNC
significantly	O
reduced	O
this	O
activation	O
in	O
ARDS	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
is	O
a	O
key	O
target	O
for	O
structure	O
-	O
based	O
drug	O
design	O
against	O
this	O
viral	O
infection	O
.	O

Entry	O
into	O
the	O
alveolar	O
compartment	O
is	O
under	O
the	O
control	O
of	O
CXC	O
chemokine	O
receptor	O
(	O
CXCR	O
)	O
2	O
and	O
its	O
ligands	O
(	O
CXC	O
chemokine	O
ligand	B-FUNC
[	O
CXCL	O
]	O
1	O
-	O
8	O
).	O

The	O
modified	O
slide	O
surface	O
is	O
satisfactory	O
to	O
immobilize	O
unmodified	O
oligonucleotide	O
by	O
covalent	O
binding	B-FUNC
,	O
which	O
enhances	O
not	O
only	O
the	O
sensitivity	O
of	O
the	O
prepared	O
oligonucleotide	O
microarray	O
but	O
also	O
the	O
binding	B-FUNC
of	O
the	O
oligonucleotide	O
to	O
the	O
slide	O
surface	O
.	O

CONCLUSIONS	O
:	O
The	O
modified	O
slide	O
surface	O
is	O
satisfactory	O
to	O
immobilize	O
unmodified	O
oligonucleotide	O
by	O
covalent	O
binding	B-FUNC
,	O
which	O
enhances	O
not	O
only	O
the	O
sensitivity	O
of	O
the	O
prepared	O
oligonucleotide	O
microarray	O
but	O
also	O
the	O
binding	B-FUNC
of	O
the	O
oligonucleotide	O
to	O
the	O
slide	O
surface	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
of	O
the	O
antibody	B-FUNC
specific	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
convalescents	O
who	O
have	O
suffered	O
from	O
SARS	O
.	O

Samples	O
of	O
peripheral	O
blood	O
were	O
collected	O
twice	O
during	O
the	O
first	O
2	O
weeks	O
after	O
discharge	O
and	O
then	O
once	O
every	O
2	O
-	O
4	O
weeks	O
from	O
310	O
convalescents	O
of	O
SARS	O
,	O
131	O
males	O
and	O
179	O
females	O
,	O
aged	O
18	O
-	O
74	O
,	O
discharged	O
from	O
hospitals	O
in	O
Beijing	O
April	O
3	O
to	O
June	O
20	O
2003	O
with	O
the	O
average	O
discharge	O
date	O
of	O
June	O
10	O
,	O
to	O
detect	O
the	O
level	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
by	O
ELISA	O
.	O

All	O
SARS	O
patients	O
generate	O
specific	O
antibody	B-FUNC
against	O
the	O
coronavirus	O
.	O

However	O
,	O
the	O
antibody	B-FUNC
level	O
gradually	O
decline	O
with	O
the	O
lapse	O
of	O
time	O
during	O
the	O
convalescence	O
.	O

CONCLUSIONS	O
:	O
All	O
SARS	O
patients	O
generate	O
specific	O
antibody	B-FUNC
against	O
the	O
coronavirus	O
.	O

The	O
incorporation	O
of	O
the	O
nucleoside	O
analog	O
,	O
cytosine	O
arabinoside	O
,	O
into	O
DNA	O
leads	O
to	O
local	O
perturbation	O
of	O
DNA	O
structure	O
and	O
reduces	O
the	O
ability	O
of	O
transcription	O
factors	O
to	O
bind	B-FUNC
to	O
their	O
specific	O
DNA	B-FUNC
binding	I-FUNC
elements	O
as	O
measured	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
following	O
indices	O
were	O
evaluated	O
:	O
fluid	O
requirements	O
for	O
resuscitation	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
),	O
arterial	O
po2	O
,	O
pco2	O
,	O
and	O
pH	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
lung	O
histology	O
and	O
cytokine	O
(	O
interleukin	O
[	O
IL	O
]-	O
1	O
alpha	O
,	O
IL	O
-	O
beta	O
1	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
beta	O
[	O
TNF	O
beta	O
],	O
IL	B-FUNC
-	I-FUNC
3	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
[	O
IFN	O
gamma	O
]),	O
and	O
mRNA	O
expression	O
in	O
the	O
lung	O
by	O
a	O
ribonuclease	O
protection	O
assay	O
(	O
RPA	O
).	O

TITLE	O
:	O
A	O
novel	O
cell	O
-	O
based	O
binding	B-FUNC
assay	O
system	O
reconstituting	O
interaction	O
between	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
its	O
cellular	O
receptor	O
.	O

In	O
order	O
to	O
study	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
this	O
highly	O
contagious	O
virus	O
,	O
we	O
established	O
a	O
clonal	O
cell	O
-	O
line	O
,	O
CHO	B-FUNC
-	O
SG	O
,	O
from	O
the	O
Chinese	O
hamster	O
ovary	O
cells	O
that	O
stably	O
expresses	O
C	O
-	O
terminally	O
EGFP	O
-	O
tagged	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
S	O
-	O
EGFP	O
).	O

The	O
ectodomain	O
of	O
the	O
S	O
glycoprotein	O
is	O
localized	O
on	O
the	O
surface	O
of	O
CHO	B-FUNC
-	O
SG	O
cells	O
with	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
-	O
terminated	O
carbohydrate	O
structure	O
.	O

CHO	B-FUNC
-	O
SG	O
cells	O
associated	O
tightly	O
with	O
Vero	O
E6	O
cells	O
,	O
a	O
SARS	O
-	O
CoV	O
receptor	O
(	O
ACE2	O
)	O
expressing	O
cell	O
-	O
line	O
,	O
and	O
the	O
interaction	O
remained	O
stable	O
under	O
highly	O
stringent	O
condition	O
(	O
1M	O
NaCl	O
).	O

This	O
interaction	O
could	O
be	O
blocked	O
by	O
either	O
the	O
serum	O
from	O
a	O
SARS	O
convalescent	O
patient	O
or	O
a	O
goat	O
anti	O
-	O
ACE2	O
antibody	B-FUNC
,	O
indicating	O
that	O
the	O
interaction	O
is	O
specific	O
.	O

A	O
binding	B-FUNC
epitope	O
with	O
lesser	O
degree	O
of	O
glycosylation	O
and	O
native	O
conformation	O
was	O
localized	O
by	O
using	O
rabbit	O
anti	O
-	O
sera	B-FUNC
raised	O
against	O
five	O
denatured	O
recombinant	O
S	O
protein	O
fragments	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

One	O
of	O
the	O
sera	B-FUNC
obtained	O
from	O
the	O
fragment	O
encompassing	O
amino	O
acids	O
48	O
-	O
358	O
significantly	O
blocked	O
the	O
interaction	O
between	O
CHO	B-FUNC
-	O
SG	O
and	O
Vero	O
E6	O
cells	O
.	O

This	O
paper	O
describes	O
an	O
easy	O
and	O
safe	O
cell	O
-	O
based	O
assay	O
suitable	O
for	O
studying	O
the	O
binding	B-FUNC
between	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
its	O
receptor	O
.	O

ABSTRACT	O
:	O
Using	O
paired	O
serum	O
samples	O
obtained	O
from	O
patients	O
with	O
illness	O
associated	O
with	O
increases	O
in	O
anti	O
-	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
or	O
anti	O
-	O
HCoV	O
-	O
229E	O
antibodies	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
false	O
-	O
positive	O
results	O
detected	O
in	O
a	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
immunoglobulin	B-FUNC
G	B-FUNC
enzyme	I-FUNC
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

None	O
of	O
these	O
samples	O
were	O
found	O
to	O
contain	O
a	O
specific	O
antibody	B-FUNC
in	O
the	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
polypeptide	O
-	O
based	O
Western	O
blot	O
assay	O
.	O

SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
-	O
encoding	O
plasmid	O
induced	O
activations	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
promoter	O
and	O
AP	O
-	O
1	O
,	O
but	O
not	O
NF	O
-	O
kappaB	O
in	O
these	O
cells	O
.	O

Recombinant	O
baculovirus	O
expressing	O
different	O
deletion	O
and	O
insertion	O
fragments	O
identified	O
the	O
functional	O
region	O
of	O
S	O
protein	O
from	O
aa	O
324	O
-	O
688	O
(	O
particularly	O
the	O
N	O
-	O
terminal	O
aa	O
324	O
-	O
488	O
and	O
the	O
C	O
-	O
terminal	O
aa	O
609	O
-	O
688	O
),	O
which	O
is	O
responsible	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
production	O
.	O

Activations	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
protein	B-FUNC
binding	I-FUNC
and	O
MAPKs	O
after	O
vAtEpGS688	O
transduction	O
were	O
demonstrated	O
,	O
and	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
promoter	O
activity	O
was	O
inhibited	O
by	O
the	O
specific	O
inhibitors	O
of	O
MAPK	B-FUNC
cascades	O
.	O

Neutralizing	O
antibodies	O
were	O
detected	O
in	O
sera	B-FUNC
at	O
day	O
7	O
p	O
.	O
i	O
.,	O
and	O
mean	O
titers	O
at	O
day	O
28	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
The	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
facilitates	O
the	O
transfer	O
of	O
murine	O
coronavirus	O
from	O
endosome	O
to	O
cytoplasm	O
during	O
virus	O
entry	O
.	O

Since	O
carboxyhemoglobin	O
has	O
a	O
negative	O
influence	O
on	O
oxygen	B-FUNC
-	I-FUNC
carrying	I-FUNC
capacity	O
,	O
this	O
effect	O
may	O
potentially	O
offset	O
the	O
beneficial	O
influence	O
(	O
if	O
any	O
)	O
of	O
inhaled	O
nitric	O
oxide	O
on	O
arterial	O
PO2	O
.	O

TITLE	O
:	O
An	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
related	O
cytokine	O
storm	O
in	O
SARS	O
patients	O
.	O

IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
TGF	O
-	O
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IP	O
-	O
10	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
MIG	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
but	O
not	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
,	O
or	O
TNFRI	O
,	O
were	O
highly	O
elevated	O
in	O
the	O
acute	O
phase	O
sera	B-FUNC
of	O
Taiwan	O
SARS	O
patients	O
.	O

IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
,	O
MIG	O
,	O
and	O
IP	O
-	O
10	O
were	O
already	O
elevated	O
at	O
early	O
days	O
post	O
fever	O
onset	O
.	O

Furthermore	O
,	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
IP	O
-	O
10	O
,	O
MIG	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
were	O
significantly	O
higher	O
in	O
the	O
death	O
group	O
than	O
in	O
the	O
survival	O
group	O
.	O

It	O
is	O
concluded	O
that	O
an	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
related	O
cytokine	O
storm	O
was	O
induced	O
post	O
SARS	O
coronavirus	O
infection	O
,	O
and	O
this	O
cytokine	O
storm	O
might	O
be	O
involved	O
in	O
the	O
immunopathological	O
damage	O
in	O
SARS	O
patients	O
.	O

The	O
results	O
on	O
150	O
sera	B-FUNC
from	O
SARS	O
patients	O
and	O
450	O
sera	B-FUNC
from	O
non	O
-	O
SARS	O
controls	O
showed	O
that	O
this	O
assay	O
had	O
a	O
high	O
level	O
of	O
sensitivity	O
(	O
96	O
.	O
2	O
%	O
for	O
late	O
serum	O
samples	O
)	O
and	O
specificity	O
(	O
97	O
.	O
8	O
%).	O

The	O
implication	O
of	O
differences	O
in	O
antibody	B-FUNC
response	O
to	O
the	O
nucleocapsid	O
protein	O
deserves	O
further	O
investigation	O
.	O

ABSTRACT	O
:	O
Abstract	O
Serum	O
levels	O
of	O
IgG	O
,	O
IgM	O
and	O
IgA	O
against	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
detected	O
serially	O
with	O
the	O
use	O
of	O
immunofluorescent	O
antibody	B-FUNC
assays	O
in	O
30	O
patients	O
with	O
SARS	O
.	O

Besides	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
RNA	O
helicase	O
,	O
and	O
protease	O
activities	O
,	O
which	O
are	O
common	O
to	O
RNA	O
viruses	O
,	O
the	O
coronavirus	O
replicase	O
was	O
recently	O
predicted	O
to	O
employ	O
a	O
variety	O
of	O
RNA	O
processing	O
enzymes	O
that	O
are	O
not	O
(	O
or	O
extremely	O
rarely	O
)	O
found	O
in	O
other	O
RNA	O
viruses	O
and	O
include	O
putative	O
sequence	O
-	O
specific	O
endoribonuclease	O
,	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
,	O
2	O
'-	O
O	O
-	O
ribose	O
methyltransferase	O
,	O
ADP	O
ribose	O
1	O
"""-"	O
phosphatase	B-FUNC
and	O
,	O
in	O
a	O
subset	O
of	O
group	O
2	O
coronaviruses	O
,	O
cyclic	O
phosphodiesterase	B-FUNC
activities	O
.	O

In	O
addition	O
to	O
viral	O
proteins	O
,	O
several	O
cellular	O
proteins	O
,	O
such	O
as	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
,	O
polypyrimidine	O
-	O
tract	O
-	O
binding	B-FUNC
(	O
PTB	O
)	O
protein	O
,	O
poly	O
(	O
A	O
)-	O
binding	B-FUNC
protein	O
(	O
PABP	O
),	O
and	O
mitochondrial	O
aconitase	O
(	O
m	O
-	O
aconitase	O
),	O
have	O
been	O
identified	O
to	O
interact	O
with	O
the	O
critical	O
cis	O
-	O
acting	O
elements	O
of	O
coronavirus	O
replication	O
.	O

Prevention	O
of	O
oxidative	O
stress	O
has	O
been	O
achieved	O
by	O
application	O
of	O
antioxidant	O
redox	O
metalloenzymes	O
such	O
as	O
superoxide	O
dismutases	O
(	O
containing	O
Cu	O
/	O
Zn	O
cytosolic	O
,	O
Mn	O
mitochondrial	O
and	O
Fe	O
bacterial	O
)	O
glutathione	O
peroxidases	O
(	O
and	O
other	O
Se	O
-	O
containing	O
proteins	O
and	O
enzymes	O
such	O
as	O
the	O
thioredoxins	O
),	O
catalases	O
(	O
Fe	O
-	O
containing	O
),	O
cytochrome	B-FUNC
c	I-FUNC
peroxidases	O
(	O
Fe	O
-	O
containing	O
),	O
ceruloplasmins	O
(	O
Cu	O
-	O
containing	O
),	O
metallothionines	O
(	O
these	O
cysteine	O
thiol	O
-	O
rich	O
proteins	O
bind	B-FUNC
ions	O
of	O
cadmium	O
and	O
mercury	O
)	O
and	O
tyrosinases	O
(	O
Cu	O
-	O
containing	O
).	O

ROS	O
are	O
generated	O
inadvertently	O
by	O
single	O
metal	O
valency	O
couples	O
such	O
as	O
FeII	O
/	O
FeIII	O
and	O
by	O
FeIII	O
/	O
FeV	O
present	O
in	O
2700	O
(	O
including	O
57	O
human	O
)	O
isoforms	O
in	O
cytochromes	B-FUNC
P450	O
mixed	O
-	O
function	O
oxidases	O
(	O
EC	O
1	O
.	O
14	O
.	O
14	O
.	O
1	O
;	O
O2	O
:	O
mono	O
-	O
oxygenase	B-FUNC
NADPH	O
/	O
NADH	O
requiring	O
).	O

He	O
developed	O
increasing	O
serum	O
levels	O
of	O
specific	O
antibodies	O
against	O
the	O
recombinant	O
nucleocapsid	O
protein	O
of	O
CoV	O
-	O
HKU1	O
,	O
with	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
)	O
titers	O
of	O
1	O
:	O
20	O
,	O
1	O
:	O
40	O
,	O
and	O
1	O
:	O
80	O
and	O
IgG	O
titers	O
of	O
<	O
1	O
:	O
1	O
,	O
000	O
,	O
1	O
:	O
2	O
,	O
000	O
,	O
and	O
1	O
:	O
8	O
,	O
000	O
in	O
the	O
first	O
,	O
second	O
and	O
fourth	O
weeks	O
of	O
the	O
illness	O
,	O
respectively	O
.	O

TITLE	O
:	O
Mass	O
spectroscopic	O
characterization	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleoprotein	O
and	O
elucidation	O
of	O
the	O
role	O
of	O
phosphorylation	O
in	O
RNA	B-FUNC
binding	I-FUNC
by	O
using	O
surface	O
plasmon	O
resonance	O
.	O

ABSTRACT	O
:	O
Phosphorylation	O
of	O
the	O
coronavirus	O
nucleoprotein	O
(	O
N	O
protein	O
)	O
has	O
been	O
predicted	O
to	O
play	O
a	O
role	O
in	O
RNA	B-FUNC
binding	I-FUNC
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
examined	O
the	O
kinetics	O
of	O
RNA	B-FUNC
binding	I-FUNC
between	O
nonphosphorylated	O
and	O
phosphorylated	O
infectious	O
bronchitis	O
virus	O
N	O
protein	O
with	O
nonviral	O
and	O
viral	O
RNA	O
by	O
surface	O
plasmon	O
resonance	O
(	O
Biacore	O
).	O

Mass	O
spectroscopic	O
analysis	O
of	O
N	O
protein	O
identified	O
phosphorylation	O
sites	O
that	O
were	O
proximal	O
to	O
RNA	B-FUNC
binding	I-FUNC
domains	O
.	O

The	O
data	O
also	O
indicated	O
that	O
a	O
known	O
N	O
protein	B-FUNC
binding	I-FUNC
site	O
(	O
involved	O
in	O
transcriptional	O
regulation	O
)	O
consisting	O
of	O
a	O
conserved	O
core	O
sequence	O
present	O
near	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
(	O
in	O
the	O
leader	O
sequence	O
)	O
functioned	O
by	O
promoting	O
high	O
association	O
rates	O
of	O
N	O
protein	B-FUNC
binding	I-FUNC
.	O

Further	O
analysis	O
of	O
the	O
leader	O
sequence	O
indicated	O
that	O
the	O
core	O
element	O
was	O
not	O
the	O
only	O
binding	B-FUNC
site	O
for	O
N	O
protein	O
and	O
that	O
other	O
regions	O
functioned	O
to	O
promote	O
high	O
-	O
affinity	O
binding	B-FUNC
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
39	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
(	O
PSAGN	O
)	O
super	O
-	O
imposed	O
on	O
long	O
-	O
term	O
immunoglobulin	B-FUNC
A	O
nephropathy	O
(	O
IgA	O
-	O
N	O
).	O

A	O
good	O
example	O
is	O
SARS	O
-	O
CoV	O
,	O
which	O
was	O
a	O
cause	O
of	O
death	O
of	O
many	O
people	O
and	O
frightened	O
the	O
entire	O
world	O
with	O
its	O
fast	B-FUNC
and	O
hard	O
to	O
prevent	O
propagation	O
.	O

Phylogenetic	O
tree	O
building	O
based	O
on	O
the	O
variations	O
of	O
the	O
M	O
protein	O
appears	O
to	O
support	O
the	O
non	O
-	O
human	O
origin	O
of	O
SARS	O
-	O
CoV	O
.	O
To	O
investigate	O
its	O
immunogenicity	O
,	O
we	O
synthesized	O
eight	O
oligopeptides	O
covering	O
69	O
.	O
2	O
%	O
of	O
the	O
entire	O
ORF	O
and	O
screened	O
them	O
by	O
using	O
ELISA	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
with	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

The	O
most	O
striking	O
physiochemical	O
feature	O
of	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
that	O
it	O
is	O
a	O
typical	O
basic	O
protein	O
with	O
a	O
high	O
predicted	O
pI	O
and	O
high	O
hydrophilicity	O
,	O
which	O
is	O
consistent	O
with	O
its	O
function	O
of	O
binding	B-FUNC
to	O
the	O
ribophosphate	O
backbone	O
of	O
the	O
RNA	O
molecule	O
.	O

The	O
predicted	O
high	O
extent	O
of	O
phosphorylation	O
of	O
the	O
N	O
protein	O
on	O
multiple	O
candidate	O
phosphorylation	O
sites	O
demonstrates	O
that	O
it	O
would	O
be	O
related	O
to	O
important	O
functions	O
,	O
such	O
as	O
RNA	O
-	O
binding	B-FUNC
and	O
localization	O
to	O
the	O
nucleolus	O
of	O
host	O
cells	O
.	O

Eleven	O
highly	O
conserved	O
regions	O
in	O
RdRp	B-FUNC
and	O
twelve	O
cleavage	O
sites	O
by	O
3CLP	O
(	O
chymotrypsin	O
-	O
like	O
protein	O
)	O
have	O
been	O
identified	O
as	O
potential	O
drug	O
targets	O
.	O

All	O
patient	O
sera	B-FUNC
in	O
this	O
study	O
displayed	O
strong	O
positive	O
immunoreactivities	O
against	O
the	O
recombinant	O
N	O
proteins	O
,	O
whereas	O
normal	O
sera	B-FUNC
gave	O
negative	O
immunoresponses	O
to	O
these	O
proteins	O
,	O
indicating	O
that	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
an	O
antigenic	O
protein	O
.	O

Furthermore	O
,	O
the	O
epitope	O
sites	O
in	O
the	O
N	O
protein	O
were	O
determined	O
by	O
competition	O
experiments	O
,	O
in	O
which	O
the	O
recombinant	O
proteins	O
or	O
the	O
synthesized	O
peptides	O
competed	O
against	O
the	O
SARS	O
-	O
CoV	O
proteins	O
to	O
bind	B-FUNC
to	O
the	O
antibodies	O
raised	O
in	O
SARS	O
sera	B-FUNC
.	O

ABSTRACT	O
:	O
In	O
the	O
face	O
of	O
the	O
worldwide	O
threat	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
human	O
life	O
,	O
some	O
of	O
the	O
most	O
urgent	O
challenges	O
are	O
to	O
develop	O
fast	B-FUNC
and	O
accurate	O
analytical	O
methods	O
for	O
early	O
diagnosis	O
of	O
this	O
disease	O
as	O
well	O
as	O
to	O
create	O
a	O
safe	O
anti	O
-	O
viral	O
vaccine	O
for	O
prevention	O
.	O

The	O
analysis	O
of	O
TRS	B-FUNC
supports	O
the	O
minus	O
strand	O
extending	O
transcription	O
mechanism	O
of	O
coronavirus	O
.	O

TITLE	O
:	O
[	O
Construction	O
and	O
screening	O
of	O
human	O
phage	O
antibody	B-FUNC
library	O
against	O
SARS	O
virus	O
].	O

Human	O
Fab	O
genes	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
lymphocytes	O
of	O
a	O
convalescent	O
SARS	O
patient	O
and	O
cloned	O
into	O
vector	O
pComb3	O
to	O
construct	O
phage	O
antibody	B-FUNC
library	O
.	O

Human	O
phage	O
antibody	B-FUNC
library	O
against	O
SARS	O
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	O
anti	O
-	O
SARS	O
virus	O
antibodies	O
were	O
obtained	O
.	O

CONCLUSIONS	O
:	O
Human	O
phage	O
antibody	B-FUNC
library	O
against	O
SARS	O
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	O
anti	O
-	O
SARS	O
virus	O
antibodies	O
were	O
obtained	O
.	O

TITLE	O
:	O
[	O
Preparation	O
of	O
specific	O
monoclonal	O
antibody	B-FUNC
against	O
nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
].	O

ABSTRACT	O
:	O
To	O
express	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
and	O
produce	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
to	O
N	O
protein	O
.	O

This	O
expressed	O
protein	O
could	O
be	O
further	O
confirmed	O
in	O
Western	O
blot	O
by	O
using	O
serum	O
from	O
a	O
convalescent	O
SARS	O
patient	O
as	O
primary	O
antibody	B-FUNC
.	O

The	O
tertiary	O
base	O
interactions	O
create	O
a	O
tunnel	O
that	O
runs	O
perpendicular	O
to	O
the	O
main	O
helical	O
axis	O
whose	O
interior	O
is	O
negatively	O
charged	O
and	O
binds	B-FUNC
two	O
magnesium	O
ions	O
.	O

Based	O
on	O
tertiary	O
structural	O
comparisons	O
,	O
we	O
propose	O
the	O
s2m	O
RNA	O
binds	B-FUNC
one	O
or	O
more	O
proteins	O
possessing	O
an	O
oligomer	O
-	O
binding	B-FUNC
-	O
like	O
fold	O
,	O
and	O
we	O
suggest	O
a	O
possible	O
mechanism	O
for	O
SARS	O
viral	O
RNA	O
hijacking	O
of	O
host	O
protein	O
synthesis	O
,	O
both	O
based	O
upon	O
observed	O
s2m	O
RNA	O
macromolecular	O
mimicry	O
of	O
a	O
relevant	O
ribosomal	B-FUNC
RNA	I-FUNC
fold	O
.	O

(	O
2	O
)	O
The	O
proportion	O
of	O
the	O
patients	O
who	O
had	O
close	O
contact	O
to	O
SARS	O
patients	O
was	O
7	O
/	O
8	O
among	O
the	O
antibody	B-FUNC
-	O
positive	O
group	O
vs	O
.	O
1	O
/	O
13	O
for	O
the	O
antibody	B-FUNC
-	O
negative	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
4	O
)	O
Among	O
23	O
parents	O
of	O
children	O
with	O
SARS	O
,	O
one	O
was	O
positive	O
for	O
IgG	O
and	O
the	O
mixed	O
antibodies	O
,	O
whose	O
grandson	O
and	O
husband	O
suffered	O
from	O
SARS	O
;	O
The	O
IgG	O
antibody	B-FUNC
and	O
the	O
mixed	O
antibodies	O
were	O
also	O
positive	O
in	O
another	O
adult	O
who	O
had	O
close	O
contact	O
with	O
adult	O
SARS	O
cases	O
(	O
3	O
%).	O

(	O
1	O
)	O
SARS	O
-	O
CoV	O
infection	O
was	O
confirmed	O
by	O
serological	O
methods	O
in	O
38	O
.	O
1	O
%	O
of	O
clinically	O
diagnosed	O
pediatric	O
SARS	O
cases	O
,	O
which	O
leads	O
to	O
the	O
assumption	O
that	O
correct	O
diagnosis	O
of	O
pediatric	O
SARS	O
requires	O
more	O
accurate	O
and	O
efficient	O
ways	O
,	O
for	O
example	O
,	O
screening	O
for	O
antigen	O
or	O
gene	O
of	O
SARS	O
-	O
CoV	O
.	O
(	O
2	O
)	O
The	O
proportion	O
of	O
the	O
patients	O
who	O
had	O
close	O
contact	O
to	O
SARS	O
patients	O
among	O
antibody	B-FUNC
-	O
positive	O
cases	O
was	O
higher	O
than	O
that	O
in	O
antibody	B-FUNC
-	O
negative	O
cases	O
.	O

(	O
4	O
)	O
Among	O
23	O
parents	O
of	O
children	O
with	O
SARS	O
,	O
one	O
was	O
positive	O
for	O
IgG	O
and	O
the	O
mixed	O
antibodies	O
,	O
whose	O
grandson	O
and	O
husband	O
suffered	O
from	O
SARS	O
;	O
The	O
IgG	O
antibody	B-FUNC
and	O
the	O
mixed	O
antibodies	O
were	O
also	O
positive	O
in	O
another	O
adult	O
who	O
had	O
close	O
contact	O
with	O
adult	O
SARS	O
cases	O
(	O
3	O
%).	O

The	O
positive	O
rates	O
of	O
IgM	O
,	O
IgG	O
and	O
total	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
in	O
146	O
sera	B-FUNC
of	O
SARS	O
patients	O
collected	O
in	O
different	O
phases	O
of	O
the	O
disease	O
were	O
61	O
.	O
64	O
%,	O
53	O
.	O
43	O
%	O
and	O
69	O
.	O
86	O
%,	O
respectively	O
.	O

Of	O
70	O
sera	B-FUNC
from	O
hepatitis	O
A	O
patients	O
,	O
2	O
showed	O
false	O
positive	O
results	O
,	O
while	O
127	O
sera	B-FUNC
from	O
other	O
patients	O
were	O
all	O
negative	O
,	O
detected	O
by	O
the	O
3	O
methods	O
.	O

RESULTS	O
:	O
The	O
positive	O
rates	O
of	O
IgM	O
,	O
IgG	O
and	O
total	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
in	O
146	O
sera	B-FUNC
of	O
SARS	O
patients	O
collected	O
in	O
different	O
phases	O
of	O
the	O
disease	O
were	O
61	O
.	O
64	O
%,	O
53	O
.	O
43	O
%	O
and	O
69	O
.	O
86	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
evidence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infection	O
among	O
close	O
contacts	O
to	O
SARS	O
patients	O
and	O
the	O
level	O
of	O
sera	B-FUNC
IgG	O
antibody	B-FUNC
in	O
SARS	O
cases	O
.	O

Specific	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
in	O
serum	O
samples	O
from	O
contacts	O
to	O
patients	O
,	O
five	O
months	O
before	O
an	O
SARS	O
outbreak	O
in	O
Beijing	O
.	O

The	O
neutralized	O
antibody	B-FUNC
levels	O
were	O
from	O
1	O
:	O
16	O
to	O
1	O
:	O
203	O
,	O
with	O
medium	O
level	O
of	O
1	O
:	O
43	O
.	O

The	O
hybridoma	O
cell	O
strains	O
were	O
screened	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
(	O
IFA	O
)	O
and	O
Western	O
blotting	O
.	O

RESULTS	O
:	O
Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	O
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	O
-	O
CoV	O
,	O
or	O
both	O
.	O

To	O
investigate	O
the	O
autocrine	O
activation	O
of	O
BALB	O
/	O
c	O
and	O
A	O
/	O
J	O
Mphi	O
,	O
we	O
activated	O
them	O
with	O
interleukin	O
-	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
)	O
and	O
/	O
or	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
quantified	O
IFNgamma	O
production	O
,	O
the	O
anti	O
-	O
MHV3	O
state	O
and	O
arginine	O
metabolism	O
.	O

In	O
bone	O
marrow	O
(	O
BM	O
)	O
or	O
peritoneal	O
(	O
P	O
)	O
Mphi	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
spf	O
)	O
mice	O
of	O
both	O
strains	O
,	O
IFNgamma	O
synthesis	O
occurred	O
only	O
with	O
a	O
synergistic	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
activation	O
and	O
showed	O
increasing	O
levels	O
from	O
24	O
to	O
72	O
h	O
of	O
activation	O
.	O

In	O
contrast	O
,	O
when	O
non	O
-	O
spf	O
mice	O
were	O
used	O
in	O
the	O
assay	O
,	O
their	O
PMphi	O
synthesized	O
higher	O
IFNgamma	O
levels	O
upon	O
activation	O
with	O
only	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
or	O
only	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
or	O
both	O
.	O

An	O
anti	O
-	O
MHV3	O
state	O
was	O
observed	O
only	O
in	O
A	O
/	O
J	O
Mphi	O
upon	O
activation	O
with	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
or	O
IFNgamma	O
regardless	O
of	O
their	O
origin	O
from	O
the	O
peritoneum	O
or	O
bone	O
marrow	O
.	O

The	O
results	O
showed	O
that	O
both	O
BALB	O
/	O
c	O
and	O
A	O
/	O
J	O
BMMphi	O
populations	O
released	O
NO	O
only	O
after	O
activation	O
with	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
or	O
IFNgamma	O
.	O

Arginase	O
was	O
not	O
induced	O
in	O
BMMphi	O
from	O
both	O
strains	O
by	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
or	O
IFNgamma	O
but	O
only	O
by	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Higher	O
arginine	O
consumption	O
was	O
observed	O
in	O
BMMphi	O
from	O
both	O
strains	O
upon	O
activation	O
with	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
or	O
IFNgamma	O
which	O
further	O
increased	O
,	O
in	O
this	O
case	O
,	O
when	O
the	O
cells	O
were	O
infected	O
with	O
MHV3	O
.	O

High	O
levels	O
of	O
ornithine	O
were	O
induced	O
only	O
upon	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
activation	O
.	O

IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
or	O
IFNgamma	O
activation	O
,	O
mainly	O
in	O
MHV3	O
infected	O
cells	O
,	O
led	O
to	O
a	O
decreased	O
synthesis	O
of	O
polyamines	O
,	O
notably	O
spermine	O
,	O
only	O
in	O
A	O
/	O
J	O
BMMphi	O
.	O

Parameters	O
studied	O
included	O
serum	O
levels	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
IgG	O
antibody	B-FUNC
,	O
tests	O
of	O
lung	O
function	O
,	O
and	O
imaging	O
data	O
to	O
evaluate	O
changes	O
in	O
lung	O
fibrosis	O
.	O

They	O
were	O
tested	O
regularly	O
for	O
serum	O
levels	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
and	O
lung	O
function	O
and	O
were	O
given	O
chest	O
X	O
-	O
rays	O
and	O
/	O
or	O
high	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
examinations	O
at	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
during	O
the	O
12	O
months	O
that	O
followed	O
their	O
release	O
from	O
the	O
hospital	O
.	O

Blockade	O
of	O
HMGB1	O
by	O
administration	O
of	O
anti	O
-	O
HMGB1	O
antibodies	O
prevented	O
hemorrhage	O
-	O
induced	O
increases	O
in	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
lungs	O
and	O
pulmonary	O
levels	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
keratinocyte	O
-	O
derived	O
chemokine	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
.	O

Decreased	O
production	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	B-FUNC
)	O
in	O
ARDS	O
may	O
favour	O
vascular	O
lesions	O
,	O
since	O
VEGF	B-FUNC
promotes	O
endothelial	O
survival	O
by	O
inhibiting	O
apoptosis	O
.	O

In	O
conclusion	O
,	O
decreased	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
levels	O
in	O
lung	O
tissue	O
may	O
participate	O
in	O
the	O
decrease	O
in	O
lung	O
perfusion	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
the	O
monoclonal	O
antibody	B-FUNC
against	O
N	O
protein	O
of	O
SARS	O
virus	O
and	O
study	O
its	O
applicability	O
.	O

The	O
infused	O
cells	O
were	O
screened	O
for	O
anti	O
-	O
N	O
protein	O
antibody	B-FUNC
with	O
ELISA	O
.	O

The	O
ELISA	O
for	O
detection	O
of	O
SARS	O
virus	O
antigen	O
was	O
developed	O
by	O
using	O
antibody	B-FUNC
with	O
the	O
highest	O
affinity	O
.	O

Eleven	O
monoclonal	O
cells	O
secreting	O
antibody	B-FUNC
have	O
been	O
developed	O
.	O

The	O
monoclonal	O
antibody	B-FUNC
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	O
virus	O
antigen	O
.	O

CONCLUSIONS	O
:	O
The	O
monoclonal	O
antibody	B-FUNC
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	O
virus	O
antigen	O
.	O

TITLE	O
:	O
[	O
Potent	O
neutralization	O
antibody	B-FUNC
elicited	O
in	O
mice	O
by	O
SARS	O
-	O
associated	O
coronavirus	O
spike	O
protein	O
S1	O
domain	O
].	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
a	O
plasmid	O
bearing	O
codon	O
-	O
optimized	O
SARS	O
-	O
CoV	O
(	O
Tor2	O
strain	O
)	O
S1	O
domain	O
and	O
then	O
boosted	O
with	O
purified	O
S1	O
protein	O
;	O
the	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-FUNC
was	O
tested	O
by	O
ELISA	O
and	O
neutralization	O
antibody	B-FUNC
was	O
determined	O
by	O
in	O
vitro	O
microneutralization	O
assay	O
.	O

S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
,	O
successfully	O
elicited	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-FUNC
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	O
protein	O
;	O
the	O
antibody	B-FUNC
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	O
infection	O
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	B-FUNC
immunized	O
with	O
S1	O
protein	O
,	O
but	O
negative	O
control	O
sera	B-FUNC
showed	O
no	O
protection	O
.	O

S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
,	O
can	O
efficiently	O
and	O
sufficiently	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
in	O
mice	O
.	O

This	O
result	O
suggested	O
that	O
S1	O
domain	O
could	O
be	O
an	O
effective	O
subunit	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
,	O
successfully	O
elicited	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-FUNC
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	O
protein	O
;	O
the	O
antibody	B-FUNC
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	O
infection	O
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	B-FUNC
immunized	O
with	O
S1	O
protein	O
,	O
but	O
negative	O
control	O
sera	B-FUNC
showed	O
no	O
protection	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
fluorescent	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
detecting	O
influenza	O
viruses	O
].	O

ABSTRACT	O
:	O
To	O
apply	O
fluorescent	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
detecting	O
influenza	O
viruses	O
.	O

This	O
study	O
showed	O
that	O
fluorescent	O
real	O
-	O
time	O
PCR	O
is	O
a	O
reliable	O
,	O
sensitive	O
,	O
and	O
fast	B-FUNC
method	O
for	O
detecting	O
influenza	O
viruses	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
showed	O
that	O
fluorescent	O
real	O
-	O
time	O
PCR	O
is	O
a	O
reliable	O
,	O
sensitive	O
,	O
and	O
fast	B-FUNC
method	O
for	O
detecting	O
influenza	O
viruses	O
.	O

Results	O
of	O
Western	O
-	O
blot	O
showed	O
that	O
this	O
expressed	O
protein	O
could	O
react	O
with	O
antibodies	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
during	O
convalescence	O
.	O

ABSTRACT	O
:	O
Pharmacophore	O
-	O
based	O
virtual	O
screening	O
is	O
an	O
effective	O
,	O
inexpensive	O
and	O
fast	B-FUNC
approach	O
to	O
discovering	O
useful	O
starting	O
points	O
for	O
drug	O
discovery	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
pharmacophore	O
model	O
for	O
the	O
main	O
proteinase	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

This	O
means	O
that	O
our	O
pharmacophore	O
model	O
can	O
lead	O
to	O
the	O
discovery	O
of	O
potent	O
anti	O
-	O
SARS	O
-	O
CoV	O
inhibitors	O
or	O
promising	O
lead	O
compounds	O
for	O
further	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-FUNC
inhibitor	I-FUNC
development	O
.	O

In	O
Western	O
blot	O
assays	O
,	O
the	O
recombinant	O
S450	O
-	O
650	O
was	O
recognized	O
by	O
monoclonal	O
Ab	O
against	O
the	O
His	O
-	O
tag	O
and	O
also	O
sera	B-FUNC
from	O
a	O
convalescent	O
SARS	O
patient	O
.	O

TITLE	O
:	O
Evasion	O
of	O
antibody	B-FUNC
neutralization	O
in	O
emerging	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	B-FUNC
-	O
based	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
reveals	O
high	O
sensitivity	O
of	O
the	O
nucleocapsid	O
protein	O
in	O
acute	O
-	O
phase	O
sera	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
.	O

In	O
this	O
study	O
,	O
829	O
serum	O
specimens	O
were	O
collected	O
from	O
643	O
patients	O
initially	O
reported	O
to	O
be	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
The	O
sera	B-FUNC
were	O
tested	O
for	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
by	O
using	O
an	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
based	O
on	O
monoclonal	O
antibodies	O
against	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
compared	O
to	O
197	O
control	O
serum	O
samples	O
from	O
healthy	O
donors	O
and	O
non	O
-	O
SARS	O
febrile	O
patients	O
.	O

From	O
27	O
SARS	O
patients	O
who	O
tested	O
positive	O
with	O
the	O
neutralization	O
test	O
,	O
100	O
%	O
of	O
the	O
24	O
sera	B-FUNC
collected	O
from	O
1	O
to	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
were	O
positive	O
for	O
the	O
N	O
protein	O
.	O

For	O
294	O
sera	B-FUNC
from	O
248	O
serological	O
test	O
-	O
negative	O
patients	O
,	O
the	O
rates	O
were	O
25	O
.	O
6	O
,	O
16	O
.	O
7	O
,	O
9	O
.	O
3	O
,	O
and	O
0	O
%,	O
respectively	O
.	O

Furthermore	O
,	O
of	O
16	O
sera	B-FUNC
collected	O
from	O
four	O
patients	O
during	O
the	O
SARS	O
recurrence	O
in	O
Guangzhou	O
,	O
5	O
sera	B-FUNC
collected	O
from	O
7	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
were	O
positive	O
for	O
the	O
N	O
protein	O
.	O

In	O
conclusion	O
,	O
an	O
antigen	O
capture	O
ELISA	O
reveals	O
a	O
high	O
N	O
protein	O
detection	O
rate	O
in	O
acute	O
-	O
phase	O
sera	B-FUNC
of	O
patients	O
with	O
SARS	O
,	O
which	O
makes	O
it	O
useful	O
for	O
early	O
diagnosis	O
of	O
SARS	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
SARS	O
-	O
CoV	O
infection	O
on	O
CXCL8	O
(	O
interleukin	O
8	O
)	O
and	O
CXCL10	O
(	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
inducible	O
protein	O
10	O
)	O
in	O
human	O
intestinal	O
epithelial	O
(	O
Caco2	O
)	O
cells	O
.	O

Electric	O
mobility	O
shift	O
assay	O
revealed	O
increased	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
the	O
cellular	O
transcription	O
factors	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
(	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

High	O
hydrocortisone	O
concentrations	O
(>	O
or	O
=	O
50	O
microg	O
/	O
ml	O
)	O
completely	O
prevented	O
increased	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
and	O
inhibited	O
up	O
-	O
regulation	O
of	O
CXCL8	O
and	O
CXCL10	O
,	O
but	O
did	O
not	O
reduce	O
chemokine	O
expression	O
to	O
basal	O
levels	O
.	O

We	O
identified	O
eight	O
human	O
MAbs	O
binding	B-FUNC
to	O
virus	O
and	O
infected	O
cells	O
,	O
six	O
of	O
which	O
could	O
be	O
mapped	O
to	O
two	O
SARS	O
-	O
CoV	O
structural	O
proteins	O
:	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
.	O

These	O
two	O
N	O
MAbs	O
did	O
not	O
compete	O
for	O
binding	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
Four	O
MAbs	O
reacted	O
with	O
the	O
S	O
glycoprotein	O
,	O
and	O
three	O
of	O
these	O
MAbs	O
neutralized	O
SARS	O
-	O
CoV	O
in	O
vitro	O
.	O

All	O
three	O
neutralizing	O
anti	O
-	O
S	O
MAbs	O
bound	O
a	O
recombinant	O
S1	O
fragment	O
comprising	O
residues	O
318	O
to	O
510	O
,	O
a	O
region	O
previously	O
identified	O
as	O
the	O
SARS	O
-	O
CoV	O
S	O
receptor	B-FUNC
binding	I-FUNC
domain	O
;	O
the	O
nonneutralizing	O
MAb	O
did	O
not	O
.	O

Two	O
strongly	O
neutralizing	O
anti	O
-	O
S1	O
MAbs	O
blocked	O
the	O
binding	B-FUNC
of	O
a	O
recombinant	O
S	O
fragment	O
(	O
residues	O
1	O
to	O
565	O
)	O
to	O
SARS	O
-	O
CoV	O
-	O
susceptible	O
Vero	O
cells	O
completely	O
,	O
whereas	O
a	O
poorly	O
neutralizing	O
S1	O
MAb	O
blocked	O
binding	B-FUNC
only	O
partially	O
.	O

Finally	O
,	O
epitope	O
mapping	O
,	O
using	O
recombinant	O
S	O
fragments	O
(	O
residues	O
318	O
to	O
510	O
)	O
containing	O
naturally	O
occurring	O
mutations	O
,	O
revealed	O
the	O
importance	O
of	O
residue	O
N479	O
for	O
the	O
binding	B-FUNC
of	O
the	O
most	O
potent	O
neutralizing	O
MAb	O
,	O
CR3014	O
.	O

High	O
titer	O
S	O
-	O
specific	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
responses	O
were	O
elicited	O
in	O
rabbits	O
immunized	O
with	O
DNA	O
against	O
various	O
segments	O
of	O
the	O
S	O
protein	O
.	O

TITLE	O
:	O
[	O
Sero	O
-	O
epidemiological	O
characteristics	O
of	O
antibody	B-FUNC
to	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Gansu	O
Province	O
].	O

The	O
levels	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
IgG	O
antibody	B-FUNC
were	O
measured	O
by	O
ELISA	O
.	O

The	O
material	O
included	O
acute	O
and	O
(	O
or	O
)	O
recovery	O
period	O
sera	B-FUNC
of	O
9	O
SARS	O
patients	O
,	O
sera	B-FUNC
from	O
1	O
,	O
109	O
doctors	O
and	O
nurses	O
closely	O
contacted	O
with	O
SARS	O
patients	O
,	O
laboratory	O
workers	O
,	O
personnel	O
for	O
disease	O
control	O
and	O
prevention	O
,	O
persons	O
who	O
contacted	O
SARS	O
patients	O
,	O
and	O
sera	B-FUNC
from	O
978	O
normal	O
subjects	O
.	O

SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
was	O
detected	O
positive	O
in	O
6	O
of	O
the	O
9	O
patients	O
,	O
it	O
was	O
still	O
positive	O
in	O
the	O
sera	B-FUNC
twelve	O
months	O
after	O
recovery	O
;	O
1	O
of	O
the	O
closely	O
contacted	O
persons	O
and	O
3	O
normal	O
subjects	O
were	O
found	O
positive	O
.	O

The	O
positive	O
rate	O
of	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
of	O
patients	O
was	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
.	O

RESULTS	O
:	O
SARS	O
coronavirus	O
IgG	O
antibody	B-FUNC
was	O
detected	O
positive	O
in	O
6	O
of	O
the	O
9	O
patients	O
,	O
it	O
was	O
still	O
positive	O
in	O
the	O
sera	B-FUNC
twelve	O
months	O
after	O
recovery	O
;	O
1	O
of	O
the	O
closely	O
contacted	O
persons	O
and	O
3	O
normal	O
subjects	O
were	O
found	O
positive	O
.	O

In	O
this	O
study	O
,	O
the	O
silencing	O
potential	O
of	O
seven	O
synthetic	O
siRNAs	O
against	O
SARS	O
-	O
CoV	O
leader	O
,	O
TRS	B-FUNC
,	O
3	O
'-	O
UTR	O
and	O
Spike	O
coding	O
sequence	O
have	O
been	O
applied	O
to	O
explore	O
the	O
possibility	O
for	O
prevention	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Specimens	O
of	O
respiratory	O
secretions	O
from	O
8	O
(	O
72	O
.	O
7	O
%)	O
of	O
11	O
children	O
with	O
Kawasaki	O
disease	O
and	O
from	O
1	O
(	O
4	O
.	O
5	O
%)	O
of	O
22	O
control	O
subjects	O
(	O
children	O
without	O
Kawasaki	O
disease	O
matched	O
by	O
age	O
and	O
the	O
time	O
the	O
specimens	O
were	O
obtained	O
)	O
tested	O
positive	O
for	O
HCoV	O
-	O
NH	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
Mantel	O
-	O
Haenszel	O
matched	O
odds	O
ratio	O
,	O
16	O
.	O
0	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
3	O
.	O
4	O
-	O
74	O
.	O
4	O
];	O
P	O
=.	O
0015	O
).	O

Both	O
MAbs	O
bound	O
to	O
S	O
glycoprotein	O
expressed	O
on	O
transfected	O
cells	O
but	O
differed	O
in	O
their	O
ability	O
to	O
block	O
binding	B-FUNC
of	O
S	O
glycoprotein	O
to	O
Vero	O
E6	O
cells	O
.	O

Clinical	O
trials	O
are	O
planned	O
to	O
test	O
MAb	O
201	O
,	O
a	O
fully	O
human	O
MAb	O
specific	O
for	O
the	O
epitope	O
within	O
the	O
receptor	O
-	O
binding	B-FUNC
region	O
.	O

Specific	O
antibody	B-FUNC
response	O
to	O
this	O
purified	O
recombinant	O
N	O
protein	O
was	O
100	O
%	O
positive	O
in	O
the	O
SARS	O
patients	O
'	O
sera	B-FUNC
,	O
while	O
none	O
of	O
the	O
control	O
sera	B-FUNC
from	O
30	O
healthy	O
people	O
gave	O
a	O
positive	O
reaction	O
in	O
the	O
same	O
assay	O
.	O

Results	O
indicated	O
that	O
orally	O
delivered	O
MG1363	O
/	O
pSECN	O
induced	O
significant	O
N	O
-	O
specific	O
IgG	O
in	O
the	O
sera	B-FUNC
.	O

TITLE	O
:	O
Intragastric	O
administration	O
of	O
Lactobacillus	O
casei	O
expressing	O
transmissible	O
gastroentritis	O
coronavirus	O
spike	O
glycoprotein	O
induced	O
specific	O
antibody	B-FUNC
production	O
.	O

While	O
civets	O
on	O
farms	O
were	O
largely	O
free	O
from	O
SARS	O
-	O
CoV	O
infection	O
,	O
approximately	O
80	O
%	O
of	O
the	O
animals	O
from	O
one	O
animal	O
market	O
in	O
Guangzhou	O
contained	O
significant	O
levels	O
of	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
,	O
which	O
suggests	O
no	O
widespread	O
infection	O
among	O
civets	O
resident	O
on	O
farms	O
,	O
and	O
the	O
infection	O
of	O
civets	O
in	O
the	O
market	O
might	O
be	O
associated	O
with	O
trading	O
activities	O
under	O
the	O
conditions	O
of	O
overcrowding	O
and	O
mixing	O
of	O
various	O
animal	O
species	O
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	O
RNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
is	O
described	O
.	O

TITLE	O
:	O
Rapid	O
differentiation	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
isolates	O
by	O
sample	O
to	O
residual	O
ratio	O
quantitation	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Virtual	O
screening	O
of	O
novel	O
noncovalent	O
inhibitors	O
for	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
is	O
considered	O
as	O
a	O
potential	O
drug	O
design	O
target	O
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Owing	O
to	O
the	O
lack	O
of	O
available	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	O
,	O
the	O
discovery	O
of	O
inhibitors	O
for	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
that	O
can	O
potentially	O
be	O
optimized	O
as	O
drugs	O
appears	O
to	O
be	O
highly	O
desirable	O
.	O

We	O
have	O
built	O
a	O
""""	O
flexible	O
""""	O
three	O
-	O
dimensional	O
model	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
by	O
homology	O
modeling	O
and	O
multicanonical	O
molecular	O
dynamics	O
method	O
and	O
used	O
the	O
model	O
for	O
virtual	O
screening	O
of	O
chemical	O
databases	O
.	O

Three	O
of	O
them	O
including	O
calmidazolium	O
,	O
a	O
well	O
-	O
known	O
antagonist	O
of	O
calmodulin	O
,	O
were	O
found	O
to	O
inhibit	O
the	O
enzyme	O
with	O
an	O
apparent	O
K	O
(	O
i	O
)	O
from	O
61	O
to	O
178	O
microM	O
.	O
These	O
active	O
compounds	O
and	O
their	O
binding	B-FUNC
modes	O
provide	O
useful	O
information	O
for	O
understanding	O
the	O
binding	B-FUNC
sites	O
and	O
for	O
further	O
selective	O
drug	O
design	O
against	O
SARS	O
and	O
other	O
coronavirus	O
.	O

This	O
recombinant	O
baculovirus	O
expressing	O
protein	O
C	O
was	O
first	O
characterized	O
using	O
five	O
SARS	O
convalescent	O
human	O
sera	B-FUNC
and	O
five	O
normal	O
human	O
sera	B-FUNC
.	O

The	O
results	O
showed	O
that	O
protein	O
C	O
is	O
an	O
authentic	O
antigen	O
against	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
.	O

The	O
results	O
were	O
compared	O
to	O
a	O
commercial	O
SARS	O
IFA	O
kit	B-FUNC
(	O
EUROIMMUN	O
,	O
Germany	O
)	O
and	O
a	O
conventional	O
IFA	O
test	O
performed	O
in	O
Singapore	O
General	O
Hospital	O
.	O

Mutagenic	O
analysis	O
of	O
the	O
SARS	O
-	O
CoV	O
shift	O
site	O
and	O
mass	O
spectrometry	O
of	O
an	O
affinity	O
tagged	O
frameshift	O
product	O
confirmed	O
tandem	O
tRNA	B-FUNC
slippage	O
on	O
the	O
sequence	O
U_UUA_AAC	O
.	O

Other	O
signs	O
of	O
IRF	O
-	O
3	O
activation	O
such	O
as	O
hyperphosphorylation	O
,	O
homodimer	O
formation	O
,	O
and	O
recruitment	O
of	O
the	O
coactivator	O
CREB	O
-	O
binding	B-FUNC
protein	O
(	O
CBP	O
)	O
were	O
found	O
late	O
after	O
infection	O
with	O
the	O
control	O
virus	O
but	O
not	O
with	O
SARS	O
-	O
CoV	O
.	O
Our	O
data	O
suggest	O
that	O
nuclear	O
transport	O
of	O
IRF	O
-	O
3	O
is	O
an	O
immediate	O
-	O
early	O
reaction	O
to	O
virus	O
infection	O
and	O
may	O
precede	O
its	O
hyperphosphorylation	O
,	O
homodimer	O
formation	O
,	O
and	O
binding	B-FUNC
to	O
CBP	O
.	O

Transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
precede	O
each	O
gene	O
and	O
include	O
a	O
conserved	O
core	O
sequence	O
(	O
CS	O
)	O
surrounded	O
by	O
relatively	O
variable	O
sequences	O
(	O
5	O
'	O
TRS	B-FUNC
and	O
3	O
'	O
TRS	B-FUNC
).	O

A	O
good	O
correlation	O
was	O
observed	O
between	O
the	O
free	O
energy	O
of	O
TRS	B-FUNC
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	O
and	O
the	O
levels	O
of	O
subgenomic	O
mRNA	O
S2	O
,	O
demonstrating	O
that	O
base	B-FUNC
pairing	I-FUNC
between	O
the	O
leader	O
and	O
body	O
beyond	O
the	O
CS	O
is	O
a	O
determinant	O
regulation	O
factor	O
in	O
coronavirus	O
transcription	O
.	O

The	O
three	O
-	O
dimensional	O
model	O
was	O
also	O
used	O
to	O
explain	O
the	O
recently	O
published	O
experimental	O
results	O
of	O
S1	O
-	O
ACE	O
-	O
2	O
binding	B-FUNC
and	O
immunizations	O
.	O

Here	O
,	O
we	O
found	O
that	O
platelet	O
depletion	O
(	O
by	O
a	O
monoclonal	O
anti	O
-	O
platelet	O
antibody	B-FUNC
)	O
prevented	O
LPS	O
-	O
induced	O
rapid	O
shock	O
,	O
but	O
increased	O
delayed	O
lethality	O
.	O

Both	O
the	O
truncated	O
recombinant	O
proteins	O
were	O
expressed	O
in	O
soluble	O
forms	O
and	O
reacted	O
specifically	O
with	O
the	O
sera	B-FUNC
from	O
immunized	O
pSecS	O
mice	O
and	O
clinically	O
diagnosed	O
SARS	O
patients	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
gene	O
vaccine	O
could	O
induce	O
the	O
production	O
of	O
specific	O
antibody	B-FUNC
,	O
which	O
offers	O
clues	O
for	O
the	O
research	O
of	O
SARS	O
DNA	O
vaccine	O
.	O

RESULTS	O
:	O
Both	O
the	O
truncated	O
recombinant	O
proteins	O
were	O
expressed	O
in	O
soluble	O
forms	O
and	O
reacted	O
specifically	O
with	O
the	O
sera	B-FUNC
from	O
immunized	O
pSecS	O
mice	O
and	O
clinically	O
diagnosed	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
function	O
of	O
HAb18G	O
/	O
CD147	O
in	O
invasion	O
of	O
host	O
cells	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
we	O
analyzed	O
the	O
protein	O
-	O
protein	O
interaction	O
among	O
HAb18G	O
/	O
CD147	O
,	O
cyclophilin	B-FUNC
A	O
(	O
CyPA	O
),	O
and	O
SARS	O
-	O
CoV	O
structural	O
proteins	O
by	O
coimmunoprecipitation	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
.	O

TITLE	O
:	O
Three	O
-	O
dimensional	O
model	O
of	O
a	O
substrate	O
-	O
bound	O
SARS	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinase	B-FUNC
predicted	O
by	O
multiple	O
molecular	O
dynamics	O
simulations	O
:	O
catalytic	O
efficiency	O
regulated	O
by	O
substrate	O
binding	B-FUNC
.	O

The	O
protein	O
sequence	O
of	O
the	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinase	B-FUNC
(	O
CCP	O
)	O
responsible	O
for	O
SARS	O
viral	O
replication	O
has	O
been	O
identified	O
as	O
a	O
target	O
for	O
developing	O
anti	O
-	O
SARS	O
drugs	O
.	O

The	O
simulations	O
of	O
the	O
CCP	O
complex	O
suggest	O
that	O
substrate	O
binding	B-FUNC
leads	O
to	O
the	O
displacement	O
of	O
a	O
water	O
molecule	O
entrapped	O
by	O
Asp187	O
and	O
His41	O
,	O
thus	O
converting	O
the	O
dyad	O
to	O
a	O
more	O
efficient	O
catalytic	O
triad	O
.	O

TITLE	O
:	O
Molecular	O
modeling	O
and	O
chemical	O
modification	O
for	O
finding	O
peptide	O
inhibitor	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
main	O
proteinase	B-FUNC
.	O

In	O
this	O
study	O
,	O
the	O
cleavage	O
mechanism	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
Mpro	O
or	O
3CLpro	O
)	O
on	O
the	O
octapeptide	O
NH2	O
-	O
AVLQ	O
downward	O
arrowSGFR	O
-	O
COOH	O
was	O
investigated	O
using	O
molecular	O
mechanics	O
and	O
quantum	O
mechanics	O
simulations	O
based	O
on	O
the	O
experimental	O
structure	O
of	O
the	O
proteinase	B-FUNC
.	O

Urine	O
UA	O
and	O
creatinine	O
levels	O
were	O
available	O
for	O
43	O
patients	O
;	O
the	O
serum	O
cytokines	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
measured	O
in	O
16	O
patients	O
.	O

Serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
correlated	O
significantly	O
with	O
FE	O
UA	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
r	O
=	O
0	O
.	O
785	O
)	O
and	O
inversely	O
with	O
serum	O
UA	O
level	O
(	O
P	O
=	O
0	O
.	O
044	O
;	O
r	O
=	O
-	O
0	O
.	O
509	O
);	O
neither	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
nor	O
TNF	O
-	O
alpha	O
level	O
showed	O
such	O
correlations	O
.	O

CONCLUSIONS	O
:	O
One	O
fourth	O
of	O
patients	O
with	O
SARS	O
developed	O
hypouricemia	O
,	O
which	O
might	O
result	O
from	O
a	O
defect	O
in	O
renal	O
UA	O
handling	O
and	O
was	O
associated	O
with	O
a	O
high	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
level	O
.	O

Our	O
data	O
showed	O
that	O
the	O
newly	O
developed	O
IFA	O
could	O
detect	O
SARS	O
-	O
CoV	O
in	O
22	O
of	O
the	O
23	O
SARS	O
-	O
CoV	O
-	O
positive	O
serum	O
samples	O
and	O
gave	O
no	O
false	O
-	O
positive	O
results	O
when	O
the	O
sera	B-FUNC
from	O
patients	O
with	O
autoimmune	O
diseases	O
and	O
healthy	O
individuals	O
were	O
tested	O
.	O

In	O
addition	O
,	O
3a	O
can	O
bind	B-FUNC
to	O
the	O
spike	O
protein	O
and	O
through	O
this	O
interaction	O
,	O
it	O
may	O
be	O
able	O
to	O
cause	O
the	O
spike	O
protein	O
to	O
become	O
internalized	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
its	O
surface	O
expression	O
.	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
amplification	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
successfully	O
detected	O
36	O
strains	O
from	O
the	O
faeces	O
of	O
mice	O
that	O
had	O
been	O
housed	O
in	O
animal	O
facilities	O
in	O
Japan	O
from	O
2000	O
to	O
2003	O
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	O
-	O
CoV	O
immunoglobulin	B-FUNC
G	O
in	O
healthcare	O
workers	O
,	O
Guangzhou	O
,	O
China	O
.	O

To	O
avoid	O
the	O
enhancement	O
antibody	B-FUNC
issue	O
,	O
genes	O
encoding	O
the	O
nucleocapsid	O
,	O
membrane	O
,	O
and	O
envelope	O
protein	O
of	O
SARS	O
-	O
CoV	O
were	O
cloned	O
and	O
their	O
expressions	O
in	O
mammalian	O
cells	O
were	O
determined	O
.	O

After	O
two	O
intramuscular	O
vaccinations	O
with	O
ADS	O
-	O
MVA	O
alone	O
,	O
the	O
50	O
%	O
inhibitory	O
concentration	O
in	O
serum	O
was	O
achieved	O
with	O
reciprocal	O
sera	B-FUNC
dilutions	O
of	O
more	O
than	O
1	O
,	O
000	O
-	O
to	O
10	O
,	O
000	O
-	O
fold	O
in	O
these	O
animals	O
.	O

Using	O
the	O
recombinant	O
His	O
-	O
Tagged	O
3CL	O
-	O
protease	O
(	O
3CLpro	O
)	O
as	O
a	O
model	O
for	O
attachment	O
to	O
chips	O
containing	O
D	O
-/	O
L	O
-	O
Glu	O
,	O
Asp	O
,	O
Orn	O
,	O
Ser	O
via	O
different	O
transitional	O
metal	O
ions	O
,	O
it	O
was	O
found	O
that	O
the	O
Orn	O
chip	O
was	O
the	O
best	O
of	O
affinity	O
binding	B-FUNC
and	O
stability	O
by	O
which	O
Zn2	O
+	O
was	O
the	O
best	O
metal	O
ion	O
for	O
affinity	O
while	O
Co2	O
+	O
was	O
the	O
best	O
metal	O
ion	O
for	O
stability	O
.	O

The	O
abnormalities	O
of	O
serum	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

The	O
average	O
levels	O
of	O
ALT	B-FUNC
of	O
the	O
patients	O
were	O
56	O
.	O
07	O
+/-	O
51	O
.	O
57	O
U	O
/	O
L	O
,	O
86	O
.	O
46	O
+/-	O
69	O
.	O
93	O
U	O
/	O
L	O
,	O
106	O
.	O
69	O
+/-	O
102	O
.	O
50	O
U	O
/	O
L	O
and	O
111	O
.	O
32	O
+/-	O
160	O
.	O
24	O
U	O
/	O
L	O
,	O
and	O
the	O
average	O
levels	O
of	O
serum	O
albumin	O
were	O
37	O
.	O
25	O
+/-	O
5	O
.	O
37	O
g	O
/	O
L	O
,	O
35	O
.	O
82	O
+/-	O
4	O
.	O
74	O
g	O
/	O
L	O
,	O
34	O
.	O
49	O
+/-	O
5	O
.	O
04	O
g	O
/	O
L	O
,	O
and	O
34	O
.	O
26	O
+/-	O
4	O
.	O
70	O
g	O
/	O
L	O
,	O
at	O
the	O
day	O
of	O
admission	O
,	O
the	O
first	O
week	O
,	O
second	O
week	O
,	O
and	O
third	O
week	O
after	O
hospitalization	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
abnormalities	O
of	O
serum	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

LPS	B-FUNC
binding	I-FUNC
to	O
its	O
receptors	O
is	O
the	O
crucial	O
step	O
in	O
the	O
causation	O
of	O
these	O
multistep	O
events	O
.	O

LPS	B-FUNC
binding	I-FUNC
and	O
signaling	O
involves	O
CD14	O
and	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
).	O

A	O
TLR4	O
blocking	O
antibody	B-FUNC
abolished	O
microvascular	O
leakage	O
,	O
neutrophil	O
accumulation	O
,	O
cytokine	O
responses	O
,	O
and	O
lung	O
pathology	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
but	O
only	O
attenuated	O
the	O
responses	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
.	O

Due	O
to	O
the	O
tested	O
safety	O
and	O
protective	O
effects	O
of	O
the	O
convalescent	O
-	O
phase	O
serological	O
antibodies	O
,	O
identification	O
of	O
their	O
complementary	O
antigens	O
may	O
enable	O
the	O
design	O
of	O
an	O
epitope	O
-	O
based	O
vaccine	O
to	O
prevent	O
potential	O
antibody	B-FUNC
-	O
mediated	O
immunopathology	O
.	O

Multistep	O
growth	O
kinetics	O
were	O
identical	O
in	O
Vero	O
E6	O
and	O
MA104	O
cells	O
,	O
with	O
maximum	O
titer	O
reached	O
24	O
h	O
postinoculation	O
(	O
hpi	B-FUNC
).	O

Virus	O
titer	O
was	O
maximal	O
96	O
hpi	B-FUNC
in	O
CaCo	O
-	O
2	O
cells	O
,	O
and	O
virus	O
was	O
continually	O
produced	O
from	O
infected	O
CaCo	O
-	O
2	O
cells	O
for	O
at	O
least	O
6	O
weeks	O
after	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
early	O
diagnostic	O
reagents	O
,	O
effective	O
vaccines	O
,	O
and	O
even	O
drugs	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
human	O
single	O
fold	O
single	O
-	O
chain	O
antibody	B-FUNC
fragments	O
,	O
(	O
scFv	O
)	O
libraries	O
I	O
+	O
J	O
(	O
Tomlinson	O
I	O
+	O
J	O
)	O
were	O
used	O
to	O
identify	O
novel	O
scFvs	O
,	O
which	O
can	O
specifically	O
bind	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
two	O
scFvs	O
(	O
B5	O
and	O
B9	O
)	O
exhibited	O
higher	O
binding	B-FUNC
specificity	O
to	O
SARS	O
-	O
CoV	O
with	O
the	O
OD	O
(	O
450	O
)	O
value	O
0	O
.	O
608	O
and	O
0	O
.	O
545	O
,	O
respectively	O
,	O
and	O
their	O
coding	O
sequences	O
shared	O
the	O
identical	O
sequence	O
composed	O
of	O
V	O
(	O
H	O
)	O
gene	O
(	O
351bp	O
)	O
and	O
V	O
(	O
L	O
)	O
gene	O
(	O
327bp	O
),	O
so	O
the	O
two	O
scFvs	O
were	O
uniformly	O
named	O
as	O
SA59B	O
and	O
chosen	O
for	O
further	O
analysis	O
.	O

The	O
soluble	O
30kDa	O
SA59B	O
scFv	O
-	O
antibody	B-FUNC
was	O
verified	O
in	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
.	O

The	O
purified	O
SA59B	O
scFv	O
-	O
antibody	B-FUNC
was	O
labeled	O
with	O
HRP	O
by	O
the	O
glutaraldehyde	O
method	O
,	O
and	O
the	O
concentration	O
of	O
HRP	O
and	O
SA59B	O
scFv	O
-	O
antibody	B-FUNC
in	O
the	O
SA59B	O
-	O
HRP	O
solution	O
reached	O
2	O
.	O
4	O
and	O
2	O
.	O
28mg	O
/	O
ml	O
,	O
respectively	O
.	O

In	O
this	O
review	O
,	O
several	O
antiviral	O
substances	O
shown	O
to	O
be	O
active	O
in	O
vitro	O
will	O
be	O
introduced	O
and	O
summarized	O
in	O
the	O
order	O
of	O
the	O
virus	O
'	O
replication	O
steps	O
;	O
that	O
is	O
,	O
binding	B-FUNC
to	O
cellular	O
receptor	O
,	O
fusion	O
and	O
entry	O
to	O
the	O
cells	O
,	O
viral	O
RNA	O
replication	O
and	O
transcription	O
,	O
protein	O
processing	O
and	O
so	O
on	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
several	O
synthetic	O
peptides	O
,	O
including	O
those	O
that	O
mimic	O
the	O
S	O
-	O
binding	B-FUNC
domain	O
,	O
the	O
HR2	O
fusion	O
protein	O
and	O
SARS	O
proteinase	B-FUNC
substrates	O
,	O
will	O
be	O
discussed	O
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
antibody	B-FUNC
,	O
in	O
the	O
absence	O
of	O
T	O
cells	O
,	O
mediates	O
demyelination	O
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
not	O
only	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
,	O
but	O
also	O
a	O
major	O
antigenic	O
determinant	O
capable	O
of	O
inducing	O
protective	O
immunity	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
S	O
protein	O
is	O
an	O
important	O
immunogenic	O
site	O
in	O
patients	O
with	O
SARS	O
and	O
rabbits	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Serum	O
samples	O
from	O
convalescent	O
SARS	O
patients	O
and	O
immunized	O
rabbits	O
had	O
potent	O
neutralizing	O
activities	O
against	O
infection	O
by	O
pseudovirus	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Two	O
monoclonal	O
antibodies	O
(	O
1A5	O
and	O
2C5	O
)	O
targeting	O
at	O
the	O
RBD	O
of	O
S	O
protein	O
were	O
isolated	O
from	O
mice	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Both	O
1A5	O
and	O
2C5	O
possessed	O
potent	O
neutralizing	O
activities	O
,	O
although	O
they	O
directed	O
against	O
distinct	O
conformation	O
-	O
dependant	O
epitopes	O
as	O
shown	O
by	O
ELISA	O
and	O
binding	B-FUNC
competition	O
assay	O
.	O

We	O
identified	O
five	O
residues	O
in	O
S	O
(	O
S33	O
,	O
L79	O
,	O
T82	O
,	O
Y162	O
and	O
K183	O
)	O
that	O
are	O
conserved	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MHV	O
strains	O
,	O
but	O
not	O
in	O
related	O
coronaviruses	O
.	O

In	O
order	O
to	O
understand	O
the	O
efficacy	O
and	O
safety	O
of	O
this	O
approach	O
,	O
it	O
is	O
important	O
to	O
know	O
the	O
antibody	B-FUNC
specificities	O
generated	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
In	O
the	O
current	O
study	O
,	O
a	O
panel	O
of	O
twelve	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
was	O
established	O
by	O
immunizing	O
Balb	O
/	O
c	O
mice	O
with	O
the	O
inactivated	O
BJ01	O
strain	O
of	O
SARS	O
-	O
CoV	O
isolated	O
from	O
the	O
lung	O
tissue	O
of	O
a	O
SARS	O
-	O
infected	O
Chinese	O
patient	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
)	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
structural	O
based	O
drug	O
design	O
against	O
SARS	O
.	O

These	O
results	O
offer	O
helpful	O
information	O
for	O
the	O
research	O
on	O
the	O
mechanism	O
of	O
substrate	O
recognition	O
of	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
detection	O
with	O
a	O
recombinant	O
COOH	O
portion	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
N13	O
(	O
amino	O
acids	O
221	O
to	O
422	O
),	O
was	O
demonstrated	O
to	O
be	O
more	O
specific	O
and	O
sensitive	O
than	O
that	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
,	O
and	O
an	O
N13	O
-	O
based	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
providing	O
a	O
convenient	O
and	O
specific	O
test	O
for	O
serodiagnosis	O
and	O
epidemiological	O
study	O
of	O
SARS	O
was	O
developed	O
.	O

Rabies	O
immunoglobulin	B-FUNC
,	O
injected	O
into	O
and	O
around	O
bite	O
wounds	O
,	O
provides	O
added	O
safety	O
for	O
the	O
severely	O
exposed	O
.	O

The	O
high	O
cost	O
of	O
rabies	O
immunoglobulin	B-FUNC
and	O
tissue	O
culture	O
vaccines	O
are	O
remaining	O
barriers	O
,	O
but	O
new	O
manufacturers	O
and	O
the	O
use	O
of	O
intradermal	O
vaccination	O
schedules	O
can	O
reduce	O
costs	O
.	O

TITLE	O
:	O
Longitudinally	O
profiling	O
neutralizing	O
antibody	B-FUNC
response	O
to	O
SARS	O
coronavirus	O
with	O
pseudotypes	O
.	O

Neutralization	O
titers	O
measured	O
by	O
this	O
assay	O
are	O
highly	O
correlated	O
to	O
those	O
measured	O
by	O
an	O
assay	O
using	O
replication	O
-	O
competent	O
SARS	O
-	O
CoV	O
.	O
No	O
cross	O
-	O
neutralization	O
occurred	O
with	O
human	O
sera	B-FUNC
known	O
to	O
contain	O
antibodies	O
to	O
coronavirus	O
strains	O
OC43	O
and	O
229E	O
.	O

Taken	O
together	O
with	O
other	O
data	O
,	O
we	O
suggest	O
that	O
N	O
protein	O
is	O
a	O
two	O
-	O
domain	O
protein	O
,	O
with	O
the	O
N	O
-	O
terminal	O
aa	O
50	O
-	O
150	O
as	O
the	O
RNA	O
-	O
binding	B-FUNC
domain	O
and	O
the	O
C	O
-	O
terminal	O
aa	O
169	O
-	O
422	O
as	O
the	O
dimerization	O
domain	O
.	O

Polyclonal	O
antibodies	O
against	O
the	O
SARS	O
N	O
protein	O
have	O
been	O
produced	O
and	O
the	O
strong	O
binding	B-FUNC
sites	O
of	O
the	O
anti	O
-	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
antibodies	O
produced	O
were	O
mapped	O
to	O
aa	O
1	O
-	O
20	O
,	O
aa	O
150	O
-	O
170	O
and	O
aa	O
390	O
-	O
410	O
.	O

These	O
sites	O
are	O
generally	O
consistent	O
with	O
those	O
mapped	O
by	O
sera	B-FUNC
obtained	O
from	O
SARS	O
patients	O
.	O

The	O
SARS	O
anti	O
-	O
NP	O
antibody	B-FUNC
was	O
able	O
to	O
clearly	O
detect	O
SARS	O
virus	O
grown	O
in	O
Vero	O
E6	O
cells	O
and	O
did	O
not	O
cross	O
-	O
react	O
with	O
the	O
NP	O
from	O
the	O
human	O
coronavirus	O
229E	O
.	O

We	O
have	O
predicted	O
several	O
antigenic	O
sites	O
(	O
15	O
-	O
20	O
amino	O
acids	O
)	O
of	O
S	O
,	O
M	O
and	O
N	O
proteins	O
and	O
produced	O
antibodies	O
against	O
those	O
peptides	O
,	O
some	O
of	O
which	O
could	O
be	O
recognized	O
by	O
sera	B-FUNC
obtained	O
from	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
oxymatrine	O
is	O
associated	O
with	O
inhibition	O
of	O
phosphorylated	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Furthermore	O
,	O
pretreatment	O
with	O
oxymatrine	O
significantly	O
alleviated	O
oleic	O
acid	O
-	O
induced	O
lung	O
injury	O
accompanied	O
by	O
reduction	O
of	O
lung	O
index	O
and	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
decreases	O
in	O
serum	O
TNF	O
-	O
alpha	O
level	O
and	O
inhibition	O
of	O
phosphorylated	O
p38	B-FUNC
MAPK	B-FUNC
.	O

These	O
findings	O
suggest	O
that	O
oxymatrine	O
has	O
a	O
beneficial	O
effect	O
on	O
acute	O
lung	O
injury	O
induced	O
by	O
oleic	O
acid	O
in	O
mice	O
and	O
may	O
inhibit	O
the	O
production	O
of	O
proinflammatory	O
cytokine	O
,	O
TNF	O
-	O
alpha	O
,	O
by	O
means	O
of	O
the	O
inhibition	O
of	O
p38	B-FUNC
MAPK	B-FUNC
.	O

SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
was	O
demonstrated	O
using	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
4	O
patients	O
.	O

Virally	O
induced	O
increases	O
in	O
interleukin	O
-	O
6	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
mRNA	O
and	O
protein	O
expression	O
correlated	O
with	O
the	O
genomic	O
induction	O
of	O
acute	O
-	O
phase	O
proteins	O
.	O

Among	O
the	O
specific	O
contact	O
history	O
or	O
infectivity	O
cases	O
,	O
the	O
antibody	B-FUNC
positive	O
rate	O
for	O
the	O
young	O
and	O
the	O
old	O
was	O
lower	O
than	O
that	O
for	O
the	O
adult	O
.	O

And	O
the	O
antibody	B-FUNC
detective	O
rate	O
was	O
decreased	O
by	O
the	O
month	O
.	O

They	O
were	O
fabricated	O
on	O
a	O
microarray	O
and	O
tested	O
with	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

An	O
indirect	O
antibody	B-FUNC
ELISA	O
method	O
was	O
developed	O
and	O
clinical	O
positive	O
and	O
negative	O
sera	B-FUNC
for	O
their	O
antibodies	O
against	O
GST	O
-	O
N2	O
fusion	O
protein	O
were	O
assayed	O
.	O

311	O
out	O
of	O
the	O
442	O
sera	B-FUNC
from	O
clinical	O
SARS	O
inpatients	O
,	O
as	O
well	O
as	O
229	O
out	O
of	O
302	O
sera	B-FUNC
from	O
convalescent	O
patients	O
gave	O
positive	O
reactivities	O
;	O
positive	O
rates	O
were	O
70	O
.	O
4	O
%	O
and	O
75	O
.	O
8	O
%	O
respectively	O
.	O

Sera	B-FUNC
from	O
a	O
total	O
of	O
2726	O
non	O
-	O
SARS	O
patients	O
and	O
healthy	O
individuals	O
were	O
tested	O
and	O
the	O
false	O
positive	O
rate	O
was	O
only	O
0	O
.	O
07	O
%.	O

Reported	O
data	O
showed	O
that	O
this	O
was	O
a	O
relatively	O
high	O
degree	O
of	O
sensitivity	O
and	O
specificity	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
testing	O
.	O

Serum	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
malondialdehyde	O
(	O
MDA	O
)	O
levels	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
)	O
and	O
lung	O
tissue	O
MPO	B-FUNC
activity	O
,	O
MDA	O
levels	O
and	O
Na	O
+-	O
K	O
+	O
ATPase	B-FUNC
activity	I-FUNC
were	O
measured	O
and	O
light	O
microscopic	O
analyses	O
of	O
lung	O
specimens	O
were	O
performed	O
.	O

The	O
MPO	B-FUNC
activities	O
in	O
serum	O
and	O
lung	O
homogenates	O
were	O
found	O
to	O
be	O
significantly	O
decreased	O
in	O
ILO	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

Serum	O
TAC	O
and	O
lung	O
tissue	O
Na	O
+-	O
K	O
+	O
ATPase	B-FUNC
activity	I-FUNC
levels	O
were	O
found	O
to	O
be	O
increased	O
in	O
ILO	O
group	O
compared	O
to	O
IR	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Neutralizing	O
antibody	B-FUNC
and	O
protective	O
immunity	O
to	O
SARS	O
coronavirus	O
infection	O
of	O
mice	O
induced	O
by	O
a	O
soluble	O
recombinant	O
polypeptide	O
containing	O
an	O
N	O
-	O
terminal	O
segment	O
of	O
the	O
spike	O
glycoprotein	O
.	O

Mice	O
received	O
the	O
affinity	O
-	O
purified	O
protein	O
with	O
either	O
a	O
saponin	O
(	O
QS21	O
)	O
or	O
a	O
Ribi	O
(	O
MPL	O
+	O
TDM	O
)	O
adjuvant	O
subcutaneously	O
and	O
were	O
challenged	O
intranasally	O
with	O
SARS	O
-	O
CoV	O
.	O
Both	O
regimens	O
induced	O
binding	B-FUNC
and	O
neutralizing	O
antibodies	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
intranasal	O
infection	O
.	O

However	O
,	O
the	O
best	O
results	O
were	O
obtained	O
with	O
QS21	O
and	O
protein	O
,	O
which	O
provided	O
the	O
highest	O
antibody	B-FUNC
as	O
well	O
as	O
complete	O
protection	O
of	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
,	O
required	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
,	O
is	O
incorporated	O
into	O
the	O
assembling	O
virion	O
by	O
interactions	O
with	O
the	O
viral	O
membrane	O
(	O
M	O
)	O
protein	O
.	O

ABSTRACT	O
:	O
Entry	O
of	O
SARS	O
-	O
CoV	O
into	O
a	O
target	O
cell	O
is	O
initiated	O
by	O
binding	B-FUNC
of	O
the	O
S1	O
domain	O
of	O
spike	O
protein	O
to	O
a	O
receptor	O
,	O
followed	O
by	O
conformational	O
changes	O
of	O
the	O
spike	O
protein	O
S2	O
domain	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
six	O
-	O
helix	O
bundle	O
by	O
the	O
heptad	O
-	O
repeat	O
(	O
HR1	O
and	O
HR2	O
)	O
regions	O
.	O

An	O
indirect	O
antigen	O
-	O
capture	O
ELISA	O
and	O
an	O
antibody	B-FUNC
-	O
detection	O
ELISA	O
as	O
well	O
as	O
geometric	O
mean	O
BCoV	O
antibody	B-FUNC
titres	O
were	O
used	O
to	O
detect	O
BoCV	O
shed	O
in	O
the	O
faeces	O
and	O
in	O
the	O
nasal	O
secretions	O
,	O
respectively	O
.	O

BCoV	O
antibody	B-FUNC
titre	O
in	O
50	O
%	O
of	O
all	O
cattle	O
was	O
<	O
or	O
=	O
100	O
as	O
detected	O
by	O
ELISA	O
while	O
27	O
.	O
1	O
%	O
of	O
the	O
cattle	O
had	O
high	O
titres	O
ranging	O
between	O
1	O
,	O
600	O
and	O
25	O
,	O
600	O
.	O

Results	O
showed	O
that	O
interleukin	O
(	O
IL	O
)-	O
10	O
and	O
transforming	B-FUNC
growth	I-FUNC
factor	I-FUNC
beta	I-FUNC
(	O
TGF	O
-	O
beta	O
)	O
were	O
continuously	O
up	O
-	O
regulated	O
during	O
the	O
entirety	O
of	O
SARS	O
.	O

Regulated	O
on	O
activation	O
normally	O
T	O
cell	O
-	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
)	O
levels	O
were	O
decreased	O
,	O
while	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
)	O
was	O
elevated	O
in	O
acute	O
patients	O
.	O

Prolonged	O
overproduction	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TGF	O
-	O
beta	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
disease	O
.	O

TITLE	O
:	O
Evaluation	O
by	O
indirect	O
immunofluorescent	O
assay	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
of	O
the	O
dynamic	O
changes	O
of	O
serum	O
antibody	B-FUNC
responses	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

To	O
study	O
the	O
humoral	O
immune	O
responses	O
to	O
SARS	O
-	O
CoV	O
,	O
the	O
authors	O
evaluated	O
IgG	O
and	O
IgM	O
specific	O
antibodies	O
in	O
patients	O
'	O
sera	B-FUNC
.	O

The	O
dimeric	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
C145A	O
mutant	O
protease	O
shows	O
that	O
the	O
active	O
site	O
of	O
one	O
protomer	O
binds	B-FUNC
with	O
the	O
C	O
-	O
terminal	O
six	O
amino	O
acids	O
of	O
the	O
protomer	O
from	O
another	O
asymmetric	O
unit	O
,	O
mimicking	O
the	O
product	O
-	O
bound	O
form	O
and	O
suggesting	O
a	O
possible	O
mechanism	O
for	O
maturation	O
.	O

The	O
P1	O
pocket	O
of	O
the	O
active	O
site	O
binds	B-FUNC
the	O
Gln	O
side	O
chain	O
specifically	O
,	O
and	O
the	O
P2	O
and	O
P4	O
sites	O
are	O
clustered	O
together	O
to	O
accommodate	O
large	O
hydrophobic	O
side	O
chains	O
.	O

Here	O
we	O
identify	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)-	O
protein	O
-	O
binding	B-FUNC
site	O
on	O
ACE2	O
.	O

The	O
lower	O
affinity	O
of	O
these	O
S	O
proteins	O
could	O
be	O
complemented	O
by	O
altering	O
specific	O
residues	O
within	O
the	O
S	O
-	O
protein	O
-	O
binding	B-FUNC
site	O
of	O
human	O
ACE2	O
to	O
those	O
of	O
civet	O
ACE2	O
,	O
or	O
by	O
altering	O
S	O
-	O
protein	O
residues	O
479	O
and	O
487	O
to	O
residues	O
conserved	O
during	O
the	O
2002	O
-	O
2003	O
outbreak	O
.	O

These	O
data	O
suggest	O
that	O
in	O
contrast	O
to	O
the	O
results	O
seen	O
with	O
MMPs	O
,	O
inhibition	O
of	O
protease	B-FUNC
activity	I-FUNC
via	O
TIMP	O
-	O
1	O
expression	O
correlates	O
with	O
the	O
differential	O
tissue	O
distribution	O
of	O
T	O
-	O
cell	O
subsets	O
during	O
acute	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

Bananin	O
,	O
iodobananin	O
,	O
vanillinbananin	O
,	O
and	O
eubananin	O
were	O
effective	O
inhibitors	O
of	O
the	O
ATPase	B-FUNC
activity	I-FUNC
of	O
the	O
SCV	O
helicase	O
with	O
IC50	O
values	O
in	O
the	O
range	O
0	O
.	O
5	O
-	O
3	O
microM	O
.	O
A	O
similar	O
trend	O
,	O
though	O
at	O
slightly	O
higher	O
inhibitor	O
concentrations	O
,	O
was	O
observed	O
for	O
inhibition	O
of	O
the	O
helicase	O
activities	O
,	O
using	O
a	O
FRET	O
-	O
based	O
fluorescent	O
assay	O
.	O

Interaction	O
with	O
alkaline	O
phosphatase	B-FUNC
-	O
labelled	O
streptavidin	O
permits	O
amplified	O
indirect	O
electrochemical	O
detection	O
.	O

To	O
determine	O
the	O
in	O
vivo	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
during	O
CNS	O
infection	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
signaling	O
was	O
inhibited	O
via	O
administration	O
of	O
a	O
neutralizing	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
specific	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
).	O

In	O
contrast	O
to	O
depletion	O
of	O
CD4	O
(+)	O
T	O
cells	O
,	O
inhibition	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
signaling	O
did	O
not	O
influence	O
CD8	O
(+)	O
T	O
cell	O
infiltration	O
,	O
effector	O
cell	O
function	O
or	O
survival	O
within	O
the	O
CNS	O
.	O

These	O
data	O
suggest	O
that	O
the	O
cellular	O
immune	O
response	O
to	O
acute	O
neurotropic	O
JHMV	O
infection	O
requires	O
a	O
distinct	O
CD4	O
(+)	O
T	O
cell	O
component	O
,	O
but	O
is	O
independent	O
of	O
a	O
requirement	O
for	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
for	O
induction	O
,	O
activation	O
,	O
recruitment	O
,	O
and	O
/	O
or	O
maintenance	O
of	O
CD8	O
(+)	O
T	O
cells	O
within	O
the	O
CNS	O
during	O
acute	O
infection	O
.	O

TITLE	O
:	O
Extending	O
the	O
limits	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
lung	O
rest	B-FUNC
for	O
a	O
child	O
with	O
non	O
-	O
specific	O
interstitial	O
pneumonia	O
.	O

On	O
day	O
20	O
after	O
admission	O
the	O
patient	O
was	O
placed	O
on	O
veno	O
-	O
venous	O
ECMO	O
for	O
lung	O
rest	B-FUNC
while	O
awaiting	O
a	O
response	O
to	O
continued	O
medical	O
treatment	O
.	O

Those	O
with	O
elevated	O
ALT	B-FUNC
were	O
compared	O
with	O
those	O
with	O
normal	O
liver	O
functions	O
for	O
clinical	O
outcome	O
.	O

Seventy	O
(	O
24	O
%)	O
patients	O
had	O
elevated	O
serum	O
ALT	B-FUNC
on	O
admission	O
and	O
204	O
(	O
69	O
%)	O
patients	O
had	O
elevated	O
ALT	B-FUNC
during	O
the	O
subsequent	O
course	O
of	O
illness	O
.	O

Using	O
peak	O
ALT	B-FUNC
>	O
5XULN	O
as	O
a	O
cut	O
-	O
off	O
and	O
after	O
adjusting	O
for	O
potential	O
confounding	O
factors	O
,	O
the	O
odds	O
ratio	O
of	O
peak	O
ALT	B-FUNC
>	O
5X	O
ULN	O
for	O
oxygen	O
desaturation	O
was	O
3	O
.	O
24	O
(	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
8	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
018	O
),	O
ICU	O
care	O
was	O
3	O
.	O
70	O
(	O
95	O
%	O
CI	O
1	O
.	O
38	O
-	O
9	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
mechanical	O
ventilation	O
was	O
6	O
.	O
64	O
(	O
95	O
%	O
CI	O
2	O
.	O
22	O
-	O
19	O
.	O
81	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
death	O
was	O
7	O
.	O
34	O
(	O
95	O
%	O
CI	O
2	O
.	O
28	O
-	O
24	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Ninety	O
-	O
three	O
percent	O
of	O
the	O
survived	O
patients	O
had	O
ALT	B-FUNC
levels	O
normalized	O
or	O
were	O
on	O
the	O
improving	O
trend	O
during	O
follow	O
-	O
up	O
.	O

SARS	O
has	O
been	O
defined	O
using	O
clinical	O
and	O
epidemiological	O
criteria	O
and	O
cases	O
are	O
considered	O
laboratory	O
-	O
confirmed	O
if	O
SARS	O
coronavirus	O
is	O
isolated	O
,	O
if	O
antibody	B-FUNC
to	O
SARS	O
coronavirus	O
is	O
detected	O
,	O
or	O
a	O
polymerase	O
chain	O
reaction	O
test	O
by	O
appropriate	O
criteria	O
is	O
positive	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
contains	O
multiple	O
conformation	O
-	O
dependent	O
epitopes	O
that	O
induce	O
highly	O
potent	O
neutralizing	O
antibodies	O
.	O

Six	O
groups	O
of	O
conformation	O
-	O
dependent	O
epitopes	O
,	O
designated	O
as	O
Conf	O
I	O
-	O
VI	O
,	O
and	O
two	O
adjacent	O
linear	O
epitopes	O
were	O
identified	O
by	O
ELISA	O
and	O
binding	B-FUNC
competition	O
assays	O
.	O

We	O
constructed	O
primers	O
for	O
inefficient	O
reverse	O
transcription	O
of	O
ribosomal	O
sequences	O
based	O
on	O
the	O
distribution	O
analysis	O
of	O
hexanucleotide	O
patterns	O
in	O
ribosomal	B-FUNC
RNA	I-FUNC
.	O

The	O
analysis	O
revealed	O
that	O
distributions	O
of	O
hexanucleotide	O
patterns	O
in	O
ribosomal	B-FUNC
RNA	I-FUNC
and	O
virus	O
genome	O
were	O
different	O
.	O

Promising	O
treatments	O
have	O
been	O
identified	O
for	O
patients	O
with	O
progressive	O
pneumonia	O
due	O
to	O
an	O
overwhelming	O
host	O
immune	O
response	O
including	O
activated	O
protein	O
C	O
and	O
intravenous	O
immunoglobulin	B-FUNC
.	O

Occasional	O
intra	O
-	O
alveolar	O
macrophages	O
were	O
also	O
weakly	O
reactive	O
to	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
.	O

Sequence	O
analysis	O
of	O
the	O
leader	O
-	O
body	O
fusion	O
sites	O
of	O
each	O
sgRNA	O
showed	O
that	O
the	O
junction	O
sequences	O
and	O
the	O
corresponding	O
transcription	O
-	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
are	O
unique	O
for	O
each	O
species	O
of	O
sgRNA	O
and	O
are	O
consistent	O
after	O
virus	O
passages	O
.	O

The	O
results	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
1	O
-	O
3	O
amino	O
acid	O
-	O
truncated	O
protease	O
maintains	O
76	O
%	O
of	O
enzyme	B-FUNC
activity	I-FUNC
and	O
that	O
the	O
major	O
form	O
is	O
a	O
dimer	O
,	O
as	O
in	O
the	O
wild	O
type	O
.	O

However	O
,	O
the	O
amino	O
acids	O
1	O
-	O
4	O
-	O
truncated	O
protease	O
showed	O
the	O
major	O
form	O
to	O
be	O
a	O
monomer	O
and	O
had	O
little	O
enzyme	B-FUNC
activity	I-FUNC
.	O

We	O
concluded	O
that	O
both	O
the	O
C	O
-	O
and	O
the	O
N	O
-	O
terminal	O
regions	O
influence	O
the	O
dimerization	O
and	O
enzyme	B-FUNC
activity	I-FUNC
of	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
.	O

For	O
this	O
approach	O
,	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
or	O
envelope	O
spike	O
protein	O
(	O
S	O
)	O
genes	O
were	O
cloned	O
between	O
the	O
RV	O
glycoprotein	O
G	O
and	O
polymerase	B-FUNC
L	I-FUNC
genes	O
.	O

Six	O
reference	O
sera	B-FUNC
from	O
SARS	O
patients	O
were	O
used	O
to	O
detect	O
virus	O
-	O
specific	O
IgG	O
in	O
an	O
ELISA	O
using	O
each	O
recombinant	O
protein	O
as	O
coating	O
antigen	O
.	O

Titers	O
of	O
specific	O
IgG	O
antibodies	O
in	O
three	O
test	O
groups	O
all	O
peaked	O
in	O
the	O
sixth	O
week	O
after	O
first	O
vaccination	O
,	O
but	O
significant	O
differences	O
existed	O
in	O
the	O
kinetics	O
of	O
specific	O
IgG	O
antibody	B-FUNC
levels	O
.	O

Using	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
against	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
screened	O
by	O
SARS	O
-	O
CoV	O
N	O
protein	O
and	O
matching	O
experiment	O
,	O
a	O
method	O
for	O
quantitative	O
detection	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
by	O
TRFIA	O
was	O
established	O
on	O
the	O
basis	O
of	O
double	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
evaluated	O
against	O
the	O
ELISA	O
kit	B-FUNC
.	O

TITLE	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
),	O
a	O
key	O
molecule	O
in	O
innate	O
immunity	O
,	O
functions	O
as	O
an	O
ante	O
-	O
antibody	B-FUNC
before	O
the	O
specific	O
antibody	B-FUNC
response	O
.	O

MBL	O
could	O
bind	B-FUNC
SARS	O
-	O
CoV	O
in	O
a	O
dose	O
-	O
and	O
calcium	O
-	O
dependent	O
and	O
mannan	O
-	O
inhibitable	O
fashion	O
in	O
vitro	O
,	O
suggesting	O
that	O
binding	B-FUNC
is	O
through	O
the	O
carbohydrate	O
recognition	O
domains	O
of	O
MBL	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
feasibility	O
of	O
using	O
Flinders	O
Technology	O
Associates	O
(	O
FTA	O
)	O
filter	O
cards	O
for	O
the	O
storage	O
of	O
allantoic	O
fluid	O
containing	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
such	O
as	O
Arkansas	O
-	O
DPI	O
,	O
Connecticut	O
,	O
and	O
Massachusetts	O
,	O
and	O
for	O
their	O
identification	O
by	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
characterization	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
or	O
nucleotide	O
sequencing	O
.	O

RT	O
-	O
PCR	O
of	O
the	O
S1	O
gene	O
showed	O
that	O
viral	O
RNA	O
in	O
allantoic	O
fluid	O
remained	O
stable	O
after	O
storage	O
on	O
FTA	O
filter	O
cards	O
and	O
that	O
the	O
stability	O
was	O
time	O
and	O
temperature	O
sensitive	O
for	O
the	O
large	O
(	O
1700	O
base	B-FUNC
pair	I-FUNC
[	O
bp	O
])	O
but	O
not	O
the	O
small	O
(	O
383	O
bp	O
)	O
PCR	O
products	O
.	O

ABSTRACT	O
:	O
The	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
a	O
potential	O
target	O
for	O
anti	O
-	O
SARS	O
drugs	O
.	O

TITLE	O
:	O
Investigation	O
into	O
the	O
causes	O
of	O
canine	O
infectious	O
respiratory	O
disease	O
:	O
antibody	B-FUNC
responses	O
to	O
canine	O
respiratory	O
coronavirus	O
and	O
canine	O
herpesvirus	O
in	O
two	O
kennelled	O
dog	O
populations	O
.	O

In	O
that	O
kennel	O
antibody	B-FUNC
responses	O
to	O
CRCoV	O
indicated	O
a	O
seasonal	O
occurrence	O
of	O
the	O
virus	O
,	O
which	O
coincided	O
with	O
two	O
outbreaks	O
of	O
respiratory	O
disease	O
.	O

CHV	O
antibody	B-FUNC
responses	O
were	O
detected	O
throughout	O
the	O
year	O
.	O

Next	O
,	O
we	O
investigated	O
whether	O
FIPV	O
and	O
fMHV	O
could	O
be	O
targeted	O
to	O
human	O
cancer	O
cells	O
by	O
constructing	O
a	O
bispecific	O
single	O
-	O
chain	O
antibody	B-FUNC
directed	O
on	O
the	O
one	O
hand	O
against	O
the	O
feline	O
coronavirus	O
spike	O
protein	O
--	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
subsequent	O
cell	O
entry	O
through	O
virus	O
-	O
cell	O
membrane	O
fusion	O
--	O
and	O
on	O
the	O
other	O
hand	O
against	O
the	O
human	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
).	O

The	O
targeting	O
antibody	B-FUNC
mediated	O
specific	O
infection	O
of	O
EGFR	B-FUNC
-	O
expressing	O
human	O
cancer	O
cells	O
by	O
both	O
coronaviruses	O
.	O

Real	O
-	O
time	O
qRT	O
-	O
PCR	O
was	O
used	O
to	O
confirm	O
the	O
regulated	O
expression	O
of	O
genes	O
related	O
to	O
several	O
functional	O
classes	O
including	O
kinases	O
,	O
interferon	O
induced	O
genes	O
,	O
chemokines	O
and	O
adhesion	O
molecules	O
,	O
vesicular	O
trafficking	O
and	O
fusion	O
protein	O
genes	O
,	O
extracellular	O
matrix	O
protein	O
genes	O
,	O
cell	O
cycle	O
,	O
metabolism	O
,	O
cell	O
physiology	O
and	O
development	O
,	O
translation	O
,	O
RNA	B-FUNC
binding	I-FUNC
,	O
lysosomal	O
,	O
protein	O
degradation	O
and	O
ubiquitination	O
related	O
genes	O
.	O

All	O
the	O
patients	O
in	O
whom	O
diagnosis	O
was	O
confirmed	O
by	O
ELISA	O
IgM	O
antibody	B-FUNC
testing	O
underwent	O
thorough	O
clinical	O
examination	O
and	O
necessary	O
biochemical	O
investigations	O
.	O

Trachea	O
,	O
lung	O
,	O
kidney	O
and	O
rectum	O
were	O
collected	O
for	O
virus	O
isolation	O
by	O
tracheal	O
organ	O
culture	O
(	O
TOC	O
)	O
or	O
embryonated	O
chicken	O
eggs	O
(	O
ECE	O
),	O
and	O
detection	O
by	O
nested	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
protein	O
is	O
posttranslationally	O
modified	O
by	O
covalent	O
attachment	O
to	O
the	O
small	O
ubiquitin	B-FUNC
-	O
like	O
modifier	O
.	O

APHS	O
did	O
not	O
affect	O
the	O
replication	O
of	O
feline	O
immunodeficiency	O
virus	O
,	O
HIV	O
-	O
2	O
and	O
a	O
HIV	O
-	O
1	O
strain	O
resistant	O
to	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTI	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
human	O
monoclonal	O
antibody	B-FUNC
80R	O
for	O
immunoprophylaxis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
by	O
an	O
animal	O
study	O
,	O
epitope	O
mapping	O
,	O
and	O
analysis	O
of	O
spike	O
variants	O
.	O

The	O
essential	O
core	O
region	O
of	O
S	O
protein	O
required	O
for	O
80R	O
binding	B-FUNC
was	O
identified	O
as	O
a	O
conformationally	O
sensitive	O
fragment	O
(	O
residues	O
324	O
to	O
503	O
)	O
that	O
overlaps	O
the	O
receptor	O
ACE2	O
-	O
binding	B-FUNC
domain	O
.	O

Amino	O
acids	O
critical	O
for	O
80R	O
binding	B-FUNC
were	O
identified	O
.	O

In	O
addition	O
,	O
the	O
effects	O
of	O
various	O
80R	O
-	O
binding	B-FUNC
domain	O
amino	O
acid	O
substitutions	O
which	O
occur	O
in	O
SARS	O
-	O
like	O
-	O
CoV	O
from	O
civet	O
cats	O
,	O
and	O
which	O
evolved	O
during	O
the	O
2002	O
/	O
2003	O
outbreak	O
and	O
in	O
a	O
2003	O
/	O
2004	O
Guangdong	O
index	O
patient	O
,	O
were	O
analyzed	O
.	O

Our	O
study	O
also	O
cautions	O
that	O
for	O
any	O
prophylaxis	O
strategy	O
based	O
on	O
neutralizing	O
antibody	B-FUNC
responses	O
,	O
whether	O
by	O
passive	O
or	O
active	O
immunization	O
,	O
a	O
genotyping	O
monitor	O
will	O
be	O
necessary	O
for	O
effective	O
use	O
.	O

Fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
showed	O
that	O
about	O
80	O
%	O
of	O
the	O
brain	O
cells	O
stained	O
with	O
anti	O
-	O
MHVR	O
antibody	B-FUNC
(	O
CC1	O
)	O
were	O
also	O
positive	O
for	O
GS	O
-	O
lectin	O
.	O

The	O
SARS	O
-	O
CoV	O
-	O
infected	O
DCs	O
showed	O
low	O
expression	O
of	O
antiviral	O
cytokines	O
(	O
interferon	O
alpha	O
[	O
IFN	O
-	O
alpha	O
],	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
gamma	O
,	O
and	O
interleukin	O
12p40	O
[	O
IL	O
-	O
12p40	O
]),	O
moderate	O
up	O
-	O
regulation	O
of	O
proinflammatory	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
but	O
significant	O
up	O
-	O
regulation	O
of	O
inflammatory	O
chemokines	O
(	O
macrophage	O
inflammatory	O
protein	O
1alpha	O
[	O
MIP	O
-	O
1alpha	O
],	O
regulated	O
on	O
activation	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
[	O
RANTES	O
]),	O
interferon	O
-	O
inducible	O
protein	O
of	O
10	O
kDa	O
[	O
IP	O
-	O
10	O
],	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
[	O
MCP	B-FUNC
-	O
1	O
]).	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
has	O
a	O
high	O
binding	B-FUNC
affinity	O
to	O
the	O
human	O
cellular	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
A1	O
.	O

In	O
this	O
report	O
,	O
based	O
on	O
the	O
relevant	O
biophysical	O
and	O
biochemical	O
assays	O
,	O
the	O
nucleocapsid	O
protein	O
of	O
SARS_CoV	O
(	O
SARS_N	O
)	O
was	O
discovered	O
to	O
exhibit	O
high	O
binding	B-FUNC
affinity	O
to	O
human	O
hnRNP	O
A1	O
.	O

Yeast	O
two	O
-	O
hybrid	O
assays	O
further	O
indicated	O
in	O
vivo	O
that	O
such	O
binding	B-FUNC
relates	O
to	O
the	O
fragment	O
(	O
aa	O
161	O
-	O
210	O
)	O
of	O
SARS_N	O
and	O
the	O
Gly	O
-	O
rich	O
domain	O
(	O
aa	O
203	O
-	O
320	O
)	O
of	O
hnRNP	O
A1	O
.	O

Moreover	O
,	O
kinetic	O
analyses	O
by	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
technology	O
revealed	O
that	O
SARS_N	O
protein	O
has	O
a	O
specific	O
binding	B-FUNC
affinity	O
against	O
human	O
hnRNP	O
A1	O
with	O
K	O
(	O
D	O
)	O
at	O
0	O
.	O
35	O
+/-	O

TITLE	O
:	O
Development	O
of	O
immunoglobulin	B-FUNC
G	B-FUNC
enzyme	I-FUNC
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
serodiagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

We	O
developed	O
an	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
using	O
whole	O
virus	O
antigen	O
of	O
SARS	O
-	O
CoV	O
.	O
Eighty	O
-	O
six	O
serum	O
samples	O
collected	O
from	O
patients	O
who	O
were	O
hospitalized	O
for	O
other	O
causes	O
were	O
examined	O
to	O
determine	O
the	O
cut	O
-	O
off	O
O	O
.	O
D	O
.	O
value	O
.	O

The	O
cut	O
-	O
off	O
O	O
.	O
D	O
.	O
value	O
was	O
defined	O
as	O
0	O
.	O
175	O
by	O
calculating	O
the	O
mean	O
O	O
.	O
D	O
.	O
value	O
of	O
the	O
86	O
sera	B-FUNC
plus	O
3	O
standard	O
deviations	O
.	O

To	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ELISA	O
,	O
56	O
positive	O
sera	B-FUNC
and	O
204	O
negative	O
sera	B-FUNC
were	O
tested	O
.	O

We	O
report	O
the	O
personal	O
respiratory	O
protection	O
and	O
environmental	O
control	O
measures	O
implemented	O
to	O
minimize	O
the	O
risk	O
of	O
droplets	O
spread	O
during	O
these	O
procedures	O
,	O
including	O
re	O
-	O
engineering	O
of	O
the	O
ventilation	O
system	O
of	O
the	O
cardiac	O
catheterization	O
laboratory	O
(	O
CCL	B-FUNC
).	O

The	O
report	O
highlights	O
the	O
importance	O
of	O
collaboration	O
of	O
CCL	B-FUNC
personnel	O
with	O
relevant	O
hospital	O
engineering	O
and	O
management	O
teams	O
to	O
develop	O
a	O
contingency	O
infection	O
control	O
plan	O
to	O
prepare	O
for	O
future	O
outbreaks	O
of	O
SARS	O
or	O
other	O
epidemics	O
.	O

Bt	O
-	O
peptides	O
were	O
used	O
to	O
assess	O
if	O
selected	O
regions	O
were	O
antigenic	O
and	O
contained	O
B	O
-	O
or	O
T	O
-	O
cell	O
epitopes	O
and	O
dt	O
-	O
peptides	O
if	O
regions	O
induced	O
an	O
antibody	B-FUNC
response	O
and	O
protection	O
against	O
virulent	O
challenge	O
.	O

All	O
S1	O
and	O
S2	O
peptides	O
were	O
antigenic	O
,	O
being	O
recognised	O
by	O
IBV	O
immune	O
sera	B-FUNC
and	O
also	O
induced	O
an	O
antibody	B-FUNC
response	O
following	O
inoculation	O
into	O
chicks	O
.	O

Monocytes	O
as	O
well	O
as	O
perivascular	O
macrophages	O
were	O
activated	O
because	O
they	O
were	O
strongly	O
positive	O
for	O
CD18	O
and	O
expressed	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interleukin	O
-	O
1beta	O
)	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
.	O

In	O
addition	O
,	O
general	O
activation	O
of	O
endothelial	O
cells	O
,	O
represented	O
by	O
major	O
histocompatibility	O
complex	B-FUNC
II	I-FUNC
upregulation	O
,	O
was	O
observed	O
in	O
all	O
cases	O
.	O

In	O
this	O
study	O
,	O
13	O
recombinant	O
proteins	O
associated	O
with	O
four	O
structural	O
proteins	O
(	O
S	O
,	O
E	O
,	O
M	O
and	O
N	O
)	O
and	O
five	O
putative	O
uncharacterized	O
proteins	O
(	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
and	O
9b	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
were	O
prepared	O
and	O
used	O
for	O
screening	O
and	O
monitoring	O
their	O
specific	O
IgG	O
antibodies	O
in	O
SARS	O
patient	O
sera	B-FUNC
by	O
protein	O
microarray	O
.	O

Antibodies	O
to	O
proteins	O
S	O
,	O
3a	O
,	O
N	O
and	O
9b	O
were	O
detected	O
in	O
the	O
sera	B-FUNC
from	O
convalescent	O
-	O
phase	O
SARS	O
patients	O
,	O
whereas	O
those	O
to	O
proteins	O
E	O
,	O
M	O
,	O
3b	O
,	O
6	O
and	O
7a	O
were	O
undetected	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
quantitative	O
fluorescent	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
for	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
RNA	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
construct	O
a	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
quantitative	O
fluorescent	O
(	O
QF	O
)	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
method	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
RNA	O
.	O

TITLE	O
:	O
Cinanserin	O
is	O
an	O
inhibitor	O
of	O
the	O
3C	O
-	O
like	O
proteinase	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
strongly	O
reduces	O
virus	O
replication	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
one	O
of	O
the	O
most	O
promising	O
targets	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
drugs	O
due	O
to	O
its	O
crucial	O
role	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

In	O
this	O
study	O
,	O
a	O
database	O
containing	O
structural	O
information	O
of	O
more	O
than	O
8	O
,	O
000	O
existing	O
drugs	O
was	O
virtually	O
screened	O
by	O
a	O
docking	O
approach	O
to	O
identify	O
potential	O
binding	B-FUNC
molecules	O
of	O
SARS	O
-	O
CoV	O
3CLpro	O
.	O

The	O
catalytic	B-FUNC
activity	I-FUNC
of	O
both	O
enzymes	O
was	O
inhibited	O
with	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
values	O
of	O
5	O
microM	O
,	O
as	O
tested	O
with	O
a	O
fluorogenic	O
substrate	O
.	O

The	O
data	O
obtained	O
thus	O
far	O
do	O
not	O
indicate	O
whether	O
macrophage	O
/	O
microglia	O
infiltration	O
,	O
in	O
the	O
absence	O
of	O
T	O
cells	O
or	O
antibody	B-FUNC
,	O
is	O
sufficient	O
to	O
mediate	O
demyelination	O
.	O

One	O
representative	O
IgG1	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
),	O
S	O
-	O
A5D5	O
,	O
was	O
selected	O
and	O
characterized	O
.	O

S	O
-	O
A5D5	O
reacted	O
specifically	O
react	O
with	O
both	O
recombinant	O
and	O
native	O
nucleocapsid	O
protein	O
of	O
SARS	O
CoV	O
.	O
The	O
reactivity	O
of	O
S	O
-	O
A5D5	O
with	O
purified	O
N195	O
protein	O
and	O
utilization	O
of	O
the	O
MAb	O
as	O
a	O
detector	O
antibody	B-FUNC
to	O
develop	O
an	O
antigen	O
capture	O
ELISA	O
was	O
assessed	O
.	O

Specific	O
binding	B-FUNC
of	O
the	O
MAb	O
S	O
-	O
A5D5	O
to	O
both	O
purified	O
N195	O
and	O
SARS	O
CoV	O
nucleocapsid	O
antigen	O
was	O
effectively	O
inhibited	O
by	O
human	O
SARS	O
positive	O
serum	O
and	O
guinea	O
pig	O
anti	O
-	O
N195	O
serum	O
.	O

This	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
antigen	O
capture	O
ELISA	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
early	O
diagnosis	O
of	O
SARS	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Production	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
spike	O
protein	O
with	O
single	O
intrasplenic	O
immunization	O
of	O
plasmid	O
DNA	O
.	O

Direct	O
intrasplenic	O
inoculation	O
of	O
plasmid	O
DNA	O
encoding	O
antigen	O
is	O
an	O
effective	O
and	O
fast	B-FUNC
approach	O
to	O
generate	O
specific	O
mAb	O
when	O
the	O
protein	O
antigen	O
is	O
difficult	O
to	O
prepare	O
or	O
dangerous	O
in	O
use	O
.	O

TITLE	O
:	O
Assays	O
for	O
the	O
assessment	O
of	O
neutralizing	O
antibody	B-FUNC
activities	O
against	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

The	O
NRS	O
neutralization	O
assay	O
was	O
adopted	O
from	O
a	O
similar	O
system	O
used	O
for	O
detecting	O
neutralizing	O
antibody	B-FUNC
responses	O
against	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
).	O

The	O
neutralizing	O
antibody	B-FUNC
titers	O
can	O
be	O
easily	O
determined	O
with	O
either	O
of	O
the	O
two	O
new	O
assays	O
.	O

An	O
analysis	O
of	O
receptor	O
engagement	O
revealed	O
that	O
NL63	O
-	O
S	O
binds	B-FUNC
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
2	O
,	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
NL63	O
uses	O
ACE2	O
as	O
a	O
receptor	O
for	O
infection	O
of	O
target	O
cells	O
.	O

Using	O
univariate	O
logistic	O
regression	O
analyses	O
,	O
APACHE	O
II	O
and	O
MOD	O
scores	O
,	O
age	O
(	O
but	O
not	O
gender	O
),	O
and	O
baseline	O
plasma	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
(	O
sTNFR	O
)	O
1	O
(	O
log	O
transformed	O
)	O
concentrations	O
were	O
all	O
predictive	O
of	O
increased	O
28	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
is	O
a	O
strong	O
candidate	O
for	O
predicting	O
clinical	O
outcome	O
in	O
patients	O
with	O
severe	O
sepsis	O
alone	O
,	O
or	O
when	O
combined	O
with	O
the	O
APACHE	O
II	O
or	O
MOD	O
scores	O
.	O

In	O
5	O
of	O
11	O
and	O
10	O
of	O
11	O
patients	O
with	O
SARS	O
,	O
paired	O
serum	O
samples	O
showed	O
a	O
>	O
or	O
=	O
4	O
-	O
fold	O
increase	O
in	O
antibody	B-FUNC
titers	O
against	O
HCoV	O
-	O
229E	O
and	O
HCoV	O
-	O
OC43	O
,	O
respectively	O
,	O
by	O
IFA	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
the	O
extract	O
'	O
s	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
and	O
its	O
inhibitory	O
effects	O
on	O
HIV	O
-	O
1	O
binding	B-FUNC
.	O

TITLE	O
:	O
The	O
effect	O
of	O
furosemide	O
infusion	O
on	O
serum	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
concentration	O
after	O
acute	O
lung	O
injury	O
.	O

The	O
serum	O
specimens	O
were	O
analyzed	O
with	O
enzyme	O
-	O
linked	O
immunoassay	O
(	O
ELISA	O
)	O
for	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
at	O
baseline	O
,	O
then	O
3	O
and	O
7	O
days	O
after	O
acute	O
lung	O
injury	O
.	O

Serum	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
levels	O
also	O
were	O
not	O
significantly	O
different	O
between	O
the	O
furosemide	O
treatment	O
group	O
and	O
the	O
control	O
group	O
(	O
P	O
>	O
.	O
05	O
).	O

Continuous	O
furosemide	O
infusion	O
improves	O
oxygenation	O
and	O
hemodynamics	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
,	O
but	O
not	O
through	O
a	O
change	O
in	O
the	O
serum	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
level	O
.	O

TITLE	O
:	O
JNK	B-FUNC
and	O
PI3k	B-FUNC
/	O
Akt	O
signaling	O
pathways	O
are	O
required	O
for	O
establishing	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
signaling	O
pathways	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK1	B-FUNC
/	O
2	O
),	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	O
kinase	O
(	O
JNK	B-FUNC
),	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
),	O
and	O
phosphatidylinositol	O
3	O
'-	O
kinase	O
(	O
PI3K	B-FUNC
)/	O
Akt	O
were	O
activated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Previous	O
studies	O
also	O
showed	O
that	O
the	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
by	O
viral	O
infection	O
-	O
induced	O
apoptosis	O
,	O
and	O
a	O
weak	O
activation	O
of	O
Akt	O
was	O
not	O
sufficient	O
to	O
protect	O
from	O
apoptosis	O
.	O

These	O
results	O
indicated	O
that	O
two	O
signaling	O
pathways	O
of	O
JNK	B-FUNC
and	O
PI3K	B-FUNC
/	O
Akt	O
were	O
important	O
for	O
the	O
establishment	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	O
.	O

We	O
hypothesized	O
that	O
these	O
variations	O
may	O
underlie	O
a	O
change	O
of	O
binding	B-FUNC
specificity	O
of	O
the	O
S	O
protein	O
to	O
the	O
host	O
cells	O
,	O
permitting	O
viral	O
transmission	O
from	O
animals	O
to	O
humans	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
evolution	O
in	O
vivo	O
:	O
functional	O
compensation	O
of	O
a	O
detrimental	O
amino	O
acid	O
substitution	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
spike	O
glycoprotein	O
.	O

These	O
in	O
vitro	O
isolated	O
mutants	O
encoded	O
two	O
amino	O
acids	O
substitutions	O
in	O
the	O
spike	O
(	O
S	O
)	O
gene	O
:	O
Q159L	O
lies	O
in	O
the	O
putative	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
S	O
,	O
and	O
H716D	O
,	O
within	O
the	O
cleavage	O
signal	O
of	O
S	O
.	O
Here	O
,	O
we	O
show	O
that	O
hepatotropic	O
revertant	O
variants	O
may	O
be	O
selected	O
from	O
these	O
in	O
vitro	O
isolated	O
mutants	O
(	O
Q159L	O
-	O
H716D	O
)	O
by	O
multiple	O
passages	O
in	O
the	O
mouse	O
liver	O
.	O

Our	O
results	O
provide	O
compelling	O
evidence	O
of	O
the	O
ability	O
of	O
coronaviruses	O
to	O
rapidly	O
evolve	O
in	O
vivo	O
to	O
highly	O
virulent	O
phenotypes	O
by	O
functional	O
compensation	O
of	O
a	O
detrimental	O
amino	O
acid	O
substitution	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
spike	O
glycoprotein	O
.	O

With	O
this	O
vast	O
array	O
of	O
antibodies	O
,	O
no	O
signal	O
was	O
observed	O
in	O
other	O
cell	O
types	O
including	O
those	O
organs	O
in	O
which	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reactions	O
were	O
reported	O
to	O
be	O
positive	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
4	O
test	O
kits	O
on	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
gene	O
,	O
antigen	O
and	O
antibody	B-FUNC
for	O
early	O
diagnose	O
of	O
SARS	O
patients	O
.	O

Three	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
were	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
IgG	O
,	O
IgM	O
and	O
N	O
protein	O
and	O
fluorescent	O
polymerase	O
chain	O
reaction	O
(	O
F	O
-	O
PCR	O
)	O
kit	B-FUNC
was	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
RNA	O
.	O

The	O
mean	O
neopterin	O
concentrations	O
were	O
34	O
.	O
2	O
nmol	O
/	O
L	O
in	O
acute	O
sera	B-FUNC
of	O
SARS	O
patients	O
,	O
5	O
.	O
1	O
nmol	O
/	O
L	O
in	O
convalescent	O
sera	B-FUNC
,	O
and	O
6	O
.	O
7	O
nmol	O
/	O
L	O
in	O
healthy	O
controls	O
.	O

In	O
contrast	O
,	O
the	O
mean	O
CRP	O
concentrations	O
in	O
both	O
acute	O
and	O
convalescent	O
sera	B-FUNC
of	O
SARS	O
patients	O
were	O
in	O
the	O
normal	O
range	O
(<	O
10	O
mg	O
/	O
L	O
).	O

TITLE	O
:	O
The	O
interaction	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
and	O
a	O
dimeric	O
inhibitor	O
by	O
capillary	O
electrophoresis	O
.	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
proteinase	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
key	O
target	O
for	O
drug	O
design	O
against	O
SARS	O
.	O

The	O
binding	B-FUNC
constants	O
were	O
estimated	O
by	O
the	O
change	O
of	O
migration	O
time	O
of	O
the	O
analytes	O
in	O
the	O
buffer	O
solution	O
containing	O
different	O
concentrations	O
of	O
SARS	O
3CL	O
proteinase	B-FUNC
.	O

Lung	O
injury	O
score	O
(	O
LIS	B-FUNC
),	O
which	O
is	O
composed	O
of	O
four	O
components	O
,	O
is	O
used	O
for	O
making	O
a	O
distinction	O
between	O
two	O
separate	O
but	O
rather	O
similar	O
syndromes	O
.	O

The	O
obtained	O
results	O
indicate	O
that	O
high	O
values	O
of	O
the	O
lung	O
injury	O
score	O
are	O
suggestive	O
of	O
the	O
severe	O
respiratory	O
dysfunction	O
as	O
well	O
as	O
that	O
lethal	O
outcome	O
is	O
dependent	O
on	O
LIS	B-FUNC
value	O
.	O

The	O
severity	O
of	O
TRALI	O
depends	O
upon	O
the	O
susceptibility	O
of	O
the	O
patient	O
to	O
develop	O
a	O
more	O
clinically	O
significant	O
reaction	O
as	O
a	O
result	O
of	O
an	O
underlying	O
disease	O
process	O
,	O
and	O
upon	O
the	O
nature	O
of	O
triggers	O
in	O
the	O
transfused	O
blood	O
components	O
,	O
including	O
granulocyte	O
-	O
binding	B-FUNC
alloantibodies	O
(	O
immune	O
TRALI	O
)	O
or	O
neutrophil	O
-	O
priming	O
substances	O
such	O
as	O
biologically	O
active	O
lipids	O
(	O
non	O
-	O
immune	O
TRALI	O
).	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
safety	O
of	O
a	O
solvent	O
/	O
detergent	O
(	O
S	O
/	O
D	O
)	O
treated	O
immunoglobulin	B-FUNC
preparation	O
.	O

The	O
work	O
reported	O
here	O
demonstrates	O
:	O
(	O
1	O
)	O
fusion	O
of	O
SUMO	O
(	O
small	O
ubiquitin	B-FUNC
-	O
related	O
modifier	O
),	O
a	O
100	O
amino	O
acid	O
polypeptide	O
,	O
to	O
the	O
N	O
-	O
termini	O
of	O
SARS	O
-	O
CoV	O
proteins	O
dramatically	O
enhances	O
expression	O
in	O
Escherichia	O
coli	O
cells	O
and	O
(	O
2	O
)	O
6x	O
His	O
-	O
tagged	O
SUMO	O
-	O
fusions	O
facilitate	O
rapid	O
purification	O
of	O
the	O
viral	O
proteins	O
on	O
a	O
large	O
scale	O
.	O

ABSTRACT	O
:	O
An	O
immune	O
antibody	B-FUNC
phage	O
-	O
display	O
library	O
was	O
constructed	O
from	O
B	O
cells	O
of	O
SARS	O
convalescent	O
patients	O
.	O

The	O
B1	O
recognized	O
SARS	O
pseudovirus	O
in	O
vivo	O
and	O
competed	O
with	O
SARS	O
sera	B-FUNC
for	O
binding	B-FUNC
to	O
SARS	O
-	O
CoV	O
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
K	O
(	O
d	O
)	O
=	O
105	O
nM	O
).	O

This	O
study	O
not	O
only	O
first	O
made	O
a	O
human	O
neutralizing	O
antibody	B-FUNC
,	O
which	O
recognized	O
an	O
epitope	O
on	O
S2	O
protein	O
like	O
natural	O
antibody	B-FUNC
in	O
sera	B-FUNC
,	O
but	O
also	O
may	O
help	O
us	O
to	O
better	O
understand	O
the	O
immunological	O
characteristics	O
of	O
SARS	O
protein	O
and	O
SARS	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
level	O
and	O
dynamic	O
change	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
-	O
specific	O
IgG	O
antibody	B-FUNC
in	O
conavalescent	O
SARS	O
patients	O
,	O
and	O
to	O
provide	O
information	O
for	O
prevention	O
and	O
vaccine	O
development	O
.	O

IgG	O
antibody	B-FUNC
against	O
coronavirus	O
was	O
detected	O
by	O
ELISA	O
in	O
the	O
blood	O
of	O
311	O
convalescent	O
SARS	O
patients	O
for	O
every	O
2	O
-	O
4	O
weeks	O
.	O

IgG	O
antibody	B-FUNC
was	O
detected	O
positive	O
on	O
each	O
testing	O
of	O
all	O
the	O
convalescent	O
patients	O
and	O
its	O
peak	O
appeared	O
35	O
days	O
after	O
recovery	O
.	O

IgG	O
antibody	B-FUNC
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

Data	O
showed	O
that	O
all	O
the	O
SARS	O
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	O
antibody	B-FUNC
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	B-FUNC
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	O
antibody	B-FUNC
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

RESULTS	O
:	O
IgG	O
antibody	B-FUNC
was	O
detected	O
positive	O
on	O
each	O
testing	O
of	O
all	O
the	O
convalescent	O
patients	O
and	O
its	O
peak	O
appeared	O
35	O
days	O
after	O
recovery	O
.	O

The	O
identification	O
of	O
antibodies	O
was	O
performed	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
indirect	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
(	O
IFA	O
),	O
and	O
Western	O
immunoblotting	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	B-FUNC
and	O
rabbit	O
polyclonal	O
antibodies	O
as	O
detecting	O
antibody	B-FUNC
then	O
triple	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	O
peroxidase	O
(	O
HRP	O
)-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
immunoglobulin	B-FUNC
G	O
.	O
The	O
recombinant	O
N	O
protein	O
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

When	O
tested	O
with	O
420	O
serum	O
specimens	O
from	O
serologically	O
confirmed	O
SARS	O
patients	O
,	O
the	O
positive	O
rates	O
of	O
serum	O
N	O
protein	O
were	O
90	O
.	O
1	O
%,	O
23	O
%	O
and	O
0	O
%,	O
in	O
which	O
sera	B-FUNC
collected	O
from	O
1	O
to	O
10	O
days	O
,	O
11	O
to	O
20	O
days	O
and	O
beyond	O
21	O
days	O
respectively	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
cytokine	O
release	O
of	O
cultured	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
peritoneal	O
macrophages	O
,	O
splenocytes	O
,	O
and	O
splenic	O
macrophages	O
and	O
plasma	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
from	O
those	O
animals	O
were	O
quantified	O
.	O

Two	O
hours	O
after	O
blunt	O
chest	O
trauma	O
,	O
plasma	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
were	O
markedly	O
increased	O
,	O
as	O
was	O
peripheral	O
blood	O
mononuclear	O
cell	O
cytokine	O
production	O
,	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
and	O
lung	O
chemokine	O
concentrations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
topically	O
applied	O
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	O
(	O
IkappaB	O
kinase	O
-	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
binding	B-FUNC
domain	O
[	O
IKK	B-FUNC
-	O
NBD	O
]	O
peptide	O
)	O
on	O
gas	O
exchange	O
,	O
lung	O
function	O
,	O
lung	O
fluids	O
,	O
and	O
inflammation	O
in	O
a	O
piglet	O
model	O
of	O
repeated	O
airway	O
lavage	O
that	O
is	O
characterized	O
by	O
surfactant	O
deficiency	O
,	O
lung	O
edema	O
,	O
and	O
an	O
inflammatory	O
response	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
avidity	O
maturation	O
during	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
maturation	O
of	O
virus	O
-	O
specific	O
immunoglobulin	B-FUNC
G	O
avidity	O
during	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
was	O
examined	O
.	O

Measurement	O
of	O
antibody	B-FUNC
avidity	O
can	O
be	O
used	O
to	O
differentiate	O
primary	O
infection	O
from	O
reexposure	O
and	O
to	O
assess	O
humoral	O
responses	O
to	O
candidate	O
vaccines	O
.	O

Strikingly	O
,	O
live	O
SARS	O
-	O
CoV	O
could	O
further	O
prime	O
cell	O
types	O
to	O
respond	O
to	O
a	O
suboptimal	O
dose	O
of	O
bacterial	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
),	O
resulting	O
in	O
massive	O
release	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
.	O

Surviving	O
SARS	O
patients	O
were	O
seen	O
at	O
least	O
twice	O
within	O
3	O
months	O
after	O
discharge	O
and	O
underwent	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
IgG	O
antibody	B-FUNC
testing	O
,	O
pulmonary	O
function	O
testing	O
,	O
and	O
chest	O
radiography	O
and	O
/	O
or	O
high	O
-	O
resolution	O
CT	O
(	O
HRCT	O
)	O
examinations	O
at	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

The	O
specific	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
against	O
N	O
protein	O
,	O
IgG	O
against	O
S1	O
domain	O
of	O
S	O
protein	O
,	O
and	O
the	O
SARS	O
-	O
CoV	O
IgG	O
in	O
these	O
sera	B-FUNC
were	O
detected	O
by	O
ELISA	O
.	O

TITLE	O
:	O
[	O
An	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
SARS	O
associated	O
coronavirus	O
antibody	B-FUNC
based	O
on	O
recombinant	O
nucleocapsid	O
antigen	O
and	O
its	O
application	O
].	O

ABSTRACT	O
:	O
To	O
establish	O
a	O
new	O
technique	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
test	O
to	O
detect	O
infection	O
of	O
severer	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Immunofluorescence	O
assay	O
(	O
IFA	O
)	O
technique	O
and	O
plaque	O
reduction	O
neutralization	O
test	O
(	O
PRNT	O
)	O
were	O
used	O
to	O
detect	O
7	O
samples	O
of	O
sera	B-FUNC
of	O
4	O
newly	O
diagnosed	O
SARS	O
patients	O
collected	O
in	O
different	O
days	O
,	O
48	O
samples	O
of	O
convalescent	O
sera	B-FUNC
of	O
SARS	O
patients	O
,	O
24	O
serum	O
samples	O
of	O
healthy	O
person	O
undergoing	O
physical	O
examination	O
,	O
and	O
40	O
serum	O
samples	O
from	O
non	O
-	O
SARS	O
patients	O
with	O
fever	O
by	O
double	O
blind	O
test	O
.	O

The	O
recombinant	O
SARS	O
-	O
specific	O
antigen	O
reacted	O
only	O
with	O
SARS	O
positive	O
sera	B-FUNC
but	O
not	O
with	O
normal	O
sera	B-FUNC
.	O

Double	O
blind	O
test	O
showed	O
that	O
45	O
of	O
the	O
46	O
PRNT	O
positive	O
sera	B-FUNC
were	O
IFA	O
positive	O
with	O
an	O
accordance	O
rate	O
of	O
97	O
.	O
8	O
%.	O

7	O
samples	O
of	O
sera	B-FUNC
from	O
4	O
SARS	O
patients	O
in	O
acute	O
progressive	O
stage	O
in	O
Guangdong	O
province	O
were	O
all	O
IFA	O
positive	O
.	O

SARS	O
antibody	B-FUNC
could	O
be	O
detected	O
since	O
the	O
sixth	O
day	O
after	O
onset	O
,	O
and	O
the	O
titer	O
increased	O
from	O
1	O
:	O
40	O
to	O
1	O
:	O
600	O
on	O
the	O
ninth	O
day	O
.	O

The	O
binding	B-FUNC
mode	O
was	O
competitive	O
,	O
and	O
the	O
inhibitory	O
effect	O
was	O
dependent	O
on	O
preincubation	O
time	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
C	O
-	O
type	O
lectin	O
CD209L	O
(	O
also	O
known	O
L	O
-	O
SIGN	O
),	O
and	O
DC	O
-	O
SIGN	O
bind	B-FUNC
SARS	O
-	O
CoV	O
,	O
but	O
ACE2	O
appears	O
to	O
be	O
the	O
key	O
functional	O
receptor	O
for	O
the	O
virus	O
.	O

There	O
is	O
a	O
prominent	O
innate	O
immune	O
response	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
including	O
acute	O
-	O
phase	O
proteins	O
,	O
chemokines	O
,	O
inflammatory	O
cytokines	O
and	O
C	O
-	O
type	O
lectins	O
such	O
as	O
mannose	O
-	O
binding	B-FUNC
lectin	O
,	O
which	O
plays	O
a	O
protective	O
role	O
against	O
SARS	O
.	O

In	O
view	O
of	O
studying	O
the	O
MHV3	O
binding	B-FUNC
to	O
cells	O
or	O
cell	O
extracts	O
,	O
we	O
performed	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
like	O
virus	O
-	O
binding	B-FUNC
assay	O
,	O
preparing	O
microplates	O
with	O
L929	O
cells	O
,	O
A	O
/	O
J	O
or	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
and	O
also	O
with	O
proteins	O
extracted	O
from	O
these	O
cells	O
.	O

The	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
activation	O
led	O
to	O
a	O
reduction	O
of	O
MHV3	O
binding	B-FUNC
only	O
to	O
proteins	O
of	O
resistant	O
A	O
/	O
J	O
mouse	O
macrophages	O
.	O

Sera	B-FUNC
of	O
mice	O
parenterally	O
primed	O
with	O
tobacco	O
-	O
derived	O
S1	O
protein	O
revealed	O
the	O
presence	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
as	O
detected	O
by	O
Western	O
blot	O
and	O
ELISA	O
analysis	O
.	O

Three	O
of	O
SARS	O
genes	O
,	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
spike	O
and	O
nucleocapsid	O
,	O
were	O
amplified	O
with	O
T7	O
promoter	O
-	O
flanked	O
primers	O
.	O

Firefly	O
luciferase	O
and	O
Renilla	O
luciferase	B-FUNC
activity	I-FUNC
were	O
measured	O
.	O

Alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
levels	O
increased	O
slightly	O
in	O
3	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
antigenic	O
structures	O
identified	O
for	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
the	O
epitope	O
-	O
specific	O
mAbs	O
,	O
and	O
the	O
serum	O
antibody	B-FUNC
profile	O
in	O
SARS	O
patients	O
have	O
potential	O
use	O
in	O
the	O
clinical	O
diagnosis	O
and	O
understanding	O
of	O
the	O
protective	O
immunity	O
to	O
SARS	O
-	O
CoV	O
.	O

Here	O
,	O
to	O
extend	O
our	O
experimental	O
observation	O
,	O
we	O
have	O
incorporated	O
protein	O
structural	O
studies	O
(	O
with	O
positive	O
/	O
negative	O
controls	O
)	O
to	O
investigate	O
the	O
potential	O
binding	B-FUNC
modes	O
/	O
sites	O
of	O
ATA	O
onto	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
from	O
SARS	O
-	O
CoV	O
and	O
other	O
pathogenic	O
positive	O
-	O
strand	O
RNA	O
-	O
viruses	O
,	O
as	O
well	O
as	O
other	O
proteins	O
in	O
SARS	O
-	O
CoV	O
based	O
on	O
the	O
fact	O
that	O
ATA	O
binds	B-FUNC
to	O
Ca2	O
+-	O
activated	O
neutral	O
protease	O
(	O
m	O
-	O
calpain	O
),	O
the	O
protein	O
tyrosine	O
phosphatase	B-FUNC
(	O
PTP	O
)	O
and	O
HIV	O
integrase	O
which	O
have	O
existing	O
crystal	O
structures	O
.	O

One	O
of	O
the	O
region	O
,	O
Rbinding	O
(	O
754	O
-	O
766	O
in	O
SARS	O
-	O
CoV	O
'	O
s	O
RdRp	B-FUNC
),	O
located	O
in	O
the	O
palm	O
sub	O
-	O
domain	O
mainly	O
constituted	O
of	O
anti	O
-	O
parallel	O
beta	O
-	O
strand	O
-	O
turn	O
-	O
beta	O
-	O
strand	O
hairpin	O
structures	O
that	O
covers	O
two	O
of	O
the	O
three	O
RdRp	B-FUNC
catalytic	O
sites	O
(	O
Asp	O
760	O
,	O
Asp761	O
),	O
was	O
also	O
predicted	O
by	O
molecular	O
docking	O
method	O
(	O
based	O
on	O
free	O
energy	O
of	O
binding	B-FUNC
DeltaG	O
)	O
to	O
be	O
important	O
binding	B-FUNC
motif	O
recognized	O
by	O
ATA	O
.	O

The	O
existence	O
of	O
this	O
strictly	O
conserved	O
region	O
that	O
incorporated	O
catalytic	O
residues	O
,	O
coupled	O
with	O
the	O
homologous	O
ATA	O
binding	B-FUNC
pockets	O
and	O
their	O
consistent	O
DeltaG	O
values	O
,	O
suggested	O
strongly	O
ATA	O
may	O
be	O
involved	O
in	O
an	O
analogous	O
inhibition	O
mechanism	O
of	O
SARS	O
-	O
COV	O
'	O
s	O
RdRp	B-FUNC
in	O
concomitant	O
to	O
the	O
case	O
in	O
m	O
-	O
calpain	O
,	O
PTP	O
and	O
HIV	O
integrase	O
.	O

Pulse	O
-	O
chase	O
analyses	O
followed	O
by	O
immunoprecipitation	O
of	O
IBV	O
N	O
proteins	O
using	O
rabbit	O
anti	O
-	O
IBV	O
N	O
polyclonal	O
antibody	B-FUNC
demonstrated	O
that	O
the	O
phosphate	O
on	O
the	O
N	O
protein	O
was	O
stable	O
for	O
at	O
least	O
1	O
h	O
.	O
Simultaneous	O
labeling	O
with	O
32P	O
-	O
orthophosphate	O
and	O
3H	O
-	O
leucine	O
identified	O
a	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
32P	O
:	O
3H	O
counts	O
per	O
minute	O
(	O
cpm	O
)	O
ratio	O
of	O
N	O
in	O
the	O
virion	O
as	O
compared	O
to	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
in	O
the	O
cell	O
lysates	O
from	O
chicken	O
embryo	O
kidney	O
cells	O
,	O
whereas	O
in	O
Vero	O
cells	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
from	O
the	O
virion	O
was	O
10	O
.	O
5	O
-	O
fold	O
greater	O
than	O
the	O
32P	O
:	O
3H	O
cpm	O
ratio	O
of	O
N	O
from	O
the	O
cell	O
lysates	O
.	O

Genetic	O
analysis	O
revealed	O
that	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
pcSARS	O
-	O
CoV	O
and	O
huSARS	O
-	O
CoV	O
was	O
subjected	O
to	O
the	O
strongest	O
positive	O
selection	O
pressure	O
during	O
transmission	O
,	O
and	O
there	O
were	O
six	O
amino	O
acid	O
residues	O
within	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
S	O
protein	O
being	O
potentially	O
important	O
for	O
SARS	O
progression	O
and	O
tropism	O
.	O

TITLE	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
convertase	O
(	O
ADAM17	O
)	O
mediates	O
regulated	O
ectodomain	O
shedding	O
of	O
the	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
).	O

A	O
soluble	O
form	O
of	O
ACE2	O
,	O
lacking	O
its	O
cytosolic	O
and	O
transmembrane	O
domains	O
,	O
has	O
been	O
shown	O
to	O
block	O
binding	B-FUNC
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
to	O
its	O
receptor	O
.	O

Normal	O
lamellar	O
body	O
formation	O
requires	O
SP	O
-	O
B	O
and	O
a	O
member	O
of	O
the	O
ATP	O
-	O
binding	B-FUNC
cassette	O
(	O
ABC	O
)	O
family	O
of	O
ATP	O
-	O
dependent	O
membrane	O
-	O
associated	O
transport	O
proteins	O
,	O
ABCA3	O
.	O

Tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentrations	O
were	O
measured	O
in	O
portal	O
and	O
systemic	O
serum	O
,	O
and	O
in	O
the	O
perfusate	O
30	O
and	O
90	O
min	O
after	O
the	O
'	O
second	O
hit	O
'.	O

We	O
observed	O
a	O
six	O
-	O
fold	O
increase	O
in	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
across	O
the	O
liver	O
during	O
AP	O
.	O

TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
neutrophil	O
activator	O
production	O
by	O
the	O
isolated	O
perfused	O
liver	O
,	O
in	O
response	O
to	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
LPS	O
,	O
does	O
not	O
appear	O
to	O
be	O
enhanced	O
during	O
AP	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
six	O
-	O
fold	O
increase	O
in	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
across	O
the	O
liver	O
during	O
AP	O
.	O

The	O
purified	O
hyperimmune	O
globulins	O
were	O
formulated	O
as	O
a	O
5	O
percent	O
solution	O
,	O
with	O
an	O
antibody	B-FUNC
titer	O
specifically	O
against	O
the	O
SARS	O
virus	O
of	O
1	O
:	O
83	O
,	O
1	O
:	O
1600	O
,	O
and	O
1	O
:	O
200	O
,	O
as	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
immunofluorescence	O
assay	O
,	O
and	O
neutralizing	O
antibody	B-FUNC
test	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
purified	O
hyperimmune	O
globulins	O
were	O
formulated	O
as	O
a	O
5	O
percent	O
solution	O
,	O
with	O
an	O
antibody	B-FUNC
titer	O
specifically	O
against	O
the	O
SARS	O
virus	O
of	O
1	O
:	O
83	O
,	O
1	O
:	O
1600	O
,	O
and	O
1	O
:	O
200	O
,	O
as	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
immunofluorescence	O
assay	O
,	O
and	O
neutralizing	O
antibody	B-FUNC
test	O
,	O
respectively	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
spike	O
polypeptide	O
DNA	O
vaccine	O
priming	O
with	O
recombinant	O
spike	O
polypeptide	O
from	O
Escherichia	O
coli	O
as	O
booster	O
induces	O
high	O
titer	O
of	O
neutralizing	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
neutralizing	O
antibody	B-FUNC
response	O
against	O
SARS	O
-	O
CoV	O
were	O
compared	O
using	O
a	O
mouse	O
model	O
.	O

S	O
-	O
peptide	O
,	O
mice	O
primed	O
with	O
oral	O
live	O
-	O
attenuated	O
S	O
.	O
typhimurium	O
that	O
contained	O
tPA	B-FUNC
-	O
optimize800	O
DNA	O
vaccine	O
(	O
Salmonella	O
-	O
tPA	B-FUNC
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

S	O
-	O
peptide	O
,	O
and	O
mice	O
primed	O
with	O
oral	O
live	O
-	O
attenuated	O
S	O
.	O
typhimurium	O
that	O
contained	O
CTLA4HingeSARS800	O
DNA	O
vaccine	O
(	O
Salmonella	O
-	O
tPA	B-FUNC
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

Sera	B-FUNC
of	O
all	O
six	O
mice	O
immunized	O
with	O
i	O
.	O
p	O
.	O

DNA	O
vaccine	O
control	O
and	O
oral	O
Salmonella	O
-	O
S	O
-	O
DNA	O
-	O
control	O
showed	O
no	O
neutralizing	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
.	O
Sera	B-FUNC
of	O
the	O
mice	O
immunized	O
with	O
i	O
.	O
m	O
.	O

tPA	B-FUNC
-	O
S	O
-	O
DNA	O
,	O
i	O
.	O
m	O
.	O

S	O
-	O
peptide	O
,	O
oral	O
Salmonella	O
-	O
tPA	B-FUNC
-	O
S	O
-	O
DNA	O
,	O
oral	O
Salmonella	O
-	O
tPA	B-FUNC
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
S	O
-	O
peptide	O
,	O
oral	O
Salmonella	O
-	O
CTLA4	O
-	O
S	O
-	O
DNA	O
and	O
oral	O
Salmonella	O
-	O
CTLA4	O
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
.	O

Sera	B-FUNC
of	O
all	O
the	O
mice	O
immunized	O
with	O
i	O
.	O
m	O
.	O

tPA	B-FUNC
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
.	O

S	O
-	O
peptide	O
showed	O
neutralizing	O
antibody	B-FUNC
titers	O
of	O
>	O
or	O
=	O
1	O
:	O
1280	O
.	O

ABSTRACT	O
:	O
Although	O
overexpression	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
165	O
in	O
the	O
lung	O
causes	O
pulmonary	O
oedema	O
,	O
its	O
role	O
in	O
human	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
unclear	O
.	O

Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
levels	O
in	O
pulmonary	O
oedema	O
fluid	O
were	O
depressed	O
both	O
in	O
acute	O
lung	O
injury	O
and	O
hydrostatic	O
pulmonary	O
oedema	O
.	O

The	O
decrease	O
in	O
air	O
space	O
concentrations	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
in	O
acute	O
lung	O
injury	O
may	O
not	O
be	O
a	O
function	O
of	O
the	O
degree	O
of	O
lung	O
injury	O
,	O
but	O
rather	O
may	O
result	O
from	O
alveolar	O
flooding	O
.	O

The	O
SARS	O
-	O
CoV	O
S	O
-	O
based	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
)	O
and	O
IgG	O
ELISAs	O
were	O
evaluated	O
and	O
compared	O
with	O
the	O
corresponding	O
N	O
-	O
based	O
ELISA	O
for	O
serodiagnosis	O
of	O
SARS	O
-	O
CoV	O
pneumonia	O
,	O
using	O
sera	B-FUNC
from	O
148	O
healthy	O
blood	O
donors	O
who	O
donated	O
blood	O
3	O
years	O
ago	O
as	O
controls	O
and	O
95	O
SARS	O
-	O
CoV	O
pneumonia	O
patients	O
in	O
Hong	O
Kong	O
.	O

To	O
develop	O
a	O
safe	O
,	O
simple	O
,	O
and	O
reliable	O
screening	O
method	O
for	O
SARS	O
diagnosis	O
and	O
epidemiological	O
study	O
,	O
two	O
recombinant	O
SARS	O
-	O
CoV	O
nucleocapsid	O
proteins	O
(	O
N	O
'	O
protein	O
and	O
(	O
N	O
)	O
Delta	O
(	O
121	O
)	O
protein	O
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
purified	O
by	O
affinity	O
chromatography	O
,	O
and	O
used	O
as	O
antigens	O
for	O
indirect	O
,	O
immunoglobulin	B-FUNC
G	B-FUNC
enzyme	I-FUNC
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
).	O

Mice	O
immunized	O
twice	O
with	O
the	O
DNA	O
vaccine	O
and	O
once	O
with	O
the	O
whole	O
killed	O
virus	O
elicited	O
higher	O
antibody	B-FUNC
responses	O
than	O
mice	O
immunized	O
three	O
times	O
with	O
the	O
DNA	O
vaccine	O
or	O
once	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
.	O

Mice	O
immunized	O
twice	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
elicited	O
higher	O
antibody	B-FUNC
responses	O
than	O
mice	O
immunized	O
three	O
times	O
with	O
the	O
DNA	O
vaccine	O
or	O
once	O
with	O
the	O
whole	O
killed	O
virus	O
vaccine	O
.	O

We	O
monitored	O
pulmonary	O
vascular	O
resistance	O
,	O
oxygenation	O
,	O
neutrophil	O
count	O
,	O
lung	O
edema	O
as	O
reflected	O
by	O
wet	O
-	O
dry	O
weights	O
of	O
lung	O
tissue	O
,	O
perfusate	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
8	O
-	O
isoprostane	O
(	O
a	O
marker	O
of	O
oxidative	O
stress	O
),	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
lung	O
tissue	O
before	O
and	O
for	O
2	O
h	O
after	O
endotoxin	O
.	O

Fresh	O
fecal	O
specimens	O
were	O
screened	O
for	O
bacteria	O
and	O
bacterial	O
toxins	O
via	O
bacteriologic	O
culture	O
and	O
ELISA	O
,	O
parvovirus	O
via	O
ELISA	O
,	O
canine	O
coronavirus	O
via	O
nested	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
protozoal	O
cysts	O
and	O
oocysts	O
via	O
a	O
direct	O
fluorescent	O
antibody	B-FUNC
technique	O
,	O
and	O
parasite	O
ova	O
and	O
larvae	O
via	O
microscopic	O
examination	O
of	O
direct	O
wet	O
mounts	O
and	O
zinc	O
sulfate	O
centrifugation	O
flotation	O
.	O

Giardia	O
lamblia	O
was	O
significantly	O
underestimated	O
by	O
fecal	O
flotation	O
,	O
compared	O
with	O
a	O
direct	O
fluorescent	O
antibody	B-FUNC
technique	O
.	O

Arg273	O
was	O
found	O
to	O
be	O
critical	O
for	O
substrate	O
binding	B-FUNC
such	O
that	O
its	O
replacement	O
causes	O
enzyme	B-FUNC
activity	I-FUNC
to	O
be	O
abolished	O
.	O

Thus	O
ACE2	O
has	O
only	O
one	O
chloride	O
-	O
binding	B-FUNC
site	O
(	O
CL1	O
)	O
whereas	O
ACE	O
has	O
two	O
sites	O
.	O

A	O
questionnaire	O
survey	O
was	O
conducted	O
and	O
serum	O
samples	O
were	O
collected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-FUNC
.	O

The	O
specificity	O
of	O
monoclonal	O
antibodies	O
were	O
tested	O
with	O
a	O
commercial	O
ELISA	O
kit	B-FUNC
for	O
detecting	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
.	O
The	O
results	O
showed	O
that	O
two	O
peptides	O
with	O
molecular	O
weights	O
of	O
34kD	O
and	O
35kD	O
expressed	O
by	O
the	O
two	O
chimeric	O
genes	O
could	O
be	O
recognized	O
by	O
SARS	O
patient	O
convalescent	O
serum	O
in	O
Western	O
blot	O
.	O

The	O
subtype	O
of	O
monoclonal	O
antibody	B-FUNC
D3C5	O
is	O
IgG2a	O
,	O
and	O
subtypes	O
of	O
all	O
other	O
five	O
monoclonal	O
antibodies	O
are	O
IgG1	O
.	O

With	O
a	O
commercial	O
SARS	O
-	O
CoV	O
antibodies	O
detection	O
ELISA	O
kit	B-FUNC
,	O
five	O
out	O
of	O
six	O
monoclonal	O
antibodies	O
were	O
positively	O
recognized	O
.	O

Peptide	O
-	O
conjugated	O
antisense	O
morpholino	O
oligomers	O
(	O
P	O
-	O
PMO	O
)	O
were	O
designed	O
to	O
bind	B-FUNC
by	O
base	B-FUNC
pairing	I-FUNC
to	O
specific	O
sequences	O
in	O
the	O
SARS	O
-	O
CoV	O
(	O
Tor2	O
strain	O
)	O
genome	O
.	O

Two	O
P	O
-	O
PMO	O
targeting	O
the	O
viral	O
transcription	O
-	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
region	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
were	O
the	O
most	O
effective	O
inhibitors	O
tested	O
.	O

However	O
,	O
the	O
MHV	O
receptor	O
is	O
not	O
present	O
in	O
lipid	O
rafts	O
,	O
and	O
anchoring	B-FUNC
of	O
the	O
MHV	O
receptor	O
to	O
lipid	O
rafts	O
did	O
not	O
enhance	O
MHV	O
infection	O
;	O
thus	O
,	O
the	O
mechanism	O
of	O
lipid	O
rafts	O
involvement	O
is	O
not	O
clear	O
.	O

Furthermore	O
,	O
MHV	O
spike	O
protein	O
bound	O
to	O
nonraftraft	O
membrane	O
at	O
4	O
degrees	O
C	O
but	O
shifted	O
to	O
lipid	O
rafts	O
at	O
37	O
degrees	O
C	O
,	O
indicating	O
a	O
redistribution	O
of	O
membrane	O
following	O
virus	O
binding	B-FUNC
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
is	O
the	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
,	O
and	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
subunit	O
of	O
S	O
protein	O
contains	O
multiple	O
conformational	O
neutralizing	O
epitopes	O
.	O

Asymptomatic	O
SARS	O
was	O
associated	O
with	O
lower	O
SARS	O
antibody	B-FUNC
titers	O
and	O
higher	O
use	O
of	O
masks	O
when	O
compared	O
to	O
pneumonic	O
SARS	O
.	O

Our	O
results	O
showed	O
that	O
all	O
of	O
the	O
immunized	O
animals	O
generated	O
humoral	O
immunity	O
against	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
and	O
the	O
sera	B-FUNC
of	O
immunized	O
rats	O
showed	O
strong	O
capable	O
of	O
protecting	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

The	O
severity	O
of	O
the	O
disease	O
combined	O
with	O
its	O
rapid	O
spread	O
requires	O
the	O
development	O
of	O
fast	B-FUNC
and	O
sensitive	O
diagnostic	O
assays	O
.	O

During	O
the	O
first	O
10	O
days	O
after	O
onset	O
,	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
,	O
SARS	O
-	O
CoV	O
RNA	O
and	O
the	O
N	O
protein	O
were	O
detected	O
in	O
21	O
.	O
4	O
,	O
42	O
.	O
9	O
,	O
and	O
90	O
%	O
of	O
the	O
patients	O
'	O
sera	B-FUNC
,	O
respectively	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
genes	O
of	O
the	O
various	O
IBVs	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
were	O
cloned	O
and	O
sequenced	O
,	O
and	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
were	O
compared	O
with	O
published	O
sequences	O
for	O
non	O
-	O
Korean	O
IBV	O
strains	O
.	O

RICT	O
with	O
several	O
pairs	O
of	O
MoAbs	O
showed	O
a	O
high	O
sensitivity	O
for	O
the	O
detection	O
of	O
recombinant	O
N	O
-	O
Ag	O
as	O
well	O
as	O
viral	O
N	O
-	O
Ag	O
of	O
SARS	O
-	O
CoV	O
.	O
rSN122	O
and	O
rSN21	O
-	O
2	O
were	O
the	O
best	O
MoAbs	O
for	O
immobilized	O
antibody	B-FUNC
and	O
enzyme	O
labeling	O
,	O
respectively	O
.	O

With	O
regard	O
to	O
analytical	O
sensitivity	O
,	O
RICT	O
detected	O
N	O
-	O
Ag	O
at	O
31	O
pg	O
/	O
mL	O
for	O
recombinant	O
N	O
-	O
Ag	O
,	O
and	O
at	O
1	O
.	O
99	O
x	O
10	O
(	O
2	O
)	O
TCID	O
(	O
50	O
)/	O
mL	O
for	O
SARS	O
-	O
CoV	O
.	O
The	O
specificity	O
of	O
RICT	O
was	O
100	O
%	O
when	O
150	O
human	O
sera	B-FUNC
and	O
50	O
nasopharyngeal	O
aspirates	O
(	O
NSPs	O
)	O
were	O
used	O
.	O

Autoantibodies	O
against	O
cell	O
nuclei	O
(	O
ANA	O
),	O
autoantibodies	O
against	O
smooth	O
muscles	O
(	O
SMA	O
),	O
autoantibodies	O
against	O
parietal	O
cells	O
(	O
PCA	O
),	O
autoantibodies	O
against	O
heart	O
cells	O
(	O
HRA	O
)	O
were	O
detected	O
by	O
using	O
immunofluorescence	O
,	O
and	O
autoantibodies	O
against	O
live	O
-	O
kidney	O
microsomes	O
(	O
LKM	O
)	O
and	O
anti	O
-	O
M2	O
antibodies	O
were	O
detected	O
by	O
ELISA	O
in	O
sera	B-FUNC
taken	O
from	O
27	O
SARS	O
patients	O
and	O
18	O
healthy	O
controls	O
.	O

ANA	O
,	O
AMA	O
,	O
LKM	O
and	O
SMA	O
were	O
found	O
positive	O
in	O
3	O
,	O
1	O
,	O
1	O
,	O
and	O
1	O
of	O
the	O
27	O
SARS	O
sera	B-FUNC
.	O

There	O
are	O
auto	O
antibodies	O
against	O
lung	O
tissues	O
in	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

RESULTS	O
:	O
ANA	O
,	O
AMA	O
,	O
LKM	O
and	O
SMA	O
were	O
found	O
positive	O
in	O
3	O
,	O
1	O
,	O
1	O
,	O
and	O
1	O
of	O
the	O
27	O
SARS	O
sera	B-FUNC
.	O

Antibodies	O
in	O
sera	B-FUNC
of	O
patients	O
and	O
healthy	O
controls	O
against	O
:	O
(	O
1	O
)	O
A549	O
human	O
pulmonary	O
epithelial	O
cell	O
-	O
line	O
,	O
(	O
2	O
)	O
human	O
umbilical	O
venous	O
endothelial	O
cells	O
(	O
HUVEC	O
),	O
(	O
3	O
)	O
primary	O
human	O
pulmonary	O
endothelial	O
cells	O
(	O
HPEC	O
)	O
were	O
detected	O
by	O
cell	O
-	O
based	O
ELISA	O
and	O
indirect	O
immunofluorescence	O
staining	O
.	O

Sera	B-FUNC
from	O
SARS	O
patients	O
at	O
phase	O
II	O
/	O
phase	O
III	O
could	O
mediate	O
complement	O
dependent	O
cytotoxicity	O
against	O
some	O
A549	O
cells	O
and	O
HPEC	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
single	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
binds	B-FUNC
to	O
its	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
induces	O
membrane	O
fusion	O
and	O
serves	O
as	O
a	O
neutralizing	O
antigen	O
.	O

VSV	O
-	O
SARS	O
-	O
St19	O
was	O
neutralized	O
by	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
and	O
soluble	O
ACE2	O
,	O
and	O
its	O
infection	O
was	O
blocked	O
by	O
treatment	O
of	O
Vero	O
E6	O
cells	O
with	O
anti	O
-	O
ACE2	O
antibody	B-FUNC
.	O

We	O
propose	O
to	O
use	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
residues	O
318	O
--	O
510	O
)	O
for	O
developing	O
a	O
safe	O
and	O
effective	O
subunit	O
SARS	O
vaccine	O
,	O
as	O
it	O
is	O
not	O
only	O
a	O
functional	O
domain	O
that	O
mediates	O
virus	O
-	O
receptor	B-FUNC
binding	I-FUNC
but	O
also	O
a	O
major	O
neutralization	O
determinant	O
of	O
SARSCoV	O
.	O
It	O
has	O
been	O
demonstrated	O
that	O
the	O
RBD	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
contains	O
multiple	O
conformational	O
epitopes	O
capable	O
of	O
inducing	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
and	O
protective	O
immunity	O
.	O

Following	O
coronavirus	O
injection	O
,	O
TNF	O
-	O
alpha	O
mRNA	O
was	O
detected	O
at	O
higher	O
levels	O
within	O
the	O
retinas	O
,	O
and	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
sTNFR1	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
proteins	O
were	O
increased	O
within	O
the	O
sera	B-FUNC
of	O
BALB	O
/	O
c	O
but	O
not	O
CD	O
-	O
1	O
mice	O
.	O

The	O
SNP362	O
-	O
370	O
peptide	O
is	O
held	O
in	O
place	O
by	O
17	O
hydrogen	O
bonds	O
to	O
the	O
alpha	O
-	O
chain	O
residues	O
and	O
by	O
nine	O
water	O
molecules	O
which	O
are	O
also	O
tightly	O
bound	O
in	O
the	O
peptide	O
-	O
binding	B-FUNC
groove	O
.	O

Mice	O
vaccinated	O
with	O
VSV	O
-	O
S	O
developed	O
SARS	O
-	O
neutralizing	O
antibody	B-FUNC
and	O
were	O
able	O
to	O
control	O
a	O
challenge	O
with	O
SARS	O
-	O
CoV	O
performed	O
at	O
1	O
month	O
or	O
4	O
months	O
after	O
a	O
single	O
vaccination	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
in	O
SARS	O
patient	O
sera	B-FUNC
there	O
were	O
autoantibodies	O
(	O
autoAbs	O
)	O
that	O
reacted	O
with	O
A549	O
cells	O
,	O
the	O
type	O
-	O
2	O
pneumocytes	O
,	O
and	O
that	O
these	O
autoAbs	O
were	O
mainly	O
IgG	O
.	O
The	O
autoAbs	O
were	O
detectable	O
20	O
days	O
after	O
fever	O
onset	O
.	O

After	O
sera	B-FUNC
IgG	O
bound	O
to	O
A549	O
cells	O
,	O
cytotoxicity	O
was	O
induced	O
.	O

Preabsorption	O
and	O
binding	B-FUNC
assays	O
indicated	O
the	O
existence	O
of	O
cross	O
-	O
reactive	O
epitopes	O
on	O
SARS	O
-	O
CoV	O
spike	O
protein	O
domain	O
2	O
(	O
S2	O
).	O

Taken	O
together	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
anti	O
-	O
S2	O
Abs	O
in	O
SARS	O
patient	O
sera	B-FUNC
cause	O
cytotoxic	O
injury	O
as	O
well	O
as	O
enhance	O
immune	O
cell	O
adhesion	O
to	O
epithelial	O
cells	O
.	O

However	O
,	O
apoptosis	O
was	O
inhibited	O
by	O
overexpressed	O
antiapoptotic	O
protein	O
Bcl	O
-	O
xL	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
SARS	O
-	O
CoV	O
E	O
protein	O
interacted	O
with	O
Bcl	O
-	O
xL	O
in	O
vitro	O
and	O
endogenous	O
Bcl	O
-	O
xL	O
in	O
vivo	O
and	O
that	O
Bcl	O
-	O
xL	O
interaction	O
with	O
SARS	O
-	O
CoV	O
E	O
protein	O
was	O
mediated	O
by	O
BH3	O
(	O
Bcl	O
-	O
2	O
homology	O
domain	O
3	O
)	O
of	O
Bcl	O
-	O
xL	O
.	O
Finally	O
,	O
we	O
identified	O
a	O
novel	O
BH3	O
-	O
like	O
region	O
located	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	O
domain	O
of	O
SARS	O
-	O
CoV	O
E	O
protein	O
,	O
which	O
mediates	O
its	O
binding	B-FUNC
to	O
Bcl	O
-	O
xL	O
.	O
These	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
molecular	O
mechanism	O
of	O
T	O
-	O
cell	O
apoptosis	O
that	O
contributes	O
to	O
the	O
SARS	O
-	O
CoV	O
-	O
induced	O
lymphopenia	O
observed	O
in	O
most	O
SARS	O
patients	O
.	O

Ligand	B-FUNC
binding	B-FUNC
to	O
LSECtin	O
was	O
inhibited	O
by	O
EGTA	O
but	O
not	O
by	O
mannan	O
,	O
suggesting	O
that	O
LSECtin	O
unlike	O
DC	O
-	O
SIGN	O
/	O
R	O
does	O
not	O
recognize	O
high	O
-	O
mannose	O
glycans	O
on	O
viral	O
GPs	O
.	O

PATIENT	O
AND	O
HISTORY	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
with	O
GIST	O
metastatic	O
to	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
treated	O
with	O
tyrosine	O
kinase	B-FUNC
inhibitors	I-FUNC
,	O
underwent	O
a	O
right	O
hepatectomy	O
requiring	O
multiple	O
transfusions	O
.	O

The	O
treatment	O
of	O
KD	O
includes	O
infusion	O
of	O
high	O
dose	O
immunoglobulin	B-FUNC
.	O

Patients	O
non	O
-	O
responsive	O
to	O
immunoglobulin	B-FUNC
therapy	O
are	O
labeled	O
as	O
having	O
""""	O
immunoglobulin	B-FUNC
resistant	O
KD	O
"""."	O

The	O
treatment	O
of	O
immunoglobulin	B-FUNC
resistant	O
KD	O
can	O
be	O
challenging	O
and	O
new	O
therapies	O
that	O
have	O
tried	O
with	O
some	O
success	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
infection	O
was	O
blocked	O
by	O
specific	O
inhibitors	O
of	O
the	O
pH	O
-	O
sensitive	O
endosomal	O
protease	O
cathepsin	O
L	O
.	O
A	O
cell	O
-	O
free	O
membrane	O
-	O
fusion	O
system	O
demonstrates	O
that	O
engagement	O
of	O
receptor	O
followed	O
by	O
proteolysis	O
is	O
required	O
for	O
SARS	O
-	O
CoV	O
membrane	O
fusion	O
and	O
indicates	O
that	O
cathepsin	O
L	O
is	O
sufficient	O
to	O
activate	O
membrane	O
fusion	O
by	O
SARS	O
-	O
CoV	O
S	O
.	O
These	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
infection	O
results	O
from	O
a	O
unique	O
,	O
three	O
-	O
step	O
process	O
:	O
receptor	B-FUNC
binding	I-FUNC
and	O
induced	O
conformational	O
changes	O
in	O
S	O
glycoprotein	O
followed	O
by	O
cathepsin	O
L	O
proteolysis	O
within	O
endosomes	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
major	O
immunodominant	O
epitopes	O
on	O
the	O
M	O
protein	O
located	O
in	O
the	O
extreme	O
N	O
-	O
terminal	O
region	O
(	O
residues	O
1	O
to	O
31	O
)	O
and	O
the	O
interior	O
C	O
-	O
terminal	O
region	O
(	O
residues	O
132	O
to	O
161	O
),	O
respectively	O
,	O
by	O
Pepscan	O
analyses	O
against	O
convalescent	O
-	O
phase	O
sera	B-FUNC
from	O
SARS	O
patients	O
and	O
antisera	O
from	O
virus	O
-	O
immunized	O
mice	O
and	O
rabbits	O
.	O

TITLE	O
:	O
First	O
external	O
quality	O
assurance	O
of	O
antibody	B-FUNC
diagnostic	O
for	O
SARS	O
-	O
new	O
coronavirus	O
.	O

ABSTRACT	O
:	O
To	O
confirm	O
an	O
infection	O
with	O
the	O
new	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
causing	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
diagnostic	O
assays	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-FUNC
are	O
necessary	O
.	O

All	O
of	O
them	O
were	O
able	O
to	O
bind	B-FUNC
to	O
the	O
surface	O
domain	O
of	O
the	O
whole	O
spike	O
protein	O
expressed	O
by	O
recombinant	O
baculovirus	O
in	O
insect	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
immune	O
responses	O
against	O
the	O
S2	O
subunit	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
which	O
were	O
vaccinated	O
either	O
with	O
plasmid	O
DNA	O
encoding	O
the	O
S2	O
domain	O
(	O
residues	O
681	O
-	O
1120	O
),	O
the	O
recombinant	O
S2	O
fragment	O
(	O
residues	O
681	O
-	O
980	O
)	O
in	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	O
,	O
or	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
The	O
increased	O
number	O
of	O
specific	O
cytotoxic	O
cells	O
(	O
CTLs	O
)	O
and	O
the	O
high	O
titer	O
of	O
specific	O
antibody	B-FUNC
showed	O
stimulation	O
of	O
both	O
arms	O
of	O
the	O
immune	O
system	O
in	O
these	O
groups	O
.	O

However	O
,	O
interleukin	O
-	O
4	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
)	O
was	O
not	O
detectable	O
in	O
two	O
groups	O
.	O

The	O
selection	O
of	O
25	O
test	O
materials	O
includes	O
eleven	O
trioxa	O
-	O
adamantane	O
-	O
triols	O
(	O
TATs	O
)	O
[	O
BN	O
,	O
IBNCA	O
,	O
ABNCA	O
,	O
VANBA	O
,	O
ethylVANBA	O
,	O
euBN	O
,	O
euVANBA	O
,	O
ansaBN	O
,	O
Ehrlich	O
BN	O
,	O
[	O
6	O
]	O
prismaneBN	O
,	O
nitrodiBN	O
],	O
trivially	O
termed	O
bananins	O
,	O
one	O
trioxa	O
-	O
adamantan	O
-	O
ol	O
(	O
TAO	O
)	O
THYMOBA	O
,	O
one	O
bis	B-FUNC
-	O
bananin	O
pi	O
-	O
bananin	O
(	O
piBN	O
),	O
one	O
triazaadamantane	O
delta	O
-	O
bananin	O
(	O
deltaBN	O
),	O
seven	O
potential	O
nucleic	O
acid	O
-	O
binding	B-FUNC
drugs	I-FUNC
(	O
XBQC	O
,	O
INDO	O
,	O
PivINDO	O
,	O
AZTRION	O
,	O
AZADO	O
,	O
AZOCYS	O
,	O
AZOGALL	O
),	O
one	O
potential	O
antiviral	O
interferon	O
-	O
inducer	O
and	O
distant	O
nucleoside	O
analog	O
diazon	O
,	O
one	O
potential	O
HIV	O
protein	O
Vif	O
antagonist	O
AZODIAZON	O
,	O
one	O
folic	O
acid	O
-	O
diazon	O
condensate	O
DIAZONOFOL	O
,	O
and	O
one	O
special	O
nucleoside	O
analog	O
(	O
fructoinosine	O
/	O
fructovir	O
).	O

Also	O
,	O
using	O
specific	O
inhibitors	O
of	O
phosphorylation	O
and	O
an	O
in	O
vitro	O
phosphorylation	O
assay	O
,	O
we	O
show	O
that	O
the	O
nucleocapsid	O
protein	O
is	O
a	O
substrate	O
of	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
(	O
CDK	B-FUNC
),	O
glycogen	O
synthase	O
kinase	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
and	O
casein	O
kinase	O
II	O
.	O

Further	O
,	O
we	O
show	O
that	O
the	O
phosphorylated	O
protein	O
is	O
translocated	O
to	O
the	O
cytoplasm	O
by	O
binding	B-FUNC
to	O
14	O
-	O
3	O
-	O
3	O
(	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
).	O

Recent	O
studies	O
by	O
us	O
and	O
other	O
investigators	O
have	O
established	O
the	O
critical	O
role	O
played	O
by	O
inflammatory	O
mediators	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
CINC	O
/	O
GRO	O
-	O
alpha	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
PAF	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
CD40L	O
,	O
C5a	O
,	O
ICAM	O
-	O
1	O
,	O
MIP1	O
-	O
alpha	O
,	O
RANTES	O
,	O
substance	O
P	O
,	O
and	O
hydrogen	O
sulfide	O
in	O
acute	O
pancreatitis	O
and	O
the	O
resultant	O
MODS	O
.	O

Anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
was	O
detected	O
using	O
indirect	O
immunofluorescence	O
technique	O
and	O
quantified	O
by	O
two	O
-	O
fold	O
serial	O
dilutions	O
.	O

Median	O
IgG	O
levels	O
in	O
convalescent	O
-	O
phase	O
sera	B-FUNC
(	O
collected	O
within	O
30	O
days	O
)	O
were	O
compared	O
among	O
patients	O
with	O
different	O
disease	O
severities	O
.	O

A	O
total	O
of	O
325	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
were	O
analyzed	O
;	O
of	O
which	O
301	O
(	O
92	O
.	O
6	O
%)	O
had	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
detected	O
in	O
their	O
sera	B-FUNC
at	O
the	O
time	O
of	O
sampling	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
325	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
were	O
analyzed	O
;	O
of	O
which	O
301	O
(	O
92	O
.	O
6	O
%)	O
had	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
detected	O
in	O
their	O
sera	B-FUNC
at	O
the	O
time	O
of	O
sampling	O
.	O

One	O
pair	O
-	O
Abs	O
,	O
consisting	O
of	O
N	O
protein	O
-	O
specific	O
rabbit	O
polyclonal	O
antibody	B-FUNC
and	O
SARS	O
-	O
CoV	O
N	O
protein	O
-	O
specific	O
mAb	O
,	O
was	O
selected	O
to	O
construct	O
a	O
sandwich	O
ELISA	O
-	O
kit	B-FUNC
.	O

The	O
kit	B-FUNC
was	O
able	O
to	O
specifically	O
detect	O
SARS	O
-	O
CoV	O
N	O
proteins	O
in	O
serum	O
samples	O
.	O

This	O
may	O
negatively	O
influence	O
the	O
virus	O
-	O
receptor	B-FUNC
binding	I-FUNC
and	O
abrogate	O
the	O
infection	O
,	O
with	O
further	O
ramifications	O
by	O
the	O
elevation	O
of	O
vesicular	O
pH	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
infection	O
and	O
spread	O
of	O
SARS	O
CoV	O
at	O
clinically	O
admissible	O
concentrations	O
.	O

This	O
may	O
negatively	O
influence	O
the	O
virus	O
-	O
receptor	B-FUNC
binding	I-FUNC
and	O
abrogate	O
the	O
infection	O
,	O
with	O
further	O
ramifications	O
by	O
the	O
elevation	O
of	O
vesicular	O
pH	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
infection	O
and	O
spread	O
of	O
SARS	O
CoV	O
at	O
clinically	O
admissible	O
concentrations	O
.	O

The	O
neutralizing	O
antibody	B-FUNC
titer	O
of	O
the	O
87	O
positive	O
sera	B-FUNC
was	O
analyzed	O
quantitatively	O
by	O
neutralization	O
assay	O
.	O

The	O
geometric	O
mean	O
titer	O
(	O
GMT	O
)	O
of	O
the	O
87	O
convalescent	O
sera	B-FUNC
was	O
1	O
:	O
61	O
.	O

The	O
Kolmogorov	O
-	O
Smirnov	O
test	O
showed	O
that	O
the	O
neutralizing	O
antibody	B-FUNC
titers	O
conform	O
to	O
normal	O
distribution	O
,	O
which	O
suggests	O
that	O
the	O
average	O
anti	O
-	O
SARS	O
antibody	B-FUNC
level	O
in	O
this	O
study	O
was	O
representative	O
of	O
the	O
convalescent	O
antibody	B-FUNC
level	O
of	O
the	O
SARS	O
population	O
.	O

The	O
relative	O
sensitivity	O
of	O
these	O
primer	O
/	O
probe	O
sets	O
was	O
also	O
examined	O
using	O
human	O
sera	B-FUNC
spiked	O
viruses	O
and	O
clinical	O
specimens	O
from	O
four	O
confirmed	O
SARS	O
patients	O
.	O

We	O
and	O
others	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
by	O
using	O
S	O
fragments	O
of	O
various	O
lengths	O
but	O
all	O
including	O
the	O
amino	O
acid	O
residue	O
318	O
and	O
two	O
other	O
potential	O
glycosylation	O
sites	O
.	O

Mutation	O
of	O
residue	O
T431	O
reduced	O
binding	B-FUNC
by	O
about	O
2	O
-	O
fold	O
,	O
and	O
mutation	O
of	O
the	O
other	O
eight	O
residues	O
--	O
by	O
more	O
than	O
10	O
-	O
fold	O
.	O

Analysis	O
of	O
these	O
data	O
and	O
the	O
mapping	O
of	O
these	O
mutations	O
on	O
the	O
recently	O
determined	O
crystal	O
structure	O
of	O
a	O
fragment	O
containing	O
the	O
RBD	O
complexed	O
to	O
ACE2	O
(	O
Li	O
,	O
F	O
,	O
Li	O
,	O
W	O
,	O
Farzan	O
,	O
M	O
,	O
and	O
Harrison	O
,	O
S	O
.	O
C	O
.,	O
submitted	O
)	O
suggested	O
the	O
existence	O
of	O
two	O
hot	O
spots	O
on	O
the	O
S	O
RBD	O
surface	O
,	O
R426	O
and	O
N473	O
,	O
which	O
are	O
likely	O
to	O
contribute	O
significant	O
portion	O
of	O
the	O
binding	B-FUNC
energy	O
.	O

The	O
finding	O
that	O
most	O
of	O
the	O
mutations	O
(	O
23	O
out	O
of	O
34	O
including	O
glycosylation	O
sites	O
)	O
do	O
not	O
affect	O
the	O
RBD	O
binding	B-FUNC
function	O
indicates	O
possible	O
mechanisms	O
for	O
evasion	O
of	O
immune	O
responses	O
.	O

Compared	O
to	O
the	O
healthy	O
control	O
or	O
the	O
convalescent	O
case	O
,	O
plenty	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
MAPK	B-FUNC
signaling	O
pathway	O
were	O
significantly	O
upregulated	O
in	O
the	O
acute	O
severe	O
case	O
.	O

On	O
the	O
contrary	O
,	O
a	O
lot	O
of	O
IFN	O
-	O
stimulated	O
genes	O
like	O
PKR	O
,	O
GBP	O
-	O
1	O
and	O
2	O
,	O
CXCL	O
-	O
10	O
and	O
11	O
,	O
and	O
JAK	B-FUNC
/	O
STAT	O
signal	O
pathway	O
were	O
downregulated	O
in	O
the	O
acute	O
severe	O
case	O
compared	O
to	O
the	O
convalescent	O
case	O
.	O

On	O
the	O
contrary	O
,	O
a	O
lot	O
of	O
IFN	O
-	O
stimulated	O
genes	O
like	O
PKR	O
,	O
GBP	O
-	O
1	O
and	O
2	O
,	O
CXCL	O
-	O
10	O
and	O
11	O
,	O
and	O
JAK	B-FUNC
/	O
STAT	O
signal	O
pathway	O
were	O
downregulated	O
in	O
the	O
acute	O
severe	O
case	O
compared	O
to	O
the	O
convalescent	O
case	O
.	O

This	O
conclusion	O
was	O
further	O
supported	O
by	O
enzyme	B-FUNC
activity	I-FUNC
assays	O
.	O

A	O
structure	O
-	O
assisted	O
optimization	O
program	O
has	O
yielded	O
compounds	O
with	O
fast	B-FUNC
in	O
vitro	O
inactivation	O
of	O
multiple	O
CoV	O
M	O
(	O
pro	O
)	O
s	O
,	O
potent	O
antiviral	O
activity	O
,	O
and	O
extremely	O
low	O
cellular	O
toxicity	O
in	O
cell	O
-	O
based	O
assays	O
.	O

TITLE	O
:	O
Rational	O
monoclonal	O
antibody	B-FUNC
development	O
to	O
emerging	O
pathogens	O
,	O
biothreat	O
agents	O
and	O
agents	O
of	O
foreign	O
animal	O
disease	O
:	O
The	O
antigen	O
scale	O
.	O

ABSTRACT	O
:	O
Many	O
factors	O
influence	O
the	O
choice	O
of	O
methods	O
used	O
to	O
develop	O
antibody	B-FUNC
to	O
infectious	O
agents	O
.	O

Laboratories	O
with	O
expertise	O
in	O
both	O
methods	O
of	O
antibody	B-FUNC
development	O
have	O
a	O
distinct	O
advantage	O
in	O
their	O
ability	O
to	O
advance	O
mAb	O
technology	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
fusion	O
protein	O
system	O
employing	O
the	O
substrate	O
-	O
binding	B-FUNC
domain	O
(	O
SBD	O
)	O
of	O
poly	O
(	O
hydroxyalkanoate	O
)	O
(	O
PHA	O
)	O
depolymerase	O
was	O
developed	O
for	O
the	O
specific	O
immobilization	O
of	O
proteins	O
on	O
PHA	O
microbeads	O
,	O
and	O
was	O
consequently	O
used	O
for	O
immunoassays	O
.	O

A	O
total	O
of	O
2892	O
clinical	O
serum	O
samples	O
were	O
tested	O
with	O
the	O
ELISA	O
kit	B-FUNC
,	O
which	O
positively	O
identified	O
25	O
of	O
35	O
(	O
71	O
.	O
4	O
%)	O
samples	O
of	O
patients	O
with	O
confirmed	O
SARS	O
infection	O
,	O
286	O
of	O
407	O
(	O
70	O
%)	O
samples	O
of	O
patients	O
suspected	O
of	O
having	O
SARS	O
,	O
229	O
of	O
302	O
(	O
75	O
.	O
8	O
%)	O
samples	O
of	O
convalescent	O
SARS	O
patients	O
,	O
and	O
0	O
of	O
544	O
samples	O
obtained	O
from	O
healthcare	O
workers	O
;	O
only	O
1	O
of	O
1604	O
clinical	O
samples	O
obtained	O
from	O
patients	O
with	O
other	O
diseases	O
demonstrated	O
a	O
weakly	O
positive	O
result	O
.	O

A	O
total	O
of	O
295	O
patients	O
with	O
unexplained	O
respiratory	O
illnesses	O
,	O
admitted	O
to	O
Queen	O
Mary	O
Hospital	O
,	O
Hong	O
Kong	O
SAR	O
,	O
China	O
,	O
in	O
March	O
to	O
July	O
2003	O
,	O
were	O
evaluated	O
for	O
clinical	O
,	O
radiological	O
,	O
haematological	O
and	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
data	O
daily	O
for	O
3	O
days	O
after	O
hospitalisation	O
.	O

The	O
scoring	O
system	O
of	O
attributing	O
11	O
,	O
10	O
,	O
3	O
,	O
3	O
and	O
3	O
points	O
to	O
the	O
presence	O
of	O
independent	O
risk	O
factors	O
,	O
namely	O
:	O
epidemiological	O
link	O
,	O
radiographical	O
deterioration	O
,	O
myalgia	O
,	O
lymphopenia	O
and	O
elevated	O
ALT	B-FUNC
respectively	O
,	O
generated	O
high	O
and	O
low	O
-	O
risk	O
(	O
total	O
score	O
11	O
-	O
30	O
and	O
0	O
-	O
10	O
,	O
respectively	O
)	O
groups	O
for	O
SARS	O
.	O

We	O
therefore	O
studied	O
patient	O
factors	O
associated	O
with	O
the	O
development	O
of	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
),	O
the	O
incidence	O
of	O
organ	O
failure	O
associated	O
with	O
IAH	B-FUNC
,	O
and	O
the	O
effect	O
on	O
outcome	O
in	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

IAH	B-FUNC
was	O
found	O
in	O
21	O
patients	O
(	O
78	O
%).	O

Mortality	O
in	O
the	O
patients	O
with	O
IAH	B-FUNC
was	O
not	O
significantly	O
higher	O
compared	O
to	O
patients	O
without	O
IAH	B-FUNC
(	O
38	O
%	O
versus	O
16	O
%,	O
p	O
=	O
0	O
.	O
63	O
),	O
but	O
patients	O
with	O
IAH	B-FUNC
stayed	O
significantly	O
longer	O
in	O
the	O
ICU	O
and	O
in	O
the	O
hospital	O
.	O

CONCLUSIONS	O
:	O
IAH	B-FUNC
is	O
a	O
frequent	O
finding	O
in	O
patients	O
admitted	O
to	O
the	O
ICU	O
because	O
of	O
SAP	O
,	O
and	O
is	O
associated	O
with	O
a	O
high	O
occurrence	O
rate	O
of	O
organ	O
dysfunction	O
.	O

We	O
characterized	O
the	O
neutralization	O
and	O
viral	O
entry	O
determinants	O
within	O
the	O
ACE2	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
S	O
glycoprotein	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
regulatory	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
NF	O
-	O
kappaB	O
by	O
luciferase	B-FUNC
activity	I-FUNC
assay	O
.	O

TITLE	O
:	O
Protection	O
of	O
mammalian	O
cells	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
by	O
equine	O
neutralizing	O
antibody	B-FUNC
.	O

Adoptive	O
immune	O
therapy	O
with	O
pathogen	O
-	O
specific	O
heterologous	O
immunoglobulin	B-FUNC
has	O
been	O
successfully	O
used	O
to	O
control	O
the	O
dissemination	O
of	O
many	O
viral	O
infections	O
.	O

To	O
investigate	O
whether	O
a	O
neutralizing	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
raised	O
in	O
an	O
artiodactylous	O
host	O
can	O
have	O
a	O
protective	O
role	O
on	O
primate	O
cells	O
,	O
we	O
prepared	O
serum	O
IgGs	O
and	O
their	O
pepsin	O
-	O
digested	O
F	O
(	O
ab	O
')	O
2	O
fragments	O
from	O
horses	O
inoculated	O
with	O
purified	O
SARS	O
-	O
CoV	O
(	O
BJ	O
-	O
01	O
strain	O
).	O

Five	O
of	O
these	O
peptides	O
showed	O
high	O
cross	O
-	O
immunoreactivities	O
(	O
approximately	O
66	O
.	O
7	O
to	O
90	O
.	O
5	O
%)	O
to	O
SARS	O
convalescent	O
patients	O
'	O
sera	B-FUNC
from	O
the	O
severest	O
epidemic	O
regions	O
of	O
the	O
China	O
mainland	O
.	O

Most	O
interestingly	O
,	O
S	O
(	O
471	O
-	O
503	O
),	O
a	O
peptide	O
located	O
at	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
,	O
could	O
specifically	O
block	O
the	O
binding	B-FUNC
between	O
the	O
RBD	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
entrance	O
into	O
host	O
cells	O
in	O
vitro	O
.	O

Using	O
a	O
matrix	O
of	O
antigens	O
specific	O
for	O
different	O
pathogens	O
,	O
a	O
specific	O
T	O
cell	O
profile	O
was	O
generated	O
for	O
each	O
individual	O
by	O
monitoring	O
the	O
intracellular	O
production	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
by	O
flow	O
cytometry	O
.	O

TITLE	O
:	O
Structure	O
of	O
SARS	O
coronavirus	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
complexed	O
with	O
receptor	O
.	O

A	O
defined	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
S	O
mediates	O
this	O
interaction	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
a	O
29	O
-	O
bp	O
insertion	O
in	O
ORF	O
8	O
of	O
bat	O
-	O
SARS	O
-	O
CoV	O
genome	O
,	O
not	O
in	O
most	O
human	O
SARS	O
-	O
CoV	O
genomes	O
,	O
suggests	O
that	O
it	O
has	O
a	O
common	O
ancestor	O
with	O
civet	O
SARS	O
-	O
CoV	O
.	O
Antibody	B-FUNC
against	O
recombinant	O
bat	O
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
by	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

Neutralizing	O
antibody	B-FUNC
to	O
human	O
SARS	O
-	O
CoV	O
also	O
was	O
detected	O
in	O
bats	O
with	O
lower	O
viral	O
loads	O
.	O

TITLE	O
:	O
Generation	O
of	O
human	O
antibody	B-FUNC
fragments	O
recognizing	O
distinct	O
epitopes	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
SARS	O
-	O
CoV	O
protein	O
using	O
a	O
phage	O
display	O
approach	O
.	O

When	O
patients	O
deteriorate	O
clinically	O
despite	O
treatment	O
with	O
ribavirin	O
and	O
corticosteroids	O
,	O
rescue	O
treatment	O
with	O
convalescent	O
plasma	O
and	O
immunoglobulin	B-FUNC
may	O
be	O
beneficial	O
.	O

TITLE	O
:	O
False	O
positive	O
antibody	B-FUNC
results	O
against	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Therefore	O
,	O
antibodies	O
against	O
HTLV	O
were	O
examined	O
in	O
paired	O
-	O
sera	B-FUNC
from	O
26	O
SARS	O
patients	O
.	O

Seroconversion	O
for	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
was	O
observed	O
in	O
all	O
patients	O
.	O

Surprisingly	O
,	O
with	O
the	O
use	O
of	O
ELISA	O
for	O
HTLV	O
,	O
sera	B-FUNC
for	O
13	O
patients	O
were	O
positive	O
for	O
HTLV	O
(	O
50	O
%),	O
and	O
seroconversion	O
for	O
HTLV	O
was	O
also	O
observed	O
in	O
10	O
patients	O
(	O
38	O
.	O
5	O
%).	O

Western	O
blot	O
for	O
HTLV	O
on	O
those	O
26	O
paired	O
-	O
sera	B-FUNC
from	O
13	O
HTLV	O
-	O
positive	O
patients	O
displayed	O
5	O
positive	O
results	O
for	O
HTLV	O
-	O
I	O
,	O
7	O
positive	O
results	O
for	O
HTLV	O
-	O
II	O
,	O
1	O
positive	O
result	O
for	O
both	O
HTLV	O
-	O
I	O
and	O
II	O
,	O
9	O
negative	O
results	O
for	O
either	O
HTLV	O
-	O
I	O
or	O
HTLV	O
-	O
II	O
,	O
and	O
4	O
""""	O
indeterminate	O
""""	O
results	O
.	O

The	O
findings	O
that	O
antibody	B-FUNC
to	O
HTLV	O
can	O
be	O
detected	O
in	O
blood	O
samples	O
collected	O
from	O
SARS	O
patients	O
provide	O
important	O
information	O
for	O
safe	O
handling	O
of	O
blood	O
products	O
.	O

The	O
binding	B-FUNC
behaviors	O
of	O
modified	O
oligodeoxynucleotides	O
to	O
the	O
complementary	O
sequence	O
were	O
studied	O
by	O
UV	O
,	O
CD	O
,	O
and	O
molecular	O
dynamics	O
simulation	O
.	O

The	O
digestion	O
of	O
modified	O
oligodeoxynucleotides	O
by	O
snake	O
venom	O
phosphodiesterase	B-FUNC
showed	O
that	O
an	O
isonucleotide	O
strongly	O
antagonizes	O
hydrolysis	O
.	O

Western	O
-	O
blot	O
showed	O
that	O
the	O
recombinant	O
N	O
protein	O
had	O
high	O
specificity	O
against	O
mouse	O
-	O
anti	O
-	O
N	O
protein	O
-	O
mAb	O
and	O
SARS	O
positive	O
sera	B-FUNC
,	O
but	O
had	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
sera	B-FUNC
.	O

ABSTRACT	O
:	O
Polymorphisms	O
of	O
human	O
Fc	O
gamma	O
-	O
receptor	O
IIA	O
(	O
FcgammaRIIA	O
)	O
and	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
genes	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
or	O
severity	O
of	O
some	O
infectious	O
diseases	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
plus	O
-	O
strand	O
RNA	O
genome	O
of	O
coronaviruses	O
and	O
synthesis	O
of	O
an	O
extensive	O
set	O
of	O
subgenome	O
-	O
length	O
RNAs	O
are	O
mediated	O
by	O
the	O
replicase	O
-	O
transcriptase	B-FUNC
,	O
a	O
membrane	O
-	O
bound	O
protein	O
complex	O
containing	O
several	O
cellular	O
proteins	O
and	O
up	O
to	O
16	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
with	O
multiple	O
enzymatic	O
activities	O
,	O
including	O
protease	O
,	O
polymerase	O
,	O
helicase	O
,	O
methyltransferase	O
,	O
and	O
RNase	O
activities	O
.	O

Levels	O
of	O
virus	O
-	O
specific	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
A	O
and	O
IgG	O
were	O
similar	O
,	O
irrespective	O
of	O
the	O
method	O
of	O
tear	O
induction	O
.	O

Our	O
results	O
showed	O
that	O
STR2	O
protein	O
expression	O
with	O
the	O
use	O
of	O
an	O
138	O
base	O
-	O
pair	O
intron	O
addition	O
increased	O
by	O
1	O
.	O
9	O
-,	O
2	O
.	O
5	O
-,	O
and	O
4	O
.	O
1	O
-	O
fold	O
in	O
Vero	O
E6	O
,	O
QBI	O
-	O
293A	O
cells	O
,	O
and	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
(	O
dihydrofolate	O
reductase	O
[	O
dhfr	B-FUNC
]	O
gene	O
deficient	O
CHO	B-FUNC
cells	O
),	O
respectively	O
.	O

Nevertheless	O
,	O
combination	O
of	O
the	O
intron	O
and	O
the	O
exon	O
splicing	O
enhancers	O
resulted	O
in	O
suppressing	O
the	O
intron	O
-	O
enhancing	O
e	O
STR2	O
protein	O
expression	O
in	O
in	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
.	O

Our	O
studies	O
also	O
demonstrated	O
the	O
STR2	O
protein	O
was	O
mainly	O
as	O
the	O
Endo	O
H	O
-	O
sensitive	O
glycoprotein	O
(	O
115	O
kDa	O
)	O
expressed	O
in	O
Vero	O
E6	O
,	O
QBI	O
-	O
293A	O
,	O
and	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
.	O

However	O
,	O
only	O
a	O
minor	O
form	O
of	O
the	O
Endo	O
H	O
-	O
resistant	O
glycoproteins	O
(	O
approximately	O
130	O
kDa	O
)	O
was	O
detected	O
in	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
.	O

The	O
chemokines	O
interferon	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
monokine	O
induced	O
by	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
MIG	O
),	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
regulated	O
upon	O
activation	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
)	O
were	O
measured	O
by	O
cytometric	O
bead	O
array	O
with	O
a	O
4	O
-	O
color	O
FACSCalibur	O
flow	O
cytometer	O
.	O

Increases	O
in	O
IP	O
-	O
10	O
,	O
MIG	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
during	O
the	O
first	O
week	O
after	O
onset	O
of	O
fever	O
were	O
associated	O
with	O
adverse	O
outcome	O
(	O
intensive	O
care	O
unit	O
admission	O
or	O
death	O
)	O
in	O
the	O
univariate	O
analysis	O
.	O

RESULTS	O
:	O
Increases	O
in	O
IP	O
-	O
10	O
,	O
MIG	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
during	O
the	O
first	O
week	O
after	O
onset	O
of	O
fever	O
were	O
associated	O
with	O
adverse	O
outcome	O
(	O
intensive	O
care	O
unit	O
admission	O
or	O
death	O
)	O
in	O
the	O
univariate	O
analysis	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
erythrocyte	O
reduced	O
glutathione	O
(	O
GSH	O
),	O
tissue	O
malondialdehyde	O
(	O
MDA	O
),	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
and	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
.	O

In	O
the	O
ethanol	O
group	O
,	O
serum	O
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	B-FUNC
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
activities	O
and	O
erythrocyte	O
GSH	O
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

RESULTS	O
:	O
In	O
the	O
ethanol	O
group	O
,	O
serum	O
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	B-FUNC
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
activities	O
and	O
erythrocyte	O
GSH	O
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

Many	O
research	O
organizations	O
require	O
screening	O
for	O
viral	O
agents	O
of	O
all	O
cell	O
lines	O
,	O
tumours	O
,	O
sera	B-FUNC
and	O
other	O
biologicals	O
before	O
implantation	O
or	O
inoculation	O
into	O
animal	O
models	O
.	O

PCR	O
-	O
based	O
detection	O
of	O
MHV	O
did	O
not	O
reveal	O
any	O
contamination	O
of	O
the	O
tumour	O
examined	O
by	O
this	O
technique	O
,	O
indicating	O
that	O
this	O
murine	O
tumour	O
apparently	O
did	O
not	O
transmit	O
MHV	O
or	O
that	O
MHV	O
was	O
eliminated	O
from	O
the	O
tissue	O
so	O
fast	B-FUNC
after	O
the	O
infection	O
that	O
it	O
could	O
not	O
be	O
transmitted	O
by	O
the	O
tumour	O
tissue	O
.	O

ABSTRACT	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
blocking	O
drugs	O
improve	O
therapy	O
for	O
rheumatic	O
diseases	O
,	O
but	O
the	O
risk	O
of	O
additional	O
immunosuppression	O
and	O
infection	O
is	O
unclear	O
.	O

FCoV	O
type	O
1	O
viruses	O
induced	O
higher	O
antibody	B-FUNC
titers	O
than	O
FCoV	O
type	O
2	O
,	O
and	O
were	O
more	O
frequently	O
associated	O
with	O
clinical	O
signs	O
and	O
/	O
or	O
feline	O
infectious	O
peritonitis	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
expressed	O
the	O
SARS	O
-	O
CoV	O
M	O
and	O
FLAP	O
proteins	O
in	O
Escherichia	O
coli	O
by	O
utilizing	O
a	O
novel	O
gene	O
fusion	O
expression	O
system	O
that	O
takes	O
advantage	O
of	O
the	O
natural	O
chaperoning	O
properties	O
of	O
the	O
SUMO	O
(	O
small	O
ubiquitin	B-FUNC
-	O
related	O
modifier	O
)	O
tag	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
SARS	O
-	O
CoV	O
genome	O
possibly	O
contains	O
a	O
putative	O
voltage	O
-	O
gated	O
ion	O
channel	O
,	O
structural	O
proteins	O
,	O
a	O
carbon	O
-	O
oxygen	O
lyase	O
,	O
oxidoreductases	O
acting	O
on	O
the	O
CH	O
-	O
OH	O
group	O
of	O
donors	O
,	O
and	O
an	O
ATP	B-FUNC
-	I-FUNC
binding	I-FUNC
cassette	I-FUNC
transporter	I-FUNC
.	O

Strong	O
humoral	O
responses	O
have	O
been	O
found	O
in	O
most	O
patients	O
following	O
SARS	O
-	O
CoV	O
infection	O
,	O
with	O
high	O
titers	O
of	O
neutralizing	O
Abs	O
present	O
in	O
their	O
convalescent	O
sera	B-FUNC
.	O

We	O
further	O
found	O
that	O
3a	O
misexpression	O
induces	O
apoptosis	O
,	O
which	O
could	O
be	O
modulated	O
by	O
cellular	O
cytochrome	B-FUNC
c	I-FUNC
levels	O
and	O
caspase	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
A	O
double	O
-	O
inactivated	O
whole	O
virus	O
candidate	O
SARS	O
coronavirus	O
vaccine	O
stimulates	O
neutralising	O
and	O
protective	O
antibody	B-FUNC
responses	O
.	O

Mice	O
that	O
were	O
immunised	O
twice	O
with	O
the	O
candidate	O
SARS	O
-	O
CoV	O
vaccine	O
developed	O
high	O
antibody	B-FUNC
titres	O
against	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
and	O
high	O
levels	O
of	O
neutralising	O
antibodies	O
.	O

In	O
addition	O
,	O
cell	O
mediated	O
immunity	O
as	O
measured	O
by	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
and	O
interleukin	O
-	O
4	O
stimulation	O
,	O
was	O
elicited	O
by	O
vaccination	O
.	O

Moreover	O
,	O
the	O
vaccine	O
confers	O
protective	O
immunity	O
as	O
demonstrated	O
by	O
prevention	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
after	O
intranasal	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Protection	O
of	O
mice	O
was	O
correlated	O
to	O
antibody	B-FUNC
titre	O
against	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
neutralising	O
antibody	B-FUNC
titre	O
.	O

Following	O
induction	O
of	O
acute	O
lung	O
injury	O
,	O
gut	O
epithelial	O
proliferation	O
and	O
apoptosis	O
were	O
assessed	O
in	O
a	O
)	O
C3H	O
/	O
HeN	O
wild	O
-	O
type	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
lack	O
functional	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
n	O
=	O
17	O
);	O
b	O
)	O
C57Bl	O
/	O
6	O
mice	O
that	O
received	O
monoclonal	O
anti	O
-	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
or	O
control	O
antibody	B-FUNC
(	O
n	O
=	O
22	O
);	O
and	O
c	O
)	O
C57Bl	O
/	O
6	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
that	O
overexpress	O
Bcl	O
-	O
2	O
in	O
their	O
gut	O
epithelium	O
(	O
n	O
=	O
21	O
).	O

Anti	O
-	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
antibody	B-FUNC
had	O
no	O
effect	O
on	O
gut	O
epithelial	O
proliferation	O
or	O
death	O
.	O

Six	O
mutants	O
,	O
including	O
four	O
at	O
the	O
putative	O
active	O
site	O
,	O
were	O
significantly	O
reduced	O
in	O
endoribonuclease	B-FUNC
activity	I-FUNC
.	O

This	O
idea	O
was	O
supported	O
by	O
titration	O
experiments	O
showing	O
that	O
enzyme	B-FUNC
activity	I-FUNC
was	O
strongly	O
concentration	O
-	O
dependent	O
,	O
indicating	O
that	O
oligomeric	O
Nsp15	O
is	O
the	O
active	O
form	O
.	O

SARS	O
-	O
Cov	O
infection	O
stimulates	O
cytokines	O
(	O
e	O
.	O
g	O
.,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
etc	O
.	O

The	O
spike	O
protein	O
and	O
neucleocapsid	O
protein	O
are	O
most	O
abundant	O
in	O
SARS	O
-	O
Cov	O
and	O
contribute	O
dominantly	O
to	O
the	O
antibody	B-FUNC
production	O
during	O
the	O
course	O
of	O
disease	O
.	O

Spike	O
protein	O
,	O
especially	O
the	O
ACE	O
-	O
2	O
binding	B-FUNC
region	O
(	O
318	O
-	O
510aa	O
)	O
is	O
capable	O
of	O
producing	O
neutralizing	O
antibody	B-FUNC
to	O
SARS	O
-	O
Cov	O
.	O

The	O
aza	O
-	O
peptide	O
component	O
of	O
APE	O
binds	B-FUNC
in	O
the	O
substrate	O
-	O
binding	B-FUNC
regions	O
of	O
M	O
(	O
pro	O
)	O
in	O
a	O
substrate	O
-	O
like	O
manner	O
,	O
with	O
excellent	O
structural	O
and	O
chemical	O
complementarity	O
.	O

In	O
addition	O
,	O
the	O
crystal	O
structure	O
of	O
unbound	O
M	O
(	O
pro	O
)	O
in	O
the	O
space	O
group	O
C2	O
revealed	O
that	O
the	O
""""	O
N	O
-	O
fingers	O
""""	O
(	O
N	O
-	O
terminal	O
residues	O
1	O
to	O
7	O
)	O
of	O
both	O
protomers	O
of	O
M	O
(	O
pro	O
)	O
are	O
well	O
defined	O
and	O
the	O
substrate	O
-	O
binding	B-FUNC
regions	O
of	O
both	O
protomers	O
are	O
in	O
the	O
catalytically	O
competent	O
conformation	O
at	O
the	O
crystallization	O
pH	O
of	O
6	O
.	O
5	O
,	O
contrary	O
to	O
the	O
previously	O
determined	O
crystal	O
structures	O
of	O
unbound	O
M	O
(	O
pro	O
)	O
in	O
the	O
space	O
group	O
P2	O
(	O
1	O
).	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	B-FUNC
to	O
protein	O
X4	O
expressed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
significance	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-FUNC
,	O
detected	O
by	O
ELISA	O
and	O
indirect	O
immunofluorescence	O
assays	O
(	O
IFA	O
)	O
for	O
the	O
SARS	O
-	O
CoV	O
Vero	O
E6	O
cell	O
lysates	O
,	O
in	O
non	O
-	O
SARS	O
subjects	O
,	O
114	O
serum	O
samples	O
from	O
healthy	O
controls	O
and	O
104	O
serum	O
specimens	O
from	O
autoimmune	O
disease	O
patients	O
were	O
collected	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
spike	O
(	O
S	O
)	O
proteins	O
are	O
responsible	O
for	O
binding	B-FUNC
and	O
fusion	O
with	O
target	O
cells	O
and	O
thus	O
play	O
an	O
essential	O
role	O
in	O
virus	O
infection	O
.	O

It	O
binds	B-FUNC
to	O
the	O
viral	O
RNA	O
genome	O
and	O
forms	O
the	O
ribonucleoprotein	O
core	O
.	O

Here	O
we	O
show	O
that	O
the	O
N	O
protein	O
consists	O
of	O
two	O
non	O
-	O
interacting	O
structural	O
domains	O
,	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
(	O
residues	O
45	O
-	O
181	O
)	O
and	O
the	O
C	O
-	O
terminal	O
dimerization	O
domain	O
(	O
residues	O
248	O
-	O
365	O
)	O
(	O
DD	O
),	O
surrounded	O
by	O
flexible	O
linkers	O
.	O

This	O
molecular	O
beacon	O
-	O
based	O
PCR	O
kit	B-FUNC
is	O
useful	O
for	O
the	O
different	O
units	O
.	O

We	O
investigated	O
the	O
possible	O
association	O
between	O
these	O
HCoVs	O
in	O
the	O
respiratory	O
tract	O
and	O
KD	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
(	O
RT	O
)	O
PCR	O
and	O
viral	O
culture	O
in	O
a	O
geographically	O
and	O
ethnically	O
diverse	O
population	O
.	O

Scalable	O
transcriptional	O
analysis	O
routine	O
(	O
STAR	O
)	O
represents	O
a	O
novel	O
integration	O
of	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
capillary	O
electrophoresis	O
that	O
allows	O
detection	O
of	O
dozens	O
of	O
gene	O
transcripts	O
in	O
a	O
multiplexed	O
format	O
using	O
amplicon	O
size	O
as	O
an	O
identifier	O
for	O
each	O
target	O
.	O

TITLE	O
:	O
pH	O
-	O
dependent	O
conformational	O
flexibility	O
of	O
the	O
SARS	O
-	O
CoV	O
main	O
proteinase	B-FUNC
(	O
M	O
(	O
pro	O
))	O
dimer	O
:	O
molecular	O
dynamics	O
simulations	O
and	O
multiple	O
X	O
-	O
ray	O
structure	O
analyses	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
M	O
(	O
pro	O
))	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
processing	O
of	O
the	O
viral	O
polyproteins	O
and	O
thus	O
an	O
attractive	O
target	O
for	O
the	O
discovery	O
of	O
drugs	O
directed	O
against	O
SARS	O
.	O

Stimulated	O
by	O
the	O
binding	B-FUNC
mechanism	O
of	O
SARS	O
-	O
CoV	O
Mpro	O
with	O
the	O
octapeptide	O
AVLQSGFR	O
reported	O
recently	O
as	O
well	O
as	O
the	O
""""	O
Chou	O
'	O
s	O
distorted	O
key	O
""""	O
theory	O
,	O
we	O
synthesized	O
the	O
octapeptide	O
AVLQSGFR	O
for	O
conducting	O
various	O
biochemical	O
experiments	O
to	O
investigate	O
the	O
antiviral	O
potential	O
of	O
the	O
octapeptide	O
against	O
SARS	O
coronavirus	O
(	O
BJ	O
-	O
01	O
).	O

The	O
expressed	O
S1	O
protein	O
of	O
CCV	O
,	O
which	O
was	O
identified	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
can	O
be	O
specifically	O
recognized	O
by	O
polyclonal	O
antibody	B-FUNC
against	O
CCV	O
.	O

We	O
describe	O
a	O
general	O
protocol	O
for	O
preparation	O
of	O
pure	B-FUNC
,	O
monodisperse	O
third	O
-	O
generation	O
mannosylated	O
poly	O
-	O
L	O
-	O
lysine	O
dendrimer	O
-	O
peptide	O
conjugates	O
using	O
direct	O
,	O
machine	O
-	O
assisted	O
Fmoc	O
/	O
t	O
-	O
Bu	O
solid	O
phase	O
peptide	O
synthesis	O
.	O

All	O
these	O
probes	O
showed	O
a	O
fast	B-FUNC
,	O
clear	O
-	O
cut	O
photochemical	O
reaction	O
,	O
which	O
suggests	O
that	O
they	O
are	O
promising	O
tools	O
for	O
use	O
in	O
photolabeling	O
studies	O
.	O

In	O
a	O
fluorimetric	O
enzyme	O
assay	O
using	O
a	O
novel	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
pair	O
labeled	O
substrate	O
,	O
compound	O
6b	O
showed	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
35	O
.	O
3	O
muM	O
.	O
Since	O
the	O
novel	O
lead	O
compound	O
does	O
not	O
target	O
the	O
S1	O
',	O
S1	O
,	O
and	O
S2	O
subsites	O
of	O
the	O
enzyme	O
'	O
s	O
substrate	O
-	O
binding	B-FUNC
pockets	O
,	O
there	O
is	O
room	O
for	O
improvement	O
that	O
underlines	O
the	O
lead	O
character	O
of	O
compound	O
6b	O
.	O

Multiple	O
factors	O
contributed	O
to	O
this	O
vascular	O
insult	O
included	O
hypercoagulabe	O
status	O
related	O
to	O
both	O
SARS	O
coronavirous	O
and	O
the	O
usage	O
of	O
intravenous	O
immunoglobulin	B-FUNC
,	O
septic	O
and	O
cardiogenic	O
shock	O
,	O
and	O
possible	O
vasculitis	O
.	O

Deletions	O
that	O
presumably	O
disrupt	O
the	O
structure	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
diminished	O
its	O
RNA	O
-	O
binding	B-FUNC
activity	O
.	O

The	O
use	O
of	O
inactivated	O
SARS	O
virus	O
with	O
MF59	O
enhanced	O
the	O
CD4	O
and	O
antibody	B-FUNC
response	O
even	O
after	O
gene	O
-	O
based	O
vaccination	O
.	O

One	O
such	O
virus	O
that	O
we	O
studied	O
had	O
acquired	O
two	O
putative	O
heparan	O
sulfate	O
-	O
binding	B-FUNC
sites	O
while	O
preserving	O
another	O
site	O
in	O
the	O
furin	O
-	O
cleavage	O
motif	O
.	O

The	O
adaptation	O
of	O
the	O
virus	O
through	O
the	O
use	O
of	O
heparan	O
sulfate	O
as	O
an	O
attachment	O
/	O
entry	O
receptor	O
was	O
demonstrated	O
by	O
increased	O
heparin	B-FUNC
binding	I-FUNC
as	O
well	O
as	O
by	O
inhibition	O
of	O
infection	O
through	O
treatment	O
of	O
cells	O
and	O
the	O
virus	O
with	O
heparinase	O
and	O
heparin	O
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
sera	B-FUNC
of	O
immunized	O
mice	O
could	O
also	O
react	O
specifically	O
with	O
SARS	O
-	O
CoV	O
particles	O
.	O

Similarly	O
,	O
the	O
sera	B-FUNC
of	O
immunized	O
mice	O
could	O
also	O
react	O
specifically	O
with	O
SARS	O
-	O
CoV	O
particles	O
.	O

Intravaginal	O
or	O
intranasal	O
immunization	O
by	O
HIV	O
-	O
NS	O
with	O
diameters	O
ranging	O
360	O
to	O
1230	O
nm	O
significantly	O
induced	O
vaginal	O
antibody	B-FUNC
responses	O
.	O

RESULTS	O
:	O
After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
were	O
induced	O
by	O
SARS	O
-	O
CoV	O
in	O
the	O
interferon	O
group	O
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

Serological	O
tests	O
included	O
SARS	O
IgG	O
antibody	B-FUNC
and	O
IgM	O
antibodies	O
against	O
influenza	O
B	O
,	O
parainfluenza	O
virus	O
types	O
1	O
-	O
3	O
,	O
adenovirus	O
type	O
3	O
,	O
7	O
and	O
respiratory	O
syncytial	O
virus	O
by	O
using	O
commercial	O
ELISA	O
kits	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
serum	O
SARS	O
IgG	O
antibody	B-FUNC
positive	O
rate	O
was	O
found	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
among	O
2	O
,	O
757	O
serum	O
samples	O
.	O

On	O
the	O
other	O
hand	O
,	O
after	O
using	O
interferon	O
,	O
all	O
four	O
respiratory	O
viruses	O
(	O
parainfluenza	O
virus	O
types	O
1	O
-	O
3	O
influenza	O
B	O
,	O
adenovirus	O
types	O
3	O
,	O
7	O
and	O
respiratory	O
syncytial	O
virus	O
)	O
in	O
interferon	O
group	O
had	O
lower	O
IgM	O
antibody	B-FUNC
positive	O
rates	O
than	O
those	O
in	O
control	O
group	O
.	O

RESULTS	O
:	O
No	O
statistically	O
significant	O
difference	O
in	O
serum	O
SARS	O
IgG	O
antibody	B-FUNC
positive	O
rate	O
was	O
found	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
among	O
2	O
,	O
757	O
serum	O
samples	O
.	O

Syncytia	O
inhibition	O
assay	O
was	O
established	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
,	O
and	O
compared	O
parallelly	O
with	O
SARS	O
pseudovirus	O
neutralization	O
assay	O
.	O

This	O
cell	O
-	O
cell	O
fusion	O
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
.	O

SARS	O
-	O
CoV	O
receptor	O
ACE	O
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
assay	O
.	O

This	O
cell	O
-	O
cell	O
fusion	O
assay	O
could	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
receptor	O
ACE	O
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
assay	O
.	O

The	O
immunogenicity	O
was	O
analyzed	O
by	O
Western	O
Blot	O
and	O
ELISA	O
using	O
serologically	O
confirmed	O
sera	B-FUNC
from	O
SARS	O
patients	O
and	O
the	O
sera	B-FUNC
from	O
healthy	O
donors	O
was	O
used	O
as	O
control	O
at	O
the	O
same	O
assay	O
.	O

Western	O
Blot	O
and	O
ELISA	O
analysis	O
showed	O
that	O
the	O
S1c	O
protein	O
could	O
be	O
specifically	O
recognized	O
by	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

Western	O
Blot	O
and	O
ELISA	O
analysis	O
showed	O
that	O
the	O
S1c	O
protein	O
could	O
be	O
specifically	O
recognized	O
by	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Cross	O
-	O
reactivity	O
of	O
antibody	B-FUNC
against	O
SARS	O
-	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
.	O

ABSTRACT	O
:	O
Infection	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
induced	O
a	O
strong	O
anti	O
-	O
nucleocapsid	O
(	O
anti	O
-	O
N	O
)	O
antibody	B-FUNC
response	O
.	O

In	O
a	O
neutralization	O
assay	O
,	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
-	O
induced	O
STAT	O
3	O
phosphorylation	O
in	O
rat	O
intestinal	O
epithelial	O
IEC	O
-	O
18	O
cells	O
was	O
completely	O
suppressed	O
by	O
the	O
anti	O
-	O
N	O
scFv	O
clone	O
L9N01	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
a	O
patient	O
with	O
severe	O
Churg	O
-	O
Strauss	O
syndrome	O
by	O
a	O
combination	O
of	O
pulse	O
corticosteroids	O
,	O
pulse	O
cyclophosphamide	O
,	O
and	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	B-FUNC
.	O

A	O
second	O
pulse	O
corticosteroids	O
and	O
pulse	O
cyclophosphamide	O
followed	O
by	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	B-FUNC
brought	O
about	O
a	O
dramatic	O
improvement	O
of	O
alveolar	O
hemorrhage	O
,	O
cardiac	O
impairment	O
,	O
and	O
peripheral	O
neuropathy	O
.	O

In	O
the	O
6	O
patients	O
from	O
whom	O
serum	O
samples	O
were	O
available	O
,	O
all	O
had	O
a	O
4	O
-	O
fold	O
change	O
in	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
titer	O
and	O
/	O
or	O
presence	O
of	O
IgM	O
against	O
CoV	O
-	O
HKU1	O
.	O

Its	O
sequence	O
is	O
similar	O
to	O
yeast	O
YBR022W	O
(	O
also	O
known	O
as	O
Poa1P	O
),	O
a	O
known	O
phosphatase	B-FUNC
that	O
acts	O
on	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphate	O
(	O
Appr	O
-	O
1	O
''-	O
p	O
).	O

The	O
SARS	O
nsP3	O
domain	O
readily	O
removes	O
the	O
1	O
''	O
phosphate	O
group	O
from	O
Appr	O
-	O
1	O
''-	O
p	O
in	O
in	O
vitro	O
assays	O
,	O
confirming	O
its	O
phosphatase	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Development	O
of	O
one	O
-	O
step	O
,	O
real	O
-	O
time	O
,	O
quantitative	O
reverse	O
transcriptase	B-FUNC
PCR	O
assays	O
for	O
absolute	O
quantitation	O
of	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
very	O
sensitive	O
and	O
specific	O
TaqMan	O
-	O
based	O
,	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
for	O
the	O
rapid	O
detection	O
and	O
quantitation	O
of	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
OC43	O
and	O
229E	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
Cov	O
spike	O
protein	O
:	O
soluble	O
expression	O
in	O
E	O
.	O
coli	O
,	O
purification	O
and	O
functional	O
characterization	O
.	O

The	O
receptor	B-FUNC
binding	I-FUNC
ability	O
of	O
the	O
purified	O
soluble	O
RBD	O
protein	O
was	O
then	O
detected	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
.	O

Further	O
flow	O
cytometry	O
assay	O
demonstrated	O
the	O
high	O
efficiency	O
of	O
RBD	O
'	O
s	O
binding	B-FUNC
ability	O
to	O
ACE2	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
positive	O
Vero	O
E6	O
cell	O
.	O

The	O
geometrical	O
mean	O
of	O
GST	O
and	O
GST	O
/	O
RBD	O
binding	B-FUNC
to	O
Vero	O
E6	O
cells	O
were	O
77	O
.	O
08	O
and	O
352	O
.	O
73	O
respectively	O
.	O

In	O
this	O
paper	O
,	O
we	O
get	O
sufficient	O
soluble	O
N	O
terminal	O
GST	O
tagged	O
RBD	O
protein	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
);	O
data	O
from	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
demonstrate	O
that	O
the	O
recombinant	O
protein	O
is	O
functional	O
and	O
binding	B-FUNC
to	O
ACE2	O
positive	O
Vero	O
E6	O
cell	O
efficiently	O
.	O

And	O
the	O
recombinant	O
RBD	O
derived	O
from	O
E	O
.	O
coli	O
can	O
be	O
used	O
to	O
developing	O
subunit	O
vaccine	O
to	O
block	O
S	O
protein	B-FUNC
binding	I-FUNC
with	O
receptor	O
and	O
to	O
neutralizing	O
SARS	O
-	O
Cov	O
infection	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
paper	O
,	O
we	O
get	O
sufficient	O
soluble	O
N	O
terminal	O
GST	O
tagged	O
RBD	O
protein	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
);	O
data	O
from	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
demonstrate	O
that	O
the	O
recombinant	O
protein	O
is	O
functional	O
and	O
binding	B-FUNC
to	O
ACE2	O
positive	O
Vero	O
E6	O
cell	O
efficiently	O
.	O

Classic	O
plasma	O
markers	O
of	O
endothelial	O
injury	O
,	O
tPA	B-FUNC
and	O
sTM	O
significantly	O
elevated	O
in	O
SARS	O
patients	O
in	O
comparison	O
to	O
controls	O
[	O
t	O
-	O
PA	O
:	O
1	O
.	O
48	O
+/-	O

Increased	O
plasma	O
concentrations	O
of	O
tPA	B-FUNC
and	O
sTM	O
in	O
patients	O
with	O
SARS	O
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

RESULTS	O
:	O
Classic	O
plasma	O
markers	O
of	O
endothelial	O
injury	O
,	O
tPA	B-FUNC
and	O
sTM	O
significantly	O
elevated	O
in	O
SARS	O
patients	O
in	O
comparison	O
to	O
controls	O
[	O
t	O
-	O
PA	O
:	O
1	O
.	O
48	O
+/-	O

CONCLUSIONS	O
:	O
Increased	O
plasma	O
concentrations	O
of	O
tPA	B-FUNC
and	O
sTM	O
in	O
patients	O
with	O
SARS	O
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

TITLE	O
:	O
Seroprevalence	O
of	O
SARS	O
coronavirus	O
antibody	B-FUNC
in	O
household	O
contacts	O
.	O

SARS	O
CoV	O
total	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
(	O
IgG	O
,	O
IgA	O
,	O
and	O
IgM	O
[	O
IgGAM	O
])	O
was	O
the	O
first	O
antibody	B-FUNC
to	O
be	O
detectable	O
.	O

In	O
contrast	O
,	O
neutralizing	O
antibody	B-FUNC
and	O
SARS	O
CoV	O
IgGAM	O
and	O
IgG	O
antibody	B-FUNC
titers	O
remained	O
stable	O
over	O
this	O
period	O
.	O

The	O
SARS	O
CoV	O
antibody	B-FUNC
response	O
was	O
sometimes	O
associated	O
with	O
an	O
increase	O
in	O
preexisting	O
IF	O
IgG	O
antibody	B-FUNC
titers	O
for	O
human	O
coronaviruses	O
OC43	O
,	O
229E	O
,	O
and	O
NL63	O
.	O

In	O
contrast	O
,	O
patients	O
who	O
had	O
OC43	O
infections	O
,	O
and	O
probably	O
also	O
229E	O
infections	O
,	O
without	O
prior	O
exposure	O
to	O
SARS	O
CoV	O
had	O
increases	O
of	O
antibodies	O
specific	O
for	O
the	O
infecting	O
virus	O
but	O
not	O
for	O
SARS	O
CoV	O
.	O
There	O
is	O
a	O
need	O
for	O
awareness	O
of	O
cross	O
-	O
reactive	O
antibody	B-FUNC
responses	O
between	O
coronaviruses	O
when	O
interpreting	O
IF	O
serology	O
.	O

Using	O
a	O
novel	O
data	O
representation	O
,	O
we	O
developed	O
a	O
system	O
termed	O
MULTIPRED	O
that	O
can	O
predict	O
peptide	B-FUNC
binding	I-FUNC
to	O
multiple	O
related	O
human	O
leukocyte	O
antigens	O
(	O
HLA	O
).	O

By	O
implementing	O
ANN	O
as	O
a	O
classification	O
engine	O
,	O
we	O
enabled	O
both	O
the	O
prediction	O
of	O
peptides	O
binding	B-FUNC
to	O
multiple	O
individual	O
HLA	O
-	O
A2	O
molecules	O
and	O
the	O
prediction	O
of	O
promiscuous	O
binders	O
using	O
a	O
single	O
model	O
.	O

ABSTRACT	O
:	O
Pyrrolobenzoxazepinones	O
(	O
PBOs	O
)	O
represent	O
a	O
new	O
class	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
nonnucleoside	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
inhibitors	O
(	O
NNRTIs	O
)	O
whose	O
prototype	O
is	O
5	O
.	O

Structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
are	O
discussed	O
in	O
terms	O
of	O
a	O
possible	O
interaction	O
with	O
the	O
RT	O
binding	B-FUNC
site	O
,	O
depending	O
on	O
the	O
nature	O
of	O
the	O
substituents	O
at	O
C	O
-	O
6	O
.	O

TITLE	O
:	O
Effect	O
of	O
mutations	O
in	O
the	O
mouse	O
hepatitis	O
virus	O
3	O
'(+)	O
42	O
protein	B-FUNC
binding	I-FUNC
element	O
on	O
RNA	O
replication	O
.	O

Defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
replication	O
assays	O
have	O
demonstrated	O
a	O
role	O
for	O
the	O
3	O
'(+)	O
42	O
host	O
protein	B-FUNC
binding	I-FUNC
element	O
in	O
the	O
MHV	O
life	O
cycle	O
.	O

Using	O
gel	O
mobility	O
shift	O
RNase	B-FUNC
T1	I-FUNC
protection	O
assays	O
and	O
secondary	O
structure	O
modeling	O
,	O
we	O
have	O
characterized	O
a	O
possible	O
role	O
for	O
RNA	O
secondary	O
structure	O
in	O
host	O
protein	B-FUNC
binding	I-FUNC
to	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	O
element	O
.	O

TITLE	O
:	O
[	O
Expression	O
and	O
renaturation	O
of	O
a	O
novel	O
human	O
single	O
-	O
chain	O
Fv	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
].	O

All	O
of	O
these	O
data	O
suggested	O
that	O
the	O
SR	O
-	O
rich	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
might	O
play	O
an	O
import	O
role	O
in	O
the	O
transformation	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
between	O
the	O
dimer	O
and	O
multimer	O
during	O
its	O
binding	B-FUNC
to	O
its	O
central	O
region	O
for	O
self	O
-	O
association	O
or	O
dissociation	O
.	O

Sera	B-FUNC
were	O
collected	O
in	O
large	O
amounts	O
at	O
the	O
peak	O
,	O
where	O
IgG	O
was	O
precipitated	O
using	O
ammonium	O
sulphate	O
and	O
subsequently	O
digested	O
with	O
pepsin	O
.	O

The	O
sera	B-FUNC
collected	O
at	O
the	O
peak	O
were	O
then	O
purified	O
.	O

RESULTS	O
:	O
The	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
peaked	O
at	O
approximately	O
week	O
7	O
after	O
the	O
first	O
immunization	O
,	O
with	O
a	O
maximum	O
value	O
of	O
1	O
:	O
14210	O
.	O

ABSTRACT	O
:	O
Rituximab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	B-FUNC
approved	O
for	O
malignant	O
lymphoma	O
,	O
is	O
being	O
increasingly	O
,	O
effectively	O
,	O
and	O
safely	O
used	O
for	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
and	O
other	O
humoral	O
autoimmune	O
disorders	O
.	O

N	O
protein	O
is	O
composed	O
of	O
three	O
distinct	O
regions	O
containing	O
RNA	O
-	O
binding	B-FUNC
motif	O
(	O
s	O
),	O
and	O
appropriate	O
signals	O
for	O
modulating	O
cell	O
signalling	O
.	O

Here	O
,	O
we	O
characterized	O
temporal	O
changes	O
in	O
N	O
protein	O
-	O
specific	O
and	O
S	O
glycoprotein	O
-	O
specific	O
neutralizing	O
antibody	B-FUNC
(	O
Nab	O
)	O
responses	O
in	O
infected	O
patients	O
who	O
have	O
either	O
recovered	O
from	O
or	O
succumbed	O
to	O
SARS	O
-	O
CoV	O
infection	O
.	O

PEDV	O
shedding	O
was	O
monitored	O
every	O
day	O
and	O
virus	O
levels	O
were	O
measured	O
using	O
a	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
7a	O
protein	O
blocks	O
cell	O
cycle	O
progression	O
at	O
G0	O
/	O
G1	O
phase	O
via	O
the	O
cyclin	B-FUNC
D3	O
/	O
pRb	O
pathway	O
.	O

After	O
analyzing	O
the	O
cellular	O
proteins	O
involving	O
in	O
regulation	O
of	O
cell	O
cycle	O
progression	O
,	O
we	O
demonstrated	O
that	O
ORF7a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	B-FUNC
D3	O
level	O
of	O
mRNA	O
transcription	O
and	O
expression	O
,	O
and	O
phosphorylation	O
of	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
ser795	O
and	O
ser809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	B-FUNC
D1	O
,	O
D2	O
,	O
cdk4	O
and	O
cdk6	O
in	O
HEK	O
293	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
insufficient	O
expression	O
of	O
cyclin	B-FUNC
D3	O
may	O
cause	O
a	O
decreased	O
activity	O
of	O
cyclin	B-FUNC
D	O
/	O
cdk4	O
/	O
6	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
Rb	O
phosphorylation	O
.	O

However	O
,	O
in	O
combination	O
with	O
JHM	O
S	O
,	O
the	O
expression	O
of	O
HE	O
,	O
regardless	O
of	O
whether	O
it	O
retained	O
esterase	B-FUNC
activity	I-FUNC
or	O
not	O
,	O
resulted	O
in	O
increased	O
viral	O
spread	O
within	O
the	O
central	O
nervous	O
system	O
and	O
in	O
increased	O
neurovirulence	O
.	O

We	O
performed	O
bioinformatics	O
analysis	O
on	O
16	O
papain	O
-	O
like	O
protease	O
domains	O
from	O
nine	O
different	O
coronaviruses	O
and	O
identified	O
a	O
putative	O
catalytic	O
triad	O
(	O
Cys1651	O
-	O
His1812	O
-	O
Asp1826	O
)	O
and	O
zinc	O
-	O
binding	B-FUNC
site	O
.	O

Mutagenesis	O
studies	O
revealed	O
that	O
Asp1826	O
and	O
the	O
four	O
cysteine	O
residues	O
involved	O
in	O
zinc	B-FUNC
binding	I-FUNC
are	O
essential	O
for	O
SARS	O
-	O
CoV	O
PLpro	O
activity	O
.	O

Structural	O
bioinformatics	O
has	O
revealed	O
a	O
relationship	O
for	O
the	O
SARS	O
-	O
CoV	O
PLpro	O
to	O
herpesvirus	O
-	O
associated	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
(	O
HAUSP	O
),	O
a	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
,	O
indicating	O
potential	O
deubiquitinating	O
activity	O
in	O
addition	O
to	O
its	O
function	O
in	O
polyprotein	O
processing	O
(	O
T	O
.	O
Sulea	O
,	O
H	O
.	O
A	O
.	O
Lindner	O
,	O
E	O
.	O
O	O
.	O
Purisima	O
,	O
and	O
R	O
.	O
Menard	O
,	O
J	O
.	O
Virol	O
.	O

The	O
purified	O
enzyme	O
hydrolyzed	O
ubiquitin	B-FUNC
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
(	O
Ub	O
-	O
AMC	O
),	O
a	O
general	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
substrate	O
,	O
with	O
a	O
catalytic	O
efficiency	O
of	O
13	O
,	O
100	O
M	O
(-	O
1	O
)	O
s	O
(-	O
1	O
),	O
220	O
-	O
fold	O
more	O
efficiently	O
than	O
the	O
small	O
synthetic	O
peptide	O
substrate	O
Z	O
-	O
LRGG	O
-	O
AMC	O
,	O
which	O
incorporates	O
the	O
C	O
-	O
terminal	O
four	O
residues	O
of	O
ubiquitin	B-FUNC
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
PLpro	O
was	O
inhibited	O
by	O
the	O
specific	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
inhibitor	O
ubiquitin	B-FUNC
aldehyde	O
,	O
with	O
an	O
inhibition	O
constant	O
of	O
210	O
nM	O
.	O
The	O
purified	O
SARS	O
-	O
CoV	O
PLpro	O
disassembles	O
branched	O
polyubiquitin	O
chains	O
with	O
lengths	O
of	O
two	O
to	O
seven	O
(	O
Ub2	O
-	O
7	O
)	O
or	O
four	O
(	O
Ub4	O
)	O
units	O
,	O
which	O
involves	O
isopeptide	O
bond	O
cleavage	O
.	O

SARS	O
-	O
CoV	O
PLpro	O
processing	O
activity	O
was	O
also	O
detected	O
against	O
a	O
protein	O
fused	O
to	O
the	O
C	O
terminus	O
of	O
the	O
ubiquitin	B-FUNC
-	O
like	O
modifier	O
ISG15	O
,	O
both	O
in	O
vitro	O
using	O
the	O
purified	O
enzyme	O
and	O
in	O
HeLa	O
cells	O
by	O
coexpression	O
with	O
SARS	O
-	O
CoV	O
PLpro	O
(	O
aa	O
1198	O
to	O
2009	O
).	O

TITLE	O
:	O
Soluble	O
receptor	O
-	O
mediated	O
targeting	O
of	O
mouse	O
hepatitis	O
coronavirus	O
to	O
the	O
human	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
.	O

ABSTRACT	O
:	O
The	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
infects	O
murine	O
cells	O
by	O
binding	B-FUNC
of	O
its	O
spike	O
(	O
S	O
)	O
protein	O
to	O
murine	O
CEACAM1a	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
this	O
cellular	O
receptor	O
(	O
soR	B-FUNC
)	O
is	O
sufficient	O
for	O
S	O
binding	B-FUNC
and	O
for	O
subsequent	O
induction	O
of	O
the	O
conformational	O
changes	O
required	O
for	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

To	O
this	O
end	O
,	O
the	O
soR	B-FUNC
domain	O
was	O
coupled	O
to	O
single	O
-	O
chain	O
monoclonal	O
antibody	B-FUNC
425	O
,	O
which	O
is	O
directed	O
against	O
the	O
human	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
),	O
resulting	O
in	O
a	O
bispecific	O
adapter	O
protein	O
(	O
soR	B-FUNC
-	O
425	O
).	O

The	O
soR	B-FUNC
and	O
soR	B-FUNC
-	O
425	O
proteins	O
,	O
both	O
produced	O
with	O
the	O
vaccinia	O
virus	O
system	O
,	O
were	O
able	O
to	O
neutralize	O
MHV	O
infection	O
of	O
murine	O
LR7	O
cells	O
.	O

However	O
,	O
only	O
soR	B-FUNC
-	O
425	O
was	O
able	O
to	O
target	O
MHV	O
to	O
human	O
EGFR	B-FUNC
-	O
expressing	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
the	O
soR	B-FUNC
-	O
425	O
-	O
mediated	O
infections	O
were	O
blocked	O
by	O
heptad	O
repeat	O
-	O
mimicking	O
peptides	O
,	O
indicating	O
that	O
virus	O
entry	O
requires	O
the	O
regular	O
S	O
protein	O
fusion	O
process	O
.	O

We	O
conclude	O
that	O
the	O
specific	O
spike	O
-	O
binding	B-FUNC
property	O
of	O
the	O
CEACAM1a	O
N	O
-	O
terminal	O
fragment	O
can	O
be	O
exploited	O
to	O
direct	O
the	O
virus	O
to	O
selected	O
cells	O
by	O
linking	O
it	O
to	O
a	O
moiety	O
able	O
to	O
bind	B-FUNC
a	O
receptor	O
on	O
those	O
cells	O
.	O

TITLE	O
:	O
Absence	O
of	O
heme	O
oxygenase	B-FUNC
-	O
1	O
expression	O
in	O
the	O
lung	O
parenchyma	O
exacerbates	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
decreases	O
surfactant	O
protein	O
-	O
B	O
levels	O
.	O

In	O
addition	O
,	O
other	O
anti	O
-	O
viral	O
treatment	O
,	O
RNA	O
interference	O
,	O
monoclonal	O
antibody	B-FUNC
,	O
synthetic	O
peptides	O
,	O
and	O
vaccines	O
are	O
being	O
developed	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-FUNC
response	O
and	O
SARS	O
severity	O
.	O

ABSTRACT	O
:	O
Using	O
the	O
Taiwan	O
nationwide	O
laboratory	O
-	O
confirmed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
database	O
,	O
we	O
analyzed	O
neutralizing	O
antibody	B-FUNC
in	O
relation	O
to	O
clinical	O
outcomes	O
.	O

With	O
a	O
linear	O
mixed	O
model	O
,	O
neutralizing	O
antibody	B-FUNC
titer	O
was	O
shown	O
to	O
peak	O
between	O
week	O
5	O
and	O
week	O
8	O
after	O
onset	O
and	O
to	O
decline	O
thereafter	O
,	O
with	O
a	O
half	O
-	O
life	O
of	O
6	O
.	O
4	O
weeks	O
.	O

Patients	O
with	O
a	O
longer	O
illness	O
showed	O
a	O
lower	O
neutralizing	O
antibody	B-FUNC
response	O
than	O
patients	O
with	O
a	O
shorter	O
illness	O
duration	O
(	O
p	O
=	O
0	O
.	O
008	O
).	O

When	O
early	O
responders	O
were	O
compared	O
with	O
most	O
patients	O
,	O
who	O
seroconverted	O
on	O
and	O
after	O
week	O
3	O
of	O
illness	O
,	O
the	O
small	O
proportion	O
(	O
17	O
.	O
4	O
%)	O
of	O
early	O
responders	O
(	O
antibody	B-FUNC
detectable	O
within	O
2	O
weeks	O
)	O
had	O
a	O
higher	O
death	O
rate	O
(	O
29	O
.	O
6	O
%	O
vs	O
.	O
7	O
.	O
8	O
%)	O
(	O
Fisher	O
exact	O
test	O
,	O
p	O
=	O
0	O
.	O
004	O
),	O
had	O
a	O
shorter	O
survival	O
time	O
of	O
<	O
2	O
weeks	O
(	O
Fisher	O
exact	O
test	O
,	O
p	O
=	O
0	O
.	O
013	O
),	O
and	O
were	O
more	O
likely	O
to	O
be	O
>	O
60	O
years	O
of	O
age	O
(	O
Fisher	O
exact	O
test	O
,	O
p	O
=	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Virtual	O
screening	O
,	O
a	O
fast	B-FUNC
,	O
computational	O
approach	O
to	O
identify	O
drug	O
leads	O
[	O
Perola	O
,	O
E	O
.;	O
Xu	O
,	O
K	O
.;	O
Kollmeyer	O
,	O
T	O
.	O
M	O
.;	O
Kaufmann	O
,	O
S	O
.	O
H	O
.;	O
Prendergast	O
,	O
F	O
.	O
G	O
.	O
J	O
.	O
Med	O
.	O

This	O
approach	O
has	O
not	O
been	O
able	O
to	O
identify	O
active	O
inhibitors	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
using	O
solely	O
the	O
crystal	O
structures	O
of	O
a	O
SARS	O
-	O
CoV	O
cysteine	O
proteinase	B-FUNC
with	O
a	O
flexible	O
loop	O
in	O
the	O
active	O
site	O
[	O
Yang	O
,	O
H	O
.	O
T	O
.;	O
Yang	O
,	O
M	O
.	O
J	O
.;	O
Ding	O
,	O
Y	O
.;	O
Liu	O
,	O
Y	O
.	O
W	O
.;	O
Lou	O
,	O
Z	O
.	O
Y	O
.	O
Proc	O
.	O

A	O
small	O
-	O
molecule	O
inhibitor	O
of	O
SARS	O
-	O
CoV	O
,	O
exhibiting	O
an	O
effective	O
concentration	O
(	O
EC50	O
)	O
of	O
23	O
microM	O
in	O
cell	O
-	O
based	O
assays	O
,	O
was	O
identified	O
through	O
virtual	O
screening	O
against	O
a	O
computer	O
-	O
predicted	O
model	O
of	O
the	O
cysteine	O
proteinase	B-FUNC
.	O

Screening	O
against	O
two	O
crystal	O
structures	O
of	O
the	O
same	O
proteinase	B-FUNC
failed	O
to	O
identify	O
the	O
23	O
-	O
microM	O
inhibitor	O
.	O

The	O
fold	O
of	O
the	O
protein	O
is	O
the	O
first	O
member	O
of	O
a	O
further	O
variation	O
of	O
the	O
immunoglobulin	B-FUNC
like	O
beta	O
-	O
sandwich	O
fold	O
.	O

High	O
structural	O
similarity	O
to	O
Dl	O
domains	O
of	O
ICAM	O
-	O
1	O
and	O
ICAM	O
-	O
2	O
,	O
and	O
common	O
features	O
in	O
amino	O
acid	O
sequence	O
between	O
X4	O
and	O
ICAM	O
-	O
1	O
,	O
suggest	O
X4	O
to	O
possess	O
binding	B-FUNC
activity	O
for	O
the	O
alpha	O
(	O
L	O
)	O
integrin	O
I	O
domain	O
of	O
LFA	O
-	O
1	O
.	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
octapeptide	O
acts	O
as	O
a	O
dimerization	O
inhibitor	O
of	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

Accurate	O
determination	O
of	O
the	O
dimer	O
dissociation	O
constant	O
and	O
the	O
role	O
of	O
the	O
N	O
-	O
finger	O
(	O
residues	O
1	O
-	O
7	O
)	O
will	O
provide	O
more	O
insights	O
into	O
the	O
enzyme	O
catalytic	O
mechanism	O
of	O
SARS	O
3CL	O
proteinase	B-FUNC
.	O

This	O
study	O
describes	O
the	O
first	O
example	O
of	O
inhibitors	O
targeting	O
the	O
dimeric	O
interface	O
of	O
SARS	O
3CL	O
proteinase	B-FUNC
,	O
providing	O
a	O
novel	O
strategy	O
for	O
drug	O
design	O
against	O
SARS	O
and	O
other	O
coronaviruses	O
.	O

The	O
binding	B-FUNC
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
to	O
cellular	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
first	O
step	O
in	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
small	O
peptides	O
designed	O
to	O
disrupt	O
the	O
binding	B-FUNC
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
ACE2	O
.	O

Like	O
the	O
N	O
-	O
terminal	O
RNA	B-FUNC
binding	I-FUNC
domain	O
(	O
SARS	O
-	O
N45	O
-	O
181	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
N	O
protein	O
,	O
the	O
crystal	O
structure	O
of	O
the	O
IBV	O
-	O
N29	O
-	O
160	O
fragment	O
at	O
1	O
.	O
85	O
A	O
resolution	O
reveals	O
a	O
protein	O
core	O
composed	O
of	O
a	O
five	O
-	O
stranded	O
antiparallel	O
beta	O
sheet	O
with	O
a	O
positively	O
charged	O
beta	O
hairpin	O
extension	O
and	O
a	O
hydrophobic	O
platform	O
that	O
are	O
probably	O
involved	O
in	O
RNA	B-FUNC
binding	I-FUNC
.	O

All	O
of	O
them	O
except	O
one	O
,	O
who	O
missed	O
blood	O
sampling	O
at	O
1	O
month	O
,	O
tested	O
positive	O
for	O
the	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibody	B-FUNC
at	O
1	O
month	O
.	O

The	O
IgG	O
antibody	B-FUNC
of	O
all	O
17	O
patients	O
,	O
whose	O
serum	O
was	O
checked	O
1	O
year	O
after	O
disease	O
onset	O
,	O
remained	O
positive	O
.	O

TITLE	O
:	O
Functional	O
and	O
genetic	O
analysis	O
of	O
coronavirus	O
replicase	O
-	O
transcriptase	B-FUNC
proteins	O
.	O

Also	O
,	O
we	O
have	O
identified	O
mutations	O
in	O
the	O
non	O
-	O
structural	O
proteins	O
nsp	O
4	O
,	O
nsp5	O
,	O
nsp10	O
,	O
nsp12	O
,	O
nsp14	O
,	O
and	O
nsp16	O
that	O
are	O
responsible	O
for	O
the	O
ts	O
phenotype	O
of	O
eight	O
MHV	O
-	O
A59	O
mutants	O
,	O
which	O
allows	O
us	O
to	O
conclude	O
that	O
these	O
proteins	O
are	O
essential	O
for	O
the	O
assembly	O
of	O
a	O
functional	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
.	O

About	O
35	O
%-	O
40	O
%	O
took	O
more	O
time	O
to	O
rest	B-FUNC
,	O
for	O
relaxation	O
or	O
doing	O
exercise	O
.	O

A	O
novel	O
theory	O
known	O
as	O
autoantigen	O
complementarity	O
suggests	O
that	O
an	O
infectious	O
agent	O
could	O
trigger	O
antineutrophil	O
cytoplasmic	O
antibody	B-FUNC
-	O
associated	O
vasculitis	O
.	O

Analyses	O
of	O
cytochrome	B-FUNC
c	I-FUNC
release	O
further	O
revealed	O
an	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
.	O

However	O
,	O
treatment	O
with	O
a	O
caspase	O
-	O
8	O
inhibitor	O
only	O
slightly	O
blocked	O
cytochrome	B-FUNC
c	I-FUNC
release	O
from	O
the	O
mitochondria	O
.	O

There	O
was	O
no	O
effect	O
of	O
milk	O
replacer	O
feeding	O
on	O
concentrations	O
of	O
nonesterified	O
fatty	O
acids	O
,	O
total	O
protein	O
,	O
or	O
growth	B-FUNC
hormone	I-FUNC
concentrations	O
.	O

TITLE	O
:	O
Binding	B-FUNC
site	O
-	O
based	O
classification	O
of	O
coronaviral	O
papain	O
-	O
like	O
proteases	O
.	O

Using	O
consensus	O
fold	O
recognition	O
with	O
the	O
3D	O
-	O
JURY	O
meta	O
-	O
predictor	O
followed	O
by	O
model	O
building	O
and	O
refinement	O
,	O
we	O
developed	O
a	O
structural	O
model	O
for	O
the	O
single	O
PLpro	O
present	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
genome	O
,	O
based	O
on	O
significant	O
structural	O
relationships	O
to	O
the	O
catalytic	O
core	O
domain	O
of	O
HAUSP	O
,	O
a	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
(	O
USP	B-FUNC
).	O

By	O
combining	O
the	O
SCoV	O
PLpro	O
model	O
with	O
comparative	O
sequence	O
analyses	O
we	O
show	O
that	O
all	O
currently	O
known	O
coronaviral	O
PLpros	O
can	O
be	O
classified	O
into	O
two	O
groups	O
according	O
to	O
their	O
binding	B-FUNC
site	O
architectures	O
.	O

One	O
group	O
includes	O
all	O
PL2pros	O
and	O
some	O
of	O
the	O
PL1pros	O
,	O
which	O
are	O
characterized	O
by	O
a	O
restricted	O
USP	B-FUNC
-	O
like	O
binding	B-FUNC
site	O
.	O

This	O
two	O
-	O
group	O
,	O
binding	B-FUNC
site	O
-	O
based	O
classification	O
is	O
consistent	O
with	O
experimental	O
data	O
accumulated	O
to	O
date	O
for	O
the	O
specificity	O
of	O
PLpro	O
-	O
mediated	O
polyprotein	O
processing	O
and	O
PLpro	O
inhibition	O
.	O

The	O
control	O
and	O
simvastatin	O
groups	O
had	O
similar	O
serum	O
levels	O
and	O
similar	O
bronchoalveolar	O
lavage	O
fluid	O
levels	O
of	O
cytokines	O
(	O
interleukin	O
-	O
1	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
)	O
and	O
P	O
-	O
selectin	B-FUNC
at	O
all	O
measurements	O
,	O
except	O
for	O
a	O
significantly	O
higher	O
level	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
P	O
-	O
selectin	B-FUNC
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
006	O
).	O

L	O
-	O
SIGN	O
,	O
encoded	O
by	O
CLEC4M	O
(	O
also	O
known	O
as	O
CD209L	O
),	O
is	O
a	O
SARS	O
-	O
CoV	O
binding	B-FUNC
receptor	O
that	O
has	O
polymorphism	O
in	O
its	O
extracellular	O
neck	O
region	O
encoded	O
by	O
the	O
tandem	O
repeat	O
domain	O
in	O
exon	O
4	O
.	O

Compared	O
with	O
cells	O
heterozygous	O
for	O
L	O
-	O
SIGN	O
,	O
cells	O
homozygous	O
for	O
L	O
-	O
SIGN	O
show	O
higher	O
binding	B-FUNC
capacity	O
for	O
SARS	O
-	O
CoV	O
,	O
higher	O
proteasome	O
-	O
dependent	O
viral	O
degradation	O
and	O
a	O
lower	O
capacity	O
for	O
trans	O
infection	O
.	O

Western	O
blot	O
analysis	O
using	O
phosphospecific	O
antibodies	O
indicated	O
that	O
7a	O
protein	O
activated	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
),	O
but	O
not	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	O
kinase	O
/	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
7a	O
protein	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
cellular	O
translation	O
and	O
activate	O
p38	B-FUNC
MAPK	B-FUNC
.	O

We	O
developed	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
SARS	O
-	O
CoV	O
nucleoprotein	O
and	O
used	O
it	O
together	O
with	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
to	O
analyze	O
the	O
autopsy	O
lung	O
tissues	O
of	O
32	O
patients	O
with	O
SARS	O
from	O
Hong	O
Kong	O
and	O
Toronto	O
.	O

Serial	O
plasma	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
(	O
IL	O
-	O
1beta	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
of	O
preserved	O
serum	O
were	O
measured	O
by	O
enzyme	O
immunoassay	O
.	O

The	O
median	O
duration	O
from	O
onset	O
of	O
fever	O
to	O
the	O
nadir	O
level	O
or	O
most	O
severe	O
condition	O
was	O
9	O
days	O
for	O
hypoxia	O
,	O
7	O
days	O
for	O
lymphocytopenia	O
,	O
6	O
.	O
5	O
days	O
for	O
thrombocytopenia	O
,	O
9	O
.	O
5	O
days	O
for	O
maximal	O
pulmonary	O
infiltrates	O
;	O
to	O
peak	O
serum	O
levels	O
was	O
9	O
days	O
for	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
10	O
.	O
5	O
days	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
13	O
.	O
5	O
days	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
12	O
days	O
for	O
TNF	O
-	O
alpha	O
;	O
to	O
defervescence	O
was	O
13	O
days	O
.	O

Rapid	O
elevation	O
of	O
inflammatory	O
cytokines	O
-	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
alpha	O
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
SARS	O
-	O
related	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
Rapid	O
elevation	O
of	O
inflammatory	O
cytokines	O
-	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
alpha	O
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
SARS	O
-	O
related	O
ARDS	O
.	O

The	O
antibody	B-FUNC
of	O
SARS	O
-	O
IgG	O
,	O
T	O
cell	O
subsets	O
,	O
chest	O
CT	O
,	O
and	O
the	O
pulmonary	O
function	O
were	O
observed	O
in	O
patients	O
1	O
month	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
and	O
2	O
years	O
after	O
convalescence	O
from	O
SARS	O
.	O

Despite	O
these	O
differences	O
,	O
however	O
,	O
the	O
immunodominant	O
T	O
-	O
cell	O
ELISpot	O
responses	O
to	O
each	O
of	O
the	O
three	O
immunogens	O
were	O
elicited	O
by	O
the	O
same	O
N	O
peptides	O
,	O
with	O
the	O
greatest	O
responses	O
being	O
generated	O
by	O
a	O
cluster	O
of	O
five	O
overlapping	O
peptides	O
,	O
N76	O
-	O
114	O
,	O
each	O
of	O
which	O
contained	O
nonameric	O
H2d	O
binding	B-FUNC
domains	O
with	O
high	O
binding	B-FUNC
scores	O
for	O
both	O
class	O
I	O
and	O
,	O
except	O
for	O
N76	O
-	O
93	O
,	O
class	O
II	O
alleles	O
.	O

The	O
pronounced	O
Th	O
-	O
2	O
and	O
humoral	O
response	O
to	O
N	O
protein	O
plus	O
adjuvant	O
are	O
in	O
contrast	O
to	O
the	O
balanced	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
responses	O
and	O
strong	O
memory	O
CTL	O
responses	O
to	O
the	O
LAMP	O
-	O
N	O
chimera	O
.	O

Antibody	B-FUNC
titers	O
were	O
measured	O
by	O
plaque	O
reduction	O
neutralization	O
test	O
.	O

We	O
assessed	O
the	O
safety	O
of	O
the	O
SARS	O
vaccine	O
and	O
observed	O
whether	O
the	O
antibody	B-FUNC
dependent	O
enhancement	O
(	O
ADE	O
)	O
occurred	O
under	O
low	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
in	O
rhesus	O
.	O

The	O
purity	O
of	O
SARS	O
vaccine	O
was	O
97	O
.	O
6	O
%	O
by	O
HPLC	O
identification	O
and	O
reacted	O
with	O
convalescent	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Under	O
low	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
,	O
no	O
exacerbation	O
of	O
clinical	O
symptoms	O
was	O
observed	O
when	O
the	O
immunized	O
monkeys	O
were	O
challenged	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
preliminary	O
animal	O
trial	O
,	O
no	O
side	O
effects	O
were	O
detected	O
when	O
monkeys	O
were	O
immunized	O
with	O
purified	O
SARS	O
vaccine	O
either	O
at	O
normal	O
or	O
large	O
doses	O
.	O

TITLE	O
:	O
Virus	O
safety	O
of	O
intravenous	O
immunoglobulin	B-FUNC
:	O
future	O
challenges	O
.	O

The	O
severe	O
""""	O
two	O
-	O
hit	O
""""	O
aspirate	O
of	O
the	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
was	O
correctly	O
predicted	O
in	O
21	O
of	O
24	O
rats	O
,	O
23	O
of	O
23	O
wild	O
-	O
type	O
mice	O
,	O
and	O
21	O
of	O
21	O
MCP	B-FUNC
-	O
1	O
(-/-)	O
mice	O
.	O

RESULTS	O
:	O
Overall	O
,	O
the	O
four	O
types	O
of	O
aspiration	O
were	O
correctly	O
discriminated	O
in	O
85	O
of	O
96	O
rats	O
(	O
89	O
%),	O
72	O
of	O
78	O
wild	O
-	O
type	O
mice	O
(	O
92	O
%),	O
and	O
59	O
of	O
73	O
MCP	B-FUNC
-	O
1	O
(-/-)	O
mice	O
(	O
81	O
%)	O
by	O
models	O
that	O
used	O
a	O
maximum	O
of	O
only	O
two	O
mediators	O
.	O

Cytokines	O
and	O
chemokines	O
that	O
best	O
predicted	O
the	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
were	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
6	O
h	O
)	O
and	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
)	O
in	O
rats	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
)	O
in	O
wild	O
-	O
type	O
mice	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
keratinocyte	O
-	O
derived	O
cytokine	O
(	O
24	O
h	O
)	O
in	O
MCP	B-FUNC
-	O
1	O
(-/-)	O
mice	O
.	O

The	O
concentrations	O
of	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
in	O
BALF	O
and	O
plasma	O
,	O
as	O
well	O
as	O
plasma	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
,	O
also	O
were	O
decreased	O
in	O
eNOS	O
-	O
Tg	O
mice	O
.	O

TITLE	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
is	O
a	O
pluripotent	O
growth	O
and	O
permeability	O
factor	O
that	O
has	O
a	O
broad	O
impact	O
on	O
endothelial	O
cell	O
function	O
.	O

This	O
method	O
uses	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
of	O
the	O
spike	O
gene	O
to	O
obtain	O
RFLP	O
patterns	O
that	O
correlate	O
with	O
serotype	O
.	O

For	O
example	O
,	O
infliximab	O
,	O
a	O
monoclonal	O
TNF	O
antibody	B-FUNC
,	O
was	O
experimentally	O
tested	O
in	O
rats	O
and	O
it	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
pathologic	O
score	O
and	O
serum	O
amylase	B-FUNC
activity	I-FUNC
,	O
and	O
also	O
alleviate	O
alveolar	O
edema	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
no	O
studies	O
are	O
available	O
in	O
clinical	O
human	O
acute	O
pancreatitis	O
.	O

(	O
4	O
)	O
Compared	O
with	O
Nc	O
group	O
,	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TGF	O
-	O
beta1	O
in	O
both	O
serum	O
and	O
BALF	O
of	O
P1	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
levels	O
of	O
these	O
cytokines	O
in	O
P2	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
P1	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
significantly	O
lower	O
in	O
P	O
+	O
D	O
group	O
compared	O
with	O
P2	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Our	O
results	O
show	O
that	O
MHV	O
can	O
be	O
genetically	O
redirected	O
via	O
adapters	O
composed	O
of	O
the	O
S	O
protein	B-FUNC
binding	I-FUNC
part	O
of	O
mCEACAM1a	O
and	O
a	O
targeting	O
peptide	O
recognizing	O
a	O
nonnative	O
receptor	O
expressed	O
on	O
human	O
cells	O
,	O
consequently	O
leading	O
to	O
rapid	O
cell	O
death	O
.	O

To	O
address	O
the	O
importance	O
of	O
these	O
fatty	O
acylations	O
to	O
coronavirus	O
infection	O
,	O
we	O
exposed	O
infected	O
cells	O
to	O
2	O
-	O
bromopalmitate	O
(	O
2	O
-	O
BP	O
),	O
a	O
specific	O
PAT	B-FUNC
inhibitor	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
(	O
S	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
interaction	O
between	O
the	O
host	O
cell	O
and	O
the	O
truncated	O
S	O
fragments	O
to	O
identify	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
two	O
recombinant	O
proteins	O
were	O
separately	O
verified	O
by	O
Western	O
blot	O
,	O
purified	O
by	O
nickel	O
-	O
affinity	O
chromatography	O
,	O
and	O
incubated	O
with	O
Vero	O
cells	O
,	O
a	O
susceptible	O
cell	O
line	O
of	O
SARS	O
-	O
CoV	O
infection	O
,	O
for	O
cell	O
binding	B-FUNC
assay	O
.	O

The	O
flow	O
cytometry	O
results	O
showed	O
that	O
the	O
both	O
proteins	O
were	O
able	O
to	O
bind	B-FUNC
Vero	O
cells	O
,	O
but	O
the	O
binding	B-FUNC
ability	O
of	O
S260	O
-	O
600	O
was	O
somewhat	O
stronger	O
than	O
that	O
of	O
S397	O
-	O
796	O
.	O

In	O
contrast	O
,	O
the	O
S260	O
-	O
600	O
protein	O
did	O
not	O
bind	B-FUNC
NIH3T3	O
cells	O
.	O

The	O
S260	O
-	O
600	O
fragment	O
probably	O
contains	O
the	O
important	O
receptor	B-FUNC
binding	I-FUNC
domain	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
the	O
development	O
of	O
SARS	O
vaccine	O
and	O
anti	O
-	O
SARS	O
therapeutics	O
.	O

CONCLUSIONS	O
:	O
Both	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
exhibited	O
different	O
receptor	B-FUNC
binding	I-FUNC
activity	O
.	O

For	O
example	O
,	O
the	O
extraordinary	O
resistance	O
of	O
SJL	O
mice	O
to	O
experimental	O
infections	O
with	O
hepatitis	O
virus	O
strain	O
A59	O
is	O
the	O
consequence	O
of	O
a	O
structural	O
alteration	O
of	O
a	O
cell	O
adhesion	O
molecule	O
which	O
normally	O
binds	B-FUNC
to	O
the	O
spikes	O
of	O
the	O
virus	O
,	O
allowing	O
its	O
entry	O
into	O
the	O
cells	O
.	O

If	O
the	O
virus	O
cannot	O
bind	B-FUNC
to	O
the	O
molecule	O
,	O
or	O
if	O
the	O
molecule	O
is	O
absent	O
,	O
epithelial	O
cells	O
of	O
the	O
intestine	O
and	O
liver	O
are	O
not	O
infected	O
and	O
mice	O
are	O
resistant	O
.	O

Two	O
methods	O
,	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
assay	O
,	O
were	O
used	O
for	O
the	O
detection	O
of	O
the	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
and	O
IgM	O
in	O
335	O
serial	O
sera	B-FUNC
from	O
98	O
SARS	O
patients	O
.	O

In	O
18	O
patients	O
,	O
serum	O
antibody	B-FUNC
profiles	O
were	O
investigated	O
and	O
antibody	B-FUNC
neutralization	O
tests	O
were	O
performed	O
from	O
7	O
to	O
720	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
ELISA	O
analysis	O
using	O
the	O
N	O
antigen	O
or	O
inactivated	O
SARS	O
-	O
CoV	O
particles	O
as	O
capture	O
antigen	O
showed	O
that	O
co	O
-	O
injection	O
of	O
SARS	O
-	O
M	O
could	O
enhance	O
N	O
-	O
induced	O
antibody	B-FUNC
production	O
,	O
especially	O
IgG2a	O
subclass	O
.	O

Cytokine	O
ELISA	O
analysis	O
revealed	O
that	O
co	O
-	O
injection	O
of	O
M	O
could	O
enhance	O
the	O
levels	O
of	O
IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
release	O
induced	O
by	O
N	O
antigen	O
.	O

Immunoglobulin	B-FUNC
kappa	O
light	O
chain	O
(	O
m	O
/	O
z	O
24	O
505	O
)	O
positively	O
correlated	O
with	O
viral	O
load	O
.	O

Specific	O
proteomic	O
fingerprints	O
in	O
the	O
sera	B-FUNC
of	O
adult	O
SARS	O
patients	O
could	O
be	O
used	O
to	O
identify	O
SARS	O
cases	O
early	O
during	O
onset	O
with	O
high	O
specificity	O
and	O
sensitivity	O
.	O

The	O
N	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
bears	O
signature	O
motifs	O
for	O
binding	B-FUNC
to	O
cyclin	B-FUNC
and	O
phosphorylation	O
by	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
(	O
CDK	B-FUNC
)	O
and	O
has	O
recently	O
been	O
reported	O
by	O
us	O
to	O
get	O
phosphorylated	O
by	O
the	O
cyclin	B-FUNC
-	O
CDK	B-FUNC
complex	O
(	O
Surjit	O
,	O
M	O
.,	O
Kumar	O
,	O
R	O
.,	O
Mishra	O
,	O
R	O
.	O
N	O
.,	O
Reddy	O
,	O
M	O
.	O
K	O
.,	O
Chow	O
,	O
V	O
.	O
T	O
.,	O
and	O
Lal	O
,	O
S	O
.	O
K	O
.	O
(	O
2005	O
)	O
J	O
.	O
Virol	O
.	O
79	O
,	O
11476	O
-	O
11486	O
).	O

N	O
protein	O
expression	O
was	O
found	O
to	O
directly	O
inhibit	O
the	O
activity	O
of	O
the	O
cyclin	B-FUNC
-	O
CDK	B-FUNC
complex	O
,	O
resulting	O
in	O
hypophosphorylation	O
of	O
retinoblastoma	O
protein	O
with	O
a	O
concomitant	O
down	O
-	O
regulation	O
in	O
E2F1	O
-	O
mediated	O
transactivation	O
.	O

Analysis	O
of	O
RXL	O
and	O
CDK	B-FUNC
phosphorylation	O
mutant	O
N	O
protein	O
identified	O
the	O
mechanism	O
of	O
inhibition	O
of	O
CDK4	O
and	O
CDK2	O
activity	O
to	O
be	O
different	O
.	O

TITLE	O
:	O
CNS	O
viral	O
infection	O
diverts	O
homing	O
of	O
antibody	B-FUNC
-	O
secreting	O
cells	O
from	O
lymphoid	O
organs	O
to	O
the	O
CNS	O
.	O

A	O
related	O
problem	O
is	O
the	O
low	O
binding	B-FUNC
affinity	O
of	O
crossreactive	O
antibodies	O
able	O
to	O
neutralize	O
a	O
variety	O
of	O
primary	O
isolates	O
.	O

TITLE	O
:	O
Therapy	O
with	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
-	O
neutralizing	O
human	O
monoclonal	O
antibody	B-FUNC
reduces	O
disease	O
severity	O
and	O
viral	O
burden	O
in	O
golden	O
Syrian	O
hamsters	O
.	O

SARS	O
-	O
CoV	O
infections	O
were	O
detected	O
by	O
using	O
enzyme	O
immunoassays	O
and	O
confirmed	O
by	O
a	O
combination	O
of	O
Western	O
blot	O
assays	O
,	O
neutralizing	O
antibody	B-FUNC
tests	O
,	O
and	O
commercial	O
SARS	O
tests	O
.	O

TITLE	O
:	O
Functional	O
peptide	O
microarrays	O
for	O
specific	O
and	O
sensitive	O
antibody	B-FUNC
diagnostics	O
.	O

By	O
using	O
spacer	O
molecules	O
of	O
different	O
type	O
and	O
length	O
for	O
NA	O
-	O
mediated	O
peptide	O
presentation	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
a	O
minimum	O
spacer	O
length	O
is	O
imperative	O
for	O
antibody	B-FUNC
binding	B-FUNC
,	O
whereas	O
the	O
peptide	O
immobilization	O
direction	O
has	O
only	O
secondary	O
importance	O
for	O
antibody	B-FUNC
affinity	O
and	O
binding	B-FUNC
.	O

Ser380	O
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
autophosphorylation	O
by	O
activation	O
of	O
the	O
C	O
-	O
terminal	O
kinase	O
domain	O
,	O
was	O
phosphorylated	O
in	O
confluent	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
,	O
and	O
this	O
phosphorylation	O
was	O
inhibited	O
by	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	B-FUNC
).	O

On	O
the	O
other	O
hand	O
,	O
Both	O
Thr573	O
and	O
Ser380	O
were	O
phosphorylated	O
by	O
treatment	O
with	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
EGF	B-FUNC
)	O
in	O
the	O
absence	O
of	O
p38	B-FUNC
MAPK	B-FUNC
activation	O
.	O

These	O
results	O
indicated	O
that	O
phosphorylation	O
status	O
of	O
p90RSK	O
by	O
SARS	O
-	O
CoV	O
infection	O
is	O
different	O
from	O
that	O
by	O
stimulation	O
of	O
EGF	B-FUNC
.	O

By	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibodies	O
against	O
ADV	O
were	O
detected	O
in	O
55	O
sera	B-FUNC
(	O
31	O
%),	O
against	O
PRCV	O
in	O
five	O
sera	B-FUNC
(	O
3	O
%),	O
PPV	O
in	O
87	O
sera	B-FUNC
(	O
49	O
%),	O
APP	O
in	O
93	O
sera	B-FUNC
(	O
52	O
%),	O
M	O
.	O
hyopneumoniae	O
in	O
38	O
sera	B-FUNC
(	O
21	O
%),	O
Salmonella	O
spp	O
.	O

in	O
85	O
sera	B-FUNC
(	O
47	O
%)	O
and	O
HPS	O
in	O
33	O
sera	B-FUNC
(	O
18	O
%).	O

Potential	O
antigenic	O
epitopes	O
were	O
identified	O
in	O
the	O
structural	O
proteins	O
(	O
nucleocapsid	O
,	O
membrane	O
,	O
spike	O
,	O
and	O
small	O
envelope	O
proteins	O
)	O
and	O
hypothetical	O
proteins	O
(	O
SARS3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
,	O
and	O
9b	O
)	O
that	O
are	O
specific	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
peptide	O
chip	O
platform	O
was	O
created	O
and	O
the	O
profiles	O
of	O
antibodies	O
to	O
these	O
epitopes	O
were	O
investigated	O
in	O
59	O
different	O
SARS	O
patients	O
'	O
sera	B-FUNC
obtained	O
6	O
-	O
103	O
days	O
after	O
the	O
onset	O
of	O
the	O
illness	O
.	O

Serial	O
sera	B-FUNC
from	O
five	O
additional	O
patients	O
were	O
also	O
studied	O
.	O

Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	O
protein	O
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	O
protein	O
elicited	O
strong	O
antibody	B-FUNC
responses	O
.	O

RESULTS	O
:	O
Epitopes	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
membrane	O
protein	O
and	O
the	O
C	O
-	O
terminus	O
of	O
nucleocapsid	O
protein	O
elicited	O
strong	O
antibody	B-FUNC
responses	O
.	O

In	O
contrast	O
,	O
of	O
the	O
898	O
canine	O
serum	O
samples	O
,	O
160	O
(	O
17	O
.	O
8	O
%)	O
were	O
positive	O
for	O
anti	O
-	O
BCoV	O
antibodies	O
,	O
and	O
the	O
antibody	B-FUNC
titers	O
ranged	O
from	O
1	O
:	O
5	O
to	O
more	O
than	O
1	O
:	O
640	O
,	O
with	O
1	O
:	O
160	O
being	O
the	O
most	O
frequent	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
developed	O
a	O
test	O
for	O
the	O
diagnosis	O
and	O
prognostic	O
assessment	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
based	O
on	O
the	O
detection	O
of	O
the	O
SARS	O
-	O
coronavirus	O
RNA	O
in	O
serum	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

An	O
automated	O
nucleic	O
acid	O
extraction	O
platform	O
using	O
the	O
MagNA	O
Pure	B-FUNC
LC	O
instrument	O
(	O
Roche	O
Diagnostics	O
)	O
was	O
evaluated	O
.	O

We	O
developed	O
a	O
modified	O
protocol	O
in	O
compliance	O
with	O
the	O
recommended	O
biosafety	O
guidelines	O
from	O
the	O
World	O
Health	O
Organization	O
based	O
on	O
the	O
use	O
of	O
the	O
MagNA	O
Pure	B-FUNC
total	O
nucleic	O
acid	O
large	O
volume	O
isolation	O
kit	B-FUNC
for	O
the	O
extraction	O
of	O
SARS	O
-	O
coronavirus	O
RNA	O
.	O

The	O
modified	O
protocol	O
was	O
compared	O
with	O
a	O
column	O
-	O
based	O
extraction	O
kit	B-FUNC
(	O
QIAamp	O
viral	O
RNA	O
mini	O
kit	B-FUNC
,	O
Qiagen	O
)	O
for	O
quantitative	O
performance	O
,	O
analytical	O
sensitivity	O
and	O
precision	O
.	O

The	O
newly	O
developed	O
automated	O
protocol	O
was	O
shown	O
to	O
be	O
free	O
from	O
carry	O
-	O
over	O
contamination	O
and	O
have	O
comparable	O
performance	O
with	O
other	O
standard	O
protocols	O
and	O
kits	O
designed	O
for	O
the	O
MagNA	O
Pure	B-FUNC
LC	O
instrument	O
.	O

RESULTS	O
:	O
The	O
newly	O
developed	O
automated	O
protocol	O
was	O
shown	O
to	O
be	O
free	O
from	O
carry	O
-	O
over	O
contamination	O
and	O
have	O
comparable	O
performance	O
with	O
other	O
standard	O
protocols	O
and	O
kits	O
designed	O
for	O
the	O
MagNA	O
Pure	B-FUNC
LC	O
instrument	O
.	O

D	O
:	O
The	O
56th	O
nucleotide	O
and	O
its	O
down	O
stream	O
TRS	B-FUNC
of	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
transcription	O
.	O

Ranked	O
by	O
the	O
luciferase	B-FUNC
activity	I-FUNC
from	O
the	O
highest	O
to	O
the	O
lowest	O
,	O
the	O
order	O
is	O
A549	O
,	O
HepG2	O
,	O
ECV304	O
,	O
HeLa	O
and	O
Vero	O
E6	O
.	O

casei	O
at	O
1	O
-	O
3	O
d	O
of	O
age	O
significantly	O
enhanced	O
the	O
production	O
of	O
anti	O
-	O
BSA	O
antibody	B-FUNC
in	O
DSD	O
-	O
fed	O
chickens	O
(	O
60	O
d	O
of	O
age	O
)	O
administered	O
orally	O
with	O
1	O
mg	O
BSA	O
at	O
32	O
and	O
33	O
d	O
of	O
age	O
and	O
subcutaneously	O
with	O
5	O
microg	O
BSA	O
at	O
33	O
d	O
of	O
age	O
.	O

These	O
results	O
show	O
that	O
crossover	O
acceptor	O
sites	O
for	O
discontinuous	O
transcription	O
(	O
i	O
)	O
need	O
not	O
include	O
the	O
UCUAAAC	O
core	O
and	O
(	O
ii	O
)	O
rest	B-FUNC
within	O
a	O
surprisingly	O
wide	O
5	O
'-	O
proximal	O
""""	O
hotspot	O
.	O

Additionally	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
contribution	O
of	O
two	O
kinases	O
,	O
the	O
MAP	O
kinase	O
p38MAPK	O
,	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	B-FUNC
)	O
delta	O
to	O
antiviral	O
protection	O
from	O
MHV	O
-	O
1	O
infection	O
.	O

The	O
overall	O
prevalence	O
of	O
antibodies	O
against	O
FCoV	O
was	O
31	O
%,	O
significantly	O
higher	O
among	O
pure	B-FUNC
breed	O
cats	O
(	O
65	O
%)	O
than	O
among	O
mixed	O
breed	O
cats	O
(	O
17	O
%).	O

A	O
high	O
proportion	O
of	O
cats	O
with	O
antibodies	O
against	O
FCoV	O
had	O
relatively	O
high	O
antibody	B-FUNC
titres	O
,	O
and	O
was	O
therefore	O
likely	O
to	O
be	O
shedding	O
FCoV	O
in	O
faeces	O
.	O

For	O
Cp	O
felis	O
,	O
the	O
majority	O
of	O
seropositive	O
animals	O
had	O
relatively	O
low	O
antibody	B-FUNC
titres	O
,	O
and	O
the	O
risk	O
of	O
these	O
animals	O
infecting	O
others	O
is	O
not	O
known	O
.	O

Finally	O
,	O
the	O
sera	B-FUNC
of	O
vaccinated	O
mice	O
contained	O
antibodies	O
to	O
S	O
,	O
further	O
suggesting	O
a	O
role	O
for	O
this	O
protein	O
in	O
conferring	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Furthermore	O
,	O
PL1	O
(	O
pro	O
)	O
was	O
confirmed	O
to	O
be	O
flanked	O
at	O
its	O
C	O
terminus	O
by	O
a	O
domain	O
(	O
called	O
X	O
)	O
that	O
mediates	O
ADP	O
-	O
ribose	O
1	O
''-	O
phosphatase	B-FUNC
activity	I-FUNC
.	O

The	O
marker	O
for	O
surfactant	O
degradation	O
was	O
associated	O
with	O
ongoing	O
alveolar	O
inflammation	O
(	O
cellularity	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
concentration	O
).	O

The	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
(	O
CXCL10	O
)	O
is	O
expressed	O
following	O
MHV	O
infection	O
and	O
signals	O
T	O
cells	O
to	O
migrate	O
into	O
the	O
CNS	O
.	O

Administration	O
of	O
anti	O
-	O
CXCR3	O
antibody	B-FUNC
reduced	O
CD4	O
+	O
T	O
cell	O
infiltration	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
05	O
),	O
while	O
CD8	O
+	O
T	O
cell	O
trafficking	O
was	O
not	O
affected	O
.	O

Induction	O
level	O
of	O
suppressor	O
of	O
cytokine	O
signaling	O
-	O
3	O
(	O
SOCS3	O
)	O
by	O
SARS	O
-	O
CoV	O
was	O
significantly	O
lower	O
than	O
that	O
by	O
RSV	O
in	O
spite	O
of	O
the	O
significant	O
production	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

They	O
were	O
interviewed	O
and	O
asked	O
to	O
provide	O
a	O
blood	O
sample	O
for	O
SARS	O
coronavirus	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
testing	O
.	O

When	O
the	O
reactivities	O
of	O
these	O
peptides	O
were	O
screened	O
with	O
human	O
sera	B-FUNC
from	O
five	O
SARS	O
patients	O
,	O
peptides	O
corresponding	O
to	O
residues	O
156	O
-	O
175	O
reacted	O
strongly	O
with	O
sera	B-FUNC
from	O
two	O
of	O
the	O
SARS	O
patients	O
.	O

In	O
contrast	O
,	O
survival	O
was	O
enhanced	O
in	O
both	O
ribavirin	O
-	O
and	O
HRC	O
203	O
-	O
treated	O
mice	O
with	O
a	O
marked	O
reduction	O
in	O
biochemical	O
[	O
ALT	B-FUNC
(	O
max	O
)	O
964	O
+/-	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
relationship	O
between	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
antibody	B-FUNC
titres	O
and	O
age	O
,	O
breed	O
,	O
gender	O
and	O
health	O
status	O
of	O
Australian	O
cats	O
Retrospective	O
study	O
Results	O
from	O
two	O
serological	O
tests	O
that	O
measure	O
FCoV	O
antibody	B-FUNC
levels	O
,	O
the	O
Coronase	O
test	O
and	O
the	O
7B	O
Feline	O
Infectious	O
Peritonitis	O
(	O
FIP	O
)	O
test	O
,	O
were	O
recorded	O
over	O
a	O
2	O
-	O
year	O
period	O
,	O
with	O
patient	O
signalment	O
,	O
history	O
,	O
presenting	O
complaint	O
and	O
the	O
reason	O
for	O
ordering	O
the	O
test	O
(	O
as	O
available	O
).	O

Results	O
from	O
each	O
antibody	B-FUNC
test	O
were	O
related	O
to	O
four	O
explanatory	O
variables	O
(	O
breed	O
,	O
age	O
,	O
gender	O
and	O
health	O
status	O
at	O
the	O
time	O
of	O
blood	O
collection	O
)	O
using	O
univariate	O
ordinal	O
logistic	O
regression	O
analyses	O
,	O
Mann	O
Whitney	O
U	O
tests	O
,	O
one	O
-	O
sample	O
sign	O
tests	O
or	O
Kruskal	O
-	O
Wallis	O
analyses	O
,	O
as	O
appropriate	O
.	O

There	O
were	O
significant	O
differences	O
in	O
median	O
Coronase	O
antibody	B-FUNC
titres	O
between	O
breeds	O
of	O
cats	O
(	O
P	O
<	O
0	O
.	O
0005	O
).	O

There	O
was	O
no	O
statistical	O
relationship	O
between	O
the	O
Coronase	O
or	O
7B	O
FIP	O
antibody	B-FUNC
titres	O
and	O
age	O
,	O
gender	O
or	O
overall	O
health	O
status	O
,	O
even	O
when	O
considering	O
only	O
those	O
cats	O
in	O
which	O
clinical	O
signs	O
suggestive	O
of	O
FIP	O
were	O
present	O
.	O

This	O
study	O
reinforces	O
the	O
complexity	O
of	O
interpreting	O
serological	O
tests	O
for	O
FCoV	O
in	O
both	O
healthy	O
cats	O
and	O
patients	O
with	O
signs	O
compatible	O
with	O
FIR	O
Unique	O
to	O
this	O
study	O
is	O
the	O
detection	O
of	O
a	O
significant	O
relationship	O
between	O
breed	O
and	O
median	O
FCoV	O
antibody	B-FUNC
titre	O
.	O

The	O
distribution	O
of	O
median	O
Coronase	O
antibody	B-FUNC
titres	O
by	O
breed	O
was	O
very	O
similar	O
to	O
the	O
pattern	O
of	O
breed	O
predisposition	O
to	O
FIP	O
recently	O
reported	O
in	O
Sydney	O
.	O

Additionally	O
,	O
pneumocytes	O
and	O
macrophages	O
in	O
the	O
patient	O
'	O
s	O
lung	O
expressed	O
P	O
-	O
selectin	B-FUNC
and	O
DC	O
-	O
SIGN	O
.	O

In	O
in	O
vitro	O
study	O
,	O
we	O
showed	O
that	O
the	O
A549	O
and	O
THP	O
-	O
1	O
cell	O
lines	O
were	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
.	O
A549	O
cells	O
produced	O
CCL2	O
/	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
)	O
and	O
CXCL8	O
/	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
after	O
interaction	O
with	O
SARS	O
-	O
CoV	O
and	O
expressed	O
P	O
-	O
selectin	B-FUNC
and	O
VCAM	O
-	O
1	O
.	O

TITLE	O
:	O
[	O
Some	O
medical	O
staff	O
positive	O
for	O
serum	O
SARS	O
coronavirus	O
antibody	B-FUNC
IgG	O
have	O
only	O
mild	O
symptoms	O
].	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
employed	O
to	O
detect	O
serum	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
in	O
the	O
lysate	O
of	O
whole	O
SARS	O
coronavirus	O
from	O
19	O
SARS	O
patients	O
and	O
200	O
medical	O
staff	O
members	O
without	O
obvious	O
SARS	O
symptoms	O
after	O
possible	O
exposure	O
to	O
the	O
virus	O
during	O
routine	O
medical	O
practice	O
.	O

Serum	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
was	O
detected	O
in	O
all	O
the	O
19	O
SARS	O
patients	O
,	O
and	O
among	O
the	O
200	O
staff	O
members	O
,	O
20	O
(	O
10	O
%)	O
were	O
found	O
positive	O
for	O
the	O
antibody	B-FUNC
but	O
with	O
no	O
obvious	O
or	O
only	O
mild	O
symptoms	O
.	O

Serum	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
is	O
positive	O
in	O
a	O
small	O
proportion	O
(	O
around	O
10	O
%)	O
of	O
the	O
medical	O
staff	O
members	O
exposed	O
to	O
the	O
virus	O
in	O
our	O
hospital	O
,	O
but	O
may	O
not	O
cause	O
obvious	O
symptoms	O
,	O
suggesting	O
SARS	O
coronavirus	O
infection	O
might	O
in	O
some	O
cases	O
have	O
mild	O
or	O
even	O
no	O
clinical	O
manifestations	O
.	O

RESULTS	O
:	O
Serum	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
was	O
detected	O
in	O
all	O
the	O
19	O
SARS	O
patients	O
,	O
and	O
among	O
the	O
200	O
staff	O
members	O
,	O
20	O
(	O
10	O
%)	O
were	O
found	O
positive	O
for	O
the	O
antibody	B-FUNC
but	O
with	O
no	O
obvious	O
or	O
only	O
mild	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
Serum	O
IgG	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
is	O
positive	O
in	O
a	O
small	O
proportion	O
(	O
around	O
10	O
%)	O
of	O
the	O
medical	O
staff	O
members	O
exposed	O
to	O
the	O
virus	O
in	O
our	O
hospital	O
,	O
but	O
may	O
not	O
cause	O
obvious	O
symptoms	O
,	O
suggesting	O
SARS	O
coronavirus	O
infection	O
might	O
in	O
some	O
cases	O
have	O
mild	O
or	O
even	O
no	O
clinical	O
manifestations	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
signaling	O
in	O
oligodendroglia	O
delays	O
coronavirus	O
clearance	O
without	O
altering	O
demyelination	O
.	O

To	O
examine	O
the	O
anti	O
-	O
viral	O
and	O
/	O
or	O
regulatory	O
role	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
signaling	O
in	O
the	O
cell	O
that	O
synthesizes	O
and	O
maintains	O
the	O
myelin	O
sheath	O
,	O
we	O
analyzed	O
JHMV	O
pathogenesis	O
in	O
transgenic	O
mice	O
expressing	O
a	O
dominant	O
-	O
negative	O
IFN	O
-	O
gamma	O
receptor	O
on	O
oligodendroglia	O
.	O

To	O
reveal	O
a	O
role	O
for	O
innate	O
effectors	O
in	O
anti	O
-	O
viral	O
immunity	O
and	O
neurological	O
disease	O
,	O
JHMV	O
pathogenesis	O
was	O
studied	O
in	O
mice	O
deficient	O
in	O
interleukin	O
-	O
15	O
(	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-/-)	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

Clinical	O
disease	O
,	O
CNS	O
inflammation	O
and	O
demyelination	O
in	O
infected	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-/-	O
mice	O
were	O
similar	O
to	O
wild	O
-	O
type	O
mice	O
.	O

Despite	O
the	O
absence	O
of	O
NK	O
cells	O
and	O
suboptimal	O
CD8	O
+	O
T	O
cell	O
responses	O
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-/-	O
mice	O
controlled	O
JHMV	O
replication	O
as	O
efficiently	O
as	O
wild	O
-	O
type	O
mice	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
as	O
an	O
active	O
C2	O
crystallographic	O
dimer	O
.	O

ABSTRACT	O
:	O
The	O
34	O
kDa	O
main	O
proteinase	B-FUNC
(	O
Mpro	O
)	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
life	O
cycle	O
through	O
the	O
specific	O
processing	O
of	O
viral	O
polyproteins	O
.	O

A	O
cross	O
-	O
neutralization	O
test	O
using	O
sera	B-FUNC
to	O
various	O
IBV	O
seroptypes	O
was	O
performed	O
.	O

This	O
study	O
should	O
aid	O
in	O
the	O
manufacture	O
of	O
neutralizing	O
antibody	B-FUNC
,	O
provide	O
a	O
better	O
understanding	O
the	O
immunological	O
characteristics	O
of	O
SARS	O
protein	O
and	O
facilitate	O
the	O
design	O
of	O
a	O
SARS	O
vaccine	O
.	O

Opportunities	O
for	O
the	O
design	O
and	O
development	O
of	O
anti	O
-	O
SARS	O
agents	O
based	O
on	O
the	O
inhibition	O
of	O
receptor	B-FUNC
binding	I-FUNC
,	O
the	O
therapeutic	O
uses	O
of	O
S	O
-	O
directed	O
monoclonal	O
antibodies	O
and	O
inhibitors	O
of	O
HR1	O
-	O
HR2	O
complex	O
formation	O
are	O
presented	O
.	O

TITLE	O
:	O
False	O
-	O
positive	O
results	O
in	O
a	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
-	O
based	O
western	O
blot	O
assay	O
were	O
rectified	O
by	O
the	O
use	O
of	O
two	O
subunits	O
(	O
S1	O
and	O
S2	O
)	O
of	O
spike	O
for	O
detection	O
of	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
To	O
evaluate	O
the	O
reactivity	O
of	O
the	O
recombinant	O
proteins	O
expressed	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
(	O
DE3	O
),	O
a	O
Western	O
blot	O
assay	O
was	O
performed	O
by	O
using	O
a	O
panel	O
of	O
78	O
serum	O
samples	O
obtained	O
,	O
respectively	O
,	O
from	O
convalescent	O
-	O
phase	O
patients	O
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
(	O
30	O
samples	O
)	O
and	O
from	O
healthy	O
donors	O
(	O
48	O
samples	O
).	O

Some	O
of	O
the	O
animals	O
surviving	O
to	O
acute	O
encephalitis	O
presented	O
an	O
abnormal	O
limb	O
clasping	O
reflex	O
and	O
a	O
decrease	O
in	O
motor	B-FUNC
activity	I-FUNC
starting	O
several	O
months	O
post	O
-	O
infection	O
.	O

In	O
case	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
inflammation	O
spill	O
over	O
from	O
the	O
lungs	O
,	O
particularly	O
there	O
is	O
a	O
persistent	O
increase	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
CRP	O
in	O
serum	O
,	O
and	O
this	O
is	O
associated	O
with	O
a	O
worst	O
prognosis	O
and	O
possible	O
development	O
of	O
sepsis	O
-	O
related	O
complications	O
.	O

Modest	O
sequence	O
conservation	O
within	O
gene	O
1	O
has	O
enabled	O
the	O
design	O
of	O
oligonucleotide	O
primers	O
for	O
use	O
in	O
diagnostic	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reactions	O
,	O
which	O
will	O
be	O
useful	O
for	O
the	O
detection	O
of	O
new	O
coronaviruses	O
.	O

These	O
microarrays	O
were	O
used	O
to	O
screen	O
approximately	O
400	O
Canadian	O
sera	B-FUNC
from	O
the	O
SARS	O
outbreak	O
,	O
including	O
samples	O
from	O
confirmed	O
SARS	O
-	O
CoV	O
cases	O
,	O
respiratory	O
illness	O
patients	O
,	O
and	O
healthcare	O
professionals	O
.	O

A	O
computer	O
algorithm	O
that	O
uses	O
multiple	O
classifiers	O
to	O
predict	O
samples	O
from	O
SARS	O
patients	O
was	O
developed	O
and	O
used	O
to	O
predict	O
206	O
sera	B-FUNC
from	O
Chinese	O
fever	O
patients	O
.	O

The	O
microarray	O
also	O
identified	O
patients	O
with	O
sera	B-FUNC
reactive	O
against	O
other	O
coronavirus	O
proteins	O
.	O

We	O
show	O
that	O
protein	O
microarrays	O
can	O
serve	O
as	O
a	O
rapid	O
,	O
sensitive	O
,	O
and	O
simple	O
tool	O
for	O
large	O
-	O
scale	O
identification	O
of	O
viral	O
-	O
specific	O
antibodies	O
in	O
sera	B-FUNC
.	O

None	O
of	O
these	O
mutations	O
affected	O
cell	O
surface	O
expression	O
or	O
binding	B-FUNC
to	O
its	O
cognate	O
ACE2	O
receptor	O
.	O

The	O
compounds	O
are	O
potent	O
inhibitors	O
of	O
integrase	B-FUNC
activity	I-FUNC
.	O

To	O
obtain	O
the	O
neutralizing	O
antibody	B-FUNC
to	O
SARS	O
virus	O
surface	O
proteins	O
,	O
the	O
library	O
panning	O
procedure	O
was	O
performed	O
on	O
purified	O
SARS	O
virions	O
and	O
the	O
specific	O
Fab	O
antibody	B-FUNC
clones	O
were	O
enriched	O
by	O
four	O
rounds	O
of	O
repeated	O
panning	O
procedure	O
and	O
screened	O
by	O
highthroughput	O
selection	O
.	O

The	O
selected	O
Fab	O
antibodies	O
expressed	O
in	O
the	O
periplasma	O
of	O
E	O
.	O
coli	O
were	O
soluble	O
and	O
further	O
purified	O
and	O
tested	O
for	O
their	O
binding	B-FUNC
properties	O
and	O
antiviral	O
function	O
to	O
SARS	O
virus	O
.	O

RESULTS	O
:	O
After	O
four	O
rounds	O
of	O
the	O
panning	O
,	O
a	O
number	O
of	O
SARS	O
-	O
CoV	O
virus	O
-	O
targeted	O
human	O
recombinant	O
Fab	O
antibodies	O
were	O
isolated	O
from	O
the	O
SARS	O
patient	O
antibody	B-FUNC
library	O
.	O

These	O
results	O
suggested	O
that	O
the	O
S	O
and	O
M	O
protein	O
-	O
specific	O
neutralizing	O
antibodies	O
could	O
recognize	O
conformational	O
epitopes	O
which	O
might	O
be	O
involved	O
in	O
the	O
binding	B-FUNC
of	O
virions	O
to	O
cellular	O
receptors	O
and	O
the	O
fusion	O
activity	O
of	O
the	O
virus	O
.	O

COX	O
-	O
2	O
promoter	O
mutations	O
suggested	O
that	O
activation	O
of	O
COX	O
-	O
2	O
transcription	O
depended	O
on	O
two	O
regulatory	O
elements	O
,	O
a	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	B-FUNC
site	O
,	O
and	O
a	O
CCAAT	O
/	O
enhancer	B-FUNC
binding	I-FUNC
protein	O
(	O
C	O
/	O
EBP	O
)	O
binding	B-FUNC
site	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
giant	O
RNA	O
genome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
synthesis	O
of	O
as	O
many	O
as	O
eight	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
are	O
mediated	O
by	O
a	O
viral	O
replicase	O
-	O
transcriptase	B-FUNC
of	O
outstanding	O
complexity	O
that	O
includes	O
an	O
essential	O
endoribonuclease	B-FUNC
activity	I-FUNC
.	O

The	O
S	O
-	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
and	O
its	O
biologic	O
activity	O
was	O
analyzed	O
by	O
binding	B-FUNC
to	O
Vero	O
cells	O
.	O

Purified	O
soluble	O
S	O
-	O
protein	O
was	O
readily	O
detected	O
by	O
Western	O
blot	O
with	O
anti	O
-	O
Myc	O
antibody	B-FUNC
and	O
showed	O
the	O
ability	O
to	O
bind	B-FUNC
to	O
surface	O
of	O
Vero	O
cells	O
,	O
demonstrating	O
that	O
the	O
soluble	O
S	O
-	O
protein	O
could	O
remain	O
the	O
biologic	O
activity	O
in	O
the	O
native	O
molecule	O
.	O

Purified	O
soluble	O
S	O
-	O
protein	O
was	O
readily	O
detected	O
by	O
Western	O
blot	O
with	O
anti	O
-	O
Myc	O
antibody	B-FUNC
and	O
showed	O
the	O
ability	O
to	O
bind	B-FUNC
to	O
surface	O
of	O
Vero	O
cells	O
,	O
demonstrating	O
that	O
the	O
soluble	O
S	O
-	O
protein	O
could	O
remain	O
the	O
biologic	O
activity	O
in	O
the	O
native	O
molecule	O
.	O

ABSTRACT	O
:	O
i	O
)	O
To	O
establish	O
the	O
seroprevalence	O
of	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
infection	O
in	O
two	O
defined	O
groups	O
of	O
cats	O
in	O
Sydney	O
:	O
owned	O
and	O
feral	O
cats	O
;	O
ii	O
)	O
to	O
identify	O
factors	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
infection	O
with	O
FCoV	O
;	O
and	O
iii	O
)	O
to	O
establish	O
the	O
seroprevalence	O
and	O
FCoV	O
antibody	B-FUNC
titres	O
of	O
owned	O
cats	O
with	O
immunohistochemically	O
confirmed	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

The	O
major	O
determinants	O
of	O
antibody	B-FUNC
score	O
of	O
owned	O
cats	O
identified	O
in	O
this	O
study	O
were	O
breed	O
,	O
age	O
and	O
the	O
number	O
of	O
cats	O
per	O
household	O
.	O

The	O
significant	O
relationship	O
between	O
the	O
breed	O
of	O
the	O
cat	O
and	O
the	O
FCoV	O
antibody	B-FUNC
titre	O
further	O
supports	O
the	O
notion	O
,	O
proposed	O
previously	O
by	O
the	O
authors	O
,	O
that	O
breed	O
related	O
differences	O
exist	O
in	O
the	O
immunological	O
response	O
to	O
FCoV	O
infection	O
.	O

In	O
contrast	O
,	O
plasma	O
samples	O
from	O
nonimprovers	O
with	O
sustained	O
elevation	O
in	O
cytokine	O
levels	O
over	O
time	O
elicited	O
only	O
a	O
modest	O
longitudinal	O
increase	O
in	O
GC	O
-	O
GRalpha	O
-	O
mediated	O
activity	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
a	O
progressive	O
increase	O
in	O
NF	O
-	O
kappaB	O
nuclear	O
binding	B-FUNC
over	O
time	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
that	O
was	O
most	O
striking	O
in	O
nonsurvivors	O
(	O
dysregulated	O
,	O
NF	O
-	O
kappaB	O
-	O
driven	O
response	O
).	O

By	O
days	O
3	O
-	O
5	O
,	O
no	O
overlap	O
was	O
observed	O
between	O
groups	O
for	O
NF	O
-	O
kappaB	O
and	O
GC	O
-	O
GRalpha	O
nuclear	O
binding	B-FUNC
.	O

TITLE	O
:	O
Only	O
one	O
protomer	O
is	O
active	O
in	O
the	O
dimer	O
of	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

The	O
enzyme	B-FUNC
activity	I-FUNC
of	O
the	O
hybrid	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
protease	O
of	O
the	O
wild	O
-	O
type	O
protein	O
and	O
the	O
inactive	O
mutant	O
proves	O
that	O
the	O
dimerization	O
is	O
important	O
for	O
enzyme	B-FUNC
activity	I-FUNC
and	O
only	O
one	O
active	O
protomer	O
in	O
the	O
dimer	O
is	O
enough	O
for	O
the	O
catalysis	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	O
-	O
CoV	O
strongly	O
induced	O
the	O
chemokines	O
IP	O
-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
colon	O
carcinoma	O
cell	O
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	O
-	O
CoV	O
strongly	O
induced	O
the	O
chemokines	O
IP	O
-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
colon	O
carcinoma	O
cell	O
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O

For	O
safe	O
and	O
effective	O
delivery	O
of	O
viral	O
antigens	O
to	O
the	O
mucosal	O
immune	O
system	O
,	O
we	O
have	O
developed	O
a	O
novel	O
surface	O
antigen	O
display	O
system	O
for	O
lactic	O
acid	O
bacteria	O
using	O
the	O
poly	O
-	O
gamma	O
-	O
glutamic	O
acid	O
synthetase	O
A	O
protein	O
(	O
PgsA	O
)	O
of	O
Bacillus	O
subtilis	O
as	O
an	O
anchoring	B-FUNC
matrix	O
.	O

Oral	O
and	O
nasal	O
inoculations	O
of	O
recombinant	O
L	O
.	O
casei	O
into	O
mice	O
resulted	O
in	O
high	O
levels	O
of	O
serum	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
and	O
mucosal	O
IgA	O
,	O
as	O
demonstrated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
using	O
S	O
protein	O
peptides	O
.	O

Orally	O
immunized	O
mice	O
mounted	O
a	O
greater	O
neutralizing	O
-	O
antibody	B-FUNC
response	O
than	O
those	O
immunized	O
intranasally	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
polyprotein	O
1a	O
of	O
equine	O
torovirus	O
(	O
EToV	O
)	O
strain	O
Berne	O
,	O
identified	O
a	O
serine	O
proteinase	B-FUNC
domain	O
,	O
flanked	O
by	O
hydrophobic	O
regions	O
.	O

With	O
respect	O
to	O
substrate	O
specificity	O
,	O
the	O
EToV	O
M	O
(	O
pro	O
)	O
resembles	O
its	O
coronavirus	O
homologue	O
in	O
its	O
preference	O
for	O
P1	O
-	O
Gln	O
,	O
but	O
its	O
substrate	O
-	O
binding	B-FUNC
subsite	O
,	O
S1	O
,	O
more	O
closely	O
resembles	O
that	O
of	O
arteri	O
-	O
and	O
ronivirus	O
M	O
(	O
pro	O
)	O
s	O
,	O
which	O
prefer	O
P1	O
-	O
Glu	O
.	O

TGEV	O
does	O
not	O
contain	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
and	O
does	O
not	O
depend	O
on	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
for	O
infection	O
of	O
cultured	O
cells	O
.	O

This	O
poses	O
a	O
hazard	O
,	O
as	O
high	O
-	O
affinity	O
virion	B-FUNC
binding	I-FUNC
to	O
any	O
of	O
such	O
""""	O
false	O
''	O
receptors	O
would	O
result	O
in	O
loss	O
of	O
infectivity	O
.	O

Here	O
,	O
the	O
structure	O
,	O
function	O
and	O
evolution	O
of	O
viral	O
sialate	O
-	O
O	O
-	O
acetylesterases	O
is	O
reviewed	O
with	O
main	O
focus	O
on	O
the	O
hemagglutinin	O
-	O
esterases	B-FUNC
of	O
nidoviruses	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
:	O
structure	O
of	O
a	O
viral	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
.	O

Key	O
features	O
,	O
however	O
,	O
distinguish	O
PLpro	O
from	O
characterized	O
deubiquitinating	O
enzymes	O
,	O
including	O
an	O
intact	O
zinc	O
-	O
binding	B-FUNC
motif	O
,	O
an	O
unobstructed	O
catalytically	O
competent	O
active	O
site	O
,	O
and	O
the	O
presence	O
of	O
an	O
intriguing	O
,	O
ubiquitin	B-FUNC
-	O
like	O
N	O
-	O
terminal	O
domain	O
.	O

Human	O
monoclonal	O
antibody	B-FUNC
blocking	O
S1	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
immunoprophylaxis	O
of	O
SARS	O
.	O

TITLE	O
:	O
Structure	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
receptor	O
-	O
binding	B-FUNC
domain	O
complexed	O
with	O
neutralizing	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
or	O
SCV	O
),	O
which	O
caused	O
a	O
world	O
-	O
wide	O
epidemic	O
in	O
2002	O
and	O
2003	O
,	O
binds	B-FUNC
to	O
a	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
through	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
its	O
envelope	O
(	O
spike	O
,	O
S	O
)	O
glycoprotein	O
.	O

However	O
,	O
the	O
structural	O
basis	O
of	O
RBD	O
immunogenicity	O
,	O
RBD	O
-	O
mediated	O
neutralization	O
,	O
and	O
the	O
role	O
of	O
RBD	O
in	O
entry	O
steps	O
following	O
its	O
binding	B-FUNC
to	O
ACE2	O
have	O
not	O
been	O
elucidated	O
.	O

By	O
mimicking	O
immune	O
responses	O
with	O
the	O
use	O
of	O
RBD	O
as	O
an	O
antigen	O
to	O
screen	O
a	O
large	O
human	O
antibody	B-FUNC
library	O
derived	O
from	O
healthy	O
volunteers	O
,	O
we	O
identified	O
a	O
novel	O
potent	O
cross	O
-	O
reactive	O
SCV	O
-	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
,	O
m396	O
,	O
which	O
competes	O
with	O
ACE2	O
for	O
binding	B-FUNC
to	O
RBD	O
,	O
and	O
determined	O
the	O
crystal	O
structure	O
of	O
the	O
RBD	O
-	O
antibody	B-FUNC
complex	O
at	O
2	O
.	O
3	O
-	O
A	O
resolution	O
.	O

The	O
antibody	B-FUNC
epitope	O
is	O
dominated	O
by	O
a	O
10	O
-	O
residue	O
-	O
long	O
protruding	O
beta6	O
-	O
beta7	O
loop	O
with	O
two	O
putative	O
ACE2	O
-	O
binding	B-FUNC
hotspot	O
residues	O
(	O
Ile	O
-	O
489	O
and	O
Tyr	O
-	O
491	O
).	O

These	O
results	O
provide	O
a	O
structural	O
rationale	O
for	O
the	O
function	O
of	O
a	O
major	O
determinant	O
of	O
SCV	O
immunogenicity	O
and	O
neutralization	O
,	O
the	O
development	O
of	O
SCV	O
therapeutics	O
based	O
on	O
the	O
antibody	B-FUNC
paratope	O
and	O
epitope	O
,	O
and	O
a	O
retrovaccinology	O
approach	O
for	O
the	O
design	O
of	O
anti	O
-	O
SCV	O
vaccines	O
.	O

Steric	O
hindrance	O
caused	O
by	O
some	O
bulky	O
or	O
beta	O
-	O
branching	O
amino	O
acids	O
in	O
P3	O
and	O
P2	O
'	O
positions	O
may	O
also	O
hinder	O
the	O
binding	B-FUNC
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

The	O
helicase	O
inhibitors	O
discussed	O
here	O
influence	O
rates	O
of	O
helicase	O
-	O
catalyzed	O
DNA	O
(	O
or	O
RNA	O
)	O
unwinding	O
by	O
preventing	O
ATP	O
hydrolysis	O
,	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
,	O
nucleic	O
acid	O
release	O
,	O
or	O
by	O
disrupting	O
the	O
interaction	O
of	O
a	O
helicase	O
with	O
a	O
required	O
cofactor	O
.	O

Measurement	O
of	O
PAT	B-FUNC
diameter	O
on	O
admission	O
CT	O
scan	O
is	O
an	O
unreliable	O
tool	O
for	O
identification	O
of	O
ARDS	O
patients	O
with	O
pulmonary	O
hypertension	O
.	O

The	O
spleen	O
,	O
mesenteric	O
lymph	O
nodes	O
and	O
bone	O
marrow	O
from	O
naturally	O
FCoV	O
-	O
infected	O
cats	O
with	O
and	O
without	O
FIP	O
and	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
control	O
cats	O
were	O
examined	O
for	O
the	O
quantity	O
and	O
activation	O
state	O
of	O
monocytes	O
/	O
macrophages	O
both	O
by	O
immunohistology	O
and	O
by	O
quantitative	O
real	O
time	O
PCR	O
for	O
the	O
transcription	O
of	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
p40	O
,	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
),	O
granulocyte	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
),	O
macrophage	O
-	O
CSF	O
(	O
M	O
-	O
CSF	O
)	O
and	O
GM	O
-	O
CSF	O
.	O

Compared	O
to	O
cats	O
with	O
FIP	O
,	O
FCoV	O
-	O
infected	O
cats	O
without	O
FIP	O
exhibited	O
significantly	O
higher	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
in	O
the	O
spleen	O
and	O
significantly	O
lower	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
G	O
-	O
and	O
M	O
-	O
CSF	O
in	O
mesenteric	O
lymph	O
nodes	O
.	O

In	O
cats	O
with	O
FIP	O
,	O
however	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
p40	O
levels	O
were	O
significantly	O
lower	O
in	O
lymphatic	O
tissues	O
in	O
comparison	O
to	O
both	O
SPF	O
cats	O
and	O
FCoV	O
-	O
infected	O
cats	O
without	O
FIP	O
.	O

Development	O
of	O
FIP	O
,	O
however	O
,	O
might	O
be	O
due	O
to	O
a	O
lack	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
which	O
inhibits	O
an	O
effective	O
cellular	O
immune	O
response	O
and	O
allows	O
for	O
monocyte	O
/	O
macrophage	O
activation	O
and	O
the	O
development	O
of	O
FIP	O
.	O

Prior	O
infection	O
and	O
passive	O
transfer	O
of	O
neutralizing	O
antibody	B-FUNC
prevent	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
.	O

In	O
addition	O
,	O
ribavirin	O
treatment	O
seemed	O
also	O
to	O
promote	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
4	O
days	O
after	O
cessation	O
of	O
treatment	O
,	O
although	O
after	O
3	O
days	O
of	O
treatment	O
ribavirin	O
inhibited	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
in	O
infected	O
mice	O
,	O
significantly	O
reducing	O
the	O
levels	O
of	O
the	O
cytokines	O
IL	O
-	O
1alpha	O
,	O
interleukin	O
-	O
5	O
(	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
),	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
).	O

In	O
addition	O
,	O
immunization	O
with	O
the	O
DNA	O
vaccine	O
elicited	O
high	O
levels	O
of	O
antibody	B-FUNC
production	O
.	O

Interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
alone	O
was	O
a	O
poor	O
inducer	O
of	O
MoDC	O
maturation	O
,	O
but	O
in	O
association	O
with	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
or	O
TLR	O
ligands	O
such	O
as	O
lipopolysaccharide	O
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
I	O
:	O
C	O
,	O
an	O
up	O
-	O
regulation	O
of	O
major	O
histocompatibility	O
complex	B-FUNC
II	I-FUNC
and	O
CD80	O
/	O
86	O
expression	O
was	O
noted	O
,	O
along	O
with	O
reduced	O
endocytic	O
activity	O
.	O

From	O
HLA	O
peptide	B-FUNC
binding	I-FUNC
predictions	O
(	O
http	O
://	O
thr	O
.	O
cit	O
.	O
nih	O
.	O
gov	O
/	O
molbio	O
/	O
hla_bind	O
/),	O
ten	O
each	O
potential	O
N	O
-	O
and	O
S	O
-	O
specific	O
HLA	O
-	O
A2	O
.	O
1	O
-	O
binding	B-FUNC
peptides	O
were	O
synthesized	O
.	O

Here	O
we	O
combined	O
screening	O
of	O
phage	O
display	O
random	O
peptide	O
libraries	O
with	O
a	O
unique	O
computer	O
algorithm	O
""""	O
Mapitope	O
""""	O
to	O
identify	O
the	O
discontinuous	O
epitope	O
of	O
80R	O
,	O
a	O
potent	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
is	O
a	O
prime	O
target	O
for	O
antiviral	O
therapy	O
.	O

Virus	O
generates	O
drug	O
resistance	O
through	O
fast	B-FUNC
mutagenesis	O
and	O
escapes	O
antiviral	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
enzymatic	O
activity	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
dimer	O
was	O
characterized	O
by	O
a	O
sensitive	O
,	O
quantitative	O
assay	O
.	O

The	O
new	O
,	O
fluorogenic	O
substrate	O
,	O
(	O
Ala	O
-	O
Arg	O
-	O
Leu	O
-	O
Gln	O
-	O
NH	O
)(	O
2	O
)-	O
Rhodamine	O
,	O
contained	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
main	O
proteinase	B-FUNC
consensus	O
cleavage	O
sequence	O
and	O
Rhodamine	O
110	O
,	O
one	O
of	O
the	O
most	O
detectable	O
compounds	O
known	O
,	O
as	O
the	O
reporter	O
group	O
.	O

Enzyme	B-FUNC
activity	I-FUNC
from	O
the	O
SARS	O
CoV	O
main	O
proteinase	B-FUNC
dimer	O
could	O
readily	O
be	O
detected	O
at	O
low	O
pM	O
concentrations	O
.	O

The	O
down	O
-	O
regulated	O
proteins	O
were	O
apolipoprotein	B-FUNC
A	O
-	O
I	O
,	O
transferrin	O
and	O
transthyretin	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
S	O
protein	O
contains	O
multiple	O
conformational	O
epitopes	O
(	O
Conf	O
I	O
-	O
VI	O
)	O
that	O
confer	O
the	O
major	O
target	O
of	O
neutralizing	O
Abs	O
.	O

Interestingly	O
,	O
the	O
Conf	O
V	O
epitope	O
,	O
which	O
may	O
overlap	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
and	O
induce	O
most	O
potent	O
neutralizing	O
Abs	O
,	O
was	O
conserved	O
in	O
these	O
mutants	O
.	O

We	O
examined	O
whether	O
polymorphisms	O
of	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
affect	O
the	O
susceptibility	O
to	O
and	O
outcome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
polymorphisms	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TNF	O
-	O
alpha	O
were	O
not	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

The	O
polymorphisms	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TNF	O
-	O
alpha	O
were	O
not	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
antigen	O
obtained	O
by	O
cloning	O
and	O
expressing	O
two	O
IBV	O
nucleocapsid	O
protein	O
fragments	O
(	O
143	O
-	O
414	O
aa	O
,	O
281	O
-	O
414	O
aa	O
)	O
in	O
Escherichia	O
coli	O
was	O
used	O
for	O
the	O
detection	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
specific	O
antibodies	O
in	O
chicken	O
sera	B-FUNC
by	O
the	O
indirect	O
ELISA	O
(	O
rNpIBV	O
-	O
ELISA	O
).	O

We	O
addressed	O
the	O
relationship	O
between	O
emulsion	O
structure	O
and	O
levels	O
of	O
in	O
vivo	O
antibody	B-FUNC
formation	O
to	O
inactivated	O
New	O
Castle	O
Disease	O
virus	O
(	O
NDV	O
)	O
and	O
Infectious	O
Bronchitis	O
virus	O
(	O
IBV	O
)	O
as	O
antigens	O
in	O
3	O
-	O
week	O
-	O
old	O
chickens	O
.	O

RESULTS	O
:	O
2	O
positive	O
clones	O
that	O
having	O
specific	O
affinity	O
to	O
SARS	O
sera	B-FUNC
were	O
obtained	O
.	O

Serum	O
samples	O
were	O
obtained	O
and	O
immunoglobulin	B-FUNC
G	O
and	O
M	O
(	O
IgG	O
and	O
IgM	O
)	O
of	O
antibodies	O
to	O
CP	O
.	O

These	O
rDIs	O
elicited	O
SARS	O
-	O
CoV	O
-	O
specific	O
serum	O
IgG	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
in	O
vaccinated	O
mice	O
following	O
intranasal	O
or	O
subcutaneous	O
administration	O
.	O

TITLE	O
:	O
Production	O
of	O
an	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
human	O
monoclonal	O
antibody	B-FUNC
Fab	O
fragment	O
by	O
using	O
a	O
combinatorial	O
immunoglobulin	B-FUNC
gene	O
library	O
derived	O
from	O
patients	O
who	O
recovered	O
from	O
SARS	O
.	O

ABSTRACT	O
:	O
A	O
combinatorial	O
human	O
immunoglobulin	B-FUNC
gene	O
library	O
was	O
constructed	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
two	O
patients	O
who	O
recovered	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
library	O
was	O
screened	O
for	O
the	O
production	O
of	O
Fab	O
antibody	B-FUNC
fragments	O
to	O
a	O
recombinant	O
spike	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

We	O
recruited	O
353	O
and	O
361	O
children	O
,	O
respectively	O
,	O
from	O
the	O
high	O
-	O
risk	O
and	O
low	O
-	O
risk	O
areas	O
and	O
collected	O
3	O
to	O
5	O
mL	O
of	O
blood	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
IgG	O
antibody	B-FUNC
testing	O
by	O
immunofluorescence	O
antibody	B-FUNC
assay	O
and	O
confirmation	O
by	O
neutralization	O
test	O
.	O

Two	O
(	O
0	O
.	O
57	O
%)	O
of	O
353	O
asymptomatic	O
children	O
from	O
the	O
high	O
-	O
risk	O
area	O
were	O
tested	O
positive	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
antibody	B-FUNC
compared	O
with	O
0	O
of	O
361	O
in	O
the	O
low	O
-	O
risk	O
region	O
.	O

RESULTS	O
:	O
Two	O
(	O
0	O
.	O
57	O
%)	O
of	O
353	O
asymptomatic	O
children	O
from	O
the	O
high	O
-	O
risk	O
area	O
were	O
tested	O
positive	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
antibody	B-FUNC
compared	O
with	O
0	O
of	O
361	O
in	O
the	O
low	O
-	O
risk	O
region	O
.	O

In	O
addition	O
,	O
we	O
identify	O
movements	O
of	O
the	O
likely	O
eukaryotic	O
ribosomal	O
helicase	O
and	O
confirm	O
a	O
direct	O
interaction	O
between	O
the	O
translocase	O
eEF2	O
and	O
the	O
P	O
-	O
site	O
tRNA	B-FUNC
.	O

A	O
peptide	O
aldehyde	O
library	O
was	O
designed	O
for	O
targeting	O
the	O
SARS	O
coronavirus	O
main	O
protease	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)(	O
also	O
known	O
as	O
3CL	O
(	O
pro	O
)),	O
on	O
the	O
basis	O
of	O
three	O
different	O
reported	O
binding	B-FUNC
modes	O
and	O
supported	O
by	O
virtual	O
screening	O
.	O

An	O
IC	O
(	O
50	O
)	O
of	O
7	O
.	O
5	O
muM	O
was	O
found	O
for	O
AcNSTSQ	O
-	O
H	O
and	O
AcESTLQ	O
-	O
H	O
.	O
Interestingly	O
,	O
the	O
most	O
potent	O
inhibitors	O
seem	O
to	O
bind	B-FUNC
to	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
in	O
a	O
noncanonical	O
binding	B-FUNC
mode	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
fully	O
recovered	O
SARS	O
individuals	O
rapidly	O
produced	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
following	O
stimulation	O
with	O
a	O
pool	O
of	O
overlapping	O
peptides	O
that	O
cover	O
the	O
entire	O
N	O
protein	O
sequence	O
.	O

TITLE	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
-	O
infected	O
monocytes	O
internalize	O
viral	O
membrane	O
-	O
bound	O
proteins	O
upon	O
antibody	B-FUNC
addition	O
.	O

Antibodies	O
seem	O
unable	O
to	O
identify	O
infected	O
cells	O
and	O
mediate	O
antibody	B-FUNC
-	O
dependent	O
cell	O
lysis	O
.	O

ABSTRACT	O
:	O
In	O
this	O
contribution	O
,	O
the	O
classification	O
of	O
protein	B-FUNC
binding	I-FUNC
sites	O
using	O
the	O
physicochemical	O
properties	O
exposed	O
to	O
their	O
pockets	O
is	O
presented	O
.	O

We	O
recently	O
introduced	O
Cavbase	O
,	O
a	O
method	O
for	O
describing	O
and	O
comparing	O
protein	B-FUNC
binding	I-FUNC
pockets	O
on	O
the	O
basis	O
of	O
the	O
geometrical	O
and	O
physicochemical	O
properties	O
of	O
their	O
active	O
sites	O
.	O

We	O
give	O
examples	O
of	O
the	O
Cavbase	O
similarity	O
analysis	O
detecting	O
pronounced	O
similarities	O
in	O
the	O
binding	B-FUNC
sites	O
of	O
proteins	O
unrelated	O
in	O
sequence	O
.	O

A	O
cluster	O
analysis	O
procedure	O
for	O
the	O
functional	O
classification	O
of	O
binding	B-FUNC
pockets	O
was	O
implemented	O
and	O
calibrated	O
using	O
a	O
diverse	O
set	O
of	O
enzyme	B-FUNC
binding	I-FUNC
sites	O
.	O

We	O
propose	O
a	O
relevant	O
classification	O
of	O
both	O
protein	O
families	O
,	O
on	O
the	O
basis	O
of	O
the	O
binding	B-FUNC
motifs	O
in	O
their	O
active	O
sites	O
.	O

Eighteen	O
surface	O
residues	O
from	O
two	O
regions	O
of	O
HRN	O
and	O
HRC	O
were	O
incorporated	O
into	O
the	O
template	O
and	O
used	O
to	O
generate	O
four	O
anti	O
-	O
sera	B-FUNC
,	O
HRN1	O
,	O
HRN2	O
,	O
HRC1	O
,	O
and	O
HRC2	O
.	O

Our	O
results	O
show	O
that	O
all	O
of	O
the	O
elicited	O
anti	O
-	O
sera	B-FUNC
can	O
specifically	O
recognize	O
HRN	O
or	O
HRC	O
peptides	O
and	O
the	O
native	O
SARS	O
-	O
CoV	O
S	O
protein	O
in	O
an	O
ELISA	O
format	O
.	O

Flow	O
cytometry	O
(	O
FACS	O
)	O
analysis	O
,	O
however	O
,	O
showed	O
only	O
HRC1	O
and	O
HRC2	O
anti	O
-	O
sera	B-FUNC
could	O
bind	B-FUNC
to	O
native	O
S	O
protein	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
i	O
.	O
e	O
.,	O
the	O
cell	O
surface	O
structure	O
of	O
the	O
S	O
glycoprotein	O
precluded	O
the	O
ability	O
of	O
the	O
HRN1	O
or	O
HRN2	O
anti	O
-	O
sera	B-FUNC
to	O
see	O
their	O
respective	O
epitope	O
sites	O
.	O

Interestingly	O
,	O
the	O
HRC1	O
anti	O
-	O
serum	O
,	O
which	O
was	O
a	O
more	O
effective	O
inhibitor	O
of	O
viral	O
infectivity	O
compared	O
to	O
HRC2	O
anti	O
-	O
serum	O
,	O
could	O
only	O
bind	B-FUNC
the	O
pre	O
-	O
fusogenic	O
state	O
of	O
HRC	O
,	O
i	O
.	O
e	O
.,	O
the	O
HRC1	O
anti	O
-	O
serum	O
did	O
not	O
recognize	O
the	O
six	O
-	O
helix	O
bundle	O
conformation	O
(	O
fusion	O
state	O
)	O
whereas	O
HRC2	O
anti	O
-	O
serum	O
did	O
.	O

This	O
study	O
aimed	O
to	O
quantify	O
LPS	O
-	O
binding	B-FUNC
protein	O
(	O
LBP	O
),	O
CD14	O
and	O
haptoglobin	O
in	O
the	O
lungs	O
throughout	O
a	O
PRCV	O
infection	O
.	O

TITLE	O
:	O
Phase	O
I	O
trial	O
of	O
the	O
trifunctional	O
anti	O
-	O
HER2	O
x	O
anti	O
-	O
CD3	O
antibody	B-FUNC
ertumaxomab	O
in	O
metastatic	O
breast	O
cancer	O
.	O

ABSTRACT	O
:	O
Ertumaxomab	O
is	O
an	O
intact	O
bispecific	O
antibody	B-FUNC
targeting	O
HER2	O
/	O
neu	O
and	O
CD3	O
with	O
selective	O
binding	B-FUNC
to	O
activatory	O
Fcgamma	O
type	O
I	O
/	O
III	O
receptors	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
tri	O
-	O
cell	O
complex	O
between	O
tumor	O
cells	O
,	O
T	O
cells	O
,	O
and	O
accessory	O
cells	O
.	O

We	O
have	O
showed	O
that	O
a	O
monoclonal	O
antibody	B-FUNC
targeting	O
HK	O
decreases	O
angiogenesis	O
and	O
arrests	O
tumor	O
growth	O
in	O
a	O
syngeneic	O
animal	O
model	O
.	O

CoV	O
N	O
proteins	O
have	O
RNA	O
chaperone	B-FUNC
activity	I-FUNC
that	O
may	O
help	O
initiate	O
template	O
switching	O
.	O

A	O
major	O
difference	O
between	O
the	O
two	O
porcine	O
coronaviruses	O
is	O
a	O
large	O
deletion	O
in	O
the	O
surface	O
protein	O
S	O
gene	O
of	O
PRCoV	O
.	O
Because	O
of	O
this	O
structural	O
difference	O
,	O
TGEV	O
but	O
not	O
PRCoV	O
has	O
a	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
that	O
allows	O
the	O
attachment	O
to	O
mucins	O
and	O
mucin	O
-	O
type	O
glycoproteins	O
.	O

The	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
may	O
allow	O
TGEV	O
to	O
overcome	O
the	O
mucus	O
barrier	O
in	O
the	O
gut	O
and	O
to	O
get	O
access	O
to	O
the	O
intestinal	O
epithelium	O
for	O
initiation	O
of	O
infection	O
.	O

The	O
biosensor	O
is	O
consistent	O
with	O
ELISA	O
that	O
the	O
antibody	B-FUNC
h12	O
showed	O
a	O
higher	O
affinity	O
in	O
encountering	O
the	O
virus	O
than	O
antibody	B-FUNC
b1	O
.	O

The	O
affinity	O
of	O
antibody	B-FUNC
b1	O
and	O
antibody	B-FUNC
h12	O
was	O
9	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
M	O
(-	O
1	O
)	O
and	O
1	O
.	O
36	O
x	O
10	O
(	O
7	O
)	O
M	O
(-	O
1	O
),	O
respectively	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
novel	O
neutralizing	O
epitopes	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
:	O
revealing	O
the	O
critical	O
antigenic	O
determinants	O
in	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
:	O
residues	O
318	O
-	O
510	O
)	O
of	O
S	O
protein	O
contains	O
multiple	O
conformation	O
-	O
dependent	O
neutralizing	O
epitopes	O
(	O
Conf	O
I	O
to	O
VI	O
)	O
and	O
serves	O
as	O
a	O
major	O
target	O
of	O
SARS	O
-	O
CoV	O
neutralization	O
.	O

Group	O
D	O
mAb	O
(	O
S25	O
)	O
was	O
directed	O
against	O
a	O
unique	O
epitope	O
by	O
its	O
competitive	O
binding	B-FUNC
.	O

Two	O
anti	O
-	O
RBD	O
mAbs	O
recognizing	O
the	O
linear	O
epitopes	O
(	O
Group	O
E	O
)	O
were	O
mapped	O
to	O
the	O
RBD	O
residues	O
335	O
-	O
352	O
and	O
442	O
-	O
458	O
,	O
respectively	O
,	O
and	O
none	O
of	O
them	O
inhibited	O
the	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
.	O

Among	O
the	O
anti	O
-	O
S1	O
MAbs	O
,	O
17	O
MAbs	O
targeted	O
the	O
N	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
12	O
to	O
327	O
),	O
9	O
MAbs	O
recognized	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
;	O
aa	O
318	O
to	O
510	O
),	O
and	O
6	O
MAbs	O
reacted	O
with	O
the	O
C	O
-	O
terminal	O
region	O
of	O
S1	O
domain	O
that	O
contains	O
the	O
major	O
immunodominant	O
site	O
(	O
aa	O
528	O
to	O
635	O
).	O

With	O
tapering	O
down	O
of	O
corticosteroid	O
dosage	O
,	O
CTx	O
started	O
to	O
return	O
to	O
previous	O
baseline	O
level	O
from	O
Day	O
51	O
onwards	O
,	O
while	O
other	O
bone	O
formation	O
markers	O
,	O
serum	O
osteocalcin	O
and	O
bone	O
-	O
specific	O
alkaline	O
phosphatase	B-FUNC
concentrations	O
(	O
OC	O
and	O
BALP	O
,	O
respectively	O
),	O
started	O
to	O
increase	O
.	O

TITLE	O
:	O
Reciprocal	O
antibody	B-FUNC
and	O
complement	O
responses	O
of	O
two	O
chicken	O
breeds	O
to	O
vaccine	O
strains	O
of	O
Newcastle	O
disease	O
virus	O
,	O
infectious	O
bursal	O
disease	O
virus	O
and	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Serum	O
antibody	B-FUNC
responses	O
and	O
haemolytic	O
complement	O
activity	O
were	O
evaluated	O
in	O
White	O
Leghorn	O
(	O
WLH	O
)	O
and	O
Rhode	O
Island	O
Red	O
(	O
RIR	O
)	O
chickens	O
that	O
were	O
vaccinated	O
with	O
live	O
-	O
attenuated	O
vaccines	O
of	O
Newcastle	O
disease	O
virus	O
,	O
or	O
infectious	O
bronchitis	O
virus	O
,	O
or	O
infectious	O
bursal	O
disease	O
virus	O
by	O
means	O
of	O
ocular	O
challenge	O
at	O
10	O
times	O
the	O
normal	O
vaccination	O
dose	O
.	O

The	O
lentogenic	O
viral	O
infection	O
resulted	O
in	O
an	O
immediate	O
stimulation	O
of	O
complement	O
activity	O
,	O
followed	O
by	O
a	O
decrease	O
to	O
initial	O
complement	O
levels	O
within	O
2	O
weeks	O
post	O
vaccination	O
,	O
when	O
the	O
antibody	B-FUNC
response	O
took	O
over	O
immune	O
defence	O
.	O

As	O
compared	O
to	O
WLH	O
chickens	O
,	O
RIR	O
birds	O
mounted	O
a	O
faster	O
and	O
significantly	O
higher	O
antibody	B-FUNC
response	O
to	O
the	O
vaccine	O
viruses	O
used	O
.	O

TITLE	O
:	O
Identification	O
of	O
effective	O
siRNA	O
blocking	O
the	O
expression	O
of	O
SARS	O
viral	O
envelope	O
E	O
and	O
RDRP	B-FUNC
genes	O
.	O

These	O
two	O
genes	O
encode	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RDRP	B-FUNC
)	O
and	O
envelope	O
E	O
protein	O
.	O

The	O
RDRP	B-FUNC
and	O
envelope	O
E	O
genes	O
,	O
based	O
on	O
published	O
sequences	O
,	O
have	O
been	O
synthesized	O
and	O
cloned	O
into	O
mammalian	O
expression	O
vectors	O
.	O

In	O
addition	O
,	O
four	O
siRNA	O
sites	O
for	O
the	O
RDRP	B-FUNC
gene	O
and	O
two	O
siRNA	O
sites	O
for	O
envelope	O
E	O
gene	O
were	O
designed	O
and	O
tested	O
.	O

The	O
siRNA	O
or	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	O
cassettes	O
were	O
co	O
-	O
transfected	O
with	O
the	O
SARS	O
viral	O
RDRP	B-FUNC
or	O
envelope	O
E	O
expression	O
vectors	O
into	O
NIH	O
3T3	O
cells	O
.	O

The	O
siRNA	O
and	O
shRNA	O
for	O
one	O
of	O
the	O
siRNA	O
sites	O
of	O
the	O
RDRP	B-FUNC
gene	O
were	O
also	O
tested	O
,	O
and	O
it	O
was	O
found	O
that	O
both	O
inhibited	O
exogenous	O
RDRP	B-FUNC
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Substitutions	O
at	O
the	O
N	O
-	O
1	O
and	O
C	O
-	O
5	O
positions	O
were	O
examined	O
to	O
elucidate	O
the	O
differences	O
in	O
substrate	O
binding	B-FUNC
sites	O
of	O
the	O
rhinovirus	O
3C	O
protease	O
and	O
SARS	O
CoV	O
3C	O
-	O
like	O
protease	O
.	O

Compound	O
5f	O
shows	O
significant	O
inhibition	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0	O
.	O
37	O
microM	O
.	O
Further	O
study	O
showed	O
that	O
,	O
unlike	O
the	O
irreversible	O
covalent	O
binding	B-FUNC
of	O
isatin	O
derivatives	O
to	O
human	O
rhinovirus	O
3C	O
protease	O
,	O
the	O
compounds	O
tested	O
in	O
this	O
study	O
are	O
all	O
noncovalent	O
reversible	O
inhibitors	O
.	O

For	O
example	O
,	O
infliximab	O
,	O
a	O
monoclonal	O
TNF	O
antibody	B-FUNC
,	O
was	O
experimentally	O
tested	O
in	O
rats	O
and	O
it	O
was	O
found	O
to	O
significantly	O
reduce	O
the	O
pathologic	O
score	O
and	O
serum	O
amylase	B-FUNC
activity	I-FUNC
and	O
also	O
to	O
alleviate	O
alveolar	O
edema	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
however	O
,	O
no	O
studies	O
are	O
available	O
in	O
clinical	O
human	O
acute	O
pancreatitis	O
.	O

None	O
of	O
the	O
remaining	O
93	O
participants	O
tested	O
positive	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
Based	O
on	O
the	O
chronological	O
order	O
,	O
resident	O
A	O
might	O
have	O
transmitted	O
infection	O
to	O
resident	O
B	O
and	O
staff	O
C	O
.	O
Sitting	O
close	O
to	O
the	O
bathroom	O
doorway	O
while	O
resident	O
A	O
took	O
a	O
shower	O
was	O
the	O
only	O
contact	O
of	O
resident	O
B	O
with	O
resident	O
A	O
.	O
The	O
only	O
opportunity	O
for	O
staff	O
C	O
to	O
have	O
contact	O
with	O
body	O
fluids	O
/	O
excreta	O
of	O
resident	O
A	O
was	O
in	O
the	O
handling	O
of	O
rubbish	O
from	O
the	O
resident	O
'	O
s	O
room	O
.	O

None	O
of	O
the	O
remaining	O
93	O
participants	O
tested	O
positive	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
Based	O
on	O
the	O
chronological	O
order	O
,	O
resident	O
A	O
might	O
have	O
transmitted	O
infection	O
to	O
resident	O
B	O
and	O
staff	O
C	O
.	O
Sitting	O
close	O
to	O
the	O
bathroom	O
doorway	O
while	O
resident	O
A	O
took	O
a	O
shower	O
was	O
the	O
only	O
contact	O
of	O
resident	O
B	O
with	O
resident	O
A	O
.	O
The	O
only	O
opportunity	O
for	O
staff	O
C	O
to	O
have	O
contact	O
with	O
body	O
fluids	O
/	O
excreta	O
of	O
resident	O
A	O
was	O
in	O
the	O
handling	O
of	O
rubbish	O
from	O
the	O
resident	O
'	O
s	O
room	O
.	O

Our	O
results	O
show	O
that	O
the	O
binding	B-FUNC
of	O
the	O
HRC	O
analogs	O
to	O
HRN	O
does	O
not	O
correlate	O
with	O
the	O
coiled	O
-	O
coil	O
stability	O
of	O
the	O
HRC	O
analogs	O
,	O
but	O
their	O
interactions	O
with	O
HRC	O
does	O
correlate	O
with	O
their	O
stability	O
,	O
except	O
for	O
HRC7	O
.	O

A	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
mfgl2	O
expression	O
by	O
mfgl2	O
antisense	O
plasmid	O
was	O
observed	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
treated	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
cytokine	O
profiles	O
of	O
clinically	O
healthy	O
cats	O
naturally	O
infected	O
with	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
of	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
cats	O
were	O
investigated	O
in	O
whole	O
blood	O
using	O
a	O
traditional	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
and	O
a	O
semi	O
-	O
quantitative	O
method	O
of	O
analysis	O
based	O
on	O
computerised	O
quantification	O
of	O
positive	O
bands	O
.	O

None	O
of	O
the	O
serum	O
specimens	O
collected	O
from	O
healthy	O
children	O
before	O
and	O
during	O
epidemic	O
in	O
Beijing	O
and	O
children	O
from	O
non	O
-	O
epidemic	O
region	O
was	O
positive	O
when	O
IFA	O
methods	O
and	O
ELISA	O
with	O
Beier	O
kits	O
were	O
used	O
for	O
detection	O
,	O
but	O
some	O
were	O
positive	O
when	O
ELISA	O
with	O
the	O
diagnostic	O
kit	B-FUNC
from	O
other	O
source	O
was	O
applied	O
.	O

None	O
of	O
the	O
serum	O
specimens	O
collected	O
from	O
healthy	O
children	O
before	O
and	O
during	O
epidemic	O
in	O
Beijing	O
and	O
children	O
from	O
non	O
-	O
epidemic	O
region	O
was	O
positive	O
when	O
IFA	O
methods	O
and	O
ELISA	O
with	O
Beier	O
kits	O
were	O
used	O
for	O
detection	O
,	O
but	O
some	O
were	O
positive	O
when	O
ELISA	O
with	O
the	O
diagnostic	O
kit	B-FUNC
from	O
other	O
source	O
was	O
applied	O
.	O

This	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-FUNC
could	O
detect	O
3a	O
protein	O
in	O
infected	O
cells	O
,	O
as	O
did	O
an	O
anti	O
-	O
3a	O
C	O
-	O
terminal	O
antibody	B-FUNC
previously	O
described	O
.	O

The	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-FUNC
could	O
detect	O
intracellular	O
3a	O
as	O
well	O
as	O
3a	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O

Interestingly	O
,	O
only	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-FUNC
can	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
although	O
the	O
binding	B-FUNC
affinity	O
of	O
the	O
anti	O
-	O
3a	O
N	O
-	O
terminal	O
antibody	B-FUNC
was	O
lower	O
than	O
the	O
anti	O
-	O
3a	O
C	O
-	O
terminal	O
antibody	B-FUNC
.	O

Analytical	O
Biochemistry	O
,	O
1996	O
,	O
233	O
,	O
1	O
-	O
14	O
),	O
the	O
knowledge	O
of	O
the	O
cleavable	O
peptides	O
by	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
main	O
proteinase	B-FUNC
)	O
can	O
provide	O
very	O
useful	O
insights	O
on	O
developing	O
drugs	O
against	O
SARS	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
multiplex	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
multiplex	O
RT	O
-	O
PCR	O
)	O
that	O
can	O
detect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
and	O
porcine	O
group	O
A	O
rotavirus	O
(	O
GAR	B-FUNC
)	O
was	O
developed	O
.	O

The	O
3	O
viruses	O
(	O
PEDV	O
,	O
TGEV	O
,	O
and	O
porcine	O
GAR	B-FUNC
)	O
are	O
major	O
agents	O
in	O
viral	O
enteric	O
diseases	O
of	O
piglets	O
.	O

A	O
mixture	O
of	O
3	O
pairs	O
of	O
published	O
primers	O
was	O
used	O
for	O
amplification	O
of	O
viral	O
nucleic	O
acids	O
,	O
yielding	O
3	O
different	O
amplicons	O
with	O
sizes	O
of	O
859	O
bp	O
,	O
651	O
bp	O
,	O
and	O
309	O
bp	O
for	O
TGEV	O
,	O
PEDV	O
,	O
and	O
porcine	O
GAR	B-FUNC
,	O
respectively	O
.	O

Using	O
the	O
2	O
,	O
3	O
-	O
bis	B-FUNC
[	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
nitro	O
-	O
5	O
-	O
sulfophenyl	O
]-	O
5	O
-[(	O
phenylamino	O
)	O
carbonyl	O
-	O
2H	O
-	O
tetrazolium	O
hydroxide	O
]	O
(	O
XTT	O
)	O
assay	O
,	O
results	O
showed	O
that	O
all	O
saikosaponins	O
tested	O
demonstrated	O
antiviral	O
activity	O
at	O
concentrations	O
of	O
0	O
.	O
25	O
-	O
25	O
micromol	O
/	O
L	O
,	O
with	O
the	O
strongest	O
activity	O
being	O
noted	O
for	O
saikosaponin	O
B2	O
(	O
IC50	O
=	O
1	O
.	O
7	O
+/-	O

TITLE	O
:	O
Recombinant	O
adeno	O
-	O
associated	O
virus	O
expressing	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	O
elicits	O
neutralizing	O
antibodies	O
:	O
Implication	O
for	O
developing	O
SARS	O
vaccines	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
is	O
a	O
major	O
target	O
of	O
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibody	B-FUNC
combination	O
against	O
SARS	O
coronavirus	O
:	O
synergy	O
and	O
coverage	O
of	O
escape	O
mutants	O
.	O

In	O
vitro	O
experiments	O
confirmed	O
that	O
binding	B-FUNC
of	O
CR3014	O
to	O
a	O
recombinant	O
S	O
fragment	O
(	O
amino	O
acid	O
residues	O
318	O
-	O
510	O
)	O
harboring	O
this	O
mutation	O
was	O
abolished	O
.	O

We	O
therefore	O
screened	O
an	O
antibody	B-FUNC
-	O
phage	O
library	O
derived	O
from	O
blood	O
of	O
a	O
convalescent	O
SARS	O
patient	O
for	O
antibodies	O
complementary	O
to	O
CR3014	O
.	O

A	O
novel	O
mAb	O
,	O
CR3022	O
,	O
was	O
identified	O
that	O
neutralized	O
CR3014	O
escape	O
viruses	O
,	O
did	O
not	O
compete	O
with	O
CR3014	O
for	O
binding	B-FUNC
to	O
recombinant	O
S1	O
fragments	O
,	O
and	O
bound	O
to	O
S1	O
fragments	O
derived	O
from	O
the	O
civet	O
cat	O
SARS	O
-	O
CoV	O
-	O
like	O
strain	O
SZ3	O
.	O

The	O
mixture	O
of	O
both	O
mAbs	O
showed	O
neutralization	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
synergistic	O
fashion	O
by	O
recognizing	O
different	O
epitopes	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
.	O

Because	O
enhancement	O
of	O
SARS	O
-	O
CoV	O
infection	O
by	O
subneutralizing	O
antibody	B-FUNC
concentrations	O
is	O
of	O
concern	O
,	O
we	O
show	O
here	O
that	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
do	O
not	O
convert	O
the	O
abortive	O
infection	O
of	O
primary	O
human	O
macrophages	O
by	O
SARS	O
-	O
CoV	O
into	O
a	O
productive	O
one	O
.	O

At	O
the	O
same	O
time	O
,	O
synergy	O
between	O
CR3014	O
and	O
CR3022	O
may	O
allow	O
for	O
a	O
lower	O
total	O
antibody	B-FUNC
dose	O
to	O
be	O
administered	O
for	O
passive	O
immune	O
prophylaxis	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
):	O
paradox	O
or	O
paradigm	O
?	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
the	O
establishment	O
of	O
cells	O
with	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
after	O
apoptotic	O
events	O
and	O
showed	O
that	O
both	O
JNK	B-FUNC
and	O
PI3K	B-FUNC
/	O
Akt	O
signaling	O
pathways	O
are	O
important	O
for	O
persistence	O
by	O
treatment	O
with	O
inhibitors	O
at	O
the	O
early	O
stages	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
which	O
signaling	O
pathways	O
play	O
important	O
roles	O
in	O
escape	O
from	O
apoptosis	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
persistently	O
infected	O
cells	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
PI3K	B-FUNC
/	O
Akt	O
,	O
JNK	B-FUNC
,	O
p38	B-FUNC
MAPK	B-FUNC
and	O
Bcl	O
-	O
2	O
were	O
phosphorylated	O
and	O
the	O
protein	O
levels	O
of	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
were	O
increased	O
.	O

Among	O
the	O
signaling	O
pathways	O
in	O
persistently	O
infected	O
cells	O
,	O
Akt	O
and	O
JNK	B-FUNC
were	O
phosphorylated	O
in	O
SARS	O
-	O
CoV	O
-	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
-	O
expressing	O
Vero	O
E6	O
cells	O
using	O
vaccinia	O
viral	O
vector	O
(	O
DIs	O
),	O
strongly	O
suggesting	O
that	O
N	O
protein	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
and	O
JNK	B-FUNC
are	O
necessary	O
to	O
establish	O
persistence	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
four	O
proteins	O
,	O
Akt	O
,	O
JNK	B-FUNC
,	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
,	O
are	O
necessary	O
for	O
survival	O
of	O
persistently	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
enters	O
cells	O
through	O
the	O
activities	O
of	O
a	O
spike	O
protein	O
(	O
S	O
)	O
which	O
has	O
receptor	O
-	O
binding	B-FUNC
(	O
S1	O
)	O
and	O
membrane	O
fusion	O
(	O
S2	O
)	O
regions	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
was	O
not	O
significantly	O
altered	O
by	O
the	O
different	O
prime	O
-	O
boost	O
immunizations	O
or	O
the	O
recombinant	O
adenovirus	O
of	O
pcDNA3	O
.	O
1	O
-	O
N	O
prime	O
-	O
rAd	O
-	O
N	O
boost	O
regimen	O
alone	O
,	O
but	O
lymphoproliferation	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
were	O
all	O
enhanced	O
by	O
heterologous	O
combination	O
immunizations	O
compared	O
to	O
homologous	O
combinations	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	O
from	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
forms	O
cation	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
in	O
planar	O
lipid	O
bilayers	O
(	O
Wilson	O
,	O
L	O
.,	O
McKinlay	O
,	O
C	O
.,	O
Gage	O
,	O
P	O
.,	O
Ewart	O
,	O
G	O
.,	O
2004	O
.	O

SARS	O
coronavirus	O
E	O
protein	O
forms	O
cation	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
.	O

We	O
now	O
report	O
that	O
three	O
other	O
E	O
proteins	O
also	O
form	O
cation	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
coronavirus	O
E	O
proteins	O
in	O
general	O
,	O
belong	O
to	O
the	O
virus	O
ion	B-FUNC
channels	I-FUNC
family	O
.	O

Taken	O
together	O
,	O
the	O
data	O
provide	O
evidence	O
of	O
a	O
link	O
between	O
inhibition	O
of	O
E	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
and	O
the	O
antiviral	O
activity	O
of	O
HMA	O
.	O

The	O
decrease	O
in	O
disease	O
severity	O
was	O
not	O
due	O
to	O
a	O
switch	O
from	O
Th1	O
to	O
Th2	O
predominance	O
in	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)-	O
infected	O
mice	O
,	O
an	O
effect	O
on	O
CD8	O
T	O
-	O
cell	O
function	O
,	O
or	O
differential	O
expression	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
by	O
JHMV	O
-	O
specific	O
CD4	O
T	O
cells	O
.	O

SARS	O
-	O
CoV	O
,	O
reovirus	O
and	O
poliovirus	O
RNA	O
was	O
detected	O
by	O
using	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
;	O
IgG	O
antibody	B-FUNC
to	O
the	O
poliovirus	O
type	O
1	O
and	O
3	O
and	O
the	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
were	O
determined	O
using	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Three	O
serum	O
specimens	O
were	O
positive	O
for	O
the	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
.	O
The	O
IgG	O
antibody	B-FUNC
to	O
poliovirus	O
were	O
detected	O
in	O
4	O
SARS	O
patients	O
and	O
23	O
healthy	O
persons	O
.	O

A	O
co	O
-	O
crystal	O
structure	O
revealed	O
an	O
allosteric	O
binding	B-FUNC
site	O
in	O
the	O
protein	O
that	O
required	O
a	O
unique	O
conformational	O
change	O
to	O
accommodate	O
inhibitor	O
binding	B-FUNC
.	O

TITLE	O
:	O
The	O
non	O
-	O
structural	O
protein	O
Nsp10	O
of	O
mouse	O
hepatitis	O
virus	O
binds	B-FUNC
zinc	O
ions	O
and	O
nucleic	O
acids	O
.	O

Moreover	O
,	O
MHV	O
Nsp10	O
interacts	O
with	O
tRNA	B-FUNC
,	O
single	O
-	O
stranded	O
RNA	O
,	O
double	O
-	O
stranded	O
DNA	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
single	O
-	O
stranded	O
DNA	O
as	O
shown	O
by	O
gel	O
-	O
shift	O
experiments	O
.	O

The	O
K	O
(	O
d	O
)	O
for	O
tRNA	B-FUNC
is	O
2	O
.	O
1	O
+/-	O
0	O
.	O
2	O
microM	O
.	O

Several	O
modified	O
RNAs	O
that	O
are	O
not	O
cleaved	O
by	O
Nsp15	O
can	O
bind	B-FUNC
Nsp15	O
as	O
competitive	O
inhibitors	O
.	O

The	O
RNA	B-FUNC
binding	I-FUNC
affinity	O
of	O
Nsp15	O
increased	O
with	O
the	O
content	O
of	O
uridylate	O
in	O
substrate	O
RNA	O
and	O
the	O
co	O
-	O
factor	O
Mn	O
(	O
2	O
+).	O

The	O
hexameric	O
form	O
of	O
Nsp15	O
was	O
found	O
to	O
bind	B-FUNC
RNA	O
in	O
solution	O
.	O

Analysis	O
of	O
SCoV	O
particles	O
that	O
were	O
purified	O
by	O
either	O
sucrose	O
gradient	O
equilibrium	O
centrifugation	O
or	O
a	O
virus	O
capture	O
assay	O
,	O
in	O
which	O
intact	O
SCoV	O
particles	O
were	O
specifically	O
immunoprecipitated	O
by	O
anti	O
-	O
S	O
protein	O
monoclonal	O
antibody	B-FUNC
,	O
demonstrated	O
that	O
7a	O
protein	O
was	O
associated	O
with	O
purified	O
SCoV	O
particles	O
.	O

The	O
structures	O
of	O
complexes	O
of	O
griffithsin	O
with	O
mannose	O
and	O
N	O
-	O
acetylglucosamine	O
defined	O
the	O
locations	O
of	O
three	O
almost	O
identical	O
carbohydrate	B-FUNC
binding	I-FUNC
sites	O
on	O
each	O
monomer	O
.	O

Antiviral	O
potency	O
of	O
griffithsin	O
is	O
likely	O
due	O
to	O
the	O
presence	O
of	O
multiple	O
,	O
similar	O
sugar	B-FUNC
binding	I-FUNC
sites	O
that	O
provide	O
redundant	O
attachment	O
points	O
for	O
complex	O
carbohydrate	O
molecules	O
present	O
on	O
viral	O
envelopes	O
.	O

TITLE	O
:	O
The	O
crystal	O
structure	O
of	O
ORF	O
-	O
9b	O
,	O
a	O
lipid	B-FUNC
binding	I-FUNC
protein	O
from	O
the	O
SARS	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
fully	O
recovered	O
SARS	O
individuals	O
rapidly	O
produced	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
following	O
stimulation	O
with	O
a	O
pool	O
of	O
9	O
peptides	O
overlapping	O
the	O
entire	O
E	O
protein	O
sequence	O
.	O

Here	O
we	O
describe	O
the	O
SARS	O
-	O
CoV	O
'	O
spike	O
'	O
structure	O
determined	O
by	O
single	O
-	O
particle	O
cryo	O
-	O
EM	O
,	O
along	O
with	O
the	O
docked	O
atomic	O
structures	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
prefusion	O
core	O
.	O

BeauR	O
-	O
M41	O
(	O
S	O
)	O
EP10	O
was	O
more	O
efficacious	O
than	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
protecting	O
more	O
birds	O
against	O
virulent	O
challenge	O
and	O
providing	O
a	O
better	O
serological	O
antibody	B-FUNC
response	O
.	O

ABSTRACT	O
:	O
We	O
have	O
solved	O
the	O
crystal	O
and	O
molecular	O
structures	O
of	O
hepatitis	O
A	O
viral	O
(	O
HAV	O
)	O
3C	O
proteinase	B-FUNC
,	O
a	O
cysteine	O
peptidase	O
having	O
a	O
chymotrypsin	O
-	O
like	O
protein	O
fold	O
,	O
in	O
complex	O
with	O
each	O
of	O
three	O
tetrapeptidyl	O
-	O
based	O
methyl	O
ketone	O
inhibitors	O
to	O
resolutions	O
beyond	O
1	O
.	O
4	O
A	O
,	O
the	O
highest	O
resolution	O
to	O
date	O
for	O
a	O
3C	O
or	O
a	O
3C	O
-	O
Like	O
(	O
e	O
.	O
g	O
.	O
SARS	O
viral	O
main	O
proteinase	B-FUNC
)	O
peptidase	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
treatment	O
of	O
Vero	O
E6	O
cells	O
with	O
interleukin	O
-	O
4	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
)	O
decreased	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
contrast	O
to	O
IFNs	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
did	O
not	O
show	O
antiviral	O
activity	O
when	O
administered	O
immediately	O
after	O
SARS	O
-	O
CoV	O
infection	O
,	O
suggesting	O
that	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
acts	O
early	O
during	O
the	O
SARS	O
-	O
CoV	O
replication	O
cycle	O
.	O

Indeed	O
,	O
binding	B-FUNC
of	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
protein	O
to	O
Vero	O
E6	O
cells	O
was	O
diminished	O
on	O
cells	O
treated	O
with	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
but	O
also	O
on	O
cells	O
exposed	O
to	O
IFN	O
-	O
gamma	O
.	O

These	O
findings	O
suggest	O
that	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IFN	O
-	O
gamma	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
partly	O
through	O
downregulation	O
of	O
ACE2	O
.	O

ABSTRACT	O
:	O
Eight	O
poultry	O
farms	O
in	O
Nigeria	O
,	O
including	O
chickens	O
from	O
nine	O
breeder	O
,	O
14	O
broiler	O
,	O
28	O
pullet	O
,	O
11	O
layer	O
,	O
and	O
three	O
cockerel	O
flocks	O
,	O
were	O
tested	O
for	O
antibody	B-FUNC
seroprevalence	O
to	O
the	O
following	O
poultry	O
viruses	O
of	O
potential	O
economic	O
importance	O
:	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
avian	O
reovirus	O
,	O
avian	O
pneumovirus	O
(	O
APV	O
),	O
infectious	O
laryngotracheitis	O
virus	O
(	O
ILTV	O
),	O
avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
and	O
avian	O
leukosis	O
virus	O
(	O
ALV	O
).	O

When	O
given	O
as	O
a	O
single	O
serotype	O
vaccine	O
,	O
the	O
Mass	O
strain	O
was	O
detected	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
only	O
in	O
the	O
tracheas	O
,	O
whereas	O
the	O
Ark	O
strain	O
was	O
detected	O
in	O
both	O
the	O
tracheas	O
and	O
cecal	O
tonsils	O
.	O

SARS	O
-	O
Cov	O
and	O
SARS	O
-	O
like	O
-	O
CoV	O
were	O
detected	O
in	O
these	O
specimens	O
using	O
diagnostic	O
kit	B-FUNC
for	O
novel	O
coronavirus	O
N	O
protein	O
(	O
ELISA	O
),	O
SARS	O
-	O
CoV	O
Virus	O
RNA	O
detection	O
kit	B-FUNC
,	O
fluorescence	O
PCR	O
,	O
Genchip	O
,	O
RT	O
-	O
PCR	O
and	O
cell	O
isolation	O
culture	O
methods	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
nonstructural	O
protein	O
10	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
reveals	O
a	O
novel	O
fold	O
with	O
two	O
zinc	O
-	O
binding	B-FUNC
motifs	O
.	O

It	O
is	O
possible	O
that	O
nsp10	O
functions	O
within	O
a	O
larger	O
RNA	O
-	O
binding	B-FUNC
protein	O
complex	O
.	O

In	O
contrast	O
,	O
AR	O
calves	O
had	O
low	O
antibody	B-FUNC
titers	O
against	O
BCV	O
at	O
arrival	O
(	O
GMT	O
,	O
102	O
)	O
and	O
64	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
65	O
%	O
in	O
feces	O
.	O

The	O
crystal	O
structure	O
of	O
TG	O
-	O
0205221	O
(	O
resolution	O
=	O
1	O
.	O
93	O
A	O
)	O
has	O
revealed	O
a	O
unique	O
binding	B-FUNC
mode	O
comprising	O
a	O
covalent	O
bond	O
,	O
hydrogen	O
bonds	O
,	O
and	O
numerous	O
hydrophobic	O
interactions	O
.	O

To	O
determine	O
the	O
prevalences	O
of	O
11	O
viruses	O
--	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
adenovirus	O
,	O
rhinovirus	O
,	O
parainfluenza	O
viruses	O
(	O
PIVs	O
)	O
1	O
and	O
3	O
,	O
influenza	O
viruses	O
A	O
and	O
B	O
,	O
hMPV	O
,	O
HCoV	O
,	O
HCoV	O
-	O
NL63	O
,	O
and	O
HBoV	O
--	O
among	O
infants	O
or	O
children	O
with	O
LRTIs	O
,	O
in	O
association	O
with	O
their	O
epidemiologic	O
characteristics	O
,	O
we	O
performed	O
multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
on	O
nasopharyngeal	O
aspirates	O
obtained	O
from	O
515	O
children	O
<	O
or	O
=	O
5	O
years	O
old	O
with	O
LRTIs	O
during	O
the	O
period	O
2000	O
-	O
2005	O
.	O

Forty	O
-	O
seven	O
recipients	O
of	O
living	O
donor	O
renal	O
transplants	O
prior	O
to	O
the	O
induction	O
era	O
who	O
received	O
conventional	O
triple	O
drug	O
immunosuppression	O
without	O
antibody	B-FUNC
induction	O
served	O
as	O
historic	O
controls	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
-	O
positive	O
samples	O
of	O
faeces	O
collected	O
in	O
an	O
Austrian	O
animal	O
shelter	O
from	O
12	O
cats	O
and	O
10	O
dogs	O
were	O
analysed	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
pcr	O
with	O
primers	O
amplifying	O
a	O
segment	O
of	O
the	O
M	O
protein	O
gene	O
,	O
and	O
by	O
sequence	O
analysis	O
.	O

The	O
putative	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
this	O
protein	O
was	O
assessed	O
in	O
3a	O
-	O
complement	O
RNA	O
-	O
injected	O
Xenopus	O
oocytes	O
by	O
two	O
-	O
electrode	O
voltage	O
clamp	O
.	O

TITLE	O
:	O
Maternal	O
antibody	B-FUNC
transfer	O
from	O
dams	O
to	O
their	O
egg	O
yolks	O
,	O
egg	O
whites	O
,	O
and	O
chicks	O
in	O
meat	O
lines	O
of	O
chickens	O
.	O

To	O
gain	O
insight	O
into	O
maternal	O
antibody	B-FUNC
transfer	O
and	O
endogenous	O
production	O
of	O
antibodies	O
in	O
broiler	O
chicks	O
,	O
total	O
IgY	O
,	O
IgA	O
,	O
IgM	O
,	O
as	O
well	O
as	O
anti	O
-	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
and	O
anti	O
-	O
infectious	O
bronchitis	O
(	O
IBV	O
)	O
antibody	B-FUNC
levels	O
were	O
examined	O
in	O
the	O
dams	O
'	O
plasma	O
,	O
egg	O
yolks	O
,	O
egg	O
whites	O
,	O
and	O
chicks	O
'	O
plasma	O
on	O
d	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
.	O

Fertile	O
eggs	O
were	O
used	O
for	O
antibody	B-FUNC
extraction	O
from	O
the	O
egg	O
yolks	O
and	O
egg	O
whites	O
(	O
4	O
to	O
5	O
eggs	O
/	O
dam	O
)	O
and	O
for	O
hatching	O
.	O

In	O
summary	O
,	O
IgY	O
levels	O
,	O
total	O
or	O
antigen	O
-	O
specific	O
,	O
in	O
the	O
dams	O
'	O
plasma	O
or	O
eggs	O
were	O
found	O
to	O
be	O
a	O
direct	O
indicator	O
of	O
maternal	O
antibody	B-FUNC
transfer	O
to	O
the	O
chicks	O
'	O
circulation	O
,	O
with	O
an	O
expected	O
percentage	O
transfer	O
of	O
approximately	O
30	O
%.	O

This	O
knowledge	O
,	O
together	O
with	O
the	O
observed	O
time	O
course	O
of	O
endogenous	O
antibody	B-FUNC
production	O
in	O
broiler	O
chicks	O
,	O
may	O
find	O
direct	O
application	O
in	O
formulating	O
strategies	O
for	O
protecting	O
chicks	O
,	O
especially	O
during	O
the	O
first	O
few	O
weeks	O
of	O
age	O
when	O
their	O
immune	O
system	O
is	O
not	O
yet	O
fully	O
functional	O
.	O

Additionally	O
,	O
serum	O
specimens	O
were	O
collected	O
and	O
assayed	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	B-FUNC
and	O
job	O
-	O
specific	O
attack	O
rates	O
were	O
calculated	O
.	O

TITLE	O
:	O
Cytokine	O
storm	O
in	O
a	O
phase	O
1	O
trial	O
of	O
the	O
anti	O
-	O
CD28	O
monoclonal	O
antibody	B-FUNC
TGN1412	O
.	O

ABSTRACT	O
:	O
Six	O
healthy	O
young	O
male	O
volunteers	O
at	O
a	O
contract	O
research	O
organization	O
were	O
enrolled	O
in	O
the	O
first	O
phase	O
1	O
clinical	O
trial	O
of	O
TGN1412	O
,	O
a	O
novel	O
superagonist	O
anti	O
-	O
CD28	O
monoclonal	O
antibody	B-FUNC
that	O
directly	O
stimulates	O
T	O
cells	O
.	O

All	O
six	O
patients	O
were	O
transferred	O
to	O
the	O
care	O
of	O
the	O
authors	O
at	O
an	O
intensive	O
care	O
unit	O
at	O
a	O
public	O
hospital	O
,	O
where	O
they	O
received	O
intensive	O
cardiopulmonary	O
support	O
(	O
including	O
dialysis	O
),	O
high	O
-	O
dose	O
methylprednisolone	O
,	O
and	O
an	O
anti	O
-	O
interleukin	O
-	O
2	O
receptor	O
antagonist	O
antibody	B-FUNC
.	O

Employing	O
mutagenic	O
analyses	O
,	O
we	O
found	O
that	O
the	O
N	O
-	O
terminal	O
unique	O
domain	O
in	O
NL63	O
-	O
S	O
,	O
which	O
is	O
absent	O
in	O
229E	O
-	O
S	O
,	O
does	O
not	O
confer	O
binding	B-FUNC
to	O
ACE2	O
.	O

Although	O
antibody	B-FUNC
-	O
based	O
diagnosis	O
of	O
SARS	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
reliable	O
proof	O
of	O
SARS	O
infection	O
,	O
it	O
is	O
not	O
sensitive	O
enough	O
for	O
detection	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
successful	O
fusion	O
and	O
inhibition	O
of	O
cell	O
-	O
based	O
binding	B-FUNC
assay	O
shows	O
that	O
it	O
can	O
be	O
well	O
used	O
for	O
the	O
study	O
of	O
SARS	O
-	O
CoV	O
entry	O
and	O
inhibition	O
.	O

Arterial	O
blood	O
gas	O
,	O
white	O
blood	O
cell	O
count	O
in	O
bronchial	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
serum	O
were	O
measured	O
at	O
the	O
indicated	O
time	O
points	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
H5N1	O
viral	O
infection	O
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	O
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

ABSTRACT	O
:	O
We	O
studied	O
the	O
immunogenicity	O
of	O
an	O
anti	O
-	O
SARS	O
subunit	O
vaccine	O
comprised	O
of	O
the	O
fragment	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
amino	O
acids	O
318	O
-	O
510	O
(	O
S318	O
-	O
510	O
)	O
containing	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
.	O

In	O
addition	O
,	O
amino	O
acids	O
286	O
-	O
295	O
,	O
316	O
-	O
325	O
and	O
361	O
-	O
367	O
that	O
represent	O
the	O
epitope	O
recognised	O
by	O
monoclonal	O
antibody	B-FUNC
6D11C1	O
converge	O
indicating	O
a	O
well	O
-	O
structured	O
C	O
-	O
terminal	O
region	O
of	O
the	O
SARS	O
virus	O
nucleocapsid	O
protein	O
and	O
functional	O
relationship	O
of	O
the	O
peptide	O
regions	O
involved	O
.	O

cDNAs	O
corresponding	O
to	O
MHV	O
/	O
SCoV	O
chimeric	O
genomes	O
were	O
constructed	O
by	O
replacing	O
the	O
complete	O
MHV	O
5	O
'	O
UTR	O
with	O
the	O
corresponding	O
SCoV	O
sequence	O
and	O
by	O
separately	O
replacing	O
MHV	O
5	O
'	O
UTR	O
putative	O
SL1	O
,	O
putative	O
SL2	O
,	O
TRS	B-FUNC
,	O
and	O
putative	O
SL4	O
with	O
the	O
corresponding	O
SCoV	O
sequences	O
.	O

TITLE	O
:	O
Animal	O
models	O
and	O
antibody	B-FUNC
assays	O
for	O
evaluating	O
candidate	O
SARS	O
vaccines	O
:	O
summary	O
of	O
a	O
technical	O
meeting	O
25	O
-	O
26	O
August	O
2005	O
,	O
London	O
,	O
UK	O
.	O

This	O
report	O
summarizes	O
the	O
recommendations	O
from	O
a	O
WHO	O
Technical	O
Meeting	O
on	O
Animal	O
Models	O
and	O
Antibody	B-FUNC
Assays	O
for	O
Evaluating	O
Candidate	O
SARS	O
Vaccines	O
held	O
on	O
25	O
-	O
26	O
August	O
2005	O
in	O
South	O
Mimms	O
,	O
UK	O
,	O
provides	O
guidance	O
on	O
the	O
use	O
of	O
animal	O
models	O
,	O
and	O
outlines	O
the	O
steps	O
to	O
develop	O
standard	O
reagents	O
and	O
assays	O
for	O
immunological	O
evaluation	O
of	O
candidate	O
SARS	O
vaccines	O
.	O

However	O
,	O
only	O
seven	O
of	O
these	O
(	O
group	O
1	O
)	O
had	O
sera	B-FUNC
which	O
also	O
reacted	O
with	O
the	O
native	O
N	O
antigen	O
expressed	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	O
,	O
N	O
-	O
transfected	O
293T	O
cells	O
,	O
and	O
tissues	O
of	O
infected	O
SARS	O
patients	O
.	O

Group	O
1	O
antibodies	O
recognized	O
epitopes	O
located	O
slightly	O
differently	O
in	O
N	O
from	O
those	O
of	O
group	O
2	O
antibodies	O
,	O
and	O
a	O
mouse	O
hybridoma	O
antibody	B-FUNC
resembling	O
the	O
former	O
type	O
was	O
generated	O
.	O

Renal	O
expression	O
of	O
the	O
sodium	O
/	O
hydrogen	O
exchanger	B-FUNC
isoform	O
3	O
and	O
of	O
aquaporin	B-FUNC
2	O
was	O
lower	O
in	O
infected	O
animals	O
,	O
whereas	O
that	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
was	O
higher	O
.	O

The	O
polyuria	O
might	O
also	O
be	O
attributed	O
to	O
reduced	O
aquaporin	B-FUNC
2	O
expression	O
and	O
the	O
attendant	O
urinary	O
concentrating	O
defect	O
.	O

In	O
the	O
lungs	O
,	O
expression	O
of	O
the	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
was	O
lower	O
,	O
and	O
NKCC1	O
expression	O
was	O
upregulated	O
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
a	O
novel	O
monoclonal	O
antibody	B-FUNC
specific	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
stool	O
specimens	O
by	O
commercially	O
available	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
assays	O
.	O

It	O
has	O
been	O
observed	O
that	O
all	O
pharmacophores	O
of	O
the	O
three	O
peptides	O
overlap	O
very	O
well	O
,	O
and	O
that	O
ATLQANEV	O
binds	B-FUNC
best	O
with	O
the	O
receptor	O
,	O
followed	O
by	O
AVLQSGFR	O
,	O
and	O
then	O
ATLQAIAS	O
.	O

ABSTRACT	O
:	O
Seven	O
-	O
mer	O
phage	O
random	O
peptide	O
libraries	O
were	O
panned	O
against	O
2C10	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
that	O
showed	O
neutralizing	O
activities	O
against	O
PEDV	O
.	O

In	O
neutralization	O
inhibition	O
assays	O
,	O
the	O
two	O
peptide	O
motifs	O
and	O
a	O
24	O
-	O
mer	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
endodomain	O
of	O
PEDV	O
S	O
protein	O
were	O
observed	O
to	O
compete	O
for	O
the	O
antigen	B-FUNC
binding	I-FUNC
site	O
of	O
2C10	O
,	O
as	O
demonstrated	O
by	O
the	O
loss	O
or	O
reduction	O
of	O
neutralizing	O
activity	O
of	O
the	O
monoclonal	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
neutralization	O
by	O
a	O
human	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
spike	O
protein	O
antibody	B-FUNC
,	O
80R	O
.	O

The	O
coronaviral	O
surface	O
spike	O
protein	O
S	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
that	O
mediates	O
initial	O
host	O
binding	B-FUNC
via	O
the	O
cell	O
surface	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
as	O
well	O
as	O
the	O
subsequent	O
membrane	O
fusion	O
events	O
required	O
for	O
cell	O
entry	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
S1	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
a	O
neutralizing	O
antibody	B-FUNC
,	O
80R	O
,	O
at	O
2	O
.	O
3	O
A	O
resolution	O
,	O
as	O
well	O
as	O
the	O
structure	O
of	O
the	O
uncomplexed	O
S1	O
RBD	O
at	O
2	O
.	O
2	O
A	O
resolution	O
.	O

We	O
show	O
that	O
the	O
80R	O
-	O
binding	B-FUNC
epitope	O
on	O
the	O
S1	O
RBD	O
overlaps	O
very	O
closely	O
with	O
the	O
ACE2	O
-	O
binding	B-FUNC
site	O
,	O
providing	O
a	O
rationale	O
for	O
the	O
strong	O
binding	B-FUNC
and	O
broad	O
neutralizing	O
ability	O
of	O
the	O
antibody	B-FUNC
.	O

We	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
differential	O
effects	O
of	O
certain	O
mutations	O
in	O
the	O
spike	O
protein	O
on	O
80R	O
versus	O
ACE2	O
binding	B-FUNC
,	O
including	O
escape	O
mutants	O
,	O
which	O
should	O
facilitate	O
the	O
design	O
of	O
immunotherapeutics	O
to	O
treat	O
a	O
future	O
SARS	O
outbreak	O
.	O

The	O
observations	O
suggest	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
S	O
protein	O
,	O
including	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
,	O
and	O
a	O
region	O
in	O
the	O
central	O
part	O
of	O
the	O
S	O
protein	O
containing	O
HR1	O
and	O
FP	O
,	O
i	O
.	O
e	O
.,	O
regions	O
far	O
apart	O
in	O
the	O
linear	O
sequence	O
,	O
communicate	O
and	O
may	O
even	O
interact	O
physically	O
in	O
the	O
higher	O
-	O
order	O
structure	O
of	O
the	O
spike	O
.	O

Cost	O
-	O
effectiveness	O
analyses	O
(	O
CEAs	B-FUNC
)	O
have	O
become	O
increasingly	O
common	O
to	O
aid	O
decisions	O
about	O
the	O
allocation	O
of	O
scarce	O
healthcare	O
resources	O
.	O

To	O
identify	O
published	O
original	O
CEAs	B-FUNC
presenting	O
cost	O
/	O
quality	O
-	O
adjusted	O
life	O
year	O
or	O
cost	O
/	O
life	O
-	O
year	O
ratios	O
for	O
treatments	O
used	O
in	O
intensive	O
care	O
units	O
,	O
to	O
summarize	O
the	O
results	O
in	O
an	O
accessible	O
format	O
,	O
and	O
to	O
identify	O
areas	O
in	O
critical	O
care	O
medicine	O
that	O
merit	O
further	O
economic	O
evaluation	O
.	O

We	O
conducted	O
a	O
systematic	O
search	O
of	O
the	O
English	O
-	O
language	O
literature	O
for	O
original	O
CEAs	B-FUNC
of	O
critical	O
care	O
interventions	O
published	O
from	O
1993	O
through	O
2003	O
.	O

We	O
identified	O
19	O
CEAs	B-FUNC
published	O
through	O
2003	O
with	O
48	O
cost	O
-	O
effectiveness	O
ratios	O
pertaining	O
to	O
treatment	O
of	O
severe	O
sepsis	O
,	O
acute	O
respiratory	O
failure	O
,	O
and	O
general	O
critical	O
care	O
interventions	O
.	O

RESULTS	O
:	O
We	O
identified	O
19	O
CEAs	B-FUNC
published	O
through	O
2003	O
with	O
48	O
cost	O
-	O
effectiveness	O
ratios	O
pertaining	O
to	O
treatment	O
of	O
severe	O
sepsis	O
,	O
acute	O
respiratory	O
failure	O
,	O
and	O
general	O
critical	O
care	O
interventions	O
.	O

Middle	O
ear	O
fluid	O
(	O
MEF	O
)	O
was	O
tested	O
for	O
viral	O
pathogens	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
for	O
bacteria	O
by	O
gram	O
-	O
staining	O
and	O
culture	O
.	O

In	O
response	O
to	O
the	O
WHO	O
request	O
we	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
published	O
literature	O
on	O
ribavirin	O
,	O
corticosteroids	O
,	O
lopinavir	O
and	O
ritonavir	O
(	O
LPV	O
/	O
r	O
),	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
),	O
and	O
SARS	O
convalescent	O
plasma	O
from	O
both	O
in	O
vitro	O
studies	O
and	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Replication	O
of	O
murine	O
hepatitis	O
virus	O
is	O
regulated	O
by	O
papain	O
-	O
like	O
proteinase	B-FUNC
1	O
processing	O
of	O
nonstructural	O
proteins	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

To	O
determine	O
the	O
role	O
in	O
replication	O
of	O
processing	O
between	O
nsp2	O
and	O
nsp3	O
at	O
cleavage	O
site	O
2	O
(	O
CS2	O
)	O
and	O
PLP1	O
proteinase	B-FUNC
activity	I-FUNC
,	O
mutations	O
were	O
engineered	O
into	O
the	O
MHV	O
genome	O
at	O
CS2	O
,	O
at	O
CS1	O
and	O
CS2	O
,	O
and	O
at	O
the	O
PLP1	O
catalytic	O
site	O
,	O
alone	O
and	O
in	O
combination	O
.	O

Fecal	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
and	O
serum	O
IgG	O
antibodies	O
were	O
first	O
detected	O
at	O
PID	O
7	O
and	O
PID	O
14	O
,	O
respectively	O
.	O

TITLE	O
:	O
Amino	O
acid	O
residues	O
critical	O
for	O
RNA	O
-	O
binding	B-FUNC
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
nucleocapsid	O
protein	O
are	O
essential	O
determinants	O
for	O
the	O
infectivity	O
of	O
coronavirus	O
in	O
cultured	O
cells	O
.	O

Alanine	O
substitution	O
of	O
either	O
Arg	O
-	O
76	O
or	O
Tyr	O
-	O
94	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
IBV	O
N	O
protein	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
its	O
RNA	O
-	O
binding	B-FUNC
activity	O
and	O
a	O
total	O
loss	O
of	O
the	O
infectivity	O
of	O
the	O
viral	O
RNA	O
to	O
Vero	O
cells	O
.	O

This	O
study	O
thus	O
identifies	O
residues	O
critical	O
for	O
RNA	B-FUNC
binding	I-FUNC
on	O
the	O
nucleocapsid	O
surface	O
,	O
and	O
presents	O
biochemical	O
and	O
genetic	O
evidence	O
that	O
directly	O
links	O
the	O
RNA	B-FUNC
binding	I-FUNC
capacity	O
of	O
the	O
coronavirus	O
N	O
protein	O
to	O
the	O
viral	O
infectivity	O
in	O
cultured	O
cells	O
.	O

By	O
using	O
Western	O
blot	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
we	O
showed	O
that	O
the	O
purified	O
recombinant	O
M	O
protein	O
could	O
be	O
recognized	O
by	O
four	O
SARS	O
-	O
CoV	O
-	O
positive	O
human	O
sera	B-FUNC
even	O
when	O
those	O
sera	B-FUNC
were	O
12	O
,	O
800	O
-	O
fold	O
diluted	O
.	O

Binding	B-FUNC
sites	O
for	O
various	O
functional	O
groups	O
were	O
identified	O
in	O
a	O
series	O
of	O
molecular	O
dynamics	O
calculation	O
.	O

The	O
subsequent	O
MD	O
simulations	O
followed	O
by	O
calculations	O
of	O
binding	B-FUNC
energies	O
of	O
the	O
designed	O
molecules	O
were	O
compared	O
to	O
ATP	O
identifying	O
the	O
most	O
successful	O
candidates	O
,	O
for	O
likely	O
inhibitors	O
-	O
molecules	O
possessing	O
two	O
phosphonic	O
acid	O
moieties	O
at	O
distal	O
ends	O
of	O
the	O
molecule	O
.	O

ABSTRACT	O
:	O
RNA	O
chaperones	O
are	O
nonspecific	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
proteins	O
with	O
long	O
disordered	O
regions	O
that	O
help	O
RNA	O
molecules	O
to	O
adopt	O
its	O
functional	O
conformation	O
.	O

Therefore	O
,	O
it	O
was	O
concluded	O
that	O
TGEV	O
N	O
protein	O
is	O
an	O
RNA	B-FUNC
chaperone	I-FUNC
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
purified	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
N	O
protein	O
also	O
has	O
RNA	O
chaperone	B-FUNC
activity	I-FUNC
.	O

pDCs	O
controlled	O
the	O
fast	B-FUNC
replicating	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
through	O
the	O
immediate	O
production	O
of	O
type	O
I	O
IFNs	O
.	O

TITLE	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
genetic	O
predisposing	O
factors	O
can	O
influence	O
clinical	O
severity	O
in	O
nephropathia	O
epidemica	O
.	O

Protection	O
based	O
criteria	O
were	O
:	O
virus	O
re	O
-	O
isolation	O
attempts	O
from	O
trachea	O
,	O
tracheal	O
and	O
renal	O
histopathology	O
as	O
well	O
as	O
IBV	O
antigens	O
detection	O
by	O
immunofluorescent	O
antibody	B-FUNC
technique	O
in	O
kidney	O
sections	O
.	O

ORF1a	O
encodes	O
several	O
membrane	O
domains	O
,	O
a	O
putative	O
ADP	O
-	O
ribose	O
1	O
"""-"	O
phosphatase	B-FUNC
,	O
and	O
a	O
chymotrypsin	O
-	O
like	O
serine	O
protease	O
whose	O
activity	O
was	O
established	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
Quantitative	O
comparison	O
of	O
the	O
efficiency	O
of	O
antibodies	O
against	O
S1	O
and	O
S2	O
subunit	O
of	O
SARS	O
coronavirus	O
spike	O
protein	O
in	O
virus	O
neutralization	O
and	O
blocking	O
of	O
receptor	B-FUNC
binding	I-FUNC
:	O
implications	O
for	O
the	O
functional	O
roles	O
of	O
S2	O
subunit	O
.	O

In	O
this	O
study	O
,	O
high	O
titered	O
mouse	O
antisera	O
against	O
the	O
N	O
-	O
terminal	O
globular	O
(	O
S1	O
)	O
and	O
S2	O
subunits	O
of	O
the	O
S	O
protein	O
were	O
generated	O
and	O
total	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
was	O
purified	O
from	O
these	O
antisera	O
.	O

The	O
efficiency	O
of	O
these	O
purified	O
IgGs	O
in	O
virus	O
neutralization	O
and	O
blocking	O
of	O
receptor	B-FUNC
binding	I-FUNC
were	O
compared	O
quantitatively	O
using	O
virus	O
neutralization	O
assay	O
and	O
a	O
previously	O
developed	O
cell	O
-	O
based	O
receptor	B-FUNC
binding	I-FUNC
assay	O
,	O
respectively	O
.	O

We	O
demonstrated	O
that	O
anti	O
-	O
S1	O
IgG	O
neutralizes	O
the	O
virus	O
and	O
binds	B-FUNC
to	O
the	O
membrane	O
associated	O
S	O
protein	O
more	O
efficiently	O
than	O
anti	O
-	O
S2	O
IgG	O
does	O
.	O

The	O
possible	O
ways	O
of	O
anti	O
-	O
S2	O
IgGs	O
to	O
abolish	O
the	O
receptor	B-FUNC
binding	I-FUNC
and	O
the	O
factors	O
restricting	O
anti	O
-	O
S2	O
IgGs	O
to	O
neutralize	O
the	O
virus	O
are	O
discussed	O
.	O

More	O
than	O
250	O
field	O
samples	O
were	O
tested	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
using	O
two	O
sets	O
of	O
primers	O
corresponding	O
to	O
the	O
most	O
conserved	O
3	O
'-	O
untranslated	O
region	O
and	O
the	O
most	O
variable	O
S1	O
gene	O
region	O
of	O
the	O
viral	O
genome	O
.	O

ABSTRACT	O
:	O
S1	O
gene	O
fragment	O
containing	O
receptor	O
-	O
binding	B-FUNC
region	O
was	O
amplified	O
by	O
several	O
sets	O
of	O
primers	O
using	O
Over	O
-	O
Lap	O
PCR	O
.	O

PNGase	B-FUNC
F	I-FUNC
deglycosylation	O
resulted	O
in	O
a	O
protein	O
band	O
of	O
30	O
kDa	O
.	O

Molecular	O
simulation	O
indicates	O
that	O
the	O
MOL376	O
(	O
a	O
compound	O
derived	O
from	O
a	O
Chinese	O
medicine	O
herb	O
with	O
the	O
therapeutic	O
efficacy	O
on	O
the	O
human	O
body	O
such	O
as	O
relieving	O
cough	O
,	O
removing	O
the	O
phlegm	O
,	O
and	O
relieving	O
asthma	O
)	O
has	O
not	O
only	O
the	O
highest	O
binding	B-FUNC
energy	O
with	O
the	O
receptor	O
but	O
also	O
the	O
good	O
match	O
in	O
geometric	O
conformation	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
binds	B-FUNC
to	O
hUbc9	O
,	O
a	O
ubiquitin	B-FUNC
conjugating	O
enzyme	O
of	O
the	O
sumoylation	O
system	O
.	O

However	O
,	O
the	O
consensus	O
motif	O
of	O
sumoylation	O
GK	O
(	O
62	O
)	O
EE	O
in	O
the	O
N	O
protein	O
is	O
not	O
responsible	O
for	O
binding	B-FUNC
to	O
hUbc9	O
.	O

TITLE	O
:	O
Carboxyl	O
terminus	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
:	O
self	O
-	O
association	O
analysis	O
and	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
characterization	O
.	O

The	O
fact	O
that	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
could	O
promote	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
C	O
-	O
terminus	O
to	O
form	O
high	O
-	O
order	O
oligomers	O
implies	O
that	O
the	O
oligomeric	O
SARS	O
-	O
CoV	O
N	O
protein	O
probably	O
combines	O
with	O
the	O
viral	O
genomic	O
RNA	O
in	O
triggering	O
long	O
nucleocapsid	O
formation	O
.	O

ABSTRACT	O
:	O
To	O
extend	O
the	O
potential	O
of	O
antibodies	O
and	O
their	O
derivatives	O
to	O
provide	O
passive	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
,	O
we	O
have	O
expressed	O
both	O
a	O
small	O
immune	O
protein	O
(	O
SIP	O
)	O
and	O
a	O
full	O
-	O
length	O
antibody	B-FUNC
in	O
plants	O
using	O
two	O
different	O
plant	O
virus	O
vectors	O
based	O
on	O
potato	O
virus	O
X	O
(	O
PVX	O
)	O
and	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
).	O

Analysis	O
of	O
crude	O
plant	O
extracts	O
revealed	O
that	O
both	O
the	O
plant	O
-	O
expressed	O
alphaSIP	O
and	O
IgA	O
molecules	O
could	O
bind	B-FUNC
to	O
and	O
neutralize	O
TGEV	O
in	O
tissue	O
culture	O
,	O
indicating	O
that	O
active	O
molecules	O
were	O
produced	O
.	O

Moreover	O
,	O
it	O
was	O
showed	O
that	O
a	O
larger	O
proportion	O
(	O
24	O
%)	O
of	O
positively	O
selected	O
sites	O
was	O
located	O
in	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
than	O
in	O
heptad	O
repeat	O
(	O
HR	O
)	O
1	O
-	O
HR2	O
region	O
in	O
02	O
-	O
04	O
interspecies	O
epidemic	O
group	O
(	O
p	O
=	O
0	O
.	O
0208	O
),	O
and	O
a	O
greater	O
percentage	O
(	O
25	O
%)	O
of	O
these	O
sites	O
occurred	O
in	O
HR1	O
-	O
HR2	O
region	O
than	O
in	O
RBD	O
in	O
03	O
-	O
early	O
-	O
mid	O
epidemic	O
group	O
(	O
p	O
=	O
0	O
.	O
0721	O
).	O

Particularly	O
noteworthy	O
,	O
the	O
serine	O
to	O
alanine	O
mutation	O
resides	O
in	O
the	O
region	O
of	O
the	O
major	O
antigenic	O
site	O
A	O
/	O
B	O
(	O
aa	O
506	O
-	O
706	O
)	O
that	O
elicits	O
neutralizing	O
antibodies	O
and	O
within	O
the	O
domain	O
mediating	O
the	O
cell	O
surface	O
receptor	O
aminopeptidase	O
N	B-FUNC
binding	I-FUNC
(	O
aa	O
522	O
-	O
744	O
).	O

Its	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
activity	O
appears	O
to	O
be	O
supplied	O
by	O
non	O
-	O
structural	O
protein	O
12	O
(	O
nsp12	O
)	O
that	O
includes	O
an	O
RdRp	B-FUNC
domain	O
conserved	O
in	O
all	O
RNA	O
viruses	O
.	O

Using	O
SARS	O
coronavirus	O
,	O
we	O
now	O
show	O
that	O
coronaviruses	O
uniquely	O
encode	O
a	O
second	O
RdRp	B-FUNC
residing	O
in	O
nsp8	O
.	O

A	O
parallel	O
between	O
the	O
nsp8	O
RdRp	B-FUNC
and	O
cellular	O
DNA	O
-	O
dependent	O
RNA	O
primases	O
is	O
drawn	O
to	O
propose	O
that	O
the	O
nsp8	O
RdRp	B-FUNC
produces	O
primers	O
utilized	O
by	O
the	O
primer	O
-	O
dependent	O
nsp12	O
RdRp	B-FUNC
.	O

In	O
the	O
present	O
study	O
,	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
assays	O
were	O
used	O
to	O
analyse	O
the	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
and	O
some	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
PICs	O
)	O
including	O
MCP	B-FUNC
-	O
1	O
,	O
TGF	O
-	O
beta1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
autopsy	O
tissues	O
from	O
four	O
patients	O
who	O
died	O
of	O
SARS	O
.	O

The	O
antibody	B-FUNC
was	O
used	O
as	O
target	O
and	O
three	O
rounds	O
of	O
bio	O
-	O
panning	O
were	O
conducted	O
with	O
phage	O
-	O
display	O
peptide	O
library	O
.	O

After	O
the	O
third	O
panning	O
,	O
20	O
phage	O
-	O
plague	O
clones	O
were	O
randomly	O
picked	O
and	O
analyzed	O
for	O
the	O
binding	B-FUNC
ability	O
with	O
the	O
MAb	O
2C5	O
by	O
ELISA	O
.	O

All	O
these	O
eight	O
phage	O
-	O
clones	O
showed	O
strongest	O
binding	B-FUNC
activity	O
with	O
2C5	O
in	O
phage	O
ELISA	O
analysis	O
.	O

into	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
receptor	O
gamma	O
-	O
chain	O
-	O
disrupted	O
NOD	O
-	O
SCID	O
mice	O
[	O
IL	B-FUNC
-	I-FUNC
2R	I-FUNC
(-/-)	O
NOD	O
-	O
SCID	O
].	O

TITLE	O
:	O
Protein	O
nanopatterns	O
and	O
biosensors	O
using	O
gold	O
binding	B-FUNC
polypeptide	O
as	O
a	O
fusion	O
partner	O
.	O

ABSTRACT	O
:	O
An	O
efficient	O
strategy	O
for	O
immobilizing	O
proteins	O
on	O
a	O
gold	O
surface	O
was	O
developed	O
by	O
employing	O
the	O
gold	O
binding	B-FUNC
polypeptide	O
(	O
GBP	O
)	O
as	O
a	O
fusion	O
partner	O
.	O

The	O
GBP	O
-	O
fused	O
SCVme	O
bound	O
to	O
gold	O
nanoparticles	O
successfully	O
interacted	O
with	O
its	O
antibody	B-FUNC
and	O
showed	O
changes	O
in	O
absorbance	O
and	O
color	O
,	O
allowing	O
efficient	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
fusion	O
proteins	O
could	O
be	O
successfully	O
immobilized	O
on	O
the	O
gold	O
surface	O
by	O
nanopatterning	O
and	O
microcontact	O
printing	O
as	O
examined	O
by	O
atomic	O
force	O
microscopy	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
.	O

We	O
then	O
generated	O
nine	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
the	O
S	O
protein	O
to	O
map	O
the	O
DC	O
-	O
SIGN	O
-	O
binding	B-FUNC
domain	O
using	O
capture	O
assays	O
with	O
pseudotyped	O
viruses	O
and	O
observed	O
that	O
MAb	O
SIa5	O
significantly	O
blocked	O
S	O
protein	O
-	O
DC	O
-	O
SIGN	O
interaction	O
.	O

Results	O
from	O
a	O
capture	O
assay	O
testing	O
three	O
pseudotyped	O
viruses	O
with	O
mutated	O
N	O
-	O
linked	O
glycosylation	O
sites	O
of	O
the	O
S	O
protein	O
indicate	O
that	O
only	O
two	O
pseudotyped	O
viruses	O
(	O
N330Q	O
and	O
N357Q	O
,	O
both	O
of	O
which	O
lost	O
glycosylation	O
sites	O
near	O
the	O
SIa5	O
epitope	O
)	O
had	O
diminished	O
DC	O
-	O
SIGN	O
-	O
binding	B-FUNC
capacity	O
.	O

Infected	O
A	O
/	O
J	O
mice	O
had	O
significantly	O
higher	O
cytokine	O
levels	O
,	O
particularly	O
macrophage	O
chemoattractant	O
protein	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
/	O
CCL	B-FUNC
-	O
2	O
),	O
gamma	O
interferon	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
.	O

In	O
parallel	O
,	O
liver	O
histology	O
,	O
virus	O
titers	O
,	O
and	O
plasma	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
activity	O
were	O
monitored	O
.	O

Nitric	O
oxide	O
synthesis	O
was	O
barely	O
detectable	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
which	O
showed	O
a	O
progressive	O
increase	O
in	O
virus	O
titers	O
and	O
ALT	B-FUNC
activity	O
.	O

The	O
latter	O
displayed	O
a	O
less	O
severe	O
infection	O
and	O
presented	O
detectable	O
levels	O
of	O
nitric	O
oxide	O
as	O
nitrosyl	O
complexes	O
in	O
blood	O
and	O
liver	O
at	O
72	O
hpi	B-FUNC
.	O

Immunized	O
mice	O
from	O
both	O
strains	O
became	O
resistant	O
to	O
MHV	O
-	O
3	O
and	O
showed	O
comparable	O
levels	O
of	O
nitrosyl	O
complexes	O
in	O
blood	O
and	O
liver	O
at	O
an	O
early	O
time	O
(	O
24	O
hpi	B-FUNC
).	O

Both	O
molecular	O
modeling	O
and	O
Q189A	O
mutation	O
revealed	O
that	O
Gln189	O
plays	O
a	O
key	O
role	O
in	O
the	O
binding	B-FUNC
.	O

Affinity	O
/	O
Insight	O
II	O
was	O
used	O
to	O
explore	O
possible	O
binding	B-FUNC
locations	O
for	O
POMs	O
/	O
3CL	O
(	O
pro	O
)	O
interaction	O
.	O

We	O
investigated	O
whether	O
a	O
recombinant	O
native	O
full	O
-	O
length	O
S	O
-	O
protein	O
trimer	O
(	O
triSpike	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
able	O
to	O
elicit	O
a	O
neutralizing	O
and	O
protective	O
immune	O
response	O
in	O
animals	O
and	O
analyzed	O
the	O
capacity	O
of	O
anti	O
-	O
S	O
antibodies	O
to	O
mediate	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
virus	O
entry	O
in	O
vitro	O
and	O
enhancement	O
of	O
replication	O
in	O
vivo	O
.	O

Serum	O
IgG	O
blocked	O
binding	B-FUNC
of	O
the	O
S	O
-	O
protein	O
to	O
the	O
ACE2	O
receptor	O
and	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

To	O
improve	O
understanding	O
of	O
the	O
immuno	O
-	O
pathological	O
processes	O
involved	O
in	O
lung	O
injury	O
associated	O
with	O
SARS	O
,	O
the	O
temporal	O
changes	O
in	O
cytokine	O
/	O
chemokine	O
profiles	O
in	O
the	O
sera	B-FUNC
of	O
SARS	O
patients	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
),	O
according	O
to	O
the	O
degree	O
of	O
lung	O
involvement	O
.	O

The	O
serum	O
levels	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
elevated	O
during	O
SARS	O
infection	O
.	O

In	O
patients	O
with	O
CAP	O
,	O
but	O
not	O
in	O
those	O
with	O
SARS	O
,	O
the	O
levels	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
monokine	O
induced	O
by	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
MIG	O
)	O
were	O
significantly	O
elevated	O
compared	O
with	O
the	O
levels	O
in	O
healthy	O
controls	O
.	O

Among	O
the	O
chemokines	O
/	O
cytokines	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
correlated	O
most	O
strongly	O
with	O
radiographic	O
scores	O
(	O
r	O
=	O
0	O
.	O
62	O
).	O

In	O
contrast	O
,	O
the	O
dynamic	O
changes	O
in	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
C	O
-	O
reactive	O
protein	O
and	O
neutrophils	O
occurred	O
synchronously	O
with	O
the	O
changes	O
in	O
radiographic	O
scores	O
.	O

The	O
mean	O
ratio	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
to	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
SARS	O
patients	O
(	O
4	O
.	O
84	O
;	O
range	O
0	O
.	O
41	O
-	O
21	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
CAP	O
patients	O
(	O
2	O
.	O
95	O
;	O
range	O
0	O
.	O
02	O
-	O
10	O
.	O
57	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

RESULTS	O
:	O
The	O
serum	O
levels	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
elevated	O
during	O
SARS	O
infection	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
the	O
RNA	B-FUNC
binding	I-FUNC
properties	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
protein	O
amino	O
-	O
terminal	O
region	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
binds	B-FUNC
viral	O
RNA	O
to	O
form	O
the	O
ribonucleocapsid	O
and	O
regulate	O
RNA	O
synthesis	O
.	O

Flow	O
cytometry	O
and	O
ELISPOT	O
analysis	O
of	O
lymphocytes	O
as	O
well	O
as	O
a	O
serologic	O
analysis	O
of	O
antibody	B-FUNC
showed	O
that	O
these	O
peptides	O
could	O
trigger	O
a	O
rapid	O
,	O
highly	O
effective	O
,	O
and	O
relatively	O
safe	O
immune	O
response	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

TITLE	O
:	O
A	O
study	O
on	O
antigenicity	O
and	O
receptor	O
-	O
binding	B-FUNC
ability	O
of	O
fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
protein	O
of	O
SARS	O
coronavirus	O
.	O

Its	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
S	O
-	O
RBM	O
)	O
is	O
located	O
between	O
residues	O
424	O
and	O
494	O
,	O
which	O
folds	O
into	O
2	O
anti	O
-	O
parallel	O
beta	O
-	O
sheets	O
,	O
beta5	O
and	O
beta6	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
patient	O
sera	B-FUNC
predominantly	O
recognized	O
2	O
linear	O
epitopes	O
outside	O
the	O
beta6	O
fragment	O
,	O
while	O
the	O
mouse	O
antisera	O
,	O
induced	O
by	O
immunization	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
recombinant	O
S450	O
-	O
650	O
,	O
mainly	O
recognized	O
the	O
beta6	O
strand	O
-	O
containing	O
region	O
.	O

Unlike	O
patient	O
sera	B-FUNC
,	O
however	O
,	O
the	O
mouse	O
antisera	O
were	O
unable	O
to	O
inhibit	O
the	O
infectivity	O
of	O
S	O
protein	O
-	O
expressing	O
(	O
SARS	O
-	O
CoV	O
-	O
S	O
)	O
pseudovirus	O
.	O

Co	O
-	O
precipitation	O
experiments	O
confirmed	O
that	O
S450	O
-	O
650	O
was	O
able	O
to	O
specifically	O
bind	B-FUNC
with	O
ACE2	O
molecules	O
in	O
lysate	O
of	O
Vero	O
E6	O
cells	O
.	O

Our	O
data	O
suggest	O
a	O
possibility	O
that	O
,	O
although	O
the	O
beta6	O
strand	O
alone	O
is	O
able	O
to	O
bind	B-FUNC
with	O
ACE2	O
with	O
relatively	O
high	O
affinity	O
,	O
residues	O
outside	O
the	O
S	O
-	O
RBM	O
could	O
also	O
assist	O
the	O
receptor	B-FUNC
binding	I-FUNC
of	O
SARS	O
-	O
CoV	O
-	O
S	O
protein	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
novel	O
vesicular	O
stomatitis	O
virus	O
pseudotype	O
-	O
based	O
assay	O
for	O
detection	O
of	O
neutralizing	O
antibody	B-FUNC
responses	O
to	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
SARS	O
.	O

A	O
total	O
of	O
56	O
serum	O
samples	O
collected	O
from	O
22	O
healthcare	O
workers	O
in	O
the	O
Hanoi	O
French	O
Hospital	O
during	O
the	O
SARS	O
epidemic	O
in	O
2003	O
were	O
evaluated	O
and	O
compared	O
to	O
the	O
conventional	O
neutralizing	O
assay	O
using	O
infectious	O
SARS	O
-	O
CoV	O
.	O
The	O
results	O
of	O
the	O
neutralization	O
assay	O
using	O
VSV	O
-	O
SARS	O
-	O
St19	O
pseudotype	O
showed	O
good	O
correlations	O
with	O
those	O
using	O
infectious	O
SARS	O
-	O
CoV	O
.	O
The	O
newly	O
developed	O
neutralization	O
assay	O
was	O
more	O
sensitive	O
to	O
low	O
antibody	B-FUNC
titers	O
in	O
serum	O
samples	O
.	O

Analysis	O
of	O
the	O
innate	O
immune	O
response	O
in	O
the	O
DNA	O
-	O
PKcs	O
-	O
deficient	O
mice	O
with	O
short	O
dysfunctional	O
telomeres	O
revealed	O
high	O
basal	O
serum	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNFalpha	O
)	O
and	O
hyper	O
-	O
active	O
cytokine	O
responses	O
upon	O
challenge	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
-	O
IC	O
).	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
human	O
coronavirus	O
strain	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cloned	O
in	O
pENTR	O
/	O
D	O
-	O
TOPO	O
plasmid	O
.	O

Sera	B-FUNC
from	O
100	O
healthcare	O
workers	O
and	O
five	O
2	O
-	O
3	O
-	O
year	O
-	O
old	O
children	O
were	O
tested	O
in	O
a	O
Western	O
blot	O
assay	O
using	O
the	O
purified	O
recombinant	O
N	O
protein	O
.	O

All	O
of	O
the	O
sera	B-FUNC
from	O
adults	O
and	O
two	O
of	O
the	O
sera	B-FUNC
from	O
children	O
have	O
a	O
positive	O
result	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
infection	O
of	O
cultured	O
cells	O
with	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
)	O
signal	O
transduction	O
pathway	O
(	O
Y	O
.	O
Cai	O
et	O
al	O
.,	O
Virology	O
355	O
:	O
152	O
-	O
163	O
,	O
2006	O
).	O

Here	O
we	O
show	O
that	O
inhibition	O
of	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signaling	O
pathway	O
by	O
the	O
MEK	O
inhibitor	O
UO126	O
significantly	O
impaired	O
MHV	O
progeny	O
production	O
(	O
a	O
reduction	O
of	O
95	O
to	O
99	O
%	O
in	O
virus	O
titer	O
),	O
which	O
correlated	O
with	O
the	O
phosphorylation	O
status	O
of	O
ERK1	B-FUNC
/	O
2	O
.	O

Moreover	O
,	O
knockdown	O
of	O
MEK1	B-FUNC
/	O
2	O
and	O
ERK1	B-FUNC
/	O
2	O
by	O
small	O
interfering	O
RNAs	O
suppressed	O
MHV	O
replication	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signaling	O
pathway	O
is	O
involved	O
in	O
MHV	O
RNA	O
synthesis	O
.	O

During	O
the	O
MD	O
simulation	O
of	O
dimer	O
,	O
three	O
interest	O
phenomena	O
of	O
protomer	O
A	O
have	O
been	O
observed	O
:	O
(	O
i	O
)	O
the	O
distance	O
between	O
NE2	O
of	O
His41	O
and	O
SG	O
of	O
Cys145	O
averages	O
3	O
.	O
72	O
A	O
,	O
which	O
agrees	O
well	O
with	O
the	O
experimental	O
observations	O
made	O
by	O
X	O
-	O
ray	O
crystallography	O
;	O
(	O
ii	O
)	O
His163	O
and	O
Glu166	O
form	O
the	O
""""	O
tooth	O
""""	O
conformational	O
properties	O
,	O
resulting	O
in	O
the	O
specificity	O
for	O
glutamine	O
at	O
substrate	O
P1	O
site	O
;	O
and	O
(	O
iii	O
)	O
the	O
substrate	O
-	O
binding	B-FUNC
pocket	O
formed	O
by	O
loop	O
140	O
-	O
146	O
and	O
loop	O
184	O
-	O
197	O
is	O
large	O
enough	O
to	O
accommodate	O
the	O
substrate	O
analog	O
.	O

The	O
effects	O
of	O
ligustrazine	O
on	O
the	O
severity	O
of	O
lung	O
injury	O
were	O
assessed	O
by	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
and	O
histopathological	O
changes	O
.	O

The	O
MPO	B-FUNC
activity	O
in	O
the	O
P	O
group	O
was	O
greatly	O
increased	O
over	O
that	O
of	O
the	O
C	O
group	O
.	O

Concentrations	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
measured	O
pre	O
-	O
continuous	O
HVHF	O
and	O
after	O
continuous	O
HVHF	O
by	O
enzyme	O
linked	O
immunoadsorbent	O
assay	O
(	O
ELISA	O
).	O

There	O
were	O
significant	O
lowering	O
of	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
after	O
HVHF	O
at	O
72	O
hours	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
also	O
in	O
MPAP	O
,	O
PVR	O
and	O
TFC	O
after	O
48	O
hours	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
There	O
were	O
significant	O
lowering	O
of	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
after	O
HVHF	O
at	O
72	O
hours	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
also	O
in	O
MPAP	O
,	O
PVR	O
and	O
TFC	O
after	O
48	O
hours	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
elicits	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
in	O
the	O
immunized	O
animals	O
.	O

Through	O
SPR	O
technology	O
-	O
based	O
assay	O
,	O
52	O
from	O
these	O
256	O
compounds	O
were	O
discovered	O
to	O
show	O
binding	B-FUNC
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

Blockade	O
of	O
infection	O
with	O
anti	O
-	O
fAPN	O
monoclonal	O
antibody	B-FUNC
RG4	O
suggested	O
that	O
these	O
three	O
regions	O
lie	O
close	O
together	O
on	O
the	O
fAPN	O
surface	O
.	O

N740	O
and	O
T742	O
in	O
fAPN	O
and	O
the	O
homologous	O
R741	O
in	O
human	O
APN	O
(	O
hAPN	O
)	O
were	O
key	O
determinants	O
of	O
host	O
range	O
for	O
FCoV	O
,	O
TGEV	O
,	O
and	O
CCoV	O
.	O
Residue	O
N740	O
in	O
fAPN	O
was	O
essential	O
only	O
for	O
CCoV	O
receptor	B-FUNC
activity	I-FUNC
.	O

Pulsed	O
methylprednisolone	O
,	O
gamma	O
-	O
globulin	O
,	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
and	O
sivelestat	O
sodium	O
hydrate	O
were	O
administrated	O
,	O
and	O
thereafter	O
the	O
patient	O
recovered	O
from	O
cytopenia	O
and	O
organ	O
failure	O
.	O

TITLE	O
:	O
Naturally	O
occurring	O
anti	O
-	O
Escherichia	O
coli	O
protein	O
antibodies	O
in	O
the	O
sera	B-FUNC
of	O
healthy	O
humans	O
cause	O
analytical	O
interference	O
in	O
a	O
recombinant	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
serodiagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
We	O
reported	O
the	O
analytical	O
interference	O
of	O
anti	O
-	O
Escherichia	O
coli	O
protein	O
(	O
EP	O
)	O
antibodies	O
in	O
human	O
sera	B-FUNC
and	O
residual	O
EP	O
in	O
a	O
recombinant	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
as	O
a	O
possible	O
source	O
of	O
false	O
positives	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
serodiagnosis	O
.	O

As	O
compared	O
to	O
wild	O
-	O
type	O
,	O
STAT6	O
-	O
deficient	O
mice	O
had	O
increased	O
lung	O
injury	O
from	O
1	O
to	O
6	O
h	O
,	O
with	O
full	O
recovery	O
by	O
12	O
h	O
.	O
An	O
opposite	O
pattern	O
was	O
observed	O
in	O
STAT4	O
-	O
deficient	O
mice	O
with	O
mild	O
injury	O
seen	O
at	O
1	O
and	O
6	O
h	O
,	O
and	O
maximal	O
injury	O
at	O
12	O
h	O
.	O
MPO	B-FUNC
activity	O
was	O
significantly	O
increased	O
at	O
6	O
h	O
in	O
caerulein	O
-	O
treated	O
wild	O
-	O
type	O
mice	O
compared	O
to	O
saline	O
-	O
treated	O
controls	O
.	O

Caerulein	O
-	O
treated	O
STAT6	O
and	O
STAT4	O
mice	O
had	O
markedly	O
increased	O
MPO	B-FUNC
activity	O
as	O
compared	O
with	O
their	O
saline	O
controls	O
during	O
the	O
first	O
6	O
h	O
.	O
Both	O
caerulein	O
-	O
treated	O
STAT4	O
-	O
and	O
STAT6	O
-	O
deficient	O
mice	O
had	O
significantly	O
increased	O
MPO	B-FUNC
activity	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
mice	O
with	O
pancreatitis	O
at	O
6	O
h	O
.	O
We	O
found	O
the	O
maximal	O
lung	O
injury	O
after	O
caerulein	O
-	O
induced	O
pancreatitis	O
occurred	O
at	O
different	O
time	O
-	O
points	O
in	O
STAT4	O
and	O
STAT6	O
-	O
deficient	O
mice	O
.	O

Caerulein	O
-	O
treated	O
STAT6	O
and	O
STAT4	O
mice	O
had	O
markedly	O
increased	O
MPO	B-FUNC
activity	O
as	O
compared	O
with	O
their	O
saline	O
controls	O
during	O
the	O
first	O
6	O
h	O
.	O
Both	O
caerulein	O
-	O
treated	O
STAT4	O
-	O
and	O
STAT6	O
-	O
deficient	O
mice	O
had	O
significantly	O
increased	O
MPO	B-FUNC
activity	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
mice	O
with	O
pancreatitis	O
at	O
6	O
h	O
.	O
CONCLUSIONS	O
:	O
We	O
found	O
the	O
maximal	O
lung	O
injury	O
after	O
caerulein	O
-	O
induced	O
pancreatitis	O
occurred	O
at	O
different	O
time	O
-	O
points	O
in	O
STAT4	O
and	O
STAT6	O
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
antiviral	O
lectins	O
,	O
small	O
proteins	O
that	O
bind	B-FUNC
carbohydrates	O
found	O
on	O
viral	O
envelopes	O
,	O
are	O
currently	O
in	O
pre	O
-	O
clinical	O
trials	O
as	O
potential	O
drugs	O
for	O
prevention	O
of	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
other	O
enveloped	O
viruses	O
,	O
such	O
as	O
the	O
Ebola	O
virus	O
and	O
the	O
coronavirus	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Although	O
all	O
these	O
proteins	O
exhibit	O
significant	O
antiviral	O
activity	O
,	O
their	O
structures	O
are	O
unrelated	O
and	O
their	O
mode	O
of	O
binding	B-FUNC
of	O
carbohydrates	O
differs	O
significantly	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
structures	O
of	O
algal	O
lectins	O
,	O
their	O
mode	O
of	O
binding	B-FUNC
of	O
carbohydrates	O
,	O
and	O
their	O
potential	O
medical	O
applications	O
.	O

RESULTS	O
:	O
Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	O
[(	O
7	O
,	O
600	O
+/-	O
2	O
,	O
400	O
)	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
],	O
and	O
remained	O
at	O
a	O
high	O
level	O
in	O
the	O
progressive	O
stage	O
[(	O
8	O
,	O
100	O
+/-	O

Pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
were	O
found	O
in	O
lung	O
secretions	O
of	O
influenza	O
virus	O
infected	O
pigs	O
,	O
and	O
correlated	O
with	O
the	O
intensity	O
of	O
clinical	O
signs	O
,	O
whereas	O
prior	O
vaccination	O
against	O
influenza	O
strongly	O
reduced	O
the	O
production	O
of	O
infectious	O
virus	O
and	O
cytokines	O
in	O
the	O
lungs	O
upon	O
challenge	O
,	O
which	O
was	O
associated	O
with	O
clinical	O
protection	O
.	O

Thus	O
,	O
nasal	O
and	O
pulmonary	O
antibody	B-FUNC
responses	O
were	O
analyzed	O
in	O
influenza	O
virus	O
infected	O
or	O
vaccinated	O
pigs	O
showing	O
short	O
-	O
lived	O
,	O
but	O
potentially	O
protective	O
local	O
IgA	O
and	O
IgG	O
antibody	B-FUNC
(	O
Ab	O
)	O
responses	O
.	O

TITLE	O
:	O
SARS	O
CoV	O
main	O
proteinase	B-FUNC
:	O
The	O
monomer	O
-	O
dimer	O
equilibrium	O
dissociation	O
constant	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
SARS	O
CoV	O
main	O
proteinase	B-FUNC
)	O
is	O
required	O
for	O
the	O
replication	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
),	O
the	O
virus	O
that	O
causes	O
SARS	O
.	O

The	O
active	O
form	O
of	O
the	O
SARS	O
CoV	O
main	O
proteinase	B-FUNC
is	O
a	O
homodimer	O
.	O

Analysis	O
of	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
data	O
from	O
a	O
series	O
of	O
measurements	O
at	O
different	O
SARS	O
CoV	O
main	O
proteinase	B-FUNC
concentrations	O
yielded	O
KD	O
values	O
of	O
5	O
.	O
8	O
+/-	O

ABSTRACT	O
:	O
A	O
combination	O
of	O
protein	O
-	O
ligand	B-FUNC
docking	O
and	O
ligand	B-FUNC
-	O
based	O
QSAR	O
approaches	O
has	O
been	O
elaborated	O
,	O
aiming	O
to	O
speed	O
-	O
up	O
the	O
process	O
of	O
virtual	O
screening	O
.	O

In	O
particular	O
,	O
this	O
approach	O
utilizes	O
docking	O
scores	O
generated	O
for	O
already	O
processed	O
compounds	O
to	O
build	O
predictive	O
QSAR	O
models	O
that	O
,	O
in	O
turn	O
,	O
assess	O
hypothetical	O
target	O
binding	B-FUNC
affinities	O
for	O
yet	O
undocked	O
entries	O
.	O

The	O
""""	O
progressive	O
docking	O
""""	O
has	O
been	O
tested	O
on	O
drug	O
-	O
like	O
substances	O
from	O
the	O
NCI	O
database	O
that	O
have	O
been	O
docked	O
into	O
several	O
unrelated	O
targets	O
,	O
including	O
human	O
sex	O
hormone	B-FUNC
binding	I-FUNC
globulin	O
(	O
SHBG	O
),	O
carbonic	O
anhydrase	O
,	O
corticosteroid	O
-	O
binding	B-FUNC
globulin	O
,	O
SARS	O
3C	O
-	O
like	O
protease	O
,	O
and	O
HIV1	O
reverse	O
transcriptase	B-FUNC
.	O

Levels	O
of	O
inflammatory	O
cytokines	O
in	O
sera	B-FUNC
and	O
lung	O
tissues	O
were	O
significantly	O
higher	O
in	O
adult	O
F344	O
rats	O
than	O
in	O
young	O
rats	O
.	O

During	O
in	O
vivo	O
passage	O
of	O
SARS	O
-	O
CoV	O
,	O
a	O
single	O
amino	O
acid	O
substitution	O
was	O
introduced	O
within	O
the	O
binding	B-FUNC
domain	O
of	O
the	O
viral	O
spike	O
protein	O
recognizing	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
is	O
known	O
as	O
a	O
SARS	O
-	O
CoV	O
receptor	O
.	O

To	O
further	O
characterize	O
the	O
earliest	O
apoptotic	O
signaling	O
events	O
,	O
here	O
we	O
treated	O
cells	O
with	O
an	O
antibody	B-FUNC
specific	O
to	O
the	O
MHV	O
receptor	O
prior	O
to	O
and	O
during	O
virus	O
infection	O
or	O
with	O
an	O
antibody	B-FUNC
specific	O
to	O
MHV	O
spike	O
protein	O
following	O
virus	O
binding	B-FUNC
.	O

Both	O
treatments	O
blocked	O
virus	O
infection	O
and	O
apoptosis	O
,	O
indicating	O
that	O
virus	O
-	O
receptor	B-FUNC
binding	I-FUNC
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
the	O
apoptosis	O
induction	O
.	O

Furthermore	O
,	O
virus	O
infection	O
significantly	O
increased	O
the	O
formation	O
of	O
the	O
""""	O
death	O
-	O
receptor	O
complexes	O
""""	O
consisting	O
of	O
Fas	O
,	O
Fas	O
-	O
associated	O
death	O
domain	O
and	O
procaspase	O
-	O
8	O
,	O
but	O
did	O
not	O
induce	O
the	O
complexes	O
involving	O
the	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
and	O
its	O
associated	O
death	O
domain	O
,	O
demonstrating	O
the	O
specific	O
activation	O
of	O
the	O
Fas	O
signaling	O
pathway	O
.	O

Treatment	O
with	O
a	O
Fas	O
/	O
Fc	O
chimera	O
,	O
which	O
blocks	O
Fas	O
-	O
Fas	O
ligand	B-FUNC
-	O
mediated	O
apoptosis	O
,	O
inhibited	O
the	O
formation	O
of	O
the	O
complexes	O
and	O
blocked	O
the	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
apoptosis	O
in	O
MHV	O
-	O
infected	O
cells	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
different	O
chicken	O
flocks	O
(	O
n	O
=	O
20	O
)	O
that	O
suffered	O
from	O
respiratory	O
disease	O
were	O
tested	O
for	O
IBV	O
antibodies	O
using	O
commercial	O
IBV	O
antibody	B-FUNC
ELISA	O
at	O
time	O
of	O
the	O
initial	O
signs	O
of	O
the	O
respiratory	O
disease	O
and	O
repeated	O
on	O
serum	O
samples	O
from	O
the	O
same	O
flocks	O
10	O
-	O
14	O
days	O
later	O
.	O

Utilizing	O
the	O
human	O
immunoglobulin	B-FUNC
transgenic	O
mouse	O
,	O
XenoMouse	O
,	O
we	O
produced	O
fully	O
human	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
specific	O
antibodies	O
.	O

Mapping	O
of	O
the	O
binding	B-FUNC
region	O
was	O
achieved	O
with	O
several	O
S1	O
recombinant	O
proteins	O
.	O

Immunoglobulin	B-FUNC
gene	O
sequence	O
analyses	O
suggested	O
at	O
least	O
8	O
different	O
binding	B-FUNC
specificities	O
.	O

TITLE	O
:	O
The	O
cytoplasmic	O
tail	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
contains	O
a	O
novel	O
endoplasmic	O
reticulum	O
retrieval	O
signal	O
that	O
binds	B-FUNC
COPI	O
and	O
promotes	O
interaction	O
with	O
membrane	O
protein	O
.	O

The	O
dibasic	O
motif	O
bound	O
the	O
coatomer	O
complex	O
I	O
(	O
COPI	O
)	O
in	O
an	O
in	O
vitro	O
binding	B-FUNC
assay	O
,	O
suggesting	O
that	O
ER	O
retrieval	O
may	O
contribute	O
to	O
the	O
accumulation	O
of	O
SARS	O
CoV	O
S	O
protein	O
near	O
the	O
virus	O
assembly	O
site	O
for	O
interaction	O
with	O
other	O
viral	O
structural	O
proteins	O
.	O

TITLE	O
:	O
Quaternary	O
structure	O
,	O
substrate	O
selectivity	O
and	O
inhibitor	O
design	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
is	O
recognized	O
as	O
a	O
potential	O
drug	O
design	O
target	O
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Though	O
the	O
enzyme	O
is	O
a	O
cysteine	O
protease	O
with	O
a	O
chymotrypsin	O
fold	O
,	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
follows	O
the	O
general	O
base	O
catalytic	O
mechanism	O
similar	O
to	O
chymotrypsin	O
.	O

However	O
,	O
when	O
BALB	O
/	O
c	O
mice	O
were	O
orally	O
immunized	O
with	O
the	O
Salmonella	O
vector	O
expressing	O
the	O
TGEV	O
epitopes	O
from	O
either	O
one	O
of	O
the	O
fusion	O
constructs	O
or	O
both	O
together	O
,	O
the	O
highest	O
level	O
of	O
anti	O
-	O
TGEV	O
antibody	B-FUNC
was	O
obtained	O
with	O
the	O
987P	O
-	O
TGEV	O
immunogen	O
-	O
displaying	O
vector	O
.	O

ABSTRACT	O
:	O
Small	O
immunoproteins	O
(	O
SIPs	O
)	O
are	O
single	O
-	O
chain	O
molecules	O
comprising	O
the	O
variable	O
regions	O
of	O
an	O
antibody	B-FUNC
assembled	O
in	O
a	O
single	O
polypeptide	O
(	O
scFv	O
)	O
and	O
joined	O
to	O
the	O
immunoglobulin	B-FUNC
heavy	O
-	O
chain	O
dimerizing	O
domain	O
.	O

The	O
specificity	O
and	O
functionality	O
of	O
the	O
recombinant	O
TGEV	O
-	O
specific	O
SIPs	O
were	O
determined	O
by	O
in	O
vitro	O
binding	B-FUNC
,	O
neutralization	O
and	O
infection	O
-	O
interference	O
assays	O
.	O

HCoV	O
-	O
NL63	O
S	O
is	O
expressed	O
as	O
a	O
single	O
-	O
chain	O
glycoprotein	O
and	O
consists	O
of	O
an	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
transmembrane	O
fusion	O
domain	O
(	O
S2	O
).	O

Loop	O
regions	O
of	O
24	O
bases	O
and	O
5	O
base	B-FUNC
pair	I-FUNC
stem	O
regions	O
in	O
the	O
beacon	O
probes	O
gave	O
optimal	O
performance	O
.	O

Target	O
binding	B-FUNC
to	O
the	O
surface	O
as	O
a	O
function	O
of	O
solution	O
concentration	O
fit	O
a	O
Sips	O
isotherm	O
with	O
Kd	O
=	O
1	O
.	O
7	O
+/-	O

TITLE	O
:	O
Long	O
-	O
term	O
persistence	O
of	O
robust	O
antibody	B-FUNC
and	O
cytotoxic	O
T	O
cell	O
responses	O
in	O
recovered	O
patients	O
infected	O
with	O
SARS	O
coronavirus	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
sequentially	O
monitored	O
30	O
recovered	O
patients	O
over	O
a	O
two	O
-	O
year	O
period	O
to	O
characterize	O
temporal	O
changes	O
in	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibody	B-FUNC
responses	O
as	O
well	O
as	O
cytotoxic	O
T	O
cell	O
(	O
CTL	O
)	O
responses	O
.	O

We	O
have	O
found	O
persistence	O
of	O
robust	O
antibody	B-FUNC
and	O
CTL	O
responses	O
in	O
all	O
of	O
the	O
study	O
subjects	O
throughout	O
the	O
study	O
period	O
,	O
with	O
a	O
moderate	O
decline	O
one	O
year	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

In	O
conclusion	O
,	O
it	O
can	O
be	O
stated	O
that	O
in	O
FIP	O
cats	O
,	O
FIPV	O
replicates	O
in	O
cells	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
without	O
carrying	O
viral	O
antigens	O
in	O
their	O
plasma	O
membrane	O
,	O
which	O
could	O
allow	O
them	O
to	O
escape	O
from	O
antibody	B-FUNC
-	O
dependent	O
cell	O
lysis	O
.	O

These	O
crystal	O
structures	O
reveal	O
that	O
the	O
first	O
residue	O
of	O
this	O
protease	O
is	O
important	O
for	O
sustaining	O
the	O
substrate	O
-	O
binding	B-FUNC
pocket	O
and	O
inhibitor	O
binding	B-FUNC
.	O

Sera	B-FUNC
from	O
35	O
confirmed	O
cases	O
of	O
severe	O
leptospirosis	O
and	O
13	O
healthy	O
subjects	O
were	O
analysed	O
.	O

TITLE	O
:	O
Crystal	O
structures	O
reveal	O
an	O
induced	O
-	O
fit	O
binding	B-FUNC
of	O
a	O
substrate	O
-	O
like	O
Aza	O
-	O
peptide	O
epoxide	O
to	O
SARS	O
coronavirus	O
main	O
peptidase	O
.	O

The	O
structural	O
data	O
further	O
suggest	O
that	O
the	O
binding	B-FUNC
of	O
APE	O
to	O
M	O
(	O
pro	O
)	O
follows	O
an	O
induced	O
-	O
fit	O
model	O
.	O

The	O
substrate	O
likely	O
also	O
binds	B-FUNC
in	O
an	O
induced	O
-	O
fit	O
manner	O
in	O
a	O
process	O
that	O
may	O
help	O
drive	O
the	O
catalytic	O
cycle	O
.	O

TITLE	O
:	O
Recombinant	O
truncated	O
nucleocapsid	O
protein	O
as	O
antigen	O
in	O
a	O
novel	O
immunoglobulin	B-FUNC
M	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
diagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
development	O
of	O
an	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
)	O
antibody	B-FUNC
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
MAC	O
-	O
ELISA	O
)	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
using	O
recombinant	O
truncated	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
as	O
the	O
antigen	O
.	O

The	O
newly	O
developed	O
MAC	O
-	O
ELISA	O
had	O
a	O
specificity	O
and	O
sensitivity	O
of	O
100	O
%	O
as	O
evaluated	O
by	O
using	O
sera	B-FUNC
from	O
healthy	O
volunteers	O
and	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
.	O

Using	O
serial	O
serum	O
samples	O
collected	O
from	O
SARS	O
patients	O
,	O
the	O
times	O
to	O
seroconversion	O
were	O
determined	O
by	O
IgM	O
antibody	B-FUNC
detection	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

Serological	O
investigations	O
on	O
216	O
dog	O
sera	B-FUNC
,	O
carried	O
out	O
by	O
an	O
ELISA	O
test	O
using	O
the	O
strictly	O
related	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
as	O
antigen	O
,	O
revealed	O
an	O
overall	O
CRCoV	O
seroprevalence	O
of	O
32	O
.	O
06	O
%	O
in	O
the	O
last	O
2	O
years	O
.	O

Synthetic	O
versions	O
of	O
predominant	O
IgA	O
antibodies	O
in	O
acute	O
Kawasaki	O
disease	O
arterial	O
tissue	O
bind	B-FUNC
to	O
an	O
antigen	O
present	O
in	O
acute	O
Kawasaki	O
disease	O
ciliated	O
bronchial	O
epithelium	O
and	O
in	O
a	O
subset	O
of	O
macrophages	O
in	O
acute	O
inflamed	O
Kawasaki	O
disease	O
tissues	O
.	O

These	O
approaches	O
were	O
able	O
to	O
achieve	O
or	O
induce	O
antibody	B-FUNC
titers	O
sufficient	O
to	O
reduce	O
viral	O
load	O
,	O
protect	O
from	O
weight	O
loss	O
and	O
reduce	O
or	O
eliminate	O
histopathologic	O
changes	O
in	O
the	O
lungs	O
of	O
aged	O
mice	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
coronaviral	O
N	O
proteins	O
(	O
N	O
-	O
NTD	O
)	O
provides	O
a	O
scaffold	O
for	O
RNA	B-FUNC
binding	I-FUNC
,	O
while	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
N	O
-	O
CTD	O
)	O
mainly	O
acts	O
as	O
oligomerization	O
modules	O
during	O
assembly	O
.	O

Tests	O
for	O
detection	O
of	O
SARS	O
coronavirus	O
antibody	B-FUNC
were	O
performed	O
for	O
HCWs	O
at	O
these	O
2	O
time	O
points	O
and	O
for	O
control	O
subjects	O
during	O
the	O
SARS	O
epidemic	O
.	O

All	O
serum	O
specimens	O
tested	O
negative	O
for	O
SARS	O
antibody	B-FUNC
.	O

RESULTS	O
:	O
All	O
serum	O
specimens	O
tested	O
negative	O
for	O
SARS	O
antibody	B-FUNC
.	O

The	O
heterogeneous	O
combinations	O
were	O
all	O
higher	O
than	O
those	O
of	O
the	O
homologous	O
combinations	O
in	O
the	O
induction	O
of	O
anti	O
-	O
N	O
antibody	B-FUNC
response	O
.	O

In	O
the	O
induction	O
of	O
IFN	O
-	O
gamma	O
production	O
,	O
the	O
homologous	O
combination	O
of	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
was	O
significantly	O
stronger	O
than	O
that	O
of	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
,	O
but	O
was	O
relatively	O
weaker	O
than	O
the	O
heterogeneous	O
combination	O
of	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
rAd	O
-	O
N	O
.	O
This	O
combination	O
was	O
a	O
most	O
efficient	O
immunization	O
regimen	O
in	O
induction	O
of	O
SARS	O
-	O
CoV	O
-	O
N	O
-	O
specific	O
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
just	O
as	O
the	O
antibody	B-FUNC
response	O
.	O

The	O
selected	O
acute	O
phase	O
proteins	O
were	O
fibrinogen	O
,	O
haptoglobin	O
,	O
serum	O
amyloid	O
-	O
A	O
,	O
lipopolysaccharide	B-FUNC
binding	I-FUNC
protein	O
and	O
alpha1	O
-	O
acid	O
glycoprotein	O
.	O

Both	O
,	O
S	O
-	O
containing	O
exosomes	O
and	O
the	O
adenoviral	O
vector	O
vaccine	O
induced	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

After	O
priming	O
with	O
the	O
SARS	O
-	O
S	O
exosomal	O
vaccine	O
and	O
boosting	O
with	O
the	O
adenoviral	O
vector	O
the	O
neutralizing	O
antibody	B-FUNC
titers	O
exceeded	O
those	O
observed	O
in	O
the	O
convalescent	O
serum	O
of	O
a	O
SARS	O
patient	O
.	O

The	O
panel	O
is	O
composed	O
of	O
25	O
positive	O
samples	O
,	O
25	O
negative	O
samples	O
,	O
7	O
diluted	O
samples	O
for	O
anti	O
-	O
N	O
antibody	B-FUNC
,	O
6	O
diluted	O
samples	O
for	O
anti	O
-	O
S	O
antibody	B-FUNC
,	O
and	O
one	O
sample	O
for	O
validating	O
precision	O
.	O

Comparison	O
of	O
detection	O
results	O
with	O
different	O
SARS	O
antibody	B-FUNC
assays	O
indicated	O
that	O
our	O
panel	O
should	O
differentiate	O
the	O
specificity	O
and	O
sensitivity	O
of	O
different	O
assays	O
.	O

However	O
,	O
the	O
ability	O
of	O
mAbs	O
to	O
bind	B-FUNC
to	O
specific	O
targets	O
and	O
utilize	O
various	O
anti	O
-	O
infective	O
modes	O
of	O
action	O
would	O
seem	O
to	O
make	O
them	O
well	O
suited	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
a	O
wider	O
variety	O
of	O
viral	O
diseases	O
.	O

Moreover	O
,	O
it	O
was	O
found	O
through	O
the	O
ligand	B-FUNC
-	O
receptor	O
docking	O
studies	O
that	O
of	O
the	O
11	O
cleavable	O
peptides	O
,	O
NH2	O
-	O
ATLQ	O
/	O
AIAS	O
-	O
COOH	O
and	O
NH2	O
-	O
ATLQ	O
/	O
AENV	O
-	O
COOH	O
had	O
the	O
highest	O
affinity	O
with	O
SARS	O
CoV	O
M	O
(	O
pro	O
).	O

PKC	B-FUNC
epsilon	O
-	O
specific	O
siRNA	O
also	O
attenuated	O
the	O
phosphorylation	O
of	O
JNK	B-FUNC
.	O

It	O
is	O
also	O
essential	O
to	O
further	O
determine	O
how	O
PTX3	O
binds	B-FUNC
to	O
pathogens	O
,	O
complement	O
,	O
and	O
apoptotic	O
cells	O
,	O
and	O
to	O
determine	O
whether	O
PTX3	O
has	O
a	O
specific	O
receptor	O
in	O
targeted	O
cells	O
.	O

Intrapulmonary	O
expression	O
of	O
Caspase	O
-	O
1	O
,	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
mRNA	O
were	O
detected	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Intrapulmonary	O
expression	O
of	O
Caspase	O
-	O
1	O
,	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
mRNA	O
were	O
observed	O
in	O
the	O
HC	O
group	O
,	O
while	O
they	O
were	O
increased	O
significantly	O
in	O
the	O
SAP	O
-	O
S	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
HC	O
).	O

The	O
expression	O
of	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
mRNA	O
were	O
decreased	O
significantly	O
in	O
the	O
SAP	O
-	O
ICE	O
-	O
I	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
SAP	O
-	O
S	O
),	O
whereas	O
Caspase	O
-	O
1	O
mRNA	O
expression	O
had	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

In	O
contrast	O
to	O
human	O
influenza	O
A	O
H1NI	O
viruses	O
,	O
the	O
H5N1	O
viruses	O
hyper	O
-	O
induce	O
cytokines	O
(	O
tumour	O
necrosis	O
factor	O
[	O
TNF	O
]	O
alpha	O
,	O
interferon	O
beta	O
)	O
and	O
chemokines	O
(	O
IP10	O
,	O
MIP1alpha	O
,	O
MCP	B-FUNC
)	O
in	O
in	O
vitro	O
cultures	O
of	O
primary	O
human	O
macrophages	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
TGEV	O
infection	O
,	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
(	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
)	O
targeting	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
of	O
TGEV	O
were	O
constructed	O
and	O
transfected	O
into	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
.	O

into	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
receptor	O
gamma	O
-	O
chain	O
disrupted	O
SCID	O
mice	O
,	O
and	O
SCID	O
-	O
PBL	O
/	O
hu	O
mice	O
were	O
constructed	O
.	O

The	O
highest	O
values	O
of	O
sICAM	O
-	O
1	O
were	O
observed	O
in	O
patients	O
with	O
TBI	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
those	O
of	O
sE	O
-	O
Selectin	B-FUNC
in	O
patients	O
with	O
sepsis	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

RESULTS	O
:	O
The	O
highest	O
values	O
of	O
sICAM	O
-	O
1	O
were	O
observed	O
in	O
patients	O
with	O
TBI	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
those	O
of	O
sE	O
-	O
Selectin	B-FUNC
in	O
patients	O
with	O
sepsis	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

Increased	O
levels	O
of	O
measured	O
molecules	O
(	O
TGF	O
-	O
beta1	O
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sE	O
-	O
Selectin	B-FUNC
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sL	O
-	O
Selectin	B-FUNC
,	O
p	O
=	O
0	O
.	O
06	O
,	O
sICAM	O
-	O
1	O
,	O
p	O
<	O
0	O
.	O
03	O
)	O
were	O
demonstrated	O
among	O
survivors	O
in	O
the	O
sepsis	O
and	O
ARDS	O
groups	O
of	O
patients	O
and	O
were	O
positively	O
correlated	O
with	O
length	O
of	O
stay	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
and	O
mechanical	O
ventilation	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
The	O
potential	O
of	O
targeted	O
antibody	B-FUNC
prophylaxis	O
in	O
SARS	O
outbreak	O
control	O
:	O
a	O
mathematic	O
analysis	O
.	O

We	O
developed	O
a	O
mathematical	O
model	O
to	O
investigate	O
the	O
effects	O
of	O
hospital	O
admission	O
and	O
targeted	O
antibody	B-FUNC
prophylaxis	O
on	O
the	O
reproduction	O
number	O
R	O
,	O
defined	O
as	O
the	O
number	O
of	O
secondary	O
cases	O
generated	O
by	O
an	O
index	O
case	O
,	O
during	O
different	O
SARS	O
outbreak	O
scenarios	O
.	O

Antibody	B-FUNC
prophylaxis	O
may	O
also	O
be	O
employed	O
to	O
reduce	O
R	O
below	O
one	O
and	O
thereby	O
restrict	O
outbreak	O
size	O
and	O
duration	O
.	O

Antibody	B-FUNC
prophylaxis	O
as	O
supplemental	O
measure	O
generally	O
allows	O
for	O
containment	O
of	O
higher	O
R	O
(	O
0	O
)	O
values	O
and	O
restricts	O
both	O
the	O
size	O
and	O
duration	O
of	O
an	O
outbreak	O
.	O

METHODS	O
:	O
We	O
developed	O
a	O
mathematical	O
model	O
to	O
investigate	O
the	O
effects	O
of	O
hospital	O
admission	O
and	O
targeted	O
antibody	B-FUNC
prophylaxis	O
on	O
the	O
reproduction	O
number	O
R	O
,	O
defined	O
as	O
the	O
number	O
of	O
secondary	O
cases	O
generated	O
by	O
an	O
index	O
case	O
,	O
during	O
different	O
SARS	O
outbreak	O
scenarios	O
.	O

Antibody	B-FUNC
prophylaxis	O
may	O
also	O
be	O
employed	O
to	O
reduce	O
R	O
below	O
one	O
and	O
thereby	O
restrict	O
outbreak	O
size	O
and	O
duration	O
.	O

Rescued	O
virus	O
-	O
infected	O
cells	O
were	O
detected	O
by	O
indirect	O
fluorescent	O
antibody	B-FUNC
staining	O
demonstrated	O
that	O
it	O
can	O
specifically	O
reaction	O
with	O
SARS	O
-	O
CoV	O
.	O
By	O
CPE	O
method	O
and	O
plaque	O
assay	O
,	O
the	O
titers	O
of	O
the	O
rescued	O
virus	O
and	O
wild	O
-	O
type	O
virus	O
were	O
assessed	O
,	O
which	O
demonstrated	O
there	O
are	O
no	O
significant	O
difference	O
between	O
the	O
viruses	O
and	O
they	O
have	O
similar	O
biological	O
characteristics	O
.	O

RESULTS	O
:	O
Unexpectedly	O
,	O
we	O
found	O
that	O
INDO	O
has	O
a	O
potent	O
direct	O
antiviral	O
activity	O
against	O
the	O
coronaviruses	O
SARS	O
-	O
CoV	O
and	O
CCoV	O
.	O
INDO	O
does	O
not	O
affect	O
coronavirus	O
binding	B-FUNC
or	O
entry	O
into	O
host	O
cells	O
,	O
but	O
acts	O
by	O
blocking	O
viral	O
RNA	O
synthesis	O
at	O
cytoprotective	O
doses	O
.	O

We	O
further	O
showed	O
that	O
M	O
protein	O
-	O
induced	O
apoptosis	O
involved	O
mitochondrial	O
release	O
of	O
cytochrome	B-FUNC
c	I-FUNC
protein	O
,	O
and	O
could	O
be	O
suppressed	O
by	O
caspase	O
inhibitors	O
.	O

By	O
performing	O
a	O
forward	O
genetic	O
modifier	O
screen	O
,	O
we	O
identified	O
phosphoinositide	O
-	O
dependent	O
kinase	O
-	O
1	O
(	O
PDK	B-FUNC
-	O
1	O
)	O
as	O
a	O
dominant	O
suppressor	O
of	O
M	O
-	O
induced	O
apoptotic	O
cell	O
death	O
.	O

Both	O
PDK	B-FUNC
-	O
1	O
and	O
Akt	O
kinases	O
play	O
essential	O
roles	O
in	O
the	O
cell	O
survival	O
signaling	O
pathway	O
.	O

Altogether	O
,	O
our	O
data	O
show	O
that	O
SARS	O
-	O
CoV	O
M	O
protein	O
induces	O
apoptosis	O
through	O
the	O
modulation	O
of	O
the	O
cellular	O
Akt	O
pro	O
-	O
survival	O
pathway	O
and	O
mitochondrial	O
cytochrome	B-FUNC
c	I-FUNC
release	O
.	O

TITLE	O
:	O
An	O
antibody	B-FUNC
derivative	O
expressed	O
from	O
viral	O
vectors	O
passively	O
immunizes	O
pigs	O
against	O
transmissible	O
gastroenteritis	O
virus	O
infection	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
potential	O
of	O
antibody	B-FUNC
derivatives	O
to	O
provide	O
passive	O
protection	O
against	O
enteric	O
infections	O
when	O
supplied	O
orally	O
in	O
crude	O
plant	O
extracts	O
,	O
we	O
have	O
expressed	O
a	O
small	O
immune	O
protein	O
(	O
SIP	O
)	O
in	O
plants	O
using	O
two	O
different	O
plant	O
virus	O
vectors	O
based	O
on	O
potato	O
virus	O
X	O
(	O
PVX	O
)	O
and	O
cowpea	O
mosaic	O
virus	O
(	O
CPMV	O
).	O

The	O
epsilonSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
-	O
chain	O
antibody	B-FUNC
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
epsilon	O
-	O
CH4	O
domain	O
from	O
human	O
immunoglobulin	B-FUNC
E	O
(	O
IgE	O
).	O

In	O
some	O
constructs	O
,	O
the	O
sequence	O
encoding	O
the	O
epsilonSIP	O
molecule	O
was	O
flanked	O
by	O
the	O
leader	O
peptide	O
from	O
the	O
original	O
murine	O
antibody	B-FUNC
at	O
its	O
N	O
-	O
terminus	O
and	O
an	O
endoplasmic	O
reticulum	O
retention	O
signal	O
(	O
HDEL	O
)	O
at	O
its	O
C	O
-	O
terminus	O
to	O
allow	O
the	O
expressed	O
protein	O
to	O
be	O
directed	O
to	O
,	O
and	O
retained	O
within	O
,	O
the	O
endoplasmic	O
reticulum	O
.	O

The	O
analysis	O
of	O
crude	O
plant	O
extracts	O
revealed	O
that	O
the	O
plant	O
-	O
expressed	O
epsilonSIP	O
molecules	O
could	O
bind	B-FUNC
to	O
and	O
neutralize	O
TGEV	O
in	O
tissue	O
culture	O
,	O
the	O
levels	O
of	O
binding	B-FUNC
and	O
neutralization	O
reflecting	O
the	O
level	O
of	O
expression	O
.	O

TITLE	O
:	O
Natural	O
mutations	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
spike	O
glycoprotein	O
determine	O
the	O
reactivity	O
of	O
cross	O
-	O
neutralization	O
between	O
palm	O
civet	O
coronavirus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Studies	O
indicate	O
that	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
contains	O
major	O
determinants	O
for	O
viral	O
entry	O
and	O
neutralization	O
.	O

Convalescence	O
-	O
phase	O
sera	B-FUNC
from	O
humans	O
were	O
similarly	O
ineffective	O
against	O
the	O
dominant	O
civet	O
pseudovirus	O
.	O

TITLE	O
:	O
Ranpirnase	O
:	O
amphibian	O
ribonuclease	B-FUNC
A	I-FUNC
,	O
P	O
-	O
30	O
protein	O
-	O
alfacell	O
.	O

Cells	O
with	O
nuclear	O
Myt1	O
immunoreactivity	O
were	O
mainly	O
OP	O
cells	O
,	O
identified	O
by	O
co	O
-	O
localization	O
with	O
platelet	B-FUNC
-	I-FUNC
derived	I-FUNC
growth	I-FUNC
factor	I-FUNC
alpha	O
receptor	O
,	O
with	O
additional	O
phenotypes	O
being	O
either	O
oligodendrocytes	O
or	O
neural	O
stem	O
cells	O
,	O
identified	O
by	O
CC1	O
antigen	O
and	O
Musashi1	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
In	O
the	O
serum	O
and	O
cerebrospinal	O
fluid	O
of	O
a	O
patient	O
with	O
recurrent	O
acute	O
episodes	O
of	O
respiratory	O
crises	O
,	O
autonomic	O
symptoms	O
and	O
total	O
insomnia	O
(	O
agrypnia	O
),	O
we	O
identified	O
a	O
novel	O
anti	O
-	O
neural	O
complement	O
fixing	O
antibody	B-FUNC
directed	O
against	O
GABA	O
(	O
B	O
)	O
receptor	O
(	O
GABA	O
(	O
B	O
)	O
R	O
).	O

Patient	O
purified	O
IgG	O
recognized	O
a	O
band	O
of	O
approximately	O
110	O
kDa	O
on	O
protein	O
extracts	O
of	O
mouse	O
cerebellum	O
,	O
cortex	O
and	O
brainstem	O
and	O
immunolabelled	O
cultured	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)	O
cells	O
,	O
transfected	O
with	O
human	O
GABA	O
(	O
B	O
)	O
R1	O
and	O
rat	O
GABA	O
(	O
B	O
)	O
R2	O
receptors	O
.	O

Western	O
blot	O
analysis	O
of	O
transfected	O
CHO	B-FUNC
homogenates	O
showed	O
the	O
same	O
band	O
using	O
both	O
patient	O
purified	O
IgG	O
and	O
anti	O
-	O
GABA	O
(	O
B	O
)	O
R1	O
antibody	B-FUNC
.	O

After	O
incubation	O
with	O
anti	O
-	O
GABA	O
(	O
B	O
)	O
R	O
antibody	B-FUNC
,	O
a	O
marked	O
reduction	O
of	O
receptor	O
immunostaining	O
was	O
found	O
with	O
relative	O
sparing	O
of	O
neuronal	O
architecture	O
.	O

In	O
order	O
to	O
establish	O
whether	O
these	O
fluctuations	O
depend	O
on	O
the	O
FCoV	O
status	O
,	O
the	O
serum	O
concentration	O
of	O
AGP	O
and	O
anti	O
-	O
FCoV	O
antibody	B-FUNC
titres	O
and	O
/	O
or	O
faecal	O
shedding	O
of	O
FCoVs	O
in	O
clinically	O
healthy	O
cats	O
from	O
catteries	O
with	O
different	O
levels	O
of	O
prevalence	O
of	O
FCoV	O
infection	O
were	O
monitored	O
over	O
time	O
.	O

Hemagglutination	O
assays	O
,	O
receptor	O
-	O
destroying	O
enzyme	B-FUNC
activity	I-FUNC
,	O
hemagglutination	O
inhibition	O
,	O
and	O
fluorescence	O
focus	O
neutralization	O
tests	O
revealed	O
close	O
biological	O
and	O
antigenic	O
relationships	O
between	O
the	O
GiCoV	O
-	O
OH3	O
isolate	O
and	O
selected	O
respiratory	O
and	O
enteric	O
bovine	O
CoV	O
(	O
BCoV	O
)	O
strains	O
.	O

ABSTRACT	O
:	O
Analysis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
by	O
either	O
sucrose	O
gradient	O
equilibrium	O
centrifugation	O
or	O
a	O
virus	O
capture	O
assay	O
using	O
an	O
anti	O
-	O
SCoV	O
S	O
protein	O
antibody	B-FUNC
demonstrated	O
that	O
the	O
SCoV	O
6	O
protein	O
,	O
which	O
is	O
one	O
of	O
the	O
accessory	O
proteins	O
of	O
SCoV	O
,	O
was	O
incorporated	O
into	O
virus	O
particles	O
.	O

TITLE	O
:	O
Carbohydrate	O
-	O
binding	B-FUNC
agents	O
:	O
a	O
potential	O
future	O
cornerstone	O
for	O
the	O
chemotherapy	O
of	O
enveloped	O
viruses	O
?	O

Examples	O
of	O
CBAs	O
include	O
the	O
procaryotic	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
plant	O
lectins	O
such	O
as	O
HHA	O
,	O
GNA	O
,	O
NPA	O
,	O
CA	O
and	O
UDA	O
,	O
the	O
monoclonal	O
antibody	B-FUNC
2G12	O
directed	O
against	O
a	O
glycan	O
-	O
containing	O
epitope	O
on	O
HIV	O
envelope	O
gp120	O
,	O
and	O
the	O
mannose	O
-	O
specific	O
non	O
-	O
peptidic	O
antibiotic	O
Pradimicin	O
A	O
,	O
which	O
inhibits	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
into	O
its	O
target	O
cells	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
cyclin	B-FUNC
D1	O
down	O
-	O
regulation	O
in	O
coronavirus	O
infected	O
cells	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
cyclin	B-FUNC
D1	O
was	O
reduced	O
post	O
-	O
transcriptionally	O
within	O
infected	O
cells	O
independently	O
of	O
the	O
cell	O
-	O
cycle	O
stage	O
at	O
the	O
time	O
of	O
infection	O
.	O

Confocal	O
microscopy	O
revealed	O
that	O
cyclin	B-FUNC
D1	O
decreased	O
in	O
IBV	O
-	O
infected	O
cells	O
as	O
infection	O
progressed	O
and	O
inhibition	O
studies	O
indicated	O
that	O
a	O
population	O
of	O
cyclin	B-FUNC
D1	O
could	O
be	O
targeted	O
for	O
degradation	O
by	O
a	O
virus	O
mediated	O
pathway	O
.	O

In	O
contrast	O
to	O
the	O
SARS	O
-	O
coronavirus	O
,	O
IBV	O
nucleocapsid	O
protein	O
did	O
not	O
interact	O
with	O
cyclin	B-FUNC
D1	O
.	O

Among	O
antibody	B-FUNC
sources	O
,	O
immunoglobulin	B-FUNC
Y	O
(	O
IgY	O
)	O
is	O
the	O
major	O
antibody	B-FUNC
found	O
in	O
chicken	O
eggs	O
and	O
can	O
be	O
used	O
as	O
an	O
alternative	O
to	O
mammalian	O
antibodies	O
normally	O
used	O
in	O
research	O
and	O
immunotherapy	O
.	O

In	O
this	O
study	O
,	O
phage	O
-	O
expressing	O
chicken	O
monoclonal	O
scFv	O
antibody	B-FUNC
was	O
chosen	O
and	O
characterized	O
with	O
phage	O
display	O
antibody	B-FUNC
technology	O
.	O

Using	O
these	O
bacteria	O
-	O
derived	O
proteins	O
to	O
immunize	O
chickens	O
,	O
it	O
was	O
found	O
that	O
polyclonal	O
IgY	O
antibodies	O
in	O
the	O
egg	O
yolk	O
and	O
sera	B-FUNC
were	O
highly	O
reactive	O
to	O
the	O
immunogens	O
,	O
as	O
shown	O
by	O
Western	O
blot	O
and	O
immunocytochemical	O
staining	O
analysis	O
.	O

In	O
sequence	O
analysis	O
with	O
chicken	O
germline	O
gene	O
,	O
five	O
phage	O
clones	O
reacted	O
,	O
with	O
large	O
dissimilarities	O
of	O
between	O
31	O
and	O
62	O
%,	O
in	O
the	O
complementarity	O
-	O
determining	O
regions	O
,	O
one	O
dominant	O
phage	O
4S1	O
had	O
strong	O
binding	B-FUNC
to	O
fragment	O
Se	O
-	O
e	O
,	O
located	O
between	O
amino	O
acid	O
residues	O
456	O
-	O
650	O
of	O
the	O
spike	O
protein	O
and	O
this	O
particular	O
phage	O
had	O
significantly	O
strong	O
binding	B-FUNC
to	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Hospitals	O
are	O
places	O
that	O
allow	O
patients	O
to	O
rest	B-FUNC
and	O
recover	O
,	O
and	O
therefore	O
must	O
be	O
quiet	O
inside	O
and	O
in	O
the	O
surrounding	O
neighborhood	O
.	O

A	O
consensus	O
sequence	O
of	O
the	O
jejunum	O
-	O
derived	O
genomic	O
RNA	O
(	O
FCoV	O
C1Je	O
)	O
was	O
determined	O
from	O
overlapping	O
cDNA	O
fragments	O
produced	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
amplification	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
positive	O
rate	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
among	O
Taiwanese	O
healthcare	O
workers	O
(	O
HCWs	O
).	O

Among	O
2197	O
subjects	O
studied	O
,	O
a	O
total	O
of	O
9	O
subjects	O
(	O
0	O
.	O
4	O
%)	O
displayed	O
positive	O
findings	O
for	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
.	O

If	O
we	O
estimated	O
the	O
HCWs	O
who	O
came	O
into	O
contact	O
with	O
SARS	O
patients	O
,	O
the	O
RR	O
for	O
positive	O
serum	O
IgG	O
antibody	B-FUNC
titer	O
among	O
HCWs	O
from	O
the	O
ER	O
was	O
significantly	O
greater	O
than	O
it	O
was	O
for	O
those	O
working	O
in	O
the	O
ordinary	O
ward	O
(	O
RR	O
9	O
.	O
45	O
,	O
95	O
%	O
CI	O
2	O
.	O
58	O
-	O
34	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
001	O
).	O

Based	O
on	O
the	O
X	O
-	O
ray	O
structures	O
of	O
SARS	O
-	O
CoV	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
functional	O
receptor	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
ACE2	O
),	O
we	O
perform	O
computational	O
simulations	O
of	O
interactions	O
between	O
three	O
representative	O
RBD	O
mutants	O
and	O
four	O
host	O
species	O
-	O
specific	O
receptors	O
.	O

The	O
recombinant	O
N	O
protein	O
was	O
migrated	O
at	O
48	O
kDa	O
and	O
reacted	O
with	O
six	O
histidine	O
tag	O
specific	O
monoclonal	O
antibody	B-FUNC
by	O
immunoblotting	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicated	O
that	O
nucleocapsid	O
protein	O
may	O
be	O
a	O
useful	O
antigen	O
for	O
the	O
sera	B-FUNC
-	O
diagnosis	O
of	O
PEDV	O
and	O
it	O
was	O
also	O
suggested	O
that	O
the	O
ELISA	O
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
test	O
for	O
detecting	O
antibodies	O
to	O
PEDV	O
.	O

TITLE	O
:	O
Computational	O
characterization	O
and	O
design	O
of	O
SARS	O
coronavirus	O
receptor	O
recognition	O
and	O
antibody	B-FUNC
neutralization	O
.	O

ABSTRACT	O
:	O
The	O
sequential	O
determination	O
of	O
crystal	O
structures	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
cellular	O
receptor	O
or	O
neutralizing	O
antibody	B-FUNC
opened	O
a	O
door	O
for	O
the	O
design	O
and	O
development	O
of	O
antiviral	O
competitive	O
inhibitors	O
.	O

Based	O
on	O
those	O
complex	O
structures	O
,	O
we	O
conduct	O
computational	O
characterization	O
and	O
design	O
of	O
RBD	O
-	O
mediated	O
receptor	O
recognition	O
and	O
antibody	B-FUNC
neutralization	O
.	O

TITLE	O
:	O
Structure	O
of	O
the	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
RNA	O
-	O
binding	B-FUNC
dimerization	O
domain	O
suggests	O
a	O
mechanism	O
for	O
helical	O
packaging	O
of	O
viral	O
RNA	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
spanning	O
residues	O
248	O
-	O
365	O
(	O
NP248	O
-	O
365	O
),	O
had	O
stronger	O
nucleic	O
acid	O
-	O
binding	B-FUNC
activity	O
than	O
the	O
NTD	O
.	O

Interactions	O
between	O
residues	O
248	O
-	O
280	O
and	O
the	O
rest	B-FUNC
of	O
the	O
molecule	O
also	O
stabilize	O
the	O
formation	O
of	O
an	O
octamer	O
in	O
the	O
asymmetric	O
unit	O
.	O

Timely	O
,	O
sensitive	O
and	O
cost	O
-	O
effective	O
,	O
EDICTS	O
complements	O
the	O
existing	O
successive	O
level	O
of	O
CDC	O
reporting	O
system	O
as	O
a	O
fast	B-FUNC
-	O
response	O
control	O
channel	O
.	O

ABSTRACT	O
:	O
The	O
pathogenicity	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
is	O
known	O
to	O
depend	O
on	O
macrophage	O
tropism	O
,	O
and	O
this	O
macrophage	O
infection	O
is	O
enhanced	O
by	O
mediation	O
via	O
anti	O
-	O
S	O
antibody	B-FUNC
(	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
,	O
ADE	O
).	O

The	O
characteristic	O
tache	O
noire	O
was	O
observed	O
on	O
the	O
lateral	O
region	O
of	O
the	O
thigh	O
and	O
elevated	O
IgM	O
antibody	B-FUNC
titres	O
against	O
R	O
.	O
conorii	O
were	O
detected	O
by	O
an	O
indirect	O
immunofluorescence	O
test	O
.	O

TITLE	O
:	O
Using	O
patient	O
-	O
collected	O
clinical	O
samples	O
and	O
sera	B-FUNC
to	O
detect	O
and	O
quantify	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Fecal	O
samples	O
were	O
frequently	O
SARS	O
-	O
CoV	O
RT	O
-	O
PCR	O
positive	O
beyond	O
40	O
days	O
,	O
and	O
occasional	O
sera	B-FUNC
still	O
had	O
SARS	O
-	O
CoV	O
detected	O
after	O
3	O
weeks	O
of	O
illness	O
.	O

RESULTS	O
:	O
SARS	O
-	O
CoV	O
detection	O
rates	O
in	O
sera	B-FUNC
were	O
highest	O
in	O
the	O
first	O
9	O
days	O
of	O
illness	O
,	O
whereas	O
detection	O
was	O
highest	O
in	O
throat	O
washes	O
5	O
-	O
14	O
days	O
after	O
onset	O
of	O
symptoms	O
.	O

Fecal	O
samples	O
were	O
frequently	O
SARS	O
-	O
CoV	O
RT	O
-	O
PCR	O
positive	O
beyond	O
40	O
days	O
,	O
and	O
occasional	O
sera	B-FUNC
still	O
had	O
SARS	O
-	O
CoV	O
detected	O
after	O
3	O
weeks	O
of	O
illness	O
.	O

Mutations	O
targeting	O
residues	O
in	O
or	O
near	O
either	O
zinc	O
-	O
binding	B-FUNC
finger	O
generated	O
nonviable	O
phenotypes	O
,	O
demonstrating	O
that	O
both	O
domains	O
are	O
essential	O
to	O
nsp10	O
function	O
and	O
MHV	O
replication	O
.	O

Furthermore	O
,	O
by	O
using	O
K48	O
-	O
linked	O
hexa	O
-	O
ubiquitin	B-FUNC
substrate	O
and	O
ubiquitin	B-FUNC
-	O
vinylsulfone	O
inhibitor	O
specific	O
for	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
),	O
we	O
confirmed	O
that	O
,	O
like	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
PLpro	O
,	O
HCoV	O
-	O
NL63	O
PLP2	O
has	O
DUB	O
activity	O
.	O

TITLE	O
:	O
Evaluating	O
the	O
3C	O
-	O
like	O
protease	B-FUNC
activity	I-FUNC
of	O
SARS	O
-	O
Coronavirus	O
:	O
recommendations	O
for	O
standardized	O
assays	O
for	O
drug	O
discovery	O
.	O

The	O
SARS	O
epidemic	O
also	O
brought	O
new	O
attention	O
to	O
the	O
proteins	O
translated	O
from	O
ORF1a	O
and	O
ORF1b	O
of	O
the	O
input	O
genome	O
RNA	O
,	O
also	O
known	O
as	O
the	O
replicase	O
/	O
transcriptase	B-FUNC
gene	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
dynamic	O
prevalence	O
of	O
serum	O
antibody	B-FUNC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
employees	O
from	O
wild	O
animal	O
market	O
in	O
Guangzhou	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
trend	O
of	O
specific	O
antibody	B-FUNC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
in	O
serum	O
collected	O
at	O
various	O
periods	O
among	O
employees	O
in	O
Guangzhou	O
Xinyuan	O
animal	O
market	O
.	O

Volunteers	O
from	O
employees	O
of	O
the	O
animal	O
market	O
were	O
recruited	O
and	O
their	O
serum	O
specific	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
were	O
determined	O
by	O
enzyme	O
linked	O
immunesorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

The	O
prevalence	O
of	O
specific	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
in	O
employees	O
of	O
the	O
animal	O
market	O
were	O
somehow	O
related	O
with	O
the	O
presence	O
or	O
absence	O
of	O
palm	O
civet	O
.	O

RESULTS	O
:	O
Positive	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibody	B-FUNC
was	O
found	O
25	O
.	O
61	O
%	O
(	O
n	O
=	O
328	O
),	O
13	O
.	O
03	O
%	O
(	O
n	O
=	O
238	O
),	O
12	O
.	O
59	O
%	O
(	O
n	O
=	O
135	O
),	O
5	O
.	O
04	O
%	O
(	O
n	O
=	O
139	O
)	O
and	O
9	O
.	O
43	O
%	O
(	O
n	O
=	O
53	O
)	O
among	O
volunteers	O
,	O
which	O
were	O
sampled	O
in	O
May	O
2003	O
,	O
Dec	O
.	O
2003	O
,	O
Jan	O
.	O
2004	O
,	O
July	O
2004	O
and	O
June	O
2005	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
specific	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
in	O
employees	O
of	O
the	O
animal	O
market	O
were	O
somehow	O
related	O
with	O
the	O
presence	O
or	O
absence	O
of	O
palm	O
civet	O
.	O

The	O
human	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
receptor	O
(	O
DTR	O
),	O
heparin	O
-	O
binding	B-FUNC
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	B-FUNC
),	O
was	O
expressed	O
under	O
the	O
control	O
of	O
the	O
lysozyme	O
M	O
(	O
LysM	O
)	O
gene	O
promoter	O
in	O
the	O
mice	O
.	O

Compared	O
with	O
the	O
mice	O
in	O
which	O
both	O
AE2	O
cells	O
and	O
macrophages	O
were	O
deleted	O
by	O
DT	O
administration	O
,	O
the	O
DT	O
-	O
treated	O
LysM	O
-	O
DTR	O
mice	O
with	O
DT	O
-	O
resistant	O
macrophages	O
showed	O
less	O
severe	O
lung	O
injury	O
with	O
a	O
reduced	O
amount	O
of	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

In	O
addition	O
,	O
confocal	O
image	O
analysis	O
has	O
shown	O
release	O
of	O
mitochondrial	O
apoptogenic	O
apoptosis	O
-	O
inducing	O
factor	O
and	O
cytochrome	B-FUNC
c	I-FUNC
into	O
the	O
cytosol	O
.	O

However	O
,	O
the	O
tight	O
link	O
between	O
hexamerization	O
and	O
enzyme	B-FUNC
activity	I-FUNC
in	O
NendoUs	O
has	O
remained	O
an	O
enigma	O
.	O

As	O
a	O
result	O
,	O
increases	O
in	O
BCoV	O
-	O
neutralizing	O
antibody	B-FUNC
titers	O
were	O
confirmed	O
in	O
all	O
pups	O
in	O
the	O
challenged	O
and	O
control	O
groups	O
.	O

Analyzing	O
the	O
cellular	O
proteins	O
involving	O
in	O
regulation	O
of	O
cell	O
cycle	O
progression	O
,	O
we	O
demonstrated	O
that	O
3a	O
expression	O
was	O
correlated	O
with	O
a	O
significant	O
reduction	O
of	O
cyclin	B-FUNC
D3	O
level	O
and	O
phosphorylation	O
of	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
Ser	O
-	O
795	O
and	O
Ser	O
-	O
809	O
/	O
811	O
,	O
not	O
with	O
the	O
expression	O
of	O
cyclin	B-FUNC
D1	O
,	O
D2	O
,	O
cdk4	O
,	O
and	O
cdk6	O
in	O
293	O
cells	O
.	O

The	O
reduction	O
of	O
cyclin	B-FUNC
D3	O
level	O
and	O
phosphorylation	O
of	O
Rb	O
were	O
further	O
confirmed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
cells	O
.	O

S100A12	O
expression	O
may	O
reflect	O
neutrophil	O
activation	O
during	O
lung	O
inflammation	O
and	O
contribute	O
to	O
pulmonary	O
inflammation	O
and	O
endothelial	O
activation	O
via	O
binding	B-FUNC
to	O
RAGE	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
by	O
equine	O
neutralizing	O
antibody	B-FUNC
in	O
golden	O
Syrian	O
hamsters	O
.	O

In	O
this	O
study	O
,	O
after	O
verification	O
by	O
various	O
methods	O
that	O
the	O
golden	O
Syrian	O
hamster	O
constitutes	O
a	O
model	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
we	O
confirmed	O
that	O
the	O
antibody	B-FUNC
could	O
protect	O
animals	O
completely	O
from	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
preventive	O
setting	O
.	O

More	O
importantly	O
,	O
the	O
antibody	B-FUNC
could	O
reduce	O
viral	O
titers	O
or	O
copies	O
by	O
approximately	O
10	O
(	O
3	O
)-	O
to	O
10	O
(	O
4	O
)-	O
fold	O
in	O
animal	O
lung	O
after	O
virus	O
exposure	O
,	O
compared	O
with	O
negative	O
control	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
to	O
warrant	O
clinical	O
studies	O
of	O
this	O
antibody	B-FUNC
in	O
the	O
treatment	O
and	O
prevention	O
of	O
SARS	O
.	O

The	O
strongest	O
anti	O
-	O
coronavirus	O
activity	O
was	O
found	O
predominantly	O
among	O
the	O
mannose	O
-	O
binding	B-FUNC
lectins	O
.	O

ABSTRACT	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
is	O
critically	O
involved	O
in	O
biological	O
responses	O
against	O
various	O
insults	O
.	O

E	O
-	O
selectin	B-FUNC
,	O
an	O
endothelial	O
leukocyte	O
adhesion	O
molecule	O
,	O
is	O
released	O
from	O
the	O
endothelial	O
cell	O
membrane	O
by	O
the	O
action	O
of	O
TNF	O
and	O
exists	O
as	O
soluble	O
E	O
-	O
selectin	B-FUNC
in	O
plasma	O
.	O

The	O
detection	O
of	O
increases	O
in	O
plasma	O
levels	O
of	O
soluble	O
E	O
-	O
selectin	B-FUNC
in	O
patients	O
with	O
systemic	O
inflammatory	O
response	O
syndrome	O
predicts	O
the	O
imminent	O
onset	O
of	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
239	O
human	O
milk	O
samples	O
collected	O
from	O
mothers	O
in	O
Chiba	O
City	O
,	O
Japan	O
during	O
1994	O
-	O
1997	O
were	O
tested	O
for	O
the	O
presence	O
of	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
.	O

This	O
report	O
is	O
noteworthy	O
because	O
it	O
is	O
the	O
first	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
demonstrating	O
the	O
presence	O
of	O
antibody	B-FUNC
against	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
in	O
human	O
milk	O
.	O

The	O
binding	B-FUNC
free	O
energy	O
between	O
a	O
peptide	O
ligand	B-FUNC
and	O
its	O
protein	O
receptor	O
is	O
calculated	O
by	O
a	O
linear	O
free	O
energy	O
equation	O
through	O
the	O
physicochemical	O
parameters	O
,	O
resulting	O
in	O
a	O
set	O
of	O
simultaneous	O
linear	O
equations	O
between	O
the	O
bioactivity	O
of	O
the	O
peptides	O
and	O
the	O
physicochemical	O
properties	O
of	O
amino	O
acids	O
.	O

Cytochrome	B-FUNC
C	I-FUNC
,	O
cleaved	O
caspase	O
(	O
cysteine	O
aspartic	O
acid	O
protease	O
)-	O
3	O
,	O
9	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
were	O
detected	O
by	O
Western	O
blot	O
.	O

After	O
removal	O
of	O
serum	O
in	O
COS	O
-	O
1	O
cells	O
,	O
we	O
observed	O
the	O
loss	O
of	O
DeltaPsim	O
,	O
the	O
increase	O
of	O
ROS	O
and	O
cytochrome	B-FUNC
C	I-FUNC
release	O
into	O
cytosol	O
and	O
subsequent	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
PARP	O
cleavage	O
.	O

Newer	O
diagnostic	O
tests	O
such	O
as	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
greatly	O
expanded	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
respiratory	O
viruses	O
.	O

First	O
,	O
potential	O
compounds	O
were	O
extracted	O
from	O
protein	O
-	O
ligand	B-FUNC
complexes	O
selected	O
from	O
Protein	O
Data	O
Bank	O
database	O
based	O
on	O
structural	O
similarity	O
to	O
the	O
target	O
protein	O
.	O

The	O
genetic	O
diversity	O
was	O
determined	O
by	O
direct	O
sequencing	O
of	O
the	O
partial	O
RdRp	B-FUNC
region	O
of	O
12	O
BNoVs	O
detected	O
from	O
the	O
fecal	O
samples	O
by	O
nested	O
PCR	O
.	O

It	O
was	O
also	O
confirmed	O
previously	O
that	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
can	O
bind	B-FUNC
to	O
PEDV	O
,	O
and	O
anti	O
-	O
pAPN	O
antibodies	O
may	O
inhibit	O
the	O
combination	O
.	O

In	O
ARDS	O
patients	O
genotypes	O
differed	O
significantly	O
between	O
those	O
with	O
severe	O
ARDS	O
[	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-FUNC
)>	O
or	O
=	O
3	O
;	O
23	O
homozygote	O
deletion	O
(	O
DD	O
),	O
heterozygote	O
(	O
ID	O
)	O
31	O
,	O
and	O
homozygote	O
insertion	O
wildtype	O
(	O
II	O
)	O
23	O
],	O
and	O
those	O
with	O
LIS	B-FUNC
below	O
3	O
(	O
1	O
DD	O
,	O
9	O
ID	O
,	O
16	O
II	O
).	O

Likewise	O
,	O
the	O
frequency	O
of	O
the	O
D	O
allele	O
was	O
significantly	O
less	O
in	O
patients	O
with	O
higher	O
LIS	B-FUNC
(	O
50	O
%	O
D	O
)	O
than	O
lower	O
LIS	B-FUNC
(	O
21	O
%	O
D	O
).	O

Antibody	B-FUNC
titers	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
parvovirus	O
(	O
CPV	O
),	O
and	O
canine	O
adenovirus	O
(	O
CAV	O
)	O
in	O
the	O
three	O
facilities	O
in	O
which	O
red	O
pandas	O
were	O
vaccinated	O
were	O
highly	O
variable	O
.	O

In	O
the	O
seven	O
unvaccinated	O
groups	O
,	O
CDV	O
titers	O
were	O
low	O
and	O
occurred	O
in	O
20	O
-	O
100	O
%	O
of	O
the	O
animals	O
;	O
antibody	B-FUNC
titers	O
against	O
CPV	O
were	O
found	O
in	O
seven	O
of	O
eight	O
areas	O
.	O

Both	O
Akt	O
and	O
p38	B-FUNC
MAPK	B-FUNC
are	O
keys	O
for	O
determination	O
of	O
cell	O
survival	O
or	O
death	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
in	O
vitro	O
.	O

TITLE	O
:	O
Patient	O
with	O
antibody	B-FUNC
-	O
negative	O
relapse	O
of	O
Goodpasture	O
syndrome	O
.	O

We	O
present	O
a	O
male	O
adolescent	O
in	O
whom	O
hemoptysis	O
was	O
mistaken	O
to	O
be	O
a	O
sign	O
of	O
airway	O
infection	O
for	O
several	O
months	O
and	O
who	O
later	O
on	O
underwent	O
an	O
unusual	O
antibody	B-FUNC
-	O
negative	O
relapse	O
.	O

TITLE	O
:	O
Comparison	O
of	O
immunoglobulin	B-FUNC
G	O
responses	O
to	O
the	O
spike	O
and	O
nucleocapsid	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
patients	O
with	O
SARS	O
.	O

Blood	O
samples	O
were	O
tested	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
by	O
an	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
which	O
has	O
previously	O
been	O
described	O
to	O
have	O
a	O
high	O
specificity	O
in	O
the	O
diagnosis	O
of	O
clinical	O
FIP	O
[	O
Simons	O
AF	O
,	O
Vennema	O
H	O
,	O
Rofina	O
JE	O
,	O
Pol	O
JM	O
,	O
Horzinek	O
MC	O
,	O
Rottier	O
PJM	O
,	O
Egberink	O
HF	O
(	O
2005	O
)	O
A	O
mRNA	O
PCR	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
.	O

Using	O
the	O
yeast	O
three	O
-	O
hybrid	O
system	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
),	O
and	O
ultraviolet	O
(	O
UV	O
)	O
cross	O
-	O
linking	O
techniques	O
,	O
we	O
have	O
shown	O
that	O
the	O
3a	O
protein	O
is	O
capable	O
of	O
binding	B-FUNC
specifically	O
to	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
5	O
'	O
UTR	O
)	O
of	O
the	O
SARS	O
virus	O
genomic	O
RNA	O
.	O

Spontaneous	O
pneumomediastinum	O
usually	O
only	O
requires	O
rest	B-FUNC
,	O
analgesia	O
and	O
management	O
of	O
the	O
underlying	O
condition	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
of	O
SARS	O
-	O
CoV	O
activates	O
interleukin	O
-	O
6	O
expression	O
through	O
cellular	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O
ABSTRACT	O
:	O
High	O
levels	O
of	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
in	O
the	O
acute	O
stage	O
associated	O
with	O
lung	O
lesions	O
were	O
found	O
in	O
SARS	O
patients	O
.	O

To	O
evaluate	O
the	O
mechanisms	O
behind	O
this	O
event	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
SARS	O
-	O
CoV	O
proteins	O
in	O
the	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Results	O
showed	O
that	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
activated	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Promoter	O
analyses	O
suggested	O
that	O
NF	B-FUNC
-	I-FUNC
kappaB	I-FUNC
binding	I-FUNC
element	O
was	O
required	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
regulated	O
by	O
N	O
protein	O
.	O

We	O
also	O
showed	O
that	O
N	O
protein	O
activated	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
through	O
NF	O
-	O
kappaB	O
by	O
facilitating	O
the	O
translocation	O
of	O
NF	O
-	O
kappaB	O
from	O
cytosol	O
to	O
nucleus	O
.	O

Mutational	O
analyses	O
revealed	O
that	O
two	O
regions	O
of	O
N	O
protein	O
were	O
essential	O
for	O
its	O
function	O
in	O
the	O
activation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Proteasome	O
inhibitors	O
,	O
such	O
as	O
lactacystin	O
and	O
NLVS	O
,	O
could	O
bypass	O
the	O
IBV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
by	O
restoring	O
the	O
expression	O
of	O
corresponding	O
cyclin	B-FUNC
/	O
Cdk	B-FUNC
complexes	O
.	O

The	O
results	O
showed	O
that	O
specific	O
humoral	O
and	O
cellular	O
immunities	O
could	O
be	O
induced	O
in	O
mice	O
by	O
inoculating	O
them	O
with	O
SARS	O
-	O
CoV	O
spike	O
DNA	O
vaccine	O
alone	O
or	O
by	O
coinoculation	O
with	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
expressing	O
plasmids	O
.	O

The	O
comparison	O
between	O
the	O
three	O
vaccination	O
routes	O
indicated	O
that	O
oral	O
vaccination	O
evoked	O
a	O
vigorous	O
T	O
-	O
cell	O
response	O
and	O
a	O
weak	O
response	O
predominantly	O
with	O
subclass	O
immunoglobulin	B-FUNC
G2a	O
(	O
IgG2a	O
)	O
antibody	B-FUNC
.	O

A	O
coronavirus	O
was	O
detected	O
by	O
electron	O
microscopy	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
in	O
the	O
faeces	O
and	O
in	O
the	O
intestinal	O
content	O
of	O
the	O
dead	O
quails	O
.	O

Moreover	O
,	O
both	O
vaccines	O
induced	O
similar	O
frequencies	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
-	O
producing	O
cells	O
in	O
bone	O
marrow	O
.	O

Shortly	O
after	O
the	O
rabbits	O
were	O
killed	O
at	O
3	O
hour	O
after	O
iv	O
OA	O
injection	O
,	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
colleted	O
,	O
and	O
the	O
concentrations	O
of	O
protein	O
,	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
),	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
interleukin	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
in	O
BALF	O
were	O
then	O
measured	O
by	O
ELISA	O
.	O

The	O
OA	O
-	O
induced	O
elevation	O
of	O
arterial	O
blood	O
oxygen	O
pressure	O
was	O
inhibited	O
,	O
as	O
well	O
as	O
PAF	O
,	O
ICAM	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
BALF	O
in	O
rupatadine	O
group	O
.	O

These	O
results	O
suggest	O
that	O
when	O
SARS	O
-	O
CoV	O
binds	B-FUNC
ACE2	O
it	O
is	O
internalized	O
and	O
penetrates	O
early	O
endosomes	O
in	O
a	O
clathrin	O
-	O
dependent	O
manner	O
and	O
that	O
the	O
cytoplasmic	O
tail	O
of	O
ACE2	O
is	O
not	O
required	O
for	O
the	O
penetration	O
of	O
SARS	O
-	O
CoV	O
.	O

Maximum	O
titers	O
of	O
antibody	B-FUNC
(	O
8	O
.	O
86	O
+/-	O
0	O
.	O
19	O
ng	O
/	O
ml	O
of	O
serum	O
)	O
were	O
attained	O
after	O
the	O
second	O
immunization	O
.	O

TITLE	O
:	O
Up	O
-	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
induced	O
by	O
SARS	O
-	O
coronavirus	O
spike	O
protein	O
in	O
murine	O
macrophages	O
via	O
NF	O
-	O
kappaB	O
pathway	O
.	O

To	O
understand	O
how	O
cells	O
response	O
in	O
the	O
early	O
stage	O
of	O
virus	O
-	O
host	O
cell	O
interaction	O
,	O
in	O
this	O
study	O
,	O
a	O
purified	O
recombinant	O
S	O
protein	O
was	O
studied	O
for	O
stimulating	O
murine	O
macrophages	O
(	O
RAW264	O
.	O
7	O
)	O
to	O
produce	O
proinflammatory	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
)	O
and	O
chemokine	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

We	O
found	O
that	O
direct	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
release	O
in	O
the	O
supernatant	O
in	O
a	O
dose	O
-,	O
time	O
-	O
dependent	O
manner	O
and	O
highly	O
spike	O
protein	O
-	O
specific	O
,	O
but	O
no	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
detected	O
.	O

Further	O
experiments	O
showed	O
that	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
production	O
were	O
dependent	O
on	O
NF	O
-	O
kappaB	O
,	O
which	O
was	O
activated	O
through	O
I	O
-	O
kappaBalpha	O
degradation	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
been	O
known	O
to	O
recognize	O
and	O
bind	B-FUNC
to	O
host	O
receptors	O
,	O
whose	O
conformational	O
changes	O
then	O
facilitate	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
host	O
cell	O
membrane	O
,	O
leading	O
to	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

The	O
population	O
of	O
Ontario	O
was	O
grouped	O
into	O
the	O
Greater	O
Toronto	O
Area	O
(	O
N	O
=	O
2	O
.	O
9	O
million	O
)	O
and	O
the	O
rest	B-FUNC
of	O
Ontario	O
(	O
N	O
=	O
9	O
.	O
3	O
million	O
)	O
based	O
upon	O
the	O
level	O
of	O
restrictions	O
on	O
delivery	O
of	O
clinical	O
services	O
during	O
the	O
SARS	O
outbreak	O
.	O

Sera	B-FUNC
from	O
pups	O
in	O
4	O
affected	O
litters	O
did	O
not	O
contain	O
antibodies	O
to	O
reovirus	O
3	O
,	O
mouse	O
coronavirus	O
,	O
rotavirus	O
,	O
or	O
mouse	O
adenovirus	O
2	O
.	O

The	O
RdRp	B-FUNC
domains	O
of	O
the	O
members	O
of	O
the	O
arterivirus	O
family	O
,	O
which	O
are	O
part	O
of	O
replicase	O
subunit	O
nsp9	O
,	O
were	O
compared	O
to	O
coronavirus	O
RdRps	O
that	O
belong	O
to	O
the	O
same	O
order	O
of	O
Nidovirales	O
,	O
as	O
well	O
as	O
to	O
other	O
RdRps	O
with	O
known	O
initiation	O
mechanisms	O
and	O
three	O
-	O
dimensional	O
structures	O
.	O

The	O
EAV	O
nsp9	O
/	O
RdRp	B-FUNC
initiates	O
RNA	O
synthesis	O
by	O
a	O
de	O
novo	O
mechanism	O
on	O
homopolymeric	O
templates	O
in	O
a	O
template	O
-	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
patients	O
with	O
poor	O
outcomes	O
showed	O
deviated	O
ISG	O
and	O
immunoglobulin	B-FUNC
gene	O
expression	O
levels	O
,	O
persistent	O
chemokine	O
levels	O
,	O
and	O
deficient	O
anti	O
-	O
SARS	O
spike	O
antibody	B-FUNC
production	O
.	O

To	O
efficiently	O
detect	O
numerous	O
viruses	O
in	O
a	O
large	O
epidemiologic	O
study	O
,	O
we	O
developed	O
a	O
fast	B-FUNC
,	O
multitarget	O
,	O
sensitive	O
,	O
and	O
specific	O
assay	O
named	O
the	O
Respiratory	O
MultiCode	O
-	O
PLx	O
Assay	O
(	O
RMA	O
).	O

Sera	B-FUNC
of	O
cats	O
which	O
were	O
clinically	O
and	O
serologically	O
diagnosed	O
as	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
possessed	O
significantly	O
higher	O
VN	O
titers	O
to	O
type	O
I	O
FCoV	O
,	O
and	O
sera	B-FUNC
from	O
cats	O
experimentally	O
infected	O
with	O
FIPV	O
type	O
II	O
had	O
high	O
VN	O
titers	O
to	O
type	O
II	O
but	O
not	O
type	O
I	O
viruses	O
.	O

A	O
total	O
of	O
79	O
cat	O
sera	B-FUNC
collected	O
in	O
the	O
years	O
between	O
2004	O
and	O
2005	O
were	O
examined	O
to	O
evaluate	O
seroprevalence	O
by	O
the	O
VN	O
test	O
,	O
showing	O
the	O
following	O
results	O
:	O
(	O
1	O
)	O
50	O
cats	O
(	O
63	O
.	O
3	O
%)	O
were	O
sero	O
-	O
positive	O
to	O
FCoV	O
;	O
(	O
2	O
)	O
of	O
the	O
50	O
FCoV	O
positive	O
cat	O
serum	O
samples	O
,	O
49	O
(	O
98	O
%)	O
showed	O
significantly	O
higher	O
titers	O
to	O
type	O
I	O
virus	O
and	O
only	O
one	O
(	O
2	O
%)	O
for	O
type	O
II	O
virus	O
.	O

TITLE	O
:	O
Isolation	O
and	O
identification	O
of	O
an	O
scFv	O
antibody	B-FUNC
against	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
To	O
develop	O
reagents	O
for	O
early	O
diagnosis	O
and	O
therapeutic	O
drugs	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
large	O
(	O
3	O
x	O
10	O
(	O
9	O
))	O
immunized	O
human	O
antibody	B-FUNC
library	O
was	O
constructed	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
six	O
SARS	O
convalescent	O
patients	O
.	O

A	O
single	O
chain	O
variable	O
fragment	O
antibody	B-FUNC
(	O
N18	O
)	O
with	O
high	O
affinity	O
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
isolated	O
.	O

Soluble	O
N18	O
antibody	B-FUNC
was	O
expressed	O
in	O
Escherichia	O
coli	O
HB2151	O
,	O
purified	O
by	O
Ni	O
-	O
NTA	O
affinity	O
chromatography	O
and	O
verified	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
.	O

The	O
potential	O
application	O
for	O
early	O
diagnosis	O
was	O
evaluated	O
using	O
N	O
protein	O
capture	O
ELISA	O
in	O
which	O
N18	O
antibody	B-FUNC
demonstrated	O
high	O
sensitive	O
activity	O
in	O
detecting	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
Finally	O
,	O
the	O
potential	O
usefulness	O
of	O
the	O
N18	O
antibody	B-FUNC
in	O
prophylaxis	O
,	O
vaccine	O
design	O
and	O
therapy	O
of	O
SARS	O
is	O
discussed	O
.	O

Lastly	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
SDF	O
-	O
1	O
receptor	O
CXCR4	B-FUNC
rises	O
in	O
a	O
similar	O
temporal	O
pattern	O
on	O
neutrophils	O
in	O
both	O
the	O
blood	O
and	O
airspace	O
of	O
LPS	O
-	O
injured	O
mice	O
and	O
that	O
Ab	O
-	O
mediated	O
SDF	O
-	O
1	O
blockade	O
significantly	O
attenuates	O
late	O
but	O
not	O
early	O
pulmonary	O
neutrophilia	O
in	O
this	O
model	O
.	O

ABSTRACT	O
:	O
Sickle	O
hemoglobin	O
(	O
Hb	O
S	O
;	O
betaGlu	O
6	O
Val	O
)	O
is	O
due	O
to	O
an	O
A	O
>	O
T	O
transversion	O
in	O
codon	O
6	O
of	O
the	O
beta	O
-	O
globin	B-FUNC
gene	O
.	O

Sickling	O
disorders	O
can	O
result	O
in	O
individuals	O
who	O
are	O
compound	O
heterozygous	O
for	O
beta	O
-	O
globin	B-FUNC
mutations	O
(	O
e	O
.	O
g	O
.,	O
Hb	O
SC	O
,	O
HbSO	O
(	O
Arab	O
)).	O

The	O
S1	O
glycoprotein	O
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
proved	O
to	O
be	O
S1	O
gene	O
by	O
sequencing	O
.	O

The	O
S1	O
protein	O
could	O
be	O
highly	O
expressed	O
in	O
M	O
.	O
smegmatis	O
mc2	O
155	O
when	O
induced	O
by	O
heating	O
and	O
was	O
detected	O
by	O
ELISA	O
and	O
Western	O
blot	O
assays	O
using	O
monoclonal	O
antibody	B-FUNC
against	O
S1	O
glycoprotein	O
of	O
IBV	O
.	O

Oral	O
immunization	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
recombinant	O
strain	O
that	O
constitutively	O
express	O
the	O
66kDa	O
fragment	O
of	O
the	O
glycoprotein	O
S	O
,	O
Specific	O
anti	O
-	O
TGEV	O
glycoprotein	O
S	O
secret	O
immunoglobulin	B-FUNC
A	O
(	O
sIgA	O
)	O
antibodies	O
were	O
detected	O
by	O
indirect	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
in	O
the	O
feces	O
after	O
immunization	O
.	O

It	O
was	O
showed	O
that	O
the	O
mice	O
immunized	O
with	O
pNZ8112	O
-	O
Sa	O
/	O
NZ9000	O
recombinant	O
strain	O
had	O
produced	O
clear	O
antibody	B-FUNC
level	O
anti	O
TGEV	O
,	O
and	O
which	O
had	O
provided	O
important	O
substance	O
foundation	O
and	O
explored	O
the	O
feasibility	O
of	O
Lactobacillus	O
as	O
oral	O
vaccine	O
.	O

This	O
system	O
was	O
applied	O
to	O
develop	O
a	O
quantitative	O
measurement	O
of	O
cell	O
-	O
cell	O
fusion	O
using	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS3	O
/	O
4A	O
protease	O
and	O
a	O
secretion	O
-	O
blocked	O
EGFP	O
-	O
4A	O
/	O
4B	O
-	O
SEAP	O
(	O
EGFP	O
:	O
enhanced	O
green	O
fluorescent	O
protein	O
;	O
4A	O
/	O
4B	O
:	O
a	O
decapeptide	O
substrate	O
of	O
NS3	O
/	O
4A	O
protease	O
;	O
SEAP	O
:	O
secreted	O
alkaline	O
phosphatase	B-FUNC
)	O
fusion	O
gene	O
.	O

Both	O
genes	O
were	O
transiently	O
expressed	O
in	O
either	O
of	O
the	O
CHO	B-FUNC
cell	O
lines	O
,	O
followed	O
by	O
fusion	O
treatment	O
.	O

Finally	O
,	O
elevated	O
antibody	B-FUNC
titers	O
against	O
Chlamydophila	O
psittasi	O
confirmed	O
a	O
diagnosis	O
of	O
Psittacosis	O
.	O

The	O
COX	O
inhibitors	O
reduced	O
MHV	O
infection	O
at	O
a	O
post	O
-	O
binding	B-FUNC
step	O
,	O
but	O
early	O
in	O
the	O
replication	O
cycle	O
.	O

Then	O
we	O
measured	O
the	O
numbers	O
of	O
total	O
cells	O
and	O
neutrophils	O
and	O
the	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
).	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
carbohydrate	O
-	O
binding	B-FUNC
agents	O
against	O
Nidovirales	O
in	O
cell	O
culture	O
.	O

Lectins	O
,	O
which	O
bind	B-FUNC
to	O
N	O
-	O
linked	O
oligosaccharide	O
elements	O
of	O
enveloped	O
viruses	O
,	O
can	O
be	O
considered	O
as	O
a	O
conceptionally	O
new	O
class	O
of	O
virus	O
inhibitors	O
.	O

The	O
presence	O
of	O
carbohydrate	O
-	O
binding	B-FUNC
agents	O
strongly	O
inhibited	O
coronaviruses	O
(	O
transmissible	O
gastroenteritis	O
virus	O
,	O
infectious	O
bronchitis	O
virus	O
,	O
feline	O
coronaviruses	O
serotypes	O
I	O
and	O
II	O
,	O
mouse	O
hepatitis	O
virus	O
),	O
arteriviruses	O
(	O
equine	O
arteritis	O
virus	O
and	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
)	O
and	O
torovirus	O
(	O
equine	O
Berne	O
virus	O
).	O

Pure	B-FUNC
virus	O
-	O
associated	O
symptoms	O
may	O
be	O
treated	O
with	O
intermittent	O
beta	O
-	O
2	O
agonist	O
or	O
anticholinergics	O
by	O
inhalation	O
.	O

ABSTRACT	O
:	O
Secondary	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
a	O
lethal	O
complication	O
after	O
resuscitation	O
from	O
burn	O
shock	O
,	O
even	O
after	O
abdominal	O
decompression	O
(	O
AD	O
)	O
is	O
performed	O
.	O

Plasma	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
elevated	O
in	O
intra	O
-	O
abdominal	O
hypertension	O
patients	O
3	O
days	O
postburn	O
.	O

Plasma	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
elevated	O
in	O
intra	O
-	O
abdominal	O
hypertension	O
patients	O
3	O
days	O
postburn	O
.	O

ABSTRACT	O
:	O
For	O
enveloped	O
viruses	O
,	O
genome	O
entry	O
into	O
the	O
target	O
cell	O
involves	O
two	O
major	O
steps	O
:	O
virion	B-FUNC
binding	I-FUNC
to	O
the	O
cell	O
-	O
surface	O
receptor	O
and	O
fusion	O
of	O
the	O
virion	O
and	O
cell	O
membranes	O
.	O

TITLE	O
:	O
Effects	O
of	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
on	O
atrophic	O
enteritis	O
in	O
piglets	O
induced	O
by	O
experimental	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

ABSTRACT	O
:	O
Epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
EGF	B-FUNC
)	O
promotes	O
gastrointestinal	O
mucosal	O
recovery	O
by	O
stimulating	O
the	O
mitogenic	O
activity	O
of	O
intestinal	O
crypt	O
epithelial	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
EGF	B-FUNC
on	O
atrophic	O
enteritis	O
induced	O
in	O
piglets	O
by	O
experimental	O
infection	O
with	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
strain	O
Dr13	O
.	O

Histologically	O
,	O
the	O
ratio	O
of	O
villous	O
height	O
:	O
crypt	O
depth	O
of	O
PEDV	B-FUNC
+	I-FUNC
EGF	I-FUNC
piglets	O
was	O
significantly	O
higher	O
than	O
PEDV	O
only	O
piglets	O
at	O
36	O
and	O
48	O
hpi	B-FUNC
.	O

Immunohistochemistry	O
for	O
Ki67	O
demonstrated	O
increased	O
proliferation	O
in	O
intestinal	O
crypt	O
epithelial	O
cells	O
of	O
PEDV	B-FUNC
+	I-FUNC
EGF	I-FUNC
piglets	O
compared	O
to	O
PEDV	O
only	O
piglets	O
at	O
36	O
,	O
48	O
and	O
60	O
hpi	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
focus	O
formation	O
assay	O
(	O
FFA	O
)	O
for	O
detection	O
and	O
titration	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
in	O
a	O
micro	O
-	O
culture	O
system	O
using	O
Vero	O
cells	O
and	O
PAP	B-FUNC
staining	O
technique	O
was	O
evaluated	O
.	O

In	O
addition	O
,	O
FFA	O
had	O
higher	O
sensitivity	O
for	O
detecting	O
field	O
isolates	O
of	O
PEDV	O
as	O
well	O
as	O
positive	O
identification	O
of	O
the	O
virus	O
with	O
the	O
antibody	B-FUNC
specific	O
reaction	O
.	O

TITLE	O
:	O
[	O
Ligand	B-FUNC
screening	O
in	O
affinity	O
chromatography	O
and	O
its	O
applications	O
].	O

Affinity	O
ligand	B-FUNC
is	O
the	O
most	O
important	O
factor	O
in	O
affinity	O
chromatography	O
,	O
therefore	O
,	O
the	O
selection	O
and	O
the	O
screening	O
of	O
affinity	O
ligand	B-FUNC
become	O
the	O
first	O
issue	O
to	O
be	O
considered	O
when	O
a	O
novel	O
type	O
of	O
affinity	O
packing	O
or	O
a	O
novel	O
system	O
of	O
affinity	O
chromatography	O
needs	O
to	O
be	O
developed	O
.	O

TITLE	O
:	O
Heterologous	O
MVA	O
-	O
S	O
prime	O
Ad5	O
-	O
S	O
boost	O
regimen	O
induces	O
high	O
and	O
persistent	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
response	O
against	O
SARS	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
SARS	O
-	O
CoV	O
.	O
In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
a	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
-	O
based	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
vaccine	O
could	O
induce	O
strong	O
neutralizing	O
antibody	B-FUNC
(	O
Nab	O
)	O
response	O
which	O
might	O
have	O
played	O
a	O
critical	O
role	O
in	O
protecting	O
Chinese	O
rhesus	O
monkeys	O
from	O
the	O
pathogenic	O
viral	O
challenge	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
previously	O
that	O
high	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
associated	O
with	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
autoantibodies	O
(	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
:	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
complexes	O
)	O
are	O
present	O
in	O
lung	O
fluids	O
from	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
correlate	O
both	O
with	O
the	O
development	O
and	O
outcome	O
of	O
ARDS	O
.	O

Moreover	O
,	O
we	O
determined	O
that	O
IgG	O
receptors	O
(	O
FcgammaRs	O
)	O
mediate	O
activity	O
of	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
:	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
complexes	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
generated	O
anti	O
-	O
KC	O
(	O
KC	O
=	O
chemokine	O
(	O
CXC	O
motif	O
)	O
ligand	B-FUNC
1	O
(	O
CXCL1	O
))	O
autoantibody	O
:	O
KC	O
immune	O
complexes	O
(	O
KC	O
-	O
functional	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
in	O
lungs	O
of	O
mice	O
to	O
develop	O
a	O
mouse	O
model	O
of	O
autoimmune	O
complex	O
-	O
induced	O
lung	O
inflammation	O
.	O

The	O
presenting	O
ALT	B-FUNC
and	O
CPK	O
level	O
and	O
the	O
day	O
7	O
and	O
day	O
10	O
platelet	O
counts	O
were	O
predictive	O
of	O
oxygenation	O
failure	O
while	O
the	O
day	O
7	O
LDH	O
was	O
predictive	O
of	O
death	O
.	O

This	O
large	O
-	O
scale	O
analysis	O
identified	O
important	O
discriminatory	O
parameters	O
related	O
to	O
the	O
patients	O
'	O
demographic	O
profile	O
(	O
age	O
and	O
gender	O
),	O
severity	O
of	O
illness	O
(	O
pulse	O
rate	O
and	O
neutrophil	O
count	O
),	O
and	O
multisystem	O
derangement	O
(	O
platelet	O
count	O
,	O
CPK	O
,	O
ALT	B-FUNC
and	O
LDH	O
),	O
all	O
of	O
which	O
prognosticated	O
adverse	O
outcomes	O
during	O
the	O
SARS	O
episode	O
.	O

Cerulein	O
injection	O
caused	O
severe	O
AP	O
,	O
confirmed	O
by	O
an	O
increase	O
in	O
serum	O
amylase	O
and	O
lipase	O
levels	O
,	O
histopathological	O
findings	O
of	O
severe	O
AP	O
,	O
and	O
pancreatic	O
MPO	B-FUNC
activity	O
,	O
compared	O
to	O
the	O
values	O
obtained	O
in	O
the	O
sham	O
group	O
.	O

In	O
the	O
leptin	O
group	O
,	O
serum	O
levels	O
of	O
MIP	O
-	O
2	O
,	O
sICMA	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IL	O
-	O
1beta	O
,	O
pancreatic	O
MPO	B-FUNC
activity	O
,	O
CD40	O
expression	O
in	O
pancreas	O
and	O
lung	O
tissues	O
,	O
and	O
NOx	O
level	O
in	O
the	O
lung	O
tissue	O
were	O
lower	O
compared	O
to	O
those	O
in	O
the	O
AP	O
group	O
.	O

Using	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
a	O
model	O
,	O
we	O
demonstrate	O
that	O
SARS	O
-	O
COV	O
ORF6	O
protein	O
is	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)/	O
Golgi	O
membrane	O
in	O
infected	O
cells	O
,	O
where	O
it	O
binds	B-FUNC
to	O
and	O
disrupts	O
nuclear	O
import	O
complex	O
formation	O
by	O
tethering	O
karyopherin	O
alpha	O
2	O
and	O
karyopherin	O
beta	O
1	O
to	O
the	O
membrane	O
.	O

We	O
mapped	O
the	O
region	O
of	O
ORF6	O
,	O
which	O
binds	B-FUNC
karyopherin	O
alpha	O
2	O
,	O
to	O
the	O
C	O
terminus	O
of	O
ORF6	O
and	O
show	O
that	O
mutations	O
in	O
the	O
C	O
terminus	O
no	O
longer	O
bind	B-FUNC
karyopherin	O
alpha	O
2	O
or	O
block	O
the	O
nuclear	O
import	O
of	O
STAT1	O
.	O

We	O
also	O
show	O
that	O
N	O
-	O
terminal	O
deletions	O
of	O
karyopherin	O
alpha	O
2	O
that	O
no	O
longer	O
bind	B-FUNC
to	O
karyopherin	O
beta	O
1	O
still	O
retain	O
ORF6	O
binding	B-FUNC
activity	O
but	O
no	O
longer	O
block	O
STAT1	O
nuclear	O
import	O
.	O

ABSTRACT	O
:	O
Virology	O
laboratories	O
historically	O
have	O
used	O
direct	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
(	O
DFA	O
)	O
and	O
culture	O
to	O
detect	O
six	O
or	O
seven	O
respiratory	O
viruses	O
.	O

Western	O
-	O
blot	O
and	O
immunofluorescent	O
antibody	B-FUNC
assays	O
were	O
used	O
to	O
detect	O
anti	O
-	O
ORF8a	O
antibody	B-FUNC
.	O

In	O
addition	O
,	O
a	O
blood	O
sample	O
was	O
taken	O
from	O
each	O
calf	O
upon	O
enrollment	O
in	O
the	O
study	O
,	O
for	O
assessment	O
of	O
maternal	O
antibody	B-FUNC
transfer	O
and	O
for	O
polymerase	O
chain	O
reaction	O
testing	O
for	O
persistent	O
bovine	O
viral	O
diarrhea	O
virus	O
infection	O
.	O

All	O
but	O
eight	O
were	O
treated	O
with	O
I	O
.	O
V	O
.	O
immunoglobulin	B-FUNC
.	O

Transient	O
deterioration	O
after	O
immunoglobulin	B-FUNC
treatment	O
occurred	O
in	O
seven	O
patients	O
,	O
two	O
suffered	O
relapsing	O
GBS	O
,	O
and	O
three	O
developed	O
CIDP	O
.	O

Combined	O
treatment	O
with	O
prednisone	O
,	O
intravenous	O
immunoglobulin	B-FUNC
,	O
ciclosporin	O
,	O
and	O
rituximab	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
bat	O
coronavirus	O
HKU2	O
from	O
Chinese	O
horseshoe	O
bats	O
revealed	O
a	O
much	O
smaller	O
spike	O
gene	O
with	O
a	O
different	O
evolutionary	O
lineage	O
from	O
the	O
rest	B-FUNC
of	O
the	O
genome	O
.	O

Complete	O
genome	O
sequencing	O
of	O
four	O
strains	O
of	O
bat	O
-	O
CoV	O
HKU2	O
revealed	O
the	O
smallest	O
coronavirus	O
genome	O
(	O
27164	O
nucleotides	O
)	O
and	O
a	O
unique	O
spike	O
protein	O
evolutionarily	O
distinct	O
from	O
the	O
rest	B-FUNC
of	O
the	O
genome	O
.	O

TITLE	O
:	O
Expression	O
of	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
from	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
results	O
in	O
protection	O
from	O
viral	O
-	O
induced	O
neurological	O
and	O
liver	O
disease	O
.	O

Both	O
antibodies	O
competed	O
with	O
the	O
SARS	O
-	O
CoV	O
receptor	O
,	O
ACE2	O
,	O
for	O
binding	B-FUNC
to	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
suggesting	O
a	O
mechanism	O
of	O
neutralization	O
that	O
involves	O
interference	O
with	O
the	O
SARS	O
-	O
CoV	O
-	O
ACE2	O
interaction	O
.	O

Two	O
putative	O
hot	O
-	O
spot	O
residues	O
in	O
the	O
RBD	O
(	O
Ile	O
-	O
489	O
and	O
Tyr	O
-	O
491	O
)	O
were	O
identified	O
within	O
the	O
SARS	O
-	O
CoV	O
spike	O
that	O
likely	O
contribute	O
to	O
most	O
of	O
the	O
m396	O
-	O
binding	B-FUNC
energy	O
.	O

Furthermore	O
,	O
blockade	O
of	O
C5a	O
ameliorated	O
the	O
buildup	O
of	O
the	O
proinflammatory	O
cytokine	O
TNF	O
-	O
alpha	O
,	O
diminished	O
the	O
increase	O
of	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
,	O
and	O
altered	O
the	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

challenge	O
with	O
the	O
PAMP	O
lipopolysaccharide	O
,	O
lipoteichoic	O
acid	O
(	O
LTA	O
),	O
and	O
Zymosan	O
-	O
A	O
(	O
containing	O
1	O
,	O
3	O
beta	O
-	O
glucan	O
)	O
on	O
primary	O
and	O
secondary	O
(	O
total	O
)	O
antibody	B-FUNC
(	O
Ab	B-FUNC
)	O
responses	O
and	O
(	O
isotype	O
)	O
IgM	O
,	O
IgG	O
,	O
and	O
IgA	O
responses	O
to	O
systemically	O
administered	O
human	O
serum	O
albumin	O
(	O
HuSA	O
),	O
and	O
Ab	B-FUNC
titers	O
to	O
infectious	O
bursal	O
disease	O
(	O
Gumboro	O
virus	O
)	O
and	O
infectious	O
bronchitis	O
vaccines	O
in	O
layer	O
hens	O
at	O
9	O
and	O
22	O
wk	O
of	O
age	O
.	O

Although	O
we	O
could	O
not	O
identify	O
the	O
antibody	B-FUNC
which	O
might	O
have	O
been	O
involved	O
in	O
the	O
respiratory	O
distress	O
,	O
the	O
clear	O
temporal	O
relationship	O
between	O
marrow	O
infusion	O
and	O
respiratory	O
distress	O
suggested	O
that	O
similar	O
acute	O
lung	O
injury	O
to	O
TRALI	O
might	O
have	O
occurred	O
following	O
allogenic	O
marrow	O
infusion	O
in	O
the	O
present	O
case	O
.	O

TITLE	O
:	O
The	O
S	O
proteins	O
of	O
human	O
coronavirus	O
NL63	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
bind	B-FUNC
overlapping	O
regions	O
of	O
ACE2	O
.	O

Several	O
ACE2	O
variants	O
that	O
reduced	O
SARS	O
-	O
CoV	O
S	O
-	O
protein	O
association	O
similarly	O
reduced	O
that	O
of	O
HCoV	O
-	O
NL63	O
,	O
whereas	O
alteration	O
of	O
a	O
number	O
of	O
solvent	O
-	O
exposed	O
ACE2	O
residues	O
did	O
not	O
interfere	O
with	O
binding	B-FUNC
by	O
either	O
S	O
protein	O
.	O

One	O
notable	O
exception	O
is	O
ACE2	O
residue	O
354	O
,	O
at	O
the	O
boundary	O
of	O
the	O
SARS	O
-	O
CoV	O
binding	B-FUNC
site	O
,	O
whose	O
alteration	O
markedly	O
inhibited	O
utilization	O
by	O
the	O
HCoV	O
-	O
NL63	O
but	O
not	O
SARS	O
-	O
CoV	O
S	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
SARS	O
-	O
CoV	O
S	O
-	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
inhibited	O
entry	O
mediated	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
.	O

In	O
this	O
Review	O
,	O
an	O
original	O
therapeutic	O
concept	O
for	O
suppressing	O
enveloped	O
viruses	O
is	O
presented	O
that	O
is	O
based	O
on	O
a	O
specific	O
interaction	O
of	O
carbohydrate	O
-	O
binding	B-FUNC
agents	O
(	O
CBAs	O
)	O
with	O
the	O
glycans	O
present	O
on	O
viral	O
-	O
envelope	O
glycoproteins	O
.	O

The	O
highly	O
conserved	O
region	O
at	O
the	O
carboxy	O
terminus	O
of	O
ORF1a	O
is	O
processed	O
by	O
the	O
nsp5	O
proteinase	B-FUNC
(	O
Mpro	O
)	O
into	O
mature	O
products	O
,	O
including	O
nsp7	O
,	O
nsp8	O
,	O
nsp9	O
,	O
and	O
nsp10	O
,	O
proteins	O
with	O
predicted	O
or	O
identified	O
activities	O
involved	O
in	O
RNA	O
synthesis	O
.	O

Serum	O
IFN	O
-	O
concentration	O
was	O
increased	O
significantly	O
but	O
the	O
concentrations	O
of	O
Il	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
had	O
no	O
significant	O
change	O
.	O

Using	O
a	O
phage	O
display	O
technology	O
in	O
a	O
chicken	O
system	O
,	O
high	O
-	O
affinity	O
monoclonal	O
antibody	B-FUNC
fragments	O
against	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
were	O
characterized	O
.	O

Following	O
the	O
immunization	O
of	O
chickens	O
with	O
these	O
recombinant	O
spike	O
proteins	O
,	O
two	O
single	O
-	O
chain	O
variable	O
fragment	O
(	O
scFv	O
)	O
antibody	B-FUNC
libraries	O
were	O
established	O
with	O
short	O
or	O
long	O
linkers	O
to	O
contain	O
5x10	O
(	O
7	O
)	O
and	O
9x10	O
(	O
6	O
)	O
transformants	O
,	O
respectively	O
.	O

More	O
interestingly	O
,	O
the	O
two	O
proteins	O
could	O
bind	B-FUNC
to	O
monoubiquitin	O
and	O
polyubiquitin	O
,	O
suggesting	O
the	O
potential	O
involvement	O
of	O
these	O
proteins	O
in	O
the	O
pathogenesis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Based	O
on	O
this	O
patient	O
population	O
,	O
advanced	O
age	O
,	O
MODS	O
score	O
,	O
and	O
LIS	B-FUNC
may	O
be	O
the	O
important	O
prognostic	O
indicators	O
for	O
ARDS	O
.	O

Predictors	O
of	O
death	O
at	O
the	O
onset	O
of	O
ARDS	O
were	O
advanced	O
age	O
,	O
MODS	O
>	O
or	O
=	O
to	O
8	O
,	O
and	O
LIS	B-FUNC
>	O
or	O
=	O
2	O
.	O
76	O
.	O

The	O
fusion	O
protein	O
was	O
determined	O
to	O
assemble	O
into	O
pentamers	O
,	O
as	O
was	O
evidenced	O
by	O
its	O
ability	O
to	O
bind	B-FUNC
to	O
GM1	O
gangliosides	O
,	O
and	O
evidenced	O
an	O
average	O
level	O
of	O
expression	O
in	O
a	O
transgenic	O
rice	O
endosperm	O
.	O

Three	O
patients	O
died	O
,	O
one	O
from	O
compromised	O
cardiac	O
function	O
,	O
one	O
from	O
overwhelming	O
sepsis	O
and	O
one	O
from	O
respiratory	O
failure	O
due	O
to	O
severe	O
bilateral	O
CCAM	O
;	O
the	O
rest	B-FUNC
of	O
the	O
patients	O
made	O
a	O
satisfactory	O
recovery	O
.	O

Global	O
gene	O
expression	O
arrays	O
and	O
hierarchical	O
clustering	O
of	O
differentially	O
expressed	O
genes	O
in	O
hearts	O
of	O
banded	O
Apelin	O
(-/	O
y	O
)	O
and	O
Apelin	O
(+/	O
y	O
)	O
mice	O
showed	O
concerted	O
upregulation	O
of	O
genes	O
involved	O
in	O
extracellular	O
matrix	O
remodeling	O
and	O
muscle	B-FUNC
contraction	I-FUNC
.	O

Mice	O
immunized	O
four	O
times	O
with	O
VLPs	O
developed	O
high	O
antibody	B-FUNC
titres	O
against	O
SARS	O
CoV	O
.	O
In	O
addition	O
,	O
VLPs	O
elicited	O
cell	O
-	O
mediated	O
immunity	O
as	O
demonstrated	O
by	O
enhanced	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
and	O
interleukin	O
-	O
4	O
production	O
.	O

Intensive	O
treatment	O
with	O
plasmapheresis	O
,	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	B-FUNC
,	O
high	O
-	O
dose	O
corticosteroids	O
,	O
cyclophosphamide	O
,	O
and	O
anticoagulants	O
eventually	O
led	O
to	O
full	O
recovery	O
.	O

Deletion	O
of	O
gene	O
7	O
had	O
no	O
effect	O
on	O
SARS	O
-	O
CoV	O
replication	O
in	O
transformed	O
cell	O
lines	O
,	O
nor	O
did	O
it	O
alter	O
the	O
induction	O
of	O
early	O
apoptosis	O
markers	O
such	O
as	O
annexin	O
V	O
binding	B-FUNC
and	O
activation	O
of	O
caspase	O
3	O
.	O

TITLE	O
:	O
Selectivity	O
in	O
ISG15	O
and	O
ubiquitin	B-FUNC
recognition	O
by	O
the	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

TITLE	O
:	O
Heparan	O
sulfate	O
is	O
a	O
binding	B-FUNC
molecule	O
but	O
not	O
a	O
receptor	O
for	O
CEACAM1	O
-	O
independent	O
infection	O
of	O
murine	O
coronavirus	O
.	O

In	O
one	O
patient	O
,	O
the	O
predominant	O
memory	O
CD4	O
(+)	O
T	O
-	O
cell	O
response	O
was	O
directed	O
against	O
an	O
epitope	O
outside	O
the	O
S	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
.	O

Analysis	O
of	O
gene	O
signatures	O
revealed	O
induction	O
of	O
a	O
strong	O
innate	O
immune	O
response	O
characterized	O
by	O
the	O
stimulation	O
of	O
various	O
cytokine	O
and	O
chemokine	O
genes	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IP	O
-	O
10	O
,	O
which	O
corresponds	O
to	O
the	O
host	O
response	O
seen	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Multiplex	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
was	O
developed	O
for	O
simultaneous	O
differential	O
quantification	O
of	O
each	O
virus	O
in	O
a	O
single	O
reaction	O
tube	O
,	O
using	O
Cy5	O
-	O
and	O
FAM	O
-	O
labeled	O
TaqMan	O
-	O
probes	O
based	O
on	O
sequences	O
from	O
the	O
TGEV	O
and	O
PEDV	O
nucleocapsid	O
genes	O
.	O

TITLE	O
:	O
The	O
carbohydrate	O
-	O
binding	B-FUNC
plant	O
lectins	O
and	O
the	O
non	O
-	O
peptidic	O
antibiotic	O
pradimicin	O
A	O
target	O
the	O
glycans	O
of	O
the	O
coronavirus	O
envelope	O
glycoproteins	O
.	O

Recently	O
,	O
carbohydrate	O
-	O
binding	B-FUNC
agents	O
(	O
CBA	O
)	O
were	O
shown	O
to	O
possess	O
antiviral	O
activity	O
towards	O
coronaviruses	O
.	O

Different	O
strains	O
of	O
two	O
coronaviruses	O
,	O
mouse	O
hepatitis	O
virus	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
,	O
were	O
exposed	O
to	O
CBA	O
:	O
the	O
plant	O
lectins	O
Galanthus	O
nivalis	O
agglutinin	O
,	O
Hippeastrum	O
hybrid	O
agglutinin	O
and	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	O
)	O
and	O
the	O
non	O
-	O
peptidic	O
mannose	O
-	O
binding	B-FUNC
antibiotic	O
pradimicin	O
A	O
.	O
Our	O
results	O
indicate	O
that	O
CBA	O
target	O
the	O
two	O
glycosylated	O
envelope	O
glycoproteins	O
,	O
the	O
spike	O
(	O
S	O
)	O
and	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
of	O
mouse	O
hepatitis	O
virus	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

Furthermore	O
,	O
CBA	O
did	O
not	O
inhibit	O
virus	O
-	O
cell	O
attachment	O
,	O
but	O
rather	O
affected	O
virus	O
entry	O
at	O
a	O
post	O
-	O
binding	B-FUNC
stage	O
.	O

Inhibition	O
of	O
mannosidases	O
in	O
host	O
cells	O
rendered	O
the	O
progeny	O
viruses	O
more	O
sensitive	O
to	O
the	O
mannose	O
-	O
binding	B-FUNC
agents	O
and	O
even	O
to	O
the	O
N	O
-	O
acetylglucosamine	O
-	O
binding	B-FUNC
UDA	O
.	O

The	O
dominant	O
CD4	O
(+)	O
T	O
cell	O
epitope	O
(	O
N60	O
)	O
and	O
CD8	O
(+)	O
T	O
cell	O
epitope	O
(	O
N50	O
)	O
located	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
CoV	O
S	O
protein	O
,	O
which	O
mediated	O
virus	O
combining	O
and	O
fusing	O
to	O
susceptible	O
cells	O
.	O

They	O
include	O
asparagine	O
residues	O
at	O
amino	O
acid	O
positions	O
109	O
,	O
118	O
,	O
119	O
,	O
158	O
,	O
227	O
,	O
589	O
,	O
and	O
699	O
,	O
which	O
are	O
distinct	O
from	O
residues	O
of	O
the	O
ACE2	O
-	O
binding	B-FUNC
domain	O
(	O
amino	O
acids	O
318	O
to	O
510	O
).	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiology	O
and	O
clinical	O
profile	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
in	O
Omani	O
Arab	O
children	O
.	O

Prospective	O
,	O
clinical	O
study	O
of	O
consecutive	O
episodes	O
of	O
ACS	B-FUNC
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
seen	O
at	O
Nizwa	O
Regional	O
Referral	O
Hospital	O
,	O
Oman	O
between	O
June	O
2001	O
and	O
May	O
2006	O
.	O

Of	O
240	O
patients	O
registered	O
with	O
SCD	O
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	B-FUNC
.	O

There	O
were	O
31	O
(	O
59	O
.	O
6	O
%)	O
males	O
and	O
ages	O
ranged	O
between	O
14	O
months	O
and	O
12	O
years	O
[	O
median	O
(	O
SD	O
)	O
6	O
.	O
5	O
(	O
2	O
.	O
49	O
)	O
years	O
];	O
ACS	B-FUNC
occurred	O
fairly	O
evenly	O
in	O
those	O
aged	O
between	O
2	O
and	O
10	O
years	O
.	O

ACS	B-FUNC
is	O
common	O
in	O
SCD	O
.	O

Prevention	O
of	O
VOCs	O
,	O
prompt	O
and	O
effective	O
treatment	O
of	O
respiratory	O
infections	O
and	O
caution	O
in	O
the	O
use	O
of	O
morphine	O
during	O
a	O
VOC	O
should	O
reduce	O
the	O
incidence	O
of	O
ACS	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
based	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
based	O
on	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
was	O
developed	O
to	O
differentiate	O
between	O
field	O
isolates	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
and	O
a	O
vaccine	O
strain	O
,	O
J	O
-	O
vac	O
.	O

In	O
addition	O
to	O
the	O
four	O
beta	O
-	O
strands	O
and	O
two	O
alpha	O
-	O
helices	O
that	O
are	O
common	O
to	O
ubiquitin	B-FUNC
-	O
like	O
folds	O
,	O
the	O
globular	O
domain	O
of	O
nsp3a	O
contains	O
two	O
short	O
helices	O
representing	O
a	O
feature	O
that	O
has	O
not	O
previously	O
been	O
observed	O
in	O
these	O
proteins	O
.	O

The	O
inhibition	O
of	O
the	O
IFN	O
response	O
does	O
not	O
require	O
the	O
protease	B-FUNC
activity	I-FUNC
of	O
PLpro	O
.	O

The	O
so	O
-	O
called	O
""""	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
""""	O
can	O
improve	O
viral	O
uptake	O
into	O
host	O
cells	O
resulting	O
in	O
increased	O
viral	O
load	O
and	O
exacerbation	O
of	O
disease	O
.	O

PCR	O
assays	O
for	O
Bartonella	O
species	O
and	O
FHV	O
-	O
1	O
and	O
a	O
reverse	O
transcriptase	B-FUNC
PCR	O
assay	O
for	O
FCV	O
were	O
performed	O
on	O
blood	O
and	O
throat	O
swabs	O
.	O

TITLE	O
:	O
Conductance	O
and	O
amantadine	O
binding	B-FUNC
of	O
a	O
pore	O
formed	O
by	O
a	O
lysine	O
-	O
flanked	O
transmembrane	O
domain	O
of	O
SARS	O
coronavirus	O
envelope	O
protein	O
.	O

Channel	B-FUNC
activity	I-FUNC
is	O
inhibited	O
by	O
the	O
anti	O
-	O
influenza	O
drug	O
amantadine	O
,	O
which	O
was	O
found	O
to	O
bind	B-FUNC
our	O
preparation	O
with	O
moderate	O
affinity	O
.	O

Administration	O
of	O
MSCs	B-FUNC
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	O
and	O
neutrophil	O
counts	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
(	O
53	O
%,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
7	O
%-	O
101	O
%;	O
and	O
60	O
%,	O
CI	O
4	O
%-	O
116	O
%,	O
respectively	O
)	O
as	O
well	O
as	O
reducing	O
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
both	O
BAL	O
fluid	O
and	O
lung	O
parenchymal	O
homogenates	O
.	O

Virus	O
-	O
induced	O
chemokine	O
expression	O
was	O
reduced	O
by	O
the	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
receptor	O
antagonist	O
,	O
suggesting	O
that	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
produced	O
by	O
infected	O
cells	O
induces	O
uninfected	O
cells	O
to	O
express	O
chemokines	O
.	O

Complexes	O
containing	O
the	O
mRNA	O
pseudoknot	O
exhibited	O
a	O
higher	O
efficiency	O
of	O
affinity	O
selection	O
than	O
that	O
those	O
without	O
,	O
indicating	O
that	O
the	O
pseudoknot	O
improves	O
stability	O
of	O
the	O
mRNA	O
-	O
ribosome	O
-	O
antibody	B-FUNC
complex	O
in	O
a	O
eukaryotic	O
translation	O
system	O
.	O

Clinicopathological	O
abnormalities	O
included	O
nonregenerative	O
anaemia	O
,	O
hypoalbuminaemia	O
,	O
increased	O
globulin	O
concentration	O
,	O
and	O
mildly	O
elevated	O
aspartate	O
aminotransferase	O
and	O
alkaline	O
phosphatase	B-FUNC
activities	O
.	O

The	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-FUNC
was	O
detected	O
for	O
all	O
of	O
them	O
by	O
ELISA	O
and	O
neutralized	O
test	O
simultaneously	O
.	O

On	O
the	O
35th	O
month	O
after	O
the	O
onset	O
,	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
were	O
still	O
having	O
the	O
neutralizing	O
antibody	B-FUNC
level	O
of	O
above	O
1	O
:	O
36	O
,	O
but	O
the	O
neutralizing	O
antibody	B-FUNC
level	O
in	O
another	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
had	O
decreased	O
to	O
as	O
low	O
as	O
1	O
:	O
10	O
,	O
when	O
the	O
cut	O
-	O
off	O
level	O
was	O
set	O
as	O
1	O
:	O
8	O
.	O

Results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
neutralizing	O
antibody	B-FUNC
of	O
SARS	O
cases	O
could	O
last	O
for	O
at	O
least	O
three	O
years	O
,	O
but	O
the	O
sera	B-FUNC
specific	O
antibody	B-FUNC
in	O
SARS	O
cases	O
decreased	O
gradually	O
when	O
time	O
went	O
by	O
.	O

However	O
,	O
neutralizing	O
antibody	B-FUNC
in	O
some	O
of	O
the	O
cases	O
decreased	O
to	O
a	O
lower	O
level	O
on	O
the	O
35th	O
month	O
.	O

Further	O
follow	O
-	O
up	O
study	O
was	O
worthwhile	O
to	O
observe	O
the	O
long	O
-	O
lasting	O
profile	O
of	O
antibody	B-FUNC
existence	O
on	O
SARS	O
cases	O
.	O

RESULTS	O
:	O
13	O
,	O
17	O
and	O
13	O
sera	B-FUNC
samples	O
were	O
collected	O
in	O
the	O
5th	O
,	O
20th	O
and	O
35th	O
month	O
after	O
onset	O
.	O

On	O
the	O
35th	O
month	O
after	O
the	O
onset	O
,	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
were	O
still	O
having	O
the	O
neutralizing	O
antibody	B-FUNC
level	O
of	O
above	O
1	O
:	O
36	O
,	O
but	O
the	O
neutralizing	O
antibody	B-FUNC
level	O
in	O
another	O
30	O
.	O
8	O
%	O
(	O
4	O
/	O
13	O
)	O
of	O
the	O
patients	O
had	O
decreased	O
to	O
as	O
low	O
as	O
1	O
:	O
10	O
,	O
when	O
the	O
cut	O
-	O
off	O
level	O
was	O
set	O
as	O
1	O
:	O
8	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
the	O
study	O
indicated	O
that	O
the	O
neutralizing	O
antibody	B-FUNC
of	O
SARS	O
cases	O
could	O
last	O
for	O
at	O
least	O
three	O
years	O
,	O
but	O
the	O
sera	B-FUNC
specific	O
antibody	B-FUNC
in	O
SARS	O
cases	O
decreased	O
gradually	O
when	O
time	O
went	O
by	O
.	O

Incorporation	O
of	O
Boc	O
-	O
Ser	O
as	O
the	O
P	O
(	O
4	O
)-	O
ligand	B-FUNC
resulted	O
in	O
enhanced	O
SARS	O
-	O
CoV	O
3CLpro	O
inhibitory	O
activity	O
.	O

Structural	O
analysis	O
of	O
the	O
inhibitor	O
-	O
bound	O
X	O
-	O
ray	O
structure	O
revealed	O
high	O
binding	B-FUNC
affinity	O
toward	O
the	O
enzyme	O
.	O

Little	O
is	O
known	O
about	O
the	O
biogenesis	O
of	O
these	O
complexes	O
,	O
the	O
membrane	O
anchoring	B-FUNC
of	O
which	O
is	O
probably	O
mediated	O
by	O
nsp3	O
,	O
nsp4	O
,	O
and	O
nsp6	O
,	O
as	O
they	O
contain	O
several	O
putative	O
transmembrane	O
domains	O
.	O

The	O
important	O
role	O
of	O
the	O
early	O
secretory	O
pathway	O
in	O
formation	O
of	O
the	O
replication	O
complexes	O
was	O
also	O
demonstrated	O
by	O
the	O
inhibition	O
of	O
coronaviral	O
replication	O
when	O
the	O
ER	O
export	O
machinery	O
was	O
blocked	O
by	O
use	O
of	O
the	O
kinase	B-FUNC
inhibitor	I-FUNC
H89	O
or	O
by	O
expression	O
of	O
a	O
mutant	O
,	O
Sar1	O
[	O
H79G	O
].	O

The	O
results	O
of	O
14	O
patients	O
(	O
7	O
adults	O
and	O
7	O
children	O
)	O
with	O
a	O
variety	O
of	O
hematologic	O
malignant	O
diseases	O
treated	O
with	O
a	O
TLI	O
-	O
based	O
reconditioning	O
regimen	O
with	O
7	O
-	O
Gy	O
single	O
-	O
dose	O
application	O
plus	O
anti	O
-	O
T	O
-	O
lymphocyte	O
antibody	B-FUNC
OKT3	O
(	O
n	O
=	O
11	O
)	O
and	O
/	O
or	O
antithymocyte	O
globulin	O
(	O
n	O
=	O
7	O
)/	O
fludarabine	O
(	O
n	O
=	O
9	O
),	O
followed	O
by	O
an	O
infusion	O
of	O
peripheral	O
blood	O
stem	O
cells	O
(	O
n	O
=	O
13	O
)	O
or	O
bone	O
marrow	O
stem	O
cells	O
(	O
n	O
=	O
1	O
)	O
from	O
related	O
or	O
unrelated	O
donors	O
,	O
were	O
retrospectively	O
analyzed	O
.	O

Strong	O
activation	O
of	O
TLR3	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
p65	O
was	O
observed	O
in	O
BRV	O
-	O
infected	O
host	O
tissues	O
,	O
but	O
not	O
in	O
tissues	O
infected	O
with	O
BCV	O
.	O

TITLE	O
:	O
Proinflammatory	O
responses	O
of	O
human	O
airway	O
cells	O
to	O
ricin	B-FUNC
involve	O
stress	O
-	O
activated	O
protein	O
kinases	O
and	O
NF	O
-	O
kappaB	O
.	O
ABSTRACT	O
:	O
Ricin	B-FUNC
is	O
a	O
potential	O
bioweapon	O
because	O
of	O
its	O
toxicity	O
,	O
availability	O
,	O
and	O
ease	O
of	O
production	O
.	O

When	O
delivered	O
to	O
the	O
lungs	O
,	O
ricin	B-FUNC
causes	O
severe	O
pulmonary	O
damage	O
with	O
symptoms	O
that	O
are	O
similar	O
to	O
those	O
observed	O
in	O
acute	O
lung	O
injury	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
airway	O
epithelium	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
many	O
lung	O
diseases	O
,	O
but	O
its	O
role	O
in	O
ricin	B-FUNC
intoxication	O
has	O
not	O
been	O
elucidated	O
.	O

Exposure	O
of	O
cultured	O
primary	O
human	O
airway	O
epithelial	O
cells	O
to	O
ricin	B-FUNC
resulted	O
in	O
the	O
activation	O
of	O
SAPKs	O
and	O
NF	O
-	O
kappaB	O
and	O
in	O
the	O
increased	O
expression	O
of	O
multiple	O
proinflammatory	O
molecules	O
.	O

Among	O
the	O
genes	O
upregulated	O
by	O
ricin	B-FUNC
and	O
identified	O
by	O
microarray	O
analysis	O
were	O
those	O
associated	O
with	O
transcription	O
,	O
nucleosome	O
assembly	O
,	O
inflammation	O
,	O
and	O
response	O
to	O
stress	O
.	O

Sequence	O
analysis	O
of	O
the	O
promoters	O
of	O
these	O
genes	O
identified	O
NF	O
-	O
kappaB	O
as	O
one	O
of	O
the	O
transcription	O
factors	O
whose	O
binding	B-FUNC
sites	O
were	O
overrepresented	O
.	O

TITLE	O
:	O
Use	O
of	O
antibody	B-FUNC
avidity	O
assays	O
for	O
diagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
immunofluorescent	O
assay	O
(	O
Euroimmun	O
AG	O
,	O
Luebeck	O
,	O
Germany	O
)	O
was	O
used	O
to	O
investigate	O
the	O
avidity	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
IgM	O
,	O
IgA	O
,	O
and	O
total	O
Ig	O
(	O
IgGAM	O
)	O
antibody	B-FUNC
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
infections	O
.	O

While	O
SARS	O
CoV	O
infections	O
induced	O
an	O
anamnestic	O
IgG	O
antibody	B-FUNC
response	O
to	O
the	O
229E	O
and	O
OC43	O
viruses	O
,	O
these	O
cross	O
-	O
reactive	O
antibodies	O
remained	O
of	O
high	O
avidity	O
from	O
early	O
(	O
the	O
first	O
month	O
)	O
postinfection	O
.	O

The	O
expression	O
of	O
full	O
length	O
recombinant	O
SARS	O
spike	O
protein	O
(	O
rSS	O
)	O
in	O
HeLa	O
cells	O
possessing	O
specific	O
reaction	O
ability	O
to	O
chicken	O
anti	O
-	O
sera	B-FUNC
was	O
confirmed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
(	O
190	O
kD	O
).	O

HeLa	O
cells	O
infected	O
with	O
rWR	O
-	O
SARS	O
-	O
S	O
also	O
showed	O
high	O
sensitivity	O
in	O
detecting	O
specific	O
serum	O
antibody	B-FUNC
by	O
indirect	O
immunofluoresence	O
assay	O
(	O
IFA	O
).	O

TITLE	O
:	O
Cold	O
antibody	B-FUNC
autoimmune	O
hemolytic	O
anemias	O
.	O

ABSTRACT	O
:	O
The	O
cold	O
antibody	B-FUNC
autoimmune	O
hemolytic	O
anemias	O
(	O
AIHAs	O
)	O
are	O
primarily	O
comprised	O
of	O
cold	O
agglutinin	O
syndrome	O
(	O
CAS	O
)	O
and	O
paroxysmal	O
cold	O
hemoglobinuria	O
(	O
PCH	O
)	O
but	O
,	O
in	O
addition	O
,	O
there	O
are	O
unusual	O
instances	O
in	O
which	O
patients	O
satisfy	O
the	O
serologic	O
criteria	O
of	O
both	O
warm	O
antibody	B-FUNC
AIHA	O
and	O
CAS	O
"("""	O
mixed	O
AIHA	O
""")."	O

The	O
responsible	O
antibody	B-FUNC
is	O
of	O
the	O
IgM	O
immunoglobulin	B-FUNC
class	O
,	O
is	O
maximally	O
reactive	O
in	O
the	O
cold	O
but	O
with	O
reactivity	O
up	O
to	O
at	O
least	O
30	O
degrees	O
C	O
.	O
Therapy	O
is	O
often	O
ineffective	O
,	O
but	O
newer	O
agents	O
such	O
as	O
rituximab	O
have	O
been	O
beneficial	O
in	O
some	O
patients	O
.	O

The	O
causative	O
antibody	B-FUNC
is	O
of	O
the	O
IgG	O
immunoglobulin	B-FUNC
class	O
and	O
is	O
a	O
biphasic	O
hemolysin	O
that	O
is	O
demonstrated	O
by	O
incubation	O
in	O
the	O
cold	O
followed	O
by	O
incubation	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
complement	O
.	O

The	O
secretion	O
level	O
of	O
IFN	O
-	O
gamma	O
was	O
much	O
higher	O
than	O
that	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
in	O
vAc	O
-	O
N	O
or	O
vAc	O
-	O
S	O
immunized	O
groups	O
,	O
suggesting	O
a	O
strong	O
Th1	O
bias	O
towards	O
cellular	O
immune	O
responses	O
.	O

The	O
levels	O
of	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
declined	O
significantly	O
with	O
time	O
in	O
the	O
PRONE	O
group	O
(	O
p	O
=	O
0	O
.	O
011	O
).	O

The	O
levels	O
of	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
at	O
enrolment	O
,	O
24	O
hours	O
and	O
72	O
hours	O
after	O
enrolment	O
also	O
predicted	O
the	O
14th	O
day	O
mortality	O
of	O
all	O
patients	O
.	O

The	O
levels	O
of	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
at	O
enrolment	O
,	O
24	O
hours	O
and	O
72	O
hours	O
after	O
enrolment	O
also	O
predicted	O
the	O
14th	O
day	O
mortality	O
of	O
all	O
patients	O
.	O

We	O
analyzed	O
this	O
cross	O
-	O
reactivity	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
Western	O
blot	O
analysis	O
using	O
specific	O
antisera	O
to	O
animal	O
CoVs	O
and	O
SARS	O
-	O
CoV	O
and	O
SARS	O
patient	O
convalescent	O
-	O
phase	O
or	O
negative	O
sera	B-FUNC
.	O

The	O
N	O
-	O
protein	O
fragments	O
comprising	O
aa	O
360	O
to	O
412	O
and	O
aa	O
1	O
to	O
213	O
reacted	O
specifically	O
with	O
SARS	O
convalescent	O
-	O
phase	O
sera	B-FUNC
but	O
not	O
with	O
negative	O
human	O
sera	B-FUNC
in	O
ELISA	O
;	O
the	O
fragment	O
comprising	O
aa	O
1	O
to	O
213	O
cross	O
-	O
reacted	O
with	O
antisera	O
to	O
animal	O
CoVs	O
,	O
whereas	O
the	O
fragment	O
comprising	O
aa	O
360	O
to	O
412	O
did	O
not	O
cross	O
-	O
react	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
SARS	O
diagnosis	O
.	O

Identification	O
of	O
the	O
cross	O
-	O
reactive	O
and	O
non	O
-	O
cross	O
-	O
reactive	O
N	O
-	O
protein	O
regions	O
allows	O
development	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibody	B-FUNC
assays	O
for	O
screening	O
animal	O
and	O
human	O
sera	B-FUNC
.	O

Herein	O
,	O
we	O
tested	O
whether	O
antiviral	O
antibody	B-FUNC
-	O
mediated	O
suppression	O
of	O
virus	O
replication	O
and	O
subsequent	O
virus	O
clearance	O
were	O
necessary	O
for	O
preventing	O
CTL	O
escape	O
in	O
coronavirus	O
-	O
infected	O
mice	O
.	O

These	O
data	O
directly	O
demonstrate	O
a	O
critical	O
role	O
for	O
antiviral	O
antibody	B-FUNC
in	O
protecting	O
from	O
the	O
selective	O
outgrowth	O
of	O
CTL	O
escape	O
variant	O
viruses	O
.	O

Virus	O
isolation	O
,	O
hemagglutination	O
and	O
receptor	O
-	O
destroying	O
enzyme	B-FUNC
activity	I-FUNC
showed	O
that	O
the	O
buffalo	O
coronavirus	O
(	O
BuCoV	O
)	O
is	O
closely	O
related	O
to	O
BCoV	O
but	O
possesses	O
some	O
different	O
biological	O
properties	O
.	O

However	O
,	O
the	O
presence	O
of	O
T	O
lymphocytes	O
or	O
anti	O
-	O
viral	O
antibody	B-FUNC
can	O
induce	O
disease	O
in	O
infected	O
immunodeficient	O
mice	O
.	O

These	O
suggest	O
that	O
severe	O
infection	O
of	O
BCV	O
in	O
the	O
cow	O
without	O
the	O
BCV	O
antibody	B-FUNC
accompanied	O
by	O
severe	O
hemorrhagic	O
anemia	O
resulted	O
in	O
the	O
cow	O
'	O
s	O
death	O
.	O

Using	O
multicolor	O
colocalization	O
techniques	O
,	O
we	O
previously	O
reported	O
that	O
SARS	O
(+)	O
cells	O
in	O
the	O
lung	O
of	O
fatally	O
infected	O
patients	O
expressed	O
the	O
only	O
known	O
functional	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
and	O
also	O
a	O
binding	B-FUNC
receptor	O
,	O
liver	O
/	O
lymph	O
node	O
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
non	O
-	O
integrin	O
(	O
CD209L	O
).	O

The	O
purified	O
recombinant	O
nsp14	O
protein	O
digested	O
a	O
5	O
'-	O
labeled	O
RNA	O
molecule	O
,	O
but	O
failed	O
to	O
digest	O
the	O
RNA	O
substrate	O
that	O
is	O
modified	O
with	O
fluorescein	O
group	O
at	O
the	O
3	O
'-	O
hydroxyl	O
group	O
,	O
suggesting	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	B-FUNC
activity	I-FUNC
.	O

The	O
exoribonuclease	B-FUNC
activity	I-FUNC
requires	O
Mg2	O
+	O
as	O
a	O
cofactor	O
.	O

Endogenous	O
tryptophan	O
fluorescence	O
and	O
circular	O
dichroism	O
(	O
CD	O
)	O
spectra	O
measurements	O
showed	O
that	O
there	O
was	O
a	O
structural	O
change	O
of	O
nsp14	O
when	O
binding	B-FUNC
with	O
metal	O
ions	O
.	O

We	O
propose	O
that	O
the	O
conformational	O
change	O
induced	O
by	O
metal	O
ions	O
may	O
be	O
a	O
prerequisite	O
for	O
catalytic	B-FUNC
activity	I-FUNC
by	O
correctly	O
positioning	O
the	O
side	O
chains	O
of	O
the	O
residues	O
located	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

In	O
both	O
lines	O
of	O
birds	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
mRNA	O
levels	O
were	O
elevated	O
in	O
the	O
kidneys	O
at	O
4	O
d	O
postinfection	O
.	O

In	O
addition	O
,	O
S	O
-	O
line	O
birds	O
also	O
showed	O
three	O
times	O
higher	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
than	O
HWL	O
birds	O
after	O
IBV	O
infection	O
.	O

These	O
findings	O
suggest	O
that	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
may	O
play	O
a	O
role	O
in	O
IBV	O
-	O
induced	O
nephritis	O
and	O
may	O
open	O
an	O
avenue	O
to	O
develop	O
alternative	O
strategies	O
,	O
such	O
as	O
the	O
use	O
of	O
antiinflammatory	O
cytokines	O
,	O
to	O
overcome	O
the	O
nephropathogenic	O
effects	O
of	O
IBV	O
.	O

The	O
pathological	O
changes	O
in	O
lungs	O
correlated	O
closely	O
with	O
the	O
dose	O
of	O
antibody	B-FUNC
administered	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
an	O
RNA	B-FUNC
binding	I-FUNC
protein	O
which	O
is	O
phosphorylated	O
at	O
two	O
conserved	O
clusters	O
.	O

TITLE	O
:	O
Molecular	O
docking	O
identifies	O
the	O
binding	B-FUNC
of	O
3	O
-	O
chloropyridine	O
moieties	O
specifically	O
to	O
the	O
S1	O
pocket	O
of	O
SARS	O
-	O
CoV	O
Mpro	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
main	O
proteinase	B-FUNC
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
),	O
is	O
widely	O
considered	O
to	O
be	O
a	O
major	O
drug	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
treatment	O
.	O

The	O
docking	O
results	O
suggest	O
two	O
major	O
modes	O
for	O
the	O
initial	O
binding	B-FUNC
of	O
these	O
inhibitors	O
to	O
the	O
active	O
site	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
).	O

In	O
addition	O
,	O
intrinsic	O
flexibility	O
in	O
the	O
S4	O
pocket	O
allows	O
for	O
the	O
accommodation	O
of	O
bulky	O
groups	O
such	O
as	O
benzene	O
rings	O
,	O
suggesting	O
that	O
this	O
structural	O
plasticity	O
can	O
be	O
further	O
exploited	O
for	O
optimizing	O
inhibitor	O
-	O
enzyme	O
interactions	O
that	O
should	O
promote	O
a	O
tighter	O
binding	B-FUNC
mode	O
.	O

Reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
the	O
partial	O
ORF3	O
gene	O
including	O
51	O
nucleotide	O
deletions	O
revealed	O
that	O
all	O
PEDVs	O
fell	O
into	O
two	O
types	O
,	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
PEDVs	O
.	O

Even	O
after	O
adjusting	O
for	O
these	O
baseline	O
differences	O
,	O
trauma	O
patients	O
had	O
significantly	O
lower	O
plasma	O
levels	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
von	O
Willebrand	O
factor	O
antigen	O
,	O
surfactant	O
protein	O
-	O
D	O
,	O
and	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
-	O
1	O
,	O
which	O
are	O
biomarkers	O
of	O
lung	O
epithelial	O
and	O
endothelial	O
injury	O
previously	O
found	O
to	O
be	O
prognostic	O
in	O
acute	O
lung	O
injury	O
.	O

Three	O
potential	O
caveolin	O
-	O
1	O
-	O
binding	B-FUNC
sites	O
were	O
reported	O
to	O
be	O
present	O
in	O
the	O
3a	O
protein	O
.	O

TITLE	O
:	O
Conformational	O
reorganization	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
following	O
receptor	B-FUNC
binding	I-FUNC
:	O
implications	O
for	O
membrane	O
fusion	O
.	O

We	O
used	O
cryo	O
-	O
electron	O
microscopy	O
and	O
image	O
processing	O
to	O
investigate	O
conformational	O
changes	O
that	O
occur	O
in	O
the	O
entire	O
spike	O
of	O
intact	O
virions	O
when	O
they	O
bind	B-FUNC
to	O
the	O
viral	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

We	O
have	O
shown	O
that	O
ACE2	O
binding	B-FUNC
results	O
in	O
structural	O
changes	O
that	O
appear	O
to	O
be	O
the	O
initial	O
step	O
in	O
viral	O
membrane	O
fusion	O
,	O
and	O
precisely	O
localized	O
the	O
receptor	O
-	O
binding	B-FUNC
and	O
fusion	O
core	O
domains	O
within	O
the	O
entire	O
spike	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
provides	O
an	O
ideal	O
model	O
system	O
to	O
study	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
in	O
the	O
native	O
state	O
,	O
employing	O
cryo	O
-	O
electron	O
microscopy	O
and	O
single	O
-	O
particle	O
image	O
analysis	O
.	O

Possible	O
activation	O
of	O
mitochondrial	O
apoptotic	O
pathway	O
in	O
S2	O
expressing	O
cells	O
was	O
suggested	O
,	O
as	O
evidenced	O
by	O
the	O
up	O
-	O
regulation	O
of	O
cytochrome	B-FUNC
c	I-FUNC
and	O
down	O
-	O
regulation	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
anti	O
-	O
apoptotic	O
members	O
.	O

12	O
,	O
1730	O
-	O
1736	O
;	O
Porter	B-FUNC
,	O
M	O
.	O
C	O
.,	O
Reggiardo	O
,	O
C	O
.,	O
Bueschel	O
,	O
D	O
.	O
M	O
.,	O
Keel	O
,	O
M	O
.	O
K	O
.,	O
Songer	O
,	O
J	O
.	O
G	O
.,	O
2002	O
.	O

In	O
an	O
effort	O
to	O
characterize	O
molecular	O
components	O
of	O
the	O
virus	O
that	O
are	O
absent	O
in	O
other	O
coronaviruses	O
,	O
all	O
of	O
which	O
are	O
considerably	O
less	O
pathogenic	O
for	O
humans	O
,	O
we	O
recombinantly	O
produced	O
the	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
within	O
non	O
-	O
structural	O
protein	O
3	O
(	O
Nsp3	O
)	O
of	O
SARS	O
-	O
CoV	O
and	O
characterized	O
its	O
nucleic	O
-	O
acid	O
binding	B-FUNC
properties	O
.	O

ABSTRACT	O
:	O
Five	O
active	O
metal	O
-	O
conjugated	O
inhibitors	O
(	O
PMA	O
,	O
TDT	B-FUNC
,	O
EPDTC	O
,	O
JMF1586	O
and	O
JMF1600	O
)	O
bound	O
with	O
the	O
3C	O
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
were	O
analyzed	O
crystallographically	O
.	O

A	O
strong	O
humoral	O
immune	O
response	O
as	O
supported	O
by	O
the	O
significantly	O
up	O
-	O
regulated	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
gamma	O
chain	O
was	O
observed	O
in	O
the	O
absence	O
of	O
innate	O
,	O
Th1	O
adaptive	O
immunity	O
,	O
or	O
IgA	O
up	O
-	O
regulation	O
after	O
the	O
secondary	O
immunization	O
,	O
indicating	O
that	O
the	O
local	O
memory	O
response	O
is	O
dominated	O
by	O
IgG	O
.	O
Overall	O
,	O
the	O
results	O
provided	O
the	O
first	O
detailed	O
kinetics	O
on	O
the	O
molecular	O
basis	O
underlying	O
the	O
development	O
of	O
primary	O
and	O
secondary	O
mucosal	O
immunity	O
.	O

Z	O
protein	O
was	O
used	O
as	O
antigen	O
to	O
immunize	O
the	O
rabbit	O
and	O
anti	O
-	O
Z	O
sera	B-FUNC
was	O
collected	O
.	O

ELISA	O
analysis	O
indicated	O
the	O
SARS	O
-	O
CoV	O
antigen	O
prepared	O
from	O
SARS	O
-	O
CoV	O
lysates	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	B-FUNC
.	O

The	O
predicted	O
epitopes	O
of	O
Z	O
protein	O
can	O
induce	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
antibody	B-FUNC
in	O
rabbits	O
,	O
which	O
provides	O
a	O
new	O
protein	O
for	O
developing	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Z	O
gene	O
was	O
successfully	O
designed	O
and	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
).	O

ELISA	O
analysis	O
indicated	O
the	O
SARS	O
-	O
CoV	O
antigen	O
prepared	O
from	O
SARS	O
-	O
CoV	O
lysates	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	B-FUNC
.	O

CONCLUSIONS	O
:	O
The	O
predicted	O
epitopes	O
of	O
Z	O
protein	O
can	O
induce	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
antibody	B-FUNC
in	O
rabbits	O
,	O
which	O
provides	O
a	O
new	O
protein	O
for	O
developing	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O

The	O
samples	O
were	O
screened	O
for	O
astrovirus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
and	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
by	O
a	O
reverse	O
transcriptase	B-FUNC
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
for	O
groups	O
1	O
and	O
2	O
adenovirus	O
by	O
PCR	O
.	O

Clinical	O
signs	O
,	O
histopathologic	O
analysis	O
,	O
detection	O
of	O
IBV	O
genomes	O
in	O
tears	O
,	O
and	O
IBV	O
-	O
specific	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
in	O
tears	O
were	O
used	O
to	O
evaluate	O
disease	O
progression	O
and	O
immune	O
response	O
.	O

The	O
S1	O
glycoprotein	O
genes	O
of	O
these	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RTPCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
pharmacokinetics	O
,	O
tolerance	O
and	O
immunity	O
of	O
this	O
kind	O
of	O
antibody	B-FUNC
in	O
macaques	O
and	O
rats	O
.	O

However	O
,	O
a	O
mild	O
inflammatory	O
response	O
in	O
local	O
injection	O
site	O
and	O
a	O
moderate	O
immune	O
response	O
against	O
this	O
antibody	B-FUNC
in	O
the	O
successively	O
injected	O
animals	O
were	O
observed	O
,	O
which	O
however	O
recovered	O
3	O
weeks	O
after	O
the	O
last	O
injection	O
.	O

The	O
considerable	O
safety	O
of	O
this	O
antibody	B-FUNC
used	O
in	O
primates	O
and	O
the	O
fact	O
that	O
the	O
immune	O
system	O
of	O
the	O
host	O
can	O
be	O
motivated	O
by	O
post	O
-	O
injection	O
of	O
the	O
F	O
(	O
ab	O
')(	O
2	O
)	O
indicate	O
that	O
this	O
type	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
can	O
be	O
used	O
for	O
prevention	O
and	O
treatment	O
of	O
SASR	O
,	O
especially	O
at	O
the	O
early	O
stage	O
of	O
this	O
virus	O
infection	O
.	O

The	O
binding	B-FUNC
is	O
increased	O
upon	O
artificial	O
cell	O
activation	O
with	O
phorbol	O
ester	O
.	O

On	O
d	O
7	O
,	O
14	O
,	O
21	O
,	O
28	O
,	O
35	O
,	O
42	O
,	O
and	O
49	O
after	O
the	O
first	O
vaccination	O
,	O
the	O
temporal	O
changes	O
in	O
serum	O
ND	O
hemagglutination	O
inhibition	O
antibody	B-FUNC
titer	O
were	O
determined	O
by	O
the	O
micromethod	O
.	O

All	O
pups	O
seroconverted	O
for	O
CCoV	O
,	O
as	O
shown	O
by	O
the	O
high	O
optical	O
density	O
values	O
and	O
antibody	B-FUNC
titres	O
detected	O
by	O
ELISA	O
and	O
virusneutralisation	O
tests	O
,	O
respectively	O
.	O

These	O
novel	O
findings	O
play	O
against	O
the	O
existing	O
data	O
that	O
suggest	O
that	O
MHV	O
host	O
range	O
determinants	O
are	O
located	O
in	O
the	O
S1	O
subunit	O
,	O
which	O
harbors	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
,	O
or	O
involve	O
coordinating	O
changes	O
in	O
both	O
S1	O
and	O
S2	O
.	O

Lung	O
tissue	O
and	O
/	O
or	O
fluid	O
and	O
/	O
or	O
the	O
peribronchial	O
lymph	O
node	O
of	O
the	O
intratracheally	O
inoculated	O
animals	O
had	O
high	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
levels	O
.	O

The	O
nine	O
antiviral	O
agents	O
comprised	O
six	O
synthetic	O
small	O
-	O
molecule	O
compounds	O
,	O
one	O
peptide	O
,	O
one	O
monoclonal	O
antibody	B-FUNC
and	O
a	O
vaccine	O
.	O

The	O
RNA	O
-	O
binding	B-FUNC
residues	O
were	O
mapped	O
by	O
a	O
method	O
linking	O
reversible	O
cross	O
-	O
linking	O
,	O
RNA	O
affinity	O
purification	O
,	O
and	O
peptide	O
fingerprinting	O
.	O

Alanine	O
substitution	O
of	O
several	O
residues	O
in	O
the	O
RNA	O
-	O
contacting	O
portion	O
of	O
Nsp15	O
did	O
not	O
affect	O
hexamer	O
formation	O
but	O
decreased	O
the	O
affinity	O
of	O
RNA	B-FUNC
binding	I-FUNC
and	O
reduced	O
endonuclease	B-FUNC
activity	I-FUNC
.	O

As	O
acid	O
-	O
fast	B-FUNC
bacilli	O
were	O
positive	O
in	O
urine	O
(	O
Gaffky	O
8	O
)	O
and	O
sputum	O
(	O
Gaffky	O
1	O
),	O
we	O
diagnosed	O
as	O
miliary	O
tuberculosis	O
and	O
pulmonary	O
tuberculosis	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
demonstrated	O
that	O
CQ	O
affects	O
the	O
activation	O
of	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
).	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
)	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
GI	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	B-FUNC
pump	I-FUNC
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

Through	O
clustering	O
analysis	O
,	O
the	O
differential	O
expression	O
of	O
immune	O
related	O
genes	O
,	O
including	O
TNF	O
receptor	O
superfamily	O
,	O
Kctd9	O
,	O
Bcl	O
-	O
2	O
,	O
Fgl2	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
etc	O
.	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	B-FUNC
pair	I-FUNC
Alu	O
repeat	O
sequence	O
polymorphism	O
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
gene	O
(	O
ACE	O
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
The	O
administration	O
of	O
hyper	O
immune	O
sera	B-FUNC
to	O
prevent	O
or	O
treat	O
life	O
-	O
threatening	O
infections	O
is	O
a	O
remarkable	O
milestone	O
in	O
medicine	O
and	O
biotechnology	O
that	O
has	O
been	O
achieved	O
more	O
than	O
a	O
century	O
ago	O
.	O

Here	O
we	O
compare	O
and	O
contrast	O
current	O
methods	O
to	O
generate	O
human	O
monoclonal	O
antibodies	O
and	O
highlight	O
the	O
advantages	O
of	O
exploiting	O
the	O
human	O
antibody	B-FUNC
repertoire	O
using	O
a	O
novel	O
method	O
that	O
allows	O
efficient	O
immortalization	O
and	O
cloning	O
of	O
human	O
memory	O
B	O
cells	O
.	O

A	O
higher	O
antibody	B-FUNC
positivity	O
is	O
expected	O
for	O
females	O
than	O
for	O
males	O
.	O

A	O
comparative	O
study	O
of	O
ANHTRs	O
for	O
antibody	B-FUNC
positivity	O
and	O
their	O
clinical	O
features	O
between	O
females	O
and	O
males	O
for	O
both	O
patients	O
and	O
donors	O
is	O
helpful	O
for	O
characterizing	O
ANHTRs	O
including	O
TRALI	O
more	O
clearly	O
,	O
but	O
such	O
studies	O
are	O
few	O
and	O
outdated	O
.	O

FCV3	O
-	O
70	O
monoclonal	O
antibody	B-FUNC
produced	O
immunolabelling	O
of	O
group	O
1	O
coronavirus	O
antigen	O
in	O
tissue	O
samples	O
from	O
eight	O
animals	O
,	O
the	O
antigen	O
being	O
present	O
in	O
the	O
cytoplasm	O
of	O
macrophages	O
in	O
the	O
different	O
types	O
of	O
granulomatous	O
lesions	O
.	O

carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
spike	O
protein	O
(	O
S	O
-	O
CT24	O
)	O
elicited	O
a	O
strong	O
antibody	B-FUNC
response	O
in	O
BALB	O
/	O
c	O
mice	O
that	O
had	O
specific	O
reactivity	O
against	O
the	O
S	O
-	O
CT24	O
and	O
PEDV	O
.	O

TITLE	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
is	O
not	O
a	O
pathogenic	O
determinant	O
in	O
acute	O
lethal	O
encephalitis	O
induced	O
by	O
a	O
highly	O
neurovirulent	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Moreover	O
,	O
the	O
immune	O
serum	O
against	O
S1D	O
showed	O
the	O
binding	B-FUNC
ability	O
to	O
the	O
native	O
S	O
protein	O
of	O
PEDV	O
.	O

Third	O
,	O
the	O
chimeric	O
S	O
covering	O
the	O
previously	O
defined	O
receptor	O
-	O
binding	B-FUNC
domain	O
gained	O
its	O
ability	O
to	O
enter	O
cells	O
via	O
human	O
ACE2	O
,	O
albeit	O
with	O
different	O
efficiencies	O
for	O
different	O
constructs	O
.	O

Fourth	O
,	O
a	O
minimal	O
insert	O
region	O
(	O
amino	O
acids	O
310	O
to	O
518	O
)	O
was	O
found	O
to	O
be	O
sufficient	O
to	O
convert	O
the	O
SL	O
-	O
CoV	O
S	O
from	O
non	O
-	O
ACE2	O
binding	B-FUNC
to	O
human	O
ACE2	O
binding	B-FUNC
,	O
indicating	O
that	O
the	O
SL	O
-	O
CoV	O
S	O
is	O
largely	O
compatible	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	O
both	O
in	O
structure	O
and	O
in	O
function	O
.	O

Isolated	O
RNAs	O
were	O
observed	O
to	O
efficiently	O
inhibit	O
double	O
-	O
stranded	O
DNA	O
unwinding	O
activity	O
of	O
the	O
helicase	O
by	O
up	O
to	O
approximately	O
85	O
%	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
1	O
.	O
2nM	O
but	O
show	O
a	O
slight	O
effect	O
on	O
ATPase	B-FUNC
activity	I-FUNC
of	O
the	O
protein	O
in	O
the	O
presence	O
of	O
cofactor	O
,	O
poly	O
(	O
rU	O
).	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
)	O
is	O
a	O
major	O
target	O
for	O
neutralizing	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Structures	O
of	O
two	O
coronavirus	O
main	O
proteases	O
:	O
implications	O
for	O
substrate	O
binding	B-FUNC
and	O
antiviral	O
drug	O
design	O
.	O

The	O
administration	O
of	O
an	O
NKG2D	O
-	O
blocking	O
antibody	B-FUNC
to	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
did	O
not	O
reduce	O
survival	O
,	O
dampen	O
IFN	O
-	O
gamma	O
production	O
in	O
the	O
brain	O
,	O
or	O
affect	O
liver	O
pathology	O
.	O

As	O
it	O
was	O
thought	O
that	O
surviving	O
neutrophils	O
would	O
also	O
be	O
damaged	O
from	O
antibodies	O
binding	B-FUNC
with	O
the	O
neutrophil	O
membrane	O
,	O
we	O
studied	O
the	O
functional	O
influence	O
of	O
neutrophil	O
antibodies	O
on	O
natural	O
phagocytosis	O
and	O
immune	O
phagocytosis	O
by	O
using	O
neutrophil	O
-	O
specific	O
monoclonal	O
antibodies	O
(	O
MoAbs	O
),	O
TAG1	O
:	O
HNA	O
-	O
la	O
on	O
FgammaRIIIb	O
,	O
TAG2	O
:	O
HNA	O
-	O
1b	O
on	O
FgammaRIIIa	O
/	O
b	O
,	O
TAG3	O
:	O
FgammaRIIIa	O
/	O
b	O
and	O
TAG4	O
:	O
HNA	O
-	O
2a	O
.	O

In	O
an	O
inhibition	O
assay	O
of	O
carbon	O
particle	O
phagocytosis	O
as	O
a	O
representation	O
of	O
natural	O
phagocytosis	O
,	O
neutrophils	O
binding	B-FUNC
with	O
TAG3	O
or	O
TAG4	O
were	O
inhibited	O
from	O
carbon	O
particle	O
-	O
phagocytosis	O
by	O
42	O
.	O
5	O
%	O
and	O
53	O
.	O
2	O
%	O
(%	O
inhibition	O
),	O
respectively	O
,	O
but	O
in	O
an	O
inhibition	O
assay	O
using	O
TAG3	O
MoAb	O
,	O
HNA	O
-	O
2a	O
strongly	O
positive	O
neutrophils	O
were	O
more	O
weakly	O
inhibited	O
than	O
HNA	O
-	O
2a	O
weak	O
-	O
positive	O
neutrophils	O
,	O
39	O
.	O
2	O
%	O
and	O
54	O
.	O
0	O
%	O
(%	O
inhibition	O
),	O
respectively	O
.	O

It	O
was	O
thought	O
that	O
neutrophil	O
immune	O
-	O
phagocytosis	O
would	O
be	O
inhibited	O
by	O
antibodies	O
binding	B-FUNC
with	O
FcgammaRIII	O
,	O
and	O
that	O
HNA	O
-	O
2a	O
was	O
not	O
related	O
to	O
immune	O
phagocytosis	O
.	O

Further	O
investigation	O
of	O
the	O
relationship	O
between	O
clinical	O
symptoms	O
and	O
antibody	B-FUNC
specificity	O
or	O
antibody	B-FUNC
quantity	O
is	O
needed	O
.	O

Management	O
included	O
placement	O
of	O
the	O
arteriovenous	O
femoral	O
transcutaneous	O
interventional	O
lung	O
-	O
assist	O
membrane	O
ventilator	O
,	O
lung	O
rest	B-FUNC
at	O
minimal	O
mechanical	O
ventilator	O
settings	O
,	O
and	O
optimization	O
of	O
systemic	O
oxygen	O
consumption	O
and	O
delivery	O
.	O

ABSTRACT	O
:	O
Mannan	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
is	O
a	O
collectin	O
that	O
mediates	O
activation	O
of	O
the	O
complement	O
system	O
and	O
is	O
of	O
importance	O
for	O
host	O
defenses	O
.	O

ABSTRACT	O
:	O
We	O
intended	O
to	O
evaluate	O
the	O
diagnostic	O
usefulness	O
of	O
a	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
kit	B-FUNC
under	O
dual	O
priming	O
oligonucleotide	O
system	O
(	O
DPO	O
)	O
for	O
the	O
childhood	O
acute	O
respiratory	O
tract	O
infections	O
.	O

Direct	O
fluorescent	O
antibody	B-FUNC
(	O
FA	O
)	O
assays	O
were	O
performed	O
with	O
fresh	O
specimens	O
;	O
then	O
,	O
mRT	O
-	O
PCRs	O
for	O
the	O
detection	O
of	O
12	O
respiratory	O
viruses	O
(	O
Seeplex	O
RV	O
detection	O
kit	B-FUNC
,	O
SeeGene	O
,	O
Seoul	O
,	O
Korea	O
)	O
were	O
tested	O
with	O
frozen	O
specimens	O
.	O

Sera	B-FUNC
of	O
SARS	O
convalescent	O
-	O
phase	O
patients	O
,	O
normal	O
human	O
sera	B-FUNC
,	O
sera	B-FUNC
of	O
patients	O
with	O
other	O
respiratory	O
diseases	O
,	O
and	O
swine	O
sera	B-FUNC
were	O
screened	O
by	O
ELISA	O
,	O
with	O
whole	O
SARS	O
-	O
CoV	O
F69	O
,	O
N	O
and	O
N199	O
proteins	O
as	O
antigens	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
N	O
and	O
N199	O
proteins	O
in	O
human	O
sera	B-FUNC
diagnosis	O
were	O
approximate	O
(	O
P	O
=	O
0	O
.	O
743	O
),	O
which	O
was	O
higher	O
than	O
whole	O
viral	O
protein	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
234	O
).	O

The	O
N199	O
protein	O
proved	O
to	O
be	O
more	O
specific	O
in	O
swine	O
sera	B-FUNC
screening	O
than	O
whole	O
viral	O
and	O
N	O
protein	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
The	O
sensitivity	O
and	O
specificity	O
of	O
N	O
and	O
N199	O
proteins	O
in	O
human	O
sera	B-FUNC
diagnosis	O
were	O
approximate	O
(	O
P	O
=	O
0	O
.	O
743	O
),	O
which	O
was	O
higher	O
than	O
whole	O
viral	O
protein	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
234	O
).	O

The	O
N199	O
protein	O
proved	O
to	O
be	O
more	O
specific	O
in	O
swine	O
sera	B-FUNC
screening	O
than	O
whole	O
viral	O
and	O
N	O
protein	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
open	O
reading	O
frame	O
7	O
(	O
ORF	O
7	O
)	O
gene	O
from	O
each	O
of	O
the	O
four	O
TGEVs	O
(	O
KT2	O
-	O
L	O
,	O
KT2	O
-	O
H	O
,	O
133	O
,	O
and	O
DAE	O
),	O
which	O
is	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
TGEV	O
genome	O
,	O
was	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
that	O
a	O
subunit	O
protein	O
vaccine	O
based	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
and	O
a	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
rAAV	O
)-	O
based	O
RBD	O
(	O
RBD	O
-	O
rAAV	O
)	O
vaccine	O
could	O
induce	O
highly	O
potent	O
neutralizing	O
Ab	O
responses	O
in	O
immunized	O
animals	O
.	O

TITLE	O
:	O
Residues	O
on	O
the	O
dimer	O
interface	O
of	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
protease	O
:	O
dimer	O
stability	O
characterization	O
and	O
enzyme	O
catalytic	B-FUNC
activity	I-FUNC
analysis	O
.	O

Seven	O
residues	O
on	O
the	O
dimer	O
interface	O
were	O
selected	O
for	O
evaluating	O
their	O
contributions	O
to	O
dimer	O
stability	O
and	O
catalytic	B-FUNC
activity	I-FUNC
by	O
biophysical	O
and	O
biochemical	O
methods	O
.	O

The	O
virus	O
neutralization	O
(	O
VN	O
)	O
was	O
performed	O
and	O
compared	O
with	O
indirect	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
IFAT	O
)	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Interestingly	O
,	O
ELISA	O
revealed	O
2	O
more	O
positive	O
sera	B-FUNC
than	O
did	O
the	O
VN	O
test	O
and	O
3	O
more	O
positive	O
sera	B-FUNC
than	O
did	O
the	O
IFAT	O
.	O

Considering	O
the	O
cross	O
-	O
reactivity	O
of	O
FCoV	O
type	O
I	O
and	O
type	O
II	O
,	O
ELISA	O
was	O
able	O
to	O
detect	O
antibodies	O
against	O
both	O
serotypes	O
,	O
allowing	O
the	O
use	O
of	O
the	O
assay	O
as	O
a	O
reference	O
test	O
for	O
sera	B-FUNC
screening	O
.	O

TITLE	O
:	O
Determination	O
and	O
application	O
of	O
immunodominant	O
regions	O
of	O
SARS	O
coronavirus	O
spike	O
and	O
nucleocapsid	O
proteins	O
recognized	O
by	O
sera	B-FUNC
from	O
different	O
animal	O
species	O
.	O

In	O
this	O
study	O
,	O
we	O
aim	O
to	O
search	O
for	O
and	O
compare	O
immunodominant	O
regions	O
of	O
the	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
which	O
are	O
recognized	O
by	O
sera	B-FUNC
from	O
different	O
animal	O
species	O
,	O
including	O
mouse	O
,	O
rat	O
,	O
rabbit	O
,	O
civet	O
,	O
pig	O
and	O
horse	O
.	O

Immunodominant	O
regions	O
containing	O
linear	O
epitopes	O
,	O
which	O
reacted	O
with	O
sera	B-FUNC
from	O
all	O
the	O
species	O
tested	O
,	O
were	O
identified	O
for	O
both	O
proteins	O
.	O

Screening	O
for	O
nucleocapsid	O
(	O
N	O
)-	O
specific	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
in	O
convalescent	O
sera	B-FUNC
reached	O
100	O
%	O
sensitivity	O
.	O

ABSTRACT	O
:	O
Both	O
,	O
the	O
influenza	O
C	O
(	O
INF	O
-	O
C	O
)	O
virus	O
haemagglutinin	O
esterase	O
fusion	O
and	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
haemagglutinin	O
esterase	O
surface	O
glycoproteins	O
exhibit	O
a	O
lectin	O
binding	B-FUNC
capability	O
and	O
a	O
receptor	O
-	O
destroying	O
9	O
-	O
O	O
-	O
acetyl	O
esterase	B-FUNC
activity	I-FUNC
that	O
recognise	O
9	O
-	O
O	O
-	O
acetyl	O
-	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
Neu5	O
,	O
9Ac	O
(	O
2	O
))-	O
containing	O
glycans	O
.	O

Here	O
we	O
report	O
nuclear	O
magnetic	O
resonance	O
and	O
molecular	O
modelling	O
studies	O
on	O
the	O
9	O
-	O
O	O
-	O
acetyl	O
esterase	O
showing	O
that	O
the	O
alpha	O
-	O
configured	O
Neu5	O
,	O
9Ac	O
(	O
2	O
)	O
is	O
strictly	O
preferred	O
by	O
the	O
INF	O
-	O
C	O
and	O
BCoV	O
esterases	B-FUNC
.	O

Analysis	O
of	O
the	O
apo	O
and	O
complexed	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
INF	O
-	O
C	O
esterase	O
revealed	O
that	O
binding	B-FUNC
of	O
9	O
-	O
O	O
-	O
acetylated	O
N	O
-	O
acetylneuraminic	O
acids	O
is	O
a	O
dynamic	O
process	O
that	O
involves	O
conformational	O
rearrangement	O
of	O
serine	O
-	O
57	O
in	O
the	O
esterase	O
active	O
site	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
glycoprotein	O
(	O
S	O
)	O
is	O
a	O
class	O
I	O
viral	O
fusion	O
protein	O
that	O
binds	B-FUNC
to	O
its	O
receptor	O
glycoprotein	O
,	O
human	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
and	O
mediates	O
virus	O
entry	O
and	O
cell	O
-	O
cell	O
fusion	O
.	O

Alanine	O
substitutions	O
for	O
one	O
or	O
two	O
of	O
the	O
six	O
aromatic	O
residues	O
in	O
the	O
JMD	O
did	O
not	O
alter	O
the	O
surface	O
expression	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
proteins	O
with	O
a	O
deletion	O
of	O
the	O
C	O
-	O
terminal	O
19	O
amino	O
acids	O
(	O
S	O
Delta19	O
)	O
or	O
reduce	O
binding	B-FUNC
to	O
soluble	O
human	O
ACE2	O
(	O
hACE2	O
).	O

In	O
one	O
design	O
,	O
a	O
biotinylated	O
target	O
is	O
used	O
and	O
the	O
detection	O
of	O
the	O
hybridization	O
reaction	O
is	O
monitored	O
using	O
alkaline	O
phosphatase	B-FUNC
labeled	O
streptavidin	O
(	O
S	O
-	O
AP	O
).	O

Serologic	O
antibody	B-FUNC
titers	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
parvovirus	O
(	O
CPV	O
),	O
canine	O
adenovirus	O
(	O
CAV	O
),	O
canine	O
coronavirus	O
(	O
CCV	O
),	O
canine	O
herpesvirus	O
,	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
Toxoplasma	O
gondii	O
,	O
Neospora	O
caninum	O
,	O
and	O
Leptospira	O
interrogans	O
were	O
measured	O
in	O
44	O
samples	O
taken	O
from	O
19	O
giant	O
pandas	O
between	O
1998	O
and	O
2003	O
at	O
the	O
Chengdu	O
Research	O
Base	O
of	O
Giant	O
Panda	O
Breeding	O
in	O
Sichuan	O
,	O
China	O
.	O

Positive	O
antibody	B-FUNC
titers	O
were	O
found	O
only	O
against	O
CDV	O
,	O
CPV	O
,	O
and	O
T	O
.	O
gondii	O
.	O

Sera	B-FUNC
were	O
negative	O
for	O
antibodies	O
against	O
the	O
other	O
six	O
pathogens	O
.	O

Interestingly	O
,	O
IBV	O
-	O
infected	O
cells	O
stably	O
expressing	O
a	O
Flag	O
-	O
tagged	O
eIF3f	O
showed	O
much	O
higher	O
translation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
coronavirus	O
S	O
protein	O
and	O
eIF3f	O
plays	O
a	O
functional	O
role	O
in	O
controlling	O
the	O
expression	O
of	O
host	O
genes	O
,	O
especially	O
genes	O
that	O
are	O
induced	O
during	O
coronavirus	O
infection	O
cycles	O
.	O

ABSTRACT	O
:	O
Only	O
recently	O
has	O
the	O
important	O
role	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
been	O
recognized	O
as	O
a	O
contributing	O
factor	O
to	O
the	O
multiple	O
organ	O
failure	O
commonly	O
seen	O
in	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

Decompressive	O
laparostomy	O
for	O
ACS	B-FUNC
is	O
a	O
life	O
-	O
saving	O
procedure	O
usually	O
performed	O
through	O
a	O
midline	O
incision	O
followed	O
by	O
a	O
negative	O
pressure	O
wound	O
dressing	O
.	O

Subcutaneous	O
fasciotomy	O
may	O
be	O
effective	O
in	O
early	O
and	O
less	O
severe	O
cases	O
of	O
ACS	B-FUNC
but	O
it	O
is	O
always	O
accompanied	O
with	O
a	O
ventral	O
hernia	O
.	O

A	O
patient	O
with	O
SAP	O
developed	O
manifest	O
ACS	B-FUNC
and	O
was	O
treated	O
with	O
bilateral	O
subcostal	O
laparostomy	O
.	O

Comparative	O
studies	O
are	O
needed	O
to	O
define	O
its	O
role	O
as	O
a	O
decompressive	O
technique	O
for	O
ACS	B-FUNC
.	O

We	O
investigated	O
the	O
association	O
of	O
polymorphisms	O
of	O
the	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
genes	O
with	O
acute	O
respiratory	O
failure	O
.	O

We	O
conclude	O
that	O
the	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
1082	O
genotype	O
may	O
be	O
a	O
risk	O
marker	O
for	O
development	O
of	O
acute	O
respiratory	O
failure	O
after	O
trauma	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
faecal	O
suspensions	O
and	O
FCoV	O
RNA	O
was	O
quantified	O
using	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

Our	O
results	O
show	O
that	O
using	O
the	O
QIAgen	O
RNA	O
mini	O
kit	B-FUNC
for	O
RNA	O
extraction	O
and	O
dilution	O
of	O
the	O
RNA	O
samples	O
helps	O
to	O
reduce	O
the	O
inhibitory	O
effects	O
.	O

Samples	O
of	O
testis	O
,	O
trachea	O
,	O
and	O
lungs	O
from	O
breeder	O
males	O
aged	O
57	O
wk	O
were	O
positive	O
for	O
IBV	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
virus	O
isolation	O
and	O
testis	O
samples	O
were	O
also	O
positive	O
for	O
aMPV	O
by	O
RT	O
-	O
PCR	O
.	O

In	O
the	O
C2	O
+	O
Mass	O
vaccination	O
trial	O
,	O
IBV	O
immunity	O
after	O
challenge	O
was	O
reduced	O
,	O
but	O
it	O
did	O
not	O
seem	O
to	O
be	O
a	O
result	O
of	O
reduced	O
Mass	O
vaccine	O
growth	O
or	O
the	O
ability	O
of	O
the	O
Mass	O
vaccine	O
to	O
induce	O
serum	O
IBV	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
small	O
proportion	O
of	O
air	O
travelers	O
make	O
disproportionately	O
more	O
journeys	O
than	O
the	O
rest	B-FUNC
of	O
travelers	O
.	O

Using	O
an	O
epidemiologic	O
model	O
,	O
we	O
simulated	O
exportation	O
of	O
cases	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
and	O
influenza	O
-	O
like	O
epidemics	O
in	O
a	O
population	O
for	O
which	O
a	O
small	O
proportion	O
travel	O
more	O
frequently	O
than	O
the	O
rest	B-FUNC
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	O
A	O
(	O
HPAI	B-FUNC
)	O
subtype	O
H5N1	O
has	O
caused	O
family	O
case	O
clusters	O
,	O
mostly	O
in	O
Southeast	O
Asia	O
,	O
that	O
could	O
be	O
due	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

We	O
used	O
statistical	O
methods	O
to	O
test	O
whether	O
observed	O
clusters	O
of	O
HPAI	B-FUNC
(	O
H5N1	O
)	O
illnesses	O
in	O
families	O
in	O
northern	O
Sumatra	O
,	O
Indonesia	O
,	O
and	O
eastern	O
Turkey	O
were	O
due	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

Effective	O
HPAI	B-FUNC
(	O
H5N1	O
)	O
surveillance	O
,	O
containment	O
response	O
,	O
and	O
field	O
evaluation	O
are	O
essential	O
to	O
monitor	O
and	O
contain	O
potential	O
pandemic	O
strains	O
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	O
CoVs	O
and	O
their	O
hosts	O
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
and	O
the	O
bat	O
cytochrome	B-FUNC
b	O
gene	O
.	O

ABSTRACT	O
:	O
Hybrid	O
hybridomas	O
(	O
quadromas	O
)	O
are	O
derived	O
by	O
fusing	O
at	O
least	O
two	O
hybridomas	O
,	O
each	O
producing	O
a	O
different	O
antibody	B-FUNC
of	O
predefined	O
specificity	O
.	O

The	O
column	O
matrix	O
has	O
the	O
ability	O
to	O
bind	B-FUNC
to	O
proteins	O
such	O
as	O
HRPO	O
with	O
vicinal	O
diols	O
.	O

The	O
presence	O
of	O
anti	O
-	O
HRPO	O
MAb	O
is	O
an	O
acceptable	O
impurity	O
as	O
it	O
will	O
not	O
bind	B-FUNC
to	O
the	O
target	O
SARS	O
-	O
CoV	O
NP	O
antigen	O
and	O
will	O
get	O
washed	O
out	O
during	O
the	O
ELISA	O
procedure	O
.	O

Neutrophils	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
ALI	O
/	O
ARDS	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
interleukin	O
-	O
8	O
)	O
has	O
been	O
identified	O
as	O
the	O
main	O
chemotactic	O
factor	O
for	O
neutrophils	O
in	O
lung	O
fluids	O
of	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

Significantly	O
,	O
studies	O
from	O
our	O
laboratory	O
have	O
revealed	O
the	O
presence	O
of	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
autoantibody	O
:	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
immune	O
complexes	O
in	O
lung	O
fluids	O
from	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

In	O
this	O
review	O
,	O
the	O
significance	O
of	O
the	O
latter	O
findings	O
are	O
explored	O
,	O
and	O
the	O
possible	O
involvement	O
of	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
autoantibody	O
:	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
immune	O
complexes	O
in	O
pathogenesis	O
of	O
ALI	O
/	O
ARDS	O
is	O
discussed	O
.	O

The	O
pIRES	O
-	O
S1	O
,	O
pIRES	O
-	O
IL2	O
and	O
pIRES	O
-	O
S1	O
/	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
plasmid	O
expressing	O
or	O
co	O
-	O
expressing	O
S1	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
gene	O
were	O
constructed	O
.	O

The	O
results	O
showed	O
that	O
coadministration	O
of	O
a	O
plasmid	O
expressing	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
with	O
the	O
S1	O
DNA	O
vaccine	O
led	O
to	O
only	O
a	O
marginal	O
increase	O
in	O
humoral	O
and	O
T	O
cell	O
responses	O
.	O

The	O
protective	O
efficacy	O
could	O
be	O
significantly	O
enhanced	O
after	O
injection	O
with	O
plasmids	O
pIRES	O
-	O
S1	O
/	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
or	O
pIRES	O
-	O
S1	O
+	O
pIRES	O
-	O
IL2	O
.	O

These	O
results	O
demonstrate	O
that	O
bicistronic	O
DNA	O
vaccine	O
containing	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
elicit	O
remarkably	O
immune	O
responses	O
and	O
suggest	O
that	O
optimal	O
humoral	O
and	O
cellular	O
responses	O
priming	O
requires	O
the	O
precise	O
temporal	O
and	O
spatial	O
codelivery	O
of	O
Ag	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
.	O

Base	B-FUNC
pairing	I-FUNC
between	O
the	O
leader	O
TRS	B-FUNC
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
the	O
complement	O
of	O
the	O
body	O
TRS	B-FUNC
(	O
cTRS	O
-	O
B	O
)	O
in	O
the	O
nascent	O
RNA	O
is	O
a	O
determinant	O
factor	O
during	O
CoV	O
transcription	O
.	O

The	O
binding	B-FUNC
of	O
S1188HA	O
was	O
not	O
affected	O
by	O
depleting	O
plasma	O
membrane	O
cholesterol	O
.	O

Despite	O
their	O
relative	O
seclusion	O
from	O
the	O
rest	B-FUNC
of	O
the	O
world	O
,	O
cats	O
and	O
dogs	O
of	O
Isabela	O
were	O
exposed	O
to	O
many	O
pathogens	O
found	O
in	O
mainland	O
South	O
America	O
.	O

While	O
the	O
upper	O
region	O
of	O
SL1	O
is	O
required	O
to	O
be	O
paired	O
,	O
we	O
observe	O
strong	O
genetic	O
selection	O
against	O
viruses	O
that	O
contain	O
a	O
deletion	O
of	O
A35	O
,	O
an	O
extrahelical	O
nucleotide	O
that	O
destabilizes	O
SL1	O
,	O
in	O
favor	O
of	O
genomes	O
that	O
contain	O
a	O
diverse	O
panel	O
of	O
destabilizing	O
second	O
-	O
site	O
mutations	O
,	O
due	O
to	O
introduction	O
of	O
a	O
noncanonical	O
base	B-FUNC
pair	I-FUNC
near	O
A35	O
.	O

We	O
propose	O
a	O
""""	O
dynamic	O
SL1	O
""""	O
model	O
,	O
in	O
which	O
the	O
base	O
of	O
SL1	O
has	O
an	O
optimized	O
lability	O
required	O
to	O
mediate	O
a	O
physical	B-FUNC
interaction	I-FUNC
between	O
the	O
5	O
'	O
UTR	O
and	O
the	O
3	O
'	O
UTR	O
that	O
stimulates	O
subgenomic	O
RNA	O
synthesis	O
.	O

The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
an	O
important	O
target	O
in	O
developing	O
safe	O
and	O
effective	O
SARS	O
vaccines	O
.	O

TITLE	O
:	O
Aryl	O
methylene	O
ketones	O
and	O
fluorinated	O
methylene	O
ketones	O
as	O
reversible	O
inhibitors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
depends	O
on	O
a	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinase	B-FUNC
(	O
3CL	O
(	O
pro	O
))	O
to	O
process	O
the	O
translated	O
polyproteins	O
to	O
functional	O
viral	O
proteins	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
critical	O
homeostasis	O
regulator	O
GADD34	O
,	O
which	O
recruits	O
protein	O
phosphatase	B-FUNC
1	O
to	O
dephosphorylate	O
eIF2alpha	O
during	O
the	O
recovery	O
phase	O
of	O
the	O
UPR	O
,	O
is	O
not	O
expressed	O
during	O
MHV	O
infection	O
.	O

Elevated	O
concentrations	O
of	O
the	O
proinflammatory	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
in	O
both	O
plasma	O
and	O
the	O
pulmonary	O
edema	O
fluid	O
,	O
suggested	O
a	O
possible	O
role	O
of	O
systemic	O
and	O
pulmonary	O
inflammation	O
in	O
the	O
development	O
of	O
this	O
acute	O
pulmonary	O
capillary	O
leak	O
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
gene	O
polymorphisms	O
with	O
the	O
occurrence	O
of	O
SARS	O
-	O
CoV	O
infection	O
and	O
its	O
role	O
in	O
prognosis	O
of	O
patients	O
with	O
lung	O
interstitial	O
fibrosis	O
and	O
femoral	O
head	O
osteonecrosis	O
.	O

We	O
have	O
identified	O
6MP	O
and	O
6TG	O
as	O
reversible	O
and	O
slow	O
-	O
binding	B-FUNC
inhibitors	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
which	O
is	O
the	O
first	O
report	O
about	O
small	O
molecule	O
reversible	O
inhibitors	O
of	O
PLpro	O
.	O

Our	O
objective	O
was	O
to	O
study	O
amiodarone	O
uptake	O
,	O
clarify	O
the	O
origin	O
of	O
vacuoles	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
amiodarone	O
on	O
the	O
life	O
cycle	O
of	O
the	O
coronavirus	O
responsible	O
for	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
),	O
which	O
,	O
to	O
enter	O
cells	O
,	O
relies	O
on	O
the	O
proteolytic	O
cleavage	O
of	O
a	O
viral	O
spike	O
protein	O
by	O
the	O
endosomal	O
proteinase	B-FUNC
cathepsin	O
L	O
.	O
Using	O
alveolar	O
macrophages	O
,	O
we	O
studied	O
uptake	O
of	O
(	O
125	O
)	O
I	O
-	O
amiodarone	O
and	O
(	O
125	O
)	O
I	O
-	O
B2	O
,	O
an	O
analog	O
lacking	O
the	O
lateral	O
group	O
diethylamino	O
-	O
beta	O
-	O
ethoxy	O
,	O
and	O
analyzed	O
the	O
effects	O
of	O
amiodarone	O
on	O
the	O
distribution	O
of	O
endosomal	O
markers	O
and	O
on	O
the	O
uptake	O
of	O
an	O
acidotropic	O
dye	O
.	O

H2S	O
also	O
inhibited	O
IL	O
(	O
interleukin	O
)-	O
1beta	O
levels	O
and	O
significantly	O
increased	O
the	O
concentration	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
lung	O
tissue	O
.	O

Two	O
of	O
the	O
peptides	O
D07	O
(	O
residues	O
927	O
-	O
937	O
)	O
and	O
D08	O
(	O
residues	O
942	O
-	O
951	O
)	O
were	O
recognized	O
by	O
the	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Another	O
peptide	O
D10	O
(	O
residues	O
490	O
-	O
502	O
)	O
stimulated	O
A549	O
to	O
proliferate	O
and	O
secrete	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

By	O
contrast	O
,	O
chemokines	O
such	O
as	O
IP	O
-	O
10	O
or	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
are	O
strongly	O
upregulated	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ELISA	O
antibody	B-FUNC
levels	O
elicited	O
by	O
either	O
monocistronic	O
or	O
bicistronic	O
DNA	O
vaccines	O
.	O

The	O
ratio	O
of	O
IFN	O
-	O
gamma	O
/	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
in	O
liver	O
decreased	O
in	O
L2	O
-	O
MHV3	O
-	O
infected	O
mice	O
,	O
while	O
it	O
was	O
not	O
(	O
or	O
low	O
)	O
altered	O
in	O
mice	O
infected	O
with	O
the	O
attenuated	O
MHV3	O
variant	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
viral	O
permissivity	O
of	O
KC	O
and	O
LSEC	O
is	O
involved	O
in	O
the	O
decrease	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
PGE2	O
,	O
while	O
KC	O
may	O
play	O
an	O
additional	O
role	O
in	O
the	O
apoptosis	O
of	O
NK	O
and	O
NK	O
T	O
cells	O
during	O
acute	O
viral	O
hepatitis	O
.	O

TITLE	O
:	O
Structural	O
,	O
biochemical	O
,	O
and	O
in	O
vivo	O
characterization	O
of	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-FUNC
from	O
the	O
Mimivirus	O
.	O

Additionally	O
mimicyp	O
lacks	O
peptidyl	O
-	O
prolyl	O
isomerase	B-FUNC
activity	I-FUNC
in	O
contrast	O
to	O
human	O
cyclophilins	O
.	O

TITLE	O
:	O
Identification	O
of	O
residues	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
protein	O
of	O
human	O
coronavirus	O
NL63	O
that	O
are	O
critical	O
for	O
the	O
RBD	O
-	O
ACE2	O
receptor	O
interaction	O
.	O

The	O
data	O
also	O
demonstrated	O
that	O
the	O
NL63	O
RBD	O
bound	O
to	O
hACE2	O
more	O
efficiently	O
than	O
its	O
full	O
-	O
length	O
counterpart	O
and	O
had	O
a	O
binding	B-FUNC
efficiency	O
comparable	O
to	O
the	O
S1	O
or	O
RBD	O
of	O
SARS	O
-	O
CoV	O
.	O
A	O
further	O
series	O
of	O
RBD	O
variants	O
was	O
generated	O
using	O
site	O
-	O
directed	O
mutagenesis	O
and	O
random	O
mutant	O
library	O
screening	O
assays	O
,	O
and	O
identified	O
15	O
residues	O
(	O
C497	O
,	O
Y498	O
,	O
V499	O
,	O
C500	O
,	O
K501	O
,	O
R518	O
,	O
R530	O
,	O
V531	O
,	O
G534	O
,	O
G537	O
,	O
D538	O
,	O
S540	O
,	O
E582	O
,	O
W585	O
and	O
T591	O
)	O
that	O
appeared	O
to	O
be	O
critical	O
for	O
the	O
RBD	O
-	O
hACE2	O
association	O
.	O

These	O
critical	O
residues	O
clustered	O
in	O
three	O
separate	O
regions	O
(	O
designated	O
RI	O
,	O
RII	O
and	O
RIII	O
)	O
inside	O
the	O
RBD	O
,	O
which	O
may	O
represent	O
three	O
receptor	O
-	O
binding	B-FUNC
sites	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
with	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
is	O
enhanced	O
in	O
the	O
presence	O
of	O
anti	O
-	O
FIPV	O
antibodies	O
(	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
or	O
ADE	O
).	O

Both	O
recombinant	O
viruses	O
stably	O
expressed	O
the	O
corresponding	O
SARS	O
-	O
CoV	O
proteins	O
,	O
grew	O
to	O
similar	O
end	O
titres	O
as	O
the	O
parental	O
strain	O
and	O
induced	O
high	O
antibody	B-FUNC
titres	O
against	O
MV	O
and	O
the	O
vectored	O
SARS	O
-	O
CoV	O
antigens	O
(	O
S	O
and	O
N	O
)	O
in	O
transgenic	O
mice	O
susceptible	O
to	O
measles	O
infection	O
.	O

No	O
significant	O
temporal	O
trends	O
in	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
transforming	O
growth	O
factor	O
-	O
beta1	O
,	O
sFasL	O
,	O
or	O
complement	O
factor	O
5a	O
were	O
found	O
.	O

In	O
smoke	O
inhalation	O
victims	O
,	O
tracheobronchial	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
increase	O
rapidly	O
and	O
high	O
initial	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
may	O
predict	O
improved	O
oxygenation	O
.	O

TITLE	O
:	O
Effects	O
of	O
different	O
immunization	O
protocols	O
and	O
adjuvant	O
on	O
antibody	B-FUNC
responses	O
to	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

With	O
an	O
intraperitoneal	O
(	O
IP	O
)	O
immunization	O
protocol	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
alone	O
induced	O
significant	O
amounts	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
antibodies	O
in	O
sera	B-FUNC
and	O
a	O
small	O
quantity	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
the	O
genital	O
tract	O
and	O
feces	O
,	O
but	O
failed	O
to	O
induce	O
any	O
detectable	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
sera	B-FUNC
,	O
saliva	O
,	O
lung	O
,	O
and	O
intestine	O
,	O
and	O
the	O
addition	O
of	O
CpG	O
ODN	O
2006	O
had	O
only	O
a	O
marginal	O
effect	O
on	O
antibody	B-FUNC
production	O
.	O

In	O
contrast	O
,	O
with	O
an	O
intranasal	O
(	O
IN	O
)	O
immunization	O
protocol	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
alone	O
failed	O
to	O
induce	O
any	O
detectable	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
sera	B-FUNC
,	O
saliva	O
,	O
lung	O
,	O
and	O
intestine	O
,	O
except	O
for	O
a	O
small	O
quantity	O
of	O
IgA	O
antibodies	O
in	O
fecal	O
extracts	O
and	O
the	O
genital	O
tract	O
,	O
along	O
with	O
IgG	O
antibodies	O
in	O
sera	B-FUNC
,	O
but	O
when	O
given	O
with	O
adjuvant	O
CpG	O
ODN	O
2006	O
,	O
inactivated	O
SARS	O
-	O
CoV	O
induced	O
significant	O
amounts	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgG	O
antibodies	O
in	O
sera	B-FUNC
,	O
and	O
a	O
detectable	O
amount	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgA	O
antibodies	O
in	O
sera	B-FUNC
and	O
all	O
tested	O
mucosal	O
secretions	O
and	O
tissues	O
(	O
i	O
.	O
e	O
.,	O
saliva	O
,	O
the	O
genital	O
tract	O
,	O
fecal	O
extract	O
,	O
lung	O
,	O
and	O
intestine	O
).	O

On	O
a	O
neutralization	O
assay	O
,	O
neutralizing	O
activity	O
with	O
the	O
IP	O
immunization	O
protocol	O
was	O
detected	O
in	O
sera	B-FUNC
and	O
mucosal	O
secretions	O
(	O
from	O
the	O
saliva	O
and	O
genital	O
tract	O
),	O
but	O
sera	B-FUNC
from	O
the	O
IN	O
protocol	O
failed	O
to	O
show	O
any	O
neutralizing	O
activity	O
.	O

Higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
intercellular	O
adhesion	O
molecule	O
1	O
were	O
independently	O
predictive	O
of	O
worse	O
outcomes	O
(	O
odds	O
ratio	O
=	O
2	O
.	O
0	O
and	O
5	O
.	O
8	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
04	O
for	O
both	O
).	O

In	O
spleen	O
samples	O
of	O
IBV	O
-	O
infected	O
animals	O
reduced	O
expression	O
of	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
and	O
IFN	O
-	O
gamma	O
mRNA	O
was	O
found	O
1dpi	O
.	O

TITLE	O
:	O
Reduced	O
incorporation	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
into	O
viral	O
particles	O
due	O
to	O
amino	O
acid	O
substitutions	O
within	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
.	O

Further	O
mutational	O
experiments	O
identified	O
two	O
substitutions	O
,	O
Y442C	O
and	O
L472F	O
,	O
within	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
that	O
could	O
be	O
critical	O
for	O
the	O
reduced	O
S	O
incorporation	O
,	O
as	O
well	O
as	O
reduced	O
binding	B-FUNC
affinity	O
between	O
the	O
S	O
protein	O
and	O
ACE2	O
receptor	O
.	O

Using	O
recombinant	O
protein	O
domains	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
we	O
identified	O
two	O
additional	O
RNA	O
-	O
binding	B-FUNC
domains	O
of	O
nsp3	O
.	O

We	O
also	O
identified	O
a	O
novel	O
cysteine	O
-	O
coordinated	O
metal	O
ion	O
-	O
binding	B-FUNC
domain	O
.	O

The	O
plasma	O
nitrate	O
/	O
nitrite	O
,	O
methylguanidine	O
,	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
interleukin	O
-	O
1beta	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
interleukin	O
-	O
10	O
),	O
neutrophil	O
elastase	O
,	O
myeloperoxidase	O
,	O
malondialdehyde	O
,	O
and	O
sodium	O
-	O
and	O
potassium	O
-	O
activated	O
adenosine	O
triphosphatase	O
(	O
Na	O
+-	O
K	O
+-	O
ATPase	O
)	O
were	O
detected	O
.	O

It	O
depressed	O
the	O
Na	O
+-	O
K	O
+-	O
ATPase	B-FUNC
activity	I-FUNC
but	O
up	O
-	O
regulated	O
inducible	O
nitric	O
oxide	O
synthase	O
.	O

On	O
immunofluorescent	O
antibody	B-FUNC
assay	O
and	O
Western	O
blotting	O
analysis	O
,	O
none	O
of	O
the	O
monoclonal	O
antibodies	O
showed	O
cross	O
-	O
reactivity	O
to	O
authentic	O
and	O
recombinant	O
NPs	O
of	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
strain	O
.	O

To	O
determine	O
the	O
region	O
on	O
the	O
NP	O
molecule	O
where	O
the	O
monoclonal	O
antibodies	O
bind	B-FUNC
,	O
we	O
generated	O
four	O
truncated	O
recombinant	O
NPs	O
and	O
analyzed	O
the	O
reactivity	O
between	O
monoclonal	O
antibodies	O
and	O
truncated	O
NPs	O
.	O

Epitope	O
mapping	O
analysis	O
indicated	O
that	O
monoclonal	O
antibody	B-FUNC
SN5	O
-	O
25	O
recognized	O
the	O
amino	O
acid	O
sequence	O
Q	O
(	O
245	O
)	O
TVTKK	O
(	O
250	O
)	O
On	O
SARS	O
-	O
NP	O
.	O

Within	O
the	O
epitope	O
,	O
Q245	O
,	O
T246	O
,	O
V247	O
,	O
K249	O
,	O
and	O
K250	O
appeared	O
to	O
form	O
an	O
essential	O
motif	O
for	O
monoclonal	O
antibody	B-FUNC
SN5	O
-	O
25	O
to	O
bind	B-FUNC
.	O

The	O
information	O
about	O
binding	B-FUNC
sites	O
and	O
epitopes	O
of	O
monoclonal	O
antibodies	O
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
new	O
diagnostic	O
methods	O
for	O
SARS	O
and	O
for	O
analyzing	O
the	O
function	O
of	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O

Subsequent	O
testing	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
confirmed	O
HCoV	O
-	O
OC43	O
infection	O
.	O

Notably	O
,	O
sera	B-FUNC
demonstrated	O
cross	O
-	O
reactivity	O
against	O
nucleocapsid	O
peptide	O
sequences	O
common	O
to	O
HCoV	O
-	O
OC43	O
and	O
SARS	O
-	O
CoV	O
.	O

The	O
competitive	O
inhibition	O
of	O
the	O
sense	O
peptide	O
in	O
the	O
competitive	O
ELISA	O
reveals	O
the	O
affinity	O
binding	B-FUNC
between	O
the	O
DP	O
and	O
SARS	O
S	O
protein	O
is	O
specific	O
and	O
directed	O
towards	O
the	O
target	O
SP	O
of	O
the	O
S	O
protein	O
.	O

The	O
introduction	O
of	O
the	O
T10651C	O
mutation	O
into	O
the	O
infectious	O
MHV	O
clone	O
resulted	O
in	O
the	O
recovery	O
of	O
a	O
mutant	O
virus	O
,	O
the	O
nsp5	O
/	O
V148A	O
virus	O
,	O
that	O
demonstrated	O
reduced	O
growth	O
and	O
nsp5	O
proteinase	B-FUNC
activity	I-FUNC
identical	O
to	O
that	O
of	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

To	O
investigate	O
whether	O
and	O
which	O
structural	O
protein	O
of	O
SARS	O
-	O
CoV	O
induced	O
transcription	O
of	O
hfgl2	O
prothrombinase	O
gene	O
,	O
three	O
eukaryotic	O
expression	O
plasmids	O
expressing	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
membrane	O
protein	O
(	O
M	O
)	O
and	O
spike	O
protein	O
2	O
(	O
S2	O
)	O
of	O
SARS	O
-	O
CoV	O
were	O
co	O
-	O
transfected	O
with	O
hfgl2	O
promoter	O
luciferase	O
-	O
reporter	O
plasmids	O
and	O
beta	O
-	O
galactosidase	O
plasmid	O
in	O
CHO	B-FUNC
cells	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Real	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
is	O
now	O
used	O
commonly	O
for	O
the	O
detection	O
of	O
viral	O
pathogens	O
in	O
respiratory	O
samples	O
.	O

We	O
found	O
that	O
the	O
vaccine	O
given	O
intramuscularly	O
induced	O
a	O
neutralizing	O
antibody	B-FUNC
response	O
to	O
SARS	O
-	O
CoV	O
that	O
was	O
approximately	O
ten	O
-	O
fold	O
greater	O
than	O
that	O
required	O
for	O
the	O
protection	O
from	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
significantly	O
greater	O
than	O
that	O
generated	O
by	O
the	O
replication	O
-	O
competent	O
vector	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	O
given	O
by	O
the	O
same	O
route	O
.	O

The	O
binding	B-FUNC
of	O
coronaviruses	O
to	O
the	O
cell	O
surface	O
is	O
mediated	O
by	O
the	O
viral	O
surface	O
protein	O
S	O
.	O
Recently	O
we	O
demonstrated	O
that	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	O
acid	O
serves	O
as	O
a	O
receptor	O
determinant	O
for	O
IBV	O
on	O
Vero	O
cells	O
and	O
primary	O
chicken	O
embryo	O
kidney	O
cells	O
.	O

Here	O
we	O
analyze	O
the	O
importance	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
for	O
the	O
infection	O
of	O
tracheal	O
organ	O
cultures	O
(	O
TOCs	O
)	O
by	O
different	O
IBV	O
strains	O
.	O

TITLE	O
:	O
Cleavage	O
of	O
group	O
1	O
coronavirus	O
spike	O
proteins	O
:	O
how	O
furin	O
cleavage	O
is	O
traded	O
off	O
against	O
heparan	B-FUNC
sulfate	I-FUNC
binding	I-FUNC
upon	O
cell	O
culture	O
adaptation	O
.	O

TITLE	O
:	O
Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
in	O
the	O
serum	O
and	O
effusions	O
of	O
cats	O
with	O
feline	O
coronavirus	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
quantify	O
and	O
compare	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
concentrations	O
in	O
the	O
serum	O
of	O
clinically	O
normal	O
cats	O
infected	O
with	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
with	O
its	O
concentration	O
in	O
the	O
sera	B-FUNC
and	O
effusions	O
of	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
a	O
disease	O
associated	O
with	O
infection	O
with	O
a	O
mutated	O
form	O
of	O
FCoV	O
.	O
Clinically	O
normal	O
FCoV	O
-	O
infected	O
cats	O
living	O
in	O
catteries	O
with	O
a	O
high	O
prevalence	O
of	O
FIP	O
had	O
the	O
highest	O
serum	O
IFN	O
-	O
gamma	O
concentrations	O
.	O

TITLE	O
:	O
Heteroaromatic	O
ester	O
inhibitors	O
of	O
hepatitis	O
A	O
virus	O
3C	O
proteinase	B-FUNC
:	O
Evaluation	O
of	O
mode	O
of	O
action	O
.	O

ABSTRACT	O
:	O
The	O
related	O
3C	O
and	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3C	O
(	O
pro	O
)	O
and	O
3CL	O
(	O
pro	O
))	O
of	O
picornaviruses	O
and	O
coronaviruses	O
,	O
respectively	O
,	O
are	O
good	O
drug	O
targets	O
.	O

As	O
part	O
of	O
an	O
effort	O
to	O
generate	O
broad	O
-	O
spectrum	O
inhibitors	O
of	O
these	O
enzymes	O
,	O
we	O
screened	O
a	O
library	O
of	O
inhibitors	O
based	O
on	O
a	O
halopyridinyl	O
ester	O
from	O
a	O
previous	O
study	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
3CL	O
proteinase	B-FUNC
against	O
Hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
3C	O
(	O
pro	O
).	O

Modeling	O
studies	O
indicated	O
that	O
the	O
halopyridinyl	O
moiety	O
of	O
the	O
inhibitor	O
fits	O
tightly	O
into	O
the	O
S1	O
-	O
binding	B-FUNC
pocket	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
tolerance	O
of	O
the	O
inhibitors	O
to	O
modification	O
in	O
this	O
portion	O
of	O
the	O
molecule	O
.	O

TITLE	O
:	O
Coronavirus	O
nonstructural	O
protein	O
16	O
is	O
a	O
cap	O
-	O
0	O
binding	B-FUNC
enzyme	O
possessing	O
(	O
nucleoside	O
-	O
2	O
'	O
O	O
)-	O
methyltransferase	B-FUNC
activity	I-FUNC
.	O

Purified	O
recombinant	O
FCoV	O
nsp16	O
selectively	O
binds	B-FUNC
to	O
short	O
capped	O
RNAs	O
.	O

Remarkably	O
,	O
an	O
N7	O
-	O
methyl	O
guanosine	O
cap	O
((	O
7Me	O
)	O
GpppAC	O
(	O
3	O
-	O
6	O
))	O
is	O
a	O
prerequisite	O
for	O
binding	B-FUNC
.	O

Furthermore	O
,	O
residues	O
Y29	O
and	O
F173	O
of	O
FCoV	O
nsp16	O
,	O
which	O
may	O
be	O
the	O
functional	O
counterparts	O
of	O
aromatic	O
residues	O
involved	O
in	O
substrate	O
recognition	O
by	O
the	O
vaccinia	O
virus	O
MTase	O
VP39	O
,	O
were	O
found	O
to	O
be	O
essential	O
for	O
both	O
substrate	O
binding	B-FUNC
and	O
2	O
'	O
O	O
-	O
MTase	O
activity	O
.	O

Finally	O
,	O
the	O
weak	O
inhibition	O
profile	O
of	O
different	O
AdoMet	O
analogues	O
indicates	O
that	O
nsp16	O
has	O
evolved	O
an	O
atypical	O
AdoMet	O
binding	B-FUNC
site	O
.	O

ABSTRACT	O
:	O
Conjugation	O
or	O
deconjugation	O
of	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
or	O
ubiquitin	B-FUNC
-	O
like	O
proteins	O
(	O
UBLs	O
)	O
to	O
or	O
from	O
cellular	O
proteins	O
is	O
a	O
multifaceted	O
and	O
universal	O
means	O
of	O
regulating	O
cellular	O
physiology	O
,	O
controlling	O
the	O
lifetime	O
,	O
localization	O
,	O
and	O
activity	O
of	O
many	O
critical	O
proteins	O
.	O

Isopeptidase	B-FUNC
activity	I-FUNC
releases	O
PLA	O
(	O
2	O
),	O
which	O
cleaves	O
its	O
substrate	O
,	O
generating	O
a	O
signal	O
that	O
is	O
linear	O
with	O
deubiquitylase	B-FUNC
(	O
DUB	B-FUNC
)	O
concentration	O
and	O
is	O
able	O
to	O
discriminate	O
DUB	B-FUNC
,	O
deSUMOylase	O
,	O
deNEDDylase	O
,	O
and	O
deISGylase	O
activities	O
.	O

Furthermore	O
,	O
direct	O
comparisons	O
with	O
the	O
current	O
Ub	O
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
(	O
Ub	O
-	O
AMC	O
)	O
assay	O
demonstrated	O
that	O
the	O
Ub	O
-	O
PLA	O
(	O
2	O
)	O
assay	O
is	O
an	O
effective	O
tool	O
for	O
characterizing	O
modulators	O
of	O
isopeptidase	B-FUNC
activity	I-FUNC
.	O

Taken	O
together	O
,	O
these	O
studies	O
illustrate	O
the	O
utility	O
of	O
the	O
reporter	O
-	O
based	O
approach	O
to	O
measuring	O
isopeptidase	B-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
A	O
new	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
),	O
CCV2	O
-	O
2	O
,	O
was	O
compared	O
with	O
the	O
widely	O
used	O
FIPV3	O
-	O
70	O
mAb	O
,	O
both	O
directed	O
against	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
as	O
a	O
diagnostic	O
and	O
research	O
tool	O
.	O

Immunohistochemically	O
,	O
all	O
cases	O
were	O
positive	O
for	O
coronavirus	O
antigen	O
using	O
monoclonal	O
antibody	B-FUNC
FIPV3	O
-	O
70	O
.	O

Histopathological	O
and	O
immunohistochemical	O
stains	O
were	O
employed	O
using	O
specific	O
antibody	B-FUNC
for	O
O	O
.	O
tsutsugamushi	O
and	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
).	O

HEPIS	O
interacted	O
specifically	O
with	O
the	O
HSP70	O
TATA	O
sequence	O
,	O
and	O
not	O
with	O
various	O
other	O
enhancer	O
elements	O
in	O
a	O
binding	B-FUNC
test	O
.	O

The	O
mean	O
summation	O
PAH	B-FUNC
levels	O
in	O
the	O
waste	O
ashes	O
varied	O
widely	O
from	O
4	O
.	O
16	O
mg	O
kg	O
(-	O
1	O
)	O
to	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
),	O
and	O
the	O
mean	O
amounts	O
of	O
carcinogenic	O
PAHs	O
ranged	O
from	O
0	O
.	O
74	O
to	O
96	O
.	O
77	O
mg	O
kg	O
(-	O
1	O
),	O
exceeding	O
the	O
limits	O
regulated	O
by	O
several	O
countries	O
.	O

Among	O
the	O
three	O
types	O
of	O
incinerators	O
,	O
two	O
medium	O
-	O
scale	O
incinerators	O
generated	O
relatively	O
high	O
levels	O
of	O
PAHs	O
(	O
mean	O
summation	O
PAH	B-FUNC
22	O
.	O
50	O
and	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
))	O
compared	O
to	O
small	O
-	O
scale	O
and	O
large	O
-	O
scale	O
incinerators	O
(	O
mean	O
summation	O
PAH	B-FUNC
4	O
.	O
16	O
and	O
16	O
.	O
43	O
mg	O
kg	O
(-	O
1	O
)).	O

Bottom	O
ashes	O
were	O
dominated	O
by	O
low	O
molecular	O
weight	O
PAHs	O
(	O
LM	O
-	O
PAH	B-FUNC
;	O
containing	O
two	O
-	O
to	O
three	O
-	O
ringed	O
PAHs	O
)	O
and	O
medium	O
molecular	O
weight	O
PAHs	O
(	O
MM	O
-	O
PAH	B-FUNC
;	O
containing	O
four	O
-	O
ringed	O
PAHs	O
),	O
while	O
fly	O
ashes	O
were	O
abundant	O
in	O
MM	O
-	O
PAH	B-FUNC
and	O
high	O
molecular	O
weight	O
PAHs	O
(	O
HM	O
-	O
PAH	B-FUNC
,	O
containing	O
five	O
-	O
to	O
six	O
-	O
ringed	O
PAHs	O
).	O

Moreover	O
,	O
it	O
was	O
found	O
that	O
PAHs	O
in	O
the	O
ashes	O
correlated	O
highly	O
with	O
some	O
metallic	O
elements	O
either	O
positively	O
(	O
e	O
.	O
g	O
.	O
Fe	O
,	O
Ti	O
,	O
Mg	O
)	O
or	O
negatively	O
(	O
Ca	O
),	O
indicating	O
that	O
these	O
elements	O
might	O
promote	O
or	O
prevent	O
PAH	B-FUNC
formation	O
during	O
HW	O
combustion	O
.	O

In	O
this	O
study	O
,	O
three	O
fragments	O
[	O
N1	O
(	O
residues	O
:	O
1	O
-	O
422	O
);	O
N2	O
(	O
residues	O
:	O
1	O
-	O
109	O
);	O
N3	O
(	O
residues	O
:	O
110	O
-	O
422	O
)]	O
of	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
analyzed	O
by	O
pooled	O
sera	B-FUNC
of	O
convalescence	O
phase	O
of	O
SARS	O
patients	O
.	O

Results	O
showed	O
that	O
N1	O
and	O
N3	O
fragments	O
of	O
N	O
protein	O
expressed	O
by	O
E	O
.	O
coli	O
were	O
able	O
to	O
react	O
with	O
sera	B-FUNC
of	O
SARS	O
patients	O
but	O
N2	O
could	O
not	O
.	O

In	O
addition	O
,	O
the	O
immune	O
response	O
levels	O
in	O
N3	O
were	O
significantly	O
higher	O
for	O
antibody	B-FUNC
responses	O
(	O
IgG	O
and	O
IgG1	O
but	O
not	O
IgG2a	O
)	O
and	O
cell	O
proliferation	O
but	O
not	O
in	O
CD4	O
(+):	O
CD8	O
(+)	O
assay	O
compared	O
to	O
N1	O
vaccine	O
.	O

TITLE	O
:	O
Heme	O
oxygenase	B-FUNC
-	O
1	O
upregulation	O
significantly	O
inhibits	O
TNF	O
-	O
alpha	O
and	O
Hmgb1	O
releasing	O
and	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

The	O
major	O
species	O
barriers	O
between	O
humans	O
and	O
civets	O
for	O
SARS	O
-	O
CoV	O
infections	O
are	O
the	O
specific	O
interactions	O
between	O
a	O
defined	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
a	O
viral	O
spike	O
protein	O
and	O
its	O
host	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

In	O
this	O
study	O
a	O
chimeric	O
ACE2	O
bearing	O
the	O
critical	O
N	O
-	O
terminal	O
helix	O
from	O
civet	O
and	O
the	O
remaining	O
peptidase	O
domain	O
from	O
human	O
was	O
constructed	O
,	O
and	O
it	O
was	O
shown	O
that	O
this	O
construct	O
has	O
the	O
same	O
receptor	B-FUNC
activity	I-FUNC
as	O
civet	O
ACE2	O
.	O

There	O
were	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
age	O
,	O
body	O
mass	O
index	O
,	O
length	O
of	O
stay	O
,	O
APACHE	O
II	O
score	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Multiple	O
-	O
factor	O
Logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
MODS	O
(	O
OR	O
=	O
67	O
.	O
358	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
APACHE	O
II	O
score	O
(	O
OR	O
=	O
9	O
.	O
716	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ACS	B-FUNC
(	O
OR	O
=	O
5	O
.	O
775	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
affecting	O
the	O
prognosis	O
of	O
SAP	O
during	O
its	O
early	O
stage	O
,	O
whereas	O
pancreatic	O
infection	O
(	O
OR	O
=	O
9	O
.	O
652	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
MODS	O
(	O
OR	O
=	O
5	O
.	O
212	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
celiac	O
hemorrhage	O
(	O
OR	O
=	O
4	O
.	O
707	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
during	O
the	O
advanced	O
stage	O
of	O
SAP	O
.	O

Multiple	O
-	O
factor	O
Logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
MODS	O
(	O
OR	O
=	O
67	O
.	O
358	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
APACHE	O
II	O
score	O
(	O
OR	O
=	O
9	O
.	O
716	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ACS	B-FUNC
(	O
OR	O
=	O
5	O
.	O
775	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
affecting	O
the	O
prognosis	O
of	O
SAP	O
during	O
its	O
early	O
stage	O
,	O
whereas	O
pancreatic	O
infection	O
(	O
OR	O
=	O
9	O
.	O
652	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
MODS	O
(	O
OR	O
=	O
5	O
.	O
212	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
celiac	O
hemorrhage	O
(	O
OR	O
=	O
4	O
.	O
707	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
during	O
the	O
advanced	O
stage	O
of	O
SAP	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	B-FUNC
(	O
Seegene	O
,	O
Korea	O
)	O
for	O
the	O
detection	O
of	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
).	O

Multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	B-FUNC
is	O
a	O
reliable	O
test	O
to	O
detect	O
rhinovirus	O
,	O
hMPV	O
,	O
and	O
coronavirus	O
.	O

The	O
culprit	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
detected	O
in	O
patient	O
specimens	O
by	O
traditional	O
cell	O
culture	O
using	O
an	O
unusual	O
cell	O
line	O
for	O
respiratory	O
viruses	O
,	O
Vero	O
E6	O
,	O
and	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
polymerase	O
1	O
B	O
region	O
of	O
the	O
genome	O
.	O

Plasma	O
cytokine	O
and	O
chemokine	O
profiles	O
showed	O
markedly	O
elevated	O
Th1	O
cytokine	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
,	O
inflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
neutrophil	O
chemokine	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
Th1	O
chemokine	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
for	O
at	O
least	O
two	O
weeks	O
after	O
disease	O
onset	O
,	O
but	O
there	O
was	O
no	O
significant	O
elevation	O
of	O
inflammatory	O
cytokine	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
and	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Corticosteroid	O
reduced	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
and	O
IP	O
-	O
10	O
concentrations	O
from	O
5	O
-	O
8	O
days	O
after	O
treatment	O
.	O

Hamsters	O
immunized	O
with	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
developed	O
high	O
serum	O
-	O
neutralizing	O
antibody	B-FUNC
titers	O
and	O
were	O
protected	O
from	O
replication	O
of	O
homologous	O
(	O
SARS	O
-	O
CoV	O
Urbani	O
)	O
and	O
heterologous	O
(	O
GD03	O
)	O
SARS	O
-	O
CoV	O
in	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
.	O

In	O
our	O
study	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
a	O
high	O
binding	B-FUNC
affinity	O
for	O
the	O
leader	O
sequence	O
of	O
SARS	O
-	O
CoV	O
genome	O
.	O

A	O
type	O
of	O
medium	O
or	O
low	O
titer	O
anti	O
-	O
lung	O
tissue	O
antibodies	O
were	O
found	O
in	O
the	O
sera	B-FUNC
of	O
SARS	O
patients	O
at	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

Anti	O
-	O
EN	O
antibody	B-FUNC
was	O
positive	O
in	O
the	O
sera	B-FUNC
of	O
40	O
.	O
9	O
%	O
of	O
SARS	O
patients	O
.	O

Adult	O
murine	O
lungs	O
,	O
which	O
had	O
significantly	O
higher	O
interleukin	O
(	O
IL	O
)-	O
4	O
and	O
lower	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
levels	O
before	O
infection	O
than	O
young	O
murine	O
lungs	O
,	O
rapidly	O
produced	O
high	O
levels	O
of	O
proinflammatory	O
chemokines	O
and	O
cytokines	O
known	O
to	O
induce	O
macrophage	O
and	O
neutrophil	O
infiltration	O
and	O
activation	O
(	O
eg	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
).	O

On	O
day	O
2	O
after	O
inoculation	O
,	O
young	O
murine	O
lungs	O
produced	O
not	O
only	O
proinflammatory	O
cytokines	O
but	O
also	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
.	O

However	O
,	O
intraperitoneal	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
injection	O
protected	O
adult	O
mice	O
from	O
the	O
lethal	O
respiratory	O
illness	O
.	O

The	O
genotypes	O
of	O
4SNPs	O
on	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
RB1	O
gene	O
,	O
+	O
705A	O
/	O
G	O
,+	O
1158T	O
/	O
C	O
,	O
+	O
1196G	O
/	O
C	O
and	O
+	O
1664	O
C	O
/	O
T	O
,	O
were	O
determined	O
by	O
PCR	O
-	O
RFLP	O
.	O

Moreover	O
,	O
it	O
caused	O
a	O
significant	O
increase	O
in	O
the	O
secretion	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
by	O
mouse	O
splenic	O
lymphocytes	O
.	O

In	O
the	O
anti	O
-	O
viral	O
aspect	O
,	O
HC	O
exhibited	O
significant	O
inhibitory	O
effects	O
on	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
and	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
).	O

The	O
distribution	O
of	O
viral	O
antigen	O
was	O
examined	O
by	O
immunohistochemical	O
labeling	O
using	O
the	O
15C5	O
anti	O
-	O
BVDV	O
monoclonal	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
identification	O
and	O
characterization	O
of	O
B	O
-	O
cell	O
epitopes	O
play	O
an	O
important	O
role	O
in	O
vaccine	O
design	O
,	O
immunodiagnostic	O
tests	O
,	O
and	O
antibody	B-FUNC
production	O
.	O

Chickens	O
immunized	O
with	O
the	O
H5N1	O
/	O
PR8	O
-	O
5B19	O
inactivated	O
vaccine	O
produced	O
high	O
levels	O
of	O
HI	O
antibody	B-FUNC
and	O
a	O
measurable	O
antibody	B-FUNC
response	O
against	O
the	O
MHV	O
5B19	O
epitope	O
,	O
and	O
were	O
fully	O
protected	O
against	O
subsequent	O
challenge	O
with	O
different	O
highly	O
pathogenic	O
H5N1	O
avian	O
influenza	O
viruses	O
.	O

H5N1	O
/	O
PR8	O
-	O
5B19	O
is	O
therefore	O
an	O
attractive	O
marker	O
vaccine	O
candidate	O
,	O
eliciting	O
a	O
strong	O
,	O
protective	O
antibody	B-FUNC
response	O
and	O
enabling	O
serological	O
discrimination	O
between	O
vaccinated	O
and	O
wild	O
-	O
type	O
virus	O
-	O
infected	O
chickens	O
.	O

The	O
second	O
antibody	B-FUNC
in	O
the	O
kit	B-FUNC
was	O
replaced	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
protein	O
-	O
A	O
(	O
HRP	O
-	O
SPA	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
binding	B-FUNC
between	O
Staphylococcus	O
aureus	O
protein	O
A	O
(	O
SPA	O
)	O
and	O
mammal	O
IgG	O
Fc	O
fragment	O
.	O

The	O
test	O
results	O
of	O
the	O
positive	O
and	O
negative	O
controls	O
in	O
the	O
kit	B-FUNC
and	O
the	O
serum	O
samples	O
from	O
convalescent	O
;	O
patient	O
were	O
consistent	O
with	O
expectation	O
.	O

CONCLUSIONS	O
:	O
This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	B-FUNC
in	O
bat	O
sera	B-FUNC
.	O

The	O
lung	O
superoxide	O
dismutase	O
(	O
SOD	B-FUNC
),	O
catalase	O
and	O
glutathione	O
peroxidase	O
activities	O
were	O
decreased	O
in	O
the	O
sepsis	O
group	O
as	O
compared	O
to	O
the	O
group	O
control	O
,	O
sham	O
,	O
leflunomide	O
and	O
sepsis	O
+	O
leflunomide	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
SOD	B-FUNC
activity	O
were	O
significantly	O
higher	O
in	O
group	O
sepsis	O
+	O
leflunomide	O
than	O
sham	O
,	O
control	O
,	O
leflunomide	O
and	O
sepsis	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

A	O
DNA	O
prime	O
-	O
protein	O
boost	O
strategy	O
greatly	O
enhanced	O
the	O
antibody	B-FUNC
generation	O
and	O
the	O
immune	O
sera	B-FUNC
not	O
only	O
reacted	O
with	O
the	O
lysates	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	O
but	O
also	O
neutralized	O
the	O
cytopathic	O
effect	O
of	O
SARS	O
by	O
75	O
%	O
at	O
1	O
:	O
160	O
dilution	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
validate	O
nephelometric	O
methods	O
for	O
CSF	O
protein	O
analysis	O
,	O
and	O
to	O
use	O
the	O
Q	O
(	O
alb	O
)	O
and	O
IgG	O
index	O
to	O
discriminate	O
blood	O
-	O
and	O
brain	O
-	O
derived	O
immunoglobulin	B-FUNC
fractions	O
in	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

Cats	O
with	O
higher	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibody	B-FUNC
titers	O
were	O
significantly	O
more	O
likely	O
to	O
shed	O
virus	O
,	O
while	O
cats	O
with	O
lower	O
titers	O
were	O
significantly	O
less	O
likely	O
to	O
be	O
shedding	O
.	O

The	O
peptide	O
is	O
deeply	O
anchored	O
in	O
the	O
B	O
and	O
F	O
pockets	O
,	O
but	O
with	O
the	O
Glu4	O
residue	O
pointing	O
away	O
from	O
the	O
floor	O
in	O
the	O
peptide	O
-	O
binding	B-FUNC
groove	O
,	O
making	O
it	O
available	O
for	O
interactions	O
with	O
a	O
potential	O
T	O
-	O
cell	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
glycoproteins	O
of	O
the	O
class	O
I	O
family	O
,	O
which	O
include	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
influenza	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
mediate	O
viral	O
entry	O
by	O
first	O
binding	B-FUNC
to	O
their	O
cellular	O
receptors	O
and	O
subsequently	O
inducing	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

The	O
pumpless	O
extracorporeal	O
lung	O
membrane	O
and	O
near	O
-	O
static	O
ventilation	O
achieved	O
a	O
significantly	O
better	O
outcome	O
than	O
conventional	O
treatment	O
in	O
this	O
pig	O
model	O
of	O
severe	O
postpneumonectomy	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
probably	O
because	O
the	O
injured	O
lungs	O
were	O
not	O
forced	O
to	O
work	O
and	O
this	O
""""	O
rest	B-FUNC
""""	O
gave	O
them	O
more	O
time	O
to	O
heal	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	B-FUNC
(	O
HEs	O
)	O
are	O
a	O
family	O
of	O
viral	O
envelope	O
glycoproteins	O
that	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
(	O
RDEs	O
).	O

Whereas	O
the	O
structural	O
design	O
of	O
the	O
RDE	O
-	O
acetylesterase	O
domain	O
remained	O
unaltered	O
,	O
the	O
HE	O
receptor	O
-	O
binding	B-FUNC
domain	O
underwent	O
remodeling	O
to	O
such	O
extent	O
that	O
the	O
ligand	B-FUNC
is	O
now	O
bound	O
in	O
opposite	O
orientation	O
.	O

Apparently	O
,	O
HA	O
and	O
HEF	O
are	O
under	O
more	O
stringent	O
selective	O
constraints	O
than	O
HE	O
,	O
limiting	O
their	O
exploration	O
of	O
alternative	O
binding	B-FUNC
-	O
site	O
topologies	O
.	O

We	O
attribute	O
the	O
plasticity	O
of	O
the	O
CoV	O
HE	O
receptor	O
-	O
binding	B-FUNC
site	O
to	O
evolutionary	O
flexibility	O
conferred	O
by	O
functional	O
redundancy	O
between	O
HE	O
and	O
its	O
companion	O
spike	O
protein	O
S	O
.	O
Our	O
findings	O
offer	O
unique	O
insights	O
into	O
the	O
structural	O
and	O
functional	O
consequences	O
of	O
independent	O
protein	O
evolution	O
after	O
interviral	O
gene	O
exchange	O
and	O
open	O
potential	O
avenues	O
to	O
broad	O
-	O
spectrum	O
antiviral	O
drug	O
design	O
.	O

The	O
inflow	O
of	O
partially	O
purified	O
cell	O
lysate	O
sample	O
containing	O
the	O
gold	O
binding	B-FUNC
polypeptide	O
(	O
GBP	O
)-	O
fusion	O
protein	O
was	O
bound	O
onto	O
the	O
gold	O
micropatterns	O
by	O
means	O
of	O
its	O
metal	B-FUNC
binding	I-FUNC
affinity	O
.	O

TITLE	O
:	O
Endocytosis	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
together	O
with	O
virus	O
receptor	O
ACE2	O
.	O

Amino	O
acids	O
319	O
-	O
510	O
on	O
the	O
S	O
protein	O
have	O
been	O
mapped	O
as	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
which	O
mediates	O
binding	B-FUNC
to	O
the	O
SARS	O
-	O
CoV	O
receptor	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
on	O
SARS	O
-	O
CoV	O
susceptible	O
cells	O
.	O

The	O
flow	O
cytometry	O
assay	O
showed	O
that	O
the	O
purified	O
RBD	O
-	O
Fc	O
protein	O
could	O
bind	B-FUNC
to	O
ACE2	O
.	O

Of	O
these	O
,	O
382	O
(	O
62	O
%)	O
had	O
sera	B-FUNC
available	O
for	O
viral	O
analysis	O
.	O

TITLE	O
:	O
A	O
structural	O
view	O
of	O
the	O
inactivation	O
of	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
by	O
benzotriazole	O
esters	O
.	O

ABSTRACT	O
:	O
The	O
main	O
proteinase	B-FUNC
(	O
M	O
(	O
pro	O
))	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
is	O
a	O
principal	O
target	O
for	O
the	O
design	O
of	O
anticoronaviral	O
compounds	O
.	O

ABSTRACT	O
:	O
The	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
contains	O
a	O
potential	O
RNA	O
-	O
binding	B-FUNC
region	O
in	O
its	O
N	O
-	O
terminal	O
portion	O
and	O
also	O
serves	O
as	O
a	O
dimerization	O
domain	O
by	O
forming	O
a	O
homodimer	O
with	O
a	O
molecular	O
mass	O
of	O
28	O
kDa	O
.	O

The	O
NMR	O
structure	O
is	O
almost	O
identical	O
with	O
the	O
previously	O
solved	O
crystal	O
structure	O
,	O
except	O
for	O
a	O
disordered	O
putative	O
RNA	O
-	O
binding	B-FUNC
domain	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Studies	O
of	O
the	O
chemical	O
shift	O
perturbations	O
caused	O
by	O
the	O
binding	B-FUNC
of	O
single	O
-	O
stranded	O
DNA	O
and	O
mutational	O
analyses	O
have	O
identified	O
the	O
disordered	O
region	O
at	O
the	O
N	O
-	O
termini	O
as	O
the	O
prime	O
site	O
for	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
.	O

Cytokine	O
levels	O
were	O
profiled	O
using	O
multiplex	O
antibody	B-FUNC
coated	O
beads	O
.	O

Significantly	O
altered	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
were	O
detected	O
within	O
the	O
first	O
7	O
days	O
after	O
admission	O
in	O
serum	O
from	O
burn	O
pediatric	O
patients	O
with	O
concomitant	O
inhalation	O
injury	O
who	O
did	O
not	O
survive	O
when	O
compared	O
with	O
similar	O
patients	O
who	O
did	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Multiple	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
patients	O
with	O
increased	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
as	O
well	O
as	O
decreased	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
serum	O
levels	O
had	O
a	O
significantly	O
greater	O
risk	O
for	O
mortality	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Early	O
alterations	O
in	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
may	O
constitute	O
useful	O
predictive	O
markers	O
for	O
identifying	O
patients	O
those	O
who	O
have	O
sustained	O
a	O
burn	O
with	O
concomitant	O
inhalation	O
injury	O
and	O
who	O
have	O
high	O
mortality	O
.	O

CONCLUSIONS	O
:	O
Early	O
alterations	O
in	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
may	O
constitute	O
useful	O
predictive	O
markers	O
for	O
identifying	O
patients	O
those	O
who	O
have	O
sustained	O
a	O
burn	O
with	O
concomitant	O
inhalation	O
injury	O
and	O
who	O
have	O
high	O
mortality	O
.	O

Reports	O
using	O
historical	O
matched	O
controls	O
have	O
suggested	O
that	O
treatment	O
with	O
interferon	O
alfacon	O
-	O
1	O
(	O
a	O
synthetic	O
interferon	O
)	O
combined	O
with	O
steroid	O
,	O
protease	O
inhibitors	O
together	O
with	O
ribavirin	O
,	O
or	O
convalescent	O
plasma	O
containing	O
neutralizing	O
antibody	B-FUNC
,	O
could	O
be	O
useful	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
an	O
illness	O
caused	O
by	O
a	O
novel	O
corona	O
virus	O
wherein	O
the	O
main	O
proteinase	B-FUNC
called	O
3CL	O
(	O
Pro	O
)	O
has	O
been	O
established	O
as	O
a	O
target	O
for	O
drug	O
design	O
.	O

TITLE	O
:	O
A	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
survey	O
of	O
infectious	O
bronchitis	O
virus	O
genotypes	O
in	O
Western	O
Europe	O
from	O
2002	O
to	O
2006	O
.	O

Identification	O
of	O
IBV	O
was	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
of	O
RNA	O
extracted	O
from	O
oropharyngeal	O
swabs	O
taken	O
from	O
poultry	O
flocks	O
exhibiting	O
signs	O
of	O
clinical	O
disease	O
thought	O
to	O
be	O
attributable	O
to	O
IBV	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
protective	O
T	O
-	O
cell	O
response	O
following	O
coronavirus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
is	O
not	O
dependent	O
on	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
23	O
signaling	O
.	O

ABSTRACT	O
:	O
The	O
functional	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
in	O
host	O
defense	O
and	O
disease	O
following	O
viral	O
infection	O
of	O
the	O
CNS	O
was	O
determined	O
.	O

Antibody	B-FUNC
-	O
mediated	O
blocking	O
of	O
either	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
(	O
anti	O
-	O
IL	O
-	O
23p19	O
)	O
or	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
(	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
23p40	O
)	O
signaling	O
did	O
not	O
mute	O
T	O
-	O
cell	O
trafficking	O
into	O
the	O
CNS	O
or	O
antiviral	O
effector	O
responses	O
and	O
mice	O
were	O
able	O
to	O
control	O
viral	O
replication	O
within	O
the	O
brain	O
.	O

Therapeutic	O
administration	O
of	O
either	O
anti	O
-	O
IL	O
-	O
23p19	O
or	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
23p40	O
to	O
mice	O
with	O
viral	O
-	O
induced	O
demyelination	O
did	O
not	O
attenuate	O
T	O
-	O
cell	O
or	O
macrophage	O
infiltration	O
into	O
the	O
CNS	O
nor	O
improve	O
clinical	O
disease	O
or	O
diminish	O
white	O
matter	O
damage	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
signaling	O
are	O
dispensable	O
in	O
generating	O
a	O
protective	O
T	O
-	O
cell	O
response	O
following	O
CNS	O
infection	O
with	O
MHV	O
,	O
and	O
(	O
2	O
)	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
do	O
not	O
contribute	O
to	O
demyelination	O
in	O
a	O
model	O
independent	O
of	O
autoimmune	O
T	O
-	O
cell	O
-	O
mediated	O
pathology	O
.	O

The	O
promoter	O
regions	O
of	O
the	O
IFN	O
-	O
alpha	O
genes	O
,	O
however	O
,	O
have	O
different	O
transcription	B-FUNC
factor	I-FUNC
binding	I-FUNC
sites	O
,	O
implying	O
differential	O
transcriptional	O
activation	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
and	O
apply	O
the	O
direct	O
immunohistochemistry	O
(	O
D	O
-	O
IHC	O
)	O
assay	O
to	O
search	O
for	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
antigens	O
in	O
formalin	O
-	O
fixed	O
embedded	O
-	O
paraffin	O
tissues	O
by	O
the	O
use	O
of	O
biotin	O
-	O
labeled	O
polyclonal	O
antibody	B-FUNC
.	O

All	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
by	O
conventional	O
RT	O
-	O
PCR	O
and	O
indirect	O
fluorescent	O
antibody	B-FUNC
assay	O
(	O
IFA	O
)	O
for	O
all	O
tested	O
samples	O
.	O

ABSTRACT	O
:	O
A	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
RNA	O
in	O
clinical	O
samples	O
is	O
described	O
.	O

Structural	O
modeling	O
predicted	O
two	O
distinct	O
biochemical	O
interaction	O
networks	O
by	O
which	O
zoonotic	O
receptor	B-FUNC
binding	I-FUNC
domain	O
architecture	O
can	O
productively	O
engage	O
hACE2	O
,	O
but	O
only	O
the	O
Urbani	O
mutational	O
repertoire	O
promoted	O
efficient	O
usage	O
of	O
both	O
hACE2	O
and	O
cACE2	O
binding	B-FUNC
interfaces	O
.	O

TITLE	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
and	O
mannose	O
-	O
binding	B-FUNC
lectin	O
-	O
associated	O
serine	O
protease	O
2	O
in	O
susceptibility	O
,	O
severity	O
,	O
and	O
outcome	O
of	O
pneumonia	O
in	O
adults	O
.	O

We	O
used	O
H5N1	O
pseudotyped	O
and	O
reverse	O
-	O
genetics	O
(	O
RG	O
)	O
virus	O
particles	O
to	O
study	O
their	O
ability	O
to	O
bind	B-FUNC
with	O
DC	O
-	O
SIGN	O
.	O

Plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
are	O
influenced	O
mainly	O
by	O
genetic	O
determinants	O
,	O
and	O
a	O
-	O
174G	O
/	O
C	O
polymorphism	O
of	O
the	O
gene	O
has	O
been	O
recently	O
associated	O
with	O
susceptibility	O
to	O
ALI	O
.	O

ABSTRACT	O
:	O
DUBs	O
(	O
deubiquitinating	O
enzymes	O
)	O
are	O
a	O
family	O
of	O
proteases	O
responsible	O
for	O
the	O
specific	O
removal	O
of	O
ubiquitin	B-FUNC
attached	O
to	O
target	O
proteins	O
and	O
thus	O
control	O
the	O
free	O
cellular	O
pools	O
of	O
this	O
molecule	O
.	O

We	O
have	O
also	O
used	O
an	O
optimal	O
tetrapeptide	O
substrate	O
,	O
acetyl	O
-	O
Lys	O
-	O
Arg	O
-	O
Gly	O
-	O
Gly	O
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
,	O
to	O
investigate	O
the	O
activation	O
mechanism	O
of	O
DUBs	O
by	O
ubiquitin	B-FUNC
and	O
elevated	O
salt	O
concentration	O
.	O

Together	O
,	O
our	O
results	O
reveal	O
the	O
importance	O
of	O
the	O
dual	O
features	O
of	O
(	O
1	O
)	O
substrate	O
specificity	O
and	O
(	O
2	O
)	O
the	O
mechanism	O
of	O
ubiquitin	B-FUNC
binding	I-FUNC
in	O
determining	O
deubiquitination	O
by	O
this	O
group	O
of	O
proteases	O
.	O

In	O
the	O
presence	O
of	O
each	O
neutralizing	O
antibody	B-FUNC
,	O
double	O
mutants	O
with	O
substitutions	O
in	O
both	O
domains	O
exhibited	O
a	O
greater	O
growth	O
advantage	O
than	O
those	O
with	O
only	O
one	O
substitution	O
.	O

Therefore	O
,	O
we	O
have	O
carried	O
out	O
a	O
study	O
of	O
the	O
binding	B-FUNC
and	O
interaction	O
with	O
model	O
membranes	O
of	O
a	O
peptide	O
corresponding	O
to	O
segment	O
873	O
-	O
888	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
,	O
peptide	O
SARS	O
IFP	O
,	O
as	O
well	O
as	O
the	O
structural	O
changes	O
taking	O
place	O
in	O
both	O
the	O
phospholipid	O
and	O
the	O
peptide	O
induced	O
by	O
the	O
binding	B-FUNC
of	O
the	O
peptide	O
to	O
the	O
membrane	O
.	O

We	O
demonstrate	O
that	O
SARS	O
IFP	O
peptide	O
binds	B-FUNC
to	O
and	O
interacts	O
with	O
phospholipid	O
model	O
membranes	O
and	O
shows	O
a	O
higher	O
affinity	O
for	O
negatively	O
charged	O
phospholipids	O
than	O
for	O
zwitterionic	O
ones	O
.	O

Treatment	O
with	O
antiviral	O
drugs	O
demonstrated	O
that	O
the	O
replication	O
could	O
be	O
significantly	O
inhibited	O
by	O
0	O
.	O
4	O
mg	O
/	O
ml	O
of	O
cysteine	O
proteinase	B-FUNC
inhibitor	I-FUNC
E	O
-	O
64D	O
,	O
but	O
not	O
by	O
ribavirin	O
.	O

Confirming	O
these	O
findings	O
,	O
Western	O
blot	O
studies	O
have	O
shown	O
lower	O
renal	O
expression	O
of	O
the	O
sodium	O
/	O
hydrogen	O
exchanger	B-FUNC
isoform	O
3	O
and	O
of	O
aquaporin	B-FUNC
2	O
,	O
together	O
with	O
higher	O
renal	O
expression	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
,	O
in	O
infected	O
animals	O
.	O

Such	O
BVLPs	O
up	O
-	O
regulated	O
the	O
level	O
of	O
CD40	O
,	O
CD80	O
,	O
CD86	O
,	O
CD83	O
,	O
and	O
enhanced	O
the	O
secretion	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TNF	O
-	O
alpha	O
in	O
immature	O
dendritic	O
cells	O
(	O
DCs	O
).	O

Further	O
study	O
indicated	O
that	O
IFN	O
-	O
gamma	O
+	O
and	O
IL	B-FUNC
-	I-FUNC
4	O
+	O
populations	O
in	O
CD4	O
+	O
T	O
cells	O
increased	O
upon	O
co	O
-	O
cultivation	O
with	O
DCs	O
pre	O
-	O
exposed	O
with	O
BVLPs	O
or	O
SARS	O
-	O
CoV	O
VLPs	O
.	O

In	O
agreement	O
,	O
SL	O
-	O
CoV	O
S	O
DNA	O
vaccine	O
evoked	O
a	O
more	O
vigorous	O
antibody	B-FUNC
response	O
and	O
a	O
stronger	O
T	O
cell	O
response	O
than	O
SARS	O
-	O
CoV	O
S	O
DNA	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Twelve	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
obtained	O
from	O
commercial	O
chickens	O
in	O
China	O
between	O
2005	O
and	O
2006	O
were	O
characterized	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
sequencing	O
of	O
the	O
entire	O
S1	O
gene	O
.	O

We	O
next	O
explored	O
the	O
potential	O
synergism	O
between	O
rhPBEF	O
challenge	O
(	O
intratracheal	O
)	O
and	O
a	O
model	O
of	O
limited	O
VILI	O
(	O
4	O
h	O
,	O
30	O
ml	O
/	O
kg	O
tidal	O
volume	O
)	O
and	O
observed	O
dramatic	O
increases	O
in	O
BAL	O
PMNs	O
,	O
BAL	O
protein	O
,	O
and	O
cytokine	O
levels	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
KC	O
)	O
compared	O
with	O
either	O
challenge	O
alone	O
.	O

Heterozygous	O
PBEF	O
(+/-)	O
mice	O
were	O
significantly	O
protected	O
(	O
reduced	O
BAL	O
protein	O
,	O
BAL	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
,	O
peak	O
inspiratory	O
pressures	O
)	O
when	O
exposed	O
to	O
a	O
model	O
of	O
severe	O
VILI	O
(	O
4	O
h	O
,	O
40	O
ml	O
/	O
kg	O
tidal	O
volume	O
)	O
and	O
exhibited	O
significantly	O
reduced	O
expression	O
of	O
VILI	O
-	O
associated	O
gene	O
expression	O
modules	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
contain	O
a	O
small	O
envelope	O
membrane	O
protein	O
with	O
cation	O
-	O
selective	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
mediated	O
by	O
its	O
transmembrane	O
domain	O
(	O
ETM	O
).	O

In	O
a	O
computational	O
study	O
,	O
we	O
proposed	O
that	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
can	O
be	O
explained	O
by	O
either	O
of	O
two	O
similar	O
ETM	O
homopentameric	O
transmembrane	O
alpha	O
-	O
helical	O
bundles	O
,	O
related	O
by	O
a	O
approximately	O
50	O
degrees	O
rotation	O
of	O
the	O
helices	O
.	O

ABSTRACT	O
:	O
Receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
is	O
a	O
membrane	O
bound	O
receptor	O
and	O
member	O
of	O
the	O
immunoglobulin	B-FUNC
super	O
family	O
and	O
is	O
normally	O
present	O
in	O
a	O
highly	O
abundant	O
basal	O
level	O
expression	O
in	O
lung	O
.	O

Of	O
these	O
pathogens	O
,	O
29	O
were	O
viruses	O
(	O
15	O
%),	O
38	O
were	O
bacteria	O
(	O
20	O
%),	O
8	O
were	O
mixed	O
(	O
4	O
%),	O
and	O
the	O
rest	B-FUNC
were	O
""""	O
unknown	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
structural	O
protein	O
9	O
(	O
Nsp9	O
)	O
of	O
coronaviruses	O
is	O
believed	O
to	O
bind	B-FUNC
single	O
-	O
stranded	O
RNA	O
in	O
the	O
viral	O
replication	O
complex	O
.	O

In	O
zone	O
-	O
interference	O
gel	O
electrophoresis	O
assays	O
and	O
surface	O
plasmon	O
resonance	O
experiments	O
,	O
the	O
HCoV	O
-	O
229E	O
wild	O
-	O
type	O
protein	O
is	O
found	O
to	O
bind	B-FUNC
oligonucleotides	O
with	O
relatively	O
high	O
affinity	O
,	O
whereas	O
binding	B-FUNC
by	O
the	O
Cys69Ala	O
and	O
Cys69Ser	O
mutants	O
is	O
observed	O
only	O
for	O
the	O
longest	O
oligonucleotides	O
.	O

The	O
corresponding	O
mutations	O
in	O
SARS	O
-	O
CoV	O
Nsp9	O
do	O
not	O
hamper	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
.	O

From	O
the	O
crystal	O
structures	O
,	O
a	O
model	O
for	O
single	B-FUNC
-	I-FUNC
stranded	I-FUNC
RNA	I-FUNC
binding	I-FUNC
by	O
Nsp9	O
is	O
deduced	O
.	O

The	O
LPS	O
challenge	O
also	O
increased	O
pulmonary	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
chloramine	O
concentrations	O
indicative	O
of	O
neutrophil	O
infiltration	O
and	O
activation	O
of	O
the	O
inflammatory	O
response	O
.	O

ABSTRACT	O
:	O
Altered	O
protease	B-FUNC
activity	I-FUNC
is	O
considered	O
important	O
for	O
tumour	O
invasion	O
and	O
metastasis	O
,	O
processes	O
in	O
which	O
the	O
cysteine	O
proteases	O
cathepsin	O
B	O
and	O
L	O
are	O
involved	O
.	O

Their	O
natural	O
inhibitor	O
cystatin	O
C	O
is	O
a	O
secreted	O
protein	O
,	O
suggesting	O
that	O
it	O
functions	O
to	O
control	O
extracellular	O
protease	B-FUNC
activity	I-FUNC
.	O

It	O
was	O
functionally	O
intact	O
and	O
extracts	O
of	O
cells	O
exposed	O
to	O
cystatin	O
C	O
showed	O
a	O
higher	O
capacity	O
to	O
inhibit	O
papain	O
and	O
cathepsin	O
B	O
than	O
control	O
cells	O
(	O
decrease	O
in	O
enzyme	B-FUNC
activity	I-FUNC
of	O
34	O
%	O
and	O
37	O
%,	O
respectively	O
).	O

Using	O
a	O
peptide	O
library	O
derived	O
from	O
N	O
,	O
we	O
found	O
that	O
amino	O
acids	O
101	O
-	O
115	O
constituted	O
a	O
novel	O
binding	B-FUNC
site	O
for	O
M	O
.	O
We	O
examined	O
the	O
ability	O
of	O
N	O
mutants	O
to	O
interact	O
with	O
M	O
and	O
form	O
pseudoparticles	O
,	O
and	O
our	O
observations	O
indicated	O
that	O
M	O
bound	O
to	O
NDelta	O
(	O
101	O
-	O
115	O
),	O
N1	O
-	O
150	O
,	O
N151	O
-	O
300	O
,	O
and	O
N301	O
-	O
422	O
,	O
but	O
not	O
to	O
N1	O
-	O
150Delta	O
(	O
101	O
-	O
115	O
).	O

However	O
,	O
it	O
was	O
found	O
that	O
a	O
mixture	O
of	O
two	O
HIV	O
-	O
1	O
proteinase	B-FUNC
inhibitors	O
,	O
lopinavir	O
and	O
ritonavir	O
,	O
exhibited	O
some	O
signs	O
of	O
effectiveness	O
against	O
the	O
SARS	O
virus	O
.	O

To	O
understand	O
the	O
fine	O
details	O
of	O
the	O
molecular	O
interactions	O
between	O
these	O
proteinase	B-FUNC
inhibitors	O
and	O
the	O
SARS	O
virus	O
via	O
complexation	O
,	O
molecular	O
dynamics	O
simulations	O
were	O
carried	O
out	O
for	O
the	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
free	O
enzyme	O
(	O
free	O
SARS	O
)	O
and	O
its	O
complexes	O
with	O
lopinavir	O
(	O
SARS	O
-	O
LPV	O
)	O
and	O
ritonavir	O
(	O
SARS	O
-	O
RTV	O
).	O

The	O
results	O
show	O
that	O
flap	O
closing	O
was	O
clearly	O
observed	O
when	O
the	O
inhibitors	O
bind	B-FUNC
to	O
the	O
active	O
site	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

The	O
binding	B-FUNC
affinities	O
of	O
LPV	O
and	O
RTV	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
do	O
not	O
show	O
any	O
significant	O
difference	O
.	O

TITLE	O
:	O
A	O
SARS	O
-	O
CoV	O
protein	O
,	O
ORF	O
-	O
6	O
,	O
induces	O
caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	B-FUNC
-	O
dependent	O
apoptosis	O
.	O

All	O
these	O
data	O
suggest	O
that	O
ORF	O
-	O
6	O
induces	O
apoptosis	O
via	O
Caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	B-FUNC
-	O
dependent	O
pathways	O
.	O

We	O
produced	O
mammalian	O
expression	O
vectors	O
encoding	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
accessory	O
proteins	O
with	O
or	O
without	O
the	O
fluorescence	O
protein	B-FUNC
tag	I-FUNC
and	O
cell	O
lines	O
with	O
stable	O
expression	O
of	O
these	O
proteins	O
.	O

Challenge	O
of	O
lymphocytes	O
and	O
monocytes	O
with	O
infectious	O
SARS	O
-	O
CoV	O
,	O
inactivated	O
virions	O
,	O
and	O
receptor	O
-	O
binding	B-FUNC
fragment	O
of	O
spike	O
protein	O
does	O
not	O
trigger	O
apoptosis	O
.	O

This	O
was	O
supported	O
by	O
in	O
vitro	O
binding	B-FUNC
studies	O
that	O
demonstrated	O
homozygous	O
L	O
-	O
SIGN	O
,	O
compared	O
to	O
heterozygous	O
,	O
had	O
higher	O
binding	B-FUNC
capacity	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
with	O
higher	O
proteasome	O
-	O
dependent	O
viral	O
degradation	O
.	O

In	O
contrast	O
,	O
homozygous	O
L	O
-	O
SIGN	O
demonstrated	O
lower	O
binding	B-FUNC
capacity	O
for	O
HIV1	O
-	O
gp120	O
.	O
3	O
.	O

Genetic	O
-	O
association	O
studies	O
for	O
single	O
nucleotide	O
polymorphisms	O
of	O
the	O
inflammatory	O
response	O
genes	O
,	O
namely	O
TNF	O
-	O
alpha	O
,	O
INF	O
-	O
alpha	O
,	O
INF	O
-	O
beta	O
,	O
INF	O
-	O
gamma	O
,	O
IL1	O
-	O
alpha	O
,	O
IL1	O
-	O
beta	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
iNOS	O
,	O
failed	O
to	O
show	O
a	O
significant	O
association	O
with	O
SARS	O
clinical	O
outcomes	O
or	O
susceptibility	O
.	O

Intranasal	O
vaccination	O
using	O
inactivated	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
vaccine	O
with	O
adjuvant	O
can	O
induce	O
strong	O
systemic	O
(	O
serum	O
immunoglobulin	B-FUNC
[	O
Ig	O
]	O
G	O
)	O
and	O
respiratory	O
tract	O
local	O
(	O
tracheal	O
-	O
lung	O
wash	O
fluid	O
IgA	O
)	O
antibody	B-FUNC
responses	O
with	O
neutralising	O
activity	O
.	O

A	O
single	O
dose	O
of	O
RBD	O
-	O
rAAV	O
vaccination	O
can	O
induce	O
adequate	O
neutralising	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

RBD	O
-	O
rAAV	O
vaccination	O
provoked	O
a	O
prolonged	O
antibody	B-FUNC
response	O
with	O
continually	O
increasing	O
levels	O
of	O
neutralising	O
activity	O
.	O

When	O
compared	O
with	O
the	O
RBD	O
-	O
rAAV	O
prime	O
/	O
boost	O
vaccination	O
,	O
RBD	O
-	O
rAAV	O
prime	O
/	O
RBD	O
-	O
peptide	O
boost	O
induced	O
similar	O
levels	O
of	O
Th1	O
and	O
neutralising	O
antibody	B-FUNC
responses	O
that	O
protected	O
vaccinated	O
mice	O
from	O
subsequent	O
SARS	O
-	O
CoV	O
challenges	O
,	O
but	O
stronger	O
Th2	O
and	O
CTL	O
responses	O
.	O

TITLE	O
:	O
RNA	O
viruses	O
and	O
the	O
mitogenic	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signal	O
transduction	O
cascade	O
.	O

ABSTRACT	O
:	O
The	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signal	O
transduction	O
cascade	O
belongs	O
to	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
cascades	O
.	O

Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signaling	O
leads	O
to	O
stimulus	O
-	O
specific	O
changes	O
in	O
gene	O
expression	O
,	O
alterations	O
in	O
cell	O
metabolism	O
or	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
),	O
and	O
thus	O
controls	O
cell	O
differentiation	O
and	O
proliferation	O
.	O

In	O
contrast	O
,	O
the	O
consequences	O
of	O
RNA	O
virus	O
-	O
induced	O
Raf	O
/	O
MEK	O
/	O
ERK	B-FUNC
signaling	O
were	O
less	O
clear	O
for	O
a	O
long	O
time	O
,	O
but	O
since	O
the	O
turn	O
of	O
the	O
century	O
the	O
number	O
of	O
publications	O
on	O
this	O
topic	O
has	O
rapidly	O
increased	O
.	O

The	O
presence	O
of	O
alpaca	O
coronavirus	O
(	O
ApCoV	O
)	O
in	O
the	O
small	O
intestine	O
was	O
demonstrated	O
by	O
immune	O
histochemistry	O
with	O
an	O
antinucleocapsid	O
monoclonal	O
antibody	B-FUNC
that	O
reacts	O
with	O
group	O
2	O
coronaviruses	O
.	O

Hence	O
two	O
strategies	O
can	O
be	O
used	O
to	O
block	O
the	O
infection	O
of	O
the	O
SARS	O
virus	O
,	O
either	O
by	O
interfering	O
with	O
the	O
binding	B-FUNC
of	O
the	O
S1	O
domain	O
to	O
the	O
receptor	O
or	O
by	O
blocking	O
the	O
fusion	O
of	O
the	O
virus	O
with	O
the	O
cell	O
membrane	O
mediated	O
by	O
the	O
S2	O
domain	O
.	O

As	O
no	O
mutation	O
has	O
been	O
found	O
in	O
the	O
S2	O
domain	O
indicating	O
that	O
this	O
region	O
is	O
more	O
conserved	O
than	O
the	O
S1	O
domain	O
,	O
it	O
may	O
be	O
a	O
better	O
target	O
for	O
antibody	B-FUNC
binding	B-FUNC
.	O

Interestingly	O
,	O
when	O
a	O
fluorescent	O
protein	B-FUNC
tag	I-FUNC
is	O
added	O
to	O
the	O
C	O
-	O
terminal	O
end	O
of	O
N	O
or	O
S	O
protein	O
,	O
but	O
not	O
M	O
protein	O
,	O
the	O
chimeric	O
viral	O
proteins	O
can	O
be	O
assembled	O
within	O
VLPs	O
and	O
allow	O
visualization	O
of	O
VLP	O
production	O
and	O
trafficking	O
in	O
living	O
cells	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
imaging	O
technologies	O
.	O

Both	O
the	O
whole	O
killed	O
SARS	O
-	O
CoV	O
vaccine	O
(	O
with	O
and	O
without	O
alum	O
)	O
and	O
adenovirus	O
-	O
based	O
vectors	O
encoding	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
protein	O
induced	O
neutralizing	O
antibody	B-FUNC
responses	O
and	O
reduced	O
viral	O
replication	O
and	O
shedding	O
in	O
the	O
upper	O
respiratory	O
tract	O
and	O
progression	O
of	O
virus	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

However	O
,	O
despite	O
high	O
neutralizing	O
antibody	B-FUNC
titres	O
,	O
protection	O
was	O
incomplete	O
for	O
all	O
vaccine	O
preparations	O
and	O
administration	O
routes	O
.	O

Internalization	O
of	O
FIPV	O
was	O
slightly	O
reduced	O
to	O
85	O
.	O
0	O
+/-	O
1	O
.	O
4	O
and	O
87	O
.	O
4	O
+/-	O
6	O
.	O
1	O
%	O
of	O
internalization	O
in	O
control	O
cells	O
by	O
the	O
sterol	O
-	O
binding	B-FUNC
drugs	I-FUNC
nystatin	O
and	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
respectively	O
.	O

Results	O
were	O
compared	O
with	O
those	O
of	O
an	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
for	O
FCoV	O
-	O
specific	O
antibody	B-FUNC
and	O
correlated	O
with	O
health	O
status	O
.	O

Appr	O
-	O
1	O
'-	O
pase	O
catalyzes	O
the	O
conversion	O
of	O
ADP	O
-	O
ribose	O
-	O
1	O
'-	O
monophosphate	O
(	O
Appr	O
-	O
1	O
'-	O
p	O
)	O
to	O
ADP	O
-	O
ribose	O
in	O
the	O
tRNA	B-FUNC
-	O
splicing	O
pathway	O
.	O

ABSTRACT	O
:	O
Rapid	O
immunochromatographic	O
assays	O
for	O
detecting	O
infections	O
with	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
rotavirus	O
A	O
and	O
Cryptosporidium	O
parvum	O
in	O
calf	O
faeces	O
were	O
evaluated	O
using	O
as	O
gold	O
standards	O
a	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
BCV	O
and	O
rotavirus	O
)	O
and	O
a	O
sedimentation	O
-	O
flotation	O
technique	O
(	O
C	O
.	O
parvum	O
).	O

Sulfation	O
of	O
CDR	O
tyrosine	O
residues	O
,	O
a	O
property	O
recently	O
shown	O
to	O
broaden	O
antibody	B-FUNC
binding	B-FUNC
affinity	O
and	O
antigen	O
recognition	O
was	O
also	O
demonstrated	O
.	O

We	O
conducted	O
a	O
study	O
of	O
nasal	O
wash	O
specimens	O
using	O
real	O
-	O
time	O
PCR	O
and	O
fluorescent	O
-	O
antibody	B-FUNC
assay	O
results	O
from	O
children	O
less	O
than	O
two	O
with	O
an	O
ICD	O
-	O
9	O
-	O
CM	O
code	O
for	O
bronchiolitis	O
.	O

Treatment	O
with	O
the	O
SOD	B-FUNC
mimetic	O
MnTBAP	O
and	O
intranasal	O
administration	O
of	O
SOD	B-FUNC
-	O
containing	O
polyketal	O
microparticles	O
reduced	O
mortality	O
,	O
prevented	O
the	O
histological	O
alterations	O
,	O
and	O
reduced	O
lung	O
superoxide	O
levels	O
.	O

The	O
cytoplasmic	O
C	O
-	O
terminus	O
domain	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
was	O
responsible	O
for	O
binding	B-FUNC
to	O
NC	O
protein	O
.	O

Since	O
these	O
changes	O
do	O
not	O
interact	O
with	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
,	O
rh	O
-	O
ACE2	O
in	O
general	O
is	O
as	O
effective	O
as	O
human	O
homolog	O
in	O
supporting	O
viral	O
entry	O
.	O

ABSTRACT	O
:	O
We	O
present	O
three	O
cases	O
of	O
patients	O
(	O
at	O
the	O
age	O
of	O
56	O
years	O
,	O
49	O
years	O
and	O
74	O
years	O
respectively	O
)	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
),	O
complicated	O
by	O
intra	O
-	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
and	O
respiratory	O
insufficiency	O
with	O
limitations	O
of	O
mechanical	O
ventilation	O
.	O

Faecal	O
samples	O
from	O
147	O
untreated	O
calves	O
suffering	O
from	O
acute	O
diarrhoea	O
were	O
analysed	O
by	O
standardised	O
diagnostic	O
methods	O
,	O
and	O
the	O
immunoglobulin	B-FUNC
status	O
of	O
each	O
calf	O
was	O
evaluated	O
.	O

The	O
immunoglobulin	B-FUNC
concentration	O
in	O
the	O
serum	O
of	O
90	O
.	O
5	O
per	O
cent	O
of	O
the	O
diarrhoeic	O
calves	O
was	O
below	O
8	O
g	O
/	O
l	O
.	O

ABSTRACT	O
:	O
Right	O
ventricular	O
failure	O
may	O
result	O
from	O
an	O
newly	O
developed	O
disease	O
(	O
e	O
.	O
g	O
.	O
as	O
a	O
consequence	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
[	O
ARDS	O
]	O
or	O
of	O
severe	O
pulmonary	O
embolism	O
)	O
or	O
of	O
already	O
present	O
pulmonary	O
hypertension	O
(	O
PHT	B-FUNC
).	O

Right	O
ventricular	O
failure	O
in	O
the	O
course	O
of	O
PHT	B-FUNC
represents	O
a	O
great	O
challenge	O
in	O
clinical	O
and	O
intensive	O
care	O
practice	O
.	O

The	O
central	O
goal	O
in	O
the	O
treatment	O
of	O
right	O
heart	O
failure	O
as	O
part	O
of	O
PHT	B-FUNC
is	O
to	O
lower	O
pulmonary	O
vascular	O
resistance	O
and	O
thus	O
decrease	O
right	O
ventricular	O
afterload	O
.	O

However	O
,	O
it	O
is	O
very	O
difficult	O
to	O
break	O
the	O
vicious	O
circle	O
involved	O
in	O
the	O
acute	O
right	O
heart	O
syndrome	O
,	O
it	O
must	O
be	O
the	O
primary	O
aim	O
of	O
treatment	O
to	O
recognize	O
as	O
early	O
as	O
possible	O
any	O
worsening	O
of	O
PHT	B-FUNC
and	O
prevent	O
acute	O
right	O
heart	O
failure	O
.	O

Lung	O
transplantation	O
or	O
surgical	O
atrioseptostomy	O
may	O
represent	O
possible	O
ultimate	O
therapeutic	O
options	O
for	O
patients	O
with	O
PHT	B-FUNC
.	O

The	O
heavily	O
glycosylated	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
binds	B-FUNC
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
which	O
serves	O
as	O
a	O
cellular	O
receptor	O
.	O

After	O
adjusting	O
for	O
confounders	O
and	O
excluding	O
patients	O
with	O
cirrhosis	O
,	O
the	O
risk	O
of	O
ALI	O
increased	O
with	O
HCV	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-FUNC
]	O
1	O
.	O
80	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
30	O
-	O
2	O
.	O
48	O
),	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
aOR	B-FUNC
7	O
.	O
43	O
;	O
95	O
%	O
CI	O
:	O
3	O
.	O
30	O
-	O
16	O
.	O
7	O
),	O
alcoholic	O
liver	O
disease	O
(	O
aOR	B-FUNC
6	O
.	O
46	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
53	O
-	O
9	O
.	O
21	O
),	O
and	O
malnutrition	O
(	O
aOR	B-FUNC
3	O
.	O
84	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
61	O
-	O
5	O
.	O
65	O
).	O

HCV	O
was	O
associated	O
with	O
greater	O
risk	O
of	O
progression	O
to	O
severe	O
liver	O
failure	O
(	O
aOR	B-FUNC
3	O
.	O
55	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
88	O
-	O
6	O
.	O
70	O
).	O

SARS	O
-	O
CoV	O
-	O
specific	O
antibody	B-FUNC
was	O
detected	O
by	O
ELISA	O
in	O
8	O
of	O
10	O
subjects	O
and	O
neutralizing	O
antibody	B-FUNC
was	O
detected	O
in	O
all	O
subjects	O
who	O
received	O
3	O
doses	O
of	O
vaccine	O
.	O

Polychromatic	O
cytometry	O
analysis	O
indicated	O
that	O
the	O
virus	O
-	O
specific	O
T	O
cells	O
from	O
the	O
severe	O
group	O
tended	O
to	O
be	O
a	O
central	O
memory	O
phenotype	O
(	O
CD27	O
(+)/	O
CD45RO	O
(+))	O
with	O
a	O
significantly	O
higher	O
frequency	O
of	O
polyfunctional	O
CD4	O
(+)	O
T	O
cells	O
producing	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
and	O
CD8	O
(+)	O
T	O
cells	O
producing	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
CD107a	O
(	O
degranulation	O
),	O
as	O
compared	O
with	O
the	O
mild	O
-	O
moderate	O
group	O
.	O

Accompanying	O
data	O
relating	O
to	O
the	O
sampled	O
animals	O
were	O
collected	O
in	O
order	O
to	O
identify	O
potential	O
factors	O
associated	O
with	O
increased	O
antibody	B-FUNC
prevalence	O
.	O

Conventional	O
herds	O
had	O
a	O
significantly	O
higher	O
mean	O
antibody	B-FUNC
prevalence	O
to	O
BCV	O
and	O
BRSV	O
than	O
the	O
organically	O
managed	O
herds	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Epitope	O
-	O
based	O
vaccines	O
designed	O
to	O
induce	O
cellular	O
immune	O
response	O
and	O
antibody	B-FUNC
responses	O
specific	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
are	O
being	O
developed	O
as	O
a	O
means	O
for	O
increasing	O
vaccine	O
potency	O
.	O

Among	O
the	O
farms	O
,	O
Farm	O
A	O
showed	O
a	O
high	O
antibody	B-FUNC
incidence	O
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
804	O
goat	O
sera	B-FUNC
were	O
collected	O
from	O
144	O
goat	O
farms	O
in	O
five	O
regions	O
of	O
South	O
Korea	O
during	O
a	O
period	O
between	O
2005	O
and	O
2006	O
and	O
screened	O
for	O
the	O
antibodies	O
of	O
viral	O
pathogens	O
in	O
ruminants	O
.	O

As	O
a	O
consequence	O
,	O
the	O
proteinase	B-FUNC
domains	O
present	O
in	O
nsp3	O
and	O
nsp5	O
would	O
be	O
separated	O
from	O
their	O
target	O
sequences	O
by	O
the	O
lipid	O
bilayer	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	B-FUNC
D	O
(	O
apoD	O
)	O
is	O
a	O
lipocalin	O
upregulated	O
in	O
the	O
nervous	O
system	O
after	O
injury	O
or	O
pathologies	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
,	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
multiple	O
sclerosis	O
.	O

DPD	B-FUNC
activity	O
was	O
evaluated	O
by	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	O
(	O
PBMC	O
)	O
radioassay	O
,	O
genotyping	O
of	O
DPYD	O
gene	O
by	O
Denaturing	O
High	O
Performance	O
Liquid	O
Chromatography	O
(	O
DHPLC	O
),	O
or	O
2	O
-(	O
13	O
)	O
C	O
uracil	O
breath	O
test	O
(	O
UraBT	O
).	O

RESULTS	O
:	O
Of	O
23	O
patients	O
with	O
excessive	O
toxicities	O
from	O
5	O
-	O
FU	O
and	O
/	O
or	O
capecitabine	O
,	O
7	O
(	O
30	O
%)	O
were	O
DPD	B-FUNC
deficient	O
with	O
a	O
median	O
age	O
of	O
66	O
years	O
,	O
M	O
:	O
F	O
ratio	O
=	O
1	O
.	O
3	O
:	O
1	O
and	O
ethnicities	O
included	O
Caucasian	O
(	O
71	O
%),	O
African	O
-	O
American	O
(	O
14	O
%)	O
and	O
South	O
-	O
Asian	O
(	O
14	O
%).	O

DPD	B-FUNC
activity	O
ranged	O
from	O
0	O
.	O
064	O
-	O
0	O
.	O
18nmol	O
/	O
min	O
/	O
mg	O
.	O

The	O
UraBT	O
in	O
two	O
patients	O
of	O
112	O
.	O
8	O
;	O
PDR	O
of	O
49	O
.	O
4	O
%)	O
and	O
borderline	O
normal	O
values	O
revealed	O
1	O
to	O
be	O
DPD	B-FUNC
-	O
deficient	O
(	O
DOB	O
(	O
50	O
)	O
of	O
130	O
.	O
9	O
;	O
PDR	O
of	O
52	O
.	O
5	O
%)	O
in	O
a	O
second	O
patient	O
.	O

There	O
were	O
2	O
toxicity	O
-	O
related	O
deaths	O
among	O
(	O
DOB	O
(	O
50	O
)	O
DPD	B-FUNC
-	O
deficient	O
patients	O
(	O
28	O
%).	O

CONCLUSIONS	O
:	O
DPD	B-FUNC
deficiency	O
was	O
observed	O
in	O
several	O
ethnicities	O
.	O

Akin	O
to	O
5	O
-	O
FU	O
,	O
capecitabine	O
can	O
also	O
lead	O
to	O
severe	O
toxicities	O
in	O
DPD	B-FUNC
-	O
deficient	O
patients	O
.	O

TITLE	O
:	O
Spike	O
protein	O
,	O
S	O
,	O
of	O
human	O
coronavirus	O
HKU1	O
:	O
role	O
in	O
viral	O
life	O
cycle	O
and	O
application	O
in	O
antibody	B-FUNC
detection	O
.	O

This	O
unique	O
protease	O
is	O
not	O
only	O
responsible	O
for	O
processing	O
the	O
viral	O
polyprotein	O
into	O
its	O
functional	O
units	O
but	O
is	O
also	O
capable	O
of	O
cleaving	O
ubiquitin	B-FUNC
and	O
ISG15	O
conjugates	O
and	O
plays	O
a	O
significant	O
role	O
in	O
helping	O
SARS	O
-	O
CoV	O
evade	O
the	O
human	O
immune	O
system	O
.	O

The	O
X	O
-	O
ray	O
structure	O
of	O
PLpro	O
in	O
complex	O
with	O
GRL0617	O
indicates	O
that	O
the	O
compound	O
has	O
a	O
unique	O
mode	O
of	O
inhibition	O
whereby	O
it	O
binds	B-FUNC
within	O
the	O
S4	O
-	O
S3	O
subsites	O
of	O
the	O
enzyme	O
and	O
induces	O
a	O
loop	O
closure	O
that	O
shuts	O
down	O
catalysis	O
at	O
the	O
active	O
site	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
liver	O
pathology	O
is	O
dependent	O
on	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphatase	B-FUNC
,	O
a	O
viral	O
function	O
conserved	O
in	O
the	O
alpha	O
-	O
like	O
supergroup	O
.	O

X	O
-	O
domain	O
(	O
also	O
called	O
macro	O
domain	O
)	O
proteins	O
possess	O
poly	B-FUNC
-	I-FUNC
ADP	I-FUNC
-	I-FUNC
ribose	I-FUNC
binding	I-FUNC
and	O
/	O
or	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
activity	O
.	O

In	O
vitro	O
,	O
the	O
mutant	O
virus	O
induced	O
only	O
low	O
levels	O
of	O
the	O
inflammatory	O
cytokines	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
).	O

In	O
vivo	O
,	O
we	O
found	O
that	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
production	O
,	O
in	O
particular	O
,	O
was	O
reduced	O
in	O
the	O
spleens	O
and	O
livers	O
of	O
mutant	O
virus	O
-	O
infected	O
mice	O
.	O

Here	O
,	O
the	O
internalization	O
and	O
subsequent	O
trafficking	O
of	O
the	O
antigen	O
-	O
antibody	B-FUNC
complexes	O
were	O
characterized	O
using	O
biochemical	O
,	O
cell	O
biological	O
and	O
genetic	O
approaches	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
viral	O
antigen	O
-	O
antibody	B-FUNC
complexes	O
were	O
not	O
internalized	O
through	O
any	O
of	O
the	O
previously	O
described	O
pathways	O
.	O

After	O
internalization	O
,	O
the	O
viral	O
antigen	O
-	O
antibody	B-FUNC
complexes	O
passed	O
through	O
the	O
early	O
endosomes	O
,	O
where	O
they	O
resided	O
only	O
briefly	O
,	O
and	O
accumulated	O
in	O
the	O
late	O
endosomes	O
.	O

Between	O
30	O
and	O
60	O
min	O
after	O
antibody	B-FUNC
addition	O
,	O
the	O
complexes	O
left	O
the	O
late	O
endosomes	O
but	O
were	O
not	O
degraded	O
in	O
the	O
lysosomes	O
.	O

Using	O
a	O
wholly	O
recombinant	O
system	O
,	O
we	O
have	O
investigated	O
the	O
ability	O
of	O
each	O
virus	O
receptor	O
-	O
binding	B-FUNC
protein	O
,	O
spike	O
or	O
S	O
protein	O
,	O
to	O
bind	B-FUNC
to	O
ACE	O
-	O
2	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surface	O
.	O

In	O
both	O
assays	O
,	O
we	O
find	O
that	O
the	O
NL63	O
S	O
protein	O
has	O
a	O
weaker	O
interaction	O
with	O
ACE	O
-	O
2	O
than	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
particularly	O
in	O
solution	O
binding	B-FUNC
,	O
but	O
the	O
residues	O
required	O
for	O
contact	O
are	O
similar	O
.	O

We	O
also	O
confirm	O
that	O
the	O
ACE	O
-	O
2	O
-	O
binding	B-FUNC
site	O
of	O
NL63	O
S	O
lies	O
between	O
residues	O
190	O
and	O
739	O
.	O

Here	O
we	O
show	O
that	O
the	O
bacterially	O
expressed	O
human	O
PP11	O
displays	O
RNA	B-FUNC
binding	I-FUNC
capability	O
and	O
cleaves	O
single	O
stranded	O
RNA	O
in	O
a	O
Mn	O
(	O
2	O
+)-	O
dependent	O
manner	O
at	O
uridylates	O
,	O
to	O
produce	O
molecules	O
with	O
2	O
',	O
3	O
'-	O
cyclic	O
phosphate	O
ends	O
.	O

Nasal	O
discharge	O
was	O
recorded	O
,	O
and	O
antibody	B-FUNC
response	O
and	O
virus	O
shedding	O
were	O
measured	O
.	O

Furthermore	O
,	O
LC16mOrVV	O
-	O
N	O
-	O
immunized	O
mice	O
upon	O
infection	O
exhibited	O
significant	O
up	O
-	O
regulation	O
of	O
both	O
Th1	O
(	O
IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
and	O
Th2	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
)	O
cytokines	O
and	O
down	O
-	O
regulation	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TGF	O
-	O
beta	O
),	O
resulting	O
in	O
robust	O
infiltration	O
of	O
neutrophils	O
,	O
eosinophils	O
,	O
and	O
lymphocytes	O
into	O
the	O
lung	O
,	O
as	O
well	O
as	O
thickening	O
of	O
the	O
alveolar	O
epithelium	O
.	O

We	O
screened	O
sera	B-FUNC
from	O
10	O
children	O
and	O
196	O
adults	O
and	O
established	O
primary	O
cutoff	O
points	O
based	O
on	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibody	B-FUNC
levels	O
of	O
the	O
predominantly	O
seronegative	O
children	O
.	O

TITLE	O
:	O
Novel	O
modifications	O
in	O
the	O
series	O
of	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)-	O
N	O
-	O
substituted	O
thiocarbamates	O
and	O
their	O
ring	O
-	O
opened	O
congeners	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
N	O
-	O
aryl	O
-	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)	O
thiocarbamates	O
(	O
C	O
-	O
TCs	O
)	O
and	O
their	O
imide	O
ring	O
-	O
opened	O
congeners	O
(	O
O	O
-	O
TCs	O
)	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
were	O
further	O
investigated	O
.	O

In	O
ELISA	O
using	O
N1	O
or	O
N3	O
as	O
the	O
antigens	O
,	O
positive	O
results	O
were	O
observed	O
in	O
10	O
of	O
10	O
(	O
100	O
%)	O
SARS	O
-	O
CoV	O
-	O
positive	O
human	O
sera	B-FUNC
.	O

None	O
of	O
50	O
healthy	O
sera	B-FUNC
gave	O
positive	O
results	O
in	O
either	O
assay	O
.	O

TITLE	O
:	O
PLP2	O
,	O
a	O
potent	O
deubiquitinase	B-FUNC
from	O
murine	O
hepatitis	O
virus	O
,	O
strongly	O
inhibits	O
cellular	O
type	O
I	O
interferon	O
production	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
Papain	O
-	O
like	O
protease	O
domain	O
2	O
(	O
PLP2	O
),	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
of	O
MHV	O
-	O
A59	O
,	O
can	O
bind	B-FUNC
to	O
IRF3	O
,	O
cause	O
its	O
deubiquitination	O
and	O
prevent	O
its	O
nuclear	O
translocation	O
.	O

As	O
a	O
consequence	O
,	O
co	O
-	O
expression	O
of	O
PLP2	O
strongly	O
inhibits	O
CARDIF	O
-,	O
TBK1	B-FUNC
-	O
and	O
IRF3	O
-	O
mediated	O
IFNbeta	O
reporter	O
activities	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
wild	O
-	O
type	O
PLP2	O
but	O
not	O
the	O
mutant	O
PLP2	O
lacking	O
the	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
activity	O
can	O
reduce	O
IFN	O
induction	O
and	O
promote	O
viral	O
growth	O
in	O
cells	O
infected	O
with	O
VSV	O
.	O

It	O
has	O
the	O
advantages	O
of	O
fast	B-FUNC
analysis	O
,	O
high	O
sensitivity	O
,	O
high	O
resolution	O
and	O
low	O
-	O
cost	O
of	O
samples	O
.	O

However	O
,	O
its	O
inhibition	O
was	O
not	O
so	O
remarkable	O
as	O
that	O
found	O
with	O
SARS	O
-	O
CoV	O
infection	O
,	O
which	O
seems	O
to	O
indicate	O
that	O
while	O
CPL	B-FUNC
is	O
involved	O
in	O
the	O
fusogenic	O
activation	O
of	O
229E	O
S	O
protein	O
in	O
endosomal	O
infection	O
,	O
not	O
-	O
yet	O
-	O
identified	O
proteases	O
could	O
also	O
play	O
a	O
part	O
in	O
that	O
activity	O
.	O

We	O
also	O
found	O
229E	O
virion	O
S	O
protein	O
to	O
be	O
cleaved	O
by	O
CPL	B-FUNC
.	O

These	O
findings	O
suggest	O
that	O
229E	O
takes	O
an	O
endosomal	O
pathway	O
for	O
cell	O
entry	O
and	O
that	O
proteases	O
like	O
CPL	B-FUNC
are	O
involved	O
in	O
this	O
mode	O
of	O
entry	O
.	O

TITLE	O
:	O
Insertion	O
of	O
the	O
CXC	O
chemokine	O
ligand	B-FUNC
9	O
(	O
CXCL9	O
)	O
into	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
results	O
in	O
protection	O
from	O
viral	O
-	O
induced	O
encephalitis	O
and	O
hepatitis	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
the	O
CXC	O
chemokine	O
ligand	B-FUNC
9	O
(	O
CXCL9	O
)	O
in	O
host	O
defense	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
determined	O
.	O

CRCoV	O
was	O
shown	O
to	O
reduce	O
the	O
mRNA	O
levels	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
the	O
chemokine	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
during	O
the	O
72	O
h	O
post	O
-	O
inoculation	O
.	O

TITLE	O
:	O
Differential	O
activities	O
of	O
cellular	O
and	O
viral	O
macro	O
domain	O
proteins	O
in	O
binding	B-FUNC
of	O
ADP	O
-	O
ribose	O
metabolites	O
.	O

MDO2	O
specifically	O
bound	O
monomeric	O
ADP	O
-	O
ribose	O
with	O
a	O
high	O
affinity	O
(	O
K	O
(	O
d	O
)=	O
0	O
.	O
15	O
microM	O
),	O
but	O
did	O
not	O
bind	B-FUNC
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
efficiently	O
.	O

MDO1	O
was	O
generally	O
active	O
in	O
these	O
reactions	O
,	O
including	O
poly	B-FUNC
(	I-FUNC
A	I-FUNC
)	I-FUNC
binding	I-FUNC
.	O

Individual	O
point	O
mutations	O
in	O
MDO1	O
abolished	O
monomeric	O
ADP	B-FUNC
-	I-FUNC
ribose	I-FUNC
binding	I-FUNC
,	O
but	O
not	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
binding	B-FUNC
;	O
in	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
binding	B-FUNC
assays	O
,	O
the	O
monomer	O
did	O
not	O
compete	O
against	O
polymer	O
binding	B-FUNC
.	O

TITLE	O
:	O
Conserved	O
amino	O
acids	O
W423	O
and	O
N424	O
in	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
are	O
potential	O
targets	O
for	O
therapeutic	O
monoclonal	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
main	O
region	O
interacting	O
with	O
the	O
viral	O
receptor	O
-	O
ACE2	O
and	O
is	O
a	O
useful	O
target	O
for	O
induction	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

A	O
human	O
-	O
mouse	O
chimeric	O
antibody	B-FUNC
,	O
based	O
upon	O
the	O
original	O
murine	O
mAb	O
,	O
was	O
also	O
constructed	O
and	O
shown	O
to	O
possess	O
good	O
neutralizing	O
activity	O
and	O
high	O
affinity	O
.	O

A549	O
cells	O
were	O
shown	O
to	O
bind	B-FUNC
purified	O
soluble	O
HCoV	O
-	O
HKU1	O
S	O
(	O
1	O
-	O
600	O
)	O
glycopeptide	O
.	O

Sequencing	O
of	O
two	O
independent	O
clones	O
revealed	O
cDNA	O
inserts	O
encoding	O
HLA	O
-	O
C	O
.	O
Inhibition	O
of	O
HLA	O
-	O
C	O
expression	O
or	O
function	O
by	O
RNAi	O
silencing	O
and	O
anti	O
-	O
HLA	O
-	O
C	O
antibody	B-FUNC
decreased	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
infection	O
of	O
A549	O
cells	O
by	O
62	O
to	O
65	O
%,	O
whereas	O
pretreatment	O
of	O
cells	O
with	O
neuraminidase	O
decreased	O
such	O
infection	O
by	O
only	O
13	O
%.	O

When	O
HLA	O
-	O
C	O
was	O
constitutively	O
expressed	O
in	O
another	O
nonpermissive	O
cell	O
line	O
,	O
NIH	O
-	O
3T3	O
,	O
quantitative	O
PCR	O
showed	O
that	O
the	O
binding	B-FUNC
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
to	O
cell	O
surfaces	O
was	O
increased	O
by	O
200	O
-	O
fold	O
,	O
but	O
the	O
cells	O
remained	O
nonsusceptible	O
to	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
infection	O
.	O

The	O
vaccines	O
stimulated	O
gamma	O
interferon	O
production	O
mainly	O
by	O
CD8	O
(+)	O
T	O
cells	O
and	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
mainly	O
by	O
CD4	O
(+)	O
T	O
cells	O
.	O

We	O
have	O
developed	O
twin	O
assays	O
(	O
slide	O
agglutination	O
test	O
[	O
SAT	O
]	O
for	O
CPV	O
antigen	O
and	O
slide	O
inhibition	O
test	O
[	O
SIT	O
]	O
for	O
CPV	O
antibody	B-FUNC
)	O
that	O
are	O
sensitive	O
,	O
specific	O
,	O
cost	O
-	O
effective	O
,	O
generic	O
for	O
all	O
genotypes	O
of	O
CPV	O
,	O
and	O
provide	O
instant	O
results	O
for	O
CPV	O
antigen	O
detection	O
in	O
feces	O
and	O
antibody	B-FUNC
quantification	O
in	O
serum	O
.	O

Data	O
revealed	O
that	O
HR	O
-	O
C	O
domains	O
(	O
1153	O
-	O
1189	O
),	O
(	O
1153	O
-	O
1172	O
)	O
and	O
(	O
1164	O
-	O
1184	O
)	O
all	O
exhibit	O
potent	O
binding	B-FUNC
interactions	O
with	O
HR	O
-	O
N	O
(	O
892	O
-	O
931	O
)	O
domain	O
.	O

Tissue	O
samples	O
were	O
taken	O
at	O
3h	O
post	O
-	O
inoculation	O
(	O
hpi	B-FUNC
),	O
and	O
1	O
,	O
2	O
,	O
4	O
and	O
7	O
days	O
post	O
-	O
inoculation	O
(	O
dpi	O
)	O
with	O
E	O
.	O
coli	O
.	O

We	O
also	O
identified	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
as	O
key	O
SARS	O
-	O
CoV	O
-	O
induced	O
epithelial	O
cytokines	O
capable	O
of	O
inhibiting	O
the	O
T	O
-	O
cell	O
-	O
priming	O
ability	O
of	O
DC	O
.	O

The	O
results	O
showed	O
that	O
substitution	O
mutation	O
of	O
a	O
conserved	O
Gly	O
(	O
G98	O
)	O
residue	O
in	O
the	O
C	O
-	O
terminal	O
alpha	O
-	O
helix	O
domain	O
with	O
an	O
Asp	O
greatly	O
destabilized	O
the	O
IBV	O
nsp9	O
homodimer	O
and	O
abolished	O
its	O
RNA	O
-	O
binding	B-FUNC
activity	O
.	O

Meanwhile	O
,	O
mutations	O
of	O
some	O
positively	O
charged	O
residues	O
in	O
the	O
beta	O
-	O
barrel	O
regions	O
of	O
the	O
IBV	O
nsp9	O
protein	O
significantly	O
reduced	O
its	O
RNA	O
-	O
binding	B-FUNC
activity	O
,	O
but	O
with	O
no	O
obvious	O
effect	O
on	O
dimerization	O
of	O
the	O
protein	O
.	O

All	O
of	O
the	O
aptamers	O
that	O
were	O
selected	O
stimulated	O
ATPase	B-FUNC
activity	I-FUNC
of	O
the	O
SARS	O
-	O
CoV	O
helicase	O
with	O
low	O
-	O
nanomolar	O
apparent	O
K	O
(	O
m	O
)	O
values	O
.	O

ABSTRACT	O
:	O
A	O
transmissible	O
gastroenteritis	O
virus	O
strain	O
was	O
isolated	O
from	O
suspect	O
samples	O
in	O
Sichuan	O
province	O
and	O
identified	O
by	O
ST	O
cell	O
culture	O
,	O
direct	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
FA	O
),	O
neutralization	O
test	O
(	O
NT	O
),	O
TME	O
examination	O
and	O
some	O
other	O
methods	O
,	O
then	O
it	O
was	O
named	O
SC	O
-	O
Y	O
.	O
The	O
isolated	O
strain	O
could	O
produce	O
obvious	O
cytopathic	O
effects	O
(	O
CPE	O
),	O
The	O
TCID50	O
was	O
10	O
(-	O
3	O
.	O
664	O
)/	O
0	O
.	O
05	O
mL	O
,	O
The	O
neutralization	O
index	O
is	O
52	O
.	O
5	O
.	O

To	O
test	O
a	O
possible	O
route	O
of	O
emergence	O
from	O
the	O
noncultivable	O
Bat	O
-	O
SCoV	O
to	O
human	O
SARS	O
-	O
CoV	O
,	O
we	O
designed	O
a	O
consensus	O
Bat	O
-	O
SCoV	O
genome	O
and	O
replaced	O
the	O
Bat	O
-	O
SCoV	O
Spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
with	O
the	O
SARS	O
-	O
CoV	O
RBD	O
(	O
Bat	O
-	O
SRBD	O
).	O

The	O
fusion	O
protein	O
was	O
analyzed	O
for	O
reactivity	O
with	O
SARS	O
patients	O
'	O
sera	B-FUNC
and	O
with	O
anti	O
-	O
sera	B-FUNC
against	O
the	O
two	O
human	O
coronaviruses	O
HCoV	O
229E	O
and	O
HCoV	O
OC43	O
by	O
ELISA	O
,	O
IFA	O
and	O
immunoblot	O
assays	O
.	O

Furthermore	O
,	O
to	O
evaluate	O
the	O
antigen	O
-	O
specific	O
humoral	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
in	O
mice	O
,	O
the	O
fusion	O
protein	O
was	O
injected	O
into	O
6	O
-	O
week	O
-	O
old	O
BALB	O
/	O
c	O
mice	O
and	O
a	O
neutralization	O
test	O
as	O
well	O
as	O
a	O
T	O
-	O
cell	O
analysis	O
was	O
performed	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
based	O
test	O
with	O
a	O
cocktail	O
of	O
nucleocapsid	O
and	O
spike	O
proteins	O
for	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
-	O
specific	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
new	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)-	O
plus	O
-	O
IgM	O
antibody	B-FUNC
detection	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
developed	O
by	O
using	O
a	O
cocktail	O
of	O
four	O
recombinant	O
polypeptides	O
as	O
the	O
antigen	O
.	O

Immunization	O
with	O
a	O
cocktail	O
of	O
these	O
four	O
polypeptides	O
yielded	O
a	O
specific	O
polyclonal	O
antibody	B-FUNC
that	O
is	O
able	O
to	O
recognize	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
by	O
an	O
immunofluorescence	O
assay	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
suggested	O
that	O
antibody	B-FUNC
overproduction	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

The	O
present	O
study	O
shows	O
that	O
:	O
(	O
1	O
)	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cells	O
was	O
higher	O
in	O
cats	O
with	O
FIP	O
than	O
in	O
SPF	O
cats	O
,	O
(	O
2	O
)	O
the	O
albumin	O
-	O
to	O
-	O
globulin	O
ratio	O
has	O
negative	O
correlation	O
with	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cell	O
,	O
(	O
3	O
)	O
cells	O
strongly	O
expressing	O
mRNA	O
of	O
the	O
plasma	O
cell	O
master	O
gene	O
,	O
B	O
-	O
lymphocyte	O
-	O
induced	O
maturation	O
protein	O
1	O
(	O
Blimp	O
-	O
1	O
),	O
were	O
increased	O
in	O
peripheral	O
blood	O
in	O
cats	O
with	O
FIP	O
,	O
(	O
4	O
)	O
mRNA	O
expression	O
of	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CD40	O
ligand	B-FUNC
,	O
and	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
belonging	O
to	O
the	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
family	O
(	O
BAFF	O
),	O
was	O
enhanced	O
in	O
macrophages	O
in	O
cats	O
with	O
FIP	O
,	O
and	O
(	O
5	O
)	O
mRNAs	O
of	O
these	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
were	O
overexpressed	O
in	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)-	O
induced	O
macrophages	O
.	O

TITLE	O
:	O
Multiple	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
sites	O
and	O
intrinsic	O
disorder	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
:	O
implications	O
for	O
ribonucleocapsid	O
protein	O
packaging	O
.	O

However	O
,	O
the	O
RNA	O
-	O
binding	B-FUNC
mechanism	O
is	O
poorly	O
understood	O
.	O

Both	O
the	O
NTD	O
and	O
the	O
CTD	O
have	O
been	O
shown	O
to	O
bind	B-FUNC
RNA	O
.	O

Constructs	O
containing	O
multiple	O
RNA	O
-	O
binding	B-FUNC
regions	O
showed	O
Hill	O
coefficients	O
greater	O
than	O
1	O
,	O
suggesting	O
that	O
the	O
N	O
protein	O
binds	B-FUNC
to	O
RNA	O
cooperatively	O
.	O

The	O
current	O
results	O
underscore	O
the	O
important	O
roles	O
of	O
multisite	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
and	O
intrinsic	O
disorder	O
in	O
N	O
protein	O
function	O
and	O
RNP	O
packaging	O
.	O

NMR	O
chemical	O
shift	O
perturbation	O
experiments	O
showed	O
that	O
SUD	O
-	O
M	O
(	O
527	O
-	O
651	O
)	O
binds	B-FUNC
single	O
-	O
stranded	O
poly	O
(	O
A	O
)	O
and	O
identified	O
the	O
contact	O
area	O
with	O
this	O
RNA	O
on	O
the	O
protein	O
surface	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
then	O
confirmed	O
that	O
SUD	O
-	O
M	O
has	O
higher	O
affinity	O
for	O
purine	O
bases	O
than	O
for	O
pyrimidine	O
bases	O
.	O

In	O
a	O
further	O
search	O
for	O
clues	O
to	O
the	O
function	O
,	O
we	O
found	O
that	O
SUD	O
-	O
M	O
(	O
527	O
-	O
651	O
)	O
has	O
the	O
closest	O
three	O
-	O
dimensional	O
structure	O
homology	O
with	O
another	O
domain	O
of	O
nsp3	O
,	O
the	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
phosphatase	B-FUNC
nsp3b	O
,	O
although	O
the	O
two	O
proteins	O
share	O
only	O
5	O
%	O
sequence	O
identity	O
in	O
the	O
homologous	O
sequence	O
regions	O
.	O

SUD	O
-	O
M	O
(	O
527	O
-	O
651	O
)	O
also	O
shows	O
three	O
-	O
dimensional	O
structure	O
homology	O
with	O
several	O
helicases	O
and	O
nucleoside	O
triphosphate	O
-	O
binding	B-FUNC
proteins	O
,	O
but	O
it	O
does	O
not	O
contain	O
the	O
motifs	O
of	O
catalytic	O
residues	O
found	O
in	O
these	O
structural	O
homologues	O
.	O

The	O
highest	O
leukocyte	O
and	O
neutrophil	O
counts	O
,	O
lactate	O
dehydrogenase	O
,	O
and	O
creatine	O
kinase	O
;	O
positive	O
end	O
-	O
expiratory	O
pressure	O
;	O
and	O
use	O
of	O
corticosteroids	O
,	O
ribavirin	O
,	O
and	O
intravenous	O
immunoglobulin	B-FUNC
were	O
higher	O
in	O
the	O
SARS	O
group	O
.	O

ABSTRACT	O
:	O
Virus	O
discovery	O
based	O
on	O
cDNA	O
-	O
AFLP	O
(	O
amplified	O
fragment	O
length	O
polymorphism	O
)	O
(	O
VIDISCA	O
)	O
is	O
a	O
novel	O
approach	O
that	O
provides	O
a	O
fast	B-FUNC
and	O
effective	O
tool	O
for	O
amplification	O
of	O
unknown	O
genomes	O
,	O
e	O
.	O
g	O
.,	O
of	O
human	O
pathogenic	O
viruses	O
.	O

Virus	O
isolation	O
and	O
detection	O
of	O
antibody	B-FUNC
,	O
antigen	O
,	O
and	O
nucleic	O
acid	O
.	O

We	O
have	O
developed	O
and	O
optimized	O
laboratory	O
diagnostic	O
techniques	O
,	O
including	O
virus	O
isolation	O
in	O
HRT	O
-	O
18	O
cell	O
cultures	O
,	O
antibody	B-FUNC
and	O
antigen	O
ELISA	O
,	O
and	O
RT	O
-	O
PCR	O
,	O
for	O
rapid	O
,	O
sensitive	O
,	O
and	O
reliable	O
diagnosis	O
of	O
BCoV	O
and	O
related	O
wild	O
ruminant	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
contains	O
a	O
spike	O
(	O
S	O
)	O
protein	O
that	O
binds	B-FUNC
to	O
a	O
receptor	O
molecule	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
;	O
ACE2	O
),	O
induces	O
membrane	O
fusion	O
,	O
and	O
serves	O
as	O
a	O
neutralizing	O
epitope	O
.	O

Neutralization	O
assay	O
with	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
revealed	O
that	O
VSV	O
-	O
SARS	O
-	O
St19	O
/	O
GFP	O
pseudotype	O
infection	O
is	O
mediated	O
by	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

The	O
VSVdeltaaG	O
*/	O
SEAP	O
system	O
,	O
which	O
secretes	O
alkaline	O
phosphatase	B-FUNC
instead	O
of	O
GFP	O
,	O
was	O
also	O
generated	O
as	O
a	O
VSV	O
pseudotype	O
having	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
VSV	O
-	O
SARS	O
-	O
CoV	O
-	O
St19	O
/	O
SEAP	O
).	O

This	O
system	O
enabled	O
high	O
-	O
throughput	O
analysis	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
cell	O
entry	O
by	O
measuring	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
.	O

In	O
addition	O
to	O
the	O
cellular	O
receptor	O
,	O
porcine	O
aminopeptidase	O
N	O
,	O
the	O
TGEV	O
spike	O
protein	O
binds	B-FUNC
to	O
sialic	O
acid	O
residues	O
.	O

We	O
have	O
shown	O
that	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
mediates	O
the	O
binding	B-FUNC
of	O
TGEV	O
to	O
a	O
mucin	O
-	O
like	O
glycoprotein	O
present	O
in	O
porcine	O
brush	O
border	O
membranes	O
.	O

This	O
was	O
shown	O
by	O
performing	O
a	O
virus	O
overlay	O
binding	B-FUNC
assay	O
with	O
proteins	O
obtained	O
from	O
brush	O
border	O
membranes	O
by	O
lectin	O
precipitation	O
.	O

Thus	O
the	O
monoclonal	O
antibody	B-FUNC
approach	O
provides	O
useful	O
tools	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
SARS	O
,	O
as	O
well	O
as	O
for	O
possible	O
antibody	B-FUNC
-	O
based	O
treatment	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
by	O
feline	O
infectious	O
peritonitis	O
virus	O
regulates	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
in	O
primary	O
blood	O
-	O
derived	O
feline	O
mononuclear	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
acylthiocarbamates	O
(	O
ATCs	O
),	O
a	O
new	O
class	O
of	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
,	O
have	O
been	O
expanded	O
.	O

CXC	O
chemokines	O
as	O
well	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
were	O
significantly	O
elevated	O
and	O
reached	O
peaks	O
at	O
6	O
h	O
in	O
the	O
Gln	O
group	O
,	O
which	O
was	O
earlier	O
than	O
in	O
the	O
control	O
group	O
.	O

TITLE	O
:	O
Infectious	O
Bronchitis	O
Virus	O
induces	O
acute	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
production	O
through	O
polyclonal	O
stimulation	O
of	O
chicken	O
leukocytes	O
.	O

Treatment	O
with	O
anti	O
-	O
FGL2	O
antibody	B-FUNC
completely	O
inhibited	O
Treg	O
activity	O
and	O
protected	O
susceptible	O
BALB	O
/	O
cJ	O
mice	O
against	O
MHV	O
-	O
3	O
-	O
liver	O
injury	O
and	O
mortality	O
.	O

Among	O
non	O
-	O
structural	O
genes	O
,	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
),	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
)	O
and	O
the	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
sequences	O
are	O
100	O
%	O
identical	O
to	O
the	O
Gray	O
strain	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
independent	O
maintenance	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
in	O
the	O
CNS	O
during	O
chronic	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
in	O
T	O
cell	O
survival	O
was	O
examined	O
during	O
chronic	O
CNS	O
coronavirus	O
infection	O
.	O

IL	B-FUNC
-	I-FUNC
15	I-FUNC
deficiency	O
also	O
had	O
no	O
affect	O
on	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
receptor	O
(	O
CD127	O
)	O
expression	O
,	O
Bcl	O
-	O
2	O
upregulation	O
,	O
granzyme	O
B	O
expression	O
,	O
or	O
IFN	O
-	O
gamma	O
secretion	O
in	O
CNS	O
persisting	O
CD8	O
(+)	O
T	O
cells	O
.	O

Immunoprecipitation	O
brought	O
down	O
both	O
N	O
and	O
GSK	B-FUNC
-	O
3	O
proteins	O
in	O
the	O
same	O
complex	O
,	O
and	O
the	O
N	O
protein	O
could	O
be	O
phosphorylated	O
directly	O
at	O
its	O
SR	O
-	O
rich	O
motif	O
by	O
GSK	B-FUNC
-	O
3	O
using	O
an	O
in	O
vitro	O
kinase	O
assay	O
.	O

Finally	O
,	O
GSK	B-FUNC
-	O
3	O
inhibitor	O
was	O
found	O
to	O
reduce	O
N	O
phosphorylation	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
-	O
infected	O
VeroE6	O
cells	O
and	O
decrease	O
the	O
viral	O
titer	O
and	O
cytopathic	O
effects	O
.	O

The	O
expression	O
of	O
LSECtin	O
in	O
myeloid	O
cells	O
was	O
further	O
corroborated	O
through	O
the	O
analysis	O
of	O
the	O
proximal	O
regulatory	O
region	O
of	O
the	O
human	O
LSECtin	O
gene	O
,	O
whose	O
activity	O
was	O
maximal	O
in	O
LSECtin	O
+	O
myeloid	O
cells	O
,	O
and	O
which	O
contains	O
a	O
highly	O
conserved	O
PU	O
.	O
1	O
-	O
binding	B-FUNC
site	O
.	O

PU	O
.	O
1	O
transactivated	O
the	O
LSECtin	O
regulatory	O
region	O
in	O
collaboration	O
with	O
hematopoietic	O
-	O
restricted	O
transcription	O
factors	O
(	O
Myb	O
,	O
RUNX3	O
),	O
and	O
was	O
found	O
to	O
bind	B-FUNC
constitutively	O
to	O
the	O
LSECtin	O
proximal	O
promoter	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
proteins	O
decrease	O
levels	O
and	O
activity	O
of	O
human	O
ENaC	O
via	O
activation	O
of	O
distinct	O
PKC	B-FUNC
isoforms	O
.	O

Consistent	O
with	O
the	O
whole	O
cell	O
data	O
,	O
expression	O
of	O
S	O
and	O
E	O
proteins	O
decreased	O
ENaC	O
single	O
-	O
channel	B-FUNC
activity	I-FUNC
in	O
oocytes	O
,	O
and	O
these	O
effects	O
were	O
partially	O
abrogated	O
by	O
PKCalpha	B-FUNC
/	O
beta1	O
inhibitors	O
.	O

These	O
findings	O
indicate	O
that	O
lung	O
edema	O
in	O
SARS	O
infection	O
may	O
be	O
due	O
at	O
least	O
in	O
part	O
to	O
activation	O
of	O
PKC	B-FUNC
by	O
SARS	O
proteins	O
,	O
leading	O
to	O
decreasing	O
levels	O
and	O
activity	O
of	O
ENaC	O
at	O
the	O
apical	O
surfaces	O
of	O
lung	O
epithelial	O
cells	O
.	O

Serology	O
results	O
,	O
from	O
a	O
neutralizing	O
antibody	B-FUNC
assay	O
,	O
were	O
considered	O
positive	O
if	O
the	O
sera	B-FUNC
inhibited	O
the	O
development	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
-	O
specific	O
cytopathic	O
effect	O
at	O
a	O
dilution	O
of	O
>	O
or	O
=	O
1	O
:	O
8	O
.	O

Neutralizing	O
antibody	B-FUNC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
was	O
demonstrated	O
in	O
8	O
of	O
25	O
children	O
admitted	O
with	O
suspect	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

RESULTS	O
:	O
Neutralizing	O
antibody	B-FUNC
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
was	O
demonstrated	O
in	O
8	O
of	O
25	O
children	O
admitted	O
with	O
suspect	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
infection	O
.	O

Using	O
a	O
rabbit	O
polyclonal	O
antibody	B-FUNC
specific	O
to	O
the	O
N	O
protein	O
,	O
N	O
-	O
protein	O
-	O
containing	O
particles	O
similar	O
in	O
size	O
to	O
the	O
VLP	O
were	O
also	O
observed	O
by	O
immunoelectron	O
microscopy	O
,	O
indicating	O
that	O
the	O
VLP	O
contained	O
the	O
N	O
protein	O
.	O

Co	O
-	O
immunoprecipitation	O
analyses	O
demonstrated	O
an	O
interaction	O
between	O
the	O
N	O
and	O
M	O
proteins	O
,	O
suggesting	O
that	O
N	O
protein	O
binds	B-FUNC
directly	O
to	O
M	O
protein	O
to	O
be	O
incorporated	O
into	O
VLP	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
dependent	O
enhancement	O
occurs	O
upon	O
re	O
-	O
infection	O
with	O
the	O
identical	O
serotype	O
virus	O
in	O
feline	O
infectious	O
peritonitis	O
virus	O
infection	O
.	O

Antibody	B-FUNC
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
macrophage	O
infection	O
occurs	O
in	O
the	O
presence	O
of	O
antibodies	O
to	O
FIPV	O
S	O
protein	O
,	O
and	O
a	O
close	O
relationship	O
between	O
ADE	O
and	O
neutralizing	O
epitopes	O
has	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
Eight	O
isolates	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
obtained	O
from	O
various	O
prefectures	O
in	O
Japan	O
during	O
2003	O
-	O
2007	O
and	O
were	O
genetically	O
analyzed	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
coupled	O
with	O
direct	O
sequencing	O
.	O

TITLE	O
:	O
Induction	O
of	O
proinflammatory	O
cytokines	O
in	O
primary	O
human	O
macrophages	O
by	O
influenza	O
A	O
virus	O
(	O
H5N1	O
)	O
is	O
selectively	O
regulated	O
by	O
IFN	O
regulatory	O
factor	O
3	O
and	O
p38	B-FUNC
MAPK	B-FUNC
.	O

IRF3	O
knockdown	O
and	O
p38	B-FUNC
kinase	O
inhibition	O
separately	O
and	O
in	O
combination	O
led	O
to	O
a	O
substantial	O
reduction	O
of	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
but	O
only	O
to	O
a	O
partial	O
reduction	O
of	O
TNF	O
-	O
alpha	O
.	O

IRF3	O
translocation	O
was	O
independent	O
of	O
p38	B-FUNC
kinase	B-FUNC
activity	I-FUNC
,	O
indicating	O
that	O
IRF3	O
and	O
p38	B-FUNC
kinase	O
are	O
distinct	O
pathways	O
leading	O
to	O
cytokine	O
production	O
by	O
H5N1	O
virus	O
.	O

The	O
presence	O
of	O
specific	O
binding	B-FUNC
pockets	O
for	O
the	O
residues	O
of	O
peptidomimetic	O
inhibitors	O
explains	O
the	O
binding	B-FUNC
specificity	O
.	O

SARS	O
-	O
CoV	O
nonstructural	O
protein	O
9	O
(	O
nsp9	O
)	O
was	O
identified	O
as	O
an	O
essential	O
protein	O
with	O
RNA	O
/	O
DNA	O
-	O
binding	B-FUNC
activity	O
,	O
and	O
yet	O
its	O
biological	O
function	O
within	O
the	O
replication	O
complex	O
remains	O
unknown	O
.	O

Further	O
experiments	O
using	O
fluorescence	O
anisotropy	O
showed	O
a	O
10	O
-	O
fold	O
reduction	O
in	O
RNA	B-FUNC
binding	I-FUNC
in	O
the	O
G100E	O
and	O
G104E	O
mutants	O
,	O
whereas	O
the	O
G104V	O
mutant	O
had	O
only	O
a	O
4	O
-	O
fold	O
reduction	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
dimerization	O
of	O
SARS	O
-	O
CoV	O
nsp9	O
at	O
the	O
GXXXG	O
motif	O
is	O
not	O
critical	O
for	O
RNA	B-FUNC
binding	I-FUNC
but	O
is	O
necessary	O
for	O
viral	O
replication	O
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
and	O
the	O
tropism	O
for	O
the	O
respiratory	O
epithelium	O
of	O
four	O
different	O
strains	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

We	O
demonstrate	O
that	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
is	O
important	O
for	O
the	O
infection	O
of	O
primary	O
chicken	O
kidney	O
cells	O
and	O
the	O
tracheal	O
epithelium	O
by	O
all	O
four	O
strains	O
.	O

TITLE	O
:	O
A	O
novel	O
replication	O
-	O
competent	O
vaccinia	O
vector	O
MVTT	O
is	O
superior	O
to	O
MVA	O
for	O
inducing	O
high	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
via	O
mucosal	O
vaccination	O
.	O

TITLE	O
:	O
The	O
identification	O
of	O
a	O
calmodulin	O
-	O
binding	B-FUNC
domain	O
within	O
the	O
cytoplasmic	O
tail	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
gel	O
shift	O
assays	O
to	O
demonstrate	O
that	O
calmodulin	O
,	O
an	O
intracellular	O
calcium	O
-	O
binding	B-FUNC
protein	O
implicated	O
in	O
the	O
regulation	O
of	O
other	O
ectodomain	O
shedding	O
events	O
,	O
binds	B-FUNC
a	O
16	O
-	O
amino	O
acid	O
synthetic	O
peptide	O
corresponding	O
to	O
residues	O
762	O
-	O
777	O
within	O
the	O
cytoplasmic	O
domain	O
of	O
human	O
ACE2	O
,	O
forming	O
a	O
calcium	O
-	O
dependent	O
calmodulin	O
-	O
peptide	O
complex	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
ACE2	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
specifically	O
binds	B-FUNC
to	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
calmodulin	O
,	O
but	O
not	O
glutathione	O
-	O
S	O
-	O
transferase	O
alone	O
,	O
in	O
pull	O
-	O
down	O
assays	O
using	O
cell	O
lysates	O
.	O

Neutrophil	O
infiltration	O
measured	O
by	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
in	O
the	O
lung	O
was	O
significantly	O
increased	O
at	O
2	O
days	O
after	O
blast	O
and	O
returned	O
to	O
controls	O
at	O
8	O
days	O
.	O

This	O
increase	O
corresponded	O
with	O
activation	O
of	O
integrin	O
CD11b	O
mRNA	O
and	O
lung	O
inflammatory	O
chemokine	O
mRNA	O
expression	O
;	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
(	O
MIP	O
-	O
1	O
),	O
monocyte	O
chemotactic	O
peptide	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
(	O
CINC	O
-	O
1	O
).	O

In	O
addition	O
,	O
expression	O
of	O
heme	O
oxygenase	B-FUNC
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
mRNA	O
increased	O
at	O
2	O
days	O
after	O
exposure	O
.	O

N	O
-	O
Acetylcysteine	O
amide	O
significantly	O
reduced	O
infiltration	O
of	O
neutrophils	O
and	O
CD11b	O
mRNA	O
activation	O
in	O
lungs	O
,	O
and	O
completely	O
blocked	O
activation	O
of	O
MIP	O
-	O
1	O
,	O
MCP	B-FUNC
-	O
1	O
and	O
CINC	O
-	O
1	O
mRNA	O
.	O

The	O
relatively	O
higher	O
inhibition	O
of	O
chemokine	O
mRNAs	O
compared	O
with	O
reduction	O
in	O
MPO	B-FUNC
activity	O
and	O
CD11b	O
is	O
in	O
accordance	O
with	O
an	O
antioxidant	O
effect	O
of	O
NACA	O
on	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
accumulation	O
,	O
rather	O
than	O
by	O
an	O
effect	O
on	O
neutrophil	O
sequestration	O
.	O

TITLE	O
:	O
Organ	O
-	O
specific	O
attenuation	O
of	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
by	O
replacement	O
of	O
catalytic	O
residues	O
in	O
the	O
putative	O
viral	O
cyclic	O
phosphodiesterase	B-FUNC
ns2	O
.	O

TITLE	O
:	O
Crystal	O
structures	O
of	O
the	O
X	O
-	O
domains	O
of	O
a	O
Group	O
-	O
1	O
and	O
a	O
Group	O
-	O
3	O
coronavirus	O
reveal	O
that	O
ADP	O
-	O
ribose	O
-	O
binding	B-FUNC
may	O
not	O
be	O
a	O
conserved	O
property	O
.	O

Among	O
these	O
domains	O
,	O
the	O
so	O
-	O
called	O
X	O
-	O
domain	O
is	O
believed	O
to	O
act	O
as	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphate	O
phosphatase	B-FUNC
or	O
to	O
bind	B-FUNC
poly	O
(	O
ADP	O
-	O
ribose	O
).	O

However	O
,	O
here	O
we	O
show	O
that	O
the	O
X	O
-	O
domain	O
of	O
Infectious	O
Bronchitis	O
Virus	O
(	O
strain	O
Beaudette	O
),	O
a	O
Group	O
-	O
3	O
coronavirus	O
,	O
fails	O
to	O
bind	B-FUNC
ADP	O
-	O
ribose	O
.	O

The	O
PCRs	O
,	O
or	O
reverse	O
transcriptase	B-FUNC
-	O
PCRs	O
,	O
may	O
be	O
general	O
,	O
designed	O
to	O
detect	O
all	O
or	O
most	O
variants	O
of	O
a	O
pathogen	O
,	O
or	O
to	O
be	O
serotype	O
,	O
genotype	O
or	O
pathotype	O
specific	O
.	O

We	O
identified	O
differential	O
mRNA	O
abundances	O
of	O
genes	O
with	O
functional	O
properties	O
associated	O
with	O
antiviral	O
(	O
CXCL10	O
)	O
and	O
inflammatory	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
responses	O
.	O

We	O
further	O
analyzed	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
prominent	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
response	O
.	O

By	O
real	O
-	O
time	O
qRT	O
-	O
PCR	O
,	O
S	O
protein	O
was	O
shown	O
to	O
stimulate	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
mRNA	O
accumulation	O
in	O
a	O
dose	O
dependent	O
manner	O
while	O
treatment	O
with	O
E	O
protein	O
did	O
not	O
.	O

The	O
increase	O
in	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
stimulated	O
by	O
a	O
concentration	O
of	O
5	O
.	O
6nM	O
of	O
S	O
was	O
comparable	O
to	O
concentrations	O
seen	O
for	O
S	O
protein	B-FUNC
binding	I-FUNC
to	O
ACE2	O
or	O
to	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
suggesting	O
a	O
physiological	O
relevance	O
.	O

An	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
TPCK	O
(	O
N	O
-	O
Tosyl	O
-	O
L	O
-	O
Phenylalanine	O
Chloromethyl	O
Ketone	O
)	O
could	O
suppress	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
production	O
and	O
secretion	O
in	O
response	O
to	O
S	O
protein	O
in	O
PBMC	O
and	O
THP	O
-	O
1	O
cells	O
and	O
in	O
HCoV	O
-	O
229E	O
virus	O
-	O
infected	O
PBMC	O
.	O

The	O
results	O
further	O
suggested	O
that	O
released	O
or	O
secreted	O
S	O
protein	O
could	O
activate	O
blood	O
monocytes	O
through	O
recognition	O
by	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
ligand	B-FUNC
.	O

Surprisingly	O
,	O
63	O
%	O
of	O
the	O
apparently	O
healthy	O
calves	O
harbored	O
potentially	O
pathogenic	O
bacteria	O
in	O
the	O
lower	O
respiratory	O
tract	O
,	O
60	O
%	O
of	O
these	O
samples	O
contained	O
either	O
pure	B-FUNC
cultures	O
or	O
many	O
pathogenic	O
bacteria	O
in	O
mixed	O
culture	O
.	O

The	O
comparison	O
between	O
the	O
three	O
vaccination	O
routes	O
indicated	O
that	O
immunization	O
intramuscularly	O
induced	O
a	O
moderate	O
T	O
cell	O
response	O
and	O
antibody	B-FUNC
response	O
.	O

Mice	O
administrated	O
by	O
electroporation	O
induced	O
the	O
highest	O
antibody	B-FUNC
response	O
among	O
the	O
three	O
immunization	O
groups	O
and	O
a	O
mid	O
-	O
level	O
of	O
cellular	O
response	O
.	O

In	O
contrast	O
,	O
the	O
orally	O
DNA	O
vaccine	O
evoked	O
vigorous	O
T	O
cell	O
response	O
and	O
a	O
weak	O
antibody	B-FUNC
production	O
.	O

Two	O
hundred	O
and	O
ninety	O
-	O
seven	O
nasopharyngeal	O
secretions	O
were	O
collected	O
and	O
multiplex	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCR	O
)/	O
polymerase	O
chain	O
reactions	O
(	O
PCR	O
)	O
were	O
performed	O
to	O
detect	O
respiratory	O
viruses	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pulmonary	O
artery	O
catheter	O
placement	O
,	O
comorbidities	O
,	O
hospital	O
-	O
acquired	O
infection	O
,	O
APACHE	O
II	O
score	O
and	O
maximum	O
LOD	B-FUNC
score	O
,	O
were	O
independent	O
risk	O
factors	O
for	O
hospital	O
mortality	O
.	O

To	O
differentiate	O
the	O
genotypes	O
without	O
sequencing	O
,	O
a	O
simple	O
technique	O
-	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
(	O
RT	O
-	O
PCR	O
/	O
RFLP	O
)-	O
was	O
developed	O
.	O

The	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
S1	O
region	O
of	O
the	O
spike	O
glycoprotein	O
contains	O
multiple	O
conformational	O
epitopes	O
that	O
induces	O
highly	O
potent	O
neutralizing	O
antibodies	O
.	O

The	O
RBD	O
of	O
the	O
spike	O
glycoprotein	O
is	O
both	O
a	O
functional	O
domain	O
for	O
cell	O
receptor	B-FUNC
binding	I-FUNC
and	O
also	O
a	O
major	O
neutralizing	O
determinant	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
progress	O
in	O
evaluating	O
a	O
therapeutic	O
or	O
vaccine	O
would	O
depend	O
on	O
the	O
avail	O
ability	O
of	O
clinically	O
relevant	O
animal	O
model	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
SARS	O
CoVMpro	O
)	O
is	O
an	O
important	O
enzyme	O
for	O
the	O
replication	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
virus	O
.	O

Understanding	O
the	O
binding	B-FUNC
mode	O
of	O
SARS	O
CoVMpro	O
with	O
a	O
specific	O
substrate	O
is	O
useful	O
and	O
contributes	O
to	O
structural	O
-	O
based	O
drug	O
design	O
.	O

The	O
purpose	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
binding	B-FUNC
mode	O
between	O
the	O
SARS	O
CoVMpro	O
and	O
two	O
octapeptides	O
,	O
especially	O
in	O
the	O
region	O
of	O
the	O
S3	O
subsite	O
,	O
through	O
a	O
molecular	O
docking	O
and	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulation	O
approach	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
spike	O
proteins	O
expressed	O
by	O
the	O
vaccinia	O
virus	O
Tiantan	O
strain	O
:	O
secreted	O
sq	O
protein	O
induces	O
robust	O
neutralization	O
antibody	B-FUNC
in	O
mice	O
.	O

Structural	O
,	O
functional	O
and	O
biochemical	O
analyses	O
[	O
corrected	O
]	O
have	O
provided	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
receptor	O
recognition	O
and	O
antibody	B-FUNC
neutralization	O
,	O
and	O
suggested	O
that	O
these	O
antibodies	O
alone	O
or	O
in	O
combination	O
could	O
fight	O
the	O
viruses	O
'	O
heterogeneity	O
and	O
mutability	O
,	O
which	O
is	O
a	O
major	O
problem	O
in	O
the	O
development	O
of	O
effective	O
therapeutic	O
agents	O
against	O
viruses	O
,	O
including	O
therapeutic	O
antibodies	O
.	O

ABSTRACT	O
:	O
As	O
anti	O
-	O
HCV	O
aryl	O
diketoacids	O
(	O
ADK	O
)	O
are	O
good	O
metal	O
chelators	O
,	O
we	O
anticipated	O
that	O
ADKs	O
might	O
serve	O
as	O
potential	O
inhibitors	O
of	O
SARS	O
CoV	O
(	O
SCV	O
)	O
NTPase	O
/	O
helicase	O
(	O
Hel	O
)	O
by	O
mimicking	O
the	O
binding	B-FUNC
modes	O
of	O
the	O
bismuth	O
complexes	O
which	O
effectively	O
competes	O
for	O
the	O
Zn	O
(	O
2	O
+)	O
ion	B-FUNC
binding	I-FUNC
sites	O
in	O
SCV	O
Hel	O
thereby	O
disrupting	O
and	O
inhibiting	O
both	O
the	O
NTPase	O
and	O
helicase	O
activities	O
.	O

Phosphate	O
release	O
assay	O
and	O
FRET	O
-	O
based	O
assay	O
of	O
the	O
ADK	O
analogues	O
showed	O
that	O
the	O
ADKs	O
selectively	O
inhibit	O
the	O
duplex	O
DNA	O
-	O
unwinding	O
activity	O
without	O
significant	O
impact	O
on	O
the	O
helicase	O
ATPase	B-FUNC
activity	I-FUNC
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
might	O
be	O
ADK	O
-	O
specific	O
binding	B-FUNC
site	O
in	O
the	O
SCV	O
Hel	O
,	O
which	O
warrants	O
further	O
investigations	O
with	O
diverse	O
ADKs	O
to	O
provide	O
valuable	O
insights	O
into	O
rational	O
design	O
of	O
specific	O
SCV	O
Hel	O
inhibitors	O
.	O

TITLE	O
:	O
[	O
Expression	O
,	O
purification	O
and	O
antibody	B-FUNC
preparation	O
of	O
recombinat	O
SARS	O
-	O
CoV	O
X5	O
protein	O
].	O

Polyclonal	O
antibody	B-FUNC
of	O
this	O
protein	O
was	O
obtained	O
,	O
and	O
Western	O
blotting	O
assay	O
indicated	O
that	O
the	O
X5	O
protein	O
has	O
the	O
strong	O
property	O
of	O
antigen	O
.	O

HCoV	O
infection	O
was	O
determined	O
on	O
the	O
basis	O
of	O
a	O
4	O
-	O
fold	O
increase	O
in	O
serum	O
antibody	B-FUNC
and	O
the	O
detection	O
of	O
HCoV	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Furthermore	O
,	O
a	O
tight	O
positive	O
correlation	O
was	O
observed	O
between	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
and	O
NO	O
production	O
level	O
in	O
lung	O
tissue	O
.	O

TITLE	O
:	O
Thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
:	O
experiments	O
and	O
numerical	O
simulations	O
.	O

We	O
reported	O
previously	O
the	O
presence	O
of	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
in	O
sera	B-FUNC
from	O
mice	O
infected	O
with	O
MHV	O
-	O
A59	O
.	O

Carbon	O
tetrachloride	O
(	O
CCl	B-FUNC
(	O
4	O
))	O
was	O
injected	O
into	O
mice	O
30	O
days	O
after	O
MHV	O
infection	O
,	O
and	O
serum	O
was	O
assayed	O
for	O
autoAb	O
and	O
total	O
IgG	O
20	O
days	O
later	O
.	O

The	O
association	O
of	O
MHV	O
infection	O
with	O
the	O
toxic	O
effects	O
of	O
CCl	B-FUNC
(	O
4	O
)	O
resulted	O
in	O
hypergammaglobulinaemia	O
and	O
the	O
production	O
of	O
autoAb	O
to	O
various	O
liver	O
and	O
kidney	O
proteins	O
.	O

Histological	O
examination	O
of	O
liver	O
samples	O
showed	O
tissue	O
damages	O
but	O
without	O
significant	O
differences	O
between	O
the	O
animals	O
submitted	O
to	O
MHV	B-FUNC
+	I-FUNC
CCl	I-FUNC
(	O
4	O
)	O
and	O
controls	O
,	O
which	O
were	O
either	O
infected	O
by	O
MHV	O
without	O
CCl	B-FUNC
(	O
4	O
),	O
or	O
poisoned	O
by	O
CCl	B-FUNC
(	O
4	O
)	O
in	O
the	O
absence	O
of	O
MHV	O
infection	O
.	O

The	O
ability	O
of	O
the	O
rAd	O
-	O
N	O
to	O
induce	O
anti	O
-	O
SARS	O
-	O
CoV	O
N	O
antibody	B-FUNC
production	O
and	O
cellular	O
immune	O
responses	O
was	O
evaluated	O
in	O
an	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
Kb	O
transgenic	O
mouse	O
model	O
.	O

The	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
S	O
protein	O
delivered	O
via	O
adeno	O
-	O
associated	O
virus	O
can	O
efficiently	O
induce	O
mucosal	O
immunity	O
and	O
provide	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

When	O
different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
a	O
neutralising	O
antibody	B-FUNC
response	O
to	O
SARS	O
-	O
CoV	O
were	O
injected	O
into	O
a	O
mouse	O
model	O
,	O
all	O
the	O
mice	O
immunised	O
with	O
intramuscular	O
tPA	B-FUNC
-	O
optimised	O
800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
and	O
intramuscular	O
CTLA4Hinge	O
SARS800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
S	O
-	O
peptide	O
had	O
neutralising	O
antibody	B-FUNC
titres	O
of	O
>	O
1	O
:	O
1280	O
.	O
2	O
.	O

The	O
polymorphisms	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
IP	O
-	O
10	O
,	O
Mig	O
and	O
MCP	B-FUNC
-	O
1	O
are	O
not	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

Vaccinated	O
mice	O
were	O
protected	O
from	O
severe	O
respiratory	O
disease	O
in	O
parallel	O
with	O
a	O
low	O
virus	O
titer	O
in	O
the	O
lungs	O
and	O
a	O
high	O
neutralizing	O
antibody	B-FUNC
titer	O
in	O
the	O
plasma	O
.	O

Importantly	O
,	O
the	O
administration	O
of	O
spike	O
protein	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
protected	O
mice	O
from	O
the	O
disease	O
,	O
indicating	O
that	O
the	O
neutralization	O
is	O
sufficient	O
for	O
protection	O
.	O

Moreover	O
,	O
a	O
high	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
MCP	B-FUNC
-	O
1	O
production	O
,	O
but	O
not	O
other	O
18	O
cytokines	O
tested	O
,	O
on	O
days	O
2	O
and	O
3	O
after	O
SARS	O
-	O
CoV	O
infection	O
was	O
closely	O
linked	O
to	O
the	O
virus	O
replication	O
and	O
disease	O
severity	O
,	O
suggesting	O
the	O
importance	O
of	O
these	O
cytokines	O
in	O
the	O
lung	O
pathogenicity	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
bacterially	O
expressed	O
nsp11	O
proteins	O
of	O
two	O
arteriviruses	O
,	O
equine	O
arteritis	O
virus	O
and	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
,	O
possess	O
pyrimidine	O
-	O
specific	O
endoribonuclease	B-FUNC
activity	I-FUNC
.	O

Our	O
data	O
provide	O
the	O
first	O
biochemical	O
evidence	O
of	O
endoribonuclease	B-FUNC
activity	I-FUNC
associated	O
with	O
arterivirus	O
nsp11	O
and	O
support	O
the	O
conclusion	O
that	O
this	O
remarkable	O
RNA	O
-	O
processing	O
enzyme	O
,	O
whose	O
substrate	O
in	O
the	O
infected	O
cell	O
remains	O
to	O
be	O
identified	O
,	O
distinguishes	O
nidoviruses	O
from	O
all	O
other	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
Recombinant	O
Ov	O
-	O
ASP	O
-	O
1	O
,	O
a	O
Th1	O
-	O
biased	O
protein	O
adjuvant	O
derived	O
from	O
the	O
helminth	O
Onchocerca	O
volvulus	O
,	O
can	O
directly	O
bind	B-FUNC
and	O
activate	O
antigen	O
-	O
presenting	O
cells	O
.	O

Consistently	O
,	O
recombinant	O
full	O
-	O
length	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
or	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
the	O
presence	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
could	O
effectively	O
induce	O
a	O
mixed	O
but	O
Th1	O
-	O
skewed	O
immune	O
response	O
in	O
immunized	O
mice	O
.	O

The	O
development	O
of	O
specific	O
mucosal	O
immune	O
system	O
against	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
infection	O
for	O
ducks	O
has	O
been	O
hindered	O
by	O
a	O
lack	O
of	O
knowledge	O
concerning	O
the	O
purification	O
of	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
of	O
duck	O
.	O

Furthermore	O
,	O
a	O
marked	O
increased	O
level	O
of	O
DEV	O
-	O
specific	O
IgA	O
and	O
IgG	O
antibodies	O
in	O
bile	O
,	O
serum	O
and	O
the	O
intestinal	O
tract	O
,	O
as	O
well	O
as	O
the	O
density	O
of	O
IgA	O
(+)	O
cells	O
in	O
intestine	O
were	O
detected	O
between	O
1	O
and	O
12days	O
p	O
.	O
i	O
.,	O
followed	O
by	O
a	O
drastic	O
reduction	O
of	O
the	O
antibody	B-FUNC
levels	O
and	O
the	O
density	O
of	O
IgA	O
(+)	O
cells	O
at	O
15days	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
Virus	O
shedding	O
and	O
serum	O
antibody	B-FUNC
responses	O
during	O
experimental	O
turkey	O
coronavirus	O
infections	O
in	O
young	O
turkey	O
poults	O
.	O

Two	O
-	O
day	O
-	O
old	O
and	O
28	O
-	O
day	O
-	O
old	O
poults	O
were	O
inoculated	O
orally	O
with	O
TCoV	O
-	O
MG10	O
to	O
examine	O
the	O
effect	O
of	O
age	O
on	O
viral	O
shedding	O
and	O
serum	O
antibody	B-FUNC
responses	O
to	O
the	O
virus	O
.	O

TCoV	O
serum	O
antibody	B-FUNC
responses	O
were	O
assessed	O
with	O
two	O
recently	O
developed	O
TCoV	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
that	O
used	O
TCoV	O
nucleocapsid	O
and	O
S1	O
polypeptides	O
as	O
coating	O
antigens	O
.	O

TITLE	O
:	O
Structural	O
insights	O
into	O
immune	O
recognition	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	O
receptor	B-FUNC
binding	I-FUNC
domain	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
SARS	O
coronavirus	O
to	O
its	O
receptor	O
damages	O
islets	O
and	O
causes	O
acute	O
diabetes	O
.	O

Levels	O
of	O
the	O
acute	O
phase	O
protein	O
Interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
correlated	O
significantly	O
with	O
injury	O
severity	O
,	O
indicating	O
that	O
a	O
range	O
in	O
severity	O
of	O
the	O
inflammatory	O
response	O
was	O
present	O
in	O
the	O
studied	O
population	O
.	O

TITLE	O
:	O
Interleukin	O
-	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
),	O
but	O
not	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
,	O
deficiency	O
ameliorates	O
viral	O
encephalitis	O
without	O
affecting	O
viral	O
control	O
.	O

ABSTRACT	O
:	O
The	O
relative	O
contributions	O
of	O
interleukin	O
-	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
)	O
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
to	O
viral	O
pathogenesis	O
have	O
not	O
been	O
extensively	O
studied	O
.	O

Infection	O
of	O
mice	O
defective	O
in	O
both	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
(	O
p40	O
(-/-)),	O
in	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
alone	O
(	O
p35	O
(-/-)),	O
and	O
in	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
alone	O
(	O
p19	O
(-/-))	O
revealed	O
that	O
the	O
symptoms	O
of	O
coronavirus	O
-	O
induced	O
encephalitis	O
are	O
regulated	O
by	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
.	O

IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
producing	O
cells	O
never	O
exceeded	O
background	O
levels	O
,	O
supporting	O
a	O
redundant	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
in	O
pathogenesis	O
.	O

Reduced	O
morbidity	O
in	O
infected	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
deficient	O
mice	O
was	O
also	O
not	O
associated	O
with	O
altered	O
recruitment	O
or	O
composition	O
of	O
inflammatory	O
cells	O
.	O

Transcription	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	O
-	O
1beta	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
but	O
not	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
,	O
were	O
initially	O
reduced	O
in	O
infected	O
p35	O
(-/-)	O
mice	O
but	O
increased	O
to	O
wild	O
-	O
type	O
levels	O
during	O
peak	O
inflammation	O
.	O

Furthermore	O
,	O
although	O
transforming	B-FUNC
growth	I-FUNC
factor	I-FUNC
beta	I-FUNC
mRNA	O
was	O
not	O
affected	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
was	O
increased	O
in	O
the	O
CNS	O
in	O
the	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
.	O

Chi	O
-	O
squared	O
tests	O
showed	O
adverse	O
outcome	O
in	O
MABC	O
scores	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
the	O
reference	O
population	O
in	O
children	O
with	O
CDH	O
,	O
sepsis	O
and	O
PPH	B-FUNC
,	O
but	O
not	O
in	O
children	O
with	O
MAS	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
genetic	O
diversity	O
of	O
the	O
S2	O
gene	O
of	O
infectious	O
bronchitis	O
viruses	O
(	O
IBV	O
)	O
isolated	O
in	O
Japan	O
,	O
we	O
determined	O
the	O
nucleotide	O
sequences	O
of	O
these	O
IBVs	O
using	O
the	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
method	O
coupled	O
with	O
direct	O
sequencing	O
.	O

Bone	O
marrow	O
biopsy	O
revealed	O
necrotizing	O
epithelioid	O
granuloma	O
and	O
acid	O
-	O
fast	B-FUNC
bacilli	O
.	O

IAH	B-FUNC
is	O
associated	O
with	O
impaired	O
organ	O
dysfunction	O
,	O
especially	O
of	O
the	O
cardiovascular	O
,	O
respiratory	O
,	O
and	O
renal	O
systems	O
.	O

Using	O
current	O
definitions	O
,	O
the	O
incidence	O
of	O
the	O
clinical	O
manifestation	O
,	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
),	O
has	O
been	O
reported	O
as	O
27	O
%	O
in	O
the	O
largest	O
study	O
so	O
far	O
.	O

Preclinical	O
studies	O
in	O
experimental	O
animals	O
suggest	O
Poly	O
ICLC	O
and	O
liposome	O
-	O
encapsulated	O
Poly	O
ICLC	O
are	O
safe	O
and	O
offer	O
broad	O
-	O
spectrum	O
protection	O
against	O
both	O
seasonal	O
and	O
HPAI	B-FUNC
viruses	O
,	O
as	O
well	O
as	O
other	O
respiratory	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
and	O
SARS	O
.	O

The	O
clinical	O
safety	O
of	O
these	O
drugs	O
and	O
their	O
efficacy	O
in	O
pre	O
-	O
clinical	O
studies	O
may	O
provide	O
sufficient	O
justification	O
for	O
regulatory	O
agencies	O
to	O
consider	O
their	O
fast	B-FUNC
track	O
development	O
for	O
use	O
in	O
future	O
outbreaks	O
of	O
pandemic	O
influenza	O
or	O
of	O
other	O
emerging	O
respiratory	O
pathogens	O
.	O

When	O
admitted	O
to	O
the	O
hospital	O
,	O
severe	O
AP	O
patients	O
had	O
increased	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
TNF	O
-	O
alpha	O
.	O

The	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
the	O
AP	O
patients	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
level	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
especially	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

It	O
was	O
noted	O
that	O
in	O
severe	O
lung	O
injury	O
,	O
myeloperoxidase	B-FUNC
activity	I-FUNC
in	O
the	O
blood	O
increased	O
significantly	O
,	O
but	O
still	O
reflected	O
the	O
processes	O
taking	O
place	O
in	O
the	O
lung	O
parenchyma	O
.	O

In	O
the	O
pathogenesis	O
of	O
respiratory	O
complications	O
in	O
AP	O
cytokines	O
,	O
chemokines	O
and	O
adhesion	O
molecules	O
,	O
in	O
particular	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
eta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
E	O
-	O
selectin	B-FUNC
play	O
major	O
roles	O
.	O

At	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
concentrations	O
>	O
650	O
pg	O
/	O
ml	O
,	O
AP	O
patients	O
are	O
likely	O
to	O
develop	O
pulmonary	O
dysfunction	O
(	O
sensitivity	O
58	O
%,	O
specificity	O
100	O
%,	O
LR	O
-	O
positive	O
>	O
58	O
)	O
which	O
allows	O
us	O
to	O
use	O
it	O
as	O
a	O
screening	O
test	O
.	O

RESULTS	O
:	O
When	O
admitted	O
to	O
the	O
hospital	O
,	O
severe	O
AP	O
patients	O
had	O
increased	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
TNF	O
-	O
alpha	O
.	O

TITLE	O
:	O
Bovine	O
coronavirus	O
nonstructural	O
protein	O
1	O
(	O
p28	O
)	O
is	O
an	O
RNA	B-FUNC
binding	I-FUNC
protein	O
that	O
binds	B-FUNC
terminal	O
genomic	O
cis	O
-	O
replication	O
elements	O
.	O

Since	O
a	O
similar	O
nsp1	O
coding	O
region	O
appears	O
in	O
all	O
characterized	O
groups	O
1	O
and	O
2	O
coronavirus	O
DI	O
RNAs	O
and	O
must	O
be	O
translated	O
in	O
cis	O
for	O
BCoV	O
DI	O
RNA	O
replication	O
,	O
we	O
hypothesized	O
that	O
nsp1	O
might	O
regulate	O
ORF	O
1	O
expression	O
by	O
binding	B-FUNC
this	O
intra	O
-	O
nsp1	O
cistronic	O
element	O
.	O

Here	O
,	O
we	O
(	O
i	O
)	O
establish	O
by	O
mutation	O
analysis	O
that	O
the	O
72	O
-	O
nt	O
intracistronic	O
SLV	O
immediately	O
upstream	O
of	O
SLVI	O
is	O
also	O
a	O
DI	O
RNA	O
cis	O
-	O
replication	O
signal	O
,	O
(	O
ii	O
)	O
show	O
by	O
gel	O
shift	O
and	O
UV	O
-	O
cross	O
-	O
linking	O
analyses	O
that	O
cellular	O
proteins	O
of	O
approximately	O
60	O
and	O
100	O
kDa	O
,	O
but	O
not	O
viral	O
proteins	O
,	O
bind	B-FUNC
SLV	O
and	O
SLVI	O
,	O
(	O
SLV	O
-	O
VI	O
)	O
and	O
(	O
iii	O
)	O
demonstrate	O
by	O
gel	O
shift	O
analysis	O
that	O
nsp1	O
purified	O
from	O
Escherichia	O
coli	O
does	O
not	O
bind	B-FUNC
SLV	O
-	O
VI	O
but	O
does	O
bind	B-FUNC
three	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)-	O
and	O
one	O
3	O
'	O
UTR	O
-	O
located	O
cis	O
-	O
replication	O
SLs	O
.	O

It	O
can	O
extend	O
to	O
the	O
rest	B-FUNC
of	O
the	O
trunk	O
and	O
the	O
limbs	O
but	O
characteristically	O
spares	O
the	O
extremities	O
.	O

Using	O
mRNA	O
display	O
selection	O
and	O
directed	O
evolution	O
,	O
we	O
designed	O
novel	O
antibody	B-FUNC
-	O
like	O
protein	O
affinity	O
reagents	O
that	O
target	O
SARS	O
N	O
protein	O
with	O
high	O
affinity	O
and	O
selectivity	O
.	O

This	O
selection	O
resulted	O
in	O
eight	O
independent	O
10Fn3	O
intrabodies	O
,	O
two	O
that	O
require	O
the	O
N	O
-	O
terminal	O
domain	O
for	O
binding	B-FUNC
and	O
six	O
that	O
recognize	O
the	O
C	O
terminus	O
,	O
one	O
with	O
Kd	O
=	O
1	O
.	O
7	O
nM	O
.	O
10Fn3	O
intrabodies	O
are	O
well	O
expressed	O
in	O
mammalian	O
cells	O
and	O
are	O
relocalized	O
by	O
N	O
in	O
SARS	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
and	O
catalytic	O
domain	O
regulate	O
antagonism	O
of	O
IRF3	O
and	O
NF	O
-	O
kappaB	O
signaling	O
.	O

PLP	O
blocks	O
these	O
pathways	O
by	O
affecting	O
activation	O
of	O
the	O
important	O
signaling	O
proteins	O
in	O
each	O
pathway	O
,	O
IRF3	O
and	O
NF	O
-	O
kappaB	O
.	O
We	O
also	O
show	O
that	O
the	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
of	O
PLP	O
is	O
necessary	O
for	O
pathway	O
antagonism	O
but	O
not	O
sufficient	O
by	O
itself	O
to	O
block	O
these	O
pathways	O
regardless	O
of	O
the	O
enzymatic	O
activity	O
of	O
the	O
protease	O
.	O

A	O
similar	O
treatment	O
of	O
the	O
HIV	O
-	O
1	O
gp120	O
yielded	O
a	O
number	O
of	O
fragments	O
that	O
are	O
associated	O
with	O
the	O
critical	O
CD4	O
binding	B-FUNC
site	O
,	O
or	O
the	O
partially	O
buried	O
CCR5	O
binding	B-FUNC
site	O
of	O
the	O
protein	O
.	O

M	O
protein	O
potently	O
antagonizes	O
the	O
activation	O
of	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
dependent	O
transcription	O
by	O
double	O
-	O
stranded	O
RNA	O
,	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
TBK1	B-FUNC
,	O
IKKepsilon	O
,	O
and	O
virus	O
-	O
induced	O
signaling	O
adaptor	O
(	O
VISA	O
)	O
but	O
has	O
no	O
influence	O
on	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
when	O
IRF3	O
or	O
IRF7	O
is	O
overexpressed	O
.	O

The	O
immunogenicity	O
of	O
the	O
vaccine	O
was	O
assessed	O
by	O
intramuscular	O
injection	O
of	O
one	O
vaccine	O
dose	O
to	O
30	O
BCoV	O
-	O
antibody	B-FUNC
negative	O
2	O
-	O
3	O
-	O
month	O
-	O
old	O
calves	O
.	O

He	O
had	O
been	O
known	O
to	O
have	O
ingested	O
2	O
ml	O
of	O
pure	B-FUNC
GBL	O
every	O
half	O
an	O
hour	O
.	O

We	O
report	O
the	O
first	O
antibody	B-FUNC
-	O
mediated	O
Western	O
blot	O
detection	O
of	O
nsp6	O
from	O
MHV	O
-	O
infected	O
cells	O
.	O

The	O
positive	O
responses	O
of	O
IgM	O
and	O
IgG	O
antibodies	O
in	O
sera	B-FUNC
against	O
SARS	O
virus	O
from	O
the	O
first	O
week	O
to	O
the	O
sixth	O
week	O
after	O
onset	O
of	O
the	O
illness	O
in	O
patients	O
with	O
SARS	O
were	O
measured	O
.	O

The	O
ELISA	O
test	O
of	O
IgG	O
antibody	B-FUNC
was	O
negative	O
in	O
200	O
community	O
controls	O
.	O

IgG	O
antibody	B-FUNC
in	O
convalescent	O
serum	O
of	O
patients	O
with	O
SARS	O
revealed	O
an	O
increasing	O
trend	O
,	O
peaking	O
at	O
the	O
22nd	O
week	O
after	O
onset	O
of	O
illness	O
followed	O
by	O
a	O
slow	O
decline	O
.	O

TITLE	O
:	O
The	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
the	O
SARS	O
-	O
coronavirus	O
3a	O
protein	O
is	O
linked	O
to	O
its	O
pro	O
-	O
apoptotic	O
function	O
.	O

It	O
was	O
previously	O
reported	O
that	O
3a	O
possesses	O
potassium	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
.	O

We	O
further	O
demonstrated	O
that	O
the	O
blockade	O
of	O
3a	O
'	O
s	O
potassium	B-FUNC
channel	I-FUNC
activity	I-FUNC
abolished	O
caspase	O
-	O
dependent	O
apoptosis	O
.	O

This	O
report	O
provides	O
the	O
first	O
evidence	O
that	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
3a	O
is	O
required	O
for	O
its	O
pro	O
-	O
apoptotic	O
function	O
.	O

One	O
case	O
-	O
control	O
study	O
has	O
reported	O
an	O
association	O
between	O
susceptibility	O
to	O
SARS	O
and	O
mannan	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
in	O
China	O
.	O

Therefore	O
,	O
we	O
have	O
carried	O
out	O
a	O
study	O
of	O
the	O
binding	B-FUNC
and	O
interaction	O
with	O
model	O
membranes	O
of	O
a	O
peptide	O
corresponding	O
to	O
segment	O
1073	O
-	O
1095	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
,	O
peptide	O
SARS	O
(	O
L	O
)	O
in	O
the	O
presence	O
of	O
different	O
membrane	O
model	O
systems	O
,	O
as	O
well	O
as	O
the	O
structural	O
changes	O
taking	O
place	O
in	O
both	O
the	O
lipid	O
and	O
the	O
peptide	O
induced	O
by	O
the	O
binding	B-FUNC
of	O
the	O
peptide	O
to	O
the	O
membrane	O
.	O

TITLE	O
:	O
Use	O
of	O
recombinant	O
S1	O
spike	O
polypeptide	O
to	O
develop	O
a	O
TCoV	O
-	O
specific	O
antibody	B-FUNC
ELISA	O
.	O

Although	O
there	O
was	O
significant	O
positive	O
correlation	O
with	O
a	O
TCoV	O
-	O
N	O
protein	O
-	O
based	O
ELISA	O
,	O
there	O
was	O
little	O
to	O
no	O
correlation	O
with	O
the	O
whole	O
IBV	O
antigen	O
-	O
based	O
ELISA	O
when	O
field	O
sera	B-FUNC
were	O
tested	O
for	O
antibodies	O
against	O
TCoV	O
.	O

We	O
found	O
that	O
two	O
of	O
these	O
GFP	O
-	O
N	O
-	O
domain	O
fusion	O
proteins	O
were	O
selectively	O
packaged	O
into	O
virions	O
as	O
the	O
result	O
of	O
tight	O
binding	B-FUNC
to	O
the	O
N	O
protein	O
in	O
the	O
viral	O
nucleocapsid	O
,	O
in	O
a	O
manner	O
that	O
did	O
not	O
involve	O
association	O
with	O
either	O
M	O
protein	O
or	O
RNA	O
.	O

The	O
nature	O
of	O
each	O
type	O
of	O
binding	B-FUNC
was	O
further	O
explored	O
through	O
genetic	O
analysis	O
.	O

These	O
MAbs	O
would	O
be	O
a	O
useful	O
tool	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
HEV	O
and	O
also	O
for	O
antibody	B-FUNC
-	O
based	O
treatment	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
mimic	O
proteins	O
(	O
AMPs	O
)	O
are	O
polypeptides	O
that	O
bind	B-FUNC
to	O
their	O
target	O
analytes	O
with	O
high	O
affinity	O
and	O
specificity	O
,	O
just	O
like	O
conventional	O
antibodies	O
,	O
but	O
are	O
much	O
smaller	O
in	O
size	O
(	O
2	O
-	O
5	O
nm	O
,	O
less	O
than	O
10	O
kDa	O
).	O

Furthermore	O
,	O
the	O
binding	B-FUNC
constant	O
of	O
the	O
AMP	O
to	O
Fn	O
was	O
determined	O
from	O
the	O
concentration	O
dependence	O
of	O
the	O
response	O
of	O
our	O
biosensors	O
.	O

TITLE	O
:	O
Antigenicity	O
and	O
immunogenicity	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
stably	O
expressed	O
in	O
CHO	B-FUNC
cells	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
contains	O
multiple	O
conformation	O
-	O
dependent	O
epitopes	O
that	O
induce	O
neutralizing	O
antibody	B-FUNC
responses	O
.	O

Here	O
we	O
used	O
CHO	B-FUNC
-	O
K1	O
cells	O
to	O
establish	O
a	O
cell	O
line	O
for	O
stable	O
expression	O
of	O
a	O
193	O
-	O
mer	O
(	O
residues	O
318	O
-	O
510	O
)	O
RBD	O
(	O
RBD193	O
-	O
CHO	B-FUNC
)	O
and	O
determined	O
its	O
antigenicity	O
and	O
immunogenicity	O
.	O

By	O
inoculating	O
a	O
rabbit	O
with	O
the	O
purified	O
pAPN	O
,	O
a	O
high	O
tittered	O
specific	O
antibody	B-FUNC
was	O
achieved	O
.	O

Biologically	O
,	O
the	O
antibody	B-FUNC
reacted	O
with	O
either	O
pAPN	O
-	O
expressing	O
E	O
.	O
coli	O
or	O
native	O
pAPN	O
on	O
the	O
surface	O
of	O
swine	O
testis	O
cells	O
.	O

The	O
pAPN	O
and	O
its	O
specific	O
antibody	B-FUNC
blocked	O
transmissible	O
gastroenteritis	O
coronavirus	O
infection	O
in	O
vitro	O
.	O

ScFvs	O
of	O
mouse	O
monoclonal	O
antibody	B-FUNC
which	O
was	O
verified	O
to	O
neutralize	O
PEDV	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
expression	O
system	O
.	O

This	O
result	O
demonstrated	O
that	O
E	O
.	O
coli	O
expressing	O
scFvs	O
on	O
the	O
cell	O
surface	O
retained	O
functional	O
potency	O
of	O
parent	O
antibody	B-FUNC
and	O
therefore	O
blocked	O
PEDV	O
infection	O
into	O
target	O
cells	O
in	O
vitro	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
validate	O
a	O
colorimetric	O
method	O
to	O
measure	O
total	O
sialic	O
acid	O
(	O
TSA	B-FUNC
)	O
in	O
feline	O
serum	O
and	O
to	O
investigate	O
the	O
serum	O
concentration	O
of	O
TSA	B-FUNC
in	O
clinically	O
healthy	O
cats	O
seronegative	O
(	O
n	O
=	O
9	O
)	O
and	O
seropositive	O
(	O
n	O
=	O
48	O
)	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
and	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
,	O
n	O
=	O
28	O
),	O
tumors	O
(	O
n	O
=	O
20	O
),	O
or	O
inflammation	O
(	O
n	O
=	O
16	O
).	O

The	O
correlation	O
between	O
TSA	B-FUNC
and	O
alpha	O
(	O
1	O
)-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
was	O
also	O
investigated	O
.	O

The	O
method	O
employed	O
in	O
this	O
study	O
is	O
precise	O
and	O
accurate	O
at	O
TSA	B-FUNC
levels	O
(	O
in	O
mg	O
/	O
L	O
)	O
commonly	O
encountered	O
in	O
feline	O
serum	O
.	O

179	O
.	O
0	O
mg	O
/	O
L	O
)	O
cats	O
were	O
detectable	O
,	O
suggesting	O
that	O
the	O
simple	O
infection	O
by	O
FCoVs	O
does	O
not	O
influence	O
TSA	B-FUNC
levels	O
.	O

Compared	O
with	O
seropositive	O
controls	O
,	O
the	O
concentration	O
of	O
TSA	B-FUNC
was	O
higher	O
in	O
cats	O
with	O
FIP	O
(	O
556	O
.	O
7	O
+/-	O

The	O
discriminating	O
power	O
of	O
TSA	B-FUNC
for	O
FIP	O
is	O
moderate	O
(	O
area	O
under	O
the	O
ROC	O
curve	O
=	O
0	O
.	O
65	O
)	O
and	O
the	O
likelihood	O
ratio	O
is	O
higher	O
than	O
3	O
.	O
0	O
only	O
at	O
high	O
TSA	B-FUNC
levels	O
.	O

Consequently	O
,	O
TSA	B-FUNC
could	O
support	O
a	O
diagnosis	O
of	O
FIP	O
only	O
at	O
extremely	O
high	O
serum	O
concentration	O
(>	O
800	O
mg	O
/	O
L	O
)	O
or	O
when	O
the	O
pre	O
-	O
test	O
probability	O
of	O
FIP	O
is	O
high	O
.	O

No	O
correlations	O
were	O
found	O
between	O
the	O
TSA	B-FUNC
and	O
AGP	O
concentrations	O
in	O
cats	O
with	O
FIP	O
,	O
suggesting	O
that	O
sialylated	O
proteins	O
other	O
than	O
AGP	O
are	O
present	O
.	O

Both	O
the	O
antibody	B-FUNC
titre	O
and	O
the	O
degree	O
of	O
AGP	O
sialylation	O
were	O
negatively	O
correlated	O
with	O
TSA	B-FUNC
levels	O
,	O
suggesting	O
that	O
increased	O
TSA	B-FUNC
may	O
contribute	O
to	O
reduce	O
the	O
burden	O
of	O
FCoVs	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
of	O
SARS	O
coronavirus	O
contains	O
two	O
macrodomains	O
that	O
bind	B-FUNC
G	O
-	O
quadruplexes	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
latter	O
,	O
SUD	O
fails	O
to	O
bind	B-FUNC
ADP	O
-	O
ribose	O
,	O
as	O
determined	O
by	O
zone	O
-	O
interference	O
gel	O
electrophoresis	O
.	O

Mutations	O
of	O
selected	O
lysine	O
residues	O
on	O
the	O
surface	O
of	O
the	O
SUD	O
-	O
N	O
subdomain	O
lead	O
to	O
reduction	O
of	O
G	O
-	O
quadruplex	O
binding	B-FUNC
,	O
whereas	O
mutations	O
in	O
the	O
SUD	O
-	O
M	O
subdomain	O
abolish	O
it	O
.	O

The	O
SARS	O
-	O
CoV	O
genome	O
is	O
devoid	O
of	O
G	O
-	O
stretches	O
longer	O
than	O
5	O
-	O
6	O
nucleotides	O
,	O
but	O
more	O
extended	O
G	O
-	O
stretches	O
are	O
found	O
in	O
the	O
3	O
'-	O
nontranslated	O
regions	O
of	O
mRNAs	O
coding	O
for	O
certain	O
host	O
-	O
cell	O
proteins	O
involved	O
in	O
apoptosis	O
or	O
signal	O
transduction	O
,	O
and	O
have	O
been	O
shown	O
to	O
bind	B-FUNC
to	O
SUD	O
in	O
vitro	O
.	O

TITLE	O
:	O
Elevated	O
plasma	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
)	O
levels	O
and	O
a	O
direct	O
correlation	O
with	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
specific	O
IgG	O
antibody	B-FUNC
in	O
SARS	O
patients	O
.	O

SP	O
-	O
D	O
is	O
recognized	O
to	O
bind	B-FUNC
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
and	O
enhance	O
phagocytosis	O
.	O

TITLE	O
:	O
Coronavirus	O
genetically	O
redirected	O
to	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
exhibits	O
effective	O
antitumor	O
activity	O
against	O
a	O
malignant	O
glioblastoma	O
.	O

To	O
investigate	O
this	O
potential	O
,	O
we	O
redirected	O
the	O
coronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
which	O
is	O
normally	O
unable	O
to	O
infect	O
human	O
cells	O
,	O
to	O
human	O
tumor	O
cells	O
by	O
using	O
a	O
soluble	O
receptor	O
(	O
soR	B-FUNC
)-	O
based	O
expression	O
construct	O
fused	O
to	O
an	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
EGF	B-FUNC
)	O
receptor	O
targeting	O
moiety	O
.	O

Addition	O
of	O
this	O
adapter	O
protein	O
to	O
MHV	O
allowed	O
infection	O
of	O
otherwise	O
nonsusceptible	O
,	O
EGF	B-FUNC
receptor	O
(	O
EGFR	B-FUNC
)-	O
expressing	O
cell	O
cultures	O
.	O

We	O
introduced	O
the	O
sequence	O
encoding	O
the	O
adaptor	O
protein	O
soR	B-FUNC
-	O
EGF	B-FUNC
into	O
the	O
MHV	O
genome	O
to	O
generate	O
a	O
self	O
-	O
targeted	O
virus	O
capable	O
of	O
multiround	O
infection	O
.	O

Treatment	O
of	O
mice	O
bearing	O
a	O
lethal	O
intracranial	O
U87DeltaEGFR	O
tumor	O
by	O
injection	O
with	O
MHVsoR	O
-	O
EGF	B-FUNC
significantly	O
prolonged	O
survival	O
compared	O
to	O
phosphate	O
-	O
buffered	O
saline	O
-	O
treated	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
control	O
virus	O
-	O
treated	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
animals	O
,	O
and	O
no	O
recurrent	O
tumor	O
load	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
conduct	O
fast	B-FUNC
screening	O
of	O
passengers	O
with	O
infections	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
pandemic	O
influenza	O
at	O
a	O
quarantine	O
depot	O
,	O
we	O
developed	O
a	O
non	O
-	O
contact	O
screening	O
system	O
with	O
a	O
self	O
-	O
produced	O
program	O
to	O
conduct	O
a	O
human	O
screening	O
within	O
five	O
seconds	O
,	O
via	O
a	O
linear	O
discriminant	O
function	O
from	O
non	O
-	O
contact	O
derived	O
variables	O
,	O
i	O
.	O
e	O
.	O
palmer	O
pulse	O
derived	O
from	O
a	O
laser	O
Doppler	O
blood	O
-	O
flow	O
meter	O
,	O
respiration	O
rate	O
determined	O
by	O
a	O
10	O
-	O
GHz	O
microwave	O
radar	O
,	O
and	O
facial	O
temperature	O
measured	O
by	O
a	O
thermography	O
.	O

The	O
proposed	O
system	O
appears	O
promising	O
for	O
future	O
application	O
in	O
fast	B-FUNC
screening	O
of	O
infection	O
at	O
a	O
quarantine	O
depot	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
intestinal	O
mucosal	O
immune	O
responses	O
in	O
ducklings	O
orally	O
inoculated	O
with	O
attenuated	O
Duck	O
enteritis	O
virus	O
(	O
DEV	O
),	O
the	O
kinetics	O
of	O
the	O
viral	O
load	O
,	O
the	O
specific	O
humoral	O
immune	O
responses	O
,	O
and	O
the	O
distribution	O
of	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
A	O
-	O
secreting	O
cells	O
in	O
the	O
intestine	O
were	O
evaluated	O
.	O

ABSTRACT	O
:	O
The	O
effects	O
of	O
glycyrrhizin	O
diammonium	O
(	O
GD	O
)	O
and	O
lithium	O
chloride	O
(	O
LiCl	O
)	O
on	O
cell	O
infection	O
by	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
investigated	O
using	O
cytopathic	O
effect	O
observation	O
,	O
plaque	O
-	O
reduction	O
assay	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Characterization	O
of	O
cytotoxic	O
T	O
-	O
lymphocyte	O
epitopes	O
and	O
immune	O
responses	O
to	O
SARS	O
coronavirus	O
spike	O
DNA	O
vaccine	O
expressing	O
the	O
RGD	O
-	O
integrin	O
-	O
binding	B-FUNC
motif	O
.	O

Significant	O
cell	O
-	O
mediated	O
immune	O
responses	O
were	O
characterized	O
by	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
51	O
)	O
Cr	O
release	O
assay	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
secretion	O
ELISPOT	O
assay	O
against	O
RMA	O
-	O
S	O
target	O
cells	O
presenting	O
predicted	O
MHC	O
class	O
I	O
H2	O
-	O
Kb	O
epitopes	O
,	O
including	O
those	O
spanning	O
residues	O
884	O
-	O
891	O
and	O
1116	O
-	O
1123	O
within	O
the	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

Moreover	O
,	O
the	O
Spike	O
-	O
His	O
DNA	O
vaccine	O
construct	O
generated	O
a	O
significant	O
antibody	B-FUNC
response	O
.	O

The	O
background	O
of	O
the	O
cat	O
,	O
its	O
history	O
,	O
the	O
clinical	O
signs	O
,	O
laboratory	O
changes	O
,	O
antibody	B-FUNC
titres	O
and	O
effusion	O
analysis	O
should	O
all	O
be	O
used	O
to	O
help	O
in	O
decision	O
-	O
making	O
about	O
further	O
diagnostic	O
procedures	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
conduct	O
fast	B-FUNC
screening	O
of	O
passengers	O
with	O
infections	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
or	O
pandemic	O
influenza	O
at	O
a	O
quarantine	O
depot	O
,	O
we	O
developed	O
a	O
non	O
-	O
contact	O
screening	O
system	O
with	O
self	O
-	O
produced	O
program	O
to	O
conduct	O
a	O
human	O
screening	O
within	O
five	O
seconds	O
,	O
via	O
a	O
linear	O
discriminant	O
function	O
from	O
non	O
-	O
contact	O
derived	O
variables	O
,	O
i	O
.	O
e	O
.	O
palmer	O
pulse	O
derived	O
from	O
a	O
laser	O
Doppler	O
blood	O
-	O
flow	O
meter	O
,	O
respiration	O
rate	O
determined	O
by	O
a	O
10	O
-	O
GHz	O
microwave	O
radar	O
,	O
and	O
facial	O
temperature	O
measured	O
by	O
thermography	O
.	O

ABSTRACT	O
:	O
Systemic	O
administration	O
of	O
corticosteroid	O
,	O
plasmapheresis	O
and	O
high	O
-	O
dose	O
immunoglobulin	B-FUNC
therapy	O
(	O
IVIG	O
)	O
are	O
the	O
main	O
treatment	O
of	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
).	O

TITLE	O
:	O
Recombinant	O
S	O
-	O
layer	O
proteins	O
of	O
Lactobacillus	O
brevis	O
mediating	O
antibody	B-FUNC
adhesion	O
to	O
calf	O
intestine	O
alleviated	O
neonatal	O
diarrhea	O
syndrome	O
.	O

ABSTRACT	O
:	O
A	O
chimeric	O
gene	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
and	O
a	O
S	O
-	O
layer	O
protein	O
from	O
Lactobacillus	O
brevis	O
KCTC3102	O
,	O
and	O
/	O
or	O
two	O
copies	O
of	O
the	O
Fc	O
-	O
binding	B-FUNC
Z	O
-	O
domain	O
,	O
a	O
synthetic	O
analog	O
of	O
the	O
B	O
-	O
domain	O
of	O
protein	O
A	O
,	O
was	O
constructed	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
).	O

The	O
field	O
isolates	O
of	O
4	O
/	O
91	O
genotype	O
IBV	O
could	O
be	O
distinguished	O
from	O
other	O
genotypes	O
by	O
using	O
the	O
BalI	O
and	O
Pst	B-FUNC
I	O
enzymes	O
in	O
addition	O
to	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
methods	O
of	O
Mase	O
et	O
al	O
.	O
[	O
16	O
]	O
using	O
Hae	O
II	O
and	O
EcoR	O
I	O
enzymes	O
.	O

By	O
using	O
cytoskeletal	O
inhibitors	O
,	O
it	O
was	O
suggested	O
that	O
propagation	O
of	O
HEV	O
and	O
PRV	O
within	O
and	O
among	O
nerve	O
cells	O
depended	O
on	O
microtubules	O
and	O
intermediate	O
filaments	O
of	O
nerve	O
cells	O
,	O
indicating	O
that	O
the	O
viruses	O
may	O
be	O
transported	O
between	O
the	O
cell	O
body	O
and	O
axonal	O
terminals	O
of	O
neurons	O
by	O
fast	B-FUNC
axonal	O
flow	O
.	O

Our	O
results	O
demonstrates	O
that	O
SARS	O
-	O
CoV	O
did	O
not	O
modulate	O
TLR	O
-	O
1	O
to	O
TLR	O
-	O
10	O
gene	O
expression	O
but	O
significantly	O
induced	O
the	O
expression	O
of	O
CCR	B-FUNC
-	O
1	O
,	O
CCR	B-FUNC
-	O
3	O
,	O
and	O
CCR	B-FUNC
-	O
5	O
.	O

SARS	O
-	O
CoV	O
protein	O
eukaryotic	O
expression	O
plasmids	O
were	O
transfected	O
respectively	O
into	O
CHO	B-FUNC
cells	O
.	O

M	O
,	O
N	O
and	O
S2	O
proteins	O
of	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
cytoplasm	O
of	O
transfected	O
CHO	B-FUNC
cells	O
.	O

Rats	O
with	O
LC	O
+	O
CASP	O
versus	O
LC	O
had	O
more	O
severe	O
inflammation	O
based	O
on	O
higher	O
levels	O
of	O
PMN	O
in	O
BAL	O
at	O
5	O
h	O
,	O
increased	O
whole	O
lung	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
at	O
5	O
and	O
24	O
h	O
,	O
and	O
increased	O
levels	O
of	O
inflammatory	O
mediators	O
in	O
BAL	O
(	O
TNFalpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
at	O
5	O
and	O
24	O
h	O
;	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
MIP	O
-	O
2	O
,	O
and	O
CINC	O
-	O
1	O
at	O
5	O
h	O
).	O

Rats	O
with	O
LC	O
+	O
CASP	O
also	O
had	O
distinct	O
aspects	O
of	O
inflammation	O
compared	O
with	O
CASP	O
alone	O
,	O
i	O
.	O
e	O
.,	O
significantly	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(	O
5	O
and	O
24	O
h	O
),	O
IL	O
-	O
1beta	O
(	O
24	O
h	O
),	O
CINC	O
-	O
1	O
(	O
24	O
h	O
),	O
and	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
),	O
and	O
significantly	O
lower	O
levels	O
of	O
MPO	B-FUNC
(	O
5	O
h	O
),	O
MIP	O
-	O
2	O
(	O
5	O
h	O
),	O
and	O
CINC	O
-	O
1	O
(	O
5	O
h	O
).	O

During	O
vaccination	O
of	O
rN	O
protein	O
,	O
the	O
expression	O
of	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
was	O
evidently	O
up	O
-	O
regulated	O
in	O
splenocytes	O
at	O
different	O
time	O
points	O
,	O
while	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
was	O
not	O
.	O

Cytometry	O
analysis	O
indicated	O
that	O
the	O
majority	O
of	O
memory	O
CD8	O
(+)	O
T	O
cells	O
produced	O
IFN	O
-	O
gamma	O
,	O
whereas	O
memory	O
CD4	O
(+)	O
T	O
cells	O
produced	O
IFN	O
-	O
gamma	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
or	O
TNF	O
-	O
alpha	O
.	O

Under	O
the	O
condition	O
of	O
the	O
establishment	O
of	O
dendrtic	O
cells	O
(	O
DC	O
)	O
culture	O
method	O
,	O
we	O
used	O
recombinant	O
adenovirus	O
to	O
infect	O
mature	O
DC	O
to	O
make	O
clear	O
the	O
development	O
changes	O
in	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
proinflammatory	O
cytokines	O
of	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
alpha	O
by	O
using	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

We	O
found	O
that	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
in	O
DC	O
had	O
increased	O
gradually	O
after	O
rAd	O
-	O
N	O
infection	O
during	O
first	O
24	O
h	O
compared	O
with	O
the	O
control	O
DC	O
infected	O
by	O
rAd	O
-	O
LacZ	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

METHODS	O
:	O
Under	O
the	O
condition	O
of	O
the	O
establishment	O
of	O
dendrtic	O
cells	O
(	O
DC	O
)	O
culture	O
method	O
,	O
we	O
used	O
recombinant	O
adenovirus	O
to	O
infect	O
mature	O
DC	O
to	O
make	O
clear	O
the	O
development	O
changes	O
in	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
proinflammatory	O
cytokines	O
of	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
alpha	O
by	O
using	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

The	O
effect	O
of	O
dobutamine	O
on	O
AFC	O
and	O
the	O
expression	O
of	O
aquaporin	B-FUNC
-	O
1	O
and	O
aquaporin	B-FUNC
-	O
5	O
were	O
examined	O
.	O

Our	O
study	O
indicates	O
that	O
dobutamine	O
may	O
enhance	O
alveolar	O
fluid	O
reabsorption	O
by	O
increasing	O
the	O
expression	O
of	O
aquaporin	B-FUNC
-	O
1	O
and	O
aquaporin	B-FUNC
-	O
5	O
.	O

Mutations	O
of	O
the	O
conserved	O
residues	O
of	O
nspl4	O
resulted	O
in	O
significant	O
attenuation	O
but	O
not	O
abolishment	O
of	O
the	O
ribonuclease	B-FUNC
activity	I-FUNC
.	O

The	O
5	O
-	O
plexed	O
immunoassays	O
using	O
sets	O
of	O
9	O
-	O
plexed	O
coupled	O
fluorescent	O
beads	O
were	O
employed	O
to	O
simultaneously	O
detect	O
five	O
representative	O
biothreat	O
agents	O
,	O
including	O
B	O
.	O
anthracis	O
spore	O
,	O
Y	O
.	O
pestis	O
,	O
SARS	O
-	O
CoV	O
,	O
staphylococcal	O
enterotoxin	O
B	O
(	O
SEB	O
)	O
and	O
ricin	B-FUNC
from	O
a	O
single	O
powder	O
sample	O
and	O
the	O
feasibility	O
for	O
field	O
samples	O
was	O
demonstrated	O
by	O
both	O
blinded	O
and	O
standard	O
laboratory	O
trials	O
.	O

The	O
limit	O
of	O
detection	O
for	O
Y	O
.	O
pestis	O
,	O
B	O
.	O
anthracis	O
spores	O
,	O
SEB	O
,	O
ricin	B-FUNC
,	O
SARS	O
-	O
CoV	O
N	O
protein	O
in	O
milk	O
powder	O
was	O
20	O
cfu	O
,	O
111	O
cfu	O
,	O
110pg	O
,	O
5	O
.	O
4	O
ng	O
and	O
2	O
ng	O
per	O
test	O
respectively	O
.	O

ABSTRACT	O
:	O
A	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)-	O
based	O
biosensor	O
was	O
developed	O
for	O
simple	O
diagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
using	O
a	O
protein	O
created	O
by	O
genetically	O
fusing	O
gold	O
binding	B-FUNC
polypeptides	O
(	O
GBPs	O
)	O
to	O
a	O
SARS	O
coronaviral	O
surface	O
antigen	O
(	O
SCVme	O
).	O

The	O
fusion	O
protein	O
provides	O
a	O
simple	O
and	O
effective	O
method	O
for	O
construction	O
of	O
SPR	O
sensing	O
platforms	O
permitting	O
sensitive	O
and	O
selective	O
detection	O
of	O
anti	O
-	O
SCVme	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
Feline	O
sera	B-FUNC
from	O
Bursa	O
province	O
(	O
Turkey	O
)	O
were	O
assayed	O
for	O
coronavirus	O
antibody	B-FUNC
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
study	O
was	O
performed	O
on	O
100	O
sera	B-FUNC
collected	O
from	O
cats	O
belonging	O
to	O
catteries	O
or	O
community	O
shelters	O
and	O
to	O
households	O
.	O

The	O
ELISA	O
-	O
negative	O
sera	B-FUNC
were	O
also	O
found	O
to	O
be	O
free	O
of	O
feline	O
coronoviruses	O
-	O
specific	O
antibodies	O
by	O
Western	O
blotting	O
.	O

Viruses	O
recovered	O
by	O
cell	O
culture	O
were	O
BVDV	O
-	O
1a	O
noncytopathic	O
(	O
NCP	B-FUNC
;	O
2	O
.	O
7	O
%),	O
BVDV	O
-	O
1a	O
cytopathic	O
(	O
CP	O
)	O
vaccine	O
strain	O
(	O
1	O
.	O
8	O
%),	O
BVDV	O
-	O
1b	O
NCP	B-FUNC
(	O
2	O
.	O
7	O
%),	O
BVDV	O
-	O
2a	O
NCP	B-FUNC
(	O
3	O
.	O
2	O
%),	O
BVDV	O
-	O
2b	O
CP	O
(	O
0	O
.	O
5	O
%),	O
and	O
Bovine	O
herpesvirus	O
1	O
(	O
2	O
.	O
3	O
%).	O

S	O
-	O
OIV	O
infection	O
was	O
confirmed	O
in	O
specimens	O
with	O
the	O
use	O
of	O
a	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assay	O
.	O

Moreover	O
,	O
the	O
immunogenicity	O
of	O
the	O
DNA	O
vaccine	O
was	O
highly	O
dependent	O
on	O
the	O
dosage	O
of	O
the	O
attenuated	O
bacteria	O
used	O
for	O
oral	O
administration	O
,	O
10	O
(	O
9	O
)	O
CFU	O
dosage	O
group	O
showed	O
higher	O
antibody	B-FUNC
response	O
than	O
10	O
(	O
8	O
)	O
CFU	O
and	O
10	O
(	O
7	O
)	O
CFU	O
dosages	O
groups	O
during	O
week	O
4	O
-	O
8	O
post	O
-	O
immunization	O
.	O

Nine	O
of	O
them	O
,	O
including	O
members	O
of	O
the	O
heterogeneous	O
ribonucleoprotein	O
family	O
of	O
proteins	O
(	O
hnRNPs	O
),	O
the	O
poly	O
(	O
A	O
)-	O
binding	B-FUNC
protein	O
(	O
PABP	O
),	O
the	O
p100	O
transcriptional	O
co	O
-	O
activator	O
protein	O
and	O
two	O
aminoacyl	O
-	O
tRNA	B-FUNC
synthetases	O
,	O
showed	O
a	O
preferential	O
binding	B-FUNC
to	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
,	O
whereas	O
only	O
the	O
polypyrimidine	O
tract	O
-	O
binding	B-FUNC
protein	O
(	O
PTB	O
)	O
was	O
preferentially	O
pulled	O
down	O
with	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
.	O

Gene	O
silencing	O
of	O
PABP	O
,	O
hnRNP	O
Q	O
,	O
and	O
glutamyl	O
-	O
prolyl	O
-	O
tRNA	B-FUNC
synthetase	O
(	O
EPRS	O
)	O
caused	O
a	O
significant	O
2	O
to	O
3	O
-	O
fold	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
.	O

After	O
adjusting	O
for	O
physiology	O
,	O
injury	O
severity	O
,	O
and	O
transfusion	O
,	O
etomidate	O
use	O
remained	O
associated	O
with	O
ARDS	O
(	O
aOR	B-FUNC
=	O
3	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
24	O
-	O
12	O
.	O
0	O
).	O

After	O
adjusting	O
for	O
physiology	O
,	O
injury	O
severity	O
,	O
and	O
transfusion	O
,	O
etomidate	O
use	O
remained	O
associated	O
with	O
ARDS	O
(	O
aOR	B-FUNC
=	O
3	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
24	O
-	O
12	O
.	O
0	O
).	O

Serum	O
and	O
BAL	O
fluid	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
ICU	O
admission	O
were	O
obtained	O
.	O

The	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
in	O
BALF	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
TNF	O
-	O
alpha	O
in	O
serum	O
were	O
higher	O
in	O
nonsurvivors	O
than	O
in	O
survivor	O
patients	O
with	O
CAP	O
.	O

Of	O
these	O
112	O
patients	O
with	O
severe	O
CAP	O
(	O
39	O
%),	O
44	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
these	O
patients	O
seemed	O
to	O
have	O
higher	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
than	O
did	O
the	O
non	O
-	O
ARDS	O
group	O
.	O

Further	O
,	O
the	O
drug	O
hexamethylene	O
amiloride	O
(	O
HMA	O
),	O
but	O
not	O
amiloride	O
,	O
inhibited	O
in	O
vitro	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
some	O
synthetic	O
coronavirus	O
E	O
proteins	O
,	O
and	O
also	O
viral	O
replication	O
.	O

We	O
have	O
previously	O
shown	O
for	O
the	O
coronavirus	O
species	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
the	O
transmembrane	O
domain	O
of	O
E	O
protein	O
(	O
ETM	O
)	O
forms	O
pentameric	O
alpha	O
-	O
helical	O
bundles	O
that	O
are	O
likely	O
responsible	O
for	O
the	O
observed	O
channel	B-FUNC
activity	I-FUNC
.	O

The	O
drug	O
HMA	O
was	O
found	O
to	O
bind	B-FUNC
inside	O
the	O
lumen	O
of	O
the	O
channel	O
,	O
at	O
both	O
the	O
C	O
-	O
terminal	O
and	O
the	O
N	O
-	O
terminal	O
openings	O
,	O
and	O
,	O
in	O
contrast	O
to	O
amiloride	O
,	O
induced	O
additional	O
chemical	O
shifts	O
in	O
ETM	O
.	O

The	O
sera	B-FUNC
had	O
low	O
cross	O
-	O
reactivity	O
,	O
but	O
no	O
neutralization	O
activity	O
,	O
for	O
the	O
HIV	O
-	O
pseudotyped	O
S	O
(	O
SARS	O
).	O

Studies	O
using	O
wild	O
bat	O
sera	B-FUNC
revealed	O
that	O
it	O
is	O
highly	O
likely	O
that	O
the	O
immunodominant	O
epitopes	O
overlap	O
with	O
the	O
major	O
neutralizing	O
sites	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
protein	O
.	O

Sera	B-FUNC
and	O
feces	O
samples	O
were	O
collected	O
once	O
a	O
week	O
for	O
7	O
weeks	O
.	O

Nested	O
RT	O
-	O
PCR	O
and	O
a	O
commercial	O
ELISA	O
kit	B-FUNC
were	O
used	O
to	O
confirm	O
the	O
infection	O
.	O

ABSTRACT	O
:	O
Chronic	O
expression	O
of	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
(	O
CXCL10	O
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
infection	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
is	O
associated	O
with	O
an	O
immune	O
-	O
mediated	O
demyelinating	O
disease	O
.	O

Treatment	O
of	O
mice	O
with	O
anti	O
-	O
CXCL10	O
neutralizing	O
antibody	B-FUNC
results	O
in	O
limited	O
CD4	O
+	O
T	O
cell	O
infiltration	O
into	O
the	O
CNS	O
accompanied	O
by	O
a	O
reduction	O
in	O
white	O
matter	O
damage	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
coverage	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
field	O
boost	O
in	O
commercial	O
broilers	O
,	O
estimate	O
the	O
relative	O
amount	O
of	O
vaccine	O
virus	O
in	O
the	O
trachea	O
,	O
and	O
follow	O
the	O
clearance	O
of	O
the	O
vaccine	O
,	O
we	O
collected	O
approximately	O
100	O
tracheal	O
swabs	O
at	O
various	O
times	O
postvaccination	O
from	O
10	O
different	O
flocks	O
and	O
used	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
the	O
virus	O
.	O

It	O
was	O
also	O
confirmed	O
previously	O
that	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
could	O
bind	B-FUNC
to	O
PEDV	O
,	O
and	O
anti	O
-	O
pAPN	O
antibodies	O
could	O
inhibit	O
the	O
combination	O
.	O

Sixty	O
-	O
two	O
percent	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
previous	O
episode	O
of	O
ACS	B-FUNC
.	O

ACS	B-FUNC
was	O
diagnosed	O
at	O
presentation	O
in	O
66	O
%,	O
in	O
the	O
remainder	O
ACS	B-FUNC
was	O
diagnosed	O
after	O
a	O
median	O
of	O
2	O
days	O
.	O

RCE	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
patients	O
with	O
sickle	O
cell	O
disease	O
and	O
ACS	B-FUNC
.	O

One	O
-	O
third	O
of	O
patients	O
who	O
received	O
RCE	O
for	O
ACS	B-FUNC
had	O
no	O
respiratory	O
symptoms	O
on	O
admission	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
two	O
percent	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
previous	O
episode	O
of	O
ACS	B-FUNC
.	O

The	O
main	O
characteristic	O
of	O
PH	O
in	O
CRD	O
and	O
particularly	O
in	O
COPD	O
is	O
its	O
mild	O
to	O
moderate	O
degree	O
,	O
resting	O
pulmonary	O
artery	O
mean	O
pressure	O
(	O
PAP	B-FUNC
)	O
in	O
a	O
stable	O
state	O
of	O
the	O
disease	O
usually	O
ranging	O
between	O
20	O
and	O
35	O
mmHg	O
.	O

A	O
minority	O
(<	O
5	O
%)	O
of	O
COPD	O
patients	O
exhibit	O
severe	O
or	O
""""	O
disproportionate	O
""""	O
PH	O
(	O
PAP	B-FUNC
>	O
40	O
mmHg	O
),	O
the	O
mechanism	O
of	O
which	O
is	O
not	O
well	O
understood	O
.	O

At	O
present	O
long	O
-	O
term	O
oxygen	O
therapy	O
(	O
LTOT	O
)	O
is	O
the	O
logical	O
treatment	O
of	O
PH	O
since	O
alveolar	O
hypoxia	O
is	O
considered	O
to	O
be	O
the	O
major	O
determinant	O
of	O
the	O
elevation	O
of	O
PAP	B-FUNC
and	O
PVR	O
.	O

LTOT	O
stabilizes	O
or	O
at	O
least	O
attenuates	O
and	O
sometimes	O
reverses	O
the	O
progression	O
of	O
PH	O
,	O
but	O
PAP	B-FUNC
seldom	O
returns	O
to	O
normal	O
.	O

Collectively	O
,	O
these	O
observations	O
suggest	O
interactive	O
effects	O
between	O
PRCV	O
and	O
PRRSV	O
via	O
early	O
innate	O
(	O
IFN	O
-	O
alpha	O
)	O
and	O
later	O
adaptive	O
Th1	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
Th2	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
)	O
immune	O
responses	O
.	O

Multivariate	O
modeling	O
revealed	O
no	O
statistical	O
difference	O
in	O
elevated	O
antibody	B-FUNC
titers	O
against	O
HEV	O
between	O
the	O
two	O
groups	O
.	O

Mutations	O
in	O
the	O
BIG2	O
Arf1	O
GEF	B-FUNC
have	O
been	O
linked	O
to	O
autosomal	O
recessive	O
periventricular	O
heterotopia	O
,	O
a	O
disorder	O
of	O
neuronal	O
migration	O
that	O
leads	O
to	O
severe	O
malformation	O
of	O
the	O
cerebral	O
cortex	O
.	O

TITLE	O
:	O
Recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
expressed	O
in	O
mammalian	O
,	O
insect	O
and	O
E	O
.	O
coli	O
cells	O
elicits	O
potent	O
neutralizing	O
antibody	B-FUNC
and	O
protective	O
immunity	O
.	O

Preference	O
will	O
be	O
given	O
to	O
rRBD	O
expressed	O
in	O
mammalian	O
cells	O
for	O
future	O
evaluation	O
of	O
the	O
vaccine	O
efficacy	O
in	O
a	O
non	O
-	O
human	O
primate	O
model	O
of	O
SARS	O
because	O
of	O
its	O
ability	O
to	O
refold	O
into	O
a	O
native	O
conformation	O
more	O
readily	O
and	O
to	O
induce	O
higher	O
level	O
of	O
neutralizing	O
antibody	B-FUNC
responses	O
than	O
those	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
insect	O
cells	O
.	O

Using	O
a	O
SELEX	O
(	O
systematic	O
evolution	O
of	O
ligand	B-FUNC
by	O
exponential	O
enrichment	O
)	O
procedure	O
and	O
recombinant	O
N	O
protein	O
,	O
we	O
selected	O
a	O
high	O
-	O
affinity	O
RNA	O
aptamer	O
capable	O
of	O
binding	B-FUNC
to	O
N	O
protein	O
with	O
a	O
dissociation	O
constant	O
of	O
1	O
.	O
65	O
nM	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
RNA	O
competition	O
experiments	O
showed	O
that	O
the	O
selected	O
aptamer	O
recognized	O
selectively	O
the	O
C	O
-	O
terminal	O
region	O
of	O
N	O
protein	O
with	O
high	O
specificity	O
.	O

These	O
aptamer	O
-	O
antibody	B-FUNC
hybrid	O
immunoassays	O
may	O
be	O
useful	O
for	O
rapid	O
,	O
sensitive	O
detection	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
human	O
monocytes	O
,	O
potential	O
precursors	O
of	O
osteoclasts	O
,	O
partly	O
express	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
cellular	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
and	O
that	O
expression	O
of	O
an	O
accessory	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
3a	O
/	O
X1	O
,	O
in	O
murine	O
macrophage	O
cell	O
line	O
RAW264	O
.	O
7	O
cells	O
,	O
enhanced	O
NF	O
-	O
kappaB	O
activity	O
and	O
differentiation	O
into	O
osteoclast	O
-	O
like	O
cells	O
in	O
the	O
presence	O
of	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
ligand	B-FUNC
(	O
RANKL	O
).	O

The	O
binding	B-FUNC
affinities	O
of	O
the	O
truncated	O
N	O
proteins	O
and	O
RNA	O
follow	O
the	O
order	O
:	O
residues	O
1	O
-	O
173	O
-	O
residues	O
233	O
-	O
300	O
>	O
residues	O
174	O
-	O
232	O
.	O

SPR	O
experiments	O
demonstrated	O
that	O
the	O
C	O
-	O
terminal	O
region	O
(	O
residues	O
301	O
-	O
448	O
)	O
of	O
HCoV	O
-	O
OC43	O
N	O
protein	O
lacks	O
RNA	O
-	O
binding	B-FUNC
activity	O
,	O
while	O
crosslinking	O
and	O
gel	O
filtration	O
analyses	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
region	O
is	O
mainly	O
involved	O
in	O
the	O
oligomerization	O
of	O
the	O
HCoV	O
-	O
OC43	O
N	O
protein	O
.	O

Postoperatively	O
,	O
he	O
appeared	O
increasingly	O
hyperthermic	O
,	O
showed	O
respiratory	O
exhaustion	O
,	O
and	O
was	O
neutropenic	O
(	O
lowest	O
white	O
blood	O
cell	O
count	O
was	O
0	O
.	O
8	O
Gpt	B-FUNC
with	O
a	O
normal	O
granulocyte	O
count	O
).	O

TITLE	O
:	O
Two	O
-	O
step	O
conformational	O
changes	O
in	O
a	O
coronavirus	O
envelope	O
glycoprotein	O
mediated	O
by	O
receptor	B-FUNC
binding	I-FUNC
and	O
proteolysis	O
.	O

Upon	O
receptor	B-FUNC
binding	I-FUNC
,	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
both	O
viruses	O
are	O
activated	O
for	O
membrane	O
fusion	O
by	O
proteases	O
,	O
such	O
as	O
trypsin	O
,	O
present	O
in	O
the	O
environment	O
,	O
facilitating	O
virus	O
entry	O
from	O
the	O
cell	O
surface	O
.	O

Liposome	O
-	O
binding	B-FUNC
assays	O
indicate	O
that	O
the	O
receptor	O
-	O
bound	O
virions	O
are	O
associated	O
with	O
the	O
target	O
membrane	O
through	O
hydrophobic	O
interactions	O
.	O

The	O
exposure	O
of	O
receptor	O
-	O
bound	O
S	O
protein	O
to	O
trypsin	O
or	O
cathepsin	O
L	O
(	O
CPL	B-FUNC
)	O
induces	O
the	O
formation	O
of	O
six	O
-	O
helix	O
bundles	O
(	O
6HB	O
),	O
the	O
final	O
conformation	O
.	O

This	O
trypsin	O
-	O
or	O
CPL	B-FUNC
-	O
mediated	O
conversion	O
to	O
6HB	O
can	O
be	O
blocked	O
by	O
a	O
heptad	O
repeat	O
peptide	O
known	O
to	O
block	O
the	O
formation	O
of	O
6HB	O
.	O

Although	O
trypsin	O
treatment	O
enabled	O
receptor	O
-	O
bound	O
MHV	O
-	O
2	O
to	O
enter	O
from	O
the	O
cell	O
surface	O
,	O
CPL	B-FUNC
failed	O
to	O
do	O
so	O
.	O

Interestingly	O
,	O
consecutive	O
treatment	O
with	O
CPL	B-FUNC
and	O
then	O
chlorpromazine	O
enabled	O
a	O
portion	O
of	O
the	O
virus	O
to	O
enter	O
from	O
cell	O
surface	O
.	O

These	O
results	O
suggest	O
that	O
trypsin	O
suffices	O
for	O
the	O
induction	O
of	O
membrane	O
fusion	O
of	O
receptor	O
-	O
primed	O
S	O
protein	O
,	O
but	O
an	O
additional	O
unidentified	O
cellular	O
factor	O
is	O
required	O
to	O
trigger	O
membrane	O
fusion	O
by	O
CPL	B-FUNC
.	O

A	O
diagnostic	O
algorithm	O
including	O
extended	O
infectiological	O
and	O
immunological	O
work	O
-	O
up	O
revealed	O
absence	O
of	O
CD40	O
-	O
ligand	B-FUNC
.	O

ARDS	O
was	O
treated	O
successfully	O
with	O
a	O
complex	O
respiratory	O
therapy	O
plus	O
intravenous	O
immunoglobulin	B-FUNC
substitution	O
.	O

TITLE	O
:	O
Absence	O
of	O
antibody	B-FUNC
-	O
dependent	O
,	O
complement	O
-	O
mediated	O
lysis	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Cats	O
infected	O
with	O
virulent	O
feline	O
coronavirus	O
which	O
causes	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
usually	O
succumb	O
to	O
disease	O
despite	O
high	O
antibody	B-FUNC
concentrations	O
.	O

One	O
of	O
the	O
mechanisms	O
that	O
can	O
help	O
resolving	O
infection	O
is	O
antibody	B-FUNC
-	O
dependent	O
,	O
complement	O
-	O
mediated	O
lysis	O
(	O
ADCML	O
)	O
of	O
infected	O
cells	O
.	O

ADCML	O
assays	O
,	O
using	O
FIPV	O
strain	O
79	O
-	O
1146	O
and	O
its	O
deletion	O
mutant	O
strain	O
Delta	O
3abc	O
/	O
Delta	O
7ab	O
,	O
were	O
performed	O
on	O
:	O
(	O
i	O
)	O
CrFK	O
cells	O
that	O
show	O
surface	O
-	O
expressed	O
viral	O
antigens	O
,	O
(	O
ii	O
)	O
monocytes	O
without	O
surface	O
-	O
expressed	O
viral	O
proteins	O
due	O
to	O
retention	O
and	O
(	O
iii	O
)	O
monocytes	O
with	O
surface	O
-	O
expressed	O
viral	O
proteins	O
since	O
the	O
antibody	B-FUNC
-	O
mediated	O
internalization	O
of	O
these	O
proteins	O
was	O
blocked	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
ligand	B-FUNC
and	O
substrate	O
recognition	O
by	O
torovirus	O
hemagglutinin	O
esterases	B-FUNC
.	O

Structure	O
-	O
guided	O
biochemical	O
analysis	O
of	O
the	O
esterase	O
domains	O
revealed	O
that	O
a	O
functionally	O
,	O
but	O
not	O
structurally	O
conserved	O
arginine	O
-	O
Sia	O
carboxylate	O
interaction	O
is	O
critical	O
for	O
the	O
binding	B-FUNC
and	O
positioning	O
of	O
glycosidically	O
bound	O
Sias	O
in	O
the	O
catalytic	O
pocket	O
.	O

Apparently	O
,	O
esterase	O
and	O
lectin	O
pockets	O
coevolved	O
;	O
also	O
the	O
porcine	O
torovirus	O
HE	O
receptor	O
-	O
binding	B-FUNC
site	O
seems	O
to	O
have	O
been	O
designed	O
to	O
use	O
9	O
-	O
mono	O
-	O
and	O
exclude	O
di	O
-	O
O	O
-	O
acetylated	O
Sias	O
,	O
possibly	O
as	O
an	O
adaptation	O
to	O
replication	O
in	O
swine	O
.	O

Our	O
findings	O
shed	O
light	O
on	O
HE	O
evolution	O
and	O
provide	O
fundamental	O
insight	O
into	O
mechanisms	O
of	O
substrate	O
binding	B-FUNC
,	O
substrate	O
recognition	O
,	O
and	O
receptor	O
selection	O
in	O
this	O
important	O
class	O
of	O
virion	O
proteins	O
.	O

A	O
single	O
priming	O
immunization	O
with	O
the	O
p	O
-	O
LAMP	O
/	O
N	O
construct	O
was	O
sufficient	O
to	O
elicit	O
an	O
antibody	B-FUNC
response	O
.	O

SARS	O
-	O
CoV	O
N	O
can	O
bind	B-FUNC
with	O
MAP19	O
in	O
cells	O
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
N	O
can	O
bind	B-FUNC
with	O
MAP19	O
in	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
new	O
commercially	O
available	O
antigen	O
-	O
capture	O
,	O
blocking	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
antigen	O
-	O
capture	O
b	O
-	O
ELISA	O
),	O
based	O
on	O
baculovirus	O
truncated	O
-	O
S	O
recombinant	O
protein	O
of	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
3	O
specific	O
monoclonal	O
antibodies	O
,	O
was	O
developed	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
453	O
positive	O
Porcine	O
respiratory	O
coronavirus	O
(	O
PRCoV	O
),	O
31	O
positive	O
TGEV	O
,	O
and	O
126	O
negative	O
field	O
sera	B-FUNC
by	O
using	O
another	O
commercially	O
available	O
differential	O
coronavirus	O
b	O
-	O
ELISA	O
as	O
the	O
reference	O
technique	O
to	O
differentiate	O
TGEV	O
-	O
from	O
PRCoV	O
-	O
induced	O
antibodies	O
.	O

The	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
production	O
was	O
related	O
rather	O
to	O
the	O
fixation	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MHV3	O
on	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
in	O
regions	O
enriched	O
in	O
heparan	O
sulphate	O
and	O
did	O
not	O
rely	O
on	O
viral	O
replication	O
,	O
as	O
demonstrated	O
with	O
denatured	O
S	O
protein	O
and	O
UV	O
-	O
inactivated	O
virus	O
.	O

High	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
were	O
produced	O
in	O
livers	O
from	O
infected	O
C57BL	O
/	O
6	O
mice	O
but	O
not	O
in	O
livers	O
from	O
Tlr2	O
(-/-)	O
mice	O
.	O

TITLE	O
:	O
A	O
synergistic	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
production	O
is	O
induced	O
by	O
mouse	O
hepatitis	O
virus	O
in	O
interleukin	O
-	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
)/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
-	O
activated	O
natural	O
killer	O
cells	O
and	O
modulated	O
by	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecules	O
(	O
CEACAM	O
)	O
1a	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
production	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
by	O
infiltrating	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
in	O
liver	O
is	O
involved	O
in	O
the	O
control	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
.	O

Ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
revealed	O
that	O
NK	O
cells	O
,	O
expressing	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecules	O
(	O
CEACAM	O
)	O
1a	O
(	O
the	O
MHV	O
receptor	O
),	O
can	O
produce	O
a	O
higher	O
level	O
of	O
IFN	O
-	O
gamma	O
in	O
the	O
presence	O
of	O
both	O
L2	O
-	O
MHV3	O
and	O
interleukin	O
-	O
12	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
)/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

These	O
results	O
suggest	O
that	O
control	O
of	O
acute	O
hepatitis	O
by	O
IFN	O
-	O
gamma	O
-	O
producing	O
NK	O
cells	O
may	O
depend	O
on	O
both	O
production	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
in	O
the	O
liver	O
environment	O
and	O
viral	O
infection	O
of	O
NK	O
cells	O
.	O

The	O
concentrations	O
of	O
chemokines	O
MCP	B-FUNC
-	O
1	O
,	O
LIX	O
and	O
CINC	O
-	O
1	O
in	O
BALF	O
increased	O
on	O
day	O
4	O
p	O
.	O
i	O
.,	O
but	O
returned	O
to	O
control	O
levels	O
by	O
day	O
8	O
.	O

These	O
mAbs	O
bind	B-FUNC
epitopes	O
within	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
or	O
upstream	O
of	O
the	O
RBD	O
.	O

One	O
mAb	O
binds	B-FUNC
upstream	O
of	O
the	O
RBD	O
and	O
prevents	O
viral	O
entry	O
by	O
inhibiting	O
a	O
post	O
-	O
binding	B-FUNC
event	O
.	O

No	O
calves	O
were	O
antibody	B-FUNC
positive	O
for	O
M	O
.	O
bovis	O
.	O

It	O
was	O
demonstrated	O
by	O
ELISA	O
that	O
the	O
purified	O
Orf	O
9b	O
protein	O
could	O
react	O
with	O
sera	B-FUNC
of	O
SARS	O
rehabilitaion	O
patients	O
but	O
not	O
with	O
sera	B-FUNC
from	O
healthy	O
donors	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
shown	O
that	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
are	O
differentially	O
induced	O
in	O
primary	O
mouse	O
astrocytes	O
by	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
and	O
MHV	O
-	O
2	O
.	O

However	O
,	O
the	O
signaling	O
events	O
that	O
trigger	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
induction	O
in	O
these	O
cells	O
upon	O
MHV	O
infection	O
remain	O
unknown	O
.	O

We	O
found	O
that	O
induction	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
occurred	O
as	O
early	O
as	O
2	O
h	O
postinfection	O
and	O
was	O
completely	O
dependent	O
on	O
viral	O
replication	O
.	O

Using	O
inhibitors	O
specific	O
for	O
three	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
,	O
we	O
showed	O
that	O
induction	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
by	O
MHV	O
-	O
A59	O
infection	O
was	O
mediated	O
through	O
activation	O
of	O
the	O
Janus	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
,	O
but	O
not	O
through	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
or	O
p38	B-FUNC
signaling	O
pathway	O
.	O

Interestingly	O
,	O
while	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
a	O
key	O
transcription	O
factor	O
required	O
for	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
most	O
cell	O
types	O
,	O
was	O
activated	O
in	O
astrocytes	O
during	O
MHV	O
-	O
A59	O
infection	O
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
peptide	O
inhibitors	O
did	O
not	O
significantly	O
inhibit	O
TNF	O
-	O
alpha	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
.	O

TITLE	O
:	O
Bid	O
cleavage	O
,	O
cytochrome	B-FUNC
c	I-FUNC
release	O
and	O
caspase	O
activation	O
in	O
canine	O
coronavirus	O
-	O
induced	O
apoptosis	O
.	O

TITLE	O
:	O
Coronavirus	O
N	O
protein	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
specifically	O
binds	B-FUNC
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
and	O
melts	O
TRS	B-FUNC
-	O
cTRS	O
RNA	O
duplexes	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
encode	O
a	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
that	O
harbors	O
two	O
independent	O
RNA	B-FUNC
binding	I-FUNC
domains	O
of	O
known	O
structure	O
,	O
but	O
poorly	O
characterized	O
RNA	B-FUNC
binding	I-FUNC
properties	O
.	O

We	O
show	O
here	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
N	O
protein	O
from	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
virus	O
most	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
,	O
employs	O
aromatic	O
amino	O
acid	O
-	O
nucleobase	O
stacking	O
interactions	O
with	O
a	O
triple	O
adenosine	O
motif	O
to	O
mediate	O
high	O
-	O
affinity	O
binding	B-FUNC
to	O
single	O
-	O
stranded	O
RNAs	O
containing	O
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
or	O
its	O
complement	O
(	O
cTRS	O
).	O

Mutation	O
of	O
the	O
solvent	O
-	O
exposed	O
Y127	O
,	O
positioned	O
on	O
the	O
beta	O
-	O
platform	O
surface	O
of	O
our	O
1	O
.	O
75	O
A	O
structure	O
,	O
binds	B-FUNC
the	O
TRS	B-FUNC
far	O
less	O
tightly	O
and	O
is	O
severely	O
crippled	O
in	O
its	O
RNA	O
unwinding	O
activity	O
.	O

This	O
study	O
demonstrated	O
that	O
chicken	O
type	O
II	O
interferon	O
increased	O
the	O
immunoprotective	O
efficacy	O
of	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
and	O
normal	O
weight	O
gain	O
in	O
vaccinated	O
chickens	O
although	O
it	O
inhibited	O
serum	O
antibody	B-FUNC
production	O
.	O

ABSTRACT	O
:	O
Enveloped	O
viruses	O
enter	O
cells	O
by	O
viral	O
glycoprotein	O
-	O
mediated	O
binding	B-FUNC
to	O
host	O
cells	O
and	O
subsequent	O
fusion	O
of	O
virus	O
and	O
host	O
cell	O
membranes	O
.	O

In	O
specifically	O
dissecting	O
the	O
effects	O
of	O
endodomain	O
mutations	O
on	O
the	O
fusion	O
process	O
,	O
we	O
used	O
antiviral	O
heptad	O
repeat	O
peptides	O
that	O
bind	B-FUNC
only	O
to	O
folding	O
intermediates	O
in	O
the	O
S	O
-	O
mediated	O
fusion	O
process	O
and	O
found	O
that	O
mutants	O
lacking	O
three	O
palmitoylated	O
cysteines	O
remained	O
in	O
transitional	O
folding	O
states	O
nearly	O
10	O
times	O
longer	O
than	O
native	O
S	O
proteins	O
.	O

These	O
findings	O
indicate	O
that	O
lipid	O
adducts	O
anchoring	B-FUNC
S	O
proteins	O
into	O
virus	O
membranes	O
are	O
necessary	O
for	O
the	O
rapid	O
,	O
productive	O
S	O
protein	O
refolding	O
events	O
that	O
culminate	O
in	O
membrane	O
fusions	O
.	O

Hantavirus	O
IgM	O
antibody	B-FUNC
-	O
capture	O
ELISA	O
was	O
positive	O
,	O
while	O
tests	O
for	O
dengue	O
,	O
leptospirosis	O
and	O
yellow	O
fever	O
were	O
negative	O
.	O

Serum	O
samples	O
from	O
251	O
dogs	O
of	O
varying	O
age	O
,	O
breed	O
and	O
clinical	O
histories	O
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
to	O
CRCoV	O
and	O
CIV	O
,	O
using	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
analysis	O
.	O

Data	O
indicated	O
that	O
neither	O
the	O
FAH	O
minimal	O
epitopes	O
nor	O
the	O
key	O
residues	O
important	O
for	O
binding	B-FUNC
to	O
Ab	O
from	O
MHV	O
-	O
infected	O
mice	O
have	O
their	O
counterparts	O
in	O
the	O
viral	O
proteins	O
.	O

After	O
infection	O
of	O
hPMEC	O
,	O
cell	O
activation	O
markers	O
E	O
-	O
selectin	B-FUNC
and	O
P	O
-	O
selectin	B-FUNC
were	O
upregulated	O
,	O
and	O
the	O
proinflammatory	O
cytokines	O
interleukin	O
-	O
6	O
and	O
beta	O
interferon	O
were	O
secreted	O
.	O

Interleukin	O
8	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
concentration	O
as	O
well	O
as	O
leukocyte	O
count	O
remained	O
unchanged	O
.	O

By	O
using	O
""""	O
rest	B-FUNC
""""	O
ventilator	O
settings	O
and	O
venovenous	O
ECLS	O
,	O
the	O
patient	O
remained	O
stable	O
for	O
a	O
total	O
of	O
6	O
.	O
5	O
days	O
(	O
160	O
hours	O
)	O
when	O
he	O
was	O
successfully	O
transitioned	O
to	O
a	O
conventional	O
ventilator	O
and	O
decannulated	O
.	O

TITLE	O
:	O
Nuclear	O
magnetic	O
resonance	O
structure	O
of	O
the	O
nucleic	O
acid	O
-	O
binding	B-FUNC
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	O
3	O
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
a	O
globular	O
domain	O
of	O
residues	O
1071	O
to	O
1178	O
within	O
the	O
previously	O
annotated	O
nucleic	O
acid	O
-	O
binding	B-FUNC
region	O
(	O
NAB	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
has	O
been	O
determined	O
,	O
and	O
N	O
-	O
and	O
C	O
-	O
terminally	O
adjoining	O
polypeptide	O
segments	O
of	O
37	O
and	O
25	O
residues	O
,	O
respectively	O
,	O
have	O
been	O
shown	O
to	O
form	O
flexibly	O
extended	O
linkers	O
to	O
the	O
preceding	O
globular	O
domain	O
and	O
to	O
the	O
following	O
,	O
as	O
yet	O
uncharacterized	O
domain	O
.	O

Chemical	O
shift	O
changes	O
upon	O
the	O
addition	O
of	O
single	O
-	O
stranded	O
RNAs	O
(	O
ssRNAs	O
)	O
identified	O
a	O
group	O
of	O
residues	O
that	O
form	O
a	O
positively	O
charged	O
patch	O
on	O
the	O
protein	O
surface	O
as	O
the	O
binding	B-FUNC
site	O
responsible	O
for	O
the	O
previously	O
reported	O
affinity	O
for	O
nucleic	O
acids	O
.	O

TCoV	O
detection	O
was	O
accomplished	O
by	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
through	O
amplification	O
of	O
the	O
3	O
'	O
UTR	O
region	O
,	O
followed	O
by	O
amplification	O
of	O
genes	O
3	O
and	O
5	O
.	O

Systemic	O
and	O
pulmonary	O
hemodynamics	O
,	O
blood	O
gas	O
exchange	O
parameters	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
and	O
angiotensin	O
II	O
levels	O
were	O
examined	O
before	O
acute	O
respiratory	O
distress	O
syndrome	O
induction	O
and	O
at	O
various	O
time	O
points	O
after	O
administering	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
or	O
saline	O
.	O

Furthermore	O
,	O
angiotensin	O
II	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
levels	O
,	O
both	O
of	O
which	O
were	O
substantially	O
increased	O
,	O
returned	O
to	O
basal	O
values	O
.	O

A	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
(	O
designated	O
as	O
15E2	O
)	O
against	O
the	O
IBV	O
M	O
protein	O
was	O
prepared	O
and	O
a	O
series	O
of	O
14	O
partially	O
-	O
overlapping	O
fragments	O
of	O
the	O
IBV	O
M	O
gene	O
were	O
expressed	O
with	O
a	O
GST	O
tag	O
.	O

Strain	O
v2163	O
increased	O
IL	O
-	O
1alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
MIP	O
-	O
1alpha	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
and	O
RANTES	O
in	O
mice	O
,	O
and	O
high	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
correlated	O
with	O
mortality	O
.	O

Ribavirin	O
,	O
UDA	O
,	O
and	O
Ampligen	O
decreased	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
.	O

Despite	O
marked	O
differences	O
in	O
infection	O
,	O
antibody	B-FUNC
responses	O
were	O
observed	O
in	O
all	O
animals	O
irrespective	O
of	O
age	O
,	O
with	O
older	O
pigs	O
tending	O
to	O
seroconvert	O
sooner	O
and	O
achieve	O
higher	O
antibody	B-FUNC
levels	O
than	O
3	O
-	O
week	O
-	O
old	O
animals	O
.	O

These	O
findings	O
show	O
that	O
animal	O
age	O
,	O
perhaps	O
due	O
to	O
increased	O
innate	O
immune	O
resistance	O
,	O
strongly	O
influences	O
the	O
outcome	O
of	O
acute	O
PRRSV	O
infection	O
,	O
whereas	O
an	O
antibody	B-FUNC
response	O
is	O
triggered	O
at	O
a	O
low	O
threshold	O
of	O
infection	O
that	O
is	O
independent	O
of	O
age	O
.	O

Prolonged	O
infection	O
was	O
not	O
due	O
to	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
mediated	O
immunosuppression	O
,	O
and	O
PRRSV	O
did	O
not	O
elicit	O
a	O
specific	O
IFN	O
gamma	O
response	O
,	O
especially	O
in	O
non	O
-	O
adult	O
animals	O
.	O

Equivalent	O
antibody	B-FUNC
responses	O
were	O
elicited	O
in	O
response	O
to	O
virulent	O
and	O
attenuated	O
viruses	O
,	O
indicating	O
that	O
the	O
antigenic	O
mass	O
necessary	O
for	O
an	O
immune	O
response	O
is	O
produced	O
at	O
a	O
low	O
level	O
of	O
infection	O
,	O
and	O
is	O
not	O
predicted	O
by	O
viremic	O
status	O
.	O

Interferon	O
gamma	O
(	O
IFN	O
gamma	O
)	O
secreting	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
more	O
abundant	O
in	O
sows	O
but	O
not	O
specifically	O
increased	O
by	O
PRRSV	O
infection	O
in	O
any	O
age	O
group	O
,	O
and	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
levels	O
in	O
blood	O
were	O
not	O
correlated	O
with	O
PRRSV	O
infection	O
status	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
mediated	O
synergy	O
and	O
interference	O
in	O
the	O
neutralization	O
of	O
SARS	O
-	O
CoV	O
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Incomplete	O
neutralization	O
of	O
virus	O
,	O
especially	O
when	O
it	O
occurs	O
in	O
the	O
presence	O
of	O
excess	O
neutralizing	O
antibody	B-FUNC
,	O
represents	O
a	O
biological	O
phenomenon	O
that	O
impacts	O
greatly	O
on	O
antibody	B-FUNC
-	O
mediated	O
immune	O
prophylaxis	O
of	O
viral	O
infection	O
and	O
on	O
successful	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
An	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
is	O
the	O
central	O
catalytic	O
subunit	O
of	O
the	O
RNA	O
-	O
synthesizing	O
machinery	O
of	O
all	O
positive	O
-	O
strand	O
RNA	O
viruses	O
.	O

Usually	O
,	O
RdRp	B-FUNC
domains	O
are	O
readily	O
identifiable	O
by	O
comparative	O
sequence	O
analysis	O
,	O
but	O
biochemical	O
confirmation	O
and	O
characterization	O
can	O
be	O
hampered	O
by	O
intrinsic	O
protein	O
properties	O
and	O
technical	O
complications	O
.	O

However	O
,	O
thus	O
far	O
full	O
-	O
length	O
nsp12	O
has	O
proven	O
refractory	O
to	O
expression	O
in	O
bacterial	O
systems	O
,	O
which	O
has	O
hindered	O
both	O
the	O
biochemical	O
characterization	O
of	O
coronavirus	O
RNA	O
synthesis	O
and	O
RdRp	B-FUNC
-	O
targeted	O
antiviral	O
drug	O
design	O
.	O

This	O
recombinant	O
protein	O
possesses	O
robust	O
in	O
vitro	O
RdRp	B-FUNC
activity	O
,	O
as	O
well	O
as	O
a	O
significant	O
DNA	O
-	O
dependent	O
activity	O
that	O
may	O
facilitate	O
future	O
inhibitor	O
studies	O
.	O

We	O
demonstrate	O
that	O
the	O
proposed	O
approach	O
to	O
measure	O
the	O
similarities	O
between	O
protein	O
structures	O
is	O
simple	O
to	O
implement	O
,	O
computationally	O
efficient	O
,	O
and	O
surprisingly	O
fast	B-FUNC
.	O

Four	O
canine	O
sera	B-FUNC
positive	O
for	O
TGEV	O
-	O
like	O
CCoV	O
,	O
six	O
sera	B-FUNC
positive	O
to	O
classical	O
CCoV	O
-	O
II	O
strains	O
and	O
10	O
negative	O
control	O
sera	B-FUNC
were	O
examined	O
.	O

The	O
recombinant	O
S	O
'	O
was	O
not	O
recognized	O
by	O
antibodies	O
to	O
classical	O
CCoV	O
-	O
II	O
,	O
as	O
only	O
sera	B-FUNC
from	O
dogs	O
infected	O
experimentally	O
with	O
TGEV	O
-	O
like	O
CCoV	O
reacted	O
strongly	O
with	O
the	O
recombinant	O
S	O
'	O
polypeptide	O
whereas	O
dog	O
sera	B-FUNC
with	O
antibodies	O
to	O
classical	O
CCoV	O
-	O
II	O
did	O
not	O
react	O
.	O

We	O
have	O
developed	O
a	O
pulmonary	O
formulation	O
of	O
tissue	O
plasminogen	O
activator	O
(	O
pf	O
-	O
tPA	B-FUNC
)	O
that	O
withstands	O
nebulization	O
and	O
reaches	O
the	O
lower	O
airways	O
.	O

Since	O
treatment	O
of	O
ARDS	O
,	O
IPF	O
and	O
plastic	O
bronchitis	O
will	O
require	O
repeated	O
administration	O
of	O
pf	O
-	O
tPA	B-FUNC
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
of	O
prolonged	O
,	O
repeated	O
administration	O
of	O
pf	O
-	O
mouse	O
tPA	B-FUNC
(	O
pf	O
-	O
mtPA	O
)	O
to	O
the	O
lungs	O
of	O
healthy	O
mice	O
.	O

This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-FUNC
.	O

CONCLUSIONS	O
:	O
This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-FUNC
.	O

Clinical	O
,	O
post	O
-	O
mortem	O
and	O
virological	O
investigations	O
showed	O
that	O
,	O
despite	O
the	O
high	O
serum	O
antibody	B-FUNC
titres	O
induced	O
by	O
the	O
prior	O
natural	O
infection	O
with	O
enteric	O
CCoV	O
,	O
dogs	O
were	O
susceptible	O
to	O
experimental	O
infection	O
with	O
strain	O
CB	O
/	O
05	O
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
mice	O
with	O
anti	O
-	O
CXCR2	O
blocking	O
antibody	B-FUNC
reduced	O
PMN	O
trafficking	O
into	O
the	O
CNS	O
by	O
>	O
95	O
%,	O
dampened	O
MMP	O
-	O
9	O
activity	O
,	O
and	O
abrogated	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
breakdown	O
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
CXCR2	O
-/-	O
mice	O
with	O
anti	O
-	O
CXCR2	O
antibody	B-FUNC
did	O
not	O
modulate	O
PMN	O
migration	O
nor	O
alter	O
viral	O
clearance	O
or	O
mortality	O
,	O
indicating	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
facilitate	O
sufficient	O
migration	O
of	O
PMNs	O
into	O
the	O
CNS	O
in	O
the	O
absence	O
of	O
CXCR2	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
NL63	O
respiratory	O
coronavirus	O
receptor	O
-	O
binding	B-FUNC
domain	O
complexed	O
with	O
its	O
human	O
receptor	O
.	O

NL63	O
-	O
CoV	O
RBD	O
has	O
a	O
novel	O
beta	O
-	O
sandwich	O
core	O
structure	O
consisting	O
of	O
2	O
layers	O
of	O
beta	O
-	O
sheets	O
,	O
presenting	O
3	O
discontinuous	O
receptor	O
-	O
binding	B-FUNC
motifs	O
(	O
RBMs	O
)	O
to	O
bind	B-FUNC
ACE2	O
.	O

NL63	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
have	O
no	O
structural	O
homology	O
in	O
RBD	O
cores	O
or	O
RBMs	O
;	O
yet	O
the	O
2	O
viruses	O
recognize	O
common	O
ACE2	O
regions	O
,	O
largely	O
because	O
of	O
a	O
""""	O
virus	O
-	O
binding	B-FUNC
hotspot	O
""""	O
on	O
ACE2	O
.	O

In	O
addition	O
,	O
143	O
of	O
226	O
FIV	O
-	O
infected	O
animals	O
(	O
63	O
%)	O
also	O
expressed	O
antibodies	O
to	O
the	O
primary	O
binding	B-FUNC
receptor	O
,	O
CD134	O
,	O
whereas	O
cats	O
infected	O
with	O
other	O
feline	O
RNA	O
viruses	O
,	O
including	O
calicivirus	O
,	O
coronavirus	O
,	O
herpesvirus	O
,	O
and	O
feline	O
leukemia	O
virus	O
,	O
did	O
not	O
.	O

Anti	O
-	O
CD134	O
binding	B-FUNC
caused	O
displacement	O
of	O
SU	O
from	O
the	O
surface	O
of	O
the	O
cell	O
and	O
inhibition	O
of	O
infection	O
.	O

Enhanced	O
production	O
of	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
and	O
interleukin	O
-	O
6	O
[	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
])	O
and	O
chemokines	O
(	O
CXCL10	O
,	O
CCL2	O
,	O
CCL3	O
,	O
and	O
CCL5	O
)	O
correlated	O
with	O
migration	O
of	O
NK	O
cells	O
,	O
macrophages	O
,	O
and	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
into	O
the	O
lungs	O
.	O

However	O
,	O
depletion	O
of	O
CD4	O
(+)	O
T	O
cells	O
resulted	O
in	O
an	O
enhanced	O
immune	O
-	O
mediated	O
interstitial	O
pneumonitis	O
and	O
delayed	O
clearance	O
of	O
SARS	O
-	O
CoV	O
from	O
the	O
lungs	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
neutralizing	O
antibody	B-FUNC
and	O
cytokine	O
production	O
and	O
reduced	O
pulmonary	O
recruitment	O
of	O
lymphocytes	O
.	O

We	O
pay	O
particular	O
attention	O
to	O
how	O
changes	O
in	O
the	O
Spike	O
attachment	O
protein	O
,	O
both	O
within	O
and	O
outside	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
,	O
mediate	O
the	O
emergence	O
of	O
coronaviruses	O
in	O
new	O
host	O
populations	O
.	O

TITLE	O
:	O
Humanized	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
chemokine	O
CXCL	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
effectively	O
prevents	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
chemotactic	O
factors	O
for	O
neutrophils	O
,	O
the	O
chemokine	O
CXCL8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
massive	O
neutrophil	O
infiltration	O
in	O
the	O
lung	O
.	O

Since	O
neutralization	O
of	O
CXCL8	O
with	O
polyclonal	O
antibody	B-FUNC
has	O
been	O
shown	O
to	O
reduce	O
the	O
severity	O
of	O
ALI	O
/	O
ARDS	O
in	O
animal	O
models	O
,	O
we	O
explored	O
the	O
potential	O
of	O
humanized	O
anti	O
-	O
CXCL8	O
antibody	B-FUNC
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
ALI	O
.	O

Treatment	O
of	O
the	O
rabbits	O
with	O
a	O
humanized	O
anti	O
-	O
CXCL8	O
antibody	B-FUNC
prevented	O
neutrophil	O
infiltration	O
in	O
the	O
lung	O
in	O
association	O
with	O
alleviated	O
ALI	O
syndrome	O
.	O

Our	O
results	O
indicate	O
a	O
promising	O
future	O
for	O
utilization	O
of	O
humanized	O
anti	O
-	O
CXCL8	O
antibody	B-FUNC
in	O
the	O
prevention	O
and	O
treatment	O
of	O
ALI	O
and	O
ARDS	O
in	O
human	O
.	O

Antibody	B-FUNC
titers	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	O
)	O
in	O
two	O
facilities	O
in	O
which	O
giant	O
pandas	O
were	O
vaccinated	O
were	O
variable	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
vaccines	O
used	O
for	O
these	O
giant	O
pandas	O
do	O
not	O
elicit	O
consistent	O
antibody	B-FUNC
titers	O
.	O

Antibody	B-FUNC
titers	O
against	O
CDV	O
,	O
CPV	O
and	O
CAV	O
-	O
1	O
in	O
unvaccinated	O
giant	O
pandas	O
were	O
highly	O
variable	O
,	O
especially	O
CPV	O
titer	O
.	O

Almost	O
half	O
of	O
sera	B-FUNC
were	O
CPV	O
antibody	B-FUNC
positive	O
,	O
and	O
CPV	O
titers	O
were	O
high	O
enough	O
to	O
suggest	O
infection	O
with	O
the	O
virus	O
.	O

The	O
fluorogenic	O
probe	O
labeled	O
with	O
a	O
reporter	O
dye	O
(	O
FAM	O
,	O
6	O
-	O
carboxytetramethylrhodamin	O
)	O
and	O
a	O
quencher	O
dye	O
(	O
AbsoluteQuencher	O
)	O
was	O
designed	O
to	O
bind	B-FUNC
to	O
a	O
186	O
base	O
-	O
pair	O
fragment	O
flanked	O
by	O
the	O
two	O
PCR	O
primers	O
targeting	O
the	O
3	O
'	O
end	O
of	O
spike	O
gene	O
of	O
TCoV	O
.	O
The	O
assay	O
was	O
performed	O
on	O
different	O
avian	O
viruses	O
and	O
bacteria	O
to	O
determine	O
the	O
specificity	O
as	O
well	O
as	O
serial	O
dilutions	O
of	O
TCoV	O
for	O
the	O
sensitivity	O
.	O

These	O
results	O
suggest	O
that	O
SARS	O
S	O
-	O
protein	O
is	O
susceptible	O
to	O
airway	O
protease	O
cleavage	O
and	O
,	O
furthermore	O
,	O
that	O
protease	O
mediated	O
enhancement	O
of	O
virus	O
entry	O
depends	O
on	O
specific	O
conformation	O
of	O
SARS	O
S	O
-	O
protein	O
upon	O
ACE2	O
binding	B-FUNC
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
of	O
respiratory	O
sample	O
for	O
novel	O
H1N1	O
virus	O
revealed	O
positive	O
results	O
.	O

The	O
Chinese	O
isolate	O
of	O
QX	O
-	O
like	O
virus	O
caused	O
the	O
most	O
severe	O
lesions	O
and	O
induced	O
the	O
highest	O
antibody	B-FUNC
titres	O
.	O

While	O
a	O
substantial	O
IFN	O
-	O
alpha	O
response	O
was	O
also	O
elicited	O
from	O
the	O
porcine	O
pDCs	O
by	O
pseudorabies	O
virus	O
(	O
PrV	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
and	O
TLR7	O
and	O
9	O
agonists	O
,	O
there	O
was	O
an	O
agent	O
-	O
dependent	O
induction	O
of	O
varying	O
amounts	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
IFN	O
-	O
gamma	O
,	O
and	O
TNF	O
-	O
alpha	O
.	O

Notably	O
,	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
failed	O
to	O
provoke	O
the	O
pDCs	O
to	O
secrete	O
any	O
of	O
the	O
measured	O
cytokines	O
except	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
.	O

In	O
this	O
line	O
,	O
mechanical	O
ventilation	O
may	O
affect	O
the	O
macromolecules	O
that	O
constitute	O
the	O
extracellular	O
matrix	O
(	O
collagen	O
,	O
elastin	B-FUNC
,	O
fibronectin	O
,	O
laminin	O
,	O
proteoglycan	O
and	O
glycosaminoglycans	O
),	O
suffer	O
changes	O
and	O
impact	O
the	O
biomechanical	O
behavior	O
of	O
lung	O
parenchyma	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
binding	B-FUNC
site	O
mapping	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
by	O
a	O
combination	O
of	O
yeast	O
surface	O
display	O
and	O
phage	O
peptide	O
library	O
screening	O
.	O

In	O
this	O
study	O
,	O
three	O
hybridoma	O
cell	O
lines	O
secreting	O
specific	O
monoclonal	O
antibodies	O
against	O
the	O
RBD	O
of	O
the	O
S	O
protein	O
were	O
generated	O
and	O
their	O
exact	O
binding	B-FUNC
sites	O
were	O
identified	O
.	O

Using	O
yeast	O
surface	O
display	O
,	O
the	O
binding	B-FUNC
sites	O
of	O
these	O
antibodies	O
were	O
defined	O
to	O
two	O
linear	O
regions	O
on	O
the	O
RBD	O
:	O
S	O
(	O
337	O
-	O
360	O
)	O
and	O
S	O
(	O
380	O
-	O
399	O
).	O

Sequence	O
comparison	O
between	O
native	O
epitopes	O
and	O
these	O
mimotopes	O
further	O
confirmed	O
the	O
binding	B-FUNC
sites	O
,	O
and	O
revealed	O
key	O
amino	O
acid	O
residues	O
involved	O
in	O
antibody	B-FUNC
binding	B-FUNC
.	O

Several	O
TGEV	O
N	O
-	O
protein	O
deletion	O
mutants	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
purified	O
,	O
and	O
their	O
RNA	B-FUNC
binding	I-FUNC
ability	O
and	O
RNA	O
chaperone	B-FUNC
activity	I-FUNC
were	O
evaluated	O
.	O

The	O
smallest	O
N	O
-	O
protein	O
domain	O
analyzed	O
with	O
RNA	O
chaperone	B-FUNC
activity	I-FUNC
,	O
facilitating	O
DNA	O
and	O
RNA	O
annealing	O
,	O
contained	O
the	O
central	O
unstructured	O
region	O
(	O
amino	O
acids	O
117	O
to	O
268	O
).	O

Interestingly	O
,	O
N	O
protein	O
and	O
its	O
deletion	O
mutants	O
with	O
RNA	O
chaperone	B-FUNC
activity	I-FUNC
enhanced	O
template	O
switching	O
in	O
a	O
retrovirus	O
-	O
derived	O
heterologous	O
system	O
,	O
reinforcing	O
the	O
concept	O
that	O
TGEV	O
N	O
protein	O
is	O
an	O
RNA	B-FUNC
chaperone	I-FUNC
that	O
could	O
be	O
involved	O
in	O
template	O
switching	O
.	O

First	O
,	O
different	O
SARS	O
-	O
CoV	O
sequences	O
were	O
analyzed	O
to	O
predict	O
eight	O
candidate	O
peptides	O
from	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
based	O
upon	O
HLA	O
-	O
A	O
*	O
0201	O
binding	B-FUNC
and	O
proteosomal	O
cleavage	O
.	O

Four	O
of	O
eight	O
candidate	O
peptides	O
were	O
tested	O
by	O
HLA	O
-	O
A	O
*	O
0201	O
binding	B-FUNC
assays	O
.	O

RESULTS	O
:	O
First	O
,	O
different	O
SARS	O
-	O
CoV	O
sequences	O
were	O
analyzed	O
to	O
predict	O
eight	O
candidate	O
peptides	O
from	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
based	O
upon	O
HLA	O
-	O
A	O
*	O
0201	O
binding	B-FUNC
and	O
proteosomal	O
cleavage	O
.	O

In	O
the	O
tetragonal	O
crystal	O
form	O
,	O
glycerol	O
-	O
3	O
-	O
phosphate	O
was	O
observed	O
in	O
the	O
ADP	O
-	O
ribose	O
-	O
binding	B-FUNC
site	O
.	O

Only	O
very	O
weak	O
binding	B-FUNC
of	O
this	O
domain	O
to	O
ADP	O
-	O
ribose	O
was	O
detected	O
in	O
vitro	O
.	O

Body	O
weight	O
was	O
measured	O
,	O
and	O
fecal	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
the	O
dogs	O
during	O
the	O
experiment	O
for	O
the	O
measurement	O
of	O
hematology	O
,	O
fecal	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
A	O
and	O
IgG	O
,	O
circulating	O
IgA	O
and	O
IgG	O
,	O
and	O
canine	O
corona	O
virus	O
(	O
CCV	O
)-	O
specific	O
IgG	O
.	O
There	O
were	O
no	O
differences	O
in	O
body	O
weights	O
among	O
the	O
groups	O
,	O
but	O
monocyte	O
counts	O
in	O
hematology	O
and	O
serum	O
IgA	O
were	O
higher	O
in	O
the	O
group	O
receiving	O
L	O
.	O
casei	O
expressing	O
cGMCSF	O
than	O
in	O
the	O
other	O
two	O
groups	O
.	O

Cell	O
immortalisation	O
can	O
occur	O
spontaneously	O
,	O
however	O
we	O
used	O
a	O
retroviral	O
system	O
to	O
immortalise	O
cells	O
via	O
the	O
transfer	O
and	O
stable	O
production	O
of	O
the	O
Simian	O
virus	O
40	O
Large	O
T	O
antigen	O
and	O
the	O
human	O
telomerase	O
reverse	O
transcriptase	B-FUNC
protein	O
.	O

We	O
previously	O
showed	O
that	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
spike	O
domain	O
2	O
(	O
S2	O
)	O
in	O
the	O
patient	O
sera	B-FUNC
can	O
cross	O
-	O
react	O
with	O
human	O
lung	O
epithelial	O
cells	O
;	O
however	O
,	O
the	O
autoantigen	O
is	O
not	O
yet	O
identified	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
proteomic	O
studies	O
and	O
identified	O
several	O
candidate	O
autoantigens	O
recognized	O
by	O
SARS	O
patient	O
sera	B-FUNC
in	O
human	O
lung	O
type	O
II	O
epithelial	O
cell	O
A549	O
.	O

By	O
confocal	O
microscopic	O
observation	O
,	O
SARS	O
patient	O
sera	B-FUNC
and	O
anti	O
-	O
S2	O
antibodies	O
were	O
co	O
-	O
localized	O
on	O
A549	O
cells	O
and	O
both	O
of	O
them	O
were	O
co	O
-	O
localized	O
with	O
anti	O
-	O
annexin	O
A2	O
antibodies	O
.	O

Furthermore	O
,	O
an	O
increased	O
surface	O
expression	O
and	O
raft	O
-	O
structure	O
distribution	O
of	O
annexin	O
A2	O
was	O
present	O
in	O
A549	O
cells	O
after	O
stimulation	O
with	O
SARS	O
-	O
induced	O
cytokines	O
interleukin	O
-	O
6	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
.	O

TITLE	O
:	O
The	O
SARS	O
Coronavirus	O
3a	O
protein	O
causes	O
endoplasmic	O
reticulum	O
stress	O
and	O
induces	O
ligand	B-FUNC
-	O
independent	O
downregulation	O
of	O
the	O
type	O
1	O
interferon	O
receptor	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
(	O
S	O
)	O
of	O
SARS	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
mediates	O
entry	O
of	O
the	O
virus	O
into	O
target	O
cells	O
,	O
including	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
.	O

Furthermore	O
,	O
treatment	O
with	O
tempol	O
decreased	O
CNS	O
viral	O
titers	O
,	O
macrophage	O
and	O
T	O
lymphocyte	O
infiltration	O
,	O
and	O
levels	O
of	O
markers	O
of	O
inflammation	O
,	O
such	O
as	O
expression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
transcription	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
and	O
protein	O
nitration	O
.	O

In	O
this	O
regards	O
,	O
we	O
have	O
created	O
a	O
mutant	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
mTNF	O
-	O
K90R	O
,	O
that	O
exhibits	O
high	O
bioactivity	O
and	O
resistance	O
to	O
proteases	O
.	O

The	O
enzymatic	O
active	O
motif	O
-	O
null	O
mutant	O
pAPN	O
still	O
retained	O
the	O
ability	O
to	O
exert	O
its	O
receptor	B-FUNC
activity	I-FUNC
and	O
consequently	O
,	O
to	O
cause	O
infectious	O
virus	O
production	O
.	O

Moreover	O
,	O
the	O
only	O
APN	O
inhibitor	O
blocking	O
the	O
protease	B-FUNC
activity	I-FUNC
site	O
had	O
no	O
obvious	O
negative	O
effect	O
on	O
viral	O
infection	O
,	O
indicating	O
that	O
the	O
enzymatic	O
role	O
of	O
APN	O
is	O
dispensable	O
for	O
the	O
process	O
of	O
virus	O
replication	O
.	O

Previously	O
,	O
we	O
have	O
identified	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
that	O
target	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRP	B-FUNC
)	O
gene	O
of	O
TGEV	O
with	O
more	O
than	O
95	O
%	O
of	O
virus	O
inhibition	O
in	O
vitro	O
.	O

It	O
is	O
a	O
low	O
-	O
affinity	O
receptor	O
for	O
IgG	O
that	O
preferentially	O
binds	B-FUNC
aggregated	O
immunoglobulins	O
and	O
immune	O
complexes	O
.	O

Statistical	O
analysis	O
calculating	O
a	O
serologic	O
association	O
between	O
the	O
serum	O
virus	O
neutralization	O
antibody	B-FUNC
titer	O
and	O
coronavirus	O
,	O
the	O
presence	O
of	O
exposure	O
history	O
on	O
40	O
animals	O
with	O
a	O
history	O
of	O
ARS	O
,	O
and	O
167	O
controls	O
provided	O
an	O
odds	O
ratio	O
of	O
121	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
36	O
.	O
54	O
and	O
402	O
.	O
84	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
Classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
relationship	O
between	O
serotypes	O
and	O
genotypes	O
of	O
strains	O
isolated	O
between	O
1998	O
and	O
2008	O
in	O
Japan	O
.	O

Components	O
from	O
the	O
Rheum	O
palmatum	O
L	O
.	O
had	O
a	O
high	O
level	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-FUNC
activity	I-FUNC
.	O

In	O
the	O
rest	B-FUNC
of	O
the	O
cases	O
,	O
each	O
interaction	O
was	O
LAB	O
-	O
cell	O
line	O
-	O
virus	O
specific	O
,	O
barring	O
general	O
conclusions	O
.	O

A	O
powerful	O
experimental	O
method	O
to	O
gain	O
insights	O
on	O
the	O
physical	O
chemical	O
nature	O
of	O
conformational	O
epitopes	O
is	O
the	O
selection	O
of	O
linear	O
peptides	O
that	O
bind	B-FUNC
with	O
high	O
affinities	O
to	O
a	O
monoclonal	O
antibody	B-FUNC
of	O
interest	O
by	O
phage	O
display	O
technology	O
.	O

In	O
all	O
these	O
examples	O
the	O
conformational	O
epitopes	O
as	O
determined	O
by	O
the	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
the	O
antibody	B-FUNC
-	O
antigen	O
complexes	O
,	O
were	O
found	O
within	O
the	O
highest	O
scoring	O
patches	O
of	O
EpiSearch	O
,	O
covering	O
in	O
most	O
cases	O
more	O
than	O
50	O
%	O
residues	O
of	O
experimental	O
observed	O
conformational	O
epitopes	O
.	O

Therapeutic	O
treatment	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
aged	O
macaques	O
with	O
type	O
I	O
IFN	O
reduces	O
pathology	O
and	O
diminishes	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
,	O
including	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
levels	O
,	O
without	O
affecting	O
virus	O
replication	O
in	O
the	O
lungs	O
.	O

TITLE	O
:	O
Escape	O
from	O
human	O
monoclonal	O
antibody	B-FUNC
neutralization	O
affects	O
in	O
vitro	O
and	O
in	O
vivo	O
fitness	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Distinct	O
but	O
partially	O
overlapping	O
sets	O
of	O
amino	O
acids	O
were	O
identified	O
that	O
are	O
critical	O
to	O
the	O
binding	B-FUNC
of	O
MAbs	O
with	O
differential	O
neutralization	O
profiles	O
.	O

These	O
data	O
provide	O
a	O
mechanism	O
for	O
overcoming	O
neutralization	O
escape	O
by	O
use	O
of	O
broadly	O
cross	O
-	O
reactive	O
cocktails	O
of	O
cross	O
-	O
neutralizing	O
MAbs	O
that	O
recognize	O
residues	O
within	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
that	O
are	O
critical	O
for	O
virus	O
replication	O
and	O
virulence	O
.	O

RESULTS	O
:	O
Distinct	O
but	O
partially	O
overlapping	O
sets	O
of	O
amino	O
acids	O
were	O
identified	O
that	O
are	O
critical	O
to	O
the	O
binding	B-FUNC
of	O
MAbs	O
with	O
differential	O
neutralization	O
profiles	O
.	O

Infants	O
with	O
an	O
SNAP	B-FUNC
>	O
or	O
=	O
10	O
were	O
considered	O
to	O
have	O
severe	O
illness	O
.	O

Infant	O
with	O
SNAP	B-FUNC
>	O
or	O
=	O
10	O
had	O
a	O
diminished	O
thyroid	O
-	O
stimulating	O
hormone	O
at	O
birth	O
.	O

There	O
were	O
no	O
differences	O
in	O
cortisol	O
in	O
those	O
infants	O
with	O
and	O
without	O
SNAP	B-FUNC
>	O
or	O
=	O
10	O
during	O
the	O
study	O
period	O
.	O

There	O
were	O
no	O
differences	O
in	O
cortisol	O
in	O
those	O
infants	O
with	O
and	O
without	O
SNAP	B-FUNC
>	O
or	O
=	O
10	O
during	O
the	O
study	O
period	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
fusion	O
proteins	O
lacking	O
all	O
three	O
transmembrane	O
domains	O
were	O
still	O
capable	O
of	O
membrane	O
binding	B-FUNC
,	O
Golgi	O
retention	O
,	O
and	O
interacting	O
with	O
M	O
.	O
The	O
data	O
suggest	O
that	O
multiple	O
SARS	O
-	O
CoV	O
M	O
regions	O
are	O
involved	O
in	O
M	O
self	O
-	O
assembly	O
and	O
subcellular	O
localization	O
.	O

ABSTRACT	O
:	O
MLK3	O
(	O
mixed	O
lineage	O
kinase	O
3	O
)	O
is	O
a	O
MAP3K	B-FUNC
[	O
MAPK	B-FUNC
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
kinase	O
kinase	O
]	O
that	O
activates	O
multiple	O
MAPK	B-FUNC
pathways	O
,	O
including	O
the	O
JNK	B-FUNC
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
pathway	O
.	O

Thus	O
this	O
novel	O
proteolytic	O
processing	O
of	O
MLK3	O
may	O
negatively	O
control	O
MLK3	O
signalling	O
to	O
JNK	B-FUNC
.	O

ABSTRACT	O
:	O
Twenty	O
1	O
-	O
day	O
-	O
old	O
specific	O
pathogen	O
free	O
chicks	O
and	O
20	O
1	O
-	O
day	O
-	O
old	O
commercially	O
derived	O
turkey	O
poults	O
were	O
inoculated	O
with	O
a	O
Brazilian	O
strain	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
to	O
study	O
the	O
pathogenicity	O
and	O
virus	O
distribution	O
up	O
to	O
14	O
days	O
post	O
-	O
inoculation	O
by	O
histopathology	O
,	O
immunohistochemistry	O
,	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
and	O
sequencing	O
.	O

The	O
model	O
achieved	O
a	O
satisfactory	O
fit	O
,	O
CFI	B-FUNC
=	O
0	O
.	O
98	O
,	O
NNFI	O
=	O
0	O
.	O
98	O
,	O
RMSEA	O
=	O
0	O
.	O
06	O
,	O
and	O
explained	O
75	O
.	O
2	O
%	O
of	O
the	O
variance	O
in	O
mental	O
health	O
status	O
.	O

We	O
examine	O
how	O
pleiotropic	O
mutations	O
that	O
have	O
antagonistic	O
effects	O
(	O
i	O
.	O
e	O
.,	O
antibody	B-FUNC
evasion	O
vs	O
.	O
receptor	B-FUNC
binding	I-FUNC
)	O
on	O
viral	O
replication	O
within	O
hosts	O
can	O
impact	O
viral	O
immune	O
escape	O
in	O
the	O
host	O
population	O
.	O

When	O
the	O
host	O
population	O
is	O
vaccinated	O
,	O
the	O
virus	O
escapes	O
from	O
passive	O
immunity	O
by	O
mutations	O
in	O
the	O
antibody	B-FUNC
-	O
binding	B-FUNC
region	O
on	O
the	O
surface	O
of	O
the	O
target	O
protein	O
.	O

However	O
,	O
the	O
reduced	O
ability	O
of	O
the	O
antibody	B-FUNC
to	O
bind	B-FUNC
the	O
virus	O
is	O
often	O
accompanied	O
by	O
a	O
reduced	O
ability	O
of	O
the	O
virus	O
to	O
bind	B-FUNC
the	O
cell	O
receptor	O
because	O
the	O
antibody	B-FUNC
-	O
binding	B-FUNC
region	O
overlaps	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
).	O

The	O
coefficients	O
describe	O
the	O
binding	B-FUNC
affinity	O
between	O
the	O
virus	O
and	O
the	O
induced	O
antibody	B-FUNC
and	O
that	O
between	O
the	O
virus	O
and	O
its	O
receptor	O
.	O

Our	O
knowledge	O
-	O
based	O
index	O
enables	O
us	O
to	O
estimate	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
a	O
binding	B-FUNC
region	O
on	O
the	O
binding	B-FUNC
affinity	O
.	O

In	O
case	O
of	O
acute	O
hypoxemia	O
that	O
evolves	O
within	O
minutes	O
the	O
organism	O
can	O
shift	O
the	O
oxygen	B-FUNC
binding	I-FUNC
curve	O
by	O
changing	O
2	O
-	O
3	O
-	O
DGP	O
erythrocytic	O
activity	O
.	O

Stem	O
loops	O
(	O
SL	O
)	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
5	O
were	O
predicted	O
in	O
all	O
CoVs	O
,	O
while	O
the	O
core	O
leader	O
transcription	O
-	O
regulating	O
sequence	O
(	O
L	O
-	O
TRS	B-FUNC
)	O
forms	O
SL3	O
in	O
only	O
some	O
CoVs	O
.	O

Adjusted	O
for	O
sex	O
,	O
health	O
care	O
worker	O
status	O
and	O
nosocomial	O
setting	O
,	O
older	O
age	O
was	O
associated	O
with	O
a	O
higher	O
fatality	O
,	O
with	O
adjusted	O
odds	O
ratio	O
(	O
AOR	B-FUNC
):	O
2	O
.	O
10	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
45	O
,	O
3	O
.	O
04	O
)	O
for	O
those	O
aged	O
51	O
-	O
60	O
;	O
AOR	B-FUNC
:	O
4	O
.	O
57	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
32	O
,	O
7	O
.	O
30	O
)	O
for	O
those	O
aged	O
above	O
60	O
compared	O
to	O
those	O
aged	O
41	O
-	O
50	O
years	O
.	O

Presence	O
of	O
pre	O
-	O
existing	O
comorbid	O
conditions	O
was	O
also	O
associated	O
with	O
greater	O
mortality	O
(	O
AOR	B-FUNC
:	O
1	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
36	O
,	O
2	O
.	O
21	O
).	O

Presence	O
of	O
pre	O
-	O
existing	O
comorbid	O
conditions	O
was	O
also	O
associated	O
with	O
greater	O
mortality	O
(	O
AOR	B-FUNC
:	O
1	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
36	O
,	O
2	O
.	O
21	O
).	O

ABSTRACT	O
:	O
To	O
observe	O
the	O
effect	O
of	O
Qingyi	O
Decoction	O
(	O
QYD	O
)	O
in	O
treating	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
and	O
its	O
impacts	O
on	O
blood	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
interleukin	O
6	O
and	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
).	O

The	O
post	O
-	O
treatment	O
incidence	O
of	O
severe	O
complication	O
,	O
mortality	O
and	O
operation	O
transferring	O
rate	O
,	O
as	O
well	O
as	O
the	O
changes	O
of	O
APACHE	O
II	O
scores	O
and	O
blood	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
patients	O
of	O
both	O
groups	O
were	O
observed	O
.	O

QYD	O
could	O
markedly	O
improve	O
the	O
prognosis	O
of	O
SAP	O
patients	O
by	O
way	O
of	O
lowering	O
the	O
blood	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

In	O
addition	O
,	O
the	O
efficacy	O
in	O
the	O
treated	O
group	O
was	O
also	O
superior	O
to	O
that	O
in	O
the	O
control	O
group	O
in	O
terms	O
of	O
reducing	O
mortality	O
,	O
operation	O
transferring	O
rate	O
,	O
and	O
blood	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
on	O
the	O
7th	O
and	O
9th	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
QYD	O
could	O
markedly	O
improve	O
the	O
prognosis	O
of	O
SAP	O
patients	O
by	O
way	O
of	O
lowering	O
the	O
blood	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

Reference	O
sera	B-FUNC
against	O
newcastle	O
disease	O
virus	O
,	O
infectious	O
bursal	O
disease	O
,	O
avian	O
influenza	O
virus	O
H5	O
and	O
H9	O
subtypes	O
were	O
all	O
negatives	O
for	O
anti	O
-	O
IBV	O
antibodies	O
using	O
the	O
GICA	O
.	O

Although	O
none	O
of	O
the	O
farms	O
had	O
clinical	O
signs	O
of	O
transmissible	O
gastroenteritis	O
(	O
TGE	O
)	O
or	O
vaccination	O
against	O
TGEV	O
,	O
VN	O
antibody	B-FUNC
was	O
detected	O
in	O
14	O
.	O
4	O
%	O
of	O
sera	B-FUNC
at	O
30	O
farms	O
(	O
17	O
.	O
5	O
%)	O
across	O
all	O
six	O
regions	O
.	O

On	O
testing	O
of	O
263	O
VN	O
antibody	B-FUNC
-	O
positive	O
sera	B-FUNC
from	O
27	O
farms	O
with	O
a	O
commercial	O
blocking	O
ELISA	O
to	O
distinguish	O
TGEV	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
antibodies	O
,	O
78	O
.	O
3	O
%	O
were	O
positive	O
for	O
PRCV	O
antibody	B-FUNC
only	O
,	O
while	O
12	O
.	O
5	O
%	O
were	O
positive	O
for	O
TGEV	O
antibody	B-FUNC
only	O
or	O
both	O
TGEV	O
and	O
PRCV	O
antibodies	O
.	O

Five	O
months	O
after	O
the	O
antibody	B-FUNC
examination	O
,	O
a	O
TGE	O
outbreak	O
occurred	O
at	O
one	O
of	O
these	O
seven	O
farms	O
.	O

There	O
were	O
only	O
4	O
of	O
52	O
subjects	O
in	O
the	O
control	O
group	O
(	O
7	O
.	O
7	O
%)	O
who	O
showed	O
positive	O
anticardiolipin	O
antibody	B-FUNC
with	O
titers	O
of	O
IgA	O
at	O
10	O
.	O
702	O
+/-	O

ABSTRACT	O
:	O
Our	O
studies	O
and	O
those	O
of	O
many	O
others	O
have	O
implicated	O
hepatocyte	O
necrosis	O
and	O
apoptosis	O
mediated	O
by	O
fibrinogen	O
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
(	O
TNFR	O
)	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
rate	O
greater	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

Both	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
in	O
chicken	O
'	O
s	O
lymphocytes	O
were	O
produced	O
by	O
this	O
strategy	O
.	O

Positive	O
sera	B-FUNC
were	O
obtained	O
from	O
6	O
-	O
week	O
-	O
old	O
,	O
female	O
C57BL	O
/	O
6JJcl	O
mice	O
inoculated	O
orally	O
with	O
MNV	O
-	O
S7	O
.	O

IFA	O
against	O
infected	O
RAW	O
264	O
cells	O
was	O
able	O
to	O
discriminate	O
positive	O
sera	B-FUNC
from	O
negative	O
sera	B-FUNC
.	O

An	O
equal	O
level	O
of	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	B-FUNC
response	O
was	O
observed	O
in	O
BALB	O
/	O
cAJcl	O
,	O
C57BL	O
/	O
6JJcl	O
,	O
DBA	O
/	O
2JJcl	O
,	O
and	O
Jcl	O
:	O
ICR	O
mice	O
;	O
whereas	O
,	O
C3H	O
/	O
HeJJcl	O
mice	O
demonstrated	O
slightly	O
lower	O
antibody	B-FUNC
production	O
4	O
weeks	O
after	O
infection	O
.	O

We	O
also	O
used	O
this	O
ELISA	O
system	O
to	O
evaluate	O
77	O
murine	O
serum	O
samples	O
obtained	O
from	O
15	O
conventional	O
mouse	O
rooms	O
in	O
research	O
facilities	O
in	O
Japan	O
and	O
found	O
that	O
approximately	O
half	O
of	O
the	O
serum	O
samples	O
contained	O
antibody	B-FUNC
to	O
MNV	O
-	O
S7	O
.	O

We	O
then	O
used	O
the	O
two	O
-	O
antibody	B-FUNC
sandwich	O
ELISA	O
method	O
to	O
detect	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
).	O

ABSTRACT	O
:	O
The	O
methods	O
of	O
repeated	O
immunization	O
with	O
inactivated	O
vaccines	O
have	O
been	O
used	O
widely	O
to	O
increase	O
antibody	B-FUNC
protection	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

In	O
particular	O
,	O
there	O
seems	O
to	O
be	O
effects	O
on	O
cytokine	O
and	O
chemokine	O
mRNA	O
expression	O
levels	O
in	O
both	O
lymphocytes	O
and	O
heterophils	O
,	O
especially	O
expression	O
of	O
the	O
proinflammatory	O
cytokines	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
and	O
chemokines	O
C	O
-	O
C	O
motif	O
,	O
ligand	B-FUNC
1	O
inflammatory	O
(	O
CCLi1	O
);	O
C	O
-	O
C	O
motif	O
,	O
ligand	B-FUNC
2	O
inflammatory	O
(	O
CCLi2	O
);	O
C	O
-	O
C	O
motif	O
,	O
ligand	B-FUNC
5	O
(	O
CCL5	O
);	O
C	O
-	O
C	O
motif	O
,	O
ligand	B-FUNC
16	O
(	O
CCL16	O
);	O
C	O
-	O
X	O
-	O
C	O
motif	O
ligand	B-FUNC
1	O
inflammatory	O
(	O
CXCLi1	O
);	O
and	O
C	O
-	O
X	O
-	O
C	O
motif	O
ligand	B-FUNC
2	O
inflammatory	O
(	O
CXCLi2	O
),	O
which	O
are	O
initially	O
upregulated	O
and	O
are	O
potentially	O
involved	O
in	O
modulating	O
the	O
adaptive	O
immune	O
response	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
connexin	B-FUNC
43	O
was	O
confirmed	O
in	O
both	O
mock	O
and	O
2B	O
-	O
transfected	O
cells	O
.	O

Here	O
,	O
we	O
present	O
a	O
thermal	O
targeting	O
strategy	O
--	O
dynamic	O
affinity	O
modulation	O
(	O
DAM	O
)--	O
using	O
elastin	B-FUNC
-	O
like	O
polypeptide	O
diblock	O
copolymers	O
(	O
ELP	O
(	O
BC	O
)	O
s	O
)	O
that	O
self	O
-	O
assemble	O
from	O
a	O
low	O
-	O
affinity	O
to	O
high	O
-	O
avidity	O
state	O
by	O
a	O
tunable	O
thermal	O
""""	O
switch	O
""","	O
thereby	O
restricting	O
activity	O
to	O
the	O
desired	O
site	O
of	O
action	O
.	O

We	O
used	O
an	O
in	O
vitro	O
cell	O
binding	B-FUNC
assay	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
thermally	O
triggered	O
self	O
-	O
assembly	O
of	O
these	O
ELP	O
(	O
BC	O
)	O
s	O
on	O
their	O
receptor	O
-	O
mediated	O
binding	B-FUNC
and	O
cellular	O
uptake	O
.	O

Serum	O
samples	O
were	O
collected	O
from	O
super	O
transmitters	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
by	O
neutralization	O
test	O
and	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Serum	O
samples	O
were	O
collected	O
from	O
32	O
highly	O
-	O
exposed	O
individuals	O
,	O
of	O
whom	O
13	O
developing	O
SARS	O
symptoms	O
after	O
contact	O
had	O
serum	O
samples	O
positive	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
.	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
.	O

Three	O
types	O
of	O
status	O
were	O
defined	O
for	O
BCV	O
and	O
BRSV	O
infections	O
,	O
based	O
on	O
1	O
)	O
the	O
dynamics	O
over	O
a	O
7	O
-	O
mo	O
period	O
of	O
BCV	O
-	O
and	O
BRSV	O
-	O
specific	O
antibody	B-FUNC
levels	O
in	O
pooled	O
milk	O
of	O
primiparous	O
cows	O
;	O
2	O
)	O
the	O
possible	O
occurrence	O
of	O
presumably	O
BCV	O
-	O
and	O
BRSV	O
-	O
related	O
clinical	O
outbreaks	O
;	O
and	O
3	O
)	O
the	O
combination	O
of	O
both	O
pieces	O
of	O
information	O
.	O

Cytochrome	B-FUNC
p450	I-FUNC
levels	O
in	O
phenobarbital	O
pre	O
-	O
treated	O
animals	O
were	O
significantly	O
higher	O
than	O
non	O
pre	O
-	O
treated	O
animals	O
(	O
300	O
vs	O
100	O
pmol	O
/	O
mg	O
protein	O
).	O

Our	O
data	O
have	O
suggested	O
that	O
nitric	O
oxide	O
(	O
NO	O
),	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
),	O
phospholipase	O
A2	O
,	O
free	O
radical	O
and	O
inflammatory	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
interleukin	O
-	O
1beta	O
and	O
interleukin	O
-	O
6	O
)	O
are	O
involved	O
in	O
the	O
biochemical	O
phase	O
of	O
FES	O
with	O
ARDS	O
.	O

After	O
that	O
,	O
the	O
protein	O
chip	O
was	O
reacted	O
with	O
the	O
corresponding	O
positive	O
serum	O
against	O
these	O
viruses	O
,	O
hybridized	O
with	O
a	O
colloidal	O
gold	O
-	O
labeled	O
secondary	O
antibody	B-FUNC
and	O
visualized	O
by	O
silver	O
staining	O
.	O

Except	O
1	O
patient	O
out	O
of	O
75	O
patients	O
died	O
,	O
and	O
the	O
rest	B-FUNC
were	O
cured	O
.	O

Except	O
1	O
patient	O
out	O
of	O
75	O
patients	O
died	O
,	O
and	O
the	O
rest	B-FUNC
were	O
cured	O
.	O

Plasma	O
exchange	O
was	O
the	O
first	O
treatment	O
in	O
Guillain	O
-	O
Barrd	O
syndrome	O
proven	O
to	O
be	O
superior	O
to	O
supportive	O
treatment	O
alone	O
and	O
intravenous	O
immunoglobulin	B-FUNC
was	O
subsequently	O
shown	O
to	O
be	O
equally	O
effective	O
and	O
is	O
now	O
commonly	O
used	O
as	O
first	O
-	O
line	O
treatment	O
.	O

A	O
five	O
-	O
day	O
course	O
of	O
daily	O
immunoglobulin	B-FUNC
(	O
0	O
.	O
4	O
g	O
/	O
kg	O
/	O
day	O
)	O
was	O
commenced	O
without	O
benefit	O
and	O
progressive	O
clinical	O
deterioration	O
.	O

This	O
case	O
suggests	O
that	O
patients	O
with	O
severe	O
Guillain	O
-	O
Barrd	O
syndrome	O
may	O
benefit	O
from	O
plasma	O
exchange	O
after	O
immunoglobulin	B-FUNC
treatment	O
in	O
refractory	O
cases	O
.	O

The	O
article	O
describes	O
rational	O
approaches	O
for	O
the	O
design	O
of	O
inhibitors	O
and	O
focuses	O
on	O
a	O
variety	O
of	O
structure	O
as	O
well	O
as	O
ligand	B-FUNC
-	O
based	O
modeling	O
strategies	O
adopted	O
for	O
the	O
discovery	O
of	O
the	O
inhibitors	O
.	O

Also	O
,	O
the	O
key	O
features	O
of	O
ligand	B-FUNC
recognition	O
against	O
these	O
targets	O
are	O
accentuated	O
.	O

Based	O
on	O
the	O
crystal	O
structures	O
,	O
a	O
key	O
residue	O
,	O
Glu	O
-	O
166	O
,	O
which	O
is	O
responsible	O
for	O
recognizing	O
the	O
Gln	O
-	O
P1	O
of	O
the	O
substrate	O
and	O
binding	B-FUNC
to	O
Ser	O
-	O
1	O
of	O
another	O
protomer	O
,	O
will	O
interact	O
with	O
Asn	O
-	O
142	O
and	O
block	O
the	O
S1	O
subsite	O
entrance	O
in	O
the	O
monomer	O
.	O

This	O
demonstrates	O
that	O
Glu	O
-	O
166	O
plays	O
a	O
pivotal	O
role	O
in	O
connecting	O
the	O
substrate	O
binding	B-FUNC
site	O
with	O
the	O
dimer	O
interface	O
.	O

Cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
infected	O
with	O
a	O
human	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
)	O
H5N1	O
virus	O
isolate	O
(	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
)	O
or	O
reassortants	O
of	O
human	O
influenza	O
virus	O
A	O
/	O
Texas	O
/	O
36	O
/	O
91	O
(	O
H1N1	O
)	O
containing	O
genes	O
from	O
the	O
1918	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
developed	O
severe	O
pneumonia	O
within	O
24	O
h	O
postinfection	O
.	O

We	O
propose	O
that	O
this	O
motif	O
is	O
a	O
linear	O
B	O
-	O
cell	O
epitope	O
of	O
N	O
protein	O
,	O
and	O
is	O
the	O
core	O
sequence	O
for	O
reactivity	O
,	O
as	O
demonstrated	O
by	O
binding	B-FUNC
of	O
2D2	O
to	O
the	O
truncated	O
peptides	O
and	O
different	O
IBV	O
strains	O
.	O

TITLE	O
:	O
A	O
219	O
-	O
mer	O
CHO	B-FUNC
-	O
expressing	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
induces	O
potent	O
immune	O
responses	O
and	O
protective	O
immunity	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
a	O
219	O
-	O
mer	O
(	O
residues	O
318	O
-	O
536	O
)	O
RBD	O
protein	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)-	O
K1	O
cells	O
(	O
RBD219	O
-	O
CHO	B-FUNC
),	O
and	O
tested	O
its	O
immune	O
responses	O
and	O
protective	O
immunity	O
in	O
a	O
mouse	O
model	O
.	O

RBD219	O
-	O
CHO	B-FUNC
protein	O
elicited	O
potent	O
protective	O
immunity	O
that	O
protected	O
all	O
vaccinated	O
mice	O
from	O
SARS	O
-	O
CoV	O
challenge	O
.	O

These	O
results	O
suggest	O
that	O
the	O
recombinant	O
RBD219	O
-	O
CHO	B-FUNC
protein	O
has	O
great	O
potential	O
for	O
the	O
development	O
of	O
an	O
effective	O
and	O
safe	O
SARS	O
subunit	O
vaccine	O
.	O

Forty	O
-	O
three	O
candidate	O
peptides	O
having	O
HLA	O
-	O
A2	O
-	O
binding	B-FUNC
motifs	O
were	O
selected	O
in	O
silico	O
and	O
HLA	O
-	O
A2	O
/	O
Db	O
chimeric	O
MHC	O
class	O
I	O
-	O
transgenic	O
mice	O
were	O
immunized	O
with	O
these	O
peptides	O
and	O
a	O
new	O
derivative	O
of	O
muramyl	O
dipeptide	O
that	O
can	O
induce	O
upregulation	O
of	O
HLA	O
-	O
DR	O
,	O
CD80	O
,	O
CD86	O
,	O
and	O
CD40	O
in	O
human	O
CD14	O
+	O
antigen	O
presenting	O
cells	O
,	O
was	O
administered	O
as	O
an	O
adjuvant	O
.	O

A	O
diagnosis	O
of	O
pulmonary	O
tuberculosis	O
was	O
given	O
because	O
of	O
multiple	O
nodular	O
shadows	O
and	O
consolidation	O
on	O
chest	O
radiography	O
and	O
positive	O
testing	O
for	O
acid	O
-	O
fast	B-FUNC
bacilli	O
in	O
his	O
sputum	O
;	O
he	O
was	O
then	O
referred	O
to	O
our	O
hospital	O
for	O
treatment	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
in	O
all	O
Hong	O
Kong	O
patient	O
contacts	O
.	O

By	O
recombinant	O
expression	O
and	O
purification	O
of	O
secretory	O
HE	O
(	O
recHE	O
)	O
proteins	O
,	O
receptor	O
-	O
binding	B-FUNC
and	O
quantitative	O
analyses	O
of	O
enzymatic	O
activities	O
displayed	O
by	O
ISAV	O
HE	O
molecules	O
are	O
presented	O
for	O
the	O
first	O
time	O
.	O

Immune	O
responses	O
,	O
including	O
the	O
production	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
serum	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
and	O
secretory	O
immunoglobulin	B-FUNC
A	O
(	O
sIgA	O
),	O
were	O
determined	O
in	O
mucosal	O
secretions	O
and	O
tissues	O
.	O

TITLE	O
:	O
A	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
assay	O
for	O
the	O
genotyping	O
of	O
avian	O
infectious	O
bronchitis	O
viruses	O
.	O

This	O
work	O
reports	O
on	O
a	O
rapid	O
and	O
reliable	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
for	O
the	O
genotyping	O
of	O
IBVs	O
.	O

Several	O
viral	O
and	O
cell	O
proteins	O
including	O
spike	O
,	O
membrane	O
,	O
non	O
-	O
structural	O
protein	O
3	O
(	O
nsp3	O
),	O
dynein	B-FUNC
heavy	O
chain	O
,	O
fatty	O
acid	O
synthase	O
and	O
transmembrane	O
protein	O
43	O
bound	O
E	O
protein	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
focused	O
on	O
the	O
binding	B-FUNC
of	O
E	O
protein	O
to	O
nsp3	O
in	O
infected	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
.	O

We	O
examined	O
NO	O
levels	O
by	O
Greiss	O
assay	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
of	O
pigs	O
infected	O
with	O
either	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
or	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
a	O
member	O
of	O
Nidovirales	O
,	O
like	O
CoV	O
.	O
The	O
antiviral	O
effects	O
of	O
NO	O
on	O
these	O
two	O
viruses	O
were	O
tested	O
in	O
an	O
in	O
vitro	O
system	O
using	O
a	O
NO	O
donor	O
,	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
(	O
SNAP	B-FUNC
).	O

There	O
was	O
no	O
significant	O
difference	O
in	O
interferon	O
(	O
IFN	O
)-	O
	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
	O
concentrations	O
in	O
BALF	O
between	O
the	O
PRCV	O
-	O
LTA	O
and	O
PRCV	O
groups	O
,	O
but	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
and	O
IFN	O
-	O
	O
were	O
higher	O
in	O
the	O
PRCV	O
-	O
LTA	O
-	O
inoculated	O
than	O
in	O
the	O
LTA	O
-	O
inoculated	O
controls	O
.	O

mCEACAM1a	O
(	O
1a	O
)	O
has	O
a	O
10	O
-	O
to	O
100	O
-	O
fold	O
-	O
higher	O
receptor	B-FUNC
activity	I-FUNC
than	O
does	O
mCEACAM1b	O
(	O
1b	O
).	O

Sixty	O
-	O
two	O
of	O
the	O
483	O
samples	O
(	O
12	O
.	O
8	O
%)	O
were	O
seropositive	O
for	O
CRCoV	O
by	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
analysis	O
.	O

Analysis	O
of	O
stretched	O
versus	O
nonstretched	O
cells	O
identified	O
significant	O
enrichment	O
for	O
genes	O
containing	O
putative	O
binding	B-FUNC
sites	O
for	O
the	O
transcription	O
factor	O
activating	O
transcription	O
factor	O
3	O
(	O
ATF3	O
).	O

Articles	O
for	O
review	O
were	O
selected	O
based	O
on	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
prospective	O
or	O
cross	O
-	O
sectional	O
study	O
,	O
(	O
ii	O
)	O
original	O
research	O
,	O
(	O
iii	O
)	O
viral	O
detection	O
used	O
the	O
highly	O
sensitive	O
techniques	O
of	O
PCR	O
and	O
/	O
or	O
Reverse	O
Transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
(	O
iv	O
)	O
viral	O
prevalence	O
in	O
AECOPD	O
defined	O
,	O
and	O
(	O
v	O
)	O
full	O
paper	O
available	O
in	O
English	O
.	O

The	O
crystallographic	O
structure	O
of	O
the	O
N28A	O
mutant	O
determined	O
at	O
2	O
.	O
35	O
A	O
resolution	O
reveals	O
the	O
critical	O
role	O
of	O
Asn28	O
in	O
maintaining	O
the	O
structural	O
integrity	O
of	O
the	O
active	O
site	O
and	O
in	O
orienting	O
key	O
residues	O
involved	O
in	O
binding	B-FUNC
at	O
the	O
dimer	O
interface	O
and	O
substrate	O
catalysis	O
.	O

We	O
show	O
that	O
MHV	O
infection	O
activated	O
both	O
transcription	O
factors	O
,	O
the	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
as	O
evidenced	O
by	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
and	O
an	O
increased	O
promoter	O
binding	B-FUNC
activity	O
for	O
IRF	O
-	O
3	O
and	O
NF	O
-	O
kappaB	O
.	O
Furthermore	O
,	O
the	O
cytoplasmic	O
pattern	O
recognition	O
receptor	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
was	O
induced	O
by	O
MHV	O
infection	O
.	O

Kolobow	O
and	O
Gattinoni	O
were	O
the	O
first	O
to	O
introduce	O
extracorporeal	O
support	O
,	O
with	O
the	O
intent	O
to	O
separate	O
carbon	O
dioxide	O
removal	O
from	O
oxygen	O
uptake	O
;	O
they	O
hypothesized	O
that	O
to	O
allow	O
the	O
lung	O
to	O
'	B-FUNC
rest	I-FUNC
'	O
oxygenation	O
via	O
mechanical	O
ventilation	O
could	O
be	O
dissociated	O
from	O
decarboxylation	O
via	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
.	O

Reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
14	O
respiratory	O
viruses	O
was	O
performed	O
on	O
nasopharyngeal	O
swabs	O
collected	O
at	O
admission	O
and	O
after	O
recovery	O
in	O
stable	O
condition	O
.	O

TITLE	O
:	O
Functional	O
and	O
genetic	O
studies	O
of	O
the	O
substrate	O
specificity	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
),	O
located	O
in	O
nonstructural	O
protein	O
5	O
(	O
nsp5	O
),	O
processes	O
the	O
replicase	O
polyproteins	O
1a	O
and	O
1ab	O
(	O
pp1a	O
and	O
pp1ab	O
)	O
at	O
11	O
specific	O
sites	O
to	O
produce	O
12	O
mature	O
nonstructural	O
proteins	O
(	O
nsp5	O
to	O
nsp16	O
).	O

Group	O
5	O
received	O
PBS	O
and	O
H120	O
and	O
group	O
6	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
H120	O
.	O

On	O
0	O
,	O
7	O
,	O
14	O
,	O
21	O
,	O
28	O
and	O
35	O
post	O
first	O
vaccination	O
,	O
the	O
dynamic	O
changes	O
of	O
peripheral	O
lymphocyte	O
proliferation	O
,	O
cytokine	O
assays	O
and	O
serum	O
antibody	B-FUNC
titers	O
were	O
assayed	O
respectively	O
by	O
MTT	O
method	O
,	O
ELISA	O
and	O
hemagglutination	O
inhibition	O
assay	O
(	O
HI	O
).	O

To	O
facilitate	O
information	O
dissemination	O
,	O
journal	O
managers	O
should	O
reengineer	O
their	O
fast	B-FUNC
-	O
track	O
channels	O
,	O
which	O
should	O
be	O
adapted	O
to	O
the	O
purpose	O
of	O
an	O
emerging	O
outbreak	O
,	O
taking	O
into	O
account	O
the	O
requirement	O
of	O
high	O
standards	O
of	O
quality	O
for	O
scientific	O
journals	O
and	O
competition	O
with	O
other	O
online	O
resources	O
.	O

Although	O
many	O
tools	O
have	O
been	O
developed	O
for	O
the	O
diagnosis	O
of	O
SARS	O
,	O
false	O
-	O
positive	O
reactions	O
in	O
negative	O
sera	B-FUNC
may	O
occur	O
because	O
of	O
cross	O
-	O
reactivity	O
with	O
other	O
coronaviruses	O
.	O

High	O
anti	O
-	O
TNF	O
-	O
alpha	O
activity	O
was	O
detected	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
peritoneal	O
lavage	O
fluids	O
and	O
serum	O
of	O
all	O
animals	O
for	O
at	O
least	O
8h	O
post	O
-	O
inoculation	O
(	O
HPI	B-FUNC
).	O

No	O
clinical	O
symptoms	O
,	O
lung	O
lesions	O
,	O
lung	O
cell	O
infiltration	O
or	O
induction	O
of	O
IFN	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
TNF	O
-	O
alpha	O
in	O
BAL	O
were	O
detected	O
.	O

No	O
significant	O
differences	O
in	O
disease	O
severity	O
,	O
lung	O
lesions	O
,	O
virus	O
replication	O
,	O
lung	O
cell	O
infiltration	O
or	O
levels	O
of	O
IFN	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
23	I-FUNC
were	O
observed	O
between	O
the	O
two	O
groups	O
.	O

Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	B-FUNC
(	O
ANCA	O
)	O
associated	O
vasculitis	O
""""	O
and	O
glomerular	O
basement	O
membrane	O
"("""	O
Goodpasture	O
'	O
s	O
""")"	O
disease	O
are	O
the	O
commonest	O
causes	O
but	O
other	O
pathologies	O
including	O
systemic	O
lupus	O
erythematosus	O
and	O
the	O
anti	O
-	O
phospholipid	O
syndrome	O
are	O
also	O
implicated	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	O
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	B-FUNC
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

Two	O
of	O
52	O
R	O
.	O
ferrumequinum	O
captured	O
from	O
different	O
Italian	O
areas	O
tested	O
positive	O
by	O
reverse	O
transcription	O
-	O
PCR	O
for	O
a	O
fragment	O
of	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
of	O
viruses	O
related	O
to	O
Coronavirus	O
.	O

ABSTRACT	O
:	O
Viral	O
ion	B-FUNC
channels	I-FUNC
are	O
short	O
membrane	O
proteins	O
with	O
50	O
-	O
120	O
amino	O
acids	O
and	O
play	O
an	O
important	O
role	O
either	O
in	O
regulating	O
virus	O
replication	O
,	O
such	O
as	O
virus	O
entry	O
,	O
assembly	O
and	O
release	O
or	O
modulating	O
the	O
electrochemical	O
balance	O
in	O
the	O
subcellular	O
compartments	O
of	O
host	O
cells	O
.	O

Moreover	O
,	O
TSL	O
-	O
1	O
treatment	O
decreased	O
the	O
cell	O
-	O
cycle	O
regulators	O
;	O
cyclin	B-FUNC
D1	O
and	O
CDK4	O
proteins	O
by	O
up	O
regulating	O
p27	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Improving	O
alveolar	O
ventilation	O
and	O
oxygenation	O
may	O
improve	O
the	O
outcome	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
).	O

Prospective	O
randomized	O
single	O
-	O
center	O
open	O
study	O
from	O
November	O
1998	O
to	O
February	O
2002	O
to	O
test	O
whether	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
was	O
more	O
effective	O
than	O
oxygen	O
alone	O
in	O
improving	O
oxygenation	O
on	O
day	O
3	O
in	O
adults	O
with	O
ACS	B-FUNC
and	O
to	O
evaluate	O
the	O
effects	O
on	O
pain	O
,	O
transfusion	O
requirements	O
,	O
and	O
length	O
of	O
stay	O
.	O

Seventy	O
-	O
one	O
consecutive	O
ACS	B-FUNC
episodes	O
in	O
67	O
patients	O
were	O
randomly	O
allocated	O
to	O
oxygen	O
(	O
n	O
=	O
36	O
)	O
or	O
NIV	O
(	O
n	O
=	O
35	O
)	O
for	O
3	O
days	O
in	O
a	O
medical	O
step	O
-	O
down	O
unit	O
.	O

TITLE	O
:	O
Upregulation	O
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
via	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
-	O
ACE2	O
signaling	O
pathway	O
.	O

Results	O
from	O
oligonucleotide	O
-	O
based	O
microarray	O
,	O
real	O
-	O
time	O
PCR	O
,	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
indicated	O
an	O
upregulation	O
of	O
the	O
fibrosis	O
-	O
associated	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
(	O
CCL2	O
)	O
by	O
the	O
viral	O
spike	O
protein	O
and	O
the	O
virus	O
-	O
like	O
particles	O
.	O

The	O
upregulation	O
of	O
CCL2	O
by	O
SARS	O
-	O
CoV	O
spike	O
protein	O
was	O
mainly	O
mediated	O
by	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
and	O
2	O
(	O
ERK1	B-FUNC
/	O
2	O
)	O
and	O
AP	O
-	O
1	O
but	O
not	O
the	O
IkappaBalpha	O
-	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

In	O
addition	O
,	O
Ras	O
and	O
Raf	O
upstream	O
of	O
the	O
ERK1	B-FUNC
/	O
2	O
signaling	O
pathway	O
were	O
involved	O
in	O
the	O
upregulation	O
of	O
CCL2	O
.	O

TITLE	O
:	O
The	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
plays	O
an	O
important	O
role	O
during	O
various	O
stages	O
of	O
the	O
coronavirus	O
infection	O
cycle	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
is	O
a	O
key	O
player	O
in	O
regulating	O
the	O
intracellular	O
sorting	O
and	O
degradation	O
of	O
proteins	O
.	O

Viral	O
protein	O
expression	O
was	O
reduced	O
in	O
cells	O
expressing	O
a	O
temperature	O
-	O
sensitive	O
ubiquitin	B-FUNC
-	O
activating	O
enzyme	O
E1	O
at	O
the	O
restrictive	O
temperature	O
,	O
as	O
well	O
as	O
in	O
cells	O
in	O
which	O
ubiquitin	B-FUNC
was	O
depleted	O
by	O
using	O
small	O
interfering	O
RNAs	O
.	O

TITLE	O
:	O
Maturation	O
mechanism	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CL	O
(	O
pro	O
))	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
plays	O
a	O
vital	O
role	O
in	O
virus	O
maturation	O
and	O
is	O
proposed	O
to	O
be	O
a	O
key	O
target	O
for	O
drug	O
design	O
against	O
SARS	O
.	O

We	O
also	O
measured	O
enzyme	B-FUNC
activity	I-FUNC
under	O
different	O
enzyme	O
concentrations	O
and	O
found	O
a	O
clear	O
tendency	O
of	O
substrate	O
-	O
induced	O
dimer	O
formation	O
.	O

Surveys	O
of	O
antibody	B-FUNC
levels	O
in	O
bulk	O
tank	O
milk	O
have	O
shown	O
very	O
high	O
nationwide	O
prevalences	O
of	O
both	O
BCV	O
and	O
BRSV	O
,	O
with	O
large	O
variations	O
between	O
regions	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
unique	O
domain	O
:	O
three	O
-	O
domain	O
molecular	O
architecture	O
in	O
solution	O
and	O
RNA	B-FUNC
binding	I-FUNC
.	O

Gel	O
-	O
shift	O
experiments	O
showed	O
that	O
both	O
SUD	O
-	O
C	O
and	O
SUD	O
-	O
MC	O
bind	B-FUNC
to	O
single	O
-	O
stranded	O
RNA	O
and	O
recognize	O
purine	O
bases	O
more	O
strongly	O
than	O
pyrimidine	O
bases	O
,	O
whereby	O
SUD	O
-	O
MC	O
binds	B-FUNC
to	O
a	O
more	O
restricted	O
set	O
of	O
purine	O
-	O
containing	O
RNA	O
sequences	O
than	O
SUD	O
-	O
M	O
.	O
NMR	O
chemical	O
shift	O
perturbation	O
experiments	O
with	O
observations	O
of	O
(	O
15	O
)	O
N	O
-	O
labeled	O
proteins	O
further	O
resulted	O
in	O
delineation	O
of	O
RNA	B-FUNC
binding	I-FUNC
sites	O
(	O
i	O
.	O
e	O
.,	O
in	O
SUD	O
-	O
M	O
,	O
a	O
positively	O
charged	O
surface	O
area	O
with	O
a	O
pronounced	O
cavity	O
,	O
and	O
in	O
SUD	O
-	O
C	O
,	O
several	O
residues	O
of	O
an	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
).	O

Overall	O
,	O
the	O
present	O
data	O
provide	O
evidence	O
for	O
molecular	O
mechanisms	O
involving	O
the	O
concerted	O
actions	O
of	O
SUD	O
-	O
M	O
and	O
SUD	O
-	O
C	O
,	O
which	O
result	O
in	O
specific	O
RNA	B-FUNC
binding	I-FUNC
that	O
might	O
be	O
unique	O
to	O
the	O
SUD	O
and	O
,	O
thus	O
,	O
to	O
the	O
SARS	O
coronavirus	O
.	O

In	O
addition	O
,	O
either	O
splenectomization	O
or	O
administration	O
of	O
the	O
anti	O
-	O
inflammatory	O
molecule	O
carbon	O
monoxide	O
led	O
to	O
a	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
sera	B-FUNC
VEGF	O
and	O
to	O
protection	O
from	O
ALI	O
.	O

Phosphorylation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
p38	B-FUNC
,	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
in	O
appropriately	O
stimulated	O
and	O
nonstimulated	O
samples	O
were	O
studied	O
using	O
phospho	O
-	O
specific	O
whole	O
-	O
blood	O
flow	O
cytometry	O
.	O

Phosphorylation	O
levels	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
induced	O
by	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
,	O
bacterial	O
lipopolysaccharide	O
,	O
muramyl	O
dipeptide	O
,	O
Escherichia	O
coli	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Staphylococcus	O
epidermidis	O
were	O
significantly	O
lower	O
in	O
patients	O
'	O
monocytes	O
than	O
monocytes	O
of	O
healthy	O
reference	O
subjects	O
,	O
whereas	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
p38	B-FUNC
phosphorylation	O
levels	O
were	O
normal	O
.	O

Phosphorylation	O
levels	O
induced	O
by	O
interleukin	O
-	O
6	O
in	O
STAT1	O
and	O
STAT3	O
and	O
by	O
combination	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
calcium	O
ionophore	B-FUNC
A23187	O
in	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
,	O
members	O
of	O
a	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
,	O
were	O
depressed	O
in	O
patients	O
'	O
monocytes	O
,	O
whereas	O
phosphorylation	O
levels	O
induced	O
by	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	O
STAT5	O
was	O
normal	O
.	O

Nonstructural	O
protein	O
9	O
(	O
nsp9	O
)	O
has	O
been	O
identified	O
as	O
a	O
protein	O
that	O
is	O
essential	O
to	O
viral	O
replication	O
because	O
of	O
its	O
single	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
ability	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
antibody	B-FUNC
status	O
to	O
bovine	O
corona	O
virus	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
and	O
disease	O
incidence	O
,	O
reproduction	O
and	O
herd	O
characteristics	O
in	O
dairy	O
herds	O
.	O

The	O
samples	O
were	O
analysed	O
for	O
immunoglobulin	B-FUNC
G	O
antibodies	O
to	O
BCV	O
and	O
BRSV	O
with	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
.	O

Our	O
result	O
shows	O
that	O
herds	O
that	O
were	O
antibody	B-FUNC
positive	O
to	O
BCV	O
and	O
/	O
or	O
BRSV	O
had	O
a	O
higher	O
BMSCC	O
compared	O
with	O
herds	O
negative	O
to	O
BCV	O
and	O
BRSV	O
.	O

RESULTS	O
:	O
Ten	O
herds	O
were	O
antibody	B-FUNC
negative	O
to	O
both	O
viruses	O
and	O
were	O
compared	O
with	O
69	O
herds	O
positive	O
to	O
BCV	O
or	O
BRSV	O
or	O
both	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
novel	O
protease	O
inhibitors	O
:	O
design	O
,	O
synthesis	O
,	O
protein	O
-	O
ligand	B-FUNC
X	O
-	O
ray	O
structure	O
and	O
biological	O
evaluation	O
.	O

Here	O
,	O
we	O
show	O
that	O
,	O
in	O
apparent	O
contrast	O
to	O
human	O
and	O
ungulate	O
host	O
range	O
variants	O
of	O
Betacoronavirus	O
-	O
1	O
,	O
murine	O
coronaviruses	O
actually	O
bind	B-FUNC
to	O
O	O
-	O
Ac	O
-	O
Sias	O
via	O
HE	O
exclusively	O
.	O

Apparently	O
,	O
expansion	O
of	O
group	O
A	O
betacoronaviruses	O
into	O
new	O
hosts	O
and	O
niches	O
was	O
accompanied	O
by	O
changes	O
in	O
HE	O
ligand	B-FUNC
and	O
substrate	O
preference	O
and	O
in	O
the	O
roles	O
of	O
HE	O
and	O
S	O
in	O
Sia	O
receptor	O
usage	O
.	O

Incubation	O
of	O
the	O
GA08	O
strain	O
of	O
IBV	O
at	O
56	O
degrees	O
C	O
and	O
passage	O
in	O
embryonated	O
eggs	O
was	O
used	O
as	O
a	O
method	O
to	O
fast	B-FUNC
track	O
the	O
attenuation	O
process	O
.	O

Vaccinated	O
birds	O
that	O
were	O
challenged	O
with	O
10	O
(	O
4	O
.	O
5	O
)	O
median	O
embryo	O
infectious	O
doses	O
of	O
pathogenic	O
GA08	O
virus	O
/	O
bird	O
at	O
28	O
days	O
of	O
age	O
were	O
protected	O
from	O
the	O
disease	O
,	O
and	O
challenge	O
virus	O
was	O
only	O
detected	O
in	O
the	O
trachea	O
of	O
one	O
of	O
21	O
birds	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
at	O
5	O
days	O
post	O
challenge	O
.	O

Direct	O
binding	B-FUNC
of	O
SF2	O
/	O
ASF	O
to	O
the	O
ESE	O
site	O
was	O
confirmed	O
by	O
RNA	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
).	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
SF2	O
/	O
ASF	O
regulates	O
the	O
function	O
of	O
CD200	O
by	O
controlling	O
CD200	O
alternative	O
splicing	O
,	O
through	O
direct	O
binding	B-FUNC
to	O
an	O
ESE	O
located	O
in	O
exon	O
2	O
of	O
CD200	O
.	O

MBL	O
was	O
found	O
to	O
selectively	O
bind	B-FUNC
to	O
retroviral	O
particles	O
pseudotyped	O
with	O
SARS	O
-	O
S	O
.	O
Unlike	O
several	O
other	O
viral	O
envelopes	O
to	O
which	O
MBL	O
can	O
bind	B-FUNC
,	O
both	O
recombinant	O
and	O
plasma	O
-	O
derived	O
human	O
MBL	O
directly	O
inhibited	O
SARS	O
-	O
S	O
-	O
mediated	O
viral	O
infection	O
.	O

Mutagenesis	O
indicated	O
that	O
a	O
single	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
N330	O
,	O
was	O
critical	O
for	O
the	O
specific	O
interactions	O
between	O
MBL	O
and	O
SARS	O
-	O
S	O
.	O
Despite	O
the	O
proximity	O
of	O
N330	O
to	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
of	O
SARS	O
-	O
S	O
,	O
MBL	O
did	O
not	O
affect	O
interactions	O
with	O
the	O
ACE2	O
receptor	O
or	O
cathepsin	O
L	O
-	O
mediated	O
activation	O
of	O
SARS	O
-	O
S	O
-	O
driven	O
membrane	O
fusion	O
.	O

Thus	O
,	O
binding	B-FUNC
of	O
MBL	O
to	O
SARS	O
-	O
S	O
may	O
interfere	O
with	O
other	O
early	O
pre	O
-	O
or	O
postreceptor	O
-	O
binding	B-FUNC
events	O
necessary	O
for	O
efficient	O
viral	O
entry	O
.	O

In	O
all	O
domestic	O
cats	O
of	O
different	O
breeds	O
:	O
female	O
Abyssinian	O
,	O
female	O
American	O
shorthair	O
,	O
male	O
Cornish	O
Rex	B-FUNC
,	O
female	O
European	O
Burmese	O
,	O
female	O
Persian	O
,	O
female	O
Siamese	O
,	O
a	O
male	O
Ragdoll	O
and	O
a	O
female	O
African	O
wildcat	O
were	O
sequenced	O
lightly	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
virus	O
entry	O
by	O
binding	B-FUNC
cellular	O
receptors	O
and	O
inducing	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
the	O
host	O
cell	O
membrane	O
.	O

Over	O
time	O
,	O
a	O
decreased	O
proportion	O
of	O
the	O
respondents	O
(	O
1	O
)	O
felt	O
susceptible	O
to	O
contracting	O
H5N1	O
,	O
(	O
2	O
)	O
expected	O
a	O
large	O
outbreak	O
would	O
eventually	O
occur	O
,	O
(	O
3	O
)	O
believed	O
that	O
the	O
impacts	O
of	O
H5N1	O
were	O
worse	O
than	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
(	O
4	O
)	O
anticipated	O
adopting	O
more	O
types	O
of	O
preventive	O
measures	O
and	O
experiencing	O
mental	O
distress	O
in	O
the	O
case	O
of	O
a	O
small	O
-	O
scale	O
outbreak	O
in	O
Hong	O
Kong	O
(	O
AOR	B-FUNC
from	O
0	O
.	O
27	O
to	O
0	O
.	O
43	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
but	O
the	O
public	O
remained	O
vigilant	O
on	O
public	O
health	O
behaviors	O
,	O
such	O
as	O
hand	O
-	O
washing	O
.	O

RESULTS	O
:	O
Over	O
time	O
,	O
a	O
decreased	O
proportion	O
of	O
the	O
respondents	O
(	O
1	O
)	O
felt	O
susceptible	O
to	O
contracting	O
H5N1	O
,	O
(	O
2	O
)	O
expected	O
a	O
large	O
outbreak	O
would	O
eventually	O
occur	O
,	O
(	O
3	O
)	O
believed	O
that	O
the	O
impacts	O
of	O
H5N1	O
were	O
worse	O
than	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
(	O
4	O
)	O
anticipated	O
adopting	O
more	O
types	O
of	O
preventive	O
measures	O
and	O
experiencing	O
mental	O
distress	O
in	O
the	O
case	O
of	O
a	O
small	O
-	O
scale	O
outbreak	O
in	O
Hong	O
Kong	O
(	O
AOR	B-FUNC
from	O
0	O
.	O
27	O
to	O
0	O
.	O
43	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
but	O
the	O
public	O
remained	O
vigilant	O
on	O
public	O
health	O
behaviors	O
,	O
such	O
as	O
hand	O
-	O
washing	O
.	O

TITLE	O
:	O
SIRS	O
score	O
on	O
admission	O
and	O
initial	O
concentration	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
as	O
severe	O
acute	O
pancreatitis	O
outcome	O
predictors	O
.	O

In	O
105	O
patients	O
with	O
SIRS	O
score	O
3	O
and	O
higher	O
,	O
initial	O
measured	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
were	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
of	O
remaining	O
129	O
patients	O
(	O
72	O
+/-	O

All	O
nonsurvivals	O
were	O
in	O
the	O
first	O
group	O
,	O
with	O
SIRS	O
score	O
3	O
and	O
4	O
and	O
initial	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
113	O
+/-	O

RESULTS	O
:	O
In	O
105	O
patients	O
with	O
SIRS	O
score	O
3	O
and	O
higher	O
,	O
initial	O
measured	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
were	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
of	O
remaining	O
129	O
patients	O
(	O
72	O
+/-	O

27	O
pg	O
/	O
mL	O
.	O
The	O
values	O
of	O
C	O
-	O
reactive	O
Protein	O
(	O
CRP	O
)	O
measured	O
after	O
48h	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
II	O
)	O
score	O
on	O
admission	O
and	O
Ranson	O
score	O
showed	O
the	O
similar	O
correlation	O
,	O
but	O
serum	O
amylase	O
level	O
did	O
not	O
correlate	O
significantly	O
with	O
Ranson	O
score	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
and	O
APACHE	O
II	O
score	O
.	O

TITLE	O
:	O
Telbivudine	O
preserves	O
T	O
-	O
helper	O
1	O
cytokine	O
production	O
and	O
downregulates	O
programmed	O
death	O
ligand	B-FUNC
1	O
in	O
a	O
mouse	O
model	O
of	O
viral	O
hepatitis	O
.	O

Serum	O
levels	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
were	O
elevated	O
significantly	O
after	O
telbivudine	O
treatment	O
in	O
MHV	O
-	O
3	O
-	O
infected	O
C3H	O
mice	O
.	O

Of	O
note	O
,	O
we	O
found	O
that	O
telbivudine	O
treatment	O
suppressed	O
programmed	O
death	O
ligand	B-FUNC
1	O
expression	O
on	O
T	O
cells	O
.	O

Previously	O
,	O
the	O
domain	O
III	O
-	O
truncated	O
enzyme	O
was	O
demonstrated	O
to	O
fold	O
independently	O
into	O
an	O
intact	O
chymotrypsin	O
-	O
like	O
fold	O
,	O
but	O
it	O
showed	O
no	O
enzyme	B-FUNC
activity	I-FUNC
.	O

However	O
,	O
no	O
enzyme	B-FUNC
activity	I-FUNC
was	O
observed	O
for	O
any	O
mutant	O
or	O
mixtures	O
.	O

JHMV	O
infection	O
induced	O
the	O
rapid	O
and	O
sustained	O
expression	O
of	O
transcripts	O
specific	O
for	O
the	O
ELR	O
+	O
chemokine	O
ligands	O
CXCL1	O
and	O
CXCL2	O
,	O
as	O
well	O
as	O
their	O
binding	B-FUNC
receptor	O
CXCR2	O
,	O
which	O
was	O
enriched	O
within	O
the	O
spinal	O
cord	O
during	O
chronic	O
infection	O
.	O

TITLE	O
:	O
HB	O
-	O
EGF	B-FUNC
protects	O
the	O
lungs	O
after	O
intestinal	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Heparin	B-FUNC
binding	I-FUNC
EGF	B-FUNC
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	B-FUNC
)	O
is	O
a	O
biologically	O
active	O
protein	O
that	O
acts	O
as	O
an	O
intestinal	O
cytoprotective	O
agent	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
HB	O
-	O
EGF	B-FUNC
protects	O
the	O
intestines	O
from	O
injury	O
in	O
several	O
different	O
animal	O
models	O
of	O
intestinal	O
injury	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
HB	O
-	O
EGF	B-FUNC
to	O
protect	O
the	O
lungs	O
from	O
remote	O
organ	O
injury	O
after	O
intestinal	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
).	O

Mice	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
groups	O
:	O
(	O
1	O
)	O
sham	O
-	O
operated	O
;	O
(	O
2	O
)	O
sham	O
+	O
HB	O
-	O
EGF	B-FUNC
(	O
1200	O
microg	O
/	O
kg	O
in	O
0	O
.	O
6	O
mL	O
administered	O
by	O
intra	O
-	O
luminal	O
injection	O
at	O
the	O
jejuno	O
-	O
ileal	O
junction	O
immediately	O
after	O
identification	O
of	O
the	O
superior	O
mesenteric	O
artery	O
);	O
(	O
3	O
)	O
superior	O
mesenteric	O
artery	O
occlusion	O
for	O
45	O
min	O
followed	O
by	O
reperfusion	O
for	O
6	O
h	O
(	O
I	O
/	O
R	O
);	O
or	O
(	O
4	O
)	O
I	O
/	O
R	O
+	O
HB	O
-	O
EGF	B-FUNC
(	O
1200	O
microg	O
/	O
kg	O
in	O
0	O
.	O
6	O
mL	O
)	O
administered	O
15	O
min	O
after	O
vascular	O
occlusion	O
.	O

Compared	O
with	O
mice	O
treated	O
with	O
HB	O
-	O
EGF	B-FUNC
(	O
I	O
/	O
R	O
+	O
HB	O
-	O
EGF	B-FUNC
),	O
the	O
I	O
/	O
R	O
group	O
had	O
more	O
severe	O
acute	O
lung	O
injury	O
,	O
and	O
decreased	O
survival	O
.	O

Our	O
results	O
demonstrate	O
that	O
HB	O
-	O
EGF	B-FUNC
reduces	O
the	O
severity	O
of	O
acute	O
lung	O
injury	O
after	O
intestinal	O
I	O
/	O
R	O
in	O
mice	O
.	O

Compared	O
with	O
mice	O
treated	O
with	O
HB	O
-	O
EGF	B-FUNC
(	O
I	O
/	O
R	O
+	O
HB	O
-	O
EGF	B-FUNC
),	O
the	O
I	O
/	O
R	O
group	O
had	O
more	O
severe	O
acute	O
lung	O
injury	O
,	O
and	O
decreased	O
survival	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
demonstrate	O
that	O
HB	O
-	O
EGF	B-FUNC
reduces	O
the	O
severity	O
of	O
acute	O
lung	O
injury	O
after	O
intestinal	O
I	O
/	O
R	O
in	O
mice	O
.	O

In	O
an	O
effort	O
to	O
survey	O
for	O
the	O
presence	O
of	O
other	O
infectious	O
agents	O
,	O
known	O
and	O
unknown	O
,	O
we	O
screened	O
sera	B-FUNC
from	O
16	O
Pteropus	O
giganteus	O
bats	O
from	O
Faridpur	O
,	O
Bangladesh	O
,	O
using	O
high	O
-	O
throughput	O
pyrosequencing	O
.	O

Hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
HGF	O
)	O
does	O
not	O
have	O
epithelial	O
specificity	O
for	O
lung	O
tissue	O
.	O

However	O
,	O
the	O
enhanced	O
effects	O
of	O
combinations	O
of	O
growth	O
factors	O
,	O
such	O
as	O
the	O
synergistic	O
effect	O
of	O
HGF	O
upon	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)-	O
mediated	O
endothelial	O
cell	O
activity	O
,	O
and	O
the	O
combined	O
effect	O
of	O
HGF	O
and	O
KGF	O
in	O
tissue	O
repair	O
should	O
be	O
investigated	O
,	O
particularly	O
as	O
the	O
latter	O
pair	O
of	O
growth	O
factors	O
are	O
frequently	O
implicated	O
in	O
processes	O
associated	O
with	O
the	O
repair	O
of	O
lung	O
damage	O
.	O

The	O
anilinoquinazoline	O
gefitinib	O
(	O
Iressa	O
(	O
R	O
))	O
belongs	O
to	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	O
that	O
inhibit	O
the	O
tyrosine	O
kinase	B-FUNC
activity	I-FUNC
of	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
).	O

PP	O
treatment	O
decreased	O
Ab	O
binding	B-FUNC
to	O
viral	O
surface	O
molecules	O
,	O
suggesting	O
some	O
coating	O
of	O
particles	O
,	O
but	O
this	O
did	O
not	O
always	O
correlate	O
with	O
loss	O
of	O
infectivity	O
.	O

The	O
pathogenesis	O
of	O
aseptic	O
pneumonitis	O
is	O
unknown	O
,	O
but	O
various	O
proinflammatory	O
cytokines	O
have	O
been	O
implicated	O
,	O
especially	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
which	O
could	O
play	O
a	O
role	O
in	O
the	O
recruitment	O
of	O
leukocytes	O
to	O
the	O
lung	O
.	O

Even	O
though	O
infection	O
by	O
both	O
mutated	O
and	O
wild	O
-	O
type	O
viruses	O
led	O
to	O
neuroinflammation	O
,	O
the	O
modified	O
neuropathogenesis	O
induced	O
by	O
the	O
mutated	O
virus	O
was	O
associated	O
with	O
increased	O
viral	O
spread	O
and	O
significantly	O
more	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
-	O
lymphocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
the	O
chemokine	O
CCL2	O
(	O
monocyte	O
chemoattractant	O
protein	O
[	O
MCP	B-FUNC
]-	O
1	O
).	O

TITLE	O
:	O
Binding	B-FUNC
characterization	O
of	O
determinants	O
in	O
porcine	O
aminopeptidase	O
N	O
,	O
the	O
cellular	O
receptor	O
for	O
transmissible	O
gastroenteritis	O
virus	O
.	O

The	O
proteins	O
showed	O
discrepant	O
binding	B-FUNC
activity	O
to	O
either	O
pAPN	O
antibody	B-FUNC
or	O
TGE	O
virions	O
.	O

The	O
results	O
suggest	O
that	O
the	O
major	O
antibody	B-FUNC
-	O
binding	B-FUNC
domains	O
of	O
pAPN	O
may	O
associate	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
determinants	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
sequential	O
nearest	O
-	O
neighbor	O
effects	O
on	O
quantum	O
-	O
chemical	O
calculations	O
of	O
(	O
13	O
)	O
C	O
(	O
alpha	O
)	O
chemical	O
shifts	O
,	O
we	O
selected	O
the	O
structure	O
of	O
the	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
(	O
NAB	O
)	O
protein	O
from	O
the	O
SARS	O
coronavirus	O
determined	O
by	O
NMR	O
in	O
solution	O
(	O
PDB	O
id	O
2K87	O
).	O

It	O
has	O
been	O
reported	O
that	O
the	O
serum	O
levels	O
of	O
prolactin	B-FUNC
(	O
PRL	O
),	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
),	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
of	O
SARS	O
patients	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
control	O
groups	O
,	O
while	O
estradiol	O
(	O
E2	O
),	O
pregnancy	O
hormone	O
(	O
P	O
),	O
and	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
are	O
considerably	O
lower	O
than	O
those	O
of	O
normal	O
controls	O
.	O

The	O
immunohistochemistry	O
and	O
quantitative	O
image	O
results	O
showed	O
that	O
compared	O
with	O
control	O
cases	O
,	O
both	O
the	O
number	O
of	O
positive	O
cells	O
and	O
the	O
staining	O
intensity	O
of	O
immunoreactivity	O
for	O
growth	B-FUNC
hormone	I-FUNC
,	O
TSH	O
,	O
and	O
adrenocorticotrophic	O
hormone	O
in	O
these	O
cells	O
were	O
remarkably	O
decreased	O
,	O
while	O
that	O
of	O
PRL	O
,	O
FSH	O
,	O
and	O
LH	O
were	O
significantly	O
increased	O
in	O
all	O
SARS	O
cases	O
studied	O
.	O

TITLE	O
:	O
An	O
interaction	O
between	O
the	O
nucleocapsid	O
protein	O
and	O
a	O
component	O
of	O
the	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
is	O
crucial	O
for	O
the	O
infectivity	O
of	O
coronavirus	O
genomic	O
RNA	O
.	O

In	O
addition	O
,	O
the	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-FUNC
)	O
and	O
the	O
APACHE	O
II	O
and	O
SOFA	O
scores	O
were	O
recorded	O
.	O

A	O
coronavirus	O
(	O
CoV	O
)	O
was	O
detected	O
in	O
archived	O
tissues	O
from	O
1	O
of	O
the	O
5	O
seals	O
via	O
a	O
degenerate	O
PCR	O
for	O
nidoviral	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
and	O
was	O
subsequently	O
confirmed	O
via	O
specific	O
PCR	O
.	O

Based	O
on	O
the	O
partial	O
RdRp	B-FUNC
sequence	O
,	O
the	O
CoV	O
was	O
identified	O
as	O
a	O
novel	O
,	O
divergent	O
member	O
of	O
the	O
CoV	O
group	O
1a	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
can	O
act	O
as	O
a	O
ligand	B-FUNC
to	O
trigger	O
the	O
conversion	O
of	O
B	O
cells	O
to	O
macrophages	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
SSDRB	O
enhanced	O
the	O
expression	O
of	O
CD86	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF1	O
),	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
or	O
STAT	O
-	O
induced	O
STAT	O
inhibitor	O
)-	O
3	O
,	O
C	O
/	O
EBP	O
,	O
insulin	B-FUNC
-	I-FUNC
like	I-FUNC
growth	I-FUNC
factor	I-FUNC
-	O
binding	B-FUNC
protein	O
3	O
(	O
IGFBP3	O
),	O
Krpple	O
-	O
like	O
factor	O
(	O
KLF	O
)-	O
5	O
,	O
and	O
CD54	O
,	O
without	O
marked	O
influence	O
on	O
C	O
/	O
EBP	O
or	O
PU	O
.	O
1	O
expression	O
in	O
transduced	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
conversion	O
of	O
B	O
cells	O
to	O
macrophage	O
-	O
like	O
cells	O
,	O
similar	O
to	O
a	O
pathophysiological	O
response	O
,	O
could	O
be	O
mediated	O
by	O
a	O
devastating	O
viral	O
ligand	B-FUNC
,	O
in	O
particular	O
spike	O
protein	O
of	O
SARS	O
virus	O
,	O
or	O
in	O
combination	O
with	O
severe	O
local	O
hypoxia	O
,	O
which	O
is	O
a	O
condition	O
often	O
observed	O
in	O
afflicted	O
lungs	O
of	O
SARS	O
patients	O
.	O

Serum	O
DNA	O
,	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
and	O
malonaldehyde	O
(	O
MDA	O
)	O
concentrations	O
were	O
measured	O
and	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
OSAHS	O
groups	O
than	O
those	O
in	O
the	O
mild	O
OSAHS	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Univariate	O
analysis	O
showed	O
that	O
serum	O
DNA	O
correlated	O
positively	O
with	O
AHI	O
,	O
oxygen	O
desaturation	O
index	O
(	O
ODI	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
MDA	O
,	O
and	O
negatively	O
correlated	O
with	O
minimal	O
oxygen	O
saturation	O
(	O
miniSaO	O
(	O
2	O
))	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
).	O

After	O
6	O
months	O
of	O
nCPAP	O
therapy	O
,	O
serum	O
concentrations	O
of	O
DNA	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
MDA	O
were	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Appearing	O
in	O
1997	O
and	O
becoming	O
epidemic	O
in	O
2003	O
,	O
influenza	O
A	O
/	O
H5N1	O
provoked	O
many	O
deadly	O
enzootics	O
in	O
poultry	O
batteries	O
(	O
highly	O
pathogenic	O
avian	O
influenza	O
of	O
HPAI	B-FUNC
).	O

A	O
CoV	O
grouping	O
criterion	O
was	O
developed	O
by	O
comparing	O
amino	O
acid	O
identities	O
across	O
an	O
816	O
-	O
bp	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
(	O
RdRp	B-FUNC
)	O
of	O
all	O
accepted	O
mammalian	O
CoV	O
species	O
(	O
RdRp	B-FUNC
-	O
based	O
grouping	O
units	O
[	O
RGU	O
]).	O

Surface	O
expression	O
of	O
spike	O
and	O
staining	O
with	O
sera	B-FUNC
of	O
SARS	O
survivors	O
suggested	O
low	O
antigenic	O
overlap	O
with	O
SARS	O
CoV	O
.	O
However	O
,	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
SARS	O
CoV	O
showed	O
higher	O
similarity	O
with	O
that	O
of	O
BtCoV	O
/	O
BM48	O
-	O
31	O
/	O
Bulgaria	O
/	O
2008	O
than	O
with	O
that	O
of	O
any	O
Chinese	O
bat	O
-	O
borne	O
CoV	O
.	O
Critical	O
spike	O
domains	O
472	O
and	O
487	O
were	O
identical	O
and	O
similar	O
,	O
respectively	O
.	O

Logistic	O
regression	O
was	O
used	O
to	O
evaluate	O
the	O
association	O
between	O
predictors	O
and	O
antibody	B-FUNC
status	O
to	O
BCV	O
and	O
BRSV	O
.	O

Large	O
herd	O
size	O
,	O
being	O
located	O
in	O
southern	O
Sweden	O
,	O
and	O
not	O
providing	O
boots	O
for	O
visitors	O
were	O
found	O
to	O
be	O
associated	O
with	O
being	O
antibody	B-FUNC
-	O
positive	O
to	O
BCV	O
and	O
BRSV	O
.	O

ABSTRACT	O
:	O
Information	O
about	O
the	O
electrophoretic	O
distribution	O
of	O
CK	B-FUNC
-	I-FUNC
MM	I-FUNC
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
,	O
and	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
,	O
serum	O
creatine	O
kinase	O
(	O
CK	O
)	O
isoenzymes	O
that	O
are	O
indicators	O
of	O
skeletal	O
muscle	O
,	O
cardiac	O
muscle	O
,	O
and	O
brain	O
lesions	O
,	O
respectively	O
,	O
and	O
CK	O
macroenzymes	O
(	O
macro	O
-	O
CK1	O
and	O
macro	O
-	O
CK2	O
)	O
in	O
dogs	O
and	O
cats	O
with	O
and	O
without	O
central	O
neurologic	O
disease	O
is	O
scant	O
and	O
equivocal	O
.	O

In	O
dogs	O
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
was	O
essentially	O
absent	O
from	O
both	O
serum	O
and	O
homogenized	O
hearts	O
.	O

CK	B-FUNC
-	I-FUNC
BB	I-FUNC
increased	O
in	O
dogs	O
with	O
neurologic	O
disease	O
.	O

In	O
cats	O
,	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
was	O
essentially	O
absent	O
from	O
serum	O
,	O
but	O
was	O
present	O
in	O
brain	O
homogenates	O
.	O

Two	O
of	O
6	O
cats	O
with	O
FIP	O
had	O
increased	O
macro	O
-	O
CK1	O
and	O
increased	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
activity	O
.	O

This	O
case	O
came	O
into	O
picture	O
when	O
killer	O
atypical	O
pneumonia	O
,	O
namely	O
,	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
),	O
spread	O
very	O
fast	B-FUNC
from	O
South	O
-	O
Asian	O
countries	O
to	O
the	O
rest	B-FUNC
of	O
the	O
world	O
.	O

Among	O
10	O
bats	O
with	O
complete	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
sequenced	O
,	O
three	O
and	O
two	O
sequence	O
clades	O
for	O
all	O
three	O
genes	O
were	O
codetected	O
in	O
two	O
and	O
five	O
bats	O
,	O
respectively	O
,	O
suggesting	O
the	O
coexistence	O
of	O
two	O
or	O
three	O
distinct	O
genotypes	O
of	O
Ro	O
-	O
BatCoV	O
HKU9	O
in	O
the	O
same	O
bat	O
.	O

ABSTRACT	O
:	O
A	O
sero	O
-	O
epidemiological	O
study	O
was	O
carried	O
out	O
on	O
5660	O
sera	B-FUNC
collected	O
,	O
between	O
2006	O
and	O
2008	O
,	O
from	O
different	O
flocks	O
in	O
different	O
regions	O
of	O
the	O
country	O
.	O

Results	O
showed	O
that	O
peptide	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
secreted	O
IFN	O
-	O
	O
,	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
expressed	O
CD107a	O
/	O
b	O
on	O
cell	O
surface	O
.	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	O
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-FUNC
)	O
and	O
p38	B-FUNC
or	O
ERK	B-FUNC
alone	O
,	O
respectively	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
variant	O
virus	O
from	O
ascitic	O
fluid	O
of	O
subacute	O
granulomatous	O
serositis	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
deficient	O
C57BL	O
/	O
6	O
mice	O
persistently	O
infected	O
with	O
murine	O
coronavirus	O
strain	O
JHM	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
showed	O
that	O
intraperitoneal	O
infection	O
with	O
murine	O
coronavirus	O
strain	O
JHM	O
(	O
JHMV	O
)	O
established	O
a	O
persistent	O
infection	O
with	O
subacute	O
granulomatous	O
serositis	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
deficient	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
is	O
an	O
important	O
constituent	O
of	O
the	O
human	O
innate	O
immune	O
system	O
,	O
and	O
can	O
bind	B-FUNC
to	O
a	O
wide	O
range	O
of	O
pathogens	O
,	O
including	O
viruses	O
such	O
as	O
influenza	O
A	O
,	O
HIV	O
,	O
herpes	O
simplex	O
2	O
,	O
and	O
SARS	O
-	O
CoV	O
.	O
MBL	O
deficiency	O
results	O
from	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
exon	O
1	O
,	O
and	O
the	O
promoter	O
region	O
of	O
the	O
human	O
MBL2	O
gene	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
susceptibility	O
to	O
a	O
number	O
of	O
infections	O
.	O

TITLE	O
:	O
Production	O
and	O
characterization	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

The	O
resulting	O
S1	O
protein	O
was	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
followed	O
by	O
the	O
generation	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
).	O

Multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
was	O
conducted	O
for	O
detection	O
of	O
11	O
respiratory	O
viruses	O
,	O
and	O
medical	O
records	O
were	O
reviewed	O
.	O

The	O
assay	O
was	O
tested	O
in	O
75	O
bovine	O
feces	O
samples	O
tested	O
previously	O
for	O
rotavirus	O
using	O
PAGE	O
and	O
for	O
BCoV	O
using	O
nested	O
RT	O
-	O
PCR	O
targeted	O
to	O
RdRp	B-FUNC
gene	O
.	O

The	O
disease	O
was	O
diagnosed	O
by	O
clinical	O
symptoms	O
,	O
gross	O
and	O
histopathology	O
and	O
viral	O
detection	O
using	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

ANP	O
treatment	O
stimulated	O
Rac	O
-	O
dependent	O
PAK1	O
phosphorylation	O
,	O
attenuated	O
endothelial	O
permeability	O
caused	O
by	O
LPS	O
,	O
TNF	O
-	O
	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
decreased	O
LPS	O
-	O
induced	O
cell	O
and	O
protein	O
accumulation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
suppressed	O
Evans	O
blue	O
extravasation	O
in	O
the	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	O
studies	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamides	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamide	O
derivatives	O
(	O
2	O
-	O
4	O
)	O
designed	O
as	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
replication	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

The	O
results	O
of	O
molecular	O
modeling	O
and	O
docking	O
within	O
the	O
RT	O
non	O
-	O
nucleoside	B-FUNC
binding	I-FUNC
site	O
using	O
AutoDock	O
confirmed	O
that	O
the	O
3	O
series	O
,	O
similar	O
to	O
other	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
such	O
as	O
N	O
-(	O
5	O
-	O
chloro	O
-	O
2	O
-	O
pyridinyl	O
)-	O
N	O
'-[	O
2	O
-(	O
4	O
-	O
ethoxy	O
-	O
3	O
-	O
fluoro	O
-	O
2	O
-	O
pyridinyl	O
)	O
ethyl	O
]-	O
thiourea	O
(	O
PETT	O
),	O
was	O
assumed	O
in	O
a	O
butterfly	O
-	O
like	O
conformation	O
and	O
helped	O
to	O
rationalize	O
some	O
SARs	O
and	O
the	O
biological	O
activity	O
data	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
has	O
been	O
used	O
to	O
detect	O
FCoV	O
and	O
is	O
rapid	O
and	O
sensitive	O
,	O
but	O
results	O
must	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
clinical	O
findings	O
.	O

Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
are	O
increasingly	O
recognized	O
and	O
treatable	O
complications	O
of	O
severe	O
illness	O
in	O
medical	O
patients	O
,	O
and	O
are	O
independent	O
predictors	O
of	O
mortality	O
.	O

Patients	O
with	O
severe	O
Clostridium	O
difficile	O
infection	O
(	O
CDI	O
)	O
are	O
at	O
increased	O
risk	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
.	O

However	O
,	O
ACS	B-FUNC
has	O
been	O
only	O
rarely	O
described	O
in	O
this	O
population	O
.	O

Although	O
patients	O
with	O
fulminant	O
CDI	O
share	O
many	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
,	O
these	O
conditions	O
were	O
rarely	O
reported	O
in	O
this	O
population	O
and	O
are	O
likely	O
under	O
recognized	O
,	O
as	O
was	O
the	O
case	O
with	O
the	O
present	O
patient	O
.	O

TITLE	O
:	O
Growth	B-FUNC
hormone	I-FUNC
releasing	O
peptide	O
-	O
2	O
,	O
a	O
ghrelin	O
agonist	O
,	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

The	O
analyses	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
showed	O
the	O
significant	O
increases	O
in	O
pulmonary	O
permeability	O
(	O
total	O
cells	O
and	O
protein	O
)	O
and	O
the	O
levels	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
).	O

To	O
establish	O
stable	O
expressing	O
cell	O
clones	O
,	O
we	O
transfected	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
with	O
the	O
amplifiable	O
vectors	O
ISID	O
(	O
IRES	O
-	O
driven	O
dhfr	B-FUNC
)	O
and	O
ISIZ	O
(	O
SV40	O
-	O
driven	O
dhfr	B-FUNC
)	O
to	O
select	O
stepwise	O
MTX	O
,	O
and	O
observed	O
enhanced	O
	O
115	O
kDa	O
glycoform	O
generation	O
through	O
gene	O
amplification	O
.	O

Following	O
stepwise	O
MTX	O
selection	O
,	O
we	O
compared	O
gene	O
amplification	O
levels	O
between	O
two	O
vectors	O
in	O
engineered	O
CHO	B-FUNC
cell	O
chromosomes	O
.	O

These	O
results	O
confirm	O
that	O
the	O
IRES	O
-	O
driven	O
dhfr	B-FUNC
promoter	O
generates	O
greater	O
gene	O
amplification	O
,	O
which	O
in	O
turn	O
enhances	O
S	O
(	O
TR2	O
)	O
expression	O
.	O

The	O
antioxidant	O
property	O
was	O
assayed	O
for	O
specific	O
activities	O
including	O
2	O
,	O
2	O
-	O
diphenyl	O
-	O
1	O
-	O
picrylhydrazyl	O
(	O
DPPH	O
)	O
hydroxy	O
radical	O
scavenging	O
activity	O
,	O
reducing	O
power	O
capacity	O
,	O
and	O
superoxide	O
dismutase	O
(	O
SOD	B-FUNC
)	O
like	O
activity	O
.	O

In	O
this	O
study	O
,	O
a	O
panel	O
of	O
peptides	O
derived	O
from	O
M	O
and	O
E	O
proteins	O
were	O
tested	O
by	O
in	O
vitro	O
refolding	O
,	O
T2	O
cell	O
-	O
binding	B-FUNC
assays	O
,	O
and	O
responses	O
stimulated	O
by	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
in	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
K	O
(	O
b	O
)	O
transgenic	O
mice	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
).	O

ABSTRACT	O
:	O
Antineutrophil	O
cytoplasmic	O
antibody	B-FUNC
-	O
associated	O
vasculitis	O
is	O
a	O
life	O
-	O
threatening	O
disorder	O
for	O
which	O
medical	O
therapy	O
has	O
greatly	O
improved	O
survival	O
.	O

However	O
,	O
there	O
is	O
still	O
significant	O
mortality	O
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	B-FUNC
-	O
associated	O
vasculitis	O
.	O

TITLE	O
:	O
[	O
Consecutive	O
five	O
-	O
year	O
follow	O
-	O
up	O
analysis	O
of	O
specific	O
IgG	O
antibody	B-FUNC
of	O
22	O
cases	O
of	O
SARS	O
patients	O
after	O
recovery	O
].	O

ABSTRACT	O
:	O
To	O
study	O
IgG	O
antibody	B-FUNC
persistence	O
and	O
temporal	O
change	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infected	O
patients	O
,	O
22	O
patients	O
recovered	O
from	O
SARS	O
in	O
Beijing	O
were	O
recruited	O
and	O
followed	O
-	O
up	O
from	O
2004	O
to	O
2008	O
,	O
serum	O
samples	O
from	O
patients	O
were	O
collected	O
every	O
year	O
.	O

We	O
checked	O
and	O
analyzed	O
the	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
(	O
Ab	O
)	O
for	O
five	O
consecutive	O
years	O
using	O
the	O
commercial	O
ELISA	O
test	O
kit	B-FUNC
.	O

The	O
results	O
showed	O
that	O
:	O
all	O
of	O
the	O
serum	O
were	O
SARS	O
-	O
IgG	O
antibody	B-FUNC
-	O
positive	O
the	O
first	O
year	O
after	O
recovery	O
,	O
the	O
titer	O
of	O
most	O
serum	O
remained	O
at	O
high	O
levels	O
at	O
the	O
2ed	O
and	O
3rd	O
year	O
post	O
infection	O
.	O

Here	O
,	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
-	O
derived	O
CTL	O
epitope	O
,	O
N1	O
(	O
QFKDNVILL	O
),	O
restricted	O
by	O
HLA	O
-	O
A	O
*	O
2402	O
was	O
identified	O
by	O
a	O
series	O
of	O
in	O
vitro	O
studies	O
,	O
including	O
a	O
computer	O
-	O
assisted	O
algorithm	O
for	O
prediction	O
,	O
stabilization	O
of	O
the	O
peptide	O
by	O
co	O
-	O
refolding	O
with	O
HLA	O
-	O
A	O
*	O
2402	O
heavy	O
chain	O
and	O
	O
(	O
2	O
)-	O
microglobulin	O
(	O
	O
(	O
2	O
)	O
m	O
),	O
and	O
T2	O
-	O
A24	O
cell	O
binding	B-FUNC
.	O

Moreover	O
,	O
the	O
fusion	O
of	O
the	O
GM	O
-	O
CSF	O
markedly	O
increased	O
spleen	O
cell	O
proliferation	O
and	O
IFN	O
-	O
	O
production	O
while	O
mild	O
increased	O
in	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
production	O
,	O
which	O
demonstrated	O
the	O
enhancement	O
of	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
secretory	O
type	O
II	O
phospholipase	B-FUNC
A	O
in	O
acute	O
lung	O
injury	O
following	O
acute	O
pancreatitis	O
and	O
interventional	O
effect	O
of	O
Qingyi	O
decoction	O
on	O
it	O
].	O

Proteasome	O
inhibition	O
also	O
blocked	O
viral	O
cytotoxicity	O
in	O
macrophages	O
,	O
as	O
well	O
as	O
the	O
induction	O
of	O
inflammatory	O
mediators	O
such	O
as	O
IP	O
-	O
10	O
,	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
),	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
).	O

Here	O
we	O
report	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
small	O
envelope	O
protein	O
(	O
E	O
)	O
binds	B-FUNC
to	O
human	O
PALS1	O
.	O

Using	O
coimmunoprecipitation	O
and	O
pull	O
-	O
down	O
assays	O
,	O
we	O
show	O
that	O
E	O
interacts	O
with	O
PALS1	O
in	O
mammalian	O
cells	O
and	O
further	O
demonstrate	O
that	O
the	O
last	O
four	O
carboxy	O
-	O
terminal	O
amino	O
acids	O
of	O
E	O
form	O
a	O
novel	O
PDZ	O
-	O
binding	B-FUNC
motif	O
that	O
binds	B-FUNC
to	O
PALS1	O
PDZ	O
domain	O
.	O

Ectopic	O
expression	O
of	O
E	O
in	O
MDCKII	O
epithelial	O
cells	O
significantly	O
alters	O
cyst	O
morphogenesis	O
and	O
,	O
furthermore	O
,	O
delays	O
formation	O
of	O
tight	O
junctions	O
,	O
affects	O
polarity	O
,	O
and	O
modifies	O
the	O
subcellular	O
distribution	O
of	O
PALS1	O
,	O
in	O
a	O
PDZ	O
-	O
binding	B-FUNC
motif	O
-	O
dependent	O
manner	O
.	O

We	O
used	O
a	O
coimmunoprecipitation	O
assay	O
to	O
show	O
that	O
only	O
the	O
NCAM	O
was	O
a	O
binding	B-FUNC
partner	O
of	O
spike	O
protein	O
.	O

We	O
found	O
that	O
a	O
soluble	O
form	O
of	O
anti	O
-	O
NCAM	O
antibody	B-FUNC
blocked	O
association	O
of	O
the	O
PHE	O
-	O
CoV	O
with	O
N2a	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
T	O
cell	O
inhibitory	O
ligand	B-FUNC
B7	O
-	O
H1	O
hinders	O
T	O
cell	O
-	O
mediated	O
virus	O
control	O
,	O
but	O
also	O
ameliorates	O
clinical	O
disease	O
during	O
autoimmune	O
and	O
virus	O
-	O
induced	O
CNS	O
disease	O
.	O

These	O
emerging	O
sublineages	O
display	O
varying	O
levels	O
of	O
drug	O
resistance	O
and	O
in	O
some	O
cases	O
an	O
increased	O
preference	O
for	O
binding	B-FUNC
to	O
human	O
2	O
,	O
6	O
-	O
linked	O
sialic	O
acid	O
cellular	O
receptors	O
.	O

The	O
purified	O
recombinant	O
M	O
protein	O
was	O
used	O
to	O
immunize	O
rabbits	O
to	O
generate	O
a	O
polyclonal	O
antibody	B-FUNC
.	O

Immunofluorescence	O
analysis	O
indicated	O
that	O
the	O
anti	O
-	O
PEDV	O
-	O
M	O
antibody	B-FUNC
reacted	O
with	O
PEDV	O
-	O
infected	O
cells	O
.	O

The	O
antibody	B-FUNC
was	O
utilized	O
to	O
develop	O
an	O
indirect	O
ELISA	O
to	O
detect	O
PEDV	O
.	O

Subsequently	O
,	O
in	O
association	O
with	O
clinical	O
signs	O
we	O
observed	O
elevated	O
levels	O
of	O
proinflammatory	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
Th	O
-	O
1	O
(	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
),	O
and	O
regulatory	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TGF	O
-	O
	O
)	O
cytokines	O
.	O

A	O
single	O
dose	O
of	O
vaccine	O
with	O
or	O
without	O
adjuvant	O
was	O
poorly	O
immunogenic	O
in	O
mice	O
;	O
a	O
second	O
dose	O
resulted	O
in	O
a	O
significant	O
boost	O
in	O
antibody	B-FUNC
levels	O
,	O
even	O
in	O
the	O
absence	O
of	O
adjuvant	O
.	O

Although	O
antibody	B-FUNC
titers	O
had	O
declined	O
in	O
all	O
groups	O
of	O
vaccinated	O
hamsters	O
18	O
wk	O
after	O
the	O
second	O
dose	O
,	O
the	O
vaccinated	O
hamsters	O
were	O
still	O
partially	O
protected	O
from	O
wild	O
-	O
type	O
virus	O
challenge	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
TNF	O
-	O
	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
increased	O
at	O
2	O
h	O
.	O
Both	O
in	O
wild	O
type	O
and	O
iNOS	O
knockout	O
mice	O
,	O
hypertonic	O
saline	O
resuscitation	O
decreased	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
levels	O
at	O
2	O
h	O
;	O
CD4	O
(+)	O
T	O
cells	O
in	O
spleen	O
and	O
thymus	O
decreased	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
,	O
and	O
Foxp3	O
(+)	O
Tregs	O
in	O
spleen	O
at	O
48	O
h	O
increased	O
,	O
however	O
,	O
hypertonic	O
saline	O
resuscitation	O
did	O
not	O
affect	O
the	O
Foxp3	O
(+).	O

In	O
silico	O
simulations	O
indicated	O
that	O
the	O
binding	B-FUNC
site	O
of	O
1	O
,	O
8	O
-	O
cineole	O
was	O
located	O
at	O
the	O
N	O
terminus	O
of	O
phosphorylated	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
with	O
interaction	O
energy	O
equaling	O
-	O
40	O
.	O
33	O
kcal	O
mol	O
(-	O
1	O
).	O

The	O
pre	O
-	O
ECMO	O
ventilator	O
time	O
was	O
shorter	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
.	O
Significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
P	O
/	O
F	O
ratio	O
and	O
LIS	B-FUNC
from	O
pre	O
-	O
ECMO	O
introduction	O
to	O
72	O
hours	O
after	O
.	O

Values	O
of	O
binding	B-FUNC
energy	O
obtained	O
in	O
a	O
molecular	O
docking	O
study	O
supported	O
the	O
results	O
of	O
enzymatic	O
assays	O
.	O

More	O
patients	O
had	O
serum	O
antibody	B-FUNC
to	O
each	O
HCoV	O
strain	O
(	O
104	O
[	O
99	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
229E	O
,	O
105	O
[	O
100	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
OC43	O
,	O
103	O
[	O
98	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
NL63	O
,	O
and	O
96	O
[	O
91	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
HKU1	O
)	O
than	O
had	O
antibody	B-FUNC
to	O
each	O
HCoV	O
strain	O
in	O
nasal	O
wash	O
specimens	O
(	O
12	O
[	O
11	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
229E	O
,	O
22	O
[	O
22	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
OC43	O
,	O
8	O
[	O
8	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
NL63	O
,	O
and	O
31	O
[	O
31	O
%]	O
had	O
antibody	B-FUNC
to	O
HCoV	O
-	O
HKU1	O
),	O
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
proportions	O
of	O
subjects	O
with	O
IgA	O
antibodies	O
in	O
nasal	O
wash	O
specimens	O
and	O
the	O
geometric	O
mean	O
IgA	O
antibody	B-FUNC
titers	O
were	O
statistically	O
higher	O
for	O
HCoV	O
-	O
OC43	O
and	O
-	O
HKU1	O
than	O
for	O
HCoV	O
-	O
229E	O
and	O
-	O
NL63	O
.	O

Correlations	O
were	O
highest	O
for	O
serum	O
antibody	B-FUNC
titers	O
between	O
group	O
I	O
strains	O
(	O
HCoV	O
-	O
229E	O
and	O
-	O
NL63	O
[	O
r	O
=	O
0	O
.	O
443	O
;	O
P	O
<	O
0	O
.	O
0001	O
])	O
and	O
between	O
group	O
II	O
strains	O
(	O
HCoV	O
-	O
OC43	O
and	O
-	O
HKU1	O
[	O
r	O
=	O
0	O
.	O
603	O
;	O
P	O
<	O
0	O
.	O
0001	O
])	O
and	O
not	O
statistically	O
significant	O
between	O
HCoV	O
-	O
NL63	O
and	O
-	O
OC43	O
and	O
between	O
HCoV	O
-	O
NL63	O
and	O
-	O
HKU1	O
.	O

TITLE	O
:	O
Construction	O
and	O
immunogenicity	O
of	O
a	O
recombinant	O
fowlpox	O
vaccine	O
coexpressing	O
S1	O
glycoprotein	O
of	O
infectious	O
bronchitis	O
virus	O
and	O
chicken	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
recombinant	O
fowlpox	O
virus	O
(	O
rFPV	O
)	O
vaccine	O
expressing	O
the	O
IBV	O
S1	O
gene	O
and	O
chicken	O
interleukin	O
-	O
18	O
gene	O
(	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
),	O
rFPV	O
-	O
S1	O
/	O
IL18	O
.	O

We	O
also	O
constructed	O
the	O
recombinant	O
fowlpox	O
virus	O
rFPV	O
-	O
S1	O
without	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

Our	O
results	O
show	O
that	O
the	O
protective	O
efficacy	O
of	O
the	O
rFPV	O
-	O
S1	O
vaccine	O
could	O
be	O
enhanced	O
significantly	O
by	O
simultaneous	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

The	O
HIS	O
-	O
tagged	O
fusion	O
protein	O
SARS	O
-	O
CoVN	O
-	O
GFP	O
was	O
then	O
built	O
and	O
purified	O
for	O
the	O
binding	B-FUNC
assay	O
in	O
vitro	O
.	O

Despite	O
SL	O
-	O
CoVs	O
and	O
SARS	O
-	O
CoV	O
share	O
identical	O
genome	O
structure	O
and	O
high	O
-	O
level	O
sequence	O
similarity	O
,	O
SL	O
-	O
CoV	O
does	O
not	O
bind	B-FUNC
to	O
the	O
same	O
cellular	O
receptor	O
as	O
for	O
SARS	O
-	O
CoV	O
and	O
the	O
N	O
-	O
terminus	O
of	O
the	O
S	O
proteins	O
only	O
share	O
64	O
%	O
amino	O
acid	O
identity	O
,	O
suggesting	O
there	O
are	O
fundamental	O
differences	O
between	O
these	O
two	O
groups	O
of	O
coronaviruses	O
.	O

However	O
,	O
the	O
induced	O
antibody	B-FUNC
from	O
these	O
mice	O
had	O
weaker	O
cross	O
-	O
reaction	O
with	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
and	O
did	O
not	O
neutralize	O
HIV	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

The	O
animal	O
also	O
was	O
antibody	B-FUNC
-	O
positive	O
for	O
canine	O
distemper	O
virus	O
,	O
feline	O
panleukopenia	O
,	O
and	O
feline	O
coronavirus	O
.	O

Further	O
,	O
an	O
assay	O
using	O
truncated	O
mutants	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
N	O
protein	O
was	O
critical	O
for	O
its	O
antagonism	O
of	O
IFN	O
induction	O
,	O
and	O
the	O
N	O
deletion	O
mutant	O
impaired	O
for	O
RNA	O
-	O
binding	B-FUNC
almost	O
completely	O
lost	O
the	O
IFN	O
-	O
	O
antagonist	O
activity	O
.	O

ACoRN	O
Respiratory	O
Score	O
was	O
correlated	O
with	O
Score	O
for	O
Neonatal	O
Acute	O
Physiology	O
-	O
Version	O
II	O
(	O
SNAP	B-FUNC
-	O
II	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

High	O
gestational	O
age	O
,	O
high	O
SNAP	B-FUNC
-	O
II	O
score	O
and	O
oxygenation	O
index	O
(	O
OI	O
),	O
and	O
Apgar	O
score	O
at	O
5	O
minutes	O
<	O
5	O
were	O
independent	O
risks	O
for	O
death	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
not	O
only	O
mediates	O
receptor	O
-	O
binding	B-FUNC
but	O
also	O
induces	O
neutralizing	O
antibodies	O
.	O

Two	O
panels	O
of	O
serum	O
samples	O
from	O
recovered	O
SARS	O
patients	O
were	O
included	O
and	O
the	O
antibody	B-FUNC
responses	O
against	O
the	O
RBD	O
were	O
measured	O
by	O
ELISA	O
and	O
micro	O
-	O
neutralization	O
assays	O
.	O

We	O
found	O
that	O
the	O
RBD	O
of	O
S	O
protein	O
induced	O
potent	O
antibody	B-FUNC
responses	O
in	O
the	O
recovered	O
SARS	O
patients	O
and	O
RBD	O
-	O
specific	O
antibodies	O
could	O
persist	O
at	O
high	O
titers	O
over	O
three	O
year	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Two	O
panels	O
of	O
serum	O
samples	O
from	O
recovered	O
SARS	O
patients	O
were	O
included	O
and	O
the	O
antibody	B-FUNC
responses	O
against	O
the	O
RBD	O
were	O
measured	O
by	O
ELISA	O
and	O
micro	O
-	O
neutralization	O
assays	O
.	O

The	O
E	O
protein	O
is	O
made	O
in	O
excess	O
during	O
infection	O
and	O
has	O
been	O
shown	O
to	O
have	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
in	O
planar	O
lipid	O
bilayers	O
.	O

However	O
,	O
a	O
role	O
in	O
infection	O
for	O
the	O
unincorporated	O
E	O
or	O
its	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
has	O
not	O
been	O
described	O
.	O

In	O
the	O
nvA	O
(	O
H1N1	O
)-	O
ARDS	O
group	O
,	O
obesity	O
and	O
lymphocytopenia	O
were	O
more	O
common	O
and	O
IP	O
-	O
10	O
,	O
interleukin	O
(	O
IL	O
)-	O
12	O
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
9	I-FUNC
were	O
significantly	O
increased	O
versus	O
control	O
.	O

In	O
nonsurvivors	O
versus	O
survivors	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
were	O
increased	O
on	O
admission	O
and	O
remained	O
higher	O
3	O
days	O
later	O
.	O

A	O
positive	O
correlation	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
levels	O
with	O
C	O
-	O
reactive	O
protein	O
and	O
with	O
>	O
5	O
-	O
day	O
interval	O
between	O
symptom	O
onset	O
and	O
admission	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	O
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
were	O
found	O
in	O
nvA	O
(	O
H1N1	O
)	O
groups	O
.	O

In	O
obese	O
patients	O
with	O
influenza	O
disease	O
,	O
a	O
significant	O
increased	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
found	O
.	O

In	O
our	O
critically	O
ill	O
patients	O
with	O
novel	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
infection	O
,	O
the	O
hallmarks	O
of	O
the	O
severity	O
of	O
disease	O
were	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
.	O

Obese	O
patients	O
with	O
nvA	O
(	O
H1N1	O
)	O
disease	O
have	O
a	O
significant	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

RESULTS	O
:	O
In	O
the	O
nvA	O
(	O
H1N1	O
)-	O
ARDS	O
group	O
,	O
obesity	O
and	O
lymphocytopenia	O
were	O
more	O
common	O
and	O
IP	O
-	O
10	O
,	O
interleukin	O
(	O
IL	O
)-	O
12	O
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
9	I-FUNC
were	O
significantly	O
increased	O
versus	O
control	O
.	O

When	O
comparing	O
viral	O
ARDS	O
with	O
bacterial	O
ARDS	O
,	O
the	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
and	O
TNF	O
was	O
significantly	O
higher	O
in	O
bacterial	O
ARDS	O
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
was	O
increased	O
only	O
in	O
viral	O
ARDS	O
.	O

In	O
this	O
regard	O
,	O
exogenous	O
erythropoietin	B-FUNC
(	O
EPO	B-FUNC
)	O
represents	O
a	O
possible	O
candidate	O
since	O
a	O
number	O
of	O
preclinical	O
studies	O
have	O
revealed	O
beneficial	O
effects	O
of	O
EPO	B-FUNC
administration	O
in	O
various	O
experimental	O
models	O
of	O
ALI	O
.	O

PTX3	O
deficiency	O
also	O
enhanced	O
LPS	O
-	O
induced	O
tissue	O
factor	O
expression	O
/	O
activation	O
in	O
the	O
lung	O
and	O
increased	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
the	O
plasma	O
.	O

PTX3	O
deficiency	O
also	O
enhanced	O
LPS	O
-	O
induced	O
tissue	O
factor	O
expression	O
/	O
activation	O
in	O
the	O
lung	O
and	O
increased	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
the	O
plasma	O
.	O

NATs	O
provide	O
fast	B-FUNC
,	O
accurate	O
and	O
sensitive	O
detection	O
of	O
respiratory	O
viruses	O
and	O
have	O
significantly	O
increased	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
these	O
viruses	O
.	O

In	O
contrast	O
to	O
pure	B-FUNC
opioid	O
agonists	O
,	O
both	O
drugs	O
are	O
believed	O
to	O
have	O
lower	O
risks	O
of	O
respiratory	O
depression	O
,	O
tolerance	O
,	O
and	O
dependence	O
.	O

The	O
RNA	O
synthesis	O
of	O
these	O
two	O
distantly	O
related	O
nidoviruses	O
is	O
catalyzed	O
by	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
which	O
is	O
the	O
core	O
enzyme	O
of	O
their	O
multiprotein	O
replication	O
and	O
transcription	O
complex	O
(	O
RTC	O
).	O

TITLE	O
:	O
Differentiation	O
between	O
human	O
coronaviruses	O
NL63	O
and	O
229E	O
using	O
a	O
novel	O
double	O
-	O
antibody	B-FUNC
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
specific	O
monoclonal	O
antibodies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
double	O
-	O
antibody	B-FUNC
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
DAS	O
-	O
ELISA	O
)	O
as	O
a	O
potential	O
tool	O
for	O
identification	O
and	O
differentiation	O
between	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Increase	O
of	O
SARS	O
-	O
CoV	O
3CL	O
peptidase	B-FUNC
activity	I-FUNC
due	O
to	O
macromolecular	O
crowding	O
effects	O
in	O
the	O
milieu	O
composition	O
.	O

In	O
this	O
study	O
,	O
the	O
increase	O
of	O
SARS	O
-	O
CoV	O
3CLpro	O
peptidase	B-FUNC
activity	I-FUNC
in	O
presence	O
of	O
kosmotropic	O
salts	O
and	O
crowding	O
agents	O
is	O
described	O
.	O

TITLE	O
:	O
Preparation	O
and	O
characterization	O
of	O
polyclonal	O
antibody	B-FUNC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
A	O
truncated	O
gene	O
(	O
designated	O
S1	O
)	O
encoding	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
amplified	O
by	O
PCR	O
.	O

Polyclonal	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
S1	O
protein	O
was	O
generated	O
in	O
a	O
rabbit	O
immunized	O
with	O
the	O
purified	O
S1	O
protein	O
.	O

The	O
reactivity	O
of	O
the	O
antibody	B-FUNC
to	O
the	O
SARS	O
-	O
CoV	O
S1	O
protein	O
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
.	O

The	O
SARS	O
-	O
CoV	O
S1	O
protein	O
and	O
its	O
antibody	B-FUNC
are	O
valuable	O
reagents	O
for	O
related	O
studies	O
.	O

Using	O
band	O
-	O
sedimentation	O
velocity	O
,	O
quaternary	O
structural	O
changes	O
and	O
an	O
enzyme	O
'	O
s	O
catalytic	B-FUNC
activity	I-FUNC
can	O
be	O
observed	O
simultaneously	O
.	O

On	O
the	O
other	O
hand	O
,	O
also	O
in	O
this	O
study	O
,	O
we	O
have	O
applied	O
size	O
-	O
and	O
-	O
shape	O
distribution	O
analysis	O
to	O
a	O
lipid	O
-	O
binding	B-FUNC
protein	O
in	O
either	O
an	O
aqueous	O
or	O
lipid	O
environment	O
.	O

The	O
peripheral	O
blood	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
lymphocytes	O
were	O
detected	O
by	O
flow	O
cytometry	O
,	O
and	O
the	O
serum	O
levels	O
of	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
were	O
assayed	O
by	O
ELISA	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
model	O
group	O
showed	O
a	O
significantly	O
higher	O
ratio	O
of	O
IFN	O
-	O
	O
/	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

MHV	O
-	O
A59	O
virus	O
is	O
the	O
main	O
cause	O
of	O
elevated	O
NF	O
-	O
B	O
expression	O
and	O
CD4	O
(+)/	O
CD8	O
(+)/	O
ratio	O
,	O
while	O
damp	O
-	O
heat	O
syndrome	O
is	O
responsible	O
for	O
increased	O
AQP4	O
expression	O
,	O
and	O
their	O
synergistic	O
effect	O
results	O
in	O
increased	O
IFN	O
-	O
	O
/	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
ratio	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
model	O
group	O
showed	O
a	O
significantly	O
higher	O
ratio	O
of	O
IFN	O
-	O
	O
/	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

TITLE	O
:	O
Expression	O
of	O
neutral	O
endopeptidase	B-FUNC
activity	I-FUNC
during	O
clinical	O
and	O
experimental	O
acute	O
lung	O
injury	O
.	O

4000	O
IU	O
),	O
enoxaparin	O
,	O
bivalirudin	O
or	O
fondaparinux	O
depending	O
on	O
the	O
diagnosis	O
(	O
STEMI	O
or	O
non	O
-	O
STEMI	O
-	O
ACS	B-FUNC
)	O
and	O
the	O
planned	O
therapeutic	O
strategy	O
.	O

The	O
canonical	O
MHV	O
receptor	O
CEACAM1a	O
and	O
its	O
spike	O
-	O
binding	B-FUNC
site	O
have	O
been	O
extensively	O
characterized	O
.	O

A	O
synthetic	O
cholera	O
toxin	O
B	O
subunit	O
gene	O
(	O
CTB	O
)	O
was	O
fused	O
with	O
a	O
synthetic	O
neutralizing	O
epitope	O
gene	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
sCTB	O
-	O
sCOE	O
),	O
and	O
the	O
sCTB	O
-	O
sCOE	O
fusion	O
gene	O
was	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
the	O
ubiquitin	B-FUNC
promoter	O
.	O

The	O
results	O
of	O
western	O
blot	O
analysis	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	B-FUNC
showed	O
the	O
synthesis	O
and	O
assembly	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
into	O
oligomeric	O
structures	O
with	O
pentameric	O
sizing	O
.	O

The	O
biological	O
activity	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
to	O
its	O
receptor	O
,	O
G	O
(	O
M1	O
)-	O
ganglioside	O
,	O
in	O
transgenic	O
plants	O
was	O
confirmed	O
via	O
G	O
(	O
M1	O
)-	O
ELISA	O
with	O
anti	O
-	O
cholera	O
toxin	O
and	O
anti	O
-	O
COE	O
antibody	B-FUNC
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
changing	O
regularity	O
of	O
special	O
antibody	B-FUNC
and	O
expression	O
of	O
stomach	O
and	O
enteric	O
involvement	O
on	O
SARS	O
-	O
coronavirus	O
infection	O
in	O
the	O
recovery	O
period	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
change	O
of	O
special	O
antibodies	O
titer	O
IgG	O
,	O
IgM	O
and	O
nucleocapsid	O
to	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
and	O
observing	O
the	O
expression	O
of	O
stomach	O
and	O
enteric	O
involvement	O
on	O
SARS	O
-	O
CoV	O
infection	O
by	O
monoclonal	O
antibody	B-FUNC
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
7	O
-	O
year	O
recovery	O
period	O
among	O
family	O
clustering	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Special	O
antibody	B-FUNC
titer	O
to	O
SARS	O
-	O
CoV	O
of	O
14	O
patients	O
from	O
5	O
different	O
families	O
and	O
their	O
10	O
kinfolks	O
continuously	O
tested	O
by	O
IFA	O
and	O
antigen	O
-	O
capturing	O
ELISA	O
methods	O
.	O

When	O
testing	O
the	O
IgG	O
antibody	B-FUNC
titer	O
of	O
the	O
14	O
SARS	O
patients	O
by	O
IFA	O
method	O
,	O
the	O
average	O
titer	O
was	O
1	O
/	O
71	O
(	O
95	O
%	O
CI	O
:	O
1	O
/	O
58	O
-	O
1	O
/	O
85	O
)	O
in	O
the	O
1	O
(	O
st	O
)	O
year	O
,	O
but	O
began	O
to	O
descend	O
in	O
the	O
following	O
years	O
,	O
and	O
the	O
IgG	O
antibody	B-FUNC
of	O
the	O
most	O
SARS	O
patients	O
disappeared	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
.	O

The	O
average	O
value	O
of	O
nucleocapsid	O
antibody	B-FUNC
titer	O
was	O
1	O
/	O
146	O
(	O
95	O
%	O
CI	O
:	O
1	O
/	O
122	O
-	O
1	O
/	O
171	O
)	O
in	O
the	O
1	O
(	O
st	O
)	O
year	O
,	O
and	O
it	O
descended	O
as	O
the	O
IgG	O
antibody	B-FUNC
titer	O
did	O
.	O

The	O
nucleocapsid	O
antibody	B-FUNC
titer	O
was	O
between	O
1	O
/	O
156	O
and	O
1	O
/	O
210	O
in	O
3	O
cases	O
,	O
and	O
2	O
cases	O
were	O
normal	O
.	O

Immunochemical	O
staining	O
with	O
mAb	O
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
identified	O
in	O
the	O
stomach	O
and	O
enteric	O
tissues	O
of	O
5	O
SARS	O
patients	O
with	O
the	O
nucleocapsid	O
antibody	B-FUNC
titer	O
increased	O
significantly	O
,	O
1	O
(	O
st	O
)-	O
7	O
(	O
th	O
)	O
year	O
later	O
.	O

3	O
cases	O
showed	O
N	O
protein	O
antibody	B-FUNC
positive	O
in	O
the	O
serum	O
,	O
and	O
positive	O
immunohistochemical	O
expression	O
in	O
most	O
of	O
the	O
cytoplasm	O
in	O
the	O
gastric	O
tissue	O
mucous	O
gland	O
epithelial	O
cells	O
.	O

By	O
testing	O
the	O
special	O
IgG	O
,	O
IgM	O
,	O
nucleocapsid	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
of	O
the	O
14	O
family	O
clustering	O
cases	O
,	O
we	O
found	O
that	O
they	O
all	O
decreased	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
,	O
and	O
most	O
of	O
them	O
disappeared	O
.	O

The	O
nucleocapsid	O
antibody	B-FUNC
titer	O
was	O
related	O
to	O
pathogenetic	O
condition	O
.	O

RESULTS	O
:	O
When	O
testing	O
the	O
IgG	O
antibody	B-FUNC
titer	O
of	O
the	O
14	O
SARS	O
patients	O
by	O
IFA	O
method	O
,	O
the	O
average	O
titer	O
was	O
1	O
/	O
71	O
(	O
95	O
%	O
CI	O
:	O
1	O
/	O
58	O
-	O
1	O
/	O
85	O
)	O
in	O
the	O
1	O
(	O
st	O
)	O
year	O
,	O
but	O
began	O
to	O
descend	O
in	O
the	O
following	O
years	O
,	O
and	O
the	O
IgG	O
antibody	B-FUNC
of	O
the	O
most	O
SARS	O
patients	O
disappeared	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
.	O

CONCLUSIONS	O
:	O
By	O
testing	O
the	O
special	O
IgG	O
,	O
IgM	O
,	O
nucleocapsid	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
of	O
the	O
14	O
family	O
clustering	O
cases	O
,	O
we	O
found	O
that	O
they	O
all	O
decreased	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
,	O
and	O
most	O
of	O
them	O
disappeared	O
.	O

However	O
,	O
frequent	O
changes	O
in	O
the	O
surface	O
antigens	O
of	O
influenza	O
viruses	O
allow	O
them	O
to	O
avoid	O
antibody	B-FUNC
-	O
mediated	O
immunity	O
.	O

To	O
evaluate	O
the	O
prevalence	O
and	O
clinical	O
presentations	O
of	O
HKU1	O
and	O
NL63	O
in	O
adults	O
with	O
acute	O
respiratory	O
tract	O
infections	O
,	O
an	O
investigation	O
of	O
HCoV	O
infections	O
in	O
Beijing	O
,	O
China	O
from	O
2005	O
to	O
2009	O
was	O
performed	O
by	O
using	O
reverse	O
transcriptase	B-FUNC
PCR	O
assays	O
and	O
sequencing	O
analysis	O
.	O

Serological	O
tests	O
did	O
not	O
show	O
any	O
antibody	B-FUNC
reactivity	O
difference	O
between	O
the	O
two	O
strains	O
.	O

While	O
PRRSV	O
also	O
inhibited	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
	O
)	O
synthesis	O
by	O
pDC	O
responding	O
to	O
either	O
agent	O
,	O
only	O
the	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
production	O
instigated	O
by	O
ODN	O
D19	O
exposure	O
was	O
blocked	O
.	O

Infection	O
induced	O
a	O
vast	O
,	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
)-	O
dependent	O
,	O
prolonged	O
increase	O
in	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
9	O
(	O
CXCL9	O
),	O
CXCL10	O
,	O
and	O
CXCL11	O
mRNA	O
,	O
supporting	O
a	O
role	O
for	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
3	O
(	O
CXCR3	O
)-	O
mediated	O
ASC	O
recruitment	O
.	O

The	O
ASC	O
survival	O
factors	O
B	O
cell	O
-	O
activating	O
factor	O
of	O
the	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
family	O
(	O
BAFF	O
)	O
and	O
a	O
proliferating	O
-	O
inducing	O
ligand	B-FUNC
(	O
APRIL	O
)	O
were	O
also	O
significantly	O
elevated	O
in	O
the	O
infected	O
CNS	O
,	O
albeit	O
delayed	O
relative	O
to	O
the	O
chemokines	O
.	O

TITLE	O
:	O
Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
negatively	O
regulates	O
Th17	O
-	O
mediated	O
immunopathology	O
during	O
mouse	O
hepatitis	O
virus	O
infection	O
.	O

We	O
show	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
levels	O
in	O
serum	O
are	O
rapidly	O
elevated	O
and	O
positively	O
correlated	O
to	O
liver	O
damage	O
and	O
death	O
of	O
the	O
mice	O
.	O

TITLE	O
:	O
A	O
type	O
-	O
specific	O
blocking	O
ELISA	O
for	O
the	O
detection	O
of	O
infectious	O
bronchitis	O
virus	O
antibody	B-FUNC
.	O

Current	O
commercially	O
available	O
ELISA	O
kits	O
detect	O
group	O
-	O
specific	O
antibodies	O
;	O
however	O
,	O
to	O
understand	O
the	O
status	O
of	O
field	O
infection	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
blocking	O
ELISA	O
(	O
b	O
-	O
ELISA	O
)	O
against	O
local	O
IBVs	O
was	O
developed	O
.	O

The	O
type	O
-	O
specificity	O
of	O
detection	O
was	O
validated	O
using	O
a	O
panel	O
of	O
chicken	O
hyperimmune	O
sera	B-FUNC
.	O

The	O
b	O
-	O
ELISA	O
specifically	O
detected	O
Taiwan	O
IBV	O
serotypes	O
but	O
not	O
three	O
non	O
-	O
Taiwan	O
IBV	O
serotypes	O
nor	O
sera	B-FUNC
against	O
other	O
avian	O
pathogens	O
.	O

This	O
b	O
-	O
ELISA	O
provides	O
type	O
-	O
specific	O
antibody	B-FUNC
detection	O
of	O
local	O
IBV	O
strains	O
.	O

PEI	O
/	O
pci	O
-	O
S	O
nanoparticles	O
produced	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
S	O
-	O
specific	O
IgG1	O
in	O
the	O
sera	B-FUNC
and	O
mucosal	O
secretory	O
IgA	O
in	O
the	O
lung	O
wash	O
than	O
those	O
in	O
mice	O
treated	O
with	O
pci	O
-	O
S	O
alone	O
.	O

The	O
percentage	O
of	O
IFN	O
-	O
	O
-,	O
TNF	O
-	O
	O
-	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
producing	O
cells	O
were	O
higher	O
in	O
PEI	O
/	O
pci	O
-	O
S	O
vaccinated	O
mice	O
than	O
in	O
control	O
mice	O
.	O

The	O
percentage	O
of	O
IFN	O
-	O
	O
-,	O
TNF	O
-	O
	O
-	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
producing	O
cells	O
were	O
higher	O
in	O
PEI	O
/	O
pci	O
-	O
S	O
vaccinated	O
mice	O
than	O
in	O
control	O
mice	O
.	O

The	O
structure	O
of	O
NTD	O
in	O
two	O
different	O
crystal	O
forms	O
was	O
solved	O
to	O
1	O
.	O
5	O
	O
.	O
The	O
higher	O
resolution	O
provides	O
more	O
detailed	O
structural	O
information	O
than	O
previous	O
reports	O
,	O
showing	O
that	O
the	O
NTD	O
structure	O
from	O
MHV	O
shares	O
a	O
similar	O
overall	O
and	O
topology	O
structure	O
with	O
that	O
of	O
SARS	O
-	O
CoV	O
and	O
IBV	O
,	O
but	O
varies	O
in	O
its	O
potential	O
surface	O
,	O
which	O
indicates	O
a	O
possible	O
difference	O
in	O
RNA	O
-	O
binding	B-FUNC
module	O
.	O

TITLE	O
:	O
Mutation	O
of	O
neutralizing	O
/	O
antibody	B-FUNC
-	O
dependent	O
enhancing	O
epitope	O
on	O
spike	O
protein	O
and	O
7b	O
gene	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
:	O
influences	O
of	O
viral	O
replication	O
in	O
monocytes	O
/	O
macrophages	O
and	O
virulence	O
in	O
cats	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
prepared	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)-	O
resistant	O
(	O
mar	O
)	O
mutant	O
viruses	O
using	O
a	O
laboratory	O
strain	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
79	O
-	O
1146	O
(	O
Kida	O
et	O
al	O
.,	O
1999	O
).	O

We	O
clarified	O
that	O
MAb	O
used	O
to	O
prepare	O
mar	O
mutant	O
viruses	O
also	O
lost	O
its	O
activity	O
to	O
enhance	O
homologous	O
mar	O
mutant	O
viruses	O
,	O
strongly	O
suggesting	O
that	O
neutralizing	O
and	O
antibody	B-FUNC
-	O
dependent	O
enhancing	O
epitopes	O
are	O
present	O
in	O
the	O
same	O
region	O
in	O
the	O
strain	O
FIPV	O
79	O
-	O
1146	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
T	O
helper	O
1	O
and	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
in	O
the	O
spike	O
2	O
domain	O
and	O
the	O
nucleocapsid	O
protein	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
has	O
been	O
recognized	O
in	O
experimentally	O
infected	O
cats	O
,	O
and	O
cellular	O
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

To	O
detect	O
the	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitope	O
,	O
we	O
investigated	O
the	O
reactivity	O
of	O
plasma	O
collected	O
from	O
FIPV	O
-	O
infected	O
cats	O
against	O
each	O
peptide	O
by	O
ELISA	O
.	O

In	O
the	O
S2	O
domain	O
of	O
type	O
II	O
FIPV	O
,	O
4	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
were	O
identified	O
in	O
the	O
HR2	O
region	O
.	O

The	O
Th1	O
epitopes	O
in	O
the	O
S2	O
domain	O
of	O
type	O
I	O
and	O
II	O
FIPV	O
were	O
located	O
in	O
different	O
regions	O
,	O
but	O
the	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
were	O
mostly	O
located	O
in	O
the	O
HR2	O
region	O
.	O

In	O
N	O
protein	O
,	O
4	O
peptides	O
containing	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
were	O
identified	O
,	O
and	O
2	O
peptides	O
derived	O
from	O
residues	O
345	O
to	O
372	O
showed	O
strong	O
reactivity	O
with	O
plasma	O
of	O
type	O
I	O
FIPV	O
-	O
and	O
type	O
II	O
FIPV	O
-	O
infected	O
cats	O
.	O

The	O
Th1	O
and	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
were	O
located	O
at	O
different	O
positions	O
in	O
both	O
the	O
S2	O
domain	O
and	O
N	O
protein	O
.	O

We	O
demonstrate	O
that	O
human	O
and	O
mouse	O
coronavirus	O
mutants	O
lacking	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
induced	O
higher	O
expression	O
of	O
type	O
I	O
interferon	O
and	O
were	O
highly	O
sensitive	O
to	O
type	O
I	O
interferon	O
.	O

This	O
study	O
determined	O
the	O
kinetics	O
for	O
binding	B-FUNC
of	O
a	O
soluble	O
S1	O
protein	O
to	O
the	O
APN	O
protein	O
.	O

An	O
RT	O
-	O
PCR	O
/	O
ESI	O
-	O
MS	O
respiratory	O
virus	O
surveillance	O
kit	B-FUNC
designed	O
to	O
detect	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
parainfluenza	O
types	O
1	O
-	O
4	O
,	O
Adenoviridae	O
types	O
A	O
-	O
F	O
,	O
Coronaviridae	O
,	O
human	O
bocavirus	O
,	O
and	O
human	O
metapneumovirus	O
was	O
evaluated	O
using	O
both	O
mock	O
-	O
ups	O
and	O
frozen	O
archived	O
NPA	O
(	O
N	O
=	O
280	O
),	O
95	O
of	O
which	O
were	O
positive	O
by	O
clinical	O
virology	O
methods	O
.	O

Symptoms	O
,	O
virus	O
replication	O
,	O
and	O
antibody	B-FUNC
-	O
titres	O
were	O
monitored	O
.	O

Eighty	O
-	O
three	O
children	O
with	O
confirmed	O
infection	O
attributable	O
to	O
pandemic	O
influenza	O
detected	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assay	O
between	O
November	O
1	O
and	O
December	O
31	O
,	O
2009	O
who	O
were	O
admitted	O
to	O
critical	O
care	O
units	O
.	O

PLpro	O
antagonized	O
IFN	O
-	O
	O
-	O
induced	O
responses	O
such	O
as	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
and	O
AP	O
-	O
1	O
-	O
driven	O
promoter	O
activation	O
,	O
protein	O
kinase	O
R	O
,	O
2	O
'-	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
),	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
expression	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
1	O
(	O
Tyr701	O
),	O
STAT1	O
(	O
Ser727	O
)	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
.	O

Combination	O
treatment	O
of	O
IFN	O
-	O
	O
and	O
the	O
proteasome	O
inhibitor	O
MG	O
-	O
132	O
showed	O
a	O
time	O
-	O
dependent	O
restoration	O
of	O
ERK1	B-FUNC
protein	O
levels	O
and	O
significant	O
increase	O
of	O
ERK1	B-FUNC
,	O
STAT1	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
express	O
the	O
nuclear	O
capsid	O
protein	O
(	O
N	O
protein	O
)	O
and	O
the	O
spike	O
protein	O
(	O
S	O
protein	O
)	O
of	O
HCoV	O
-	O
HKU1	O
,	O
and	O
to	O
develop	O
the	O
corresponding	O
serum	O
assay	O
for	O
antibody	B-FUNC
detection	O
.	O

The	O
N	O
protein	O
of	O
HCoV	O
-	O
HKU1	O
was	O
expressed	O
in	O
E	O
.	O
Coli	O
,	O
anti	O
-	O
N	O
antibody	B-FUNC
assay	O
was	O
established	O
using	O
Western	O
Blotting	O
with	O
turn	O
-	O
based	O
membrane	O
.	O

HCoV	O
-	O
HKU1	O
S	O
protein	O
was	O
constructed	O
in	O
the	O
eukaryotic	O
expression	O
plasmids	O
,	O
and	O
confirmed	O
by	O
Western	O
Blotting	O
,	O
S	O
antibody	B-FUNC
assay	O
was	O
established	O
using	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
).	O

We	O
analyzed	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
antibody	B-FUNC
among	O
100	O
normal	O
adult	O
serum	O
.	O

Expression	O
of	O
S	O
and	O
N	O
protein	O
were	O
confirmed	O
;	O
100	O
normal	O
adult	O
serum	O
were	O
analyzed	O
using	O
the	O
established	O
serological	O
detection	O
assay	O
,	O
in	O
which	O
HCoV	O
-	O
HKU1	O
S	O
antibody	B-FUNC
positive	O
rate	O
was	O
47	O
%,	O
N	O
antibody	B-FUNC
positive	O
rate	O
was	O
48	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
positive	O
were	O
21	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
negative	O
were	O
22	O
%.	O

Co	O
-	O
detection	O
S	O
and	O
N	O
antibody	B-FUNC
was	O
achieved	O
74	O
%	O
positive	O
rate	O
.	O

Higher	O
positive	O
detection	O
rate	O
of	O
anti	O
-	O
S	O
or	O
anti	O
-	O
N	O
antibody	B-FUNC
was	O
found	O
in	O
the	O
normal	O
adults	O
.	O

One	O
month	O
after	O
vaccination	O
(	O
T1	O
),	O
both	O
groups	O
showed	O
significant	O
increases	O
in	O
the	O
antibody	B-FUNC
geometric	O
mean	O
titers	O
(	O
GMTs	O
)	O
for	O
all	O
antigens	O
.	O

In	O
a	O
test	O
case	O
,	O
it	O
also	O
enabled	O
automated	O
model	O
building	O
when	O
>	O
50	O
%	O
of	O
an	O
antigen	O
-	O
antibody	B-FUNC
complex	O
was	O
absent	O
.	O

The	O
most	O
obvious	O
example	O
is	O
anti	O
-	O
AIDS	O
research	O
,	O
where	O
HIV	O
protease	O
and	O
reverse	O
transcriptase	B-FUNC
have	O
triggered	O
enormous	O
efforts	O
in	O
developing	O
and	O
improving	O
computational	O
methods	O
.	O

Methods	O
applied	O
to	O
anti	O
-	O
viral	O
research	O
include	O
(	O
i	O
)	O
ligand	B-FUNC
-	O
based	O
approaches	O
that	O
rely	O
on	O
known	O
active	O
compounds	O
to	O
extrapolate	O
biological	O
activity	O
,	O
such	O
as	O
machine	O
learning	O
techniques	O
or	O
classical	O
QSAR	O
,	O
(	O
ii	O
)	O
structure	O
-	O
based	O
methods	O
that	O
rely	O
on	O
an	O
experimentally	O
determined	O
3D	O
structure	O
of	O
the	O
targets	O
,	O
such	O
as	O
molecular	O
docking	O
or	O
molecular	O
dynamics	O
,	O
and	O
(	O
iii	O
)	O
universal	O
approaches	O
that	O
can	O
be	O
applied	O
in	O
a	O
structure	O
-	O
or	O
ligand	B-FUNC
-	O
based	O
way	O
,	O
such	O
as	O
3D	O
QSAR	O
or	O
3D	O
pharmacophore	O
elucidation	O
.	O

We	O
discuss	O
the	O
role	O
of	O
computational	O
chemistry	O
in	O
the	O
development	O
of	O
small	O
molecules	O
as	O
agents	O
against	O
HIV	O
integrase	O
,	O
HIV	O
-	O
1	O
protease	O
,	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
,	O
the	O
influenza	O
virus	O
M2	O
channel	O
protein	O
,	O
influenza	O
virus	O
neuraminidase	O
,	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
and	O
spike	O
protein	O
,	O
thymidine	O
kinases	O
of	O
herpes	O
viruses	O
,	O
hepatitis	O
c	O
virus	O
proteins	O
and	O
other	O
flaviviruses	O
as	O
well	O
as	O
human	O
rhinovirus	O
coat	O
protein	O
and	O
proteases	O
,	O
and	O
other	O
picornaviridae	O
.	O

TITLE	O
:	O
The	O
leader	O
proteinase	B-FUNC
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
negatively	O
regulates	O
the	O
type	O
I	O
interferon	O
pathway	O
by	O
acting	O
as	O
a	O
viral	O
deubiquitinase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
leader	O
proteinase	B-FUNC
(	O
L	O
(	O
pro	O
))	O
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
(	O
FMDV	O
)	O
is	O
a	O
papain	O
-	O
like	O
proteinase	B-FUNC
that	O
plays	O
an	O
important	O
role	O
in	O
FMDV	O
pathogenesis	O
.	O

Sequence	O
alignment	O
and	O
structural	O
bioinformatics	O
analyses	O
revealed	O
that	O
the	O
catalytic	O
residues	O
(	O
Cys51	O
and	O
His148	O
)	O
are	O
highly	O
conserved	O
in	O
FMDV	O
Lb	O
(	O
pro	O
)	O
of	O
all	O
seven	O
serotypes	O
and	O
that	O
the	O
topology	O
of	O
FMDV	O
Lb	O
(	O
pro	O
)	O
is	O
remarkably	O
similar	O
to	O
that	O
of	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
14	O
(	O
USP14	O
),	O
a	O
cellular	O
deubiquitylation	O
enzyme	O
(	O
DUB	O
),	O
and	O
to	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
coronaviral	O
DUB	O
.	O

Furthermore	O
,	O
Lb	O
(	O
pro	O
)	O
significantly	O
inhibited	O
ubiquitination	O
of	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
),	O
TANK	O
-	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
),	O
TNF	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF6	O
),	O
and	O
TRAF3	O
,	O
key	O
signaling	O
molecules	O
in	O
activation	O
of	O
type	O
I	O
IFN	O
response	O
.	O

Mutations	O
in	O
Lb	O
(	O
pro	O
)	O
that	O
ablate	O
the	O
catalytic	B-FUNC
activity	I-FUNC
(	O
C51A	O
or	O
D163N	O
/	O
D164N	O
)	O
or	O
disrupt	O
the	O
SAP	O
(	O
for	O
SAF	O
-	O
A	O
/	O
B	O
,	O
Acinus	O
,	O
and	O
PIAS	O
)	O
domain	O
(	O
I83A	O
/	O
L86A	O
)	O
abrogated	O
the	O
DUB	O
activity	O
of	O
Lb	O
(	O
pro	O
)	O
as	O
well	O
as	O
its	O
ability	O
to	O
block	O
signaling	O
to	O
the	O
IFN	O
-	O
	O
promoter	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
FMDV	O
Lb	O
(	O
pro	O
)	O
possesses	O
DUB	O
activity	O
in	O
addition	O
to	O
serving	O
as	O
a	O
viral	O
proteinase	B-FUNC
and	O
describe	O
a	O
novel	O
mechanism	O
evolved	O
by	O
FMDV	O
to	O
counteract	O
host	O
innate	O
antiviral	O
responses	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
prognostic	O
value	O
of	O
corpus	O
callosum	O
lesions	O
(	O
CCL	B-FUNC
)	O
and	O
brain	O
stem	O
lesions	O
(	O
BSL	O
)	O
in	O
diffuse	O
axonal	O
injury	O
(	O
DAI	O
)	O
patients	O
.	O

From	O
December	O
1989	O
to	O
December	O
2008	O
,	O
102	O
consecutive	O
patients	O
with	O
pure	B-FUNC
DAI	O
were	O
admitted	O
to	O
our	O
neurosurgical	O
intensive	O
care	O
unit	O
.	O

Four	O
variables	O
predicted	O
unfavorable	O
Glasgow	O
Outcome	O
Scale	O
(	O
likelihood	O
ratio	O
p	O
<	O
0	O
.	O
0001	O
;	O
Area	O
Under	O
the	O
Receiver	O
Operator	O
Curve	O
(	O
AUROC	O
)=	O
0	O
.	O
92	O
;	O
Naglekerke	O
'	O
s	O
R	O
=	O
0	O
.	O
64	O
;	O
Goodness	O
-	O
of	O
-	O
Fit	O
p	O
=	O
0	O
.	O
8679	O
):	O
age	O
(	O
5	O
-	O
year	O
odds	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
44	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
14	O
-	O
1	O
.	O
82	O
;	O
p	O
=	O
0	O
.	O
002	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
(	O
OR	O
,	O
11	O
.	O
11	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
19	O
-	O
57	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
004	O
),	O
multiplicity	O
of	O
CCL	B-FUNC
(	O
OR	O
,	O
29	O
.	O
23	O
;	O
95	O
%	O
CI	O
,	O
7	O
.	O
06	O
-	O
121	O
.	O
01	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
multiplicity	O
of	O
BSL	O
(	O
OR	O
,	O
9	O
.	O
43	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
44	O
-	O
36	O
.	O
42	O
;	O
p	O
=	O
0	O
.	O
001	O
).	O

Four	O
variables	O
affected	O
time	O
to	O
recovery	O
of	O
consciousness	O
:	O
age	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
98	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
97	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
51	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
041	O
),	O
multiplicity	O
of	O
CCL	B-FUNC
(	O
hazard	O
ratio	O
,	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
25	O
-	O
0	O
.	O
66	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
total	O
GCS	O
on	O
admission	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
45	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
23	O
-	O
1	O
.	O
71	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

In	O
DAI	O
patients	O
,	O
bad	O
outcome	O
is	O
predicted	O
by	O
age	O
,	O
bilateral	O
absence	O
of	O
pupillary	O
light	O
reflexes	O
,	O
multiplicity	O
of	O
CCL	B-FUNC
,	O
and	O
BSL	O
on	O
MRI	O
.	O

Time	O
to	O
recovery	O
of	O
consciousness	O
is	O
predicted	O
by	O
age	O
,	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
,	O
multiplicity	O
of	O
CCL	B-FUNC
on	O
MRI	O
,	O
and	O
GCS	O
on	O
admission	O
.	O

RESULTS	O
:	O
Four	O
variables	O
predicted	O
unfavorable	O
Glasgow	O
Outcome	O
Scale	O
(	O
likelihood	O
ratio	O
p	O
<	O
0	O
.	O
0001	O
;	O
Area	O
Under	O
the	O
Receiver	O
Operator	O
Curve	O
(	O
AUROC	O
)=	O
0	O
.	O
92	O
;	O
Naglekerke	O
'	O
s	O
R	O
=	O
0	O
.	O
64	O
;	O
Goodness	O
-	O
of	O
-	O
Fit	O
p	O
=	O
0	O
.	O
8679	O
):	O
age	O
(	O
5	O
-	O
year	O
odds	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
44	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
14	O
-	O
1	O
.	O
82	O
;	O
p	O
=	O
0	O
.	O
002	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
(	O
OR	O
,	O
11	O
.	O
11	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
19	O
-	O
57	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
004	O
),	O
multiplicity	O
of	O
CCL	B-FUNC
(	O
OR	O
,	O
29	O
.	O
23	O
;	O
95	O
%	O
CI	O
,	O
7	O
.	O
06	O
-	O
121	O
.	O
01	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
multiplicity	O
of	O
BSL	O
(	O
OR	O
,	O
9	O
.	O
43	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
44	O
-	O
36	O
.	O
42	O
;	O
p	O
=	O
0	O
.	O
001	O
).	O

Four	O
variables	O
affected	O
time	O
to	O
recovery	O
of	O
consciousness	O
:	O
age	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
98	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
97	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
51	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
041	O
),	O
multiplicity	O
of	O
CCL	B-FUNC
(	O
hazard	O
ratio	O
,	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
25	O
-	O
0	O
.	O
66	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
total	O
GCS	O
on	O
admission	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
45	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
23	O
-	O
1	O
.	O
71	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Sixteen	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
field	O
isolates	O
obtained	O
from	O
vaccinated	O
commercial	O
broiler	O
chickens	O
showing	O
clinical	O
respiratory	O
disease	O
were	O
characterized	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	O
spike	O
glycoprotein	O
gene	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
presence	O
of	O
infectious	O
bronchitis	O
virus	O
or	O
avian	O
coronavirus	O
,	O
a	O
nested	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
was	O
developed	O
with	O
the	O
aim	O
of	O
amplifying	O
a	O
fragment	O
of	O
530	O
bases	O
,	O
comprising	O
the	O
gene	O
coding	O
S1	O
protein	O
.	O

ABSTRACT	O
:	O
Rett	O
syndrome	O
is	O
a	O
severe	O
neurodevelopmental	O
disease	O
caused	O
by	O
mutations	O
of	O
the	O
transcriptional	O
repressor	O
methyl	O
-	O
CpG	O
-	O
binding	B-FUNC
protein	O
2	O
(	O
MeCP2	O
)	O
that	O
induce	O
complex	O
,	O
disabling	O
symptoms	O
,	O
including	O
breathing	O
symptoms	O
.	O

TITLE	O
:	O
Highly	O
activated	O
cytotoxic	O
CD8	O
T	O
cells	O
express	O
protective	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
at	O
the	O
peak	O
of	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
a	O
potent	O
anti	O
-	O
inflammatory	O
cytokine	O
,	O
is	O
produced	O
transiently	O
at	O
the	O
peak	O
of	O
infection	O
by	O
CD8	O
T	O
cells	O
in	O
the	O
brains	O
of	O
coronavirus	O
-	O
infected	O
mice	O
.	O

IL	B-FUNC
-	I-FUNC
10	I-FUNC
(+)	O
CD8	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(-)	O
CD8	O
T	O
cells	O
interconvert	O
during	O
acute	O
disease	O
,	O
possibly	O
based	O
on	O
recent	O
Ag	O
exposure	O
.	O

Strikingly	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(+)	O
CD8	O
T	O
cells	O
were	O
more	O
highly	O
activated	O
and	O
cytolytic	O
than	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(-)	O
CD8	O
T	O
cells	O
,	O
expressing	O
greater	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
as	O
well	O
as	O
cytotoxic	O
proteins	O
.	O

Furthermore	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
produced	O
by	O
CD8	O
T	O
cells	O
diminished	O
disease	O
severity	O
in	O
mice	O
with	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	O
,	O
suggesting	O
a	O
self	O
-	O
regulatory	O
mechanism	O
that	O
minimizes	O
immunopathological	O
changes	O
.	O

TITLE	O
:	O
Down	O
-	O
regulation	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
by	O
3C	O
-	O
like	O
proteinase	B-FUNC
in	O
transfected	O
A549	O
human	O
lung	O
carcinoma	O
cells	O
.	O

Expression	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
was	O
significantly	O
decreased	O
in	O
3CLpro	O
-	O
transfected	O
cells	O
by	O
both	O
RT	O
-	O
PCR	O
and	O
ELISA	O
,	O
but	O
without	O
changes	O
in	O
other	O
cytokines	O
,	O
i	O
.	O
e	O
.,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL12p40	O
,	O
TNF	O
-	O
	O
,	O
and	O
TGF	O
-	O
	O
.	O

Inflammatory	O
cytokines	O
,	O
such	O
as	O
interleukin	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
play	O
a	O
major	O
role	O
in	O
mediating	O
and	O
amplifying	O
ALI	O
/	O
ARDS	O
by	O
stimulating	O
chemotaxis	O
and	O
activation	O
of	O
neutrophils	O
.	O

Inflammatory	O
cytokines	O
that	O
play	O
a	O
major	O
role	O
in	O
mediating	O
and	O
amplifying	O
ALI	O
/	O
ARDS	O
or	O
have	O
neutrophil	O
chemoattractant	B-FUNC
activity	I-FUNC
,	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
CXCL1	O
,	O
and	O
CXCL2	O
,	O
were	O
,	O
however	O
,	O
induced	O
only	O
in	O
macaques	O
.	O

cis	O
-	O
cleavage	O
resulted	O
in	O
release	O
of	O
SARS	O
S	O
fragments	O
into	O
the	O
cellular	O
supernatant	O
and	O
in	O
inhibition	O
of	O
antibody	B-FUNC
-	O
mediated	O
neutralization	O
,	O
most	O
likely	O
because	O
SARS	O
S	O
fragments	O
function	O
as	O
antibody	B-FUNC
decoys	O
.	O

The	O
enhanced	O
binding	B-FUNC
of	O
bacteria	O
correlated	O
with	O
an	O
increased	O
expression	O
level	O
of	O
the	O
platelet	O
-	O
activating	O
factor	O
receptor	O
(	O
PAF	O
-	O
R	O
),	O
but	O
detailed	O
evaluation	O
of	O
the	O
bacterium	O
-	O
PAF	O
-	O
R	O
interaction	O
revealed	O
a	O
limited	O
relevance	O
of	O
this	O
process	O
.	O

Subsequently	O
,	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assays	O
for	O
the	O
detection	O
of	O
51	O
immune	O
-	O
related	O
and	O
four	O
internal	O
reference	O
genes	O
were	O
developed	O
.	O

Ribosomal	B-FUNC
protein	I-FUNC
L18	O
was	O
identified	O
as	O
the	O
most	O
stable	O
internal	O
reference	O
gene	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
UDA	O
neutralizes	O
the	O
virus	O
infectivity	O
,	O
presumably	O
by	O
binding	B-FUNC
to	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

To	O
establish	O
the	O
reciprocal	O
binding	B-FUNC
of	O
CCoV	O
on	O
plasma	O
membrane	O
,	O
A72	O
cells	O
on	O
a	O
permeable	O
support	O
were	O
preincubated	O
with	O
a	O
mAb	O
specific	O
for	O
CCoV	O
.	O
Infection	O
from	O
the	O
apical	O
side	O
was	O
blocked	O
by	O
mAb	O
applied	O
to	O
that	O
side	O
;	O
in	O
contrast	O
,	O
such	O
treatment	O
on	O
the	O
basolateral	O
side	O
had	O
no	O
effect	O
on	O
the	O
infectious	O
process	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
has	O
two	O
associated	O
activities	O
,	O
DNA	O
polymerase	O
and	O
RNase	O
H	O
,	O
both	O
essential	O
for	O
viral	O
replication	O
and	O
validated	O
drug	O
targets	O
.	O

Although	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
DNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
,	O
the	O
search	O
for	O
new	O
RT	O
inhibitors	O
that	O
target	O
the	O
RNase	O
H	O
function	O
and	O
are	O
possibly	O
active	O
on	O
RTs	O
resistant	O
to	O
the	O
known	O
non	O
-	O
nucleoside	O
inhibitors	O
(	O
NNRTI	O
)	O
is	O
a	O
viable	O
approach	O
for	O
anti	O
-	O
HIV	O
drug	O
development	O
.	O

Kinetic	O
studies	O
demonstrated	O
that	O
they	O
are	O
noncompetitive	O
inhibitors	O
,	O
they	O
do	O
not	O
bind	B-FUNC
to	O
the	O
RNase	O
H	O
active	O
site	O
or	O
to	O
the	O
classical	O
NNRTI	O
binding	B-FUNC
pocket	O
,	O
even	O
though	O
efavirenz	O
binding	B-FUNC
negatively	O
influenced	O
K	O
-	O
49	O
/	O
KNA	O
-	O
53	O
binding	B-FUNC
and	O
vice	O
versa	O
.	O

This	O
behavior	O
suggested	O
that	O
the	O
alizarine	O
derivatives	O
binding	B-FUNC
site	O
might	O
be	O
close	O
to	O
the	O
NNRTI	O
binding	B-FUNC
pocket	O
.	O

Docking	O
experiments	O
and	O
molecular	O
dynamic	O
simulation	O
confirmed	O
the	O
experimental	O
data	O
and	O
the	O
ability	O
of	O
these	O
compounds	O
to	O
occupy	O
a	O
binding	B-FUNC
pocket	O
close	O
to	O
the	O
NNRTI	O
site	O
.	O

The	O
binding	B-FUNC
energies	O
of	O
them	O
are	O
-	O
36	O
.	O
83	O
and	O
-	O
35	O
.	O
59	O
kcal	O
mol	O
-	O
1	O
,	O
respectively	O
.	O

The	O
efficacy	O
of	O
this	O
vaccine	O
is	O
highly	O
dose	O
dependent	O
and	O
the	O
flock	O
antibody	B-FUNC
response	O
is	O
weak	O
.	O

Following	O
administration	O
of	O
MG	O
ts	O
-	O
11	O
C3	O
(+	O
CS	O
)	O
to	O
chickens	O
by	O
eye	O
-	O
drop	O
,	O
an	O
antibody	B-FUNC
response	O
to	O
MG	O
and	O
IBV	O
-	O
S1	O
,	O
as	O
determined	O
by	O
the	O
rapid	O
serum	O
agglutination	O
test	O
(	O
RSA	O
)	O
and	O
Western	O
blotting	O
,	O
respectively	O
,	O
could	O
be	O
detected	O
.	O

TITLE	O
:	O
PLP2	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
targets	O
TBK1	B-FUNC
to	O
negatively	O
regulate	O
cellular	O
type	O
I	O
interferon	O
signaling	O
pathway	O
.	O

We	O
have	O
previously	O
shown	O
that	O
papain	O
-	O
like	O
protease	O
domain	O
2	O
(	O
PLP2	O
),	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
of	O
MHV	O
-	O
A59	O
,	O
encodes	O
a	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
and	O
inactivates	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
thereby	O
the	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
response	O
.	O

Here	O
we	O
provide	O
further	O
evidence	O
that	O
PLP2	O
may	O
also	O
target	O
TANK	O
-	O
binding	B-FUNC
kinase	O
-	O
1	O
(	O
TBK1	B-FUNC
),	O
the	O
upstream	O
kinase	O
of	O
IRF3	O
in	O
the	O
IFN	O
signaling	O
pathway	O
.	O

Overexpression	O
experiments	O
showed	O
that	O
PLP2	O
deubiquitinated	O
TBK1	B-FUNC
and	O
reduced	O
its	O
kinase	B-FUNC
activity	I-FUNC
,	O
hence	O
inhibited	O
IFN	O
-	O
	O
reporter	O
activity	O
.	O

Albeit	O
promiscuous	O
in	O
deubiquitinating	O
cellular	O
proteins	O
,	O
PLP2	O
inactivated	O
TBK1	B-FUNC
and	O
IFN	O
-	O
	O
response	O
in	O
TNF	O
receptor	O
associated	O
factor	O
3	O
(	O
TRAF3	O
)	O
deficient	O
cells	O
,	O
suggesting	O
that	O
targeting	O
TBK1	B-FUNC
would	O
be	O
sufficient	O
for	O
PLP2	O
to	O
inhibit	O
IRF3	O
activation	O
.	O

This	O
notion	O
was	O
further	O
supported	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
in	O
which	O
prior	O
treatment	O
of	O
TBK1	B-FUNC
with	O
PLP2	O
inhibited	O
its	O
kinase	B-FUNC
activity	I-FUNC
to	O
phosphorylate	O
IRF3	O
.	O

Intriguing	O
enough	O
,	O
results	O
of	O
PLP2	O
overexpression	O
system	O
and	O
MHV	O
-	O
A59	O
infection	O
system	O
proved	O
that	O
PLP2	O
formed	O
an	O
inactive	O
complex	O
with	O
TBK1	B-FUNC
and	O
IRF3	O
in	O
the	O
cytoplasm	O
and	O
the	O
presence	O
of	O
PLP2	O
stabilized	O
the	O
hypo	O
-	O
phosphorylated	O
IRF3	O
-	O
TBK1	B-FUNC
complex	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
PLP2	O
not	O
only	O
inactivates	O
TBK1	B-FUNC
,	O
but	O
also	O
prevents	O
IRF3	O
nuclear	O
translocation	O
hence	O
inhibits	O
IFN	O
transcription	O
activation	O
.	O

TITLE	O
:	O
Longitudinal	O
profiles	O
of	O
immunoglobulin	B-FUNC
G	O
antibodies	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
components	O
and	O
neutralizing	O
activities	O
in	O
recovered	O
patients	O
.	O

Currently	O
,	O
the	O
longitudinal	O
profiles	O
of	O
antibody	B-FUNC
responses	O
in	O
recovered	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

We	O
found	O
that	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
and	O
their	O
neutralizing	O
activities	O
decreased	O
throughout	O
the	O
entire	O
phase	O
of	O
the	O
study	O
.	O

For	O
IgG	O
antibodies	O
in	O
the	O
3rd	O
y	O
,	O
the	O
positive	O
rate	O
of	O
whole	O
-	O
virus	O
-	O
specific	O
antibodies	O
was	O
42	O
%,	O
which	O
was	O
tested	O
with	O
commercial	O
kits	O
at	O
1	O
/	O
10	O
dilution	O
of	O
the	O
sera	B-FUNC
.	O

RESULTS	O
:	O
We	O
found	O
that	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
and	O
their	O
neutralizing	O
activities	O
decreased	O
throughout	O
the	O
entire	O
phase	O
of	O
the	O
study	O
.	O

Both	O
processes	O
are	O
regulated	O
by	O
RNA	O
sequences	O
such	O
as	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTRs	O
),	O
and	O
the	O
transcription	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
of	O
the	O
leader	O
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
those	O
preceding	O
each	O
gene	O
(	O
TRS	B-FUNC
-	O
Bs	O
).	O

By	O
analogy	O
to	O
other	O
plus	O
-	O
stranded	O
RNA	O
viruses	O
,	O
such	O
as	O
polioviruses	O
,	O
in	O
which	O
translation	O
and	O
replication	O
switch	O
involves	O
a	O
cellular	O
factor	O
(	O
PCBP	O
)	O
and	O
a	O
viral	O
protein	O
(	O
3CD	O
)	O
it	O
is	O
conceivable	O
that	O
in	O
CoVs	O
the	O
switch	O
between	O
replication	O
and	O
transcription	O
is	O
also	O
associated	O
with	O
the	O
binding	B-FUNC
of	O
proteins	O
that	O
are	O
specifically	O
recruited	O
by	O
the	O
replication	O
or	O
transcription	O
complexes	O
.	O

Complexes	O
between	O
RNA	O
motifs	O
such	O
as	O
TRS	B-FUNC
-	O
L	O
and	O
the	O
TRS	B-FUNC
-	O
Bs	O
located	O
along	O
the	O
CoV	O
genome	O
are	O
probably	O
formed	O
previously	O
to	O
the	O
transcription	O
start	O
,	O
and	O
most	O
likely	O
promote	O
template	O
-	O
switch	O
of	O
the	O
nascent	O
minus	O
RNA	O
to	O
the	O
TRS	B-FUNC
-	O
L	O
region	O
.	O

These	O
proteins	O
mostly	O
related	O
to	O
the	O
cytoskeleton	O
,	O
binding	B-FUNC
of	O
calcium	O
ions	O
,	O
the	O
stress	O
response	O
,	O
anti	O
-	O
oxidative	O
,	O
and	O
macromolecular	O
metabolism	O
.	O

This	O
process	O
involves	O
a	O
discontinuous	O
step	O
during	O
the	O
synthesis	O
of	O
minus	O
-	O
sense	O
RNA	O
that	O
is	O
modulated	O
by	O
transcription	O
-	O
regulating	O
sequences	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
leader	O
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
also	O
preceding	O
each	O
viral	O
gene	O
(	O
TRS	B-FUNC
-	O
Bs	O
).	O

It	O
has	O
been	O
previously	O
proposed	O
that	O
TRS	B-FUNC
-	O
Bs	O
act	O
as	O
attenuation	O
or	O
stop	O
signals	O
during	O
the	O
synthesis	O
of	O
minus	O
-	O
sense	O
RNAs	O
.	O

To	O
study	O
whether	O
the	O
TRS	B-FUNC
-	O
L	O
is	O
structured	O
and	O
to	O
determine	O
whether	O
this	O
structure	O
has	O
a	O
functional	O
impact	O
on	O
genomic	O
and	O
subgenomic	O
viral	O
RNA	O
synthesis	O
,	O
we	O
have	O
used	O
a	O
combination	O
of	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
and	O
UV	O
thermal	O
denaturation	O
approaches	O
together	O
with	O
site	O
-	O
directed	O
mutagenesis	O
and	O
in	O
vivo	O
transcriptional	O
analyses	O
.	O

The	O
results	O
indicated	O
that	O
a	O
36	O
-	O
nucleotide	O
oligomer	O
encompassing	O
the	O
wild	O
-	O
type	O
TRS	B-FUNC
-	O
L	O
forms	O
a	O
structured	O
hairpin	O
closed	O
by	O
an	O
apical	O
AACUAAA	O
heptaloop	O
.	O

ABSTRACT	O
:	O
An	O
immunochromatographic	O
strip	O
was	O
developed	O
for	O
the	O
detection	O
of	O
an	O
antibody	B-FUNC
against	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
).	O

Colloidal	O
gold	O
-	O
labeled	O
rabbit	O
anti	O
-	O
pig	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
was	O
used	O
as	O
the	O
detection	O
reagent	O
,	O
and	O
the	O
PHEV	O
recombinant	O
antigens	O
and	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
were	O
coated	O
on	O
the	O
prototype	O
strip	O
and	O
the	O
control	O
lines	O
,	O
respectively	O
.	O

Using	O
immunohistochemistry	O
,	O
virus	O
neutralization	O
,	O
fluorescent	O
antibody	B-FUNC
test	O
,	O
and	O
nested	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
Porcine	O
teschovirus	O
was	O
identified	O
in	O
tissues	O
from	O
affected	O
individuals	O
.	O

Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
an	O
acute	O
lung	O
injury	O
often	O
preceded	O
by	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
and	O
triggered	O
by	O
different	O
factors	O
including	O
:	O
hypoventilation	O
,	O
pulmonary	O
infectious	O
disease	O
and	O
vascular	O
occlusions	O
.	O

Exchange	O
transfusion	O
may	O
be	O
indicated	O
in	O
severe	O
forms	O
of	O
ACS	B-FUNC
,	O
characterized	O
by	O
a	O
right	O
ventricular	O
dysfunction	O
and	O
acute	O
respiratory	O
failure	O
.	O

Studying	O
RVP	O
FAST	B-FUNC
efficacy	O
in	O
detecting	O
respiratory	O
viruses	O
in	O
67	O
aspirate	O
samples	O
from	O
the	O
nasal	O
cavities	O
of	O
children	O
with	O
acute	O
respiratory	O
infection	O
,	O
we	O
compared	O
RVP	O
FAST	B-FUNC
results	O
to	O
those	O
of	O
conventional	O
nucleic	O
acid	O
amplification	O
tests	O
(	O
NAT	O
),	O
e	O
.	O
g	O
.,	O
real	O
-	O
time	O
PCR	O
,	O
targeting	O
8	O
strains	O
.	O

RVP	O
FAST	B-FUNC
assay	O
detected	O
13	O
strains	O
(	O
98	O
isolates	O
)	O
in	O
59	O
of	O
67	O
samples	O
.	O

RVP	O
FAST	B-FUNC
also	O
detected	O
coronavirus	O
(	O
CoV	O
)	O
229E	O
,	O
OC43	O
,	O
NL63	O
,	O
and	O
HKU1	O
from	O
10	O
virus	O
strain	O
samples	O
and	O
enterovirus	O
and	O
/	O
or	O
rhinovirus	O
from	O
35	O
.	O

RVP	O
FAST	B-FUNC
assay	O
thus	O
comprehensively	O
detects	O
clinically	O
important	O
viruses	O
in	O
a	O
single	O
measurement	O
,	O
making	O
RVP	O
FAST	B-FUNC
assay	O
useful	O
in	O
detecting	O
causative	O
respiratory	O
tract	O
viruses	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
discontinuous	O
transcription	O
mechanism	O
is	O
driven	O
by	O
long	O
-	O
distance	O
RNA	O
-	O
RNA	O
interactions	O
between	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
located	O
at	O
the	O
5	O
'	O
terminal	O
leader	O
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
also	O
preceding	O
each	O
mRNA	O
-	O
coding	O
sequence	O
(	O
TRS	B-FUNC
-	O
B	O
).	O

TITLE	O
:	O
A	O
virus	O
-	O
binding	B-FUNC
hot	O
spot	O
on	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
is	O
critical	O
for	O
binding	B-FUNC
of	O
two	O
different	O
coronaviruses	O
.	O

We	O
recently	O
determined	O
the	O
crystal	O
structures	O
of	O
NL63	O
coronavirus	O
(	O
NL63	O
-	O
CoV	O
)	O
and	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
-	O
binding	B-FUNC
domains	O
(	O
RBDs	O
),	O
each	O
complexed	O
with	O
their	O
common	O
receptor	O
,	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
and	O
proposed	O
the	O
existence	O
of	O
a	O
virus	O
-	O
binding	B-FUNC
hot	O
spot	O
on	O
hACE2	O
.	O

The	O
tunnel	O
structure	O
at	O
the	O
NL63	O
-	O
CoV	O
/	O
hACE2	O
interface	O
is	O
more	O
compact	O
than	O
that	O
at	O
the	O
SARS	O
-	O
CoV	O
/	O
hACE2	O
interface	O
,	O
and	O
hence	O
RBD	O
/	O
hACE2	O
binding	B-FUNC
affinities	O
are	O
decreased	O
either	O
by	O
NL63	O
-	O
CoV	O
mutations	O
decreasing	O
the	O
tunnel	O
space	O
or	O
by	O
SARS	O
-	O
CoV	O
mutations	O
increasing	O
the	O
tunnel	O
space	O
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
Luminex	O
xTAG	O
respiratory	O
viral	O
panel	O
with	O
xTAG	O
respiratory	O
viral	O
panel	O
fast	B-FUNC
for	O
diagnosis	O
of	O
respiratory	O
virus	O
infections	O
.	O

A	O
newer	O
generation	O
of	O
this	O
kit	B-FUNC
,	O
released	O
in	O
Canada	O
in	O
early	O
2010	O
,	O
is	O
designed	O
to	O
simplify	O
the	O
procedure	O
and	O
reduce	O
the	O
turnaround	O
time	O
by	O
about	O
24	O
h	O
.	O
The	O
assay	O
methodology	O
and	O
targets	O
included	O
in	O
this	O
version	O
of	O
the	O
kit	B-FUNC
are	O
different	O
;	O
consequently	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
detection	O
of	O
a	O
panel	O
of	O
respiratory	O
viral	O
targets	O
using	O
the	O
older	O
Luminex	O
xTAG	O
RVP	O
(	O
RVP	O
Classic	O
)	O
assay	O
with	O
that	O
using	O
the	O
newer	O
xTAG	O
RVP	O
Fast	B-FUNC
assay	O
.	O

Overall	O
,	O
the	O
RVP	O
Classic	O
assay	O
was	O
more	O
sensitive	O
than	O
the	O
RVP	O
Fast	B-FUNC
assay	O
(	O
88	O
.	O
6	O
%	O
and	O
77	O
.	O
5	O
%	O
sensitivities	O
,	O
respectively	O
)	O
for	O
all	O
the	O
viral	O
targets	O
combined	O
.	O

Targets	O
not	O
detected	O
by	O
the	O
RVP	O
Fast	B-FUNC
assay	O
included	O
primarily	O
influenza	O
B	O
virus	O
,	O
parainfluenza	O
virus	O
type	O
2	O
,	O
and	O
human	O
coronavirus	O
229E	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
Goodpasture	O
syndrome	O
positive	O
for	O
anti	O
-	O
GBM	O
antibody	B-FUNC
and	O
MPO	B-FUNC
-	O
ANCA	O
complicated	O
by	O
a	O
variety	O
of	O
serious	O
infections	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
new	O
microsphere	O
-	O
based	O
multiplex	O
fluorescent	O
immunoassay	O
(	O
MFI	O
)	O
using	O
recombinant	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
proteins	O
to	O
detect	O
antibodies	O
to	O
coronaviruses	O
in	O
mouse	O
and	O
rat	O
sera	B-FUNC
.	O

The	O
MFI	O
was	O
evaluated	O
for	O
its	O
diagnostic	O
power	O
,	O
with	O
panels	O
of	O
mouse	O
sera	B-FUNC
classified	O
as	O
positive	O
or	O
negative	O
for	O
anti	O
-	O
MHV	O
antibodies	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
MHV	O
virion	O
antigen	O
and	O
indirect	O
fluorescent	O
antibody	B-FUNC
assay	O
.	O

ABSTRACT	O
:	O
Fundamental	O
step	O
of	O
an	O
adaptive	O
immune	O
response	O
to	O
pathogen	O
or	O
vaccine	O
is	O
the	O
binding	B-FUNC
of	O
short	O
peptides	O
(	O
also	O
called	O
epitopes	O
)	O
to	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
molecules	O
.	O

The	O
various	O
prediction	O
algorithms	O
are	O
being	O
used	O
to	O
capture	O
the	O
MHC	O
peptide	B-FUNC
binding	I-FUNC
preference	O
,	O
allowing	O
the	O
rapid	O
scan	O
of	O
entire	O
pathogen	O
proteomes	O
for	O
peptide	O
likely	O
to	O
bind	B-FUNC
MHC	O
,	O
saving	O
the	O
cost	O
,	O
effort	O
,	O
and	O
time	O
.	O

In	O
case	O
of	O
variable	O
learning	O
rate	O
,	O
of	O
the	O
90	O
datasets	O
the	O
value	O
of	O
AROC	O
for	O
76	O
datasets	O
is	O
between	O
0	O
.	O
806	O
and	O
1	O
.	O
0	O
and	O
for	O
7	O
datasets	O
the	O
value	O
is	O
between	O
0	O
.	O
7	O
and	O
0	O
.	O
8	O
and	O
for	O
rest	B-FUNC
of	O
7	O
datasets	O
it	O
is	O
between	O
0	O
.	O
5	O
and	O
0	O
.	O
7	O
,	O
which	O
indicates	O
very	O
good	O
performance	O
in	O
most	O
of	O
the	O
cases	O
.	O

Because	O
of	O
their	O
clinical	O
similarities	O
to	O
patients	O
with	O
fibromyalgia	O
syndrome	O
(	O
FMS	B-FUNC
)	O
these	O
post	O
-	O
SARS	O
subjects	O
were	O
similarly	O
compared	O
to	O
21	O
drug	O
free	O
female	O
patients	O
,	O
(	O
mean	O
age	O
42	O
.	O
4	O
+/-	O

Post	O
-	O
SARS	O
patients	O
had	O
symptoms	O
of	O
pre	O
and	O
post	O
-	O
sleep	O
fatigue	O
and	O
post	O
sleep	O
sleepiness	O
that	O
were	O
similar	O
to	O
the	O
symptoms	O
of	O
patients	O
with	O
FMS	B-FUNC
,	O
and	O
similar	O
to	O
symptoms	O
of	O
patients	O
with	O
chronic	O
fatigue	O
syndrome	O
.	O

The	O
post	O
-	O
SARS	O
group	O
had	O
a	O
lower	O
rating	O
of	O
the	O
alpha	O
EEG	O
sleep	O
anomaly	O
as	O
compared	O
to	O
the	O
FMS	B-FUNC
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
two	O
bacterial	O
pathogens	O
(	O
Fusobacterium	O
necrophorum	O
and	O
Acinetobacter	O
baumannii	O
)	O
causing	O
sepsis	O
were	O
detected	O
by	O
DNA	O
-	O
probe	O
hybridization	O
and	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
was	O
detected	O
by	O
antigen	O
-	O
antibody	B-FUNC
interaction	O
using	O
the	O
functional	O
PCs	O
.	O

ABSTRACT	O
:	O
Three	O
hundred	O
sera	B-FUNC
were	O
collected	O
from	O
horses	O
in	O
various	O
parts	O
of	O
Mongolia	O
in	O
2007	O
and	O
seroepidemiological	O
surveys	O
for	O
several	O
equine	O
viruses	O
performed	O
on	O
them	O
.	O

Equid	O
herpesvirus	O
1	O
and	O
equine	O
rhinitis	O
A	O
virus	O
were	O
prevalent	O
,	O
and	O
equine	O
arteritis	O
virus	O
and	O
equid	O
herpesvirus	O
3	O
were	O
detected	O
over	O
a	O
wide	O
area	O
though	O
their	O
rates	O
of	O
antibody	B-FUNC
-	O
positivity	O
were	O
not	O
high	O
.	O

The	O
rates	O
of	O
horses	O
antibody	B-FUNC
-	O
positive	O
for	O
Japanese	O
encephalitis	O
virus	O
and	O
equine	O
influenza	O
virus	O
were	O
low	O
,	O
but	O
these	O
were	O
detected	O
.	O

Nasopharyngeal	O
and	O
rectal	O
swabs	O
revealed	O
pandemic	O
2009	O
(	O
H1N1	O
)	O
virus	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assay	O
.	O

The	O
top	O
1468	O
ranked	O
compounds	O
with	O
free	O
binding	B-FUNC
energy	O
ranging	O
from	O
-	O
14	O
.	O
0	O
to	O
-	O
17	O
.	O
09	O
kcal	O
mol	O
(-	O
1	O
)	O
were	O
selected	O
to	O
check	O
the	O
hydrogen	O
bond	O
interaction	O
with	O
amino	O
acid	O
residues	O
in	O
the	O
active	O
site	O
of	O
3CL	O
(	O
pro	O
).	O

In	O
an	O
airtight	O
environment	O
,	O
rabbit	O
ARDS	O
model	O
can	O
be	O
reproduced	O
successfully	O
by	O
blast	O
injury	O
with	O
1	O
917	O
.	O
3	O
mm	O
Hg	O
explosion	O
pressure	O
;	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
are	O
involved	O
in	O
the	O
pathogenesis	O
and	O
development	O
of	O
ARDS	O
in	O
blast	O
injury	O
.	O

The	O
contents	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
(	O
TNF	O
-	O
	O
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
in	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
also	O
increased	O
distinctly	O
compared	O
with	O
the	O
control	O
group	O
[	O
TNF	O
-	O
	O
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
328	O
.	O
89	O
	O
6	O
.	O
26	O
vs	O
.	O
62	O
.	O
12	O
	O
2	O
.	O
98	O
,	O
TNF	O
-	O
	O
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
164	O
.	O
87	O
	O
4	O
.	O
59	O
vs	O
.	O
29	O
.	O
51	O
	O
1	O
.	O
12	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
128	O
.	O
51	O
	O
4	O
.	O
13	O
vs	O
.	O
19	O
.	O
32	O
	O
1	O
.	O
53	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
94	O
.	O
97	O
	O
1	O
.	O
14	O
vs	O
.	O
22	O
.	O
72	O
	O
0	O
.	O
19	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
].	O

CONCLUSIONS	O
:	O
In	O
an	O
airtight	O
environment	O
,	O
rabbit	O
ARDS	O
model	O
can	O
be	O
reproduced	O
successfully	O
by	O
blast	O
injury	O
with	O
1	O
917	O
.	O
3	O
mm	O
Hg	O
explosion	O
pressure	O
;	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
are	O
involved	O
in	O
the	O
pathogenesis	O
and	O
development	O
of	O
ARDS	O
in	O
blast	O
injury	O
.	O

TITLE	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
),	O
produced	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
virus	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
,	O
induces	O
vascular	O
permeability	O
and	O
effusion	O
in	O
cats	O
with	O
FIP	O
.	O

We	O
investigated	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	B-FUNC
)	O
to	O
examine	O
the	O
relationship	O
between	O
VEGF	B-FUNC
levels	O
and	O
the	O
amounts	O
of	O
effusion	O
in	O
cats	O
with	O
FIP	O
.	O

Using	O
a	O
newly	O
designed	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assay	O
specific	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
turkey	O
coronaviruses	O
(	O
TCoV	O
),	O
coronaviruses	O
were	O
identified	O
in	O
37	O
%	O
of	O
the	O
intestinal	O
samples	O
collected	O
from	O
diseased	O
turkey	O
flocks	O
.	O

Herein	O
we	O
describe	O
a	O
molecule	O
from	O
this	O
screen	O
that	O
prevents	O
the	O
interaction	O
between	O
eIF4E	O
(	O
the	O
cap	O
-	O
binding	B-FUNC
protein	O
)	O
and	O
eIF4G	O
(	O
a	O
large	O
scaffolding	O
protein	O
),	O
inhibiting	O
cap	O
-	O
dependent	O
translation	O
.	O

ABSTRACT	O
:	O
Immunoglobulin	B-FUNC
in	O
cerebral	O
spinal	O
fluid	O
and	O
antibody	B-FUNC
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
parenchyma	O
are	O
common	O
hallmarks	O
of	O
microbial	O
infections	O
and	O
autoimmune	O
disorders	O
.	O

A	O
key	O
enzyme	O
of	O
this	O
replication	O
complex	O
is	O
the	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
).	O

To	O
study	O
the	O
replication	O
of	O
coronavirus	O
genome	O
,	O
six	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
specific	O
for	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
RdRp	B-FUNC
were	O
generated	O
and	O
characterized	O
.	O

His	O
-	O
tagged	O
RdRp	B-FUNC
was	O
expressed	O
in	O
baculovirus	O
,	O
purified	O
and	O
used	O
as	O
immunogen	O
to	O
produce	O
mAbs	O
.	O

The	O
TGEV	O
RdRp	B-FUNC
was	O
recognized	O
by	O
these	O
mAbs	O
in	O
the	O
context	O
of	O
virus	O
infection	O
by	O
immunofluorescence	O
analysis	O
and	O
Western	O
blot	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
sialosides	O
modified	O
at	O
the	O
4	O
-	O
and	O
9	O
-	O
hydroxy	O
group	O
were	O
synthesised	O
and	O
tested	O
for	O
inhibition	O
of	O
the	O
viral	O
haemagglutinin	O
-	O
esterase	B-FUNC
activity	I-FUNC
from	O
various	O
Orthomyxoviruses	O
and	O
Coronaviruses	O
.	O

This	O
case	O
report	O
reveals	O
a	O
patient	O
with	O
ARDS	O
secondary	O
to	O
influenza	O
A	O
with	O
deteriorating	O
clinical	O
status	O
,	O
who	O
improved	O
tremendously	O
after	O
intravenous	O
immunoglobulin	B-FUNC
G	O
(	O
IV	O
IgG	O
).	O

These	O
domains	O
possess	O
ADP	O
-	O
ribose	O
-	O
1	O
-	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
activity	O
and	O
/	O
or	O
bind	B-FUNC
poly	O
(	O
ADP	O
-	O
ribose	O
),	O
poly	O
(	O
A	O
)	O
or	O
poly	O
(	O
G	O
).	O

ABSTRACT	O
:	O
Interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
mRNA	O
is	O
rapidly	O
upregulated	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
infection	O
with	O
neurotropic	O
coronavirus	O
and	O
remains	O
elevated	O
during	O
persistent	O
infection	O
.	O

Infection	O
of	O
transgenic	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
/	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
reporter	O
mice	O
revealed	O
that	O
CNS	O
-	O
infiltrating	O
T	O
cells	O
were	O
the	O
major	O
source	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
with	O
minimal	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
by	O
macrophages	O
and	O
resident	O
microglia	O
.	O

The	O
proportions	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
producing	O
cells	O
were	O
initially	O
similar	O
in	O
CD8	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cells	O
but	O
diminished	O
rapidly	O
in	O
CD8	O
(+)	O
T	O
cells	O
as	O
the	O
virus	O
was	O
controlled	O
.	O

Overall	O
,	O
the	O
majority	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
producing	O
CD8	O
(+)	O
T	O
cells	O
were	O
specific	O
for	O
the	O
immunodominant	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
epitope	O
.	O

Unlike	O
CD8	O
(+)	O
T	O
cells	O
,	O
a	O
large	O
proportion	O
of	O
CD4	O
(+)	O
T	O
cells	O
within	O
the	O
CNS	O
retained	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
throughout	O
persistence	O
.	O

Furthermore	O
,	O
elevated	O
frequencies	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
producing	O
CD4	O
(+)	O
T	O
cells	O
in	O
the	O
spinal	O
cord	O
supported	O
preferential	O
maintenance	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
at	O
the	O
site	O
of	O
viral	O
persistence	O
and	O
tissue	O
damage	O
.	O

IL	B-FUNC
-	I-FUNC
10	I-FUNC
was	O
produced	O
primarily	O
by	O
the	O
CD25	O
(+)	O
CD4	O
(+)	O
T	O
cell	O
subset	O
during	O
acute	O
infection	O
but	O
prevailed	O
in	O
CD25	O
(-)	O
CD4	O
(+)	O
T	O
cells	O
during	O
the	O
transition	O
to	O
persistent	O
infection	O
and	O
thereafter	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
significant	O
fluidity	O
in	O
the	O
T	O
-	O
cell	O
-	O
mediated	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
response	O
during	O
viral	O
encephalitis	O
and	O
persistence	O
.	O

While	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
by	O
CD8	O
(+)	O
T	O
cells	O
was	O
limited	O
primarily	O
to	O
the	O
time	O
of	O
acute	O
effector	O
function	O
,	O
CD4	O
(+)	O
T	O
cells	O
continued	O
to	O
produce	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
throughout	O
infection	O
.	O

Moreover	O
,	O
a	O
shift	O
from	O
predominant	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
by	O
CD25	O
(+)	O
CD4	O
(+)	O
T	O
cells	O
to	O
CD25	O
(-)	O
CD4	O
(+)	O
T	O
cells	O
suggests	O
that	O
a	O
transition	O
to	O
nonclassical	O
regulatory	O
T	O
cells	O
precedes	O
and	O
is	O
retained	O
during	O
CNS	O
viral	O
persistence	O
.	O

ABSTRACT	O
:	O
The	O
bacterially	O
expressed	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
was	O
used	O
as	O
immunogen	O
to	O
generate	O
a	O
rabbit	O
-	O
derived	O
polyclonal	O
antibody	B-FUNC
.	O

The	O
polyclonal	O
antibody	B-FUNC
against	O
PRRSV	O
N	O
protein	O
used	O
as	O
a	O
diagnostic	O
agent	O
was	O
capable	O
of	O
differentiating	O
PRRSV	O
from	O
the	O
other	O
viruses	O
.	O

Although	O
HFOV	O
has	O
failed	O
to	O
show	O
a	O
mortality	O
benefit	O
in	O
ARDS	O
patients	O
,	O
the	O
unique	O
lung	O
recruitment	O
by	O
HFOV	O
can	O
be	O
a	O
useful	O
therapeutic	O
option	O
for	O
severe	O
ARDS	O
patients	O
in	O
combination	O
with	O
sufficient	O
lung	O
rest	B-FUNC
produced	O
by	O
ECMO	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
accessory	O
protein	O
3b	O
induces	O
AP	O
-	O
1	O
transcriptional	O
activity	O
through	O
activation	O
of	O
JNK	B-FUNC
and	O
ERK	B-FUNC
pathways	O
.	O

Reporter	O
gene	O
and	O
mobility	O
shift	O
assays	O
depict	O
an	O
increase	O
in	O
the	O
AP	O
-	O
1	O
transcriptional	O
and	O
DNA	B-FUNC
binding	I-FUNC
activity	O
in	O
the	O
presence	O
of	O
3b	O
.	O

This	O
increase	O
in	O
activity	O
correlates	O
with	O
the	O
activation	O
of	O
ERK	B-FUNC
and	O
JNK	B-FUNC
pathways	O
.	O

Furthermore	O
,	O
3b	O
expression	O
potentiates	O
AP	O
-	O
1	O
-	O
driven	O
promoter	O
activity	O
of	O
proinflammatory	O
cytokine	O
MCP	B-FUNC
-	O
1	O
,	O
suggesting	O
a	O
plausible	O
role	O
for	O
3b	O
as	O
a	O
virulence	O
factor	O
that	O
might	O
function	O
by	O
upregulating	O
AP	O
-	O
1	O
-	O
dependent	O
cytokine	O
levels	O
in	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
ADAM17	O
,	O
also	O
known	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
-	O
converting	O
enzyme	O
,	O
is	O
involved	O
in	O
the	O
ectodomain	O
shedding	O
of	O
many	O
integral	O
membrane	O
proteins	O
.	O

The	O
observation	O
of	O
the	O
shedding	O
profiles	O
of	O
ACE2	O
mutants	O
expressing	O
CHO	B-FUNC
-	O
K1	O
and	O
CHO	B-FUNC
-	O
P	O
cells	O
indicates	O
that	O
the	O
Arg	O
(	O
708	O
)	O
	O
Glu	O
(	O
708	O
)	O
mutation	O
and	O
the	O
Arg	O
(	O
708	O
)	O
Arg	O
(	O
710	O
)	O
	O
Glu	O
(	O
708	O
)	O
Glu	O
(	O
710	O
)	O
double	O
mutation	O
produced	O
increases	O
in	O
the	O
amount	O
of	O
ACE2	O
shed	O
when	O
stimulated	O
by	O
phorbol	O
ester	O
PMA	O
.	O

Patients	O
homozygous	O
for	O
the	O
4	O
base	B-FUNC
pair	I-FUNC
deletion	O
in	O
the	O
promoter	O
of	O
NFKB1	O
(	O
del	O
/	O
del	O
)	O
did	O
not	O
have	O
an	O
increased	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
developing	O
ARDS	O
in	O
unadjusted	O
analysis	O
but	O
were	O
more	O
likely	O
to	O
develop	O
ARDS	O
in	O
the	O
presence	O
of	O
a	O
significant	O
interaction	O
between	O
the	O
del	O
/	O
del	O
genotype	O
and	O
age	O
(	O
OR	O
5	O
.	O
21	O
,	O
95	O
%	O
CI	O
1	O
.	O
35	O
-	O
20	O
.	O
0	O
).	O

RESULTS	O
:	O
Patients	O
homozygous	O
for	O
the	O
4	O
base	B-FUNC
pair	I-FUNC
deletion	O
in	O
the	O
promoter	O
of	O
NFKB1	O
(	O
del	O
/	O
del	O
)	O
did	O
not	O
have	O
an	O
increased	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
developing	O
ARDS	O
in	O
unadjusted	O
analysis	O
but	O
were	O
more	O
likely	O
to	O
develop	O
ARDS	O
in	O
the	O
presence	O
of	O
a	O
significant	O
interaction	O
between	O
the	O
del	O
/	O
del	O
genotype	O
and	O
age	O
(	O
OR	O
5	O
.	O
21	O
,	O
95	O
%	O
CI	O
1	O
.	O
35	O
-	O
20	O
.	O
0	O
).	O

Finally	O
,	O
a	O
SARS	O
pseudovirus	O
neutralization	O
assay	O
was	O
introduced	O
in	O
the	O
protocol	O
and	O
used	O
to	O
detect	O
the	O
neutralizing	O
activity	O
of	O
sera	B-FUNC
of	O
mice	O
vaccinated	O
with	O
rRBD	O
protein	O
.	O

TITLE	O
:	O
Identification	O
of	O
RNA	O
pseudoknot	O
-	O
binding	B-FUNC
ligand	B-FUNC
that	O
inhibits	O
the	O
-	O
1	O
ribosomal	O
frameshifting	O
of	O
SARS	O
-	O
coronavirus	O
by	O
structure	O
-	O
based	O
virtual	O
screening	O
.	O

We	O
successfully	O
identified	O
a	O
novel	O
ligand	B-FUNC
43	O
that	O
dramatically	O
inhibits	O
the	O
-	O
1	O
RF	O
of	O
SARS	O
-	O
CoV	O
.	O
This	O
antiframeshift	O
agent	O
is	O
an	O
interesting	O
lead	O
for	O
the	O
design	O
of	O
novel	O
antiviral	O
agents	O
against	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Fully	O
human	O
monoclonal	O
antibody	B-FUNC
directed	O
to	O
proteolytic	O
cleavage	O
site	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
S	O
protein	O
neutralizes	O
the	O
virus	O
in	O
a	O
rhesus	O
macaque	O
SARS	O
model	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
efficacy	O
of	O
a	O
fully	O
human	O
monoclonal	O
antibody	B-FUNC
capable	O
of	O
neutralizing	O
SARS	O
-	O
CoV	O
in	O
vitro	O
in	O
a	O
Rhesus	O
macaque	O
model	O
of	O
SARS	O
.	O

The	O
antibody	B-FUNC
5H10	O
was	O
obtained	O
by	O
vaccination	O
of	O
KM	O
mice	O
bearing	O
human	O
immunoglobulin	B-FUNC
genes	O
with	O
Escherichia	O
coli	O
-	O
producing	O
recombinant	O
peptide	O
containing	O
the	O
dominant	O
epitope	O
of	O
the	O
viral	O
spike	O
protein	O
found	O
in	O
convalescent	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
absence	O
of	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
),	O
a	O
potent	O
anti	O
-	O
inflammatory	O
cytokine	O
results	O
in	O
increased	O
immune	O
-	O
mediated	O
demyelination	O
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
(	O
recombinant	O
J2	O
.	O
2	O
-	O
V	O
-	O
1	O
[	O
rJ2	O
.	O
2	O
]).	O

Here	O
,	O
we	O
examined	O
the	O
therapeutic	O
effects	O
of	O
increased	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
at	O
early	O
times	O
after	O
infection	O
by	O
engineering	O
a	O
recombinant	O
J2	O
.	O
2	O
virus	O
to	O
produce	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

The	O
protective	O
effects	O
of	O
increased	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
were	O
associated	O
with	O
reductions	O
in	O
microglial	O
activation	O
,	O
inflammatory	O
cell	O
infiltration	O
into	O
the	O
brain	O
,	O
and	O
proinflammatory	O
cytokine	O
and	O
chemokine	O
production	O
.	O

Additionally	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
increased	O
both	O
the	O
frequency	O
and	O
number	O
of	O
Foxp3	O
(+)	O
regulatory	O
CD4	O
T	O
cells	O
in	O
the	O
infected	O
central	O
nervous	O
system	O
.	O

Most	O
strikingly	O
,	O
the	O
ameliorating	O
effects	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
produced	O
during	O
the	O
first	O
5	O
days	O
after	O
infection	O
were	O
long	O
acting	O
,	O
resulting	O
in	O
decreased	O
demyelination	O
during	O
the	O
resolution	O
phase	O
of	O
the	O
infection	O
.	O

IL	B-FUNC
-	I-FUNC
10	I-FUNC
functions	O
by	O
dampening	O
the	O
innate	O
or	O
very	O
early	O
T	O
cell	O
immune	O
response	O
.	O

Further	O
,	O
they	O
suggest	O
that	O
early	O
treatment	O
with	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
may	O
be	O
useful	O
adjunct	O
therapy	O
in	O
some	O
types	O
of	O
viral	O
encephalitis	O
.	O

The	O
CoVs	O
,	O
including	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
SARS	O
-	O
CoV	O
,	O
encode	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	B-FUNC
activity	I-FUNC
(	O
ExoN	O
)	O
in	O
nsp14	O
.	O

The	O
discovery	O
of	O
a	O
protein	O
distinct	O
from	O
a	O
viral	O
RdRp	B-FUNC
that	O
regulates	O
replication	O
fidelity	O
also	O
raises	O
the	O
possibility	O
that	O
RNA	O
genome	O
replication	O
fidelity	O
may	O
be	O
adaptable	O
to	O
differing	O
replication	O
environments	O
and	O
selective	O
pressures	O
,	O
rather	O
than	O
being	O
a	O
fixed	O
determinant	O
.	O

Compared	O
with	O
untreated	O
rats	O
,	O
the	O
lungs	O
of	O
rats	O
treated	O
with	O
DCQD	O
showed	O
significantly	O
lower	O
levels	O
of	O
proinflammatory	O
cytokine	O
IL	O
-	O
1	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
mRNA	O
.	O

It	O
was	O
found	O
that	O
FIPV	O
I	O
binding	B-FUNC
and	O
infection	O
were	O
not	O
affected	O
by	O
blocking	O
fAPN	O
while	O
blocking	O
fDC	O
-	O
SIGN	O
reduced	O
FIPV	O
I	O
binding	B-FUNC
to	O
36	O
%	O
and	O
practically	O
completely	O
inhibited	O
infection	O
.	O

Blocking	O
fAPN	O
reduced	O
FIPV	O
II	O
binding	B-FUNC
by	O
53	O
%	O
and	O
infection	O
by	O
80	O
%.	O

fDC	O
-	O
SIGN	O
was	O
not	O
involved	O
in	O
FIPV	O
II	O
binding	B-FUNC
but	O
infection	O
was	O
reduced	O
with	O
64	O
%	O
when	O
fDC	O
-	O
SIGN	O
was	O
blocked	O
.	O

Microbiology	O
from	O
one	O
ferret	O
yielded	O
a	O
pure	B-FUNC
culture	O
of	O
gram	O
-	O
negative	O
bacteria	O
identified	O
phenotypically	O
as	O
Pseudomonas	O
luteola	O
.	O

A	O
combined	O
ligand	B-FUNC
and	O
structure	O
-	O
based	O
virtual	O
screening	O
was	O
carried	O
out	O
against	O
the	O
Asinex	O
Platinum	O
collection	O
.	O

Furthermore	O
,	O
multinanosecond	O
explicit	O
solvent	O
simulations	O
were	O
carried	O
out	O
using	O
the	O
docking	O
poses	O
of	O
the	O
identified	O
hits	O
to	O
study	O
the	O
overall	O
stability	O
of	O
the	O
binding	B-FUNC
site	O
interactions	O
as	O
well	O
as	O
identify	O
important	O
changes	O
in	O
the	O
interaction	O
profile	O
that	O
were	O
not	O
apparent	O
from	O
the	O
docking	O
study	O
.	O

Cumulative	O
analysis	O
of	O
the	O
evaluated	O
compounds	O
and	O
the	O
simulation	O
studies	O
led	O
to	O
the	O
identification	O
of	O
certain	O
protein	O
-	O
ligand	B-FUNC
interaction	O
patterns	O
which	O
would	O
be	O
useful	O
in	O
further	O
structure	O
based	O
design	O
efforts	O
.	O

Because	O
HMGB1	O
is	O
activated	O
through	O
binding	B-FUNC
to	O
interleukin	O
1	O
,	O
and	O
that	O
this	O
cytokine	O
is	O
produced	O
by	O
the	O
NLRP3	O
inflammasome	O
that	O
could	O
be	O
stimulated	O
by	O
uric	O
acid	O
,	O
we	O
propose	O
that	O
both	O
alarmins	O
could	O
be	O
acting	O
in	O
concert	O
with	O
the	O
induction	O
of	O
the	O
autoAb	O
to	O
FAH	O
in	O
MHV	O
-	O
infected	O
mice	O
.	O

TITLE	O
:	O
Soluble	O
endothelial	O
selectin	B-FUNC
in	O
acute	O
lung	O
injury	O
complicated	O
by	O
severe	O
pneumonia	O
.	O

This	O
case	O
suggests	O
that	O
ECMO	O
permits	O
large	O
reductions	O
in	O
lung	O
inflation	O
and	O
ventilation	O
to	O
rest	B-FUNC
the	O
lungs	O
,	O
while	O
maintaining	O
acceptable	O
oxygenation	O
.	O

TITLE	O
:	O
Kidney	O
transplantation	O
from	O
hepatitis	O
B	O
virus	O
core	O
antibody	B-FUNC
-	O
positive	O
donors	O
:	O
prophylaxis	O
with	O
hepatitis	O
B	O
immunoglobulin	B-FUNC
.	O

ABSTRACT	O
:	O
Hepatitis	O
B	O
virus	O
core	O
antibody	B-FUNC
(	O
HBcAb	O
)-	O
positive	O
organ	O
donors	O
have	O
the	O
potential	O
to	O
transmit	O
infection	O
to	O
transplant	O
recipients	O
.	O

Furthermore	O
,	O
PADRE	O
administration	O
amplified	O
the	O
MHV	O
effect	O
,	O
extending	O
the	O
duration	O
of	O
hypergammaglobulinemia	O
and	O
increasing	O
the	O
binding	B-FUNC
of	O
autoAb	O
as	O
well	O
as	O
the	O
degree	O
of	O
hepatic	O
infiltrates	O
.	O

Functional	O
assays	O
identify	O
key	O
residues	O
involved	O
in	O
nsp10	O
/	O
nsp16	O
association	O
,	O
and	O
in	O
RNA	B-FUNC
binding	I-FUNC
or	O
catalysis	O
,	O
the	O
latter	O
likely	O
through	O
a	O
SN2	O
-	O
like	O
mechanism	O
.	O

We	O
present	O
two	O
other	O
crystal	O
structures	O
,	O
the	O
inhibitor	O
Sinefungin	O
bound	O
in	O
the	O
S	O
-	O
adenosylmethionine	O
binding	B-FUNC
pocket	O
and	O
the	O
tighter	O
complex	O
nsp10	O
(	O
Y96F	O
)/	O
nsp16	O
,	O
providing	O
the	O
first	O
structural	O
insight	O
into	O
the	O
regulation	O
of	O
RNA	O
capping	O
enzymes	O
in	O
+	O
RNA	O
viruses	O
.	O

A	O
clinical	O
diagnosis	O
of	O
ACS	B-FUNC
was	O
made	O
.	O

Life	O
-	O
threatening	O
delayed	O
retroperitoneal	O
bleeding	O
may	O
occur	O
suddenly	O
two	O
weeks	O
after	O
trauma	O
causing	O
ACS	B-FUNC
.	O

ABSTRACT	O
:	O
Africa	O
,	O
as	O
the	O
rest	B-FUNC
of	O
the	O
world	O
,	O
was	O
touched	O
by	O
the	O
2009	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
).	O

TITLE	O
:	O
Synthesis	O
of	O
enantiomerically	O
pure	B-FUNC
D	O
-	O
and	O
L	O
-	O
bicyclo	O
[	O
3	O
.	O
1	O
.	O
0	O
]	O
hexenyl	O
carbanucleosides	O
and	O
their	O
antiviral	O
evaluation	O
.	O

For	O
the	O
first	O
time	O
in	O
this	O
condition	O
,	O
we	O
used	O
venovenous	O
ECMO	O
management	O
,	O
to	O
rest	B-FUNC
the	O
lung	O
,	O
sustain	O
blood	O
oxygenation	O
and	O
end	O
-	O
organ	O
oxygen	O
delivery	O
,	O
and	O
promote	O
potential	O
lung	O
recovery	O
.	O

However	O
,	O
trypsin	O
treatment	O
of	O
viruses	O
before	O
receptor	B-FUNC
binding	I-FUNC
did	O
not	O
enhance	O
infectivity	O
,	O
indicating	O
that	O
receptor	B-FUNC
binding	I-FUNC
is	O
essentially	O
required	O
for	O
trypsin	O
-	O
mediated	O
entry	O
upon	O
PEDV	O
infection	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
PEDV	O
S	O
protein	O
may	O
undergo	O
a	O
conformational	O
change	O
after	O
receptor	B-FUNC
binding	I-FUNC
and	O
cleavage	O
by	O
exogenous	O
trypsin	O
,	O
which	O
induces	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
mouse	O
coronavirus	O
receptor	O
-	O
binding	B-FUNC
domain	O
complexed	O
with	O
its	O
murine	O
receptor	O
.	O

Mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
uses	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
its	O
spike	O
protein	O
as	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
.	O

Despite	O
its	O
galectin	O
fold	O
,	O
MHV	O
NTD	O
does	O
not	O
bind	B-FUNC
sugars	O
,	O
but	O
instead	O
binds	B-FUNC
mCEACAM1a	O
through	O
exclusive	O
protein	O
-	O
protein	O
interactions	O
.	O

Structural	O
analysis	O
and	O
mutagenesis	O
localize	O
the	O
sugar	O
-	O
binding	B-FUNC
site	O
in	O
coronavirus	O
NTDs	O
to	O
be	O
above	O
the	O
	O
-	O
sandwich	O
core	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
a	O
frequent	O
cause	O
of	O
morbidity	O
and	O
leading	O
cause	O
of	O
death	O
among	O
individuals	O
with	O
sickle	O
cell	O
disease	O
.	O

Yet	O
,	O
ACS	B-FUNC
in	O
hemoglobin	O
SC	O
disease	O
is	O
not	O
well	O
characterized	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
presentation	O
and	O
clinical	O
course	O
of	O
ACS	B-FUNC
in	O
individuals	O
with	O
hemoglobin	O
SC	O
disease	O
to	O
that	O
observed	O
in	O
individuals	O
with	O
hemoglobin	O
SS	O
disease	O
.	O

Continuous	O
and	O
categorical	O
data	O
from	O
index	O
cases	O
were	O
compared	O
with	O
that	O
from	O
71	O
control	O
cases	O
of	O
ACS	B-FUNC
in	O
patients	O
with	O
hemoglobin	O
SS	O
disease	O
.	O

ACS	B-FUNC
appears	O
to	O
be	O
less	O
severe	O
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
compared	O
to	O
that	O
in	O
children	O
with	O
SS	O
disease	O
.	O

Asthma	O
and	O
wheezing	O
may	O
represent	O
more	O
significant	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ACS	B-FUNC
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
.	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	B-FUNC
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	O
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	O
SC	O
and	O
SS	O
episodes	O
of	O
ACS	B-FUNC
.	O

Blood	O
tests	O
,	O
including	O
complete	O
blood	O
count	O
,	O
protein	O
C	O
,	O
protein	O
S	O
,	O
antithrombin	O
III	O
,	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
,	O
immunologic	O
and	O
antibody	B-FUNC
profiles	O
were	O
normal	O
.	O

In	O
fact	O
,	O
pull	O
-	O
down	O
assays	O
demonstrated	O
the	O
interaction	O
between	O
TGEV	O
protein	O
7	O
,	O
but	O
not	O
a	O
protein	O
7	O
mutant	O
lacking	O
PP1c	O
binding	B-FUNC
motif	O
,	O
with	O
PP1	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
avian	O
coronavirus	O
spike	O
proteins	O
to	O
host	O
factors	O
reflects	O
virus	O
tropism	O
and	O
pathogenicity	O
.	O

Protein	O
histochemistry	O
showed	O
that	O
S1	O
of	O
IBV	O
strain	O
M41	O
and	O
HA	O
of	O
IAV	O
subtype	O
H5N1	O
displayed	O
sialic	O
acid	O
-	O
dependent	O
binding	B-FUNC
to	O
chicken	O
respiratory	O
tract	O
tissue	O
.	O

While	O
the	O
S1	O
protein	O
derived	O
from	O
the	O
nephropathogenic	O
IBV	O
strain	O
B1648	O
also	O
hardly	O
displayed	O
binding	B-FUNC
to	O
respiratory	O
tract	O
cells	O
,	O
distinct	O
binding	B-FUNC
to	O
kidney	O
cells	O
was	O
observed	O
,	O
but	O
only	O
after	O
the	O
removal	O
of	O
sialic	O
acid	O
from	O
S1	O
.	O

The	O
S	O
protein	O
is	O
a	O
type	O
I	O
membrane	O
glycoprotein	O
located	O
in	O
the	O
viral	O
envelope	O
and	O
is	O
responsible	O
for	O
mediating	O
the	O
binding	B-FUNC
of	O
viral	O
particles	O
to	O
specific	O
cell	O
receptors	O
and	O
therefore	O
specific	O
cell	O
types	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
subgenomic	O
mRNA	O
(	O
sgmRNA	O
)	O
transcription	O
requires	O
a	O
discontinuous	O
RNA	O
synthesis	O
mechanism	O
driven	O
by	O
the	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
),	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
genomic	O
leader	O
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
also	O
preceding	O
each	O
gene	O
(	O
TRS	B-FUNC
-	O
B	O
).	O

In	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
the	O
free	O
energy	O
of	O
TRS	B-FUNC
-	O
L	O
and	O
cTRS	O
-	O
B	O
(	O
complement	O
of	O
TRS	B-FUNC
-	O
B	O
)	O
duplex	O
formation	O
is	O
one	O
of	O
the	O
factors	O
regulating	O
the	O
transcription	O
of	O
sgmRNAs	O
.	O

Relocation	O
of	O
the	O
active	O
domain	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	B-FUNC
core	O
sequence	O
in	O
the	O
absence	O
of	O
the	O
proximal	O
and	O
distal	O
elements	O
also	O
enhanced	O
sgmRNA	O
N	O
transcription	O
.	O

TITLE	O
:	O
P2Y	B-FUNC
receptors	O
as	O
regulators	O
of	O
lung	O
endothelial	O
barrier	O
integrity	O
.	O

It	O
is	O
now	O
well	O
accepted	O
that	O
extracellular	O
purines	O
and	O
pyrimidines	O
are	O
promising	O
and	O
physiologically	O
relevant	O
barrier	O
-	O
protective	O
agents	O
and	O
their	O
effects	O
are	O
mediated	O
by	O
interaction	O
with	O
cell	O
surface	O
P2Y	B-FUNC
receptors	O
which	O
belong	O
to	O
the	O
superfamily	O
of	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
.	O

The	O
therapeutic	O
potential	O
of	O
P2Y	B-FUNC
receptors	O
is	O
rapidly	O
expanding	O
field	O
in	O
pharmacology	O
and	O
some	O
selective	O
agonists	O
became	O
recently	O
available	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
susceptibility	O
to	O
bovine	O
tuberculosis	O
(	O
bTB	O
),	O
and	O
the	O
prevalence	O
of	O
antibody	B-FUNC
to	O
feline	O
viruses	O
of	O
native	O
lions	O
,	O
and	O
compared	O
the	O
findings	O
with	O
those	O
from	O
translocated	O
outbred	O
lions	O
and	O
their	O
offspring	O
.	O

Antibodies	O
to	O
feline	O
herpesvirus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
parvovirus	O
,	O
and	O
feline	O
coronavirus	O
were	O
present	O
in	O
the	O
lion	O
population	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
antibody	B-FUNC
prevalence	O
between	O
native	O
and	O
translocated	O
lions	O
and	O
their	O
offspring	O
,	O
and	O
these	O
feline	O
viruses	O
did	O
not	O
appear	O
to	O
have	O
an	O
effect	O
on	O
the	O
clinical	O
health	O
of	O
HiP	O
lions	O
.	O

Within	O
7	O
yr	O
,	O
the	O
prevalence	O
of	O
antibody	B-FUNC
to	O
FIV	O
increased	O
up	O
to	O
42	O
%.	O

A	O
2	O
-	O
dimensional	O
Doppler	O
echocardiogram	O
showed	O
a	O
dilated	O
and	O
poorly	O
contractile	B-FUNC
left	O
ventricle	O
,	O
severe	O
aortic	O
regurgitation	O
,	O
and	O
a	O
large	O
aneurysm	O
of	O
the	O
sinus	O
of	O
Valsalva	O
.	O

TITLE	O
:	O
Quasi	O
-	O
life	O
self	O
-	O
organizing	O
systems	O
:	O
based	O
on	O
ensembles	O
of	O
succinylated	O
derivatives	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
.	O

TITLE	O
:	O
The	O
NS1	O
glycoprotein	O
can	O
generate	O
dramatic	O
antibody	B-FUNC
-	O
enhanced	O
dengue	O
viral	O
replication	O
in	O
normal	O
out	O
-	O
bred	O
mice	O
resulting	O
in	O
lethal	O
multi	O
-	O
organ	O
disease	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
expression	O
of	O
the	O
prominent	O
CsA	O
targets	O
cyclophilin	B-FUNC
A	O
and	O
B	O
did	O
not	O
affect	O
SARS	O
-	O
CoV	O
replication	O
,	O
suggesting	O
either	O
that	O
these	O
specific	O
cyclophilin	B-FUNC
family	O
members	O
are	O
dispensable	O
or	O
that	O
the	O
reduced	O
expression	O
levels	O
suffice	O
to	O
support	O
replication	O
.	O

We	O
wished	O
to	O
determine	O
the	O
potential	O
for	O
pulmonary	O
overexpression	O
of	O
the	O
extracellular	O
isoform	O
of	O
superoxide	O
dismutase	O
(	O
EC	O
-	O
SOD	B-FUNC
)	O
to	O
reduce	O
the	O
severity	O
of	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
.	O

Animals	O
were	O
randomly	O
allocated	O
to	O
undergo	O
intratracheal	O
instillation	O
of	O
(	O
1	O
)	O
surfactant	O
alone	O
(	O
vehicle	O
);	O
(	O
2	O
)	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
vectors	O
containing	O
a	O
null	O
transgene	O
(	O
AAV	O
-	O
null	O
);	O
and	O
(	O
3	O
)	O
adeno	O
-	O
associated	O
virus	O
vectors	O
containing	O
the	O
EC	O
-	O
SOD	B-FUNC
transgene	O
(	O
AAV	O
-	O
EC	O
-	O
SOD	B-FUNC
)	O
and	O
endotoxin	O
was	O
subsequently	O
administered	O
intratracheally	O
.	O

Two	O
additional	O
groups	O
were	O
randomized	O
to	O
receive	O
(	O
1	O
)	O
vehicle	O
or	O
(	O
2	O
)	O
AAV	O
-	O
EC	O
-	O
SOD	B-FUNC
,	O
and	O
to	O
undergo	O
sham	O
(	O
vehicle	O
)	O
injury	O
.	O

The	O
AAV	O
vector	O
encoding	O
EC	O
-	O
SOD	B-FUNC
increased	O
lung	O
EC	O
-	O
SOD	B-FUNC
concentrations	O
,	O
and	O
enhanced	O
the	O
antioxidant	O
capacity	O
of	O
the	O
lung	O
.	O

EC	O
-	O
SOD	B-FUNC
overexpression	O
decreased	O
the	O
severity	O
of	O
endotoxin	O
-	O
induced	O
ALI	O
,	O
reducing	O
the	O
decrement	O
in	O
systemic	O
oxygenation	O
and	O
lung	O
compliance	O
,	O
decreasing	O
lung	O
permeability	O
and	O
decreasing	O
histologic	O
injury	O
.	O

EC	O
-	O
SOD	B-FUNC
attenuated	O
pulmonary	O
inflammation	O
,	O
decreased	O
bronchoalveolar	O
lavage	O
neutrophil	O
counts	O
,	O
and	O
reduced	O
interleukin	O
-	O
6	O
and	O
CINC	O
-	O
1	O
concentrations	O
.	O

Pulmonary	O
overexpression	O
of	O
EC	O
-	O
SOD	B-FUNC
protects	O
the	O
lung	O
against	O
endotoxin	O
-	O
induced	O
ALI	O
.	O

To	O
this	O
end	O
,	O
RdRp	B-FUNC
sequence	O
of	O
Coronavirinae	O
was	O
targeted	O
by	O
RT	O
-	O
PCR	O
in	O
non	O
-	O
invasive	O
samples	O
from	O
bats	O
collected	O
in	O
Thailand	O
.	O

Phylogenetic	O
analysis	O
of	O
a	O
conserved	O
CoV	O
genome	O
region	O
(	O
RdRp	B-FUNC
gene	O
)	O
shows	O
a	O
wide	O
diversity	O
and	O
distribution	O
of	O
alpha	O
and	O
betacoronavirus	O
in	O
Spain	O
.	O

We	O
detected	O
anti	O
-	O
HCoV	O
-	O
NL63	O
antibodies	O
among	O
50	O
sera	B-FUNC
samples	O
collected	O
from	O
adult	O
for	O
health	O
-	O
examination	O
by	O
WBLA	O
.	O

The	O
results	O
showed	O
that	O
:	O
25	O
(	O
50	O
%),	O
27	O
(	O
54	O
%),	O
36	O
(	O
72	O
%)	O
of	O
50	O
sera	B-FUNC
were	O
indentified	O
as	O
anti	O
-	O
HCoV	O
-	O
NL63	O
antibody	B-FUNC
positive	O
when	O
the	O
antigen	O
was	O
from	O
Nf	O
,	O
Np	O
and	O
Cp	O
,	O
respectively	O
.	O

Among	O
these	O
sera	B-FUNC
with	O
positive	O
anti	O
-	O
HCoV	O
-	O
NL63	O
antibody	B-FUNC
,	O
Cp	O
showed	O
highest	O
antibody	B-FUNC
positive	O
rate	O
in	O
WBLA	O
,	O
and	O
consistent	O
rates	O
of	O
detection	O
were	O
64	O
%	O
between	O
Nf	O
and	O
Np	O
,	O
54	O
%	O
between	O
Nf	O
and	O
Cp	O
,	O
54	O
%	O
between	O
Np	O
and	O
Cp	O
.	O

ABSTRACT	O
:	O
More	O
than	O
a	O
decade	O
ago	O
,	O
three	O
viral	O
oncoproteins	O
,	O
adenovirus	O
type	O
9	O
E4	O
-	O
ORF1	O
,	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
1	O
Tax	O
,	O
and	O
high	O
-	O
risk	O
human	O
papillomavirus	O
E6	O
,	O
were	O
found	O
to	O
encode	O
a	O
related	O
carboxyl	O
-	O
terminal	O
PDZ	O
domain	O
-	O
binding	B-FUNC
motif	O
(	O
PBM	O
)	O
that	O
mediates	O
interactions	O
with	O
a	O
select	O
group	O
of	O
cellular	O
PDZ	O
proteins	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
many	O
other	O
viruses	O
also	O
encode	O
PBM	O
-	O
containing	O
proteins	O
that	O
bind	B-FUNC
to	O
cellular	O
PDZ	O
proteins	O
.	O

Examination	O
of	O
the	O
cellular	O
PDZ	O
proteins	O
that	O
are	O
targets	O
of	O
viral	O
PBMs	O
reveals	O
that	O
the	O
viral	O
proteins	O
often	O
interact	O
with	O
the	O
same	O
or	O
similar	O
types	O
of	O
PDZ	O
proteins	O
,	O
most	O
notably	O
Dlg1	O
and	O
other	O
members	O
of	O
the	O
membrane	B-FUNC
-	I-FUNC
associated	I-FUNC
guanylate	I-FUNC
kinase	I-FUNC
protein	O
family	O
,	O
as	O
well	O
as	O
Scribble	O
.	O

Antibody	B-FUNC
-	O
mediated	O
infection	O
was	O
dependent	O
on	O
Fc	O
receptor	O
II	O
but	O
did	O
not	O
use	O
the	O
endosomal	O
/	O
lysosomal	O
pathway	O
utilized	O
by	O
angiotensin	O
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
accepted	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
This	O
suggests	O
that	O
ADE	O
of	O
SARS	O
-	O
CoV	O
utilizes	O
a	O
novel	O
cell	O
entry	O
mechanism	O
into	O
immune	O
cells	O
.	O

Tracer	O
gas	O
was	O
continuously	O
released	O
from	O
a	O
point	O
source	O
located	O
at	O
different	O
positions	O
,	O
and	O
a	O
time	O
series	O
of	O
fluctuating	O
concentrations	O
were	O
recorded	O
at	O
a	O
large	O
number	O
of	O
points	O
using	O
fast	B-FUNC
flame	O
ionization	O
detectors	O
.	O

Levels	O
of	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
interleukin	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
and	O
interleukin	O
1	O
beta	O
(	O
IL	O
-	O
1	O
)	O
were	O
meassured	O
in	O
these	O
samples	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

Our	O
results	O
support	O
previous	O
findings	O
which	O
suggest	O
that	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
serum	O
somehow	O
participate	O
in	O
the	O
inflammatory	O
response	O
in	O
severe	O
cases	O
of	O
pandemic	O
influenza	O
pneumonia	O
.	O

TITLE	O
:	O
Under	O
-	O
three	O
minute	O
PCR	O
:	O
probing	O
the	O
limits	O
of	O
fast	B-FUNC
amplification	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
spike	O
protein	O
of	O
human	O
coronavirus	O
NL63	O
in	O
receptor	B-FUNC
binding	I-FUNC
and	O
pseudotype	O
virus	O
entry	O
.	O

We	O
have	O
previously	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
and	O
residues	O
important	O
for	O
RBD	O
-	O
hACE2	O
association	O
.	O

Here	O
,	O
we	O
further	O
characterized	O
the	O
S	O
protein	O
by	O
investigating	O
the	O
roles	O
of	O
the	O
cytoplasmic	O
tail	O
and	O
19	O
residues	O
located	O
in	O
the	O
RBD	O
in	O
protein	O
accumulation	O
,	O
receptor	B-FUNC
binding	I-FUNC
,	O
and	O
pseudotype	O
virus	O
entry	O
.	O

They	O
probably	O
form	O
three	O
receptor	B-FUNC
binding	I-FUNC
motifs	O
,	O
and	O
the	O
third	O
motif	O
is	O
conserved	O
between	O
NL63	O
and	O
SARS	O
-	O
CoV	O
.	O

Combining	O
structure	O
-	O
based	O
virtual	O
screening	O
and	O
experimental	O
approaches	O
,	O
we	O
identified	O
four	O
molecules	O
that	O
specifically	O
inhibited	O
the	O
catalytic	B-FUNC
activity	I-FUNC
of	O
XendoU	O
and	O
PP11	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
pain	O
or	O
ACS	B-FUNC
rate	O
,	O
lung	O
function	O
,	O
or	O
risk	O
of	O
death	O
between	O
adults	O
with	O
and	O
without	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	O
.	O

In	O
contrast	O
,	O
adults	O
who	O
reported	O
recurrent	O
,	O
severe	O
episodes	O
of	O
wheezing	O
(	O
N	O
=	O
34	O
),	O
regardless	O
of	O
asthma	O
,	O
had	O
twice	O
the	O
rates	O
of	O
pain	O
and	O
ACS	B-FUNC
,	O
decreased	O
lung	O
function	O
and	O
increased	O
risk	O
of	O
death	O
compared	O
with	O
adults	O
without	O
recurrent	O
,	O
severe	O
wheezing	O
.	O

Furthermore	O
,	O
ELISA	O
performed	O
using	O
these	O
peptides	O
was	O
more	O
sensitive	O
than	O
commercial	O
ELISA	O
used	O
for	O
a	O
screening	O
sera	B-FUNC
from	O
mice	O
infected	O
accidentally	O
to	O
MHV	O
maintained	O
in	O
cages	O
,	O
suggesting	O
that	O
these	O
peptides	O
are	O
useful	O
for	O
serological	O
diagnosis	O
of	O
MHV	O
infection	O
.	O

They	O
were	O
able	O
to	O
degranulate	O
and	O
produce	O
gamma	O
interferon	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
and	O
macrophage	O
inflammatory	O
proteins	O
1	O
and	O
1	O
after	O
antigenic	O
stimulation	O
.	O

Bacteria	O
were	O
cultured	O
from	O
nasopharyngeal	O
swabs	O
and	O
seroconversion	O
against	O
viruses	O
and	O
Mycoplasma	O
bovis	O
was	O
determined	O
on	O
paired	O
sera	B-FUNC
.	O

Expression	O
of	O
l	O
-	O
selectin	B-FUNC
,	O
CXCR2	O
and	O
C5aR	O
was	O
partially	O
restored	O
at	O
24	O
h	O
after	O
injury	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
avian	O
influenza	O
virus	O
,	O
infectious	O
bronchitis	O
virus	O
,	O
and	O
Newcastle	O
disease	O
virus	O
among	O
domestic	O
and	O
wild	O
birds	O
in	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
)	O
H5N1	O
outbreaks	O
areas	O
.	O

In	O
a	O
standard	O
case	O
-	O
report	O
form	O
,	O
we	O
collected	O
epidemiological	O
characteristics	O
,	O
results	O
of	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
--	O
polymerase	O
-	O
chain	O
-	O
reaction	O
viral	O
diagnostic	O
tests	O
,	O
oxygenation	O
variables	O
,	O
acid	O
-	O
base	O
status	O
,	O
respiratory	O
mechanics	O
,	O
ventilation	O
management	O
and	O
laboratory	O
tests	O
.	O

Twenty	O
-	O
nine	O
HCoV	O
-	O
OC43	O
strains	O
from	O
nasopharyngeal	O
aspirates	O
,	O
collected	O
from	O
2004	O
to	O
2011	O
,	O
were	O
subjected	O
to	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
spike	O
,	O
and	O
nucleocapsid	O
gene	O
analysis	O
.	O

Phylogenetic	O
analysis	O
showed	O
at	O
least	O
three	O
distinct	O
clusters	O
of	O
HCoV	O
-	O
OC43	O
,	O
although	O
10	O
unusual	O
strains	O
displayed	O
incongruent	O
phylogenetic	O
positions	O
between	O
RdRp	B-FUNC
and	O
spike	O
genes	O
.	O

The	O
following	O
results	O
were	O
obtained	O
:	O
pressure	O
catecholamine	O
index	O
significantly	O
decreased	O
at	O
3	O
h	O
after	O
initiation	O
of	O
septic	O
shock	O
,	O
PaO	O
(	O
2	O
)/	O
F	O
(	O
IO2	O
)	O
significantly	O
increased	O
at	O
1	O
h	O
after	O
initiation	O
of	O
septic	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
a	O
significant	O
decrease	O
in	O
interleukin	O
(	O
IL	O
)-	O
6	O
level	O
for	O
3	O
days	O
was	O
observed	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
effectively	O
adsorbed	O
in	O
one	O
pass	O
through	O
the	O
filter	O
.	O

These	O
results	O
may	O
help	O
in	O
designing	O
gene	O
delivery	O
systems	O
capable	O
of	O
binding	B-FUNC
the	O
minimum	O
possible	O
quantity	O
of	O
proteins	O
that	O
influence	O
transfection	O
negatively	O
,	O
binding	B-FUNC
selectively	O
proteins	O
capable	O
of	O
helping	O
in	O
steering	O
in	O
vivo	O
the	O
vector	O
toward	O
the	O
target	O
,	O
and	O
obtaining	O
more	O
efficient	O
and	O
effective	O
gene	O
therapy	O
.	O

Two	O
primer	O
sets	O
were	O
used	O
for	O
the	O
detection	O
of	O
BtCoV	O
:	O
one	O
was	O
for	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
region	O
and	O
the	O
other	O
was	O
for	O
the	O
spike	O
(	O
S	O
)	O
protein	O
region	O
.	O

Eleven	O
and	O
73	O
%	O
of	O
intestinal	O
and	O
fecal	O
specimens	O
,	O
respectively	O
,	O
were	O
positive	O
for	O
RdRp	B-FUNC
region	O
,	O
and	O
2	O
and	O
40	O
%	O
of	O
those	O
were	O
positive	O
for	O
S	O
protein	O
region	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
often	O
exhale	O
along	O
the	O
same	O
flow	O
-	O
volume	O
curve	O
during	O
quiet	O
breathing	O
as	O
they	O
do	O
during	O
the	O
forced	O
expiratory	O
vital	O
capacity	O
manoeuvre	O
,	O
and	O
this	O
has	O
been	O
taken	O
as	O
an	O
indicator	O
of	O
expiratory	O
flow	O
limitation	O
at	O
rest	B-FUNC
(	O
EFL	O
(	O
T	O
)).	O

Further	O
analysis	O
suggested	O
that	O
LF	O
was	O
able	O
to	O
block	O
the	O
binding	B-FUNC
of	O
spike	O
protein	O
to	O
host	O
cells	O
at	O
4	O
	O
C	O
,	O
indicating	O
that	O
LF	O
exerted	O
its	O
inhibitory	O
function	O
at	O
the	O
viral	O
attachment	O
stage	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
heparinase	O
or	O
exogenous	O
heparin	O
prevented	O
binding	B-FUNC
of	O
spike	O
protein	O
to	O
host	O
cells	O
and	O
inhibited	O
SARS	O
pseudovirus	O
infection	O
,	O
demonstrating	O
that	O
HSPGs	O
provide	O
the	O
binding	B-FUNC
sites	O
for	O
SARS	O
-	O
CoV	O
invasion	O
at	O
the	O
early	O
attachment	O
phase	O
.	O

LF	O
may	O
play	O
a	O
protective	O
role	O
in	O
host	O
defense	O
against	O
SARS	O
-	O
CoV	O
infection	O
through	O
binding	B-FUNC
to	O
HSPGs	O
and	O
blocking	O
the	O
preliminary	O
interaction	O
between	O
SARS	O
-	O
CoV	O
and	O
host	O
cells	O
.	O

Some	O
patients	O
needed	O
ventilatory	O
support	O
due	O
to	O
severe	O
neurological	O
complications	O
,	O
which	O
arose	O
1	O
week	O
after	O
onset	O
of	O
enteritis	O
,	O
suggesting	O
an	O
antibody	B-FUNC
-	O
mediated	O
mechanism	O
.	O

A	O
mutation	O
in	O
tRNA	B-FUNC
(	O
Lys	O
)	O
that	O
causes	O
myoclonic	O
epilepsy	O
with	O
ragged	O
-	O
red	O
fibers	O
(	O
MERRF	O
)	O
is	O
also	O
reported	O
to	O
prevent	O
modification	O
of	O
the	O
wobble	O
U	O
.	O
Here	O
we	O
show	O
that	O
mitochondrial	O
translation	O
is	O
unaffected	O
in	O
fibroblasts	O
from	O
an	O
MTU1	O
patient	O
,	O
in	O
which	O
MTU1	O
is	O
undetectable	O
by	O
immunoblotting	O
,	O
despite	O
the	O
severe	O
reduction	O
in	O
the	O
2	O
-	O
thiolation	O
of	O
mitochondrial	O
tRNA	B-FUNC
(	O
Lys	O
),	O
tRNA	B-FUNC
(	O
Glu	O
)	O
and	O
tRNA	B-FUNC
(	O
Gln	O
).	O

The	O
only	O
respiratory	O
chain	O
abnormality	O
that	O
we	O
could	O
observe	O
in	O
these	O
cells	O
was	O
an	O
accumulation	O
of	O
a	O
Complex	B-FUNC
II	I-FUNC
assembly	O
intermediate	O
,	O
which	O
,	O
however	O
,	O
did	O
not	O
affect	O
the	O
level	O
of	O
the	O
fully	O
assembled	O
enzyme	O
.	O

In	O
the	O
Guangzhou	O
cohort	O
study	O
,	O
after	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
two	O
AHSG	O
SNPs	O
and	O
one	O
CYP4F3	O
SNP	O
were	O
found	O
to	O
be	O
associated	O
with	O
SARS	O
susceptibility	O
:	O
rs2248690	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-FUNC
]	O
2	O
.	O
42	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
30	O
-	O
4	O
.	O
51	O
);	O
rs4917	O
(	O
AOR	B-FUNC
1	O
.	O
84	O
;	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
3	O
.	O
34	O
);	O
and	O
rs3794987	O
(	O
AOR	B-FUNC
2	O
.	O
01	O
;	O
95	O
%	O
CI	O
1	O
.	O
10	O
-	O
3	O
.	O
68	O
).	O

The	O
combined	O
analysis	O
of	O
the	O
two	O
studies	O
confirmed	O
tag	O
SNP	O
rs2248690	O
in	O
AHSG	O
as	O
a	O
susceptibility	O
variant	O
(	O
AOR	B-FUNC
1	O
.	O
70	O
;	O
95	O
%	O
CI	O
1	O
.	O
37	O
-	O
2	O
.	O
09	O
).	O

However	O
,	O
several	O
hmAbs	O
that	O
can	O
bind	B-FUNC
to	O
epitopes	O
either	O
within	O
the	O
RBD	O
,	O
located	O
N	O
terminal	O
of	O
the	O
RBD	O
or	O
in	O
the	O
S2	O
domain	O
,	O
and	O
neutralize	O
the	O
virus	O
with	O
or	O
without	O
inhibiting	O
receptor	B-FUNC
binding	I-FUNC
have	O
been	O
identified	O
.	O

These	O
results	O
suggest	O
that	O
a	O
cocktail	O
of	O
hmAbs	O
that	O
can	O
bind	B-FUNC
to	O
unique	O
epitopes	O
and	O
have	O
different	O
mechanisms	O
of	O
action	O
might	O
be	O
of	O
clinical	O
utility	O
against	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
indicate	O
that	O
a	O
similar	O
approach	O
may	O
be	O
applied	O
to	O
treat	O
other	O
viral	O
infections	O
.	O

TITLE	O
:	O
The	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
the	O
S	O
protein	O
facilitates	O
infection	O
by	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
effect	O
of	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
for	O
the	O
infection	O
of	O
cultured	O
cells	O
under	O
unfavorable	O
conditions	O
,	O
and	O
comparison	O
of	O
TGEV	O
strains	O
and	O
mutants	O
,	O
as	O
well	O
as	O
the	O
avian	O
coronavirus	O
IBV	O
concerning	O
their	O
dependence	O
on	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
.	O

A	O
TGEV	O
PUR46	O
mutant	O
(	O
HAD3	O
)	O
deficient	O
in	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
showed	O
a	O
77	O
%	O
lower	O
titer	O
than	O
the	O
parental	O
virus	O
after	O
a	O
5	O
min	O
adsorption	O
time	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
facilitates	O
the	O
infection	O
by	O
TGEV	O
under	O
unfavorable	O
environmental	O
conditions	O
.	O

The	O
dependence	O
on	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
for	O
an	O
efficient	O
infection	O
differs	O
in	O
the	O
analyzed	O
TGEV	O
strains	O
.	O

The	O
primary	O
endpoint	O
occurred	O
in	O
271	O
PAC	O
patients	O
versus	O
196	O
without	O
PAC	O
(	O
21	O
.	O
3	O
%	O
vs	O
.	O
15	O
.	O
4	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-FUNC
],	O
1	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
24	O
to	O
2	O
.	O
26	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
PAC	O
group	O
had	O
an	O
increased	O
risk	O
of	O
all	O
-	O
cause	O
mortality	O
,	O
3	O
.	O
5	O
%	O
vs	O
1	O
.	O
7	O
%	O
(	O
AOR	B-FUNC
,	O
2	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
to	O
3	O
.	O
88	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
an	O
increased	O
risk	O
of	O
cardiac	O
(	O
AOR	B-FUNC
,	O
1	O
.	O
58	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
14	O
to	O
2	O
.	O
20	O
;	O
P	O
=	O
0	O
.	O
007	O
),	O
cerebral	O
(	O
AOR	B-FUNC
,	O
2	O
.	O
02	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
08	O
to	O
3	O
.	O
77	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
renal	O
(	O
AOR	B-FUNC
,	O
2	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
68	O
to	O
3	O
.	O
62	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
morbid	O
outcomes	O
.	O

Use	O
of	O
PAC	O
was	O
also	O
associated	O
with	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
(	O
14	O
.	O
5	O
%	O
vs	O
10	O
.	O
1	O
%;	O
AOR	B-FUNC
,	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
to	O
2	O
.	O
27	O
;	O
P	O
=	O
0	O
.	O
02	O
).	O

Use	O
of	O
PAC	O
was	O
also	O
associated	O
with	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
(	O
14	O
.	O
5	O
%	O
vs	O
10	O
.	O
1	O
%;	O
AOR	B-FUNC
,	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
to	O
2	O
.	O
27	O
;	O
P	O
=	O
0	O
.	O
02	O
).	O

Suppression	O
of	O
the	O
ATR	O
kinase	B-FUNC
activity	I-FUNC
by	O
chemical	O
inhibitors	O
and	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
ATR	O
reduced	O
the	O
IBV	O
-	O
induced	O
ATR	O
signaling	O
and	O
inhibited	O
the	O
replication	O
of	O
IBV	O
.	O

TITLE	O
:	O
Annexin	O
A2	O
binds	B-FUNC
RNA	O
and	O
reduces	O
the	O
frameshifting	O
efficiency	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

We	O
first	O
confirmed	O
the	O
binding	B-FUNC
of	O
ANXA2	O
to	O
IBV	O
pseudoknot	O
RNA	O
by	O
ultraviolet	O
crosslinking	O
and	O
showed	O
its	O
binding	B-FUNC
to	O
RNA	O
pseudoknot	O
with	O
ANXA2	O
protein	O
in	O
vitro	O
and	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
an	O
ssDNA	O
aptamer	O
that	O
specifically	O
binds	B-FUNC
to	O
SARS	O
CoV	O
nucleocapsid	O
protein	O
was	O
isolated	O
from	O
a	O
DNA	O
library	O
containing	O
45	O
-	O
nuceotide	O
random	O
sequences	O
in	O
the	O
middle	O
of	O
an	O
88mer	O
single	O
-	O
stranded	O
DNA	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
analysis	O
was	O
then	O
used	O
to	O
identify	O
the	O
aptamer	O
with	O
the	O
highest	O
binding	B-FUNC
affinity	O
to	O
the	O
SARS	O
CoV	O
nucleocapsid	O
protein	O
.	O

Using	O
this	O
approach	O
,	O
an	O
ssDNA	O
aptamer	O
that	O
binds	B-FUNC
to	O
the	O
nucleocapsid	O
protein	O
with	O
a	O
K	O
(	O
d	O
)	O
of	O
4	O
.	O
93	O
	O
0	O
.	O
30nM	O
was	O
identified	O
.	O

Western	O
blot	O
analysis	O
further	O
demonstrated	O
that	O
this	O
ssDNA	O
aptamer	O
could	O
be	O
used	O
to	O
efficiently	O
detect	O
the	O
SARS	O
CoV	O
nucleocapsid	O
protein	O
when	O
compared	O
with	O
a	O
nucleocapsid	O
antibody	B-FUNC
.	O

TITLE	O
:	O
2	O
,	O
6	O
-	O
Bis	B-FUNC
-	O
arylmethyloxy	O
-	O
5	O
-	O
hydroxychromones	O
with	O
antiviral	O
activity	O
against	O
both	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
and	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

In	O
addition	O
,	O
unlike	O
the	O
ADKs	O
which	O
showed	O
selective	O
inhibition	O
against	O
the	O
helicase	B-FUNC
activity	I-FUNC
of	O
the	O
SCV	O
NTPase	O
/	O
helicase	O
,	O
the	O
5	O
-	O
hydroxychromones	O
(	O
5b	O
-	O
5f	O
)	O
were	O
active	O
against	O
both	O
NTPase	O
and	O
helicase	O
activities	O
of	O
the	O
target	O
enzyme	O
.	O

TITLE	O
:	O
Clinical	O
features	O
in	O
a	O
series	O
of	O
fast	B-FUNC
channel	O
congenital	O
myasthenia	O
syndrome	O
.	O

ABSTRACT	O
:	O
Fast	B-FUNC
channel	O
congenital	O
myasthenic	O
syndromes	O
are	O
rare	O
,	O
but	O
frequently	O
result	O
in	O
severe	O
weakness	O
.	O

We	O
report	O
a	O
case	O
of	O
12	O
fast	B-FUNC
channel	O
patients	O
to	O
highlight	O
clinical	O
features	O
and	O
management	O
difficulties	O
.	O

Fast	B-FUNC
channel	O
syndrome	O
contrasted	O
with	O
AChR	O
deficiency	O
in	O
the	O
occurrence	O
of	O
severe	O
respiratory	O
crises	O
in	O
infancy	O
and	O
childhood	O
.	O

A	O
specific	O
therapy	O
by	O
intravenous	O
polyvalent	O
immunoglobulin	B-FUNC
was	O
prescribed	O
for	O
14	O
patients	O
.	O

Although	O
activation	O
of	O
NF	O
-	O
B	O
and	O
Erk	B-FUNC
MAPK	B-FUNC
has	O
been	O
implicated	O
for	O
HSV	O
replication	O
and	O
growth	O
,	O
HCWE	O
showed	O
no	O
effect	O
on	O
HSV	O
-	O
2	O
-	O
induced	O
Erk	B-FUNC
activation	O
.	O

Interleukin	O
(	O
IL	O
)	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
were	O
measured	O
on	O
admission	O
and	O
at	O
days	O
1	O
,	O
2	O
,	O
and	O
14	O
in	O
60	O
patients	O
admitted	O
with	O
first	O
attack	O
of	O
AP	O
.	O

Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

Synchronous	O
measurements	O
of	O
4	O
cytokines	O
demonstrated	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
to	O
be	O
predictive	O
as	O
early	O
surrogate	O
markers	O
with	O
regard	O
to	O
organ	O
failures	O
in	O
AP	O
.	O

RESULTS	O
:	O
Interleukin	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
developed	O
renal	O
,	O
respiratory	O
,	O
and	O
circulatory	O
failure	O
,	O
as	O
was	O
the	O
case	O
for	O
patients	O
with	O
multiorgan	O
failure	O
.	O

Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
dual	O
-	O
specificity	O
phosphatase	B-FUNC
1	O
feedback	O
loop	O
modulates	O
the	O
induction	O
of	O
interleukin	O
6	O
and	O
8	O
in	O
cells	O
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
cellular	O
mechanisms	O
exploited	O
by	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
to	O
regulate	O
the	O
induction	O
of	O
two	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
results	O
showed	O
that	O
IBV	O
infection	O
of	O
cultured	O
human	O
and	O
animal	O
cells	O
activated	O
the	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
pathway	O
and	O
induced	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

Meanwhile	O
,	O
IBV	O
has	O
developed	O
a	O
strategy	O
to	O
counteract	O
the	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
by	O
inducing	O
the	O
expression	O
of	O
dual	O
-	O
specificity	O
phosphatase	B-FUNC
1	O
(	O
DUSP1	O
),	O
a	O
negative	O
regulator	O
of	O
the	O
p38	B-FUNC
MAPK	B-FUNC
,	O
in	O
order	O
to	O
limit	O
the	O
production	O
of	O
an	O
excessive	O
amount	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
infected	O
cells	O
.	O

As	O
activation	O
of	O
the	O
p38	B-FUNC
MAPK	B-FUNC
pathway	O
and	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
may	O
have	O
multiple	O
pathogenic	O
effects	O
on	O
the	O
whole	O
host	O
as	O
well	O
as	O
on	O
individual	O
infected	O
cells	O
,	O
regulation	O
of	O
the	O
p38	B-FUNC
MAPK	B-FUNC
and	O
DUSP1	O
feedback	O
loop	O
by	O
IBV	O
may	O
modulate	O
the	O
pathogenesis	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
boosts	O
proinflammatory	O
outcome	O
of	O
antiviral	O
response	O
in	O
human	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
commonly	O
produced	O
during	O
viral	O
infection	O
specifically	O
augments	O
a	O
proinflammatory	O
response	O
by	O
directly	O
synergizing	O
with	O
antiviral	O
signaling	O
.	O

Costimulation	O
of	O
primary	O
human	O
fibroblasts	O
with	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
greatly	O
enhanced	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
or	O
synthetic	O
dsRNA	O
-	O
based	O
viral	O
mimic	O
polyinosinic	O
:	O
polycytidylic	O
acid	O
-	O
induced	O
expression	O
of	O
proinflammatory	O
genes	O
without	O
affecting	O
expression	O
of	O
IFN	O
-	O
	O
-	O
stimulated	O
or	O
IFN	O
-	O
stimulated	O
genes	O
.	O

These	O
findings	O
shed	O
light	O
on	O
the	O
molecular	O
mechanisms	O
behind	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
dependent	O
immunopathology	O
observed	O
in	O
viral	O
infections	O
.	O

Here	O
,	O
we	O
show	O
that	O
APE1	O
cleaves	O
RNA	O
in	O
the	O
absence	O
of	O
divalent	O
metal	O
ions	O
and	O
,	O
at	O
2	O
mM	O
,	O
Zn	O
(	O
2	O
+),	O
Ni	O
(	O
2	O
+),	O
Cu	O
(	O
2	O
+),	O
or	O
Co	O
(	O
2	O
+)	O
inhibited	O
the	O
endoribonuclease	B-FUNC
activity	I-FUNC
of	O
APE1	O
.	O

The	O
protease	O
cleavage	O
site	O
in	O
S	O
protein	O
is	O
thought	O
to	O
be	O
exposed	O
only	O
after	O
receptor	B-FUNC
binding	I-FUNC
.	O

TITLE	O
:	O
Comparison	O
of	O
SARS	O
and	O
NL63	O
papain	O
-	O
like	O
protease	B-FUNC
binding	I-FUNC
sites	O
and	O
binding	B-FUNC
site	O
dynamics	O
:	O
inhibitor	O
design	O
implications	O
.	O

Three	O
recent	O
inhibitor	O
-	O
bound	O
PLpro	O
structures	O
highlight	O
the	O
role	O
of	O
an	O
extremely	O
flexible	O
six	O
-	O
residue	O
loop	O
in	O
inhibitor	O
binding	B-FUNC
.	O

From	O
conventional	O
molecular	O
dynamics	O
and	O
accelerated	O
molecular	O
dynamics	O
(	O
aMD	O
)	O
simulations	O
,	O
we	O
find	O
that	O
with	O
conventional	O
molecular	O
dynamics	O
simulation	O
,	O
PLpro	O
translationally	O
samples	O
the	O
open	O
and	O
closed	O
conformation	O
of	O
BL2	O
loop	O
on	O
a	O
picosecond	O
-	O
nanosecond	O
timescale	O
but	O
does	O
not	O
reproduce	O
the	O
peptide	O
bond	O
inversion	O
between	O
loop	O
residues	O
Tyr269	O
and	O
Gln270	O
that	O
is	O
observed	O
on	O
inhibitor	O
GRL0617	O
binding	B-FUNC
.	O

Superimposition	O
of	O
the	O
PLP2	O
model	O
on	O
the	O
PLpro	O
X	O
-	O
ray	O
structure	O
identifies	O
binding	B-FUNC
site	O
residues	O
in	O
PLP2	O
that	O
contribute	O
to	O
the	O
distinct	O
substrate	O
cleavage	O
site	O
specificities	O
between	O
the	O
two	O
proteases	O
.	O

The	O
topological	O
and	O
electrostatic	O
differences	O
between	O
the	O
two	O
protease	B-FUNC
binding	I-FUNC
sites	O
also	O
help	O
explain	O
the	O
selectivity	O
of	O
non	O
-	O
covalent	O
PLpro	O
inhibitors	O
.	O

Intravenous	O
administration	O
of	O
immunoglobulin	B-FUNC
resolved	O
her	O
potentially	O
life	O
-	O
threatening	O
autonomic	O
instability	O
.	O

TITLE	O
:	O
A	O
polyclonal	O
antibody	B-FUNC
against	O
the	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	O
N	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

After	O
confirming	O
reactivity	O
of	O
the	O
recombinant	O
protein	O
pAPN	O
-	O
C	O
to	O
antibody	B-FUNC
against	O
native	O
pAPN	O
,	O
polyclonal	O
antibody	B-FUNC
against	O
the	O
recombinant	O
protein	O
pAPN	O
-	O
C	O
was	O
prepared	O
in	O
rabbit	O
using	O
purified	O
protein	O
as	O
immunogen	O
.	O

In	O
Western	O
blot	O
analysis	O
,	O
the	O
antibody	B-FUNC
elicited	O
by	O
the	O
recombinant	O
protein	O
pAPN	O
-	O
C	O
could	O
recognize	O
the	O
native	O
pAPN	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
pAPN	O
-	O
C	O
recombinant	O
protein	O
and	O
its	O
polyclonal	O
antibody	B-FUNC
can	O
provide	O
some	O
basis	O
for	O
further	O
receptor	O
antagonist	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
),	O
a	O
C	O
-	O
type	O
collectin	O
with	O
structural	O
similarities	O
to	O
C1q	O
,	O
is	O
an	O
innate	O
pattern	O
-	O
recognition	O
molecule	O
that	O
is	O
sequestered	O
to	O
sites	O
of	O
inflammation	O
and	O
infections	O
.	O

MBL	O
selectively	O
binds	B-FUNC
distinct	O
chemical	O
patterns	O
,	O
including	O
carbohydrates	O
expressed	O
on	O
all	O
kinds	O
of	O
pathogens	O
.	O

The	O
primary	O
IBV	O
infection	O
induced	O
changes	O
in	O
circulating	O
T	O
-	O
cell	O
populations	O
and	O
in	O
the	O
specific	O
antibody	B-FUNC
responses	O
.	O

Moreover	O
,	O
addition	O
of	O
mannose	O
to	O
an	O
IBV	O
vaccine	O
altered	O
both	O
vaccine	O
-	O
induced	O
changes	O
in	O
circulating	O
T	O
-	O
cell	O
populations	O
and	O
IBV	O
specific	O
vaccine	O
and	O
infection	O
-	O
induced	O
antibody	B-FUNC
responses	O
in	O
chickens	O
with	O
high	O
serum	O
MBL	O
levels	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
-	O
induced	O
neuronal	O
programmed	O
cell	O
death	O
is	O
cyclophilin	B-FUNC
d	O
dependent	O
and	O
potentially	O
caspase	O
dispensable	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
proapoptotic	O
proteins	O
BAX	O
,	O
cytochrome	B-FUNC
c	I-FUNC
(	O
CytC	O
),	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
were	O
relocalized	O
toward	O
the	O
mitochondria	O
,	O
cytosol	O
,	O
and	O
nucleus	O
,	O
respectively	O
,	O
after	O
infection	O
by	O
both	O
virus	O
variants	O
.	O

Moreover	O
,	O
LA	O
-	O
N	O
-	O
5	O
neuronal	O
cells	O
treated	O
with	O
cyclosporine	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
),	O
or	O
knocked	O
down	O
for	O
cyclophilin	B-FUNC
D	O
(	O
CypD	O
)	O
were	O
completely	O
protected	O
from	O
rOC	O
/	O
ATCC	O
-	O
induced	O
neuronal	O
PCD	O
,	O
underlining	O
the	O
involvement	O
of	O
CypD	O
in	O
the	O
process	O
.	O

X	O
-	O
ray	O
crystallography	O
provided	O
insights	O
into	O
the	O
protein	O
-	O
ligand	B-FUNC
interactions	O
.	O

Phylogenetic	O
analysis	O
on	O
a	O
527	O
base	B-FUNC
pair	I-FUNC
-	O
long	O
region	O
from	O
the	O
NS1	O
gene	O
revealed	O
two	O
main	O
clusters	O
,	O
a	O
chicken	O
parvovirus	O
(	O
ChPV	O
)	O
and	O
a	O
TuPV	O
group	O
,	O
but	O
also	O
the	O
presence	O
of	O
a	O
divergent	O
branch	O
of	O
tentatively	O
named	O
""""	O
TuPV	O
-	O
like	O
ChPV	O
""""	O
strains	O
.	O

We	O
demonstrated	O
that	O
nsp10	O
is	O
required	O
for	O
nsp16	O
to	O
bind	B-FUNC
both	O
m7GpppA	O
-	O
RNA	O
substrate	O
and	O
SAM	O
cofactor	O
.	O

The	O
structure	O
of	O
the	O
nsp16	O
/	O
nsp10	O
interaction	O
interface	O
shows	O
that	O
nsp10	O
may	O
stabilize	O
the	O
SAM	O
-	O
binding	B-FUNC
pocket	O
and	O
extend	O
the	O
substrate	O
RNA	O
-	O
binding	B-FUNC
groove	O
of	O
nsp16	O
,	O
consistent	O
with	O
the	O
findings	O
in	O
biochemical	O
assays	O
.	O

We	O
compared	O
this	O
with	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
,	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
serum	O
procalcitonin	O
(	O
PCT	O
),	O
urine	O
output	O
,	O
creatinine	O
clearance	O
(	O
CCr	B-FUNC
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
).	O

For	O
17	O
sepsis	O
cases	O
diagnosed	O
with	O
secondary	O
AKI	O
,	O
comparisons	O
between	O
their	O
urine	O
sTREM	O
-	O
1	O
,	O
urine	O
output	O
,	O
CCr	B-FUNC
,	O
SCr	O
and	O
BUN	O
at	O
diagnosis	O
and	O
48	O
h	O
before	O
diagnosis	O
were	O
made	O
.	O

For	O
17	O
patients	O
with	O
AKI	O
,	O
urine	O
sTREM	O
-	O
1	O
,	O
SCr	O
and	O
BUN	O
levels	O
at	O
48	O
h	O
before	O
AKI	O
diagnosis	O
were	O
higher	O
,	O
and	O
CCr	B-FUNC
level	O
was	O
lower	O
than	O
those	O
for	O
non	O
-	O
AKI	O
subjects	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Based	O
on	O
epidemiology	O
analysis	O
of	O
recent	O
field	O
isolates	O
of	O
nephropathogenic	O
IB	O
in	O
vaccinated	O
farms	O
in	O
China	O
,	O
YL6	O
strain	O
were	O
used	O
for	O
vaccination	O
and	O
evaluated	O
by	O
antibody	B-FUNC
titer	O
and	O
challenge	O
tests	O
.	O

RESULTS	O
:	O
Based	O
on	O
epidemiology	O
analysis	O
of	O
recent	O
field	O
isolates	O
of	O
nephropathogenic	O
IB	O
in	O
vaccinated	O
farms	O
in	O
China	O
,	O
YL6	O
strain	O
were	O
used	O
for	O
vaccination	O
and	O
evaluated	O
by	O
antibody	B-FUNC
titer	O
and	O
challenge	O
tests	O
.	O

ABSTRACT	O
:	O
Uniquely	O
among	O
RNA	O
viruses	O
,	O
replication	O
of	O
the	O
~	O
30	O
-	O
kb	O
SARS	O
-	O
coronavirus	O
genome	O
is	O
believed	O
to	O
involve	O
two	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
activities	O
.	O

We	O
found	O
that	O
in	O
particular	O
the	O
exposure	O
of	O
nsp8	O
'	O
s	O
natural	O
N	O
-	O
terminal	O
residue	O
was	O
paramount	O
for	O
both	O
the	O
protein	O
'	O
s	O
ability	O
to	O
associate	O
with	O
nsp7	O
and	O
for	O
boosting	O
its	O
RdRp	B-FUNC
activity	O
.	O

The	O
latter	O
activity	O
is	O
,	O
however	O
,	O
~	O
20	O
-	O
fold	O
weaker	O
than	O
that	O
of	O
the	O
primer	O
-	O
dependent	O
nsp12	O
-	O
RdRp	B-FUNC
at	O
equal	O
monomer	O
concentrations	O
.	O

Finally	O
,	O
site	O
-	O
directed	O
mutagenesis	O
of	O
conserved	O
D	O
/	O
ExD	O
/	O
E	O
motifs	O
was	O
employed	O
to	O
identify	O
residues	O
crucial	O
for	O
nsp	O
(	O
7	O
+	O
8	O
)	O
RdRp	B-FUNC
activity	O
.	O

These	O
molecules	O
modulate	O
the	O
Calcineurin	B-FUNC
/	O
NFAT	O
pathway	O
that	O
plays	O
an	O
important	O
role	O
in	O
immune	O
cell	O
activation	O
.	O

Overexpression	O
of	O
NSP1	O
and	O
infection	O
with	O
live	O
SARS	O
-	O
CoV	O
strongly	O
increased	O
signalling	O
through	O
the	O
Calcineurin	B-FUNC
/	O
NFAT	O
pathway	O
and	O
enhanced	O
the	O
induction	O
of	O
interleukin	O
2	O
,	O
compatible	O
with	O
late	O
-	O
stage	O
immunopathogenicity	O
and	O
long	O
-	O
term	O
cytokine	O
dysregulation	O
as	O
observed	O
in	O
severe	O
SARS	O
cases	O
.	O

One	O
way	O
to	O
prevent	O
oxygen	O
toxicity	O
is	O
to	O
augment	O
antioxidant	O
enzyme	B-FUNC
activity	I-FUNC
in	O
the	O
respiratory	O
system	O
.	O

Recombinant	O
human	O
EC	O
-	O
SOD	B-FUNC
(	O
rhEC	O
-	O
SOD	B-FUNC
)	O
was	O
produced	O
from	O
a	O
synthetic	O
cassette	O
constructed	O
in	O
the	O
methylotrophic	O
yeast	O
Pichia	O
pastoris	O
.	O

The	O
therapeutic	O
effects	O
of	O
EC	O
-	O
SOD	B-FUNC
and	O
copper	O
-	O
zinc	O
SOD	B-FUNC
(	O
CuZn	O
-	O
SOD	B-FUNC
)	O
via	O
an	O
aerosol	O
delivery	O
system	O
for	O
lung	O
injury	O
and	O
systemic	O
oxidative	O
stress	O
at	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
h	O
of	O
hyperoxia	O
were	O
measured	O
by	O
bronchoalveolar	O
lavage	O
,	O
wet	O
/	O
dry	O
ratio	O
,	O
lung	O
histology	O
,	O
and	O
8	O
-	O
oxo	O
-	O
2	O
'-	O
deoxyguanosine	O
(	O
8	O
-	O
oxo	O
-	O
dG	O
)	O
in	O
lung	O
and	O
liver	O
tissues	O
.	O

Treatment	O
with	O
aerosolized	O
rhEC	O
-	O
SOD	B-FUNC
increased	O
the	O
survival	O
rate	O
at	O
day	O
3	O
under	O
hyperoxia	O
to	O
95	O
.	O
8	O
%,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
57	O
.	O
1	O
%),	O
albumin	O
treated	O
group	O
(	O
33	O
.	O
3	O
%),	O
and	O
CuZn	O
-	O
SOD	B-FUNC
treated	O
group	O
(	O
75	O
%).	O

Aerosolized	O
EC	O
-	O
SOD	B-FUNC
protected	O
mice	O
against	O
oxygen	O
toxicity	O
and	O
reduced	O
mortality	O
in	O
a	O
hyperoxic	O
model	O
.	O

Among	O
the	O
most	O
potent	O
were	O
the	O
bis	B-FUNC
-	O
triazoloquinoline	O
1m	O
,	O
the	O
imidazoquinolines	O
2e	O
and	O
2h	O
,	O
and	O
the	O
pyridoquinoxalines	O
4h	O
,	O
4j	O
and	O
5n	O
(	O
EC	O
(	O
50	O
)	O
range	O
1	O
-	O
5	O
M	O
).	O

In	O
enzyme	O
assays	O
,	O
1m	O
,	O
2h	O
,	O
5m	O
and	O
5n	O
proved	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
BVDV	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
while	O
only	O
2h	O
also	O
inhibited	O
the	O
recombinant	O
HCV	O
enzyme	O
.	O

Treatment	O
requires	O
prompt	O
administration	O
of	O
safe	O
and	O
fast	B-FUNC
-	O
acting	O
antimalarials	O
,	O
which	O
in	O
severe	O
malaria	O
is	O
treatment	O
with	O
quinine	O
or	O
artesunate	O
.	O

In	O
total	O
,	O
540	O
one	O
-	O
day	O
-	O
old	O
Cobb	B-FUNC
500	O
broilers	O
were	O
randomly	O
assigned	O
to	O
receive	O
1	O
of	O
5	O
(	O
n	O
=	O
108	O
birds	O
/	O
group	O
)	O
treatments	O
:	O
1	O
)	O
no	O
vaccination	O
;	O
2	O
)	O
simplified	O
vaccination	O
,	O
which	O
included	O
the	O
infectious	O
bronchitis	O
vaccine	O
(	O
H120	O
),	O
the	O
inactivated	O
avian	O
influenza	O
vaccine	O
(	O
AI	O
),	O
the	O
live	O
vaccine	O
strain	O
Clone	O
-	O
30	O
of	O
the	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
the	O
combined	O
inactive	O
vaccine	O
for	O
infectious	O
bursal	O
diseases	O
and	O
the	O
Newcastle	O
disease	O
vaccine	O
(	O
ND	O
-	O
IB	O
);	O
3	O
)	O
normal	O
vaccination	O
(	O
simplified	O
vaccination	O
+	O
second	O
dose	O
of	O
ND	O
-	O
IB	O
,	O
H120	O
,	O
and	O
AI	O
);	O
4	O
)	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stress	O
(	O
normal	O
vaccination	O
+	O
LPS	O
);	O
or	O
5	O
)	O
cyclophosphamide	O
(	O
CPM	O
)	O
stress	O
(	O
normal	O
vaccination	O
+	O
CPM	O
).	O
The	O
results	O
showed	O
that	O
the	O
average	O
BW	O
and	O
average	O
feed	O
intake	O
decreased	O
significantly	O
after	O
treatment	O
with	O
LPS	O
or	O
CPM	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
total	O
,	O
ninety	O
7	O
-	O
d	O
-	O
old	O
poults	O
,	O
which	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
astrovirus	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
reovirus	O
by	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
PCR	O
,	O
were	O
divided	O
evenly	O
into	O
3	O
groups	O
:	O
A	O
,	O
B	O
,	O
and	O
C	O
.	O
Birds	O
in	O
group	O
A	O
were	O
inoculated	O
orally	O
with	O
turkey	O
astrovirus	O
-	O
positive	O
intestinal	O
contents	O
from	O
birds	O
affected	O
with	O
PES	O
.	O

By	O
western	O
blotting	O
and	O
ELISA	O
test	O
,	O
all	O
recombinant	O
proteins	O
were	O
recognized	O
by	O
the	O
antibody	B-FUNC
against	O
native	O
porcine	O
aminopeptidase	O
N	O
.	O
Recombinant	O
proteins	O
,	O
rpAPN	O
-	O
C2	O
(	O
aa	O
623	O
-	O
722	O
)	O
and	O
rpAPN	O
-	O
C3	O
(	O
aa	O
673	O
-	O
772	O
),	O
had	O
the	O
highest	O
binding	B-FUNC
activity	O
with	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
among	O
the	O
truncated	O
pAPN	O
-	O
C	O
recombinant	O
proteins	O
.	O

In	O
addition	O
,	O
CCoV	O
-	O
II	O
induces	O
a	O
remarkable	O
increase	O
in	O
the	O
expression	O
of	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-FUNC
(	O
TRAIL	O
),	O
while	O
we	O
observed	O
a	O
slight	O
up	O
-	O
regulation	O
of	O
FasL	O
/	O
Fas	O
at	O
36	O
p	O
.	O
i	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
replication	O
and	O
transcription	O
are	O
processes	O
mediated	O
by	O
a	O
protein	O
complex	O
,	O
with	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
as	O
a	O
main	O
component	O
.	O

Proteomic	O
analysis	O
of	O
highly	O
purified	O
transmissible	O
gastroenteritis	O
virus	O
showed	O
the	O
RdRp	B-FUNC
to	O
be	O
a	O
component	O
of	O
the	O
viral	O
particles	O
.	O

Interestingly	O
,	O
the	O
replicase	O
nonstructural	O
proteins	O
2	O
,	O
3	O
,	O
and	O
8	O
colocalized	O
with	O
the	O
RdRp	B-FUNC
in	O
the	O
viral	O
factories	O
and	O
were	O
also	O
incorporated	O
into	O
the	O
virions	O
.	O

Fluorescent	O
antibody	B-FUNC
staining	O
indicated	O
that	O
HCoV	O
-	O
229E	O
could	O
readily	O
infect	O
AMs	O
,	O
but	O
no	O
evidence	O
was	O
found	O
for	O
infection	O
in	O
differentiated	O
alveolar	O
epithelial	O
type	O
II	O
cells	O
and	O
only	O
a	O
very	O
low	O
level	O
of	O
infection	O
in	O
type	O
II	O
cells	O
transitioning	O
to	O
the	O
type	O
I	O
-	O
like	O
cell	O
phenotype	O
.	O

There	O
was	O
neither	O
a	O
difference	O
in	O
quality	O
of	O
life	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
892	O
),	O
in	O
the	O
amount	O
of	O
effusion	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
710	O
),	O
the	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
concentration	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
355	O
),	O
nor	O
in	O
any	O
other	O
variable	O
investigated	O
in	O
this	O
study	O
,	O
including	O
a	O
complete	O
blood	O
count	O
,	O
and	O
a	O
small	O
animal	O
biochemistry	O
profile	O
.	O

There	O
was	O
neither	O
a	O
difference	O
in	O
quality	O
of	O
life	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
892	O
),	O
in	O
the	O
amount	O
of	O
effusion	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
710	O
),	O
the	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
concentration	O
(	O
day	O
7	O
,	O
P	O
=	O
.	O
355	O
),	O
nor	O
in	O
any	O
other	O
variable	O
investigated	O
in	O
this	O
study	O
,	O
including	O
a	O
complete	O
blood	O
count	O
,	O
and	O
a	O
small	O
animal	O
biochemistry	O
profile	O
.	O

TITLE	O
:	O
Construction	O
and	O
characterization	O
of	O
single	O
-	O
chain	O
variable	O
fragment	O
antibody	B-FUNC
library	O
derived	O
from	O
germline	O
rearranged	O
immunoglobulin	B-FUNC
variable	O
genes	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
repertoires	O
for	O
library	O
construction	O
are	O
conventionally	O
harvested	O
from	O
mRNAs	O
of	O
immune	O
cells	O
.	O

Despite	O
showing	O
similar	O
binding	B-FUNC
characteristics	O
towards	O
phOx	O
,	O
the	O
scFv	O
clones	O
that	O
were	O
obtained	O
from	O
the	O
L3G7C	O
-	O
derived	O
antibody	B-FUNC
library	O
gave	O
a	O
lower	O
non	O
-	O
specific	O
binding	B-FUNC
than	O
that	O
of	O
the	O
parental	O
L3G7C	O
clone	O
.	O

In	O
conclusion	O
,	O
highly	O
diversified	O
antibody	B-FUNC
library	O
can	O
be	O
efficiently	O
constructed	O
using	O
germline	O
rearranged	O
immunoglobulin	B-FUNC
variable	O
genes	O
as	O
source	O
of	O
antibody	B-FUNC
repertoires	O
and	O
fsPCR	O
to	O
diversify	O
the	O
CDR3	O
.	O

After	O
examination	O
at	O
rest	B-FUNC
,	O
all	O
subjects	O
performed	O
a	O
maximal	O
cycling	O
exercise	O
test	O
.	O

At	O
rest	B-FUNC
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
TBARS	O
level	O
was	O
higher	O
in	O
groups	O
II	O
,	O
III	O
and	O
IV	O
patients	O
,	O
and	O
the	O
RAA	O
level	O
was	O
lower	O
in	O
groups	O
III	O
and	O
IV	O
.	O

RESULTS	O
:	O
At	O
rest	B-FUNC
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
TBARS	O
level	O
was	O
higher	O
in	O
groups	O
II	O
,	O
III	O
and	O
IV	O
patients	O
,	O
and	O
the	O
RAA	O
level	O
was	O
lower	O
in	O
groups	O
III	O
and	O
IV	O
.	O

The	O
results	O
of	O
ELISA	O
analysis	O
showed	O
that	O
N	O
protein	O
was	O
capable	O
of	O
inducing	O
a	O
higher	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
IFN	O
-	O
	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
S1	O
protein	O
in	O
the	O
immunized	O
mice	O
.	O

In	O
vitro	O
experiments	O
showed	O
that	O
FXR	O
activation	O
blocked	O
TNF	O
-	O
induced	O
expression	O
of	O
P	O
-	O
selectin	B-FUNC
but	O
stimulated	O
proliferation	O
of	O
lung	O
microvascular	O
endothelial	O
cells	O
through	O
up	O
-	O
regulation	O
of	O
Foxm1b	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
death	O
in	O
adults	O
in	O
the	O
industrialised	O
countries	O
and	O
in	O
the	O
rest	B-FUNC
of	O
the	O
world	O
in	O
infants	O
.	O

The	O
effect	O
of	O
NSC158362	O
on	O
PLP	O
protease	O
,	O
deubiquitinase	B-FUNC
and	O
anti	O
-	O
interferon	O
activities	O
was	O
investigated	O
but	O
the	O
compound	O
did	O
not	O
alter	O
these	O
activities	O
.	O

Another	O
suppressor	O
,	O
NSC158011	O
,	O
demonstrated	O
the	O
ability	O
to	O
inhibit	O
PLP	O
protease	B-FUNC
activity	I-FUNC
in	O
a	O
cell	O
-	O
based	O
assay	O
.	O

Furthermore	O
,	O
three	O
commercially	O
available	O
multiplex	O
NAAT	B-FUNC
tests	O
-	O
the	O
ResPlex	O
(	O
Qiagen	O
GmbH	O
,	O
Hilden	O
,	O
Germany	O
),	O
RespiFinder	O
plus	O
(	O
PathoFinder	O
,	O
Maastricht	O
,	O
The	O
Netherlands	O
),	O
and	O
RespiFinder	O
Smart	O
21	O
(	O
PathoFinder	O
)	O
tests	O
-	O
were	O
evaluated	O
by	O
examination	O
of	O
the	O
same	O
EQA	O
panel	O
by	O
the	O
manufacturer	O
.	O

Criteria	O
for	O
ECMO	O
center	O
activation	O
were	O
:	O
potentially	O
reversibile	O
respiratory	O
failure	O
,	O
PaO	O
<	O
50	O
mmHg	O
with	O
FiO	O
>	O
0	O
.	O
6	O
for	O
>	O
12	O
hours	O
,	O
PEEP	O
>	O
5	O
cmH0	O
,	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-FUNC
)	O
	O
3	O
or	O
respiratory	O
acidosis	O
with	O
pH	O
<	O
7	O
.	O
2	O
,	O
no	O
intracranial	O
bleeding	O
,	O
and	O
no	O
absolute	O
contraindication	O
to	O
anticoagulation	O
.	O

These	O
tests	O
are	O
more	O
sensitive	O
than	O
other	O
diagnostic	O
approaches	O
,	O
including	O
virus	O
isolation	O
in	O
cell	O
culture	O
,	O
shell	O
vial	O
culture	O
(	O
SVC	O
),	O
antigen	O
detection	O
by	O
direct	O
fluorescent	O
antibody	B-FUNC
(	O
DFA	O
)	O
staining	O
,	O
and	O
rapid	O
enzyme	O
immunoassay	O
(	O
EIA	O
),	O
and	O
now	O
form	O
the	O
backbone	O
of	O
clinical	O
virology	O
laboratory	O
testing	O
around	O
the	O
world	O
.	O

NATs	O
not	O
only	O
provide	O
fast	B-FUNC
,	O
accurate	O
and	O
sensitive	O
detection	O
of	O
respiratory	O
viruses	O
in	O
clinical	O
specimens	O
but	O
also	O
have	O
increased	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
both	O
new	O
emerging	O
viruses	O
such	O
as	O
the	O
pandemic	O
H1N1	O
influenza	O
virus	O
of	O
2009	O
,	O
and	O
conventional	O
viruses	O
such	O
as	O
the	O
common	O
cold	O
viruses	O
,	O
including	O
rhinovirus	O
and	O
coronavirus	O
.	O

METHODS	O
:	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
3	O
-	O
10	O
/	O
group	O
)	O
were	O
given	O
15	O
mg	O
/	O
kg	O
or	O
150	O
mg	O
/	O
kg	O
l	O
-	O
ergothioneine	O
intravenously	O
1h	O
before	O
or	O
18	O
h	O
after	O
cytokine	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IFN	O
)	O
insufflation	O
.	O

Analysis	O
of	O
c	O
-	O
dependent	O
cytokine	O
expression	O
indicated	O
interleukin	O
-	O
21	O
(	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
)	O
as	O
a	O
primary	O
candidate	O
optimizing	O
CD8	O
T	O
cell	O
activity	O
within	O
the	O
CNS	O
.	O

TITLE	O
:	O
Evidence	O
for	O
a	O
common	O
evolutionary	O
origin	O
of	O
coronavirus	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
subunits	O
.	O

There	O
have	O
been	O
few	O
reports	O
on	O
children	O
who	O
developed	O
common	O
variable	O
immunodeficiency	O
(	O
CVID	O
)	O
in	O
association	O
with	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
and	O
IgG2	O
deficiencies	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
).	O

A	O
diagnosis	O
of	O
IgA	O
and	O
IgG2	O
deficiency	O
and	O
SLE	O
was	O
made	O
on	O
the	O
basis	O
of	O
severe	O
proteinuria	O
,	O
hematuria	O
,	O
hypocomplementemia	O
,	O
high	O
anti	O
-	O
DNA	O
antibody	B-FUNC
and	O
antinuclear	O
antibody	B-FUNC
(	O
ANA	O
)	O
titers	O
,	O
and	O
malar	O
rash	O
.	O

The	O
administration	O
of	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
was	O
required	O
to	O
prevent	O
subsequent	O
infections	O
,	O
and	O
no	O
relapse	O
of	O
SLE	O
was	O
observed	O
.	O

We	O
focused	O
on	O
neutrophil	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
as	O
a	O
potent	O
tissue	O
damage	O
factor	O
and	O
examined	O
its	O
contribution	O
in	O
influenza	O
pneumonia	O
by	O
using	O
mice	O
genetically	O
lacking	O
in	O
MPO	B-FUNC
.	O

The	O
absence	O
of	O
MPO	B-FUNC
reduced	O
inflammatory	O
damage	O
with	O
suppression	O
of	O
leakage	O
of	O
total	O
BALF	O
proteins	O
associated	O
with	O
alteration	O
of	O
claudins	O
in	O
the	O
lung	O
.	O

MPO	B-FUNC
(-/-)	O
mice	O
also	O
suppressed	O
viral	O
load	O
in	O
the	O
lung	O
.	O

The	O
binding	B-FUNC
domains	O
of	O
these	O
two	O
proteins	O
were	O
also	O
determined	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

The	O
physical	B-FUNC
interaction	I-FUNC
between	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
and	O
cellular	O
pyruvate	O
kinase	O
(	O
liver	O
)	O
proteins	O
was	O
further	O
confirmed	O
by	O
GST	O
pull	O
-	O
down	O
assay	O
,	O
co	O
-	O
immunoprecipitation	O
assay	O
and	O
confocal	O
microscopy	O
.	O

Cellular	O
pyruvate	B-FUNC
kinase	I-FUNC
activity	I-FUNC
in	O
hepatoma	O
cells	O
was	O
repressed	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
either	O
transiently	O
transfected	O
or	O
stably	O
transfected	O
cells	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
could	O
reduce	O
pyruvate	B-FUNC
kinase	I-FUNC
activity	I-FUNC
via	O
its	O
nucleocapsid	O
protein	O
,	O
and	O
this	O
may	O
in	O
turn	O
cause	O
disease	O
.	O

Vaccination	O
with	O
H120	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
rS1	O
,	O
induced	O
HI	O
and	O
virus	O
-	O
specific	O
IgG	O
antibody	B-FUNC
production	O
.	O

TITLE	O
:	O
Characterization	O
of	O
germline	O
antibody	B-FUNC
libraries	O
from	O
human	O
umbilical	O
cord	O
blood	O
and	O
selection	O
of	O
monoclonal	O
antibodies	O
to	O
viral	O
envelope	O
glycoproteins	O
:	O
Implications	O
for	O
mechanisms	O
of	O
immune	O
evasion	O
and	O
design	O
of	O
vaccine	O
immunogens	O
.	O

They	O
were	O
panned	O
against	O
different	O
HIV	O
-	O
1	O
envelope	O
glycoproteins	O
(	O
Envs	O
),	O
SARS	O
CoV	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
and	O
soluble	O
Hendra	O
virus	O
G	O
protein	O
(	O
sG	O
).	O

Despite	O
a	O
high	O
sequence	O
and	O
combinatorial	O
diversity	O
observed	O
in	O
the	O
cord	O
blood	O
-	O
derived	O
IgM	O
antibody	B-FUNC
repertoire	O
,	O
no	O
enrichment	O
for	O
binders	O
of	O
Envs	O
was	O
observed	O
in	O
contrast	O
to	O
considerable	O
specific	O
enrichments	O
produced	O
with	O
panning	O
against	O
RBD	O
and	O
sG	O
;	O
one	O
of	O
the	O
selected	O
monoclonal	O
antibodies	O
(	O
against	O
the	O
RBD	O
)	O
was	O
of	O
high	O
(	O
nM	O
)	O
affinity	O
with	O
only	O
few	O
somatic	O
mutations	O
.	O

HIV	O
-	O
1	O
uses	O
a	O
strategy	O
to	O
minimize	O
or	O
eliminate	O
strong	O
binding	B-FUNC
of	O
germline	O
antibodies	O
to	O
its	O
Env	O
;	O
in	O
contrast	O
,	O
SARS	O
CoV	O
and	O
Hendra	O
virus	O
,	O
and	O
perhaps	O
other	O
viruses	O
causing	O
acute	O
infections	O
,	O
can	O
bind	B-FUNC
germline	O
antibody	B-FUNC
or	O
minimally	O
somatically	O
mutated	O
antibodies	O
with	O
relatively	O
high	O
affinity	O
which	O
could	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
success	O
of	O
sG	O
and	O
RBD	O
as	O
vaccine	O
immunogens	O
.	O

When	O
comparing	O
the	O
baseline	O
cytokine	O
production	O
prior	O
to	O
microbial	O
stimulation	O
,	O
we	O
observed	O
that	O
cord	O
plasmacytoid	O
DC	O
were	O
stronger	O
inducers	O
of	O
Th2	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
)	O
compared	O
with	O
cord	O
myeloid	O
DC	O
and	O
to	O
adult	O
DC	O
.	O

When	O
adding	O
microbes	O
to	O
these	O
cultures	O
,	O
bacteria	O
and	O
virus	O
differed	O
in	O
two	O
major	O
respects	O
;	O
Firstly	O
,	O
all	O
enveloped	O
viruses	O
,	O
but	O
none	O
of	O
the	O
bacteria	O
,	O
blocked	O
Th2	O
(	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
)	O
production	O
by	O
cord	O
CD4	O
(+)	O
cells	O
.	O

HSA	O
displays	O
an	O
extraordinary	O
ligand	B-FUNC
binding	B-FUNC
capacity	O
,	O
providing	O
a	O
depot	O
and	O
carrier	O
for	O
many	O
endogenous	O
and	O
exogenous	O
compounds	O
.	O

Recently	O
,	O
biotechnological	O
applications	O
of	O
HSA	O
,	O
including	O
implantable	O
biomaterials	O
,	O
surgical	O
adhesives	O
and	O
sealants	O
,	O
biochromatography	O
,	O
ligand	B-FUNC
trapping	O
,	O
and	O
fusion	O
proteins	O
,	O
have	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
contains	O
two	O
structurally	O
independent	O
RNA	B-FUNC
binding	I-FUNC
domains	O
.	O

In	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
the	O
NTD	O
binds	B-FUNC
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
RNA	O
,	O
a	O
conserved	O
hexanucleotide	O
sequence	O
required	O
for	O
subgenomic	O
RNA	O
synthesis	O
.	O

We	O
show	O
here	O
that	O
three	O
residues	O
on	O
the	O
3	O
(	O
Arg	O
-	O
125	O
and	O
Tyr	O
-	O
127	O
)	O
and	O
5	O
(	O
Tyr	O
-	O
190	O
)	O
strands	O
play	O
key	O
roles	O
in	O
TRS	B-FUNC
RNA	B-FUNC
binding	I-FUNC
and	O
helix	O
destabilization	O
with	O
Ala	O
substitutions	O
of	O
these	O
residues	O
lethal	O
to	O
the	O
virus	O
.	O

Characterization	O
of	O
CoV	O
N	O
NTDs	O
from	O
infectious	O
bronchitis	O
virus	O
and	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
revealed	O
that	O
,	O
although	O
detailed	O
NTD	O
-	O
TRS	B-FUNC
determinants	O
are	O
distinct	O
from	O
those	O
of	O
MHV	O
NTD	O
,	O
rapid	O
helix	O
destabilization	O
activity	O
of	O
CoV	O
N	O
NTDs	O
is	O
most	O
strongly	O
correlated	O
with	O
CoV	O
function	O
and	O
virus	O
viability	O
.	O

Interestingly	O
,	O
the	O
ORF3	O
gene	O
from	O
an	O
attenuated	O
PEDV	O
encodes	O
a	O
truncated	O
protein	O
with	O
49	O
nucleotide	O
deletions	O
,	O
which	O
lacks	O
the	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
We	O
determined	O
prevalence	O
of	O
antibody	B-FUNC
to	O
selected	O
viral	O
pathogens	O
important	O
for	O
domestic	O
pigs	O
and	O
livestock	O
in	O
556	O
wild	O
boar	O
(	O
Sus	O
scrofa	O
)	O
sera	B-FUNC
collected	O
during	O
2005	O
-	O
06	O
and	O
2009	O
-	O
10	O
in	O
four	O
counties	O
in	O
Croatia	O
.	O

Domestic	O
dogs	O
(	O
Canis	O
familiaris	O
)	O
were	O
tested	O
as	O
a	O
potential	O
source	O
for	O
CDV	O
;	O
16	O
%	O
were	O
vaccinated	O
against	O
CDV	O
and	O
58	O
%	O
of	O
unvaccinated	O
dogs	O
were	O
antibody	B-FUNC
positive	O
for	O
CDV	O
.	O

We	O
further	O
demonstrate	O
that	O
PI4KB	O
does	O
not	O
affect	O
virus	O
entry	O
at	O
the	O
SARS	O
-	O
CoV	O
S	O
-	O
ACE2	O
binding	B-FUNC
interface	O
or	O
at	O
the	O
stage	O
of	O
virus	O
internalization	O
but	O
rather	O
at	O
or	O
before	O
virus	O
fusion	O
.	O

Kinase	O
assay	O
and	O
pharmacological	O
inhibitor	O
treatment	O
implied	O
that	O
3b	O
also	O
affect	O
RUNX1b	O
transcriptional	O
activity	O
by	O
regulating	O
its	O
ERK	B-FUNC
dependent	O
phosphorylation	O
levels	O
.	O

Inhibition	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
MEK	O
/	O
ERK	B-FUNC
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	B-FUNC
/	O
Akt	O
)	O
signaling	O
pathways	O
by	O
chemical	O
inhibitors	O
and	O
knockdown	O
of	O
GADD153	O
by	O
siRNA	O
demonstrated	O
the	O
involvement	O
of	O
ER	O
-	O
stress	O
response	O
in	O
regulation	O
of	O
IBV	O
-	O
induced	O
Mcl	O
-	O
1	O
expression	O
.	O

It	O
significantly	O
lowered	O
plasma	O
concentrations	O
of	O
interleukin	O
1	O
(	O
IL	O
-	O
1	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

TITLE	O
:	O
A	O
hexapeptide	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
corona	O
virus	O
spike	O
protein	O
blocks	O
viral	O
entry	O
into	O
host	O
cells	O
via	O
the	O
human	O
receptor	O
ACE2	O
.	O

Peptide	O
(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
is	O
part	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
Peptide	O
libraries	O
were	O
screened	O
by	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
to	O
identify	O
RBD	O
binding	B-FUNC
epitopes	O
.	O

(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
carries	O
the	O
dominant	O
binding	B-FUNC
epitope	O
and	O
binds	B-FUNC
to	O
ACE2	O
with	O
K	O
(	O
D	O
)=	O
46	O
M	O
.	O
The	O
binding	B-FUNC
mode	O
was	O
further	O
characterized	O
by	O
saturation	O
transfer	O
difference	O
(	O
STD	O
)	O
NMR	O
spectroscopy	O
and	O
molecular	O
dynamic	O
simulations	O
.	O

In	O
primary	O
rat	O
alveolar	O
type	O
II	O
cells	O
alcohol	O
and	O
adenosine	O
decreased	O
the	O
abundance	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
basolateral	O
membrane	O
via	O
a	O
mechanism	O
that	O
required	O
activation	O
of	O
the	O
AMPK	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
from	O
palm	O
civets	O
has	O
twice	O
evolved	O
the	O
capacity	O
to	O
infect	O
humans	O
by	O
gaining	O
binding	B-FUNC
affinity	O
for	O
human	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Numerous	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
different	O
SARS	O
-	O
CoV	O
strains	O
isolated	O
from	O
humans	O
or	O
civets	O
.	O

TITLE	O
:	O
The	O
murine	O
coronavirus	O
hemagglutinin	O
-	O
esterase	O
receptor	O
-	O
binding	B-FUNC
site	O
:	O
a	O
major	O
shift	O
in	O
ligand	B-FUNC
specificity	O
through	O
modest	O
changes	O
in	O
architecture	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	B-FUNC
(	O
HEs	O
),	O
envelope	O
glycoproteins	O
of	O
corona	O
-,	O
toro	O
-	O
and	O
orthomyxoviruses	O
,	O
mediate	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
(	O
O	O
-	O
Ac	O
-	O
Sias	O
).	O

They	O
do	O
so	O
through	O
concerted	O
action	O
of	O
distinct	O
receptor	O
-	O
binding	B-FUNC
"("""	O
lectin	O
""")"	O
and	O
receptor	O
-	O
destroying	O
sialate	O
O	O
-	O
acetylesterase	O
"("""	O
esterase	O
""")"	O
domains	O
.	O

In	O
one	O
lineage	O
of	O
murine	O
coronaviruses	O
,	O
however	O
,	O
HE	O
esterase	O
substrate	O
and	O
lectin	O
ligand	B-FUNC
specificity	O
changed	O
dramatically	O
as	O
these	O
viruses	O
evolved	O
to	O
use	O
4	O
-	O
O	O
-	O
acetylated	O
Sias	O
instead	O
.	O

The	O
data	O
show	O
that	O
the	O
shift	O
from	O
9	O
-	O
O	O
-	O
to	O
4	O
-	O
O	O
-	O
Ac	O
-	O
Sia	O
receptor	O
usage	O
primarily	O
entailed	O
a	O
change	O
in	O
ligand	B-FUNC
binding	B-FUNC
topology	O
and	O
,	O
surprisingly	O
,	O
only	O
modest	O
changes	O
in	O
receptor	O
-	O
binding	B-FUNC
site	O
architecture	O
.	O

Sequence	O
analysis	O
revealed	O
a	O
retinoblastoma	O
protein	O
-	O
binding	B-FUNC
motif	O
(	O
LXCXE	O
/	O
D	O
)	O
in	O
the	O
majority	O
of	O
the	O
Nsp15	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
its	O
orthologs	O
in	O
the	O
alpha	O
and	O
beta	O
coronaviruses	O
.	O

Mutations	O
in	O
the	O
pRb	O
-	O
binding	B-FUNC
motif	O
rendered	O
sNsp15	O
to	O
be	O
differentially	O
modified	O
by	O
ubiquitin	B-FUNC
in	O
cells	O
,	O
and	O
cytotoxicity	O
was	O
observed	O
upon	O
its	O
expression	O
.	O

We	O
have	O
cloned	O
a	O
novel	O
full	O
-	O
length	O
isoform	O
of	O
psg16	O
that	O
is	O
also	O
expressed	O
in	O
the	O
brain	O
,	O
placenta	O
,	O
and	O
retina	O
but	O
,	O
like	O
the	O
truncated	O
form	O
,	O
lacks	O
MHV	O
receptor	B-FUNC
activity	I-FUNC
when	O
expressed	O
on	O
293T	O
cells	O
,	O
suggesting	O
that	O
PSG16	O
does	O
not	O
mediate	O
CEACAM1a	O
-	O
independent	O
spread	O
of	O
MHV	O
.	O

Oral	O
vaccination	O
of	O
an	O
attenuated	O
Salmonella	O
typhimurium	O
strain	O
transformed	O
with	O
plasmids	O
encoding	O
CEA	O
-	O
SARS	O
-	O
CoV	O
fusion	O
gene	O
into	O
BALB	O
/	O
c	O
mice	O
elicited	O
significant	O
increases	O
in	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
the	O
serum	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
is	O
useful	O
for	O
the	O
rapid	O
diagnosis	O
of	O
coronavirus	O
infections	O
.	O

Although	O
CoV	O
-	O
HKU1	O
was	O
not	O
identified	O
in	O
any	O
of	O
the	O
studied	O
animals	O
,	O
a	O
coronavirus	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
(	O
bat	O
-	O
SARS	O
-	O
CoV	O
)	O
was	O
identified	O
in	O
23	O
(	O
19	O
%)	O
of	O
118	O
wild	O
Chinese	O
horseshoe	O
bats	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Antibody	B-FUNC
against	O
recombinant	O
bat	O
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

Neutralising	O
antibody	B-FUNC
to	O
human	O
SARS	O
-	O
CoV	O
was	O
also	O
detected	O
in	O
those	O
with	O
lower	O
viral	O
loads	O
.	O
5	O
.	O

Antibody	B-FUNC
-	O
mediated	O
enhancement	O
of	O
SARS	O
-	O
CoV	O
infection	O
with	O
anti	O
-	O
SARS	O
-	O
CoV	O
Spike	O
immune	O
-	O
serum	O
was	O
observed	O
in	O
vitro	O
.	O

Antibody	B-FUNC
-	O
mediated	O
infection	O
of	O
SARS	O
-	O
CoV	O
triggers	O
entry	O
into	O
human	O
haematopoietic	O
cells	O
via	O
an	O
FcR	O
-	O
dependent	O
and	O
ACE2	O
-,	O
pH	O
-,	O
cysteine	O
-	O
protease	O
-	O
independent	O
pathways	O
.	O

The	O
antibody	B-FUNC
-	O
mediated	O
enhancement	O
phenomenon	O
is	O
not	O
a	O
mandatory	O
component	O
of	O
the	O
humoral	O
immune	O
response	O
elicited	O
by	O
SARS	O
vaccines	O
,	O
as	O
pure	B-FUNC
neutralising	O
antibody	B-FUNC
only	O
could	O
be	O
obtained	O
.	O

STING	O
dimerization	O
was	O
also	O
substantially	O
reduced	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
level	O
of	O
ubiquitinated	O
forms	O
of	O
STING	O
,	O
RIG	O
-	O
I	O
,	O
TBK1	B-FUNC
and	O
IRF	O
-	O
3	O
are	O
reduced	O
in	O
cells	O
expressing	O
wild	O
type	O
or	O
catalytic	O
mutants	O
of	O
PLP2	O
-	O
TM	O
,	O
likely	O
contributing	O
to	O
disruption	O
of	O
signaling	O
required	O
for	O
IFN	O
induction	O
.	O

Between	O
2005	O
-	O
2007	O
,	O
95	O
pet	O
and	O
10	O
feral	O
cats	O
tested	O
negative	O
by	O
indirect	O
immunofluorescence	O
antibody	B-FUNC
(	O
IFA	O
)	O
analysis	O
using	O
two	O
strains	O
of	O
type	O
II	O
FCoV	O
,	O
two	O
transmissible	O
gastroenteritis	O
virus	O
assays	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
rapid	O
immunomigration	O
test	O
.	O

As	O
compared	O
to	O
that	O
of	O
pre	O
-	O
treatment	O
period	O
,	O
white	O
blood	O
cells	O
[	O
WBC	O
,	O
	O
10	O
(	O
9	O
)/	O
L	O
:	O
12	O
.	O
18	O
	O
4	O
.	O
76	O
vs	O
.	O
21	O
.	O
93	O
	O
6	O
.	O
21	O
],	O
neutrophil	O
percentage	O
(	O
0	O
.	O
87	O
	O
0	O
.	O
05	O
vs	O
.	O
0	O
.	O
92	O
	O
0	O
.	O
03	O
),	O
hemoglobin	O
(	O
Hb	O
,	O
g	O
/	O
L	O
:	O
128	O
.	O
12	O
	O
25	O
.	O
65	O
vs	O
.	O
173	O
.	O
71	O
	O
23	O
.	O
53	O
),	O
blood	O
platelet	O
count	O
[	O
PLT	O
,	O
10	O
(	O
9	O
)/	O
L	O
:	O
165	O
.	O
12	O
	O
31	O
.	O
70	O
vs	O
.	O
254	O
.	O
47	O
	O
70	O
.	O
80	O
],	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
,	O
U	O
/	O
L	O
:	O
70	O
.	O
71	O
	O
46	O
.	O
70	O
vs	O
.	O
212	O
.	O
71	O
	O
141	O
.	O
34	O
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
,	O
U	O
/	O
L	O
:	O
52	O
.	O
47	O
	O
34	O
.	O
68	O
vs	O
.	O
82	O
.	O
41	O
	O
34	O
.	O
60	O
),	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
,	O
mmol	O
/	O
L	O
:	O
5	O
.	O
83	O
	O
4	O
.	O
09	O
vs	O
.	O
7	O
.	O
89	O
	O
5	O
.	O
96	O
),	O
serum	O
creatinine	O
(	O
SCr	O
,	O
mol	O
/	O
L	O
:	O
48	O
.	O
13	O
	O
14	O
.	O
97	O
vs	O
.	O
67	O
.	O
25	O
	O
24	O
.	O
29	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
,	O
U	O
/	O
L	O
:	O
280	O
.	O
10	O
	O
81	O
.	O
77	O
vs	O
.	O
586	O
.	O
35	O
	O
186	O
.	O
71	O
),	O
creatine	O
kinase	O
(	O
CK	O
,	O
U	O
/	O
L	O
:	O
199	O
.	O
12	O
	O
106	O
.	O
75	O
vs	O
.	O
683	O
.	O
00	O
	O
323	O
.	O
21	O
),	O
MB	O
isoenzyme	O
of	O
creatine	O
kinase	O
(	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
,	O
U	O
/	O
L	O
:	O
26	O
.	O
94	O
	O
9	O
.	O
13	O
vs	O
.	O
45	O
.	O
59	O
	O
11	O
.	O
21	O
),	O
serum	O
chlorine	O
anion	O
[	O
Cl	O
(-),	O
mmol	O
/	O
L	O
:	O
95	O
.	O
88	O
	O
6	O
.	O
06	O
vs	O
.	O
102	O
.	O
29	O
	O
7	O
.	O
28	O
],	O
respiratory	O
rate	O
(	O
RR	O
,	O
beats	O
/	O
min	O
:	O
20	O
.	O
88	O
	O
4	O
.	O
30	O
vs	O
.	O
30	O
.	O
06	O
	O
5	O
.	O
78	O
),	O
heart	O
rate	O
(	O
HR	O
,	O
beats	O
/	O
min	O
:	O
82	O
.	O
76	O
	O
17	O
.	O
16	O
vs	O
.	O
113	O
.	O
35	O
	O
16	O
.	O
90	O
),	O
blood	O
pH	O
value	O
(	O
7	O
.	O
34	O
	O
0	O
.	O
44	O
vs	O
.	O
7	O
.	O
39	O
	O
0	O
.	O
03	O
)	O
were	O
all	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

Remarkably	O
,	O
the	O
same	O
protein	O
harboring	O
the	O
sequence	O
GPLG	O
instead	O
of	O
the	O
His	O
(	O
6	O
)	O
tag	O
at	O
its	O
N	O
terminus	O
exhibits	O
a	O
substantially	O
increased	O
,	O
primer	O
-	O
independent	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
.	O

Upon	O
addition	O
of	O
Nsp7	O
,	O
the	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
is	O
further	O
enhanced	O
so	O
that	O
RNA	O
up	O
to	O
template	O
length	O
(	O
67	O
nucleotides	O
)	O
can	O
be	O
synthesized	O
.	O

These	O
results	O
indicate	O
that	O
in	O
case	O
of	O
FCoV	O
as	O
well	O
as	O
of	O
HCoV	O
229E	O
,	O
the	O
formation	O
of	O
a	O
hexadecameric	O
Nsp7	O
:	O
Nsp8	O
complex	O
is	O
not	O
necessary	O
for	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
.	O

The	O
ferret	O
subsequently	O
showed	O
decreasing	O
motor	B-FUNC
activity	I-FUNC
and	O
recumbency	O
and	O
was	O
euthanized	O
at	O
14	O
months	O
of	O
age	O
.	O

As	O
an	O
effective	O
measure	O
of	O
respiratory	O
supports	O
,	O
ECMO	O
may	O
provide	O
pulmonary	O
rest	B-FUNC
and	O
improve	O
gas	O
exchanges	O
in	O
severe	O
ARDS	O
induced	O
by	O
novel	O
H1N1	O
Influenza	O
.	O

TITLE	O
:	O
Diagnostics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
antigen	O
using	O
chicken	O
immunoglobulin	B-FUNC
Y	O
.	O
ABSTRACT	O
:	O

Full	O
-	O
length	O
NP	O
was	O
used	O
for	O
the	O
preparation	O
of	O
mouse	O
monoclonal	O
antibody	B-FUNC
and	O
chicken	O
polyclonal	O
IgY	O
antibodies	O
for	O
the	O
development	O
of	O
heterosandwich	O
ELISA	O
for	O
early	O
diagnostics	O
of	O
SARS	O
-	O
suspected	O
individuals	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
was	O
the	O
use	O
of	O
inexpensive	O
polyclonal	O
IgY	O
antibody	B-FUNC
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
detection	O
system	O
for	O
SARS	O
-	O
CoV	O
at	O
the	O
picogram	O
level	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	B-FUNC
c	I-FUNC
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

Analysis	O
of	O
multiple	O
CoV	O
nsp5	O
structures	O
,	O
and	O
alignment	O
of	O
nonredundant	O
nsp5	O
primary	O
sequences	O
,	O
demonstrated	O
that	O
ts	O
and	O
suppressor	O
residues	O
are	O
not	O
conserved	O
across	O
CoVs	O
and	O
are	O
physically	O
distant	O
(>	O
10	O
	O
)	O
from	O
each	O
other	O
,	O
from	O
catalytic	O
and	O
substrate	O
-	O
binding	B-FUNC
residues	O
,	O
and	O
from	O
the	O
nsp5	O
dimer	O
interface	O
.	O

Here	O
,	O
we	O
describe	O
suppressor	O
mutations	O
within	O
the	O
transplanted	O
BCoV	O
32	O
-	O
nt	O
domain	O
that	O
along	O
with	O
appearance	O
of	O
potential	O
base	B-FUNC
pairings	I-FUNC
identify	O
an	O
RNA	O
-	O
RNA	O
interaction	O
between	O
this	O
domain	O
and	O
a	O
32	O
-	O
nt	O
region	O
	O
200	O
nt	O
downstream	O
within	O
the	O
nonstructural	O
protein	O
1	O
(	O
Nsp1	O
)-	O
coding	O
region	O
.	O

This	O
study	O
represents	O
one	O
of	O
the	O
first	O
comprehensive	O
analyses	O
of	O
lung	O
immunity	O
,	O
including	O
changes	O
in	O
leukocyte	O
populations	O
,	O
lung	O
-	O
specific	O
cytokines	O
,	O
and	O
antibody	B-FUNC
responses	O
following	O
SARS	O
-	O
CoV	O
rechallenge	O
in	O
AGMs	O
.	O

ABSTRACT	O
:	O
Recent	O
research	O
has	O
shown	O
that	O
Coronavirus	O
(	O
CoV	O
)	O
replication	O
depends	O
on	O
active	O
immunophilin	B-FUNC
pathways	O
.	O

Knockdown	O
of	O
the	O
cellular	O
FK506	O
-	O
binding	B-FUNC
proteins	O
FKBP1A	O
and	O
FKBP1B	O
in	O
CaCo2	O
cells	O
prevented	O
replication	O
of	O
HCoV	O
-	O
NL63	O
,	O
suggesting	O
the	O
requirement	O
of	O
these	O
members	O
of	O
the	O
immunophilin	B-FUNC
family	O
for	O
virus	O
growth	O
.	O

GCG	O
showed	O
a	O
competitive	O
inhibition	O
pattern	O
with	O
K	O
(	O
i	O
)	O
value	O
of	O
25	O
	O
1	O
.	O
7	O
M	O
.	O
In	O
molecular	O
docking	O
experiments	O
,	O
GCG	O
displayed	O
a	O
binding	B-FUNC
energy	O
of	O
-	O
14	O
kcal	O
mol	O
(-	O
1	O
)	O
to	O
the	O
active	O
site	O
of	O
3CL	O
(	O
pro	O
)	O
and	O
the	O
galloyl	O
moiety	O
at	O
3	O
-	O
OH	O
position	O
was	O
required	O
for	O
3CL	O
(	O
pro	O
)	O
inhibition	O
activity	O
.	O

Real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
testing	O
yielded	O
a	O
positive	O
result	O
for	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
).	O

The	O
bfFp	O
is	O
a	O
recombinant	O
fusion	O
protein	O
consisting	O
of	O
truncated	O
core	O
-	O
streptavidin	O
fused	O
with	O
anti	O
-	O
DEC	O
-	O
205	O
single	O
chain	O
antibody	B-FUNC
(	O
scFv	O
).	O

The	O
core	O
-	O
streptavidin	O
arm	O
of	O
fusion	O
protein	O
binds	B-FUNC
with	O
biotinylated	O
nanoparticles	O
,	O
while	O
anti	O
-	O
DEC	O
-	O
205	O
scFv	O
imparts	O
targeting	O
specificity	O
to	O
DC	O
DEC	O
-	O
205	O
receptor	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
coronavirus	O
RNA	O
to	O
zinc	O
finger	O
CCHC	O
-	O
type	O
and	O
RNA	O
-	O
binding	B-FUNC
motif	O
1	O
enhances	O
viral	O
replication	O
and	O
transcription	O
.	O

In	O
a	O
screen	O
based	O
on	O
a	O
yeast	O
three	O
-	O
hybrid	O
system	O
using	O
the	O
5	O
'-	O
untranslated	O
region	O
(	O
5	O
'-	O
UTR	O
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
RNA	O
as	O
bait	O
against	O
a	O
human	O
cDNA	O
library	O
derived	O
from	O
HeLa	O
cells	O
,	O
we	O
found	O
a	O
positive	O
candidate	O
cellular	O
protein	O
,	O
zinc	O
finger	O
CCHC	O
-	O
type	O
and	O
RNA	O
-	O
binding	B-FUNC
motif	O
1	O
(	O
MADP1	O
),	O
to	O
be	O
able	O
to	O
interact	O
with	O
this	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
.	O

The	O
RNA	O
-	O
binding	B-FUNC
domain	O
was	O
mapped	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
MADP1	O
and	O
the	O
protein	B-FUNC
binding	I-FUNC
sequence	O
to	O
stem	O
-	O
loop	O
I	O
of	O
IBV	O
5	O
'-	O
UTR	O
.	O

MADP1	O
was	O
found	O
to	O
be	O
translocated	O
to	O
the	O
cytoplasm	O
and	O
partially	O
co	O
-	O
localized	O
with	O
the	O
viral	O
replicase	O
/	O
transcriptase	B-FUNC
complexes	O
(	O
RTCs	O
)	O
in	O
IBV	O
-	O
infected	O
cells	O
,	O
deviating	O
from	O
its	O
usual	O
nuclear	O
localization	O
in	O
a	O
normal	O
cell	O
using	O
indirect	O
immunofluorescence	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
timely	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
catheter	O
in	O
children	O
with	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
while	O
supported	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

In	O
each	O
of	O
these	O
patients	O
,	O
a	O
PD	O
catheter	O
was	O
placed	O
for	O
severe	O
abdominal	O
distension	O
and	O
proven	O
/	O
suspected	O
ACS	B-FUNC
.	O

After	O
ruling	O
out	O
common	O
causes	O
for	O
decreased	O
venous	O
return	O
,	O
ACS	B-FUNC
should	O
be	O
suspected	O
as	O
one	O
of	O
the	O
important	O
causes	O
,	O
especially	O
in	O
patients	O
with	O
massive	O
capillary	O
leak	O
and	O
increasing	O
abdominal	O
distension	O
,	O
among	O
patients	O
supported	O
on	O
ECMO	O
.	O

Timely	O
placement	O
of	O
a	O
PD	O
catheter	O
in	O
patients	O
who	O
develop	O
abdominal	O
distension	O
and	O
ACS	B-FUNC
can	O
substantially	O
improve	O
venous	O
return	O
and	O
thus	O
help	O
maintain	O
adequate	O
tissue	O
perfusion	O
by	O
improving	O
ECMO	O
flows	O
.	O

Although	O
a	O
variety	O
of	O
serologic	O
assays	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
techniques	O
are	O
available	O
for	O
the	O
diagnosis	O
of	O
MP	O
infections	O
,	O
early	O
diagnosis	O
of	O
MP	O
pneumonia	O
is	O
limited	O
by	O
the	O
lack	O
of	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
M	O
antibodies	O
and	O
variable	O
PCR	O
results	O
in	O
the	O
early	O
stages	O
of	O
the	O
infection	O
.	O

An	O
80	O
%	O
lost	O
of	O
its	O
enzymatic	O
activity	O
at	O
a	O
urea	O
concentration	O
lower	O
than	O
1M	O
showed	O
a	O
close	O
correlation	O
with	O
unfolding	O
of	O
the	O
zinc	O
-	O
binding	B-FUNC
domain	O
.	O

The	O
virus	O
was	O
detected	O
in	O
11	O
(	O
8	O
.	O
1	O
%)	O
of	O
136	O
rabbit	O
fecal	O
samples	O
by	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
a	O
viral	O
load	O
of	O
up	O
to	O
10	O
(	O
8	O
)	O
copies	O
/	O
ml	O
.	O

A	O
comparison	O
of	O
the	O
conserved	O
replicase	O
domains	O
showed	O
that	O
RbCoV	O
HKU14	O
possessed	O
<	O
90	O
%	O
amino	O
acid	O
identities	O
to	O
most	O
members	O
of	O
Betacoronavirus	O
1	O
in	O
ADP	O
-	O
ribose	O
1	O
-	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
and	O
nidoviral	O
uridylate	O
-	O
specific	O
endoribonuclease	O
(	O
NendoU	O
),	O
indicating	O
that	O
RbCoV	O
HKU14	O
should	O
represent	O
a	O
separate	O
species	O
.	O

Domestic	O
crossbred	O
,	O
Persian	O
and	O
Himalayan	O
cats	O
were	O
significantly	O
under	O
-	O
represented	O
in	O
the	O
FIP	O
cohort	O
,	O
while	O
several	O
breeds	O
were	O
over	O
-	O
represented	O
,	O
including	O
British	O
Shorthair	O
,	O
Devon	O
Rex	B-FUNC
and	O
Abyssinian	O
.	O

TITLE	O
:	O
Ameliorative	O
effect	O
of	O
a	O
microbial	O
feed	O
additive	O
on	O
infectious	O
bronchitis	O
virus	O
antibody	B-FUNC
titer	O
and	O
stress	O
index	O
in	O
broiler	O
chicks	O
fed	O
deoxynivalenol	O
.	O

Therefore	O
,	O
an	O
experiment	O
with	O
1	O
-	O
d	O
-	O
old	O
male	O
broilers	O
(	O
Ross	O
308	O
)	O
was	O
carried	O
out	O
to	O
examine	O
the	O
effects	O
of	O
feeding	O
DON	O
-	O
contaminated	O
low	O
-	O
protein	O
grower	O
diets	O
on	O
performance	O
,	O
serum	O
biochemical	O
parameters	O
,	O
lymphoid	O
organ	O
weight	O
,	O
and	O
antibody	B-FUNC
titers	O
to	O
infectious	O
bronchitis	O
vaccination	O
in	O
serum	O
and	O
to	O
evaluate	O
the	O
effects	O
of	O
Mycofix	O
select	O
dietary	O
supplementation	O
in	O
either	O
the	O
presence	O
or	O
absence	O
of	O
DON	O
in	O
broilers	O
.	O

ABSTRACT	O
:	O
A	O
one	O
-	O
step	O
multiplex	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
method	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
five	O
viruses	O
causing	O
diarrhea	O
in	O
adult	O
cattle	O
:	O
bovine	O
group	O
A	O
rotavirus	O
(	O
GAR	B-FUNC
),	O
bovine	O
group	O
B	O
rotavirus	O
(	O
GBR	O
),	O
bovine	O
group	O
C	O
rotavirus	O
(	O
GCR	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
and	O
bovine	O
torovirus	O
(	O
BToV	O
).	O

The	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
with	O
newly	O
designed	O
primers	O
to	O
detect	O
GAR	B-FUNC
had	O
higher	O
sensitivity	O
than	O
a	O
single	O
RT	O
-	O
PCR	O
with	O
conventional	O
primers	O
,	O
with	O
no	O
false	O
-	O
positive	O
reactions	O
observed	O
for	O
ten	O
other	O
kinds	O
of	O
bovine	O
RNA	O
viruses	O
To	O
assess	O
its	O
field	O
applicability	O
,	O
59	O
of	O
60	O
fecal	O
samples	O
containing	O
one	O
of	O
these	O
five	O
viruses	O
from	O
all	O
25	O
epidemic	O
diarrhea	O
outbreaks	O
in	O
adult	O
cattle	O
were	O
positive	O
in	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
assay	O
.	O

Biflavonoids	O
appeared	O
to	O
be	O
potent	O
inhibitors	O
of	O
DV	O
-	O
NS5	O
RdRp	B-FUNC
with	O
IC	O
(	O
50	O
)	O
s	O
between	O
0	O
.	O
26	O
and	O
3	O
.	O
12	O
M	O
.	O
Inhibitory	O
activity	O
evaluations	O
against	O
the	O
RNA	O
polymerase	O
from	O
other	O
Flaviviridae	O
viruses	O
allowed	O
us	O
to	O
conclude	O
that	O
these	O
compounds	O
are	O
specific	O
inhibitors	O
of	O
the	O
DV	O
RNA	O
polymerase	O
.	O

Compared	O
with	O
nonobstetric	O
rabbits	O
,	O
obstetric	O
rabbits	O
had	O
more	O
severe	O
lung	O
injury	O
as	O
indicated	O
by	O
alveolar	O
and	O
interstitial	O
fluid	O
accumulation	O
and	O
marked	O
neutrophil	O
sequestration	O
and	O
greater	O
lung	O
injury	O
score	O
,	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
levels	O
,	O
and	O
nuclear	O
factor	O
-	O
B	O
activation	O
,	O
and	O
lower	O
serum	O
interleukin	O
-	O
10	O
levels	O
(	O
p	O
<.	O
05	O
for	O
all	O
).	O

Pathway	O
enrichment	O
analysis	O
also	O
identified	O
a	O
potential	O
novel	O
host	O
response	O
,	O
the	O
Parkin	O
-	O
Ubiquitin	B-FUNC
Proteasomal	O
System	O
(	O
Parkin	O
-	O
UPS	O
)	O
pathway	O
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
progression	O
of	O
neurodegenerative	O
Parkinson	O
'	O
s	O
disease	O
.	O

ABSTRACT	O
:	O
Viruses	O
enter	O
the	O
host	O
cell	O
by	O
binding	B-FUNC
cellular	O
receptors	O
that	O
allow	O
appropriate	O
delivery	O
of	O
the	O
viral	O
genome	O
.	O

Similarly	O
,	O
the	O
mean	O
IBV	O
ELISA	O
antibody	B-FUNC
titres	O
in	O
the	O
toxin	O
fed	O
groups	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
as	O
compared	O
with	O
the	O
IBV	O
ELISA	O
antibody	B-FUNC
titres	O
of	O
IBV	O
infected	O
but	O
not	O
toxin	O
fed	O
group	O
,	O
at	O
all	O
intervals	O
.	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	O
protease	O
TMPRSS2	O
activates	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
on	O
the	O
cell	O
surface	O
following	O
receptor	B-FUNC
binding	I-FUNC
during	O
viral	O
entry	O
into	O
cells	O
.	O

The	O
IPV	O
induced	O
the	O
IgG1	O
subclass	O
of	O
serum	O
antibodies	O
and	O
expression	O
of	O
the	O
cytokine	O
interleukin	O
-	O
4	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
),	O
suggesting	O
that	O
the	O
IPV	O
generated	O
a	O
predominantly	O
Th2	O
-	O
type	O
immune	O
response	O
.	O

The	O
DNA	O
vaccine	O
was	O
found	O
to	O
mediate	O
primarily	O
a	O
cellular	O
immune	O
response	O
with	O
high	O
levels	O
of	O
IgG2a	O
and	O
the	O
cytokines	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
).	O

However	O
,	O
mice	O
that	O
were	O
vaccinated	O
twice	O
with	O
the	O
DNA	O
vaccine	O
and	O
boosted	O
with	O
the	O
IPV	O
could	O
mount	O
a	O
sufficient	O
neutralizing	O
antibody	B-FUNC
response	O
against	O
live	O
PHE	O
-	O
CoV	O
,	O
with	O
little	O
variation	O
in	O
IgG1	O
and	O
IgG2a	O
levels	O
,	O
and	O
showed	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
commercial	O
rapid	O
test	O
kit	B-FUNC
for	O
detecting	O
bovine	O
enteric	O
pathogens	O
in	O
feces	O
.	O

ABSTRACT	O
:	O
Recently	O
a	O
commercial	O
antigen	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	B-FUNC
in	O
the	O
form	O
of	O
a	O
dipstick	O
(	O
Bovine	O
Enterichek	O
,	O
Biovet	O
Inc	O
.)	O
was	O
made	O
available	O
to	O
bovine	O
practitioners	O
and	O
producers	O
for	O
the	O
rapid	O
detection	O
of	O
Betacoronavirus	O
1	O
(	O
BCV	O
-	O
1	O
),	O
Rotavirus	O
A	O
(	O
RV	O
-	O
A	O
),	O
Escherichia	O
coli	O
K99	O
(+),	O
and	O
Cryptosporidium	O
parvum	O
in	O
feces	O
from	O
diarrheic	O
calves	O
.	O

However	O
,	O
test	O
results	O
for	O
BCV	O
-	O
1	O
by	O
the	O
kit	B-FUNC
should	O
be	O
interpreted	O
with	O
caution	O
due	O
to	O
low	O
specificity	O
and	O
sensitivity	O
of	O
the	O
kit	B-FUNC
.	O

ABSTRACT	O
:	O
Fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
(	O
S450	O
-	O
650	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
epitopes	O
capable	O
of	O
being	O
recognized	O
by	O
convalescent	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Kn2	O
-	O
7	O
could	O
inhibit	O
all	O
members	O
of	O
a	O
standard	O
reference	O
panel	O
of	O
HIV	O
-	O
1	O
subtype	O
B	O
pseudotyped	O
virus	O
(	O
PV	O
)	O
with	O
CCR5	O
-	O
tropic	O
and	O
CXCR4	B-FUNC
-	O
tropic	O
NL4	O
-	O
3	O
PV	O
strain	O
.	O

Binding	B-FUNC
assay	O
of	O
Kn2	O
-	O
7	O
to	O
HIV	O
-	O
1	O
PV	O
by	O
Octet	O
Red	O
system	O
suggested	O
the	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
was	O
correlated	O
with	O
a	O
direct	O
interaction	O
between	O
Kn2	O
-	O
7	O
and	O
HIV	O
-	O
1	O
envelope	O
.	O

These	O
SARS	O
-	O
CoV	O
vaccines	O
all	O
induced	O
antibody	B-FUNC
and	O
protection	O
against	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
challenge	O
of	O
mice	O
given	O
any	O
of	O
the	O
vaccines	O
led	O
to	O
occurrence	O
of	O
Th2	O
-	O
type	O
immunopathology	O
suggesting	O
hypersensitivity	O
to	O
SARS	O
-	O
CoV	O
components	O
was	O
induced	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
immunosuppressive	O
agent	O
that	O
targets	O
the	O
nuclear	O
factor	O
pathway	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
bind	B-FUNC
cellular	O
cyclophilins	O
(	O
CyP	O
),	O
dose	O
-	O
dependently	O
inhibited	O
FIPV	O
replication	O
in	O
vitro	O
.	O

FK506	O
(	O
an	O
immunosuppressor	O
of	O
the	O
pathway	O
that	O
binds	B-FUNC
cellular	O
FK506	O
-	O
binding	B-FUNC
protein	O
(	O
FKBP	O
)	O
but	O
not	O
CyP	O
)	O
did	O
not	O
affect	O
FIPV	O
replication	O
.	O

Cell	O
death	O
induced	O
by	O
HCoV	O
-	O
229E	O
is	O
independent	O
of	O
TRAIL	O
,	O
FasL	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
and	O
caspase	B-FUNC
activity	I-FUNC
,	O
indicating	O
that	O
viral	O
replication	O
is	O
directly	O
responsible	O
for	O
the	O
observed	O
cytopathic	O
effects	O
.	O

Data	O
indicated	O
that	O
the	O
number	O
of	O
infected	O
chickens	O
and	O
viral	O
RNA	O
detection	O
from	O
tissues	O
was	O
reduced	O
with	O
increasing	O
antibody	B-FUNC
titer	O
on	O
day	O
20	O
PI	O
.	O

The	O
E	O
protein	O
has	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
in	O
vitro	O
,	O
although	O
a	O
role	O
for	O
channel	B-FUNC
activity	I-FUNC
in	O
infection	O
has	O
not	O
been	O
established	O
.	O

The	O
substrate	O
used	O
is	O
a	O
quenched	O
peptide	O
(	O
bis	B-FUNC
-	O
AAF	O
-	O
R110	O
)	O
that	O
releases	O
a	O
fluorophore	O
upon	O
proteolytic	O
-	O
cleavage	O
by	O
proteases	O
;	O
the	O
latter	O
released	O
from	O
dead	O
cells	O
.	O

While	O
none	O
of	O
the	O
compounds	O
,	O
examined	O
in	O
our	O
study	O
inhibited	O
the	O
DNA	O
unwinding	O
activity	O
or	O
ATPase	B-FUNC
activity	I-FUNC
of	O
human	O
HCV	O
helicase	O
protein	O
,	O
we	O
found	O
that	O
myricetin	O
and	O
scutellarein	O
potently	O
inhibit	O
the	O
SARS	O
-	O
CoV	O
helicase	O
protein	O
in	O
vitro	O
by	O
affecting	O
the	O
ATPase	B-FUNC
activity	I-FUNC
,	O
but	O
not	O
the	O
unwinding	O
activity	O
,	O
nsP13	O
.	O

Additionally	O
,	O
the	O
E	O
protein	O
has	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
,	O
interacts	O
with	O
host	O
proteins	O
,	O
and	O
may	O
have	O
multiple	O
membrane	O
topologies	O
.	O

Positive	O
specimens	O
were	O
used	O
to	O
develop	O
novel	O
reverse	O
transcriptase	B-FUNC
real	O
-	O
time	O
PCRs	O
(	O
RT	O
-	O
rtPCRs	O
)	O
for	O
HCoV	O
detection	O
.	O

The	O
majority	O
of	O
published	O
reports	O
of	O
ACS	B-FUNC
are	O
in	O
neonates	O
with	O
abdominal	O
wall	O
defects	O
and	O
in	O
adults	O
following	O
trauma	O
or	O
burns	O
,	O
but	O
it	O
is	O
poorly	O
described	O
in	O
children	O
.	O

We	O
describe	O
the	O
unusual	O
presentation	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
with	O
a	O
long	O
history	O
of	O
chronic	O
constipation	O
who	O
developed	O
acute	O
ACS	B-FUNC
requiring	O
resuscitative	O
measures	O
and	O
emergent	O
disimpaction	O
.	O

Although	O
ACS	B-FUNC
secondary	O
to	O
constipation	O
is	O
extremely	O
unusual	O
,	O
this	O
case	O
illustrates	O
the	O
need	O
to	O
actively	O
treat	O
constipation	O
and	O
what	O
can	O
happen	O
if	O
it	O
is	O
not	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
series	O
of	O
3	O
-	O
hydroxyquinolin	O
-	O
2	O
(	O
1H	O
)-	O
ones	O
as	O
selective	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
associated	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
.	O

Most	O
compounds	O
presented	O
selective	O
inhibitory	O
properties	O
in	O
the	O
10	O
-	O
20	O
M	O
range	O
against	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
associated	O
ribonuclease	B-FUNC
H	I-FUNC
activity	I-FUNC
,	O
without	O
affecting	O
the	O
integrase	O
and	O
reverse	O
transcriptase	B-FUNC
DNA	O
polymerase	O
activities	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
recombinant	O
canine	O
coronavirus	O
with	O
a	O
distinct	O
receptor	O
-	O
binding	B-FUNC
(	O
S1	O
)	O
domain	O
.	O

To	O
elucidate	O
the	O
nature	O
of	O
the	O
intermediates	O
we	O
carried	O
out	O
transient	O
kinetic	O
analysis	O
of	O
the	O
nsp13	O
helicase	B-FUNC
activity	I-FUNC
.	O

We	O
also	O
showed	O
that	O
nsp12	O
,	O
the	O
SARS	O
-	O
CoV	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
enhances	O
(	O
2	O
-	O
fold	O
)	O
the	O
catalytic	O
efficiency	O
of	O
nsp13	O
by	O
increasing	O
the	O
step	O
size	O
of	O
nucleic	O
acid	O
(	O
RNA	O
/	O
RNA	O
or	O
DNA	O
/	O
DNA	O
)	O
unwinding	O
.	O

This	O
effect	O
is	O
specific	O
for	O
SARS	O
-	O
CoV	O
nsp12	O
,	O
as	O
no	O
change	O
in	O
nsp13	O
activity	O
was	O
observed	O
when	O
foot	O
-	O
and	O
-	O
mouth	O
-	O
disease	O
virus	O
RdRp	B-FUNC
was	O
used	O
in	O
place	O
of	O
nsp12	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
established	O
rOv	O
-	O
ASP	O
-	O
1	O
'	O
s	O
adjuvanticity	O
in	O
mice	O
during	O
the	O
course	O
of	O
two	O
sequential	O
vaccinations	O
using	O
two	O
vaccine	O
model	O
systems	O
:	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
and	O
a	O
commercial	O
influenza	O
virus	O
hemagglutinin	O
(	O
HA	O
)	O
vaccine	O
comprised	O
of	O
three	O
virus	O
strains	O
.	O

Moreover	O
,	O
the	O
adjuvanticity	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
was	O
retained	O
with	O
an	O
efficacy	O
similar	O
to	O
that	O
obtained	O
when	O
it	O
was	O
used	O
for	O
a	O
first	O
vaccination	O
,	O
even	O
though	O
a	O
high	O
level	O
of	O
anti	O
-	O
rOv	O
-	O
ASP	O
-	O
1	O
antibodies	O
was	O
present	O
in	O
the	O
sera	B-FUNC
of	O
mice	O
before	O
the	O
administration	O
of	O
the	O
second	O
vaccine	O
.	O

To	O
further	O
demonstrate	O
its	O
utility	O
as	O
an	O
adjuvant	O
for	O
human	O
use	O
,	O
we	O
also	O
immunized	O
non	O
-	O
human	O
primates	O
(	O
NHPs	O
)	O
with	O
RBD	O
plus	O
rOv	O
-	O
ASP	O
-	O
1	O
and	O
showed	O
that	O
rOv	O
-	O
ASP	O
-	O
1	O
could	O
induce	O
high	O
titres	O
of	O
functional	O
and	O
protective	O
anti	O
-	O
RBD	O
antibody	B-FUNC
responses	O
in	O
NHPs	O
.	O

(-)-	O
catechin	O
gallate	O
and	O
(-)-	O
gallocatechin	O
gallate	O
attenuated	O
the	O
binding	B-FUNC
affinity	O
in	O
a	O
concentrated	O
manner	O
as	O
evidenced	O
by	O
QDs	O
-	O
conjugated	O
RNA	O
oligonucleotide	O
on	O
a	O
designed	O
biochip	O
.	O

Hence	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
a	O
broader	O
range	O
of	O
antigenic	O
regions	O
that	O
have	O
strong	O
antibody	B-FUNC
eliciting	O
ability	O
;	O
these	O
could	O
then	O
be	O
applied	O
for	O
development	O
of	O
an	O
IBV	O
-	O
diagnostic	O
tool	O
.	O

The	O
antigenicity	O
was	O
confirmed	O
using	O
IBV	O
immunized	O
sera	B-FUNC
.	O

Performance	O
of	O
the	O
S	O
subfragments	O
was	O
evaluated	O
by	O
ELISA	O
using	O
a	O
panel	O
of	O
field	O
chicken	O
sera	B-FUNC
with	O
known	O
IBV	O
titres	O
determined	O
by	O
a	O
commercial	O
kit	B-FUNC
.	O

The	O
B	O
and	O
T	O
lymphocyte	O
attenuator	O
(	O
BTLA	O
)	O
is	O
an	O
immunoglobulin	B-FUNC
-	O
domain	O
-	O
containing	O
protein	O
that	O
has	O
the	O
capacity	O
to	O
maintain	O
peripheral	O
tolerance	O
and	O
limit	O
immunopathological	O
damage	O
during	O
immune	O
responses	O
.	O

This	O
effect	O
is	O
due	O
to	O
rapid	O
,	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-FUNC
)-	O
dependent	O
apoptosis	O
of	O
MHV	O
-	O
3	O
-	O
infected	O
macrophages	O
in	O
BTLA	O
-/-	O
mice	O
.	O

TITLE	O
:	O
IFN	O
-	O
	O
protects	O
from	O
lethal	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
mediated	O
viral	O
encephalomyelitis	O
independent	O
of	O
neutrophils	O
.	O

In	O
contrast	O
to	O
recipients	O
of	O
WT	O
CD4	O
+	O
T	O
cells	O
,	O
extensive	O
neutrophil	O
infiltration	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
within	O
the	O
CNS	O
in	O
recipients	O
of	O
GKO	O
CD4	O
+	O
T	O
cells	O
provided	O
a	O
model	O
to	O
directly	O
assess	O
their	O
contribution	O
(	O
s	O
)	O
to	O
disease	O
.	O

Recipients	O
of	O
WT	O
CD4	O
+	O
T	O
cells	O
depleted	O
of	O
IFN	O
-	O
	O
did	O
not	O
express	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
and	O
were	O
spared	O
from	O
mortality	O
despite	O
abundant	O
CNS	O
neutrophil	O
infiltration	O
,	O
indicating	O
that	O
mortality	O
was	O
not	O
mediated	O
by	O
excessive	O
CNS	O
neutrophil	O
accumulation	O
.	O

These	O
data	O
demonstrate	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
mediates	O
detrimental	O
clinical	O
consequences	O
in	O
an	O
IFN	O
-	O
	O
-	O
deprived	O
environment	O
,	O
independent	O
of	O
extensive	O
neutrophil	O
accumulation	O
or	O
GM	O
-	O
CSF	O
upregulation	O
.	O

The	O
results	O
also	O
suggest	O
that	O
IFN	O
-	O
	O
overrides	O
the	O
detrimental	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
effector	O
responses	O
via	O
a	O
mechanism	O
downstream	O
of	O
transcriptional	O
regulation	O
.	O

Furthermore	O
,	O
co	O
-	O
transfer	O
of	O
WT	O
and	O
GKO	O
CD4	O
+	O
T	O
cells	O
prolonged	O
survival	O
in	O
an	O
IFN	O
-	O
	O
dependent	O
manner	O
,	O
although	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
transcription	O
was	O
not	O
reduced	O
.	O

TITLE	O
:	O
Immune	O
responses	O
induced	O
by	O
DNA	O
vaccines	O
bearing	O
Spike	O
gene	O
of	O
PEDV	O
combined	O
with	O
porcine	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

Herein	O
,	O
we	O
generated	O
three	O
distinct	O
DNA	O
constructs	O
in	O
the	O
eukaryotic	O
expression	O
plasmid	O
pVAX1	O
;	O
one	O
encoding	O
the	O
S	O
protein	O
[	O
pVAX1	O
-(	O
PEDV	O
-	O
S	O
)],	O
the	O
second	O
encoding	O
the	O
N	O
-	O
terminal	O
fragment	O
(	O
S1	O
)	O
[	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
)]	O
containing	O
potent	O
antigenic	O
sites	O
,	O
and	O
the	O
third	O
expressing	O
the	O
porcine	O
interleukin	O
-	O
18	O
(	O
pIL	O
-	O
18	O
)	O
[	O
pVAX1	O
-(	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
)].	O

Kunming	O
mice	O
were	O
injected	O
separately	O
with	O
each	O
of	O
these	O
constructs	O
or	O
with	O
a	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
)/	O
pVAX1	O
-(	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
)	O
combination	O
,	O
an	O
attenuated	O
PEDV	O
vaccine	O
,	O
or	O
vector	O
only	O
control	O
.	O

In	O
all	O
cases	O
,	O
results	O
showed	O
that	O
pVAX1	O
-(	O
PEDV	O
-	O
S	O
)	O
and	O
the	O
combination	O
of	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
)	O
with	O
pVAX1	O
-(	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
)	O
induced	O
the	O
strongest	O
responses	O
;	O
however	O
,	O
pIL	O
-	O
18	O
had	O
no	O
adjuvant	O
effects	O
when	O
given	O
in	O
combination	O
with	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
).	O

TITLE	O
:	O
Short	O
peptides	O
derived	O
from	O
the	O
interaction	O
domain	O
of	O
SARS	O
coronavirus	O
nonstructural	O
protein	O
nsp10	O
can	O
suppress	O
the	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
of	O
nsp10	O
/	O
nsp16	O
complex	O
.	O

As	O
nsp10	O
acts	O
as	O
an	O
essential	O
trigger	O
to	O
activate	O
the	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
of	O
nsp16	O
,	O
short	O
peptides	O
derived	O
from	O
nsp10	O
may	O
have	O
inhibitory	O
effect	O
on	O
viral	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
revealed	O
that	O
the	O
domain	O
of	O
aa	O
65	O
-	O
107	O
of	O
nsp10	O
was	O
sufficient	O
for	O
its	O
interaction	O
with	O
nsp16	O
and	O
the	O
region	O
of	O
aa	O
42	O
-	O
120	O
in	O
nsp10	O
,	O
which	O
is	O
larger	O
than	O
the	O
interaction	O
domain	O
,	O
was	O
needed	O
for	O
stimulating	O
the	O
nsp16	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
.	O

We	O
further	O
showed	O
that	O
two	O
short	O
peptides	O
derived	O
from	O
the	O
interaction	O
domain	O
of	O
nsp10	O
could	O
inhibit	O
the	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
of	O
SARS	O
-	O
CoV	O
nsp16	O
/	O
10	O
complex	O
,	O
thus	O
providing	O
a	O
novel	O
strategy	O
and	O
proof	O
-	O
of	O
-	O
principle	O
study	O
for	O
developing	O
peptide	O
inhibitors	O
against	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
A	O
85	O
-	O
year	O
-	O
old	O
patient	O
,	O
initially	O
treated	O
for	O
aspiration	O
pneumonia	O
on	O
the	O
intensive	O
care	O
unit	O
acutely	O
complained	O
again	O
of	O
nausea	O
which	O
was	O
immediately	O
treated	O
by	O
an	O
i	O
.	O
v	O
.	O
bolus	O
of	O
metoclopramide	O
(	O
MCP	B-FUNC
).	O

Blood	O
gas	O
analysis	O
(	O
BGA	O
)	O
however	O
showed	O
a	O
massive	O
increase	O
in	O
methemoglobinemia	O
from	O
0	O
.	O
5	O
%	O
just	O
prior	O
to	O
MCP	B-FUNC
injection	O
to	O
53	O
.	O
1	O
%	O
after	O
MCP	B-FUNC
injection	O
;	O
simultaneously	O
the	O
pO2	O
decreased	O
from	O
74	O
auf	O
54	O
mmHg	O
and	O
the	O
pCO2	O
from	O
37	O
.	O
7	O
to	O
34	O
.	O
1	O
mmHg	O
.	O

The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	O
following	O
the	O
administration	O
of	O
MCP	B-FUNC
is	O
described	O
in	O
this	O
case	O
report	O
.	O

Rapidly	O
evolving	O
dyspnoea	O
following	O
administration	O
of	O
MCP	B-FUNC
should	O
instantly	O
lead	O
to	O
the	O
consideration	O
of	O
acute	O
methemoglobinemia	O
as	O
differential	O
diagnosis	O
.	O

CONCLUSIONS	O
:	O
The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	O
following	O
the	O
administration	O
of	O
MCP	B-FUNC
is	O
described	O
in	O
this	O
case	O
report	O
.	O

Through	O
two	O
national	O
case	O
-	O
series	O
conducted	O
during	O
spring	O
and	O
fall	O
of	O
2009	O
,	O
medical	O
charts	O
were	O
reviewed	O
on	O
ICU	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
pH1N1	O
infection	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

Nebulized	O
A77	O
-	O
1726	O
also	O
reversed	O
influenza	O
-	O
induced	O
increases	O
in	O
lung	O
water	O
content	O
and	O
volume	O
,	O
improved	O
pulmonary	O
mechanics	O
,	O
reduced	O
bronchoalveolar	O
lavage	O
fluid	O
ATP	O
and	O
neutrophil	O
content	O
,	O
and	O
increased	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentrations	O
.	O

ABSTRACT	O
:	O
Even	O
though	O
the	O
effect	O
of	O
antibody	B-FUNC
affinity	O
on	O
neutralization	O
potency	O
is	O
well	O
documented	O
,	O
surprisingly	O
,	O
its	O
impact	O
on	O
neutralization	O
breadth	O
and	O
escape	O
has	O
not	O
been	O
systematically	O
determined	O
.	O

As	O
expected	O
,	O
antigen	O
affinity	O
was	O
shown	O
to	O
correlate	O
directly	O
with	O
neutralization	O
potency	O
toward	O
the	O
icUrbani	O
strain	O
of	O
SARS	O
-	O
CoV	O
.	O
Additionally	O
,	O
the	O
highest	O
-	O
affinity	O
antibody	B-FUNC
fragment	O
displayed	O
10	O
-	O
fold	O
-	O
increased	O
broad	O
neutralization	O
in	O
vitro	O
and	O
completely	O
protected	O
against	O
several	O
SARS	O
-	O
CoV	O
strains	O
containing	O
substitutions	O
associated	O
with	O
antibody	B-FUNC
escape	O
.	O

Escape	O
from	O
the	O
highest	O
-	O
affinity	O
variant	O
required	O
reduced	O
selective	O
pressure	O
and	O
multiple	O
substitutions	O
in	O
the	O
binding	B-FUNC
epitope	O
.	O

A	O
screen	O
utilizing	O
a	O
recombinant	O
Vesicular	O
Stomatitis	O
Virus	O
(	O
VSV	O
)	O
encoding	O
Zaire	O
ebolavirus	O
GP	O
identified	O
four	O
Chinese	O
Hamster	O
Ovary	O
(	O
CHO	B-FUNC
)	O
cell	O
lines	O
resistant	O
to	O
GP	O
-	O
mediated	O
viral	O
entry	O
.	O

Washes	O
and	O
flocked	O
swabs	O
collected	O
from	O
children	O
<	O
3	O
years	O
old	O
hospitalized	O
with	O
a	O
lower	O
respiratory	O
tract	O
infection	O
were	O
tested	O
for	O
parainfluenza	O
virus	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
and	O
metapneumovirus	O
(	O
Group	O
1	O
)	O
and	O
adenovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
(	O
Group	O
2	O
)	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

Effects	O
of	O
PTX3	O
on	O
viral	O
binding	B-FUNC
and	O
infectivity	O
were	O
determined	O
in	O
vitro	O
.	O

Moreover	O
,	O
SSYA10	O
-	O
001	O
does	O
not	O
affect	O
ATP	O
hydrolysis	O
or	O
nsp13	O
binding	B-FUNC
to	O
the	O
nucleic	O
acid	O
substrate	O
.	O

SSYA10	O
-	O
001	O
did	O
not	O
inhibit	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
other	O
bacterial	O
and	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
,	O
or	O
reverse	O
transcriptase	B-FUNC
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
neutralizing	O
epitope	O
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
:	O
M	O
cell	O
targeting	O
ligand	B-FUNC
fusion	O
protein	O
expressed	O
in	O
transgenic	O
rice	O
calli	O
.	O

Mice	O
immunized	O
with	O
transgenic	O
rice	O
calli	O
protein	O
extracts	O
induced	O
significant	O
serum	O
IgG	O
and	O
fecal	O
IgA	O
antibody	B-FUNC
levels	O
against	O
purified	O
bacterial	O
COE	O
.	O

The	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
were	O
confirmed	O
by	O
measuring	O
COE	O
-	O
specific	O
IgG	O
and	O
IgA	O
antibody	B-FUNC
-	O
secreting	O
cells	O
in	O
the	O
lymphocytes	O
extracted	O
from	O
the	O
spleen	O
and	O
COE	O
-	O
specific	O
IgA	O
antibody	B-FUNC
-	O
secreting	O
cells	O
in	O
the	O
Peyer	O
'	O
s	O
patches	O
from	O
immunized	O
mice	O
.	O

A	O
fast	B-FUNC
-	O
track	O
and	O
cost	O
-	O
effective	O
ventilation	O
strategy	O
for	O
the	O
retrofitting	O
of	O
existing	O
general	O
wards	O
could	O
help	O
hospitals	O
deal	O
with	O
patient	O
surges	O
.	O

This	O
article	O
reviews	O
the	O
effectiveness	O
of	O
a	O
fast	B-FUNC
-	O
track	O
,	O
makeshift	O
isolation	O
approach	O
employed	O
during	O
the	O
SARS	O
outbreak	O
which	O
involved	O
installing	O
simple	O
window	O
-	O
mounted	O
exhaust	O
fans	O
to	O
create	O
negative	O
-	O
pressure	O
airflow	O
in	O
hospital	O
general	O
wards	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
that	O
proteomic	O
fingerprints	O
were	O
present	O
in	O
sera	B-FUNC
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
could	O
separate	O
patients	O
into	O
subgroups	O
with	O
different	O
prognoses	O
.	O

It	O
was	O
found	O
that	O
these	O
cells	O
were	O
hyperactivated	O
after	O
MHV	O
-	O
3	O
infection	O
with	O
a	O
production	O
of	O
TNF	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	O
-	O
17A	O
.	O

We	O
demonstrate	O
that	O
activation	O
of	O
TLR3	O
with	O
the	O
synthetic	O
ligand	B-FUNC
poly	O
I	O
:	O
C	O
mediates	O
antiviral	O
immunity	O
that	O
diminishes	O
(	O
MHV	O
-	O
A59	O
)	O
or	O
suppresses	O
(	O
MHV	O
-	O
JHM	O
,	O
MHV	O
-	O
3	O
)	O
virus	O
production	O
in	O
macrophages	O
.	O

TITLE	O
:	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
Still	O
Remains	O
a	O
New	O
Drug	O
Target	O
:	O
Structure	O
,	O
Function	O
,	O
Classical	O
Inhibitors	O
,	O
and	O
New	O
Inhibitors	O
with	O
Innovative	O
Mechanisms	O
of	O
Actions	O
.	O

This	O
process	O
is	O
accomplished	O
by	O
the	O
virus	O
-	O
coded	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
protein	O
,	O
which	O
is	O
a	O
primary	O
target	O
in	O
the	O
current	O
treatments	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
is	O
involved	O
in	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
biochemical	O
properties	O
of	O
a	O
full	O
-	O
length	O
recombinant	O
SARS	O
-	O
CoV	O
nsp12	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

The	O
RdRp	B-FUNC
activity	O
was	O
strictly	O
dependent	O
on	O
Mn	O
(	O
2	O
+).	O

The	O
in	O
vitro	O
RdRp	B-FUNC
assay	O
system	O
established	O
with	O
a	O
full	O
-	O
length	O
nsp12	O
will	O
be	O
useful	O
for	O
understanding	O
the	O
mechanisms	O
of	O
coronavirus	O
replication	O
and	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

It	O
is	O
classified	O
as	O
a	O
class	O
I	O
fusion	O
protein	O
,	O
and	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
the	O
receptor	O
on	O
the	O
host	O
cell	O
as	O
well	O
as	O
mediating	O
the	O
fusion	O
of	O
host	O
and	O
viral	O
membranes	O
-	O
A	O
process	O
driven	O
by	O
major	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
.	O

This	O
review	O
discusses	O
coronavirus	O
entry	O
mechanisms	O
focusing	O
on	O
the	O
different	O
triggers	O
used	O
by	O
coronaviruses	O
to	O
initiate	O
the	O
conformational	O
change	O
of	O
the	O
S	O
protein	O
:	O
receptor	B-FUNC
binding	I-FUNC
,	O
low	O
pH	O
exposure	O
and	O
proteolytic	O
activation	O
.	O

The	O
results	O
of	O
the	O
study	O
suggest	O
that	O
zinc	O
salts	O
do	O
not	O
interfere	O
with	O
TGEV	O
-	O
cell	O
binding	B-FUNC
but	O
that	O
they	O
mediate	O
antiviral	O
effects	O
through	O
inhibition	O
of	O
viral	O
penetration	O
or	O
egress	O
or	O
the	O
intracellular	O
phase	O
of	O
the	O
viral	O
life	O
-	O
cycle	O
.	O

TITLE	O
:	O
Comparison	O
of	O
three	O
multiplex	O
PCR	O
assays	O
for	O
the	O
detection	O
of	O
respiratory	O
viral	O
infections	O
:	O
evaluation	O
of	O
xTAG	O
respiratory	O
virus	O
panel	O
fast	B-FUNC
assay	O
,	O
RespiFinder	O
19	O
assay	O
and	O
RespiFinder	O
SMART	O
22	O
assay	O
.	O

The	O
analytical	O
sensitivity	O
of	O
three	O
multiplex	O
PCR	O
assays	O
,	O
RespiFinder	O
-	O
19	O
,	O
RespiFinder	O
-	O
SMART	O
-	O
22	O
and	O
xTAG	O
-	O
Respiratory	O
-	O
Virus	O
-	O
Panel	O
-	O
Fast	B-FUNC
-	O
Assay	O
(	O
RVP	O
),	O
were	O
compared	O
to	O
monoplex	O
real	O
-	O
time	O
PCR	O
with	O
quantified	O
standardized	O
control	O
material	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
was	O
determined	O
in	O
channels	O
formed	O
in	O
planar	O
lipid	O
bilayers	O
by	O
peptides	O
representing	O
either	O
the	O
transmembrane	O
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
E	O
protein	O
,	O
or	O
the	O
full	O
-	O
length	O
E	O
protein	O
.	O

Western	O
blotting	O
revealed	O
that	O
66	O
.	O
5	O
%	O
of	O
bat	O
sera	B-FUNC
had	O
antibodies	O
to	O
BtCoV	O
.	O
These	O
surveys	O
suggested	O
the	O
endemic	O
presence	O
of	O
BtCoVs	O
in	O
the	O
Philippines	O
.	O

To	O
identify	O
the	O
HCoVs	O
,	O
pancoronavirus	O
and	O
species	O
-	O
specific	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assays	O
were	O
performed	O
.	O

Nine	O
mRNAs	O
carrying	O
a	O
set	O
of	O
common	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
synthesized	O
from	O
the	O
incoming	O
viral	O
genomic	O
RNA	O
in	O
cells	O
infected	O
with	O
SCoV	O
.	O
A	O
nonstructural	O
SCoV	O
nsp1	O
protein	O
causes	O
a	O
severe	O
translational	O
shutoff	O
by	O
binding	B-FUNC
to	O
the	O
40S	O
ribosomal	O
subunits	O
.	O

High	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
thrombomodulin	O
,	O
and	O
mini	O
-	O
BAL	O
protein	O
were	O
all	O
significantly	O
associated	O
with	O
fewer	O
ventilator	O
-	O
free	O
days	O
(	O
VFDs	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
05	O
,	O
respectively	O
);	O
no	O
markers	O
were	O
associated	O
with	O
mortality	O
,	O
but	O
we	O
hypothesized	O
that	O
this	O
was	O
due	O
to	O
the	O
small	O
size	O
of	O
our	O
cohort	O
and	O
the	O
low	O
death	O
rate	O
.	O

We	O
retested	O
the	O
associations	O
of	O
the	O
significant	O
biomarkers	O
with	O
markers	O
of	O
severity	O
and	O
clinical	O
outcomes	O
and	O
studied	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
as	O
an	O
additional	O
biomarker	O
given	O
its	O
important	O
predictive	O
value	O
in	O
prior	O
studies	O
.	O

In	O
this	O
restricted	O
cohort	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
significantly	O
associated	O
with	O
oxygenation	O
index	O
(	O
P	O
=	O
0	O
.	O
02	O
).	O

Both	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
associated	O
with	O
decreased	O
VFDs	O
and	O
increased	O
28	O
-	O
day	O
mortality	O
.	O

The	O
data	O
provide	O
detailed	O
information	O
on	O
the	O
architecture	O
of	O
the	O
dimeric	O
pAPN	O
ectodomain	O
and	O
its	O
interaction	O
with	O
the	O
CoV	O
S	O
.	O
We	O
show	O
that	O
a	O
protruding	O
receptor	O
-	O
binding	B-FUNC
edge	O
in	O
the	O
S	O
determines	O
virus	O
-	O
binding	B-FUNC
specificity	O
for	O
recessed	O
glycan	O
-	O
containing	O
surfaces	O
in	O
the	O
membrane	O
-	O
distal	O
region	O
of	O
the	O
pAPN	O
ectodomain	O
.	O

Comparison	O
of	O
the	O
RBDs	O
of	O
TGEV	O
and	O
PRCV	O
to	O
those	O
of	O
other	O
related	O
CoVs	O
,	O
suggests	O
that	O
the	O
conformation	O
of	O
the	O
S	O
receptor	O
-	O
binding	B-FUNC
region	O
determines	O
cell	O
entry	O
receptor	O
specificity	O
.	O

Moreover	O
,	O
the	O
receptor	O
-	O
binding	B-FUNC
edge	O
is	O
a	O
major	O
antigenic	O
determinant	O
in	O
the	O
TGEV	O
envelope	O
S	O
that	O
is	O
targeted	O
by	O
neutralizing	O
antibodies	O
.	O

ABSTRACT	O
:	O
Our	O
understanding	O
of	O
how	O
antibodies	O
are	O
generated	O
and	O
function	O
could	O
help	O
develop	O
effective	O
vaccines	O
and	O
antibody	B-FUNC
-	O
based	O
therapeutics	O
against	O
viruses	O
such	O
as	O
HIV	O
-	O
1	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
CoV	O
),	O
and	O
Hendra	O
and	O
Nipah	O
viruses	O
(	O
henipaviruses	O
).	O

We	O
previously	O
hypothesized	O
that	O
HIV	O
-	O
1	O
could	O
have	O
evolved	O
a	O
strategy	O
to	O
evade	O
the	O
immune	O
system	O
due	O
to	O
absent	O
or	O
very	O
weak	O
binding	B-FUNC
of	O
germline	O
antibodies	O
to	O
the	O
conserved	O
epitopes	O
that	O
may	O
not	O
be	O
sufficient	O
to	O
initiate	O
and	O
/	O
or	O
maintain	O
an	O
effective	O
immune	O
response	O
.	O

To	O
further	O
explore	O
our	O
hypothesis	O
,	O
we	O
used	O
the	O
454	O
sequence	O
analysis	O
of	O
a	O
large	O
nave	O
library	O
of	O
human	O
IgM	O
antibodies	O
which	O
had	O
been	O
used	O
for	O
selecting	O
antibodies	O
against	O
SARS	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
and	O
soluble	O
G	O
proteins	O
(	O
sG	O
)	O
of	O
henipaviruses	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
antibody	B-FUNC
maturation	O
intermediates	O
that	O
are	O
related	O
to	O
bnAbs	O
against	O
the	O
HIV	O
-	O
1	O
and	O
other	O
viruses	O
as	O
observed	O
in	O
normal	O
individuals	O
,	O
and	O
compared	O
their	O
genetic	O
diversity	O
and	O
somatic	O
mutation	O
level	O
along	O
with	O
available	O
structural	O
and	O
functional	O
data	O
.	O

TITLE	O
:	O
Contribution	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
to	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
-	O
induced	O
acute	O
liver	O
failure	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
the	O
Th17	O
cells	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
have	O
been	O
shown	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
immune	O
-	O
mediated	O
liver	O
injury	O
in	O
hepatitis	O
B	O
,	O
while	O
their	O
functions	O
in	O
acute	O
liver	O
failure	O
have	O
not	O
been	O
well	O
elucidated	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
primarily	O
investigated	O
the	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
in	O
the	O
development	O
of	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
acute	O
liver	O
failure	O
.	O

It	O
was	O
concluded	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
MHV	O
-	O
3	O
-	O
induced	O
acute	O
liver	O
failure	O
.	O

TITLE	O
:	O
Sequence	O
alignment	O
of	O
viral	O
channel	O
proteins	O
with	O
cellular	O
ion	B-FUNC
channels	I-FUNC
.	O

Here	O
,	O
alignments	O
of	O
transmembrane	O
domains	O
(	O
TMDs	O
)	O
of	O
viral	O
channel	O
forming	O
proteins	O
with	O
host	O
ion	B-FUNC
channels	I-FUNC
and	O
toxins	O
are	O
evaluated	O
.	O

The	O
analysis	O
reveals	O
that	O
p7	O
and	O
2B	O
TMDs	O
align	O
with	O
the	O
pore	O
-	O
facing	O
TMD	O
of	O
MscL	O
,	O
and	O
3a	O
-	O
TMDs	O
align	O
with	O
those	O
of	O
ligand	B-FUNC
-	O
gated	O
ion	B-FUNC
channels	I-FUNC
.	O

The	O
isolated	O
strains	O
were	O
characterized	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
3	O
of	O
the	O
S1	O
spike	O
glycoprotein	O
gene	O
.	O

Texas	O
Veterinary	O
Medical	O
Diagnostic	O
Laboratory	O
current	O
methods	O
for	O
calf	O
diarrhea	O
pathogen	O
identification	O
include	O
electron	O
microscopy	O
(	O
EM	O
)	O
for	O
BCV	O
and	O
BRV	O
and	O
a	O
direct	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
DFAT	O
)	O
for	O
organism	O
detection	O
of	O
Cryptosporidium	O
spp	O
.	O

We	O
found	O
that	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
(	O
S	O
protein	O
),	O
a	O
key	O
molecule	O
for	O
viral	O
entry	O
,	O
binds	B-FUNC
to	O
calnexin	O
,	O
a	O
molecular	O
chaperone	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
),	O
but	O
not	O
to	O
calreticulin	O
,	O
a	O
homolog	O
of	O
calnexin	O
.	O

These	O
findings	O
demonstrated	O
that	O
calnexin	O
strictly	O
monitors	O
the	O
maturation	O
of	O
S	O
protein	O
by	O
its	O
direct	O
binding	B-FUNC
,	O
resulting	O
in	O
conferring	O
infectivity	O
on	O
SARS	O
-	O
CoV	O
.	O

Poly	O
(	O
I	O
	O
C	O
)	O
pretreatment	O
upregulated	O
beta	O
interferon	O
(	O
IFN	O
-	O
	O
),	O
IFN	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
gene	O
expression	O
in	O
the	O
lungs	O
.	O

We	O
developed	O
Western	O
-	O
Bolt	O
and	O
ELISA	O
to	O
detect	O
antibody	B-FUNC
reactivity	O
between	O
truncated	O
N	O
fragments	O
with	O
sera	B-FUNC
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
or	O
SARS	O
-	O
CoV	O
patient	O
convalescent	O
sera	B-FUNC
.	O

Western	O
-	O
Bolt	O
results	O
show	O
that	O
all	O
the	O
six	O
fragments	O
have	O
reacted	O
with	O
the	O
SARS	O
patient	O
convalescent	O
sera	B-FUNC
,	O
but	O
the	O
PN360	O
and	O
PN301	O
showed	O
obvious	O
cross	O
-	O
reaction	O
with	O
sera	B-FUNC
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
;	O
sensitivity	O
analysis	O
using	O
an	O
ELISA	O
coating	O
with	O
PN199	O
,	O
PN185	O
,	O
PN155b	O
,	O
PN125	O
as	O
antigen	O
showed	O
that	O
the	O
PN185	O
and	O
PN155b	O
are	O
better	O
than	O
PN125	O
.	O

Truncated	O
N	O
protein	O
PN185	O
and	O
PN155b	O
expressed	O
in	O
E	O
.	O
Coli	O
are	O
better	O
antigen	O
candidates	O
used	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-FUNC
.	O

CONCLUSIONS	O
:	O
Truncated	O
N	O
protein	O
PN185	O
and	O
PN155b	O
expressed	O
in	O
E	O
.	O
Coli	O
are	O
better	O
antigen	O
candidates	O
used	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
specific	O
antibody	B-FUNC
.	O

Cytokine	O
levels	O
,	O
including	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
macrophage	O
-	O
inflammatory	O
peptide	O
(	O
MIP	O
)-	O
2	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
in	O
BALF	O
were	O
also	O
significantly	O
inhibited	O
at	O
16h	O
after	O
LPS	O
administration	O
in	O
the	O
MCR	O
-	O
LPS	O
group	O
.	O

Myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
in	O
lung	O
tissue	O
was	O
reduced	O
in	O
the	O
MCR	O
-	O
LPS	O
and	O
LPS	O
-	O
MCR	O
groups	O
at	O
16h	O
after	O
LPS	O
administration	O
.	O

The	O
levels	O
of	O
creatine	O
kinase	O
(	O
CK	O
),	O
creatine	O
kinase	O
-	O
MB	O
(	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
in	O
milder	O
,	O
moderate	O
and	O
severe	O
poisoning	O
groups	O
were	O
significantly	O
elevated	O
compared	O
by	O
the	O
healthy	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
levels	O
of	O
CK	O
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
and	O
cTnI	O
were	O
higher	O
especially	O
in	O
patients	O
with	O
intermediate	O
myasthenic	O
syndrome	O
(	O
IMS	O
)	O
than	O
patients	O
without	O
IMS	O
.	O

The	O
elevation	O
of	O
CK	O
and	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
in	O
serum	O
could	O
not	O
be	O
judged	O
as	O
the	O
criteria	O
of	O
myocardial	O
damage	O
in	O
AOPP	O
,	O
the	O
ratio	O
of	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
to	O
CK	O
were	O
more	O
valuable	O
;	O
the	O
value	O
of	O
cTnI	O
in	O
myocardial	O
damage	O
was	O
still	O
in	O
suspect	O
.	O

CK	O
,	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
and	O
cTnI	O
could	O
be	O
used	O
as	O
auxiliary	O
criteria	O
of	O
AOPP	O
classification	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
creatine	O
kinase	O
(	O
CK	O
),	O
creatine	O
kinase	O
-	O
MB	O
(	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
in	O
milder	O
,	O
moderate	O
and	O
severe	O
poisoning	O
groups	O
were	O
significantly	O
elevated	O
compared	O
by	O
the	O
healthy	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Meanwhile	O
,	O
the	O
levels	O
of	O
CK	O
and	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
were	O
elevated	O
in	O
patients	O
with	O
respiratory	O
failure	O
compared	O
by	O
non	O
-	O
failure	O
ones	O
,	O
but	O
decreased	O
in	O
the	O
ratios	O
of	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
to	O
CK	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
,	O
demonstrates	O
inactivation	O
of	O
interferon	O
(	O
IFN	O
)	O
regulatory	O
factor	O
3	O
and	O
NF	O
-	O
B	O
,	O
reduction	O
of	O
IFN	O
induction	O
,	O
and	O
suppression	O
of	O
type	O
I	O
IFN	O
signaling	O
pathway	O
.	O

PLpro	O
-	O
activated	O
ubiquitin	B-FUNC
proteasome	O
pathway	O
via	O
upregulation	O
of	O
ubiquitin	B-FUNC
-	O
conjugating	O
enzyme	O
E2	O
-	O
25k	O
and	O
proteasome	O
subunit	O
alpha	O
type	O
5	O
.	O

PLpro	O
upregulated	O
HSP27	O
,	O
linking	O
with	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
ERK1	B-FUNC
/	O
2	O
signaling	O
.	O

Results	O
point	O
to	O
SARS	O
-	O
CoV	O
PLpro	O
triggering	O
TGF	O
-	O
1	O
production	O
via	O
ubiquitin	B-FUNC
proteasome	O
,	O
p38	B-FUNC
MAPK	B-FUNC
,	O
and	O
ERK1	B-FUNC
/	O
2	O
-	O
mediated	O
signaling	O
.	O

ANN	O
was	O
used	O
to	O
estimate	O
the	O
binding	B-FUNC
affinity	O
of	O
single	O
S366	O
-	O
374	O
mutants	O
to	O
H	O
-	O
2	O
Kd	O
.	O

Y367	O
and	O
L374	O
were	O
predicated	O
to	O
possess	O
the	O
most	O
important	O
role	O
in	O
peptide	B-FUNC
binding	I-FUNC
.	O

A	O
VRDAL	O
multiplex	O
PCR	O
for	O
10	O
common	O
respiratory	O
viruses	O
was	O
performed	O
on	O
collected	O
specimens	O
compared	O
with	O
the	O
Seeplex	O
	O
RV15	O
ACE	O
Detection	O
kit	B-FUNC
for	O
15	O
respiratory	O
viruses	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
mRT	O
-	O
PCR	O
were	O
determined	O
by	O
comparing	O
it	O
to	O
a	O
rapid	O
antigen	O
test	O
(	O
RAT	O
)	O
or	O
immuno	O
-	O
chromatography	O
test	O
kit	B-FUNC
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
the	O
detection	O
of	O
CDV	O
,	O
CRCoV	O
and	O
CIV	O
antigens	O
present	O
in	O
100	O
clinical	O
samples	O
(	O
nasal	O
swabs	O
and	O
whole	O
blood	O
samples	O
)	O
from	O
50	O
dogs	O
with	O
respiratory	O
disease	O
symptoms	O
.	O

Blood	O
gases	O
,	O
breathing	O
rate	O
,	O
lung	O
index	O
,	O
total	O
protein	O
,	O
and	O
proinflammatory	O
cytokines	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
,	O
interleukin	O
1	O
,	O
interleukin	O
6	O
)	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
),	O
and	O
lung	O
histology	O
were	O
examined	O
.	O

ABSTRACT	O
:	O
to	O
evaluate	O
the	O
specificity	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
-	O
based	O
IgG	O
ELISA	O
assay	O
for	O
detection	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
in	O
plasma	O
samples	O
obtained	O
from	O
HIV	O
-	O
1	O
positive	O
and	O
HIV	O
-	O
1	O
negative	O
intravenous	O
drug	O
users	O
(	O
IDUs	O
).	O

RESULTS	O
:	O
all	O
sera	B-FUNC
samples	O
from	O
patients	O
with	O
SARS	O
positive	O
were	O
the	O
ELISA	O
positive	O
(	O
100	O
%	O
sensitivity	O
).	O

These	O
antibody	B-FUNC
responses	O
are	O
comparable	O
to	O
those	O
induced	O
by	O
intranasal	O
(	O
i	O
.	O
n	O
.)	O
administration	O
.	O

The	O
sandwich	O
ELISA	O
was	O
formed	O
by	O
using	O
F26G18	O
as	O
a	O
coating	O
antibody	B-FUNC
and	O
biotinylated	O
F26G18	O
as	O
a	O
detection	O
antibody	B-FUNC
with	O
a	O
detection	O
limit	O
of	O
0	O
.	O
037g	O
/	O
ml	O
(	O
p	O
<	O
0	O
.	O
02	O
).	O

The	O
same	O
detection	O
limit	O
was	O
found	O
with	O
P136	O
.	O
8D12	O
as	O
a	O
coating	O
antibody	B-FUNC
and	O
biotinylated	O
F26G18	O
as	O
a	O
detection	O
antibody	B-FUNC
.	O

The	O
sensitivity	O
was	O
improved	O
(	O
detection	O
limit	O
of	O
0	O
.	O
019g	O
/	O
ml	O
),	O
however	O
,	O
when	O
using	O
bi	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
(	O
F157	O
)	O
as	O
the	O
detection	O
antibody	B-FUNC
.	O

In	O
conclusion	O
,	O
the	O
method	O
described	O
in	O
this	O
study	O
allows	O
sensitive	O
detection	O
of	O
a	O
recombinant	O
SARS	O
spike	O
protein	O
by	O
sandwich	O
ELISA	O
with	O
bi	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
and	O
could	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
patients	O
suspected	O
with	O
SARS	O
.	O

In	O
addition	O
,	O
both	O
R	O
-	O
H120	O
and	O
H120	O
induced	O
a	O
comparable	O
titer	O
of	O
HA	O
inhibition	O
(	O
HI	O
)	O
antibody	B-FUNC
in	O
immunized	O
chickens	O
and	O
also	O
provided	O
up	O
to	O
85	O
%	O
of	O
immune	O
protection	O
to	O
the	O
chickens	O
that	O
were	O
challenged	O
with	O
Mass41	O
IBV	O
strain	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
employed	O
to	O
screen	O
for	O
coronavirus	O
NL63	O
,	O
which	O
is	O
a	O
255	O
bp	O
fragment	O
of	O
a	O
part	O
of	O
N	O
gene	O
.	O

BCoV	O
was	O
detected	O
in	O
nasal	O
swabs	O
and	O
pulmonary	O
lesions	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
and	O
virus	O
isolation	O
.	O

Compared	O
with	O
atropine	O
group	O
,	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
had	O
a	O
low	O
death	O
rate	O
,	O
high	O
cure	O
rate	O
,	O
less	O
complications	O
,	O
ChE	O
activity	O
recover	O
fast	B-FUNC
,	O
short	O
hospital	O
days	O
,	O
and	O
the	O
hospitalization	O
expenses	O
were	O
lower	O
than	O
that	O
of	O
the	O
single	O
use	O
of	O
atropine	O
or	O
single	O
use	O
of	O
penehyclidine	O
hydrochloride	O
group	O
,	O
and	O
the	O
differences	O
were	O
statistically	O
significant	O
(	O
all	O
P	O
	O
0	O
.	O
01	O
).	O

One	O
hybridoma	O
cell	O
line	O
secreting	O
anti	O
-	O
M	O
protein	O
monoclonal	O
antibody	B-FUNC
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

RESULTS	O
:	O
One	O
hybridoma	O
cell	O
line	O
secreting	O
anti	O
-	O
M	O
protein	O
monoclonal	O
antibody	B-FUNC
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

In	O
ovo	O
vaccination	O
with	O
a	O
low	O
dose	O
of	O
AdArkIBV	O
.	O
S1	O
(	O
ck	O
)	O
resulted	O
in	O
a	O
mild	O
increase	O
of	O
systemic	O
antibody	B-FUNC
and	O
reduced	O
viral	O
shedding	O
but	O
no	O
protection	O
against	O
IBV	O
signs	O
and	O
lesions	O
.	O

The	O
position	O
of	O
bands	O
at	O
630	O
,	O
802	O
,	O
and	O
1120	O
base	B-FUNC
pairs	I-FUNC
on	O
agarose	O
gel	O
confirmed	O
the	O
presence	O
of	O
rotavirus	O
,	O
TAstV	O
-	O
2	O
,	O
and	O
reovirus	O
,	O
respectively	O
.	O

We	O
found	O
high	O
prevalences	O
of	O
antibody	B-FUNC
to	O
canine	O
distemper	O
virus	O
(	O
CDV	O
;	O
13	O
/	O
14	O
),	O
canine	O
parvovirus	O
(	O
CPV	O
;	O
4	O
/	O
14	O
),	O
canine	O
adenovirus	O
type	O
2	O
(	O
13	O
/	O
14	O
),	O
canine	O
coronavirus	O
(	O
5	O
/	O
11	O
),	O
canine	O
parainfluenza	O
virus	O
(	O
5	O
/	O
5	O
),	O
and	O
Toxoplasma	O
gondii	O
(	O
6	O
/	O
8	O
),	O
along	O
with	O
Ancylostomidae	O
eggs	O
in	O
all	O
feces	O
samples	O
.	O

Captured	O
in	O
a	O
catalytically	O
active	O
state	O
,	O
these	O
structures	O
of	O
APN	O
illustrate	O
a	O
detailed	O
catalytic	O
mechanism	O
for	O
its	O
aminopeptidase	B-FUNC
activity	I-FUNC
.	O

The	O
active	O
site	O
and	O
peptide	O
-	O
binding	B-FUNC
channel	O
of	O
APN	O
reside	O
in	O
cavities	O
with	O
wide	O
openings	O
,	O
allowing	O
easy	O
access	O
to	O
peptides	O
.	O

The	O
cavities	O
can	O
potentially	O
open	O
up	O
further	O
to	O
bind	B-FUNC
the	O
exposed	O
N	O
terminus	O
of	O
proteins	O
.	O

The	O
active	O
site	O
anchors	O
the	O
N	O
-	O
terminal	O
neutral	O
residue	O
of	O
peptides	O
/	O
proteins	O
,	O
and	O
the	O
peptide	O
-	O
binding	B-FUNC
channel	O
binds	B-FUNC
the	O
remainder	O
of	O
the	O
peptides	O
/	O
proteins	O
in	O
a	O
sequence	O
-	O
independent	O
fashion	O
.	O

Current	O
opinion	O
is	O
that	O
by	O
reducing	O
the	O
pressure	O
and	O
volume	O
of	O
gas	O
delivered	O
to	O
the	O
lungs	O
during	O
mechanical	O
ventilation	O
,	O
the	O
stress	O
applied	O
to	O
the	O
lungs	O
is	O
eased	O
,	O
enabling	O
them	O
to	O
rest	B-FUNC
and	O
recover	O
.	O

For	O
these	O
reasons	O
,	O
extracorporeal	O
lung	O
support	O
technologies	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
lung	O
failure	O
,	O
allowing	O
not	O
only	O
the	O
transfer	O
of	O
oxygen	O
and	O
carbon	O
dioxide	O
(	O
CO	O
(	O
2	O
))	O
but	O
also	O
buying	O
the	O
lungs	O
the	O
time	O
needed	O
to	O
rest	B-FUNC
and	O
heal	O
.	O

We	O
recently	O
determined	O
the	O
crystal	O
structure	O
of	O
MHV	O
NTD	O
complexed	O
with	O
its	O
protein	O
receptor	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
1	O
(	O
CEACAM1	O
),	O
which	O
surprisingly	O
revealed	O
a	O
human	O
galectin	O
(	O
galactose	O
-	O
binding	B-FUNC
lectin	O
)	O
fold	O
in	O
MHV	O
NTD	O
.	O

Using	O
mutagenesis	O
,	O
we	O
have	O
located	O
the	O
sugar	O
-	O
binding	B-FUNC
site	O
in	O
BCoV	O
NTD	O
,	O
which	O
overlaps	O
with	O
the	O
galactose	O
-	O
binding	B-FUNC
site	O
in	O
human	O
galectins	O
.	O

Subtle	O
structural	O
differences	O
between	O
BCoV	O
and	O
MHV	O
NTDs	O
,	O
primarily	O
involving	O
different	O
conformations	O
of	O
receptor	O
-	O
binding	B-FUNC
loops	O
,	O
explain	O
why	O
BCoV	O
NTD	O
does	O
not	O
bind	B-FUNC
CEACAM1	O
and	O
why	O
MHV	O
NTD	O
does	O
not	O
bind	B-FUNC
sugar	O
.	O

These	O
results	O
suggest	O
a	O
successful	O
viral	O
evolution	O
strategy	O
in	O
which	O
coronaviruses	O
stole	O
a	O
galectin	O
from	O
hosts	O
,	O
incorporated	O
it	O
into	O
their	O
spike	O
protein	O
,	O
and	O
evolved	O
it	O
into	O
viral	O
receptor	O
-	O
binding	B-FUNC
domains	O
with	O
altered	O
sugar	O
specificity	O
in	O
contemporary	O
BCoV	O
or	O
novel	O
protein	O
specificity	O
in	O
contemporary	O
MHV	O
.	O

The	O
results	O
indicate	O
that	O
the	O
behavior	O
of	O
the	O
pandemic	O
was	O
similar	O
to	O
that	O
observed	O
in	O
the	O
rest	B-FUNC
of	O
the	O
country	O
,	O
with	O
an	O
increase	O
in	O
emergency	O
room	O
visits	O
for	O
ILI	O
.	O

ABSTRACT	O
:	O
The	O
perioperative	O
inflammatory	O
response	O
as	O
measured	O
by	O
elevated	O
levels	O
of	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
has	O
been	O
linked	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
postoperative	O
confusion	O
,	O
and	O
fever	O
.	O

We	O
had	O
found	O
a	O
significant	O
decrease	O
in	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
patients	O
having	O
bilateral	O
total	O
knee	O
replacement	O
who	O
received	O
two	O
doses	O
of	O
100	O
mg	O
of	O
hydrocortisone	O
eight	O
hours	O
apart	O
;	O
however	O
,	O
by	O
twenty	O
-	O
four	O
hours	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
were	O
equal	O
to	O
those	O
in	O
the	O
group	O
that	O
received	O
a	O
placebo	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
administration	O
of	O
three	O
doses	O
would	O
reduce	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
at	O
twenty	O
-	O
four	O
hours	O
and	O
affect	O
other	O
outcomes	O
such	O
as	O
desmosine	O
level	O
,	O
a	O
marker	O
of	O
lung	O
injury	O
.	O

The	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
measured	O
at	O
baseline	O
and	O
at	O
six	O
,	O
ten	O
,	O
twenty	O
-	O
four	O
,	O
and	O
forty	O
-	O
eight	O
hours	O
postoperatively	O
.	O

The	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
increased	O
in	O
both	O
groups	O
,	O
but	O
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
,	O
peaking	O
at	O
twenty	O
-	O
four	O
hours	O
(	O
mean	O
and	O
standard	O
deviation	O
,	O
623	O
.	O
74	O
	O
610	O
.	O
35	O
pg	O
/	O
mL	O
versus	O
148	O
.	O
13	O
	O
119	O
.	O
35	O
pg	O
/	O
mL	O
;	O
p	O
=	O
0	O
.	O
006	O
).	O

Hydrocortisone	O
(	O
100	O
mg	O
)	O
given	O
over	O
three	O
doses	O
,	O
each	O
eight	O
hours	O
apart	O
,	O
decreased	O
and	O
maintained	O
a	O
lower	O
degree	O
of	O
inflammation	O
with	O
bilateral	O
total	O
knee	O
replacement	O
as	O
measured	O
by	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
level	O
.	O

IFN	O
-	O
	O
secretion	O
from	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
isolated	O
from	O
infected	O
EBI3	O
-/-	O
mice	O
was	O
augmented	O
while	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
expression	O
muted	O
in	O
comparison	O
to	O
infected	O
WT	O
mice	O
.	O

In	O
vitro	O
experiments	O
,	O
the	O
result	O
showed	O
the	O
representative	O
SARS	O
-	O
CoV	O
ssRNAs	O
had	O
powerful	O
immunostimulatory	O
activities	O
to	O
induce	O
considerable	O
level	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
TNF	O
-	O
a	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
release	O
via	O
the	O
TLR7	O
and	O
TLR8	O
,	O
almost	O
2	O
-	O
fold	O
higher	O
than	O
the	O
strong	O
stimulatory	O
ssRNA40	O
that	O
was	O
found	O
previously	O
from	O
other	O
virus	O
.	O

TITLE	O
:	O
New	O
anthraquinone	O
derivatives	O
as	O
inhibitors	O
of	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
ribonuclease	O
H	O
function	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
analytical	O
performance	O
and	O
clinical	O
potential	O
of	O
a	O
one	O
-	O
step	O
multiplex	O
real	O
-	O
time	O
PCR	O
assay	O
for	O
the	O
simultaneous	O
detection	O
of	O
14	O
types	O
of	O
respiratory	O
viruses	O
using	O
the	O
AdvanSure	O
RV	O
real	O
-	O
time	O
PCR	O
Kit	B-FUNC
(	O
LG	O
Life	O
Sciences	O
,	O
Korea	O
).	O

The	O
assay	O
results	O
were	O
analyzed	O
and	O
the	O
one	O
-	O
step	O
AdvanSure	O
RV	O
real	O
-	O
time	O
PCR	O
Kit	B-FUNC
was	O
compared	O
with	O
the	O
conventional	O
multiplex	O
RT	O
-	O
PCR	O
assay	O
with	O
respect	O
to	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
detection	O
of	O
respiratory	O
viruses	O
.	O

The	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

The	O
N	O
-	O
terminal	O
most	O
domain	O
of	O
nsp3	O
,	O
nsp3a	O
,	O
has	O
been	O
identified	O
by	O
reverse	O
genetics	O
as	O
a	O
likely	O
binding	B-FUNC
partner	O
of	O
MHV	O
nucleocapsid	O
protein	O
.	O

Our	O
results	O
showed	O
that	O
mice	O
immunized	O
orogastrically	O
with	O
L	O
.	O
casei	O
expressing	O
COE	O
or	O
LTB	O
-	O
COE	O
produced	O
secretory	O
immunoglobulin	B-FUNC
A	O
and	O
immunoglobulin	B-FUNC
G	O
with	O
the	O
ability	O
to	O
neutralize	O
PEDV	O
in	O
sera	B-FUNC
and	O
mucus	O
.	O

SAA	O
was	O
positively	O
correlated	O
with	O
serum	O
CRP	O
(	O
R	O
=	O
0	O
.	O
346	O
,	O
P	O
=	O
0	O
.	O
042	O
),	O
Ranson	O
score	O
(	O
R	O
=	O
0	O
.	O
442	O
,	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
R	O
=	O
0	O
.	O
359	O
,	O
P	O
=	O
0	O
.	O
034	O
).	O

Viral	O
respiratory	O
pathogens	O
were	O
detected	O
by	O
multiplex	O
RT	O
-	O
PCR	O
(	O
Seeplex	O
RV15	O
kit	B-FUNC
,	O
Seegene	O
,	O
Eschborn	O
,	O
Germany	O
).	O

Laboratory	O
analyses	O
,	O
carried	O
out	O
immediately	O
after	O
the	O
patient	O
'	O
s	O
admission	O
to	O
the	O
Emergency	O
Center	O
,	O
registered	O
the	O
following	O
disturbances	O
:	O
high	O
hyperkalemia	O
level	O
(	O
K	O
+	O
9	O
.	O
9	O
m	O
mol	O
/	O
L	O
),	O
increased	O
levels	O
of	O
urea	O
(	O
30	O
.	O
1	O
mmol	O
/	O
L	O
),	O
creatinine	O
(	O
400	O
micromol	O
/	O
L	O
),	O
creatine	O
phosphokinase	O
--	O
CK	O
(	O
12	O
,	O
0350	O
IU	O
/	O
L	O
),	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
(	O
2500	O
IU	O
/	O
L	O
)	O
and	O
myoglobin	O
(	O
57000	O
microg	O
/	O
L	O
),	O
with	O
normal	O
levels	O
of	O
troponin	O
I	O
(<	O
0	O
.	O
01	O
microg	O
/	O
L	O
),	O
as	O
well	O
as	O
signs	O
of	O
anemia	O
(	O
Hgb	O
92	O
g	O
/	O
L	O
,	O
Er	O
3	O
.	O
61	O
x	O
10	O
(	O
12	O
)/	O
L	O
),	O
infection	O
(	O
C	O
-	O
reactive	O
proteine	O
184	O
microg	O
/	O
mL	O
,	O
Le	O
16	O
.	O
1	O
x	O
10	O
(	O
9	O
)/	O
L	O
)	O
and	O
acidosis	O
(	O
base	O
excess	O
--	O
18	O
.	O
4	O
mmol	O
/	O
L	O
,	O
pH	O
7	O
.	O
26	O
.	O

Normalization	O
of	O
kalemia	O
and	O
fast	B-FUNC
regression	O
of	O
electrocardiographic	O
changes	O
were	O
registered	O
.	O

Based	O
on	O
the	O
crystal	O
structure	O
of	O
the	O
NTD	O
,	O
the	O
stereographic	O
positions	O
of	O
both	O
predicted	O
selected	O
sites	O
do	O
not	O
fall	O
close	O
to	O
the	O
RNA	O
-	O
binding	B-FUNC
groove	O
.	O

This	O
study	O
illustrates	O
that	O
the	O
N	O
protein	O
of	O
the	O
current	O
TW	O
IBV	O
variant	O
has	O
been	O
shaped	O
by	O
both	O
RNA	O
recombination	O
and	O
positive	O
selection	O
and	O
that	O
the	O
latter	O
may	O
promote	O
viral	O
survival	O
and	O
fitness	O
,	O
potentially	O
by	O
increasing	O
the	O
RNA	O
-	O
binding	B-FUNC
capacity	O
of	O
the	O
N	O
protein	O
.	O

TRALI	O
is	O
a	O
non	O
-	O
hemolytic	O
transfusion	O
reaction	O
induced	O
by	O
infusions	O
of	O
intravenous	O
immunoglobulin	B-FUNC
,	O
platelets	O
(	O
suspended	O
in	O
plasma	O
),	O
whole	O
blood	O
,	O
cryoprecipitates	O
,	O
and	O
fresh	O
frozen	O
plasma	O
(	O
FFP	O
).	O

Using	O
the	O
purified	O
recombinant	O
NP	O
as	O
an	O
antigen	O
,	O
a	O
polyclonal	O
antibody	B-FUNC
from	O
rabbit	O
serum	O
with	O
specificity	O
for	O
HCoV	O
-	O
OC43	O
NP	O
was	O
generated	O
;	O
this	O
antibody	B-FUNC
reacts	O
specifically	O
with	O
HCoV	O
-	O
OC43	O
NP	O
and	O
does	O
not	O
cross	O
-	O
react	O
with	O
other	O
human	O
CoV	O
NPs	O
(	O
including	O
those	O
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
229E	O
)	O
by	O
Western	O
blot	O
.	O

Sera	B-FUNC
from	O
26	O
young	O
adults	O
,	O
17	O
middle	O
-	O
aged	O
and	O
elderly	O
patients	O
with	O
respiratory	O
infection	O
,	O
and	O
15	O
cord	O
blood	O
samples	O
were	O
also	O
tested	O
.	O

The	O
rabbit	O
polyclonal	O
antibody	B-FUNC
demonstrated	O
greater	O
immunoreactivity	O
to	O
the	O
central	O
-	O
linker	O
region	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
than	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

Compared	O
to	O
virus	O
-	O
negative	O
well	O
weeks	O
,	O
nasal	O
aspirate	O
IFN	O
-	O
	O
,	O
CXCL8	O
/	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
CXCL10	O
/	O
IP	O
-	O
10	O
,	O
CCL5	O
/	O
RANTES	O
,	O
CCL11	O
/	O
eotaxin	O
-	O
1	O
,	O
CCL2	O
/	O
MCP	B-FUNC
-	O
1	O
,	O
CCL4	O
/	O
MIP	O
-	O
1	O
,	O
CCL7	O
/	O
MCP	B-FUNC
-	O
3	O
,	O
and	O
CCL20	O
/	O
MIP3	O
protein	O
levels	O
increased	O
during	O
virus	O
-	O
positive	O
sick	O
weeks	O
.	O

ABSTRACT	O
:	O
Immune	O
sera	B-FUNC
from	O
convalescent	O
patients	O
have	O
been	O
shown	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Virus	O
(	O
SARS	O
-	O
CoV	O
)	O
making	O
passive	O
immune	O
therapy	O
with	O
human	O
monoclonal	O
antibodies	O
an	O
attractive	O
treatment	O
strategy	O
for	O
SARS	O
.	O

However	O
,	O
unlike	O
the	O
S1	O
specific	O
HmAbs	O
,	O
the	O
S2	O
specific	O
HmAbs	O
can	O
neutralize	O
pseudotyped	O
viruses	O
expressing	O
different	O
S	O
proteins	O
containing	O
receptor	B-FUNC
binding	I-FUNC
domain	O
sequences	O
of	O
various	O
clinical	O
isolates	O
.	O

These	O
data	O
indicate	O
that	O
HmAbs	O
which	O
bind	B-FUNC
to	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
are	O
more	O
suitable	O
for	O
conferring	O
protection	O
against	O
a	O
wide	O
range	O
of	O
SARS	O
-	O
CoV	O
variants	O
and	O
have	O
implications	O
for	O
generating	O
therapeutic	O
antibodies	O
or	O
subunit	O
vaccines	O
against	O
other	O
enveloped	O
viruses	O
.	O

This	O
review	O
will	O
summarize	O
the	O
current	O
knowledge	O
on	O
the	O
biogenesis	O
of	O
the	O
replicative	O
structures	O
,	O
the	O
membrane	O
anchoring	B-FUNC
of	O
the	O
replication	O
-	O
transcription	O
complexes	O
,	O
and	O
the	O
location	O
of	O
viral	O
RNA	O
synthesis	O
,	O
with	O
particular	O
focus	O
on	O
the	O
dynamics	O
of	O
the	O
coronavirus	O
replicative	O
structures	O
and	O
individual	O
replication	O
-	O
associated	O
proteins	O
.	O

Crystal	O
structures	O
of	O
the	O
enzyme	O
-	O
inhibitor	O
complexes	O
showed	O
that	O
the	O
nitrile	O
warhead	O
inhibits	O
3CL	O
(	O
pro	O
)	O
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
catalytic	O
Cys145	O
residue	O
,	O
while	O
the	O
AVLQ	O
peptide	O
forms	O
a	O
number	O
of	O
favourable	O
interactions	O
with	O
the	O
S1	O
-	O
S4	O
substrate	O
-	O
binding	B-FUNC
pockets	O
.	O

CXCR2	O
is	O
a	O
chemokine	O
receptor	O
that	O
upon	O
binding	B-FUNC
to	O
specific	O
ligands	O
promotes	O
host	O
defense	O
through	O
recruitment	O
of	O
myeloid	O
cells	O
to	O
the	O
CNS	O
as	O
well	O
as	O
protecting	O
oligodendroglia	O
from	O
cytokine	O
-	O
mediated	O
death	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

TITLE	O
:	O
Samples	O
with	O
high	O
virus	O
load	O
cause	O
a	O
trend	O
toward	O
lower	O
signal	O
in	O
feline	O
coronavirus	O
antibody	B-FUNC
tests	O
.	O

ABSTRACT	O
:	O
Measurement	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibody	B-FUNC
titres	O
is	O
utilised	O
mainly	O
for	O
diagnosing	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
for	O
quarantine	O
purposes	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
such	O
results	O
are	O
due	O
to	O
virus	O
in	O
the	O
sample	O
binding	B-FUNC
antibody	B-FUNC
and	O
rendering	O
it	O
unavailable	O
to	O
antigen	O
in	O
the	O
test	O
.	O

We	O
conclude	O
that	O
falsely	O
low	O
or	O
negative	O
FCoV	O
antibody	B-FUNC
tests	O
can	O
occur	O
in	O
samples	O
rich	O
in	O
virus	O
.	O

An	O
anti	O
-	O
histone	O
antibody	B-FUNC
could	O
reduce	O
these	O
changes	O
and	O
protect	O
mice	O
from	O
histone	O
-	O
induced	O
lethality	O
.	O

Several	O
gammacoronaviruses	O
including	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
contain	O
a	O
putative	O
open	O
reading	O
frame	O
(	O
ORF	O
),	O
localized	O
between	O
the	O
M	O
gene	O
and	O
gene	O
5	O
,	O
which	O
is	O
controversial	O
due	O
to	O
the	O
perceived	O
absence	O
of	O
a	O
TRS	B-FUNC
.	O

We	O
confirmed	O
previous	O
reports	O
that	O
coronaviruses	O
can	O
produce	O
sgmRNAs	O
from	O
noncanonical	O
TRS	B-FUNC
-	O
Bs	O
,	O
which	O
may	O
expand	O
their	O
repertoire	O
of	O
proteins	O
.	O

We	O
also	O
demonstrated	O
that	O
noncanonical	O
TRS	B-FUNC
-	O
Bs	O
may	O
provide	O
a	O
mechanism	O
by	O
which	O
coronaviruses	O
can	O
control	O
protein	O
expression	O
levels	O
by	O
reducing	O
sgmRNA	O
synthesis	O
.	O

Two	O
additional	O
RT	O
-	O
PCR	O
assays	O
for	O
sequencing	O
are	O
described	O
,	O
targeting	O
the	O
RdRp	B-FUNC
gene	O
(	O
RdRpSeq	O
assay	O
)	O
and	O
N	O
gene	O
(	O
NSeq	O
assay	O
),	O
where	O
an	O
insertion	O
/	O
deletion	O
polymorphism	O
might	O
exist	O
among	O
different	O
hCoV	O
-	O
EMC	O
strains	O
.	O

Finally	O
,	O
a	O
simplified	O
and	O
biologically	O
safe	O
protocol	O
for	O
detection	O
of	O
antibody	B-FUNC
response	O
by	O
immunofluorescence	O
microscopy	O
was	O
developed	O
using	O
convalescent	O
patient	O
serum	O
.	O

Enhanced	O
production	O
of	O
IFN	O
-	O
	O
,	O
interleukin	O
(	O
IL	O
)-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
mRNA	O
was	O
seen	O
in	O
CD4	O
T	O
cells	O
from	O
infected	O
B7	O
-	O
H1	O
-/-	O
compared	O
with	O
WT	O
mice	O
,	O
suggesting	O
that	O
over	O
-	O
activated	O
CD4	O
T	O
cells	O
primarily	O
contribute	O
to	O
the	O
increased	O
pathology	O
.	O

Enhanced	O
production	O
of	O
IFN	O
-	O
	O
,	O
interleukin	O
(	O
IL	O
)-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
mRNA	O
was	O
seen	O
in	O
CD4	O
T	O
cells	O
from	O
infected	O
B7	O
-	O
H1	O
-/-	O
compared	O
with	O
WT	O
mice	O
,	O
suggesting	O
that	O
over	O
-	O
activated	O
CD4	O
T	O
cells	O
primarily	O
contribute	O
to	O
the	O
increased	O
pathology	O
.	O

A	O
docking	O
study	O
involving	O
binding	B-FUNC
between	O
the	O
initial	O
lead	O
compound	O
1	O
and	O
the	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
motivated	O
the	O
replacement	O
of	O
a	O
thiazole	O
with	O
a	O
benzothiazole	O
unit	O
as	O
a	O
warhead	O
moiety	O
at	O
the	O
P1	O
'	O
site	O
.	O

The	O
DN	O
T	O
cells	O
with	O
production	O
of	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
are	O
able	O
to	O
kill	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
via	O
the	O
Fas	O
/	O
FasL	O
dependent	O
pathway	O
.	O

To	O
investigate	O
and	O
analyze	O
the	O
reason	O
of	O
this	O
outbreak	O
,	O
the	O
M	O
and	O
ORF3	O
genes	O
of	O
15	O
porcine	O
epidemic	O
diarrhea	O
viruses	O
(	O
PEDV	O
),	O
which	O
were	O
collected	O
from	O
different	O
areas	O
of	O
central	O
China	O
during	O
October	O
2010	O
and	O
December	O
2011	O
,	O
were	O
amplified	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
sequenced	O
,	O
and	O
analyzed	O
.	O

ABSTRACT	O
:	O
Chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
(	O
CCL2	O
),	O
a	O
chemoattractant	O
for	O
macrophages	O
,	O
T	O
cells	O
,	O
and	O
cells	O
expressing	O
CCR2	O
,	O
is	O
upregulated	O
during	O
acute	O
and	O
chronic	O
inflammation	O
.	O

Interestingly	O
,	O
the	O
two	O
constructs	O
have	O
the	O
same	O
binding	B-FUNC
affinity	O
for	O
nucleic	O
acids	O
.	O

We	O
,	O
therefore	O
propose	O
that	O
the	O
difference	O
in	O
the	O
catalytic	O
efficiency	O
of	O
these	O
two	O
constructs	O
is	O
due	O
to	O
the	O
interference	O
of	O
ATP	B-FUNC
binding	I-FUNC
by	O
the	O
histidine	O
tag	O
at	O
the	O
amino	O
	O
terminus	O
of	O
nsp13	O
.	O

TITLE	O
:	O
The	O
acetyl	O
-	O
esterase	B-FUNC
activity	I-FUNC
of	O
the	O
hemagglutinin	O
-	O
esterase	O
protein	O
of	O
human	O
coronavirus	O
OC43	O
strongly	O
enhances	O
the	O
production	O
of	O
infectious	O
virus	O
.	O

Making	O
use	O
of	O
neutralizing	O
antibody	B-FUNC
and	O
of	O
molecular	O
clones	O
of	O
recombinant	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
),	O
our	O
results	O
suggest	O
that	O
the	O
HE	O
protein	O
of	O
this	O
HCoV	O
could	O
be	O
associated	O
with	O
infection	O
of	O
target	O
cells	O
and	O
,	O
most	O
notably	O
,	O
is	O
important	O
in	O
the	O
production	O
of	O
infectious	O
viral	O
particles	O
.	O

The	O
APACHEIIscore	O
(	O
13	O
.	O
3	O
	O
1	O
.	O
0	O
vs	O
14	O
.	O
1	O
	O
1	O
.	O
2	O
)	O
and	O
the	O
level	O
of	O
TBil	O
[(	O
20	O
.	O
4	O
	O
11	O
.	O
3	O
)	O
mol	O
/	O
L	O
vs	O
(	O
28	O
.	O
1	O
	O
10	O
.	O
9	O
)	O
mol	O
/	O
L	O
],	O
creatinine	O
[(	O
178	O
.	O
7	O
	O
71	O
.	O
8	O
)	O
mol	O
/	O
L	O
vs	O
(	O
215	O
.	O
6	O
	O
51	O
.	O
3	O
)	O
mol	O
/	O
L	O
],	O
blood	O
urea	O
nitrogen	O
[(	O
10	O
.	O
1	O
	O
5	O
.	O
6	O
)	O
mmol	O
/	O
L	O
vs	O
(	O
13	O
.	O
2	O
	O
3	O
.	O
8	O
)	O
mmol	O
/	O
L	O
]	O
and	O
ALT	B-FUNC
[(	O
51	O
.	O
3	O
	O
13	O
.	O
2	O
)	O
U	O
/	O
L	O
vs	O
(	O
62	O
.	O
5	O
	O
14	O
.	O
3	O
)	O
U	O
/	O
L	O
]	O
were	O
decreased	O
compared	O
to	O
those	O
in	O
the	O
control	O
group	O
(	O
all	O
P	O
values	O
<	O
0	O
.	O
05	O
).	O

The	O
purpose	O
of	O
this	O
prospective	O
case	O
-	O
control	O
study	O
was	O
to	O
survey	O
the	O
detection	O
rate	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
Kawasaki	O
disease	O
(	O
KD	O
)	O
by	O
using	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
to	O
investigate	O
the	O
clinical	O
implications	O
of	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
during	O
the	O
acute	O
phase	O
of	O
KD	O
.	O

This	O
study	O
demonstrates	O
that	O
CNS	O
-	O
expressed	O
CXCR3	O
ligand	B-FUNC
CXCL10	O
is	O
the	O
critical	O
chemokine	O
regulating	O
ASC	O
accumulation	O
.	O

The	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
contains	O
two	O
structurally	O
independent	O
RNA	B-FUNC
binding	I-FUNC
domains	O
,	O
designated	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
and	O
the	O
dimeric	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
joined	O
by	O
a	O
charged	O
linker	O
region	O
rich	O
in	O
serine	O
and	O
arginine	O
residues	O
(	O
SR	O
-	O
rich	O
linker	O
).	O

Here	O
we	O
present	O
the	O
solution	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp3a	O
and	O
show	O
,	O
using	O
isothermal	O
titration	O
calorimetry	O
,	O
that	O
MHV	O
N219	O
,	O
an	O
N	O
construct	O
that	O
extends	O
into	O
the	O
SR	O
-	O
rich	O
linker	O
(	O
residues	O
60	O
to	O
219	O
),	O
binds	B-FUNC
cognate	O
nsp3a	O
with	O
high	O
affinity	O
(	O
equilibrium	O
association	O
constant	O
[	O
K	O
(	O
a	O
)],	O
[	O
1	O
.	O
4	O
	O
0	O
.	O
3	O
]	O
	O
10	O
(	O
6	O
)	O
M	O
(-	O
1	O
)).	O

In	O
contrast	O
,	O
neither	O
N197	O
,	O
an	O
N	O
construct	O
containing	O
only	O
the	O
folded	O
NTD	O
(	O
residues	O
60	O
to	O
197	O
),	O
nor	O
the	O
CTD	O
dimer	O
(	O
residues	O
260	O
to	O
380	O
)	O
binds	B-FUNC
nsp3a	O
with	O
detectable	O
affinity	O
.	O

These	O
studies	O
reveal	O
that	O
the	O
SR	O
-	O
rich	O
linker	O
of	O
MHV	O
N	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
maintain	O
this	O
high	O
-	O
affinity	O
binding	B-FUNC
to	O
N	O
.	O

The	O
insert	O
coded	O
for	O
three	O
arginine	O
residues	O
,	O
occurred	O
in	O
a	O
region	O
associated	O
with	O
fusion	O
entry	O
into	O
host	O
cells	O
,	O
and	O
may	O
allow	O
infection	O
of	O
new	O
cell	O
types	O
via	O
heparin	O
sulfate	B-FUNC
binding	I-FUNC
.	O

Activated	O
PMNs	O
release	O
heparin	O
-	O
binding	B-FUNC
protein	O
(	O
HBP	O
),	O
a	O
granule	O
protein	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
acute	O
inflammatory	O
reactions	O
.	O

Interleukin	O
1	O
(	O
IL	O
-	O
1	O
),	O
a	O
cytokine	O
released	O
within	O
the	O
airspace	O
in	O
ALI	O
,	O
downregulates	O
the	O
	O
subunit	O
of	O
the	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
(	O
ENaC	O
)	O
transcription	O
and	O
protein	O
expression	O
via	O
p38	B-FUNC
MAP	O
kinase	O
-	O
dependent	O
signaling	O
.	O

Heat	O
shock	O
results	O
in	O
IRAK1	O
detergent	O
insolubility	O
and	O
a	O
disruption	O
of	O
Hsp90	B-FUNC
binding	I-FUNC
to	O
IRAK1	O
.	O

Remarkably	O
,	O
IL	O
-	O
1	O
-	O
dependent	O
p38	B-FUNC
activation	O
24	O
h	O
after	O
heat	O
shock	O
did	O
not	O
result	O
in	O
an	O
inhibition	O
of	O
ENaC	O
mRNA	O
expression	O
and	O
channel	O
function	O
.	O

Inhibition	O
of	O
Hsp70	O
at	O
24	O
h	O
after	O
heat	O
shock	O
results	O
in	O
p38	B-FUNC
-	O
dependent	O
IL	O
-	O
1	O
inhibition	O
of	O
ENaC	O
mRNA	O
expression	O
,	O
whereas	O
overexpression	O
of	O
Hsp70	O
attenuates	O
the	O
p38	B-FUNC
-	O
dependent	O
IL	O
-	O
1	O
inhibition	O
of	O
ENaC	O
mRNA	O
expression	O
.	O

The	O
PEDV	O
E	O
protein	O
has	O
no	O
effect	O
on	O
the	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
growth	O
,	O
cell	O
cycle	O
and	O
cyclin	B-FUNC
A	O
expression	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	O
E	O
protein	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activated	O
NF	O
-	O
B	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

In	O
addition	O
,	O
the	O
PEDV	O
E	O
protein	O
is	O
able	O
to	O
up	O
-	O
regulate	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	O
E	O
protein	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activated	O
NF	O
-	O
B	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

The	O
adjuvanticity	O
of	O
Sargassum	O
pallidum	O
polysaccharides	O
in	O
Newcastle	O
disease	O
(	O
ND	O
),	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
and	O
avian	O
influenza	O
(	O
AI	O
)	O
was	O
investigated	O
by	O
examining	O
the	O
antibody	B-FUNC
titers	O
and	O
lymphocyte	O
proliferation	O
following	O
immunization	O
in	O
chickens	O
.	O

Examination	O
of	O
sputum	O
and	O
urine	O
revealed	O
acid	O
-	O
fast	B-FUNC
bacilli	O
,	O
which	O
were	O
later	O
confirmed	O
as	O
Mycobacterium	O
tuberculosis	O
sensitive	O
to	O
all	O
drugs	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
multiplex	O
real	O
-	O
time	O
PCR	O
approach	O
(	O
Anyplex	O
II	O
RV16	O
[	O
RV16	O
];	O
Seegene	O
,	O
South	O
Korea	O
)	O
was	O
compared	O
with	O
a	O
multiplex	O
endpoint	O
PCR	O
kit	B-FUNC
(	O
Seeplex	O
RV15	O
ACE	O
detection	O
kit	B-FUNC
[	O
RV15	O
];	O
Seegene	O
)	O
and	O
a	O
liquid	O
bead	O
-	O
based	O
assay	O
(	O
xTAG	O
respiratory	O
viral	O
panel	O
[	O
xTAG	O
];	O
Abbott	O
,	O
United	O
States	O
).	O

We	O
genotyped	O
the	O
insertion	O
/	O
deletion	O
polymorphism	O
of	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
(	O
polymerase	O
chain	O
reaction	O
)	O
and	O
the	O
following	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
TaqMan	O
SNP	O
genotyping	O
assay	O
):	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
-	O
376	O
G	O
/	O
A	O
,	O
-	O
308	O
G	O
/	O
A	O
,	O
and	O
-	O
238	O
G	O
/	O
A	O
;	O
interleukin	O
8	O
-	O
251	O
T	O
/	O
A	O
;	O
pre	O
-	O
B	O
cell	O
colony	O
-	O
enhancing	O
factor	O
-	O
1001	O
G	O
/	O
T	O
;	O
and	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
+	O
405	O
C	O
/	O
G	O
and	O
+	O
936	O
C	O
/	O
T	O
.	O
Polymorphisms	O
were	O
selected	O
based	O
on	O
reports	O
on	O
their	O
association	O
with	O
ARDS	O
.	O

Virus	O
-	O
neutralizing	O
test	O
on	O
tracheal	O
organ	O
cultures	O
(	O
TOC	O
)	O
with	O
chicken	O
embryo	O
were	O
used	O
to	O
evaluate	O
relatedness	O
values	O
of	O
the	O
antigenicity	O
based	O
on	O
the	O
antibody	B-FUNC
titer	O
,	O
to	O
analyze	O
the	O
antigenic	O
relationships	O
between	O
the	O
isolates	O
and	O
vaccine	O
strains	O
,	O
as	O
well	O
as	O
to	O
determine	O
the	O
serotypes	O
of	O
26	O
IB	O
viruses	O
isolated	O
from	O
the	O
field	O
in	O
Guangxi	O
between	O
1985	O
and	O
2008	O
.	O

Antibody	B-FUNC
titers	O
of	O
the	O
chickens	O
immunized	O
with	O
pVAX1	O
-	O
16S1	O
/	O
M	O
/	O
N	O
were	O
much	O
higher	O
than	O
those	O
of	O
the	O
monovalent	O
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Angiogenic	O
factors	O
and	O
their	O
receptors	O
,	O
including	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	B-FUNC
)/	O
VEGF	B-FUNC
-	O
receptor	O
(	O
VEGFR	O
)	O
and	O
the	O
angiopoietin	O
(	O
Ang	O
)/	O
Tie2	O
signaling	O
pathways	O
,	O
play	O
pivotal	O
roles	O
in	O
both	O
angiogenesis	O
and	O
microvascular	O
permeability	O
.	O

Plasma	O
kallistatin	O
,	O
kallikrein	O
,	O
and	O
other	O
biomarkers	O
of	O
inflammation	O
(	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)),	O
and	O
anti	O
-	O
coagulation	O
(	O
protein	O
C	O
,	O
anti	O
-	O
thrombin	O
III	O
)	O
were	O
measured	O
on	O
days	O
1	O
and	O
4	O
of	O
ICU	O
admission	O
.	O

Two	O
ArkDPI	O
-	O
derived	O
vaccines	O
that	O
contain	O
a	O
higher	O
proportion	O
of	O
viruses	O
with	O
S1	O
genes	O
that	O
become	O
selected	O
during	O
replication	O
in	O
chickens	O
exhibited	O
more	O
rapid	O
establishment	O
of	O
those	O
selected	O
subpopulations	O
in	O
chickens	O
,	O
produced	O
significantly	O
higher	O
viral	O
loads	O
in	O
tears	O
,	O
and	O
induced	O
higher	O
antibody	B-FUNC
responses	O
compared	O
with	O
two	O
other	O
ArkDPI	O
vaccines	O
with	O
lower	O
proportions	O
of	O
viruses	O
that	O
become	O
selected	O
in	O
chickens	O
.	O

We	O
observed	O
lower	O
antibody	B-FUNC
responses	O
to	O
the	O
vaccines	O
that	O
produced	O
lower	O
viral	O
loads	O
,	O
which	O
might	O
contribute	O
to	O
the	O
persistence	O
of	O
Ark	O
serotype	O
IBV	O
vaccines	O
observed	O
in	O
commercial	O
flocks	O
.	O

TITLE	O
:	O
Deubiquitinase	B-FUNC
function	O
of	O
arterivirus	O
papain	O
-	O
like	O
protease	O
2	O
suppresses	O
the	O
innate	O
immune	O
response	O
in	O
infected	O
host	O
cells	O
.	O

This	O
enzyme	O
is	O
essential	O
for	O
arterivirus	O
replication	O
by	O
cleaving	O
a	O
site	O
within	O
the	O
viral	O
replicase	O
polyproteins	O
and	O
also	O
removes	O
ubiquitin	B-FUNC
from	O
cellular	O
proteins	O
.	O

PLP2	O
binds	B-FUNC
ubiquitin	B-FUNC
using	O
a	O
zinc	O
finger	O
that	O
is	O
uniquely	O
integrated	O
into	O
an	O
exceptionally	O
compact	O
OTU	O
-	O
domain	O
fold	O
that	O
represents	O
a	O
new	O
subclass	O
of	O
zinc	O
-	O
dependent	O
OTU	O
DUBs	O
.	O

ABSTRACT	O
:	O
Heparin	O
-	O
binding	B-FUNC
protein	O
(	O
HBP	O
)	O
is	O
an	O
inducer	O
of	O
vascular	O
endothelial	O
leakage	O
in	O
severe	O
infections	O
.	O

ABSTRACT	O
:	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
contributes	O
to	O
organ	O
dysfunction	O
and	O
leads	O
to	O
the	O
development	O
of	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
).	O

IAH	B-FUNC
and	O
ACS	B-FUNC
are	O
relatively	O
frequent	O
findings	O
in	O
patiens	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
and	O
are	O
associated	O
with	O
deterioration	O
in	O
organ	O
functions	O
.	O

Bacterial	O
translocation	O
has	O
been	O
described	O
in	O
patients	O
with	O
ACS	B-FUNC
,	O
and	O
this	O
may	O
apply	O
to	O
patients	O
with	O
SAP	O
.	O

Approximately	O
30	O
-	O
40	O
%	O
of	O
SAP	O
patients	O
develop	O
ACS	B-FUNC
because	O
of	O
pancreatic	O
(	O
retroperitoneal	O
)	O
inflammation	O
,	O
peripancreatic	O
tissue	O
edema	O
,	O
formation	O
of	O
fluid	O
collections	O
or	O
abdominal	O
distension	O
.	O

Furthermore	O
,	O
IFN	O
-	O
	O
production	O
in	O
the	O
lungs	O
was	O
significantly	O
reduced	O
in	O
IFN	O
-	O
	O
-	O
treated	O
mice	O
,	O
compared	O
with	O
control	O
mice	O
,	O
but	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
	O
production	O
was	O
almost	O
equivalent	O
for	O
both	O
groups	O
.	O

ABSTRACT	O
:	O
In	O
continuation	O
of	O
our	O
efforts	O
toward	O
identification	O
and	O
optimization	O
of	O
novel	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTIs	O
),	O
we	O
have	O
employed	O
a	O
structure	O
-	O
based	O
bioisosterism	O
strategy	O
,	O
with	O
which	O
a	O
new	O
series	O
of	O
diarylpyridazine	O
(	O
DAPD	O
)	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
-	O
1	O
(	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
)	O
activity	O
.	O

The	O
turkeys	O
in	O
G3	O
-	O
750DDP	O
produced	O
the	O
highest	O
level	O
of	O
TCoV	O
S	O
protein	O
-	O
specific	O
antibody	B-FUNC
and	O
virus	O
neutralization	O
(	O
VN	O
)	O
titer	O
.	O

Further	O
76	O
hospital	O
contacts	O
also	O
tested	O
negative	O
,	O
including	O
two	O
sera	B-FUNC
initially	O
reactive	O
in	O
the	O
screening	O
test	O
.	O

The	O
MHV	O
PS	O
is	O
an	O
RNA	O
structure	O
that	O
maps	O
to	O
the	O
region	O
of	O
the	O
replicase	O
gene	O
encoding	O
the	O
nonstructural	O
protein	O
15	O
subunit	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
.	O

We	O
demonstrate	O
that	O
cathepsin	O
G	O
(	O
CG	O
),	O
neutrophil	O
elastase	O
(	O
NE	O
),	O
and	O
to	O
a	O
lesser	O
extent	O
proteinase	B-FUNC
3	O
(	O
PR3	O
),	O
degrade	O
endocan	O
.	O

Identification	O
of	O
shared	O
receptor	O
-	O
binding	B-FUNC
preferences	O
,	O
host	O
responses	O
,	O
and	O
laboratory	O
modeling	O
protocols	O
among	O
these	O
viruses	O
provides	O
a	O
needed	O
bridge	O
between	O
clinical	O
and	O
laboratory	O
studies	O
of	O
virus	O
tropism	O
.	O

Prevaccination	O
antibody	B-FUNC
titers	O
to	O
Newcastle	O
disease	O
,	O
infectious	O
bronchitis	O
,	O
and	O
infectious	O
bursal	O
disease	O
virus	O
were	O
higher	O
in	O
HYPER	O
chicks	O
during	O
1	O
wk	O
of	O
age	O
,	O
although	O
not	O
different	O
in	O
their	O
dams	O
.	O

Antibodies	O
to	O
T	O
.	O
gondii	O
were	O
determined	O
using	O
the	O
modified	O
agglutination	O
test	O
(	O
MAT	B-FUNC
,	O
1	O
:	O
25	O
or	O
higher	O
).	O

Antibody	B-FUNC
titers	O
ranged	O
from	O
1	O
:	O
25	O
to	O
1	O
:	O
400	O
,	O
with	O
titers	O
of	O
1	O
:	O
200	O
detected	O
in	O
4	O
of	O
the	O
5	O
bat	O
species	O
.	O

Studies	O
in	O
humans	O
and	O
animals	O
have	O
demonstrated	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
proximal	O
sodium	O
(	O
NHE3	O
)	O
and	O
water	O
tubular	O
transporter	O
,	O
aquaporin	B-FUNC
1	O
(	O
AQP1	O
)	O
together	O
with	O
higher	O
renal	O
expression	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
NKCC2	O
.	O

The	O
status	O
of	O
79	O
dairy	O
herds	O
located	O
in	O
two	O
Northern	O
and	O
two	O
Southern	O
Regions	O
of	O
Sweden	O
were	O
surveyed	O
by	O
measuring	O
antibody	B-FUNC
concentrations	O
to	O
BCV	O
and	O
BRSV	O
in	O
pooled	O
milk	O
samples	O
from	O
primiparous	O
cows	O
,	O
and	O
in	O
bulk	O
-	O
tank	O
milk	O
twice	O
annually	O
.	O

In	O
the	O
Southern	O
Regions	O
the	O
percentage	O
of	O
antibody	B-FUNC
-	O
positive	O
herds	O
remained	O
persistently	O
high	O
(	O
75	O
-	O
100	O
%),	O
whereas	O
in	O
herds	O
based	O
in	O
the	O
Northern	O
Region	O
,	O
the	O
percentage	O
of	O
positive	O
herds	O
for	O
BCV	O
and	O
BRSV	O
was	O
38	O
-	O
80	O
%	O
and	O
0	O
-	O
80	O
%,	O
respectively	O
,	O
with	O
antibody	B-FUNC
levels	O
to	O
BRSV	O
decreasing	O
over	O
time	O
.	O

Only	O
TMD2	O
and	O
TMD3	O
induce	O
channel	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Crystal	O
structure	O
-	O
based	O
exploration	O
of	O
the	O
important	O
role	O
of	O
Arg106	O
in	O
the	O
RNA	O
-	O
binding	B-FUNC
domain	O
of	O
human	O
coronavirus	O
OC43	O
nucleocapsid	O
protein	O
.	O

This	O
finding	O
suggests	O
that	O
R106	O
,	O
by	O
enhancing	O
binding	B-FUNC
of	O
the	O
N	O
protein	O
to	O
viral	O
RNA	O
plays	O
a	O
critical	O
role	O
in	O
the	O
viral	O
replication	O
.	O

We	O
tested	O
acute	O
and	O
convalescent	O
sera	B-FUNC
for	O
antigen	O
and	O
antibody	B-FUNC
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
avian	O
influenza	O
,	O
and	O
plague	O
.	O

IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
on	O
the	O
fourth	O
and	O
seventh	O
days	O
were	O
significantly	O
improved	O
in	O
the	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

RESULTS	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
on	O
the	O
fourth	O
and	O
seventh	O
days	O
,	O
and	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
on	O
the	O
seventh	O
day	O
after	O
treatment	O
showed	O
significant	O
decrease	O
in	O
the	O
somatostatin	O
,	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

External	O
primers	O
were	O
used	O
to	O
amplify	O
a	O
fragment	O
of	O
the	O
expected	O
size	O
(	O
441	O
bp	O
)	O
in	O
all	O
the	O
samples	O
evaluated	O
using	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
but	O
with	O
very	O
low	O
intensity	O
.	O

TGEV	O
/	O
PEDV	O
specific	O
antibody	B-FUNC
responses	O
as	O
well	O
as	O
kinetic	O
changes	O
of	O
T	O
lymphocyte	O
subgroups	O
of	O
the	O
immunized	O
mice	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
TMPRSS2	O
(	O
transmembrane	O
serine	O
proteinase	B-FUNC
2	O
)	O
is	O
a	O
multidomain	O
type	O
II	O
transmembrane	O
serine	O
protease	O
that	O
cleaves	O
the	O
surface	O
glycoprotein	O
HA	O
(	O
haemagglutinin	O
)	O
of	O
influenza	O
viruses	O
with	O
a	O
monobasic	O
cleavage	O
site	O
,	O
which	O
is	O
a	O
prerequisite	O
for	O
virus	O
fusion	O
and	O
propagation	O
.	O

The	O
other	O
10	O
critical	O
residues	O
were	O
distributed	O
throughout	O
the	O
N7	O
-	O
MTase	O
domain	O
but	O
localized	O
mainly	O
in	O
the	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	O
)-	O
binding	B-FUNC
pocket	O
and	O
key	O
structural	O
elements	O
of	O
the	O
MTase	O
fold	O
of	O
nsp14	O
.	O

The	O
sequence	O
motif	O
DxGxPxA	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
331	O
to	O
338	O
)	O
was	O
identified	O
as	O
the	O
key	O
part	O
of	O
the	O
SAM	O
-	O
binding	B-FUNC
site	O
.	O

ABSTRACT	O
:	O
Human	O
T	O
-	O
cell	O
Immunoglobulin	B-FUNC
and	O
Mucin	O
-	O
domain	O
containing	O
proteins	O
(	O
TIM1	O
,	O
3	O
,	O
and	O
4	O
)	O
specifically	O
bind	B-FUNC
phosphatidylserine	O
(	O
PS	O
).	O

In	O
addition	O
,	O
other	O
PS	O
-	O
binding	B-FUNC
proteins	O
,	O
such	O
as	O
Axl	O
and	O
TIM4	O
,	O
promoted	O
infection	O
similarly	O
to	O
TIM1	O
.	O

Taken	O
together	O
our	O
data	O
show	O
that	O
TIM1	O
and	O
related	O
PS	O
-	O
binding	B-FUNC
proteins	O
promote	O
infection	O
of	O
diverse	O
families	O
of	O
enveloped	O
viruses	O
,	O
and	O
may	O
therefore	O
be	O
useful	O
targets	O
for	O
broad	O
-	O
spectrum	O
antiviral	O
therapies	O
.	O

These	O
included	O
16	O
dogs	O
exhibiting	O
ECA	O
positive	O
for	O
CPV	O
-	O
2	O
and	O
negative	O
for	O
Canine	O
distemper	O
virus	O
and	O
Canine	O
coronavirus	O
by	O
immunohistochemistry	O
and	O
fluorescent	O
antibody	B-FUNC
test	O
,	O
12	O
dogs	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
),	O
and	O
6	O
non	O
-	O
ECA	O
/	O
non	O
-	O
IBD	O
(	O
control	O
)	O
dogs	O
.	O

We	O
also	O
investigate	O
the	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	O
N	O
protein	O
by	O
examining	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cycle	O
progression	O
,	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
expression	O
,	O
and	O
survival	O
.	O

The	O
S	O
-	O
phase	O
is	O
prolonged	O
which	O
is	O
associated	O
with	O
a	O
decrease	O
of	O
cyclin	B-FUNC
A	O
transcription	O
level	O
and	O
an	O
increase	O
of	O
cyclin	B-FUNC
A	O
degradation	O
.	O

The	O
IEC	O
expressing	O
PEDV	O
N	O
protein	O
can	O
express	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
than	O
control	O
cells	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
series	O
of	O
truncated	O
expressed	O
SSL	O
fragments	O
and	O
SSL	O
specific	O
mouse	O
sera	B-FUNC
,	O
we	O
identified	O
two	O
immunogenic	O
determinants	O
for	O
SSL	O
.	O

Compared	O
to	O
rU	O
-	O
E	O
,	O
rMA15	O
-	O
E	O
immunization	O
resulted	O
in	O
significantly	O
greater	O
neutralizing	O
antibody	B-FUNC
and	O
SARS	O
-	O
CoV	O
-	O
specific	O
CD4	O
and	O
CD8	O
T	O
cell	O
responses	O
.	O

Respiratory	O
specimens	O
were	O
tested	O
for	O
influenza	O
and	O
other	O
respiratory	O
viruses	O
by	O
means	O
of	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assays	O
,	O
viral	O
culturing	O
,	O
and	O
sequence	O
analyses	O
.	O

However	O
,	O
fibrinogen	O
in	O
its	O
soluble	O
form	O
also	O
binds	B-FUNC
to	O
MAC	O
-	O
1	O
,	O
albeit	O
with	O
low	O
affinity	O
.	O

In	O
addition	O
,	O
soluble	O
fibrinogen	O
inhibited	O
lymphocyte	O
function	O
-	O
associated	O
antigen	O
1	O
-	O
dependent	O
lymphocyte	O
binding	B-FUNC
to	O
ICAM	O
-	O
1	O
through	O
a	O
direct	O
interaction	O
with	O
ICAM	O
-	O
1	O
.	O

Soluble	O
fibrinogen	O
reduced	O
MAC	O
-	O
1	O
-	O
dependent	O
binding	B-FUNC
of	O
interleukin	O
-	O
8	O
-	O
activated	O
neutrophils	O
to	O
ICAM	O
-	O
1	O
-	O
expressing	O
cells	O
under	O
flow	O
conditions	O
.	O

Importantly	O
soluble	O
fibrinogen	O
in	O
acute	O
-	O
phase	O
concentrations	O
(	O
4	O
-	O
10	O
mg	O
mL	O
(-	O
1	O
)	O
)	O
dose	O
-	O
dependently	O
reduced	O
neutrophil	O
firm	O
adhesion	O
to	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
-	O
activated	O
endothelium	O
to	O
40	O
%	O
under	O
flow	O
conditions	O
.	O

TITLE	O
:	O
Cross	O
-	O
reactive	O
antibodies	O
in	O
convalescent	O
SARS	O
patients	O
'	O
sera	B-FUNC
against	O
the	O
emerging	O
novel	O
human	O
coronavirus	O
EMC	O
(	O
2012	O
)	O
by	O
both	O
immunofluorescent	O
and	O
neutralizing	O
antibody	B-FUNC
tests	O
.	O

Anti	O
-	O
HCoV	O
-	O
EMC	O
and	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
were	O
detected	O
using	O
screening	O
indirect	O
immunofluorescence	O
(	O
IF	O
)	O
and	O
confirmatory	O
neutralizing	O
antibody	B-FUNC
tests	O
.	O

Two	O
(	O
2	O
.	O
1	O
%)	O
animal	O
handlers	O
had	O
IF	O
antibody	B-FUNC
titer	O
of	O
	O
1	O
:	O
20	O
against	O
both	O
HCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
with	O
neutralizing	O
antibody	B-FUNC
titer	O
of	O
<	O
1	O
:	O
10	O
.	O

Surprisingly	O
,	O
17	O
/	O
28	O
(	O
60	O
.	O
7	O
%)	O
of	O
SARS	O
patients	O
had	O
significant	O
IF	O
antibody	B-FUNC
titers	O
with	O
7	O
/	O
28	O
(	O
25	O
%)	O
having	O
anti	O
-	O
HCoV	O
-	O
EMC	O
neutralizing	O
antibodies	O
at	O
low	O
titers	O
which	O
significantly	O
correlated	O
with	O
that	O
of	O
HCoV	O
-	O
OC43	O
.	O

Immunofluorescent	O
antibody	B-FUNC
staining	O
showed	O
that	O
all	O
recombinants	O
expressed	O
the	O
inserted	O
IBV	O
genes	O
in	O
vitro	O
and	O
furthermore	O
,	O
all	O
recombinant	O
viruses	O
were	O
found	O
to	O
be	O
highly	O
stable	O
during	O
serial	O
passage	O
.	O

The	O
assay	O
has	O
been	O
validated	O
extensively	O
using	O
putative	O
cross	O
-	O
reacting	O
sera	B-FUNC
of	O
patient	O
cohorts	O
exposed	O
to	O
the	O
four	O
common	O
hCoVs	O
and	O
sera	B-FUNC
from	O
convalescent	O
patients	O
infected	O
with	O
hCoV	O
-	O
EMC	O
or	O
SARS	O
-	O
CoV	O
.	O

We	O
identified	O
PEDV	O
replicase	O
encoded	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
as	O
an	O
IFN	O
antagonist	O
that	O
depends	O
on	O
catalytic	B-FUNC
activity	I-FUNC
for	O
its	O
function	O
.	O

We	O
show	O
that	O
levels	O
of	O
ubiquitinated	O
proteins	O
are	O
reduced	O
during	O
PEDV	O
infection	O
and	O
that	O
PEDV	O
PLP2	O
has	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
activity	O
that	O
recognizes	O
and	O
processes	O
both	O
K	O
-	O
48	O
and	O
K	O
-	O
63	O
linked	O
polyubiquitin	O
chains	O
.	O

TITLE	O
:	O
Ultra	O
-	O
fast	B-FUNC
separation	O
of	O
infectious	O
disease	O
-	O
related	O
small	O
DNA	O
molecules	O
by	O
single	O
-	O
and	O
multi	O
-	O
channel	O
microchip	O
electrophoresis	O
.	O

ABSTRACT	O
:	O
An	O
ultra	O
-	O
fast	B-FUNC
and	O
precise	O
microchip	O
electrophoresis	O
(	O
ME	O
)	O
method	O
was	O
developed	O
for	O
the	O
separation	O
of	O
infectious	O
disease	O
-	O
related	O
small	O
DNA	O
molecules	O
.	O

The	O
ME	O
assay	O
technique	O
provides	O
a	O
simple	O
,	O
precise	O
and	O
accurate	O
method	O
for	O
ultra	O
-	O
fast	B-FUNC
analysis	O
of	O
infectious	O
disease	O
-	O
related	O
DNA	O
under	O
400	O
-	O
bp	O
.	O

Complications	O
and	O
outcomes	O
including	O
respiratory	O
and	O
abdominal	O
infection	O
,	O
sepsis	O
,	O
abdominal	O
hemorrhage	O
,	O
intra	O
-	O
abdominal	O
hypertension	O
,	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
),	O
renal	O
failure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
),	O
operation	O
intervention	O
,	O
length	O
of	O
intensive	O
care	O
unit	O
stay	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
and	O
mortality	O
at	O
60	O
d	O
were	O
compared	O
.	O

Compared	O
to	O
the	O
NS	O
group	O
,	O
incidence	O
of	O
renal	O
dysfunction	O
,	O
ARDS	O
,	O
MODS	O
and	O
ACS	B-FUNC
in	O
the	O
SH	O
and	O
SHG	O
groups	O
was	O
obviously	O
lower	O
.	O

Moreover	O
,	O
the	O
serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
,	O
interleukin	O
-	O
8	O
and	O
C	O
-	O
reactive	O
protein	O
levels	O
in	O
the	O
SH	O
and	O
SHG	O
groups	O
were	O
obviously	O
lower	O
than	O
in	O
the	O
NS	O
group	O
at	O
each	O
time	O
point	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	B-FUNC
against	O
membrane	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

In	O
this	O
study	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
designated	O
7G7	O
,	O
against	O
the	O
TGEV	O
M	O
protein	O
was	O
generated	O
by	O
inoculating	O
BALB	O
/	O
c	O
mice	O
with	O
TGEV	O
followed	O
by	O
hybridoma	O
technique	O
.	O

TITLE	O
:	O
Expression	O
and	O
Purification	O
of	O
the	O
scFv	O
from	O
hybridoma	O
cells	O
secreting	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
S	O
PROTEIN	O
of	O
PEDV	O
.	O

ABSTRACT	O
:	O
The	O
variable	O
regions	O
of	O
the	O
heavy	O
chain	O
(	O
VH	O
)	O
and	O
light	O
chain	O
(	O
VL	O
)	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
the	O
hybridoma	O
6E6	O
,	O
which	O
secretes	O
the	O
monoclonal	O
antibody	B-FUNC
against	O
PEDV	O
S	O
protein	O
.	O

TITLE	O
:	O
A	O
monoclonal	O
antibody	B-FUNC
against	O
transmissible	O
gastroenteritis	O
virus	O
generated	O
via	O
immunization	O
of	O
a	O
DNA	O
plasmid	O
bearing	O
TGEV	O
S1	O
gene	O
.	O

Herein	O
,	O
DNA	O
plasmid	O
bearing	O
TGEV	O
S1	O
gene	O
(	O
the	O
N	O
terminal	O
half	O
of	O
TGEV	O
S	O
gene	O
)	O
was	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
followed	O
by	O
generation	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
using	O
the	O
hybridoma	O
technique	O
.	O

The	O
transmission	O
tracking	O
analysis	O
technique	O
was	O
established	O
based	O
on	O
the	O
modeling	O
platform	O
ArcGIS	O
Engine	O
Developer	O
Kit	B-FUNC
9	O
.	O
3	O
,	O
using	O
the	O
techniques	O
of	O
address	O
matching	O
,	O
shortest	O
path	O
analysis	O
and	O
buffer	O
analysis	O
,	O
and	O
programming	O
by	O
Visual	O
C	O
++.	O

As	O
TCoV	O
does	O
not	O
induce	O
lesions	O
in	O
the	O
embryo	O
,	O
virus	O
replication	O
in	O
the	O
jejunum	O
and	O
ileum	O
of	O
the	O
embryos	O
was	O
detected	O
4	O
days	O
post	O
inoculation	O
,	O
using	O
RNA	O
extraction	O
and	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
based	O
on	O
the	O
nucleocapsid	O
gene	O
.	O

High	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
),	O
which	O
was	O
identified	O
originally	O
as	O
a	O
DNA	B-FUNC
binding	I-FUNC
protein	O
,	O
has	O
been	O
proposed	O
as	O
a	O
mediator	O
of	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Anti	O
-	O
NMDA	B-FUNC
receptor	I-FUNC
encephalitis	O
in	O
children	O
:	O
the	O
disorder	O
,	O
its	O
diagnosis	O
,	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
NMDA	B-FUNC
receptor	I-FUNC
encephalitis	O
is	O
a	O
newly	O
characterized	O
severe	O
neuroautoimmune	O
syndrome	O
with	O
a	O
progressive	O
,	O
clinical	O
course	O
.	O

A	O
unique	O
set	O
of	O
207	O
genes	O
was	O
dysregulated	O
early	O
and	O
permanently	O
throughout	O
infection	O
with	O
HCoV	O
-	O
EMC	O
,	O
and	O
was	O
used	O
in	O
a	O
computational	O
screen	O
to	O
predict	O
potential	O
antiviral	O
compounds	O
,	O
including	O
kinase	B-FUNC
inhibitors	I-FUNC
and	O
glucocorticoids	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
a	O
C	O
-	O
terminal	O
residue	O
,	O
Arg298	O
,	O
interacts	O
with	O
Ser123	O
of	O
the	O
other	O
monomer	O
in	O
the	O
dimer	O
,	O
and	O
mutation	O
of	O
Arg298	O
results	O
in	O
a	O
monomeric	O
structure	O
with	O
a	O
collapsed	O
substrate	O
-	O
binding	B-FUNC
pocket	O
.	O

The	O
presence	O
of	O
a	O
complete	O
substrate	O
-	O
binding	B-FUNC
pocket	O
and	O
oxyanion	O
hole	O
in	O
both	O
protomers	O
suggests	O
that	O
they	O
are	O
both	O
catalytically	O
active	O
,	O
while	O
the	O
two	O
domain	O
IIIs	O
show	O
minor	O
reorganization	O
.	O

Mutagenesis	O
to	O
disrupt	O
or	O
restore	O
base	B-FUNC
pairs	I-FUNC
in	O
the	O
potential	O
hairpin	O
stem	O
reveals	O
that	O
base	O
-	O
pair	O
formation	O
is	O
required	O
for	O
-	O
1	O
frameshifting	O
attenuation	O
in	O
vitro	O
and	O
in	O
293T	O
cells	O
.	O

All	O
paired	O
sera	B-FUNC
(	O
9	O
/	O
9	O
)	O
collected	O
from	O
febrile	O
horses	O
showed	O
seroconversion	O
by	O
neutralization	O
test	O
.	O

Seven	O
patients	O
presented	O
with	O
thrombocytopenia	O
and	O
hypoalbuminemia	O
,	O
five	O
of	O
which	O
had	O
hemoconcentration	O
and	O
increased	O
ALT	B-FUNC
and	O
AST	O
indicative	O
of	O
liver	O
damage	O
.	O

TITLE	O
:	O
Probe	O
Reports	O
from	O
the	O
NIH	O
Molecular	O
Libraries	O
Program	O
ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
high	O
throughput	O
screening	O
(	O
HTS	O
)	O
screening	O
and	O
optimization	O
of	O
a	O
lead	O
series	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
main	O
proteinase	B-FUNC
3CLpro	O
inhibitors	O
leading	O
to	O
the	O
identification	O
of	O
ML188	O
,	O
((	O

Both	O
PEDV	O
N	O
protein	O
and	O
the	O
polyclonal	O
antibody	B-FUNC
generated	O
in	O
this	O
study	O
are	O
valuable	O
diagnostic	O
reagents	O
for	O
PEDV	O
surveillance	O
.	O

After	O
four	O
rounds	O
of	O
biopanning	O
,	O
10	O
monoclonal	O
phages	O
with	O
specific	O
binding	B-FUNC
activity	O
to	O
the	O
S1	O
-	O
RBD	O
protein	O
were	O
obtained	O
and	O
subjected	O
to	O
binding	B-FUNC
and	O
diagnostic	O
assays	O
.	O

We	O
suggest	O
the	O
use	O
of	O
epitope	O
prediction	O
methods	O
in	O
combination	O
with	O
3D	O
structural	O
modelling	O
of	O
peptide	O
-	O
MHC	O
-	O
TCR	O
complex	O
to	O
identify	O
MHC	O
class	O
I	O
restricted	O
T	O
-	O
cell	O
epitopes	O
for	O
use	O
in	O
epitope	O
based	O
vaccines	O
like	O
HIV	O
and	O
human	O
cancers	O
,	O
which	O
should	O
provide	O
a	O
valuable	O
step	O
forward	O
for	O
the	O
design	O
of	O
better	O
vaccines	O
and	O
may	O
provide	O
in	O
depth	O
understanding	O
about	O
activation	O
of	O
T	O
-	O
cell	O
epitopes	O
by	O
MHC	O
binding	B-FUNC
peptides	O
.	O

Cell	O
therapy	O
,	O
particularly	O
with	O
allogeneic	O
mesenchymal	O
stem	O
/	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
),	O
has	O
emerged	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
ARDS	O
,	O
favorably	O
modulating	O
the	O
immune	O
response	O
to	O
reduce	O
lung	O
injury	O
,	O
while	O
facilitating	O
lung	O
regeneration	O
and	O
repair	O
.	O

In	O
this	O
issue	O
of	O
the	O
journal	O
,	O
Rojas	O
and	O
colleagues	O
provide	O
us	O
with	O
a	O
rationale	O
to	O
consider	O
autologous	O
bone	O
marrow	O
-	O
mononuclear	O
cells	O
as	O
an	O
alternative	O
to	O
MSCs	B-FUNC
for	O
this	O
devastating	O
disease	O
.	O

This	O
review	O
focuses	O
on	O
existing	O
studies	O
that	O
have	O
tested	O
the	O
use	O
of	O
MSCs	B-FUNC
in	O
models	O
of	O
ALI	O
/	O
ARDS	O
,	O
and	O
the	O
potential	O
mechanisms	O
underlying	O
their	O
therapeutic	O
effects	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
p53	O
and	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	B-FUNC
)	O
signalling	O
pathways	O
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

TGEV	O
infection	O
induced	O
the	O
transient	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
in	O
the	O
early	O
phase	O
of	O
inoculation	O
and	O
constant	O
activation	O
in	O
the	O
later	O
phase	O
of	O
infection	O
.	O

However	O
,	O
UV	O
-	O
irradiated	O
TGEV	O
did	O
not	O
promote	O
the	O
activation	O
of	O
p53	O
and	O
p38	B-FUNC
MAPK	B-FUNC
in	O
the	O
later	O
phase	O
,	O
whereas	O
it	O
only	O
triggered	O
the	O
transient	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
in	O
the	O
early	O
phase	O
.	O

However	O
,	O
inhibition	O
of	O
p38	B-FUNC
and	O
p53	O
activity	O
had	O
no	O
significant	O
effects	O
on	O
viral	O
gene	O
transcription	O
at	O
12	O
and	O
24	O
h	O
post	O
-	O
infection	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
infection	O
promoted	O
the	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
p53	O
signalling	O
,	O
and	O
p53	O
signalling	O
might	O
play	O
a	O
dominant	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
apoptosis	O
.	O

These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
function	O
of	O
p53	O
and	O
p38	B-FUNC
MAPK	B-FUNC
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

ABSTRACT	O
:	O
Blinatumomab	O
is	O
a	O
CD19	O
/	O
CD3	O
-	O
bispecific	O
T	O
-	O
cell	O
receptor	O
-	O
engaging	O
(	O
BiTE	O
)	O
antibody	B-FUNC
with	O
efficacy	O
in	O
refractory	O
B	O
-	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Interestingly	O
,	O
knockdown	O
of	O
protein	O
kinase	O
R	O
(	O
PKR	O
)	O
by	O
siRNA	O
and	O
inhibition	O
of	O
the	O
PKR	O
kinase	B-FUNC
activity	I-FUNC
by	O
2	O
-	O
aminopurine	O
(	O
2	O
-	O
AP	O
)	O
also	O
reduced	O
the	O
IBV	O
-	O
induced	O
upregulation	O
of	O
GADD153	O
and	O
apoptosis	O
induction	O
.	O

Analysis	O
of	O
the	O
pathways	O
downstream	O
of	O
GADD153	O
revealed	O
much	O
more	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-FUNC
)	O
pathway	O
in	O
GADD153	O
-	O
knockdown	O
cells	O
during	O
IBV	O
infection	O
,	O
indicating	O
that	O
GADD153	O
may	O
modulate	O
apoptosis	O
through	O
suppression	O
of	O
the	O
pathway	O
.	O

TITLE	O
:	O
Analysis	O
of	O
SARS	O
-	O
CoV	O
E	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
by	O
tuning	O
the	O
protein	O
and	O
lipid	O
charge	O
.	O

ABSTRACT	O
:	O
A	O
partial	O
characterization	O
of	O
the	O
ion	B-FUNC
channels	I-FUNC
formed	O
by	O
the	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	O
was	O
previously	O
reported	O
(	O
C	O
.	O
Verdi	O
-	O
Bguena	O
et	O
al	O
.,	O
2012	O
[	O
12	O
]).	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
mechanisms	O
of	O
apolipoprotein	B-FUNC
A	O
-	O
I	O
mimetic	O
peptide	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
sepsis	O
.	O

Peptides	O
such	O
as	O
L	O
-	O
4F	O
mimic	O
the	O
secondary	O
structural	O
features	O
and	O
functions	O
of	O
apolipoprotein	B-FUNC
(	O
apo	O
)	O
A	O
-	O
I	O
,	O
the	O
major	O
protein	O
component	O
of	O
HDL	O
.	O

Compared	O
to	O
controls	O
,	O
ARDS	O
demonstrates	O
increased	O
serum	O
endotoxin	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
,	O
and	O
decreased	O
HDL	O
,	O
apoA	O
-	O
I	O
and	O
activity	O
of	O
anti	O
-	O
oxidant	O
HDL	O
-	O
associated	O
paraoxanase	O
-	O
1	O
.	O

Further	O
,	O
L	O
-	O
4F	O
decreased	O
endotoxin	B-FUNC
activity	I-FUNC
and	O
preserved	O
anti	O
-	O
oxidant	O
properties	O
of	O
HDL	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Typical	O
examples	O
include	O
poisoning	O
due	O
to	O
calcium	B-FUNC
channel	I-FUNC
antagonists	O
,	O
beta	O
-	O
blockers	O
,	O
tricyclic	O
antidepressants	O
,	O
chloroquine	O
and	O
colchicine	O
.	O

The	O
median	O
times	O
from	O
the	O
onset	O
of	O
illness	O
and	O
from	O
the	O
initiation	O
of	O
antiviral	O
therapy	O
to	O
a	O
negative	O
viral	O
test	O
result	O
on	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assay	O
were	O
11	O
days	O
(	O
interquartile	O
range	O
,	O
9	O
to	O
16	O
)	O
and	O
6	O
days	O
(	O
interquartile	O
range	O
,	O
4	O
to	O
7	O
),	O
respectively	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nonstructural	O
protein	O
2	O
(	O
ns2	O
)	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
that	O
inhibits	O
activation	O
of	O
the	O
interferon	O
-	O
induced	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	O
L	O
pathway	O
.	O

The	O
replication	O
of	O
wild	O
-	O
type	O
MHV	O
strain	O
A59	O
(	O
A59	O
)	O
and	O
a	O
mutant	O
with	O
an	O
inactive	O
phosphodiesterase	B-FUNC
(	O
ns2	O
-	O
H126R	O
)	O
was	O
assessed	O
in	O
primary	O
hepatocytes	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
cell	O
types	O
-	O
neurons	O
,	O
astrocytes	O
,	O
and	O
oligodendrocytes	O
.	O

TITLE	O
:	O
Suppression	O
of	O
coronavirus	O
replication	O
by	O
cyclophilin	B-FUNC
inhibitors	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
cyclophilin	B-FUNC
inhibitor	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
could	O
inhibit	O
the	O
replication	O
of	O
coronaviruses	O
.	O

CsA	O
is	O
a	O
well	O
-	O
known	O
immunosuppressive	O
drug	O
that	O
binds	B-FUNC
to	O
cellular	O
cyclophilins	O
to	O
inhibit	O
calcineurin	B-FUNC
,	O
a	O
calcium	O
-	O
calmodulin	O
-	O
activated	O
serine	O
/	O
threonine	O
-	O
specific	O
phosphatase	B-FUNC
.	O

The	O
inhibition	O
of	O
calcineurin	B-FUNC
blocks	O
the	O
translocation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
,	O
thus	O
preventing	O
the	O
transcription	O
of	O
genes	O
encoding	O
cytokines	O
such	O
as	O
interleukin	O
-	O
2	O
.	O

He	O
received	O
a	O
BSc	O
(	O
Honors	O
)	O
and	O
a	O
PhD	B-FUNC
(	O
1986	O
)	O
in	O
biochemistry	O
at	O
the	O
University	O
of	O
Alberta	O
,	O
Canada	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
guanine	O
-	O
N7	O
methyltransferase	B-FUNC
activity	I-FUNC
of	O
coronavirus	O
nsp14	O
on	O
nucleotide	O
GTP	O
.	O

TITLE	O
:	O
Binding	B-FUNC
and	O
repressive	O
activities	O
of	O
apolipoprotein	B-FUNC
E3	O
and	O
E4	O
isoforms	O
on	O
the	O
human	O
ApoD	O
promoter	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	B-FUNC
D	O
(	O
ApoD	O
)	O
gene	O
expression	O
is	O
increased	O
in	O
several	O
neurological	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
multiple	O
sclerosis	O
.	O

Here	O
,	O
we	O
identified	O
several	O
nuclear	O
factors	O
from	O
the	O
cortex	O
of	O
control	O
and	O
OC43	O
-	O
infected	O
mice	O
which	O
bind	B-FUNC
a	O
fragment	O
of	O
the	O
proximal	O
ApoD	O
promoter	O
in	O
vitro	O
.	O

Of	O
interest	O
,	O
we	O
detected	O
apolipoprotein	B-FUNC
E	O
(	O
ApoE	O
).	O

Consistent	O
with	O
these	O
results	O
,	O
we	O
also	O
demonstrated	O
by	O
ChIP	O
assay	O
that	O
E3	O
and	O
E4	O
isoforms	O
,	O
but	O
not	O
E2	O
,	O
bind	B-FUNC
the	O
ApoD	O
promoter	O
.	O

Haematology	O
and	O
serum	O
biochemistry	O
revealed	O
severe	O
panleukopenia	O
,	O
thrombocytopenia	O
,	O
markedly	O
elevated	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
five	O
-	O
fold	O
increased	O
pre	O
-	O
prandial	O
bile	O
acids	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)	O
is	O
contraindicated	O
or	O
at	O
least	O
not	O
recommended	O
in	O
patients	O
with	O
altered	O
consciousness	O
syndrome	O
(	O
ACS	B-FUNC
)	O
given	O
to	O
the	O
poor	O
compliance	O
of	O
confused	O
/	O
agitated	O
patients	O
,	O
difficult	O
management	O
of	O
accumulated	O
secretion	O
in	O
depressed	O
cough	O
reflex	O
,	O
and	O
risk	O
of	O
aspirative	O
pneumonia	O
in	O
absence	O
of	O
airways	O
protection	O
.	O

Conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
via	O
endotracheal	O
intubation	O
(	O
ETI	O
)	O
has	O
been	O
usually	O
considered	O
as	O
the	O
""""	O
golden	O
standard	O
""""	O
ventilator	O
treatment	O
in	O
ACS	B-FUNC
.	O

The	O
available	O
published	O
data	O
dealing	O
with	O
the	O
use	O
of	O
NIV	O
in	O
ACS	B-FUNC
were	O
obtained	O
in	O
patients	O
with	O
hypercapnic	O
encephalopathy	O
complicating	O
severe	O
exacerbations	O
of	O
COPD	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
was	O
to	O
review	O
rationale	O
,	O
clinical	O
feasibility	O
,	O
advantages	O
and	O
risks	O
correlated	O
with	O
the	O
use	O
of	O
NIV	O
in	O
ACS	B-FUNC
.	O

The	O
positivity	O
was	O
significantly	O
higher	O
in	O
males	O
(	O
51	O
.	O
5	O
%)	O
than	O
in	O
females	O
(	O
35	O
.	O
7	O
%)	O
(	O
P	O
<	O
0	O
.	O
0001	O
),	O
whereas	O
no	O
gender	O
difference	O
has	O
generally	O
been	O
noted	O
in	O
FCoV	O
antibody	B-FUNC
prevalence	O
,	O
indicating	O
that	O
FIP	O
more	O
frequently	O
develops	O
in	O
males	O
among	O
FCoV	O
-	O
infected	O
cats	O
.	O

Sequencing	O
of	O
their	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
revealed	O
that	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
Pi	O
-	O
BatCoV	O
HKU5	O
in	O
RdRp	B-FUNC
(	O
92	O
.	O
1	O
%	O
to	O
92	O
.	O
3	O
%	O
amino	O
acid	O
[	O
aa	O
]	O
identity	O
)	O
but	O
is	O
more	O
closely	O
related	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
in	O
S	O
(	O
66	O
.	O
8	O
%	O
to	O
67	O
.	O
4	O
%	O
aa	O
identity	O
)	O
and	O
N	O
(	O
71	O
.	O
9	O
%	O
to	O
72	O
.	O
3	O
%	O
aa	O
identity	O
).	O

A	O
flow	O
cytometric	O
method	O
based	O
on	O
ingestion	O
of	O
fluoresceinated	O
bacteria	O
and	O
adapted	O
to	O
feline	O
blood	O
was	O
used	O
to	O
assess	O
phagocytosis	O
of	O
leukocytes	O
incubated	O
with	O
'	O
non	O
-	O
pathological	O
'	O
fAGP	O
(	O
purified	O
from	O
sera	B-FUNC
with	O
normal	O
concentrations	O
of	O
AGP	O
)	O
and	O
'	O
pathological	O
'	O
fAGP	O
(	O
purified	O
from	O
sera	B-FUNC
with	O
>	O
1	O
.	O
5mg	O
/	O
mL	O
hyposialylated	O
AGP	O
).	O

French	O
Institute	O
for	O
Public	O
Health	O
Surveillance	O
,	O
ANR	B-FUNC
grant	O
Labex	O
Integrative	O
Biology	O
of	O
Emerging	O
Infectious	O
Diseases	O
,	O
and	O
the	O
European	O
Community	O
'	O
s	O
Seventh	O
Framework	O
Programme	O
projects	O
EMPERIE	O
and	O
PREDEMICS	O
.	O

ABSTRACT	O
:	O
Various	O
kinds	O
of	O
commercial	O
molecular	O
systems	O
have	O
been	O
developed	O
for	O
fast	B-FUNC
and	O
more	O
accurate	O
detection	O
of	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
[	O
Prokaryotic	O
expression	O
and	O
characterization	O
of	O
two	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
proteins	O
of	O
human	O
coronavirus	O
NL63	O
(	O
HcoV	O
-	O
NL63	O
)].	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
protein	O
of	O
HCoV	O
-	O
NL63	O
is	O
a	O
major	O
target	O
in	O
the	O
development	O
of	O
diagnostic	O
assay	O
and	O
vaccine	O
,	O
it	O
has	O
a	O
pivotal	O
role	O
in	O
receptor	O
attachment	O
,	O
viral	O
entry	O
and	O
membrane	O
fusion	O
.	O

RL	O
or	O
RS	O
protein	O
with	O
95	O
%	O
purity	O
was	O
obtained	O
and	O
reacted	O
positively	O
with	O
anti	O
-	O
sera	B-FUNC
from	O
mice	O
immunized	O
with	O
the	O
recombinant	O
vaccinia	O
virus	O
(	O
Tiantan	O
strain	O
)	O
in	O
which	O
HCoV	O
-	O
NL63	O
RL	O
or	O
RS	O
protein	O
was	O
expressed	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
critical	O
interaction	O
between	O
the	O
coronavirus	O
nucleocapsid	O
protein	O
and	O
nonstructural	O
protein	O
3	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
.	O

We	O
previously	O
uncovered	O
an	O
unanticipated	O
interaction	O
between	O
N	O
and	O
the	O
largest	O
subunit	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
,	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
).	O

We	O
found	O
that	O
the	O
N	O
-	O
nsp3	O
interaction	O
maps	O
to	O
the	O
amino	O
-	O
terminal	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
of	O
nsp3	O
,	O
which	O
is	O
essential	O
for	O
the	O
virus	O
.	O

Our	O
results	O
support	O
a	O
model	O
in	O
which	O
the	O
N	O
-	O
nsp3	O
interaction	O
serves	O
to	O
tether	O
the	O
genome	O
to	O
the	O
newly	O
translated	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
at	O
a	O
very	O
early	O
stage	O
of	O
infection	O
.	O

Based	O
on	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)-	O
based	O
grouping	O
units	O
(	O
RGUs	O
)	O
as	O
a	O
surrogate	O
for	O
CoV	O
species	O
identification	O
,	O
the	O
50	O
viruses	O
represented	O
five	O
different	O
alphacoronavirus	O
RGUs	O
and	O
two	O
betacoronavirus	O
RGUs	O
.	O

We	O
used	O
sputum	O
and	O
blood	O
cultures	O
,	O
IgG	O
/	O
IgM	O
serology	O
and	O
molecular	O
diagnostic	O
techniques	O
(	O
PCR	O
,	O
reverse	O
transcriptase	B-FUNC
PCR	O
)	O
for	O
detection	O
of	O
classical	O
and	O
atypical	O
bacteria	O
(	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydia	O
pneumoniae	O
,	O
Legionella	O
pneumoniae	O
)	O
and	O
respiratory	O
viruses	O
(	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
,	O
influenza	O
virus	O
,	O
parainfluenzavirus	O
,	O
rhinovirus	O
,	O
coronavirus	O
)	O
in	O
adults	O
>	O
18	O
years	O
old	O
presenting	O
with	O
CAP	O
in	O
Santiago	O
from	O
February	O
2005	O
to	O
September	O
2007	O
.	O

TITLE	O
:	O
The	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
new	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
maps	O
to	O
a	O
231	O
-	O
residue	O
region	O
in	O
the	O
spike	O
protein	O
that	O
efficiently	O
elicits	O
neutralizing	O
antibodies	O
.	O

Here	O
we	O
mapped	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
in	O
the	O
S	O
protein	O
to	O
a	O
231	O
-	O
amino	O
-	O
acid	O
fragment	O
(	O
residues	O
358	O
to	O
588	O
)	O
by	O
evaluating	O
the	O
interaction	O
of	O
spike	O
truncation	O
variants	O
with	O
receptor	O
-	O
expressing	O
cells	O
and	O
soluble	O
DPP4	O
.	O

TITLE	O
:	O
Synergistic	O
inhibitor	O
binding	B-FUNC
to	O
the	O
papain	O
-	O
like	O
protease	O
of	O
human	O
SARS	O
coronavirus	O
:	O
mechanistic	O
and	O
inhibitor	O
design	O
implications	O
.	O

Surface	O
plasmon	O
resonance	O
measurements	O
showed	O
that	O
three	O
fragments	O
bind	B-FUNC
specifically	O
to	O
the	O
PLpro	O
enzyme	O
.	O

TITLE	O
:	O
Solution	O
NMR	O
analyses	O
of	O
the	O
C	O
-	O
type	O
carbohydrate	O
recognition	O
domain	O
of	O
DC	O
-	O
SIGNR	O
protein	O
reveal	O
different	O
binding	B-FUNC
modes	O
for	O
HIV	O
-	O
derived	O
oligosaccharides	O
and	O
smaller	O
glycan	O
fragments	O
.	O

Direct	O
interactions	O
with	O
the	O
small	O
sugar	O
fragments	O
Man3	O
,	O
Man5	O
,	O
and	O
(	O
GlcNAc	O
)	O
2Man3	O
were	O
investigated	O
alongside	O
Man9GlcNAc	O
derived	O
from	O
recombinant	O
gp120	O
(	O
present	O
on	O
the	O
HIV	O
viral	O
envelope	O
),	O
providing	O
the	O
first	O
structural	O
data	O
for	O
DC	O
-	O
SIGNR	O
in	O
complex	O
with	O
a	O
virus	O
-	O
associated	O
ligand	B-FUNC
,	O
and	O
unique	O
binding	B-FUNC
modes	O
were	O
observed	O
for	O
each	O
glycan	O
.	O

In	O
particular	O
,	O
our	O
data	O
show	O
that	O
DC	O
-	O
SIGNR	O
has	O
a	O
different	O
binding	B-FUNC
mode	O
for	O
glycans	O
on	O
the	O
HIV	O
viral	O
envelope	O
compared	O
with	O
the	O
smaller	O
glycans	O
previously	O
observed	O
in	O
the	O
crystalline	O
state	O
.	O

This	O
suggests	O
that	O
using	O
the	O
binding	B-FUNC
mode	O
of	O
Man9GlcNAc	O
,	O
instead	O
of	O
those	O
of	O
small	O
glycans	O
,	O
may	O
provide	O
a	O
platform	O
for	O
the	O
design	O
of	O
DC	O
-	O
SIGNR	O
inhibitors	O
selective	O
for	O
high	O
mannose	O
glycans	O
(	O
like	O
those	O
on	O
HIV	O
).	O

Beside	O
the	O
well	O
known	O
capacity	O
to	O
act	O
as	O
plasma	O
-	O
expander	O
,	O
HSA	O
is	O
provided	O
of	O
many	O
other	O
properties	O
which	O
are	O
unrelated	O
to	O
the	O
regulation	O
of	O
fluid	O
compartmentalization	O
,	O
including	O
binding	B-FUNC
and	O
transport	O
of	O
many	O
endogenous	O
and	O
exogenous	O
substances	O
,	O
antioxidant	O
function	O
,	O
immuno	O
-	O
modulation	O
,	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
endothelial	O
stabilization	O
.	O

Two	O
strongly	O
positive	O
selection	O
sites	O
were	O
detected	O
along	O
the	O
receptor	O
-	O
binding	B-FUNC
subunit	O
of	O
the	O
S	O
protein	O
gene	O
:	O
spanning	O
amino	O
acid	O
residues	O
109	O
-	O
131	O
and	O
495	O
-	O
527	O
.	O

TITLE	O
:	O
Hypericum	O
hircinum	O
L	O
.	O
components	O
as	O
new	O
single	O
-	O
molecule	O
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
DNA	O
polymerase	O
and	O
ribonuclease	O
H	O
activities	O
.	O

While	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
the	O
DNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
,	O
there	O
is	O
the	O
pressing	O
need	O
for	O
new	O
RT	O
inhibitors	O
possibly	O
targeting	O
the	O
RNase	O
H	O
function	O
.	O

We	O
discover	O
that	O
the	O
H7N9	O
virus	O
can	O
bind	B-FUNC
to	O
both	O
avian	O
-	O
type	O
(	O
2	O
,	O
3	O
-	O
linked	O
sialic	O
acid	O
)	O
and	O
human	O
-	O
type	O
(	O
2	O
,	O
6	O
-	O
linked	O
sialic	O
acid	O
)	O
receptors	O
.	O

In	O
acute	O
serum	O
samples	O
of	O
H7N9	O
-	O
infected	O
patients	O
,	O
increased	O
levels	O
of	O
the	O
chemokines	O
and	O
cytokines	O
IP	O
-	O
10	O
,	O
MIG	O
,	O
MIP	O
-	O
1	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
IFN	O
-	O
	O
were	O
detected	O
.	O

The	O
analysis	O
of	O
the	O
4E6	O
escape	O
mutants	O
demonstrated	O
that	O
the	O
4E6	O
antibody	B-FUNC
bound	O
to	O
a	O
conserved	O
epitope	O
region	O
containing	O
two	O
amino	O
acids	O
on	O
the	O
globular	O
head	O
of	O
HA	O
.	O

In	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
as	O
a	O
model	O
,	O
we	O
previously	O
reported	O
that	O
accessory	O
gene	O
7	O
counteracts	O
the	O
host	O
antiviral	O
response	O
by	O
associating	O
with	O
the	O
catalytic	O
subunit	O
of	O
protein	O
phosphatase	B-FUNC
1	O
(	O
PP1c	O
).	O

Here	O
we	O
showed	O
that	O
residues	O
377	O
to	O
662	O
in	O
the	O
S	O
protein	O
of	O
MERS	O
-	O
CoV	O
specifically	O
bound	O
to	O
DPP4	O
-	O
expressing	O
cells	O
and	O
soluble	O
DPP4	O
protein	O
and	O
induced	O
significant	O
neutralizing	O
antibody	B-FUNC
responses	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
which	O
has	O
a	O
potential	O
to	O
be	O
developed	O
as	O
a	O
MERS	O
-	O
CoV	O
vaccine	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
:	O
identification	O
of	O
M	O
protein	O
-	O
binding	B-FUNC
peptide	O
ligands	O
with	O
antiviral	O
and	O
diagnostic	O
potential	O
.	O

Three	O
phages	O
expressing	O
TGEV	O
-	O
M	O
-	O
binding	B-FUNC
peptides	O
were	O
identified	O
and	O
characterized	O
in	O
more	O
depth	O
.	O

When	O
the	O
phage	O
-	O
ELISA	O
was	O
compared	O
to	O
conventional	O
antibody	B-FUNC
-	O
based	O
ELISA	O
for	O
detecting	O
infections	O
,	O
phage	O
-	O
ELISA	O
exhibited	O
greater	O
sensitivity	O
.	O

TITLE	O
:	O
Molecular	O
basis	O
of	O
binding	B-FUNC
between	O
novel	O
human	O
coronavirus	O
MERS	O
-	O
CoV	O
and	O
its	O
receptor	O
CD26	O
.	O

Here	O
we	O
delineate	O
the	O
molecular	O
basis	O
of	O
this	O
specific	O
interaction	O
by	O
presenting	O
the	O
first	O
crystal	O
structures	O
of	O
both	O
the	O
free	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
and	O
its	O
complex	O
with	O
CD26	O
.	O

Furthermore	O
,	O
binding	B-FUNC
between	O
the	O
RBD	O
and	O
CD26	O
is	O
measured	O
using	O
real	O
-	O
time	O
surface	O
plasmon	O
resonance	O
with	O
a	O
dissociation	O
constant	O
of	O
16	O
.	O
7	O
nM	O
.	O
The	O
viral	O
RBD	O
is	O
composed	O
of	O
a	O
core	O
subdomain	O
homologous	O
to	O
that	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
and	O
a	O
unique	O
strand	O
-	O
dominated	O
external	O
receptor	B-FUNC
binding	I-FUNC
motif	O
that	O
recognizes	O
blades	O
IV	O
and	O
V	O
of	O
the	O
CD26	O
	O
-	O
propeller	O
.	O

The	O
atomic	O
details	O
at	O
the	O
interface	O
between	O
the	O
two	O
binding	B-FUNC
entities	O
reveal	O
a	O
surprising	O
protein	O
-	O
protein	O
contact	O
mediated	O
mainly	O
by	O
hydrophilic	O
residues	O
.	O

TITLE	O
:	O
Lactococcus	O
lactis	O
anchoring	B-FUNC
avian	O
infectious	O
bronchitis	O
virus	O
multi	O
-	O
epitope	O
peptide	O
EpiC	O
induced	O
specific	O
immune	O
responses	O
in	O
chickens	O
.	O

These	O
results	O
indicate	O
that	O
needle	O
-	O
free	O
recombinant	O
lactococci	O
anchoring	B-FUNC
the	O
IBV	O
antigen	O
makes	O
a	O
promising	O
vaccine	O
candidate	O
against	O
the	O
spread	O
of	O
IB	O
.	O

Therapeutic	O
effects	O
of	O
MSCs	B-FUNC
were	O
noticed	O
in	O
various	O
delivery	O
approaches	O
(	O
systemic	O
,	O
local	O
,	O
or	O
other	O
locations	O
),	O
multiple	O
origins	O
(	O
bone	O
marrow	O
or	O
other	O
tissues	O
),	O
or	O
different	O
schedules	O
of	O
administrations	O
(	O
before	O
or	O
after	O
the	O
challenges	O
).	O

MSCs	B-FUNC
could	O
reduce	O
the	O
over	O
-	O
production	O
of	O
inflammatory	O
mediators	O
,	O
leucocyte	O
infiltration	O
,	O
tissue	O
injury	O
and	O
pulmonary	O
failure	O
,	O
and	O
produce	O
a	O
number	O
of	O
benefit	O
factors	O
through	O
interaction	O
with	O
other	O
cells	O
in	O
the	O
process	O
of	O
lung	O
tissue	O
repair	O
.	O

Sequence	O
comparison	O
and	O
modeling	O
analysis	O
have	O
revealed	O
a	O
putative	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
the	O
viral	O
spike	O
,	O
which	O
mediates	O
this	O
interaction	O
.	O

MERS	O
-	O
CoV	O
RBD	O
and	O
related	O
SARS	O
-	O
CoV	O
RBD	O
share	O
a	O
high	O
degree	O
of	O
structural	O
similarity	O
in	O
their	O
core	O
subdomains	O
,	O
but	O
are	O
notably	O
divergent	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
subdomain	O
.	O

The	O
lack	O
of	O
efficient	O
respiratory	O
droplet	O
transmission	O
was	O
corroborated	O
by	O
low	O
receptor	O
-	O
binding	B-FUNC
specificity	O
for	O
human	O
-	O
like	O
2	O
,	O
6	O
-	O
linked	O
sialosides	O
.	O

Current	O
studies	O
revealed	O
that	O
MHV	O
infection	O
is	O
associated	O
with	O
the	O
pronounced	O
activation	O
of	O
microglia	O
during	O
acute	O
inflammation	O
,	O
as	O
evidenced	O
by	O
characteristic	O
changes	O
in	O
cellular	O
morphology	O
and	O
increased	O
expression	O
of	O
microglia	O
-	O
specific	O
proteins	O
,	O
Iba1	O
(	O
ionized	O
calcium	O
-	O
binding	B-FUNC
adaptor	O
molecule	O
1	O
),	O
which	O
is	O
a	O
macrophage	O
/	O
microglia	O
-	O
specific	O
novel	O
calcium	O
-	O
binding	B-FUNC
protein	O
and	O
involved	O
in	O
membrane	O
ruffling	O
and	O
phagocytosis	O
.	O

ABSTRACT	O
:	O
The	O
antibody	B-FUNC
and	O
cellular	O
immune	O
responses	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
evaluated	O
at	O
mucosal	O
sites	O
of	O
chickens	O
after	O
immunization	O
with	O
various	O
doses	O
of	O
an	O
attenuated	O
vaccine	O
at	O
1	O
day	O
of	O
age	O
.	O

TITLE	O
:	O
A	O
sorghum	O
xylanase	B-FUNC
inhibitor	O
-	O
like	O
protein	O
with	O
highly	O
potent	O
antifungal	O
,	O
antitumor	O
and	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitory	O
activities	O
.	O

XILP	O
reduced	O
the	O
activity	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
with	O
an	O
IC50	O
of	O
11	O
.	O
1M	O
,	O
but	O
lacked	O
inhibitory	O
activity	O
toward	O
HIV	O
-	O
1	O
integrase	O
and	O
SARS	O
coronavirus	O
proteinase	B-FUNC
.	O

In	O
conclusion	O
,	O
sorghum	O
XILP	O
is	O
thermostable	O
and	O
pH	O
stable	O
and	O
exhibits	O
potent	O
antifungal	O
,	O
antiproliferative	O
,	O
and	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitory	O
activities	O
.	O

In	O
the	O
serum	O
the	O
acute	O
phase	O
proteins	O
(	O
haptoglobin	O
and	O
serum	O
amyloid	O
A	O
),	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
interferon	O
-	O
	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
),	O
and	O
serum	O
sialic	O
acid	O
(	O
total	O
,	O
TSA	B-FUNC
;	O
lipid	O
-	O
bound	O
,	O
LBSA	O
;	O
and	O
protein	O
-	O
bound	O
,	O
PBSA	O
)	O
concentrations	O
were	O
measured	O
using	O
validated	O
standard	O
procedures	O
.	O

We	O
previously	O
showed	O
that	O
murine	O
coronavirus	O
(	O
MHV	O
)	O
accessory	O
protein	O
ns2	O
,	O
a	O
2H	O
phosphoesterase	O
superfamily	O
member	O
,	O
is	O
a	O
phosphodiesterase	B-FUNC
(	O
PDE	B-FUNC
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
preventing	O
activation	O
of	O
RNase	O
L	O
.	O
The	O
PDE	B-FUNC
activity	O
of	O
ns2	O
is	O
required	O
for	O
MHV	O
replication	O
in	O
macrophages	O
and	O
for	O
hepatitis	O
.	O

Here	O
,	O
we	O
show	O
that	O
group	O
A	O
rotavirus	O
(	O
RVA	O
),	O
an	O
important	O
cause	O
of	O
acute	O
gastroenteritis	O
in	O
children	O
worldwide	O
,	O
encodes	O
a	O
similar	O
PDE	B-FUNC
.	O

The	O
RVA	O
PDE	B-FUNC
forms	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
minor	O
core	O
protein	O
VP3	O
(	O
VP3	O
-	O
CTD	O
)	O
and	O
shares	O
sequence	O
and	O
predicted	O
structural	O
homology	O
with	O
ns2	O
,	O
including	O
two	O
catalytic	O
HxT	O
/	O
S	O
motifs	O
.	O

Bacterially	O
expressed	O
VP3	O
-	O
CTD	O
exhibited	O
2	O
',	O
5	B-FUNC
'-	I-FUNC
PDE	I-FUNC
activity	I-FUNC
,	O
which	O
cleaved	O
2	O
-	O
5A	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
chimeric	O
viruses	O
expressing	O
either	O
active	O
ns2	O
or	O
VP3	O
-	O
CTD	O
,	O
but	O
not	O
nonfunctional	O
equivalents	O
,	O
were	O
able	O
to	O
protect	O
ribosomal	B-FUNC
RNA	I-FUNC
from	O
RNase	O
L	O
-	O
mediated	O
degradation	O
.	O

No	O
bacteria	O
or	O
acid	O
-	O
fast	B-FUNC
bacilli	O
were	O
found	O
.	O

ABSTRACT	O
:	O
Total	O
internal	O
reflection	O
microscopy	O
combined	O
with	O
microfluidics	O
and	O
supported	O
bilayers	O
is	O
a	O
powerful	O
,	O
single	O
particle	O
tracking	O
(	O
SPT	B-FUNC
)	O
platform	O
for	O
host	O
-	O
pathogen	O
membrane	O
fusion	O
studies	O
.	O

SPT	B-FUNC
is	O
then	O
used	O
to	O
identify	O
fusion	O
intermediates	O
and	O
measure	O
membrane	O
fusion	O
kinetics	O
for	O
FCoV	O
.	O
Overall	O
,	O
the	O
fusion	O
results	O
recapitulate	O
what	O
is	O
observed	O
in	O
vivo	O
,	O
that	O
coronavirus	O
entry	O
requires	O
binding	B-FUNC
to	O
specific	O
receptors	O
,	O
a	O
low	O
-	O
pH	O
environment	O
,	O
and	O
that	O
membrane	O
fusion	O
is	O
receptor	O
-	O
and	O
protease	O
-	O
dependent	O
.	O

At	O
72	O
hours	O
post	O
inoculation	O
,	O
HCoV	O
-	O
HKU1	O
infection	O
of	O
type	O
II	O
cells	O
induced	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
IL29	O
,	O
CXCL10	O
,	O
CCL5	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
with	O
no	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
IFN	O
.	O

TITLE	O
:	O
Sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
properties	O
of	O
soluble	O
coronavirus	O
spike	O
(	O
S1	O
)	O
proteins	O
:	O
differences	O
between	O
infectious	O
bronchitis	O
virus	O
and	O
transmissible	O
gastroenteritis	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
proteins	O
of	O
a	O
number	O
of	O
coronaviruses	O
are	O
able	O
to	O
bind	B-FUNC
to	O
sialic	O
acids	O
present	O
on	O
the	O
cell	O
surface	O
.	O

Binding	B-FUNC
tests	O
with	O
soluble	O
spike	O
proteins	O
carrying	O
an	O
IgG	O
Fc	O
-	O
tag	O
revealed	O
pronounced	O
differences	O
between	O
these	O
two	O
viral	O
proteins	O
.	O

Binding	B-FUNC
of	O
the	O
IBV	O
spike	O
protein	O
to	O
host	O
cells	O
was	O
in	O
all	O
experiments	O
sialic	O
acid	O
dependent	O
,	O
whereas	O
the	O
soluble	O
TGEV	O
spike	O
showed	O
binding	B-FUNC
to	O
APN	O
but	O
had	O
no	O
detectable	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
.	O

Our	O
results	O
underline	O
the	O
different	O
ways	O
in	O
which	O
binding	B-FUNC
to	O
sialoglycoconjugates	O
is	O
mediated	O
by	O
coronavirus	O
spike	O
proteins	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
from	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Here	O
we	O
have	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
from	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
and	O
determined	O
its	O
crystal	O
structure	O
.	O

This	O
study	O
also	O
presents	O
a	O
structural	O
comparison	O
of	O
MERS	O
-	O
CoV	O
RBD	O
with	O
other	O
coronavirus	O
RBDs	O
,	O
successfully	O
positioning	O
MERS	O
-	O
CoV	O
on	O
the	O
landscape	O
of	O
coronavirus	O
evolution	O
and	O
providing	O
insights	O
into	O
receptor	B-FUNC
binding	I-FUNC
by	O
MERS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
MERS	O
-	O
CoV	O
RBD	O
functions	O
as	O
an	O
effective	O
entry	O
inhibitor	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
identified	O
MERS	O
-	O
CoV	O
RBD	O
may	O
also	O
serve	O
as	O
a	O
potential	O
candidate	O
for	O
MERS	O
-	O
CoV	O
subunit	O
vaccines	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
9	I-FUNC
,	O
IFN	O
-	O
	O
and	O
TNF	O
-	O
	O
)	O
were	O
also	O
examined	O
by	O
using	O
intracellular	O
staining	O
.	O

The	O
expression	O
of	O
CD107a	O
and	O
NKG2D	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
TNF	O
-	O
	O
,	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
9	I-FUNC
in	O
hepatic	O
CD69	O
+	O
NK	O
cells	O
was	O
all	O
significantly	O
up	O
-	O
regulated	O
during	O
48	O
-	O
72	O
h	O
post	O
-	O
infection	O
.	O

First	O
,	O
the	O
full	O
-	O
length	O
gene	O
of	O
SARS	O
-	O
S	O
protein	O
was	O
PCR	O
amplified	O
,	O
purified	O
and	O
then	O
digested	O
with	O
DNase	B-FUNC
I	I-FUNC
to	O
obtain	O
DNA	O
fragments	O
in	O
the	O
size	O
range	O
of	O
50	O
-	O
500	O
bp	O
.	O

To	O
combat	O
SARS	O
,	O
scientists	O
applied	O
for	O
patents	O
on	O
various	O
therapeutic	O
agents	O
,	O
including	O
small	O
-	O
molecule	O
inhibitors	O
targeting	O
the	O
essential	O
proteases	O
,	O
helicase	O
and	O
other	O
proteins	O
of	O
the	O
virus	O
,	O
natural	O
products	O
,	O
approved	O
drugs	O
,	O
molecules	O
binding	B-FUNC
to	O
the	O
virus	O
,	O
neutralizing	O
antibodies	O
,	O
vaccines	O
,	O
anti	O
-	O
sense	O
RNA	O
,	O
siRNA	O
and	O
ribozyme	O
against	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
article	O
,	O
the	O
patents	O
published	O
from	O
2008	O
to	O
the	O
present	O
for	O
the	O
new	O
therapeutics	O
that	O
could	O
potentially	O
be	O
used	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
SARS	O
are	O
reviewed	O
.	O

The	O
ORF4a	O
proteins	O
formed	O
homo	O
-	O
oligomers	O
through	O
disulfide	O
bridges	O
and	O
possessed	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
in	O
both	O
Xenopus	O
oocytes	O
and	O
yeast	O
.	O

Between	O
October	O
2008	O
and	O
September	O
2010	O
,	O
nose	O
and	O
throat	O
swabs	O
from	O
adults	O
and	O
children	O
(	O
approximately	O
20	O
per	O
week	O
)	O
presenting	O
with	O
an	O
acute	O
respiratory	O
illness	O
to	O
the	O
Ninh	O
Hoa	B-FUNC
General	O
Hospital	O
were	O
collected	O
.	O

MERS	O
-	O
CoV	O
infection	O
in	O
the	O
latter	O
2	O
patients	O
was	O
confirmed	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
testing	O
.	O

Here	O
,	O
by	O
ligating	O
head	O
-	O
to	O
-	O
tail	O
viral	O
RNAs	O
from	O
bovine	O
coronavirus	O
-	O
infected	O
cells	O
and	O
sequencing	O
across	O
the	O
ligated	O
junctions	O
,	O
it	O
was	O
learned	O
that	O
at	O
the	O
time	O
of	O
peak	O
viral	O
RNA	O
synthesis	O
[	O
6	O
hours	O
postinfection	O
(	O
hpi	B-FUNC
)]	O
the	O
3	O
'	O
poly	O
(	O
A	O
)	O
tail	O
on	O
genomic	O
and	O
sgmRNAs	O
is	O
~	O
65	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
.	O

Mutations	O
at	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
receptor	B-FUNC
binding	I-FUNC
site	O
(	O
RBS	O
)	O
have	O
been	O
associated	O
with	O
increased	O
virulence	O
and	O
disease	O
severity	O
,	O
representing	O
a	O
potential	O
marker	O
of	O
critical	O
illness	O
.	O

Cattle	O
(	O
n	O
=	O
80	O
),	O
sheep	O
(	O
n	O
=	O
40	O
),	O
goats	O
(	O
n	O
=	O
40	O
),	O
dromedary	O
camels	O
(	O
n	O
=	O
155	O
),	O
and	O
various	O
other	O
camelid	O
species	O
(	O
n	O
=	O
34	O
)	O
were	O
tested	O
for	O
specific	O
serum	O
IgG	O
by	O
protein	O
microarray	O
using	O
the	O
receptor	O
-	O
binding	B-FUNC
S1	O
subunits	O
of	O
spike	O
proteins	O
of	O
MERS	O
-	O
CoV	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
human	O
coronavirus	O
OC43	O
.	O

50	O
of	O
50	O
(	O
100	O
%)	O
sera	B-FUNC
from	O
Omani	O
camels	O
and	O
15	O
of	O
105	O
(	O
14	O
%)	O
from	O
Spanish	O
camels	O
had	O
protein	O
-	O
specific	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
spike	O
.	O

MERS	O
-	O
CoV	O
neutralising	O
antibody	B-FUNC
titres	O
varied	O
between	O
1	O
/	O
320	O
and	O
1	O
/	O
2560	O
for	O
the	O
Omani	O
camel	O
sera	B-FUNC
and	O
between	O
1	O
/	O
20	O
and	O
1	O
/	O
320	O
for	O
the	O
Spanish	O
camel	O
sera	B-FUNC
.	O

Both	O
titres	O
and	O
seroprevalences	O
in	O
sera	B-FUNC
from	O
different	O
locations	O
in	O
Oman	O
suggest	O
widespread	O
infection	O
.	O

In	O
two	O
recent	O
papers	O
,	O
one	O
published	O
in	O
Cell	O
Research	O
,	O
the	O
crystal	O
structure	O
of	O
the	O
viral	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
complex	O
with	O
the	O
host	O
CD26	O
/	O
dipeptidyl	O
peptidase	O
4	O
receptor	O
has	O
now	O
been	O
characterized	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	O
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	O
-	O
and	O
human	O
Telomerase	O
Reverse	O
Transcriptase	B-FUNC
(	O
hTERT	O
)-	O
induced	O
immortalization	O
.	O

TITLE	O
:	O
Coronaviruses	O
lacking	O
exoribonuclease	B-FUNC
activity	I-FUNC
are	O
susceptible	O
to	O
lethal	O
mutagenesis	O
:	O
evidence	O
for	O
proofreading	O
and	O
potential	O
therapeutics	O
.	O

Furthermore	O
,	O
these	O
studies	O
identify	O
ExoN	O
as	O
the	O
first	O
viral	O
protein	O
distinct	O
from	O
the	O
RdRp	B-FUNC
that	O
determines	O
the	O
sensitivity	O
of	O
RNA	O
viruses	O
to	O
mutagens	O
.	O

The	O
antibody	B-FUNC
activity	I-FUNC
was	O
measured	O
by	O
ELISA	O
.	O

All	O
used	O
vaccines	O
induced	O
the	O
rise	O
of	O
IgY	O
antibody	B-FUNC
in	O
egg	O
yolks	O
.	O

Based	O
on	O
the	O
duration	O
and	O
the	O
highest	O
level	O
of	O
IgY	O
antibody	B-FUNC
against	O
bovine	O
alimentary	O
tract	O
pathogens	O
C	O
vaccine	O
was	O
further	O
used	O
in	O
next	O
two	O
trials	O
for	O
vaccination	O
of	O
1000	O
hens	O
each	O
time	O
.	O

In	O
particular	O
,	O
RBD	O
of	O
S	O
protein	O
contains	O
the	O
critical	O
neutralizing	O
domain	O
(	O
CND	O
),	O
which	O
is	O
able	O
to	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
response	O
and	O
cross	O
-	O
protection	O
against	O
divergent	O
SARS	O
-	O
CoV	O
strains	O
.	O

Taken	O
together	O
,	O
the	O
established	O
MERS	O
-	O
CoV	O
inhibition	O
assay	O
is	O
a	O
safe	O
and	O
convenient	O
pseudovirus	O
-	O
based	O
alternative	O
to	O
BSL	O
-	O
3	O
live	O
-	O
virus	O
restrictions	O
and	O
can	O
be	O
used	O
to	O
rapidly	O
screen	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	O
,	O
as	O
well	O
as	O
evaluate	O
vaccine	O
-	O
induced	O
neutralizing	O
antibodies	O
against	O
the	O
highly	O
pathogenic	O
MERS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Our	O
results	O
demonstrated	O
that	O
the	O
generated	O
MERS	O
-	O
CoV	O
pseudovirus	O
allows	O
for	O
single	O
-	O
cycle	O
infection	O
of	O
a	O
variety	O
of	O
cells	O
expressing	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
the	O
confirmed	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Consistent	O
with	O
the	O
results	O
from	O
a	O
live	O
MERS	O
-	O
CoV	O
-	O
based	O
inhibition	O
assay	O
,	O
the	O
antisera	O
of	O
mice	O
vaccinated	O
with	O
a	O
recombinant	O
protein	O
containing	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
,	O
residues	O
377	O
-	O
662	O
)	O
of	O
MERS	O
-	O
CoV	O
S	O
fused	O
with	O
Fc	O
of	O
human	O
IgG	O
exhibited	O
neutralizing	O
antibody	B-FUNC
response	O
against	O
infection	O
of	O
MERS	O
-	O
CoV	O
pseudovirus	O
.	O

Overall	O
,	O
the	O
protease	O
expression	O
and	O
biosensor	O
assays	O
developed	O
here	O
allow	O
for	O
rapid	O
evaluation	O
of	O
viral	O
protease	B-FUNC
activity	I-FUNC
and	O
the	O
identification	O
of	O
protease	O
inhibitors	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
optimizes	O
T	O
cell	O
and	O
humoral	O
responses	O
in	O
the	O
central	O
nervous	O
system	O
during	O
viral	O
encephalitis	O
.	O

IL	B-FUNC
-	I-FUNC
21	I-FUNC
receptor	O
deficiency	O
did	O
not	O
affect	O
peripheral	O
T	O
cell	O
activation	O
or	O
trafficking	O
,	O
but	O
dampened	O
granzyme	O
B	O
,	O
gamma	O
interferon	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
expression	O
by	O
CNS	O
T	O
cells	O
and	O
reduced	O
serum	O
and	O
intrathecal	O
humoral	O
responses	O
.	O

These	O
data	O
demonstrate	O
a	O
critical	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
in	O
regulating	O
CNS	O
immunity	O
,	O
sustaining	O
viral	O
persistence	O
and	O
preventing	O
mortality	O
.	O

A	O
docking	O
study	O
involving	O
binding	B-FUNC
between	O
the	O
dipeptidic	O
lead	O
compound	O
4	O
and	O
3CLpro	O
suggested	O
the	O
modification	O
of	O
a	O
structurally	O
flexible	O
P3	O
N	O
-(	O
3	O
-	O
methoxyphenyl	O
)	O
glycine	O
with	O
various	O
rigid	O
P3	O
moieties	O
in	O
4	O
.	O

In	O
addition	O
,	O
the	O
Ki	O
value	O
of	O
5h	O
was	O
in	O
very	O
good	O
agreement	O
with	O
the	O
binding	B-FUNC
affinity	O
(	O
16	O
nM	O
)	O
observed	O
in	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
).	O

This	O
systems	O
biology	O
approach	O
captures	O
the	O
complexity	O
of	O
both	O
the	O
pathogen	O
and	O
drug	O
host	O
response	O
in	O
the	O
form	O
of	O
expression	O
patterns	O
or	O
molecular	B-FUNC
interaction	I-FUNC
networks	O
without	O
having	O
to	O
understand	O
the	O
underlying	O
mechanisms	O
of	O
action	O
.	O

Our	O
results	O
identify	O
high	O
-	O
molecular	O
weight	O
	O
-	O
PGA	O
as	O
a	O
TLR4	O
ligand	B-FUNC
and	O
demonstrate	O
that	O
	O
-	O
PGA	O
requires	O
both	O
CD14	O
and	O
MD2	O
for	O
the	O
activation	O
of	O
type	O
I	O
IFN	O
responses	O
.	O

Infections	O
were	O
associated	O
with	O
transient	O
lung	O
function	O
loss	O
and	O
high	O
calcineurin	B-FUNC
inhibitor	O
blood	O
levels	O
.	O

TITLE	O
:	O
Chimeric	O
exchange	O
of	O
coronavirus	O
nsp5	O
proteases	O
(	O
3CLpro	O
)	O
identifies	O
common	O
and	O
divergent	O
regulatory	O
determinants	O
of	O
protease	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Induced	O
expression	O
and	O
functional	O
effects	O
of	O
aquaporin	B-FUNC
-	O
1	O
in	O
human	O
leukocytes	O
in	O
sepsis	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
how	O
the	O
water	O
channel	O
aquaporin	B-FUNC
-	O
1	O
is	O
involved	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
critically	O
ill	O
patients	O
during	O
infection	O
acquired	O
in	O
the	O
ICU	O
.	O

We	O
additionally	O
determined	O
aquaporin	B-FUNC
-	O
1	O
expression	O
upon	O
lipopolysaccharide	O
(	O
LPS	O
)	O
exposure	O
and	O
explored	O
functional	O
effects	O
of	O
aquaporin	B-FUNC
-	O
1	O
induction	O
in	O
polymorphonuclear	O
granulocytes	O
(	O
PMNs	O
).	O

Leukocyte	O
aquaporin	B-FUNC
-	O
1	O
expression	O
was	O
induced	O
at	O
the	O
onset	O
of	O
sepsis	O
(	O
median	O
1	O
.	O
71	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
0	O
.	O
99	O
to	O
2	O
.	O
42	O
,	O
P	O
=	O
0	O
.	O
012	O
from	O
baseline	O
)	O
and	O
was	O
further	O
increased	O
upon	O
septic	O
shock	O
(	O
median	O
3	O
.	O
00	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
1	O
.	O
20	O
to	O
5	O
.	O
40	O
,	O
P	O
=	O
0	O
.	O
023	O
from	O
sepsis	O
,	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
);	O
no	O
difference	O
was	O
observed	O
between	O
baseline	O
and	O
discharge	O
in	O
patients	O
who	O
did	O
not	O
develop	O
sepsis	O
.	O

Stimulation	O
of	O
PMNs	O
by	O
LPS	O
led	O
to	O
increased	O
expression	O
of	O
aquaporin	B-FUNC
-	O
1	O
in	O
vitro	O
,	O
which	O
could	O
be	O
abrogated	O
by	O
the	O
NF	O
-	O
B	O
inhibitor	O
EF	O
-	O
24	O
.	O

The	O
latter	O
could	O
be	O
abolished	O
by	O
blocking	O
aquaporin	B-FUNC
-	O
1	O
with	O
mercury	O
and	O
restored	O
by	O
incubation	O
in	O
	O
-	O
mercaptoethanol	O
,	O
which	O
abrogated	O
the	O
action	O
of	O
mercury	O
inhibition	O
.	O

RESULTS	O
:	O
Leukocyte	O
aquaporin	B-FUNC
-	O
1	O
expression	O
was	O
induced	O
at	O
the	O
onset	O
of	O
sepsis	O
(	O
median	O
1	O
.	O
71	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
0	O
.	O
99	O
to	O
2	O
.	O
42	O
,	O
P	O
=	O
0	O
.	O
012	O
from	O
baseline	O
)	O
and	O
was	O
further	O
increased	O
upon	O
septic	O
shock	O
(	O
median	O
3	O
.	O
00	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
1	O
.	O
20	O
to	O
5	O
.	O
40	O
,	O
P	O
=	O
0	O
.	O
023	O
from	O
sepsis	O
,	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
);	O
no	O
difference	O
was	O
observed	O
between	O
baseline	O
and	O
discharge	O
in	O
patients	O
who	O
did	O
not	O
develop	O
sepsis	O
.	O

The	O
latter	O
could	O
be	O
abolished	O
by	O
blocking	O
aquaporin	B-FUNC
-	O
1	O
with	O
mercury	O
and	O
restored	O
by	O
incubation	O
in	O
	O
-	O
mercaptoethanol	O
,	O
which	O
abrogated	O
the	O
action	O
of	O
mercury	O
inhibition	O
.	O

To	O
asses	O
the	O
risk	O
factor	O
related	O
to	O
clinical	O
material	O
,	O
climatic	O
condition	O
and	O
type	O
of	O
RT	O
-	O
PCR	O
applied	O
,	O
cloacal	O
swabs	O
(	O
CS	O
),	O
faeces	O
,	O
sera	B-FUNC
,	O
bursa	O
of	O
Fabricius	O
(	O
BF	O
),	O
thymus	O
(	O
TH	O
)	O
and	O
spleen	O
(	O
SP	O
)	O
and	O
ileum	O
-	O
caeca	O
region	O
were	O
collected	O
from	O
30	O
-	O
day	O
-	O
old	O
poults	O
suffering	O
of	O
enteritis	O
episode	O
characterized	O
as	O
poult	O
enteritis	O
mortality	O
syndrome	O
(	O
PEMS	O
).	O

The	O
preoperative	O
evaluation	O
showed	O
a	O
severe	O
alteration	O
of	O
diffusion	O
(	O
pO2	O
68	O
mm	O
Hg	O
),	O
without	O
hepatopulmonary	O
syndrome	O
or	O
portopulmonary	O
hypertension	O
(	O
PPH	B-FUNC
)	O
upon	O
basal	O
and	O
dobutamine	O
stress	O
echocardiography	O
.	O

TITLE	O
:	O
Thrombin	O
selectively	O
engages	O
LIM	O
kinase	O
1	O
and	O
slingshot	O
-	O
1L	O
phosphatase	B-FUNC
to	O
regulate	O
NF	O
-	O
B	O
activation	O
and	O
endothelial	O
cell	O
inflammation	O
.	O

Previously	O
,	O
we	O
have	O
described	O
a	O
role	O
of	O
actin	B-FUNC
binding	I-FUNC
protein	O
cofilin	O
in	O
mediating	O
cytoskeletal	O
alterations	O
essential	O
for	O
NF	O
-	O
B	O
activation	O
and	O
EC	O
inflammation	O
.	O

Further	O
mechanistic	O
analyses	O
reveal	O
that	O
knockdown	O
of	O
LIMK1	O
or	O
SSH	O
-	O
1L	O
each	O
attenuates	O
nuclear	O
translocation	O
and	O
thereby	O
DNA	B-FUNC
binding	I-FUNC
of	O
RelA	O
/	O
p65	O
.	O

However	O
,	O
we	O
have	O
previously	O
shown	O
that	O
this	O
domain	O
of	O
the	O
embryo	O
-	O
and	O
cell	O
culture	O
adapted	O
Beaudette	O
strain	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
virulent	O
M41	O
strain	O
,	O
is	O
not	O
sufficient	O
for	O
binding	B-FUNC
to	O
chicken	O
trachea	O
(	O
Wickramasinghe	O
et	O
al	O
.,	O
2011	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
lack	O
of	O
binding	B-FUNC
of	O
Beaudette	O
S1	O
was	O
not	O
due	O
to	O
absence	O
of	O
virus	O
receptors	O
on	O
this	O
tissue	O
nor	O
due	O
to	O
the	O
production	O
of	O
S1	O
from	O
mammalian	O
cells	O
,	O
as	O
S1	O
proteins	O
expressed	O
from	O
chicken	O
cells	O
also	O
lacked	O
the	O
ability	O
to	O
bind	B-FUNC
IBV	O
-	O
susceptible	O
embryonic	O
tissue	O
.	O

Recombinant	O
IBV	O
Beaudette	O
spike	O
ectodomains	O
,	O
comprising	O
the	O
entire	O
S1	O
domain	O
and	O
the	O
S2	O
ectodomain	O
,	O
were	O
expressed	O
and	O
analyzed	O
for	O
binding	B-FUNC
to	O
susceptible	O
embryonic	O
chorio	O
-	O
allantoic	O
membrane	O
(	O
CAM	O
)	O
in	O
our	O
previously	O
developed	O
spike	O
histochemistry	O
assay	O
.	O

We	O
observed	O
that	O
extension	O
of	O
the	O
S1	O
domain	O
with	O
the	O
S2	O
subunit	O
of	O
the	O
Beaudette	O
spike	O
was	O
sufficient	O
to	O
gain	O
binding	B-FUNC
to	O
CAM	O
.	O

A	O
previously	O
suggested	O
heparin	O
sulfate	B-FUNC
binding	I-FUNC
site	O
in	O
Beaudette	O
S2	O
was	O
not	O
required	O
for	O
the	O
observed	O
binding	B-FUNC
to	O
CAM	O
,	O
while	O
sialic	O
acids	O
on	O
the	O
host	O
tissues	O
were	O
essential	O
for	O
the	O
attachment	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
S2	O
the	O
spike	O
ectodomains	O
of	O
virulent	O
IBV	O
M41	O
and	O
chimeras	O
of	O
M41	O
and	O
Beaudette	O
were	O
analyzed	O
for	O
their	O
binding	B-FUNC
to	O
CAM	O
,	O
chicken	O
trachea	O
and	O
mammalian	O
cell	O
lines	O
.	O

While	O
the	O
M41	O
spike	O
ectodomain	O
showed	O
increased	O
attachment	O
to	O
both	O
CAM	O
and	O
chicken	O
trachea	O
,	O
no	O
binding	B-FUNC
to	O
mammalian	O
cells	O
was	O
observed	O
.	O

Binding	B-FUNC
patterns	O
of	O
chimeric	O
spike	O
ectodomains	O
to	O
these	O
tissues	O
and	O
cells	O
indicate	O
that	O
S2	O
subunits	O
most	O
likely	O
do	O
not	O
contain	O
an	O
additional	O
independent	O
receptor	O
-	O
binding	B-FUNC
site	O
.	O

T	O
cell	O
epitope	O
mapping	O
strategies	O
increasingly	O
rely	O
on	O
algorithms	O
that	O
predict	O
the	O
binding	B-FUNC
of	O
peptides	O
to	O
MHC	O
molecules	O
.	O

These	O
results	O
highlight	O
the	O
limited	O
applicability	O
of	O
the	O
NetMHCpan	O
algorithm	O
for	O
populations	O
expressing	O
HLA	O
molecules	O
for	O
which	O
there	O
are	O
little	O
or	O
no	O
experimental	O
binding	B-FUNC
data	O
,	O
such	O
as	O
those	O
of	O
Asian	O
ethnicity	O
.	O

ABSTRACT	O
:	O
The	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
/	O
ST2	O
axis	O
is	O
known	O
to	O
be	O
involved	O
in	O
liver	O
pathologies	O
.	O

Although	O
,	O
the	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
levels	O
increased	O
in	O
sera	B-FUNC
of	O
viral	O
hepatitis	O
patients	O
in	O
human	O
,	O
the	O
cellular	O
sources	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
in	O
viral	O
hepatitis	O
remained	O
obscure	O
.	O

The	O
administration	O
of	O
poly	O
(	O
I	O
:	O
C	O
)	O
plus	O
D	O
-	O
galactosamine	O
(	O
D	O
-	O
GalN	O
)	O
in	O
mice	O
led	O
to	O
acute	O
liver	O
injury	O
associated	O
with	O
the	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
in	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSEC	O
)	O
and	O
vascular	O
endothelial	O
cells	O
(	O
VEC	O
),	O
while	O
the	O
administration	O
of	O
poly	O
(	O
I	O
:	O
C	O
)	O
alone	O
led	O
to	O
hepatocyte	O
specific	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
in	O
addition	O
to	O
vascular	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
.	O

The	O
hepatocyte	O
-	O
specific	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
was	O
down	O
-	O
regulated	O
in	O
NK	O
-	O
depleted	O
poly	O
(	O
I	O
:	O
C	O
)	O
treated	O
mice	O
suggesting	O
a	O
partial	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
by	O
NK	O
cells	O
.	O

In	O
parallel	O
,	O
the	O
L2	O
-	O
MHV3	O
infection	O
in	O
mice	O
induced	O
fulminant	O
hepatitis	O
associated	O
with	O
up	O
-	O
regulated	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
as	O
well	O
as	O
pro	O
-	O
inflammatory	O
cytokine	O
microenvironment	O
in	O
liver	O
.	O

In	O
conclusion	O
,	O
the	O
alarmin	O
cytokine	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
was	O
over	O
-	O
expressed	O
during	O
fulminant	O
hepatitis	O
in	O
mice	O
with	O
LSEC	O
,	O
VEC	O
and	O
hepatocytes	O
as	O
potential	O
sources	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
.	O

Both	O
viruses	O
were	O
unable	O
to	O
significantly	O
stimulate	O
the	O
expression	O
of	O
antiviral	O
cytokines	O
(	O
interferon	O
	O
[	O
IFN	O
-	O
	O
]	O
and	O
IFN	O
-	O
	O
)	O
but	O
induced	O
comparable	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
and	O
interleukin	O
6	O
.	O

Notably	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
expression	O
levels	O
of	O
interleukin	O
12	O
,	O
IFN	O
-	O
	O
,	O
and	O
chemokines	O
(	O
IP	O
-	O
10	O
/	O
CXCL	O
-	O
10	O
,	O
MCP	B-FUNC
-	O
1	O
/	O
CCL	B-FUNC
-	O
2	O
,	O
MIP	O
-	O
1	O
/	O
CCL	B-FUNC
-	O
3	O
,	O
RANTES	O
/	O
CCL	B-FUNC
-	O
5	O
,	O
and	O
interleukin	O
8	O
)	O
than	O
SARS	O
-	O
CoV	O
.	O
The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
and	O
costimulatory	O
molecules	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
MDMs	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Dietary	O
vitamin	O
A	O
restriction	O
increases	O
marbling	O
in	O
feedlot	O
cattle	O
;	O
however	O
,	O
its	O
effect	O
on	O
antibody	B-FUNC
responses	O
to	O
vaccines	O
is	O
unknown	O
.	O

A	O
low	O
vitamin	O
A	O
diet	O
compromised	O
the	O
serum	O
IgG1	O
responses	O
against	O
inactivated	O
BCoV	O
vaccine	O
,	O
which	O
suggested	O
suppressed	O
T	O
-	O
helper	O
2	O
-	O
associated	O
antibody	B-FUNC
(	O
IgG1	O
)	O
responses	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
by	O
anti	O
-	O
CD26	O
monoclonal	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
We	O
identified	O
the	O
domains	O
of	O
CD26	O
involved	O
in	O
the	O
binding	B-FUNC
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
using	O
distinct	O
clones	O
of	O
anti	O
-	O
CD26	O
monoclonal	O
antibodies	O
(	O
MAbs	O
).	O

Among	O
the	O
eight	O
cytokine	O
genes	O
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
induced	O
by	O
MERS	O
-	O
CoV	O
were	O
markedly	O
higher	O
than	O
those	O
induced	O
by	O
SARS	O
-	O
CoV	O
at	O
30	O
h	O
,	O
whilst	O
TNF	O
-	O
	O
,	O
IFN	O
-	O
	O
and	O
IP	O
-	O
10	O
induced	O
by	O
SARS	O
-	O
CoV	O
were	O
markedly	O
higher	O
than	O
those	O
induced	O
by	O
MERS	O
-	O
CoV	O
at	O
24	O
and	O
30	O
h	O
in	O
infected	O
Calu	O
-	O
3	O
cells	O
.	O

The	O
activation	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
attenuated	O
IFN	O
-	O
	O
response	O
by	O
MERS	O
-	O
CoV	O
were	O
also	O
confirmed	O
by	O
protein	O
measurements	O
in	O
the	O
culture	O
supernatant	O
when	O
compared	O
with	O
SARS	O
-	O
CoV	O
and	O
Sendai	O
virus	O
.	O

TITLE	O
:	O
Seroepidemiology	O
for	O
MERS	O
coronavirus	O
using	O
microneutralisation	O
and	O
pseudoparticle	O
virus	O
neutralisation	O
assays	O
reveal	O
a	O
high	O
prevalence	O
of	O
antibody	B-FUNC
in	O
dromedary	O
camels	O
in	O
Egypt	O
,	O
June	O
2013	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
novel	O
spike	O
pseudoparticle	O
neutralisation	O
assay	O
(	O
ppNT	O
)	O
for	O
seroepidemiological	O
studies	O
on	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERSCoV	O
)	O
and	O
apply	O
this	O
assay	O
together	O
with	O
conventional	O
microneutralisation	O
(	O
MN	O
)	O
tests	O
to	O
investigate	O
1	O
,	O
343	O
human	O
and	O
625	O
animal	O
sera	B-FUNC
.	O

The	O
sera	B-FUNC
were	O
collected	O
in	O
Egypt	O
as	O
a	O
region	O
adjacent	O
to	O
areas	O
where	O
MERS	O
has	O
been	O
described	O
,	O
and	O
in	O
Hong	O
Kong	O
,	O
China	O
as	O
a	O
control	O
region	O
.	O

TITLE	O
:	O
Discovery	O
of	O
N	O
-(	O
benzo	O
[	O
1	O
,	O
2	O
,	O
3	O
]	O
triazol	O
-	O
1	O
-	O
yl	O
)-	O
N	O
-(	O
benzyl	O
)	O
acetamido	O
)	O
phenyl	O
)	O
carboxamides	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3CLpro	O
inhibitors	O
:	O
identification	O
of	O
ML300	O
and	O
noncovalent	O
nanomolar	O
inhibitors	O
with	O
an	O
induced	O
-	O
fit	O
binding	B-FUNC
.	O

Over	O
the	O
past	O
decades	O
,	O
inhaled	O
NO	O
remains	O
the	O
central	O
therapy	O
for	O
PPHN	O
and	O
is	O
commonly	O
used	O
for	O
acute	O
pulmonary	O
vasoreactivity	O
testing	O
during	O
right	O
heart	O
catheterization	O
and	O
for	O
treating	O
pediatric	O
and	O
adult	O
patients	O
with	O
PAH	B-FUNC
associated	O
with	O
postoperative	O
cardiac	O
surgery	O
,	O
severe	O
respiratory	O
failure	O
,	O
pulmonary	O
hypertension	O
crises	O
,	O
and	O
other	O
disorders	O
.	O

Further	O
studies	O
showed	O
that	O
inhibition	O
of	O
p53	O
signaling	O
could	O
attenuate	O
the	O
TGEV	O
-	O
induced	O
S	O
-	O
and	O
G2	O
/	O
M	O
-	O
phase	O
arrest	O
by	O
reversing	O
the	O
expression	O
of	O
p21	O
and	O
corresponding	O
cyclin	B-FUNC
/	O
cdk	B-FUNC
.	O

TITLE	O
:	O
Human	O
coronavirus	O
OC43	O
nucleocapsid	O
protein	O
binds	B-FUNC
microRNA	O
9	O
and	O
potentiates	O
NF	O
-	O
B	O
activation	O
.	O

This	O
prolonged	O
activation	O
is	O
the	O
direct	O
result	O
of	O
the	O
ability	O
of	O
the	O
nucleocapsid	O
to	O
bind	B-FUNC
RNA	O
,	O
specifically	O
microRNA	O
9	O
(	O
miR	O
-	O
9	O
),	O
which	O
is	O
a	O
negative	O
regulator	O
of	O
NF	O
-	O
B	O
.	O
This	O
previously	O
undescribed	O
interaction	O
between	O
virus	O
and	O
host	O
is	O
a	O
potential	O
mechanism	O
of	O
immune	O
evasion	O
in	O
RNA	O
viruses	O
.	O

After	O
five	O
rounds	O
of	O
biopanning	O
,	O
five	O
phage	O
clones	O
showed	O
specific	O
binding	B-FUNC
affinities	O
to	O
rpAPN	O
-	O
C	O
.	O
In	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assays	O
,	O
the	O
phage	O
clone	O
PM1	O
,	O
which	O
contained	O
the	O
HDAISWTHYHPW	O
peptide	O
sequence	O
,	O
had	O
a	O
protective	O
effect	O
against	O
TGEV	O
infection	O
in	O
swine	O
testis	O
cells	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
to	O
S1	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Then	O
,	O
female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
S1	O
protein	O
(	O
rS1	O
),	O
and	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
designated	O
as	O
5E12	O
)	O
against	O
the	O
rS1	O
protein	O
was	O
achieved	O
by	O
hybridoma	O
technique	O
.	O

Clinical	O
characteristics	O
and	O
distribution	O
of	O
respiratory	O
viruses	O
in	O
patients	O
with	O
and	O
without	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
were	O
evaluated	O
.	O

Nine	O
(	O
15	O
%)	O
patients	O
had	O
ACS	B-FUNC
;	O
a	O
respiratory	O
virus	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O

The	O
demographic	O
characteristics	O
of	O
patients	O
with	O
and	O
without	O
ACS	B-FUNC
were	O
similar	O
.	O

Co	O
-	O
infection	O
with	O
at	O
least	O
one	O
additional	O
respiratory	O
virus	O
was	O
seen	O
in	O
14	O
(	O
30	O
%)	O
infected	O
patients	O
,	O
and	O
was	O
not	O
significantly	O
higher	O
in	O
patients	O
with	O
ACS	B-FUNC
(	O
P	O
=	O
0	O
.	O
10	O
).	O

Co	O
-	O
infections	O
with	O
more	O
than	O
two	O
respiratory	O
viruses	O
were	O
seen	O
in	O
seven	O
patients	O
,	O
all	O
in	O
patients	O
without	O
ACS	B-FUNC
.	O

Larger	O
prospective	O
studies	O
with	O
asymptomatic	O
controls	O
are	O
needed	O
to	O
study	O
the	O
association	O
of	O
these	O
emerging	O
respiratory	O
viruses	O
with	O
ACS	B-FUNC
in	O
children	O
with	O
sickle	O
cell	O
disease	O
.	O

High	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
in	O
males	O
correlated	O
with	O
poorer	O
prognosis	O
and	O
shorter	O
longevity	O
.	O

To	O
overcome	O
the	O
innate	O
antiviral	O
response	O
,	O
RNA	O
viruses	O
encode	O
suppressors	O
of	O
IFN	O
-	O
	O
/	O
	O
induction	O
,	O
which	O
block	O
RLRs	O
recognition	O
of	O
dsRNA	O
by	O
means	O
of	O
different	O
mechanisms	O
that	O
can	O
be	O
categorized	O
into	O
:	O
(	O
i	O
)	O
dsRNA	B-FUNC
binding	I-FUNC
and	O
/	O
or	O
shielding	O
"("""	O
hide	O
"""),"	O
(	O
ii	O
)	O
dsRNA	O
termini	O
processing	O
"("""	O
mask	O
""")"	O
and	O
(	O
iii	O
)	O
direct	O
interaction	O
with	O
components	O
of	O
the	O
RLRs	O
pathway	O
"("""	O
hit	O
""")."	O

As	O
RNA	O
viruses	O
may	O
coevolve	O
with	O
their	O
hosts	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
closest	O
sister	O
taxon	O
to	O
bats	O
,	O
the	O
Eulipotyphla	O
,	O
and	O
screened	O
European	O
hedgehogs	O
(	O
Erinaceus	O
europaeus	O
)	O
from	O
Germany	O
for	O
CoV	O
by	O
nested	O
reverse	O
transcriptase	B-FUNC
PCR	O
.	O

We	O
sought	O
to	O
identify	O
evidence	O
-	O
based	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
in	O
order	O
to	O
guide	O
identification	O
of	O
the	O
source	O
population	O
for	O
future	O
IAH	B-FUNC
/	O
ACS	B-FUNC
treatment	O
trials	O
and	O
to	O
stratify	O
patients	O
into	O
risk	O
groups	O
based	O
on	O
prognosis	O
.	O

Risk	O
factors	O
with	O
pooled	O
evidence	O
supporting	O
an	O
increased	O
risk	O
for	O
IAH	B-FUNC
among	O
mixed	O
ICU	O
patients	O
included	O
obesity	O
(	O
four	O
studies	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
5	O
.	O
10	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
92	O
to	O
13	O
.	O
58	O
),	O
sepsis	O
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
38	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
34	O
to	O
4	O
.	O
23	O
),	O
abdominal	O
surgery	O
(	O
four	O
studies	O
;	O
OR	O
1	O
.	O
93	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
to	O
2	O
.	O
85	O
),	O
ileus	O
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
05	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
40	O
to	O
2	O
.	O
98	O
),	O
and	O
large	O
volume	O
fluid	O
resuscitation	O
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
to	O
3	O
.	O
63	O
).	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	B-FUNC
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

Although	O
several	O
IAH	B-FUNC
/	O
ACS	B-FUNC
risk	O
factors	O
transcend	O
across	O
presenting	O
patient	O
diagnoses	O
,	O
some	O
appear	O
specific	O
to	O
the	O
population	O
under	O
study	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	B-FUNC
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
-	O
alga	O
-	O
derived	O
lectin	O
that	O
binds	B-FUNC
the	O
terminal	O
mannose	O
residues	O
of	O
N	O
-	O
linked	O
glycans	O
found	O
on	O
the	O
surface	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
),	O
HIV	O
-	O
2	O
,	O
and	O
other	O
enveloped	O
viruses	O
,	O
including	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
Ebola	O
virus	O
.	O

In	O
June	O
2012	O
,	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
authorized	O
emergency	O
use	O
of	O
the	O
rRT	O
-	O
PCR	O
assay	O
panel	O
as	O
an	O
in	O
vitro	O
diagnostic	O
test	O
for	O
MERS	O
-	O
CoV	O
.	O
A	O
kit	B-FUNC
consisting	O
of	O
the	O
three	O
assay	O
signatures	O
and	O
a	O
positive	O
control	O
was	O
assembled	O
and	O
distributed	O
to	O
public	O
health	O
laboratories	O
in	O
the	O
United	O
States	O
and	O
internationally	O
to	O
support	O
MERS	O
-	O
CoV	O
surveillance	O
and	O
public	O
health	O
responses	O
.	O

RESULTS	O
:	O
Using	O
the	O
five	O
best	O
-	O
performing	O
biomarkers	O
(	O
surfactant	O
protein	O
-	O
D	O
(	O
SP	O
-	O
D	O
),	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
),	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
club	O
cell	O
secretory	O
protein	O
(	O
CC	O
-	O
16	O
),	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
))	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
to	O
0	O
.	O
84	O
)	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

Diagnosis	O
of	O
botulinum	O
toxin	O
poisoning	O
was	O
made	O
and	O
confirmed	O
by	O
serum	O
antibody	B-FUNC
testing	O
in	O
the	O
mouse	O
inoculation	O
test	O
.	O

These	O
viruses	O
are	O
far	O
more	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
than	O
any	O
previously	O
identified	O
bat	O
coronaviruses	O
,	O
particularly	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
spike	O
protein	O
.	O

TITLE	O
:	O
Aquaporin	B-FUNC
-	O
4	O
antibodies	O
,	O
CNS	O
acidosis	O
and	O
neuromyelitis	O
optica	O
:	O
a	O
potential	O
link	O
.	O

In	O
around	O
80	O
%	O
of	O
cases	O
,	O
NMO	O
is	O
caused	O
by	O
autoantibodies	O
to	O
astrocytic	O
aquaporin	B-FUNC
-	O
4	O
(	O
AQP4	O
),	O
the	O
most	O
abundant	O
water	O
channel	O
in	O
the	O
CNS	O
.	O

In	O
130	O
blood	O
donors	O
sampled	O
during	O
2012	O
in	O
Jeddah	O
and	O
226	O
slaughterhouse	O
workers	O
sampled	O
in	O
October	O
2012	O
in	O
Jeddah	O
and	O
Makkah	O
,	O
Saudi	O
Arabia	O
,	O
8	O
reactive	O
sera	B-FUNC
were	O
seen	O
in	O
IFA	O
but	O
were	O
resolved	O
to	O
be	O
specific	O
for	O
established	O
HCoVs	O
by	O
discriminative	O
testing	O
.	O

The	O
infected	O
monkeys	O
showed	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	O
replication	O
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-FUNC
production	O
,	O
indicating	O
that	O
this	O
monkey	O
model	O
is	O
suitable	O
for	O
studies	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

Interleukin	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
NOx	O
concentrations	O
were	O
quantified	O
in	O
supernatants	O
of	O
cultured	O
lung	O
tissue	O
.	O

We	O
have	O
found	O
that	O
intestinal	O
I	O
/	O
R	O
increased	O
the	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
Evans	O
blue	O
dye	O
extravasation	O
,	O
which	O
were	O
reduced	O
by	O
treatment	O
of	O
rats	O
with	O
E2	O
.	O

Furthermore	O
,	O
the	O
two	O
scavengers	O
significantly	O
inhibited	O
the	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
p53	O
and	O
further	O
blocked	O
apoptosis	O
occurrence	O
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
redistribution	O
,	O
cytochrome	B-FUNC
c	I-FUNC
release	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

In	O
this	O
issue	O
,	O
Klaus	O
et	O
al	O
.	O
(	O
2013	O
)	O
identify	O
the	O
cargo	O
receptor	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
53	O
kDa	O
protein	O
(	O
ERGIC	O
-	O
53	O
)	O
as	O
a	O
binding	B-FUNC
partner	O
for	O
viral	O
GPs	O
and	O
a	O
crucial	O
cellular	O
factor	O
required	O
for	O
infectious	O
virus	O
production	O
.	O

ERGIC	O
-	O
53	O
binds	B-FUNC
to	O
arenavirus	O
GPs	O
through	O
a	O
lectin	O
-	O
independent	O
mechanism	O
,	O
traffics	O
to	O
arenavirus	O
budding	O
sites	O
,	O
and	O
is	O
incorporated	O
into	O
virions	O
.	O

Sequence	O
analysis	O
of	O
the	O
816	O
-	O
bp	O
obtained	O
RdRp	B-FUNC
sequence	O
fragment	O
indicates	O
a	O
96	O
.	O
9	O
%	O
amino	O
acid	O
identity	O
of	O
the	O
Italian	O
lineage	O
C	O
betaCoV	O
with	O
the	O
recent	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
,	O
Genbank	O
accession	O
number	O
KF192507	O
).	O

Degradation	O
of	O
the	O
glycosaminoglycan	O
,	O
hyaluronan	O
(	O
HA	O
),	O
is	O
involved	O
in	O
reduction	O
of	O
the	O
endothelial	O
glycocalyx	O
,	O
disruption	O
of	O
endothelial	O
cell	O
-	O
cell	O
contacts	O
and	O
activation	O
of	O
HA	O
binding	B-FUNC
proteins	O
upregulated	O
in	O
ALI	O
/	O
ARDS	O
which	O
promote	O
a	O
loss	O
of	O
pulmonary	O
vascular	O
integrity	O
.	O

This	O
review	O
focuses	O
on	O
the	O
dichotomous	O
role	O
of	O
HA	O
to	O
both	O
promote	O
and	O
inhibit	O
ALI	O
based	O
on	O
its	O
size	O
and	O
the	O
HA	O
binding	B-FUNC
proteins	O
present	O
.	O

TITLE	O
:	O
Active	O
site	O
and	O
allosteric	O
inhibitors	O
of	O
the	O
ribonuclease	B-FUNC
H	I-FUNC
activity	I-FUNC
of	O
HIV	O
reverse	O
transcriptase	B-FUNC
.	O

ABSTRACT	O
:	O
Despite	O
the	O
wealth	O
of	O
information	O
available	O
for	O
the	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNaseH	O
)	O
domain	O
of	O
lentiviruses	O
,	O
gammaretroviruses	O
and	O
long	O
terminal	O
repeat	O
containing	O
retrotransposons	O
,	O
exploiting	O
this	O
information	O
in	O
the	O
form	O
of	O
an	O
RNaseH	O
inhibitor	O
with	O
high	O
specificity	O
and	O
low	O
cellular	O
toxicity	O
has	O
been	O
disappointing	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
targeting	O
the	O
RNaseH	O
active	O
site	O
,	O
identifying	O
small	O
molecules	O
that	O
bind	B-FUNC
elsewhere	O
and	O
disrupt	O
catalysis	O
allosterically	O
by	O
impairing	O
conformational	O
flexibility	O
is	O
gaining	O
increased	O
attention	O
.	O

However	O
,	O
optimal	O
use	O
of	O
this	O
core	O
public	O
health	O
laboratory	O
capacity	O
requires	O
a	O
fundamental	O
understanding	O
of	O
kinetics	O
of	O
viral	O
shedding	O
and	O
antibody	B-FUNC
response	O
,	O
of	O
assay	O
validation	O
and	O
of	O
interpretation	O
of	O
test	O
outcomes	O
.	O

Additionally	O
,	O
aptamers	O
can	O
potentially	O
bind	B-FUNC
any	O
targets	O
and	O
any	O
pathogen	O
that	O
is	O
theoretically	O
amenable	O
to	O
rapid	O
targeting	O
,	O
making	O
aptamers	O
invaluable	O
tools	O
for	O
treating	O
a	O
wide	O
range	O
of	O
diseases	O
.	O

Although	O
the	O
incidence	O
of	O
tuberculosis	O
has	O
decreased	O
in	O
the	O
developed	O
world	O
,	O
it	O
is	O
still	O
a	O
significant	O
public	O
health	O
problem	O
in	O
the	O
rest	B-FUNC
of	O
the	O
world	O
.	O

The	O
present	O
study	O
shows	O
that	O
MBL	O
has	O
the	O
capability	O
to	O
bind	B-FUNC
to	O
IBV	O
in	O
vitro	O
.	O

The	O
L10H	O
chickens	O
as	O
well	O
as	O
the	O
L10L	O
chickens	O
also	O
showed	O
an	O
increased	O
number	O
of	O
CD4	O
-	O
CD8	O
-	O
	O
T	O
-	O
cells	O
when	O
an	O
MBL	O
ligand	B-FUNC
was	O
added	O
to	O
the	O
vaccine	O
,	O
most	O
pronouncedly	O
after	O
the	O
first	O
vaccination	O
.	O

Hence	O
,	O
in	O
order	O
to	O
investigate	O
the	O
test	O
agreement	O
between	O
serum	O
and	O
milk	O
,	O
both	O
serum	O
and	O
milk	O
samples	O
from	O
105	O
cows	O
in	O
27	O
dairy	O
herds	O
were	O
analyzed	O
in	O
parallel	O
for	O
presence	O
of	O
immunoglobulin	B-FUNC
G	O
antibodies	O
to	O
BCV	O
and	O
BRSV	O
.	O

The	O
Bland	O
-	O
Altman	O
analyses	O
of	O
data	O
demonstrated	O
good	O
agreement	O
between	O
serum	O
and	O
milk	O
antibody	B-FUNC
titers	O
for	O
both	O
viruses	O
.	O

Tracking	O
of	O
in	O
vivo	O
transduced	O
DCs	O
revealed	O
that	O
vectors	O
encoding	O
for	O
Fms	B-FUNC
-	O
like	O
tyrosine	O
kinase	O
3	O
ligand	B-FUNC
(	O
Flt3L	O
)	O
exhibited	O
a	O
higher	O
capacity	O
to	O
induce	O
DC	O
maturation	O
compared	O
to	O
vectors	O
delivering	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
or	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
.	O

In	O
contrast	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
or	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-	O
encoding	O
vectors	O
showed	O
a	O
substantially	O
lower	O
efficacy	O
in	O
CD8	O
(+)	O
T	O
cell	O
priming	O
and	O
failed	O
to	O
protect	O
the	O
host	O
once	O
tumors	O
had	O
been	O
established	O
.	O

ABSTRACT	O
:	O
The	O
infection	O
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
initiated	O
by	O
the	O
binding	B-FUNC
of	O
the	O
spike	O
glycoprotein	O
S	O
to	O
sialic	O
acids	O
on	O
the	O
chicken	O
host	O
cell	O
.	O

By	O
analyzing	O
the	O
ability	O
of	O
recombinantly	O
expressed	O
chimeric	O
and	O
truncated	O
spike	O
proteins	O
to	O
bind	B-FUNC
to	O
chicken	O
tissues	O
,	O
we	O
demonstrate	O
that	O
the	O
N	O
-	O
terminal	O
253	O
amino	O
acids	O
of	O
the	O
spike	O
are	O
both	O
required	O
and	O
sufficient	O
for	O
binding	B-FUNC
to	O
chicken	O
respiratory	O
tract	O
in	O
an	O
	O
-	O
2	O
,	O
3	O
-	O
sialic	O
acid	O
-	O
dependent	O
manner	O
.	O

Structure	O
-	O
activity	O
relationship	O
was	O
analyzed	O
,	O
and	O
possible	O
binding	B-FUNC
interaction	O
modes	O
were	O
proposed	O
by	O
molecular	O
docking	O
studies	O
.	O

TITLE	O
:	O
A	O
truncated	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
potently	O
inhibits	O
MERS	O
-	O
CoV	O
infection	O
and	O
induces	O
strong	O
neutralizing	O
antibody	B-FUNC
responses	O
:	O
implication	O
for	O
developing	O
therapeutics	O
and	O
vaccines	O
.	O

Development	O
of	O
effective	O
therapeutics	O
and	O
vaccines	O
is	O
crucial	O
to	O
save	O
lives	O
and	O
halt	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
show	O
that	O
a	O
recombinant	O
protein	O
containing	O
a	O
212	O
-	O
amino	O
acid	O
fragment	O
(	O
residues	O
377	O
-	O
588	O
)	O
in	O
the	O
truncated	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
:	O
residues	O
367	O
-	O
606	O
)	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
fused	O
with	O
human	O
IgG	O
Fc	O
fragment	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
is	O
highly	O
expressed	O
in	O
the	O
culture	O
supernatant	O
of	O
transfected	O
293T	O
cells	O
.	O

The	O
purified	O
S377	O
-	O
588	O
-	O
Fc	O
protein	O
efficiently	O
binds	B-FUNC
to	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
the	O
receptor	O
of	O
MERS	O
-	O
CoV	O
,	O
and	O
potently	O
inhibited	O
MERS	O
-	O
CoV	O
infection	O
,	O
suggesting	O
its	O
potential	O
to	O
be	O
further	O
developed	O
as	O
a	O
therapeutic	O
modality	O
for	O
treating	O
MERS	O
-	O
CoV	O
infection	O
and	O
saving	O
the	O
patients	O
'	O
lives	O
.	O

SVM	O
performed	O
better	O
than	O
other	O
machine	O
learning	O
techniques	O
used	O
like	O
ANN	O
,	O
KNN	O
and	O
REP	B-FUNC
Tree	O
.	O

SVM	O
performed	O
better	O
than	O
other	O
machine	O
learning	O
techniques	O
used	O
like	O
ANN	O
,	O
KNN	O
and	O
REP	B-FUNC
Tree	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
antibody	B-FUNC
levels	O
against	O
IBV	O
post	O
-	O
immunization	O
were	O
measured	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
in	O
the	O
serum	O
of	O
511	O
individuals	O
from	O
a	O
commercial	O
chicken	O
(	O
Gallus	O
gallus	O
)	O
population	O
.	O

This	O
study	O
detected	O
20	O
significant	O
(	O
P	O
<	O
1	O
.	O
16	O
	O
10	O
(-	O
6	O
))	O
effect	O
single	O
nucleotide	O
polymorphisms	O
for	O
the	O
antibody	B-FUNC
level	O
against	O
IBV	O
.	O

The	O
genes	O
in	O
the	O
1	O
-	O
Mb	O
windows	O
surrounding	O
each	O
single	O
nucleotide	O
polymorphism	O
with	O
significant	O
effect	O
for	O
the	O
antibody	B-FUNC
level	O
against	O
IBV	O
were	O
associated	O
with	O
many	O
biological	O
processes	O
or	O
pathways	O
related	O
to	O
immunity	O
,	O
such	O
as	O
the	O
defense	O
response	O
and	O
mTOR	O
signaling	O
pathway	O
.	O

In	O
addition	O
,	O
the	O
major	O
loci	O
significantly	O
associated	O
with	O
the	O
antibody	B-FUNC
level	O
against	O
IBV	O
on	O
GGA1	O
and	O
GGA5	O
could	O
explain	O
about	O
12	O
%	O
and	O
13	O
%	O
of	O
the	O
phenotypic	O
variation	O
,	O
respectively	O
.	O

The	O
identification	O
of	O
the	O
structures	O
of	O
both	O
the	O
MERS	O
-	O
CoV	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
and	O
its	O
complex	O
with	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
raises	O
the	O
hope	O
of	O
alleviating	O
this	O
currently	O
severe	O
situation	O
.	O

ABSTRACT	O
:	O
Between	O
June	O
and	O
September	O
2013	O
,	O
sera	B-FUNC
from	O
11	O
dromedary	O
camels	O
,	O
150	O
goats	O
,	O
126	O
sheep	O
and	O
91	O
cows	O
were	O
collected	O
in	O
Jordan	O
,	O
where	O
the	O
first	O
human	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
cluster	O
appeared	O
in	O
2012	O
.	O

All	O
sera	B-FUNC
were	O
tested	O
for	O
MERS	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
specific	O
antibodies	O
by	O
protein	O
microarray	O
with	O
confirmation	O
by	O
virus	O
neutralisation	O
.	O

Neutralising	O
antibodies	O
were	O
found	O
in	O
all	O
camel	O
sera	B-FUNC
while	O
sera	B-FUNC
from	O
goats	O
and	O
cattle	O
tested	O
negative	O
.	O

Although	O
six	O
sheep	O
sera	B-FUNC
reacted	O
with	O
MERS	O
-	O
CoV	O
antigen	O
,	O
neutralising	O
antibodies	O
were	O
not	O
detected	O
.	O

Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
infected	O
sera	B-FUNC
from	O
cattle	O
had	O
no	O
cross	O
-	O
reactivity	O
in	O
MERS	O
-	O
CoV	O
ppNT	O
or	O
MNT	O
,	O
while	O
many	O
dromedary	O
camels	O
	O
sera	B-FUNC
reacted	O
to	O
both	O
BCoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Some	O
nevertheless	O
displayed	O
specific	O
serologic	O
reaction	O
profiles	O
to	O
MERS	O
-	O
CoV	O
.	O

All	O
camels	O
had	O
MERS	O
-	O
CoV	O
spike	O
-	O
binding	B-FUNC
antibodies	O
that	O
correlated	O
well	O
with	O
the	O
presence	O
of	O
neutralising	O
antibodies	O
to	O
MERS	O
-	O
CoV	O
.	O
Our	O
study	O
provides	O
virological	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
in	O
camels	O
and	O
suggests	O
a	O
recent	O
outbreak	O
affecting	O
both	O
human	O
beings	O
and	O
camels	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
a	O
candidate	O
SARS	O
vaccine	O
antigen	O
consisting	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
can	O
induce	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
vaccinated	O
animals	O
.	O

More	O
importantly	O
,	O
RBD219	O
-	O
N1	O
induced	O
significantly	O
stronger	O
RBD	O
-	O
specific	O
antibody	B-FUNC
responses	O
and	O
a	O
higher	O
level	O
of	O
neutralizing	O
antibodies	O
in	O
immunized	O
mice	O
than	O
RBD193	O
-	O
WT	O
,	O
RBD193	O
-	O
N1	O
,	O
RBD193	O
-	O
N3	O
,	O
or	O
RBD219	O
-	O
WT	O
.	O

Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
was	O
originally	O
identified	O
as	O
a	O
vascular	O
permeability	O
factor	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
/	O
ARDS	O
.	O

TITLE	O
:	O
Proteolytic	O
processing	O
,	O
deubiquitinase	B-FUNC
and	O
interferon	O
antagonist	O
activities	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

We	O
previously	O
reported	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
acts	O
as	O
both	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
and	O
IFN	O
antagonist	O
,	O
but	O
the	O
function	O
of	O
the	O
MERS	O
-	O
CoV	O
PLpro	O
was	O
poorly	O
understood	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
-	O
esterases	B-FUNC
(	O
HE	O
)	O
are	O
viral	O
envelope	O
proteins	O
present	O
in	O
some	O
members	O
from	O
the	O
toro	O
-,	O
corona	O
-	O
and	O
orthomyxovirus	O
families	O
,	O
all	O
related	O
with	O
enteric	O
and	O
/	O
or	O
respiratory	O
tract	O
infections	O
.	O

HE	O
proteins	O
mediate	O
reversible	O
binding	B-FUNC
to	O
sialic	O
acid	O
receptor	O
determinants	O
,	O
very	O
abundant	O
glycan	O
residues	O
in	O
the	O
enteric	O
and	O
respiratory	O
tracts	O
.	O

Probing	O
the	O
host	O
factors	O
contributing	O
to	O
disease	O
severity	O
,	O
we	O
found	O
that	O
lower	O
levels	O
of	O
plasma	O
inflammatory	O
cytokines	O
on	O
hospital	O
admission	O
correlated	O
with	O
faster	O
recovery	O
in	O
18	O
patients	O
with	O
A	O
/	O
H7N9	O
influenza	O
virus	O
,	O
whereas	O
high	O
concentrations	O
of	O
(	O
in	O
particular	O
)	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
were	O
predictive	O
of	O
a	O
less	O
favorable	O
or	O
fatal	O
outcome	O
.	O

The	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
were	O
dose	O
-	O
dependently	O
suppressed	O
by	O
FJU	O
-	O
C4	O
both	O
in	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
activities	O
of	O
ERK	B-FUNC
,	O
JNK	B-FUNC
,	O
and	O
p38MAPK	O
were	O
induced	O
by	O
LPS	O
stimulation	O
on	O
murine	O
macrophage	O
cell	O
line	O
,	O
but	O
only	O
p38MAPK	O
signaling	O
was	O
dramatically	O
suppressed	O
by	O
pretreatment	O
with	O
the	O
FJU	O
-	O
C4	O
compound	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
chimeric	O
VLPs	O
elicited	O
significantly	O
higher	O
S1	O
-	O
specific	O
antibody	B-FUNC
responses	O
in	O
intramuscularly	O
immunized	O
mice	O
and	O
chickens	O
than	O
inactivated	O
IBV	O
viruses	O
.	O

Furthermore	O
,	O
the	O
chimeric	O
VLPs	O
induced	O
significantly	O
higher	O
neutralization	O
antibody	B-FUNC
levels	O
than	O
inactivated	O
H120	O
virus	O
in	O
SPF	O
chickens	O
.	O

Finally	O
,	O
the	O
chimeric	O
VLPs	O
induced	O
significantly	O
higher	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
production	O
in	O
mice	O
.	O

Genotypes	O
HKU1	O
A	O
and	O
B	O
were	O
both	O
isolated	O
from	O
clinical	O
specimens	O
and	O
propagated	O
on	O
primary	O
human	O
tracheal	O
-	O
bronchial	O
epithelial	O
cells	O
cultured	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
and	O
were	O
neutralized	O
in	O
vitro	O
by	O
human	O
intravenous	O
immunoglobulin	B-FUNC
and	O
by	O
polyclonal	O
rabbit	O
antibodies	O
to	O
the	O
spike	O
glycoprotein	O
of	O
HKU1	O
.	O

Only	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
significantly	O
higher	O
in	O
the	O
injured	O
patients	O
.	O

Levels	O
of	O
the	O
regulatory	O
cytokines	O
,	O
transformed	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
higher	O
in	O
the	O
injured	O
patients	O
,	O
but	O
significant	O
only	O
for	O
TGF	O
-	O
	O
.	O

Levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
were	O
significantly	O
lower	O
in	O
the	O
injured	O
groups	O
as	O
compared	O
to	O
the	O
controls	O
.	O

High	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
TGF	O
and	O
low	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
were	O
found	O
to	O
be	O
reliable	O
markers	O
for	O
the	O
existence	O
of	O
immune	O
reactivity	O
in	O
trauma	O
patients	O
.	O

The	O
only	O
significant	O
correlation	O
between	O
clinical	O
periodontal	O
parameters	O
and	O
salivary	O
cytokines	O
was	O
found	O
between	O
clinical	O
attachment	O
level	O
(	O
CAL	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
(	O
P	O
=	O
0	O
.	O
02	O
).	O

The	O
present	O
findings	O
suggest	O
that	O
OSAS	O
may	O
have	O
an	O
increasing	O
effect	O
on	O
salivary	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
concentrations	O
regardless	O
of	O
OSAS	O
severity	O
.	O

RESULTS	O
:	O
Salivary	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
concentrations	O
were	O
similar	O
in	O
the	O
two	O
OSAS	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
),	O
which	O
were	O
statistically	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ELISA	O
kits	O
were	O
used	O
to	O
detect	O
the	O
human	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
.	O

The	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
level	O
was	O
found	O
to	O
increase	O
for	O
both	O
24	O
and	O
48	O
h	O
time	O
points	O
following	O
Ns	O
extract	O
treatment	O
.	O

The	O
virus	O
load	O
decreased	O
when	O
any	O
of	O
the	O
Ah	O
,	O
Ns	O
or	O
Cs	O
extracts	O
was	O
added	O
to	O
the	O
CoV	O
infected	O
cells	O
with	O
Ah	O
extract	O
treatment	O
leading	O
to	O
undetectable	O
virus	O
load	O
for	O
both	O
6	O
and	O
8	O
hpi	B-FUNC
.	O

Although	O
all	O
the	O
extract	O
treatments	O
had	O
an	O
effect	O
on	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
secretion	O
,	O
TRP	O
gene	O
expression	O
and	O
virus	O
load	O
after	O
CoV	O
infection	O
,	O
it	O
was	O
the	O
Ah	O
extract	O
treatment	O
that	O
showed	O
the	O
biggest	O
difference	O
in	O
virus	O
load	O
.	O

It	O
was	O
also	O
demonstrated	O
that	O
N	O
-	O
protein	O
binds	B-FUNC
to	O
nucleic	O
acid	O
at	O
multiple	O
sites	O
with	O
a	O
coupled	O
-	O
allostery	O
manner	O
.	O

TITLE	O
:	O
Anti	O
-	O
frameshifting	O
ligand	B-FUNC
reduces	O
the	O
conformational	O
plasticity	O
of	O
the	O
SARS	O
virus	O
pseudoknot	O
.	O

We	O
tested	O
whether	O
pseudoknots	O
bound	O
with	O
an	O
anti	O
-	O
frameshifting	O
ligand	B-FUNC
exhibited	O
a	O
similar	O
correlation	O
between	O
conformational	O
plasticity	O
and	O
-	O
1	O
PRF	O
efficiency	O
by	O
measuring	O
the	O
effects	O
of	O
a	O
ligand	B-FUNC
that	O
was	O
found	O
to	O
inhibit	O
-	O
1	O
PRF	O
in	O
the	O
SARS	O
coronavirus	O
on	O
the	O
conformational	O
dynamics	O
of	O
the	O
SARS	O
pseudoknot	O
.	O

Using	O
single	O
-	O
molecule	O
force	O
spectroscopy	O
to	O
unfold	O
pseudoknots	O
mechanically	O
,	O
we	O
found	O
that	O
the	O
ligand	B-FUNC
binding	B-FUNC
effectively	O
abolished	O
the	O
formation	O
of	O
alternate	O
conformers	O
.	O

Their	O
action	O
is	O
essential	O
in	O
living	O
organisms	O
facilitating	O
electric	O
signaling	O
,	O
muscle	B-FUNC
contraction	I-FUNC
or	O
osmotic	O
stress	O
response	O
among	O
other	O
effects	O
.	O

We	O
suggest	O
that	O
viral	O
ion	B-FUNC
channels	I-FUNC
,	O
in	O
general	O
,	O
may	O
be	O
a	O
good	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
agents	O
,	O
and	O
that	O
,	O
in	O
particular	O
,	O
kaempferol	O
glycosides	O
are	O
good	O
candidates	O
for	O
3a	O
channel	O
proteins	O
of	O
coronaviruses	O
.	O

TITLE	O
:	O
Granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
-	O
producing	O
lung	O
cancer	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
G	O
-	O
CSF	O
)-	O
producing	O
lung	O
cancers	O
are	O
known	O
to	O
cause	O
extreme	O
leukocytosis	O
.	O

Furthermore	O
,	O
the	O
pigs	O
infected	O
with	O
HP	O
-	O
PRRSV	O
showed	O
the	O
higher	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
interleukin	O
(	O
IL	O
)-	O
8	O
and	O
histamine	O
,	O
leukotriene	O
B4	O
(	O
LTB4	O
),	O
platelet	O
activation	O
factor	O
(	O
PAF	O
)	O
in	O
sera	B-FUNC
than	O
those	O
inoculated	O
with	O
LP	O
-	O
PRRSV	O
.	O

Multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
identified	O
viral	O
pathogens	O
in	O
nasal	O
/	O
throat	O
swabs	O
from	O
556	O
episodes	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
ILI	O
,	O
defined	O
as	O
ILI	O
with	O
pneumonia	O
,	O
hospitalization	O
,	O
or	O
maximum	O
daily	O
influenza	O
symptom	O
severity	O
score	O
(	O
ISS	O
)	O
>	O
2	O
.	O

Moreover	O
,	O
we	O
showed	O
that	O
the	O
expression	O
of	O
pulmonary	O
myeloperoxidase	O
(	O
MPO	B-FUNC
),	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
of	O
endothelial	O
cells	O
and	O
CD11b	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
induced	O
by	O
LPS	O
were	O
significantly	O
decreased	O
by	O
PFC	O
treatment	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
MSCs	B-FUNC
may	O
be	O
able	O
to	O
enhance	O
the	O
repair	O
and	O
resolution	O
of	O
lung	O
injury	O
.	O

MSCs	B-FUNC
appear	O
to	O
restore	O
epithelial	O
and	O
endothelial	O
function	O
,	O
via	O
both	O
paracrine	O
and	O
cell	O
contact	O
dependent	O
effects	O
.	O

MSCs	B-FUNC
have	O
been	O
demonstrated	O
to	O
decrease	O
injury	O
and	O
/	O
or	O
restore	O
function	O
in	O
other	O
organs	O
,	O
including	O
the	O
kidney	O
,	O
liver	O
and	O
heart	O
.	O

MSCs	B-FUNC
may	O
directly	O
attenuate	O
bacterial	O
sepsis	O
,	O
the	O
commonest	O
and	O
most	O
severe	O
cause	O
of	O
ALI	O
/	O
ARDS	O
.	O

The	O
fact	O
that	O
MSCs	B-FUNC
are	O
in	O
clinical	O
studies	O
for	O
a	O
wide	O
range	O
of	O
disease	O
processes	O
is	O
a	O
clear	O
advantage	O
for	O
translating	O
MSCs	B-FUNC
to	O
clinical	O
testing	O
in	O
patients	O
with	O
ARDS	O
.	O

The	O
ultimate	O
success	O
of	O
MSCs	B-FUNC
as	O
a	O
therapy	O
for	O
patients	O
with	O
ARDS	O
will	O
likely	O
be	O
dependent	O
on	O
a	O
greater	O
knowledge	O
of	O
their	O
mechanisms	O
of	O
action	O
and	O
the	O
determination	O
of	O
the	O
optimal	O
strategies	O
for	O
their	O
use	O
in	O
the	O
clinical	O
setting	O
.	O

Multiplex	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
was	O
undertaken	O
on	O
archived	O
nasopharyngeal	O
aspirates	O
from	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
(<	O
2	O
years	O
age	O
)	O
hospitalized	O
for	O
LRTI	O
,	O
who	O
had	O
been	O
previously	O
investigated	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
parainfluenza	O
I	O
-	O
III	O
,	O
adenovirus	O
and	O
influenza	O
A	O
/	O
B	O
.	O
At	O
least	O
one	O
of	O
these	O
viruses	O
were	O
identified	O
in	O
274	O
(	O
53	O
.	O
0	O
%)	O
of	O
517	O
and	O
in	O
509	O
(	O
54	O
.	O
0	O
%)	O
of	O
943	O
LRTI	O
-	O
episodes	O
in	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
,	O
respectively	O
.	O

TITLE	O
:	O
Recognition	O
of	O
the	O
murine	O
coronavirus	O
genomic	O
RNA	O
packaging	O
signal	O
depends	O
on	O
the	O
second	O
RNA	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
forms	O
a	O
helical	O
ribonucleoprotein	O
with	O
the	O
viral	O
positive	O
-	O
strand	O
RNA	O
genome	O
and	O
binds	B-FUNC
to	O
the	O
principal	O
constituent	O
of	O
the	O
virion	O
envelope	O
,	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
to	O
facilitate	O
assembly	O
and	O
budding	O
.	O

Besides	O
these	O
structural	O
roles	O
,	O
N	O
protein	O
associates	O
with	O
a	O
component	O
of	O
the	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
,	O
nonstructural	O
protein	O
3	O
,	O
at	O
a	O
critical	O
early	O
stage	O
of	O
infection	O
.	O

Mapping	O
of	O
revertants	O
of	O
the	O
resulting	O
chimeric	O
viruses	O
provided	O
evidence	O
for	O
extensive	O
intramolecular	O
interactions	O
between	O
the	O
two	O
RNA	O
-	O
binding	B-FUNC
domains	O
.	O

Through	O
analysis	O
of	O
viral	O
RNA	O
that	O
was	O
packaged	O
into	O
virions	O
we	O
identified	O
the	O
second	O
of	O
the	O
two	O
RNA	O
-	O
binding	B-FUNC
domains	O
as	O
a	O
principal	O
determinant	O
of	O
MHV	O
packaging	O
signal	O
recognition	O
.	O

Mechanistically	O
,	O
TM1	O
is	O
capable	O
of	O
binding	B-FUNC
with	O
RIG	O
-	O
I	O
,	O
TRAF3	O
,	O
TBK1	B-FUNC
and	O
IKK	O
,	O
and	O
preventing	O
the	O
interaction	O
of	O
TRAF3	O
with	O
its	O
downstream	O
effectors	O
.	O

Direct	O
florescent	O
antibody	B-FUNC
technique	O
(	O
dFAT	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
to	O
confirm	O
the	O
isolated	O
virus	O
strains	O
at	O
antigenic	O
and	O
genomic	O
levels	O
,	O
respectively	O
.	O

Furthermore	O
,	O
viral	O
DUBs	O
can	O
also	O
remove	O
the	O
protective	O
effect	O
of	O
conjugated	O
ubiquitin	B-FUNC
-	O
like	O
molecules	O
such	O
as	O
interferon	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
).	O

In	O
these	O
groups	O
100	O
%	O
of	O
the	O
PBFIPV	O
-	O
DF	O
-	O
2	O
-	O
R3i	O
immunised	O
animals	O
developed	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
).	O

Recombinant	O
FCoV	O
nucleocapsid	O
protein	O
(	O
rNP	O
)	O
was	O
used	O
as	O
a	O
conjugate	O
or	O
test	O
line	O
in	O
all	O
3	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
,	O
CJNP	O
/	O
TNP	O
,	O
and	O
CJNP	O
/	O
TPA	B-FUNC
).	O

On	O
the	O
other	O
hand	O
,	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
using	O
the	O
ICA	O
kit	B-FUNC
with	O
protein	O
A	O
blotted	O
as	O
the	O
test	O
line	O
(	O
CJNP	O
/	O
TPA	B-FUNC
).	O

In	O
addition	O
,	O
the	O
specificity	O
and	O
sensitivity	O
of	O
ICA	O
(	O
CJNP	O
/	O
TPA	B-FUNC
)	O
were	O
equivalent	O
to	O
those	O
of	O
the	O
reference	O
ELISA	O
.	O

The	O
development	O
of	O
simple	O
antibody	B-FUNC
test	O
methods	O
using	O
the	O
principle	O
of	O
ICA	O
(	O
CJNP	O
/	O
TPA	B-FUNC
)	O
for	O
other	O
coronavirus	O
and	O
feline	O
viral	O
infections	O
is	O
expected	O
in	O
the	O
future	O
.	O

TITLE	O
:	O
Myosins	O
1	O
and	O
6	O
,	O
myosin	O
light	O
chain	O
kinase	O
,	O
actin	O
and	O
microtubules	O
cooperate	O
during	O
antibody	B-FUNC
-	O
mediated	O
internalisation	O
and	O
trafficking	O
of	O
membrane	O
-	O
expressed	O
viral	O
antigens	O
in	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
monocytes	O
.	O

Upon	O
binding	B-FUNC
of	O
antibodies	O
,	O
these	O
proteins	O
are	O
quickly	O
internalised	O
through	O
a	O
new	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
internalisation	O
pathway	O
.	O

By	O
doing	O
so	O
,	O
the	O
infected	O
monocytes	O
can	O
escape	O
antibody	B-FUNC
-	O
dependent	O
cell	O
lysis	O
.	O

The	O
experiments	O
showed	O
that	O
myosin	O
light	O
chain	O
kinase	O
(	O
MLCK	B-FUNC
)	O
and	O
myosin	O
1	O
are	O
crucial	O
for	O
the	O
initiation	O
of	O
the	O
internalisation	O
.	O

With	O
co	O
-	O
localisation	O
stainings	O
,	O
it	O
was	O
found	O
that	O
MLCK	B-FUNC
and	O
myosin	O
1	O
co	O
-	O
localise	O
with	O
antigens	O
even	O
before	O
internalisation	O
started	O
.	O

Intracellular	O
trafficking	O
over	O
microtubules	O
was	O
mediated	O
by	O
MLCK	B-FUNC
,	O
myosin	O
1	O
and	O
a	O
small	O
actin	O
tail	O
.	O

Since	O
inhibiting	O
MLCK	B-FUNC
with	O
ML	O
-	O
7	O
was	O
so	O
efficient	O
in	O
blocking	O
the	O
internalisation	O
pathway	O
,	O
this	O
target	O
can	O
be	O
used	O
for	O
the	O
development	O
of	O
a	O
new	O
treatment	O
for	O
FIPV	O
.	O

TITLE	O
:	O
Middle	O
east	O
respiratory	O
syndrome	O
coronavirus	O
4a	O
protein	O
is	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
protein	O
that	O
suppresses	O
PACT	O
-	O
induced	O
activation	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
in	O
the	O
innate	O
antiviral	O
response	O
.	O

RNA	B-FUNC
binding	I-FUNC
of	O
MERS	O
-	O
CoV	O
4a	O
protein	O
was	O
required	O
for	O
IFN	O
antagonism	O
,	O
a	O
property	O
shared	O
by	O
4a	O
protein	O
of	O
bat	O
coronavirus	O
HKU5	O
but	O
not	O
by	O
the	O
counterpart	O
in	O
bat	O
coronavirus	O
HKU4	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
a	O
new	O
mechanism	O
through	O
which	O
MERS	O
-	O
CoV	O
employs	O
a	O
viral	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
protein	O
to	O
circumvent	O
the	O
innate	O
antiviral	O
response	O
by	O
perturbing	O
the	O
function	O
of	O
cellular	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	B-FUNC
protein	O
PACT	O
.	O

TGEV	O
infection	O
induced	O
the	O
occurring	O
of	O
apoptosis	O
in	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	O
,	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
Bax	O
,	O
altered	O
mitochondrial	O
membrane	O
potential	O
,	O
activated	O
p38	B-FUNC
MAPK	B-FUNC
signal	O
pathway	O
,	O
and	O
increased	O
expression	O
of	O
p53	O
as	O
evidenced	O
by	O
immunofluorescence	O
assays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
flow	O
cytometry	O
and	O
Western	O
blot	O
.	O

Moreover	O
,	O
further	O
results	O
showed	O
that	O
Ag	O
NPs	O
and	O
silver	O
nanowires	O
decreased	O
the	O
number	O
of	O
apoptotic	O
cells	O
induced	O
by	O
TGEV	O
through	O
regulating	O
p38	B-FUNC
/	O
mitochondria	O
-	O
caspase	O
-	O
3	O
signaling	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
synthetic	O
peptides	O
including	O
Th1	O
and	O
a	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitope	O
in	O
the	O
S1	O
domain	O
and	O
M	O
protein	O
of	O
FIPV	O
.	O

In	O
contrast	O
,	O
7	O
Th1	O
epitope	O
-	O
containing	O
peptides	O
were	O
identified	O
in	O
the	O
S1	O
domain	O
of	O
type	O
II	O
FIPV	O
,	O
and	O
no	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitope	O
was	O
contained	O
in	O
any	O
of	O
these	O
peptides	O
.	O

Eleven	O
Th1	O
epitope	O
-	O
containing	O
peptides	O
common	O
to	O
each	O
serotype	O
were	O
identified	O
in	O
the	O
M	O
protein	O
-	O
derived	O
peptides	O
,	O
and	O
2	O
peptides	O
(	O
M	O
-	O
11	O
and	O
M	O
-	O
12	O
)	O
contained	O
the	O
linear	O
immunodominant	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitope	O
.	O

TITLE	O
:	O
Cell	O
adhesion	O
as	O
a	O
novel	O
approach	O
to	O
determining	O
the	O
cellular	O
binding	B-FUNC
motif	O
on	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
quick	O
,	O
and	O
safe	O
cell	O
adhesion	O
inhibition	O
assay	O
was	O
developed	O
to	O
determine	O
the	O
potential	O
cellular	O
binding	B-FUNC
site	O
on	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

Various	O
synthetic	O
peptides	O
covering	O
the	O
potential	O
binding	B-FUNC
site	O
helped	O
to	O
minimize	O
further	O
the	O
binding	B-FUNC
motif	O
to	O
10	O
-	O
25	O
residues	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
catalysis	O
and	O
ubiquitin	B-FUNC
recognition	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
C112S	O
mutant	O
in	O
complex	O
with	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
is	O
reported	O
at	O
1	O
.	O
4	O
	O
resolution	O
.	O

Mutations	O
of	O
residues	O
in	O
the	O
PLpro	O
-	O
Ub	O
interface	O
lead	O
to	O
reduced	O
catalytic	B-FUNC
activity	I-FUNC
,	O
confirming	O
their	O
importance	O
for	O
Ub	O
binding	B-FUNC
and	O
/	O
or	O
catalysis	O
.	O

ABSTRACT	O
:	O
Intravenous	O
immunoglobulin	B-FUNC
(	O
IVIg	O
)	O
is	O
the	O
treatment	O
of	O
choice	O
for	O
Guillain	O
-	O
Barr	O
syndrome	O
(	O
GBS	O
),	O
an	O
immune	O
-	O
mediated	O
peripheral	O
neuropathy	O
causing	O
rapidly	O
progressive	O
limb	O
weakness	O
and	O
respiratory	O
failure	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	O
cycle	O
progression	O
demonstrated	O
that	O
the	O
expression	O
of	O
N	O
gene	O
resulted	O
in	O
an	O
accumulation	O
of	O
p53	O
and	O
p21	O
,	O
which	O
suppressed	O
cyclin	B-FUNC
B1	O
,	O
cdc2	O
and	O
cdk2	O
expression	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
TGEV	O
N	O
gene	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	B-FUNC
c	I-FUNC
,	O
followed	O
by	O
activation	O
of	O
caspase	O
-	O
3	O
,	O
resulting	O
in	O
cell	O
apoptosis	O
in	O
the	O
transfected	O
PK	O
-	O
15	O
cells	O
following	O
cell	O
cycle	O
arrest	O
.	O

Further	O
studies	O
showed	O
that	O
p53	O
inhibitor	O
attenuated	O
TGEV	O
N	O
protein	O
induced	O
cell	O
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
through	O
reversing	O
the	O
expression	O
changes	O
of	O
cdc2	O
,	O
cdk2	O
and	O
cyclin	B-FUNC
B1	O
and	O
the	O
translocation	O
changes	O
of	O
Bax	O
and	O
cytochrome	B-FUNC
c	I-FUNC
induced	O
by	O
TGEV	O
N	O
protein	O
.	O

Broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	O
)	O
of	O
the	O
first	O
week	O
and	O
sera	B-FUNC
of	O
the	O
first	O
month	O
from	O
the	O
two	O
patients	O
were	O
used	O
in	O
this	O
study	O
.	O

BAL	O
supernatants	O
and	O
sera	B-FUNC
were	O
used	O
to	O
assess	O
cytokines	O
and	O
chemokines	O
secretion	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Finally	O
,	O
we	O
confirm	O
previous	O
in	O
vitro	O
findings	O
that	O
MERS	O
-	O
CoV	O
can	O
drive	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
production	O
in	O
humans	O
.	O

Cell	O
entry	O
begins	O
with	O
virus	O
spike	O
(	O
S	O
)	O
protein	B-FUNC
binding	I-FUNC
to	O
DPP4	O
receptors	O
.	O

We	O
constructed	O
chimeric	O
DPP4	O
receptors	O
that	O
have	O
the	O
virus	O
-	O
binding	B-FUNC
domains	O
of	O
indigenous	O
Middle	O
Eastern	O
animals	O
and	O
assessed	O
the	O
activities	O
of	O
these	O
receptors	O
in	O
supporting	O
S	O
protein	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
.	O

Sera	B-FUNC
from	O
noninfected	O
and	O
infected	O
pigs	O
were	O
used	O
to	O
set	O
the	O
median	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
cutoffs	O
and	O
as	O
positive	O
controls	O
,	O
respectively	O
.	O

Cross	O
-	O
reactivity	O
with	O
sera	B-FUNC
from	O
pigs	O
infected	O
with	O
Mycoplasma	O
hyopneumoniae	O
,	O
Porcine	O
circovirus	O
-	O
2	O
,	O
Porcine	O
parvovirus	O
,	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
,	O
and	O
Porcine	O
respiratory	O
coronavirus	O
with	O
this	O
MIA	O
was	O
not	O
observed	O
.	O

In	O
summary	O
,	O
the	O
MIA	O
is	O
specific	O
and	O
more	O
sensitive	O
than	O
qPCR	O
and	O
IHA	O
,	O
providing	O
simultaneous	O
evaluation	O
of	O
antibody	B-FUNC
response	O
to	O
M	O
.	O
suis	O
antigens	O
.	O

TITLE	O
:	O
Intranasal	O
vaccination	O
with	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
induces	O
much	O
stronger	O
local	O
mucosal	O
immune	O
responses	O
than	O
subcutaneous	O
immunization	O
:	O
Implication	O
for	O
designing	O
novel	O
mucosal	O
MERS	O
vaccines	O
.	O

vaccination	O
of	O
a	O
recombinant	O
protein	O
containing	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
S	O
fused	O
with	O
Fc	O
of	O
human	O
IgG	O
(	O
RBD	O
-	O
Fc	O
)	O
induced	O
strong	O
systemic	O
neutralizing	O
antibody	B-FUNC
responses	O
in	O
vaccinated	O
mice	O
.	O

By	O
targeting	O
this	O
pocket	O
,	O
we	O
identified	O
and	O
developed	O
a	O
new	O
coronavirus	O
N	O
protein	O
inhibitor	O
,	O
N	O
-(	O
6	O
-	O
oxo	O
-	O
5	O
,	O
6	O
-	O
dihydrophenanthridin	O
-	O
2	O
-	O
yl	O
)(	O
N	O
,	O
N	O
-	O
dimethylamino	O
)	O
acetamide	O
hydrochloride	O
(	O
PJ34	O
),	O
using	O
virtual	O
screening	O
;	O
this	O
inhibitor	O
reduced	O
the	O
N	O
protein	O
'	O
s	O
RNA	O
-	O
binding	B-FUNC
affinity	O
and	O
hindered	O
viral	O
replication	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL63	O
replication	O
is	O
cyclophilin	B-FUNC
A	O
-	O
dependent	O
and	O
inhibited	O
by	O
non	O
-	O
immunosuppressive	O
cyclosporine	O
A	O
-	O
derivatives	O
including	O
Alisporivir	O
.	O

Knockdown	O
of	O
the	O
cellular	O
Cyclophilin	B-FUNC
A	O
(	O
CypA	O
/	O
PPIA	O
)	O
gene	O
in	O
Caco	O
-	O
2	O
cells	O
prevents	O
replication	O
of	O
HCoV	O
-	O
NL63	O
,	O
suggesting	O
that	O
CypA	O
is	O
required	O
for	O
virus	O
replication	O
.	O

Collectively	O
,	O
our	O
results	O
uncover	O
Cyclophilin	B-FUNC
A	O
as	O
a	O
host	O
target	O
for	O
CoV	O
infection	O
and	O
provide	O
new	O
strategies	O
for	O
urgently	O
needed	O
therapeutic	O
approaches	O
.	O

X	O
-	O
ray	O
structural	O
analyses	O
of	O
inhibitor	O
-	O
bound	O
crystal	O
structures	O
revealed	O
subtle	O
differences	O
between	O
binding	B-FUNC
modes	O
of	O
the	O
initial	O
benzodioxolane	O
lead	O
(	O
15g	O
)	O
and	O
the	O
most	O
potent	O
analogues	O
3k	O
and	O
3j	O
,	O
featuring	O
a	O
monofluoro	O
substitution	O
at	O
para	O
and	O
meta	O
positions	O
of	O
the	O
benzyl	O
ring	O
,	O
respectively	O
.	O

Advances	O
have	O
been	O
made	O
in	O
the	O
clinical	O
diagnosis	O
of	O
FIP	O
,	O
based	O
on	O
the	O
clinical	O
pathologic	O
findings	O
,	O
serologic	O
testing	O
,	O
and	O
detection	O
of	O
virus	O
using	O
molecular	O
(	O
polymerase	O
chain	O
reaction	O
)	O
or	O
antibody	B-FUNC
-	O
based	O
methods	O
.	O

T	O
.	O
brucei	O
rhodesiense	O
subspecies	O
was	O
finally	O
identified	O
on	O
the	O
basis	O
of	O
the	O
characteristic	O
serum	O
resistance	O
-	O
associated	O
gene	O
using	O
a	O
polymerase	O
chain	O
reaction	O
,	O
and	O
a	O
seroconversion	O
of	O
specific	O
immunoglobulin	B-FUNC
M	O
and	O
G	O
antibodies	O
in	O
the	O
peripheral	O
blood	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
AdvanSure	O
	O
kit	B-FUNC
based	O
on	O
multiplex	O
real	O
-	O
time	O
PCR	O
was	O
developed	O
for	O
simultaneous	O
detection	O
of	O
14	O
respiratory	O
viruses	O
(	O
RVs	O
).	O

Swabs	O
were	O
processed	O
by	O
molecular	O
techniques	O
for	O
viruses	O
detection	O
and	O
antibody	B-FUNC
titres	O
were	O
evaluated	O
.	O

TITLE	O
:	O
Discovery	O
of	O
nitropyridine	O
derivatives	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
via	O
a	O
structure	O
-	O
based	O
core	O
refining	O
approach	O
.	O

Furthermore	O
,	O
inhibiting	O
ERK1	B-FUNC
/	O
2	O
and	O
p38	B-FUNC
efficiently	O
blocks	O
C5a	O
-	O
mediated	O
Fgl2	O
production	O
during	O
viral	O
infections	O
.	O

Our	O
recent	O
assessment	O
of	O
mitochondrial	O
function	O
in	O
MeCP2	O
(	O
methyl	O
-	O
CpG	O
-	O
binding	B-FUNC
protein	O
2	O
)-	O
deficient	O
mouse	O
(	O
Mecp2	O
(-)	O
(/	O
y	O
))	O
hippocampus	O
confirmed	O
early	O
metabolic	O
alterations	O
,	O
an	O
increased	O
oxidative	O
burden	O
,	O
and	O
a	O
more	O
vulnerable	O
cellular	O
redox	O
balance	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
STAT	O
/	O
NF	O
-	O
B	O
inhibitor	O
and	O
free	O
radical	O
scavenger	O
,	O
was	O
administered	O
systemically	O
to	O
a	O
subset	O
of	O
mice	O
to	O
determine	O
whether	O
this	O
altered	O
the	O
muscle	B-FUNC
contraction	I-FUNC
response	O
.	O

LoFS	O
increased	O
muscle	O
phosphorylated	O
-	O
AMP	O
-	O
activated	O
protein	O
kinase	O
and	O
p38	B-FUNC
in	O
BL	O
-	O
6	O
and	O
Min	O
mice	O
.	O

These	O
data	O
demonstrate	O
that	O
cachexia	O
alters	O
the	O
muscle	O
metabolic	O
response	O
to	O
acute	O
LoFS	O
,	O
and	O
combination	O
therapies	O
in	O
concert	O
with	O
muscle	B-FUNC
contraction	I-FUNC
may	O
be	O
beneficial	O
for	O
improving	O
muscle	O
mass	O
and	O
function	O
during	O
cachexia	O
.	O

Gene	O
expression	O
of	O
IL	O
-	O
1	O
and	O
IL	O
-	O
6receptors	O
in	O
the	O
tubular	O
gland	O
cells	O
of	O
the	O
isthmus	O
and	O
uterus	O
was	O
analyzed	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

In	O
both	O
,	O
MS	O
and	O
coronavirus	O
-	O
induced	O
encephalomyelitis	O
,	O
this	O
was	O
associated	O
with	O
massive	O
microglial	O
and	O
macrophage	O
activation	O
,	O
accompanied	O
by	O
the	O
expression	O
of	O
the	O
NADPH	B-FUNC
oxidase	I-FUNC
subunit	O
p22phox	O
but	O
only	O
sparse	O
expression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
).	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	O
-	O
like	O
protease	O
inhibits	O
the	O
type	O
I	O
interferon	O
signaling	O
pathway	O
through	O
interaction	O
with	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-FUNC
complex	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
-	O
anchored	O
PLpro	O
domain	O
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	O
-	O
CoV	O
inhibits	O
STING	O
/	O
TBK1	B-FUNC
/	O
IKK	O
-	O
mediated	O
activation	O
of	O
type	O
I	O
IFNs	O
and	O
disrupts	O
the	O
phosphorylation	O
and	O
dimerization	O
of	O
IRF3	O
,	O
which	O
are	O
activated	O
by	O
STING	O
and	O
TBK1	B-FUNC
.	O

Meanwhile	O
,	O
we	O
showed	O
that	O
PLpro	O
-	O
TM	O
physically	O
interacts	O
with	O
TRAF3	O
,	O
TBK1	B-FUNC
,	O
IKK	O
,	O
STING	O
,	O
and	O
IRF3	O
,	O
the	O
key	O
components	O
that	O
assemble	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-FUNC
complex	O
for	O
activation	O
of	O
IFN	O
expression	O
.	O

However	O
,	O
the	O
interaction	O
between	O
the	O
components	O
in	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-FUNC
complex	O
is	O
disrupted	O
by	O
PLpro	O
-	O
TM	O
.	O

Furthermore	O
,	O
SARS	O
PLpro	O
-	O
TM	O
reduces	O
the	O
levels	O
of	O
ubiquitinated	O
forms	O
of	O
RIG	O
-	O
I	O
,	O
STING	O
,	O
TRAF3	O
,	O
TBK1	B-FUNC
,	O
and	O
IRF3	O
in	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-FUNC
complex	O
.	O

These	O
results	O
collectively	O
point	O
to	O
a	O
new	O
mechanism	O
used	O
by	O
SARS	O
-	O
CoV	O
through	O
which	O
PLpro	O
negatively	O
regulates	O
IRF3	O
activation	O
by	O
interaction	O
with	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-FUNC
complex	O
,	O
yielding	O
a	O
SARS	O
-	O
CoV	O
countermeasure	O
against	O
host	O
innate	O
immunity	O
.	O

Although	O
a	O
small	O
number	O
of	O
camels	O
have	O
been	O
found	O
to	O
have	O
positive	O
nasal	O
swabs	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
to	O
carry	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
,	O
the	O
transmission	O
route	O
and	O
the	O
intermediary	O
animal	O
source	O
remain	O
uncertain	O
amongst	O
the	O
sporadic	O
primary	O
cases	O
.	O

Serum	O
proinflammatory	O
cytokines	O
were	O
similar	O
in	O
both	O
age	O
groups	O
,	O
whereas	O
significantly	O
lower	O
levels	O
of	O
IL	O
-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
were	O
detected	O
in	O
the	O
lungs	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
aged	O
monkeys	O
at	O
either	O
5	O
or	O
10	O
days	O
post	O
infection	O
.	O

TITLE	O
:	O
PKR	O
mediated	O
regulation	O
of	O
inflammation	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
during	O
viral	O
encephalomyelitis	O
.	O

Furthermore	O
,	O
PKR	O
deficiency	O
selectively	O
reduced	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
in	O
CD4	O
,	O
but	O
not	O
CD8	O
T	O
cells	O
,	O
without	O
affecting	O
CNS	O
pathology	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
a	O
deubiquitinating	O
protein	O
,	O
the	O
papain	O
-	O
like	O
protease	O
-	O
2	O
(	O
PLP2	O
),	O
that	O
removes	O
both	O
ubiquitin	B-FUNC
and	O
the	O
ubiquitin	B-FUNC
-	O
like	O
interferon	O
(	O
IFN	O
)-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
protein	O
from	O
target	O
proteins	O
.	O

Mice	O
deficient	O
in	O
the	O
ISG15	O
deconjugating	O
enzyme	O
,	O
ubiquitin	B-FUNC
-	O
specific	O
peptidase	O
-	O
18	O
(	O
USP18	O
),	O
accumulate	O
high	O
levels	O
of	O
ISG15	O
-	O
conjugated	O
proteins	O
and	O
are	O
hypersensitive	O
to	O
type	O
I	O
IFN	O
.	O

Decreasing	O
ISGylation	O
by	O
knockdown	O
of	O
the	O
ISG15	O
E1	O
enzyme	O
,	O
Ube1L	B-FUNC
,	O
in	O
primary	O
USP18	O
(+/+)	O
and	O
USP18	O
(-/-)	O
hepatocytes	O
led	O
to	O
increased	O
MHV	O
-	O
3	O
replication	O
.	O

Most	O
(	O
389	O
/	O
651	O
,	O
59	O
.	O
8	O
%)	O
serum	O
samples	O
had	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-FUNC
titers	O
>	O
1	O
,	O
280	O
.	O

Next	O
to	O
methods	O
for	O
nucleic	O
acid	O
detection	O
,	O
validated	O
serological	O
assays	O
are	O
particularly	O
important	O
as	O
the	O
timeframe	O
for	O
antibody	B-FUNC
detection	O
is	O
less	O
restricted	O
.	O

Finally	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
documented	O
an	O
earlier	O
and	O
higher	O
systemic	O
TGEV	O
-	O
specific	O
serum	O
antibody	B-FUNC
response	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
4	O
-(	O
naphthalen	O
-	O
1	O
-	O
yl	O
)-	O
1	O
,	O
2	O
,	O
5	O
-	O
thiadiazol	O
-	O
3	O
-	O
hydroxyl	O
derivatives	O
(	O
Ia	O
-	O
Im	O
and	O
IIa	O
-	O
IIe	O
)	O
designed	O
as	O
novel	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTIs	O
)	O
was	O
synthesized	O
via	O
an	O
expeditious	O
route	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
activities	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

Molecular	O
docking	O
of	O
compound	O
Ih	O
with	O
wt	O
HIV	O
-	O
1	O
RT	O
was	O
performed	O
to	O
understand	O
the	O
binding	B-FUNC
mode	O
between	O
these	O
inhibitors	O
and	O
the	O
wt	O
HIV	O
-	O
1	O
RT	O
and	O
to	O
rationalize	O
some	O
SARs	O
.	O

Antibody	B-FUNC
titer	O
against	O
Newcastle	O
disease	O
(	O
ND	O
),	O
infectious	O
bursal	O
disease	O
(	O
IBD	O
),	O
and	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
T2	O
and	O
T3	O
groups	O
.	O

Both	O
USP	B-FUNC
-	O
10	O
and	O
USP	B-FUNC
-	O
50	O
strains	O
caused	O
similar	O
pathological	O
patterns	O
by	O
either	O
route	O
of	O
inoculation	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
28	I-FUNC
,	O
IL	O
-	O
29	O
,	O
IL	O
-	O
37	O
,	O
TGF	O
-	O
	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
,	O
and	O
Tbet	O
were	O
directly	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

A	O
negative	O
correlation	O
between	O
antiviral	O
cytokines	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
,	O
IL	O
-	O
37	O
,	O
FOXP3	O
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
strongly	O
correlated	O
with	O
antiviral	O
cytokines	O
.	O

A	O
negative	O
correlation	O
between	O
antiviral	O
cytokines	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
,	O
IL	O
-	O
37	O
,	O
FOXP3	O
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
strongly	O
correlated	O
with	O
antiviral	O
cytokines	O
.	O

Peripheral	O
blood	O
smear	O
and	O
bone	O
marrow	O
aspirate	O
examinations	O
revealed	O
abnormal	O
large	O
intracytoplasmic	O
granules	O
,	O
which	O
was	O
diagnostic	O
of	O
CHS	B-FUNC
.	O

The	O
child	O
'	O
s	O
investigations	O
revealed	O
coexistent	O
hemophagocytic	O
lymphohistiocytosis	O
,	O
confirming	O
the	O
diagnosis	O
of	O
CHS	B-FUNC
in	O
'	O
accelerated	O
phase	O
',	O
which	O
is	O
fatal	O
if	O
not	O
treated	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
detection	O
of	O
IBV	O
vaccine	O
virus	O
early	O
after	O
administration	O
,	O
regardless	O
of	O
strain	O
or	O
route	O
,	O
correlated	O
with	O
protection	O
against	O
homologous	O
challenge	O
and	O
may	O
thus	O
be	O
a	O
good	O
indicator	O
of	O
vaccine	O
efficacy	O
in	O
the	O
field	O
because	O
humoral	O
antibody	B-FUNC
titers	O
are	O
typically	O
low	O
or	O
undetectable	O
after	O
vaccination	O
.	O

Quantitative	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
that	O
the	O
most	O
strongly	O
affected	O
of	O
these	O
,	O
the	O
nsp3	O
mutant	O
,	O
produced	O
more	O
viral	O
RNA	O
than	O
wild	O
-	O
type	O
virus	O
.	O

According	O
to	O
laboratory	O
examinations	O
,	O
increased	O
C	O
reactive	O
protein	O
(	O
CRP	O
),	O
Procalcitonin	O
(	O
PCT	O
),	O
Plasma	O
thromboplastin	O
antecedent	O
(	O
PTA	B-FUNC
)	O
and	O
virus	O
positive	O
time	O
(	O
days	O
)	O
were	O
indicative	O
of	O
patients	O
'	O
mortality	O
.	O

Certain	O
laboratory	O
parameters	O
such	O
as	O
plasma	O
CRP	O
,	O
PCT	O
,	O
PTA	B-FUNC
and	O
virus	O
positive	O
days	O
predicted	O
mortality	O
of	O
H7N9	O
infection	O
and	O
plasma	O
CRP	O
is	O
an	O
independent	O
predictor	O
of	O
mortality	O
in	O
these	O
patients	O
.	O

As	O
determined	O
by	O
commercial	O
multi	O
-	O
PCR	O
kit	B-FUNC
and	O
conventional	O
PCR	O
(	O
for	O
HBoV	O
and	O
WUPyV	O
),	O
the	O
diagnostic	O
sensitivity	O
of	O
the	O
Respiratory	O
Panel	O
for	O
each	O
viral	O
targets	O
ranged	O
from	O
50	O
.	O
0	O
%	O
to	O
100	O
.	O
0	O
%,	O
the	O
diagnostic	O
specificity	O
was	O
96	O
.	O
2	O
%-	O
100	O
.	O
0	O
%,	O
and	O
accordance	O
rate	O
was	O
93	O
.	O
2	O
%	O
-	O
100	O
.	O
0	O
%,	O
the	O
kappa	O
correlation	O
of	O
eight	O
viral	O
targets	O
was	O
>	O
0	O
.	O
75	O
.	O

As	O
determined	O
by	O
commercial	O
multi	O
-	O
PCR	O
kit	B-FUNC
and	O
conventional	O
PCR	O
(	O
for	O
HBoV	O
and	O
WUPyV	O
),	O
the	O
diagnostic	O
sensitivity	O
of	O
the	O
Respiratory	O
Panel	O
for	O
each	O
viral	O
targets	O
ranged	O
from	O
50	O
.	O
0	O
%	O
to	O
100	O
.	O
0	O
%,	O
the	O
diagnostic	O
specificity	O
was	O
96	O
.	O
2	O
%-	O
100	O
.	O
0	O
%,	O
and	O
accordance	O
rate	O
was	O
93	O
.	O
2	O
%	O
-	O
100	O
.	O
0	O
%,	O
the	O
kappa	O
correlation	O
of	O
eight	O
viral	O
targets	O
was	O
>	O
0	O
.	O
75	O
.	O

Furthermore	O
,	O
the	O
binding	B-FUNC
of	O
the	O
circular	O
TFO	O
RNA	O
with	O
the	O
targeted	O
viral	O
genome	O
segment	O
was	O
also	O
confirmed	O
using	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Among	O
these	O
extracts	O
,	O
CBM	O
and	O
DBM	O
also	O
showed	O
significant	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-FUNC
activity	I-FUNC
with	O
IC50	O
values	O
of	O
39	O
g	O
/	O
ml	O
and	O
44	O
g	O
/	O
ml	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Human	O
disease	O
caused	O
by	O
highly	O
pathogenic	O
avian	O
influenza	O
A	O
(	O
HPAI	B-FUNC
)	O
(	O
H5N1	O
)	O
is	O
associated	O
with	O
fulminant	O
viral	O
pneumonia	O
and	O
mortality	O
rates	O
in	O
excess	O
of	O
60	O
%.	O

TITLE	O
:	O
A	O
conformation	O
-	O
dependent	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
specifically	O
targeting	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
.	O

Here	O
,	O
we	O
have	O
developed	O
a	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
),	O
designated	O
Mersmab1	O
,	O
which	O
potently	O
blocks	O
MERS	O
-	O
CoV	O
entry	O
into	O
human	O
cells	O
.	O

Biochemical	O
assays	O
reveal	O
that	O
Mersmab1	O
specifically	O
binds	B-FUNC
to	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
and	O
thereby	O
competitively	O
blocks	O
the	O
binding	B-FUNC
of	O
the	O
RBD	O
to	O
its	O
cellular	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

These	O
results	O
suggest	O
that	O
if	O
humanized	O
,	O
Mersmab1	O
could	O
potentially	O
function	O
as	O
a	O
therapeutic	O
antibody	B-FUNC
for	O
treating	O
and	O
preventing	O
MERS	O
-	O
CoV	O
infections	O
.	O

If	O
humanized	O
,	O
this	O
antibody	B-FUNC
may	O
be	O
used	O
as	O
a	O
prophylactic	O
and	O
therapeutic	O
agent	O
against	O
MERS	O
-	O
CoV	O
infections	O
.	O

Specifically	O
,	O
when	O
given	O
to	O
a	O
person	O
(	O
e	O
.	O
g	O
.,	O
a	O
patient	O
'	O
s	O
family	O
member	O
or	O
a	O
health	O
care	O
worker	O
)	O
either	O
before	O
or	O
after	O
exposure	O
to	O
MERS	O
-	O
CoV	O
,	O
the	O
humanized	O
antibody	B-FUNC
may	O
prevent	O
or	O
inhibit	O
MERS	O
-	O
CoV	O
infection	O
,	O
thereby	O
stopping	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
in	O
humans	O
.	O

This	O
antibody	B-FUNC
can	O
also	O
serve	O
as	O
a	O
useful	O
tool	O
to	O
guide	O
the	O
design	O
of	O
effective	O
MERS	O
-	O
CoV	O
vaccines	O
.	O

ABSTRACT	O
:	O
Although	O
many	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronaviruses	O
(	O
SARS	O
-	O
like	O
CoVs	O
)	O
have	O
been	O
identified	O
in	O
bats	O
in	O
China	O
,	O
Europe	O
,	O
and	O
Africa	O
,	O
most	O
have	O
a	O
genetic	O
organization	O
significantly	O
distinct	O
from	O
human	O
/	O
civet	O
SARS	O
CoVs	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
which	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
and	O
determines	O
the	O
host	O
spectrum	O
,	O
resulting	O
in	O
their	O
failure	O
to	O
cause	O
human	O
infections	O
and	O
making	O
them	O
unlikely	O
progenitors	O
of	O
human	O
/	O
civet	O
SARS	O
CoVs	O
.	O

TITLE	O
:	O
Phagocytic	O
cells	O
contribute	O
to	O
the	O
antibody	B-FUNC
-	O
mediated	O
elimination	O
of	O
pulmonary	O
-	O
infected	O
SARS	O
coronavirus	O
.	O

Second	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
levels	O
of	O
IFN	O
-	O
	O
,	O
IP	O
-	O
10	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
and	O
RANTES	O
expression	O
than	O
SARS	O
-	O
CoV	O
.	O
Third	O
,	O
MERS	O
-	O
CoV	O
-	O
infection	O
induced	O
higher	O
surface	O
expression	O
of	O
MHC	O
class	O
II	O
(	O
HLA	O
-	O
DR	O
)	O
and	O
the	O
co	O
-	O
stimulatory	O
molecule	O
CD86	O
than	O
SARS	O
-	O
CoV	O
-	O
infection	O
.	O

TITLE	O
:	O
Performance	O
and	O
clinical	O
validation	O
of	O
the	O
RealStar	O
MERS	O
-	O
CoV	O
Kit	B-FUNC
for	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
RNA	O
.	O

Fast	B-FUNC
diagnosis	O
is	O
important	O
to	O
manage	O
human	O
cases	O
and	O
trace	O
possible	O
contacts	O
.	O

Based	O
on	O
these	O
assays	O
,	O
a	O
ready	O
-	O
to	O
-	O
use	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
kit	B-FUNC
featuring	O
both	O
the	O
upE	O
and	O
ORF1A	O
assays	O
was	O
developed	O
,	O
validated	O
and	O
compared	O
to	O
the	O
established	O
in	O
-	O
house	O
versions	O
.	O

The	O
performance	O
of	O
both	O
RT	O
-	O
PCR	O
assays	O
included	O
in	O
the	O
kit	B-FUNC
is	O
comparable	O
to	O
the	O
in	O
-	O
house	O
assays	O
.	O

The	O
kit	B-FUNC
is	O
a	O
valuable	O
tool	O
for	O
assisting	O
in	O
the	O
rapid	O
diagnosis	O
,	O
patient	O
management	O
and	O
epidemiology	O
of	O
suspected	O
MERS	O
-	O
CoV	O
cases	O
.	O

RESULTS	O
:	O
The	O
performance	O
of	O
both	O
RT	O
-	O
PCR	O
assays	O
included	O
in	O
the	O
kit	B-FUNC
is	O
comparable	O
to	O
the	O
in	O
-	O
house	O
assays	O
.	O

CONCLUSIONS	O
:	O
The	O
kit	B-FUNC
is	O
a	O
valuable	O
tool	O
for	O
assisting	O
in	O
the	O
rapid	O
diagnosis	O
,	O
patient	O
management	O
and	O
epidemiology	O
of	O
suspected	O
MERS	O
-	O
CoV	O
cases	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
bacterial	O
and	O
viral	O
etiology	O
of	O
hospitalized	O
CAP	O
cases	O
and	O
compare	O
clinical	O
and	O
laboratory	O
findings	O
of	O
patients	O
with	O
pure	B-FUNC
bacterial	O
and	O
bacterial	O
and	O
viral	O
(	O
mixed	O
)	O
infections	O
.	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	B-FUNC
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	O
in	O
liver	O
and	O
gut	O
).	O

TITLE	O
:	O
Comparison	O
of	O
vaccine	O
subpopulation	O
selection	O
,	O
viral	O
loads	O
,	O
vaccine	O
virus	O
persistence	O
in	O
trachea	O
and	O
cloaca	O
,	O
and	O
mucosal	O
antibody	B-FUNC
responses	O
after	O
vaccination	O
with	O
two	O
different	O
Arkansas	O
Delmarva	O
Poultry	O
Industry	O
-	O
derived	O
infectious	O
bronchitis	O
virus	O
vaccines	O
.	O

Chickens	O
vaccinated	O
with	O
vaccine	O
B	O
had	O
significantly	O
higher	O
viral	O
loads	O
in	O
tears	O
at	O
5	O
days	O
postvaccination	O
(	O
DPV	O
)	O
than	O
those	O
vaccinated	O
with	O
vaccine	O
A	O
.	O
Vaccine	O
B	O
also	O
induced	O
a	O
significantly	O
higher	O
lachrymal	O
immunoglobulin	B-FUNC
M	O
response	O
at	O
11	O
DPV	O
,	O
an	O
earlier	O
peak	O
of	O
IBV	O
-	O
specific	O
lachrymal	O
immunoglobulin	B-FUNC
A	O
,	O
and	O
higher	O
serum	O
antibodies	O
than	O
vaccine	O
A	O
.	O
In	O
addition	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
birds	O
vaccinated	O
with	O
vaccine	O
B	O
had	O
vaccine	O
virus	O
detected	O
in	O
the	O
trachea	O
at	O
20	O
DPV	O
than	O
those	O
vaccinated	O
with	O
vaccine	O
A	O
.	O
Furthermore	O
,	O
the	O
virus	O
detected	O
at	O
20	O
DPV	O
in	O
most	O
of	O
the	O
chickens	O
vaccinated	O
with	O
vaccine	O
B	O
was	O
a	O
single	O
specific	O
subpopulation	O
(	O
subpopulation	O
4	O
)	O
selected	O
from	O
multiple	O
vaccine	O
subpopulations	O
detected	O
earlier	O
at	O
5	O
and	O
7	O
DPV	O
in	O
the	O
same	O
chickens	O
.	O

Immunofluorescence	O
assays	O
detected	O
no	O
difference	O
in	O
HCoV	O
-	O
NL63	O
antibody	B-FUNC
positivity	O
between	O
the	O
patients	O
with	O
Kawasaki	O
disease	O
and	O
controls	O
,	O
whereas	O
the	O
rate	O
of	O
HCoV	O
-	O
229E	O
antibody	B-FUNC
positivity	O
was	O
higher	O
in	O
the	O
patients	O
with	O
Kawasaki	O
disease	O
than	O
that	O
in	O
controls	O
.	O

Although	O
the	O
catalytic	B-FUNC
activity	I-FUNC
of	O
the	O
ACE2	O
,	O
APN	O
,	O
and	O
DPP4	O
peptidases	O
is	O
not	O
required	O
for	O
virus	O
entry	O
,	O
co	O
-	O
expression	O
of	O
other	O
host	O
proteases	O
allows	O
efficient	O
viral	O
entry	O
.	O

In	O
this	O
review	O
,	O
the	O
current	O
advancements	O
and	O
potential	O
strategies	O
in	O
the	O
development	O
of	O
MERS	O
vaccines	O
,	O
particularly	O
subunit	O
vaccines	O
based	O
on	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
are	O
discussed	O
.	O

TITLE	O
:	O
Act	O
fast	B-FUNC
and	O
ventilate	O
soft	O
:	O
the	O
Dsseldorf	O
hands	O
-	O
on	O
translation	O
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
Berlin	O
definition	O
.	O

Interestingly	O
,	O
the	O
degree	O
of	O
liver	O
damage	O
in	O
these	O
patients	O
significantly	O
correlated	O
with	O
their	O
serum	O
levels	O
of	O
Th2	O
cytokines	O
,	O
interleukin	O
(	O
IL	O
)-	O
4	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
9	I-FUNC
.	O

These	O
nAbs	O
bind	B-FUNC
to	O
three	O
different	O
epitopes	O
in	O
the	O
RBD	O
and	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
interface	O
with	O
subnanomolar	O
/	O
nanomolar	O
binding	B-FUNC
affinities	O
and	O
block	O
the	O
binding	B-FUNC
of	O
MERS	O
-	O
CoV	O
Spike	O
protein	O
with	O
its	O
hDPP4	O
receptor	O
.	O

Importantly	O
,	O
the	O
majority	O
of	O
escape	O
mutations	O
had	O
negative	O
impacts	O
on	O
hDPP4	O
receptor	B-FUNC
binding	I-FUNC
and	O
viral	O
fitness	O
.	O

Entry	O
of	O
MERS	O
-	O
CoV	O
into	O
target	O
cells	O
depends	O
on	O
binding	B-FUNC
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
envelope	O
spike	O
glycoprotein	O
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
promotes	O
virus	O
fitness	O
and	O
pathogenesis	O
.	O

Reduction	O
of	O
IL	O
-	O
1	O
was	O
accompanied	O
by	O
diminished	O
amounts	O
of	O
TNF	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
the	O
absence	O
of	O
E	O
protein	O
ion	O
conductivity	O
.	O

We	O
identified	O
three	O
human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
),	O
m336	O
,	O
m337	O
,	O
and	O
m338	O
,	O
targeting	O
the	O
receptor	O
(	O
CD26	O
/	O
DPP4	O
)	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
from	O
a	O
very	O
large	O
nave	O
-	O
antibody	B-FUNC
library	O
(	O
containing	O
	O
10	O
(	O
11	O
)	O
antibodies	O
).	O

They	O
bound	O
with	O
high	O
affinity	O
:	O
equilibrium	O
dissociation	O
constants	O
for	O
the	O
three	O
MAbs	O
were	O
equal	O
to	O
4	O
.	O
2	O
,	O
9	O
.	O
3	O
,	O
and	O
15	O
nM	O
,	O
respectively	O
,	O
as	O
measured	O
by	O
Biacore	O
for	O
Fabs	O
binding	B-FUNC
to	O
RBD	O
.	O

The	O
antibodies	O
bound	O
to	O
overlapping	O
epitopes	O
that	O
overlap	O
the	O
receptor	B-FUNC
binding	I-FUNC
site	O
on	O
the	O
RBD	O
as	O
suggested	O
by	O
competition	O
experiments	O
and	O
further	O
supported	O
by	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
RBD	O
and	O
a	O
docking	O
model	O
of	O
the	O
m336	O
-	O
RBD	O
complex	O
.	O

The	O
highest	O
-	O
affinity	O
MAb	O
,	O
m336	O
,	O
neutralized	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
with	O
exceptional	O
potency	O
,	O
50	O
%	O
neutralization	O
at	O
0	O
.	O
005	O
and	O
0	O
.	O
07	O
g	O
/	O
ml	O
,	O
respectively	O
,	O
likely	O
by	O
competing	O
with	O
DPP4	O
for	O
binding	B-FUNC
to	O
the	O
S	O
glycoprotein	O
.	O

The	O
rapid	O
identification	O
(	O
within	O
several	O
weeks	O
)	O
of	O
potent	O
MAbs	O
suggests	O
a	O
possibility	O
to	O
use	O
the	O
new	O
large	O
antibody	B-FUNC
library	O
and	O
related	O
methodology	O
for	O
a	O
quick	O
response	O
to	O
the	O
public	O
threat	O
resulting	O
from	O
emerging	O
coronaviruses	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
human	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
from	O
a	O
large	O
nonimmune	O
antibody	B-FUNC
library	O
that	O
target	O
MERS	O
-	O
CoV	O
.	O
One	O
of	O
the	O
antibodies	O
,	O
m336	O
,	O
neutralized	O
the	O
virus	O
with	O
exceptional	O
potency	O
.	O

ABSTRACT	O
:	O
Peptides	O
that	O
bind	B-FUNC
poorly	O
to	O
MHC	O
class	O
I	O
molecules	O
often	O
elicit	O
low	O
-	O
functional	O
avidity	O
T	O
cell	O
responses	O
.	O

Peptide	O
modification	O
by	O
altering	O
the	O
anchor	O
residue	O
facilitates	O
increased	O
binding	B-FUNC
affinity	O
and	O
may	O
elicit	O
T	O
cells	O
with	O
increased	O
functional	O
avidity	O
toward	O
the	O
native	O
epitope	O
"("""	O
heteroclitic	O
""")."	O

This	O
augmented	O
MHC	O
binding	B-FUNC
is	O
likely	O
to	O
increase	O
the	O
half	O
-	O
life	O
and	O
surface	O
density	O
of	O
the	O
heteroclitic	O
complex	O
,	O
but	O
precisely	O
how	O
this	O
enhanced	O
T	O
cell	O
response	O
occurs	O
in	O
vivo	O
is	O
not	O
known	O
.	O

Paired	O
specimens	O
of	O
nasopharyngeal	O
swabs	O
and	O
sputum	O
were	O
obtained	O
from	O
154	O
subjects	O
,	O
and	O
RNA	O
was	O
extracted	O
and	O
tested	O
for	O
16	O
different	O
respiratory	O
viruses	O
using	O
the	O
Anyplex	O
II	O
RV16	O
Detection	O
kit	B-FUNC
(	O
Seegene	O
,	O
Seoul	O
,	O
Korea	O
).	O

To	O
address	O
this	O
deficiency	O
,	O
high	O
-	O
throughput	O
real	O
time	O
RT	O
-	O
PCR	O
TaqMan	O
assays	O
were	O
developed	O
to	O
measure	O
the	O
expression	O
of	O
fifteen	O
immune	O
mediators	O
associated	O
with	O
the	O
innate	O
and	O
adaptive	O
immune	O
responses	O
(	O
IFN	O
,	O
IFN	O
,	O
IFN	O
,	O
IL1	O
,	O
IL1	O
,	O
IL2	O
,	O
IL4	O
,	O
IL6	O
,	O
IL8	O
,	O
IL10	O
,	O
IL12p40	O
,	O
IL17	O
,	O
Granzyme	O
A	O
,	O
MCP1	O
,	O
TNF	O
),	O
as	O
well	O
as	O
four	O
endogenous	O
housekeeping	O
genes	O
(	O
ATF4	O
,	O
HPRT	B-FUNC
,	O
GAPDH	O
,	O
L32	O
).	O

TITLE	O
:	O
Inhibition	O
of	O
foamy	O
virus	O
reverse	O
transcriptase	B-FUNC
by	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
RNase	O
H	O
inhibitors	O
.	O

NMR	O
titration	O
experiments	O
with	O
the	O
PFV	O
RNase	O
H	O
domain	O
and	O
the	O
RHI	O
RDS1643	O
(	O
6	O
-[	O
1	O
-(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
-	O
1H	O
-	O
pyrrol	O
-	O
2	O
-	O
yl	O
)]-	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
hexenoic	O
acid	O
ethyl	O
ester	O
)	O
were	O
performed	O
to	O
determine	O
its	O
binding	B-FUNC
site	O
.	O

Based	O
on	O
these	O
results	O
and	O
previous	O
data	O
,	O
in	O
silico	O
docking	O
analysis	O
showed	O
a	O
putative	O
RDS1643	O
binding	B-FUNC
region	O
that	O
reaches	O
into	O
the	O
PFV	O
RNase	O
H	O
active	O
site	O
.	O

Structural	O
overlays	O
were	O
performed	O
with	O
HIV	O
-	O
1	O
and	O
PFV	O
RNase	O
H	O
to	O
propose	O
the	O
RDS1643	O
binding	B-FUNC
site	O
in	O
HIV	O
-	O
1	O
RNase	O
H	O
.	O
Our	O
results	O
suggest	O
that	O
this	O
approach	O
can	O
be	O
used	O
to	O
establish	O
PFV	O
RNase	O
H	O
as	O
a	O
model	O
system	O
for	O
HIV	O
-	O
1	O
RNase	O
H	O
in	O
order	O
to	O
identify	O
putative	O
inhibitor	O
binding	B-FUNC
sites	O
in	O
HIV	O
-	O
1	O
RNase	O
H	O
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	B-FUNC
activity	I-FUNC
on	O
infection	O
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	O
-	O
independent	O
cell	O
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

We	O
demonstrate	O
that	O
trypsin	O
acts	O
on	O
the	O
wtPEDV	O
spike	O
protein	O
after	O
receptor	B-FUNC
binding	I-FUNC
.	O

In	O
the	O
presence	O
of	O
vertebral	O
fracture	O
,	O
treatment	O
options	O
listed	O
in	O
the	O
literature	O
are	O
conservative	O
(	O
rest	B-FUNC
,	O
symptomatic	O
therapy	O
,	O
orthosis	O
),	O
because	O
of	O
the	O
high	O
incidence	O
of	O
intra	O
-	O
and	O
perioperative	O
complications	O
(	O
acute	O
respiratory	O
syndrome	O
,	O
vaso	O
-	O
occlusive	O
crisis	O
),	O
in	O
addition	O
to	O
the	O
increased	O
rate	O
of	O
implant	O
failure	O
.	O

Prompt	O
diagnosis	O
,	O
multidisciplinary	O
management	O
,	O
including	O
aggressive	O
resuscitation	O
,	O
cardiorespiratory	O
support	O
,	O
intravenous	O
immunoglobulin	B-FUNC
therapy	O
,	O
and	O
daily	O
wound	O
care	O
resulted	O
in	O
a	O
positive	O
outcome	O
despite	O
a	O
predicted	O
mortality	O
greater	O
than	O
60	O
%.	O

A	O
strong	O
neutralizing	O
antibody	B-FUNC
response	O
generated	O
against	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	O
-	O
CoV	O
is	O
completely	O
protective	O
in	O
the	O
susceptible	O
host	O
.	O

Employing	O
models	O
of	O
the	O
human	O
airway	O
,	O
transcriptomics	O
and	O
proteomics	O
datasets	O
were	O
used	O
to	O
compare	O
ISG	O
response	O
patterns	O
following	O
highly	O
pathogenic	O
H5N1	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
)	O
A	O
virus	O
,	O
2009	O
pandemic	O
H1N1	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
.	O

ABSTRACT	O
:	O
A	O
small	O
library	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
was	O
designed	O
and	O
synthesized	O
as	O
dual	O
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
DNA	O
polymerase	O
(	O
DP	O
)	O
and	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
associated	O
functions	O
.	O

Interestingly	O
,	O
mutations	O
in	O
the	O
non	O
-	O
nucleoside	O
RT	O
inhibitor	O
binding	B-FUNC
pocket	O
strongly	O
affected	O
RNase	O
H	O
inhibition	O
by	O
the	O
propenone	O
derivatives	O
without	O
decreasing	O
their	O
capacity	O
to	O
inhibit	O
DP	O
activity	O
,	O
which	O
suggests	O
long	O
-	O
range	O
RT	O
structural	O
effects	O
.	O

Biochemical	O
and	O
computational	O
studies	O
indicated	O
that	O
the	O
propenone	O
derivatives	O
bind	B-FUNC
two	O
different	O
interdependent	O
allosteric	O
pockets	O
.	O

PLUS	O
was	O
performed	O
daily	O
to	O
monitor	O
the	O
disease	O
'	O
s	O
progression	O
and	O
response	O
to	O
treatment	O
during	O
lung	O
rest	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
zoonotic	O
diseases	O
such	O
as	O
Highly	O
Pathogenic	O
Avian	O
Influenza	O
(	O
HPAI	B-FUNC
)	O
and	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
have	O
contributed	O
to	O
dominant	O
Global	O
Health	O
narratives	O
around	O
health	O
securitisation	O
and	O
pandemic	O
preparedness	O
,	O
calling	O
for	O
greater	O
co	O
-	O
operation	O
between	O
the	O
health	O
,	O
veterinary	O
and	O
environmental	O
sectors	O
in	O
the	O
ever	O
-	O
evolving	O
One	O
Health	O
movement	O
.	O

Each	O
case	O
examines	O
a	O
significant	O
aspect	O
of	O
One	O
Health	O
operationalisation	O
,	O
framed	O
around	O
the	O
control	O
of	O
both	O
emerging	O
and	O
Neglected	O
Zoonotic	O
Diseases	O
including	O
HPAI	B-FUNC
,	O
Human	O
African	O
Trypanosomiasis	O
and	O
rabies	O
.	O

Multiplex	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
assays	O
for	O
detection	O
of	O
multiple	O
viruses	O
are	O
being	O
used	O
increasingly	O
in	O
clinical	O
settings	O
.	O

TITLE	O
:	O
Structural	O
Basis	O
for	O
the	O
Ubiquitin	B-FUNC
-	O
Linkage	O
Specificity	O
and	O
deISGylating	O
activity	O
of	O
SARS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
.	O

We	O
present	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
PLpro	O
in	O
complex	O
with	O
ubiquitin	B-FUNC
-	O
aldehyde	O
and	O
model	O
the	O
interaction	O
of	O
PLpro	O
with	O
other	O
ubiquitin	B-FUNC
-	O
chain	O
and	O
ISG15	O
substrates	O
.	O

We	O
propose	O
that	O
PLpro	O
'	O
s	O
higher	O
affinity	O
for	O
K48	O
-	O
linked	O
ubiquitin	B-FUNC
chains	O
and	O
ISG15	O
stems	O
from	O
a	O
bivalent	O
mechanism	O
of	O
binding	B-FUNC
,	O
where	O
two	O
ubiquitin	B-FUNC
-	O
like	O
domains	O
prefer	O
to	O
bind	B-FUNC
in	O
the	O
palm	O
domain	O
of	O
PLpro	O
with	O
the	O
most	O
distal	O
ubiquitin	B-FUNC
domain	O
interacting	O
with	O
a	O
""""	O
ridge	O
""""	O
region	O
of	O
the	O
thumb	O
domain	O
.	O

Mutagenesis	O
of	O
residues	O
within	O
this	O
ridge	O
region	O
revealed	O
that	O
these	O
mutants	O
retain	O
viral	O
protease	B-FUNC
activity	I-FUNC
and	O
the	O
ability	O
to	O
catalyze	O
hydrolysis	O
of	O
mono	O
-	O
ubiquitin	B-FUNC
.	O

This	O
identification	O
of	O
key	O
and	O
unique	O
sites	O
in	O
PLpro	O
required	O
for	O
recognition	O
and	O
processing	O
of	O
diubiquitin	O
and	O
ISG15	O
versus	O
mono	O
-	O
ubiquitin	B-FUNC
and	O
protease	B-FUNC
activity	I-FUNC
provides	O
new	O
insight	O
into	O
ubiquitin	B-FUNC
-	O
chain	O
and	O
ISG15	O
recognition	O
and	O
highlights	O
a	O
role	O
for	O
PLpro	O
DUB	O
and	O
deISGylase	O
activity	O
in	O
antagonism	O
of	O
the	O
innate	O
immune	O
response	O
.	O

The	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
)	O
H5N1	O
,	O
avian	O
influenza	O
H7N9	O
,	O
and	O
severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	O
(	O
SFTS	O
),	O
and	O
the	O
re	O
-	O
emergence	O
of	O
rabies	O
,	O
brucellosis	O
,	O
and	O
other	O
zoonoses	O
have	O
had	O
a	O
significant	O
effect	O
on	O
the	O
national	O
economy	O
and	O
public	O
health	O
in	O
China	O
,	O
and	O
have	O
affected	O
other	O
countries	O
.	O

A	O
mouse	O
RPE	O
/	O
choroid	O
DNA	O
expression	O
library	O
was	O
screened	O
using	O
sera	B-FUNC
from	O
virus	O
infected	O
BALB	O
/	O
c	O
mice	O
.	O

	O
-	O
Fodrin	O
protein	O
was	O
used	O
for	O
further	O
analysis	O
and	O
western	O
blot	O
reactivity	O
was	O
seen	O
only	O
in	O
sera	B-FUNC
from	O
virus	O
infected	O
BALB	O
/	O
c	O
mice	O
.	O

These	O
studies	O
clearly	O
identified	O
both	O
antibody	B-FUNC
and	O
CD4	O
T	O
cell	O
reactivities	O
to	O
	O
-	O
fodrin	O
in	O
sera	B-FUNC
from	O
virus	O
infected	O
,	O
retinal	O
degenerative	O
susceptible	O
BALB	O
/	O
c	O
mice	O
.	O

The	O
phase	O
of	O
T	O
cell	O
-	O
dependent	O
,	O
antibody	B-FUNC
-	O
independent	O
control	O
of	O
infectious	O
virus	O
was	O
associated	O
with	O
a	O
similar	O
recruitment	O
of	O
naive	O
/	O
early	O
-	O
activated	O
IgD	O
(+)	O
IgM	O
(+)	O
B	O
cells	O
into	O
both	O
the	O
brain	O
and	O
spinal	O
cord	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
nucleocapsid	O
protein	O
antagonizes	O
beta	O
interferon	O
production	O
by	O
sequestering	O
the	O
interaction	O
between	O
IRF3	O
and	O
TBK1	B-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PEDV	O
-	O
encoded	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
also	O
inhibits	O
Sendai	O
virus	O
-	O
induced	O
IFN	O
-	O
	O
production	O
,	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
,	O
and	O
activation	O
of	O
the	O
transcription	O
factors	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
and	O
NF	O
-	O
B	O
.	O
We	O
also	O
found	O
that	O
N	O
protein	O
significantly	O
impedes	O
the	O
activation	O
of	O
the	O
IFN	O
-	O
	O
promoter	O
stimulated	O
by	O
TBK1	B-FUNC
or	O
its	O
upstream	O
molecules	O
(	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
IPS	O
-	O
1	O
,	O
and	O
TRAF3	O
)	O
but	O
does	O
not	O
counteract	O
its	O
activation	O
by	O
IRF3	O
.	O

A	O
detailed	O
analysis	O
revealed	O
that	O
the	O
PEDV	O
N	O
protein	O
targets	O
TBK1	B-FUNC
by	O
direct	O
interaction	O
and	O
that	O
this	O
binding	B-FUNC
sequesters	O
the	O
association	O
between	O
TBK1	B-FUNC
and	O
IRF3	O
,	O
which	O
in	O
turn	O
inhibits	O
both	O
IRF3	O
activation	O
and	O
type	O
I	O
IFN	O
production	O
.	O

Knowing	O
that	O
NA	O
treatment	O
of	O
coronaviruses	O
can	O
unmask	O
viral	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
,	O
replication	O
of	O
untreated	O
and	O
NA	O
-	O
treated	O
viruses	O
was	O
compared	O
,	O
showing	O
that	O
NA	O
treatment	O
of	O
the	O
virus	O
enhanced	O
infectivity	O
in	O
untreated	O
cells	O
,	O
but	O
was	O
detrimental	O
in	O
NA	O
-	O
treated	O
cells	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrated	O
that	O
FECV	O
had	O
a	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
capacity	O
,	O
which	O
was	O
partially	O
masked	O
by	O
virus	O
-	O
associated	O
sialic	O
acids	O
,	O
and	O
that	O
attachment	O
to	O
sialylated	O
compounds	O
could	O
facilitate	O
enterocyte	O
infections	O
.	O

However	O
,	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
was	O
not	O
a	O
prerequisite	O
for	O
the	O
initiation	O
of	O
infection	O
and	O
virus	O
-	O
receptor	O
engagement	O
was	O
even	O
more	O
efficient	O
after	O
desialylation	O
of	O
cells	O
,	O
indicating	O
that	O
FECV	O
requires	O
sialidases	O
for	O
efficient	O
enterocyte	O
infections	O
.	O

Sodium	O
enters	O
through	O
apical	O
channels	O
,	O
primarily	O
the	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
,	O
and	O
is	O
pumped	O
into	O
the	O
lung	O
interstitium	O
by	O
basolaterally	O
located	O
Na	O
/	O
K	O
-	O
ATPase	O
,	O
thus	O
creating	O
a	O
local	O
osmotic	O
gradient	O
to	O
reabsorb	O
the	O
water	O
fraction	O
of	O
the	O
edema	O
fluid	O
from	O
the	O
airspaces	O
of	O
the	O
lungs	O
.	O

TITLE	O
:	O
Serum	O
activin	B-FUNC
A	O
and	O
B	O
,	O
and	O
follistatin	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
.	O

Interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
which	O
in	O
experimental	O
studies	O
increases	O
after	O
activin	B-FUNC
A	O
release	O
,	O
is	O
known	O
to	O
be	O
related	O
to	O
the	O
severity	O
of	O
H1N1	O
infection	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
levels	O
of	O
activin	B-FUNC
A	O
,	O
activin	B-FUNC
B	O
,	O
FS	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
their	O
association	O
with	O
the	O
severity	O
of	O
respiratory	O
failure	O
in	O
critically	O
ill	O
H1N1	O
patients	O
.	O

Clinical	O
information	O
was	O
recorded	O
during	O
ICU	O
treatment	O
,	O
and	O
serum	O
activin	B-FUNC
A	O
,	O
activin	B-FUNC
B	O
,	O
FS	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
measured	O
at	O
admission	O
to	O
ICU	O
and	O
on	O
days	O
2	O
and	O
7	O
.	O

At	O
the	O
time	O
of	O
admission	O
to	O
intensive	O
care	O
unit	O
,	O
elevated	O
serum	O
levels	O
above	O
the	O
normal	O
range	O
for	O
respective	O
age	O
group	O
and	O
sex	O
were	O
observed	O
in	O
44	O
%	O
for	O
activin	B-FUNC
A	O
,	O
57	O
%	O
for	O
activin	B-FUNC
B	O
,	O
and	O
39	O
%	O
for	O
FS	O
.	O

In	O
13	O
of	O
the	O
29	O
patients	O
,	O
serial	O
samples	O
at	O
all	O
time	O
points	O
were	O
available	O
and	O
in	O
these	O
the	O
highest	O
activin	B-FUNC
A	O
,	O
activin	B-FUNC
B	O
and	O
FS	O
were	O
above	O
the	O
normal	O
range	O
in	O
85	O
%,	O
100	O
%	O
and	O
46	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

No	O
difference	O
in	O
baseline	O
or	O
highest	O
activin	B-FUNC
A	O
or	O
activin	B-FUNC
B	O
was	O
found	O
in	O
patients	O
with	O
or	O
without	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
ARDS	O
(	O
P	O
>	O
0	O
.	O
05	O
for	O
all	O
).	O

Peak	O
activin	B-FUNC
A	O
and	O
activin	B-FUNC
A	O
/	O
FS	O
were	O
associated	O
with	O
ventilatory	O
support	O
free	O
-	O
days	O
,	O
severity	O
of	O
acute	O
illness	O
and	O
length	O
of	O
ICU	O
stay	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
).	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
dependent	O
infection	O
of	O
human	O
macrophages	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

These	O
observations	O
prompted	O
us	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
and	O
responses	O
to	O
antibody	B-FUNC
-	O
mediated	O
infection	O
in	O
human	O
macrophages	O
.	O

Fluorescence	O
microscopy	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
utilized	O
to	O
assess	O
occurrence	O
and	O
consequences	O
of	O
infection	O
.	O

To	O
gain	O
insight	O
into	O
the	O
underlying	O
molecular	O
mechanism	O
,	O
we	O
performed	O
mutational	O
analysis	O
with	O
a	O
series	O
of	O
truncated	O
and	O
chimeric	O
constructs	O
of	O
fragment	O
crystallizable	O
	O
receptors	O
(	O
FcR	O
),	O
which	O
bind	B-FUNC
antibody	B-FUNC
-	O
coated	O
pathogens	O
.	O

These	O
results	O
demonstrate	O
that	O
human	O
macrophages	O
can	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
as	O
a	O
result	O
of	O
IgG	O
-	O
mediated	O
ADE	O
and	O
indicate	O
that	O
this	O
infection	O
route	O
requires	O
signaling	O
pathways	O
activated	O
downstream	O
of	O
binding	B-FUNC
to	O
FcRII	O
receptors	O
.	O

Mesenchymal	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
;	O
'	O
adult	O
stem	O
cells	O
')	O
could	O
represent	O
a	O
promising	O
new	O
therapy	O
for	O
this	O
syndrome	O
,	O
since	O
preclinical	O
evidence	O
suggests	O
that	O
MSCs	B-FUNC
may	O
ameliorate	O
lung	O
injury	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
limits	O
central	O
nervous	O
system	O
viral	O
clearance	O
by	O
promoting	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
enhances	O
demyelination	O
.	O

ABSTRACT	O
:	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
is	O
a	O
pleiotropic	O
member	O
of	O
the	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
cytokine	O
family	O
composed	O
of	O
the	O
IL	O
-	O
27p28	O
and	O
the	O
EBV	O
-	O
induced	O
gene	O
3	O
.	O

IL	B-FUNC
-	I-FUNC
27	I-FUNC
and	O
its	O
receptor	O
mRNA	O
are	O
both	O
upregulated	O
in	O
the	O
CNS	O
during	O
acute	O
encephalomyelitis	O
induced	O
by	O
the	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
and	O
sustained	O
during	O
viral	O
persistence	O
.	O

Contributions	O
of	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
to	O
viral	O
pathogenesis	O
were	O
evaluated	O
by	O
infection	O
of	O
IL	O
-	O
27R	O
-	O
chain	O
-	O
deficient	O
(	O
IL	O
-	O
27R	O
(-/-))	O
mice	O
.	O

The	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
signaling	O
accelerated	O
virus	O
control	O
within	O
the	O
CNS	O
associated	O
with	O
increased	O
IFN	O
-	O
	O
secreting	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
.	O

Abrogation	O
of	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
signaling	O
did	O
not	O
affect	O
virus	O
-	O
specific	O
CD8	O
+	O
T	O
cell	O
-	O
mediated	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
or	O
cytolytic	O
activity	O
or	O
Foxp3	O
+	O
regulatory	O
T	O
cell	O
populations	O
.	O

However	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
by	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	O
was	O
reduced	O
significantly	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
in	O
contrast	O
to	O
viral	O
infections	O
at	O
other	O
sites	O
,	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
does	O
not	O
play	O
a	O
proinflammatory	O
role	O
during	O
JHMV	O
-	O
induced	O
encephalomyelitis	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
its	O
protective	O
role	O
in	O
limiting	O
CNS	O
autoimmunity	O
and	O
preventing	O
immunopathology	O
,	O
these	O
data	O
define	O
a	O
detrimental	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
27	I-FUNC
in	O
promoting	O
demyelination	O
by	O
delaying	O
viral	O
control	O
.	O

Cultured	O
NPCs	O
derived	O
from	O
C57BL	O
/	O
6	O
(	O
H	O
-	O
2	O
(	O
b	O
)	O
)	O
mice	O
express	O
the	O
NKG2D	O
ligand	B-FUNC
retinoic	O
acid	O
early	O
precursor	O
transcript	O
(	O
RAE	O
)-	O
1	O
but	O
expression	O
was	O
dramatically	O
reduced	O
upon	O
differentiation	O
into	O
either	O
glia	O
or	O
neurons	O
.	O

Transplantation	O
of	O
C57BL	O
/	O
6	O
-	O
derived	O
NPCs	O
into	O
JHMV	O
-	O
infected	O
BALB	O
/	O
c	O
(	O
H	O
-	O
2	O
(	O
d	O
)	O
)	O
mice	O
resulted	O
in	O
infiltration	O
of	O
NKG2D	O
(+)	O
CD49b	O
(+)	O
NK	O
cells	O
and	O
treatment	O
with	O
blocking	O
antibody	B-FUNC
specific	O
for	O
NKG2D	O
increased	O
survival	O
of	O
allogeneic	O
NPCs	O
.	O

Recently	O
,	O
the	O
MERS	O
-	O
CoV	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
was	O
identified	O
and	O
the	O
specific	O
interaction	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
and	O
DPP4	O
was	O
determined	O
by	O
crystallography	O
.	O

Modeling	O
of	O
the	O
DPP4	O
and	O
MERS	O
-	O
CoV	O
RBD	O
interaction	O
predicted	O
the	O
ability	O
of	O
MERS	O
-	O
CoV	O
to	O
bind	B-FUNC
the	O
DPP4s	O
of	O
camel	O
,	O
goat	O
,	O
cow	O
,	O
and	O
sheep	O
.	O

Of	O
these	O
,	O
59	O
were	O
influenced	O
by	O
strain	O
-	O
specific	O
mutations	O
within	O
2	O
base	B-FUNC
pairs	I-FUNC
of	O
key	O
intron	O
-	O
exon	O
boundaries	O
,	O
suggesting	O
cis	O
-	O
regulated	O
expression	O
.	O

The	O
MHV	O
spike	O
protein	O
(	O
S	O
)	O
is	O
a	O
major	O
virulence	O
determinant	O
which	O
in	O
addition	O
to	O
binding	B-FUNC
to	O
cellular	O
receptors	O
to	O
mediate	O
cell	O
entry	O
and	O
facilitate	O
virus	O
spread	O
to	O
adjacent	O
cells	O
by	O
cell	O
-	O
cell	O
fusion	O
,	O
also	O
is	O
a	O
molecular	O
mimic	O
of	O
the	O
FcRII	O
receptor	O
.	O

We	O
analysed	O
infectivity	O
and	O
binding	B-FUNC
properties	O
of	O
the	O
QX	O
strain	O
and	O
compared	O
them	O
with	O
those	O
of	O
the	O
nephropathogenic	O
strain	O
B1648	O
.	O

Binding	B-FUNC
tests	O
with	O
isolated	O
primary	O
oviduct	O
epithelial	O
cells	O
and	O
soluble	O
S1	O
proteins	O
revealed	O
that	O
S1	O
proteins	O
of	O
two	O
IBV	O
strains	O
bound	O
with	O
the	O
same	O
efficiency	O
to	O
oviduct	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
suppressor	O
of	O
cytokine	O
signaling	O
-	O
3	O
(	O
SOCS3	O
)	O
has	O
been	O
shown	O
to	O
be	O
an	O
inducible	O
endogenous	O
negative	O
regulator	O
of	O
Janus	O
kinase	O
/	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
JAK	B-FUNC
/	O
STAT	O
)	O
pathway	O
which	O
is	O
relevant	O
in	O
inflammatory	O
response	O
,	O
while	O
its	O
functions	O
in	O
acute	O
liver	O
failure	O
and	O
HBV	O
-	O
induced	O
acute	O
-	O
on	O
-	O
chronic	O
liver	O
failure	O
(	O
HBV	O
-	O
ACLF	O
)	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

There	O
was	O
a	O
close	O
correlation	O
between	O
hepatic	O
SOCS3	O
level	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
the	O
severity	O
of	O
liver	O
injury	O
defined	O
by	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
levels	O
,	O
respectively	O
.	O

The	O
downstream	O
pseudoknot	O
in	O
the	O
mRNA	O
impairs	O
the	O
closing	O
movement	O
of	O
the	O
30S	O
subunit	O
head	O
,	O
the	O
dissociation	O
of	O
EF	O
-	O
G	O
,	O
and	O
the	O
release	O
of	O
tRNA	B-FUNC
from	O
the	O
ribosome	O
.	O

The	O
collectins	O
surfactant	O
protein	O
(	O
SP	O
)-	O
A1	O
,	O
-	O
A2	O
,	O
and	O
-	O
D	O
and	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
neutralize	O
IAV	O
infectivity	O
,	O
although	O
only	O
SP	O
-	O
A2	O
can	O
establish	O
an	O
efficient	O
neutralization	O
of	O
poorly	O
glycosylated	O
pandemic	O
IAV	O
strains	O
.	O

Antiviral	O
therapy	O
in	O
the	O
early	O
stage	O
and	O
sufficient	O
supportive	O
management	O
are	O
key	O
to	O
the	O
treatment	O
of	O
infections	O
with	O
this	O
virus	O
,	O
and	O
proper	O
doses	O
of	O
methylprednisolone	O
and	O
intravenous	O
immunoglobulin	B-FUNC
are	O
recommended	O
.	O

Preexisting	O
neutralizing	O
antibody	B-FUNC
did	O
not	O
appear	O
to	O
protect	O
against	O
infection	O
.	O

TITLE	O
:	O
Utility	O
of	O
feline	O
coronavirus	O
antibody	B-FUNC
tests	O
.	O

We	O
compared	O
four	O
indirect	O
immunofluorescent	O
antibody	B-FUNC
tests	O
(	O
IFAT	O
),	O
one	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
(	O
FCoV	O
Immunocomb	O
;	O
Biogal	O
)	O
and	O
three	O
rapid	O
immunochromatographic	O
(	O
RIM	O
)	O
tests	O
against	O
a	O
panel	O
of	O
samples	O
designated	O
by	O
consensus	O
as	O
positive	O
or	O
negative	O
.	O

The	O
most	O
appropriate	O
FCoV	O
antibody	B-FUNC
test	O
to	O
use	O
depends	O
on	O
the	O
reason	O
for	O
testing	O
:	O
in	O
excluding	O
a	O
diagnosis	O
of	O
FIP	O
,	O
sensitivity	O
,	O
specificity	O
,	O
small	O
sample	O
quantity	O
,	O
rapidity	O
and	O
ability	O
to	O
work	O
in	O
the	O
presence	O
of	O
virus	O
all	O
matter	O
.	O

The	O
upregulated	O
genes	O
were	O
mainly	O
involved	O
in	O
immune	O
system	O
processes	O
,	O
antigen	O
processing	O
and	O
presentation	O
,	O
the	O
Jak	B-FUNC
-	O
STAT	O
signalling	O
pathway	O
,	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
signalling	O
pathway	O
,	O
Toll	O
-	O
like	O
receptor	O
signalling	O
and	O
apoptosis	O
-	O
related	O
proteases	O
.	O

TITLE	O
:	O
Murine	O
AKAP7	O
has	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
domain	O
that	O
can	O
complement	O
an	O
inactive	O
murine	O
coronavirus	O
ns2	O
gene	O
.	O

ABSTRACT	O
:	O
Viral	O
2	O
',	O
5	O
'-	O
phosphodiesterases	O
(	O
2	O
',	O
5	O
'-	O
PDEs	O
)	O
help	O
disparate	O
RNA	O
viruses	O
evade	O
the	O
antiviral	O
activity	O
of	O
interferon	O
(	O
IFN	O
)	O
by	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	O
L	O
.	O
A	O
kinase	O
anchoring	B-FUNC
proteins	O
(	O
AKAPs	O
)	O
bind	B-FUNC
the	O
regulatory	O
subunits	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	B-FUNC
)	O
to	O
localize	O
and	O
organize	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
signaling	O
during	O
diverse	O
physiological	O
processes	O
.	O

To	O
determine	O
whether	O
AKAP7	O
could	O
substitute	O
for	O
a	O
viral	O
2	O
',	O
5	O
'-	O
PDE	B-FUNC
,	O
we	O
inserted	O
AKAP7	O
cDNA	O
into	O
an	O
MHV	O
genome	O
with	O
an	O
inactivated	O
ns2	O
gene	O
.	O

Interestingly	O
,	O
the	O
AKAP7	O
PDE	B-FUNC
domain	O
and	O
N	O
-	O
terminally	O
deleted	O
AKAP7	O
were	O
present	O
in	O
the	O
cytoplasm	O
(	O
the	O
site	O
of	O
MHV	O
replication	O
),	O
whereas	O
full	O
-	O
length	O
AKAP7	O
was	O
observed	O
only	O
in	O
nuclei	O
.	O

We	O
suggest	O
the	O
possibility	O
that	O
viral	O
acquisition	O
of	O
the	O
host	O
AKAP7	O
PDE	B-FUNC
domain	O
might	O
have	O
occurred	O
during	O
evolution	O
,	O
allowing	O
diverse	O
RNA	O
viruses	O
to	O
antagonize	O
the	O
RNase	O
L	O
pathway	O
.	O

Here	O
we	O
report	O
that	O
a	O
cellular	O
protein	O
,	O
AKAP7	O
,	O
has	O
an	O
analogous	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
(	O
2	O
',	O
5	O
'-	O
PDE	B-FUNC
)	O
domain	O
that	O
is	O
able	O
to	O
restore	O
the	O
growth	O
of	O
chimeric	O
MHV	O
expressing	O
inactive	O
ns2	O
.	O

The	O
proviral	O
effect	O
requires	O
cytoplasmic	O
localization	O
of	O
the	O
AKAP7	O
PDE	B-FUNC
domain	O
.	O

Introduction	O
of	O
a	O
side	O
-	O
chain	O
capable	O
of	O
oxyanion	O
stabilization	O
through	O
the	O
Leu106Trp	O
mutation	O
greatly	O
enhances	O
the	O
in	O
vitro	O
catalytic	B-FUNC
activity	I-FUNC
of	O
the	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
).	O

Notably	O
,	O
treatment	O
of	O
mice	O
with	O
L	O
.	O
casei	O
expressing	O
20MT	O
and	O
40MT	O
enhanced	O
the	O
anti	O
-	O
TGEV	O
antibody	B-FUNC
immune	O
responses	O
of	O
both	O
the	O
humoral	O
and	O
mucosal	O
immune	O
systems	O
.	O

These	O
molecules	O
inhibit	O
not	O
only	O
HIV	O
integrase	O
catalytic	B-FUNC
activity	I-FUNC
,	O
but	O
they	O
also	O
interfere	O
with	O
the	O
function	O
of	O
the	O
RNase	O
H	O
component	O
of	O
the	O
HIV	O
reverse	O
transcriptase	B-FUNC
.	O

Pre	O
-	O
and	O
post	O
-	O
treatment	O
lymphopenia	O
and	O
pre	O
-	O
treatment	O
serum	O
albumin	O
should	O
be	O
considered	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
FN	O
when	O
selecting	O
patients	O
with	O
prostate	O
cancer	O
for	O
docetaxel	O
therapy	O
,	O
and	O
when	O
considering	O
dose	O
modifications	O
,	O
and	O
the	O
prophylactic	O
use	O
of	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
.	O

This	O
report	O
highlights	O
the	O
benefits	O
of	O
combining	O
MAT	B-FUNC
and	O
PCR	O
methods	O
in	O
early	O
diagnosis	O
of	O
leptospirosis	O
.	O

Since	O
the	O
S1	O
domain	O
is	O
involved	O
in	O
a	O
specific	O
high	O
-	O
affinity	O
interaction	O
with	O
the	O
cellular	O
receptor	O
and	O
induction	O
of	O
neutralizing	O
antibody	B-FUNC
in	O
the	O
natural	O
host	O
,	O
it	O
is	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
effective	O
vaccines	O
against	O
PEDV	O
.	O

The	O
purified	O
recombinant	O
S1	O
protein	O
was	O
found	O
to	O
mediate	O
highly	O
potent	O
antibody	B-FUNC
responses	O
in	O
immunized	O
rabbits	O
.	O

Interestingly	O
,	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
was	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
during	O
PEDV	O
infection	O
,	O
and	O
AIF	O
relocalization	O
was	O
completely	O
abrogated	O
by	O
the	O
presence	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
cyclophilin	B-FUNC
D	O
(	O
CypD	O
)	O
that	O
is	O
an	O
essential	O
component	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
)	O
complex	O
.	O

Our	O
data	O
showed	O
significant	O
differential	O
up	O
-	O
regulation	O
of	O
IFN	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
CXCLi2	O
)	O
and	O
MIP	O
-	O
1	O
genes	O
and	O
suppression	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
gene	O
expression	O
being	O
associated	O
with	O
inhibition	O
of	O
IBV	O
replication	O
in	O
lungs	O
tissue	O
retrieved	O
from	O
embryos	O
pre	O
-	O
treated	O
with	O
CpG	O
ODN	O
.	O

Respiratory	O
viruses	O
were	O
investigated	O
from	O
nasopharyngeal	O
swabs	O
of	O
76	O
patients	O
diagnosed	O
with	O
atypical	O
pneumonia	O
and	O
64	O
healthy	O
controls	O
using	O
the	O
CLART	O
Pneumovir	O
(	O
Genomica	O
,	O
Spain	O
)	O
kit	B-FUNC
and	O
from	O
10	O
mL	O
blood	O
samples	O
of	O
the	O
same	O
subjects	O
.	O

Our	O
results	O
showed	O
that	O
the	O
specificity	O
(	O
100	O
%)	O
and	O
the	O
positive	O
predictive	O
value	O
(	O
100	O
%)	O
of	O
the	O
CLART	O
Pneumovir	O
kit	B-FUNC
were	O
high	O
,	O
but	O
its	O
sensitivity	O
(	O
53	O
%),	O
its	O
negative	O
predictive	O
value	O
(	O
64	O
%),	O
and	O
its	O
kappa	O
value	O
(	O
50	O
%)	O
were	O
low	O
.	O

TITLE	O
:	O
Substitution	O
at	O
aspartic	O
acid	O
1128	O
in	O
the	O
SARS	O
coronavirus	O
spike	O
glycoprotein	O
mediates	O
escape	O
from	O
a	O
S2	O
domain	O
-	O
targeting	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
.	O

The	O
SARS	O
-	O
CoV	O
surface	O
Spike	O
(	O
S	O
)	O
protein	O
is	O
a	O
major	O
antigenic	O
determinant	O
in	O
eliciting	O
neutralizing	O
antibody	B-FUNC
production	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
our	O
findings	O
on	O
the	O
characterization	O
of	O
one	O
of	O
these	O
mAbs	O
,	O
known	O
as	O
1A9	O
,	O
which	O
binds	B-FUNC
to	O
the	O
S	O
protein	O
at	O
a	O
novel	O
epitope	O
within	O
the	O
S2	O
subunit	O
at	O
amino	O
acids	O
1111	O
-	O
1130	O
.	O

TITLE	O
:	O
Dissecting	O
virus	O
entry	O
:	O
replication	O
-	O
independent	O
analysis	O
of	O
virus	O
binding	B-FUNC
,	O
internalization	O
,	O
and	O
penetration	O
using	O
minimal	O
complementation	O
of	O
	O
-	O
galactosidase	O
.	O

Enzyme	B-FUNC
activity	I-FUNC
is	O
reconstituted	O
when	O
a	O
small	O
intravirion	O
peptide	O
(	O
	O
-	O
peptide	O
)	O
is	O
complementing	O
the	O
inactive	O
mutant	O
form	O
M15	O
of	O
	O
-	O
galactosidase	O
.	O

The	O
method	O
allows	O
to	O
dissect	O
and	O
to	O
independently	O
detect	O
binding	B-FUNC
,	O
internalization	O
,	O
and	O
fusion	O
of	O
viruses	O
during	O
host	O
cell	O
entry	O
.	O

TITLE	O
:	O
The	O
effectiveness	O
of	O
convalescent	O
plasma	O
and	O
hyperimmune	O
immunoglobulin	B-FUNC
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
infections	O
of	O
viral	O
etiology	O
:	O
a	O
systematic	O
review	O
and	O
exploratory	O
meta	O
-	O
analysis	O
.	O

ABSTRACT	O
:	O
Administration	O
of	O
convalescent	O
plasma	O
,	O
serum	O
,	O
or	O
hyperimmune	O
immunoglobulin	B-FUNC
may	O
be	O
of	O
clinical	O
benefit	O
for	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
infections	O
(	O
SARIs	O
)	O
of	O
viral	O
etiology	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
SARS	O
coronavirus	O
PL	O
(	O
pro	O
)	O
and	O
its	O
complex	O
with	O
ubiquitin	B-FUNC
is	O
also	O
discussed	O
,	O
as	O
is	O
its	O
orthologue	O
from	O
MERS	O
coronavirus	O
.	O

Moreover	O
,	O
increased	O
numbers	O
of	O
both	O
IgA	O
and	O
IgG	O
IBV	O
-	O
specific	O
antibody	B-FUNC
secreting	O
lymphocytes	O
were	O
detected	O
in	O
the	O
spleen	O
after	O
challenge	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
chickens	O
were	O
ocularly	O
vaccinated	O
with	O
a	O
commercially	O
available	O
live	O
attenuated	O
IBV	O
Ark	O
-	O
Delmarva	O
Poultry	O
Industry	O
vaccine	O
strain	O
and	O
both	O
mucosal	O
and	O
systemic	O
antibody	B-FUNC
responses	O
were	O
measured	O
.	O

The	O
highest	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
spot	O
-	O
forming	O
cell	O
(	O
SFC	O
)	O
response	O
was	O
observed	O
in	O
the	O
Harderian	O
glands	O
(	O
HG	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
spleen	O
and	O
conjunctiva	O
-	O
associated	O
lymphoid	O
tissues	O
,	O
while	O
a	O
limited	O
IgG	O
SFC	O
response	O
was	O
observed	O
in	O
either	O
the	O
mucosal	O
or	O
systemic	O
immune	O
compartment	O
.	O

In	O
the	O
secondary	O
response	O
the	O
IBV	O
antibody	B-FUNC
levels	O
significantly	O
increased	O
over	O
controls	O
starting	O
on	O
day	O
1	O
after	O
boosting	O
,	O
and	O
the	O
IgG	O
antibody	B-FUNC
levels	O
were	O
higher	O
than	O
the	O
IgA	O
antibody	B-FUNC
levels	O
in	O
both	O
tears	O
and	O
plasma	O
.	O

Thus	O
,	O
lower	O
mucosal	O
IgA	O
antibody	B-FUNC
levels	O
are	O
observed	O
upon	O
secondary	O
exposure	O
to	O
IBV	O
,	O
which	O
may	O
contribute	O
to	O
vulnerability	O
of	O
host	O
epithelial	O
cells	O
to	O
infection	O
by	O
IBV	O
and	O
persistence	O
of	O
the	O
Ark	O
serotype	O
.	O

Recently	O
turkey	O
integrators	O
in	O
the	O
Southeastern	O
United	O
States	O
and	O
Arkansas	O
experienced	O
an	O
outbreak	O
of	O
moderate	O
to	O
severe	O
enteritis	O
associated	O
with	O
turkey	O
enteric	O
coronavirus	O
(	O
TCoV	O
),	O
and	O
numerous	O
enteric	O
samples	O
collected	O
from	O
turkey	O
flocks	O
in	O
these	O
areas	O
tested	O
positive	O
for	O
TCoV	O
via	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
(	O
RRT	O
-	O
PCR	O
).	O

Diagnostic	O
viral	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nose	O
and	O
throat	O
swabs	O
(	O
NTS	O
)	O
is	O
useful	O
for	O
patient	O
care	O
by	O
informing	O
antiviral	O
use	O
and	O
appropriate	O
isolation	O
.	O

However	O
,	O
the	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
response	O
is	O
short	O
-	O
lived	O
in	O
patients	O
who	O
have	O
recovered	O
from	O
SARS	O
,	O
making	O
it	O
critical	O
to	O
develop	O
additional	O
vaccine	O
strategies	O
.	O

Overall	O
,	O
our	O
results	O
show	O
that	O
SARS	O
-	O
CoV	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
protect	O
susceptible	O
hosts	O
from	O
lethal	O
SARS	O
-	O
CoV	O
infection	O
,	O
but	O
they	O
also	O
suggest	O
that	O
SARS	O
-	O
CoV	O
-	O
specific	O
CD4	O
T	O
cell	O
and	O
antibody	B-FUNC
responses	O
are	O
necessary	O
for	O
complete	O
protection	O
.	O

Antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
is	O
a	O
mechanism	O
through	O
which	O
dengue	O
viruses	O
,	O
feline	O
coronaviruses	O
,	O
and	O
HIV	O
viruses	O
take	O
advantage	O
of	O
anti	O
-	O
viral	O
humoral	O
immune	O
responses	O
to	O
infect	O
host	O
target	O
cells	O
.	O

We	O
found	O
that	O
higher	O
concentrations	O
of	O
anti	O
-	O
sera	B-FUNC
against	O
SARS	O
-	O
CoV	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
,	O
while	O
highly	O
diluted	O
anti	O
-	O
sera	B-FUNC
significantly	O
increased	O
SARS	O
-	O
CoV	O
infection	O
and	O
induced	O
higher	O
levels	O
of	O
apoptosis	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assay	O
targeted	O
the	O
UpE	O
and	O
Orf1a	O
regions	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
.	O

The	O
functional	O
consequences	O
of	O
mutations	O
introduced	O
at	O
these	O
positions	O
were	O
first	O
evaluated	O
biochemically	O
by	O
monitoring	O
nsp14	O
exoribonuclease	B-FUNC
activity	I-FUNC
.	O

Testing	O
for	O
circulating	O
FIV	O
antibody	B-FUNC
and	O
FeLV	O
antigen	O
,	O
a	O
PCR	O
assay	O
for	O
feline	O
coronavirus	O
performed	O
on	O
a	O
sample	O
of	O
peritoneal	O
fluid	O
,	O
and	O
fecal	O
flotation	O
yielded	O
negative	O
results	O
.	O

Nasal	O
/	O
Nasopharyngeal	O
swabs	O
were	O
tested	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
HCoV	O
-	O
22E	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
using	O
Reverse	O
Transcriptase	B-FUNC
Real	O
-	O
Time	O
Polymerase	O
Chain	O
Reaction	O
.	O

TITLE	O
:	O
Varying	O
antibody	B-FUNC
responses	O
of	O
laying	O
hens	O
housed	O
in	O
an	O
aviary	O
system	O
and	O
in	O
furnished	O
cages	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
titers	O
after	O
vaccination	O
against	O
Infectious	O
Bronchitis	O
Virus	O
(	O
IBV	O
),	O
Newcastle	O
Disease	O
Virus	O
(	O
NDV	O
)	O
and	O
after	O
natural	O
infection	O
with	O
Campylobacter	O
were	O
analyzed	O
in	O
five	O
trials	O
with	O
Lohmann	O
Silver	O
laying	O
hens	O
kept	O
in	O
two	O
different	O
housing	O
systems	O
.	O

Similar	O
to	O
other	O
coronaviruses	O
,	O
PEDV	O
spike	O
protein	O
mediates	O
its	O
cell	O
entry	O
by	O
binding	B-FUNC
to	O
cellular	O
receptors	O
and	O
inducing	O
membrane	O
fusion	O
between	O
viral	O
envelopes	O
and	O
cellular	O
membranes	O
.	O

Because	O
of	O
the	O
high	O
sequence	O
homology	O
among	O
FCoV	O
,	O
CCoV	O
,	O
and	O
TGEV	O
,	O
a	O
nucleotide	O
preceding	O
the	O
last	O
pair	O
of	O
dissimilar	O
nucleotides	O
in	O
S3	O
and	O
S4	O
was	O
substituted	O
with	O
an	O
inosine	O
to	O
allow	O
primer	O
binding	B-FUNC
.	O

The	O
respiratory	O
viruses	O
detected	O
using	O
a	O
multiplex	O
real	O
-	O
time	O
-	O
polymerase	O
chain	O
reaction	O
kit	B-FUNC
were	O
influenza	O
virus	O
(	O
A	O
/	O
H1N1	O
,	O
A	O
/	O
H3N2	O
,	O
A	O
/	O
H5N1	O
,	O
and	O
B	O
),	O
adenovirus	O
,	O
parainfluenza	O
virus	O
(	O
type	O
1	O
,	O
2	O
,	O
3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
type	O
A	O
,	O
B	O
),	O
human	O
rhinovirus	O
,	O
human	O
coronavirus	O
(	O
OC43	O
/	O
229E	O
,	O
NL63	O
),	O
human	O
bocavirus	O
,	O
and	O
enterovirus	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
is	O
an	O
essential	O
function	O
in	O
viral	O
genome	O
retrotranscription	O
.	O

Diketo	O
acid	O
(	O
DKA	O
)	O
derivatives	O
are	O
active	O
site	O
Mg	O
(	O
2	O
+)-	O
binding	B-FUNC
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
RNase	O
H	O
and	O
integrase	O
(	O
IN	O
)	O
activities	O
.	O

To	O
investigate	O
the	O
DKA	O
binding	B-FUNC
site	O
of	O
RNase	O
H	O
and	O
the	O
mechanism	O
of	O
action	O
,	O
six	O
couples	O
of	O
ester	O
and	O
acid	O
DKAs	O
,	O
derived	O
from	O
6	O
-[	O
1	O
-(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
-	O
1H	O
-	O
pyrrol	O
-	O
2	O
-	O
yl	O
)]-	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
hexenoic	O
acid	O
ethyl	O
ester	O
(	O
RDS1643	O
),	O
were	O
synthesized	O
and	O
tested	O
on	O
both	O
RNase	O
H	O
and	O
IN	O
functions	O
.	O

Molecular	O
modeling	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
on	O
the	O
RNase	O
H	O
domain	O
demonstrated	O
different	O
binding	B-FUNC
poses	O
for	O
ester	O
and	O
acid	O
DKAs	O
and	O
proved	O
that	O
DKAs	O
interact	O
with	O
residues	O
(	O
R448	O
,	O
N474	O
,	O
Q475	O
,	O
Y501	O
,	O
and	O
R557	O
)	O
involved	O
not	O
in	O
the	O
catalytic	O
motif	O
but	O
in	O
highly	O
conserved	O
portions	O
of	O
the	O
RNase	O
H	O
primer	O
grip	O
motif	O
.	O

The	O
ester	O
derivative	O
RDS1759	O
selectively	O
inhibited	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
and	O
viral	O
replication	O
in	O
the	O
low	O
micromolar	O
range	O
,	O
making	O
contacts	O
with	O
residues	O
Q475	O
,	O
N474	O
,	O
and	O
Y501	O
.	O

MHV	O
-	O
induced	O
macropinocytosis	O
requires	O
fusogenic	O
spike	O
protein	O
on	O
the	O
cell	O
surface	O
and	O
is	O
dependent	O
on	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
activation	O
.	O

Murine	O
hepatitis	O
virus	O
macropinocytosis	O
requires	O
a	O
fusogenic	O
virus	O
spike	O
protein	O
and	O
signals	O
through	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
and	O
the	O
classical	O
macropinocytosis	O
pathway	O
.	O

TITLE	O
:	O
No	O
evidence	O
of	O
coronavirus	O
infection	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
in	O
bats	O
in	O
Belgium	O
.	O

Biochemical	O
analysis	O
verified	O
double	O
-	O
mutant	O
3CLpro	O
enzyme	O
as	O
impaired	O
for	O
protease	B-FUNC
activity	I-FUNC
and	O
exhibiting	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	O
and	O
revealed	O
a	O
delayed	O
kinetics	O
of	O
inhibitor	O
hydrolysis	O
and	O
activity	O
restoration	O
.	O

On	O
DOI	O
12	O
,	O
his	O
serum	O
tested	O
positive	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
for	O
MERS	O
-	O
CoV	O
and	O
showed	O
high	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
titers	O
,	O
whereas	O
his	O
nasopharyngeal	O
swab	O
was	O
rRT	O
-	O
PCR	O
negative	O
.	O

Both	O
sera	B-FUNC
and	O
sputum	O
were	O
rRT	O
-	O
PCR	O
positive	O
when	O
nasopharyngeal	O
specimens	O
were	O
negative	O
.	O

TITLE	O
:	O
The	O
SARS	O
Coronavirus	O
3a	O
protein	O
binds	B-FUNC
calcium	O
in	O
its	O
cytoplasmic	O
domain	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
the	O
orf3a	O
aligned	O
to	O
one	O
calcium	B-FUNC
pump	I-FUNC
present	O
in	O
Plasmodium	O
falciparum	O
and	O
the	O
enzyme	O
glutamine	O
synthetase	O
found	O
in	O
Leptospira	O
interrogans	O
.	O

Furthermore	O
,	O
this	O
region	O
was	O
predicted	O
to	O
be	O
involved	O
in	O
the	O
calcium	O
binding	B-FUNC
.	O

Owing	O
to	O
this	O
hypothesis	O
,	O
we	O
were	O
driven	O
to	O
establish	O
its	O
calcium	O
binding	B-FUNC
property	O
in	O
vitro	O
.	O

The	O
calcium	O
binding	B-FUNC
nature	O
was	O
established	O
by	O
performing	O
various	O
staining	O
methods	O
such	O
as	O
ruthenium	O
red	O
and	O
stains	O
-	O
all	O
.	O

Since	O
the	O
3a	O
protein	O
forms	O
ion	B-FUNC
channels	I-FUNC
,	O
we	O
were	O
interested	O
to	O
see	O
any	O
conformational	O
changes	O
occurring	O
in	O
the	O
Cyot3a	O
upon	O
calcium	O
binding	B-FUNC
,	O
using	O
fluorescence	O
spectroscopy	O
and	O
circular	O
dichroism	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
3a	O
protein	O
of	O
SARS	O
-	O
CoV	O
binds	B-FUNC
calcium	O
in	O
vitro	O
,	O
causing	O
a	O
change	O
in	O
protein	O
conformation	O
.	O

TITLE	O
:	O
The	O
PDZ	O
-	O
binding	B-FUNC
motif	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
is	O
a	O
determinant	O
of	O
viral	O
pathogenesis	O
.	O

Here	O
we	O
report	O
that	O
E	O
protein	O
PDZ	O
-	O
binding	B-FUNC
motif	O
(	O
PBM	O
),	O
a	O
domain	O
involved	O
in	O
protein	O
-	O
protein	O
interactions	O
,	O
is	O
a	O
major	O
determinant	O
of	O
virulence	O
.	O

Cellular	O
protein	O
syntenin	O
was	O
identified	O
to	O
bind	B-FUNC
the	O
E	O
protein	O
PBM	O
during	O
SARS	O
-	O
CoV	O
infection	O
by	O
using	O
three	O
complementary	O
strategies	O
,	O
yeast	O
two	O
-	O
hybrid	O
,	O
reciprocal	O
coimmunoprecipitation	O
and	O
confocal	O
microscopy	O
assays	O
.	O

Syntenin	O
redistributed	O
from	O
the	O
nucleus	O
to	O
the	O
cell	O
cytoplasm	O
during	O
infection	O
with	O
viruses	O
containing	O
the	O
E	O
protein	O
PBM	O
,	O
activating	O
p38	B-FUNC
MAPK	B-FUNC
and	O
leading	O
to	O
the	O
overexpression	O
of	O
inflammatory	O
cytokines	O
.	O

Silencing	O
of	O
syntenin	O
using	O
siRNAs	O
led	O
to	O
a	O
decrease	O
in	O
p38	B-FUNC
MAPK	B-FUNC
activation	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
further	O
reinforcing	O
their	O
functional	O
relationship	O
.	O

Moreover	O
,	O
most	O
of	O
the	O
cats	O
(	O
84	O
.	O
6	O
%,	O
22	O
/	O
26	O
)	O
infected	O
with	O
a	O
genotypic	O
untypable	O
virus	O
bearing	O
a	O
type	O
I	O
FCoV	O
antibody	B-FUNC
.	O

Moreover	O
,	O
most	O
of	O
the	O
cats	O
(	O
84	O
.	O
6	O
%,	O
22	O
/	O
26	O
)	O
infected	O
with	O
a	O
genotypic	O
untypable	O
virus	O
bearing	O
a	O
type	O
I	O
FCoV	O
antibody	B-FUNC
.	O

From	O
the	O
31	O
positive	O
samples	O
,	O
only	O
10	O
gave	O
positive	O
results	O
in	O
molecular	O
tests	O
aimed	O
at	O
various	O
IBV	O
genome	O
fragments	O
:	O
five	O
samples	O
were	O
positive	O
for	O
the	O
RdRp	B-FUNC
gene	O
,	O
four	O
for	O
gene	O
3	O
,	O
eight	O
for	O
gene	O
N	O
and	O
eight	O
for	O
the	O
3	O
'-	O
untranslated	O
region	O
fragment	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
anti	O
-	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
ELISA	O
based	O
on	O
the	O
S1	O
portion	O
of	O
the	O
spike	O
protein	O
was	O
validated	O
and	O
compared	O
with	O
an	O
indirect	O
immunofluorescence	O
assay	O
.	O

Levels	O
of	O
brain	O
damage	O
markers	O
S100	O
calcium	O
binding	B-FUNC
protein	O
B	O
and	O
neuron	O
-	O
specific	O
enolase	O
,	O
interleukin	O
-	O
6	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
as	O
well	O
as	O
matrix	O
metalloproteinase	O
-	O
9	O
increased	O
significantly	O
after	O
treating	O
brain	O
cells	O
with	O
	O
2	O
%	O
conditioned	O
medium	O
.	O

MERS	O
-	O
CoV	O
PLpro	O
constructs	O
with	O
and	O
without	O
the	O
putative	O
ubiquitin	B-FUNC
-	O
like	O
(	O
UBL	O
)	O
domain	O
at	O
the	O
N	O
terminus	O
were	O
found	O
to	O
possess	O
protease	O
,	O
deubiquitinating	O
,	O
deISGylating	O
,	O
and	O
interferon	O
antagonism	O
activities	O
in	O
transfected	O
HEK293T	O
cells	O
.	O

Steady	O
-	O
state	O
kinetic	O
analyses	O
of	O
purified	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
PLpros	O
uncovered	O
significant	O
differences	O
in	O
their	O
rates	O
of	O
hydrolysis	O
of	O
5	O
-	O
aminomethyl	O
coumarin	O
(	O
AMC	O
)	O
from	O
C	O
-	O
terminally	O
labeled	O
peptide	O
,	O
ubiquitin	B-FUNC
,	O
and	O
ISG15	O
substrates	O
,	O
as	O
well	O
as	O
in	O
their	O
rates	O
of	O
isopeptide	O
bond	O
cleavage	O
of	O
K48	O
-	O
and	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

However	O
,	O
SARS	O
-	O
CoV	O
PLpro	O
much	O
preferred	O
K48	O
-	O
linked	O
polyubiquitin	O
chains	O
to	O
K63	O
-	O
linked	O
chains	O
,	O
and	O
it	O
rapidly	O
produced	O
di	O
-	O
ubiquitin	B-FUNC
molecules	O
from	O
K48	O
-	O
linked	O
chains	O
.	O

As	O
a	O
consequence	O
,	O
decoding	O
the	O
mechanisms	O
of	O
PLpro	O
-	O
mediated	O
antagonism	O
of	O
the	O
host	O
innate	O
immune	O
response	O
and	O
the	O
development	O
of	O
anti	O
-	O
CoV	O
PLpro	O
enzyme	B-FUNC
inhibitors	I-FUNC
will	O
be	O
a	O
challenging	O
undertaking	O
.	O

Moreover	O
,	O
IRE1	O
antagonized	O
IBV	O
-	O
induced	O
apoptosis	O
by	O
modulating	O
the	O
phosphorylation	O
status	O
of	O
the	O
proapoptotic	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
)	O
and	O
the	O
prosurvival	O
RAC	O
-	O
alpha	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
(	O
Akt	O
).	O

Therefore	O
,	O
we	O
examined	O
the	O
ability	O
of	O
LM22A	O
-	O
4	O
,	O
a	O
small	O
-	O
molecule	O
BDNF	O
loop	O
-	O
domain	O
mimetic	O
and	O
TrkB	O
partial	O
agonist	O
,	O
to	O
modulate	O
synaptic	O
excitability	O
within	O
respiratory	O
cell	O
groups	O
in	O
the	O
brainstem	O
nucleus	O
tractus	O
solitarius	O
(	O
nTS	O
)	O
and	O
to	O
acutely	O
reverse	O
abnormalities	O
in	O
breathing	O
at	O
rest	B-FUNC
and	O
during	O
behavioral	O
arousal	O
in	O
Mecp2	O
mutants	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
pyrimidinylthioacetanilides	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
biological	O
activity	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTIs	O
).	O

A	O
total	O
of	O
310	O
chicken	O
sera	B-FUNC
samples	O
were	O
tested	O
using	O
the	O
commercial	O
IDEXX	O
kit	B-FUNC
along	O
with	O
the	O
assay	O
developed	O
.	O

A	O
four	O
-	O
fold	O
or	O
greater	O
increase	O
of	O
IgG	O
-	O
titres	O
against	O
respiratory	O
viruses	O
in	O
pair	O
sera	B-FUNC
was	O
tested	O
by	O
means	O
of	O
hemagglutination	O
inhibition	O
assay	O
or	O
indirect	O
immunofluorescence	O
.	O

Sera	B-FUNC
from	O
a	O
cat	O
experimentally	O
infected	O
with	O
type	O
I	O
FCoV	O
was	O
unable	O
to	O
neutralize	O
type	O
II	O
CCoV	O
infection	O
,	O
indicating	O
that	O
cats	O
persistently	O
infected	O
with	O
type	O
I	O
FCoV	O
may	O
be	O
superinfected	O
with	O
type	O
II	O
CCoV	O
.	O
Our	O
previous	O
study	O
reported	O
that	O
few	O
Japanese	O
cats	O
have	O
antibody	B-FUNC
against	O
type	O
II	O
FCoV	O
.	O
All	O
of	O
these	O
observations	O
suggest	O
that	O
type	O
II	O
FCoV	O
emerged	O
inside	O
the	O
cat	O
body	O
and	O
is	O
unable	O
to	O
readily	O
spread	O
among	O
cats	O
,	O
indicating	O
that	O
these	O
recombination	O
events	O
for	O
emergence	O
of	O
pathogenic	O
coronaviruses	O
occur	O
frequently	O
.	O

Previous	O
studies	O
showed	O
that	O
HCoV	O
-	O
NL63	O
and	O
the	O
genetically	O
distant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
employ	O
the	O
same	O
receptor	O
for	O
host	O
cell	O
entry	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
but	O
it	O
is	O
largely	O
unclear	O
whether	O
ACE2	O
interactions	O
are	O
sufficient	O
to	O
allow	O
HCoV	O
-	O
NL63	O
binding	B-FUNC
to	O
cells	O
.	O

In	O
contrast	O
,	O
binding	B-FUNC
of	O
HCoV	O
-	O
NL63	O
to	O
heparan	O
sulfates	O
was	O
required	O
for	O
viral	O
attachment	O
and	O
infection	O
of	O
target	O
cells	O
,	O
showing	O
that	O
these	O
molecules	O
serve	O
as	O
attachment	O
receptors	O
for	O
HCoV	O
-	O
NL63	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
ACE2	O
protein	O
is	O
required	O
for	O
viral	O
entry	O
but	O
that	O
it	O
is	O
not	O
the	O
primary	O
binding	B-FUNC
site	O
on	O
the	O
cell	O
surface	O
.	O

All	O
the	O
vaccinated	O
animals	O
had	O
antibody	B-FUNC
responses	O
against	O
spike	O
protein	O
,	O
which	O
neutralized	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

TITLE	O
:	O
Evidence	O
for	O
substrate	O
binding	B-FUNC
-	O
induced	O
zwitterion	O
formation	O
in	O
the	O
catalytic	O
Cys	O
-	O
His	O
dyad	O
of	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
.	O

Our	O
computational	O
data	O
are	O
in	O
line	O
with	O
available	O
experimental	O
results	O
,	O
such	O
as	O
X	O
-	O
ray	O
geometries	O
,	O
measured	O
pKa	B-FUNC
values	O
,	O
mutagenesis	O
experiments	O
,	O
and	O
the	O
measured	O
differences	O
between	O
the	O
kinetic	O
parameters	O
of	O
substrates	O
and	O
inhibitors	O
.	O

SARS	O
-	O
CoV	O
nsp12	O
,	O
the	O
canonical	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
exhibits	O
poorly	O
processive	O
RNA	O
synthesis	O
in	O
vitro	O
,	O
at	O
odds	O
with	O
the	O
efficient	O
replication	O
of	O
a	O
very	O
large	O
RNA	O
genome	O
in	O
vivo	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
SARs	O
of	O
indole	O
-	O
based	O
	O
-	O
amino	O
acids	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
derived	O
from	O
indole	O
-	O
based	O
	O
-	O
amino	O
acids	O
were	O
designed	O
and	O
synthesized	O
.	O

We	O
found	O
that	O
HKU4	O
-	O
RBD	O
,	O
but	O
not	O
HKU5	O
-	O
RBD	O
,	O
binds	B-FUNC
to	O
hCD26	O
,	O
and	O
pseudotyped	O
viruses	O
embedding	O
HKU4	O
spike	O
can	O
infect	O
cells	O
via	O
hCD26	O
recognition	O
.	O

HKU4	O
-	O
RBD	O
,	O
however	O
,	O
is	O
less	O
adapted	O
to	O
hCD26	O
than	O
MERS	O
-	O
RBD	O
,	O
explaining	O
its	O
lower	O
affinity	O
for	O
receptor	B-FUNC
binding	I-FUNC
.	O

TITLE	O
:	O
[	O
High	O
-	O
efficiency	O
expression	O
of	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
tobacco	O
chloroplasts	O
].	O

To	O
verify	O
the	O
feasibility	O
of	O
obtaining	O
high	O
-	O
level	O
expression	O
of	O
the	O
SARS	O
subunit	O
vaccine	O
and	O
to	O
provide	O
a	O
suitable	O
plant	O
-	O
derived	O
vaccine	O
production	O
platform	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
193	O
-	O
amino	O
acid	O
fragment	O
of	O
SARS	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
fused	O
with	O
the	O
peptide	O
vector	O
cholera	O
toxin	O
B	O
subunit	O
(	O
CTB	O
),	O
was	O
expressed	O
in	O
tobacco	O
chloroplasts	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
highly	O
expressing	O
SARS	O
subunit	O
vaccine	O
RBD	O
,	O
indicating	O
its	O
potential	O
in	O
subsequent	O
development	O
of	O
a	O
plant	O
-	O
derived	O
recombinant	O
subunit	O
vaccine	O
and	O
reagents	O
production	O
for	O
antibody	B-FUNC
detection	O
in	O
SARS	O
serological	O
tests	O
.	O

However	O
,	O
it	O
has	O
not	O
been	O
well	O
established	O
whether	O
the	O
level	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
is	O
associated	O
with	O
the	O
severity	O
of	O
lung	O
injury	O
and	O
whether	O
it	O
is	O
a	O
prognosis	O
marker	O
for	O
severe	O
lung	O
contusion	O
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
of	O
plasma	O
vWF	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
their	O
association	O
with	O
the	O
severity	O
and	O
outcomes	O
of	O
severe	O
pulmonary	O
contusion	O
.	O

The	O
levels	O
of	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
days	O
after	O
injury	O
.	O

The	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
showed	O
a	O
similar	O
expression	O
pattern	O
in	O
both	O
groups	O
,	O
but	O
the	O
expression	O
increased	O
more	O
significantly	O
in	O
the	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
ARDS	O
group	O
.	O

The	O
level	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
ISS	O
	O
20	O
group	O
was	O
consistently	O
high	O
,	O
while	O
that	O
in	O
the	O
ISS	O
<	O
20	O
group	O
peaked	O
at	O
day	O
3	O
and	O
decreased	O
at	O
day	O
5	O
.	O

The	O
level	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	O
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	O
index	O
.	O

The	O
elevated	O
levels	O
of	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
severe	O
pulmonary	O
contusion	O
patients	O
reflect	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
patients	O
outcomes	O
,	O
suggesting	O
that	O
the	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
are	O
sensitive	O
markers	O
for	O
clinical	O
evaluation	O
of	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
predication	O
of	O
patient	O
prognosis	O
.	O

RESULTS	O
:	O
The	O
concentrations	O
of	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
significantly	O
increased	O
in	O
all	O
severe	O
pulmonary	O
contusion	O
patients	O
at	O
all	O
time	O
points	O
in	O
comparison	O
with	O
the	O
control	O
group	O
.	O

The	O
level	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	O
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	O
index	O
.	O

Consequently	O
,	O
we	O
have	O
hypothesized	O
that	O
germline	O
antibodies	O
may	O
not	O
bind	B-FUNC
to	O
the	O
HIV	O
-	O
1	O
envelope	O
glycoprotein	O
(	O
Env	O
)	O
because	O
they	O
are	O
so	O
different	O
compared	O
to	O
the	O
highly	O
somatically	O
mutated	O
HIV	O
-	O
1	O
-	O
specific	O
bnAbs	O
.	O

Here	O
,	O
we	O
discuss	O
studies	O
exploring	O
the	O
antibody	B-FUNC
germline	O
/	O
maturation	O
hypothesis	O
as	O
related	O
to	O
elicitation	O
of	O
bnAbs	O
against	O
HIV	O
-	O
1	O
and	O
present	O
our	O
recent	O
data	O
demonstrating	O
the	O
existence	O
of	O
germline	O
-	O
like	O
precursors	O
of	O
VRC01	O
antibodies	O
in	O
a	O
human	O
cord	O
blood	O
IgM	O
library	O
.	O

TBIL	O
and	O
ALT	B-FUNC
decreased	O
more	O
significantly	O
after	O
treatment	O
in	O
the	O
PE	O
+	O
CVVHDF	O
and	O
PE	O
+	O
HP	O
+	O
CVVHDF	O
groups	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
are	O
promising	O
therapeutic	O
cells	O
for	O
preventing	O
apoptosis	O
and	O
eliminating	O
cellular	O
injury	O
.	O

Promotion	O
of	O
AMs	O
survival	O
by	O
BMSCs	O
required	O
down	O
-	O
regulation	O
of	O
p	O
-	O
GSK	B-FUNC
-	O
3	O
and	O
	O
-	O
catenin	O
in	O
AMs	O
.	O

TITLE	O
:	O
Effects	O
of	O
human	O
anti	O
-	O
spike	O
protein	O
receptor	B-FUNC
binding	I-FUNC
domain	O
antibodies	O
on	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
neutralization	O
escape	O
and	O
fitness	O
.	O

ABSTRACT	O
:	O
The	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
target	O
of	O
protective	O
immunity	O
in	O
vivo	O
.	O

We	O
also	O
investigated	O
the	O
neutralization	O
escape	O
profiles	O
of	O
these	O
nAbs	O
and	O
evaluated	O
their	O
effects	O
on	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
fitness	O
in	O
vitro	O
and	O
in	O
mice	O
.	O

Interestingly	O
,	O
in	O
mice	O
the	O
neutralization	O
escape	O
mutant	O
viruses	O
showed	O
either	O
attenuation	O
(	O
Urbani	O
background	O
)	O
or	O
increased	O
virulence	O
(	O
GD03	O
background	O
)	O
consistent	O
with	O
the	O
different	O
binding	B-FUNC
affinities	O
between	O
their	O
RBDs	O
and	O
the	O
mouse	O
ACE2	O
.	O

Here	O
,	O
we	O
used	O
SARS	O
-	O
CoV	O
as	O
a	O
research	O
model	O
and	O
examined	O
the	O
escape	O
pathways	O
of	O
broad	O
nAbs	O
that	O
target	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Searching	O
for	O
an	O
ideal	O
vaccine	O
candidate	O
among	O
different	O
MERS	O
coronavirus	O
receptor	O
-	O
binding	B-FUNC
fragments	O
--	O
the	O
importance	O
of	O
immunofocusing	O
in	O
subunit	O
vaccine	O
design	O
.	O

A	O
defined	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
MERS	O
-	O
CoV	O
spike	O
protein	O
can	O
potentially	O
serve	O
as	O
a	O
subunit	O
vaccine	O
candidate	O
against	O
MERS	O
-	O
CoV	O
infections	O
.	O

To	O
identify	O
an	O
ideal	O
vaccine	O
candidate	O
,	O
we	O
have	O
constructed	O
five	O
different	O
versions	O
of	O
RBD	O
fragments	O
,	O
S350	O
-	O
588	O
-	O
Fc	O
,	O
S358	O
-	O
588	O
-	O
Fc	O
,	O
S367	O
-	O
588	O
-	O
Fc	O
,	O
S367	O
-	O
606	O
-	O
Fc	O
,	O
and	O
S377	O
-	O
588	O
-	O
Fc	O
(	O
their	O
names	O
indicate	O
their	O
residue	O
range	O
in	O
the	O
spike	O
protein	O
and	O
their	O
C	O
-	O
terminal	O
Fc	O
tag	O
),	O
and	O
further	O
investigated	O
their	O
receptor	B-FUNC
binding	I-FUNC
affinity	O
,	O
antigenicity	O
,	O
immunogenicity	O
,	O
and	O
neutralizing	O
potential	O
.	O

The	O
results	O
showed	O
that	O
S377	O
-	O
588	O
-	O
Fc	O
is	O
among	O
the	O
RBD	O
fragments	O
that	O
demonstrated	O
the	O
highest	O
DPP4	O
-	O
binding	B-FUNC
affinity	O
and	O
induced	O
the	O
highest	O
-	O
titer	O
IgG	O
antibodies	O
in	O
mice	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
RBD	O
fragment	O
encompassing	O
spike	O
residues	O
377	O
-	O
588	O
is	O
a	O
critical	O
neutralizing	O
receptor	O
-	O
binding	B-FUNC
fragment	O
and	O
an	O
ideal	O
candidate	O
for	O
development	O
of	O
effective	O
MERS	O
vaccines	O
,	O
and	O
that	O
adding	O
non	O
-	O
neutralizing	O
structures	O
to	O
this	O
RBD	O
fragment	O
diminishes	O
its	O
neutralizing	O
potential	O
.	O

Significantly	O
higher	O
CD4	O
/	O
CD8	O
ratio	O
,	O
IFN	O
-	O
	O
concentration	O
and	O
IL12	O
/	O
IL4	O
ratio	O
and	O
significantly	O
lower	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
concentration	O
and	O
proportion	O
of	O
shedders	O
were	O
found	O
in	O
HB	O
than	O
in	O
other	O
breeds	O
.	O

Moreover	O
,	O
by	O
engineering	O
cell	O
lines	O
conditionally	O
expressing	O
various	O
TRIM56	O
mutants	O
,	O
we	O
demonstrated	O
that	O
TRIM56	O
'	O
s	O
antiflavivirus	O
effects	O
required	O
both	O
the	O
E3	O
ligase	B-FUNC
activity	I-FUNC
that	O
lies	O
in	O
the	O
N	O
-	O
terminal	O
RING	O
domain	O
and	O
the	O
integrity	O
of	O
its	O
C	O
-	O
terminal	O
portion	O
,	O
while	O
the	O
restriction	O
of	O
HCoV	O
-	O
OC43	O
relied	O
upon	O
the	O
TRIM56	O
E3	O
ligase	B-FUNC
activity	I-FUNC
alone	O
.	O

Further	O
,	O
we	O
show	O
that	O
TRIM56	O
-	O
mediated	O
inhibition	O
of	O
HCoV	O
-	O
OC43	O
multiplication	O
depends	O
solely	O
on	O
its	O
E3	O
ligase	B-FUNC
activity	I-FUNC
,	O
whereas	O
its	O
restriction	O
of	O
YFV	O
and	O
DENV2	O
requires	O
both	O
the	O
E3	O
ligase	B-FUNC
activity	I-FUNC
and	O
integrity	O
of	O
the	O
C	O
-	O
terminal	O
portion	O
.	O

However	O
,	O
the	O
stretch	O
-	O
induced	O
[	O
Ca	O
(	O
2	O
+)]	O
i	O
elevation	O
was	O
not	O
inhibited	O
by	O
ATP	B-FUNC
diphosphohydrolase	I-FUNC
apyrase	O
or	O
a	O
purinergic	O
receptor	O
antagonist	O
suramin	O
.	O

Depending	O
on	O
the	O
predominant	O
symptoms	O
and	O
signs	O
,	O
a	O
child	O
presenting	O
to	O
the	O
clinician	O
can	O
be	O
divided	O
into	O
six	O
groups	O
,	O
viz	O
.,	O
stridor	O
;	O
cough	O
,	O
fever	O
and	O
difficulty	O
in	O
breathing	O
or	O
fast	B-FUNC
breathing	O
;	O
wheezing	O
;	O
mediastinal	O
shift	O
with	O
severe	O
respiratory	O
distress	O
;	O
slow	O
or	O
irregular	O
breathing	O
in	O
absence	O
of	O
any	O
pulmonary	O
sign	O
;	O
and	O
respiratory	O
distress	O
with	O
cardiac	O
findings	O
.	O

Molecular	O
docking	O
study	O
was	O
also	O
employed	O
to	O
check	O
the	O
affinity	O
of	O
the	O
potential	O
epitope	O
towards	O
the	O
binding	B-FUNC
cleft	O
of	O
the	O
specific	O
HLA	O
allele	O
.	O

Moreover	O
,	O
in	O
molecular	O
docking	O
study	O
,	O
this	O
epitope	O
was	O
found	O
to	O
have	O
a	O
significant	O
binding	B-FUNC
affinity	O
of	O
-	O
8	O
.	O
5	O
kcal	O
/	O
mol	O
towards	O
the	O
binding	B-FUNC
cleft	O
of	O
the	O
HLA	O
-	O
C	O
*	O
12	O
:	O
03	O
molecule	O
.	O

Arterial	O
blood	O
gas	O
analysis	O
was	O
conducted	O
and	O
serum	O
cytokine	O
levels	O
,	O
including	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
4	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
as	O
well	O
as	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
were	O
evaluated	O
respectively	O
both	O
before	O
and	O
6h	O
,	O
12h	O
,	O
and	O
24h	O
after	O
CRRT	O
therapy	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
coronavirus	O
membrane	O
protein	O
induces	O
apoptosis	O
via	O
interfering	O
with	O
PDK1	B-FUNC
-	O
PKB	O
/	O
Akt	O
signalling	O
.	O

We	O
also	O
showed	O
that	O
overexpression	O
of	O
PDK1	B-FUNC
(	O
3	O
-	O
phosphoinositide	O
-	O
dependent	O
protein	O
kinase	O
1	O
),	O
the	O
immediate	O
upstream	O
kinase	O
of	O
PKB	O
/	O
Akt	O
,	O
suppressed	O
M	O
-	O
induced	O
apoptosis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
C	O
-	O
terminus	O
of	O
M	O
-	O
protein	O
interacts	O
with	O
the	O
PH	O
(	O
pleckstrin	O
homology	O
)	O
domain	O
of	O
PDK1	B-FUNC
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
-	O
protein	O
induces	O
apoptosis	O
through	O
disrupting	O
the	O
interaction	O
of	O
PDK1	B-FUNC
with	O
PKB	O
/	O
Akt	O
,	O
and	O
this	O
causes	O
the	O
activation	O
of	O
apoptosis	O
.	O

Preventing	O
the	O
interaction	O
between	O
M	O
-	O
protein	O
and	O
PDK1	B-FUNC
is	O
a	O
plausible	O
therapeutic	O
approach	O
to	O
target	O
the	O
pro	O
-	O
apoptotic	O
property	O
of	O
SARS	O
-	O
CoV	O
.	O

Mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
pathways	O
are	O
involved	O
in	O
cytokine	O
production	O
,	O
but	O
the	O
mechanisms	O
that	O
regulate	O
these	O
pathways	O
remain	O
poorly	O
characterized	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
Sprouty	O
-	O
related	O
EVH1	O
-	O
domain	O
-	O
containing	O
protein	O
(	O
Spred	O
)-	O
2	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)-	O
MAPK	B-FUNC
pathway	O
,	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

After	O
LPS	O
-	O
injection	O
,	O
the	O
lungs	O
were	O
harvested	O
to	O
assess	O
leukocyte	O
infiltration	O
,	O
cytokine	O
and	O
chemokine	O
production	O
,	O
ERK	B-FUNC
-	O
MAPK	B-FUNC
activation	O
and	O
immunopathology	O
.	O

U0126	O
,	O
a	O
selective	O
MEK	O
/	O
ERK	B-FUNC
inhibitor	O
,	O
reduced	O
the	O
augmented	O
LPS	O
-	O
induced	O
inflammation	O
in	O
Spred	O
-	O
2	O
(-/-)	O
mice	O
.	O

The	O
ERK	B-FUNC
-	O
MAPK	B-FUNC
pathway	O
is	O
involved	O
in	O
LPS	O
-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

Spred	O
-	O
2	O
controls	O
the	O
development	O
of	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
by	O
negatively	O
regulating	O
the	O
ERK	B-FUNC
-	O
MAPK	B-FUNC
pathway	O
.	O

This	O
report	O
describes	O
timing	O
of	O
antibody	B-FUNC
generation	O
and	O
disease	O
progression	O
following	O
infection	O
with	O
a	O
US	O
PEDV	O
isolate	O
by	O
assessing	O
fecal	O
viral	O
shedding	O
,	O
morphometric	O
analysis	O
of	O
intestinal	O
lesions	O
,	O
and	O
magnitude	O
of	O
immunohistochemical	O
staining	O
.	O

We	O
report	O
here	O
a	O
carbohydrate	O
microarray	O
analysis	O
of	O
a	O
number	O
of	O
tumor	O
-	O
associated	O
carbohydrates	O
for	O
their	O
serum	O
antibody	B-FUNC
reactivities	O
and	O
potential	O
immunogenicity	O
in	O
humans	O
.	O

We	O
find	O
that	O
phosphorylation	O
of	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
by	O
host	O
glycogen	O
synthase	O
kinase	O
-	O
3	O
(	O
GSK	B-FUNC
-	O
3	O
)	O
is	O
required	O
for	O
template	O
switching	O
.	O

GSK	B-FUNC
-	O
3	O
inhibition	O
selectively	O
reduces	O
the	O
generation	O
of	O
gRNA	O
and	O
longer	O
sgmRNAs	O
,	O
but	O
not	O
shorter	O
sgmRNAs	O
.	O

DDX1	O
knockdown	O
or	O
loss	O
of	O
helicase	B-FUNC
activity	I-FUNC
markedly	O
reduces	O
the	O
levels	O
of	O
longer	O
sgmRNAs	O
.	O

RESULTS	O
:	O
Maximum	O
enrolled	O
children	O
were	O
of	O
viral	O
encephalitis	O
(	O
46	O
.	O
59	O
%)	O
and	O
rest	B-FUNC
,	O
were	O
of	O
pyogenic	O
meningitis	O
,	O
tuberculosis	O
meningitis	O
and	O
cerebral	O
malaria	O
.	O

We	O
conclude	O
that	O
neurodegenerative	O
bladder	O
dysfunction	O
in	O
this	O
model	O
of	O
multiple	O
sclerosis	O
may	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
pathologic	O
changes	O
in	O
the	O
mucosa	O
that	O
causes	O
suppression	O
of	O
muscarinic	O
receptor	O
-	O
mediated	O
contractile	B-FUNC
response	O
and	O
augmentation	O
of	O
purinergic	O
response	O
of	O
the	O
underlying	O
muscle	O
.	O

Severe	O
malaria	O
requires	O
fast	B-FUNC
diagnosis	O
allied	O
to	O
a	O
quick	O
access	O
to	O
an	O
intensive	O
care	O
treatment	O
,	O
since	O
any	O
delay	O
increases	O
the	O
morbid	O
-	O
mortality	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	O
1	O
,	O
interleukin	O
6	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
,	O
and	O
interferon	O
in	O
BALF	O
and	O
serum	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
how	O
the	O
infectious	O
disease	O
outbreaks	O
H1N1	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
affected	O
community	O
-	O
based	O
GPs	O
and	O
FPs	B-FUNC
.	O

A	O
total	O
of	O
183	O
randomly	O
selected	O
GPs	O
and	O
FPs	B-FUNC
who	O
provided	O
office	O
-	O
based	O
care	O
.	O

The	O
responses	O
from	O
this	O
survey	O
were	O
compared	O
with	O
the	O
responses	O
of	O
GPs	O
and	O
FPs	B-FUNC
in	O
the	O
greater	O
Toronto	O
area	O
who	O
completed	O
a	O
similar	O
survey	O
in	O
2003	O
after	O
the	O
SARS	O
outbreak	O
.	O

After	O
the	O
H1N1	O
outbreak	O
,	O
GPs	O
and	O
FPs	B-FUNC
still	O
had	O
substantial	O
concerns	O
about	O
the	O
effects	O
of	O
serious	O
infectious	O
disease	O
outbreaks	O
on	O
the	O
health	O
of	O
their	O
family	O
members	O
.	O

Serious	O
community	O
-	O
based	O
infectious	O
diseases	O
are	O
a	O
personal	O
concern	O
for	O
GPs	O
and	O
FPs	B-FUNC
,	O
and	O
have	O
considerable	O
effects	O
on	O
their	O
clinical	O
practice	O
.	O

RESULTS	O
:	O
After	O
the	O
H1N1	O
outbreak	O
,	O
GPs	O
and	O
FPs	B-FUNC
still	O
had	O
substantial	O
concerns	O
about	O
the	O
effects	O
of	O
serious	O
infectious	O
disease	O
outbreaks	O
on	O
the	O
health	O
of	O
their	O
family	O
members	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
the	O
leading	O
cause	O
of	O
ICU	O
admission	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
and	O
is	O
characterized	O
by	O
golden	O
sputum	O
,	O
which	O
is	O
commonly	O
attributed	O
to	O
the	O
presence	O
of	O
bilirubin	O
.	O

In	O
addition	O
to	O
this	O
replicative	O
function	O
,	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
was	O
recently	O
shown	O
to	O
be	O
a	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
(	O
DUB	O
)	O
and	O
to	O
possess	O
deISGylating	O
activity	O
,	O
as	O
previously	O
reported	O
for	O
other	O
coronaviral	O
PL	O
(	O
pro	O
)	O
domains	O
,	O
including	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
for	O
ubiquitin	B-FUNC
(	O
Ub	B-FUNC
)	O
recognition	O
and	O
deconjugation	O
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
),	O
we	O
determined	O
its	O
crystal	O
structure	O
in	O
complex	O
with	O
Ub	B-FUNC
.	O

ABSTRACT	O
:	O
Acute	O
pancreatitis	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
).	O

IAH	B-FUNC
contributes	O
to	O
multiple	O
physiologic	O
alterations	O
and	O
leads	O
to	O
the	O
development	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
that	O
induces	O
multiorgan	O
failure	O
.	O

We	O
report	O
a	O
case	O
of	O
ACS	B-FUNC
in	O
a	O
patient	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

With	O
a	O
presumptive	O
diagnosis	O
of	O
ACS	B-FUNC
,	O
abdominal	O
decompression	O
through	O
percutaneous	O
catheter	O
drainage	O
was	O
performed	O
immediately	O
.	O

We	O
present	O
a	O
case	O
of	O
ACS	B-FUNC
managed	O
with	O
percutaneous	O
catheter	O
decompression	O
.	O

After	O
72	O
h	O
of	O
LPS	O
stimulation	O
,	O
pulmonary	O
pathological	O
changes	O
,	O
lung	O
injury	O
scores	O
,	O
pulmonary	O
edema	O
,	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	O
-	O
1	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
),	O
and	O
MCP	B-FUNC
-	O
1	O
and	O
E	O
-	O
selectin	B-FUNC
expression	O
were	O
notably	O
attenuated	O
by	O
emodin	O
in	O
mice	O
.	O

Meanwhile	O
,	O
our	O
data	O
also	O
revealed	O
that	O
emodin	O
significantly	O
inhibited	O
the	O
LPS	O
-	O
enhanced	O
the	O
phosphorylation	O
of	O
NF	O
-	O
B	O
p65	O
and	O
NF	O
-	O
B	O
p65	O
DNA	B-FUNC
binding	I-FUNC
activity	O
in	O
lung	O
.	O

Our	O
data	O
indicates	O
that	O
emodin	O
potently	O
inhibits	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
pulmonary	O
edema	O
and	O
MCP	B-FUNC
-	O
1	O
and	O
E	O
-	O
selectin	B-FUNC
expression	O
,	O
and	O
that	O
these	O
effects	O
were	O
very	O
likely	O
mediated	O
by	O
inactivation	O
of	O
NF	O
-	O
B	O
in	O
mice	O
.	O

Hence	O
,	O
in	O
addition	O
to	O
reducing	O
the	O
production	O
of	O
infectious	O
virions	O
,	O
inhibition	O
of	O
ER	O
glucosidases	O
also	O
impairs	O
the	O
entry	O
of	O
selected	O
viruses	O
via	O
a	O
post	O
-	O
receptor	O
-	O
binding	B-FUNC
mechanism	O
.	O

Video	O
bronchoscopy	O
showed	O
an	O
immediate	O
and	O
complete	O
(	O
within	O
5	O
seconds	O
)	O
re	O
-	O
opening	O
of	O
MCh	B-FUNC
-	O
constricted	O
airways	O
following	O
treatment	O
with	O
S	O
-	O
1226	O
.	O

Video	O
bronchoscopy	O
showed	O
an	O
immediate	O
and	O
complete	O
(	O
within	O
5	O
seconds	O
)	O
re	O
-	O
opening	O
of	O
MCh	B-FUNC
-	O
constricted	O
airways	O
following	O
treatment	O
with	O
S	O
-	O
1226	O
.	O

TITLE	O
:	O
Quantitative	O
proteomic	O
analysis	O
reveals	O
that	O
transmissible	O
gastroenteritis	O
virus	O
activates	O
the	O
JAK	B-FUNC
-	O
STAT1	O
signaling	O
pathway	O
.	O

RSA59	O
induced	O
neuropathology	O
is	O
partially	O
caused	O
by	O
activation	O
of	O
CNS	O
resident	O
microglia	O
,	O
as	O
demonstrated	O
by	O
changes	O
in	O
cellular	O
morphology	O
and	O
increased	O
expression	O
of	O
a	O
microglia	O
/	O
macrophage	O
specific	O
calcium	B-FUNC
ion	I-FUNC
binding	I-FUNC
factor	O
,	O
Iba1	O
.	O

The	O
authors	O
found	O
that	O
:	O
(	O
1	O
)	O
UP	O
-	O
MVcontr	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
in	O
dorsal	O
lung	O
zones	O
(	O
median	O
[	O
interquartile	O
])	O
(	O
12	O
.	O
0	O
[	O
7	O
.	O
0	O
to	O
16	O
.	O
8	O
]	O
vs	O
.	O
22	O
.	O
5	O
[	O
13	O
.	O
8	O
to	O
40	O
.	O
8	O
]),	O
but	O
worsened	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
compared	O
to	O
P	O
-	O
MVcontr	O
;	O
(	O
2	O
)	O
UP	O
-	O
MVspont	O
and	O
UP	O
-	O
MVPS	O
improved	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
and	O
redistributed	O
ventilation	O
towards	O
dorsal	O
areas	O
,	O
as	O
compared	O
to	O
UP	O
-	O
MVcontr	O
;	O
(	O
3	O
)	O
compared	O
to	O
P	O
-	O
MVcontr	O
,	O
UP	O
-	O
MVcontr	O
and	O
UP	O
-	O
MVspont	O
,	O
UP	O
-	O
MVPS	O
yielded	O
higher	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
6	O
.	O
9	O
[	O
6	O
.	O
5	O
to	O
10	O
.	O
1	O
]	O
vs	O
.	O
2	O
.	O
8	O
[	O
2	O
.	O
2	O
to	O
3	O
.	O
0	O
],	O
3	O
.	O
6	O
[	O
3	O
.	O
0	O
to	O
4	O
.	O
7	O
]	O
and	O
4	O
.	O
0	O
[	O
2	O
.	O
8	O
to	O
4	O
.	O
4	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
and	O
interleukin	O
-	O
8	O
(	O
216	O
.	O
8	O
[	O
113	O
.	O
5	O
to	O
343	O
.	O
5	O
]	O
vs	O
.	O
59	O
.	O
8	O
[	O
45	O
.	O
3	O
to	O
66	O
.	O
7	O
],	O
37	O
.	O
6	O
[	O
18	O
.	O
8	O
to	O
52	O
.	O
0	O
],	O
and	O
59	O
.	O
5	O
[	O
36	O
.	O
1	O
to	O
79	O
.	O
7	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
in	O
dorsal	O
lung	O
zones	O
.	O

RESULTS	O
:	O
The	O
authors	O
found	O
that	O
:	O
(	O
1	O
)	O
UP	O
-	O
MVcontr	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
in	O
dorsal	O
lung	O
zones	O
(	O
median	O
[	O
interquartile	O
])	O
(	O
12	O
.	O
0	O
[	O
7	O
.	O
0	O
to	O
16	O
.	O
8	O
]	O
vs	O
.	O
22	O
.	O
5	O
[	O
13	O
.	O
8	O
to	O
40	O
.	O
8	O
]),	O
but	O
worsened	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
compared	O
to	O
P	O
-	O
MVcontr	O
;	O
(	O
2	O
)	O
UP	O
-	O
MVspont	O
and	O
UP	O
-	O
MVPS	O
improved	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
and	O
redistributed	O
ventilation	O
towards	O
dorsal	O
areas	O
,	O
as	O
compared	O
to	O
UP	O
-	O
MVcontr	O
;	O
(	O
3	O
)	O
compared	O
to	O
P	O
-	O
MVcontr	O
,	O
UP	O
-	O
MVcontr	O
and	O
UP	O
-	O
MVspont	O
,	O
UP	O
-	O
MVPS	O
yielded	O
higher	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
6	O
.	O
9	O
[	O
6	O
.	O
5	O
to	O
10	O
.	O
1	O
]	O
vs	O
.	O
2	O
.	O
8	O
[	O
2	O
.	O
2	O
to	O
3	O
.	O
0	O
],	O
3	O
.	O
6	O
[	O
3	O
.	O
0	O
to	O
4	O
.	O
7	O
]	O
and	O
4	O
.	O
0	O
[	O
2	O
.	O
8	O
to	O
4	O
.	O
4	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
and	O
interleukin	O
-	O
8	O
(	O
216	O
.	O
8	O
[	O
113	O
.	O
5	O
to	O
343	O
.	O
5	O
]	O
vs	O
.	O
59	O
.	O
8	O
[	O
45	O
.	O
3	O
to	O
66	O
.	O
7	O
],	O
37	O
.	O
6	O
[	O
18	O
.	O
8	O
to	O
52	O
.	O
0	O
],	O
and	O
59	O
.	O
5	O
[	O
36	O
.	O
1	O
to	O
79	O
.	O
7	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
in	O
dorsal	O
lung	O
zones	O
.	O

We	O
isolated	O
RNA	O
from	O
frozen	O
samples	O
and	O
performed	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
using	O
a	O
published	O
universal	O
CoV	O
primer	O
set	O
.	O

Its	O
efficacy	O
is	O
believed	O
to	O
be	O
due	O
to	O
	O
-	O
opioid	O
receptor	B-FUNC
agonist	I-FUNC
activity	I-FUNC
and	O
inhibition	O
of	O
norepinephrine	O
reuptake	O
resulting	O
in	O
increased	O
norepinephrine	O
concentrations	O
.	O

In	O
addition	O
,	O
the	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
was	O
used	O
to	O
raise	O
polyclonal	O
antibodies	O
in	O
mice	O
.	O

The	O
RBD	O
efficiently	O
elicited	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
by	O
blocking	O
viral	O
entry	O
at	O
the	O
binding	B-FUNC
step	O
.	O

Calculations	O
on	O
8a	O
are	O
compared	O
to	O
data	O
derived	O
for	O
a	O
pentameric	O
bundle	O
consisting	O
of	O
the	O
M2	O
helices	O
of	O
the	O
bacterial	O
pentameric	O
ligand	B-FUNC
gated	O
ion	O
channel	O
GLIC	O
(	O
3EHZ	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
antibody	B-FUNC
response	O
of	O
killed	O
and	O
live	O
vaccines	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
a	O
field	O
study	O
.	O

Antibody	B-FUNC
titers	O
in	O
sow	O
and	O
piglet	O
serum	O
one	O
week	O
after	O
farrowing	O
and	O
that	O
in	O
colostrum	O
were	O
compared	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
serum	O
neutralization	O
test	O
.	O

The	O
major	O
neutralizing	O
activity	O
was	O
also	O
found	O
in	O
the	O
K	O
/	O
K	O
group	O
,	O
particularly	O
in	O
colostrum	O
,	O
with	O
piglets	O
bearing	O
higher	O
neutralizing	O
activity	O
compared	O
to	O
sow	O
sera	B-FUNC
.	O

Killed	O
PEDV	O
SM98	O
vaccine	O
induced	O
higher	O
antibody	B-FUNC
levels	O
.	O

This	O
study	O
clearly	O
confirms	O
that	O
killed	O
vaccine	O
has	O
induced	O
higher	O
antibody	B-FUNC
levels	O
and	O
may	O
contribute	O
to	O
the	O
design	O
of	O
future	O
research	O
and	O
vaccine	O
programs	O
.	O

Among	O
recombinant	O
spike	O
S1	O
,	O
S2	O
,	O
S3	O
,	O
and	O
nucleocapsid	O
N	O
protein	O
of	O
PEDV	O
,	O
S3	O
protein	O
presented	O
the	O
highest	O
antibody	B-FUNC
level	O
in	O
the	O
K	O
/	O
K	O
group	O
.	O

CONCLUSIONS	O
:	O
Killed	O
PEDV	O
SM98	O
vaccine	O
induced	O
higher	O
antibody	B-FUNC
levels	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
respiratory	O
infections	O
in	O
children	O
in	O
southwestern	O
Saudi	O
Arabia	O
using	O
multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
oxygenation	O
index	O
(	O
PaO	O
/	O
FiO	O
),	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
were	O
recorded	O
within	O
24	O
hours	O
after	O
admission	O
.	O

And	O
the	O
plasma	O
levels	O
of	O
Ang	O
-	O
2	O
,	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
C	O
-	O
reaction	O
protein	O
(	O
CRP	O
)	O
were	O
measured	O
.	O

Compared	O
with	O
non	O
-	O
ARDS	O
group	O
,	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
LIS	B-FUNC
score	O
,	O
mortality	O
were	O
significantly	O
increased	O
,	O
PaO2	O
/	O
FiO2	O
was	O
significantly	O
decreased	O
,	O
and	O
plasma	O
Ang	O
-	O
2	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CRP	O
were	O
significantly	O
elevated	O
[	O
APACHEII	O
score	O
:	O
20	O
.	O
7	O
	O
5	O
.	O
0	O
vs	O
.	O
14	O
.	O
1	O
	O
5	O
.	O
3	O
,	O
SOFA	O
score	O
:	O
7	O
.	O
7	O
	O
3	O
.	O
5	O
vs	O
.	O
3	O
.	O
5	O
	O
2	O
.	O
1	O
,	O
LIS	B-FUNC
score	O
:	O
1	O
.	O
69	O
	O
0	O
.	O
71	O
vs	O
.	O
0	O
.	O
28	O
	O
0	O
.	O
27	O
,	O
PaO	O
/	O
FiO	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
159	O
.	O
5	O
	O
61	O
.	O
3	O
vs	O
.	O
394	O
.	O
0	O
	O
3	O
.	O
2	O
,	O
mortality	O
:	O
45	O
.	O
3	O
%	O
(	O
24	O
/	O
53	O
)	O
vs	O
.	O
20	O
.	O
0	O
%	O
(	O
4	O
/	O
20	O
),	O
Ang	O
-	O
2	O
(	O
g	O
/	O
L	O
):	O
4	O
.	O
73	O
(	O
2	O
.	O
59	O
,	O
6	O
.	O
99	O
)	O
vs	O
.	O

It	O
was	O
shown	O
by	O
correlation	O
analysis	O
that	O
the	O
plasma	O
levels	O
of	O
Ang	O
-	O
2	O
was	O
significantly	O
positive	O
correlated	O
with	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
r	O
=	O
0	O
.	O
468	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
CRP	O
(	O
r	O
=	O
0	O
.	O
492	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
APACHEII	O
score	O
(	O
r	O
=	O
0	O
.	O
560	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
SOFA	O
score	O
(	O
r	O
=	O
0	O
.	O
508	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
and	O
LIS	B-FUNC
score	O
(	O
r	O
=	O
0	O
.	O
588	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
significantly	O
negatively	O
correlated	O
with	O
PaO2	O
/	O
FiO2	O
(	O
r	O
=-	O
0	O
.	O
685	O
,	O
P	O
=	O
0	O
.	O
000	O
).	O

Plasma	O
levels	O
of	O
Ang	O
-	O
2	O
was	O
better	O
in	O
predicting	O
ARDS	O
than	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

RESULTS	O
:	O
Compared	O
with	O
non	O
-	O
ARDS	O
group	O
,	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
LIS	B-FUNC
score	O
,	O
mortality	O
were	O
significantly	O
increased	O
,	O
PaO2	O
/	O
FiO2	O
was	O
significantly	O
decreased	O
,	O
and	O
plasma	O
Ang	O
-	O
2	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CRP	O
were	O
significantly	O
elevated	O
[	O
APACHEII	O
score	O
:	O
20	O
.	O
7	O
	O
5	O
.	O
0	O
vs	O
.	O
14	O
.	O
1	O
	O
5	O
.	O
3	O
,	O
SOFA	O
score	O
:	O
7	O
.	O
7	O
	O
3	O
.	O
5	O
vs	O
.	O
3	O
.	O
5	O
	O
2	O
.	O
1	O
,	O
LIS	B-FUNC
score	O
:	O
1	O
.	O
69	O
	O
0	O
.	O
71	O
vs	O
.	O
0	O
.	O
28	O
	O
0	O
.	O
27	O
,	O
PaO	O
/	O
FiO	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
159	O
.	O
5	O
	O
61	O
.	O
3	O
vs	O
.	O
394	O
.	O
0	O
	O
3	O
.	O
2	O
,	O
mortality	O
:	O
45	O
.	O
3	O
%	O
(	O
24	O
/	O
53	O
)	O
vs	O
.	O
20	O
.	O
0	O
%	O
(	O
4	O
/	O
20	O
),	O
Ang	O
-	O
2	O
(	O
g	O
/	O
L	O
):	O
4	O
.	O
73	O
(	O
2	O
.	O
59	O
,	O
6	O
.	O
99	O
)	O
vs	O
.	O

TITLE	O
:	O
Tailoring	O
subunit	O
vaccine	O
immunity	O
with	O
adjuvant	O
combinations	O
and	O
delivery	O
routes	O
using	O
the	O
Middle	O
East	O
respiratory	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
receptor	O
-	O
binding	B-FUNC
domain	O
as	O
an	O
antigen	O
.	O

Interestingly	O
,	O
robust	O
RBD	O
-	O
specific	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
were	O
induced	O
in	O
mice	O
immunized	O
with	O
the	O
rRBD	O
protein	O
in	O
combination	O
with	O
IFA	O
and	O
CpG	O
ODN	O
,	O
but	O
low	O
level	O
of	O
neutralizing	O
antibodies	O
were	O
elicited	O
.	O

Virus	O
-	O
positive	O
exacerbations	O
were	O
associated	O
with	O
a	O
greater	O
increase	O
in	O
markers	O
of	O
systemic	O
and	O
airway	O
inflammation	O
(	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
;	O
sputum	O
IL	O
-	O
1	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
)	O
compared	O
with	O
virus	O
-	O
negative	O
exacerbations	O
,	O
but	O
the	O
differences	O
in	O
spirometric	O
indexes	O
,	O
quality	O
of	O
life	O
,	O
and	O
bacterial	O
density	O
were	O
unremarkable	O
.	O

TITLE	O
:	O
Comparison	O
of	O
serum	O
neutralization	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
on	O
sera	B-FUNC
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
vaccinated	O
pigs	O
.	O

Sera	B-FUNC
with	O
higher	O
neutralizing	O
activity	O
also	O
had	O
higher	O
IgG	O
titer	O
.	O

Colonic	O
tissues	O
from	O
all	O
4	O
animals	O
were	O
positive	O
by	O
fluorescent	O
antibody	B-FUNC
testing	O
and	O
/	O
or	O
immunohistochemical	O
staining	O
for	O
BoCV	O
antigen	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
encode	O
a	O
macrodomain	O
containing	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
activity	O
within	O
the	O
N	O
terminus	O
of	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
).	O

Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)	O
and	O
interferon	O
(	O
IFN	O
)	O
signaling	O
were	O
not	O
required	O
for	O
effective	O
host	O
control	O
of	O
mutant	O
virus	O
as	O
all	O
N1347A	O
virus	O
-	O
infected	O
mice	O
survived	O
the	O
infection	O
.	O

The	O
coronavirus	O
macrodomain	O
has	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
phosphatase	B-FUNC
activity	I-FUNC
;	O
however	O
,	O
its	O
function	O
during	O
infection	O
remains	O
unclear	O
as	O
does	O
the	O
reason	O
that	O
coronaviruses	O
have	O
maintained	O
this	O
enzymatic	O
activity	O
throughout	O
evolution	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
-	O
based	O
subunit	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Development	O
of	O
effective	O
vaccines	O
,	O
in	O
particular	O
,	O
subunit	O
-	O
based	O
vaccines	O
,	O
against	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
caused	O
by	O
the	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
will	O
provide	O
the	O
safest	O
means	O
of	O
preventing	O
the	O
continuous	O
spread	O
of	O
MERS	O
in	O
humans	O
and	O
camels	O
.	O

This	O
review	O
briefly	O
describes	O
the	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
discusses	O
the	O
current	O
status	O
of	O
MERS	O
vaccine	O
development	O
and	O
illustrates	O
the	O
strategies	O
used	O
to	O
develop	O
RBD	O
-	O
based	O
subunit	O
vaccines	O
against	O
MERS	O
.	O

Coronavirus	O
spike	O
proteins	O
are	O
the	O
main	O
determinant	O
of	O
entry	O
as	O
they	O
possess	O
both	O
receptor	B-FUNC
binding	I-FUNC
and	O
fusion	O
functions	O
.	O

Whereas	O
binding	B-FUNC
to	O
the	O
host	O
cell	O
receptor	O
is	O
an	O
essential	O
first	O
step	O
in	O
establishing	O
infection	O
,	O
the	O
proteolytic	O
activation	O
step	O
is	O
often	O
critical	O
for	O
the	O
fusion	O
function	O
of	O
spike	O
,	O
as	O
it	O
allows	O
for	O
controlled	O
release	O
of	O
the	O
fusion	O
peptide	O
into	O
target	O
cellular	O
membranes	O
.	O

To	O
penetrate	O
host	O
cells	O
,	O
the	O
CoV	O
can	O
use	O
various	O
cell	O
surface	O
molecules	O
,	O
although	O
they	O
preferentially	O
bind	B-FUNC
to	O
ectoenzymes	O
.	O

Here	O
we	O
discuss	O
the	O
most	O
recent	O
studies	O
on	O
the	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
and	O
its	O
role	O
in	O
virus	O
binding	B-FUNC
and	O
entry	O
,	O
and	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
entry	O
/	O
fusion	O
inhibitors	O
targeting	O
the	O
S1	O
subunit	O
,	O
particularly	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
and	O
the	O
S2	O
subunit	O
,	O
especially	O
the	O
HR1	O
region	O
,	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

SHFV	O
infection	O
induced	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
23	O
(	O
p40	O
),	O
TNF	O
-	O
	O
and	O
MIP	O
-	O
1	O
,	O
in	O
macaque	O
cells	O
but	O
not	O
baboon	O
cells	O
.	O

Here	O
,	O
we	O
report	O
identification	O
of	O
critical	O
residues	O
on	O
hDPP4	O
for	O
RBD	O
binding	B-FUNC
and	O
virus	O
entry	O
through	O
analysis	O
of	O
a	O
panel	O
of	O
hDPP4	O
mutants	O
.	O

Using	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
binding	B-FUNC
analysis	O
and	O
pseudovirus	O
infection	O
assay	O
,	O
we	O
showed	O
that	O
several	O
residues	O
in	O
hDPP4	O
-	O
RBD	O
binding	B-FUNC
interface	O
were	O
important	O
on	O
hDPP4	O
-	O
RBD	O
binding	B-FUNC
and	O
viral	O
entry	O
.	O

The	O
pattern	O
of	O
SHAPE	O
reactivity	O
of	O
in	O
virio	O
genomic	O
RNA	O
,	O
ex	O
virio	O
genomic	O
RNA	O
,	O
and	O
in	O
vitro	O
synthesized	O
RNA	O
was	O
similar	O
,	O
suggesting	O
that	O
binding	B-FUNC
of	O
N	O
protein	O
or	O
other	O
proteins	O
to	O
virion	O
RNA	O
fails	O
to	O
protect	O
the	O
RNA	O
from	O
reaction	O
with	O
lipid	O
permeable	O
SHAPE	O
reagent	O
.	O

In	O
contrast	O
,	O
LRNV	O
harbored	O
by	O
Rattus	O
norvegicus	O
formed	O
a	O
distinct	O
lineage	O
within	O
the	O
genus	O
Alphacoronavirus	O
in	O
the	O
3CL	O
(	O
pro	O
),	O
RdRp	B-FUNC
,	O
and	O
Hel	O
gene	O
trees	O
,	O
but	O
formed	O
a	O
more	O
divergent	O
lineage	O
in	O
the	O
N	O
and	O
S	O
gene	O
trees	O
,	O
indicative	O
of	O
a	O
recombinant	O
origin	O
.	O

The	O
viral	O
genome	O
has	O
an	O
abundance	O
of	O
codons	O
that	O
are	O
rare	O
in	O
the	O
host	O
and	O
are	O
decoded	O
by	O
wobble	O
tRNA	B-FUNC
pairing	O
,	O
although	O
the	O
phage	O
grows	O
well	O
and	O
expression	O
of	O
most	O
of	O
the	O
genes	O
is	O
detected	O
by	O
mass	O
spectrometry	O
.	O

Sera	B-FUNC
from	O
300	O
animal	O
workers	O
(	O
17	O
%	O
with	O
daily	O
camel	O
exposure	O
)	O
and	O
50	O
non	O
-	O
animal	O
-	O
exposed	O
controls	O
were	O
examined	O
for	O
serological	O
evidence	O
of	O
MERS	O
-	O
CoV	O
infection	O
by	O
a	O
pseudoparticle	O
MERS	O
-	O
CoV	O
spike	O
protein	O
neutralization	O
assay	O
.	O

None	O
of	O
the	O
sera	B-FUNC
reproducibly	O
neutralized	O
the	O
MERS	O
-	O
CoV	O
-	O
pseudotyped	O
lentiviral	O
vector	O
.	O

We	O
found	O
that	O
PLpro	O
is	O
able	O
to	O
block	O
the	O
type	O
I	O
IFN	O
induction	O
of	O
a	O
constitutively	O
active	O
IRF3	O
,	O
but	O
does	O
not	O
inhibit	O
IRF3	O
dimerization	O
,	O
nuclear	O
localization	O
or	O
DNA	B-FUNC
binding	I-FUNC
.	O

Interestingly	O
,	O
molecular	O
analyses	O
targeting	O
small	O
subunit	O
ribosomal	B-FUNC
RNA	I-FUNC
as	O
well	O
as	O
glycoprotein	O
60	O
(	O
GP60	O
)	O
genes	O
revealed	O
that	O
the	O
C	O
.	O
parvum	O
nucleotide	O
sequences	O
from	O
the	O
two	O
prefectures	O
were	O
identical	O
,	O
indicating	O
that	O
C	O
.	O
parvum	O
with	O
a	O
uniform	O
characteristic	O
is	O
distributed	O
throughout	O
Japan	O
.	O

Haemagglutination	O
inhibition	O
(	O
HI	O
)	O
NDV	O
antibody	B-FUNC
titres	O
were	O
similar	O
across	O
all	O
groups	O
but	O
were	O
above	O
protective	O
titres	O
.	O

We	O
present	O
here	O
a	O
new	O
method	O
for	O
virus	O
discovery	O
that	O
requires	O
a	O
virus	O
culture	O
on	O
primary	O
cells	O
and	O
an	O
antibody	B-FUNC
detection	O
.	O

CONCLUSIONS	O
:	O
We	O
present	O
here	O
a	O
new	O
method	O
for	O
virus	O
discovery	O
that	O
requires	O
a	O
virus	O
culture	O
on	O
primary	O
cells	O
and	O
an	O
antibody	B-FUNC
detection	O
.	O

Nonstructural	O
protein	O
9	O
,	O
which	O
binds	B-FUNC
to	O
the	O
single	O
-	O
stranded	O
DNA	O
/	O
RNA	O
,	O
has	O
been	O
shown	O
to	O
be	O
indispensible	O
for	O
viral	O
replication	O
.	O

TITLE	O
:	O
Antiviral	O
potential	O
of	O
ERK	B-FUNC
/	O
MAPK	B-FUNC
and	O
PI3K	B-FUNC
/	O
AKT	O
/	O
mTOR	O
signaling	O
modulation	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
as	O
identified	O
by	O
temporal	O
kinome	O
analysis	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
the	O
effects	O
of	O
specific	O
kinase	B-FUNC
inhibitors	I-FUNC
on	O
MERS	O
-	O
CoV	O
infection	O
in	O
tissue	O
culture	O
models	O
confirmed	O
these	O
cellular	O
response	O
observations	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
ERK	B-FUNC
/	O
MAPK	B-FUNC
and	O
PI3K	B-FUNC
/	O
AKT	O
/	O
mTOR	O
signaling	O
responses	O
play	O
important	O
roles	O
in	O
MERS	O
-	O
CoV	O
infection	O
and	O
may	O
represent	O
novel	O
drug	O
targets	O
for	O
therapeutic	O
intervention	O
strategies	O
.	O

Its	O
hallmark	O
is	O
the	O
presence	O
of	O
an	O
N	O
-	O
terminal	O
multi	O
-	O
nuclear	O
zinc	O
-	O
binding	B-FUNC
domain	O
,	O
the	O
nidoviral	O
genetic	O
marker	O
and	O
one	O
of	O
the	O
most	O
conserved	O
domains	O
across	O
members	O
of	O
the	O
order	O
.	O

This	O
study	O
aimed	O
at	O
evaluating	O
cytokine	O
-	O
associated	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
),	O
i	O
.	O
e	O
.,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
	O
),	O
receptor	O
-	O
associated	O
SNPs	O
,	O
i	O
.	O
e	O
.,	O
C	O
-	O
type	O
lectin	O
DC	O
-	O
SIGN	O
(	O
CD209	O
),	O
and	O
the	O
five	O
FIP	O
-	O
associated	O
SNPs	O
identified	O
from	O
Birman	O
cats	O
of	O
USA	O
and	O
Denmark	O
origins	O
and	O
their	O
associations	O
with	O
the	O
outcome	O
of	O
FCoV	O
infection	O
in	O
71	O
FIP	O
cats	O
and	O
93	O
FCoV	O
infected	O
non	O
-	O
FIP	O
cats	O
in	O
a	O
genetically	O
more	O
diverse	O
cat	O
populations	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	O
bronchitis	O
virus	O
with	O
the	O
use	O
of	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
and	O
correlation	O
with	O
virus	O
detection	O
in	O
embryonated	O
eggs	O
.	O

ABSTRACT	O
:	O
Real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assays	O
have	O
been	O
used	O
to	O
detect	O
the	O
presence	O
of	O
challenge	O
virus	O
when	O
the	O
efficacy	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
against	O
field	O
viruses	O
is	O
being	O
experimentally	O
evaluated	O
.	O

Recently	O
,	O
dipeptidyle	O
peptidase	O
(	O
CD26	O
,	O
DPP4	O
)	O
was	O
identified	O
as	O
the	O
host	O
cell	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
despite	O
of	O
common	O
presence	O
of	O
DPP4	O
receptors	O
the	O
binding	B-FUNC
and	O
infection	O
of	O
various	O
cells	O
shows	O
imminent	O
variability	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
a	O
tool	O
for	O
prediction	O
of	O
the	O
host	O
tropism	O
of	O
the	O
virus	O
based	O
on	O
the	O
host	O
receptor	B-FUNC
binding	I-FUNC
interface	O
.	O

We	O
found	O
out	O
that	O
,	O
in	O
the	O
binding	B-FUNC
of	O
MERS	O
-	O
CoV	O
to	O
cells	O
the	O
amino	O
acid	O
residues	O
in	O
lancets	O
4	O
and	O
5	O
of	O
DPP4	O
receptor	O
,	O
namely	O
K267	O
,	O
Q286	O
,	O
T288	O
,	O
R317	O
,	O
R336	O
,	O
Q344	O
A291	O
,	O
L294	O
,	O
and	O
I295	O
are	O
involved	O
.	O

Changes	O
in	O
these	O
residues	O
correspond	O
to	O
profound	O
decrease	O
in	O
virus	O
binding	B-FUNC
to	O
cells	O
.	O

This	O
study	O
shows	O
that	O
formulation	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
or	O
inactivated	O
whole	O
-	O
virus	O
vaccines	O
with	O
novel	O
delta	O
inulin	O
-	O
based	O
polysaccharide	O
adjuvants	O
enhances	O
neutralizing	O
-	O
antibody	B-FUNC
titers	O
and	O
protection	O
against	O
clinical	O
disease	O
but	O
at	O
the	O
same	O
time	O
also	O
protects	O
against	O
development	O
of	O
lung	O
eosinophilic	O
immunopathology	O
.	O

ALT	B-FUNC
levels	O
were	O
elevated	O
in	O
25	O
children	O
(	O
41	O
%)	O
and	O
31	O
(	O
51	O
.	O
66	O
%)	O
children	O
had	O
increased	O
levels	O
of	O
AST	O
.	O

Preclinical	O
studies	O
support	O
the	O
efficacy	O
of	O
mesenchymal	O
stem	O
(	O
stromal	O
)	O
cells	O
(	O
MSCs	B-FUNC
)	O
in	O
the	O
treatment	O
of	O
lung	O
injury	O
.	O

We	O
aimed	O
to	O
test	O
the	O
safety	O
of	O
a	O
single	O
dose	O
of	O
allogeneic	O
bone	O
marrow	O
-	O
derived	O
MSCs	B-FUNC
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
.	O

A	O
single	O
intravenous	O
infusion	O
of	O
allogeneic	O
,	O
bone	O
marrow	O
-	O
derived	O
human	O
MSCs	B-FUNC
was	O
well	O
tolerated	O
in	O
nine	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
.	O

The	O
full	O
-	O
length	O
spike	O
(	O
S	O
),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
were	O
amplified	O
from	O
each	O
respiratory	O
sample	O
collected	O
from	O
65	O
HCoV	O
-	O
OC43	O
-	O
positive	O
patients	O
between	O
2005	O
and	O
2012	O
.	O

Sixty	O
of	O
these	O
65	O
samples	O
belong	O
to	O
genotypes	O
B	O
,	O
C	O
and	O
D	O
.	O
The	O
remaining	O
five	O
strains	O
had	O
incongruent	O
positions	O
in	O
the	O
phylogenetic	O
trees	O
of	O
the	O
S	O
,	O
RdRp	B-FUNC
and	O
N	O
genes	O
,	O
suggesting	O
a	O
novel	O
genotype	O
emerging	O
,	O
designated	O
as	O
genotype	O
E	O
.	O
Whole	O
genome	O
sequencing	O
and	O
bootscan	O
analysis	O
indicated	O
that	O
genotype	O
E	O
is	O
generated	O
by	O
recombination	O
between	O
genotypes	O
B	O
,	O
C	O
and	O
D	O
.	O
Temporal	O
analysis	O
revealed	O
a	O
sequential	O
genotype	O
replacement	O
of	O
C	O
,	O
B	O
,	O
D	O
and	O
E	O
over	O
the	O
study	O
period	O
with	O
genotype	O
D	O
being	O
the	O
dominant	O
genotype	O
since	O
2007	O
.	O

RESULTS	O
:	O
Sixty	O
of	O
these	O
65	O
samples	O
belong	O
to	O
genotypes	O
B	O
,	O
C	O
and	O
D	O
.	O
The	O
remaining	O
five	O
strains	O
had	O
incongruent	O
positions	O
in	O
the	O
phylogenetic	O
trees	O
of	O
the	O
S	O
,	O
RdRp	B-FUNC
and	O
N	O
genes	O
,	O
suggesting	O
a	O
novel	O
genotype	O
emerging	O
,	O
designated	O
as	O
genotype	O
E	O
.	O
Whole	O
genome	O
sequencing	O
and	O
bootscan	O
analysis	O
indicated	O
that	O
genotype	O
E	O
is	O
generated	O
by	O
recombination	O
between	O
genotypes	O
B	O
,	O
C	O
and	O
D	O
.	O
Temporal	O
analysis	O
revealed	O
a	O
sequential	O
genotype	O
replacement	O
of	O
C	O
,	O
B	O
,	O
D	O
and	O
E	O
over	O
the	O
study	O
period	O
with	O
genotype	O
D	O
being	O
the	O
dominant	O
genotype	O
since	O
2007	O
.	O

Their	O
inhibition	O
mechanisms	O
and	O
mutually	O
binding	B-FUNC
synergistic	O
effect	O
were	O
also	O
investigated	O
.	O

For	O
EBOV	O
,	O
the	O
long	O
lag	O
is	O
not	O
due	O
to	O
the	O
large	O
size	O
or	O
unusual	O
shape	O
of	O
EBOV	O
filaments	O
,	O
the	O
need	O
to	O
prime	O
EBOV	O
GP	O
to	O
the	O
19	O
-	O
kDa	O
receptor	O
-	O
binding	B-FUNC
species	O
,	O
or	O
a	O
need	O
for	O
unusually	O
low	O
endosomal	O
pH	O
.	O
In	O
contrast	O
,	O
since	O
we	O
observed	O
that	O
EBOV	O
entry	O
occurs	O
upon	O
arrival	O
in	O
Niemann	O
-	O
Pick	O
C1	O
(	O
NPC1	O
)-	O
positive	O
endolysosomes	O
(	O
LE	O
/	O
Lys	O
),	O
we	O
propose	O
that	O
trafficking	O
to	O
LE	O
/	O
Lys	O
is	O
a	O
key	O
rate	O
-	O
defining	O
step	O
.	O

Its	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
demonstrated	O
higher	O
sequence	O
identity	O
to	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
NTD	O
than	O
to	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
NTD	O
,	O
with	O
3	O
of	O
4	O
critical	O
sugar	O
-	O
binding	B-FUNC
residues	O
in	O
BCoV	O
and	O
2	O
of	O
14	O
contact	O
residues	O
at	O
the	O
MHV	O
NTD	O
/	O
murine	O
CEACAM1a	O
interface	O
being	O
conserved	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
SARS	O
-	O
CoV	O
pandemic	O
infected	O
over	O
8500	O
individuals	O
,	O
claimed	O
over	O
800	O
lives	O
and	O
cost	O
billions	O
of	O
dollars	O
in	O
economic	O
loss	O
worldwide	O
,	O
there	O
still	O
are	O
no	O
clinically	O
approved	O
antiviral	O
drugs	O
,	O
vaccines	O
or	O
monoclonal	O
antibody	B-FUNC
therapies	O
to	O
treat	O
SARS	O
-	O
CoV	O
infections	O
.	O

LiCl	O
significantly	O
suppressed	O
the	O
synthesis	O
of	O
viral	O
RNA	O
and	O
protein	O
;	O
however	O
,	O
it	O
did	O
not	O
block	O
PRRSV	O
binding	B-FUNC
and	O
entry	O
.	O

RESULTS	O
:	O
LiCl	O
significantly	O
suppressed	O
the	O
synthesis	O
of	O
viral	O
RNA	O
and	O
protein	O
;	O
however	O
,	O
it	O
did	O
not	O
block	O
PRRSV	O
binding	B-FUNC
and	O
entry	O
.	O

Since	O
CESAR	O
trial	O
,	O
the	O
clinical	O
application	O
of	O
ECLA	O
for	O
ARDS	O
as	O
a	O
method	O
to	O
achieve	O
lung	O
rest	B-FUNC
has	O
wide	O
spread	O
.	O

Since	O
indoleamine	O
-	O
2	O
,	O
3	O
-	O
dioxygenase	O
(	O
IDO	B-FUNC
)	O
is	O
the	O
key	O
and	O
rate	O
-	O
limiting	O
enzyme	O
of	O
tryptophan	O
catabolism	O
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
explore	O
whether	O
specific	O
inhibition	O
of	O
IDO	B-FUNC
by	O
Levo	O
-	O
1	O
-	O
methyl	O
tryptophan	O
(	O
MT	O
)	O
could	O
affect	O
MHV	O
actions	O
.	O

Furthermore	O
,	O
histological	O
liver	O
examination	O
indicated	O
that	O
MT	O
induced	O
fibrosis	O
in	O
MHV	O
-	O
infected	O
animals	O
,	O
whereas	O
MT	O
itself	O
increased	O
uric	O
acid	O
levels	O
without	O
shortening	O
the	O
animal	O
life	O
Thus	O
,	O
under	O
our	O
experimental	O
conditions	O
,	O
results	O
indicated	O
an	O
exacerbated	O
response	O
to	O
MHV	O
infection	O
when	O
IDO	B-FUNC
was	O
blocked	O
by	O
MT	O
.	O

The	O
antibody	B-FUNC
status	O
regarding	O
BRSV	O
and	O
BoCV	O
was	O
analysed	O
with	O
commercial	O
indirect	O
ELISAs	O
.	O

TITLE	O
:	O
Genome	O
-	O
wide	O
association	O
study	O
of	O
antibody	B-FUNC
level	O
response	O
to	O
NDV	O
and	O
IBV	O
in	O
Jinghai	O
yellow	O
chicken	O
based	O
on	O
SLAF	O
-	O
seq	O
technology	O
.	O

To	O
identify	O
genes	O
associated	O
with	O
antibody	B-FUNC
levels	O
against	O
ND	O
and	O
IB	O
,	O
a	O
genome	O
-	O
wide	O
association	O
study	O
was	O
performed	O
using	O
specific	O
-	O
locus	O
amplified	O
fragment	O
sequencing	O
(	O
SLAF	O
-	O
seq	O
)	O
technology	O
in	O
Jinghai	O
yellow	O
chickens	O
.	O

This	O
determined	O
six	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
that	O
were	O
associated	O
with	O
antibody	B-FUNC
levels	O
against	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
):	O
rsZ2494661	O
,	O
rsZ2494710	O
,	O
rs1211307701	O
,	O
rs1211307711	O
,	O
rs1218289310	O
and	O
rs420701988	O
.	O

Compelling	O
pre	O
-	O
clinical	O
data	O
from	O
mouse	O
,	O
rat	O
,	O
sheep	O
and	O
ex	O
vivo	O
perfused	O
human	O
lung	O
models	O
support	O
the	O
use	O
of	O
human	O
mesenchymal	O
stem	O
(	O
stromal	O
)	O
cells	O
(	O
MSCs	B-FUNC
)	O
as	O
a	O
novel	O
intravenous	O
therapy	O
for	O
the	O
early	O
treatment	O
of	O
ARDS	O
.	O

A	O
trial	O
enrolling	O
69	O
subjects	O
is	O
planned	O
(	O
9	O
subjects	O
in	O
phase	O
1	O
,	O
60	O
subjects	O
in	O
phase	O
2	O
treated	O
with	O
MSCs	B-FUNC
or	O
placebo	O
in	O
a	O
2	O
:	O
1	O
ratio	O
).	O

A	O
model	O
of	O
ubiquitin	B-FUNC
-	O
bound	O
IBV	O
CoV	O
PLpro	O
brings	O
out	O
key	O
differences	O
in	O
substrate	O
binding	B-FUNC
sites	O
of	O
PLpros	O
.	O

In	O
particular	O
,	O
P3	O
and	O
P4	O
subsites	O
as	O
well	O
as	O
residues	O
interacting	O
with	O
the	O
	O
-	O
barrel	O
of	O
ubiquitin	B-FUNC
are	O
different	O
,	O
suggesting	O
different	O
catalytic	O
efficiencies	O
and	O
substrate	O
specificities	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
of	O
pyrrolyl	O
diketo	O
acid	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	O
and	O
reverse	O
transcriptase	B-FUNC
ribonuclease	O
H	O
domain	O
.	O

The	O
relative	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
were	O
found	O
to	O
be	O
93	O
.	O
90	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
compared	O
to	O
that	O
of	O
the	O
UpE	O
and	O
open	O
reading	O
frame	O
1A	O
(	O
Orf1A	O
)	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
PCR	O
).	O

We	O
previously	O
demonstrated	O
that	O
residues	O
377	O
-	O
588	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
is	O
a	O
very	O
promising	O
MERS	O
subunit	O
vaccine	O
candidate	O
,	O
capable	O
of	O
inducing	O
potent	O
neutralization	O
antibody	B-FUNC
responses	O
.	O

In	O
the	O
absence	O
of	O
adjuvant	O
,	O
S377	O
-	O
588	O
-	O
Fc	O
alone	O
induced	O
readily	O
detectable	O
neutralizing	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
in	O
immunized	O
mice	O
.	O

The	O
addition	O
of	O
MF59	O
significantly	O
augmented	O
the	O
immunogenicity	O
of	O
S377	O
-	O
588	O
-	O
Fc	O
to	O
induce	O
strong	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
responses	O
as	O
well	O
as	O
protection	O
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
mice	O
,	O
suggesting	O
that	O
MF59	O
is	O
an	O
optimal	O
adjuvant	O
for	O
MERS	O
-	O
CoV	O
RBD	O
-	O
based	O
subunit	O
vaccines	O
.	O

TITLE	O
:	O
Insulated	O
Isothermal	O
Reverse	O
Transcriptase	B-FUNC
PCR	O
(	O
iiRT	O
-	O
PCR	O
)	O
for	O
Rapid	O
and	O
Sensitive	O
Detection	O
of	O
Classical	O
Swine	O
Fever	O
Virus	O
.	O

RdRp	B-FUNC
sequences	O
allocated	O
all	O
Costa	O
Rican	O
bat	O
CoVs	O
to	O
the	O
	O
-	O
CoV	O
group	O
.	O

The	O
antiviral	O
effect	O
of	O
ouabain	O
could	O
be	O
relieved	O
by	O
the	O
addition	O
of	O
different	O
Src	O
kinase	B-FUNC
inhibitors	I-FUNC
,	O
indicating	O
that	O
Src	O
signaling	O
mediated	O
via	O
ATP1A1	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
inhibition	O
of	O
CoV	O
and	O
VSV	O
infections	O
.	O

Targeting	O
ATP1A1	O
either	O
by	O
gene	O
silencing	O
or	O
by	O
low	O
concentrations	O
of	O
the	O
ATP1A1	O
-	O
binding	B-FUNC
cardiotonic	O
steroids	O
ouabain	O
and	O
bufalin	O
resulted	O
in	O
inhibition	O
of	O
infection	O
with	O
murine	O
,	O
feline	O
,	O
and	O
MERS	O
-	O
CoVs	O
at	O
an	O
early	O
entry	O
stage	O
.	O

The	O
UPLC	O
-	O
DAD	O
method	O
was	O
evaluated	O
with	O
linearity	O
,	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
),	O
limit	O
of	O
quantification	O
(	O
LOQ	O
),	O
precision	O
,	O
stability	O
,	O
repeatability	O
,	O
and	O
recovery	O
tests	O
.	O

A	O
method	O
,	O
termed	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
AC	O
-	O
ELISA	O
),	O
which	O
used	O
the	O
monoclonal	O
antibody	B-FUNC
5D7	O
as	O
the	O
detecting	O
antibody	B-FUNC
and	O
rabbit	O
antiserum	O
of	O
PEDV	O
protein	O
S	O
as	O
the	O
capture	O
antibody	B-FUNC
,	O
was	O
developed	O
.	O

Plasma	O
samples	O
were	O
collected	O
within	O
24	O
hours	O
and	O
levels	O
of	O
sRAGE	O
were	O
determined	O
using	O
a	O
commercially	O
available	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	B-FUNC
.	O

52	O
%	O
of	O
cases	O
were	O
identified	O
as	O
primary	O
,	O
with	O
the	O
rest	B-FUNC
being	O
secondary	O
.	O

After	O
encouraging	O
successes	O
with	O
the	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
pandemic	O
,	O
the	O
intent	O
of	O
the	O
legally	O
binding	B-FUNC
Treaty	O
to	O
improve	O
the	O
capacity	O
of	O
all	O
countries	O
to	O
detect	O
,	O
assess	O
,	O
notify	O
,	O
and	O
respond	O
to	O
public	O
health	O
threats	O
has	O
shamefully	O
lapsed	O
.	O

ABSTRACT	O
:	O
Aptamers	O
are	O
in	O
vitro	O
selected	O
DNA	O
or	O
RNA	O
molecules	O
that	O
are	O
capable	O
of	O
binding	B-FUNC
a	O
wide	O
range	O
of	O
nucleic	O
and	O
non	O
-	O
nucleic	O
acid	O
molecules	O
with	O
high	O
affinity	O
and	O
specificity	O
.	O

ABSTRACT	O
:	O
Ubiquitin	B-FUNC
-	O
like	O
domains	O
(	O
Ubls	O
)	O
now	O
are	O
recognized	O
as	O
common	O
elements	O
adjacent	O
to	O
viral	O
and	O
cellular	O
proteases	O
;	O
however	O
,	O
their	O
function	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
tested	O
the	O
effect	O
of	O
altering	O
the	O
Ubl	O
adjacent	O
to	O
PLP2	O
of	O
MHV	O
on	O
enzyme	B-FUNC
activity	I-FUNC
,	O
viral	O
replication	O
,	O
and	O
pathogenesis	O
.	O

Using	O
deletion	O
and	O
substitution	O
approaches	O
,	O
we	O
identified	O
sites	O
within	O
the	O
Ubl	O
domain	O
,	O
residues	O
785	O
to	O
787	O
of	O
nonstructural	O
protein	O
3	O
,	O
which	O
negatively	O
affect	O
protease	B-FUNC
activity	I-FUNC
,	O
and	O
valine	O
residues	O
785	O
and	O
787	O
,	O
which	O
negatively	O
affect	O
deubiquitinating	O
activity	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
the	O
mutation	O
on	O
protease	B-FUNC
activity	I-FUNC
,	O
we	O
purified	O
WT	O
and	O
Ubl	O
mutant	O
PLP2	O
and	O
found	O
that	O
the	O
proteases	O
exhibit	O
similar	O
specific	O
activities	O
at	O
25	O
	O
C	O
.	O

We	O
asked	O
if	O
changes	O
in	O
the	O
Ubl	O
domain	O
,	O
a	O
conserved	O
domain	O
adjacent	O
to	O
the	O
coronavirus	O
papain	O
-	O
like	O
protease	O
,	O
altered	O
the	O
viral	O
protease	B-FUNC
activity	I-FUNC
or	O
affected	O
viral	O
replication	O
or	O
pathogenesis	O
.	O

Biochemical	O
analyses	O
revealed	O
that	O
the	O
protein	O
shares	O
characteristics	O
with	O
homologous	O
proteins	O
encoded	O
in	O
other	O
coronaviral	O
genomes	O
,	O
with	O
the	O
N	O
-	O
terminal	O
domain	O
responsible	O
for	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
and	O
the	O
C	O
-	O
terminal	O
domain	O
involved	O
in	O
protein	O
oligomerization	O
.	O

The	O
E	O
protein	O
possesses	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
.	O

Hexamethylene	O
amiloride	O
(	O
HMA	O
),	O
a	O
viroporin	O
inhibitor	O
,	O
can	O
inhibit	O
the	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
the	O
E	O
protein	O
and	O
replication	O
of	O
several	O
coronaviruses	O
.	O

We	O
investigated	O
whether	O
there	O
is	O
a	O
difference	O
in	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
the	O
E	O
protein	O
between	O
viral	O
serotypes	O
using	O
E	O
.	O
coli	O
cells	O
expressing	O
the	O
E	O
protein	O
of	O
FIPV	O
serotypes	O
I	O
and	O
II	O
.	O

The	O
presentation	O
of	O
E2S	O
-	O
like	O
,	O
SARS	O
spike	O
protein	O
-	O
like	O
,	O
or	O
toxin	O
-	O
like	O
domains	O
by	O
the	O
N10	O
and	O
N11	O
proteins	O
in	O
these	O
emerging	O
viruses	O
may	O
indicate	O
that	O
H17N10	O
and	O
H18N11	O
sialidase	O
-	O
facilitated	O
cell	O
entry	O
has	O
been	O
supplemented	O
or	O
replaced	O
by	O
sialidase	O
-	O
independent	O
receptor	B-FUNC
binding	I-FUNC
to	O
an	O
expanded	O
cell	O
population	O
that	O
may	O
include	O
neurons	O
and	O
T	O
-	O
cells	O
.	O

To	O
this	O
end	O
,	O
we	O
compared	O
the	O
Rapid	O
Diagnostic	O
Kit	B-FUNC
of	O
Canine	O
Parvovirus	O
,	O
Coronavirus	O
and	O
Rotavirus	O
antigen	O
(	O
Quicking	O
())	O
to	O
PCR	O
,	O
which	O
is	O
considered	O
as	O
the	O
most	O
reliable	O
diagnostic	O
method	O
.	O

To	O
assess	O
the	O
association	O
between	O
BRD	O
and	O
antibody	B-FUNC
titers	O
,	O
38	O
calves	O
<	O
3	O
months	O
old	O
that	O
were	O
treated	O
for	O
BRD	O
were	O
matched	O
with	O
38	O
untreated	O
calves	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
vaccination	O
on	O
antibody	B-FUNC
titers	O
,	O
24	O
calves	O
were	O
randomly	O
assigned	O
to	O
be	O
vaccinated	O
against	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
bovine	O
viral	O
diarrhea	O
virus	O
types	O
1	O
and	O
2	O
,	O
bovine	O
herpesvirus	O
type	O
1	O
(	O
BHV1	O
),	O
and	O
parainfluenza	O
virus	O
type	O
3	O
at	O
2	O
weeks	O
of	O
age	O
(	O
n	O
=	O
6	O
),	O
5	O
weeks	O
of	O
age	O
(	O
6	O
),	O
and	O
both	O
2	O
and	O
5	O
weeks	O
of	O
age	O
(	O
6	O
)	O
or	O
were	O
assigned	O
to	O
be	O
unvaccinated	O
controls	O
(	O
6	O
).	O

Blood	O
samples	O
were	O
obtained	O
at	O
I	O
,	O
2	O
,	O
5	O
,	O
and	O
12	O
weeks	O
for	O
determination	O
of	O
serum	O
neutralization	O
antibody	B-FUNC
titers	O
against	O
the	O
vaccine	O
viruses	O
,	O
bovine	O
coronavirus	O
,	O
and	O
Mannheimia	O
haemolytica	O
.	O

Calves	O
with	O
high	O
initial	O
antibody	B-FUNC
titers	O
against	O
BRSV	O
and	O
BHV1	O
had	O
lower	O
odds	O
of	O
BRD	O
than	O
did	O
calves	O
with	O
low	O
initial	O
antibody	B-FUNC
titers	O
against	O
those	O
2	O
pathogens	O
.	O

Vaccination	O
at	O
2	O
or	O
5	O
weeks	O
of	O
age	O
had	O
no	O
effect	O
on	O
the	O
rate	O
of	O
antibody	B-FUNC
decay	O
.	O

Clinical	O
BRD	O
and	O
the	O
serologic	O
response	O
of	O
dairy	O
calves	O
were	O
associated	O
with	O
initial	O
antibody	B-FUNC
titers	O
against	O
BRSV	O
and	O
BHV1	O
.	O

ABSTRACT	O
:	O
The	O
immunochromatographic	O
assay	O
(	O
ICA	O
)	O
is	O
a	O
simple	O
antibody	B-FUNC
-	O
antigen	O
detection	O
method	O
,	O
the	O
results	O
of	O
which	O
can	O
be	O
rapidly	O
obtained	O
at	O
a	O
low	O
cost	O
.	O

TITLE	O
:	O
Protein	O
histochemistry	O
using	O
coronaviral	O
spike	O
proteins	O
:	O
studying	O
binding	B-FUNC
profiles	O
and	O
sialic	O
acid	O
requirements	O
for	O
attachment	O
to	O
tissues	O
.	O

In	O
particular	O
,	O
sialic	O
acid	O
-	O
mediated	O
tissue	O
binding	B-FUNC
of	O
spike	O
proteins	O
can	O
be	O
analyzed	O
by	O
pretreating	O
tissues	O
with	O
various	O
neuraminidases	O
or	O
by	O
blocking	O
the	O
binding	B-FUNC
of	O
the	O
viral	O
proteins	O
with	O
specific	O
lectins	O
.	O

ABSTRACT	O
:	O
Single	O
particle	O
tracking	O
(	O
SPT	B-FUNC
)	O
of	O
individual	O
virion	O
fusion	O
with	O
host	O
cell	O
membranes	O
using	O
total	O
internal	O
reflection	O
microscopy	O
(	O
TIRFM	O
)	O
is	O
a	O
powerful	O
technique	O
for	O
quantitatively	O
characterizing	O
virus	O
-	O
host	O
interactions	O
.	O

This	O
receptor	O
binds	B-FUNC
feline	O
coronavirus	O
(	O
FECV	O
1683	O
).	O

Here	O
,	O
we	O
detail	O
the	O
RNAi	O
method	O
we	O
have	O
developed	O
and	O
used	O
to	O
specifically	O
knock	O
down	O
the	O
expression	O
of	O
ezrin	O
,	O
an	O
actin	B-FUNC
binding	I-FUNC
protein	O
that	O
was	O
identified	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
to	O
interact	O
with	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Compared	O
with	O
VicS	O
-	O
v	O
,	O
the	O
more	O
attenuated	O
VicS	O
-	O
del	O
strain	O
had	O
two	O
non	O
-	O
synonymous	O
changes	O
in	O
the	O
non	O
-	O
structural	O
protein	O
6	O
(	O
nsp6	O
),	O
a	O
transmembrane	O
(	O
TM	O
)	O
domain	O
that	O
may	O
participate	O
in	O
autocatalytic	O
release	O
of	O
the	O
3	O
-	O
chymotrypsin	O
-	O
like	O
protease	O
,	O
a	O
polymorphic	O
difference	O
at	O
the	O
end	O
of	O
the	O
S2	O
gene	O
,	O
which	O
coincided	O
with	O
the	O
body	O
transcription	O
-	O
regulating	O
sequence	O
(	O
B	O
-	O
TRS	B-FUNC
)	O
of	O
mRNA	O
3	O
and	O
a	O
truncated	O
open	O
reading	O
frame	O
for	O
a	O
peptide	O
encoded	O
by	O
gene	O
4	O
(	O
4b	O
).	O

This	O
study	O
suggests	O
the	O
potential	O
role	O
of	O
the	O
TM	O
domain	O
in	O
nsp6	O
,	O
the	O
integrity	O
of	O
the	O
S2	O
protein	O
and	O
the	O
B	O
-	O
TRS	B-FUNC
3	O
,	O
and	O
the	O
putative	O
accessory	O
protein	O
4b	O
,	O
as	O
well	O
as	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
in	O
the	O
virulence	O
and	O
replication	O
of	O
IBV	O
and	O
has	O
provided	O
a	O
better	O
understanding	O
of	O
relationships	O
between	O
the	O
Australian	O
vaccine	O
strain	O
of	O
IBV	O
and	O
those	O
used	O
elsewhere	O
.	O

Female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
S	O
protein	O
,	O
and	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
designated	O
as	O
2D1	O
against	O
S	O
protein	O
was	O
achieved	O
by	O
hybridoma	O
technique	O
.	O

The	O
anti	O
-	O
S1	O
MAbs	O
produced	O
in	O
the	O
present	O
work	O
may	O
be	O
valuable	O
in	O
developing	O
an	O
antigen	O
-	O
capture	O
ELISA	O
test	O
for	O
antigen	O
detection	O
or	O
a	O
competitive	O
ELISA	O
test	O
for	O
antibody	B-FUNC
detection	O
or	O
therapeutic	O
medicine	O
for	O
IB	O
in	O
poultry	O
.	O

TITLE	O
:	O
(	O
3Z	O
)-	O
3	O
-(	O
2	O
-[	O
4	O
-(	O
aryl	O
)-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
yl	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
)-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
(	O
RT	O
)	O
is	O
a	O
validated	O
and	O
deeply	O
explored	O
biological	O
target	O
for	O
the	O
treatment	O
of	O
AIDS	O
.	O

TITLE	O
:	O
MERS	O
coronavirus	O
envelope	O
protein	O
has	O
a	O
single	O
transmembrane	O
domain	O
that	O
forms	O
pentameric	O
ion	B-FUNC
channels	I-FUNC
.	O

In	O
both	O
cases	O
,	O
abolishment	O
of	O
channel	B-FUNC
activity	I-FUNC
may	O
be	O
a	O
contributor	O
to	O
the	O
attenuation	O
observed	O
in	O
E	O
-	O
deleted	O
viruses	O
.	O

Based	O
on	O
these	O
similarities	O
,	O
and	O
the	O
proposed	O
involvement	O
of	O
channel	B-FUNC
activity	I-FUNC
as	O
virulence	O
factor	O
in	O
SARS	O
-	O
CoV	O
E	O
protein	O
,	O
MERS	O
-	O
CoV	O
E	O
protein	O
may	O
constitute	O
a	O
potential	O
drug	O
target	O
.	O

A	O
number	O
of	O
host	O
RNA	O
proteins	O
have	O
been	O
shown	O
to	O
bind	B-FUNC
to	O
the	O
5	O
'	O
and	O
3	O
'	O
cis	O
-	O
acting	O
regions	O
,	O
but	O
the	O
significance	O
of	O
these	O
in	O
viral	O
replication	O
is	O
not	O
clear	O
.	O

Two	O
viral	O
proteins	O
have	O
been	O
identified	O
as	O
binding	B-FUNC
to	O
the	O
5	O
'	O
cis	O
-	O
acting	O
region	O
,	O
nsp1	O
and	O
N	O
protein	O
.	O

A	O
genetic	O
interaction	O
between	O
nsp8	O
and	O
nsp9	O
and	O
the	O
region	O
of	O
the	O
3	O
'	O
UTR	O
that	O
contains	O
the	O
putative	O
molecular	O
switch	O
suggests	O
that	O
these	O
two	O
proteins	O
bind	B-FUNC
to	O
this	O
region	O
.	O

TITLE	O
:	O
From	O
the	O
traditional	O
Chinese	O
medicine	O
plant	O
Schisandra	O
chinensis	O
new	O
scaffolds	O
effective	O
on	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
resistant	O
to	O
non	O
-	O
nucleoside	O
inhibitors	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
an	O
adult	O
patient	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
ventilator	O
associated	O
pneumonia	O
(	O
VAP	O
)	O
caused	O
by	O
multidrug	O
resistant	O
(	O
MDR	B-FUNC
)	O
bacteria	O
that	O
was	O
successfully	O
managed	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

HIV	O
infected	O
patients	O
with	O
ARDS	O
and	O
MDR	B-FUNC
bacterial	O
VAP	O
whose	O
HIV	O
replication	O
is	O
controlled	O
by	O
ART	O
could	O
be	O
successfully	O
managed	O
with	O
ECMO	O
.	O

CONCLUSIONS	O
:	O
HIV	O
infected	O
patients	O
with	O
ARDS	O
and	O
MDR	B-FUNC
bacterial	O
VAP	O
whose	O
HIV	O
replication	O
is	O
controlled	O
by	O
ART	O
could	O
be	O
successfully	O
managed	O
with	O
ECMO	O
.	O

TITLE	O
:	O
Recombinant	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
detection	O
of	O
antibody	B-FUNC
to	O
turkey	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
(	O
N	O
)	O
protein	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
was	O
expressed	O
in	O
a	O
prokaryotic	O
system	O
and	O
used	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	B-FUNC
to	O
TCoV	O
.	O
Anti	O
-	O
TCoV	O
hyperimmune	O
turkey	O
serum	O
and	O
normal	O
turkey	O
serum	O
were	O
used	O
as	O
positive	O
or	O
negative	O
controls	O
for	O
optimization	O
of	O
the	O
ELISA	O
.	O

Goat	O
anti	O
-	O
turkey	O
IgG	O
(	O
H	O
+	O
L	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-FUNC
.	O

Three	O
hundred	O
and	O
twenty	O
two	O
turkey	O
sera	B-FUNC
from	O
the	O
field	O
were	O
used	O
to	O
evaluate	O
the	O
performance	O
of	O
ELISA	O
and	O
determine	O
the	O
cut	O
-	O
off	O
point	O
of	O
ELISA	O
.	O

Of	O
the	O
322	O
sera	B-FUNC
from	O
the	O
field	O
,	O
101	O
were	O
positive	O
for	O
TCoV	O
by	O
immunofluorescent	O
antibody	B-FUNC
assay	O
(	O
IFA	O
).	O

These	O
results	O
indicated	O
that	O
the	O
established	O
antibody	B-FUNC
-	O
capture	O
ELISA	O
in	O
conjunction	O
with	O
recombinant	O
TCoV	O
N	O
protein	O
as	O
the	O
coating	O
protein	O
can	O
be	O
utilized	O
for	O
detection	O
of	O
antibodies	O
to	O
TCoV	O
in	O
turkey	O
flocks	O
.	O

TITLE	O
:	O
Inhibitor	O
recognition	O
specificity	O
of	O
MERS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
may	O
differ	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
blocking	O
loop	O
2	O
(	O
BL2	O
)	O
structure	O
differs	O
significantly	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
where	O
it	O
has	O
been	O
proven	O
to	O
play	O
a	O
crucial	O
role	O
in	O
SARS	O
-	O
CoV	O
PLpro	O
inhibitor	O
binding	B-FUNC
.	O

Structure	O
and	O
sequence	O
alignments	O
revealed	O
that	O
two	O
residues	O
,	O
Y269	O
and	O
Q270	O
,	O
responsible	O
for	O
inhibitor	O
binding	B-FUNC
to	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
were	O
replaced	O
by	O
T274	O
and	O
A275	O
in	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
making	O
critical	O
binding	B-FUNC
interactions	O
difficult	O
to	O
form	O
for	O
similar	O
types	O
of	O
inhibitors	O
.	O

In	O
addition	O
,	O
inhibitory	O
activity	O
of	O
this	O
compound	O
was	O
selective	O
for	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
PLpro	O
enzymes	O
over	O
two	O
human	O
homologues	O
,	O
the	O
ubiquitin	B-FUNC
C	O
-	O
terminal	O
hydrolases	O
1	O
and	O
3	O
(	O
hUCH	O
-	O
L1	O
and	O
hUCH	O
-	O
L3	O
).	O

ABSTRACT	O
:	O
A	O
32	O
-	O
nucleotide	O
(	O
nt	O
)	O
RNA	O
motif	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
genome	O
was	O
found	O
to	O
specifically	O
interact	O
with	O
the	O
host	O
proteins	O
glutamyl	O
-	O
prolyl	O
-	O
tRNA	B-FUNC
synthetase	O
(	O
EPRS	O
)	O
and	O
arginyl	O
-	O
tRNA	B-FUNC
synthetase	O
(	O
RRS	O
).	O

The	O
combination	O
of	O
anti	O
-	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
immunoglobulin	B-FUNC
and	O
entecavir	O
was	O
initiated	O
for	O
anti	O
-	O
HBV	O
therapy	O
.	O

Intragastric	O
administration	O
of	O
either	O
Ad5	O
-	O
S	O
or	O
Ad41	O
-	O
S	O
induced	O
antigen	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
in	O
serum	O
;	O
however	O
,	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
responses	O
were	O
not	O
detected	O
.	O

TITLE	O
:	O
SARS	O
hCoV	O
papain	O
-	O
like	O
protease	O
is	O
a	O
unique	O
Lys48	O
linkage	O
-	O
specific	O
di	O
-	O
distributive	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
.	O

ABSTRACT	O
:	O
Ubiquitin	B-FUNC
(	O
Ub	B-FUNC
)	O
and	O
the	O
Ub	B-FUNC
-	O
like	O
(	O
Ubl	O
)	O
modifier	O
interferon	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
participate	O
in	O
the	O
host	O
defence	O
of	O
viral	O
infections	O
.	O

The	O
di	O
-	O
distributive	O
cleavage	O
mechanism	O
for	O
SARS	O
PLpro	O
appears	O
to	O
be	O
uncommon	O
among	O
USP	B-FUNC
(	O
Ub	O
-	O
specific	O
protease	O
)-	O
family	O
DUBs	O
,	O
as	O
related	O
USP	B-FUNC
family	O
members	O
from	O
humans	O
do	O
not	O
display	O
such	O
a	O
mechanism	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS5B	O
RNA	O
-	O
depended	O
-	O
RNA	O
-	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
is	O
an	O
essential	O
enzyme	O
in	O
HCV	O
viral	O
replication	O
and	O
has	O
no	O
functional	O
equivalent	O
in	O
mammalian	O
cells	O
.	O

Thus	O
,	O
exploring	O
glycan	O
-	O
binding	B-FUNC
profiles	O
of	O
broad	O
-	O
spectrum	O
virus	O
-	O
neutralizing	O
agents	O
may	O
provide	O
key	O
information	O
to	O
uncover	O
the	O
carbohydrate	O
-	O
based	O
virus	O
-	O
neutralizing	O
epitopes	O
.	O

Although	O
these	O
agents	O
were	O
known	O
to	O
be	O
specific	O
for	O
oligomannosyl	O
antigens	O
,	O
they	O
differ	O
strikingly	O
in	O
virus	O
-	O
binding	B-FUNC
activities	O
.	O

These	O
findings	O
highlight	O
the	O
potential	O
of	O
N	O
-	O
glycan	O
cryptic	O
sugar	O
moieties	O
as	O
conserved	O
targets	O
for	O
broad	O
-	O
spectrum	O
virus	O
neutralization	O
and	O
suggest	O
the	O
GNA	O
-	O
model	O
of	O
glycan	O
-	O
binding	B-FUNC
warrants	O
focused	O
investigation	O
.	O

A	O
total	O
of	O
126	O
proteins	O
were	O
identified	O
that	O
were	O
differentially	O
expressed	O
between	O
the	O
PEDV	O
-	O
infected	O
and	O
mock	O
-	O
infected	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
quantitative	O
ratio	O
	O
1	O
.	O
2	O
),	O
among	O
which	O
the	O
expression	O
of	O
58	O
proteins	O
was	O
up	O
-	O
regulated	O
and	O
that	O
of	O
68	O
proteins	O
was	O
down	O
-	O
regulated	O
in	O
the	O
PEDV	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
involving	O
in	O
integrin	O
2	O
/	O
3	O
,	O
cystatin	O
-	O
C	O
.	O
The	O
Gene	O
Ontology	O
analysis	O
indicated	O
that	O
the	O
molecular	B-FUNC
function	I-FUNC
of	O
the	O
differentially	O
expressed	O
proteins	O
(	O
DEPs	O
)	O
was	O
primarily	O
related	O
to	O
binding	B-FUNC
and	O
catalytic	B-FUNC
activity	I-FUNC
,	O
and	O
that	O
the	O
biological	O
functions	O
in	O
which	O
the	O
DEPs	O
are	O
involved	O
included	O
metabolism	O
,	O
organismal	O
systems	O
,	O
cellular	O
processes	O
,	O
genetic	O
information	O
processing	O
,	O
environmental	O
information	O
processing	O
,	O
and	O
diseases	O
.	O

Among	O
the	O
disease	O
-	O
related	O
functions	O
,	O
certain	O
anti	O
-	O
viral	O
pathways	O
and	O
proteins	O
,	O
such	O
as	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
,	O
Rap1	O
,	O
autophagy	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
PI3K	B-FUNC
-	O
Akt	O
and	O
Jak	B-FUNC
-	O
STAT	O
signaling	O
pathways	O
,	O
and	O
integrin	O
2	O
/	O
3	O
and	O
cystatin	O
-	O
C	O
proteins	O
,	O
represented	O
potential	O
factors	O
in	O
PEDV	O
infection	O
.	O

One	O
promising	O
approach	O
is	O
passive	O
administration	O
of	O
sera	B-FUNC
from	O
convalescent	O
human	O
MERS	O
patients	O
or	O
other	O
animals	O
to	O
exposed	O
or	O
infected	O
patients	O
.	O

The	O
vast	O
majority	O
of	O
,	O
if	O
not	O
all	O
,	O
camels	O
in	O
the	O
Middle	O
East	O
have	O
been	O
infected	O
with	O
MERS	O
-	O
CoV	O
,	O
and	O
some	O
contain	O
high	O
titers	O
of	O
antibody	B-FUNC
to	O
the	O
virus	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
antibody	B-FUNC
is	O
protective	O
if	O
delivered	O
either	O
prophylactically	O
or	O
therapeutically	O
to	O
mice	O
infected	O
with	O
MERS	O
-	O
CoV	O
,	O
indicating	O
that	O
this	O
may	O
be	O
a	O
useful	O
intervention	O
in	O
infected	O
patients	O
.	O

RNA	O
synthesis	O
by	O
the	O
prototype	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
is	O
carried	O
out	O
by	O
a	O
replicase	O
-	O
transcriptase	B-FUNC
composed	O
of	O
16	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
subunits	O
.	O

The	O
largest	O
component	O
of	O
the	O
coronavirus	O
replicase	O
-	O
transcriptase	B-FUNC
complex	O
,	O
nsp3	O
,	O
contains	O
multiple	O
modules	O
,	O
many	O
of	O
which	O
do	O
not	O
have	O
clearly	O
defined	O
functions	O
in	O
genome	O
replication	O
or	O
transcription	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
associations	O
between	O
the	O
functional	O
polymorphisms	O
G	O
-	O
2518A	O
at	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
gene	O
(	O
CCL2	O
)	O
and	O
mannose	B-FUNC
binding	I-FUNC
lectin	I-FUNC
(	O
MBL	O
)	O
codon	O
54	O
variant	O
(	O
A	O
/	O
B	O
)	O
and	O
susceptibility	O
to	O
SARS	O
.	O

It	O
was	O
identified	O
to	O
be	O
approximately	O
32	O
kDa	O
as	O
a	O
His	O
-	O
tagged	O
fusion	O
protein	O
and	O
can	O
bind	B-FUNC
IBV	O
positive	O
serum	O
by	O
western	O
blot	O
analysis	O
.	O

The	O
relative	O
sensitivity	O
and	O
specificity	O
between	O
the	O
SE	O
-	O
ELISA	O
and	O
IDEXX	O
ELISA	O
kit	B-FUNC
were	O
92	O
.	O
38	O
and	O
89	O
.	O
83	O
%,	O
respectively	O
,	O
with	O
an	O
accuracy	O
of	O
91	O
.	O
46	O
%.	O

For	O
the	O
systemic	O
response	O
,	O
we	O
obtained	O
plasma	O
levels	O
of	O
Tumor	B-FUNC
Necrosis	I-FUNC
Factor	I-FUNC
-	O
	O
,	O
Interleukin	O
-	O
6	O
and	O
Matrix	O
-	O
Metalloprotease	O
-	O
9	O
by	O
ELISA	O
.	O

There	O
was	O
a	O
3	O
-	O
fold	O
increase	O
in	O
plasma	O
Tumor	B-FUNC
Necrosis	I-FUNC
Factor	I-FUNC
-	O
	O
,	O
a	O
7	O
-	O
fold	O
increase	O
in	O
plasma	O
Interleukin	O
-	O
6	O
and	O
a	O
20	O
-	O
fold	O
increase	O
in	O
lavage	O
fluid	O
Matrix	O
-	O
Metalloprotease	O
-	O
9	O
by	O
HVt	O
but	O
simvastatin	O
reduced	O
these	O
levels	O
to	O
control	O
.	O

nsp14	O
associates	O
with	O
the	O
CoV	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
nsp12	O
-	O
RdRp	B-FUNC
),	O
and	O
nsp14	O
-	O
ExoN	O
activity	O
is	O
enhanced	O
by	O
binding	B-FUNC
nsp10	O
,	O
a	O
small	O
nonenzymatic	O
protein	O
.	O

TITLE	O
:	O
Optimization	O
of	O
antigen	O
dose	O
for	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
-	O
based	O
subunit	O
vaccine	O
against	O
MERS	O
coronavirus	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
recombinant	O
protein	O
containing	O
residues	O
377	O
-	O
588	O
of	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
fused	O
with	O
human	O
Fc	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
induced	O
highly	O
potent	O
anti	O
-	O
MERS	O
-	O
CoV	O
neutralizing	O
antibodies	O
in	O
the	O
presence	O
of	O
MF59	O
adjuvant	O
.	O

IgM	O
antibody	B-FUNC
was	O
positive	O
in	O
all	O
the	O
17	O
cases	O
,	O
which	O
included	O
9	O
male	O
cases	O
,	O
8	O
female	O
cases	O
,	O
and	O
their	O
age	O
was	O
from	O
2	O
months	O
to	O
10	O
years	O
.	O

TITLE	O
:	O
Plasma	O
level	O
of	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
and	O
aquaporin	B-FUNC
5	O
in	O
preterm	O
infants	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
plasma	O
level	O
of	O
soluble	O
receptors	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
sRAGE	O
)	O
and	O
aquaporin	B-FUNC
5	O
(	O
AQP5	O
)	O
in	O
preterm	O
infants	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
).	O

Inactivated	O
adjuvanted	O
monovalent	O
vaccines	O
were	O
administered	O
intramuscularly	O
to	O
five	O
week	O
old	O
pigs	O
in	O
a	O
dose	O
titration	O
experimental	O
design	O
,	O
ranging	O
from	O
6	O
.	O
0	O
-	O
8	O
.	O
0	O
log10	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
/	O
mL	O
),	O
to	O
evaluate	O
immunogenicity	O
using	O
a	O
fluorescent	O
foci	O
neutralization	O
assay	O
(	O
FFN	O
),	O
fluorescent	O
microsphere	O
immunoassay	O
(	O
FMIA	O
),	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
on	O
sera	B-FUNC
.	O

The	O
end	O
point	O
was	O
6	O
h	O
.	O
Plasma	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
keratinocyte	O
chemoattractant	O
(	O
KC	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
),	O
and	O
lung	O
histology	O
were	O
carried	O
out	O
.	O

RESULTS	O
:	O
The	O
posttraumatic	O
lung	O
injury	O
group	O
demonstrated	O
significantly	O
higher	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
when	O
compared	O
with	O
HS	O
group	O
(	O
744	O
.	O
8	O
	O
104	O
versus	O
297	O
.	O
7	O
	O
134	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
004	O
).	O

The	O
successful	O
outcome	O
in	O
this	O
case	O
resulted	O
from	O
the	O
central	O
ECMO	O
,	O
which	O
enabled	O
""""	O
lung	O
rest	B-FUNC
""""	O
and	O
adequate	O
cerebral	O
blood	O
flow	O
.	O

CONCLUSIONS	O
:	O
The	O
successful	O
outcome	O
in	O
this	O
case	O
resulted	O
from	O
the	O
central	O
ECMO	O
,	O
which	O
enabled	O
""""	O
lung	O
rest	B-FUNC
""""	O
and	O
adequate	O
cerebral	O
blood	O
flow	O
.	O

At	O
baseline	O
,	O
48	O
patients	O
had	O
mild	O
to	O
severe	O
ARDS	O
according	O
to	O
Berlin	O
and	O
87	O
according	O
to	O
LIS	B-FUNC
(	O
Rs	O
=	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Low	O
baseline	O
albumin	O
levels	O
were	O
moderately	O
associated	O
with	O
maximum	O
Berlin	O
and	O
LIS	B-FUNC
categories	O
within	O
7	O
days	O
;	O
an	O
elevated	O
CRP	O
level	O
was	O
moderately	O
associated	O
with	O
maximum	O
Berlin	O
categories	O
only	O
.	O

The	O
day	O
-	O
by	O
-	O
day	O
Berlin	O
and	O
LIS	B-FUNC
categories	O
were	O
inversely	O
associated	O
with	O
albumin	O
levels	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
directly	O
with	O
CRP	O
levels	O
(	O
P	O
=	O
0	O
.	O
02	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
respectively	O
).	O

When	O
the	O
LIS	B-FUNC
decreased	O
,	O
albumin	O
levels	O
increased	O
	O
1	O
g	O
/	O
L	O
(	O
AUROC	O
0	O
.	O
68	O
,	O
P	O
=	O
0	O
.	O
02	O
).	O

We	O
analyzed	O
fecal	O
and	O
throat	O
swabs	O
to	O
detect	O
the	O
presence	O
of	O
virus	O
through	O
amplification	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
all	O
known	O
coronaviruses	O
.	O

A	O
series	O
of	O
new	O
curcumin	O
analogs	O
were	O
synthesized	O
and	O
screened	O
for	O
their	O
inhibitory	O
effects	O
on	O
the	O
production	O
of	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
mouse	O
peritoneal	O
macrophages	O
by	O
ELISA	O
.	O

The	O
bioscreeening	O
assay	O
showed	O
that	O
most	O
compounds	O
inhibited	O
LPS	O
-	O
induced	O
production	O
of	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Furthermore	O
,	O
the	O
active	O
compound	O
c26	O
dose	O
-	O
dependently	O
inhibited	O
ERK	B-FUNC
phosphorylation	O
.	O

However	O
,	O
pretreatment	O
with	O
c26	O
attenuated	O
the	O
LPS	O
induced	O
increase	O
through	O
ERK	B-FUNC
pathway	O
in	O
vivo	O
.	O

These	O
effects	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
suppress	O
production	O
of	O
inflammatory	O
cytokines	O
through	O
ERK	B-FUNC
pathway	O
.	O

It	O
is	O
important	O
to	O
identify	O
alveolar	O
hemorrhage	O
due	O
to	O
sepsis	O
,	O
then	O
separate	O
an	O
autoimmune	O
cause	O
(	O
vasculitis	O
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	B-FUNC
,	O
connective	O
tissue	O
disease	O
and	O
Goodpasture	O
'	O
s	O
syndrome	O
)	O
with	O
the	O
search	O
for	O
autoantibodies	O
and	O
biopsies	O
from	O
readily	O
accessible	O
organs	O
,	O
from	O
a	O
non	O
-	O
immune	O
cause	O
,	O
performing	O
echocardiography	O
.	O

The	O
results	O
showed	O
that	O
DON	O
reduced	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
the	O
titre	O
against	O
IBV	O
,	O
decreased	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
the	O
level	O
of	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
(	O
4	O
.	O
2	O
	O
0	O
.	O
5	O
U	O
/	O
l	O
)	O
compared	O
with	O
control	O
birds	O
(	O
6	O
.	O
4	O
	O
0	O
.	O
5	O
U	O
/	O
l	O
),	O
increased	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
the	O
serum	O
cholesterol	O
concentration	O
(	O
144	O
	O
6	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
their	O
control	O
counterparts	O
(	O
123	O
	O
5	O
mg	O
/	O
dl	O
)	O
and	O
increased	O
(	O
p	O
=	O
0	O
.	O
074	O
)	O
the	O
amount	O
of	O
circulating	O
triglycerides	O
(	O
62	O
.	O
25	O
	O
7	O
.	O
50	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
controls	O
(	O
39	O
.	O
55	O
	O
4	O
.	O
74	O
).	O

With	O
the	O
combined	O
use	O
of	O
intravenous	O
immunoglobulin	B-FUNC
,	O
rituximab	O
and	O
plasma	O
exchange	O
,	O
we	O
achieved	O
rapid	O
clearance	O
of	O
the	O
factor	O
V	O
inhibitor	O
within	O
1	O
week	O
so	O
as	O
to	O
allow	O
safe	O
decannulation	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
6	O
mediates	O
ubiquitin	B-FUNC
-	O
dependent	O
proteosomal	O
degradation	O
of	O
N	O
-	O
Myc	O
(	O
and	O
STAT	O
)	O
interactor	O
.	O

The	O
results	O
showed	O
that	O
P6	O
can	O
promote	O
the	O
ubiquitin	B-FUNC
-	O
dependent	O
proteosomal	O
degradation	O
of	O
Nmi	O
.	O

This	O
demonstrated	O
a	O
delayed	O
production	O
of	O
IgG	O
and	O
IgA	O
plasma	O
antibodies	O
in	O
the	O
1	O
,	O
7	O
and	O
14	O
-	O
day	O
-	O
old	O
vaccination	O
groups	O
and	O
also	O
lower	O
IgA	O
antibody	B-FUNC
levels	O
were	O
observed	O
in	O
plasma	O
of	O
the	O
1	O
-	O
day	O
-	O
old	O
group	O
.	O

The	O
delayed	O
and	O
/	O
or	O
lower	O
antibody	B-FUNC
response	O
combined	O
with	O
lower	O
IgG	O
avidity	O
indices	O
coincided	O
with	O
increased	O
tracheal	O
inflammation	O
and	O
depletion	O
of	O
tracheal	O
epithelia	O
cells	O
and	O
goblet	O
cells	O
upon	O
IBV	O
field	O
strain	O
challenge	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
from	O
the	O
lung	O
,	O
spleen	O
,	O
and	O
kidney	O
was	O
negative	O
for	O
FRSCV	O
and	O
positive	O
for	O
ferret	O
enteric	O
coronavirus	O
(	O
FRECV	O
).	O

We	O
also	O
identified	O
a	O
unique	O
amino	O
acid	O
substitution	O
in	O
the	O
spike	O
receptor	B-FUNC
binding	I-FUNC
domain	O
that	O
may	O
have	O
implications	O
for	O
receptor	B-FUNC
binding	I-FUNC
efficiency	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
may	O
mediate	O
infection	O
by	O
binding	B-FUNC
to	O
a	O
cellular	O
neural	O
cell	O
adhesion	O
molecule	O
(	O
NCAM	O
).	O

This	O
fragment	O
may	O
be	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
that	O
mediates	O
PHEV	O
binding	B-FUNC
to	O
NCAM	O
.	O

Pretreatment	O
of	O
RD	O
cells	O
with	O
neuraminidase	O
(	O
NA	O
)	O
and	O
trypsin	O
greatly	O
reduced	O
the	O
binding	B-FUNC
,	O
suggesting	O
that	O
the	O
binding	B-FUNC
was	O
mediated	O
by	O
sialic	O
acids	O
on	O
glycoproteins	O
.	O

Nonetheless	O
,	O
the	O
HKU1	O
-	O
HE	O
was	O
similar	O
to	O
OC43	O
-	O
HE	O
,	O
also	O
possessed	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-FUNC
activity	I-FUNC
,	O
and	O
acted	O
as	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
)	O
capable	O
of	O
eliminating	O
the	O
binding	B-FUNC
of	O
HKU1	O
-	O
S1	O
to	O
RD	O
cells	O
,	O
whereas	O
the	O
O	O
-	O
acetylesterase	O
-	O
inactive	O
HKU1	O
-	O
HE	O
mutant	O
lost	O
this	O
capacity	O
.	O

MODELLER	O
was	O
used	O
to	O
generate	O
a	O
suitable	O
three	O
-	O
dimensional	O
model	O
of	O
the	O
OC43	O
3CL	O
(	O
pro	O
)	O
and	O
the	O
Prime	O
module	O
of	O
Schrdinger	O
predicted	O
the	O
binding	B-FUNC
conformation	O
and	O
free	O
energy	O
of	O
binding	B-FUNC
of	O
16R	O
within	O
the	O
3CL	O
(	O
pro	O
)	O
active	O
site	O
.	O

Further	O
studies	O
reproduced	O
the	O
binding	B-FUNC
pose	O
of	O
16R	O
within	O
the	O
active	O
site	O
of	O
the	O
generated	O
model	O
,	O
where	O
its	O
free	O
energy	O
of	O
binding	B-FUNC
was	O
shown	O
to	O
equal	O
that	O
of	O
the	O
3CL	O
(	O
pro	O
)	O
of	O
SARS	O
-	O
CoV	O
,	O
a	O
receptor	O
it	O
is	O
experimentally	O
proven	O
to	O
inhibit	O
.	O

TITLE	O
:	O
Prediction	O
of	O
respiratory	O
disease	O
and	O
diarrhea	O
in	O
veal	O
calves	O
based	O
on	O
immunoglobulin	B-FUNC
levels	O
and	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

At	O
present	O
it	O
is	O
unknown	O
whether	O
the	O
risk	O
for	O
respiratory	O
disease	O
(	O
BRD	O
)	O
or	O
neonatal	O
calf	O
diarrhea	O
(	O
NCD	O
)	O
in	O
the	O
veal	O
herd	O
is	O
associated	O
with	O
total	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
and	O
/	O
or	O
on	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

Pigs	O
S3	O
and	O
S4	O
were	O
PCR	O
and	O
antibody	B-FUNC
negative	O
following	O
commingling	O
.	O

Under	O
VCV	O
mode	O
,	O
compared	O
with	O
the	O
initial	O
level	O
,	O
38	O
.	O
6	O
%	O
and	O
37	O
.	O
5	O
%	O
increase	O
in	O
peak	O
airway	O
pressure	O
(	O
PAP	B-FUNC
)	O
were	O
found	O
at	O
1	O
min	O
and	O
10	O
min	O
,	O
respectively	O
.	O

Additionally	O
,	O
microbiota	O
from	O
LPS	O
-	O
treated	O
mice	O
intensified	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
-	O
induced	O
lung	O
inflammation	O
in	O
naive	O
mice	O
.	O

This	O
study	O
aimed	O
at	O
screening	O
available	O
sera	B-FUNC
from	O
100	O
free	O
-	O
ranging	O
,	O
frugivorous	O
bats	O
(	O
Eidolon	O
helvum	O
)	O
sampled	O
in	O
2009	O
/	O
10	O
in	O
Ghana	O
,	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
the	O
complete	O
panel	O
of	O
influenza	O
A	O
haemagglutinin	O
(	O
HA	O
)	O
types	O
ranging	O
from	O
H1	O
to	O
H18	O
by	O
means	O
of	O
a	O
protein	O
microarray	O
platform	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
activity	O
of	O
EAV	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
is	O
important	O
for	O
the	O
inhibition	O
of	O
innate	O
immune	O
activation	O
during	O
infection	O
.	O

She	O
received	O
intravenous	O
immunoglobulin	B-FUNC
early	O
on	O
for	O
suspected	O
Guillain	O
-	O
barre	O
syndrome	O
but	O
remained	O
wheelchair	O
-	O
bound	O
until	O
6	O
Plasma	O
exchange	O
sessions	O
were	O
completed	O
.	O

The	O
cutaneous	O
basophil	O
hypersensivity	O
(	O
CBH	O
)	O
test	O
was	O
measured	O
at	O
day	O
10	O
of	O
age	O
after	O
toe	O
web	O
injection	O
with	O
phytohemagglutinin	O
-	O
P	O
.	O
In	O
addition	O
,	O
sera	B-FUNC
samples	O
were	O
collected	O
after	O
different	O
antigen	O
inoculations	O
to	O
investigate	O
antibody	B-FUNC
responses	O
.	O

Similarly	O
,	O
CBH	O
response	O
and	O
antibody	B-FUNC
titers	O
against	O
Newcastle	O
and	O
infectious	O
bronchitis	O
disease	O
viruses	O
were	O
markedly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
greater	O
in	O
chicks	O
fed	O
on	O
diets	O
supplemented	O
with	O
20	O
to	O
80	O
mg	O
/	O
kg	O
of	O
genistein	O
.	O

Blockade	O
of	O
PI3K	B-FUNC
/	O
Akt	O
and	O
MEK1	B-FUNC
/	O
2	O
kinase	O
pathways	O
completely	O
abrogated	O
lung	O
injury	O
.	O

TITLE	O
:	O
Phage	O
display	O
for	O
identifying	O
peptides	O
that	O
bind	B-FUNC
the	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	O
virus	O
and	O
possess	O
diagnostic	O
potential	O
.	O

Antibodies	O
against	O
influenza	O
viruses	O
A	O
/	O
H1N1	O
/	O
pdm09	O
California	O
/	O
07	O
/	O
09	O
,	O
epidemic	O
reference	O
strains	O
of	O
influenza	O
viruses	O
A	O
/	O
H1N1	O
/	O
Brisbane	O
/	O
59	O
/	O
07	O
,	O
A	O
/	O
H3N2	O
/	O
Victoria	O
/	O
361	O
/	O
201	O
1	O
,	O
B	O
/	O
Wisconsin	O
/	O
1	O
/	O
10	O
,	O
against	O
PI	O
viruses	O
type	O
1	O
,	O
2	O
,	O
3	O
were	O
determined	O
in	O
paired	O
sera	B-FUNC
by	O
HAI	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
the	O
levels	O
of	O
MIF	O
,	O
SCF	B-FUNC
,	O
MCP	B-FUNC
-	O
1	O
,	O
HGF	O
,	O
and	O
SCGF	O
-	O
	O
are	O
highly	O
positively	O
linked	O
to	O
disease	O
severity	O
and	O
the	O
profile	O
of	O
mediators	O
MIF	O
,	O
SCF	B-FUNC
,	O
MCP	B-FUNC
-	O
1	O
,	O
HGF	O
,	O
SCGF	O
-	O
	O
,	O
IP	O
-	O
10	O
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
IFN	O
-	O
	O
is	O
an	O
independent	O
outcome	O
predictor	O
.	O

TITLE	O
:	O
Influenza	O
induces	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
GM	O
-	O
CSF	O
secretion	O
by	O
human	O
alveolar	O
epithelial	O
cells	O
through	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
	O
/	O
EGFR	B-FUNC
signaling	O
.	O

Hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
HGF	O
)/	O
c	O
-	O
Met	O
and	O
transforming	O
growth	O
factor	O
-	O
	O
(	O
TGF	O
-	O
	O
)/	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
are	O
well	O
known	O
to	O
regulate	O
repair	O
of	O
damaged	O
alveolar	O
epithelium	O
by	O
stimulating	O
cell	O
migration	O
and	O
proliferation	O
.	O

We	O
hypothesized	O
that	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
	O
/	O
EGFR	B-FUNC
would	O
regulate	O
innate	O
immune	O
responses	O
to	O
influenza	O
A	O
virus	O
infection	O
in	O
human	O
AECs	O
.	O

We	O
found	O
that	O
recombinant	O
human	O
HGF	O
(	O
rhHGF	O
)	O
and	O
rhTGF	O
-	O
	O
stimulated	O
primary	O
human	O
AECs	O
to	O
secrete	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
granulocyte	B-FUNC
macrophage	I-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
GM	O
-	O
CSF	O
)	O
strongly	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
monocyte	O
chemotactic	O
protein	O
1	O
moderately	O
.	O

Influenza	O
infection	O
stimulated	O
the	O
secretion	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
GM	O
-	O
CSF	O
by	O
AECs	O
plated	O
on	O
rat	O
-	O
tail	O
collagen	O
through	O
EGFR	B-FUNC
activation	O
likely	O
by	O
TGF	O
-	O
	O
released	O
from	O
AECs	O
and	O
through	O
c	O
-	O
Met	O
activated	O
by	O
HGF	O
secreted	O
from	O
lung	O
fibroblasts	O
.	O

We	O
conclude	O
that	O
HGF	O
/	O
c	O
-	O
Met	O
and	O
TGF	O
-	O
	O
/	O
EGFR	B-FUNC
signaling	O
enhances	O
the	O
innate	O
immune	O
responses	O
by	O
human	O
AECs	O
during	O
influenza	O
infections	O
.	O

Tissue	O
binding	B-FUNC
profiles	O
of	O
avian	O
viral	O
attachment	O
proteins	O
were	O
studied	O
by	O
performing	O
histochemistry	O
on	O
multi	O
-	O
species	O
TMA	O
,	O
comprising	O
of	O
selected	O
tissues	O
from	O
ten	O
avian	O
species	O
,	O
and	O
single	O
-	O
species	O
TMAs	O
,	O
grouping	O
organ	O
systems	O
of	O
each	O
species	O
together	O
.	O

The	O
previously	O
believed	O
chicken	O
-	O
specific	O
coronavirus	O
(	O
CoV	O
)	O
M41	O
spike	O
(	O
S1	O
)	O
protein	O
displayed	O
a	O
broad	O
attachment	O
pattern	O
to	O
respiratory	O
tissues	O
of	O
various	O
avian	O
species	O
,	O
albeit	O
with	O
lower	O
affinity	O
than	O
hemagglutinin	O
,	O
suggesting	O
that	O
other	O
avian	O
species	O
might	O
be	O
susceptible	O
for	O
chicken	O
CoV	O
.	O
When	O
comparing	O
tissue	O
-	O
specific	O
binding	B-FUNC
patterns	O
of	O
various	O
avian	O
coronaviral	O
S1	O
proteins	O
on	O
the	O
single	O
-	O
species	O
TMAs	O
,	O
chicken	O
and	O
partridge	O
CoV	O
S1	O
had	O
predominant	O
affinity	O
for	O
the	O
trachea	O
,	O
while	O
pigeon	O
CoV	O
S1	O
showed	O
marked	O
preference	O
for	O
lung	O
of	O
their	O
respective	O
hosts	O
.	O

Taken	O
together	O
,	O
TMAs	O
provide	O
a	O
novel	O
platform	O
in	O
the	O
field	O
of	O
infectious	O
diseases	O
to	O
allow	O
identification	O
of	O
binding	B-FUNC
specificities	O
of	O
viral	O
attachment	O
proteins	O
and	O
are	O
helpful	O
to	O
gain	O
insight	O
into	O
the	O
susceptibility	O
of	O
host	O
and	O
organ	O
for	O
avian	O
pathogens	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domains	O
of	O
spike	O
proteins	O
of	O
emerging	O
or	O
re	O
-	O
emerging	O
viruses	O
as	O
targets	O
for	O
development	O
of	O
antiviral	O
vaccines	O
.	O

In	O
addition	O
,	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
6	O
(	O
CDK6	O
)	O
was	O
identified	O
as	O
a	O
novel	O
antiviral	O
host	O
factor	O
in	O
SARS	O
-	O
CoV	O
replication	O
.	O

These	O
should	O
complement	O
current	O
efforts	O
to	O
block	O
viroporin	O
channel	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Ligand	B-FUNC
-	O
induced	O
Dimerization	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
Coronavirus	O
nsp5	O
Protease	O
(	O
3CLpro	O
):	O
IMPLICATIONS	O
FOR	O
nsp5	O
REGULATION	O
AND	O
THE	O
DEVELOPMENT	O
OF	O
ANTIVIRALS	O
.	O

Peptidomimetic	O
inhibitors	O
of	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
were	O
synthesized	O
and	O
utilized	O
in	O
analytical	O
ultracentrifugation	O
experiments	O
and	O
demonstrate	O
that	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
undergoes	O
significant	O
ligand	B-FUNC
-	O
induced	O
dimerization	O
.	O

Protein	O
histochemistry	O
showed	O
that	O
the	O
tissue	O
binding	B-FUNC
specificity	O
of	O
S1	O
proteins	O
of	O
turkey	O
,	O
quail	O
,	O
and	O
guineafowl	O
CoVs	O
was	O
limited	O
to	O
intestinal	O
tissues	O
of	O
each	O
particular	O
host	O
,	O
in	O
accordance	O
with	O
the	O
reported	O
pathogenicity	O
of	O
these	O
viruses	O
in	O
vivo	O
.	O

Lectin	O
histochemistry	O
as	O
well	O
as	O
tissue	O
binding	B-FUNC
patterns	O
of	O
TCoV	O
S1	O
further	O
indicated	O
that	O
these	O
complex	O
N	O
-	O
glycans	O
are	O
prominently	O
expressed	O
on	O
the	O
intestinal	O
tract	O
of	O
various	O
avian	O
species	O
.	O

Our	O
results	O
show	O
that	O
the	O
expression	O
of	O
Mo	O
-	O
DC	O
surface	O
markers	O
such	O
as	O
SWC3a	O
(+)	O
CD1a	O
(+),	O
SWC3a	O
(+)	O
CD80	O
/	O
86	O
(+)	O
and	O
SWC3a	O
(+)	O
SLA	O
-	O
II	O
-	O
DR	O
(+)	O
is	O
increased	O
after	O
infection	O
with	O
CV777	O
for	O
24	O
h	O
.	O
Mo	O
-	O
DCs	O
infected	O
with	O
CV777	O
produce	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
INF	O
-	O
	O
compared	O
to	O
mock	O
-	O
infected	O
Mo	O
-	O
DCs	O
but	O
the	O
expression	O
profile	O
for	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
does	O
not	O
change	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
LeTx	O
inactivation	O
of	O
p38	B-FUNC
MAP	O
kinase	O
signaling	O
via	O
degradation	O
of	O
MKK3	O
in	O
pulmonary	O
vascular	O
endothelial	O
cells	O
can	O
be	O
linked	O
to	O
compromise	O
of	O
the	O
endothelial	O
permeability	O
barrier	O
.	O

LeTx	O
effects	O
were	O
linked	O
specifically	O
to	O
blocking	O
activation	O
of	O
p38	B-FUNC
substrate	O
and	O
MAP	O
kinase	O
-	O
activated	O
protein	O
kinase	O
2	O
(	O
MAPKAPK2	O
or	O
MK2	O
)	O
and	O
phosphorylation	O
of	O
the	O
latter	O
'	O
s	O
substrate	O
,	O
heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
).	O

We	O
tested	O
the	O
effects	O
of	O
MVs	O
derived	O
from	O
human	O
MSCs	B-FUNC
on	O
Escherichia	O
coli	O
pneumonia	O
in	O
mice	O
.	O

Administration	O
of	O
MVs	O
derived	O
from	O
human	O
MSCs	B-FUNC
improved	O
survival	O
in	O
part	O
through	O
keratinocyte	O
growth	O
factor	O
secretion	O
and	O
decreased	O
the	O
influx	O
of	O
inflammatory	O
cells	O
,	O
cytokines	O
,	O
protein	O
,	O
and	O
bacteria	O
in	O
mice	O
injured	O
with	O
bacterial	O
pneumonia	O
.	O

Prestimulation	O
of	O
MSCs	B-FUNC
with	O
a	O
toll	O
-	O
like	O
receptor	O
3	O
agonist	O
further	O
enhanced	O
the	O
therapeutic	O
effects	O
of	O
the	O
released	O
MVs	O
.	O

Furthermore	O
,	O
transfection	O
with	O
small	O
-	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
of	O
Src	O
,	O
AKT	O
,	O
p42	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
),	O
or	O
p300	O
downregulated	O
the	O
respective	O
proteins	O
and	O
significantly	O
attenuated	O
ET	O
-	O
1	O
-	O
induced	O
VCAM	O
-	O
1	O
expression	O
.	O

ET	O
-	O
1	O
also	O
stimulated	O
phosphorylation	O
of	O
Src	O
,	O
EGFR	B-FUNC
,	O
PDGFR	O
,	O
AKT	O
,	O
p42	O
/	O
p44	O
MAPK	B-FUNC
,	O
and	O
Elk	O
-	O
1	O
and	O
acetylation	O
of	O
histone	O
H4	O
on	O
HTSMCs	O
.	O

Influenza	O
virus	O
type	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	O
and	O
parainfluenza	O
virus	O
type	O
1	O
-	O
3	O
were	O
investigated	O
using	O
shell	O
-	O
vial	O
cell	O
culture	O
method	O
and	O
direct	O
fluorescent	O
antibody	B-FUNC
test	O
and	O
/	O
or	O
multiplex	O
PCR	O
test	O
.	O

Multiple	O
therapeutic	O
transfusions	O
are	O
required	O
,	O
and	O
the	O
risks	O
of	O
iron	O
overload	O
and	O
blood	O
antibody	B-FUNC
development	O
are	O
high	O
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
of	O
the	O
Spike	O
Glycoprotein	O
of	O
Human	O
Betacoronavirus	O
HKU1	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
spike	O
(	O
S	O
)	O
glycoproteins	O
mediate	O
receptor	B-FUNC
binding	I-FUNC
,	O
membrane	O
fusion	O
,	O
and	O
virus	O
entry	O
and	O
determine	O
host	O
range	O
.	O

Murine	O
betacoronavirus	O
(	O
	O
-	O
CoV	O
)	O
in	O
group	O
A	O
uses	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
S	O
protein	O
to	O
bind	B-FUNC
to	O
its	O
receptor	O
,	O
whereas	O
the	O
	O
-	O
CoVs	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
in	O
group	O
B	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
in	O
group	O
C	O
and	O
several	O
	O
-	O
CoVs	O
use	O
the	O
downstream	O
C	O
domain	O
in	O
their	O
S	O
proteins	O
to	O
recognize	O
their	O
receptor	O
proteins	O
.	O

To	O
identify	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
the	O
spike	O
of	O
human	O
	O
-	O
CoV	O
HKU1	O
in	O
group	O
A	O
,	O
we	O
generated	O
and	O
mapped	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
to	O
the	O
ectodomain	O
of	O
HKU1	O
spike	O
protein	O
.	O

These	O
data	O
suggest	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
HKU1	O
spike	O
protein	O
is	O
located	O
in	O
the	O
C	O
domain	O
,	O
where	O
the	O
spike	O
proteins	O
of	O
	O
-	O
CoVs	O
and	O
	O
-	O
CoVs	O
in	O
groups	O
B	O
and	O
C	O
bind	B-FUNC
to	O
their	O
specific	O
receptor	O
proteins	O
.	O

In	O
marked	O
contrast	O
,	O
the	O
NTD	O
of	O
the	O
spike	O
glycoprotein	O
of	O
human	O
respiratory	O
	O
-	O
CoV	O
HKU1	O
,	O
which	O
is	O
also	O
in	O
group	O
A	O
,	O
does	O
not	O
bind	B-FUNC
sugar	O
.	O

TITLE	O
:	O
Platelet	B-FUNC
-	I-FUNC
Derived	I-FUNC
Growth	I-FUNC
Factor	I-FUNC
and	O
Transforming	O
Growth	O
Factor	O
1	O
Regulate	O
ARDS	O
-	O
Associated	O
Lung	O
Fibrosis	O
Through	O
Distinct	O
Signaling	O
Pathways	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
platelet	B-FUNC
-	I-FUNC
derived	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
PDGF	B-FUNC
)	O
and	O
transforming	O
growth	O
factor	O
1	O
(	O
TGF1	O
)	O
participate	O
in	O
the	O
pathogenesis	O
of	O
ARDS	O
by	O
stimulation	O
of	O
fibroblast	O
proliferation	O
,	O
leading	O
to	O
the	O
development	O
of	O
pulmonary	O
fibrosis	O
.	O

However	O
,	O
the	O
exact	O
pathways	O
downstream	O
of	O
PDGF	B-FUNC
and	O
TGF	O
receptor	O
signaling	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O

We	O
treated	O
human	O
lung	O
fibroblasts	O
(	O
HLF	O
)	O
with	O
PDGF	B-FUNC
,	O
or	O
TGF1	O
,	O
or	O
combined	O
,	O
and	O
examined	O
the	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
,	O
p42	O
/	O
p44	O
MAPK	B-FUNC
and	O
SMAD3	O
.	O

We	O
then	O
examined	O
the	O
effects	O
of	O
these	O
inhibitors	O
on	O
the	O
activation	O
of	O
collagen	O
I	O
and	O
	O
-	O
smooth	O
muscle	O
actin	O
(	O
	O
-	O
SMA	O
)	O
induced	O
by	O
PDGF	B-FUNC
or	O
TGF1	O
stimulation	O
.	O

PDGF	B-FUNC
activated	O
p38	B-FUNC
MAPK	B-FUNC
and	O
p42	O
/	O
p44	O
MAPK	B-FUNC
,	O
but	O
not	O
SMAD3	O
in	O
HLF	O
cells	O
.	O

Treatments	O
with	O
both	O
PDGF	B-FUNC
and	O
TGF1	O
antagonists	O
may	O
result	O
in	O
a	O
better	O
anti	O
-	O
fibrotic	O
outcome	O
for	O
ALI	O
-	O
induced	O
lung	O
fibrosis	O
.	O

METHODS	O
:	O
We	O
treated	O
human	O
lung	O
fibroblasts	O
(	O
HLF	O
)	O
with	O
PDGF	B-FUNC
,	O
or	O
TGF1	O
,	O
or	O
combined	O
,	O
and	O
examined	O
the	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
,	O
p42	O
/	O
p44	O
MAPK	B-FUNC
and	O
SMAD3	O
.	O

CONCLUSIONS	O
:	O
PDGF	B-FUNC
and	O
TGF1	O
regulate	O
ARDS	O
-	O
associated	O
lung	O
fibrosis	O
through	O
distinct	O
signaling	O
pathway	O
-	O
mediated	O
activation	O
of	O
fibrosis	O
-	O
related	O
proteins	O
.	O

Viral	O
etiology	O
was	O
determined	O
using	O
conventional	O
cell	O
culture	O
and	O
a	O
commercial	O
respiratory	O
virus	O
panel	O
fast	B-FUNC
assay	O
(	O
xTAG	O
RVP	O
),	O
capable	O
of	O
detecting	O
19	O
different	O
respiratory	O
viruses	O
and	O
subtype	O
targets	O
.	O

The	O
RVP	O
fast	B-FUNC
assay	O
identified	O
at	O
least	O
one	O
respiratory	O
virus	O
in	O
130	O
of	O
the	O
216	O
specimens	O
examined	O
(	O
60	O
.	O
2	O
%)	O
and	O
rose	O
to	O
137	O
(	O
63	O
.	O
4	O
%)	O
by	O
combining	O
the	O
results	O
of	O
cell	O
culture	O
and	O
RVP	O
fast	B-FUNC
assay	O
.	O

TITLE	O
:	O
Neutralization	O
Analysis	O
of	O
a	O
Chicken	O
Single	O
-	O
Chain	O
Variable	O
Fragment	O
Derived	O
from	O
an	O
Immune	O
Antibody	B-FUNC
Library	O
Against	O
Infectious	O
Bronchitis	O
Virus	O
.	O

In	O
this	O
study	O
,	O
six	O
anti	O
-	O
IBV	O
chicken	O
scFvs	O
,	O
ZL	O
.	O
10	O
,	O
ZL	O
.	O
64	O
,	O
ZL	O
.	O
78	O
,	O
ZL	O
.	O
80	O
,	O
ZL	O
.	O
138	O
,	O
and	O
ZL	O
.	O
256	O
,	O
were	O
obtained	O
by	O
screening	O
random	O
clones	O
from	O
an	O
immune	O
antibody	B-FUNC
library	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
suggested	O
that	O
specific	O
and	O
neutralizing	O
chicken	O
scFvs	O
against	O
IBV	O
,	O
which	O
can	O
be	O
safe	O
and	O
economical	O
antibody	B-FUNC
reagents	O
,	O
can	O
be	O
produced	O
in	O
vitro	O
through	O
prokaryotic	O
expression	O
.	O

All	O
piglets	O
orally	O
inoculated	O
developed	O
severe	O
watery	O
diarrhea	O
and	O
vomiting	O
within	O
24	O
hours	O
post	O
-	O
inoculation	O
(	O
hpi	B-FUNC
)	O
and	O
died	O
within	O
72	O
hpi	B-FUNC
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
prognostic	O
value	O
of	O
plasma	O
soluble	O
urokinase	B-FUNC
plasminogen	I-FUNC
activator	I-FUNC
receptor	I-FUNC
(	O
suPAR	O
)	O
on	O
day	O
1	O
in	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
for	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
mortality	O
and	O
compared	O
it	O
with	O
established	O
disease	O
severity	O
scores	O
on	O
day	O
1	O
.	O

TITLE	O
:	O
Immunoprophylactic	O
effect	O
of	O
chicken	O
egg	O
yolk	O
antibody	B-FUNC
(	O
IgY	O
)	O
against	O
a	O
recombinant	O
S1	O
domain	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
spike	O
protein	O
in	O
piglets	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
PEDV	O
consists	O
of	O
the	O
S1	O
and	O
S2	O
domains	O
,	O
responsible	O
for	O
virus	O
binding	B-FUNC
and	O
fusion	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
Randomized	O
Dose	O
-	O
Escalation	O
Study	O
of	O
the	O
Safety	O
and	O
Anti	O
-	O
Inflammatory	O
Activity	O
of	O
the	O
p38	B-FUNC
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	B-FUNC
Inhibitor	I-FUNC
Dilmapimod	O
in	O
Severe	O
Trauma	O
Subjects	O
at	O
Risk	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
is	O
central	O
to	O
the	O
regulation	O
of	O
multiple	O
inflammatory	O
mediators	O
implicated	O
in	O
acute	O
organ	O
dysfunction	O
and	O
is	O
the	O
target	O
for	O
a	O
novel	O
class	O
of	O
cytokine	O
-	O
suppressive	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

In	O
preclinical	O
models	O
,	O
p38	B-FUNC
inhibitors	O
reduce	O
lung	O
injury	O
following	O
pancreatitis	O
and	O
burn	O
injury	O
.	O

We	O
conducted	O
a	O
phase	O
IIa	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
dilmapimod	O
,	O
a	O
novel	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	B-FUNC
inhibitor	I-FUNC
,	O
in	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
with	O
an	O
Injury	O
Severity	O
Score	O
more	O
than	O
16	O
,	O
excluding	O
head	O
trauma	O
.	O

Likewise	O
,	O
measures	O
of	O
soluble	O
inflammatory	O
markers	O
including	O
interleukin	O
-	O
6	O
,	O
C	O
-	O
reactive	O
peptide	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
soluble	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
1	O
were	O
most	O
different	O
between	O
this	O
dosing	O
arm	O
and	O
placebo	O
.	O

The	O
novel	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	B-FUNC
inhibitor	I-FUNC
dilmapimod	O
appears	O
well	O
tolerated	O
and	O
may	O
merit	O
further	O
evaluation	O
for	O
prevention	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
other	O
organ	O
injury	O
in	O
larger	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
compared	O
the	O
performances	O
of	O
four	O
commercial	O
multiplex	O
kits	O
used	O
in	O
French	O
University	O
Hospital	O
diagnostic	O
microbiology	O
laboratories	O
for	O
the	O
detection	O
of	O
ARI	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
the	O
xTAG	O
Respiratory	O
Viral	O
Panel	O
Fast	B-FUNC
,	O
RespiFinder	O
SMART	O
22	O
,	O
CLART	O
PneumoVir	O
and	O
Fast	B-FUNC
Track	O
Diagnostics	O
Respiratory	O
Pathogen	O
33	O
kits	O
).	O

Reovirus	O
binds	B-FUNC
to	O
cell	O
surface	O
glycans	O
,	O
junctional	O
adhesion	O
molecule	O
A	O
(	O
JAM	O
-	O
A	O
),	O
and	O
the	O
Nogo	O
-	O
1	O
receptor	O
(	O
depending	O
on	O
the	O
cell	O
type	O
)	O
and	O
enters	O
cells	O
by	O
receptor	O
-	O
mediated	O
endocytosis	O
.	O

Consistent	O
with	O
an	O
inhibition	O
of	O
viral	O
disassembly	O
,	O
5	O
-	O
NT	O
treatment	O
did	O
not	O
alter	O
infection	O
by	O
in	O
vitro	O
-	O
generated	O
infectious	O
subvirion	O
particles	O
,	O
which	O
bind	B-FUNC
to	O
JAM	O
-	O
A	O
but	O
bypass	O
a	O
requirement	O
for	O
proteolytic	O
uncoating	O
in	O
endosomes	O
to	O
infect	O
cells	O
.	O

One	O
piglet	O
had	O
a	O
positive	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
test	O
on	O
rectal	O
swab	O
at	O
12	O
hpi	B-FUNC
,	O
and	O
all	O
remaining	O
piglets	O
were	O
positive	O
thereafter	O
,	O
with	O
highest	O
viral	O
quantities	O
detected	O
at	O
24	O
and	O
36	O
hpi	B-FUNC
.	O

Diarrhea	O
was	O
evident	O
in	O
30	O
%	O
and	O
100	O
%	O
of	O
challenged	O
piglets	O
at	O
18	O
and	O
24	O
hpi	B-FUNC
,	O
respectively	O
.	O

Viral	O
antigen	O
was	O
detected	O
in	O
enterocytes	O
by	O
immunohistochemistry	O
in	O
the	O
duodenum	O
and	O
ileum	O
of	O
piglets	O
euthanized	O
at	O
12	O
hpi	B-FUNC
and	O
was	O
apparent	O
throughout	O
the	O
small	O
intestine	O
of	O
all	O
piglets	O
thereafter	O
,	O
with	O
villus	O
height	O
:	O
crypt	O
depth	O
ratios	O
consistently	O
below	O
4	O
:	O
1	O
.	O

TITLE	O
:	O
Extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
activation	O
is	O
required	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
replication	O
.	O

The	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
that	O
serves	O
as	O
a	O
critical	O
component	O
of	O
cellular	O
signal	O
transduction	O
pathways	O
to	O
modulate	O
a	O
variety	O
of	O
cellular	O
functions	O
has	O
been	O
shown	O
to	O
regulate	O
several	O
viral	O
infections	O
.	O

The	O
PEDV	O
-	O
induced	O
ERK1	B-FUNC
/	O
2	O
activation	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
its	O
downstream	O
substrate	O
Elk	O
-	O
1	O
in	O
infected	O
cells	O
.	O

Treatment	O
with	O
ERK	B-FUNC
inhibitors	O
or	O
ERK1	B-FUNC
/	O
2	O
knockdown	O
significantly	O
suppressed	O
viral	O
progeny	O
production	O
.	O

Inhibition	O
of	O
ERK	B-FUNC
activation	O
also	O
diminished	O
viral	O
protein	O
expression	O
and	O
genomic	O
and	O
subgenomic	O
RNA	O
transcription	O
.	O

Five	O
children	O
had	O
GBS	O
,	O
one	O
Bickerstaff	O
brain	O
stem	O
encephalitis	O
(	O
BBE	B-FUNC
),	O
and	O
one	O
acute	O
-	O
onset	O
chronic	O
inflammatory	O
demyelinating	O
polyneuropathy	O
(	O
A	O
-	O
CIDP	O
).	O

Furthermore	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
deficiency	O
impaired	O
astrocyte	O
organization	O
into	O
mesh	O
like	O
structures	O
at	O
the	O
lesion	O
borders	O
,	O
but	O
did	O
not	O
prevent	O
astrocyte	O
hypertrophy	O
.	O

The	O
formation	O
of	O
discrete	O
foci	O
of	O
demyelination	O
in	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
sufficient	O
mice	O
correlated	O
with	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
receptor	O
expression	O
exclusively	O
on	O
astrocytes	O
in	O
areas	O
of	O
demyelination	O
suggesting	O
a	O
critical	O
role	O
for	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
signaling	O
to	O
astrocytes	O
in	O
limiting	O
expansion	O
of	O
initial	O
areas	O
of	O
white	O
matter	O
damage	O
.	O

CoV	O
E	O
has	O
a	O
single	O
hydrophobic	O
domain	O
(	O
HD	O
),	O
is	O
targeted	O
to	O
Golgi	O
complex	O
membranes	O
,	O
and	O
has	O
cation	B-FUNC
channel	I-FUNC
activity	I-FUNC
in	O
vitro	O
.	O

Additionally	O
,	O
disruption	O
of	O
the	O
secretory	O
pathway	O
by	O
IBV	O
E	O
correlates	O
with	O
a	O
form	O
that	O
is	O
likely	O
monomeric	O
,	O
suggesting	O
that	O
the	O
effects	O
on	O
the	O
secretory	O
pathway	O
are	O
independent	O
of	O
E	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
(	O
Co	O
-	O
V	O
)	O
contains	O
a	O
single	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
binds	B-FUNC
to	O
a	O
receptor	O
molecule	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
;	O
also	O
known	O
as	O
CD26	O
),	O
and	O
serves	O
as	O
a	O
neutralizing	O
antigen	O
.	O

Moreover	O
,	O
alanine	O
replacement	O
of	O
charged	O
amino	O
-	O
acid	O
residues	O
of	O
the	O
SUD	O
-	O
M	O
domain	O
,	O
which	O
are	O
likely	O
involved	O
in	O
G	O
-	O
quadruplex	O
-	O
binding	B-FUNC
,	O
caused	O
abrogation	O
of	O
RTC	O
activity	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
a	O
number	O
of	O
polymorphisms	O
involved	O
in	O
RNA	O
-	O
binding	B-FUNC
were	O
shared	O
between	O
macaques	O
and	O
chimpanzees	O
.	O

The	O
cap	O
-	O
precursor	O
guanosine	O
-	O
P3	O
-	O
adenosine	O
-	O
5	O
',	O
5	O
'-	O
triphosphate	O
and	O
S	O
-	O
adenosyl	O
methionine	O
bind	B-FUNC
in	O
proximity	O
in	O
a	O
highly	O
constricted	O
pocket	O
between	O
two	O
	O
-	O
sheets	O
to	O
accomplish	O
methyl	O
transfer	O
.	O

Binding	B-FUNC
of	O
HAdV	O
-	O
B14p1	O
to	O
the	O
apical	O
surface	O
of	O
differentiated	O
human	O
bronchial	O
epithelial	O
cells	O
and	O
subsequent	O
internalization	O
of	O
HAdV	O
DNA	O
was	O
10	O
fold	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
the	O
less	O
-	O
pneumotropic	O
HAdV	O
-	O
C5	O
one	O
hour	O
after	O
infection	O
.	O

After	O
treatment	O
,	O
the	O
levels	O
of	O
blood	O
amylase	O
,	O
white	O
blood	O
cell	O
(	O
WBC	O
),	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
of	O
observation	O
group	O
(	O
107	O
.	O
2	O
	O
9	O
.	O
1	O
U	O
/	O
L	O
,	O
6	O
.	O
2	O
	O
1	O
.	O
0	O
	O
10	O
(	O
9	O
)/	O
L	O
,	O
7	O
.	O
3	O
	O
3	O
.	O
4	O
mg	O
/	O
L	O
,	O
28	O
.	O
3	O
	O
4	O
.	O
3	O
pg	O
/	O
ml	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
group	O
(	O
430	O
.	O
8	O
	O
20	O
.	O
2	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
2	O
	O
1	O
.	O
2	O
)	O
	O
10	O
(	O
9	O
)/	O
L	O
,	O
(	O
16	O
.	O
3	O
	O
5	O
.	O
2	O
)	O
mg	O
/	O
L	O
,	O
(	O
45	O
.	O
3	O
	O
5	O
.	O
9	O
)	O
ng	O
/	O
L	O
,	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Genotyping	O
of	O
seven	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
isolated	O
in	O
Brazil	O
showed	O
that	O
all	O
belonged	O
to	O
the	O
common	O
Brazilian	O
genotype	O
and	O
that	O
these	O
strains	O
were	O
closest	O
to	O
the	O
subcluster	O
of	O
strain	O
IBV	O
/	O
Brazil	O
/	O
2007	O
/	O
USP	B-FUNC
-	O
19	O
.	O

We	O
established	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
describing	O
the	O
important	O
ligand	B-FUNC
-	O
based	O
features	O
required	O
for	O
potent	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibition	O
and	O
identified	O
a	O
seemingly	O
favored	O
peptidic	O
backbone	O
for	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibition	O
.	O

Sequence	O
alignment	O
of	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	O
),	O
and	O
two	O
other	O
lineage	O
C	O
Betacoronaviruses	O
3CL	O
(	O
pro	O
)'	O
s	O
,	O
HKU5	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
),	O
show	O
that	O
the	O
active	O
site	O
residues	O
of	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
that	O
participate	O
in	O
inhibitor	O
binding	B-FUNC
are	O
conserved	O
in	O
HKU5	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

After	O
bleeding	O
was	O
controlled	O
by	O
operation	O
,	O
fluid	O
resuscitation	O
was	O
done	O
as	O
fast	B-FUNC
as	O
possible	O
and	O
the	O
plasma	O
was	O
transfused	O
early	O
according	O
to	O
the	O
proportion	O
of	O
plasma	O
and	O
red	O
cell	O
suspension	O
(	O
2	O
U	O
:	O
1	O
U	O
-	O
3	O
U	O
:	O
2	O
U	O
).	O

The	O
inactivated	O
KNU	O
-	O
141112	O
virus	O
was	O
found	O
to	O
mediate	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
in	O
immunized	O
guinea	O
pigs	O
.	O

TITLE	O
:	O
Silencing	O
of	O
Tumor	B-FUNC
Necrosis	I-FUNC
Factor	I-FUNC
Receptor	O
-	O
1	O
in	O
Human	O
Lung	O
Microvascular	O
Endothelial	O
Cells	O
Using	O
Particle	O
Platforms	O
for	O
siRNA	O
Delivery	O
.	O

Here	O
,	O
we	O
summarize	O
the	O
progress	O
made	O
in	O
the	O
past	O
decade	O
in	O
understanding	O
the	O
cross	O
-	O
species	O
transmission	O
of	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
by	O
focusing	O
on	O
the	O
features	O
of	O
the	O
S	O
protein	O
,	O
its	O
receptor	O
-	O
binding	B-FUNC
characteristics	O
,	O
and	O
the	O
cleavage	O
process	O
involved	O
in	O
priming	O
.	O

TITLE	O
:	O
Quantitative	O
Proteomics	O
Identifies	O
Serum	O
Response	O
Factor	O
Binding	B-FUNC
Protein	O
1	O
as	O
a	O
Host	O
Factor	O
for	O
Hepatitis	O
C	O
Virus	O
Entry	O
.	O

How	O
CD81	O
governs	O
HCV	O
entry	O
is	O
poorly	O
characterized	O
,	O
and	O
CD81	O
protein	O
interactions	O
after	O
virus	O
binding	B-FUNC
remain	O
elusive	O
.	O

We	O
have	O
developed	O
a	O
quantitative	O
proteomics	O
protocol	O
to	O
identify	O
HCV	O
-	O
triggered	O
CD81	O
interactions	O
and	O
found	O
26	O
dynamic	O
binding	B-FUNC
partners	O
.	O

We	O
further	O
characterized	O
serum	O
response	O
factor	O
binding	B-FUNC
protein	O
1	O
(	O
SRFBP1	O
),	O
which	O
is	O
recruited	O
to	O
CD81	O
during	O
HCV	O
uptake	O
and	O
supports	O
HCV	O
infection	O
in	O
hepatoma	O
cells	O
and	O
primary	O
human	O
hepatocytes	O
.	O

TITLE	O
:	O
Prophylactic	O
and	O
postexposure	O
efficacy	O
of	O
a	O
potent	O
human	O
monoclonal	O
antibody	B-FUNC
against	O
MERS	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
isolation	O
of	O
a	O
potent	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-FUNC
from	O
memory	O
B	O
cells	O
of	O
an	O
infected	O
individual	O
.	O

This	O
antibody	B-FUNC
can	O
be	O
used	O
for	O
prophylaxis	O
,	O
for	O
postexposure	O
prophylaxis	O
of	O
individuals	O
at	O
risk	O
,	O
or	O
for	O
the	O
treatment	O
of	O
human	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
fact	O
that	O
it	O
took	O
only	O
4	O
mo	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	O
derived	O
from	O
a	O
convalescent	O
patient	O
for	O
the	O
development	O
of	O
a	O
stable	O
chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)	O
cell	O
line	O
producing	O
neutralizing	O
antibodies	O
at	O
more	O
than	O
5	O
g	O
/	O
L	O
provides	O
an	O
example	O
of	O
a	O
rapid	O
pathway	O
toward	O
the	O
generation	O
of	O
effective	O
antiviral	O
therapies	O
against	O
emerging	O
viruses	O
.	O

Efforts	O
focused	O
solely	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
may	O
not	O
optimize	O
neutralizing	O
antibody	B-FUNC
(	O
NAb	O
)	O
responses	O
.	O

The	O
lung	O
from	O
rats	O
with	O
endotoxic	O
shock	O
exhibited	O
significant	O
decreases	O
in	O
the	O
levels	O
of	O
Wnt3a	O
,	O
Fzd1	O
,	O
Dsh1	O
,	O
phosphorylated	O
GSK	B-FUNC
-	O
3	O
at	O
Ser9	O
,	O
and	O
	O
-	O
catenin	O
.	O

K40	O
/	O
09	O
HP50	O
provided	O
almost	O
complete	O
protection	O
against	O
two	O
distinct	O
subgroups	O
of	O
a	O
nephropathogenic	O
strain	O
(	O
KM91	O
-	O
like	O
and	O
QX	O
-	O
like	O
subgroup	O
)	O
and	O
elicited	O
the	O
production	O
of	O
high	O
titers	O
of	O
neutralizing	O
antibody	B-FUNC
(	O
neutralization	O
index	O
of	O
3	O
.	O
6	O
).	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
multiple	O
improved	O
serological	O
assays	O
for	O
PEDV	O
,	O
including	O
an	O
indirect	O
ELISA	O
(	O
iELISA	O
);	O
a	O
highly	O
specific	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
blocking	O
ELISA	O
(	O
bELISA	O
);	O
fluorescent	O
microsphere	O
immunoassays	O
(	O
FMIA	O
)	O
that	O
can	O
be	O
multiplexed	O
to	O
monitor	O
exposure	O
to	O
multiple	O
antigens	O
and	O
pathogens	O
simultaneously	O
;	O
and	O
a	O
fluorescent	O
focus	O
neutralization	O
assay	O
(	O
FFN	O
)	O
to	O
measure	O
functional	O
virus	O
neutralizing	O
antibodies	O
.	O

In	O
addition	O
,	O
these	O
PEDV	O
mAbs	O
are	O
useful	O
for	O
immunohistochemistry	O
,	O
fluorescent	O
antibody	B-FUNC
staining	O
and	O
other	O
antigen	O
-	O
based	O
tests	O
.	O

Measurement	O
of	O
neutralizing	O
antibody	B-FUNC
responses	O
using	O
the	O
FFN	O
assay	O
may	O
provide	O
a	O
valuable	O
tool	O
for	O
assessment	O
of	O
vaccine	O
candidates	O
or	O
protective	O
immunity	O
.	O

Indications	O
for	O
surgery	O
include	O
refractory	O
hypotension	O
not	O
responding	O
to	O
resuscitation	O
due	O
to	O
uncontrolled	O
hemorrhage	O
from	O
liver	O
trauma	O
;	O
massive	O
hemoperitonem	O
on	O
Focused	O
assessment	O
by	O
ultrasound	O
for	O
trauma	O
(	O
FAST	B-FUNC
)	O
and	O
/	O
or	O
Diagnostic	O
peritoneal	O
lavage	O
(	O
DPL	O
)	O
as	O
well	O
as	O
Multislice	O
Computed	O
Tomography	O
(	O
MSCT	O
)	O
findings	O
of	O
the	O
severe	O
liver	O
injury	O
and	O
major	O
vascular	O
injuries	O
with	O
active	O
bleeding	O
.	O

ABSTRACT	O
:	O
Immunoadhesins	O
are	O
recombinant	O
proteins	O
that	O
combine	O
the	O
ligand	B-FUNC
-	O
binding	B-FUNC
region	O
of	O
a	O
receptor	O
or	O
adhesion	O
molecule	O
with	O
immunoglobulin	B-FUNC
constant	O
domains	O
.	O

All	O
FDA	O
-	O
approved	O
immunoadhesins	O
are	O
designed	O
to	O
modulate	O
the	O
interaction	O
of	O
a	O
human	O
receptor	O
with	O
its	O
normal	O
ligand	B-FUNC
,	O
such	O
as	O
Etanercept	O
(	O
Enbrel	O
()	O
),	O
which	O
interferes	O
with	O
the	O
binding	B-FUNC
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
to	O
the	O
TNF	O
-	O
alpha	O
receptor	O
and	O
is	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

An	O
immunoadhesin	O
incorporating	O
the	O
cellular	O
receptor	O
for	O
anthrax	O
toxin	O
,	O
CMG2	O
,	O
potently	O
blocks	O
toxin	B-FUNC
activity	I-FUNC
in	O
vitro	O
and	O
protects	O
animals	O
against	O
inhalational	O
anthrax	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
nucleocapsid	O
protein	O
from	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
NP	O
-	O
NTD	O
)	O
contains	O
many	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
to	O
be	O
responsible	O
for	O
RNA	B-FUNC
binding	I-FUNC
during	O
ribonucleocapsid	O
formation	O
by	O
the	O
virus	O
.	O

Antineutrophil	O
cytoplasm	O
antibodies	O
were	O
proteinase	B-FUNC
3	O
-	O
positive	O
in	O
65	O
.	O
5	O
%	O
of	O
the	O
patients	O
(	O
50	O
%	O
of	O
those	O
with	O
SGS	O
).	O
Despite	O
conventional	O
GPA	O
therapy	O
,	O
62	O
%	O
patients	O
experienced	O
	O
1	O
stenosis	O
relapse	O
(	O
s	O
)	O
(	O
81	O
%	O
of	O
SGS	O
patients	O
,	O
for	O
a	O
total	O
of	O
1	O
-	O
8	O
relapses	O
per	O
patient	O
).	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
by	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
MERS	O
-	O
27	O
.	O

The	O
envelope	O
spike	O
glycoprotein	O
on	O
the	O
surface	O
of	O
MERS	O
-	O
CoV	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
,	O
membrane	O
fusion	O
,	O
and	O
viral	O
entry	O
.	O

The	O
MERS	O
-	O
27	O
epitope	O
in	O
the	O
RBD	O
overlaps	O
with	O
the	O
binding	B-FUNC
site	O
of	O
the	O
MERS	O
-	O
CoV	O
receptor	O
DPP4	O
.	O

Further	O
biochemical	O
,	O
viral	O
entry	O
,	O
and	O
neutralization	O
analyses	O
identified	O
two	O
critical	O
residues	O
in	O
the	O
RBD	O
for	O
both	O
MERS	O
-	O
27	O
recognition	O
and	O
DPP4	O
binding	B-FUNC
.	O

Upon	O
receptor	B-FUNC
binding	I-FUNC
,	O
Trp535	O
interacts	O
with	O
the	O
N	O
-	O
linked	O
carbohydrate	O
moiety	O
of	O
DPP4	O
.	O

In	O
the	O
upstream	O
of	O
IRF	O
-	O
3	O
,	O
TANK	O
-	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
)-	O
or	O
inhibitor	O
of	O
B	O
kinase	O
-	O
	O
(	O
IKK	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	O
-	O
I	O
-	O
and	O
its	O
adapter	O
molecule	O
IFN	O
-	O
	O
promoter	O
stimulator	O
1	O
(	O
IPS	O
-	O
1	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	O
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
)	O
have	O
been	O
investigated	O
as	O
a	O
treatment	O
for	O
various	O
inflammatory	O
diseases	O
because	O
of	O
their	O
immunomodulatory	O
and	O
reparative	O
properties	O
.	O

We	O
performed	O
a	O
detailed	O
analysis	O
of	O
the	O
immunomodulatory	O
properties	O
and	O
proteomic	O
profile	O
of	O
MSCs	B-FUNC
systemically	O
administered	O
to	O
two	O
patients	O
with	O
severe	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
on	O
a	O
compassionate	O
use	O
basis	O
and	O
attempted	O
to	O
correlate	O
these	O
with	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
actions	O
.	O

The	O
findings	O
also	O
suggest	O
,	O
but	O
do	O
not	O
prove	O
,	O
a	O
beneficial	O
effect	O
of	O
lung	O
protective	O
strategies	O
using	O
adoptively	O
transferred	O
MSCs	B-FUNC
in	O
ARDS	O
.	O

Inoculation	O
of	O
early	O
CEK	O
passages	O
into	O
chickens	O
induced	O
higher	O
antibody	B-FUNC
levels	O
and	O
CEKp4	O
induced	O
increased	O
respiratory	O
signs	O
compared	O
to	O
CEKp7	O
.	O

To	O
identify	O
antigen	O
epitopes	O
with	O
specificity	O
for	O
PEDV	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
-	O
5E12	O
)	O
against	O
the	O
immunodominant	O
region	O
of	O
the	O
PEDV	O
Spike	O
protein	O
(	O
S1	O
)	O
was	O
used	O
as	O
the	O
target	O
for	O
biopanning	O
a	O
12	O
-	O
mer	O
phage	O
display	O
,	O
random	O
peptide	O
library	O
.	O

The	O
most	O
effective	O
and	O
safest	O
dose	O
for	O
yielding	O
a	O
clinically	O
significant	O
increase	O
in	O
PaO2	O
and	O
reduction	O
in	O
pulmonary	O
artery	O
pressure	O
(	O
PAP	B-FUNC
)	O
appears	O
to	O
be	O
20	O
-	O
30	O
ng	O
/	O
kg	O
/	O
min	O
in	O
adults	O
and	O
30	O
ng	O
/	O
kg	O
/	O
min	O
in	O
pediatric	O
patients	O
.	O

Results	O
of	O
antibody	B-FUNC
and	O
cytokine	O
detection	O
indicated	O
that	O
SL7207	O
(	O
pVAX	O
-	O
N	O
)	O
could	O
significantly	O
induce	O
antibody	B-FUNC
-	O
IgG	O
,	O
antibody	B-FUNC
-	O
IgA	O
,	O
interleukin	O
-	O
4	O
,	O
and	O
	O
-	O
interferon	O
,	O
whose	O
value	O
was	O
maximized	O
on	O
the	O
6th	O
week	O
.	O

Multiplexing	O
would	O
allow	O
their	O
cost	O
to	O
be	O
spread	O
over	O
multiple	O
targets	O
,	O
but	O
often	O
only	O
with	O
lower	O
sensitivity	O
and	O
accuracy	O
,	O
noise	O
,	O
false	O
positives	O
,	O
and	O
false	O
negatives	O
;	O
these	O
arise	O
by	O
interactions	O
between	O
the	O
multiple	O
nucleic	O
acid	O
primers	O
and	O
probes	O
in	O
a	O
multiplexed	O
kit	B-FUNC
.	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	O
and	O
complement	O
factors	O
(	O
LCR	O
-	O
1	O
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	O
signaling	O
molecules	O
(	O
inhibitory	O
protein	O
phosphatase	B-FUNC
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	O
and	O
complement	O
factors	O
(	O
LCR	O
-	O
1	O
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	O
signaling	O
molecules	O
(	O
inhibitory	O
protein	O
phosphatase	B-FUNC
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

ABSTRACT	O
:	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
that	O
catalyzes	O
the	O
synthesis	O
of	O
their	O
RNA	O
(	O
s	O
).	O

Bioinformatics	O
analysis	O
of	O
this	O
non	O
-	O
structural	O
protein	O
has	O
now	O
revealed	O
a	O
nidoviral	O
signature	O
domain	O
(	O
genetic	O
marker	O
)	O
that	O
is	O
N	O
-	O
terminally	O
adjacent	O
to	O
the	O
RdRp	B-FUNC
and	O
has	O
no	O
apparent	O
homologs	O
elsewhere	O
.	O

Most	O
likely	O
this	O
was	O
the	O
invariant	O
lysine	O
of	O
the	O
newly	O
identified	O
domain	O
,	O
named	O
nidovirus	O
RdRp	B-FUNC
-	O
associated	O
nucleotidyltransferase	O
(	O
NiRAN	O
),	O
whose	O
substitution	O
with	O
alanine	O
severely	O
diminished	O
the	O
described	O
binding	B-FUNC
.	O

Both	O
groups	O
had	O
the	O
same	O
frequency	O
of	O
upper	O
respiratory	O
and	O
gastrointestinal	O
symptoms	O
and	O
had	O
the	O
same	O
incidence	O
of	O
admission	O
to	O
the	O
PICU	O
,	O
intravenous	O
immunoglobulin	B-FUNC
-	O
resistant	O
disease	O
,	O
and	O
coronary	O
artery	O
lesions	O
.	O

Both	O
groups	O
had	O
the	O
same	O
frequency	O
of	O
upper	O
respiratory	O
and	O
gastrointestinal	O
symptoms	O
and	O
had	O
the	O
same	O
incidence	O
of	O
admission	O
to	O
the	O
PICU	O
,	O
intravenous	O
immunoglobulin	B-FUNC
-	O
resistant	O
disease	O
,	O
and	O
coronary	O
artery	O
lesions	O
.	O

The	O
parameters	O
of	O
the	O
iELISA	O
were	O
optimized	O
,	O
and	O
the	O
cutoff	O
value	O
determined	O
as	O
0	O
.	O
259	O
by	O
analyzing	O
optical	O
density	O
(	O
OD	O
)	O
values	O
of	O
80	O
PEDV	O
negative	O
sera	B-FUNC
confirmed	O
by	O
western	O
blot	O
.	O

Repeatability	O
tests	O
revealed	O
that	O
the	O
coefficients	O
of	O
variation	O
of	O
positive	O
sera	B-FUNC
within	O
and	O
between	O
runs	O
were	O
both	O
less	O
than	O
10	O
%.	O

Further	O
studies	O
should	O
focus	O
on	O
the	O
relationship	O
between	O
OD	O
values	O
of	O
sera	B-FUNC
and	O
its	O
virus	O
neutralization	O
.	O

Thirty	O
of	O
these	O
hits	O
can	O
be	O
placed	O
in	O
a	O
network	O
of	O
interactions	O
with	O
viral	O
proteins	O
and	O
are	O
involved	O
in	O
RNA	O
splicing	O
,	O
membrane	O
trafficking	O
,	O
and	O
ubiquitin	B-FUNC
conjugation	O
.	O

While	O
SARS	O
-	O
CoV	O
nsp1	O
is	O
localized	O
exclusively	O
in	O
the	O
cytoplasm	O
and	O
binds	B-FUNC
to	O
the	O
40S	O
ribosomal	O
subunit	O
to	O
gain	O
access	O
to	O
translating	O
mRNAs	O
,	O
MERS	O
-	O
CoV	O
nsp1	O
was	O
distributed	O
in	O
both	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
did	O
not	O
bind	B-FUNC
stably	O
to	O
the	O
40S	O
subunit	O
,	O
suggesting	O
a	O
distinctly	O
different	O
mode	O
of	O
targeting	O
translating	O
mRNAs	O
.	O

Detection	O
of	O
viral	O
RNA	O
was	O
performed	O
by	O
using	O
a	O
commercial	O
real	O
-	O
time	O
PCR	O
kit	B-FUNC
(	O
hCoV	O
-	O
EMC	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
,	O
Fast	B-FUNC
Track	O
Diagnostics	O
,	O
Luxembourg	O
)	O
targeting	O
the	O
MERS	O
-	O
CoV	O
E	O
protein	O
(	O
upE	O
),	O
ORF1a	O
and	O
ORF1b	O
gene	O
regions	O
.	O

TITLE	O
:	O
Genetic	O
deficiency	O
and	O
polymorphisms	O
of	O
cyclophilin	B-FUNC
A	O
reveal	O
its	O
essential	O
role	O
for	O
Human	O
Coronavirus	O
229E	O
replication	O
.	O

Here	O
,	O
we	O
summarize	O
present	O
knowledge	O
on	O
the	O
role	O
of	O
cyclophilin	B-FUNC
A	O
during	O
coronavirus	O
replication	O
.	O

We	O
present	O
data	O
on	O
the	O
effect	O
of	O
cyclophilin	B-FUNC
A	O
single	O
nucleotide	O
polymorphism	O
mutants	O
on	O
the	O
replication	O
of	O
human	O
CoV	O
-	O
229E	O
demonstrating	O
the	O
requirement	O
of	O
proper	O
cyclophilin	B-FUNC
A	O
function	O
for	O
virus	O
propagation	O
.	O

Results	O
define	O
cellular	O
cyclophilin	B-FUNC
A	O
as	O
a	O
host	O
target	O
for	O
inhibition	O
of	O
coronaviruses	O
ranging	O
from	O
relatively	O
mild	O
common	O
cold	O
to	O
highly	O
pathogenic	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
viruses	O
with	O
the	O
perspective	O
of	O
disclosing	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
analogs	O
to	O
broadly	O
inactivate	O
the	O
coronavirus	O
family	O
.	O

Histologically	O
,	O
granulomas	O
were	O
observed	O
in	O
the	O
liver	O
,	O
spleen	O
,	O
bone	O
marrow	O
,	O
and	O
lymph	O
nodes	O
,	O
composed	O
mainly	O
of	O
aggregated	O
epithelioid	O
macrophages	O
,	O
some	O
of	O
which	O
were	O
positive	O
to	O
an	O
anti	O
-	O
feline	O
coronavirus	O
(	O
FCoV	O
;	O
Alphacoronavirus	O
1	O
)	O
antibody	B-FUNC
in	O
immunohistochemistry	O
.	O

The	O
coimmunoprecipitation	O
assay	O
demonstrated	O
the	O
direct	O
binding	B-FUNC
of	O
ORF6	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPIPB3	O
in	O
vitro	O
.	O

The	O
dual	O
luciferase	O
reporter	O
assay	O
showed	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPIPB3	O
attenuated	O
the	O
antagonistic	O
activity	O
of	O
SARS	O
-	O
CoV	O
ORF6	O
on	O
IFN	O
-	O
	O
-	O
induced	O
ISRE	O
(	O
IFN	O
stimulated	O
response	O
element	O
)-	O
responsive	O
firefly	B-FUNC
luciferase	I-FUNC
activity	I-FUNC
.	O

Murine	O
sialic	O
acid	O
-	O
binding	B-FUNC
immunoglobulin	B-FUNC
-	O
like	O
lectin	O
-	O
E	O
(	O
Siglec	O
-	O
E	O
)	O
and	O
its	O
human	O
orthologs	O
Siglec	O
-	O
7	O
and	O
Siglec	O
-	O
9	O
are	O
immunomodulatory	O
receptors	O
found	O
predominantly	O
on	O
hematopoietic	O
cells	O
.	O

This	O
nanoparticle	O
induced	O
enhanced	O
oligomerization	O
of	O
the	O
murine	O
Siglec	O
-	O
E	O
receptor	O
on	O
the	O
surface	O
of	O
macrophages	O
,	O
unlike	O
the	O
free	O
2	O
,	O
8	O
NANA	O
ligand	B-FUNC
.	O

We	O
also	O
established	O
that	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
induced	O
Siglec	O
-	O
E	O
expression	O
and	O
2	O
,	O
8	O
NANA	O
-	O
NP	O
further	O
augmented	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Indeed	O
,	O
the	O
effectiveness	O
of	O
the	O
nanoparticle	O
depended	O
on	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

The	O
ns12	O
.	O
9	O
accessory	O
protein	O
is	O
a	O
transmembrane	O
protein	O
and	O
forms	O
ion	B-FUNC
channels	I-FUNC
in	O
both	O
Xenopus	O
oocytes	O
and	O
yeast	O
through	O
homo	O
-	O
oligomerization	O
,	O
suggesting	O
that	O
ns12	O
.	O
9	O
is	O
a	O
newly	O
recognized	O
viroporin	O
.	O

Intriguingly	O
,	O
exogenous	O
ns12	O
.	O
9	O
and	O
heterologous	O
viroporins	O
with	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
could	O
compensate	O
for	O
the	O
production	O
of	O
HCoV	O
-	O
OC43	O
-	O
ns12	O
.	O
9	O
,	O
indicating	O
that	O
the	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
ns12	O
.	O
9	O
plays	O
a	O
significant	O
role	O
in	O
the	O
production	O
of	O
infectious	O
virions	O
.	O

Here	O
,	O
we	O
developed	O
an	O
IC	O
assay	O
that	O
detected	O
PEDV	O
antigens	O
with	O
96	O
.	O
0	O
%	O
(	O
218	O
/	O
227	O
)	O
sensitivity	O
and	O
98	O
.	O
5	O
%	O
(	O
262	O
/	O
266	O
)	O
specificity	O
when	O
compared	O
with	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
using	O
FAM	O
-	O
labeled	O
probes	O
based	O
on	O
sequences	O
from	O
nucleocapsid	O
genes	O
.	O

A	O
significant	O
increase	O
of	O
both	O
IgM	O
and	O
IgG	O
antibody	B-FUNC
titres	O
found	O
in	O
paired	O
acute	O
-	O
and	O
convalescent	O
-	O
phase	O
serum	O
confirmed	O
the	O
diagnosis	O
of	O
acute	O
MSF	O
.	O

Here	O
,	O
a	O
docking	O
-	O
based	O
virtual	O
screening	O
has	O
been	O
applied	O
to	O
a	O
small	O
library	O
of	O
natural	O
ligands	O
to	O
identify	O
new	O
allosteric	O
IN	O
inhibitors	O
that	O
target	O
the	O
sucrose	O
binding	B-FUNC
pocket	O
.	O

Biochemical	O
studies	O
showed	O
that	O
kuwanon	O
-	O
L	O
is	O
able	O
to	O
inhibit	O
the	O
HIV	O
-	O
1	O
IN	O
catalytic	B-FUNC
activity	I-FUNC
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
LEDGF	O
/	O
p75	O
protein	O
,	O
the	O
IN	O
dimerization	O
,	O
and	O
the	O
IN	O
/	O
LEDGF	O
binding	B-FUNC
.	O

Overall	O
,	O
docking	O
and	O
biochemical	O
results	O
suggest	O
that	O
kuwanon	O
-	O
L	O
binds	B-FUNC
to	O
an	O
allosteric	O
binding	B-FUNC
pocket	O
and	O
can	O
be	O
considered	O
an	O
attractive	O
lead	O
for	O
the	O
development	O
of	O
new	O
allosteric	O
IN	O
antiviral	O
agents	O
.	O

Multivariate	O
analysis	O
demonstrated	O
an	O
association	O
between	O
the	O
NL	O
group	O
and	O
development	O
of	O
pulmonary	O
complications	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-FUNC
],	O
2	O
.	O
1	O
;	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
15	O
-	O
3	O
.	O
78	O
).	O

Emergency	O
department	O
mechanical	O
ventilation	O
was	O
independently	O
associated	O
with	O
development	O
of	O
ARDS	O
(	O
aOR	B-FUNC
,	O
3	O
.	O
5	O
;	O
1	O
.	O
8	O
-	O
7	O
.	O
0	O
).	O

TITLE	O
:	O
Real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assays	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Here	O
we	O
designed	O
and	O
tested	O
two	O
highly	O
specific	O
quantitative	O
TaqMan	O
()-	O
MGB	O
-	O
based	O
reverse	O
transcriptase	B-FUNC
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
assays	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
).	O

The	O
primers	O
and	O
probes	O
for	O
these	O
assays	O
were	O
evaluated	O
and	O
found	O
to	O
have	O
a	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
of	O
0	O
.	O
005	O
plaque	O
-	O
forming	O
units	O
/	O
PCR	O
(	O
pfu	O
/	O
PCR	O
).	O

TITLE	O
:	O
Junctional	O
and	O
allele	O
-	O
specific	O
residues	O
are	O
critical	O
for	O
MERS	O
-	O
CoV	O
neutralization	O
by	O
an	O
exceptionally	O
potent	O
germline	O
-	O
like	O
antibody	B-FUNC
.	O

Analysis	O
of	O
antibodies	O
from	O
69	O
healthy	O
humans	O
suggests	O
an	O
important	O
role	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
recombination	O
-	O
generated	O
junctional	O
and	O
allele	O
-	O
specific	O
residues	O
for	O
achieving	O
high	O
affinity	O
of	O
binding	B-FUNC
at	O
such	O
low	O
levels	O
of	O
somatic	O
hypermutation	O
.	O

We	O
further	O
characterized	O
the	O
mechanism	O
of	O
BST	O
-	O
2	O
inhibition	O
by	O
ORF7a	O
and	O
found	O
that	O
ORF7a	O
localization	O
changes	O
when	O
BST	O
-	O
2	O
is	O
overexpressed	O
and	O
ORF7a	O
binds	B-FUNC
directly	O
to	O
BST	O
-	O
2	O
.	O

Bat	O
viruses	O
were	O
5	O
-	O
and	O
6	O
-	O
fold	O
more	O
diversified	O
than	O
HCoV	O
-	O
229E	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
spike	O
genes	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
need	O
to	O
develop	O
technologies	O
that	O
can	O
meet	O
the	O
heavy	O
demand	O
of	O
an	O
all	O
-	O
embedded	O
,	O
inexpensive	O
,	O
specific	O
and	O
fast	B-FUNC
biosensing	O
for	O
the	O
detection	O
and	O
screening	O
of	O
pathogens	O
in	O
active	O
or	O
latent	O
forms	O
to	O
offer	O
quick	O
diagnosis	O
and	O
early	O
treatments	O
in	O
order	O
to	O
avoid	O
disease	O
aggravation	O
and	O
unnecessary	O
late	O
treatment	O
costs	O
.	O

Nucleic	O
acid	O
aptamers	O
are	O
short	O
,	O
single	O
-	O
stranded	O
RNA	O
or	O
DNA	O
sequences	O
that	O
can	O
selectively	O
bind	B-FUNC
to	O
specific	O
cellular	O
and	O
biomolecular	O
targets	O
.	O

Flow	O
cytometry	O
was	O
used	O
to	O
determine	O
mode	O
of	O
cell	O
death	O
in	O
first	O
42	O
h	O
post	O
infection	O
(	O
hpi	B-FUNC
).	O

FIPV	O
infected	O
cells	O
underwent	O
early	O
apoptosis	O
at	O
9	O
hpi	B-FUNC
(	O
p	O
<	O
0	O
.	O
05	O
)	O
followed	O
by	O
late	O
apoptosis	O
at	O
12	O
hpi	B-FUNC
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
necrosis	O
from	O
24	O
hpi	B-FUNC
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Up	O
-	O
regulations	O
of	O
both	O
pro	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
PDCD5	O
)	O
and	O
anti	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
TRAF2	O
)	O
were	O
detected	O
from	O
first	O
hpi	B-FUNC
and	O
continuing	O
to	O
deregulate	O
during	O
apoptosis	O
process	O
in	O
the	O
infected	O
cells	O
.	O

TITLE	O
:	O
A	O
humanized	O
neutralizing	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
targeting	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
spike	O
protein	O
.	O

Using	O
the	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
(	O
MERS	O
-	O
RBD	O
)	O
to	O
immunize	O
mice	O
,	O
we	O
identified	O
two	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
4C2	O
and	O
2E6	O
.	O

The	O
structure	O
showed	O
that	O
4C2	O
recognizes	O
an	O
epitope	O
that	O
partially	O
overlaps	O
the	O
receptor	O
-	O
binding	B-FUNC
footprint	O
in	O
MERS	O
-	O
RBD	O
,	O
thereby	O
interfering	O
with	O
the	O
virus	O
/	O
receptor	O
interactions	O
by	O
both	O
steric	O
hindrance	O
and	O
interface	O
-	O
residue	O
competition	O
.	O

The	O
humanized	O
4C2	O
(	O
4C2h	O
)	O
antibody	B-FUNC
sustained	O
similar	O
neutralizing	O
activity	O
and	O
biochemical	O
characteristics	O
to	O
the	O
parental	O
mouse	O
antibody	B-FUNC
.	O

No	O
difference	O
in	O
complications	O
and	O
outcome	O
is	O
found	O
in	O
treatment	O
regimens	O
of	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
and	O
plasma	O
exchange	O
.	O

Cytokine	O
production	O
by	O
innate	O
and	O
adaptive	O
immune	O
cells	O
was	O
largely	O
intact	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
but	O
perforin	O
induction	O
by	O
natural	O
killer	O
cells	O
and	O
levels	O
of	O
interferon	O
gamma	O
,	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
	O
)	O
in	O
serum	O
were	O
elevated	O
.	O

Although	O
they	O
are	O
both	O
autoimmune	O
conditions	O
that	O
benefit	O
from	O
the	O
administration	O
of	O
plasma	O
exchange	O
or	O
IV	O
immunoglobulin	B-FUNC
(	O
IVIg	O
),	O
they	O
are	O
otherwise	O
very	O
different	O
disorders	O
with	O
unique	O
features	O
and	O
distinct	O
complications	O
.	O

This	O
study	O
investigates	O
the	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	O
M	O
protein	O
through	O
examination	O
of	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
interleukin	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
expression	O
.	O

The	O
M	O
protein	O
altered	O
swine	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
IEC	O
)	O
growth	O
and	O
induced	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
-	O
phase	O
via	O
the	O
cyclin	B-FUNC
A	O
pathway	O
.	O

The	O
S	O
-	O
phase	O
arrest	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
level	O
of	O
cyclin	B-FUNC
A	O
.	O
Furthermore	O
,	O
our	O
results	O
revealed	O
that	O
the	O
M	O
protein	O
of	O
PEDV	O
does	O
not	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
does	O
not	O
activate	O
NF	O
-	O
B	O
which	O
is	O
responsible	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

ABSTRACT	O
:	O
Different	O
host	O
genetic	O
variants	O
may	O
be	O
related	O
to	O
the	O
virulence	O
and	O
transmissibility	O
of	O
pandemic	O
Influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
influencing	O
events	O
such	O
as	O
binding	B-FUNC
of	O
the	O
virus	O
to	O
the	O
entry	O
receptor	O
on	O
the	O
cell	O
of	O
infected	O
individuals	O
and	O
the	O
host	O
immune	O
response	O
.	O

In	O
the	O
present	O
study	O
,	O
two	O
genetic	O
variants	O
of	O
the	O
ST3GAL1	O
gene	O
,	O
which	O
encodes	O
the	O
Sia2	O
-	O
3Gal1	O
-	O
receptor	O
to	O
which	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
binds	B-FUNC
for	O
entry	O
into	O
the	O
host	O
cell	O
,	O
were	O
investigated	O
in	O
an	O
admixed	O
Brazilian	O
population	O
.	O

In	O
21	O
-	O
day	O
-	O
old	O
pigs	O
,	O
10ml	O
of	O
inoculum	O
with	O
titers	O
560	O
-	O
5	O
.	O
6	O
TCID50	O
/	O
ml	O
(	O
Ct	O
24	O
.	O
2	O
-	O
31	O
.	O
4	O
)	O
resulted	O
in	O
100	O
%	O
infection	O
in	O
each	O
group	O
while	O
10ml	O
of	O
inoculum	O
with	O
titers	O
0	O
.	O
56	O
-	O
0	O
.	O
0056	O
TCID50	O
/	O
ml	O
(	O
Ct	O
values	O
35	O
.	O
3	O
->	O
45	O
)	O
did	O
not	O
establish	O
infection	O
in	O
any	O
pigs	O
under	O
study	O
conditions	O
as	O
determined	O
by	O
clinical	O
signs	O
,	O
PCR	O
,	O
histopathology	O
,	O
immunohistochemistry	O
,	O
and	O
antibody	B-FUNC
response	O
.	O

Neutralizing	O
antibody	B-FUNC
developed	O
in	O
the	O
surviving	O
mice	O
from	O
the	O
ID50	O
/	O
LD50	O
determinations	O
,	O
and	O
all	O
were	O
fully	O
immune	O
to	O
challenge	O
with	O
100	O
LD50	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
tissue	O
distribution	O
and	O
histopathology	O
in	O
mice	O
challenged	O
with	O
a	O
potential	O
working	O
dose	O
of	O
10	O
LD50	O
of	O
MERS	O
-	O
CoV	O
were	O
subsequently	O
evaluated	O
.	O

Finally	O
,	O
using	O
a	O
receptor	B-FUNC
binding	I-FUNC
domain	O
protein	O
vaccine	O
and	O
a	O
MERS	O
-	O
CoV	O
fusion	O
inhibitor	O
,	O
we	O
demonstrated	O
the	O
value	O
of	O
this	O
model	O
for	O
evaluating	O
vaccines	O
and	O
antivirals	O
against	O
MERS	O
.	O

We	O
further	O
characterized	O
this	O
model	O
by	O
determining	O
both	O
the	O
ID50	O
and	O
the	O
LD50	O
of	O
MERS	O
-	O
CoV	O
in	O
order	O
to	O
establish	O
both	O
an	O
infection	O
model	O
and	O
a	O
lethal	O
model	O
for	O
MERS	O
and	O
followed	O
this	O
by	O
investigating	O
the	O
antibody	B-FUNC
responses	O
and	O
immunity	O
of	O
the	O
mice	O
that	O
survived	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
sera	B-FUNC
were	O
tested	O
with	O
a	O
neutralizing	O
antibody	B-FUNC
test	O
.	O

ECMO	O
gives	O
the	O
lungs	O
an	O
opportunity	O
to	O
rest	B-FUNC
and	O
recover	O
.	O

From	O
cloacal	O
swabs	O
and	O
intestines	O
,	O
TCoV	O
was	O
consistently	O
detected	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
throughout	O
the	O
experimental	O
period	O
(	O
1	O
-	O
21	O
days	O
postinoculation	O
[	O
DPI	O
])	O
from	O
all	O
age	O
groups	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
on	O
effusion	O
samples	O
in	O
cats	O
with	O
and	O
without	O
feline	O
infectious	O
peritonitis	O
.	O

Feline	O
coronavirus	O
RNA	O
was	O
detected	O
using	O
a	O
reverse	O
transcriptase	B-FUNC
quantitative	O
polymerase	O
chain	O
reaction	O
assay	O
(	O
qRT	O
-	O
PCR	O
),	O
and	O
positive	O
samples	O
underwent	O
pyrosequencing	O
of	O
position	O
1058	O
with	O
or	O
without	O
Sanger	O
sequencing	O
of	O
position	O
1060	O
in	O
the	O
FCoV	O
spike	O
protein	O
.	O

These	O
DN	O
T	O
cells	O
were	O
predominantly	O
consisted	O
of	O
a	O
TCR	O
(+)	O
subset	O
expressing	O
high	O
levels	O
of	O
CD44	O
and	O
did	O
not	O
produce	O
cytokine	O
except	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
.	O

TITLE	O
:	O
Reconstitution	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
of	O
the	O
SARS	O
coronavirus	O
.	O

The	O
SARS	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
amino	O
acids	O
N318	O
-	O
T509	O
of	O
S	O
protein	O
)	O
harbors	O
an	O
extended	O
excursion	O
along	O
its	O
periphery	O
that	O
contacts	O
ACE2	O
and	O
is	O
designated	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RBM	O
,	O
amino	O
acids	O
S432	O
-	O
T486	O
).	O

The	O
study	O
was	O
an	O
analysis	O
of	O
the	O
safety	O
of	O
erythropoietin	B-FUNC
administration	O
and	O
transfusion	O
threshold	O
on	O
the	O
incidence	O
of	O
ARDS	O
in	O
severe	O
TBI	O
patients	O
.	O

Previously	O
,	O
potent	O
primer	O
-	O
dependent	O
RdRp	B-FUNC
activity	O
has	O
been	O
demonstrated	O
for	O
the	O
homologous	O
polymerase	O
subunit	O
(	O
nsp12	O
)	O
of	O
the	O
distantly	O
related	O
coronaviruses	O
.	O

Based	O
on	O
the	O
properties	O
of	O
active	O
-	O
site	O
mutants	O
,	O
we	O
conclude	O
that	O
the	O
RNA	O
-	O
synthesizing	O
activities	O
observed	O
in	O
de	O
novo	O
and	O
primer	O
-	O
dependent	O
polymerase	O
and	O
terminal	O
transferase	O
assays	O
cannot	O
be	O
attributed	O
to	O
recombinant	O
EAV	O
nsp9	O
-	O
RdRp	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
study	O
aimed	O
at	O
exploring	O
bereavement	O
and	O
complicated	O
grief	O
(	O
CG	O
)	O
symptoms	O
among	O
subjects	O
without	O
a	O
history	O
of	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
at	O
the	O
time	O
of	O
a	O
first	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
and	O
to	O
evaluate	O
the	O
relationship	O
of	O
CG	O
symptoms	O
and	O
ACS	B-FUNC
.	O

Overall	O
,	O
149	O
subjects	O
with	O
ACS	B-FUNC
(	O
namely	O
,	O
acute	O
myocardial	O
infarct	O
with	O
or	O
without	O
ST	O
-	O
segment	O
elevation	O
or	O
unstable	O
angina	O
),	O
with	O
no	O
previous	O
history	O
of	O
CHD	O
,	O
admitted	O
to	O
three	O
cardiac	O
intensive	O
care	O
units	O
were	O
included	O
and	O
evaluated	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
Complicated	O
Grief	O
(	O
SCI	O
-	O
CG	O
),	O
Hamilton	O
Depression	O
Rating	O
Scale	O
,	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
,	O
and	O
the	O
36	O
-	O
item	O
Short	O
-	O
Form	O
Health	O
Survey	O
(	O
MOS	O
-	O
SF	O
-	O
36	O
).	O

Of	O
the	O
total	O
sample	O
of	O
149	O
subjects	O
with	O
ACS	B-FUNC
,	O
118	O
(	O
79	O
.	O
2	O
%)	O
met	O
criteria	O
for	O
DSM	O
-	O
5	O
persistent	O
complex	O
bereavement	O
disorder	O
.	O

Among	O
these	O
,	O
subjects	O
who	O
lost	O
a	O
partner	O
,	O
child	O
,	O
or	O
sibling	O
were	O
older	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
less	O
likely	O
to	O
be	O
working	O
(	O
P	O
=	O
0	O
.	O
032	O
),	O
and	O
more	O
likely	O
to	O
be	O
suffering	O
from	O
hypertension	O
(	O
P	O
=	O
0	O
.	O
021	O
),	O
returned	O
higher	O
scores	O
on	O
the	O
SCI	O
-	O
CG	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
developed	O
the	O
index	O
ACS	B-FUNC
more	O
frequently	O
between	O
12	O
and	O
48	O
months	O
after	O
the	O
death	O
than	O
those	O
who	O
lost	O
a	O
parent	O
or	O
another	O
relative	O
(	O
P	O
	O
0	O
.	O
0001	O
).	O

The	O
occurrence	O
of	O
ACS	B-FUNC
12	O
-	O
48	O
months	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
after	O
the	O
loss	O
was	O
positively	O
correlated	O
with	O
SCI	O
-	O
CG	O
scores	O
.	O

An	O
inverse	O
relationship	O
with	O
SCI	O
-	O
CG	O
scores	O
was	O
observed	O
for	O
patients	O
who	O
experienced	O
ACS	B-FUNC
more	O
than	O
48	O
months	O
after	O
the	O
loss	O
(	O
P	O
=	O
0	O
.	O
005	O
).	O

A	O
great	O
proportion	O
of	O
subjects	O
with	O
ACS	B-FUNC
report	O
the	O
loss	O
of	O
a	O
loved	O
one	O
.	O

CONCLUSIONS	O
:	O
A	O
great	O
proportion	O
of	O
subjects	O
with	O
ACS	B-FUNC
report	O
the	O
loss	O
of	O
a	O
loved	O
one	O
.	O

The	O
RT	O
-	O
Bst	O
method	O
amplifies	O
cDNA	O
through	O
reverse	O
transcription	O
of	O
viral	O
RNA	O
using	O
reverse	O
transcriptase	B-FUNC
and	O
amplification	O
of	O
cDNA	O
using	O
Bst	O
DNA	O
polymerase	O
.	O

When	O
the	O
full	O
-	O
length	O
E	O
protein	O
was	O
deleted	O
or	O
its	O
PDZ	O
-	O
binding	B-FUNC
motif	O
(	O
PBM	O
)	O
was	O
mutated	O
,	O
the	O
revertant	O
viruses	O
either	O
incorporated	O
a	O
novel	O
chimeric	O
protein	O
with	O
a	O
PBM	O
or	O
restored	O
the	O
sequence	O
of	O
the	O
PBM	O
on	O
the	O
E	O
protein	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Plaque	O
reduction	O
neutralisation	O
tests	O
(	O
PRNT	O
),	O
microneutralisation	O
(	O
MN	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
spike	O
pseudoparticle	O
neutralisation	O
(	O
ppNT	O
)	O
and	O
MERS	O
S1	O
-	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibody	B-FUNC
titres	O
were	O
compared	O
using	O
95	O
sera	B-FUNC
from	O
17	O
patients	O
with	O
MERS	O
,	O
collected	O
two	O
to	O
46	O
days	O
after	O
symptom	O
onset	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
protein	O
(	O
NP	O
),	O
an	O
essential	O
RNA	O
-	O
binding	B-FUNC
viral	O
protein	O
in	O
human	O
coronavirus	O
(	O
CoV	O
)-	O
infected	O
cells	O
,	O
is	O
required	O
for	O
the	O
replication	O
and	O
transcription	O
of	O
viral	O
RNA	O
.	O

Surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
analysis	O
indicated	O
that	O
one	O
among	O
the	O
potential	O
leads	O
,	O
6	O
-	O
chloro	O
-	O
7	O
-(	O
2	O
-	O
morpholin	O
-	O
4	O
-	O
yl	O
-	O
ethylamino	O
)	O
quinoxaline	O
-	O
5	O
,	O
8	O
-	O
dione	O
(	O
small	O
-	O
compound	O
H3	O
),	O
exhibited	O
a	O
significant	O
decrease	O
of	O
RNA	O
-	O
binding	B-FUNC
capacity	O
of	O
NP	O
by	O
more	O
than	O
20	O
%.	O

Fluorescence	O
titration	O
and	O
X	O
-	O
ray	O
crystallography	O
studies	O
indicated	O
that	O
H3	O
antagonizes	O
the	O
binding	B-FUNC
between	O
HCoV	O
-	O
OC43	O
NP	O
and	O
RNA	O
by	O
interacting	O
with	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
NP	O
.	O

The	O
envelope	O
spike	O
glycoprotein	O
on	O
the	O
surface	O
of	O
MERS	O
-	O
CoV	O
which	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
,	O
membrane	O
fusion	O
and	O
viral	O
entry	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
MERS	O
-	O
CoV	O
.	O
No	O
specific	O
and	O
effective	O
treatment	O
for	O
MERS	O
-	O
CoV	O
is	O
currently	O
recommended	O
,	O
although	O
supportive	O
treatment	O
has	O
played	O
an	O
important	O
role	O
.	O

TITLE	O
:	O
Viral	O
Shedding	O
and	O
Antibody	B-FUNC
Response	O
in	O
37	O
Patients	O
With	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Immunoglobulin	B-FUNC
M	O
detection	O
provided	O
no	O
advantage	O
in	O
sensitivity	O
over	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
detection	O
.	O

Five	O
necropsied	O
cats	O
that	O
were	O
naturally	O
infected	O
with	O
FIP	O
virus	O
,	O
confirmed	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	O
,	O
with	O
different	O
intensities	O
of	O
CNS	O
lesions	O
,	O
were	O
studied	O
.	O

In	O
most	O
patients	O
,	O
robust	O
antibody	B-FUNC
responses	O
developed	O
by	O
the	O
third	O
week	O
of	O
illness	O
.	O

Delayed	O
antibody	B-FUNC
responses	O
with	O
the	O
neutralization	O
test	O
were	O
associated	O
with	O
more	O
severe	O
disease	O
.	O

Pseudotypes	O
allow	O
for	O
accurate	O
,	O
sequence	O
-	O
directed	O
,	O
sensitive	O
antibody	B-FUNC
neutralisation	O
assays	O
and	O
antiviral	O
screening	O
to	O
be	O
conducted	O
within	O
a	O
low	O
biosecurity	O
facility	O
and	O
offer	O
a	O
safe	O
and	O
efficient	O
alternative	O
to	O
wildtype	O
virus	O
use	O
.	O

The	O
study	O
comprises	O
computationally	O
demanding	O
ab	O
initio	O
approaches	O
(	O
HF	O
,	O
CC2	O
,	O
MP2	O
,	O
SCS	B-FUNC
-	O
CC2	O
,	O
SCS	B-FUNC
-	O
MP2	O
,	O
CCSD	O
(	O
T	O
)),	O
popular	O
density	O
functional	O
theories	O
(	O
BLYP	O
,	O
B3LYP	O
,	O
M06	O
-	O
2X	O
),	O
and	O
semiempirical	O
methods	O
(	O
MNDO	O
/	O
d	O
,	O
AM1	O
,	O
RM1	O
,	O
PM3	O
,	O
PM6	O
).	O

As	O
an	O
example	O
HF	O
,	O
CC2	O
,	O
MP2	O
,	O
and	O
their	O
SCS	B-FUNC
variants	O
show	O
similar	O
errors	O
for	O
gas	O
phase	O
,	O
COSMO	O
,	O
or	O
QM	O
/	O
MM	O
computations	O
.	O

Immunotherapy	O
with	O
intravenous	O
steroids	O
or	O
intravenous	O
immunoglobulin	B-FUNC
(	O
three	O
patients	O
had	O
both	O
)	O
was	O
tried	O
in	O
six	O
of	O
seven	O
patients	O
with	O
a	O
poor	O
response	O
.	O

The	O
IgG	O
antibody	B-FUNC
levels	O
of	O
serum	O
from	O
mice	O
immunized	O
with	O
purified	O
S	O
protein	O
were	O
markedly	O
high	O
.	O

We	O
performed	O
intratracheal	O
administration	O
of	O
autologous	O
peripheral	O
blood	O
-	O
derived	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
erythropoietin	B-FUNC
(	O
EPO	O
).	O

The	O
resulting	O
limits	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
for	O
virus	O
-	O
spiked	O
samples	O
,	O
bacteria	O
and	O
DNA	O
fragments	O
were	O
0	O
.	O
16	O
-	O
1	O
.	O
6	O
TCID50	O
(	O
PFU	O
/	O
reaction	O
),	O
1	O
.	O
3	O
-	O
13	O
CFU	O
/	O
reaction	O
and	O
10	O
-	O
100	O
copies	O
/	O
reaction	O
,	O
respectively	O
.	O

In	O
the	O
CP	O
collection	O
phase	O
,	O
potential	O
donors	O
will	O
be	O
tested	O
by	O
the	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
the	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
techniques	O
for	O
the	O
presence	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	O
.	O

In	O
this	O
study	O
,	O
based	O
on	O
the	O
peptide	O
-	O
binding	B-FUNC
motifs	O
of	O
chicken	O
MHC	O
I	O
molecules	O
for	O
the	O
BF2	O
*	O
4	O
,	O
BF2	O
*	O
12	O
,	O
BF2	O
*	O
15	O
,	O
and	O
BF2	O
*	O
19	O
haplotypes	O
,	O
potential	O
CTL	O
epitopes	O
were	O
predicted	O
using	O
S1	O
proteins	O
from	O
different	O
IBV	O
strains	O
.	O

Here	O
,	O
we	O
found	O
that	O
ORF4b	O
in	O
the	O
cytoplasm	O
could	O
specifically	O
bind	B-FUNC
to	O
TANK	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
)	O
and	O
IB	O
kinase	O
epsilon	O
(	O
IKK	O
),	O
suppress	O
the	O
molecular	B-FUNC
interaction	I-FUNC
between	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
)	O
and	O
IKK	O
,	O
and	O
inhibit	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
phosphorylation	O
and	O
subsequent	O
IFN	O
-	O
	O
production	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
MERS	O
-	O
CoV	O
ORF4b	O
inhibits	O
the	O
induction	O
of	O
type	O
I	O
IFN	O
through	O
a	O
direct	O
interaction	O
with	O
IKK	O
/	O
TBK1	B-FUNC
in	O
the	O
cytoplasm	O
,	O
and	O
also	O
in	O
the	O
nucleus	O
with	O
unknown	O
mechanism	O
.	O

MERS	O
-	O
CoV	O
ORF4b	O
inhibits	O
the	O
production	O
of	O
type	O
I	O
IFN	O
through	O
a	O
direct	O
interaction	O
with	O
IKK	O
/	O
TBK1	B-FUNC
in	O
the	O
cytoplasm	O
,	O
and	O
also	O
in	O
the	O
nucleus	O
with	O
unknown	O
mechanism	O
.	O

The	O
development	O
of	O
a	O
rapid	O
antigen	O
detection	O
kit	B-FUNC
for	O
instantaneous	O
diagnosis	O
is	O
warranted	O
.	O

Based	O
on	O
the	O
maximum	O
HLA	O
binding	B-FUNC
alleles	O
,	O
top	O
10	O
helper	O
T	O
-	O
cell	O
epitopes	O
and	O
CTL	O
epitopes	O
that	O
may	O
elicit	O
protective	O
cellular	O
immune	O
responses	O
against	O
MERS	O
-	O
CoV	O
were	O
selected	O
as	O
MERS	O
vaccine	O
candidates	O
.	O

Mutations	O
specifically	O
disrupting	O
the	O
cysteine	B-FUNC
protease	I-FUNC
activity	I-FUNC
of	O
PEDV	O
nsp5	O
abrogated	O
NEMO	O
cleavage	O
and	O
the	O
inhibition	O
of	O
IFN	O
induction	O
.	O

Mechanistically	O
,	O
the	O
cysteine	B-FUNC
protease	I-FUNC
activity	I-FUNC
of	O
PEDV	O
nsp5	O
mediates	O
proteolysis	O
of	O
NEMO	O
,	O
the	O
key	O
adaptor	O
for	O
IFN	O
synthesis	O
,	O
and	O
NEMO	O
is	O
cleaved	O
at	O
glutamine	O
231	O
(	O
Q231	O
).	O

The	O
mutagenesis	O
of	O
other	O
residues	O
found	O
on	O
the	O
dimerization	O
interface	O
indicate	O
that	O
dimerization	O
of	O
MERS	O
-	O
CoV	O
Mpro	O
is	O
required	O
for	O
its	O
catalytic	B-FUNC
activity	I-FUNC
.	O

Plasma	O
Ang	O
-	O
2	O
,	O
von	O
Willebrand	O
Factor	O
antigen	O
(	O
vWF	O
),	O
and	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
were	O
measured	O
on	O
ARDS	O
days	O
1	O
and	O
3	O
and	O
correlated	O
with	O
patient	O
outcomes	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
prototype	O
automated	O
microarray	O
that	O
integrates	O
and	O
automates	O
all	O
steps	O
of	O
post	O
-	O
PCR	O
microarray	O
processing	O
for	O
the	O
simultaneous	O
detection	O
and	O
typing	O
of	O
eight	O
bacteria	O
and	O
viruses	O
commonly	O
associated	O
with	O
PRDC	O
is	O
described	O
along	O
with	O
associated	O
multiplex	O
reverse	O
transcriptase	B-FUNC
PCR	O
.	O

Comprehensive	O
information	O
on	O
the	O
levels	O
and	O
duration	O
of	O
effector	O
/	O
memory	O
IgA	O
and	O
IgG	O
antibody	B-FUNC
secreting	O
B	O
cell	O
response	O
in	O
the	O
intestines	O
and	O
lymphoid	O
organs	O
of	O
PEDV	O
-	O
infected	O
sows	O
,	O
and	O
their	O
association	O
with	O
specific	O
antibody	B-FUNC
levels	O
in	O
clinical	O
samples	O
such	O
as	O
plasma	O
,	O
oral	O
fluid	O
,	O
and	O
feces	O
is	O
important	O
.	O

Our	O
data	O
indicated	O
that	O
evaluation	O
of	O
both	O
PEDV	O
specific	O
IgA	O
and	O
IgG	O
antibody	B-FUNC
levels	O
in	O
the	O
plasma	O
and	O
oral	O
fluid	O
(	O
but	O
not	O
feces	O
)	O
samples	O
is	O
beneficial	O
in	O
disease	O
diagnosis	O
.	O

CsA	O
and	O
FK506	O
are	O
targets	O
of	O
clinically	O
relevant	O
immunosuppressive	O
drugs	O
and	O
bind	B-FUNC
to	O
cellular	O
cyclophilins	O
(	O
Cyps	O
)	O
or	O
FK506	B-FUNC
binding	I-FUNC
proteins	O
(	O
FKBPs	O
),	O
respectively	O
.	O

However	O
,	O
protein	O
interacting	O
with	O
NIMA	O
(	O
Pin1	O
),	O
a	O
member	O
of	O
the	O
parvulin	B-FUNC
subfamily	O
of	O
PPIases	O
that	O
differs	O
from	O
Cyps	O
and	O
FKBPs	O
,	O
is	O
essential	O
for	O
various	O
signaling	O
pathways	O
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
promoter	O
activities	O
of	O
TNF	O
-	O
	O
and	O
MX1	O
were	O
downregulated	O
in	O
G6PD	O
-	O
knockdown	O
cells	O
,	O
and	O
that	O
the	O
IB	O
degradation	O
and	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
NF	O
-	O
B	O
were	O
decreased	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
use	O
of	O
a	O
combined	O
reverse	O
transcriptase	B-FUNC
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nPCR	O
)	O
and	O
sequencing	O
approach	O
in	O
the	O
diagnosis	O
of	O
FIP	O
,	O
detecting	O
mutations	O
at	O
two	O
different	O
nucleotide	O
positions	O
within	O
the	O
spike	O
(	O
S	O
)	O
gene	O
.	O

Here	O
,	O
we	O
explored	O
the	O
association	O
between	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
and	O
development	O
of	O
ALI	O
using	O
LPS	O
-	O
induced	O
murine	O
model	O
.	O

Upregulation	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
resulted	O
in	O
increased	O
severity	O
of	O
ALI	O
as	O
evidenced	O
by	O
decreased	O
body	O
weight	O
and	O
survival	O
rate	O
,	O
elevated	O
level	O
of	O
total	O
protein	O
and	O
albumin	O
in	O
BAL	O
fluid	O
,	O
as	O
well	O
as	O
more	O
apparent	O
histopathology	O
changes	O
of	O
lung	O
.	O

Induction	O
of	O
ALI	O
was	O
impaired	O
in	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
deficient	O
mice	O
.	O

Management	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
could	O
modulate	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
the	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
BAL	O
fluid	O
.	O

Of	O
note	O
,	O
blockade	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
effectively	O
inhibited	O
the	O
lung	O
inflammation	O
and	O
alleviated	O
ALI	O
severity	O
.	O

Finally	O
,	O
we	O
confirmed	O
the	O
clinical	O
relevance	O
and	O
found	O
that	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
was	O
elevated	O
and	O
associated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
the	O
serum	O
creatinine	O
(	O
SCr	O
),	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	B-FUNC
),	O
urine	O
dipstick	O
tests	O
,	O
urinary	O
protein	O
quantitation	O
(	O
ACR	O
or	O
PCR	O
),	O
and	O
other	O
clinical	O
parameters	O
in	O
all	O
patients	O
.	O

Our	O
goal	O
was	O
to	O
elucidate	O
the	O
prevalence	O
of	O
AHR	O
,	O
as	O
measured	O
by	O
a	O
methacholine	O
challenge	O
test	O
(	O
MCT	O
),	O
in	O
children	O
with	O
SCD	O
who	O
did	O
not	O
have	O
concomitant	O
asthma	O
or	O
any	O
recent	O
history	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
).	O

Infection	O
of	O
H9N2	O
on	O
HPMECs	O
induced	O
a	O
high	O
level	O
of	O
chemokines	O
and	O
cytokines	O
production	O
including	O
IP	O
-	O
10	O
,	O
RANTES	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IFN	O
-	O
	O
and	O
IFN	O
-	O
1	O
.	O

The	O
conjugation	O
of	O
double	O
strand	O
probes	O
onto	O
polymeric	O
microgels	O
allows	O
for	O
a	O
sensitive	O
detection	O
of	O
DNA	O
sequences	O
from	O
HIV	O
,	O
HCV	O
and	O
SARS	O
corona	O
viruses	O
with	O
a	O
LOD	B-FUNC
of	O
1	O
.	O
4	O
fM	O
,	O
3	O
.	O
7	O
fM	O
and	O
1	O
.	O
4	O
fM	O
,	O
respectively	O
,	O
and	O
with	O
a	O
dynamic	O
range	O
of	O
10	O
(-	O
9	O
)-	O
10	O
(-	O
15	O
)	O
M	O
.	O
Such	O
combination	O
enhances	O
the	O
sensitivity	O
of	O
the	O
detection	O
of	O
almost	O
five	O
orders	O
of	O
magnitude	O
when	O
compared	O
to	O
the	O
only	O
probe	O
.	O

Upon	O
sensing	O
double	O
-	O
stranded	O
RNA	O
,	O
OAS	O
produces	O
2	O
',	O
5	O
'-	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
),	O
which	O
activate	O
RNase	O
L	O
.	O
Murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
nonstructural	O
protein	O
2	O
(	O
ns2	O
)	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
(	O
PDE	B-FUNC
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
antagonizing	O
RNase	O
L	O
activation	O
.	O

PDE	B-FUNC
activity	O
is	O
required	O
for	O
robust	O
replication	O
in	O
myeloid	O
cells	O
,	O
as	O
a	O
mutant	O
of	O
MHV	O
(	O
ns2	O
(	O
H126R	O
))	O
encoding	O
an	O
inactive	O
PDE	B-FUNC
fails	O
to	O
antagonize	O
RNase	O
L	O
activation	O
and	O
replicates	O
poorly	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMM	O
),	O
while	O
ns2	O
(	O
H126R	O
)	O
replicates	O
to	O
high	O
titer	O
in	O
several	O
types	O
of	O
nonmyeloid	O
cells	O
,	O
as	O
well	O
as	O
in	O
IFN	O
receptor	O
-	O
deficient	O
(	O
Ifnar1	O
(-/-))	O
BMM	O
.	O

However	O
,	O
ns2	O
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	O
L	O
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	O
-	O
blocking	O
antibody	B-FUNC
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	O
genes	O
.	O

Comparison	O
of	O
macro	O
domains	O
from	O
MERS	O
-	O
CoV	O
and	O
other	O
human	O
CoVs	O
revealed	O
structural	O
differences	O
in	O
the	O
1	O
helix	O
alters	O
how	O
the	O
conserved	O
Asp	O
-	O
20	O
interacts	O
with	O
ADP	O
-	O
ribose	O
and	O
may	O
explain	O
the	O
efficient	O
binding	B-FUNC
of	O
the	O
MERS	O
-	O
CoV	O
macro	O
domain	O
to	O
ADP	O
-	O
ribose	O
.	O

This	O
study	O
provides	O
structural	O
and	O
biophysical	O
bases	O
to	O
further	O
evaluate	O
the	O
role	O
of	O
the	O
MERS	O
-	O
CoV	O
macro	O
domain	O
in	O
the	O
host	O
response	O
via	O
ADP	B-FUNC
-	I-FUNC
ribose	I-FUNC
binding	I-FUNC
but	O
also	O
as	O
a	O
potential	O
target	O
for	O
drug	O
design	O
.	O

The	O
levels	O
of	O
Interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
lung	O
tissue	O
and	O
plasma	O
were	O
measured	O
by	O
qRT	O
-	O
PCR	O
and	O
ELISA	O
respectively	O
.	O

For	O
the	O
comparable	O
ventilator	O
setting	O
,	O
as	O
compared	O
with	O
BIPAPSB	O
group	O
,	O
the	O
BIPAPAP	O
group	O
presented	O
higher	O
EELV	O
(	O
427	O
	O
47	O
vs	O
.	O
366	O
	O
38	O
ml	O
)	O
and	O
oxygenation	O
index	O
(	O
293	O
	O
36	O
vs	O
.	O
226	O
	O
31	O
mmHg	O
),	O
lower	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
216	O
.	O
6	O
	O
48	O
.	O
0	O
vs	O
.	O
297	O
.	O
5	O
	O
71	O
.	O
2	O
pg	O
/	O
ml	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
246	O
.	O
8	O
	O
78	O
.	O
2	O
vs	O
.	O
357	O
.	O
5	O
	O
69	O
.	O
3	O
pg	O
/	O
ml	O
)	O
in	O
plasma	O
,	O
and	O
lower	O
express	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
mRNA	O
(	O
15	O
.	O
0	O
	O
3	O
.	O
8	O
vs	O
.	O
21	O
.	O
2	O
	O
3	O
.	O
7	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
mRNA	O
(	O
18	O
.	O
9	O
	O
6	O
.	O
8	O
vs	O
.	O
29	O
.	O
5	O
	O
7	O
.	O
9	O
)	O
in	O
lung	O
tissues	O
.	O

And	O
there	O
is	O
a	O
need	O
for	O
fast	B-FUNC
and	O
efficient	O
access	O
to	O
the	O
best	O
specialized	O
clinic	O
.	O

Compound	O
showed	O
selective	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
thanks	O
to	O
its	O
ability	O
to	O
inhibit	O
the	O
reverse	O
transcriptase	B-FUNC
.	O

Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	B-FUNC
from	O
the	O
ARDS	O
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Stiffening	O
correlated	O
with	O
the	O
cytokines	O
interleukin	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
TNF	O
-	O
	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
but	O
not	O
with	O
interferon	O
-	O
	O
,	O
transforming	O
growth	O
factor	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
or	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
.	O

Strong	O
stiffening	O
was	O
induced	O
by	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
TNF	O
-	O
	O
but	O
not	O
by	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
incubations	O
with	O
sera	B-FUNC
and	O
blocking	O
antibodies	O
against	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
or	O
TNF	O
-	O
	O
significantly	O
diminished	O
the	O
stiffening	O
effect	O
of	O
serum	O
.	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	O
expression	O
(	O
CD11b	O
,	O
CD11a	O
,	O
CD18	O
,	O
CD49d	O
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	O
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	B-FUNC
of	O
patients	O
with	O
ARDS	O
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	O
in	O
early	O
ARDS	O
.	O

RESULTS	O
:	O
Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	B-FUNC
from	O
the	O
ARDS	O
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	O
expression	O
(	O
CD11b	O
,	O
CD11a	O
,	O
CD18	O
,	O
CD49d	O
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	O
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	B-FUNC
of	O
patients	O
with	O
ARDS	O
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	O
in	O
early	O
ARDS	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
ns2	O
phosphodiesterase	B-FUNC
domain	O
that	O
antagonizes	O
RNase	O
L	O
activation	O
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
have	O
demonstrated	O
that	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
strain	O
ns2	O
protein	O
is	O
a	O
member	O
of	O
the	O
2H	O
phosphoesterase	O
family	O
and	O
exhibits	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
(	O
PDE	B-FUNC
)	O
activity	O
.	O

These	O
findings	O
provide	O
insight	O
into	O
the	O
structural	O
basis	O
for	O
2	O
-	O
5A	O
binding	B-FUNC
of	O
MHV	O
ns2	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
Neutralizing	O
Monoclonal	O
Antibody	B-FUNC
Against	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
S1	O
Protein	O
.	O

8A3A10	O
monoclonal	O
antibody	B-FUNC
showed	O
a	O
neutralizing	O
activity	O
to	O
PEDV	O
,	O
as	O
demonstrated	O
in	O
the	O
results	O
of	O
fluorescent	O
focus	O
neutralization	O
assay	O
.	O

TITLE	O
:	O
Suppression	O
of	O
type	O
I	O
interferon	O
production	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
degradation	O
of	O
CREB	O
-	O
binding	B-FUNC
protein	O
by	O
nsp1	O
.	O

PEDV	O
nsp1	O
did	O
not	O
interfere	O
the	O
IRF3	O
phosphorylation	O
and	O
nuclear	O
translocation	O
but	O
interrupted	O
the	O
enhanceosome	O
assembly	O
of	O
IRF3	O
and	O
CREB	O
-	O
binding	B-FUNC
protein	O
(	O
CBP	O
)	O
by	O
degrading	O
CBP	O
.	O

In	O
this	O
review	O
we	O
will	O
introduce	O
various	O
pseudotyping	O
systems	O
for	O
emerging	O
viruses	O
,	O
including	O
chikungunya	O
virus	O
,	O
Ebola	O
virus	O
,	O
SARS	O
and	O
MERS	O
coronaviruses	O
and	O
Nipah	O
virus	O
,	O
as	O
well	O
as	O
their	O
use	O
in	O
diverse	O
studies	O
including	O
drug	O
screening	O
and	O
antibody	B-FUNC
neutralization	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
detecting	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
serum	O
in	O
comparison	O
with	O
the	O
same	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
in	O
cell	O
-	O
free	O
body	O
cavity	O
effusion	O
.	O

TITLE	O
:	O
The	O
Hemagglutinin	O
Stem	O
-	O
Binding	B-FUNC
Monoclonal	O
Antibody	B-FUNC
VIS410	O
Controls	O
Influenza	O
Virus	O
-	O
Induced	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
treatment	O
with	O
VIS410	O
,	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
targeting	O
the	O
HA	O
stem	O
region	O
,	O
on	O
the	O
development	O
of	O
ARDS	O
in	O
BALB	O
/	O
c	O
mice	O
after	O
infection	O
with	O
influenza	O
A	O
(	O
H7N9	O
)	O
viruses	O
.	O

Low	O
serum	O
levels	O
of	O
immunoglobulin	B-FUNC
A	O
,	O
G2	O
,	O
and	O
G4	O
were	O
also	O
observed	O
before	O
HSCT	O
;	O
however	O
,	O
these	O
values	O
normalized	O
after	O
transplantation	O
.	O

Although	O
HSCT	O
effects	O
on	O
the	O
clinical	O
manifestations	O
were	O
limited	O
,	O
laboratory	O
data	O
including	O
plasma	O
lysosomal	O
enzyme	O
activities	O
and	O
serum	O
levels	O
of	O
immunoglobulin	B-FUNC
showed	O
improvement	O
.	O

Many	O
of	O
these	O
variants	O
were	O
present	O
at	O
high	O
frequencies	O
and	O
could	O
potentially	O
influence	O
viral	O
phenotype	O
and	O
the	O
sensitivity	O
of	O
detection	O
assays	O
that	O
target	O
these	O
regions	O
for	O
primer	O
or	O
probe	O
binding	B-FUNC
.	O

During	O
coronavirus	O
encephalomyelitis	O
CXCL13	O
deficiency	O
impaired	O
CNS	O
accumulation	O
of	O
memory	O
B	O
cells	O
and	O
antibody	B-FUNC
-	O
secreting	O
cells	O
(	O
ASC	O
)	O
but	O
not	O
nave	O
/	O
early	O
-	O
activated	O
B	O
cells	O
.	O

TITLE	O
:	O
Ribonuclease	O
H	O
/	O
DNA	O
Polymerase	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
Dual	O
Inhibitor	O
:	O
Mechanistic	O
Studies	O
on	O
the	O
Allosteric	O
Mode	O
of	O
Action	O
of	O
Isatin	O
-	O
Based	O
Compound	O
RMNC6	O
.	O

Blind	O
docking	O
studies	O
predict	O
that	O
RMNC6	O
could	O
bind	B-FUNC
two	O
different	O
pockets	O
in	O
the	O
RT	O
:	O
one	O
in	O
the	O
DNA	O
polymerase	O
domain	O
(	O
partially	O
overlapping	O
the	O
non	O
-	O
nucleoside	O
RT	O
inhibitor	O
[	O
NNRTI	O
]	O
binding	B-FUNC
pocket	O
),	O
and	O
a	O
second	O
one	O
close	O
to	O
the	O
RNase	O
H	O
active	O
site	O
.	O

The	O
compound	O
was	O
also	O
an	O
inhibitor	O
of	O
the	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
of	O
wild	O
-	O
type	O
HIV	O
-	O
1	O
group	O
O	O
RT	O
,	O
although	O
we	O
observed	O
a	O
6	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
IC50	O
in	O
comparison	O
with	O
the	O
prototypic	O
HIV	O
-	O
1	O
group	O
M	O
subtype	O
B	O
enzyme	O
.	O

In	O
addition	O
,	O
antibody	B-FUNC
neutralization	O
assay	O
and	O
shRNA	O
knockdown	O
experiments	O
indicated	O
a	O
vital	O
role	O
of	O
vimentin	O
in	O
cell	O
binding	B-FUNC
and	O
uptake	O
of	O
SARS	O
-	O
CoV	O
VLPs	O
and	O
the	O
viral	O
spike	O
protein	O
.	O

In	O
addition	O
,	O
antibody	B-FUNC
neutralization	O
assay	O
and	O
shRNA	O
knockdown	O
experiments	O
indicated	O
a	O
vital	O
role	O
of	O
vimentin	O
in	O
cell	O
binding	B-FUNC
and	O
uptake	O
of	O
SARS	O
-	O
CoV	O
VLPs	O
and	O
the	O
viral	O
spike	O
protein	O
.	O

Several	O
cytokines	O
,	O
including	O
MIP	O
-	O
1	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
IP	O
-	O
10	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
were	O
observed	O
to	O
have	O
significantly	O
positive	O
relationships	O
with	O
CRP	O
levels	O
,	O
whereas	O
IL	O
-	O
17A	O
was	O
negatively	O
associated	O
with	O
CRP	O
levels	O
.	O

Several	O
cytokines	O
,	O
including	O
MIP	O
-	O
1	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
IP	O
-	O
10	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
were	O
observed	O
to	O
have	O
significantly	O
positive	O
relationships	O
with	O
CRP	O
levels	O
,	O
whereas	O
IL	O
-	O
17A	O
was	O
negatively	O
associated	O
with	O
CRP	O
levels	O
.	O

According	O
to	O
the	O
severity	O
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
(	O
Mild	O
group	O
,	O
Moderate	O
group	O
and	O
Severe	O
group	O
);	O
the	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
system	O
II	O
score	O
(	O
APACHE	O
II	O
),	O
the	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
),	O
the	O
pulse	O
contour	O
curve	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
other	O
clinical	O
indicators	O
were	O
respectively	O
monitored	O
in	O
the	O
period	O
of	O
24	O
,	O
48	O
,	O
72	O
hrs	O
after	O
admission	O
;	O
then	O
the	O
correlation	O
of	O
EVLWI	O
,	O
PVPI	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
among	O
groups	O
were	O
analyzed	O
;	O
According	O
to	O
the	O
prognosis	O
,	O
patients	O
were	O
divided	O
into	O
the	O
survival	O
group	O
and	O
the	O
death	O
group	O
,	O
both	O
given	O
the	O
univariate	O
and	O
multivariate	O
Logistic	O
regression	O
analysis	O
;	O
EVLWI	O
,	O
PVPI	O
,	O
APACHE	O
II	O
score	O
,	O
LIS	B-FUNC
and	O
lactic	O
acid	O
were	O
admitted	O
into	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
,	O
and	O
the	O
prognosis	O
was	O
evaluated	O
respectively	O
.	O

With	O
the	O
increase	O
of	O
disease	O
severity	O
,	O
LIS	B-FUNC
and	O
lactic	O
acid	O
gradually	O
increased	O
,	O
the	O
difference	O
was	O
significant	O
among	O
the	O
three	O
groups	O
of	O
Mild	O
,	O
Moderate	O
and	O
Severe	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
EVLWI	O
and	O
OI	O
or	O
between	O
PVPI	O
and	O
OI	O
(	O
r	O
=-	O
0	O
.	O
666	O
,	O
-	O
0	O
.	O
763	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
a	O
significant	O
positive	O
correlation	O
between	O
EVLWI	O
and	O
PVPI	O
,	O
the	O
APACHE	O
II	O
score	O
or	O
LIS	B-FUNC
(	O
r	O
=	O
0	O
.	O
929	O
,	O
0	O
.	O
895	O
,	O
0	O
.	O
661	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
With	O
the	O
increase	O
of	O
disease	O
severity	O
,	O
LIS	B-FUNC
and	O
lactic	O
acid	O
gradually	O
increased	O
,	O
the	O
difference	O
was	O
significant	O
among	O
the	O
three	O
groups	O
of	O
Mild	O
,	O
Moderate	O
and	O
Severe	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
RNA	O
sequencing	O
-	O
based	O
analysis	O
of	O
the	O
spleen	O
transcriptome	O
following	O
infectious	O
bronchitis	O
virus	O
infection	O
of	O
chickens	O
selected	O
for	O
different	O
mannose	O
-	O
binding	B-FUNC
lectin	O
serum	O
concentrations	O
.	O

To	O
this	O
end	O
,	O
two	O
chicken	O
lines	O
,	O
selected	O
for	O
high	O
(	O
L10H	O
line	O
)	O
and	O
low	O
(	O
L10L	O
line	O
)	O
serum	O
concentration	O
of	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
were	O
studied	O
.	O

Two	O
cats	O
showed	O
mild	O
clinical	O
signs	O
,	O
faecal	O
shedding	O
of	O
infectious	O
virus	O
from	O
4	O
dpi	O
,	O
a	O
cell	O
-	O
associated	O
viraemia	O
at	O
inconsistent	O
time	O
points	O
from	O
5	O
dpi	O
,	O
a	O
highly	O
neutralising	O
antibody	B-FUNC
response	O
from	O
9	O
dpi	O
,	O
and	O
no	O
major	O
abnormalities	O
in	O
leukocyte	O
numbers	O
.	O

TITLE	O
:	O
3B11	O
-	O
N	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
,	O
reduces	O
lung	O
pathology	O
in	O
rhesus	O
monkeys	O
following	O
intratracheal	O
inoculation	O
of	O
MERS	O
-	O
CoV	O
Jordan	O
-	O
n3	O
/	O
2012	O
.	O

Two	O
groups	O
of	O
NHPs	O
were	O
treated	O
with	O
either	O
a	O
human	O
anti	O
-	O
MERS	O
monoclonal	O
antibody	B-FUNC
3B11	O
-	O
N	O
or	O
E410	O
-	O
N	O
,	O
an	O
anti	O
-	O
HIV	O
antibody	B-FUNC
.	O

3B11	O
-	O
N	O
treated	O
subjects	O
developed	O
significantly	O
reduced	O
lung	O
pathology	O
when	O
compared	O
to	O
infected	O
,	O
untreated	O
subjects	O
,	O
indicating	O
that	O
this	O
antibody	B-FUNC
may	O
be	O
a	O
suitable	O
MERS	O
-	O
CoV	O
treatment	O
.	O

By	O
means	O
of	O
histological	O
examination	O
and	O
biochemical	O
assays	O
,	O
the	O
severity	O
of	O
lung	O
injury	O
was	O
assessed	O
in	O
the	O
aspects	O
of	O
tissue	O
damages	O
,	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
and	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Mice	O
immunized	O
with	O
1	O
	O
10	O
(	O
9	O
)	O
CFU	O
of	O
SL7207	O
(	O
pVAX	O
-	O
M	O
)	O
elicited	O
specific	O
anti	O
-	O
TGEV	O
local	O
mucosal	O
and	O
humoral	O
responses	O
including	O
levels	O
of	O
IgA	O
,	O
IgG	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
and	O
IFN	O
-	O
	O
as	O
measured	O
by	O
indirect	O
ELISA	O
assay	O
.	O

Based	O
on	O
400	O
-	O
nt	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRP	B-FUNC
)	O
sequence	O
analysis	O
,	O
eight	O
belonged	O
to	O
genus	O
Alphacoronavirus	O
and	O
42	O
to	O
Betacoronavirus	O
.	O

TITLE	O
:	O
Therapeutic	O
effect	O
of	O
anti	O
-	O
feline	O
TNF	O
-	O
alpha	O
monoclonal	O
antibody	B-FUNC
for	O
feline	O
infectious	O
peritonitis	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
replication	O
in	O
macrophages	O
/	O
monocytes	O
induced	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	B-FUNC
)-	O
alpha	O
production	O
,	O
and	O
that	O
the	O
TNF	B-FUNC
-	O
alpha	O
produced	O
was	O
involved	O
in	O
aggravating	O
the	O
pathology	O
of	O
FIP	O
.	O

We	O
previously	O
reported	O
the	O
preparation	O
of	O
a	O
feline	O
TNF	O
-	O
alpha	O
(	O
fTNF	O
-	O
alpha	O
)-	O
neutralizing	O
mouse	O
monoclonal	O
antibody	B-FUNC
(	O
anti	O
-	O
fTNF	O
-	O
alpha	O
mAb	O
).	O

Plasma	O
alpha1	O
-	O
glycoprotein	O
and	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
levels	O
were	O
improved	O
by	O
the	O
administration	O
of	O
mAb	O
2	O
-	O
4	O
,	O
and	O
the	O
peripheral	O
lymphocyte	O
count	O
also	O
recovered	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
multi	O
-	O
drug	O
resistant	O
HIV	O
-	O
1	O
subtype	O
AG	O
reverse	O
transcriptase	B-FUNC
:	O
antagonism	O
of	O
AZT	O
discrimination	O
and	O
excision	O
pathways	O
and	O
sensitivity	O
to	O
RNase	O
H	O
inhibitors	O
.	O

Aspartate	O
aminotransferase	O
(	O
AST	O
)	O
and	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
levels	O
were	O
highest	O
on	O
the	O
day	O
that	O
the	O
patient	O
developed	O
ALF	O
.	O

Using	O
an	O
extensive	O
set	O
of	O
N	O
-	O
and	O
C	O
-	O
terminally	O
truncated	O
7b	O
proteins	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
a	O
synthetic	O
peptide	O
,	O
the	O
binding	B-FUNC
sites	O
of	O
mAbs	O
5B6	O
and	O
14D8	O
were	O
mapped	O
to	O
an	O
18	O
-	O
residue	O
region	O
that	O
comprises	O
the	O
only	O
potential	O
N	O
-	O
glycosylation	O
site	O
of	O
the	O
FCoV	O
7b	O
protein	O
.	O

Both	O
NF	O
-	O
B	O
and	O
TBK1	B-FUNC
-	O
IRF3	O
signaling	O
cascades	O
are	O
activated	O
by	O
M	O
gene	O
products	O
.	O

ABSTRACT	O
:	O
Although	O
HIV	O
antibody	B-FUNC
tests	O
have	O
been	O
widely	O
accepted	O
in	O
clinical	O
diagnosis	O
of	O
HIV	O
infection	O
,	O
they	O
may	O
not	O
be	O
sufficient	O
to	O
diagnose	O
all	O
subjects	O
with	O
HIV	O
infection	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	B-FUNC
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	O
infection	O
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	B-FUNC
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	O
infection	O
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

ABSTRACT	O
:	O
Carbohydrate	B-FUNC
binding	I-FUNC
agents	O
(	O
CBAs	O
),	O
including	O
natural	O
lectins	O
,	O
are	O
more	O
and	O
more	O
considered	O
as	O
broad	O
-	O
spectrum	O
antivirals	O
.	O

These	O
molecules	O
are	O
able	O
to	O
directly	O
inhibit	O
many	O
viruses	O
such	O
as	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
),	O
Hepatitis	O
C	O
Virus	O
(	O
HCV	O
),	O
Dengue	O
Virus	O
,	O
Ebola	O
Virus	O
or	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
through	O
binding	B-FUNC
to	O
envelope	O
protein	O
N	O
-	O
glycans	O
.	O

The	O
effect	O
of	O
these	O
mutations	O
on	O
viral	O
fitness	O
as	O
well	O
as	O
on	O
sensitivity	O
to	O
inhibition	O
by	O
lectins	O
,	O
soluble	O
CD81	O
or	O
the	O
3	O
/	O
11	O
neutralizing	O
antibody	B-FUNC
was	O
assessed	O
.	O

With	O
the	O
emerging	O
development	O
of	O
monoclonal	O
antibodies	O
as	O
therapeutics	O
,	O
the	O
potential	O
implications	O
of	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
of	O
disease	O
were	O
also	O
addressed	O
.	O

Attempts	O
have	O
been	O
made	O
to	O
provide	O
a	O
complete	O
description	O
of	O
the	O
structural	O
features	O
and	O
binding	B-FUNC
modes	O
of	O
these	O
inhibitors	O
under	O
many	O
conditions	O
.	O

TITLE	O
:	O
Conformational	O
Flexibility	O
of	O
a	O
Short	O
Loop	O
near	O
the	O
Active	O
Site	O
of	O
the	O
SARS	O
-	O
3CLpro	O
is	O
Essential	O
to	O
Maintain	O
Catalytic	B-FUNC
Activity	I-FUNC
.	O

ABSTRACT	O
:	O
The	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
SARS	O
-	O
3CLpro	O
),	O
which	O
is	O
the	O
main	O
proteinase	B-FUNC
of	O
the	O
SARS	O
coronavirus	O
,	O
is	O
essential	O
to	O
the	O
virus	O
life	O
cycle	O
.	O

The	O
coil	O
-	O
3	O
(	O
10	O
)-	O
helix	O
conformational	O
transition	O
of	O
the	O
Ser139	O
-	O
Leu141	O
loop	O
serves	O
as	O
an	O
enzyme	B-FUNC
activity	I-FUNC
switch	O
.	O

Two	O
experimental	O
MERS	O
-	O
CoV	O
vaccines	O
were	O
used	O
to	O
vaccinate	O
two	O
groups	O
of	O
transchromosomic	O
(	O
Tc	O
)	O
bovines	O
that	O
were	O
genetically	O
modified	O
to	O
produce	O
large	O
quantities	O
of	O
fully	O
human	O
polyclonal	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
.	O

Vaccination	O
with	O
a	O
clade	O
A	O
	O
-	O
irradiated	O
whole	O
killed	O
virion	O
vaccine	O
(	O
Jordan	O
strain	O
)	O
or	O
a	O
clade	O
B	O
spike	O
protein	O
nanoparticle	O
vaccine	O
(	O
Al	O
-	O
Hasa	O
strain	O
)	O
resulted	O
in	O
Tc	O
bovine	O
sera	B-FUNC
with	O
high	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
in	O
vitro	O
.	O

Two	O
purified	O
Tc	O
bovine	O
human	O
IgG	O
immunoglobulins	O
(	O
Tc	O
hIgG	O
),	O
SAB	O
-	O
300	O
(	O
produced	O
after	O
Jordan	O
strain	O
vaccination	O
)	O
and	O
SAB	O
-	O
301	O
(	O
produced	O
after	O
Al	O
-	O
Hasa	O
strain	O
vaccination	O
),	O
also	O
had	O
high	O
ELISA	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
without	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
in	O
vitro	O
.	O

Of	O
>	O
70	O
TRIMs	O
,	O
TRIM56	O
is	O
a	O
restriction	O
factor	O
of	O
several	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
including	O
three	O
members	O
of	O
the	O
family	O
Flaviviridae	O
(	O
yellow	O
fever	O
virus	O
,	O
dengue	O
virus	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
)	O
and	O
a	O
human	O
coronavirus	O
(	O
OC43	O
),	O
and	O
this	O
ability	O
invariably	O
depends	O
upon	O
the	O
E3	O
ligase	B-FUNC
activity	I-FUNC
of	O
TRIM56	O
.	O

Interestingly	O
,	O
the	O
anti	O
-	O
influenza	O
virus	O
activity	O
was	O
independent	O
of	O
the	O
E3	O
ligase	B-FUNC
activity	I-FUNC
,	O
B	O
-	O
box	O
,	O
or	O
coiled	O
-	O
coil	O
domain	O
.	O

Unlike	O
its	O
antiviral	O
actions	O
against	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
the	O
anti	O
-	O
influenza	O
virus	O
activity	O
of	O
TRIM56	O
was	O
independent	O
of	O
the	O
E3	O
ligase	B-FUNC
activity	I-FUNC
.	O

The	O
number	O
of	O
syncytial	O
cells	O
was	O
reduced	O
after	O
treatment	O
of	O
the	O
infected	O
PECs	O
with	O
anti	O
-	O
Le	O
(	O
x	O
)	O
antibody	B-FUNC
,	O
during	O
the	O
late	O
phase	O
of	O
infection	O
.	O

In	O
addition	O
,	O
the	O
antibody	B-FUNC
treatment	O
induced	O
a	O
marked	O
reduction	O
in	O
the	O
number	O
of	O
the	O
infected	O
cells	O
at	O
24	O
hours	O
post	O
inoculation	O
,	O
without	O
changing	O
the	O
infected	O
cell	O
numbers	O
during	O
the	O
initial	O
phase	O
of	O
infection	O
.	O

TITLE	O
:	O
Identification	O
and	O
Comparison	O
of	O
Receptor	B-FUNC
Binding	I-FUNC
Characteristics	O
of	O
the	O
Spike	O
Protein	O
of	O
Two	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Strains	O
.	O

The	O
prototype	O
strain	O
demonstrated	O
similar	O
receptor	O
-	O
binding	B-FUNC
activity	O
compared	O
with	O
the	O
variant	O
field	O
isolate	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
PEDV	O
S1	O
domain	O
could	O
bind	B-FUNC
sugar	O
,	O
a	O
possible	O
co	O
-	O
receptor	O
for	O
PEDV	O
.	O

The	O
prototype	O
strain	O
exhibited	O
weaker	O
sugar	O
-	O
binding	B-FUNC
activity	O
compared	O
with	O
the	O
variant	O
field	O
isolate	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
glycoproteins	O
of	O
coronaviruses	O
play	O
an	O
important	O
role	O
in	O
receptor	B-FUNC
binding	I-FUNC
and	O
cell	O
entry	O
.	O

Both	O
live	O
and	O
pseudoviruses	O
could	O
infected	O
Vero	O
-	O
CCL	B-FUNC
-	O
81	O
(	O
monkey	O
kidney	O
),	O
Huh	O
-	O
7	O
(	O
human	O
liver	O
),	O
and	O
PK	O
-	O
15	O
(	O
pig	O
kidney	O
)	O
cells	O
efficiently	O
.	O

In	O
light	O
of	O
the	O
broad	O
antiviral	O
activity	O
of	O
	O
-	O
defensins	O
,	O
we	O
tested	O
the	O
antiviral	O
activity	O
of	O
11	O
peptides	O
derived	O
from	O
mouse	O
	O
-	O
defensin	O
-	O
4	O
and	O
found	O
that	O
a	O
short	O
peptide	O
,	O
P9	O
,	O
exhibited	O
potent	O
and	O
broad	O
-	O
spectrum	O
antiviral	O
effects	O
against	O
multiple	O
respiratory	O
viruses	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
including	O
influenza	O
A	O
virus	O
H1N1	O
,	O
H3N2	O
,	O
H5N1	O
,	O
H7N7	O
,	O
H7N9	O
,	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
antiviral	O
activity	O
of	O
P9	O
was	O
attributed	O
to	O
its	O
high	O
-	O
affinity	O
binding	B-FUNC
to	O
viral	O
glycoproteins	O
,	O
as	O
well	O
as	O
the	O
abundance	O
of	O
basic	O
amino	O
acids	O
in	O
its	O
composition	O
.	O

Mutations	O
of	O
the	O
major	O
dimerization	O
site	O
determinants	O
(	O
Ser74	O
and	O
Phe76	O
)	O
in	O
the	O
dimerization	O
interface	O
destabilized	O
the	O
dimer	O
in	O
solution	O
and	O
severely	O
diminished	O
endoribonuclease	B-FUNC
activity	I-FUNC
,	O
indicating	O
that	O
the	O
dimer	O
is	O
the	O
biologically	O
functional	O
unit	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
structure	O
,	O
the	O
replication	O
,	O
and	O
the	O
transcription	O
of	O
CoV	O
.	O
This	O
protein	O
,	O
which	O
has	O
a	O
helix	O
and	O
flexible	O
structure	O
,	O
and	O
capable	O
of	O
binding	B-FUNC
on	O
to	O
the	O
viral	O
genomic	O
RNA	O
,	O
is	O
a	O
non	O
-	O
structural	O
protein	O
(	O
nsp3	O
).	O

Sequenced	O
partial	O
RdRp	B-FUNC
fragments	O
had	O
80	O
%-	O
99	O
%	O
nucleic	O
acid	O
sequence	O
identity	O
with	O
well	O
-	O
characterized	O
Alphacoronavirus	O
species	O
,	O
including	O
BtCoV	O
HKU2	O
,	O
BtCoV	O
HKU8	O
,	O
and	O
BtCoV1	O
,	O
and	O
unassigned	O
species	O
BtCoV	O
HKU7	O
and	O
BtCoV	O
HKU10	O
.	O

Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
3	O
and	O
TRAF6	O
were	O
upregulated	O
expression	O
in	O
both	O
tissues	O
.	O

Six	O
of	O
12	O
used	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
),	O
mostly	O
in	O
combination	O
with	O
RBV	O
.	O

We	O
isolated	O
13	O
new	O
viral	O
genomes	O
from	O
14	O
infected	O
patients	O
treated	O
at	O
a	O
hospital	O
and	O
found	O
that	O
12	O
of	O
these	O
genomes	O
possess	O
a	O
point	O
mutation	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
.	O

Strikingly	O
,	O
both	O
mutations	O
result	O
in	O
reduced	O
affinity	O
of	O
RBD	O
to	O
human	O
CD26	O
compared	O
to	O
wild	O
-	O
type	O
RBD	O
,	O
as	O
measured	O
by	O
surface	O
plasmon	O
resonance	O
analysis	O
and	O
cellular	O
binding	B-FUNC
assay	O
.	O

Here	O
,	O
we	O
isolated	O
13	O
new	O
viral	O
genomes	O
and	O
found	O
that	O
12	O
of	O
them	O
possess	O
a	O
point	O
mutation	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
viral	O
spike	O
protein	O
,	O
resulting	O
in	O
reduced	O
affinity	O
to	O
the	O
human	O
cognate	O
receptor	O
,	O
CD26	O
,	O
compared	O
to	O
the	O
wild	O
-	O
type	O
virus	O
.	O

TITLE	O
:	O
The	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
regulates	O
cofilin	O
activity	O
and	O
promotes	O
transmissible	O
gastroenteritis	O
virus	O
entry	O
into	O
intestinal	O
epithelial	O
cells	O
.	O

Inhibition	O
of	O
EGFR	B-FUNC
and	O
PI3K	B-FUNC
decreases	O
the	O
entry	O
of	O
TGEV	O
.	O

EGFR	B-FUNC
is	O
also	O
the	O
upstream	O
activator	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
signaling	O
pathways	O
that	O
is	O
involved	O
in	O
F	O
-	O
actin	O
reorganization	O
.	O

Surprisingly	O
,	O
the	O
S1	O
C	O
-	O
terminal	O
domains	O
are	O
interdigitated	O
and	O
form	O
extensive	O
quaternary	O
interactions	O
that	O
occlude	O
surfaces	O
known	O
in	O
other	O
coronaviruses	O
to	O
bind	B-FUNC
protein	O
receptors	O
.	O

Serological	O
test	O
was	O
carried	O
out	O
using	O
sera	B-FUNC
or	O
plasma	O
of	O
ferrets	O
in	O
Japan	O
.	O

1	O
-	O
179	O
of	O
the	O
N	O
protein	O
is	O
useful	O
for	O
detection	O
of	O
antibody	B-FUNC
to	O
FRCoV	O
for	O
diagnosis	O
and	O
seroepidemiology	O
of	O
FRCoV	O
infection	O
.	O

TITLE	O
:	O
Prophylaxis	O
With	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
Specific	O
Human	O
Monoclonal	O
Antibody	B-FUNC
Protects	O
Rabbits	O
From	O
MERS	O
-	O
CoV	O
Infection	O
.	O

An	O
antibody	B-FUNC
response	O
against	O
IBV	O
was	O
detectable	O
and	O
the	O
ratio	O
of	O
CD4	O
(+)/	O
CD8	O
(+)	O
T	O
-	O
lymphocytes	O
decreased	O
at	O
7	O
days	O
post	O
-	O
vaccination	O
in	O
each	O
vaccinated	O
group	O
,	O
suggesting	O
that	O
humoral	O
and	O
cellular	O
responses	O
were	O
elicited	O
in	O
each	O
group	O
as	O
early	O
as	O
7	O
days	O
post	O
-	O
immunization	O
.	O

Anti	O
-	O
glycolipid	O
antibody	B-FUNC
activity	I-FUNC
was	O
found	O
in	O
13	O
(	O
31	O
%)	O
patients	O
,	O
and	O
notably	O
against	O
GA1	O
in	O
eight	O
(	O
19	O
%)	O
patients	O
,	O
by	O
ELISA	O
and	O
19	O
(	O
46	O
%)	O
of	O
41	O
by	O
glycoarray	O
at	O
admission	O
.	O

Treatment	O
with	O
intravenous	O
immunoglobulin	B-FUNC
or	O
plasma	O
exchange	O
is	O
the	O
optimal	O
management	O
approach	O
,	O
alongside	O
supportive	O
care	O
.	O

After	O
establishment	O
of	O
mice	O
model	O
,	O
we	O
observed	O
the	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	O
replication	O
,	O
immunopathogenesis	O
and	O
antibody	B-FUNC
response	O
.	O

The	O
results	O
indicated	O
that	O
the	O
infected	O
mice	O
showed	O
typical	O
pneumonia	O
,	O
virus	O
replication	O
,	O
histological	O
lesions	O
,	O
and	O
neutralizing	O
antibody	B-FUNC
production	O
.	O

Fourteen	O
days	O
after	O
infection	O
,	O
the	O
specific	O
antibody	B-FUNC
to	O
virus	O
structural	O
protein	O
and	O
neutralizing	O
antibody	B-FUNC
were	O
analyzed	O
,	O
the	O
high	O
dosage	O
group	O
induced	O
higher	O
level	O
antibody	B-FUNC
.	O

In	O
summary	O
,	O
the	O
MERS	O
-	O
CoV	O
infected	O
mice	O
model	O
were	O
established	O
prior	O
transduction	O
with	O
DPP4	O
,	O
and	O
the	O
level	O
of	O
DPP4	O
influenced	O
the	O
clinical	O
signs	O
of	O
disease	O
,	O
virus	O
replication	O
and	O
antibody	B-FUNC
response	O
in	O
this	O
model	O
.	O

We	O
illuminate	O
the	O
determinants	O
of	O
specificity	O
utilized	O
by	O
different	O
glycan	O
-	O
binding	B-FUNC
viruses	O
and	O
explore	O
the	O
potential	O
of	O
these	O
interactions	O
for	O
switching	O
receptor	O
specificities	O
within	O
or	O
even	O
between	O
glycan	O
classes	O
.	O

A	O
detailed	O
understanding	O
of	O
these	O
parameters	O
is	O
important	O
for	O
the	O
prediction	O
of	O
binding	B-FUNC
sites	O
where	O
structural	O
information	O
is	O
not	O
available	O
,	O
and	O
is	O
invaluable	O
for	O
the	O
development	O
of	O
antiviral	O
therapeutics	O
.	O

Coronavirus	O
transcription	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
the	O
extent	O
of	O
base	O
-	O
pairing	O
between	O
transcription	O
-	O
regulating	O
sequences	O
of	O
positive	O
and	O
negative	O
polarity	O
,	O
viral	O
and	O
cell	O
protein	O
-	O
RNA	B-FUNC
binding	I-FUNC
,	O
and	O
high	O
-	O
order	O
RNA	O
-	O
RNA	O
interactions	O
.	O

Ingredients	O
imported	O
to	O
the	O
USA	O
from	O
China	O
,	O
including	O
organic	O
&	O
conventional	O
soybeans	O
and	O
meal	O
,	O
lysine	O
hydrochloride	O
,	O
D	O
-	O
L	O
methionine	O
,	O
tryptophan	O
,	O
Vitamins	O
A	O
,	O
D	O
&	O
E	O
,	O
choline	O
,	O
carriers	O
(	O
rice	O
hulls	O
,	O
corn	O
cobs	B-FUNC
)	O
and	O
feed	O
grade	O
tetracycline	O
,	O
were	O
inoculated	O
with	O
PEDV	O
.	O

RESULTS	O
:	O
Ingredients	O
imported	O
to	O
the	O
USA	O
from	O
China	O
,	O
including	O
organic	O
&	O
conventional	O
soybeans	O
and	O
meal	O
,	O
lysine	O
hydrochloride	O
,	O
D	O
-	O
L	O
methionine	O
,	O
tryptophan	O
,	O
Vitamins	O
A	O
,	O
D	O
&	O
E	O
,	O
choline	O
,	O
carriers	O
(	O
rice	O
hulls	O
,	O
corn	O
cobs	B-FUNC
)	O
and	O
feed	O
grade	O
tetracycline	O
,	O
were	O
inoculated	O
with	O
PEDV	O
.	O

Antituberculous	O
drugs	O
were	O
administered	O
because	O
a	O
previous	O
blood	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
release	O
assay	O
was	O
positive	O
,	O
however	O
,	O
the	O
patient	O
died	O
of	O
severe	O
respiratory	O
failure	O
within	O
several	O
days	O
,	O
and	O
cultures	O
of	O
her	O
blood	O
,	O
urine	O
and	O
bone	O
marrow	O
posthumously	O
revealed	O
Mycobacterium	O
tuberculosis	O
.	O

The	O
neutrophils	O
that	O
infiltrate	O
the	O
lungs	O
and	O
migrate	O
into	O
the	O
airways	O
express	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
),	O
and	O
contribute	O
to	O
both	O
the	O
endothelial	O
and	O
epithelial	O
integrity	O
disruption	O
of	O
the	O
barriers	O
.	O

Humoral	O
immune	O
responses	O
,	O
as	O
reflected	O
by	O
virus	O
neutralizing	O
antibodies	O
and	O
specific	O
IgG	O
and	O
sIgA	O
,	O
and	O
cellular	O
immune	O
responses	O
,	O
as	O
reflected	O
by	O
IFN	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
and	O
lymphocyte	O
proliferation	O
,	O
were	O
evaluated	O
.	O

In	O
particular	O
,	O
the	O
levels	O
of	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
were	O
higher	O
than	O
those	O
induced	O
by	O
the	O
single	O
-	O
gene	O
vaccine	O
SL7207	O
(	O
pVAXD	O
-	O
PS1	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Novel	O
kinase	B-FUNC
inhibitors	I-FUNC
SB203580	O
(	O
MAPK	B-FUNC
-	O
2	O
antagonist	O
)	O
and	O
LY294002	O
(	O
phosphoinositide	O
-	O
3	O
kinases	O
antagonist	O
)	O
exhibit	O
promising	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
.	O

Palivizumab	O
,	O
an	O
anti	O
-	O
RSV	O
monoclonal	O
antibody	B-FUNC
,	O
effectively	O
prevents	O
RSV	O
infection	O
in	O
high	O
-	O
risk	O
paediatric	O
populations	O
.	O

Intense	O
research	O
has	O
shown	O
that	O
macro	O
domains	O
bind	B-FUNC
ADP	O
-	O
ribose	O
and	O
other	O
derivatives	O
,	O
but	O
it	O
still	O
remains	O
intangible	O
about	O
their	O
exact	O
function	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
novel	O
HIV	O
-	O
1	O
NNRTIs	O
with	O
dual	O
structural	O
conformations	O
targeting	O
the	O
entrance	O
channel	O
of	O
the	O
NNRTI	O
binding	B-FUNC
pocket	O
.	O

The	O
present	O
study	O
reports	O
the	O
case	O
of	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
with	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
-	O
type	O
MM	O
who	O
was	O
treated	O
with	O
bortezomib	O
,	O
thalidomide	O
and	O
dexamethasone	O
.	O

The	O
expression	O
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
),	O
and	O
interferon	O
-	O
stimulated	O
genes	O
in	O
cells	O
infected	O
with	O
mutant	O
rTGEV	O
-	O
ZF	O
-	O
C	O
was	O
reduced	O
compared	O
to	O
the	O
levels	O
seen	O
with	O
the	O
parental	O
virus	O
.	O

We	O
evaluated	O
respiratory	O
indexes	O
(	O
PaO2	O
,	O
PaO2	O
/	O
FiO2	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
,	O
intrapulmonary	O
arteriovenous	O
shunt	O
percentage	O
,	O
and	O
respiratory	O
rate	O
),	O
blood	O
biochemical	O
(	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
,	O
alanine	O
aminotransferase	O
,	O
and	O
lactate	O
levels	O
)	O
and	O
inflammatory	O
(	O
CRP	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
TNF	O
-	O
	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
/	O
TNF	O
-	O
	O
ratio	O
)	O
markers	O
,	O
and	O
prognostic	O
outcomes	O
(	O
multiple	O
organ	O
dysfunction	O
syndrome	O
[	O
MODS	O
]	O
and	O
APACHE	O
II	O
scores	O
)	O
before	O
and	O
72	O
hours	O
after	O
the	O
treatment	O
.	O

Twenty	O
-	O
seven	O
cats	O
(	O
30	O
.	O
0	O
%)	O
were	O
seroreactive	O
by	O
indirect	O
fluorescent	O
antibody	B-FUNC
test	O
(	O
IFAT	O
),	O
with	O
an	O
antibody	B-FUNC
titer	O
of	O
1	O
:	O
40	O
for	O
16	O
(	O
17	O
.	O
7	O
%)	O
cats	O
and	O
1	O
:	O
80	O
(	O
cut	O
-	O
off	O
for	O
feline	O
L	O
.	O
infantum	O
infection	O
)	O
for	O
11	O
(	O
12	O
.	O
2	O
%)	O
cats	O
.	O

We	O
found	O
that	O
the	O
recombinant	O
Lactobacillus	O
stimulated	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
in	O
both	O
the	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
against	O
TGEV	O
infection	O
.	O

Here	O
we	O
report	O
that	O
MERS	O
-	O
CoV	O
,	O
a	O
lineage	O
CBetacoronavirus	O
,	O
and	O
related	O
bat	O
CoV	O
NS4b	O
accessory	O
proteins	O
have	O
phosphodiesterase	B-FUNC
(	O
PDE	B-FUNC
)	O
activity	O
and	O
antagonize	O
OAS	O
-	O
RNase	O
L	O
by	O
enzymatically	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
),	O
activators	O
of	O
RNase	O
L	O
.	O
This	O
is	O
a	O
novel	O
function	O
for	O
NS4b	O
,	O
which	O
has	O
previously	O
been	O
reported	O
to	O
antagonize	O
IFN	O
signaling	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
NS4b	O
and	O
homologs	O
from	O
related	O
lineage	O
C	O
bat	O
betacoronaviruses	O
BtCoV	O
-	O
SC2013	O
(	O
SC2013	O
)	O
and	O
BtCoV	O
-	O
HKU5	O
(	O
HKU5	O
)	O
are	O
members	O
of	O
the	O
2H	O
-	O
phosphoesterase	O
(	O
2H	O
-	O
PE	O
)	O
enzyme	O
family	O
with	O
phosphodiesterase	B-FUNC
(	O
PDE	B-FUNC
)	O
activity	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
mutants	O
with	O
deletion	O
of	O
genes	O
encoding	O
accessory	O
proteins	O
NS3	O
to	O
NS5	O
or	O
NS4b	O
alone	O
or	O
inactivation	O
of	O
the	O
PDE	B-FUNC
can	O
activate	O
RNase	O
L	O
during	O
infection	O
of	O
Calu	O
-	O
3	O
cells	O
.	O

The	O
location	O
and	O
properties	O
of	O
the	O
FPs	B-FUNC
in	O
the	O
spike	O
(	O
S	O
)	O
glycoproteins	O
of	O
different	O
coronaviruses	O
(	O
CoV	O
)	O
have	O
not	O
yet	O
been	O
determined	O
.	O

Through	O
amino	O
acid	O
sequence	O
analysis	O
of	O
S	O
proteins	O
of	O
representative	O
CoVs	O
,	O
we	O
identified	O
a	O
common	O
region	O
as	O
a	O
possible	O
FP	O
(	O
pFP	O
)	O
that	O
shares	O
the	O
characteristics	O
of	O
FPs	B-FUNC
of	O
class	O
I	O
viral	O
fusion	O
proteins	O
,	O
including	O
high	O
Ala	O
/	O
Gly	O
content	O
,	O
intermediate	O
hydrophobicity	O
,	O
and	O
few	O
charged	O
residues	O
.	O

Although	O
the	O
amino	O
acid	O
sequences	O
of	O
these	O
two	O
pFPs	O
differed	O
significantly	O
from	O
that	O
of	O
MERS	O
-	O
CoV	O
and	O
each	O
other	O
,	O
most	O
of	O
the	O
pFP	O
mutants	O
of	O
SARS	O
-	O
CoV	O
and	O
MHV	O
also	O
failed	O
to	O
mediate	O
membrane	O
fusion	O
,	O
suggesting	O
that	O
these	O
pFPs	O
are	O
also	O
the	O
functional	O
FPs	B-FUNC
.	O

Thus	O
,	O
the	O
FPs	B-FUNC
of	O
3	O
different	O
lineages	O
of	O
	O
-	O
CoVs	O
are	O
conserved	O
in	O
location	O
within	O
the	O
S	O
glycoproteins	O
and	O
in	O
their	O
functions	O
,	O
although	O
their	O
amino	O
acid	O
sequences	O
have	O
diverged	O
significantly	O
during	O
CoV	O
evolution	O
.	O

FPs	B-FUNC
from	O
within	O
a	O
virus	O
family	O
,	O
like	O
influenza	O
viruses	O
or	O
human	O
immunodeficiency	O
viruses	O
(	O
HIV	O
),	O
tend	O
to	O
share	O
high	O
amino	O
acid	O
sequence	O
identity	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
location	O
and	O
amino	O
acid	O
sequences	O
of	O
the	O
FPs	B-FUNC
of	O
S	O
glycoproteins	O
of	O
3	O
	O
-	O
CoVs	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
MHV	O
,	O
and	O
demonstrated	O
that	O
they	O
were	O
essential	O
for	O
mediating	O
cell	O
-	O
cell	O
fusion	O
and	O
virus	O
entry	O
.	O

Interestingly	O
,	O
in	O
marked	O
contrast	O
to	O
the	O
FPs	B-FUNC
of	O
influenza	O
and	O
HIV	O
,	O
the	O
primary	O
amino	O
acid	O
sequences	O
of	O
the	O
FPs	B-FUNC
of	O
	O
-	O
CoVs	O
in	O
3	O
different	O
lineages	O
differed	O
significantly	O
.	O

Thus	O
,	O
during	O
evolution	O
the	O
FPs	B-FUNC
of	O
	O
-	O
CoVs	O
have	O
diverged	O
significantly	O
in	O
their	O
primary	O
sequences	O
while	O
maintaining	O
the	O
same	O
essential	O
biological	O
functions	O
.	O

The	O
peptide	O
-	O
like	O
E64d	O
inhibitor	O
was	O
found	O
to	O
bind	B-FUNC
beneath	O
a	O
	O
-	O
hairpin	O
at	O
the	O
interface	O
of	O
the	O
SAM	O
MTase	O
and	O
protease	O
domains	O
.	O

To	O
identify	O
key	O
residues	O
involved	O
in	O
substrate	O
binding	B-FUNC
,	O
a	O
number	O
of	O
mutants	O
were	O
analyzed	O
.	O

N475	O
forms	O
the	O
base	O
of	O
the	O
P1	O
binding	B-FUNC
site	O
and	O
likely	O
orients	O
the	O
substrate	O
for	O
nucleophilic	O
attack	O
or	O
plays	O
a	O
role	O
in	O
product	O
release	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
interferon	O
-	O
	O
(	O
IFN	O
-	O
	O
)	O
in	O
ligated	O
intestine	O
segments	O
increased	O
significantly	O
after	O
injection	O
with	O
ITGEV	O
plus	O
CpG	O
DNA	O
(	O
P	O
	O
0	O
.	O
05	O
).	O

PEDV	O
-	O
specific	O
immune	O
responses	O
in	O
sera	B-FUNC
and	O
colostrum	O
of	O
the	O
sow	O
and	O
piglets	O
were	O
assayed	O
by	O
ELISA	O
and	O
virus	O
neutralization	O
assays	O
.	O

Serum	O
samples	O
collected	O
at	O
0	O
,	O
7	O
,	O
14	O
,	O
21	O
and	O
28	O
days	O
post	O
inoculation	O
were	O
evaluated	O
by	O
the	O
following	O
PEDV	O
serological	O
assays	O
:	O
1	O
)	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
assays	O
using	O
the	O
prototype	O
and	O
S	O
-	O
INDEL	O
-	O
variant	O
strains	O
as	O
indicator	O
viruses	O
;	O
2	O
)	O
virus	O
neutralization	O
(	O
VN	O
)	O
tests	O
against	O
the	O
prototype	O
and	O
S	O
-	O
INDEL	O
-	O
variant	O
viruses	O
;	O
3	O
)	O
PEDV	O
prototype	O
strain	O
whole	O
virus	O
based	O
ELISA	O
;	O
4	O
)	O
PEDV	O
prototype	O
strain	O
S1	O
-	O
based	O
ELISA	O
;	O
and	O
5	O
)	O
PEDV	O
S	O
-	O
INDEL	O
-	O
variant	O
strain	O
S1	O
-	O
based	O
ELISA	O
.	O

The	O
positive	O
antisera	O
against	O
the	O
prototype	O
strain	O
reacted	O
to	O
and	O
neutralized	O
both	O
prototype	O
and	O
S	O
-	O
INDEL	O
-	O
variant	O
viruses	O
,	O
and	O
the	O
positive	O
antisera	O
against	O
the	O
S	O
-	O
INDEL	O
-	O
variant	O
strain	O
also	O
reacted	O
to	O
and	O
neutralized	O
both	O
prototype	O
and	O
S	O
-	O
INDEL	O
-	O
variant	O
viruses	O
,	O
as	O
examined	O
by	O
IFA	O
antibody	B-FUNC
assays	O
and	O
VN	O
tests	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
circulating	O
antibody	B-FUNC
to	O
the	O
protection	O
of	O
nave	O
piglets	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
evaluated	O
using	O
a	O
passive	O
antibody	B-FUNC
transfer	O
model	O
.	O

Each	O
treatment	O
was	O
designed	O
to	O
achieve	O
a	O
different	O
level	O
of	O
circulating	O
anti	O
-	O
PEDV	O
antibody	B-FUNC
via	O
intraperitoneally	O
administration	O
of	O
concentrated	O
serum	O
antibody	B-FUNC
.	O

Fecal	O
samples	O
were	O
tested	O
by	O
PEDV	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
.	O

However	O
,	O
lowered	O
systemic	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
and	O
leukocyte	O
counts	O
in	O
the	O
BAC	O
group	O
were	O
also	O
detected	O
after	O
matching	O
,	O
indicating	O
that	O
this	O
effect	O
is	O
ISS	O
-	O
independent	O
.	O

However	O
,	O
lowered	O
systemic	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
and	O
leukocyte	O
counts	O
in	O
the	O
BAC	O
group	O
were	O
also	O
detected	O
after	O
matching	O
,	O
indicating	O
that	O
this	O
effect	O
is	O
ISS	O
-	O
independent	O
.	O

The	O
presence	O
of	O
respiratory	O
viruses	O
in	O
the	O
samples	O
were	O
detected	O
by	O
real	O
-	O
time	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
FTD	O
	O
Respiratory	O
Pathogens	O
21	O
Multiplex	O
RT	O
-	O
PCR	O
,	O
Fast	B-FUNC
Track	O
Diagnostics	O
,	O
Luxemburg	O
),	O
and	O
76	O
(	O
2	O
.	O
6	O
%)	O
samples	O
positive	O
for	O
HMPV	O
were	O
included	O
in	O
the	O
study	O
.	O

In	O
this	O
study	O
,	O
coronavirus	O
sequences	O
were	O
detected	O
using	O
a	O
nested	O
RT	O
-	O
PCR	O
targeting	O
440	O
bp	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
in	O
six	O
of	O
79	O
fecal	O
samples	O
collected	O
from	O
an	O
urban	O
colony	O
of	O
E	O
.	O
helvum	O
in	O
Ibadan	O
,	O
Nigeria	O
.	O

In	O
22	O
(	O
32	O
%)	O
of	O
the	O
68	O
cases	O
of	O
P	O
aeruginosa	O
with	O
antibiogram	O
data	O
,	O
the	O
isolates	O
were	O
MDR	B-FUNC
.	O

Prior	O
antibiotic	O
treatment	O
was	O
more	O
frequent	O
in	O
MDR	B-FUNC
P	O
aeruginosa	O
CAP	O
compared	O
with	O
non	O
-	O
MDR	B-FUNC
P	O
aeruginosa	O
(	O
58	O
%	O
vs	O
29	O
%,	O
P	O
=	O
.	O
029	O
),	O
and	O
was	O
the	O
only	O
risk	O
factor	O
associated	O
with	O
CAP	O
resulting	O
from	O
MDR	B-FUNC
P	O
aeruginosa	O
.	O

The	O
risk	O
factors	O
described	O
can	O
help	O
clinicians	O
to	O
suspect	O
P	O
aeruginosa	O
and	O
MDR	B-FUNC
P	O
aeruginosa	O
.	O

Methods	O
Antibody	B-FUNC
-	O
mediated	O
TRALI	O
was	O
experimentally	O
induced	O
in	O
mice	O
by	O
lipopolysaccharide	O
priming	O
followed	O
by	O
the	O
administration	O
of	O
an	O
anti	O
-	O
MHC	O
I	O
mAb	O
.	O

The	O
high	O
case	O
fatality	O
rate	O
,	O
growing	O
geographic	O
distribution	O
and	O
vaguely	O
defined	O
epidemiology	O
of	O
MERS	O
-	O
CoV	O
have	O
created	O
an	O
urgent	O
need	O
for	O
effective	O
public	O
health	O
countermeasures	O
,	O
paramount	O
of	O
which	O
is	O
an	O
effective	O
means	O
of	O
prevention	O
through	O
a	O
vaccine	O
or	O
antibody	B-FUNC
prophylaxis	O
.	O

Western	O
blot	O
analysis	O
revealed	O
the	O
rNP	O
from	O
CRCoV	O
could	O
cross	O
-	O
react	O
with	O
mice	O
antisera	O
against	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
),	O
while	O
rNP	O
of	O
CCoV	O
had	O
cross	O
-	O
reactivity	O
with	O
only	O
anti	O
-	O
sera	B-FUNC
against	O
viruses	O
belonging	O
to	O
the	O
same	O
group	O
(	O
HCoV	O
-	O
229E	O
and	O
NL63	O
).	O

Detection	O
of	O
amplification	O
products	O
based	O
on	O
labeled	O
probe	O
primers	O
was	O
conducted	O
with	O
strip	O
binding	B-FUNC
antibody	B-FUNC
of	O
labeled	O
markers	O
.	O

The	O
samples	O
were	O
tested	O
by	O
viral	O
culture	O
with	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
using	O
MERS	O
-	O
CoV	O
Spike	O
antibody	B-FUNC
,	O
and	O
electron	O
microscopy	O
(	O
EM	O
).	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
suppresses	O
type	O
I	O
interferon	O
expression	O
through	O
the	O
inhibition	O
of	O
TBK1	B-FUNC
-	O
dependent	O
phosphorylation	O
of	O
IRF3	O
.	O

This	O
suppressive	O
effect	O
was	O
found	O
to	O
be	O
specific	O
for	O
the	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
but	O
not	O
nuclear	O
factor	O
-	O
B	O
.	O
MERS	O
-	O
CoV	O
M	O
protein	O
interacted	O
with	O
TRAF3	O
and	O
disrupted	O
TRAF3	O
-	O
TBK1	B-FUNC
association	O
leading	O
to	O
reduced	O
IRF3	O
activation	O
.	O

About	O
15	O
or	O
52	O
cytokines	O
showed	O
significant	O
difference	O
between	O
SP	O
and	O
SP	O
-	O
ARDS	O
patients	O
with	O
controls	O
or	O
13	O
between	O
SP	O
-	O
ARDS	O
with	O
SP	O
alone	O
and	O
controls	O
,	O
including	O
bone	O
morphogenetic	O
protein	O
-	O
15	O
(	O
BMP	O
-	O
15	O
),	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
16	O
(	O
CXCL16	O
),	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
3	O
(	O
CXCR3	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
protein	O
NOV	O
homolog	O
(	O
NOV	O
/	O
CCN3	O
),	O
glypican	O
3	O
,	O
insulin	B-FUNC
-	I-FUNC
like	I-FUNC
growth	I-FUNC
factor	I-FUNC
binding	I-FUNC
protein	O
4	O
(	O
IGFBP	O
-	O
4	O
),	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
R	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
BP	O
,	O
leptin	O
,	O
MIP	O
-	O
1d	O
,	O
and	O
orexin	O
B	O
with	O
a	O
significant	O
correlation	O
with	O
Digital	O
Evaluation	O
Score	O
System	O
(	O
DESS	O
)	O
scores	O
.	O

ARDS	O
patients	O
with	O
overexpressed	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CXCL16	O
,	O
or	O
IGFBP	O
-	O
4	O
had	O
significantly	O
longer	O
hospital	O
stay	O
and	O
higher	O
incidence	O
of	O
secondary	O
infection	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
role	O
of	O
G6PD	O
on	O
the	O
inflammatory	O
response	O
was	O
determined	O
in	O
both	O
scramble	O
control	O
and	O
G6PD	O
-	O
knockdown	O
(	O
G6PD	O
-	O
kd	O
)	O
A549	O
cells	O
upon	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
)	O
stimulation	O
.	O

TNF	O
-	O
	O
-	O
induced	O
antiviral	O
activity	O
revealed	O
that	O
decreased	O
COX	O
-	O
2	O
expression	O
enhanced	O
the	O
susceptibility	O
to	O
coronavirus	O
229E	O
infection	O
in	O
G6PD	O
-	O
kd	O
A549	O
cells	O
and	O
was	O
a	O
result	O
of	O
the	O
decreased	O
phosphorylation	O
levels	O
of	O
MAPK	B-FUNC
(	O
p38	B-FUNC
and	O
ERK1	B-FUNC
/	O
2	O
)	O
and	O
NF	O
-	O
B	O
.	O
The	O
impaired	O
inflammatory	O
response	O
in	O
G6PD	O
-	O
kd	O
A549	O
cells	O
was	O
found	O
to	O
be	O
mediated	O
through	O
NADPH	B-FUNC
oxidase	I-FUNC
(	O
NOX	B-FUNC
)	O
signaling	O
as	O
elucidated	O
by	O
cell	O
pretreatment	O
with	O
a	O
NOX2	O
-	O
siRNA	O
or	O
NOX	B-FUNC
inhibitor	O
,	O
diphenyleneiodonium	O
chloride	O
(	O
DPI	O
).	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
G6PD	O
deficiency	O
affects	O
the	O
cellular	O
inflammatory	O
response	O
and	O
the	O
decreased	O
TNF	O
-	O
	O
-	O
mediated	O
antiviral	O
response	O
in	O
G6PD	O
-	O
kd	O
A549	O
cells	O
is	O
a	O
result	O
of	O
dysregulated	O
NOX	O
/	O
MAPK	B-FUNC
/	O
NF	O
-	O
B	O
/	O
COX	O
-	O
2	O
signaling	O
.	O

Almost	O
a	O
quarter	O
of	O
the	O
patients	O
were	O
healthcare	O
workers	O
(	O
23	O
.	O
5	O
%)	O
and	O
41	O
%	O
had	O
a	O
known	O
exposure	O
to	O
another	O
person	O
with	O
MERS	O
-	O
CoV	O
.	O
Survival	O
was	O
associated	O
with	O
male	O
gender	O
,	O
working	O
as	O
a	O
healthcare	O
worker	O
,	O
history	O
of	O
hypertension	O
,	O
vomiting	O
on	O
admission	O
,	O
elevated	O
respiratory	O
rate	O
,	O
abnormal	O
lung	O
exam	O
,	O
elevated	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
),	O
clearance	O
of	O
MERS	O
-	O
CoV	O
on	O
repeat	O
PCR	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
testing	O
,	O
and	O
mycophenolate	O
mofetil	O
treatment	O
.	O

LCA60	O
antibody	B-FUNC
was	O
generated	O
using	O
the	O
Cellclone	O
Technology	O
from	O
the	O
immortalized	O
B	O
cells	O
of	O
a	O
human	O
donor	O
recovering	O
from	O
MERS	O
.	O

In	O
the	O
immune	O
protective	O
efficiency	O
tests	O
,	O
the	O
neutralizing	O
antibody	B-FUNC
titers	O
in	O
sera	B-FUNC
,	O
the	O
colostrum	O
and	O
the	O
milk	O
on	O
7th	O
day	O
after	O
farrowing	O
of	O
the	O
inactivated	O
YC2014	O
PEDV	O
strain	O
immunized	O
group	O
were	O
significantly	O
higher	O
than	O
the	O
inactivated	O
CV777	O
immunized	O
group	O
and	O
the	O
inactivated	O
DR13	O
immunized	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
this	O
study	O
,	O
an	O
easy	O
-	O
to	O
-	O
perform	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
nucleocapsid	O
gene	O
of	O
IBV	O
was	O
developed	O
and	O
compared	O
with	O
conventional	O
agarose	O
gel	O
-	O
based	O
RT	O
-	O
PCR	O
for	O
the	O
detection	O
of	O
IBV	O
infection	O
.	O

Swabs	O
and	O
tissue	O
homogenates	O
were	O
tested	O
by	O
gel	O
based	O
PCR	O
(	O
G	O
-	O
PCR	O
),	O
quantitative	O
-	O
PCR	O
(	O
qPCR	O
)	O
and	O
quantitative	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
and	O
viral	O
culture	O
.	O

We	O
determined	O
the	O
kinetics	O
of	O
antibody	B-FUNC
(	O
IgG	O
and	O
IgM	O
)	O
and	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
this	O
case	O
before	O
discharge	O
.	O

However	O
,	O
during	O
the	O
initial	O
phase	O
of	O
infection	O
between	O
12	O
and	O
24	O
h	O
post	O
-	O
inoculation	O
(	O
hpi	B-FUNC
),	O
the	O
viral	O
antigens	O
are	O
detected	O
only	O
in	O
the	O
meninges	O
,	O
followed	O
by	O
viral	O
spread	O
into	O
the	O
ventricular	O
wall	O
before	O
invasion	O
into	O
the	O
brain	O
parenchyma	O
,	O
indicating	O
that	O
the	O
viruses	O
employ	O
a	O
passage	O
between	O
the	O
meninges	O
and	O
ventricular	O
wall	O
as	O
an	O
entry	O
route	O
into	O
the	O
brain	O
parenchyma	O
.	O

At	O
48	O
hpi	B-FUNC
,	O
the	O
passage	O
was	O
found	O
to	O
be	O
constructed	O
by	O
ER	O
-	O
TR7	O
antigen	O
(	O
ERag	O
)-	O
positive	O
fibers	O
(	O
ERfibs	O
)	O
associated	O
with	O
laminin	O
and	O
collagen	O
III	O
between	O
the	O
fourth	O
ventricle	O
and	O
meninges	O
at	O
the	O
cerebellopontine	O
angle	O
.	O

This	O
recombinant	O
protein	O
may	O
be	O
suitable	O
to	O
investigate	O
to	O
produce	O
immunoglobulin	B-FUNC
,	O
recombinant	O
vaccine	O
and	O
diagnostic	O
kit	B-FUNC
in	O
future	O
studies	O
after	O
it	O
passes	O
biological	O
activity	O
tests	O
in	O
vivo	O
in	O
animal	O
model	O
and	O
or	O
other	O
suitable	O
procedure	O
.	O

Structural	O
characterization	O
,	O
mutagenesis	O
and	O
biochemical	O
analysis	O
reveal	O
the	O
substrate	O
-	O
binding	B-FUNC
pockets	O
and	O
the	O
residues	O
that	O
comprise	O
the	O
active	O
site	O
of	O
PEDV	O
3CL	O
(	O
pro	O
).	O

Our	O
analyses	O
show	O
:	O
1	O
)	O
28	O
potential	O
recombinant	O
sequences	O
were	O
detected	O
and	O
they	O
can	O
be	O
classified	O
into	O
seven	O
potential	O
recombinant	O
types	O
;	O
2	O
)	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MERS	O
-	O
CoV	O
was	O
under	O
strong	O
positive	O
selection	O
when	O
MERS	O
-	O
CoV	O
transmitted	O
from	O
their	O
natural	O
host	O
to	O
human	O
;	O
3	O
)	O
Six	O
out	O
of	O
nine	O
positive	O
selection	O
sites	O
detected	O
in	O
spike	O
(	O
S	O
)	O
protein	O
are	O
located	O
in	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
which	O
is	O
in	O
direct	O
contact	O
with	O
host	O
cells	O
;	O
4	O
)	O
MERS	O
-	O
CoV	O
frequently	O
transmitted	O
back	O
and	O
forth	O
between	O
human	O
and	O
camel	O
after	O
it	O
had	O
acquired	O
the	O
human	O
-	O
camel	O
infection	O
capability	O
.	O

In	O
an	O
indirect	O
ELISA	O
,	O
purified	O
proteins	O
showed	O
immune	O
reactivity	O
with	O
pig	O
anti	O
-	O
PEDV	O
immune	O
sera	B-FUNC
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
g	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	O
IgG	O
and	O
serum	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

Retrospective	O
analysis	O
of	O
cytokine	O
production	O
in	O
non	O
-	O
fatal	O
case	O
revealed	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
interferon	O
-	O
	O
level	O
of	O
acute	O
phase	O
was	O
low	O
and	O
could	O
be	O
potential	O
prognostic	O
factors	O
.	O

As	O
there	O
are	O
no	O
epidemiological	O
studies	O
of	O
positive	O
rate	O
of	O
SFTSV	O
antibody	B-FUNC
in	O
people	O
living	O
in	O
endemic	O
areas	O
in	O
Japan	O
,	O
a	O
field	O
study	O
was	O
performed	O
.	O

Three	O
hundred	O
and	O
twenty	O
six	O
volunteers	O
in	O
Nagasaki	O
prefecture	O
were	O
examined	O
and	O
none	O
of	O
these	O
tested	O
positive	O
for	O
the	O
SFTSV	O
antibody	B-FUNC
.	O

Comparative	O
and	O
kinetic	O
analyses	O
revealed	O
that	O
high	O
viral	O
loads	O
,	O
weak	O
antibody	B-FUNC
responses	O
,	O
and	O
lymphopenia	O
accompanying	O
thrombocytopenia	O
were	O
associated	O
with	O
disease	O
mortality	O
,	O
whereas	O
persistent	O
and	O
gradual	O
increases	O
in	O
lymphocyte	O
responses	O
might	O
be	O
required	O
for	O
effective	O
immunity	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
blood	O
levels	O
of	O
cytokines	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
TGF	O
-	O
	O
,	O
and	O
EGF	B-FUNC
were	O
either	O
positively	O
or	O
negatively	O
correlated	O
with	O
disease	O
mortality	O
.	O

TITLE	O
:	O
Development	O
of	O
Monoclonal	O
Antibody	B-FUNC
and	O
Diagnostic	O
Test	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Using	O
Cell	O
-	O
Free	O
Synthesized	O
Nucleocapsid	O
Antigen	O
.	O

TITLE	O
:	O
Monoclonal	O
Antibody	B-FUNC
to	O
Bone	O
Marrow	O
Stromal	O
Cell	O
Antigen	O
2	O
Protein	O
of	O
Swine	O
.	O

After	O
subcloning	O
,	O
one	O
strain	O
of	O
hybridoma	O
cells	O
named	O
1B2	O
secreting	O
porcine	O
BST	O
-	O
2	O
protein	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
was	O
obtained	O
.	O

All	O
RVA	O
isolates	O
were	O
confirmed	O
by	O
LSI	O
VetMAX	O
	O
Triplex	O
Ruminant	O
Rotavirus	O
&	O
Coronavirus	O
Real	O
-	O
Time	O
PCR	O
kit	B-FUNC
.	O

TITLE	O
:	O
Serum	O
antibody	B-FUNC
responses	O
to	O
vaccinal	O
antigens	O
in	O
lean	O
and	O
obese	O
geriatric	O
dogs	O
.	O

Molecular	O
simulation	O
study	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
confirmed	O
that	O
compound	O
8	O
stabilized	O
HA2	O
subunit	O
of	O
hemagglutinin	O
(	O
HA	O
)	O
by	O
binding	B-FUNC
with	O
amino	O
acid	O
residues	O
LYS	O
-	O
26	O
,	O
ASN	O
-	O
53	O
,	O
ASN	O
-	O
27	O
and	O
ASN	O
-	O
50	O
,	O
therefore	O
may	O
prevent	O
HA	O
from	O
conformational	O
rearranging	O
,	O
which	O
is	O
a	O
critical	O
step	O
for	O
viral	O
entry	O
.	O

TITLE	O
:	O
A	O
combined	O
in	O
silico	O
/	O
in	O
vitro	O
approach	O
unveils	O
common	O
molecular	O
requirements	O
for	O
efficient	O
BVDV	O
RdRp	B-FUNC
binding	B-FUNC
of	O
linear	O
aromatic	O
N	O
-	O
polycyclic	O
systems	O
.	O

A	O
coupled	O
in	O
silico	O
/	O
in	O
vitro	O
investigation	O
was	O
employed	O
to	O
formulate	O
a	O
molecular	O
rationale	O
explaining	O
the	O
notable	O
affinity	O
of	O
all	O
molecules	O
to	O
BVDV	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
NS5B	O
.	O

The	O
pharmacophoric	O
information	O
was	O
used	O
to	O
retrieve	O
a	O
putative	O
binding	B-FUNC
site	O
on	O
the	O
surface	O
of	O
the	O
BVDV	O
RdRp	B-FUNC
and	O
to	O
guide	O
compound	O
docking	O
within	O
the	O
protein	B-FUNC
binding	I-FUNC
site	O
.	O

Three	O
RdRp	B-FUNC
(	O
K263	O
,	O
R295	O
and	O
Y674	O
)	O
residues	O
critical	O
for	O
drug	B-FUNC
binding	I-FUNC
were	O
selected	O
and	O
mutagenized	O
,	O
both	O
in	O
silico	O
and	O
in	O
vitro	O
,	O
into	O
alanine	O
,	O
and	O
the	O
affinity	O
of	O
a	O
set	O
of	O
selected	O
compounds	O
towards	O
the	O
mutant	O
RdRp	B-FUNC
isoforms	O
was	O
determined	O
accordingly	O
.	O

The	O
agreement	O
between	O
predicted	O
and	O
experimental	O
data	O
confirmed	O
the	O
proposed	O
common	O
molecular	O
rationale	O
shared	O
by	O
molecules	O
characterized	O
by	O
different	O
chemical	O
scaffolds	O
in	O
binding	B-FUNC
to	O
the	O
BVDV	O
RdRp	B-FUNC
,	O
ultimately	O
yielding	O
compound	O
6b	O
(	O
EC50	O
=	O
0	O
.	O
3	O
M	O
;	O
IC50	O
=	O
0	O
.	O
48	O
M	O
)	O
as	O
a	O
new	O
,	O
potent	O
inhibitor	O
of	O
this	O
Pestivirus	O
.	O

Western	O
blot	O
analysis	O
with	O
anti	O
-	O
Lys48	O
and	O
anti	O
-	O
Lys63	O
ubiquitin	B-FUNC
antibodies	O
indicated	O
the	O
SARS	O
-	O
CoV	O
PLPro	O
removed	O
Lys63	O
-	O
linked	O
ubiquitin	B-FUNC
chains	O
of	O
TRAF3	O
and	O
TRAF6	O
,	O
but	O
not	O
Lys48	O
-	O
linked	O
ubiquitin	B-FUNC
chains	O
in	O
un	O
-	O
treated	O
and	O
treated	O
cells	O
.	O

The	O
decrease	O
in	O
the	O
activated	O
state	O
of	O
TRAF3	O
and	O
TRAF6	O
correlated	O
with	O
the	O
inactivation	O
of	O
TBK1	B-FUNC
in	O
response	O
to	O
IMQ	O
by	O
PLPro	O
.	O

The	O
results	O
revealed	O
that	O
the	O
antagonism	O
of	O
SARS	O
-	O
CoV	O
PLPro	O
on	O
TLR7	O
-	O
mediated	O
innate	O
immunity	O
was	O
associated	O
with	O
the	O
negative	O
regulation	O
of	O
TRAF3	O
/	O
6	O
-	O
TBK1	B-FUNC
-	O
IRF3	O
/	O
NF	O
-	O
B	O
/	O
AP1	O
signals	O
.	O

Antibodies	O
against	O
DcCoV	O
UAE	O
-	O
HKU23	O
were	O
detected	O
in	O
58	O
(	O
98	O
.	O
3	O
%)	O
and	O
59	O
(	O
100	O
%)	O
of	O
the	O
59	O
dromedary	O
sera	B-FUNC
by	O
immunofluorescence	O
and	O
neutralization	O
antibody	B-FUNC
tests	O
,	O
respectively	O
.	O

There	O
was	O
significant	O
correlation	O
between	O
the	O
antibody	B-FUNC
titers	O
determined	O
by	O
immunofluorescence	O
and	O
neutralization	O
assays	O
(	O
Pearson	O
coefficient	O
=	O
0	O
.	O
525	O
,	O
p	O
<	O
0	O
.	O
0001	O
).	O

Immunization	O
of	O
mice	O
using	O
recombinant	O
N	O
proteins	O
of	O
DcCoV	O
UAE	O
-	O
HKU23	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
respectively	O
,	O
and	O
heat	O
-	O
inactivated	O
DcCoV	O
UAE	O
-	O
HKU23	O
showed	O
minimal	O
cross	O
-	O
antigenicity	O
between	O
DcCoV	O
UAE	O
-	O
HKU23	O
and	O
MERS	O
-	O
CoV	O
by	O
Western	O
blot	O
and	O
neutralization	O
antibody	B-FUNC
assays	O
.	O

Codon	O
usage	O
and	O
genetic	O
distance	O
analysis	O
of	O
RdRp	B-FUNC
,	O
S	O
and	O
N	O
genes	O
showed	O
that	O
the	O
14	O
strains	O
of	O
DcCoV	O
UAE	O
-	O
HKU23	O
formed	O
a	O
distinct	O
cluster	O
,	O
separated	O
from	O
those	O
of	O
other	O
closely	O
related	O
members	O
of	O
Betacoronavirus	O
1	O
,	O
including	O
alpaca	O
CoV	O
,	O
confirming	O
that	O
DcCoV	O
UAE	O
-	O
HKU23	O
is	O
a	O
novel	O
member	O
of	O
Betacoronavirus	O
1	O
.	O

During	O
infection	O
of	O
target	O
cell	O
,	O
MERS	O
-	O
CoV	O
S	O
protein	O
S1	O
subunit	O
binds	B-FUNC
to	O
the	O
cellular	O
receptor	O
(	O
DPP4	O
),	O
and	O
its	O
S2	O
subunit	O
HR1	O
and	O
HR2	O
regions	O
intact	O
with	O
each	O
other	O
to	O
form	O
a	O
stable	O
six	O
-	O
helix	O
bundle	O
to	O
mediate	O
the	O
fusion	O
between	O
virus	O
and	O
target	O
cell	O
membranes	O
.	O

Dual	O
luciferase	O
reporter	O
assays	O
with	O
TGF	O
-	O
1	O
promoter	O
plasmids	O
indicated	O
that	O
TGF	O
-	O
1	O
promoter	O
region	O
between	O
-	O
175	O
to	O
-	O
60	O
,	O
the	O
Egr	O
-	O
1	O
binding	B-FUNC
site	O
,	O
was	O
responsible	O
for	O
TGF	O
-	O
1	O
promoter	O
activation	O
induced	O
by	O
SARS	O
-	O
CoV	O
PLpro	O
.	O

The	O
results	O
revealed	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
significantly	O
triggered	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
1	O
promoter	O
via	O
ROS	O
/	O
p38	B-FUNC
MAPK	B-FUNC
/	O
STAT3	O
pathway	O
,	O
correlating	O
with	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
fibrotic	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

TITLE	O
:	O
Andrographolide	O
sulfonate	O
ameliorates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
down	O
-	O
regulating	O
MAPK	B-FUNC
and	O
NF	O
-	O
B	O
pathways	O
.	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
andrographolide	O
sulfonate	O
ameliorated	O
LPS	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibiting	O
NF	O
-	O
B	O
and	O
MAPK	B-FUNC
-	O
mediated	O
inflammatory	O
responses	O
.	O

TITLE	O
:	O
Qingfei	O
Xiaoyan	O
Wan	O
,	O
a	O
traditional	O
Chinese	O
medicine	O
formula	O
,	O
ameliorates	O
Pseudomonas	O
aeruginosa	O
-	O
induced	O
acute	O
lung	O
inflammation	O
by	O
regulation	O
of	O
PI3K	B-FUNC
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-FUNC
pathways	O
.	O

The	O
results	O
showed	O
that	O
pretreatment	O
with	O
QF	O
significantly	O
inhibits	O
the	O
release	O
of	O
cytokines	O
(	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
chemokines	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
RANTES	O
),	O
reduces	O
leukocytes	O
recruitment	O
into	O
inflamed	O
tissues	O
and	O
ameliorates	O
pulmonary	O
edema	O
and	O
necrosis	O
.	O

In	O
addition	O
,	O
ATG	O
was	O
identified	O
as	O
the	O
primary	O
anti	O
-	O
inflammatory	O
agent	O
with	O
action	O
on	O
the	O
PI3K	B-FUNC
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-FUNC
pathways	O
.	O

CLA	O
and	O
CGA	O
enhanced	O
the	O
actions	O
of	O
ATG	O
and	O
exhibited	O
synergistic	O
NF	O
-	O
B	O
inactivation	O
effects	O
possibly	O
via	O
the	O
Ras	O
/	O
MAPK	B-FUNC
signaling	O
pathway	O
.	O

Moreover	O
,	O
CLA	O
is	O
speculated	O
to	O
target	O
FGFR	B-FUNC
and	O
MEK	O
firstly	O
.	O

We	O
identified	O
several	O
bat	O
MHC	O
class	O
I	O
-	O
binding	B-FUNC
partners	O
,	O
including	O
calnexin	O
,	O
calreticulin	O
,	O
protein	O
disulfide	O
isomerase	O
A3	O
,	O
tapasin	O
,	O
TAP1	O
,	O
and	O
TAP2	O
.	O

Furthermore	O
,	O
strong	O
neutralizing	O
antibody	B-FUNC
responses	O
to	O
PEDV	O
were	O
verified	O
in	O
immunized	O
sows	O
and	O
their	O
offspring	O
,	O
but	O
were	O
absent	O
in	O
the	O
unvaccinated	O
controls	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
-	O
esterases	B-FUNC
(	O
HEs	O
)	O
are	O
bimodular	O
envelope	O
proteins	O
of	O
orthomyxoviruses	O
,	O
toroviruses	O
,	O
and	O
coronaviruses	O
with	O
a	O
carbohydrate	O
-	O
binding	B-FUNC
""""	O
lectin	O
""""	O
domain	O
appended	O
to	O
a	O
receptor	O
-	O
destroying	O
sialate	O
-	O
O	O
-	O
acetylesterase	O
"("""	O
esterase	O
""")."	O

This	O
specificity	O
shift	O
required	O
quasisynchronous	O
adaptations	O
in	O
the	O
Sia	O
-	O
binding	B-FUNC
sites	O
of	O
both	O
lectin	O
and	O
esterase	O
domains	O
.	O

Previously	O
,	O
a	O
partially	O
disordered	O
crystal	O
structure	O
of	O
a	O
type	O
II	O
HE	O
revealed	O
how	O
the	O
shift	O
in	O
lectin	O
ligand	B-FUNC
specificity	O
was	O
achieved	O
.	O

Molecular	O
assays	O
such	O
as	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
became	O
the	O
methods	O
of	O
choice	O
for	O
the	O
diagnosis	O
of	O
PEDV	O
infection	O
,	O
providing	O
sensitive	O
,	O
specific	O
and	O
rapid	O
detection	O
of	O
the	O
virus	O
RNA	O
in	O
clinical	O
samples	O
.	O

Intestinal	O
content	O
samples	O
were	O
collected	O
from	O
101	O
broiler	O
flocks	O
from	O
several	O
regions	O
of	O
Jordan	O
to	O
detect	O
the	O
presence	O
of	O
astrovirus	O
,	O
coronavirus	O
,	O
reovirus	O
,	O
and	O
rotavirus	O
,	O
by	O
using	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

TITLE	O
:	O
Antibody	B-FUNC
Response	O
and	O
Disease	O
Severity	O
in	O
Healthcare	O
Worker	O
MERS	O
Survivors	O
.	O

Among	O
patients	O
who	O
had	O
experienced	O
severe	O
pneumonia	O
,	O
antibody	B-FUNC
was	O
detected	O
for	O
>	O
18	O
months	O
after	O
infection	O
.	O

Antibody	B-FUNC
longevity	O
was	O
more	O
variable	O
in	O
patients	O
who	O
had	O
experienced	O
milder	O
disease	O
.	O

Levels	O
of	O
TNF	O
-	O
a	O
,	O
Interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
HMGB1	O
,	O
tissue	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
neutrophil	O
counts	O
and	O
total	O
protein	O
concentration	O
were	O
measured	O
.	O

In	O
LPS	O
-	O
induced	O
severe	O
ARDS	O
,	O
RIP3	O
knock	O
-	O
out	O
alleviated	O
the	O
hypothermia	O
symptom	O
,	O
increased	O
survival	O
rate	O
and	O
ameliorated	O
the	O
lung	O
tissue	O
injury	O
RIP3	O
depletion	O
also	O
attenuated	O
LPS	O
-	O
induced	O
increase	O
in	O
IL	O
-	O
1	O
/	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
HMGB1	O
release	O
,	O
decreased	O
tissue	O
MPO	B-FUNC
activity	O
,	O
and	O
reduced	O
neutrophil	O
influx	O
and	O
total	O
protein	O
concentration	O
in	O
BALF	O
in	O
severe	O
ARDS	O
.	O

Viral	O
infection	O
was	O
detected	O
by	O
multiplex	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
primers	O
specific	O
to	O
the	O
subtypes	O
HCoV	O
-	O
229E	O
/	O
NL63	O
and	O
OC43	O
/	O
HKU1	O
.	O

ABSTRACT	O
:	O
We	O
collected	O
blood	O
samples	O
from	O
wolves	O
(	O
Canis	O
lupus	O
)	O
on	O
the	O
Alaska	O
Peninsula	O
,	O
southwest	O
Alaska	O
,	O
US	O
,	O
2006	O
-	O
11	O
and	O
tested	O
sera	B-FUNC
for	O
antibodies	O
to	O
canine	O
adenovirus	O
(	O
CAV	O
),	O
canine	O
coronavirus	O
(	O
CCV	O
),	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
herpesvirus	O
(	O
CHV	O
),	O
canine	O
parainfluenza	O
(	O
CPI	O
),	O
canine	O
parvovirus	O
(	O
CPV	O
),	O
Neospora	O
caninum	O
,	O
and	O
Toxoplasma	O
gondii	O
.	O

Detected	O
antibody	B-FUNC
prevalence	O
was	O
90	O
%	O
for	O
CAV	O
,	O
28	O
%	O
for	O
CCV	O
,	O
12	O
%	O
for	O
CDV	O
,	O
93	O
%	O
for	O
CHV	O
,	O
0	O
%	O
for	O
CPI	O
,	O
20	O
%	O
for	O
CPV	O
,	O
0	O
%	O
for	O
N	O
.	O
caninum	O
,	O
and	O
86	O
%	O
for	O
T	O
.	O
gondii	O
.	O

SARS	O
PLpro	O
binds	B-FUNC
diUb	O
(	O
Lys48	O
)	O
in	O
an	O
extended	O
conformation	O
via	O
two	O
contact	O
sites	O
,	O
S1	O
and	O
S2	O
,	O
which	O
are	O
proximal	O
and	O
distal	O
to	O
the	O
active	O
site	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
death	O
among	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
adult	O
patients	O
.	O

Pulmonary	O
vascular	O
dysfunction	O
(	O
PVD	O
)	O
and	O
acute	O
cor	O
pulmonale	O
(	O
ACP	O
)	O
are	O
common	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
their	O
prevalence	O
may	O
be	O
even	O
more	O
important	O
during	O
ARDS	O
related	O
to	O
ACS	B-FUNC
(	O
ACS	B-FUNC
-	O
ARDS	O
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	O
and	O
prognosis	O
of	O
PVD	O
and	O
ACP	O
during	O
ACS	B-FUNC
-	O
ARDS	O
.	O

A	O
total	O
of	O
362	O
patients	O
were	O
analyzed	O
,	O
including	O
24	O
ACS	B-FUNC
-	O
ARDS	O
.	O

PVD	O
and	O
ACP	O
were	O
identified	O
,	O
respectively	O
,	O
in	O
24	O
(	O
100	O
%)	O
and	O
20	O
(	O
83	O
%)	O
ACS	B-FUNC
-	O
ARDS	O
patients	O
,	O
as	O
compared	O
with	O
204	O
(	O
60	O
%)	O
and	O
68	O
(	O
20	O
%)	O
nonACS	O
-	O
ARDS	O
patients	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
mortality	O
did	O
not	O
differ	O
between	O
ACS	B-FUNC
-	O
ARDS	O
and	O
nonACS	O
-	O
ARDS	O
patients	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	B-FUNC
-	O
ARDS	O
and	O
ACP	O
.	O

All	O
SCD	O
patients	O
presenting	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
as	O
a	O
consequence	O
of	O
ACS	B-FUNC
experienced	O
PVD	O
and	O
more	O
than	O
80	O
%	O
of	O
them	O
exhibited	O
ACP	O
.	O

These	O
results	O
suggest	O
a	O
predominant	O
role	O
for	O
PVD	O
in	O
the	O
pathogenesis	O
of	O
severe	O
forms	O
of	O
ACS	B-FUNC
.	O

RESULTS	O
:	O
A	O
total	O
of	O
362	O
patients	O
were	O
analyzed	O
,	O
including	O
24	O
ACS	B-FUNC
-	O
ARDS	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	B-FUNC
-	O
ARDS	O
and	O
ACP	O
.	O

In	O
this	O
study	O
,	O
consensus	O
primer	O
-	O
based	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCRs	O
)	O
and	O
high	O
-	O
throughput	O
sequencing	O
were	O
performed	O
to	O
investigate	O
viruses	O
in	O
bat	O
faecal	O
samples	O
collected	O
at	O
11	O
natural	O
bat	O
habitat	O
sites	O
from	O
July	O
to	O
December	O
2015	O
in	O
Korea	O
.	O

ABSTRACT	O
:	O
The	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
pathways	O
,	O
which	O
are	O
central	O
building	O
blocks	O
in	O
the	O
intracellular	O
signaling	O
network	O
,	O
are	O
often	O
manipulated	O
by	O
viruses	O
of	O
diverse	O
families	O
to	O
favor	O
their	O
replication	O
.	O

Among	O
the	O
MAPK	B-FUNC
family	O
,	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
pathway	O
is	O
known	O
to	O
be	O
modulated	O
during	O
the	O
infection	O
with	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
);	O
however	O
,	O
involvement	O
of	O
stress	O
-	O
activated	O
protein	O
kinases	O
(	O
SAPKs	O
)	O
comprising	O
p38	B-FUNC
MAPK	B-FUNC
and	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
)	O
remains	O
to	O
be	O
determined	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
JNK	B-FUNC
cascades	O
is	O
required	O
for	O
PEDV	O
replication	O
.	O

Our	O
results	O
showed	O
that	O
PEDV	O
activates	O
p38	B-FUNC
MAPK	B-FUNC
and	O
JNK1	O
/	O
2	O
up	O
to	O
24h	O
post	O
-	O
infection	O
,	O
whereas	O
,	O
thereafter	O
their	O
phosphorylation	O
levels	O
recede	O
to	O
baseline	O
levels	O
or	O
even	O
fall	O
below	O
them	O
.	O

Notably	O
,	O
UV	O
-	O
irradiated	O
inactivated	O
PEDV	O
,	O
which	O
can	O
enter	O
cells	O
but	O
cannot	O
replicate	O
inside	O
them	O
,	O
failed	O
to	O
induce	O
phosphorylation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
and	O
JNK1	O
/	O
2	O
suggesting	O
that	O
viral	O
biosynthesis	O
is	O
essential	O
for	O
activation	O
of	O
these	O
kinases	O
.	O

Treatment	O
of	O
cells	O
with	O
selective	O
p38	B-FUNC
or	O
JNK	B-FUNC
inhibitors	O
markedly	O
impaired	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
these	O
antiviral	O
effects	O
were	O
found	O
to	O
be	O
maximal	O
during	O
the	O
early	O
times	O
of	O
the	O
infection	O
.	O

Furthermore	O
,	O
direct	O
pharmacological	O
inhibition	O
of	O
p38	B-FUNC
MAPK	B-FUNC
or	O
JNK1	O
/	O
2	O
activation	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
,	O
viral	O
protein	O
expression	O
,	O
and	O
progeny	O
release	O
.	O

However	O
,	O
independent	O
treatments	O
with	O
either	O
SAPK	B-FUNC
inhibitor	O
did	O
not	O
inhibit	O
PEDV	O
-	O
induced	O
apoptotic	O
cell	O
death	O
mediated	O
by	O
activation	O
of	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
suggesting	O
that	O
SAPKs	O
are	O
irrelevant	O
to	O
the	O
apoptosis	O
pathway	O
during	O
PEDV	O
infection	O
.	O

Paired	O
sera	B-FUNC
were	O
tested	O
for	O
detection	O
of	O
MERS	O
-	O
CoV	O
antibodies	O
by	O
using	O
an	O
indirect	O
ELISA	O
.	O

The	O
computationally	O
designed	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
validated	O
using	O
169	O
field	O
sera	B-FUNC
,	O
whose	O
statuses	O
were	O
determined	O
by	O
a	O
PEDV	O
-	O
specific	O
immunofluorescence	O
assay	O
.	O

Mo	O
-	O
DCs	O
incubated	O
with	O
UV	O
-	O
PEDV	O
produce	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
INF	O
-	O
	O
compared	O
to	O
mock	O
-	O
infected	O
Mo	O
-	O
DCs	O
.	O

TITLE	O
:	O
Structural	O
and	O
mutational	O
analysis	O
of	O
the	O
interaction	O
between	O
the	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
and	O
human	O
ubiquitin	B-FUNC
.	O

To	O
contribute	O
to	O
an	O
understanding	O
of	O
this	O
process	O
,	O
we	O
present	O
here	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
a	O
complex	O
between	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
and	O
human	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
that	O
is	O
devoid	O
of	O
any	O
covalent	O
linkage	O
between	O
the	O
two	O
proteins	O
.	O

TITLE	O
:	O
Mutagenesis	O
of	O
S	O
-	O
Adenosyl	O
-	O
l	O
-	O
Methionine	O
-	O
Binding	B-FUNC
Residues	O
in	O
Coronavirus	O
nsp14	O
N7	O
-	O
Methyltransferase	O
Demonstrates	O
Differing	O
Requirements	O
for	O
Genome	O
Translation	O
and	O
Resistance	O
to	O
Innate	O
Immunity	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
conserved	O
MHV	O
N7	O
-	O
MTase	O
SAM	O
-	O
binding	B-FUNC
-	O
site	O
residues	O
are	O
not	O
required	O
for	O
MHV	O
viability	O
and	O
suggest	O
that	O
the	O
determinants	O
of	O
CoV	O
N7	O
-	O
MTase	O
activity	O
differ	O
in	O
vitro	O
and	O
during	O
virus	O
infection	O
.	O

It	O
is	O
unclear	O
as	O
to	O
when	O
the	O
virus	O
was	O
introduced	O
to	O
dromedary	O
camels	O
,	O
but	O
data	O
from	O
studies	O
that	O
investigated	O
stored	O
dromedary	O
camel	O
sera	B-FUNC
and	O
geographical	O
distribution	O
of	O
involved	O
dromedary	O
camel	O
populations	O
suggested	O
that	O
the	O
virus	O
was	O
present	O
in	O
dromedary	O
camels	O
several	O
decades	O
ago	O
.	O

The	O
virion	O
-	O
associated	O
host	O
proteins	O
had	O
a	O
diverse	O
range	O
of	O
functional	O
attributions	O
,	O
being	O
involved	O
in	O
cytoskeleton	O
formation	O
,	O
RNA	B-FUNC
binding	I-FUNC
and	O
protein	O
folding	O
pathways	O
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
S1	O
domain	O
of	O
PEDV	O
spike	O
protein	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
the	O
5	O
-	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
Neu5Ac	O
),	O
a	O
possible	O
sugar	O
co	O
-	O
receptor	O
.	O

In	O
an	O
indirect	O
ELISA	O
,	O
purified	O
S25	O
-	O
229	O
showed	O
strong	O
reactivity	O
with	O
mouse	O
anti	O
-	O
PEDV	O
sera	B-FUNC
.	O

Lung	O
mononuclear	O
infiltrates	O
occurred	O
in	O
all	O
groups	O
after	O
virus	O
challenge	O
but	O
with	O
increased	O
infiltrates	O
that	O
contained	O
eosinophils	O
and	O
increases	O
in	O
the	O
eosinophil	O
promoting	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
cytokines	O
only	O
in	O
the	O
vaccine	O
groups	O
.	O

Among	O
the	O
virological	O
methods	O
,	O
PDCoV	O
-	O
specific	O
RT	O
-	O
PCR	O
remains	O
the	O
method	O
of	O
choice	O
for	O
the	O
detection	O
of	O
PDCoV	O
;	O
immunohistochemistry	O
combined	O
with	O
hematoxylin	O
and	O
eosin	O
staining	O
has	O
also	O
been	O
commonly	O
used	O
to	O
examine	O
histopathological	O
lesions	O
caused	O
by	O
PDCoV	O
.	O
Serological	O
assays	O
can	O
provide	O
information	O
about	O
previous	O
exposure	O
to	O
PDCoV	O
and	O
also	O
determine	O
antibody	B-FUNC
responses	O
to	O
infection	O
or	O
vaccination	O
.	O

MHV3	O
in	O
vitro	O
infection	O
of	O
macrophagic	O
cells	O
induced	O
rapid	O
and	O
higher	O
viral	O
replication	O
and	O
/	O
or	O
interleukin	O
-	O
6	O
induction	O
in	O
comparison	O
to	O
MHV	O
-	O
A59	O
,	O
and	O
depended	O
on	O
viral	O
activation	O
of	O
TLR2	O
and	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Since	O
PDCoV	O
was	O
just	O
recently	O
linked	O
with	O
clinical	O
disease	O
,	O
few	O
specific	O
antibody	B-FUNC
-	O
based	O
reagents	O
were	O
available	O
to	O
assist	O
in	O
diagnosis	O
of	O
PDCoV	O
and	O
limited	O
serological	O
capabilities	O
were	O
available	O
to	O
detect	O
an	O
antibody	B-FUNC
response	O
to	O
this	O
virus	O
.	O

Therefore	O
,	O
the	O
overall	O
objective	O
of	O
this	O
project	O
was	O
to	O
develop	O
and	O
validate	O
selected	O
diagnostic	O
reagents	O
and	O
assays	O
for	O
PDCoV	O
antigen	O
and	O
antibody	B-FUNC
detection	O
.	O

The	O
resulting	O
mAbs	O
were	O
evaluated	O
for	O
use	O
in	O
fluorescent	O
antibody	B-FUNC
staining	O
methods	O
to	O
detect	O
PDCoV	O
infected	O
cells	O
following	O
virus	O
isolation	O
attempts	O
and	O
for	O
immunohistochemistry	O
staining	O
of	O
intestinal	O
tissues	O
of	O
infected	O
pigs	O
.	O

RESULTS	O
:	O
The	O
nucleoprotein	O
of	O
PDCoV	O
was	O
expressed	O
as	O
a	O
recombinant	O
protein	O
and	O
purified	O
for	O
use	O
as	O
an	O
antigen	O
to	O
immunize	O
mice	O
for	O
polyclonal	O
,	O
hyperimmune	O
sera	B-FUNC
and	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
production	O
.	O

An	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
test	O
was	O
also	O
developed	O
using	O
cell	O
culture	O
adapted	O
PDCoV	O
for	O
comparative	O
purposes	O
.	O

TITLE	O
:	O
Influence	O
of	O
Breed	O
Size	O
,	O
Age	O
,	O
Fecal	O
Quality	O
,	O
and	O
Enteropathogen	O
Shedding	O
on	O
Fecal	O
Calprotectin	O
and	O
Immunoglobulin	B-FUNC
A	O
Concentrations	O
in	O
Puppies	O
During	O
the	O
Weaning	O
Period	O
.	O

ABSTRACT	O
:	O
Fecal	O
calprotectin	O
and	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
are	O
markers	O
of	O
intestinal	O
inflammation	O
and	O
immunity	O
in	O
adult	O
dogs	O
.	O

It	O
is	O
unknown	O
to	O
what	O
extent	O
the	O
CoV	O
polymerase	O
(	O
nsp12	O
-	O
RdRp	B-FUNC
)	O
participates	O
in	O
replication	O
fidelity	O
.	O

We	O
modeled	O
the	O
CoV	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp12	O
-	O
RdRp	B-FUNC
structure	O
and	O
superimposed	O
it	O
on	O
solved	O
picornaviral	O
RdRp	B-FUNC
structures	O
.	O

Fidelity	O
-	O
altering	O
mutations	O
previously	O
identified	O
in	O
coxsackie	O
virus	O
B3	O
(	O
CVB3	O
)	O
were	O
mapped	O
onto	O
the	O
nsp12	O
-	O
RdRp	B-FUNC
model	O
structure	O
and	O
then	O
engineered	O
into	O
the	O
MHV	O
genome	O
with	O
[	O
nsp14	O
-	O
ExoN	O
(+)]	O
or	O
without	O
[	O
nsp14	O
-	O
ExoN	O
(-)]	O
ExoN	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
nsp12	O
-	O
RdRp	B-FUNC
likely	O
functions	O
in	O
fidelity	O
regulation	O
and	O
that	O
,	O
despite	O
low	O
sequence	O
conservation	O
,	O
some	O
determinants	O
of	O
RdRp	B-FUNC
nucleotide	O
selectivity	O
are	O
conserved	O
across	O
RNA	O
viruses	O
.	O

The	O
results	O
also	O
indicate	O
that	O
,	O
with	O
regard	O
to	O
nucleotide	O
selectivity	O
,	O
nsp14	O
-	O
ExoN	O
is	O
epistatic	O
to	O
nsp12	O
-	O
RdRp	B-FUNC
,	O
consistent	O
with	O
its	O
proposed	O
role	O
in	O
a	O
multiprotein	O
replicase	O
-	O
proofreading	O
complex	O
.	O

Trauma	O
and	O
surgical	O
patients	O
with	O
severe	O
ARDS	O
should	O
be	O
considered	O
for	O
ECMO	O
early	O
in	O
their	O
clinical	O
course	O
to	O
provide	O
optimal	O
lung	O
rest	B-FUNC
.	O

ABSTRACT	O
:	O
Longitudinal	O
samples	O
from	O
two	O
production	O
sites	O
were	O
used	O
to	O
(	O
1	O
)	O
describe	O
the	O
pattern	O
of	O
PEDV	O
shedding	O
(	O
rRT	O
-	O
PCR	O
)	O
in	O
individual	O
rectal	O
swabs	O
,	O
pen	O
fecal	O
samples	O
,	O
and	O
pen	O
oral	O
fluids	O
(	O
OF	O
);	O
(	O
2	O
)	O
describe	O
the	O
kinetics	O
of	O
PEDV	O
antibody	B-FUNC
by	O
ELISA	O
(	O
IgA	O
,	O
IgG	O
)	O
testing	O
of	O
pig	O
serum	O
and	O
pen	O
oral	O
fluid	O
samples	O
;	O
and	O
(	O
3	O
)	O
establish	O
cutoffs	O
and	O
performance	O
estimates	O
for	O
PEDV	O
WV	O
ELISAs	O
(	O
IgA	O
,	O
IgG	O
).	O

On	O
Site	O
One	O
,	O
pen	O
samples	O
(	O
feces	O
and	O
oral	O
fluids	O
)	O
and	O
pig	O
samples	O
(	O
rectal	O
swabs	O
and	O
sera	B-FUNC
)	O
were	O
collected	O
both	O
before	O
and	O
after	O
the	O
population	O
was	O
exposed	O
to	O
PEDV	O
.	O

On	O
Site	O
Two	O
,	O
pen	O
oral	O
fluid	O
samples	O
and	O
individual	O
pig	O
serum	O
samples	O
were	O
negative	O
for	O
both	O
PEDV	O
antibody	B-FUNC
and	O
nucleic	O
acid	O
.	O

This	O
study	O
showed	O
that	O
oral	O
fluid	O
-	O
based	O
testing	O
could	O
provide	O
an	O
easy	O
and	O
""""	O
animal	O
-	O
friendly	O
""""	O
approach	O
to	O
sample	O
collection	O
for	O
nucleic	O
acid	O
and	O
/	O
or	O
antibody	B-FUNC
-	O
based	O
surveillance	O
of	O
PEDV	O
in	O
swine	O
populations	O
.	O

RESULTS	O
:	O
On	O
Site	O
Two	O
,	O
pen	O
oral	O
fluid	O
samples	O
and	O
individual	O
pig	O
serum	O
samples	O
were	O
negative	O
for	O
both	O
PEDV	O
antibody	B-FUNC
and	O
nucleic	O
acid	O
.	O

The	O
kinetics	O
of	O
NA	O
decline	O
were	O
associated	O
with	O
total	O
IgA	O
and	O
IgG	O
antibody	B-FUNC
levels	O
.	O

TITLE	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
prevents	O
lipopolysaccharide	O
-	O
induced	O
rat	O
acute	O
lung	O
injury	O
via	O
suppressing	O
the	O
ERK1	B-FUNC
/	O
2	O
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
.	O

Importantly	O
,	O
the	O
blockade	O
of	O
ACE2	O
on	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
ERK1	B-FUNC
/	O
2	O
,	O
p38	B-FUNC
and	O
p50	O
/	O
p65	O
was	O
also	O
abolished	O
by	O
A779	O
.	O

Whereas	O
,	O
only	O
the	O
ERK1	B-FUNC
/	O
2	O
inhibitor	O
significantly	O
attenuated	O
lung	O
injury	O
in	O
ACE2	O
overexpressing	O
rats	O
pretreated	O
with	O
A779	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	O
-	O
induced	O
ARDS	O
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	O
pathway	O
by	O
inhibiting	O
ERK	B-FUNC
/	O
NF	O
-	O
B	O
activation	O
.	O

Ligands	O
binding	B-FUNC
to	O
ncRNA	O
architectures	O
are	O
able	O
to	O
affect	O
interactions	O
,	O
structural	O
stability	O
or	O
conformational	O
changes	O
and	O
thereby	O
block	O
processes	O
essential	O
for	O
viral	O
replication	O
.	O

Strategies	O
to	O
identify	O
antiviral	O
compounds	O
as	O
inhibitors	O
of	O
ncRNA	O
are	O
increasingly	O
emphasizing	O
consideration	O
of	O
drug	O
-	O
like	O
properties	O
of	O
candidate	O
molecules	O
emerging	O
from	O
screening	O
and	O
ligand	B-FUNC
design	O
.	O

TITLE	O
:	O
Single	O
-	O
dose	O
treatment	O
with	O
a	O
humanized	O
neutralizing	O
antibody	B-FUNC
affords	O
full	O
protection	O
of	O
a	O
human	O
transgenic	O
mouse	O
model	O
from	O
lethal	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
coronavirus	O
infection	O
.	O

hMS	O
-	O
1	O
significantly	O
blocked	O
MERS	O
-	O
CoV	O
RBD	O
binding	B-FUNC
to	O
its	O
viral	O
receptor	O
,	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
),	O
potently	O
neutralized	O
infection	O
by	O
a	O
prototype	O
MERS	O
-	O
CoV	O
,	O
and	O
effectively	O
cross	O
-	O
neutralized	O
evolved	O
MERS	O
-	O
CoV	O
isolates	O
through	O
recognizing	O
highly	O
conserved	O
RBD	O
epitopes	O
.	O

The	O
extracts	O
showed	O
a	O
high	O
antioxidant	B-FUNC
activity	I-FUNC
and	O
were	O
a	O
good	O
source	O
of	O
total	O
polyphenols	O
and	O
flavonoids	O
.	O

The	O
S	O
protein	O
has	O
a	O
multidomain	O
architecture	O
and	O
has	O
been	O
reported	O
to	O
bind	B-FUNC
to	O
carbohydrate	O
(	O
sialic	O
acid	O
)	O
and	O
proteinaceous	O
(	O
aminopeptidase	O
N	O
)	O
cell	O
surface	O
molecules	O
.	O

Here	O
we	O
review	O
the	O
current	O
data	O
on	O
PEDV	O
entry	O
into	O
its	O
host	O
cell	O
,	O
including	O
therein	O
our	O
new	O
observations	O
regarding	O
the	O
functional	O
role	O
of	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
the	O
S	O
protein	O
in	O
virus	O
infection	O
.	O

Serological	O
results	O
from	O
archived	O
camel	O
sera	B-FUNC
provide	O
evidence	O
for	O
circulation	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
among	O
dromedary	O
camels	O
in	O
the	O
Greater	O
Horn	O
of	O
Africa	O
as	O
far	O
back	O
as	O
1983	O
and	O
in	O
Saudi	O
Arabia	O
as	O
far	O
back	O
as	O
1992	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
how	O
long	O
antibodies	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
persist	O
,	O
we	O
measured	O
long	O
-	O
term	O
antibody	B-FUNC
responses	O
among	O
persons	O
serologically	O
positive	O
or	O
indeterminate	O
after	O
a	O
2012	O
outbreak	O
in	O
Jordan	O
.	O

Sonography	O
,	O
however	O
,	O
revealed	O
a	O
retrochorial	O
hematoma	O
;	O
the	O
patient	O
was	O
diagnosed	O
with	O
abortus	O
imminens	O
and	O
successfully	O
treated	O
with	O
magnesium	O
substitution	O
and	O
bed	O
rest	B-FUNC
.	O

Nine	O
specimens	O
were	O
positive	O
and	O
eight	O
was	O
suitable	O
for	O
RdRp	B-FUNC
gene	O
sequencing	O
.	O

RdRp	B-FUNC
gene	O
phylogeny	O
showed	O
that	O
all	O
CoVs	O
strains	O
from	O
this	O
study	O
cluster	O
in	O
Alphacoronavirus	O
genus	O
,	O
with	O
one	O
Molossidae	O
and	O
one	O
Phlyllostomidae	O
-	O
CoV	O
specific	O
groups	O
.	O

In	O
obese	O
mice	O
with	O
pneumonia	O
,	O
plasma	O
leptin	O
levels	O
were	O
associated	O
with	O
pneumonia	O
severity	O
,	O
and	O
in	O
obese	O
mice	O
with	O
sterile	O
lung	O
injury	O
,	O
leptin	O
levels	O
were	O
inversely	O
related	O
to	O
bronchoalveolar	O
lavage	O
neutrophilia	O
,	O
as	O
well	O
as	O
to	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
G	O
-	O
CSF	O
levels	O
.	O

ABSTRACT	O
:	O
In	O
an	O
epidemiological	O
study	O
of	O
ferret	O
coronaviruses	O
(	O
FRCoVs	O
),	O
novel	O
FRCoV	O
strains	O
(	O
Saitama	O
-	O
1	O
and	O
Aichi	O
-	O
1	O
)	O
were	O
detected	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
nucleotide	O
sequence	O
analysis	O
of	O
partial	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
genes	O
.	O

Limits	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
with	O
95	O
%	O
probability	O
values	O
were	O
estimated	O
by	O
testing	O
16	O
replicates	O
of	O
upstream	O
of	O
the	O
envelope	O
gene	O
(	O
upE	O
)	O
and	O
open	O
reading	O
frame	O
1a	O
(	O
ORF1a	O
)	O
RNA	O
transcripts	O
.	O

We	O
evaluated	O
the	O
following	O
three	O
sputum	O
-	O
homogenization	O
methods	O
:	O
proteinase	B-FUNC
K	O
and	O
DNase	B-FUNC
I	I-FUNC
(	O
PK	O
-	O
DNase	O
)	O
treatment	O
,	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
treatment	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
sodium	O
citrate	O
(	O
NALC	O
)	O
treatment	O
.	O

Beraprost	O
and	O
silvestat	O
,	O
phosphodiesterase	B-FUNC
3	O
(	O
PDE3	O
)	O
inhibitors	O
,	O
are	O
often	O
administered	O
in	O
clinical	O
practice	O
.	O

However	O
,	O
exaggerated	O
,	O
excessive	O
synthesis	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
while	O
fighting	O
environmental	O
stress	O
leads	O
to	O
an	O
acute	O
severe	O
systemic	O
inflammatory	O
response	O
known	O
as	O
'	O
cytokine	O
storm	O
',	O
since	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
can	O
activate	O
the	O
coagulation	O
pathway	O
and	O
vascular	O
endothelial	O
cells	O
but	O
inhibit	O
myocardial	O
function	O
.	O

In	O
this	O
review	O
we	O
propose	O
the	O
possibility	O
that	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
blockade	O
may	O
constitute	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
other	O
types	O
of	O
cytokine	O
storm	O
,	O
such	O
as	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
including	O
sepsis	O
,	O
macrophage	O
activation	O
syndrome	O
and	O
hemophagocytic	O
lymphohistiocytosis	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
seeks	O
to	O
design	O
a	O
valid	O
and	O
reliable	O
questionnaire	O
to	O
assess	O
sleep	O
disturbance	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
hospitalized	O
in	O
CCUs	O
.	O

TNF	O
-	O
a	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
in	O
alveolar	O
lavage	O
were	O
also	O
measured	O
.	O

TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
concentrations	O
in	O
the	O
alveolar	O
lavage	O
,	O
probability	O
of	O
survival	O
and	O
days	O
without	O
organ	O
failure	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Since	O
PEDV	O
infection	O
-	O
induced	O
STAT1	O
degradation	O
was	O
evident	O
in	O
cells	O
pretreated	O
with	O
the	O
general	O
tyrosine	O
kinase	B-FUNC
inhibitor	I-FUNC
,	O
we	O
conclude	O
that	O
STAT1	O
degradation	O
is	O
independent	O
of	O
the	O
IFN	O
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
The	O
presence	O
of	O
immunoglobulin	B-FUNC
oligoclonal	O
bands	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
Multiple	O
Sclerosis	O
(	O
MS	O
)	O
patients	O
supports	O
the	O
hypothesis	O
of	O
an	O
infectious	O
etiology	O
,	O
although	O
the	O
antigenic	O
targets	O
remain	O
elusive	O
.	O

The	O
study	O
reveals	O
that	O
during	O
the	O
acute	O
stage	O
of	O
infection	O
,	O
both	O
strains	O
induce	O
inflammatory	O
innate	O
immune	O
response	O
genes	O
,	O
whereas	O
upregulation	O
of	O
several	O
immunoglobulin	B-FUNC
genes	O
during	O
chronic	O
stage	O
infection	O
is	O
unique	O
to	O
infection	O
with	O
the	O
demyelinating	O
strain	O
.	O

Results	O
suggest	O
that	O
the	O
demyelinating	O
strain	O
induced	O
an	O
innate	O
-	O
immune	O
response	O
during	O
acute	O
infection	O
that	O
may	O
promote	O
switching	O
of	O
Ig	O
isotype	O
genes	O
during	O
chronic	O
infection	O
,	O
potentially	O
playing	O
a	O
role	O
in	O
antibody	B-FUNC
-	O
mediated	O
progressive	O
demyelination	O
even	O
after	O
viral	O
clearance	O
.	O

Mesenchymal	O
stromal	O
/	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
are	O
adult	O
multi	O
-	O
progenitor	O
cells	O
that	O
can	O
modulate	O
the	O
immune	O
response	O
and	O
enhance	O
repair	O
of	O
damaged	O
tissue	O
and	O
thus	O
may	O
provide	O
a	O
therapeutic	O
option	O
for	O
ARDS	O
.	O

MSCs	B-FUNC
demonstrate	O
efficacy	O
in	O
diverse	O
in	O
vivo	O
models	O
of	O
ARDS	O
,	O
decreasing	O
bacterial	O
pneumonia	O
and	O
ischemia	O
-	O
reperfusion	O
-	O
induced	O
injury	O
while	O
enhancing	O
repair	O
following	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

MSCs	B-FUNC
reduce	O
the	O
pro	O
-	O
inflammatory	O
response	O
to	O
injury	O
while	O
augmenting	O
the	O
host	O
response	O
to	O
bacterial	O
infection	O
.	O

MSCs	B-FUNC
appear	O
to	O
exert	O
their	O
effects	O
via	O
multiple	O
mechanisms	O
-	O
some	O
are	O
cell	O
interaction	O
dependent	O
whereas	O
others	O
are	O
paracrine	O
dependent	O
resulting	O
from	O
both	O
soluble	O
secreted	O
products	O
and	O
microvesicles	O
/	O
exosomes	O
derived	O
from	O
the	O
cells	O
.	O

Strategies	O
to	O
further	O
enhance	O
the	O
efficacy	O
of	O
MSCs	B-FUNC
,	O
such	O
as	O
by	O
overexpressing	O
anti	O
-	O
inflammatory	O
or	O
pro	O
-	O
repair	O
molecules	O
,	O
are	O
also	O
being	O
investigated	O
.	O

Although	O
considerable	O
translational	O
challenges	O
,	O
such	O
as	O
concerns	O
regarding	O
cell	O
manufacture	O
scale	O
-	O
up	O
and	O
issues	O
regarding	O
cell	O
potency	O
and	O
batch	O
variability	O
,	O
must	O
be	O
overcome	O
,	O
MSCs	B-FUNC
constitute	O
a	O
highly	O
promising	O
potential	O
therapy	O
for	O
ARDS	O
.	O

The	O
rest	B-FUNC
24	O
cases	O
were	O
all	O
improved	O
and	O
discharged	O
.	O

Spike	O
proteins	O
have	O
a	O
dual	O
function	O
during	O
entry	O
,	O
they	O
mediate	O
binding	B-FUNC
to	O
the	O
host	O
cell	O
surface	O
and	O
also	O
the	O
fusion	O
of	O
the	O
viral	O
envelope	O
with	O
host	O
cell	O
membrane	O
.	O

Time	O
course	O
experiments	O
show	O
that	O
griffithsin	O
inhibits	O
MERS	O
-	O
CoV	O
infection	O
at	O
the	O
binding	B-FUNC
step	O
.	O

ABSTRACT	O
:	O
Transient	O
receptor	O
potential	O
ion	B-FUNC
channels	I-FUNC
(	O
TRP	O
)	O
are	O
a	O
superfamily	O
of	O
non	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
which	O
are	O
opened	O
in	O
response	O
to	O
a	O
diverse	O
range	O
of	O
stimuli	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
with	O
autoimmune	O
SPS	B-FUNC
diagnosed	O
during	O
an	O
episode	O
of	O
acute	O
respiratory	O
failure	O
secondary	O
to	O
repetitive	O
episodes	O
of	O
apnea	O
,	O
requiring	O
intensive	O
care	O
.	O

Sudden	O
and	O
unexpected	O
deaths	O
have	O
been	O
reported	O
in	O
SPS	B-FUNC
,	O
and	O
all	O
described	O
cases	O
have	O
been	O
associated	O
with	O
apnea	O
.	O

Thus	O
,	O
the	O
onset	O
of	O
apnea	O
during	O
SPS	B-FUNC
should	O
be	O
considered	O
a	O
criterion	O
of	O
high	O
severity	O
and	O
should	O
lead	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
for	O
continuous	O
monitoring	O
.	O

Onset	O
of	O
apneas	O
during	O
SPS	B-FUNC
should	O
be	O
considered	O
as	O
a	O
signal	O
of	O
possible	O
progression	O
toward	O
acute	O
respiratory	O
failure	O
and	O
sudden	O
death	O
,	O
and	O
should	O
lead	O
to	O
ICU	O
admission	O
for	O
continuous	O
monitoring	O
.	O

RESULTS	O
:	O
Acute	O
respiratory	O
failure	O
manifesting	O
with	O
apneic	O
episodes	O
is	O
a	O
life	O
-	O
threatening	O
and	O
unpredictable	O
complication	O
of	O
SPS	B-FUNC
.	O

CONCLUSIONS	O
:	O
Onset	O
of	O
apneas	O
during	O
SPS	B-FUNC
should	O
be	O
considered	O
as	O
a	O
signal	O
of	O
possible	O
progression	O
toward	O
acute	O
respiratory	O
failure	O
and	O
sudden	O
death	O
,	O
and	O
should	O
lead	O
to	O
ICU	O
admission	O
for	O
continuous	O
monitoring	O
.	O

Neutropenic	O
subjects	O
had	O
higher	O
plasma	O
interleukin	O
(	O
IL	O
)-	O
6	O
(	O
457	O
vs	O
.	O
249	O
pg	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
03	O
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
581	O
vs	O
.	O
94	O
pg	O
/	O
ml	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
G	O
-	O
CSF	O
)	O
(	O
3624	O
vs	O
.	O
99	O
pg	O
/	O
ml	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

Angiopoietin	O
-	O
2	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
receptor	O
antagonist	O
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

Neutropenic	O
sepsis	O
is	O
associated	O
with	O
a	O
higher	O
AKI	O
risk	O
and	O
concentrations	O
of	O
inflammatory	O
mediators	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
G	O
-	O
CSF	O
relative	O
to	O
non	O
-	O
neutropenic	O
patients	O
.	O

Angiopoietin	O
-	O
2	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
receptor	O
antagonist	O
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

ABSTRACT	O
:	O
Three	O
experiments	O
were	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
yeast	O
-	O
derived	O
carbohydrates	O
(	O
YDC	O
),	O
and	O
a	O
blend	O
of	O
probiotics	O
and	O
YDC	O
(	O
synbiotic	O
,	O
SNB	O
)	O
on	O
serum	O
IgG	O
concentration	O
,	O
maternal	O
-	O
derived	O
antibody	B-FUNC
(	O
MDA	O
)	O
decay	O
,	O
and	O
specific	O
antibody	B-FUNC
-	O
mediated	O
immune	O
response	O
in	O
chick	O
pullets	O
following	O
immunization	O
with	O
T	O
-	O
cell	O
dependent	O
antigens	O
.	O

The	O
second	O
experiment	O
examined	O
the	O
specific	O
antibody	B-FUNC
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
pullet	O
chicks	O
following	O
vaccination	O
against	O
IBV	O
at	O
d	O
1	O
.	O

Finally	O
,	O
in	O
experiment	O
3	O
,	O
on	O
d	O
21	O
and	O
28	O
posthatch	O
,	O
10	O
birds	O
per	O
treatment	O
were	O
immunized	O
intramuscularly	O
with	O
both	O
sheep	O
red	O
blood	O
cells	O
(	O
SRBC	O
)	O
and	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
),	O
and	O
11	O
after	O
immunization	O
serum	O
samples	O
were	O
analyzed	O
by	O
hemagglutination	O
assay	O
for	O
antibody	B-FUNC
response	O
to	O
SRBC	O
,	O
and	O
by	O
ELISA	O
for	O
serum	O
IgM	O
and	O
IgG	O
response	O
to	O
BSA	O
.	O

MERS	O
-	O
CoV	O
infection	O
was	O
diagnosed	O
using	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assay	O
.	O

In	O
lung	O
tissue	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
monocyte	O
chemo	O
attractant	B-FUNC
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
)	O
and	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
was	O
elevated	O
in	O
both	O
C5	O
-/-	O
mice	O
and	O
wildtype	O
littermates	O
(	O
wt	O
),	O
whereas	O
caspase	O
-	O
3	O
was	O
reduced	O
in	O
lungs	O
after	O
DH	O
in	O
C5	O
-/-	O
mice	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	O
(	O
MPO	B-FUNC
),	O
protein	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	O
(	O
MPO	B-FUNC
),	O
protein	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

The	O
presence	O
of	O
the	O
HEV	O
helicase	O
in	O
cis	O
dramatically	O
increases	O
the	O
binding	B-FUNC
of	O
the	O
macro	O
domain	O
to	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
stimulates	O
the	O
de	O
-	O
PARylation	O
activity	O
.	O

In	O
the	O
case	O
of	O
hepatitis	O
E	O
virus	O
,	O
the	O
adjacent	O
viral	O
helicase	O
domain	O
dramatically	O
increases	O
the	O
binding	B-FUNC
of	O
the	O
macro	O
domain	O
to	O
PAR	O
and	O
simulates	O
the	O
demodification	O
activity	O
.	O

TITLE	O
:	O
Porcine	O
aminopeptidase	O
N	O
is	O
not	O
a	O
cellular	O
receptor	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
but	O
promotes	O
its	O
infectivity	O
via	O
aminopeptidase	B-FUNC
activity	I-FUNC
.	O

However	O
,	O
overexpression	O
of	O
pAPN	O
in	O
porcine	O
CPK	O
cells	O
(	O
CPK	O
-	O
pAPN	O
cells	O
)	O
slightly	O
increased	O
the	O
production	O
of	O
PEDV	O
,	O
and	O
the	O
increased	O
replication	O
in	O
CPK	O
-	O
pAPN	O
cells	O
was	O
inhibited	O
by	O
bestatin	O
,	O
an	O
inhibitor	O
of	O
the	O
protease	B-FUNC
activity	I-FUNC
of	O
aminopeptidase	O
N	O
.	O
These	O
results	O
suggest	O
that	O
pAPN	O
is	O
not	O
a	O
functional	O
receptor	O
for	O
PEDV	O
,	O
but	O
promotes	O
the	O
infection	O
of	O
PEDV	O
through	O
its	O
protease	B-FUNC
activity	I-FUNC
.	O

We	O
estimate	O
that	O
12	O
%	O
[	O
95	O
%	O
credible	O
interval	O
(	O
CI	O
):	O
9	O
%,	O
15	O
%]	O
of	O
cases	O
were	O
infected	O
from	O
the	O
reservoir	O
,	O
the	O
rest	B-FUNC
via	O
human	O
-	O
to	O
-	O
human	O
transmission	O
in	O
clusters	O
(	O
60	O
%;	O
CI	O
:	O
57	O
%,	O
63	O
%),	O
within	O
(	O
23	O
%;	O
CI	O
:	O
20	O
%,	O
27	O
%),	O
or	O
between	O
(	O
5	O
%;	O
CI	O
:	O
2	O
%,	O
8	O
%)	O
regions	O
.	O

ABSTRACT	O
:	O
Enzyme	O
immunoassays	O
(	O
EIAs	O
)	O
to	O
detect	O
and	O
quantify	O
antibodies	O
against	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
RSV	O
proteins	O
in	O
human	O
plasma	O
or	O
sera	B-FUNC
are	O
described	O
.	O

All	O
three	O
EIAs	O
have	O
been	O
evaluated	O
for	O
detecting	O
and	O
quantifying	O
the	O
respective	O
antibodies	O
in	O
human	O
sera	B-FUNC
or	O
plasma	O
.	O

We	O
previously	O
screened	O
a	O
library	O
of	O
FDA	O
-	O
approved	O
drugs	O
for	O
inhibitors	O
of	O
coronavirus	O
replication	O
in	O
which	O
we	O
identified	O
Abelson	O
(	O
Abl	O
)	O
kinase	B-FUNC
inhibitors	I-FUNC
,	O
including	O
the	O
anticancer	O
drug	O
imatinib	O
,	O
as	O
inhibitors	O
of	O
both	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
in	O
vitro	O
Here	O
we	O
show	O
that	O
the	O
anti	O
-	O
CoV	O
activity	O
of	O
imatinib	O
occurs	O
at	O
the	O
early	O
stages	O
of	O
infection	O
,	O
after	O
internalization	O
and	O
endosomal	O
trafficking	O
,	O
by	O
inhibiting	O
fusion	O
of	O
the	O
virions	O
at	O
the	O
endosomal	O
membrane	O
.	O

The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
an	O
important	O
viral	O
antigen	O
known	O
to	O
mediate	O
host	O
-	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
,	O
as	O
well	O
as	O
induce	O
robust	O
humoral	O
and	O
cell	O
-	O
mediated	O
responses	O
in	O
humans	O
during	O
infection	O
.	O

We	O
evaluated	O
the	O
prevalence	O
of	O
MERS	O
coronavirus	O
(	O
CoV	O
)	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
in	O
HCWs	O
exposed	O
to	O
MERS	O
patients	O
and	O
calculated	O
the	O
incidence	O
of	O
MERS	O
-	O
affected	O
cases	O
in	O
HCWs	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
of	O
the	O
Middle	O
East	O
respiratory	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
facilitates	O
receptor	B-FUNC
binding	I-FUNC
and	O
cell	O
entry	O
.	O

HPIVs	O
bind	B-FUNC
and	O
replicate	O
in	O
the	O
ciliated	O
epithelial	O
cells	O
of	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
and	O
the	O
extent	O
of	O
the	O
infection	O
correlates	O
with	O
the	O
location	O
involved	O
.	O

TITLE	O
:	O
Production	O
and	O
characterization	O
of	O
egg	O
yolk	O
antibody	B-FUNC
(	O
IgY	O
)	O
against	O
recombinant	O
VP8	O
-	O
S2	O
antigen	O
.	O

Studies	O
showed	O
that	O
immunoglobulin	B-FUNC
of	O
egg	O
yolk	O
(	O
IgY	O
)	O
from	O
immunized	O
hens	O
has	O
been	O
identified	O
to	O
be	O
a	O
convenient	O
source	O
for	O
specific	O
antibodies	O
for	O
using	O
in	O
immunotherapy	O
and	O
immunodiagnostic	O
to	O
limit	O
the	O
infections	O
.	O

The	O
anti	O
-	O
VP8	O
-	O
S2	O
IgY	O
was	O
showed	O
to	O
bind	B-FUNC
specifically	O
to	O
the	O
chimeric	O
VP8	O
-	O
S2	O
protein	O
by	O
dot	O
-	O
blotting	O
,	O
Western	O
-	O
blotting	O
analyses	O
and	O
indirect	O
ELISA	O
.	O

However	O
,	O
additional	O
cellular	O
binding	B-FUNC
targets	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
that	O
may	O
augment	O
MERS	O
-	O
CoV	O
infection	O
have	O
not	O
been	O
further	O
explored	O
.	O

In	O
the	O
current	O
study	O
,	O
using	O
the	O
virus	O
overlay	O
protein	B-FUNC
binding	I-FUNC
assay	O
(	O
VOPBA	O
),	O
we	O
identified	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
5	O
(	O
CEACAM5	O
)	O
as	O
a	O
novel	O
cell	B-FUNC
surface	I-FUNC
binding	I-FUNC
target	O
of	O
MERS	O
-	O
CoV	O
.	O
CEACAM5	O
coimmunoprecipitated	O
with	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
in	O
both	O
overexpressed	O
and	O
endogenous	O
settings	O
.	O

Disrupting	O
the	O
interaction	O
between	O
CEACAM5	O
and	O
MERS	O
-	O
CoV	O
spike	O
with	O
anti	O
-	O
CEACAM5	O
antibody	B-FUNC
,	O
recombinant	O
CEACAM5	O
protein	O
,	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
knockdown	O
of	O
CEACAM5	O
significantly	O
inhibited	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
Recombinant	O
expression	O
of	O
CEACAM5	O
did	O
not	O
render	O
nonpermissive	O
baby	O
hamster	O
kidney	O
(	O
BHK21	O
)	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
our	O
study	O
identified	O
CEACAM5	O
as	O
a	O
novel	O
cell	B-FUNC
surface	I-FUNC
binding	I-FUNC
target	O
of	O
MERS	O
-	O
CoV	O
that	O
facilitates	O
MERS	O
-	O
CoV	O
infection	O
by	O
augmenting	O
the	O
attachment	O
of	O
the	O
virus	O
to	O
the	O
host	O
cell	O
surface	O
.	O

Of	O
29	O
identified	O
S1	O
genes	O
,	O
the	O
SS2	O
epitope	O
(	O
Y748SNIGVCK755	O
)	O
was	O
highly	O
conserved	O
,	O
while	O
the	O
SS6	O
epitope	O
(	O
L764QDGQVKI771	O
)	O
and	O
pAPN	O
receptor	O
-	O
binding	B-FUNC
region	O
(	O
aa	O
490	O
-	O
615	O
)	O
exhibited	O
amino	O
substitutions	O
.	O

Neutrophil	O
chemotaxis	O
to	O
ARDS	O
BAL	O
fluid	O
was	O
evaluated	O
and	O
the	O
contribution	O
of	O
each	O
was	O
assessed	O
and	O
compared	O
with	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
8	O
(	O
CXCL8	O
).	O

We	O
conducted	O
a	O
histologic	O
analysis	O
and	O
measured	O
HMGB1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	O
-	O
1	O
,	O
and	O
TNF	O
-	O
	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
on	O
day	O
3	O
after	O
pneumonectomy	O
.	O

The	O
level	O
of	O
HMGB1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	O
-	O
1	O
,	O
and	O
TNF	O
-	O
	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
significantly	O
increased	O
by	O
LPS	O
administration	O
after	O
pneumonectomy	O
and	O
significantly	O
decreased	O
by	O
rTM	O
administration	O
with	O
LPS	O
and	O
pneumonectomy	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

On	O
subsequent	O
days	O
,	O
the	O
patient	O
'	O
s	O
Leptospira	O
antibody	B-FUNC
results	O
were	O
available	O
,	O
showing	O
titers	O
of	O
more	O
than	O
1	O
:	O
3200	O
.	O

Antibody	B-FUNC
testing	O
often	O
takes	O
time	O
and	O
delays	O
in	O
treatment	O
can	O
cause	O
rapid	O
clinical	O
deterioration	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
CD14	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
),	O
and	O
the	O
activity	O
of	O
SMS	O
and	O
expression	O
of	O
SMS2	B-FUNC
were	O
significantly	O
upregulated	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
)	O
in	O
the	O
model	O
group	O
.	O

The	O
increases	O
of	O
SMS2	B-FUNC
and	O
CD14	O
in	O
the	O
PDTC	O
group	O
were	O
less	O
marked	O
,	O
compared	O
with	O
those	O
in	O
the	O
model	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
n	O
=	O
5	O
).	O

TITLE	O
:	O
p53	O
down	O
-	O
regulates	O
SARS	O
coronavirus	O
replication	O
and	O
is	O
targeted	O
by	O
the	O
SARS	O
-	O
unique	O
domain	O
and	O
PLpro	O
via	O
E3	O
ubiquitin	B-FUNC
ligase	O
RCHY1	O
.	O

The	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
delta	O
(	O
CAMK2D	O
),	O
which	O
normally	O
influences	O
RCHY1	O
stability	O
by	O
phosphorylation	O
,	O
also	O
binds	B-FUNC
to	O
SUD	O
.	O

TITLE	O
:	O
Rational	O
design	O
of	O
a	O
synthetic	O
mammalian	O
riboswitch	O
as	O
a	O
ligand	B-FUNC
-	O
responsive	O
-	O
1	O
ribosomal	O
frame	O
-	O
shifting	O
stimulator	O
.	O

However	O
,	O
its	O
general	O
application	O
has	O
been	O
hampered	O
by	O
difficulty	O
in	O
identifying	O
a	O
specific	O
ligand	B-FUNC
-	O
responsive	O
pseudoknot	O
that	O
also	O
functions	O
as	O
a	O
ligand	B-FUNC
-	O
dependent	O
-	O
1	O
PRF	O
stimulator	O
.	O

We	O
addressed	O
this	O
problem	O
by	O
using	O
the	O
-	O
1	O
PRF	O
stimulation	O
pseudoknot	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
PK	O
)	O
to	O
build	O
a	O
ligand	B-FUNC
-	O
dependent	O
-	O
1	O
PRF	O
stimulator	O
.	O

In	O
particular	O
,	O
the	O
extra	O
stem	O
of	O
SARS	O
-	O
PK	O
was	O
replaced	O
by	O
an	O
RNA	O
aptamer	O
of	O
theophylline	O
and	O
designed	O
to	O
couple	O
theophylline	O
binding	B-FUNC
with	O
the	O
stimulation	O
of	O
-	O
1	O
PRF	O
.	O

Thus	O
,	O
RNA	O
-	O
ligand	B-FUNC
interaction	O
repertoire	O
provided	O
by	O
in	O
vitro	O
selection	O
becomes	O
accessible	O
to	O
ligand	B-FUNC
-	O
specific	O
-	O
1	O
PRF	O
stimulator	O
engineering	O
using	O
SARS	O
-	O
PK	O
as	O
the	O
scaffold	O
for	O
synthetic	O
biology	O
application	O
.	O

Interestingly	O
,	O
Hx	O
-	O
XO	O
-	O
derived	O
ROS	O
induced	O
the	O
same	O
biphasic	O
effect	O
on	O
the	O
phosphorylation	O
of	O
the	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
),	O
a	O
nonreceptor	O
tyrosine	O
kinase	O
critical	O
for	O
cell	O
adhesion	O
,	O
but	O
not	O
on	O
ERK1	B-FUNC
/	O
2	O
phosphorylation	O
.	O

The	O
biphasic	O
effect	O
was	O
not	O
seen	O
with	O
ERK1	B-FUNC
/	O
2	O
where	O
a	O
decrease	O
in	O
phosphorylation	O
only	O
was	O
observed	O
.	O

Wortmannin	O
,	O
a	O
PI3	O
-	O
kinase	B-FUNC
inhibitor	I-FUNC
,	O
inhibited	O
ROS	O
-	O
induced	O
cell	O
adhesion	O
and	O
FAK	O
phosphorylation	O
.	O

This	O
study	O
shows	O
that	O
ROS	O
could	O
have	O
both	O
stimulatory	O
and	O
inhibitory	O
effects	O
on	O
HUVEC	O
adhesion	O
and	O
FAK	O
phosphorylation	O
and	O
suggests	O
that	O
PI3	O
-	O
kinase	O
and	O
tyrosine	O
phosphatase	B-FUNC
control	O
these	O
effects	O
.	O

Six	O
of	O
the	O
seven	O
field	O
isolates	O
(	O
all	O
except	O
for	O
cK	O
/	O
CH	O
/	O
SCYB	O
/	O
140913	O
)	O
cross	O
-	O
reacted	O
well	O
with	O
anti	O
-	O
sera	B-FUNC
against	O
other	O
field	O
strains	O
.	O

Activation	O
of	O
the	O
pro	O
-	O
inflammatory	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
)	O
results	O
in	O
muscle	O
wasting	O
during	O
disuse	O
-	O
induced	O
skeletal	O
muscle	O
atrophy	O
(	O
ICU	O
bed	O
rest	B-FUNC
)	O
and	O
septic	O
shock	O
.	O

In	O
addition	O
,	O
NF	O
-	O
B	O
-	O
mediated	O
signaling	O
plays	O
a	O
significant	O
role	O
in	O
mechanical	O
ventilation	O
-	O
induced	O
diaphragmatic	O
atrophy	O
and	O
contractile	B-FUNC
dysfunction	O
.	O

However	O
,	O
prolonged	O
low	O
-	O
to	O
-	O
moderate	O
dose	O
glucocorticoid	O
treatment	O
of	O
sepsis	O
and	O
ARDS	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
NF	O
-	O
B	O
DNA	O
-	O
binding	B-FUNC
,	O
decreased	O
transcription	O
of	O
inflammatory	O
cytokines	O
,	O
enhanced	O
resolution	O
of	O
systemic	O
and	O
pulmonary	O
inflammation	O
,	O
leading	O
to	O
fewer	O
days	O
of	O
mechanical	O
ventilation	O
,	O
and	O
lower	O
mortality	O
.	O

ABSTRACT	O
:	O
We	O
explored	O
the	O
feasibility	O
of	O
collecting	O
convalescent	O
plasma	O
for	O
passive	O
immunotherapy	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
by	O
using	O
ELISA	O
to	O
screen	O
serum	O
samples	O
from	O
443	O
potential	O
plasma	O
donors	O
:	O
196	O
patients	O
with	O
suspected	O
or	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	O
,	O
230	O
healthcare	O
workers	O
,	O
and	O
17	O
household	O
contacts	O
exposed	O
to	O
MERS	O
-	O
CoV	O
.	O
ELISA	O
-	O
reactive	O
samples	O
were	O
further	O
tested	O
by	O
indirect	O
fluorescent	O
antibody	B-FUNC
and	O
microneutralization	O
assays	O
.	O

Undertaking	O
clinical	O
trials	O
of	O
convalescent	O
plasma	O
for	O
passive	O
immunotherapy	O
of	O
MERS	O
-	O
CoV	O
infection	O
may	O
be	O
feasible	O
,	O
but	O
such	O
trials	O
would	O
be	O
challenging	O
because	O
of	O
the	O
small	O
pool	O
of	O
potential	O
donors	O
with	O
sufficiently	O
high	O
antibody	B-FUNC
titers	O
.	O

Alternative	O
strategies	O
to	O
identify	O
convalescent	O
plasma	O
donors	O
with	O
adequate	O
antibody	B-FUNC
titers	O
should	O
be	O
explored	O
,	O
including	O
the	O
sampling	O
of	O
serum	O
from	O
patients	O
with	O
more	O
severe	O
disease	O
and	O
sampling	O
at	O
earlier	O
points	O
during	O
illness	O
.	O

TITLE	O
:	O
Passive	O
Transfer	O
of	O
A	O
Germline	O
-	O
like	O
Neutralizing	O
Human	O
Monoclonal	O
Antibody	B-FUNC
Protects	O
Transgenic	O
Mice	O
Against	O
Lethal	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Immunofluorescence	O
analysis	O
revealed	O
that	O
the	O
endothelial	O
expression	O
of	O
P	O
-	O
selectin	B-FUNC
,	O
E	O
-	O
selectin	B-FUNC
,	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
was	O
elevated	O
in	O
veins	O
close	O
to	O
granulomatous	O
infiltrates	O
in	O
the	O
renal	O
cortex	O
of	O
FIP	O
patients	O
compared	O
to	O
non	O
-	O
infiltrated	O
regions	O
and	O
specimens	O
from	O
healthy	O
cats	O
.	O

TMPRSS2	O
,	O
which	O
is	O
localized	O
to	O
the	O
plasma	O
membrane	O
,	O
is	O
a	O
serine	O
protease	O
responsible	O
for	O
the	O
proteolysis	O
of	O
S	O
in	O
the	O
post	O
-	O
receptor	O
-	O
binding	B-FUNC
stage	O
.	O

As	O
compared	O
to	O
inoculation	O
with	O
free	O
proteins	O
,	O
vaccination	O
with	O
the	O
sVLPs	O
showed	O
enhanced	O
lymphatic	O
antigen	O
delivery	O
,	O
stronger	O
antibody	B-FUNC
titers	O
,	O
increased	O
splenic	O
T	O
-	O
cell	O
response	O
,	O
and	O
reduced	O
infection	O
-	O
associated	O
symptoms	O
in	O
an	O
avian	O
model	O
of	O
coronavirus	O
infection	O
.	O

We	O
identified	O
four	O
NF	O
-	O
B	O
transcription	B-FUNC
factor	I-FUNC
binding	I-FUNC
sites	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
using	O
luciferase	O
reporter	O
system	O
,	O
chromatin	O
immunoprecipitation	O
,	O
electromobility	O
shift	O
assay	O
,	O
and	O
supershift	O
analysis	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
approaches	O
available	O
to	O
monitor	O
RNA	O
packaging	O
:	O
Northern	O
blot	O
analysis	O
,	O
ribonuclease	O
protection	O
assay	O
and	O
quantitative	O
reverse	O
transcriptase	B-FUNC
-	O
coupled	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
the	O
most	O
recent	O
RNA	O
imaging	O
and	O
sequencing	O
technologies	O
.	O

Three	O
intramuscular	O
(	O
IM	O
)	O
immunizations	O
with	O
the	O
recombinant	O
ORFV	O
-	O
PEDV	O
-	O
S	O
in	O
3	O
-	O
week	O
-	O
old	O
pigs	O
elicited	O
robust	O
serum	O
IgG	O
,	O
IgA	O
and	O
neutralizing	O
antibody	B-FUNC
responses	O
against	O
PEDV	O
.	O

TITLE	O
:	O
Suppression	O
of	O
Virulent	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Proliferation	O
by	O
the	O
PI3K	B-FUNC
/	O
Akt	O
/	O
GSK	B-FUNC
-	O
3	O
/	O
	O
Pathway	O
.	O

Inhibiting	O
PI3K	B-FUNC
,	O
an	O
upstream	O
activator	O
of	O
Akt	O
,	O
enhanced	O
PEDV	O
replication	O
.	O

Inhibiting	O
GSK	B-FUNC
-	O
3	O
/	O
	O
,	O
one	O
of	O
the	O
downstream	O
effectors	O
of	O
PI3K	B-FUNC
/	O
Akt	O
pathway	O
and	O
regulated	O
by	O
Akt	O
during	O
PEDV	O
infected	O
Vero	O
cells	O
,	O
also	O
enhanced	O
PEDV	O
replication	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
PI3K	B-FUNC
/	O
Akt	O
/	O
GSK	B-FUNC
-	O
3	O
/	O
	O
signaling	O
pathway	O
is	O
activated	O
by	O
PEDV	O
and	O
functions	O
in	O
inhibiting	O
PEDV	O
replication	O
.	O

Differential	O
plasma	O
expression	O
of	O
pulmonary	O
surfactant	O
associated	O
protein	O
A	O
,	O
apolipoprotein	B-FUNC
A1	O
,	O
and	O
deleted	O
in	O
malignant	O
brain	O
tumors	O
1	O
protein	O
(	O
DMBT1	O
)	O
was	O
verified	O
in	O
plasma	O
samples	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
induced	O
apoptosis	O
through	O
upregulation	O
of	O
Smad7	O
and	O
fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
2	O
(	O
FGF2	O
)	O
expression	O
in	O
both	O
kidney	O
and	O
lung	O
cells	O
.	O

We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	O
-	O
expression	O
at	O
rest	B-FUNC
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	O
-	O
expression	O
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	O
-	O
expression	O
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	O
-	O
expression	O
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	O
stressors	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	O
-	O
expression	O
at	O
rest	B-FUNC
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	O
-	O
expression	O
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	O
-	O
expression	O
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	O
-	O
expression	O
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	O
stressors	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
severe	O
chronic	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
with	O
monoclonal	O
gammopathy	O
of	O
undetermined	O
significance	O
with	O
alternating	O
immunoglobulin	B-FUNC
class	O
to	O
IgM	O
from	O
IgA	O
.	O
ABSTRACT	O
:	O
A	O
71	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
(	O
CIDP	O
)	O
with	O
IgA	O
-	O
	O
monoclonal	O
gammopathy	O
of	O
undetermined	O
significance	O
(	O
MGUS	O
)	O
showed	O
the	O
acute	O
development	O
of	O
tetraplegia	O
,	O
respiratory	O
failure	O
,	O
and	O
a	O
marked	O
fluctuation	O
of	O
the	O
blood	O
pressure	O
.	O

Intravenous	O
(	O
IV	O
)	O
high	O
-	O
dose	O
steroid	O
therapy	O
(	O
methylprednisolone	O
:	O
1	O
g	O
/	O
day	O
	O
3	O
days	O
),	O
followed	O
by	O
oral	O
prednisolone	O
(	O
PSL	O
)	O
(	O
40	O
mg	O
/	O
day	O
),	O
and	O
IV	O
immunoglobulin	B-FUNC
(	O
IVIg	O
,	O
0	O
.	O
4	O
g	O
/	O
kg	O
/	O
day	O
	O
5	O
days	O
)	O
administrations	O
resulted	O
in	O
the	O
amelioration	O
of	O
these	O
symptoms	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
case	O
is	O
the	O
first	O
report	O
of	O
CIDP	O
with	O
MGUS	O
showing	O
an	O
alternating	O
immunoglobulin	B-FUNC
class	O
.	O

Birds	O
of	O
LK	O
and	O
SN	O
varieties	O
also	O
indicated	O
maximum	O
antibody	B-FUNC
titer	O
against	O
NDV	O
and	O
IBV	O
,	O
respectively	O
.	O

Interaction	O
of	O
SN	O
with	O
FR	O
revealed	O
maximum	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
cholesterol	O
whereas	O
interaction	O
of	O
PW	O
with	O
SI	O
indicated	O
maximum	O
antibody	B-FUNC
titer	O
against	O
NDV	O
.	O

The	O
results	O
highlight	O
that	O
CF	O
rearing	O
system	O
expediently	O
affects	O
glucose	O
and	O
total	O
protein	O
levels	O
in	O
birds	O
;	O
SI	O
and	O
FR	O
confer	O
maximum	O
antibody	B-FUNC
titers	O
to	O
NDV	O
and	O
IBV	O
.	O

Birds	O
of	O
PW	O
variety	O
indicated	O
higher	O
glucose	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
uric	O
acid	O
,	O
and	O
creatinine	O
,	O
the	O
lowest	O
cholesterol	O
under	O
FR	O
and	O
the	O
enhanced	O
antibody	B-FUNC
titer	O
against	O
NDV	O
and	O
IBV	O
.	O

A	O
deletion	O
at	O
position	O
63	O
and	O
an	O
I69A	O
/	O
S	O
substitution	O
mutation	O
associated	O
with	O
virus	O
tropism	O
were	O
detected	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
sites	O
.	O

T	O
cells	O
harvested	O
from	O
infected	O
mice	O
were	O
used	O
to	O
examine	O
cytolytic	O
activity	O
,	O
cytokine	B-FUNC
activity	I-FUNC
,	O
and	O
expression	O
of	O
certain	O
chemokine	O
receptors	O
.	O

Based	O
on	O
the	O
DNA	O
sequence	O
for	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
,	O
the	O
strains	O
isolated	O
from	O
quail	O
clustered	O
within	O
either	O
the	O
Gammacoronavirus	O
or	O
Deltacoronavirus	O
genus	O
,	O
and	O
sequences	O
from	O
both	O
genera	O
were	O
found	O
in	O
one	O
quail	O
sample	O
.	O

The	O
structure	O
reveals	O
the	O
complete	O
architecture	O
of	O
the	O
fusion	O
machinery	O
including	O
the	O
triggering	O
loop	O
and	O
the	O
C	O
-	O
terminal	O
domains	O
,	O
which	O
contribute	O
to	O
anchoring	B-FUNC
the	O
trimer	O
to	O
the	O
viral	O
membrane	O
.	O

Pigs	O
(	O
n	O
=	O
3	O
)	O
were	O
euthanized	O
for	O
pathologic	O
examination	O
at	O
post	O
-	O
inoculation	O
day	O
(	O
PID	O
)	O
3	O
,	O
and	O
the	O
remainder	O
were	O
monitored	O
for	O
clinical	O
signs	O
,	O
virus	O
shedding	O
,	O
and	O
serum	O
antibody	B-FUNC
responses	O
until	O
PID	O
28	O
.	O

TITLE	O
:	O
Polymorphisms	O
in	O
the	O
S1	O
spike	O
glycoprotein	O
of	O
Arkansas	O
-	O
type	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
show	O
differential	O
binding	B-FUNC
to	O
host	O
tissues	O
and	O
altered	O
antigenicity	O
.	O

Using	O
recombinant	O
ArkDPI	O
S1	O
proteins	O
,	O
we	O
conducted	O
binding	B-FUNC
assays	O
on	O
chicken	O
tracheas	O
and	O
embryonic	O
chorioallantoic	O
membrane	O
(	O
CAM	O
).	O

Protein	O
histochemistry	O
showed	O
that	O
the	O
Y43H	O
change	O
allows	O
for	O
enhanced	O
binding	B-FUNC
to	O
trachea	O
,	O
whereas	O
the	O
ArkDPI	O
S1	O
spike	O
with	O
H43	O
alone	O
was	O
able	O
to	O
bind	B-FUNC
CAM	O
.	O

These	O
findings	O
are	O
important	O
because	O
they	O
propose	O
that	O
specific	O
changes	O
in	O
S1	O
enhances	O
virus	O
fitness	O
by	O
more	O
effective	O
binding	B-FUNC
to	O
host	O
tissues	O
(	O
Y43H	O
)	O
and	O
by	O
evading	O
a	O
vaccine	O
-	O
induced	O
antibody	B-FUNC
response	O
(	O
344	O
).	O

The	O
two	O
multiplex	O
PCR	O
assays	O
were	O
then	O
validated	O
on	O
102	O
respiratory	O
samples	O
collected	O
from	O
51	O
dogs	O
with	O
respiratory	O
illness	O
by	O
sensitivity	O
and	O
specificity	O
determination	O
in	O
comparison	O
to	O
conventional	O
simplex	O
PCR	O
and	O
a	O
rapid	O
three	O
-	O
antigen	O
test	O
kit	B-FUNC
.	O

TITLE	O
:	O
Plasma	O
cytokines	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
are	O
associated	O
with	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
.	O

Plasma	O
proinflammatory	O
markers	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
anti	O
-	O
inflammatory	O
marker	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
associated	O
with	O
the	O
development	O
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
).	O

Plasma	O
proinflammatory	O
markers	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
anti	O
-	O
inflammatory	O
marker	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
associated	O
with	O
the	O
development	O
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
).	O

CONCLUSIONS	O
:	O
Plasma	O
markers	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
are	O
associated	O
with	O
ARDS	O
in	O
patients	O
with	O
severe	O
TBI	O
.	O

Thirteen	O
subjects	O
with	O
cardiovascular	O
dysfunction	O
were	O
treated	O
with	O
the	O
interleukin	O
-	O
6	O
receptor	O
antibody	B-FUNC
tocilizumab	O
.	O

Chromatin	O
immunoprecipitation	O
,	O
dual	O
-	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
illustrated	O
that	O
PEDV	O
-	O
N	O
could	O
induce	O
HMGB1	O
transcription	O
by	O
interacting	O
with	O
C	O
/	O
EBP	O
-	O
	O
,	O
which	O
could	O
bind	B-FUNC
to	O
C	O
/	O
EBP	O
motif	O
in	O
HMGB1	O
promotor	O
region	O
.	O

A	O
total	O
of	O
250	O
swabs	O
were	O
randomly	O
selected	O
and	O
analyzed	O
by	O
multiplex	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
including	O
research	O
of	O
18	O
viruses	O
and	O
4	O
bacteria	O
.	O

During	O
gliatropic	O
coronavirus	O
induced	O
encephalomyelitis	O
,	O
accumulation	O
of	O
protective	O
antibody	B-FUNC
secreting	O
cells	O
is	O
preceded	O
by	O
infiltration	O
of	O
B	O
cells	O
with	O
a	O
nave	O
and	O
early	O
differentiation	O
phenotype	O
(	O
Phares	O
et	O
al	O
.,	O
2014	O
).	O

To	O
characterize	O
potential	O
for	O
interspecies	O
transmission	O
associated	O
with	O
feeding	O
behavior	O
,	O
we	O
also	O
analyzed	O
cytochrome	B-FUNC
B	O
sequences	O
from	O
fecal	O
samples	O
to	O
identify	O
prey	O
species	O
and	O
found	O
that	O
domestic	O
cattle	O
(	O
Bos	O
taurus	O
)	O
made	O
up	O
the	O
majority	O
of	O
blood	O
meals	O
.	O

Here	O
,	O
we	O
identified	O
the	O
leader	O
-	O
body	O
junction	O
sites	O
of	O
NS6	O
subgenomic	O
RNA	O
(	O
sgRNA	O
)	O
and	O
found	O
that	O
the	O
actual	O
transcription	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
utilized	O
by	O
NS6	O
is	O
non	O
-	O
canonical	O
and	O
is	O
located	O
upstream	O
of	O
the	O
predicted	O
TRS	B-FUNC
.	O

We	O
also	O
found	O
that	O
receptors	O
for	O
the	O
proinflammatory	O
cytokine	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
)	O
promote	O
pathogenesis	O
,	O
presumably	O
through	O
excessive	O
inflammation	O
.	O

We	O
also	O
found	O
that	O
receptors	O
for	O
the	O
proinflammatory	O
cytokine	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
)	O
promote	O
pathogenesis	O
,	O
presumably	O
through	O
excessive	O
inflammation	O
.	O

Both	O
AST	O
,	O
and	O
ALT	B-FUNC
values	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
infected	O
group	O
(	O
AST	O
median	O
42	O
vs	O
36	O
,	O
P	O
:	O
0	O
.	O
03	O
,	O
and	O
ALT	B-FUNC
median	O
33	O
vs	O
28	O
,	O
P	O
:	O
0	O
.	O
003	O
).	O

Mice	O
that	O
received	O
injections	O
of	O
the	O
neutrophil	O
-	O
depleting	O
Ly6G	O
antibody	B-FUNC
had	O
impaired	O
AT2	O
proliferation	O
24	O
and	O
72	O
h	O
after	O
acid	O
instillation	O
,	O
which	O
was	O
associated	O
with	O
decreased	O
reepithelialization	O
and	O
increased	O
alveolar	O
protein	O
concentration	O
72	O
h	O
after	O
injury	O
.	O

TITLE	O
:	O
Putative	O
Receptor	B-FUNC
Binding	I-FUNC
Domain	O
of	O
Bat	O
-	O
Derived	O
Coronavirus	O
HKU9	O
Spike	O
Protein	O
:	O
Evolution	O
of	O
Betacoronavirus	O
Receptor	B-FUNC
Binding	I-FUNC
Motifs	O
.	O

By	O
using	O
surface	O
plasmon	O
resonance	O
,	O
we	O
demonstrated	O
that	O
HKU9	O
-	O
RBD	O
binds	B-FUNC
to	O
neither	O
SARS	O
-	O
CoV	O
receptor	O
ACE2	O
nor	O
MERS	O
-	O
CoV	O
receptor	O
CD26	O
.	O

TITLE	O
:	O
Tissue	O
localization	O
,	O
shedding	O
,	O
virus	O
carriage	O
,	O
antibody	B-FUNC
response	O
,	O
and	O
aerosol	O
transmission	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
following	O
inoculation	O
of	O
4	O
-	O
week	O
-	O
old	O
feeder	O
pigs	O
.	O

ABSTRACT	O
:	O
We	O
determined	O
tissue	O
localization	O
,	O
shedding	O
patterns	O
,	O
virus	O
carriage	O
,	O
antibody	B-FUNC
response	O
,	O
and	O
aerosol	O
transmission	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
following	O
inoculation	O
of	O
4	O
-	O
week	O
-	O
old	O
feeder	O
pigs	O
.	O

Antibody	B-FUNC
titers	O
were	O
measurable	O
between	O
14	O
and	O
42	O
dpi	O
.	O

In	O
HULEC	O
,	O
human	O
influenza	O
viruses	O
were	O
capable	O
of	O
binding	B-FUNC
to	O
host	O
cellular	O
receptors	O
,	O
becoming	O
internalized	O
and	O
initiating	O
hemifusion	O
but	O
failing	O
to	O
uncoat	O
the	O
viral	O
nucleocapsid	O
and	O
to	O
replicate	O
in	O
host	O
nuclei	O
.	O

Antigen	O
-	O
specific	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
secreting	O
CD4	O

In	O
the	O
second	O
week	O
of	O
illness	O
,	O
the	O
severe	O
group	O
had	O
higher	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
54	O
vs	O
.	O
4	O
pg	O
/	O
mL	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
CXCL	O
-	O
10	O
(	O
2	O
,	O
642	O
vs	O
.	O
382	O
pg	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
protein	O
complex	O
is	O
thought	O
to	O
bind	B-FUNC
specific	O
cis	O
-	O
acting	O
RNA	O
elements	O
primarily	O
located	O
in	O
the	O
5	O
'-	O
and	O
3	O
'-	O
terminal	O
genome	O
regions	O
and	O
upstream	O
of	O
the	O
open	O
reading	O
frames	O
located	O
in	O
the	O
3	O
'-	O
proximal	O
one	O
-	O
third	O
of	O
the	O
genome	O
.	O

Trimers	O
of	O
the	O
S	O
glycoproteins	O
on	O
the	O
virion	O
surface	O
accommodate	O
binding	B-FUNC
to	O
a	O
cell	O
surface	O
receptor	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membrane	O
.	O

TITLE	O
:	O
Porcine	O
amino	O
peptidase	O
N	O
domain	O
VII	O
has	O
critical	O
role	O
in	O
binding	B-FUNC
and	O
entry	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

To	O
gain	O
insights	O
into	O
mechanisms	O
of	O
PEDV	O
-	O
pAPN	O
interactions	O
,	O
the	O
present	O
study	O
aimed	O
at	O
identifying	O
the	O
domain	O
that	O
is	O
critical	O
for	O
PEDV	O
binding	B-FUNC
.	O

Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
utilizes	O
endosomal	O
cathepsin	O
L	O
to	O
activate	O
the	O
spike	O
protein	O
after	O
receptor	B-FUNC
binding	I-FUNC
.	O

However	O
,	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
analyses	O
showed	O
the	O
susceptibility	O
of	O
quail	O
also	O
to	O
Deltacoronaviruses	O
,	O
suggesting	O
that	O
quail	O
and	O
pheasant	O
avian	O
coronaviruses	O
share	O
spike	O
genes	O
identical	O
to	O
chicken	O
IBV	O
spike	O
genes	O
and	O
quail	O
might	O
host	O
Deltacoronavirus	O
.	O

TITLE	O
:	O
A	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
in	O
trimeric	O
form	O
protects	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
transgenic	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
further	O
explore	O
the	O
chemical	O
space	O
around	O
the	O
entrance	O
channel	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
),	O
a	O
series	O
of	O
novel	O
indolylarylsulfones	O
(	O
IASs	O
)	O
bearing	O
N	O
-	O
substituted	O
piperidine	O
at	O
indole	O
-	O
2	O
-	O
carboxamide	O
were	O
identified	O
as	O
potent	O
HIV	O
NNRTIs	O
by	O
structure	O
-	O
guided	O
scaffold	O
morphing	O
and	O
fragment	O
rearrangement	O
.	O

High	O
antibody	B-FUNC
prevalence	O
(>	O
90	O
%)	O
was	O
only	O
found	O
to	O
FHV	O
-	O
1	O
and	O
FIV	O
in	O
lions	O
.	O

Only	O
hyenas	O
(	O
26	O
%,	O
5	O
/	O
19	O
)	O
were	O
positive	O
for	O
CDV	O
antibody	B-FUNC
.	O

extracts	O
along	O
with	O
their	O
main	O
single	O
isolated	O
constituents	O
anthraquinone	O
derivatives	O
were	O
tested	O
on	O
both	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
in	O
biochemical	O
assays	O
.	O

Sennoside	O
A	O
was	O
less	O
potent	O
when	O
tested	O
on	O
K103N	O
,	O
Y181C	O
,	O
Y188L	O
,	O
N474A	O
and	O
Q475A	O
mutated	O
RTs	O
,	O
suggesting	O
the	O
involvement	O
of	O
two	O
RT	O
binding	B-FUNC
sites	O
for	O
its	O
antiviral	O
activity	O
.	O

TITLE	O
:	O
Nur77	O
attenuates	O
endothelin	O
-	O
1	O
expression	O
via	O
downregulation	O
of	O
NF	O
-	O
B	O
and	O
p38	B-FUNC
MAPK	B-FUNC
in	O
A549	O
cells	O
and	O
in	O
an	O
ARDS	O
rat	O
model	O
.	O

LPS	O
-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
B	O
and	O
p38	B-FUNC
MAPK	B-FUNC
were	O
blocked	O
by	O
Nur77	O
overexpression	O
and	O
augmented	O
by	O
Nur77	O
knockdown	O
in	O
A549	O
cells	O
.	O

Pharmacological	O
activation	O
of	O
Nur77	O
by	O
cytosporone	O
B	O
(	O
CsnB	O
)	O
inhibited	O
ET	O
-	O
1	O
expression	O
in	O
ARDS	O
rats	O
,	O
decreased	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
B	O
and	O
p38	B-FUNC
MAPK	B-FUNC
,	O
and	O
relieved	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
injury	O
.	O

Pharmacological	O
deactivation	O
of	O
Nur77	O
by	O
1	O
,	O
1	O
-	O
bis	B-FUNC
-(	O
3	O
'-	O
indolyl	O
)-	O
1	O
-(	O
p	O
-	O
hydroxyphenyl	O
)	O
methane	O
(	O
DIM	O
-	O
C	O
-	O
pPhOH	O
,	O
C	O
-	O
DIM8	O
)	O
had	O
no	O
effect	O
on	O
ET	O
-	O
1	O
expression	O
and	O
lung	O
injury	O
.	O

These	O
results	O
indicated	O
that	O
Nur77	O
decreases	O
ET	O
-	O
1	O
expression	O
by	O
suppressing	O
NF	O
-	O
B	O
and	O
p38	B-FUNC
MAPK	B-FUNC
in	O
LPS	O
-	O
stimulated	O
A549	O
cells	O
in	O
vitro	O
,	O
and	O
,	O
in	O
an	O
LPS	O
-	O
induced	O
ARDS	O
rat	O
model	O
,	O
CsnB	O
reduced	O
ET	O
-	O
1	O
expression	O
and	O
lung	O
injury	O
in	O
ARDS	O
rats	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
3	O
-	O
3	O
-{	O
2	O
-[	O
2	O
-	O
3	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
ylidene	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
derivatives	O
has	O
been	O
designed	O
and	O
synthesized	O
to	O
study	O
their	O
activity	O
on	O
both	O
HIV	O
-	O
1	O
(	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
)	O
RT	O
(	O
Reverse	O
Transcriptase	B-FUNC
)	O
associated	O
functions	O
.	O

For	O
the	O
aHUS	O
the	O
initial	O
management	O
is	O
supportive	O
and	O
similar	O
to	O
the	O
approach	O
for	O
STEC	O
-	O
HUS	O
;	O
currently	O
we	O
have	O
moved	O
from	O
the	O
historic	O
plasma	O
therapy	O
to	O
new	O
therapeutic	O
approaches	O
,	O
first	O
of	O
all	O
eculizumab	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
that	O
blocks	O
the	O
C5	O
cascade	O
.	O

ABSTRACT	O
:	O
In	O
typical	O
kinase	B-FUNC
inhibitor	I-FUNC
programs	O
,	O
a	O
hinge	O
binder	O
showing	O
best	O
potency	O
with	O
preferential	O
specificity	O
is	O
initially	O
selected	O
,	O
followed	O
by	O
fine	O
-	O
tuning	O
of	O
the	O
accompanying	O
substituents	O
on	O
its	O
core	O
module	O
.	O

MERS	O
-	O
CoV	O
p4a	O
is	O
a	O
dsRNA	B-FUNC
binding	I-FUNC
protein	O
.	O

Mutation	O
of	O
the	O
dsRNA	B-FUNC
binding	I-FUNC
motif	O
in	O
p4a	O
disrupted	O
its	O
PKR	O
antagonistic	O
activity	O
.	O

The	O
PEDV	O
S	O
antigen	O
was	O
delivered	O
to	O
the	O
dendritic	O
cells	O
through	O
a	O
single	O
-	O
chain	O
antibody	B-FUNC
specific	O
to	O
Langerin	O
and	O
the	O
targeted	O
cells	O
were	O
stimulated	O
with	O
cholera	O
toxin	O
adjuvant	O
.	O

Virions	O
require	O
spike	O
(	O
S	O
)	O
glycoproteins	O
for	O
binding	B-FUNC
to	O
cell	O
receptors	O
and	O
for	O
catalyzing	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

Fusion	O
occurs	O
only	O
after	O
S	O
proteins	O
are	O
cleaved	O
sequentially	O
,	O
first	O
during	O
their	O
secretion	O
through	O
the	O
exocytic	O
organelles	O
of	O
virus	O
-	O
producing	O
cells	O
,	O
and	O
second	O
after	O
virus	O
binding	B-FUNC
to	O
target	O
-	O
cell	O
receptors	O
.	O

Nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
the	O
RNA	O
-	O
binding	B-FUNC
protein	O
of	O
PEDV	O
,	O
which	O
plays	O
an	O
important	O
role	O
for	O
virus	O
life	O
cycle	O
.	O

There	O
were	O
1	O
,	O
286	O
compounds	O
of	O
FDA	O
-	O
approved	O
drug	O
database	O
that	O
could	O
virtually	O
bind	B-FUNC
to	O
the	O
RNA	O
-	O
binding	B-FUNC
region	O
of	O
N	O
protein	O
.	O

ABSTRACT	O
:	O
20	O
(	O
enfuvirtide	O
)	O
and	O
other	O
peptides	O
derived	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
gp41	O
C	O
-	O
terminal	O
heptad	O
repeat	O
(	O
CHR	O
)	O
region	O
inhibit	O
HIV	O
fusion	O
by	O
binding	B-FUNC
to	O
the	O
hydrophobic	O
grooves	O
on	O
the	O
N	O
-	O
terminal	O
heptad	O
repeat	O
(	O
NHR	O
)	O
trimer	O
and	O
blocking	O
six	O
-	O
helix	O
-	O
bundle	O
(	O
6	O
-	O
HB	O
)	O
formation	O
.	O

This	O
new	O
approach	O
of	O
identifying	O
a	O
potential	O
binding	B-FUNC
pocket	O
outside	O
the	O
traditional	O
target	O
and	O
creating	O
an	O
artificial	O
tail	O
anchor	O
can	O
be	O
widely	O
applied	O
to	O
design	O
novel	O
fusion	O
inhibitors	O
against	O
other	O
class	O
I	O
enveloped	O
viruses	O
,	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Recombinant	O
Receptor	O
-	O
Binding	B-FUNC
Domains	O
of	O
Multiple	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronaviruses	O
(	O
MERS	O
-	O
CoVs	O
)	O
Induce	O
Cross	O
-	O
Neutralizing	O
Antibodies	O
against	O
Divergent	O
Human	O
and	O
Camel	O
MERS	O
-	O
CoVs	O
and	O
Antibody	B-FUNC
Escape	O
Mutants	O
.	O

Since	O
RBD	O
mutations	O
occur	O
in	O
different	O
MERS	O
-	O
CoV	O
isolates	O
and	O
antibody	B-FUNC
escape	O
mutants	O
,	O
cross	O
-	O
neutralization	O
of	O
divergent	O
MERS	O
-	O
CoV	O
strains	O
by	O
RBD	O
-	O
induced	O
antibodies	O
remains	O
unknown	O
.	O

Like	O
the	O
RBD	O
of	O
prototype	O
EMC2012	O
(	O
EMC	O
-	O
RBD	O
),	O
all	O
five	O
RBDs	O
maintained	O
good	O
antigenicity	O
and	O
functionality	O
,	O
the	O
ability	O
to	O
bind	B-FUNC
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
and	O
the	O
DPP4	O
receptor	O
,	O
and	O
high	O
immunogenicity	O
,	O
able	O
to	O
elicit	O
S	O
-	O
specific	O
antibodies	O
.	O

We	O
then	O
constructed	O
two	O
RBDs	O
mutated	O
in	O
multiple	O
key	O
residues	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RBM	O
)	O
of	O
RBD	O
and	O
demonstrated	O
their	O
strong	O
cross	O
-	O
reactivity	O
with	O
anti	O
-	O
EMC	O
-	O
RBD	O
antibodies	O
.	O

These	O
RBD	O
mutants	O
with	O
diminished	O
DPP4	O
binding	B-FUNC
also	O
led	O
to	O
virus	O
attenuation	O
,	O
suggesting	O
that	O
immunoevasion	O
after	O
RBD	O
immunization	O
is	O
accompanied	O
by	O
loss	O
of	O
viral	O
fitness	O
.	O

Mutations	O
in	O
its	O
spike	O
(	O
S	O
)	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
a	O
key	O
vaccine	O
target	O
,	O
have	O
been	O
identified	O
,	O
raising	O
concerns	O
over	O
the	O
efficacy	O
of	O
RBD	O
-	O
based	O
MERS	O
vaccines	O
against	O
circulating	O
human	O
and	O
camel	O
MERS	O
-	O
CoV	O
strains	O
.	O

These	O
RBD	O
-	O
based	O
vaccine	O
candidates	O
maintained	O
good	O
functionality	O
,	O
antigenicity	O
,	O
and	O
immunogenicity	O
,	O
and	O
they	O
induced	O
strong	O
cross	O
-	O
neutralizing	O
antibodies	O
against	O
infection	O
by	O
divergent	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
strains	O
,	O
as	O
well	O
as	O
antibody	B-FUNC
escape	O
MERS	O
-	O
CoV	O
mutants	O
.	O

We	O
found	O
here	O
that	O
production	O
of	O
the	O
cytokine	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
by	O
FRCs	O
was	O
essential	O
for	O
the	O
maintenance	O
of	O
group	O
1	O
innate	O
lymphoid	O
cells	O
(	O
ILCs	O
)	O
in	O
Peyer	O
'	O
s	O
patches	O
and	O
mesenteric	O
lymph	O
nodes	O
.	O

Moreover	O
,	O
FRC	O
-	O
specific	O
ablation	O
of	O
the	O
innate	O
immunological	O
sensing	O
adaptor	O
MyD88	O
unleashed	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
production	O
by	O
FRCs	O
during	O
infection	O
with	O
an	O
enteropathogenic	O
virus	O
,	O
which	O
led	O
to	O
hyperactivation	O
of	O
group	O
1	O
ILCs	O
and	O
substantially	O
altered	O
the	O
differentiation	O
of	O
helper	O
T	O
cells	O
.	O

The	O
MPLEx	O
method	O
is	O
a	O
simple	O
,	O
fast	B-FUNC
,	O
and	O
robust	O
protocol	O
that	O
can	O
be	O
applied	O
for	O
integrative	O
multi	O
-	O
omic	O
measurements	O
from	O
diverse	O
sample	O
types	O
(	O
e	O
.	O
g	O
.,	O
environmental	O
,	O

Cytoplasmic	O
GLTSCR2	O
was	O
able	O
to	O
interact	O
with	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
the	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
15	O
(	O
USP15	O
),	O
and	O
the	O
triple	O
interaction	O
induced	O
USP15	O
activity	O
to	O
remove	O
K63	O
-	O
linked	O
ubiquitination	O
of	O
RIG	O
-	O
I	O
,	O
leading	O
to	O
attenuation	O
of	O
RIG	O
-	O
I	O
and	O
IFN	O
-	O
	O
.	O

ABSTRACT	O
:	O
The	O
first	O
imported	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
in	O
China	O
recently	O
occurred	O
,	O
allowing	O
for	O
the	O
characterization	O
of	O
antibody	B-FUNC
titers	O
in	O
a	O
series	O
of	O
the	O
patient	O
'	O
s	O
sera	B-FUNC
using	O
the	O
following	O
methods	O
based	O
on	O
recombinant	O
viral	O
structural	O
antigens	O
:	O
inactivated	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
recombinant	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
,	O
or	O
fragments	O
of	O
S	O
)	O
ELISA	O
,	O
nucleoprotein	O
(	O
NP	O
)	O
ELISA	O
and	O
MERS	O
S	O
pseudovirus	O
particle	O
-	O
based	O
neutralization	O
test	O
(	O
ppNT	O
).	O

A	O
longitudinal	O
profile	O
of	O
the	O
infection	O
showed	O
that	O
seroconversion	O
detected	O
by	O
ELISAs	O
based	O
on	O
the	O
recombinant	O
extracellular	O
domain	O
,	O
S	O
,	O
S1	O
and	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
antigens	O
occurred	O
as	O
early	O
as	O
neutralizing	O
antibodies	O
were	O
detected	O
by	O
the	O
ppNT	O
and	O
earlier	O
than	O
antibodies	O
were	O
detected	O
by	O
the	O
inactivated	O
MERS	O
-	O
CoV	O
and	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
ELISAs	O
.	O

For	O
instance	O
,	O
we	O
observed	O
that	O
all	O
four	O
residues	O
(	O
38	O
,	O
43	O
,	O
63	O
,	O
and	O
68	O
)	O
that	O
have	O
been	O
shown	O
to	O
be	O
critical	O
for	O
binding	B-FUNC
to	O
host	O
tissues	O
,	O
were	O
found	O
at	O
the	O
surface	O
of	O
the	O
predicted	O
structure	O
of	O
Massachusetts	O
(	O
Mass	O
)	O
S1	O
spike	O
.	O

Together	O
with	O
antigenicity	O
index	O
analysis	O
,	O
we	O
were	O
also	O
able	O
to	O
show	O
that	O
Ma5	O
vaccine	O
has	O
higher	O
antigenicity	O
indices	O
at	O
residues	O
close	O
to	O
the	O
receptor	O
-	O
binding	B-FUNC
region	O
than	O
M41	O
vaccine	O
,	O
thereby	O
providing	O
a	O
possible	O
mechanism	O
on	O
how	O
Ma5	O
achieves	O
better	O
protection	O
against	O
challenge	O
.	O

ECMO	O
is	O
a	O
complex	O
network	O
that	O
provides	O
oxygenation	O
and	O
ventilation	O
and	O
allows	O
the	O
lungs	O
to	O
rest	B-FUNC
and	O
recover	O
from	O
respiratory	O
failure	O
while	O
minimizing	O
iatrogenic	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Case	O
n	O
In	O
dermatomyositis	O
,	O
anti	O
-	O
MDA5	O
antibody	B-FUNC
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

CONCLUSIONS	O
:	O
In	O
dermatomyositis	O
,	O
anti	O
-	O
MDA5	O
antibody	B-FUNC
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

The	O
results	O
showed	O
that	O
antibody	B-FUNC
against	O
CCoV	O
-	O
II	O
was	O
present	O
in	O
87	O
dogs	O
(	O
43	O
.	O
3	O
%).	O

ABSTRACT	O
:	O
Eptifibatide	O
is	O
a	O
platelet	O
glycoprotein	O
IIb	O
/	O
IIIa	O
(	O
GP	O
IIb	O
/	O
IIIa	O
)	O
receptor	O
antagonist	O
that	O
inhibits	O
fibrinogen	B-FUNC
binding	I-FUNC
to	O
the	O
activated	O
GP	O
IIb	O
/	O
IIIa	O
site	O
and	O
prevents	O
platelet	O
-	O
platelet	O
interaction	O
and	O
clot	O
formation	O
.	O

Our	O
data	O
demonstrate	O
that	O
infection	O
with	O
TGEV	O
resulted	O
in	O
increased	O
glucose	O
uptake	O
and	O
augmented	O
expression	O
of	O
EGFR	B-FUNC
,	O
SGLT1	O
and	O
GLUT2	O
.	O

Moreover	O
,	O
inhibition	O
studies	O
showed	O
that	O
EGFR	B-FUNC
modulated	O
glucose	O
uptake	O
in	O
control	O
and	O
TGEV	O
infected	O
cells	O
.	O

Given	O
the	O
lack	O
of	O
clinical	O
signs	O
,	O
positive	O
antibody	B-FUNC
titers	O
for	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
,	O
Porcine	O
parvovirus	O
,	O
and	O
Influenza	O
A	O
confirm	O
the	O
efficacy	O
of	O
the	O
herd	O
vaccination	O
program	O
.	O

Based	O
on	O
this	O
novel	O
design	O
,	O
simple	O
agglutination	O
tests	O
of	O
the	O
IgG	O
antibodies	O
of	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
nucleoprotein	O
(	O
NP	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Virus	O
(	O
MERS	O
)	O
NP	O
in	O
rabbit	O
sera	B-FUNC
were	O
successfully	O
developed	O
by	O
conjugating	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
with	O
two	O
fusion	O
proteins	O
EBOV	O
NP	O
-	O
CBD	O
and	O
MERS	O
NP	O
-	O
CBD	O
,	O
respectively	O
.	O

Using	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
of	O
pediatric	O
patients	O
revealed	O
that	O
9	O
out	O
of	O
552	O
(	O
1	O
.	O
6	O
%)	O
was	O
positive	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

As	O
proof	O
-	O
of	O
-	O
concept	O
,	O
we	O
measure	O
the	O
NII	O
for	O
different	O
epitopes	O
on	O
an	O
immunogen	O
comprised	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
from	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

These	O
mutations	O
were	O
located	O
on	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
.	O

These	O
findings	O
illustrated	O
the	O
existence	O
of	O
genetic	O
diversity	O
among	O
geographically	O
distinct	O
PEDV	O
strains	O
,	O
and	O
our	O
study	O
has	O
provided	O
an	O
impetus	O
to	O
conduct	O
further	O
research	O
on	O
the	O
PEDV	O
receptor	B-FUNC
binding	I-FUNC
protein	O
and	O
on	O
the	O
new	O
and	O
efficacious	O
vaccines	O
design	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
protein	O
levels	O
in	O
both	O
induced	O
sputum	O
and	O
plasma	O
are	O
increased	O
in	O
stable	O
but	O
not	O
acute	O
asthma	O
individuals	O
with	O
obesity	O
.	O

IL	B-FUNC
-	I-FUNC
17	I-FUNC
is	O
associated	O
with	O
neutrophilic	O
inflammation	O
,	O
steroid	O
resistance	O
and	O
severe	O
asthma	O
,	O
but	O
its	O
importance	O
in	O
the	O
association	O
between	O
asthma	O
and	O
obesity	O
is	O
unknown	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
in	O
obese	O
asthma	O
in	O
both	O
acute	O
and	O
stable	O
settings	O
.	O

Correlations	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
with	O
other	O
measures	O
were	O
explored	O
.	O

In	O
stable	O
subjects	O
,	O
airway	O
neutrophilia	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
concentrations	O
were	O
most	O
prominent	O
in	O
the	O
obese	O
,	O
and	O
correlated	O
positively	O
with	O
each	O
other	O
.	O

Significant	O
increase	O
in	O
plasma	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
levels	O
was	O
also	O
noted	O
and	O
associated	O
with	O
elevated	O
depressive	O
symptoms	O
in	O
obesity	O
.	O

In	O
acute	O
asthma	O
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
,	O
like	O
most	O
other	O
clinical	O
measures	O
,	O
was	O
similar	O
among	O
lean	O
,	O
overweight	O
and	O
obese	O
groups	O
,	O
but	O
was	O
higher	O
in	O
acute	O
versus	O
stable	O
asthma	O
subjects	O
,	O
with	O
sputum	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
correlating	O
positively	O
with	O
sputum	O
neutrophils	O
and	O
negatively	O
with	O
FEV	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
contributes	O
to	O
worse	O
disease	O
control	O
in	O
obese	O
asthma	O
through	O
enhancing	O
airway	O
neutrophilia	O
and	O
depression	O
,	O
and	O
may	O
implicate	O
in	O
asthma	O
exacerbations	O
.	O

RESULTS	O
:	O
In	O
stable	O
subjects	O
,	O
airway	O
neutrophilia	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
concentrations	O
were	O
most	O
prominent	O
in	O
the	O
obese	O
,	O
and	O
correlated	O
positively	O
with	O
each	O
other	O
.	O

In	O
acute	O
asthma	O
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
expression	O
,	O
like	O
most	O
other	O
clinical	O
measures	O
,	O
was	O
similar	O
among	O
lean	O
,	O
overweight	O
and	O
obese	O
groups	O
,	O
but	O
was	O
higher	O
in	O
acute	O
versus	O
stable	O
asthma	O
subjects	O
,	O
with	O
sputum	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
correlating	O
positively	O
with	O
sputum	O
neutrophils	O
and	O
negatively	O
with	O
FEV	O

TITLE	O
:	O
Passive	O
immunotherapy	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
infection	O
with	O
equine	O
immunoglobulin	B-FUNC
or	O
immunoglobulin	B-FUNC
fragments	O
in	O
a	O
mouse	O
model	O
.	O

Here	O
we	O
employed	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
and	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	O
fusion	O
mechanism	O
promoted	O
by	O
two	O
putative	O
SARS	O
FPs	B-FUNC
.	O

Importantly	O
,	O
therapeutic	O
countermeasures	O
comprising	O
MERS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
treatment	O
or	O
a	O
MERS	O
-	O
CoV	O
spike	O
protein	O
vaccine	O
protected	O
the	O
engineered	O
mice	O
against	O
MERS	O
-	O
CoV	O
-	O
induced	O
ARDS	O
.	O

Previous	O
studies	O
have	O
focused	O
mainly	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
on	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O
Herein	O
,	O
we	O
investigated	O
the	O
immunogenicity	O
and	O
protective	O
potential	O
of	O
the	O
recombinant	O
N	O
-	O
terminal	O
domain	O
(	O
rNTD	O
)	O
of	O
spike	O
proteins	O
as	O
a	O
vaccine	O
candidate	O
.	O

Analysis	O
of	O
intrapatient	O
heterogeneity	O
revealed	O
a	O
relationship	O
between	O
D510G	O
and	O
I529T	O
mutations	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
spike	O
glycoprotein	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
),	O
a	O
cyclophilin	B-FUNC
(	O
Cyp	O
)	O
inhibitor	O
,	O
inhibits	O
the	O
replication	O
of	O
FCoV	O
in	O
vitro	O
and	O
in	O
vivo	O
as	O
well	O
as	O
the	O
replication	O
of	O
human	O
and	O
animal	O
coronaviruses	O
.	O

Prompt	O
recognition	O
and	O
initiation	O
of	O
immunotherapy	O
including	O
intravenous	O
immunoglobulin	B-FUNC
or	O
plasmapheresis	O
,	O
together	O
with	O
supportive	O
care	O
including	O
treatment	O
of	O
underlying	O
infections	O
and	O
physical	O
therapy	O
,	O
can	O
improve	O
outcomes	O
in	O
both	O
myasthenic	O
crisis	O
and	O
GBS	O
.	O

Nucleotide	O
deletions	O
were	O
seen	O
only	O
in	O
the	O
group	O
given	O
the	O
combination	O
of	O
Mass	O
and	O
Ark	O
.	O
Of	O
the	O
16	O
sequenced	O
samples	O
in	O
this	O
group	O
,	O
13	O
contained	O
the	O
same	O
AAT	B-FUNC
deletion	O
at	O
position	O
1033	O
1035	O
in	O
the	O
Ark	O
strains	O
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
a	O
noninfectious	O
interstitial	O
lung	O
disease	O
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
infliximab	O
,	O
an	O
antitumor	O
necrosis	O
factor	O
alpha	O
antibody	B-FUNC
.	O

Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
was	O
not	O
detected	O
by	O
PCR	O
,	O
but	O
variable	O
levels	O
of	O
anti	O
-	O
NDV	O
HI	O
antibody	B-FUNC
titres	O
shows	O
possible	O
exposure	O
to	O
virulent	O
strains	O
or	O
poor	O
vaccine	O
take	O
,	O
or	O
both	O
.	O

Sera	B-FUNC
,	O
fecal	O
swabs	O
,	O
and	O
different	O
tissue	O
samples	O
were	O
collected	O
on	O
different	O
days	O
post	O
infection	O
.	O

Using	O
Pteropus	O
alecto	O
(	O
P	O
.	O
alecto	O
)	O
GM	O
-	O
CSF	O
plus	O
IL4	O
,	O
FLT3L	O
and	O
CSF	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
we	O
successfully	O
generated	O
bat	O
bone	O
marrow	O
-	O
derived	O
DC	O
and	O
macrophages	O
.	O

Cells	O
with	O
the	O
phenotype	O
,	O
morphology	O
and	O
functional	O
features	O
of	O
monocyte	O
-	O
derived	O
DC	O
,	O
bona	O
fide	O
DC	O
or	O
macrophages	O
were	O
obtained	O
in	O
GM	O
-	O
CSF	O
/	O
IL4	O
,	O
FLT3L	O
or	O
CSF	B-FUNC
-	I-FUNC
1	I-FUNC
cultures	O
,	O
respectively	O
.	O

To	O
assess	O
the	O
properties	O
of	O
various	O
diagnostic	O
assays	O
for	O
the	O
detection	O
of	O
PEDV	O
infection	O
,	O
multiple	O
panels	O
of	O
porcine	O
sera	B-FUNC
have	O
been	O
shared	O
and	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
PEDV	O
in	O
an	O
inter	O
-	O
laboratory	O
ring	O
trial	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
lactogenic	O
antibody	B-FUNC
to	O
the	O
protection	O
of	O
piglets	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
evaluated	O
.	O

Group	O
2	O
-	O
8	O
serum	O
antibody	B-FUNC
-	O
positive	O
sows	O
and	O
their	O
91	O
piglets	O
.	O

Group	O
3	O
-	O
2	O
PEDV	O
serum	O
antibody	B-FUNC
-	O
negative	O
sows	O
and	O
22	O
piglets	O
,	O
provided	O
a	O
baseline	O
for	O
piglet	O
survivability	O
and	O
growth	O
rate	O
.	O

Serum	O
and	O
mammary	O
secretions	O
were	O
tested	O
for	O
PEDV	O
IgG	O
,	O
IgA	O
,	O
and	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
.	O

Feces	O
were	O
tested	O
by	O
PEDV	O
real	O
-	O
time	O
,	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

Piglets	O
on	O
sows	O
without	O
(	O
Group	O
1	O
)	O
or	O
with	O
(	O
Group	O
2	O
)	O
anti	O
-	O
PEDV	O
antibody	B-FUNC
showed	O
significantly	O
different	O
responses	O
to	O
PEDV	O
infection	O
in	O
virus	O
shedding	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
thermoregulation	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
growth	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
survivability	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

The	O
number	O
of	O
sows	O
and	O
litters	O
in	O
Group	O
2	O
was	O
insufficient	O
to	O
derive	O
the	O
relationship	O
between	O
specific	O
levels	O
of	O
lactogenic	O
antibody	B-FUNC
(	O
FFN	O
,	O
IgA	O
,	O
and	O
IgG	O
)	O
and	O
the	O
amelioration	O
of	O
clinical	O
effects	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
the	O
epitope	O
identified	O
in	O
this	O
study	O
to	O
stimulate	O
antibody	B-FUNC
production	O
was	O
also	O
evaluated	O
.	O

After	O
5	O
days	O
of	O
treatment	O
,	O
the	O
low	O
-	O
and	O
high	O
-	O
dose	O
groups	O
had	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
reductions	O
of	O
these	O
markers	O
between	O
the	O
two	O
groups	O
.	O

RESULTS	O
:	O
After	O
5	O
days	O
of	O
treatment	O
,	O
the	O
low	O
-	O
and	O
high	O
-	O
dose	O
groups	O
had	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
reductions	O
of	O
these	O
markers	O
between	O
the	O
two	O
groups	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
previously	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
two	O
point	O
mutations	O
,	O
N15A	O
and	O
V25F	O
,	O
in	O
the	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
of	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
abolished	O
channel	B-FUNC
activity	I-FUNC
and	O
led	O
to	O

TITLE	O
:	O
Natural	O
Product	O
Kuwanon	O
-	O
L	O
Inhibits	O
HIV	O
-	O
1	O
Replication	O
through	O
Multiple	O
Target	O
Binding	B-FUNC
.	O

Here	O
we	O
present	O
a	O
work	O
in	O
which	O
we	O
suggest	O
that	O
kuwanon	O
-	O
L	O
,	O
a	O
natural	O
product	O
active	O
as	O
an	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
inhibitor	O
,	O
might	O
exert	O
its	O
overall	O
antiviral	O
activity	O
through	O
binding	B-FUNC
to	O
multiple	O
viral	O
targets	O
.	O

Specific	O
enzymatic	O
tests	O
,	O
together	O
with	O
a	O
time	O
-	O
of	O
-	O
addition	O
(	O
TOA	O
)	O
experiment	O
,	O
support	O
our	O
hypothesis	O
of	O
binding	B-FUNC
both	O
to	O
IN	O
and	O
to	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
).	O

Overall	O
,	O
this	O
compound	O
can	O
be	O
considered	O
an	O
attractive	O
lead	O
for	O
the	O
development	O
of	O
new	O
classes	O
of	O
antiviral	O
agents	O
able	O
to	O
overcome	O
the	O
problem	O
of	O
resistance	O
,	O
due	O
to	O
its	O
ability	O
to	O
exert	O
its	O
action	O
by	O
binding	B-FUNC
simultaneously	O
to	O
multiple	O
viral	O
targets	O
.	O

Proliferation	O
,	O
regeneration	O
and	O
anti	O
-	O
inflammatory	O
activity	O
that	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
exhibit	O
make	O
it	O
possible	O
to	O
regulate	O
the	O
homeostatic	O
control	O
of	O
S1P	O
.	O

By	O
building	O
a	O
pulmonary	O
endothelial	O
cell	O
model	O
of	O
acute	O
injury	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
S1P	O
receptors	O
and	O
sphingosine	O
kinases	O
expression	O
by	O
MSCs	B-FUNC
during	O
the	O
treatment	O
of	O
acute	O
lung	O
injury	O
using	O
RT	O
-	O
PCR	O
,	O
and	O
investigated	O
the	O
HPAECs	O
Micro	O
-	O
electronics	O
impedance	O
using	O
Real	O
Time	O
Cellular	O
Analysis	O
.	O

It	O
was	O
found	O
that	O
the	O
down	O
-	O
regulation	O
of	O
TNF	O
-	O
The	O
study	O
found	O
that	O
,	O
as	O
a	O
potential	O
treatment	O
,	O
MSCs	B-FUNC
could	O
work	O
on	O
multiple	O
S1P	O
related	O
genes	O
simultaneously	O
.	O

This	O
study	O
establishes	O
the	O
experimental	O
basis	O
for	O
further	O
exploring	O
the	O
efficacy	O
of	O
improving	O
endothelial	O
barrier	O
function	O
in	O
acute	O
lung	O
injury	O
,	O
using	O
MSCs	B-FUNC
in	O
combination	O
with	O
S1P	O
and	O
their	O
possible	O
synergistic	O
mechanism	O
.	O

ABSTRACT	O
:	O
Dilmapimod	O
is	O
a	O
potent	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
inhibitor	O
and	O
was	O
investigated	O
in	O
a	O
study	O
(	O
NCT00996840	O
)	O
for	O
its	O
anti	O
-	O
inflammatory	O
effect	O
in	O
non	O
-	O
head	O
injury	O
trauma	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
binding	B-FUNC
of	O
the	O
""""	O
down	O
""""	O
CTD1s	O
to	O
the	O
SARS	O
-	O
CoV	O
receptor	O
ACE2	O
is	O
not	O
possible	O
due	O
to	O
steric	O
clashes	O
,	O
suggesting	O
that	O
the	O
conformation	O
1	O
represents	O
a	O
receptor	O
-	O
binding	B-FUNC
inactive	O
state	O
.	O

The	O
""""	O
up	O
""""	O
CTD1	O
exposes	O
the	O
receptor	O
-	O
binding	B-FUNC
site	O
for	O
ACE2	O
engagement	O
,	O
suggesting	O
that	O
the	O
conformations	O
2	O
-	O
4	O
represent	O
a	O
receptor	O
-	O
binding	B-FUNC
active	O
state	O
.	O

This	O
conformational	O
change	O
is	O
also	O
required	O
for	O
the	O
binding	B-FUNC
of	O
SARS	O
-	O
CoV	O
neutralizing	O
antibodies	O
targeting	O
the	O
CTD1	O
.	O

Total	O
RNA	O
isolated	O
from	O
allantoic	O
fluid	O
of	O
SPF	O
embryo	O
passaged	O
with	O
infected	O
chicken	O
sample	O
was	O
sequenced	O
by	O
whole	O
genome	O
shotgun	O
sequencing	O
using	O
ion	O
-	O
torrent	O
PGM	B-FUNC
platform	O
.	O

The	O
genome	O
was	O
comprised	O
of	O
13	O
bp	O
5	O
'-	O
UTR	O
,	O
three	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
including	O
ORF1a	O
encoding	O
serine	O
protease	O
,	O
ORF1b	O
encoding	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
ORF2	O
encoding	O
capsid	O
protein	O
,	O
and	O
298	O
bp	O
of	O
3	O
'-	O
UTR	O
which	O
harboured	O
two	O
corona	O
virus	O
stem	O
loop	O
II	O
like	O
""""	O
s2m	O
""""	O
motifs	O
and	O
a	O
poly	O
A	O
stretch	O
of	O
19	O
nucleotides	O
.	O

TITLE	O
:	O
Binding	B-FUNC
of	O
the	O
Methyl	O
Donor	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
nonstructural	O
protein	O
16	O
(	O
nsp16	O
)	O
is	O
an	O

We	O
report	O
here	O
the	O
efficacy	O
of	O
a	O
vaccine	O
consisting	O
of	O
chimeric	O
virus	O
-	O
like	O
particles	O
(	O
VLP	O
)	O
expressing	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
a	O
fusion	O
of	O
the	O
canine	O
parvovirus	O
(	O
CPV	O
)	O
VP2	O
structural	O
protein	O
gene	O
with	O
the	O
RBD	O
of	O
MERS	O
-	O
CoV	O
can	O
self	O
-	O
assemble	O
into	O
chimeric	O
,	O
spherical	O
VLP	O
(	O
sVLP	O
).	O

sVLP	O
-	O
specific	O
antisera	O
from	O
these	O
animals	O
were	O
able	O
to	O
prevent	O
pseudotyped	O
MERS	O
-	O
CoV	O
entry	O
into	O
susceptible	O
cells	O
,	O
with	O
neutralizing	O
antibody	B-FUNC
titers	O
reaching	O
1	O
:	O
320	O
.	O

In	O
vitro	O
binding	B-FUNC
studies	O
indicated	O
that	O
aa	O
148	O
-	O
294	O
of	O
N	O
and	O
aa	O
118	O
-	O
188	O
of	O
NPM1	O
were	O
required	O
for	O
binding	B-FUNC
.	O

In	O
addition	O
,	O
binding	B-FUNC
of	O
N	O
protein	O
to	O
NPM1	O
protects	O
it	O
from	O
proteolytic	O
degradation	O
by	O
caspase	O
-	O
3	O
,	O
leading	O
to	O
increased	O
cell	O
survival	O
.	O

His	O
non	O
-	O
structural	O
protein	O
1	O
antigen	O
and	O
Anti	O
-	O
DENV	O
Immunoglobulin	B-FUNC
M	O
tests	O
were	O
positive	O
.	O

TITLE	O
:	O
A	O
novel	O
swine	O
model	O
of	O
ricin	B-FUNC
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
,	O
the	O
monitoring	O
of	O
barometric	O
whole	O
body	O
plethysmography	O
for	O
pulmonary	O
function	O
tests	O
in	O
non	O
-	O
anesthetized	O
ricin	B-FUNC
-	O
treated	O
pigs	O
.	O

Ricin	B-FUNC
-	O
intoxicated	O
pigs	O
suffered	O
from	O
increased	O
lung	O
permeability	O
accompanied	O
by	O
cytokine	O
storming	O
.	O

Charting	O
the	O
decline	O
in	O
PaO2	O
/	O
FiO2	O
ratio	O
in	O
a	O
mechanically	O
ventilated	O
pig	O
confirmed	O
that	O
ricin	B-FUNC
-	O
induced	O
respiratory	O
damage	O
complies	O
with	O
the	O
accepted	O
diagnostic	O
criteria	O
for	O
ARDS	O
.	O

The	O
establishment	O
of	O
this	O
animal	O
model	O
of	O
pulmonary	O
ricinosis	O
should	O
help	O
in	O
the	O
pursuit	O
of	O
efficient	O
medical	O
countermeasures	O
specifically	O
tailored	O
to	O
deal	O
with	O
the	O
respiratory	O
deficiencies	O
stemming	O
from	O
ricin	B-FUNC
-	O
induced	O
ARDS	O
.	O

ABSTRACT	O
:	O
Ubiquitin	B-FUNC
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
)	O
is	O
immediately	O
adjacent	O
to	O
the	O
N	O
-	O
terminus	O
of	O
the	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
domain	O
in	O
coronavirus	O
polyproteins	O
,	O
and	O
it	O
may	O
play	O
a	O
critical	O
role	O
in	O
protease	O
regulation	O
and	O
stability	O
as	O
well	O
as	O
in	O
viral	O
infection	O
.	O

While	O
the	O
structures	O
were	O
nearly	O
identical	O
,	O
the	O
PLpro	O
-	O
Ubl2	O
enzyme	O
revealed	O
the	O
intact	O
structure	O
of	O
the	O
substrate	O
-	O
binding	B-FUNC
loop	O
.	O

This	O
single	O
-	O
sample	O
metabolite	O
,	O
protein	O
and	O
lipid	O
extraction	O
(	O
MPLEx	O
)	O
method	O
resulted	O
in	O
complete	O
inactivation	O
of	O
clinically	O
important	O
bacterial	O
and	O
viral	O
pathogens	O
with	O
exposed	O
lipid	O
membranes	O
,	O
including	O
Yersinia	O
pestis	O
,	O
Salmonella	O
Typhimurium	O
,	O
and	O
Campylobacter	O
jejuni	O
in	O
pure	B-FUNC
culture	O
,	O
and	O
Yersinia	O
pestis	O
,	O
Campylobacter	O
jejuni	O
,	O
and	O
West	O
Nile	O
,	O
MERS	O
-	O
CoV	O
,	O
Ebola	O
,	O
and	O
influenza	O
H7N9	O
viruses	O
in	O
infection	O
studies	O
.	O

TITLE	O
:	O
Effect	O
of	O
the	O
Protein	O
Corona	O
on	O
Antibody	B-FUNC
-	O
Antigen	B-FUNC
Binding	I-FUNC
in	O
Nanoparticle	O
Sandwich	O
Immunoassays	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
the	O
protein	O
corona	O
on	O
the	O
function	O
of	O
nanoparticle	O
(	O
NP	O
)	O
antibody	B-FUNC
(	O
Ab	O
)	O
conjugates	O
in	O
dipstick	O
sandwich	O
immunoassays	O
.	O

Langmuir	O
binding	B-FUNC
analysis	O
determined	O
how	O
the	O
immobilized	O
Ab	O
affinity	O
for	O
the	O
NP	O
-	O
Ab	O
/	O
NS1	O
was	O
impacted	O
by	O
corona	O
formation	O
conditions	O
,	O
quantified	O
as	O
an	O
effective	O
dissociation	O
constant	O
,	O
K	O

TITLE	O
:	O
Monitoring	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
and	O
its	O
soluble	O
receptor	O
levels	O
in	O
early	O
trauma	O
.	O

ABSTRACT	O
:	O
This	O
clinical	O
observation	O
study	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
serum	O
levels	O
of	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
and	O
its	O
soluble	O
receptors	O
with	O
the	O
severity	O
and	O
the	O
occurrence	O
of	O
late	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
early	O
trauma	O
.	O

Cytokine	O
analysis	O
revealed	O
that	O
the	O
level	O
of	O
serum	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
G	O
-	O
CSF	O
)	O
was	O
significantly	O
higher	O
in	O
both	O
CoV	O
-	O
CNS	O
and	O
CoV	O
-	O
respiratory	O
tract	O
infection	O
compared	O
with	O
healthy	O
controls	O
.	O

In	O
patients	O
with	O
CoV	O
-	O
CNS	O
infection	O
,	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
MCP	B-FUNC
-	O
1	O
,	O
and	O
GM	O
-	O
CSF	O
were	O
significantly	O
higher	O
in	O
their	O
cerebrospinal	O
fluid	O
samples	O
than	O
in	O
matched	O
serum	O
samples	O
.	O

TITLE	O
:	O
Clinical	O
validation	O
of	O
3	O
commercial	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assays	O
for	O
the	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
from	O
upper	O
respiratory	O
tract	O
specimens	O
.	O

ABSTRACT	O
:	O
Since	O
discovery	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
novel	O
betacoronavirus	O
first	O
isolated	O
and	O
characterized	O
in	O
2012	O
,	O
MERS	O
-	O
CoV	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
represent	O
one	O
of	O
the	O
most	O
rapidly	O
expanding	O
commercial	O
tests	O
.	O

TITLE	O
:	O
Reverse	O
transcriptase	B-FUNC
loop	O
-	O
mediated	O
isothermal	O
amplification	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
.	O

FmoPV	O
RNA	O
-	O
positive	O
cats	O
had	O
lower	O
median	O
red	O
blood	O
cell	O
count	O
,	O
haemoglobin	O
,	O
albumin	O
,	O
albumin	O
/	O
globulin	O
and	O
urobilinogen	O
and	O
higher	O
alanine	O
transaminase	O
,	O
alkaline	O
phosphatase	B-FUNC
and	O
bilirubin	O
compared	O
with	O
non	O
-	O
infected	O
cats	O
.	O

Cases	O
(	O
n	O
=	O
34	O
)	O
and	O
controls	O
(	O
n	O
=	O
86	O
)	O
were	O
compared	O
with	O
respect	O
to	O
bacteremia	O
(	O
as	O
defined	O
by	O
pure	B-FUNC
culture	O
of	O
a	O
single	O
bacterial	O
agent	O
from	O
lung	O
and	O
/	O
or	O
liver	O
),	O
species	O
of	O
bacteria	O
isolated	O
,	O
and	O
for	O
the	O
presence	O
of	O
K99	O
Escherichia	O
coli	O
(	O
calves	O
	O
5	O
d	O
),	O
attaching	O
and	O
effacing	O
E	O
.	O
coli	O
,	O
Cryptosporidium	O
(	O
calves	O
	O
5	O
d	O
of	O
age	O
),	O
Salmonella	O
isolation	O
from	O
the	O
intestine	O
,	O
rotavirus	O
,	O
Bovine	O
coronavirus	O
,	O
and	O
Bovine	O
viral	O
diarrhea	O
virus	O
.	O

The	O
absence	O
of	O
pure	B-FUNC
QX	O
-	O
like	O
viruses	O
before	O
the	O
appearance	O
of	O
the	O
early	O
viruses	O
suggests	O
that	O
the	O
viruses	O
were	O
introduced	O
from	O
other	O
countries	O
after	O
recombination	O
,	O
but	O
the	O
NC1	O
viruses	O
originated	O
in	O
Korea	O
.	O

MERS	O
-	O
CoV	O
infects	O
cells	O
via	O
its	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
that	O
binds	B-FUNC
on	O
Dipeptidyl	O
-	O
Peptidase	O
4	O
(	O
DPP4	O
)	O
receptor	O
present	O
on	O
macrophages	O
.	O

Herein	O
we	O
demonstrated	O
that	O
infection	O
of	O
macrophages	O
with	O
lentiviral	O
particles	O
pseudotyped	O
with	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
results	O
in	O
suppression	O
of	O
macrophage	O
responses	O
since	O
it	O
reduced	O
the	O
capacity	O
of	O
macrophages	O
to	O
produce	O
TNF	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
naive	O
and	O
LPS	O
-	O
activated	O
THP	O
-	O
1	O
macrophages	O
and	O
augmented	O
LPS	O
-	O
induced	O
production	O
of	O
the	O
immunosuppressive	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

Inhibition	O
of	O
DPP4	O
by	O
its	O
inhibitor	O
sitagliptin	O
or	O
siRNA	O
abrogated	O
the	O
effects	O
of	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
on	O
IRAK	O
-	O
M	O
,	O
PPAR	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
confirming	O
that	O
its	O
immunosuppressive	O
effects	O
were	O
mediated	O
by	O
DPP4	O
receptor	O
.	O

Expert	O
opinion	O
:	O
Vaccines	O
must	O
be	O
combined	O
with	O
delivery	O
systems	O
,	O
administration	O
routes	O
,	O
and	O
adjuvants	O
to	O
maximize	O
T	O
-	O
cell	O
responses	O
as	O
well	O
as	O
neutralizing	O
antibody	B-FUNC
production	O
.	O

Using	O
confocal	O
and	O
super	O
-	O
resolution	O
imaging	O
and	O
high	O
content	O
single	O
particle	O
tracking	O
,	O
we	O
investigated	O
DENV	O
binding	B-FUNC
,	O
DC	O
-	O
SIGN	O
surface	O
transport	O
,	O
endocytosis	O
,	O
as	O
well	O
as	O
cell	O
infectivity	O
.	O

As	O
the	O
patient	O
did	O
not	O
improve	O
after	O
3	O
days	O
of	O
antibiotics	O
and	O
donor	O
-	O
specific	O
HLA	O
antibodies	O
had	O
been	O
detected	O
,	O
an	O
acute	O
antibody	B-FUNC
-	O
mediated	O
graft	O
rejection	O
was	O
treated	O
with	O
high	O
-	O
dose	O
corticosteroids	O
,	O
plasma	O
exchange	O
,	O
intravenous	O
immunoglobulin	B-FUNC
,	O
and	O
rituximab	O
.	O

In	O
this	O
study	O
,	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
was	O
found	O
to	O
bind	B-FUNC
to	O
the	O
SPRY	O
domain	O
of	O
the	O
tripartite	O
motif	O
protein	O
25	O
(	O
TRIM25	O
)	O
E3	O
ubiquitin	B-FUNC
ligase	O
,	O
thereby	O
interfering	O
with	O
the	O
association	O
between	O
TRIM25	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
inhibiting	O
TRIM25	O
-	O
mediated	O
RIG	O
-	O
I	O
ubiquitination	O
and	O
activation	O
.	O

In	O
macrophages	O
we	O
found	O
immediate	O
induction	O
of	O
IFN	O
-	O
I	O
expression	O
and	O
RNase	O
L	O
-	O
mediated	O
breakdown	O
of	O
ribosomal	B-FUNC
RNA	I-FUNC
.	O

Generic	O
treatments	O
with	O
intravenous	O
immunoglobulin	B-FUNC
,	O
ribavirin	O
,	O
and	O
interferons	O
may	O
benefit	O
select	O
severe	O
viral	O
pneumonia	O
patients	O
,	O
whereas	O
cidofovir	O
has	O
activity	O
for	O
severe	O
adenoviral	O
pneumonia	O
.	O

Coronaviruses	O
(	O
26	O
-	O
34	O
kilobases	O
)	O
have	O
the	O
largest	O
known	O
RNA	O
genomes	O
and	O
their	O
replication	O
presumably	O
requires	O
a	O
processive	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
enzymatic	O
functions	O
that	O
suppress	O
the	O
consequences	O
of	O
the	O
typically	O
high	O
error	O
rate	O
of	O
viral	O
RdRps	O
.	O

The	O
RdRp	B-FUNC
domain	O
of	O
nidoviruses	O
resides	O
in	O
a	O
cleavage	O
product	O
of	O
the	O
replicase	O
polyprotein	O
named	O
non	O
-	O
structural	O
protein	O
(	O
nsp	O
)	O
12	O
in	O
coronaviruses	O
and	O
nsp9	O
in	O
arteriviruses	O
.	O

In	O
all	O
nidoviruses	O
,	O
the	O
C	O
-	O
terminal	O
RdRp	B-FUNC
domain	O
is	O
linked	O
to	O
a	O
conserved	O
N	O
-	O
terminal	O
domain	O
,	O
which	O
has	O
been	O
coined	O
NiRAN	O
(	O
nidovirus	O
RdRp	B-FUNC
-	O
associated	O
nucleotidyl	O
transferase	O
).	O

Although	O
no	O
structural	O
information	O
is	O
available	O
,	O
the	O
functional	O
characterization	O
of	O
the	O
nidovirus	O
RdRp	B-FUNC
and	O
the	O
larger	O
enzyme	O
complex	O
of	O
which	O
it	O
is	O
part	O
,	O
has	O
progressed	O
significantly	O
over	O
the	O
past	O
decade	O
.	O

Nevertheless	O
,	O
only	O
22	O
%	O
of	O
respondents	O
believed	O
that	O
camels	O
are	O
the	O
zoonotic	O
reservoir	O
of	O
MERS	O
-	O
CoV	O
.	O
Those	O
who	O
were	O
concerned	O
about	O
contracting	O
MERS	O
-	O
CoV	O
(	O
aOR	B-FUNC
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
2	O
-	O
2	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
those	O
who	O
thought	O
MERS	O
-	O
CoV	O
to	O
be	O
a	O
severe	O
disease	O
only	O
for	O
those	O
with	O
high	O
-	O
risk	O
conditions	O
(	O
aOR	B-FUNC
:	O
1	O
.	O
5	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
more	O
likely	O
to	O
believe	O
that	O
camels	O
are	O
the	O
zoonotic	O
source	O
.	O

However	O
,	O
residents	O
of	O
KSA	O
(	O
aOR	B-FUNC
:	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
01	O
-	O
0	O
.	O
07	O
,	O
p	O
<	O
0	O
.	O
01	O
),	O
UAE	O
(	O
aOR	B-FUNC
:	O
0	O
.	O
01	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
004	O
-	O
0	O
.	O
02	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
Kuwait	O
(	O
aOR	B-FUNC
:	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
01	O
-	O
0	O
.	O
07	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
less	O
likely	O
to	O
believe	O
that	O
camels	O
are	O
the	O
main	O
zoonotic	O
source	O
compared	O
to	O
respondents	O
from	O
the	O
other	O
countries	O
.	O

Laboratory	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
dromedaries	O
can	O
be	O
achieved	O
through	O
virus	O
isolation	O
using	O
Vero	O
cells	O
,	O
RNA	O
detection	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
and	O
antigen	O
detection	O
using	O
respiratory	O
specimens	O
or	O
serum	O
.	O

With	O
increasing	O
numbers	O
of	O
infections	O
and	O
deaths	O
from	O
MERS	O
-	O
CoV	O
,	O
development	O
of	O
a	O
rapid	O
and	O
reliable	O
kit	B-FUNC
was	O
crucial	O
to	O
prevent	O
further	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
we	O
present	O
two	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
for	O
in	O
-	O
house	O
rapid	O
and	O
sensitive	O
diagnostic	O
testing	O
of	O
MERS	O
-	O
CoV	O
,	O
detecting	O
the	O
regions	O
upstream	O
of	O
the	O
envelope	O
gene	O
(	O
upE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
,	O
respectively	O
,	O
for	O
initial	O
screening	O
and	O
final	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
infection	O
,	O
as	O
recommended	O
by	O
the	O
world	O
health	O
organization	O
(	O
WHO	O
).	O

This	O
study	O
showed	O
that	O
the	O
developed	O
rRT	O
-	O
PCR	O
assays	O
are	O
rapid	O
,	O
reliable	O
,	O
reproducible	O
,	O
specific	O
,	O
sensitive	O
,	O
and	O
simple	O
tools	O
for	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
Finally	O
,	O
a	O
kit	B-FUNC
consisting	O
of	O
two	O
assay	O
signatures	O
and	O
controls	O
was	O
assembled	O
,	O
which	O
can	O
be	O
distributed	O
to	O
public	O
health	O
laboratories	O
in	O
Iran	O
to	O
support	O
international	O
MERS	O
-	O
CoV	O
surveillance	O
and	O
public	O
health	O
response	O
.	O

These	O
characteristics	O
of	O
HCoV	O
-	O
OC43	O
may	O
affect	O
viral	O
replication	O
dynamics	O
,	O
receptor	B-FUNC
binding	I-FUNC
,	O
antigenicity	O
,	O
evolution	O
,	O
transmission	O
,	O
and	O
clinical	O
illness	O
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
antibody	B-FUNC
-	O
based	O
assays	O
is	O
important	O
for	O
detecting	O
infected	O
animals	O
,	O
confirming	O
previous	O
virus	O
exposure	O
,	O
and	O
monitoring	O
sow	O
herd	O
immunity	O
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
nsp5	O
-	O
ELISA	O
for	O
the	O
detection	O
of	O
antibody	B-FUNC
to	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
current	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
for	O
IBV	O
specific	O
antibody	B-FUNC
detection	O
are	O
mostly	O
based	O
on	O
the	O
whole	O
virion	O
,	O
and	O
few	O
serological	O
tests	O
based	O
on	O
nonstructural	O
proteins	O
of	O
IBV	O
have	O
been	O
developed	O
.	O

Using	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
and	O
a	O
commercial	O
ELISA	O
kit	B-FUNC
as	O
reference	O
,	O
we	O
optimized	O
the	O
nsp5	O
-	O
ELISA	O
and	O
determined	O
its	O
cut	O
-	O
off	O
as	O
0	O
.	O
12	O
.	O

Furthermore	O
,	O
a	O
time	O
course	O
of	O
IBV	O
specific	O
antibody	B-FUNC
level	O
detected	O
by	O
nsp5	O
-	O
ELISA	O
following	O
IBV	O
infection	O
and	O
vaccination	O
is	O
consistent	O
with	O
that	O
of	O
IBV	O
antibody	B-FUNC
detected	O
by	O
the	O
commercial	O
ELISA	O
kit	B-FUNC
.	O

The	O
results	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
nsp5	O
-	O
ELISA	O
has	O
the	O
potential	O
to	O
serve	O
as	O
a	O
rapid	O
,	O
reliable	O
and	O
cost	O
-	O
effective	O
method	O
for	O
IBV	O
antibody	B-FUNC
detection	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
development	O
of	O
an	O
nsp	O
-	O
based	O
ELISA	O
to	O
detect	O
an	O
antibody	B-FUNC
to	O
IBV	O
.	O

A	O
binding	B-FUNC
domain	O
that	O
mediates	O
the	O
attachment	O
of	O
the	O
virus	O
to	O
its	O
receptor	O
has	O
been	O
identified	O
in	O
the	O
S1	O
protein	O
of	O
prototype	O
IBV	O
strain	O
M41	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
this	O
binding	B-FUNC
domain	O
in	O
a	O
different	O
strain	O
,	O
as	O
well	O
as	O
the	O
cellular	O
proteins	O
that	O
interact	O
with	O
it	O
.	O

TITLE	O
:	O
Comparison	O
of	O
Luminex	O
NxTAG	O
Respiratory	O
Pathogen	O
Panel	O
and	O
xTAG	O
Respiratory	O
Viral	O
Panel	O
FAST	B-FUNC
Version	O
2	O
for	O
the	O
Detection	O
of	O
Respiratory	O
Viruses	O
.	O

We	O
compared	O
the	O
clinical	O
performance	O
of	O
this	O
new	O
assay	O
with	O
that	O
of	O
the	O
xTAG	O
respiratory	O
viral	O
panel	O
(	O
xTAG	O
RVP	O
)	O
FAST	B-FUNC
v2	O
using	O
142	O
clinical	O
samples	O
and	O
12	O
external	O
quality	O
assessment	O
samples	O
.	O

It	O
detected	O
one	O
coronavirus	O
229E	O
and	O
eight	O
influenza	O
A	O
/	O
H3N2	O
viruses	O
that	O
were	O
missed	O
by	O
the	O
xTAG	O
RVP	O
FAST	B-FUNC
v2	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
NxTAG	O
RPP	O
missed	O
one	O
enterovirus	O
/	O
rhinovirus	O
and	O
one	O
metapneumovirus	O
that	O
were	O
detected	O
by	O
FAST	B-FUNC
v2	O
.	O

Of	O
note	O
,	O
it	O
was	O
better	O
able	O
to	O
subtype	O
the	O
influenza	O
A	O
/	O
H3N2	O
viruses	O
compared	O
with	O
the	O
xTAG	O
RVP	O
FAST	B-FUNC
v2	O
.	O

CBP	O
treatment	O
cleared	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
partially	O
from	O
serum	O
and	O
BALF	O
.	O

Although	O
Thai	O
PEDV	O
have	O
been	O
evolved	O
into	O
6	O
subgroups	O
(	O
TH1	O
-	O
6	O
),	O
Subgroup	O
TH1	O
strains	O
with	O
the	O
unique	O
9	O
nucleotides	O
(	O
CAA	O
GGG	O
AAT	B-FUNC
)	O
insertion	O
between	O
688th	O
-	O
689th	O
position	O
of	O
spike	O
(	O
changing	O
amino	O
acid	O
from	O
N	O
to	O
TREY	O
)	O
insertion	O
has	O
become	O
the	O
dominant	O
subgroup	O
since	O
2014	O
.	O

There	O
are	O
currently	O
no	O
approved	O
therapeutics	O
or	O
vaccinations	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
virion	O
entry	O
to	O
cells	O
,	O
is	O
immunodominant	O
and	O
induces	O
neutralizing	O
antibodies	O
in	O
vivo	O
,	O
all	O
of	O
which	O
,	O
make	O
the	O
S	O
protein	O
an	O
ideal	O
target	O
for	O
anti	O
-	O
MERS	O
-	O
CoV	O
vaccines	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
different	O
testing	O
modalities	O
available	O
for	O
the	O
ongoing	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
epidemic	O
including	O
cell	O
culture	O
,	O
nucleic	O
acid	O
amplification	O
,	O
antigen	O
detection	O
,	O
and	O
antibody	B-FUNC
detection	O
assays	O
.	O

Interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
8	O
,	O
interleukin	O
-	O
10	O
,	O
interleukin	O
-	O
18	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
R2	O
were	O
each	O
strongly	O
associated	O
with	O
all	O
-	O
cause	O
mortality	O
,	O
multiple	O
markers	O
of	O
ICU	O
morbidity	O
,	O
and	O
endothelial	O
injury	O
.	O

A	O
multiple	O
logistic	O
regression	O
model	O
incorporating	O
oxygenation	O
index	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
R2	O
was	O
superior	O
to	O
a	O
model	O
of	O
oxygenation	O
index	O
alone	O
in	O
predicting	O
the	O
composite	O
outcome	O
of	O
mortality	O
or	O
severe	O
morbidity	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
,	O
0	O
.	O
77	O
[	O
0	O
.	O
70	O
-	O
0	O
.	O
83	O
]	O
vs	O
0	O
.	O
70	O
[	O
0	O
.	O
62	O
-	O
0	O
.	O
77	O
];	O
p	O
=	O
0	O
.	O
042	O
).	O

We	O
also	O
discussed	O
the	O
substrate	O
selection	O
and	O
binding	B-FUNC
mode	O
of	O
PDCoV	O
nsp5	O
by	O
homologous	O
modeling	O
of	O
PDCoV	O
nsp5	O
with	O
the	O
two	O
cleaved	O
peptide	O
substrates	O
.	O

The	O
number	O
of	O
residues	O
and	O
total	O
interactions	O
with	O
ubiquitin	B-FUNC
were	O
lower	O
for	O
the	O
MERS	O
CoV	O
Plpro	O
than	O
for	O
the	O
SARS	O
CoV	O
.	O
These	O
factors	O
contribute	O
to	O
the	O
lower	O
deubiquitinating	O
actions	O
of	O
MERS	O
CoV	O
NSP3	O
and	O
its	O
subsequently	O
lower	O
interaction	O
with	O
the	O
host	O
immune	O
system	O
.	O

IFIT1	O
forms	O
a	O
water	O
-	O
filled	O
,	O
positively	O
charged	O
RNA	O
-	O
binding	B-FUNC
tunnel	O
with	O
a	O
separate	O
hydrophobic	O
extension	O
that	O
unexpectedly	O
engages	O
the	O
cap	O
in	O
multiple	O
conformations	O
(	O

TITLE	O
:	O
Natural	O
product	O
-	O
inspired	O
esters	O
and	O
amides	O
of	O
ferulic	O
and	O
caffeic	O
acid	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
.	O

ABSTRACT	O
:	O
Using	O
an	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
RNase	O
H	O
inhibition	O
assay	O
as	O
lead	O
,	O
bioguided	O
fractionation	O
of	O
the	O
dichloromethane	O
extract	O
of	O
the	O
Ocimum	O
sanctum	O
leaves	O
led	O
to	O
the	O
isolation	O
of	O
five	O
triterpenes	O
(	O
1	O
-	O
5	O
)	O
along	O
with	O
three	O
3	O
-	O
methoxy	O
-	O
4	O
-	O
hydroxy	O
phenyl	O
derivatives	O
(	O
6	O
-	O
8	O
).	O

Following	O
BD	O
administration	O
,	O
the	O
ACOS	O
patients	O
exhibited	O
lower	O
left	O
LH	O
,	O
bilateral	O
APLD	O
,	O
and	O
bilateral	O
ASDA	O
,	O
but	O
higher	O
right	O
DH	O
,	O
compared	O
to	O
pure	B-FUNC
COPD	O
patients	O
(	O
P	O
values	O
all	O
<	O
0	O
.	O
05	O
).	O

Besides	O
,	O
variations	O
of	O
all	O
sagittal	O
-	O
lung	O
CT	O
measurements	O
were	O
significantly	O
larger	O
in	O
patients	O
with	O
ACOS	O
than	O
in	O
patients	O
with	O
pure	B-FUNC
COPD	O
(	O
P	O
values	O
all	O
<	O
0	O
.	O
001	O
)	O
and	O
showed	O
high	O
performance	O
in	O
differentiating	O
these	O
two	O
kinds	O
of	O
patient	O
,	O
with	O
diagnostic	O
sensitivities	O
ranging	O
from	O
76	O
.	O
4	O
to	O
97	O
.	O
2	O
%,	O
specificities	O
ranging	O
from	O
86	O
.	O
2	O
to	O
100	O
.	O
0	O
%,	O
and	O
accuracies	O
ranging	O
from	O
80	O
.	O
9	O
to	O
90	O
.	O
7	O
%.	O

Sagittal	O
-	O
lung	O
CT	O
measurements	O
allow	O
for	O
differentiating	O
patients	O
with	O
ACOS	O
from	O
those	O
with	O
pure	B-FUNC
COPD	O
.	O

The	O
ACOS	O
patients	O
had	O
larger	O
post	O
-	O
BD	O
variations	O
of	O
sagittal	O
-	O
lung	O
CT	O
measurements	O
than	O
patients	O
with	O
pure	B-FUNC
COPD	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
dimerization	O
and	O
RNA	B-FUNC
binding	I-FUNC
of	O
avian	O
infectious	O
bronchitis	O
virus	O
nsp9	O
.	O

We	O
found	O
that	O
three	O
residues	O
are	O
critical	O
for	O
nsp9	O
dimerization	O
and	O
its	O
abitlity	O
to	O
bind	B-FUNC
RNA	O
.	O

ABSTRACT	O
:	O
PTA	B-FUNC
is	O
a	O
collection	O
of	O
pus	O
located	O
between	O
the	O
tonsillar	O
capsule	O
and	O
the	O
pharyngeal	O
constrictor	O
muscle	O
.	O

Group	O
A	O
streptococcus	O
(	O
GAS	O
)	O
is	O
the	O
only	O
established	O
pathogen	O
in	O
PTA	B-FUNC
.	O

Culturing	O
of	O
PTA	B-FUNC
pus	O
aspirates	O
often	O
yields	O
a	O
polymicrobial	O
mixture	O
of	O
aerobes	O
and	O
anaerobes	O
.	O

In	O
addition	O
,	O
when	O
studying	O
PTA	B-FUNC
microbiology	O
,	O
one	O
must	O
consider	O
diagnostic	O
precision	O
,	O
collection	O
,	O
handling	O
,	O
and	O
transportation	O
of	O
appropriate	O
specimens	O
,	O
choice	O
of	O
methodology	O
for	O
detection	O
and	O
quantification	O
of	O
microorganisms	O
,	O
current	O
or	O
recent	O
antibiotic	O
treatment	O
of	O
patients	O
,	O
potential	O
shift	O
in	O
significant	O
pathogens	O
during	O
the	O
course	O
of	O
infection	O
,	O
and	O
factors	O
associated	O
with	O
increased	O
risk	O
of	O
PTA	B-FUNC
development	O
.	O

The	O
trend	O
towards	O
de	O
-	O
escalated	O
surgical	O
intervention	O
and	O
increasing	O
reliance	O
on	O
antibiotic	O
treatment	O
,	O
require	O
studies	O
defining	O
the	O
significant	O
pathogens	O
in	O
PTA	B-FUNC
in	O
order	O
to	O
determine	O
optimal	O
antibiotic	O
regimens	O
.	O

Complications	O
secondary	O
to	O
PTA	B-FUNC
may	O
be	O
avoided	O
or	O
better	O
controlled	O
with	O
improved	O
knowledge	O
concerning	O
the	O
significant	O
pathogens	O
in	O
PTA	B-FUNC
.	O

Furthermore	O
,	O
we	O
occationally	O
observed	O
concomitant	O
PPA	O
in	O
addition	O
to	O
a	O
PTA	B-FUNC
,	O
which	O
made	O
us	O
hypothesize	O
that	O
PPA	O
and	O
PTA	B-FUNC
is	O
often	O
closely	O
related	O
and	O
may	O
share	O
significant	O
pathogens	O
.	O

To	O
elucidate	O
whether	O
smoking	O
,	O
age	O
,	O
gender	O
,	O
and	O
seasons	O
are	O
risk	O
factors	O
for	O
the	O
development	O
of	O
PTA	B-FUNC
.	O

To	O
characterize	O
patients	O
with	O
PPA	O
,	O
explore	O
the	O
relationship	O
between	O
PPA	O
and	O
PTA	B-FUNC
,	O
identify	O
the	O
pathogens	O
associated	O
with	O
PPA	O
,	O
and	O
review	O
our	O
management	O
of	O
PPA	O
.	O

In	O
a	O
subsequent	O
prospective	O
and	O
comparative	O
study	O
on	O
36	O
PTA	B-FUNC
patients	O
and	O
80	O
patients	O
undergoing	O
elective	O
tonsillectomy	O
(	O
controls	O
),	O
we	O
recovered	O
FN	O
from	O
58	O
%	O
of	O
PTA	B-FUNC
aspirates	O
.	O

Furthermore	O
,	O
FN	O
was	O
detected	O
significantly	O
more	O
frequently	O
in	O
the	O
tonsillar	O
cores	O
of	O
PTA	B-FUNC
patients	O
(	O
56	O
%)	O
compared	O
to	O
the	O
tonsillar	O
cores	O
of	O
the	O
controls	O
(	O
24	O
%)	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

We	O
found	O
increasing	O
levels	O
(	O
at	O
least	O
two	O
-	O
fold	O
)	O
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
eight	O
of	O
11	O
FN	O
-	O
positive	O
(	O
in	O
the	O
tonsillar	O
cultures	O
)	O
PTA	B-FUNC
patients	O
,	O
which	O
was	O
significantly	O
more	O
frequent	O
compared	O
to	O
none	O
of	O
four	O
FN	O
-	O
negative	O
PTA	B-FUNC
patients	O
and	O
nine	O
of	O
47	O
electively	O
tonsillectomized	O
controls	O
(	O
P	O
=	O
0	O
.	O
026	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

However	O
,	O
bacteremia	O
during	O
elective	O
tonsillectomy	O
was	O
at	O
least	O
as	O
prevalent	O
as	O
bacteremia	O
during	O
quinsy	O
tonsillectomy	O
,	O
which	O
challenges	O
the	O
distinction	O
made	O
by	O
the	O
European	O
Society	O
of	O
Cardiology	O
between	O
quinsy	O
and	O
elective	O
tonsillectomy	O
,	O
namely	O
that	O
antibiotic	O
prophylaxis	O
is	O
only	O
recommended	O
to	O
patients	O
undergoing	O
procedures	O
to	O
treat	O
an	O
established	O
infection	O
(	O
i	O
.	O
e	O
.	O
PTA	B-FUNC
).	O

Using	O
PCR	O
analysis	O
for	O
the	O
presence	O
of	O
herpes	O
simplex	O
1	O
and	O
2	O
,	O
adenovirus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
we	O
explored	O
a	O
possible	O
role	O
of	O
viruses	O
in	O
PTA	B-FUNC
.	O

However	O
,	O
our	O
results	O
did	O
not	O
indicate	O
that	O
any	O
of	O
these	O
viruses	O
are	O
involved	O
in	O
the	O
development	O
of	O
PTA	B-FUNC
.	O

Privious	O
studies	O
have	O
documented	O
an	O
association	O
between	O
EBV	O
and	O
PTA	B-FUNC
in	O
approximately	O
4	O
%	O
of	O
PTA	B-FUNC
cases	O
.	O

In	O
addition	O
to	O
the	O
involvement	O
of	O
GAS	O
,	O
the	O
following	O
findings	O
suggest	O
a	O
pathogenic	O
role	O
for	O
FN	O
in	O
PTA	B-FUNC
:	O
1	O
.	O

Repeated	O
high	O
isolation	O
rates	O
of	O
FN	O
in	O
PTA	B-FUNC
pus	O
aspirates	O
.	O

Higher	O
isolation	O
rates	O
in	O
PTA	B-FUNC
patients	O
compared	O
to	O
electively	O
tonsillectomised	O
controls	O
.	O

Development	O
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
patients	O
with	O
PTA	B-FUNC
.	O

We	O
studied	O
the	O
smoking	O
habits	O
among	O
the	O
same	O
847	O
PTA	B-FUNC
patients	O
admitted	O
to	O
the	O
ENT	O
department	O
,	O
AUH	O
from	O
2001	O
to	O
2006	O
.	O

We	O
found	O
that	O
smoking	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
PTA	B-FUNC
for	O
both	O
genders	O
and	O
across	O
all	O
age	O
groups	O
.	O

The	O
increased	O
risk	O
of	O
PTA	B-FUNC
among	O
smokers	O
was	O
not	O
related	O
to	O
specific	O
bacteria	O
.	O

Conclusions	O
on	O
causality	O
cannot	O
be	O
drawn	O
from	O
this	O
retrospective	O
study	O
,	O
but	O
the	O
pathophysiology	O
behind	O
the	O
increased	O
risk	O
of	O
PTA	B-FUNC
in	O
smokers	O
may	O
be	O
related	O
to	O
,	O
previously	O
shown	O
,	O
alterations	O
in	O
the	O
tonsillar	O
,	O
bacterial	O
flora	O
or	O
the	O
local	O
and	O
systemical	O
inflammatory	O
and	O
immunological	O
milieu	O
.	O

Studying	O
all	O
1	O
,	O
620	O
patients	O
with	O
PTA	B-FUNC
in	O
Aarhus	O
County	O
from	O
2001	O
to	O
2006	O
and	O
using	O
population	O
data	O
for	O
Aarhus	O
County	O
for	O
the	O
same	O
six	O
years	O
,	O
age	O
-	O
and	O
gender	O
-	O
stratified	O
mean	O
annual	O
incidence	O
rates	O
of	O
PTA	B-FUNC
were	O
calculated	O
.	O

The	O
seasonal	O
variation	O
of	O
PTA	B-FUNC
was	O
insignificant	O
.	O

In	O
a	O
series	O
of	O
63	O
patients	O
with	O
PPA	O
,	O
we	O
found	O
that	O
33	O
(	O
52	O
%)	O
patients	O
had	O
concomitant	O
PTA	B-FUNC
.	O

Furthermore	O
,	O
cultures	O
made	O
from	O
PTA	B-FUNC
aspirates	O
should	O
include	O
a	O
selective	O
FN	O
-	O
agar	O
plate	O
in	O
order	O
to	O
identify	O
growth	O
of	O
this	O
bacterium	O
.	O

FN	O
is	O
a	O
significant	O
and	O
prevalent	O
pathogen	O
in	O
PTA	B-FUNC
.	O

The	O
development	O
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
PTA	B-FUNC
patients	O
.	O

In	O
summary	O
,	O
a	O
single	O
infection	O
at	O
gilt	O
acclimatization	O
resulted	O
in	O
slightly	O
increased	O
serum	O
antibody	B-FUNC
titers	O
as	O
determined	O
by	O
VN	O
assay	O
and	O
IgG	O
ELISA	O
,	O
but	O
not	O
by	O
IgA	O
ELISA	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
fragment	O
containing	O
residues	O
377	O
-	O
588	O
of	O
MERS	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
is	O
a	O
critical	O
neutralizing	O
domain	O
and	O
an	O
important	O
vaccine	O
target	O
.	O

1CoV	O
receptor	B-FUNC
binding	I-FUNC
is	O
typically	O
controlled	O
by	O
attachment	O
/	O
fusion	O
spike	O
protein	O
S	O
and	O
receptor	O
-	O
binding	B-FUNC
/	O
receptor	O
-	O
destroying	O
hemagglutinin	O
-	O
esterase	O
protein	O
HE	O
.	O

We	O
show	O
that	O
following	O
OC43	O
'	O
s	O
introduction	O
into	O
humans	O
,	O
HE	O
-	O
mediated	O
receptor	B-FUNC
binding	I-FUNC
was	O
selected	O
against	O
and	O
ultimately	O
lost	O
through	O
progressive	O
accumulation	O
of	O
mutations	O
in	O
the	O
HE	O
lectin	O
domain	O
.	O

Serological	O
data	O
suggest	O
that	O
lineage	O
A	O
betacoronavirus	O
infections	O
are	O
commonly	O
infecting	O
horses	O
in	O
Saudi	O
Arabia	O
and	O
Oman	O
but	O
antibody	B-FUNC
cross	O
-	O
reactivities	O
between	O
these	O
viruses	O
do	O
not	O
permit	O
us	O
to	O
use	O
serological	O
data	O
alone	O
to	O
identify	O
which	O
coronaviruses	O
are	O
causing	O
these	O
infections	O
.	O

PELs	O
are	O
approximately	O
100	O
-	O
nm	O
drug	O
carriers	O
coated	O
with	O
antibodies	O
that	O
bind	B-FUNC
to	O
the	O
pulmonary	O
capillary	O
endothelium	O
.	O

In	O
addition	O
,	O
mutations	O
of	O
the	O
catalytic	O
residues	O
of	O
PLP	O
-	O
TM	O
,	O
Cys1274Ser	O
and	O
His1437Lys	O
,	O
reduced	O
DUB	O
activity	O
against	O
Ub	O
-,	O
K48	O
-	O
and	O
K63	O
-	O
conjugated	O
proteins	O
,	O
indicating	O
that	O
the	O
DUB	O
activity	O
of	O
the	O
PLP	O
-	O
TM	O
wild	O
-	O
type	O
protein	O
is	O
not	O
completely	O
dependent	O
on	O
its	O
catalytic	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
suppresses	O
the	O
infection	O
of	O
porcine	O
enteric	O
coronaviruses	O
and	O
rotavirus	O
by	O
activating	O
STAT3	O
signal	O
pathway	O
.	O

ABSTRACT	O
:	O
Interleukin	O
-	O
22	O
(	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
),	O
a	O
member	O
of	O
the	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
superfamily	O
,	O
plays	O
essential	O
roles	O
in	O
fighting	O
against	O
mucosal	O
microbial	O
infection	O
and	O
maintaining	O
mucosal	O
barrier	O
integrity	O
within	O
the	O
intestine	O
.	O

However	O
,	O
little	O
knowledge	O
exists	O
on	O
the	O
ability	O
of	O
porcine	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
(	O
pIL	O
-	O
22	O
)	O
to	O
fight	O
against	O
viral	O
infection	O
in	O
the	O
gut	O
.	O

mpIL	O
-	O
22	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
the	O
antimicrobial	O
peptide	O
beta	O
-	O
defensin	O
(	O
BD	O
-	O
2	O
),	O
cytokine	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
and	O
IFN	O
-	O
	O
.	O

Inhibition	O
of	O
STAT3	O
phosphorylation	O
by	O
S3I	O
-	O
201	O
abrogated	O
the	O
antiviral	O
ability	O
of	O
mpIL	O
-	O
22	O
and	O
the	O
mpIL	O
-	O
22	O
-	O
induced	O
expression	O
of	O
BD	O
-	O
2	O
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
and	O
IFN	O
-	O
	O
.	O

Moreover	O
,	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
RNA	B-FUNC
binding	I-FUNC
and	O
nucleocapsid	O
formation	O
remains	O
incomplete	O
.	O

A	O
total	O
of	O
1	O
,	O
031	O
sera	B-FUNC
,	O
1	O
,	O
078	O
nasal	O
swabs	O
,	O
13	O
rectal	O
swabs	O
,	O
and	O
38	O
milk	O
samples	O
were	O
collected	O
from	O
1	O
,	O
078	O
camels	O
in	O
different	O
types	O
of	O
sites	O
.	O

ABSTRACT	O
:	O
The	O
inflammatory	O
chemokine	O
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
inducible	O
protein	O
of	O
10kDa	O
(	O
IP	O
-	O
10	O
),	O
is	O
a	O
biomarker	O
associated	O
with	O
several	O
conditions	O
.	O

Compared	O
to	O
treatment	O
with	O
the	O
prototypical	O
inflammatory	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
HCoV	O
-	O
229E	O
replication	O
was	O
found	O
to	O
attenuate	O
the	O
inducible	O
activity	O
of	O
the	O
transcription	O
factor	O
(	O
TF	O
)	O
NF	O
-	O
B	O
and	O
to	O
restrict	O
the	O
nuclear	O
concentration	O
of	O
NF	O
-	O
B	O
subunits	O
by	O
(	O
i	O
)	O
an	O
unusual	O
mechanism	O
involving	O
partial	O
degradation	O
of	O
IKK	O
,	O
NEMO	O
and	O
IB	O
and	O
(	O
ii	O
)	O
upregulation	O
of	O
TNFAIP3	O
(	O
A20	O
),	O
although	O
constitutive	O
IKK	B-FUNC
activity	O
and	O
basal	O
TNFAIP3	O
expression	O
levels	O
were	O
shown	O
to	O
be	O
required	O
for	O
efficient	O
virus	O
replication	O
.	O

Furthermore	O
,	O
both	O
HCoV	O
-	O
229E	O
replication	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
were	O
shown	O
to	O
upregulate	O
a	O
small	O
set	O
of	O
genes	O
encoding	O
immunomodulatory	O
factors	O
that	O
bind	B-FUNC
p65	O
at	O
promoters	O
and	O
require	O
IKK	O
activity	O
and	O
p65	O
for	O
expression	O
.	O

Also	O
,	O
HCoV	O
-	O
229E	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
activated	O
a	O
common	O
set	O
of	O
440	O
p65	O
-	O
bound	O
enhancers	O
that	O
differed	O
from	O
another	O
992	O
HCoV	O
-	O
229E	O
-	O
specific	O
enhancer	O
regions	O
by	O
distinct	O
TF	O
-	O
binding	B-FUNC
motif	O
combinations	O
.	O

Microneutralization	O
assays	O
and	O
ELISpot	O
analysis	O
demonstrated	O
that	O
PEDV	O
VLPs	O
induced	O
highly	O
specific	O
antibody	B-FUNC
responses	O
and	O
Th2	O
-	O
mediated	O
humoral	O
immunity	O
.	O

Endobronchial	O
valves	O
(	O
EBV	O
)	O
are	O
frequently	O
deployed	O
after	O
pulmonary	O
resection	O
in	O
noncritically	O
ill	O
patients	O
to	O
reduce	O
and	O
eliminate	O
bronchopleural	O
fistulas	O
(	O
BPFs	O
)	O
with	O
persistent	O
air	O
leak	O
(	O
PAL	B-FUNC
).	O

In	O
each	O
case	O
,	O
EBV	O
placement	O
led	O
to	O
immediate	O
resolution	O
of	O
PAL	B-FUNC
.	O

Comparison	O
of	O
particle	O
stability	O
and	O
protein	O
corona	O
formation	O
in	O
media	O
containing	O
sera	B-FUNC
from	O
different	O
species	O
suggests	O
that	O
NPpT	O
-	O
CA	O
has	O
been	O
activated	O
and	O
opsonized	O
in	O
mouse	O
blood	O
to	O
a	O
greater	O
extent	O
than	O
those	O
in	O
bovine	O
serum	O
-	O
containing	O
medium	O
,	O
thus	O
losing	O
the	O
benefits	O
of	O
pH	O
-	O
sensitivity	O
expected	O
from	O
in	O
vitro	O
experiments	O
.	O

After	O
adjusting	O
for	O
severity	O
of	O
illness	O
,	O
risk	O
factors	O
for	O
mortality	O
were	O
:	O
hospital	O
acquired	O
pneumonia	O
(	O
HAP	O
)	O
(	O
aOR	B-FUNC
:	O
2	O
.	O
92	O
[	O
95	O
%	O
CI	O
1	O
.	O
15	O
,	O
7	O
.	O
40	O
];	O
P	O
=	O
0	O
.	O
024	O
)	O
and	O
bacteremia	O
(	O
aOR	B-FUNC
:	O
5	O
.	O
03	O
[	O
95	O
%	O
CI	O
1	O
.	O
77	O
,	O
14	O
.	O
35	O
];	O
P	O
=	O
0	O
.	O
003	O
).	O

After	O
adjusting	O
for	O
severity	O
of	O
illness	O
,	O
risk	O
factors	O
for	O
mortality	O
were	O
:	O
hospital	O
acquired	O
pneumonia	O
(	O
HAP	O
)	O
(	O
aOR	B-FUNC
:	O
2	O
.	O
92	O
[	O
95	O
%	O
CI	O
1	O
.	O
15	O
,	O
7	O
.	O
40	O
];	O
P	O
=	O
0	O
.	O
024	O
)	O
and	O
bacteremia	O
(	O
aOR	B-FUNC
:	O
5	O
.	O
03	O
[	O
95	O
%	O
CI	O
1	O
.	O
77	O
,	O
14	O
.	O
35	O
];	O
P	O
=	O
0	O
.	O
003	O
).	O

HIV	O
-	O
1	O
IN	O
and	O
Reverse	O
Transcriptase	B-FUNC
-	O
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
active	O
sites	O
show	O
structural	O
homologies	O
,	O
with	O
the	O
presence	O
of	O
two	O
Mg	O
(	O
II	O
)	O
cofactors	O
,	O
hence	O
it	O
seems	O
possible	O
to	O
inhibit	O
both	O
enzymes	O
by	O
means	O
of	O
chelating	O
ligands	O
with	O
analogous	O
structural	O
features	O
.	O

Body	O
temperature	O
of	O
	O
38	O
.	O
5	O
	O
C	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-FUNC
],	O
5	O
.	O
54	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
38	O
-	O
22	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
016	O
),	O
pulmonary	O
infiltration	O
of	O
	O
3	O
lung	O
zones	O
(	O
aOR	B-FUNC
,	O
7	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
93	O
-	O
27	O
.	O
79	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
a	O
more	O
nonisolated	O
in	O
-	O
hospital	O
days	O
(	O
aOR	B-FUNC
,	O
1	O
.	O
32	O
per	O
1	O
day	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
1	O
.	O
60	O
;	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
significant	O
risk	O
factors	O
in	O
the	O
spreader	O
group	O
.	O

For	O
classification	O
,	O
sensitivities	O
and	O
specificities	O
for	O
ACR	O
classification	O
criteria	O
were	O
,	O
respectively	O
,	O
81	O
.	O
1	O
%	O
and	O
94	O
.	O
9	O
%	O
for	O
GCA	B-FUNC
;	O
73	O
.	O
6	O
%	O
and	O
98	O
.	O
3	O
%	O
for	O
Takayasu	O
'	O
s	O
arteritis	O
;	O
65	O
.	O
6	O
%	O
and	O
88	O
.	O
7	O
%	O
for	O
granulomatosis	O
with	O
polyangiitis	O
;	O
57	O
.	O
0	O
%	O
and	O
99	O
.	O
8	O
%	O
for	O
eosinophilic	O
granulomatosis	O
with	O
polyangiitis	O
;	O
40	O
.	O
6	O
%	O
and	O
87	O
.	O
8	O
%	O
for	O
polyarteritis	O
nodosa	O
;	O
28	O
.	O
9	O
%	O
and	O
88	O
.	O
5	O
%	O
for	O
microscopic	O
polyangiitis	O
;	O
and	O
72	O
.	O
7	O
%	O
and	O
96	O
.	O
3	O
%	O
for	O
IgA	O
-	O
vasculitis	O
.	O

To	O
systematically	O
investigate	O
the	O
genetic	O
diversity	O
of	O
RVAs	O
,	O
547	O
bat	O
anal	O
swabs	O
or	O
gut	O
samples	O
along	O
with	O
448	O
bat	O
sera	B-FUNC
were	O
collected	O
from	O
five	O
South	O
Chinese	O
provinces	O
.	O

The	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
cell	O
entry	O
,	O
is	O
the	O
major	O
target	O
for	O
neutralizing	O
antibodies	O
.	O

The	O
epitopes	O
of	O
potent	O
neutralizing	O
antibodies	O
segregated	O
into	O
two	O
epitope	O
classes	O
and	O
mapped	O
within	O
the	O
N	O
-	O
terminal	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
domain	O
and	O
in	O
the	O
more	O
C	O
-	O
terminal	O
receptor	B-FUNC
binding	I-FUNC
domain	O
.	O

Antibody	B-FUNC
neutralization	O
escape	O
mutants	O
displayed	O
single	O
amino	O
acid	O
substitutions	O
that	O
impaired	O
antibody	B-FUNC
binding	B-FUNC
and	O
neutralization	O
and	O
defined	O
the	O
locations	O
of	O
the	O
epitopes	O
.	O

TITLE	O
:	O
The	O
Impact	O
of	O
the	O
Interferon	O
/	O
TNF	O
-	O
Related	O
Apoptosis	O
-	O
Inducing	O
Ligand	B-FUNC
Signaling	O
Axis	O
on	O
Disease	O
Progression	O
in	O
Respiratory	O
Viral	O
Infection	O
and	O
Beyond	O
.	O

After	O
binding	B-FUNC
to	O
their	O
respective	O
IFN	O
receptors	O
and	O
activation	O
of	O
the	O
cellular	O
JAK	B-FUNC
/	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
signaling	O
cascade	O
,	O
they	O
stimulate	O
the	O
transcription	O
of	O
a	O
plethora	O
of	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
infected	O
as	O
well	O
as	O
bystander	O
cells	O
such	O
as	O
the	O
non	O
-	O
infected	O
epithelium	O
and	O
cells	O
of	O
the	O
immune	O
system	O
.	O

A	O
prominent	O
regulator	O
of	O
disease	O
outcome	O
,	O
especially	O
in	O
-	O
but	O
not	O
limited	O
to	O
-	O
respiratory	O
viral	O
infection	O
,	O
is	O
the	O
IFN	O
-	O
dependent	O
mediator	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-FUNC
)	O
produced	O
by	O
several	O
cell	O
types	O
including	O
immune	O
cells	O
such	O
as	O
macrophages	O
or	O
T	O
cells	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
antibody	B-FUNC
-	O
based	O
therapies	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
common	O
marmosets	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
signaling	O
in	O
SARS	O
coronavirus	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O

In	O
this	O
article	O
,	O
we	O
summarize	O
pulmonary	O
fibrotic	O
changes	O
observed	O
after	O
a	O
SARS	O
-	O
CoV	O
infection	O
,	O
discuss	O
the	O
extent	O
to	O
which	O
other	O
respiratory	O
viruses	O
induce	O
fibrosis	O
,	O
describe	O
available	O
animal	O
models	O
to	O
study	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
induced	O
fibrosis	O
and	O
review	O
evidence	O
that	O
pulmonary	O
fibrosis	O
is	O
caused	O
by	O
a	O
hyperactive	O
host	O
response	O
to	O
lung	O
injury	O
mediated	O
by	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
signaling	O
.	O

We	O
summarize	O
work	O
from	O
our	O
group	O
and	O
others	O
indicating	O
that	O
inhibiting	O
EGFR	B-FUNC
signaling	O
may	O
prevent	O
an	O
excessive	O
fibrotic	O
response	O
to	O
SARS	O
-	O
CoV	O
and	O
other	O
respiratory	O
viral	O
infections	O
and	O
propose	O
directions	O
for	O
future	O
research	O
.	O

TITLE	O
:	O
Cryo	O
-	O
EM	O
structures	O
of	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
spike	O
glycoproteins	O
reveal	O
the	O
dynamic	O
receptor	B-FUNC
binding	I-FUNC
domains	O
.	O

We	O
captured	O
two	O
states	O
of	O
the	O
RBD	O
with	O
receptor	B-FUNC
binding	I-FUNC
region	O
either	O
buried	O
(	O
lying	O
state	O
)	O
or	O
exposed	O
(	O
standing	O
state	O
),	O
demonstrating	O
an	O
inherently	O
flexible	O
RBD	O
readily	O
recognized	O
by	O
the	O
receptor	O
.	O

Small	O
drugs	O
that	O
bind	B-FUNC
to	O
the	O
APN	O
active	O
site	O
inhibit	O
catalysis	O
and	O
suppress	O
tumor	O
growth	O
.	O

APN	O
is	O
also	O
a	O
major	O
cell	O
entry	O
receptor	O
for	O
coronavirus	O
,	O
which	O
binds	B-FUNC
to	O
a	O
region	O
distant	O
from	O
the	O
active	O
site	O
.	O

In	O
addition	O
,	O
drugs	O
that	O
bind	B-FUNC
the	O
active	O
site	O
inhibited	O
both	O
coronavirus	O
binding	B-FUNC
to	O
cell	O
surface	O
APN	O
and	O
infection	O
;	O
the	O
drugs	O
probably	O
hindered	O
APN	O
transition	O
to	O
the	O
virus	O
-	O
specific	O
open	O
form	O
.	O

We	O
conclude	O
that	O
allosteric	O
inhibition	O
of	O
APN	O
functions	O
occurs	O
by	O
ligand	B-FUNC
suppression	O
of	O
ectodomain	O
motions	O
necessary	O
for	O
catalysis	O
and	O
virus	O
cell	O
entry	O
,	O
as	O
validated	O
by	O
locking	O
APN	O
with	O
disulfides	O
.	O

In	O
mice	O
with	O
constitutively	O
active	O
EGFR	B-FUNC
[	O
EGFR	B-FUNC
(	O
DSK5	O
)	O
mice	O
],	O
we	O
find	O
that	O
SARS	O
-	O
CoV	O
infection	O
causes	O
enhanced	O
lung	O
disease	O
.	O

Our	O
data	O
demonstrate	O
a	O
key	O
role	O
of	O
EGFR	B-FUNC
in	O
the	O
host	O
response	O
to	O
SARS	O
-	O
CoV	O
and	O
how	O
it	O
may	O
be	O
implicated	O
in	O
lung	O
disease	O
induced	O
by	O
other	O
highly	O
pathogenic	O
respiratory	O
viruses	O
.	O

We	O
hypothesized	O
that	O
lower	O
airway	O
symptoms	O
in	O
ENS	O
could	O
be	O
explained	O
by	O
HVS	B-FUNC
.	O

HVS	B-FUNC
was	O
defined	O
by	O
a	O
delayed	O
return	O
of	O
the	O
end	O
-	O
tidal	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
in	O
the	O
expired	O
gas	O
to	O
baseline	O
during	O
HVPT	O
.	O

Patients	O
with	O
HVS	B-FUNC
were	O
asked	O
to	O
complete	O
the	O
Sinonasal	O
Outcome	O
Test	O
(	O
SNOT	O
)-	O
16	O
questionnaire	O
before	O
and	O
after	O
a	O
specific	O
eight	O
-	O
session	O
respiratory	O
rehabilitation	O
program	O
.	O

HVS	B-FUNC
was	O
diagnosed	O
in	O
17	O
of	O
these	O
patients	O
(	O
77	O
.	O
3	O
%).	O

This	O
study	O
suggests	O
that	O
HVS	B-FUNC
is	O
frequent	O
in	O
patients	O
with	O
ENS	O
,	O
and	O
that	O
symptoms	O
can	O
be	O
improved	O
by	O
respiratory	O
rehabilitation	O
.	O

Pathophysiological	O
links	O
between	O
ENS	O
and	O
HVS	B-FUNC
deserve	O
to	O
be	O
further	O
explored	O
.	O

Prospective	O
cohort	O
study	O
comparing	O
children	O
with	O
severe	O
sepsis	O
and	O
any	O
of	O
three	O
phenotypes	O
:	O
1	O
)	O
immunoparalysis	O
-	O
associated	O
multiple	O
organ	O
failure	O
(	O
whole	O
blood	O
ex	O
vivo	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
response	O
to	O
endotoxin	O
<	O
200	O
pg	O
/	O
mL	O
),	O
2	O
)	O
thrombocytopenia	O
-	O
associated	O
multiple	O
organ	O
failure	O
(	O
new	O
onset	O
thrombocytopenia	O
with	O
acute	O
kidney	O
injury	O
and	O
a	O
disintegrin	O
and	O
metalloproteinase	O
with	O
a	O
thrombospondin	O
type	O
1	O
motif	O
,	O
member	O
13	O
activity	O
<	O
57	O
%),	O
and	O
/	O
or	O
3	O
)	O
sequential	O
multiple	O
organ	O
failure	O
with	O
hepatobiliary	O
dysfunction	O
(	O
respiratory	O
distress	O
followed	O
by	O
liver	O
dysfunction	O
with	O
soluble	O
Fas	O
ligand	B-FUNC
>	O
200	O
pg	O
/	O
mL	O
),	O
to	O
those	O
without	O
any	O
of	O
these	O
phenotypes	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
reportedly	O
induced	O
the	O
production	O
of	O
TGF	O
-	O
1	O
through	O
p38	B-FUNC
MAPK	B-FUNC
/	O
STAT3	O
-	O
meidated	O
Egr	O
-	O
1	O
-	O
dependent	O
activation	O
(	O
Sci	O
.	O

Rep	B-FUNC
.	O
6	O
,	O
25754	O
).	O

Comprehensive	O
analysis	O
of	O
ubiquitin	B-FUNC
-	O
conjugated	O
proteins	O
using	O
immunoprecipitation	O
and	O
nanoLC	O
-	O
MS	O
/	O
MS	O
indicated	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
caused	O
the	O
change	O
in	O
the	O
ubiquitination	O
profile	O
of	O
Rho	O
GTPase	O
family	O
proteins	O
,	O
in	O
which	O
linked	O
with	O
the	O
increase	O
of	O
Rho	O
-	O
like	O
GTPase	O
family	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
international	O
community	O
vastly	O
underestimates	O
the	O
risk	O
and	O
scale	O
of	O
our	O
shared	O
vulnerability	O
to	O
fast	B-FUNC
moving	O
pathogens	O
.	O

TITLE	O
:	O
C	O
-	O
C	O
Motif	O
Chemokine	O
Ligand	B-FUNC
2	O
(	O
CCL2	O
)	O
Mediates	O
Acute	O
Lung	O
Injury	O
Induced	O
by	O
Lethal	O
Influenza	O
H7N9	O
Virus	O
.	O

The	O
results	O
suggested	O
a	O
close	O
association	O
between	O
C	O
-	O
C	O
motif	O
chemokine	O
ligand	B-FUNC
2	O
(	O
CCL2	O
)	O
expressions	O
and	O
ALI	O
induced	O
by	O
a	O
lethal	O
H7N9	O
virus	O
strain	O
(	O
A	O
/	O
Hebei	O
/	O
01	O
/	O
2013	O
).	O

ABSTRACT	O
:	O
Interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
is	O
a	O
predictive	O
factor	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
used	O
adult	O
C57Bl6	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
knock	O
-	O
out	O
(	O
IL	O
-	O
6KO	O
)	O
mice	O
.	O

The	O
animals	O
received	O
intravenous	O
recombinant	O
human	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
rHuIL	O
-	O
6	O
)	O
or	O
vehicle	O
followed	O
by	O
intratracheal	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
saline	O
before	O
undergoing	O
low	O
tidal	O
volume	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
for	O
5	O
h	O
.	O
Before	O
sacrifice	O
,	O
right	O
ventricular	O
systolic	O
pressure	O
and	O
cardiac	O
output	O
were	O
measured	O
and	O
total	O
pulmonary	O
resistance	O
was	O
calculated	O
.	O

IL	O
-	O
6KO	O
In	O
a	O
double	O
-	O
hit	O
murine	O
model	O
of	O
ARDS	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
deficient	O
mice	O
experienced	O
more	O
severe	O
bronchoalveolar	O
cellular	O
inflammation	O
as	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Furthermore	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
deficiency	O
caused	O
marked	O
acute	O
pulmonary	O
hypertension	O
,	O
which	O
may	O
be	O
,	O
at	O
least	O
partially	O
,	O
due	O
to	O
vasoactive	O
mechanisms	O
.	O

Here	O
,	O
we	O
solved	O
the	O
crystal	O
structure	O
of	O
the	O
S1	O
subunit	O
C	O
-	O
terminal	O
domain	O
of	O
HKU5	O
(	O
HKU5	O
-	O
CTD	O
),	O
another	O
BatCoV	O
that	O
is	O
phylogenetically	O
related	O
to	O
MERS	O
-	O
CoV	O
but	O
cannot	O
bind	B-FUNC
to	O
CD26	O
.	O

However	O
,	O
two	O
deletions	O
in	O
two	O
respective	O
loops	O
located	O
in	O
HKU5	O
-	O
CTD	O
result	O
in	O
conformational	O
variations	O
in	O
CD26	O
-	O
binding	B-FUNC
interface	O
and	O
are	O
responsible	O
for	O
the	O
non	O
-	O
binding	B-FUNC
of	O
HKU5	O
-	O
CTD	O
to	O
CD26	O
.	O

The	O
latter	O
function	O
involves	O
reversing	O
the	O
post	O
-	O
translational	O
modification	O
of	O
cellular	O
proteins	O
conjugated	O
with	O
either	O
ubiquitin	B-FUNC
(	O
Ub	B-FUNC
)	O
or	O
Ub	B-FUNC
-	O
like	O
interferon	O
-	O
stimulated	O
gene	O
product	O
15	O
(	O
ISG15	O
).	O

TITLE	O
:	O
Optimization	O
of	O
the	O
Production	O
Process	O
and	O
Characterization	O
of	O
the	O
Yeast	O
-	O
Expressed	O
SARS	O
-	O
CoV	O
Recombinant	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
(	O
RBD219	O
-	O
N1	O
),	O
a	O
SARS	O
Vaccine	O
Candidate	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
5	O
L	O
scale	O
expression	O
and	O
purification	O
of	O
a	O
promising	O
recombinant	O
SARS	O
vaccine	O
candidate	O
,	O
RBD219	O
-	O
N1	O
,	O
the	O
218	O
-	O
amino	O
acid	O
residue	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
coronavirus	O
expressed	O
in	O
yeast	O
-	O
Pichia	O
pastoris	O
X	O
-	O
33	O
.	O

When	O
adjuvanted	O
with	O
aluminum	O
hydroxide	O
,	O
this	O
protein	O
elicited	O
high	O
neutralizing	O
antibody	B-FUNC
titers	O
and	O
high	O
RBD	O
-	O
specific	O
antibody	B-FUNC
titers	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
attenuates	O
LPS	O
-	O
induced	O
inflammation	O
and	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

Inhibition	O
of	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
has	O
been	O
found	O
to	O
be	O
able	O
to	O
reduce	O
inflammatory	O
response	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
EGFR	B-FUNC
inhibition	O
can	O
prevent	O
ALI	O
.	O

This	O
study	O
aimed	O
to	O
validate	O
the	O
EGFR	B-FUNC
'	O
s	O
role	O
in	O
ALI	O
and	O
investigated	O
the	O
effects	O
of	O
EGFR	B-FUNC
inhibition	O
on	O
lipopolysaccharides	O
(	O
LPS	O
)-	O
induced	O
ALI	O
in	O
rats	O
.	O

In	O
vitro	O
,	O
both	O
pharmacological	O
inhibitors	O
(	O
AG1478	O
and	O
451	O
)	O
and	O
si	O
-	O
RNA	O
silencing	O
of	O
EGFR	B-FUNC
significantly	O
inhibited	O
LPS	O
-	O
induced	O
EGFR	B-FUNC
signaling	O
activation	O
and	O
inflammatory	O
response	O
in	O
human	O
lung	O
epithelial	O
cells	O
or	O
macrophages	O
.	O

Mechanistically	O
,	O
LPS	O
induced	O
EGFR	B-FUNC
activation	O
via	O
TLR4	O
and	O
c	O
-	O
Src	O
signaling	O
.	O

This	O
study	O
demonstrates	O
that	O
TLR4	O
/	O
c	O
-	O
Src	O
-	O
dependent	O
EGFR	B-FUNC
signaling	O
plays	O
an	O
important	O
role	O
in	O
LPS	O
-	O
induced	O
ALI	O
,	O
and	O
that	O
EGFR	B-FUNC
may	O
be	O
a	O
potential	O
target	O
in	O
treating	O
ALI	O
.	O

TITLE	O
:	O
Neutralization	O
of	O
genotype	O
2	O
porcine	O
epidemic	O
diarrhea	O
virus	O
strains	O
by	O
a	O
novel	O
monoclonal	O
antibody	B-FUNC
.	O

To	O
research	O
the	O
immunogenicity	O
differences	O
of	O
PEDV	O
G1	O
and	O
G2	O
genotype	O
strains	O
and	O
obtain	O
a	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
),	O
we	O
inoculated	O
specific	O
-	O
pathogen	O
-	O
free	O
BALB	O
/	O
c	O
mice	O
with	O
a	O
newly	O
emerged	O
strain	O
,	O
PEDV	O
-	O
LNCT2	O
.	O

TITLE	O
:	O
Human	O
Neutralizing	O
Monoclonal	O
Antibody	B-FUNC
Inhibition	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Replication	O
in	O
the	O
Common	O
Marmoset	O
.	O

We	O
isolated	O
a	O
fully	O
human	O
neutralizing	O
antibody	B-FUNC
,	O
MCA1	O
,	O
from	O
a	O
human	O
survivor	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
a	O
human	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
that	O
completely	O
inhibits	O
MERS	O
-	O
CoV	O
replication	O
in	O
common	O
marmosets	O
.	O

The	O
present	O
study	O
was	O
done	O
in	O
a	O
tertiary	O
care	O
children	O
'	O
s	O
hospital	O
for	O
rapid	O
identification	O
of	O
viruses	O
causing	O
SARI	O
among	O
children	O
less	O
than	O
or	O
equal	O
to	O
five	O
years	O
of	O
age	O
using	O
multiplex	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
kit	B-FUNC
.	O

Naturally	O
Occurring	O
Recombinant	O
Enterovirus	O
Expresses	O
a	O
Torovirus	O
Deubiquitinase	B-FUNC
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
expression	O
in	O
pyramidal	O
neurons	O
after	O
neuropathogenic	O
coronaviral	O
infection	O
.	O

However	O
,	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
was	O
produced	O
by	O
pyramidal	O
neurons	O
of	O
CA2	O
and	O
CA3	O
at	O
3	O
dpi	O
when	O
there	O
is	O
no	O
destructive	O
change	O
or	O
viral	O
invasion	O
in	O
the	O
hippocampus	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
protects	O
murine	O
viral	O
fulminant	O
hepatitis	O
by	O
targeting	O
coagulation	O
hallmark	O
protein	O
FGL2	O
/	O
fibroleukin	O
expression	O
.	O

IL	B-FUNC
-	I-FUNC
33	I-FUNC
is	O
a	O
member	O
of	O
the	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
-	O
related	O
cytokines	O
,	O
considered	O
to	O
be	O
an	O
""""	O
alarmin	O
""""	O
that	O
participates	O
in	O
various	O
diseases	O
,	O
but	O
its	O
precise	O
role	O
in	O
the	O
coagulation	O
of	O
FH	O
is	O
not	O
very	O
clear	O
.	O

In	O
our	O
study	O
,	O
we	O
found	O
that	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
is	O
significantly	O
elevated	O
in	O
mice	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
).	O

In	O
vitro	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
treatment	O
abrogated	O
MHV	O
-	O
3	O
and	O
IFN	O
-	O
	O
induced	O
FGL2	O
expression	O
in	O
RAW264	O
.	O
7	O
and	O
THP	O
-	O
1	O
cells	O
,	O
respectively	O
.	O

With	O
regard	O
to	O
adaptive	O
immune	O
parameters	O
such	O
as	O
IgY	O
concentration	O
in	O
blood	O
and	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)-	O
specific	O
antibody	B-FUNC
titres	O
,	O
the	O
Hellevad	O
and	O
Hisex	O
chickens	O
had	O
lower	O
levels	O
than	O
the	O
Bovans	O
.	O

GLS	O
-	O
5300	O
,	O
a	O
prophylactic	O
DNA	O
-	O
plasmid	O
vaccine	O
encoding	O
S	O
protein	O
,	O
is	O
the	O
first	O
MERS	O
-	O
CoV	O
vaccine	O
to	O
be	O
tested	O
in	O
humans	O
,	O
while	O
monoclonal	O
antibody	B-FUNC
,	O
m336	O
has	O
given	O
promising	O
results	O
in	O
animal	O
models	O
and	O
has	O
potential	O
for	O
use	O
in	O
outbreak	O
situations	O
.	O

In	O
most	O
cases	O
,	O
making	O
an	O
early	O
diagnosis	O
is	O
challenging	O
due	O
to	O
the	O
treatments	O
that	O
consist	O
in	O
the	O
rapid	O
administration	O
of	O
intravenous	O
immunoglobulin	B-FUNC
or	O
plasma	O
exchange	O
.	O

Infection	O
with	O
YC2014	O
could	O
activate	O
the	O
JAK	B-FUNC
-	O
STAT	O
signaling	O
pathway	O
and	O
the	O
NF	O
-	O
B	O
pathway	O
more	O
intensively	O
than	O
CV777	O
.	O

Anecdotal	O
reports	O
suggest	O
that	O
plasma	O
with	O
high	O
antibody	B-FUNC
titres	O
to	O
influenza	O
might	O
be	O
of	O
benefit	O
in	O
the	O
treatment	O
of	O
severe	O
influenza	O
.	O

The	O
S1	O
subunit	O
of	O
the	O
viral	O
S	O
glycoprotein	O
is	O
responsible	O
for	O
virus	O
binding	B-FUNC
to	O
host	O
-	O
cell	O
receptors	O
,	O
induction	O
of	O
neutralizing	O
antibody	B-FUNC
and	O
hemagglutinin	O
activity	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
spike	O
glycoprotein	O
of	O
human	O
betacoronavirus	O
HKU1	O
.	O

HKU1	O
virus	O
uses	O
its	O
S1	O
subunit	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
and	O
not	O
the	O
N	O
-	O
terminal	O
domain	O
like	O
other	O
lineage	O
A	O
	O
-	O
CoVs	O
to	O
bind	B-FUNC
to	O
its	O
yet	O
unknown	O
human	O
receptor	O
.	O

The	O
pathogenicity	O
and	O
host	O
antibody	B-FUNC
responses	O
elicited	O
by	O
low	O
-	O
passage	O
(	O
passage	O
5	O
;	O
PEDVPT	O
-	O
P5	O
)	O
and	O
high	O
-	O
passage	O
(	O
passage	O
96	O
;	O
PEDVPT	O
-	O
P96	O
)	O
PEDVPT	O
strains	O
were	O
compared	O
in	O
post	O
-	O
weaning	O
PEDV	O
-	O
seronegative	O
pigs	O
by	O
oral	O
inoculation	O
.	O

Although	O
PEDVPT	O
-	O
P96	O
elicited	O
slightly	O
lower	O
neutralizing	O
antibodies	O
and	O
PEDV	O
-	O
specific	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
and	O
immunoglobulin	B-FUNC
A	O
(	O
IgA	O
)	O
titers	O
,	O
a	O
reduction	O
in	O
pathogenicity	O
and	O
viral	O
shedding	O
of	O
the	O
subsequent	O
challenge	O
with	O
PEDVPT	O
-	O
P5	O
were	O
noted	O
in	O
both	O
PEDVPT	O
-	O
P5	O
-	O
and	O
PEDVPT	O
-	O
P96	O
-	O
inoculated	O
pigs	O
.	O

TITLE	O
:	O
A	O
novel	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
targeting	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

In	O
addition	O
to	O
mAbs	O
with	O
neutralizing	O
epitopes	O
located	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
,	O
one	O
mAb	O
,	O
5F9	O
,	O
which	O
binds	B-FUNC
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
,	O
showed	O
efficient	O
neutralizing	O
activity	O
against	O
the	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
strain	O
EMC	O
/	O
2012	O
,	O
with	O
a	O
half	O
maximal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
g	O
/	O
mL	O
.	O
We	O
concluded	O
that	O
a	O
novel	O
neutralizing	O
epitope	O
for	O
MERS	O
-	O
CoV	O
also	O
resides	O
on	O
the	O
NTD	O
of	O
the	O
S	O
protein	O
,	O
indicating	O
that	O
the	O
NTD	O
might	O
be	O
important	O
during	O
the	O
viral	O
infection	O
process	O
.	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
and	O
ribonucleaser	O
H	O
(	O
RNase	O
H	O
)	O
functions	O
are	O
both	O
essential	O
for	O
HIV	O
-	O
1	O
genome	O
replication	O
,	O
and	O
the	O
identification	O
of	O
new	O
inhibitors	O
to	O
block	O
both	O
of	O
them	O
is	O
a	O
goal	O
actively	O
pursued	O
by	O
the	O
scientific	O
community	O
.	O

ABSTRACT	O
:	O
Kallistatin	O
,	O
an	O
endogenous	O
serine	O
proteinase	B-FUNC
inhibitor	I-FUNC
,	O
is	O
protective	O
against	O
sepsis	O
in	O
animal	O
models	O
.	O

Their	O
plasma	O
concentrations	O
of	O
kallistatin	O
,	O
kallikrein	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

In	O
addition	O
,	O
there	O
were	O
inverse	O
correlations	O
between	O
day	O
1	O
kallistatin	O
levels	O
and	O
the	O
levels	O
of	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
SOFA	O
scores	O
on	O
day	O
1	O
.	O

TITLE	O
:	O
Potent	O
and	O
selective	O
inhibition	O
of	O
pathogenic	O
viruses	O
by	O
engineered	O
ubiquitin	B-FUNC
variants	O
.	O

They	O
bind	B-FUNC
and	O
remove	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
and	O
interferon	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
from	O
cellular	O
proteins	O
to	O
suppress	O
host	O
antiviral	O
innate	O
immune	O
responses	O
.	O

Here	O
,	O
we	O
report	O
the	O
use	O
of	O
phage	O
-	O
displayed	O
ubiquitin	B-FUNC
variant	O
(	O
UbV	O
)	O
libraries	O
to	O
rapidly	O
identify	O
potent	O
and	O
highly	O
selective	O
protein	O
-	O
based	O
inhibitors	O
targeting	O
the	O
DUB	O
domains	O
of	O
MERS	O
-	O
CoV	O
and	O
CCHFV	O
.	O

Co	O
-	O
crystallization	O
studies	O
further	O
revealed	O
critical	O
molecular	O
interactions	O
between	O
UbVs	O
and	O
MERS	O
-	O
CoV	O
or	O
CCHFV	O
vDUBs	O
,	O
accounting	O
for	O
the	O
observed	O
binding	B-FUNC
specificity	O
and	O
high	O
affinity	O
.	O

Neutrophils	O
increase	O
in	O
the	O
respiratory	O
tract	O
during	O
infection	O
with	O
mild	O
seasonal	O
IAV	O
,	O
moderate	O
and	O
severe	O
epidemic	O
IAV	O
infection	O
,	O
and	O
emerging	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
).	O

During	O
severe	O
influenza	O
pneumonia	O
and	O
HPAI	B-FUNC
infection	O
,	O
the	O
number	O
of	O
neutrophils	O
in	O
the	O
lower	O
respiratory	O
tract	O
is	O
correlated	O
with	O
disease	O
severity	O
.	O

Positive	O
BDR	O
according	O
to	O
the	O
GOLD	O
criteria	O
was	O
significantly	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
severe	O
AE	O
(	O
adjusted	O
odds	O
ratio	O
(	O
aOR	B-FUNC
)	O
=	O
0	O
.	O
38	O
;	O
95	O
%	O
Confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
15	O
-	O
0	O
.	O
93	O
).	O

TITLE	O
:	O
Microtubule	O
-	O
assisted	O
altered	O
trafficking	O
of	O
astrocytic	O
gap	O
junction	O
protein	O
connexin	B-FUNC
43	O
is	O
associated	O
with	O
depletion	O
of	O
connexin	B-FUNC
47	O
during	O
mouse	O
hepatitis	O
virus	O
infection	O
.	O

All	O
vaccines	O
contained	O
the	O
full	O
-	O
length	O
spike	O
gene	O
of	O
MERS	O
-	O
CoV	O
;	O
ChAdOx1	O
MERS	O
vaccines	O
were	O
produced	O
with	O
or	O
without	O
the	O
leader	O
sequence	O
of	O
the	O
human	O
tissue	O
plasminogen	O
activator	O
gene	O
(	O
tPA	B-FUNC
)	O
where	O
MVA	O
MERS	O
vaccines	O
were	O
produced	O
with	O
tPA	B-FUNC
,	O
but	O
either	O
the	O
mH5	O
or	O
F11	O
promoter	O
driving	O
expression	O
of	O
the	O
spike	O
gene	O
.	O

ChAdOx1	O
MERS	O
with	O
tPA	B-FUNC
induced	O
higher	O
neutralising	O
antibodies	O
than	O
ChAdOx1	O
MERS	O
without	O
tPA	B-FUNC
.	O

The	O
humoral	O
immunogenicity	O
of	O
a	O
single	O
dose	O
of	O
ChAdOx1	O
MERS	O
with	O
tPA	B-FUNC
was	O
equivalent	O
to	O
two	O
doses	O
of	O
MVA	O
MERS	O
(	O
also	O
with	O
tPA	B-FUNC
).	O

MVA	O
MERS	O
with	O
mH5	O
or	O
F11	O
promoter	O
induced	O
similar	O
antibody	B-FUNC
levels	O
;	O
however	O
,	O
F11	O
promoter	O
enhanced	O
the	O
cellular	O
immunogenicity	O
of	O
MVA	O
MERS	O
to	O
significantly	O
higher	O
magnitudes	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Antibody	B-FUNC
Responses	O
1	O
Year	O
after	O
Symptom	O
Onset	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
kinetics	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
neutralizing	O
and	O
spike	O
protein	O
antibody	B-FUNC
titers	O
over	O
the	O
course	O
of	O
1	O
year	O
in	O
11	O
patients	O
who	O
were	O
confirmed	O
by	O
reverse	O
transcription	O
PCR	O
to	O
have	O
been	O
infected	O
during	O
the	O
outbreak	O
in	O
South	O
Korea	O
in	O
2015	O
.	O

Robust	O
antibody	B-FUNC
responses	O
were	O
detected	O
in	O
all	O
survivors	O
who	O
had	O
severe	O
disease	O
;	O
responses	O
remained	O
detectable	O
,	O
albeit	O
with	O
some	O
waning	O
,	O
for	O
<	O
1	O
year	O
.	O

The	O
duration	O
of	O
viral	O
RNA	O
detection	O
(	O
but	O
not	O
viral	O
load	O
)	O
in	O
sputum	O
significantly	O
correlated	O
with	O
the	O
antibody	B-FUNC
response	O
magnitude	O
.	O

The	O
MERS	O
S1	O
ELISA	O
antibody	B-FUNC
titers	O
correlated	O
well	O
with	O
the	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

Obtaining	O
convalescent	O
-	O
phase	O
plasma	O
with	O
high	O
antibody	B-FUNC
titers	O
to	O
treat	O
MERS	O
will	O
be	O
challenging	O
.	O

Further	O
studies	O
showed	O
that	O
both	O
MHV	O
and	O
SARS	O
-	O
CoV	O
N	O
proteins	O
directly	O
interacted	O
with	O
protein	O
activator	O
of	O
protein	O
kinase	O
R	O
(	O
PACT	O
),	O
a	O
cellular	O
dsRNA	O
-	O
binding	B-FUNC
protein	O
that	O
can	O
bind	B-FUNC
to	O
RIG	O
-	O
I	O
and	O
MDA5	O
to	O
activate	O
IFN	O
production	O
.	O

Although	O
the	O
typical	O
genome	O
structure	O
of	O
NS1	O
-	O
NP1	O
-	O
VP1	O
/	O
VP2	O
was	O
observed	O
in	O
DBoV1	O
and	O
DBoV2	O
,	O
no	O
phospholipase	O
A2	O
motif	O
and	O
associated	O
calcium	O
binding	B-FUNC
site	O
were	O
observed	O
in	O
the	O
predicted	O
VP1	O
sequences	O
for	O
any	O
of	O
the	O
18	O
sequenced	O
DBoV2	O
,	O
and	O
no	O
start	O
codons	O
were	O
found	O
for	O
their	O
VP1	O
.	O

This	O
finding	O
presents	O
various	O
hypotheses	O
about	O
the	O
timing	O
of	O
the	O
emergence	O
and	O
spread	O
of	O
MERS	O
-	O
CoV	O
throughout	O
populations	O
of	O
camels	O
in	O
Africa	O
and	O
Asia	O
,	O
which	O
can	O
be	O
partially	O
resolved	O
by	O
testing	O
sera	B-FUNC
from	O
camels	O
from	O
the	O
original	O
source	O
region	O
,	O
which	O
we	O
have	O
inferred	O
was	O
mainly	O
northwestern	O
Pakistan	O
.	O

Laboratory	O
investigation	O
revealed	O
low	O
vitamin	O
B12	O
,	O
high	O
methylmalonic	O
acid	O
,	O
high	O
homocysteine	O
,	O
high	O
lactate	O
dehydrogenase	O
,	O
low	O
haptoglobin	O
,	O
high	O
anti	O
-	O
parietal	O
antibody	B-FUNC
and	O
high	O
anti	O
-	O
intrinsic	O
factor	O
antibody	B-FUNC
.	O

TITLE	O
:	O
A	O
spike	O
-	O
specific	O
whole	O
-	O
porcine	O
antibody	B-FUNC
isolated	O
from	O
a	O
porcine	O
B	O
cell	O
that	O
neutralizes	O
both	O
genogroup	O
1	O
and	O
2	O
PEDV	O
strains	O
.	O

The	O
antibody	B-FUNC
,	O
named	O
PC10	O
,	O
was	O
demonstrated	O
to	O
target	O
the	O
conformational	O
epitope	O
of	O
PEDV	O
spike	O
protein	O
,	O
specifically	O
bind	B-FUNC
to	O
the	O
infected	O
cells	O
of	O
PEDV	O
genogroup	O
1	O
and	O
2	O
strains	O
,	O
and	O
potently	O
neutralize	O
PEDV	O
infection	O
.	O

We	O
used	O
the	O
2016	O
World	O
Bank	O
countries	O
classification	O
to	O
define	O
three	O
major	O
geo	O
-	O
economic	O
groupings	O
,	O
namely	O
European	O
high	O
-	O
income	O
countries	O
(	O
Europe	O
-	O
High	O
),	O
high	O
-	O
income	O
countries	O
in	O
the	O
rest	B-FUNC
of	O
the	O
world	O
(	O
rWORLD	O
-	O
High	O
),	O
and	O
middle	O
-	O
income	O
countries	O
(	O
Middle	O
).	O

Blood	O
samples	O
were	O
collected	O
for	O
analysis	O
of	O
oxidative	O
parameters	O
and	O
specific	O
antibody	B-FUNC
titers	O
,	O
and	O
splenocytes	O
were	O
prepared	O
for	O
lymphocyte	O
proliferative	O
assay	O
.	O

Evidence	O
of	O
MERS	O
-	O
CoV	O
infection	O
was	O
confirmed	O
in	O
one	O
herd	O
on	O
the	O
basis	O
of	O
detection	O
of	O
virus	O
RNA	O
in	O
nasal	O
swabs	O
from	O
three	O
camels	O
and	O
significant	O
increases	O
in	O
the	O
antibody	B-FUNC
titers	O
from	O
three	O
others	O
.	O

We	O
then	O
performed	O
combination	O
studies	O
of	O
Lupeol	O
and	O
the	O
active	O
site	O
RNase	O
H	O
inhibitor	O
RDS1759	O
,	O
and	O
blind	O
docking	O
calculations	O
,	O
demonstrating	O
that	O
Lupeol	O
binds	B-FUNC
to	O
an	O
HIV	O
-	O
1	O
RT	O
allosteric	O
pocket	O
.	O

In	O
fact	O
,	O
by	O
virtue	O
of	O
its	O
numerous	O
active	O
metabolites	O
,	O
H	O
.	O
indicus	O
was	O
able	O
to	O
inhibit	O
not	O
only	O
the	O
RT	O
-	O
associated	O
RNase	O
H	O
function	O
,	O
but	O
also	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNA	B-FUNC
-	I-FUNC
dependent	I-FUNC
DNA	I-FUNC
polymerase	I-FUNC
activity	I-FUNC
and	O
the	O
cellular	O
	O
-	O
glucosidase	O
.	O

JAK2	O
inhibition	O
either	O
by	O
CYT387	O
(	O
a	O
JAK	B-FUNC
family	O
inhibitor	O
)	O
or	O
by	O
silencing	O
JAK2	O
-	O
expression	O
revealed	O
a	O
dominant	O
JAK2	O
mediated	O
p65	O
phosphorylation	O
pathway	O
for	O
NF	O
-	O
B	O
activation	O
and	O
resulted	O
in	O
NF	O
-	O
B	O
inhibition	O
,	O
which	O
overrode	O
the	O
IB	O
regulation	O
via	O
the	O
IKK	B-FUNC
-	I-FUNC
2	I-FUNC
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
Luminex	O
xTAG	O
Respiratory	O
Viral	O
Panel	O
Fast	B-FUNC
v2	O
Assay	O
With	O
Anyplex	O
II	O
RV16	O
Detection	O
Kit	B-FUNC
and	O
AdvanSure	O
RV	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
Assay	O
for	O
the	O
Detection	O
of	O
Respiratory	O
Viruses	O
.	O

We	O
compared	O
the	O
results	O
of	O
a	O
newly	O
upgraded	O
,	O
multiplex	O
,	O
molecular	O
bead	O
-	O
based	O
respiratory	O
viral	O
panel	O
(	O
RVP	O
)	O
assay	O
with	O
the	O
results	O
of	O
Anyplex	O
II	O
RV16	O
detection	O
kit	B-FUNC
and	O
AdvanSure	O
RV	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

Of	O
the	O
254	O
respiratory	O
specimens	O
,	O
there	O
was	O
total	O
agreement	O
in	O
the	O
results	O
between	O
the	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
and	O
the	O
other	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
94	O
.	O
1	O
-	O
100	O
%	O
of	O
the	O
specimens	O
.	O

In	O
comparison	O
to	O
the	O
other	O
assay	O
,	O
the	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
detected	O
a	O
higher	O
number	O
of	O
parainfluenza	O
type	O
3	O
(	O
4	O
cases	O
)	O
and	O
metapneumovirus	O
(	O
9	O
cases	O
).	O

In	O
comparison	O
to	O
the	O
other	O
assay	O
,	O
the	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
detected	O
a	O
higher	O
number	O
of	O
parainfluenza	O
type	O
3	O
(	O
4	O
cases	O
)	O
and	O
metapneumovirus	O
(	O
9	O
cases	O
).	O

Alone	O
,	O
resveratrol	O
does	O
not	O
inhibit	O
HIV	O
-	O
1	O
infection	O
of	O
activated	O
T	O
cells	O
,	O
but	O
it	O
does	O
synergize	O
with	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
in	O
these	O
cells	O
to	O
inhibit	O
reverse	O
transcription	O
.	O

ABSTRACT	O
:	O
Lateral	O
medullary	O
infarction	O
rarely	O
leads	O
to	O
central	O
hypoventilation	O
syndrome	O
(	O
CHS	B-FUNC
).	O

Intensive	O
respiratory	O
care	O
including	O
intubation	O
,	O
tracheostomy	O
,	O
mechanical	O
ventilation	O
,	O
and	O
rehabilitation	O
prevented	O
subsequent	O
recurrence	O
of	O
apnea	O
and	O
the	O
CHS	B-FUNC
resolved	O
completely	O
.	O

CHS	B-FUNC
after	O
unilateral	O
medullary	O
infarction	O
involving	O
respiratory	O
centers	O
tends	O
to	O
occur	O
in	O
the	O
acute	O
and	O
subacute	O
phase	O
and	O
may	O
be	O
lethal	O
without	O
careful	O
respiratory	O
management	O
.	O

Using	O
the	O
recombinant	O
S	O
proteins	O
as	O
probes	O
to	O
perform	O
S	O
protein	O
affinity	O
histochemistry	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
although	O
no	O
tissue	O
or	O
enteric	O
binding	B-FUNC
of	O
FECV	O
UU7	O
S	O
protein	O
was	O
detected	O
,	O
it	O
was	O
found	O
that	O
by	O
immunohistochemistry	O
that	O
the	O
tissue	O
distribution	O
of	O
FIPV	O
UU4	O
S	O
protein	O
-	O
bound	O
cells	O
correlated	O
with	O
that	O
of	O
FIPV	O
antigen	O
-	O
positive	O
cells	O
and	O
lesions	O
associated	O
with	O
FIP	O
and	O
that	O
the	O
affinity	O
binding	B-FUNC
of	O
FIPV	O
UU4	O
S	O
protein	O
on	O
macrophages	O
was	O
not	O
affected	O
by	O
enzymatic	O
removal	O
of	O
host	O
cell	O
-	O
surface	O
sialic	O
acid	O
with	O
neuraminidase	O
.	O

TITLE	O
:	O
Asthma	O
-	O
COPD	O
Overlap	O
Shows	O
Favorable	O
Clinical	O
Outcomes	O
Compared	O
to	O
Pure	B-FUNC
COPD	O
in	O
a	O
Korean	O
COPD	O
Cohort	O
.	O

Men	O
(	O
95	O
.	O
5	O
%)	O
and	O
current	O
smokers	O
(	O
32	O
.	O
9	O
%)	O
were	O
more	O
prevalent	O
in	O
the	O
ACO	O
group	O
compared	O
with	O
the	O
pure	B-FUNC
COPD	O
group	O
(	O
90	O
.	O
5	O
%	O
and	O
25	O
.	O
3	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
015	O
and	O
P	O
=	O
0	O
.	O
026	O
,	O
respectively	O
).	O

Although	O
the	O
prevalence	O
of	O
acute	O
exacerbation	O
was	O
not	O
different	O
between	O
the	O
2	O
groups	O
,	O
patients	O
with	O
severe	O
exacerbation	O
required	O
hospital	O
admission	O
significantly	O
more	O
frequently	O
in	O
the	O
pure	B-FUNC
COPD	O
group	O
than	O
in	O
the	O
ACO	O
group	O
.	O

Patients	O
with	O
ACO	O
showed	O
a	O
higher	O
likelihood	O
of	O
FEV1	O
recovery	O
than	O
those	O
with	O
pure	B-FUNC
COPD	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
evaluated	O
variability	O
in	O
delayed	O
fixation	O
(	O
24	O
hours	O
)	O
between	O
trauma	O
centers	O
participating	O
in	O
the	O
American	O
College	O
of	O
Surgeons	O
(	O
ACS	B-FUNC
)	O

A	O
retrospective	O
cohort	O
study	O
was	O
performed	O
using	O
data	O
derived	O
from	O
the	O
ACS	B-FUNC
TQIP	O
database	O
.	O

Adults	O
with	O
severe	O
injury	O
who	O
underwent	O
definitive	O
fixation	O
of	O
a	O
femoral	O
shaft	O
fracture	O
at	O
a	O
level	O
I	O
or	O
II	O
trauma	O
center	O
participating	O
in	O
ACS	B-FUNC
TQIP	O
(	O
2012	O
-	O
2015	O
)	O
were	O
included	O
.	O

	O
-	O
bisabolol	O
(	O
	O
-	O
bis	B-FUNC
),	O
a	O
constituent	O
of	O
the	O
essential	O
oil	O
from	O
chamomile	O
,	O
has	O
elicited	O
pharmacological	O
interest	O
.	O

	O
-	O
bis	B-FUNC
-	O
loaded	O
LNCs	O
(	O
	O
-	O
bis	B-FUNC
-	O
LNCs	O
)	O
were	O
prepared	O
by	O
interfacial	O
deposition	O
of	O
poly	O
(	O
	O
-	O
caprolactone	O
)	O
and	O
orally	O
administered	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
triggered	O
by	O
an	O
intranasal	O
administration	O
of	O
lipopolysaccharide	O
(	O
LPS	O
).	O

TITLE	O
:	O
Chicken	O
mannose	B-FUNC
binding	I-FUNC
lectin	I-FUNC
has	O
antiviral	O
activity	O
towards	O
infectious	O
bronchitis	O
virus	O
.	O

It	O
can	O
bind	B-FUNC
to	O
carbohydrates	O
on	O
the	O
surface	O
of	O
a	O
wide	O
range	O
of	O
pathogens	O
,	O
including	O
viruses	O
.	O

TITLE	O
:	O
Suggested	O
new	O
breakpoints	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
ELISA	O
titers	O
:	O
performance	O
analysis	O
of	O
serologic	O
tests	O
.	O

In	O
predicting	O
neutralization	O
activity	O
,	O
ELISA	O
IgG	O
tests	O
showed	O
optimal	O
performance	O
using	O
sera	B-FUNC
collected	O
after	O
21	O
dpoi	O
at	O
cut	O
-	O
off	O
values	O
of	O
OD	O
ratio	O
0	O
.	O
4	O
(	O
sensitivity	O
100	O
%	O
and	O
specificity	O
100	O
%),	O
and	O
ELISA	O
IgA	O
showed	O
optimal	O
performance	O
using	O
sera	B-FUNC
collected	O
after	O
14	O
dpoi	O
at	O
cut	O
-	O
off	O
value	O
of	O
OD	O
ratio	O
0	O
.	O
2	O
(	O
sensitivity	O
85	O
.	O
2	O
%	O
and	O
specificity	O
100	O
%).	O

In	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	O
,	O
ELISA	O
IgG	O
exhibited	O
optimal	O
performance	O
using	O
sera	B-FUNC
collected	O
after	O
28	O
dpex	O
,	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
OD	O
ratio	O
0	O
.	O
2	O
(	O
sensitivity	O
97	O
.	O
3	O
%	O
and	O
specificity	O
92	O
.	O
9	O
%).	O

We	O
tested	O
in	O
naso	O
-	O
pharyngeal	O
washings	O
B	O
.	O
pertussis	O
and	O
14	O
respiratory	O
viruses	O
with	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
recombination	O
occurred	O
in	O
South	O
America	O
and	O
produced	O
two	O
viral	O
variants	O
that	O
have	O
retained	O
the	O
full	O
-	O
length	O
S1	O
sequences	O
of	O
the	O
parental	O
lineages	O
but	O
are	O
extremely	O
similar	O
in	O
the	O
rest	B-FUNC
of	O
their	O
genomes	O
.	O

In	O
2013	O
,	O
760	O
human	O
and	O
879	O
camel	O
sera	B-FUNC
were	O
collected	O
from	O
275	O
and	O
85	O
households	O
respectively	O
in	O
Marsabit	O
County	O
.	O

Human	O
and	O
camel	O
sera	B-FUNC
were	O
tested	O
for	O
anti	O
-	O
MERS	O
-	O
CoV	O
IgG	O
using	O
a	O
commercial	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
test	O
.	O

Of	O
the	O
camel	O
sera	B-FUNC
,	O
791	O
(	O
90	O
%)	O
were	O
positive	O
on	O
ELISA	O
.	O

The	O
fact	O
that	O
these	O
regions	O
can	O
bind	B-FUNC
reciprocally	O
between	O
themselves	O
provides	O
a	O
possible	O
molecular	O
basis	O
for	O
N	O
protein	O
oligomerization	O
.	O

Based	O
on	O
our	O
data	O
,	O
we	O
propose	O
a	O
model	O
where	O
constitutive	O
N	O
protein	O
oligomerization	O
allows	O
the	O
optimal	O
loading	O
of	O
the	O
genomic	O
viral	O
RNA	O
into	O
a	O
ribonucleoprotein	O
complex	O
via	O
the	O
presentation	O
of	O
multiple	O
viral	O
RNA	B-FUNC
binding	I-FUNC
motifs	O
.	O

In	O
addition	O
,	O
severe	O
signs	O
of	O
inflammation	O
at	O
initial	O
presentation	O
(	O
at	O
hospital	O
days	O
1	O
-	O
4	O
),	O
such	O
as	O
high	O
inducible	O
protein	O
-	O
10	O
(	O
p	O
=	O
0	O
.	O
0013	O
),	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
and	O
interleukin	O
6	O
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
concentrations	O
,	O
and	O
poor	O
viral	O
control	O
(	O
high	O
viral	O
load	O
at	O
hospital	O
days	O
5	O
-	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
adequate	O
antibody	B-FUNC
titres	O
(	O
low	O
antibody	B-FUNC
titre	O
at	O
hospital	O
days	O
11	O
-	O
16	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
during	O
the	O
course	O
of	O
disease	O
,	O
were	O
associated	O
with	O
mortality	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
dependent	O
enhancement	O
of	O
serotype	O
II	O
feline	O
enteric	O
coronavirus	O
infection	O
in	O
primary	O
feline	O
monocytes	O
.	O

In	O
FIPV	O
infection	O
,	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
has	O
been	O
reported	O
and	O
was	O
shown	O
to	O
be	O
associated	O
with	O
severe	O
clinical	O
disease	O
.	O

As	O
with	O
ADE	O
of	O
FIPV	O
79	O
-	O
1146	O
infection	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
spike	O
protein	O
of	O
FCoV	O
(	O
mAb	O
6	O
-	O
4	O
-	O
2	O
)	O
enhanced	O
FECV	O
79	O
-	O
1683	O
replication	O
in	O
U937	O
cells	O
and	O
primary	O
feline	O
monocytes	O
.	O

ABSTRACT	O
:	O
An	O
analysis	O
of	O
cardiac	O
injury	O
markers	O
in	O
patients	O
with	O
OSA	O
who	O
sustain	O
an	O
episode	O
of	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
interactions	O
and	O
impact	O
of	O
OSA	O
in	O
subjects	O
with	O
ACS	B-FUNC
.	O

We	O
compared	O
peak	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
levels	O
in	O
patients	O
with	O
OSA	O
and	O
patients	O
without	O
OSA	O
who	O
were	O
admitted	O
for	O
ACS	B-FUNC
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
peak	O
cTnI	O
value	O
and	O
patient	O
group	O
,	O
age	O
,	O
sex	O
,	O
and	O
type	O
of	O
ACS	B-FUNC
showed	O
that	O
the	O
presence	O
or	O
absence	O
of	O
OSA	O
significantly	O
contributed	O
to	O
the	O
peak	O
cTnI	O
level	O
,	O
which	O
was	O
54	O
%	O
lower	O
in	O
patients	O
with	O
OSA	O
than	O
in	O
those	O
without	O
OSA	O
.	O

Hence	O
,	O
the	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
sow	O
sera	B-FUNC
and	O
determine	O
the	O
correlation	O
between	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
results	O
(	O
involving	O
a	O
newly	O
isolated	O
GDS01	O
virus	O
-	O
based	O
ELISA	O
and	O
ELISAs	O
based	O
on	O
seven	O
recombinant	O
fragments	O
comprising	O
overlapping	O
S1	O
and	O
partial	O
S2	O
sequences	O
)	O
and	O
SN	O
titers	O
.	O

The	O
majority	O
of	O
the	O
literature	O
regarding	O
LIS	B-FUNC
is	O
based	O
on	O
case	O
reports	O
that	O
utilized	O
multidisciplinary	O
interventions	O
focused	O
on	O
improving	O
functional	O
communication	O
and	O
respiratory	O
care	O
with	O
minimal	O
focus	O
on	O
motor	O
retraining	O
.	O

There	O
are	O
additional	O
types	O
of	O
technology	O
frequently	O
used	O
in	O
the	O
general	O
stroke	O
population	O
that	O
can	O
address	O
similar	O
motor	O
deficits	O
that	O
occur	O
in	O
the	O
LIS	B-FUNC
population	O
.	O

With	O
the	O
aim	O
of	O
enhancing	O
understanding	O
of	O
the	O
binding	B-FUNC
properties	O
of	O
scytovirin	O
,	O
we	O
performed	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
scytovirin	O
complexed	O
with	O
Man4	O
.	O

We	O
also	O
detected	O
one	O
novel	O
variant	O
with	O
an	O
8	O
-	O
amino	O
acid	O
insertion	O
located	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
region	O
for	O
porcine	O
aminopeptidase	O
N	O
.	O
Compared	O
to	O
the	O
commercial	O
vaccine	O
strains	O
,	O
the	O
emerging	O
Vietnamese	O
strains	O
were	O
genetically	O
distant	O
and	O
had	O
various	O
amino	O
acid	O
differences	O
in	O
epitope	O
regions	O
and	O
N	O
-	O
glycosylation	O
sites	O
in	O
the	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
Infection	O
by	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
)	O
initiates	O
with	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
binding	B-FUNC
to	O
cellular	O
receptors	O
,	O
and	O
is	O
followed	O
by	O
proteolytic	O
cleavage	O
of	O
receptor	O
-	O
bound	O
S	O
proteins	O
,	O
which	O
prompts	O
S	O
protein	O
-	O
mediated	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
Sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
detecting	O
feline	O
coronavirus	O
mutations	O
in	O
effusion	O
and	O
serum	O
/	O
plasma	O
of	O
cats	O
to	O
diagnose	O
feline	O
infectious	O
peritonitis	O
.	O

Additionally	O
,	O
virtual	O
screening	O
and	O
binding	B-FUNC
experiments	O
were	O
able	O
to	O
identify	O
three	O
new	O
virus	O
-	O
encoded	O
helicase	O
binding	B-FUNC
compounds	O
.	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	O
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	O
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

MERS	O
was	O
recently	O
identified	O
as	O
a	O
candidate	O
for	O
vaccine	O
development	O
,	O
but	O
most	O
efforts	O
focus	O
on	O
antibody	B-FUNC
responses	O
,	O
which	O
are	O
often	O
transient	O
after	O
CoV	O
infections	O
.	O

Using	O
Gene	O
Ontology	O
(	O
GO	O
)	O
enrichment	O
prediction	O
,	O
the	O
DE	O
miRNAs	O
were	O
shown	O
to	O
be	O
mostly	O
associated	O
with	O
metabolic	O
processes	O
,	O
catalytic	O
activities	O
,	O
gene	O
expression	O
,	O
binding	B-FUNC
activities	O
and	O
immune	O
responses	O
.	O

TITLE	O
:	O
Effect	O
of	O
Booster	O
Vaccination	O
with	O
Inactivated	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
on	O
Neutralizing	O
Antibody	B-FUNC
Response	O
in	O
Mammary	O
Secretions	O
.	O

Since	O
neutralizing	O
antibodies	O
in	O
the	O
gut	O
are	O
critical	O
for	O
protection	O
against	O
enteric	O
viral	O
infections	O
such	O
as	O
PEDV	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
a	O
conditionally	O
licensed	O
,	O
adjuvanted	O
inactivated	O
PEDV	O
vaccine	O
on	O
neutralizing	O
antibody	B-FUNC
levels	O
in	O
milk	O
and	O
colostrum	O
in	O
both	O
naive	O
and	O
previously	O
naturally	O
exposed	O
sow	O
herds	O
.	O

The	O
results	O
illustrate	O
that	O
intramuscular	O
vaccination	O
increased	O
neutralizing	O
antibody	B-FUNC
titers	O
,	O
and	O
anti	O
-	O
PEDV	O
IgA	O
and	O
IgG	O
in	O
milk	O
and	O
colostrum	O
of	O
sows	O
that	O
were	O
previously	O
infected	O
.	O

Fusion	O
-	O
inhibiting	O
peptides	O
bind	B-FUNC
to	O
S	O
proteins	O
,	O
interfere	O
with	O
refolding	O
,	O
and	O
prevent	O
infection	O
.	O

The	O
identity	O
of	O
the	O
Chowsingha	O
tissues	O
used	O
for	O
PPRV	O
isolation	O
was	O
confirmed	O
by	O
the	O
12S	O
ribosomal	B-FUNC
RNA	I-FUNC
gene	O
sequencing	O
,	O
and	O
the	O
amplified	O
gene	O
was	O
analysed	O
identically	O
to	O
the	O
Chowsingha	O
mitochondrial	O
12S	O
ribosomal	B-FUNC
RNA	I-FUNC
gene	O
.	O

The	O
structures	O
reveal	O
that	O
G4	O
recognizes	O
a	O
glycosylated	O
loop	O
that	O
is	O
variable	O
among	O
coronaviruses	O
and	O
they	O
define	O
four	O
conformational	O
states	O
of	O
the	O
trimer	O
wherein	O
each	O
receptor	O
-	O
binding	B-FUNC
domain	O
is	O
either	O
tightly	O
packed	O
at	O
the	O
membrane	O
-	O
distal	O
apex	O
or	O
rotated	O
into	O
a	O
receptor	O
-	O
accessible	O
conformation	O
.	O

ABSTRACT	O
:	O
Activation	O
of	O
C	O
-	O
X	O
-	O
C	O
motif	O
chemokine	O
receptor	O
4	O
(	O
CXCR4	B-FUNC
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
lung	O
protective	O
effects	O
in	O
various	O
experimental	O
models	O
.	O

The	O
effects	O
of	O
pharmacological	O
CXCR4	B-FUNC
modulation	O
on	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
lung	O
injury	O
,	O
however	O
,	O
are	O
unknown	O
.	O

Thus	O
,	O
we	O
studied	O
whether	O
blockade	O
and	O
activation	O
of	O
CXCR4	B-FUNC
influences	O
development	O
of	O
ARDS	O
in	O
a	O
unilateral	O
lung	O
ischaemia	O
-	O
reperfusion	O
injury	O
rat	O
model	O
.	O

New	O
Zealand	O
white	O
rabbits	O
are	O
a	O
possible	O
model	O
for	O
asymptomatic	O
infection	O
with	O
MERS	O
-	O
CoV	O
.	O
In	O
order	O
to	O
discover	O
more	O
about	O
non	O
-	O
lethal	O
infections	O
and	O
to	O
learn	O
whether	O
a	O
single	O
infection	O
with	O
MERS	O
-	O
CoV	O
would	O
protect	O
against	O
reinfection	O
,	O
we	O
inoculated	O
rabbits	O
with	O
MERS	O
-	O
CoV	O
and	O
monitored	O
the	O
antibody	B-FUNC
and	O
inflammatory	O
response	O
.	O

Our	O
data	O
from	O
the	O
rabbit	O
model	O
suggests	O
that	O
people	O
exposed	O
to	O
MERS	O
-	O
CoV	O
who	O
fail	O
to	O
develop	O
a	O
neutralizing	O
antibody	B-FUNC
response	O
,	O
or	O
persons	O
whose	O
neutralizing	O
antibody	B-FUNC
titers	O
have	O
waned	O
,	O
may	O
be	O
at	O
risk	O
for	O
severe	O
lung	O
disease	O
on	O
re	O
-	O
exposure	O
to	O
MERS	O
-	O
CoV	O
.	O

The	O
median	O
SOFA	O
Score	O
was	O
13	O
(	O
10	O
to	O
19	O
)	O
and	O
the	O
median	O
LIS	B-FUNC
was	O
3	O
.	O
5	O
(	O
2	O
.	O
67	O
to	O
4	O
).	O

Group	O
3	O
patients	O
showed	O
delayed	O
increment	O
of	O
antibody	B-FUNC
titers	O
during	O
the	O
fourth	O
week	O
,	O
while	O
Group	O
2	O
patients	O
showed	O
robust	O
increment	O
of	O
antibody	B-FUNC
titer	O
during	O
the	O
third	O
week	O
.	O

At	O
14	O
,	O
28	O
,	O
and	O
42	O
days	O
after	O
the	O
first	O
vaccination	O
,	O
serum	O
anti	O
-	O
IBV	O
antibody	B-FUNC
titers	O
;	O
peripheral	O
lymphocyte	O
proliferation	O
;	O
and	O
the	O
mRNA	O
expression	O
of	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
TNF	O
-	O
	O
in	O
the	O
spleen	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
the	O
cell	O
counting	O
kit	B-FUNC
-	O
8	O
(	O
CCK	O
-	O
8	O
),	O
and	O
real	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
respectively	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
effect	O
of	O
serum	O
antibody	B-FUNC
abundance	O
against	O
bovine	O
coronavirus	O
on	O
bovine	O
coronavirus	O
shedding	O
and	O
risk	O
of	O
respiratory	O
tract	O
disease	O
in	O
beef	O
calves	O
from	O
birth	O
through	O
the	O
first	O
five	O
weeks	O
in	O
a	O
feedlot	O
.	O

ABSTRACT	O
:	O
OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
serum	O
antibody	B-FUNC
abundance	O
against	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
on	O
BCV	O
shedding	O
and	O
risk	O
of	O
bovine	O
respiratory	O
disease	O
(	O
BRD	O
)	O
in	O
beef	O
calves	O
from	O
birth	O
through	O
the	O
first	O
5	O
weeks	O
in	O
a	O
feedlot	O
.	O

PROCEDURES	O
Serial	O
blood	O
samples	O
for	O
measurement	O
of	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
abundance	O
by	O
an	O
ELISA	O
and	O
nasal	O
swab	O
specimens	O
for	O
detection	O
of	O
BCV	O
and	O
other	O
viral	O
and	O
bacterial	O
BRD	O
pathogens	O
by	O
real	O
-	O
time	O
PCR	O
methods	O
were	O
collected	O
from	O
all	O
calves	O
or	O
subsets	O
of	O
calves	O
at	O
predetermined	O
times	O
from	O
birth	O
through	O
the	O
first	O
5	O
weeks	O
after	O
feedlot	O
entry	O
.	O

The	O
mean	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
abundance	O
at	O
weaning	O
for	O
a	O
group	O
of	O
calves	O
was	O
inversely	O
related	O
with	O
the	O
subsequent	O
incidence	O
of	O
BRD	O
in	O
that	O
group	O
;	O
however	O
,	O
the	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
abundance	O
at	O
weaning	O
for	O
individual	O
calves	O
was	O
not	O
predictive	O
of	O
which	O
calves	O
would	O
develop	O
BRD	O
after	O
feedlot	O
entry	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Results	O
indicated	O
that	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
abundance	O
as	O
determined	O
with	O
ELISA	O
were	O
not	O
associated	O
with	O
BCV	O
shedding	O
or	O
risk	O
of	O
BRD	O
in	O
individual	O
beef	O
calves	O
from	O
birth	O
through	O
the	O
first	O
5	O
weeks	O
after	O
feedlot	O
entry	O
.	O

The	O
IL	O
-	O
17A	O
levels	O
were	O
significantly	O
correlated	O
with	O
those	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
25	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
IFN	O
-	O
	O
in	O
patients	O
with	O
uncontrolled	O
asthma	O
,	O
and	O
the	O
patients	O
with	O
the	O
highest	O
levels	O
of	O
all	O
the	O
above	O
cytokines	O
were	O
refractory	O
to	O
high	O
-	O
dose	O
of	O
inhaled	O
corticosteroid	O
therapy	O
and	O
have	O
a	O
history	O
of	O
acute	O
exacerbation	O
within	O
1	O
year	O
,	O
requiring	O
systemic	O
steroid	O
therapy	O
.	O

TITLE	O
:	O
Performance	O
Evaluation	O
of	O
the	O
PowerChek	O
MERS	O
(	O
upE	O
&	O
ORF1a	O
)	O
Real	O
-	O
Time	O
PCR	O
Kit	B-FUNC
for	O
the	O
Detection	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
RNA	O
.	O

We	O
evaluated	O
the	O
performance	O
of	O
the	O
PowerChek	O
MERS	O
(	O
upE	O
&	O
ORF1a	O
)	O
real	O
-	O
time	O
PCR	O
Kit	B-FUNC
(	O
PowerChek	O
MERS	O
assay	O
;	O
Kogene	O
Biotech	O
,	O
Korea	O
)	O
a	O
one	O
-	O
step	O
rRT	O
-	O
PCR	O
assay	O
for	O
the	O
qualitative	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
evaluated	O
PowerChek	O
MERS	O
assay	O
performance	O
in	O
comparison	O
with	O
nested	O
RT	O
-	O
PCR	O
and	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
N	O
genes	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
VP1	O
and	O
RdRP	B-FUNC
genes	O
of	O
Brazilian	O
aichivirus	O
B	O
strains	O
involved	O
in	O
a	O
diarrhea	O
outbreak	O
in	O
dairy	O
calves	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
molecular	O
characteristics	O
of	O
the	O
RdRP	B-FUNC
and	O
VP1	O
genes	O
of	O
aichivirus	O
B	O
strains	O
identified	O
as	O
the	O
most	O
frequent	O
etiologic	O
agent	O
in	O
a	O
neonatal	O
diarrhea	O
outbreak	O
in	O
a	O
high	O
-	O
production	O
Brazilian	O
dairy	O
cattle	O
herd	O
.	O

RT	O
-	O
PCR	O
assays	O
were	O
performed	O
for	O
the	O
detection	O
of	O
aichivirus	O
B	O
RdRP	B-FUNC
and	O
VP1	O
genes	O
and	O
for	O
rotavirus	O
A	O
VP7	O
and	O
VP4	O
genes	O
in	O
fecal	O
samples	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
RdRP	B-FUNC
gene	O
grouped	O
the	O
Brazilian	O
strains	O
in	O
a	O
new	O
branch	O
within	O
the	O
aichivirus	O
B	O
group	O
.	O

The	O
positive	O
rate	O
of	O
PDCoV	O
antibody	B-FUNC
was	O
44	O
.	O
17	O
%	O
(	O
269	O
/	O
609	O
).	O

ABSTRACT	O
:	O
Entry	O
of	O
the	O
	O
-	O
coronavirus	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
requires	O
specific	O
proteases	O
to	O
activate	O
spike	O
(	O
S	O
)	O
protein	O
for	O
the	O
membrane	O
fusion	O
of	O
the	O
virion	O
to	O
the	O
host	O
cell	O
following	O
receptor	B-FUNC
binding	I-FUNC
.	O

The	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
is	O
the	O
only	O
viral	O
-	O
encoded	O
enzymatic	O
activity	O
that	O
still	O
lacks	O
an	O
efficient	O
inhibitor	O
.	O

We	O
synthesized	O
a	O
library	O
of	O
3	O
,	O
5	O
-	O
diamino	O
-	O
N	O
-	O
aryl	O
-	O
1H	O
-	O
pyrazole	O
-	O
4	O
-	O
carbothioamide	O
and	O
4	O
-	O
amino	O
-	O
5	O
-	O
benzoyl	O
-	O
N	O
-	O
phenyl	O
-	O
2	O
-(	O
substituted	O
-	O
amino	O
)-	O
1H	O
-	O
pyrrole	O
-	O
3	O
-	O
carbothioamide	O
derivatives	O
and	O
tested	O
them	O
against	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
.	O

Docking	O
simulations	O
hypothesized	O
its	O
binding	B-FUNC
to	O
two	O
RT	O
pockets	O
.	O

Then	O
cytokines	O
including	O
lung	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
plasma	O
HMGB1	O
,	O
apoptosis	O
of	O
splenic	O
immune	O
cells	O
and	O
Foxp3	O
level	O
on	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
were	O
studied	O
to	O
demonstrate	O
the	O
mechanisms	O
of	O
EP	O
administration	O
on	O
two	O
-	O
hit	O
mice	O
.	O

We	O
found	O
that	O
the	O
susceptibility	O
of	O
septic	O
mice	O
to	O
Secondary	O
Pseudomonas	O
aeruginosa	O
pneumonia	O
could	O
be	O
down	O
-	O
regulated	O
by	O
ethyl	O
pyruvate	O
treatment	O
and	O
the	O
protective	O
effects	O
of	O
EP	O
may	O
via	O
decreasing	O
lung	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
plasma	O
HMGB1	O
expression	O
,	O
inhibiting	O
the	O
function	O
of	O
Tregs	O
and	O
relieving	O
the	O
apoptosis	O
of	O
splenic	O
immune	O
cells	O
.	O

Currently	O
,	O
several	O
therapeutic	O
options	O
have	O
been	O
employed	O
,	O
such	O
as	O
convalescent	O
plasma	O
(	O
CP	O
),	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
),	O
monoclonal	O
antibodies	O
and	O
repurposing	O
of	O
existing	O
clinically	O
approved	O
drugs	O
.	O

In	O
the	O
absence	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
mice	O
had	O
elevated	O
viral	O
replication	O
and	O
poor	O
survival	O
,	O
and	O
this	O
protective	O
effect	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
was	O
found	O
to	O
be	O
due	O
to	O
promotion	O
of	O
interferon	O
gamma	O
production	O
in	O
	O
T	O
cells	O
.	O

Using	O
IBV	O
Arkansas	O
-	O
type	O
(	O
Ark	O
)	O
S	O
protein	O
histochemistry	O
,	O
we	O
show	O
that	O
extension	O
of	O
S1	O
with	O
the	O
S2	O
ectodomain	O
improves	O
binding	B-FUNC
to	O
chicken	O
tissues	O
.	O

The	O
demonstrated	O
contribution	O
of	O
S2	O
ectodomain	O
to	O
binding	B-FUNC
to	O
chicken	O
tissues	O
suggests	O
that	O
vaccination	O
with	O
the	O
ectodomain	O
might	O
improve	O
protection	O
compared	O
to	O
vaccination	O
with	O
S1	O
alone	O
.	O

TITLE	O
:	O
Structural	O
insights	O
into	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
4a	O
protein	O
and	O
its	O
dsRNA	B-FUNC
binding	I-FUNC
mechanism	O
.	O

The	O
structural	O
analysis	O
revealed	O
that	O
p4a	O
exhibits	O
a	O
typical	O
	O
fold	O
structure	O
,	O
as	O
found	O
in	O
other	O
dsRNA	O
-	O
binding	B-FUNC
proteins	O
.	O

What	O
we	O
found	O
was	O
that	O
MERS	O
-	O
5HB	O
could	O
bind	B-FUNC
to	O
HR2P	O
,	O
a	O
peptide	O
derived	O
from	O
HR2	O
,	O
with	O
a	O
strong	O
affinity	O
value	O
(	O

Vaccination	O
of	O
swine	O
with	O
rSPV	O
-	O
St	O
elicited	O
a	O
robust	O
antibody	B-FUNC
response	O
specific	O
for	O
the	O
homologous	O
PEDV	O
SQ2014	O
.	O

When	O
challenged	O
with	O
the	O
homologous	O
virus	O
,	O
sera	B-FUNC
from	O
rSPV	O
-	O
St	O
vaccination	O
provided	O
complete	O
protection	O
.	O

The	O
new	O
test	O
is	O
based	O
on	O
the	O
analysis	O
of	O
virus	O
-	O
elicited	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibody	B-FUNC
present	O
in	O
the	O
protein	O
corona	O
of	O
a	O
gold	O
nanoparticle	O
surface	O
upon	O
mixing	O
the	O
gold	O
nanoparticles	O
with	O
blood	O
sera	B-FUNC
.	O

Transcriptional	O
regulatory	O
sequences	O
(	O
TRS	B-FUNC
)	O
of	O
SARS	O
-	O
CoV	O
and	O
Mouse	O
Hepatitis	O
Virus	O
(	O
MHV	O
)	O
sgmRNAs	O
contain	O
a	O
species	O
specific	O
core	O
element	O
(	O
CE	O
).	O

As	O
part	O
of	O
its	O
viral	O
genome	O
,	O
MERS	O
-	O
CoV	O
encodes	O
a	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
that	O
has	O
been	O
observed	O
to	O
act	O
as	O
a	O
deubiquitinase	B-FUNC
and	O
deISGylase	O
to	O
antagonize	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
immune	O
pathways	O
.	O

Utilizing	O
this	O
structural	O
information	O
,	O
mutants	O
were	O
generated	O
that	O
lacked	O
appreciable	O
deISGylase	O
activity	O
but	O
retained	O
wild	O
-	O
type	O
deubiquitinase	B-FUNC
and	O
peptide	O
cleavage	O
activities	O
.	O

We	O
also	O
discuss	O
various	O
cellular	O
processes	O
,	O
such	O
as	O
apoptosis	O
,	O
innate	O
immunity	O
,	O
ER	O
stress	O
response	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
pathway	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
pathway	O
that	O
may	O
be	O
modulated	O
by	O
HCoVs	O
.	O

After	O
immunizing	O
BALB	O
/	O
c	O
mice	O
intramuscularly	O
,	O
rH7HA	O
proteins	O
formulated	O
in	O
this	O
adjuvant	O
instead	O
of	O
an	O
alum	O
adjuvant	O
elicited	O
higher	O
IgG	O
,	O
hemagglutination	O
-	O
inhibition	O
,	O
and	O
virus	O
neutralizing	O
antibodies	O
in	O
sera	B-FUNC
;	O
induced	O
higher	O
numbers	O
of	O
H7HA	O
-	O
specific	O
IFN	O
-	O
	O
-	O
secreting	O
T	O
cells	O
and	O
antibody	B-FUNC
secreting	O
cells	O
in	O
spleen	O
;	O
and	O
provided	O
improved	O
protection	O
against	O
live	O
virus	O
challenges	O
.	O

The	O
serum	O
zinc	O
level	O
and	O
the	O
pulmonary	O
function	O
tests	O
and	O
liver	O
function	O
tests	O
including	O
total	O
lung	O
capacity	O
(	O
TLC	O
),	O
forced	O
vital	O
capacity	O
(	O
FVC	O
),	O
forced	O
expiratory	O
pressure	O
in	O
1	O
second	O
(	O
FEV1	O
),	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
and	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
were	O
analyzed	O
.	O

Three	O
selected	O
isolates	O
were	O
identified	O
as	O
IBV	O
using	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
assay	O
targeted	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
further	O
characterized	O
by	O
partial	O
spike	O
(	O
S	O
)	O
gene	O
sequence	O
analysis	O
.	O

TITLE	O
:	O
Plasma	O
long	O
noncoding	O
RNA	O
IL	B-FUNC
-	I-FUNC
7R	I-FUNC
as	O
a	O
prognostic	O
biomarker	O
for	O
clinical	O
outcomes	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
clinical	O
significance	O
of	O
mechanical	O
ventilation	O
on	O
ischemic	O
-	O
reperfusion	O
injury	O
caused	O
by	O
lung	O
chest	O
trauma	O
as	O
well	O
as	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
)	O
expression	O
levels	O
in	O
peripheral	O
blood	O
.	O

stigmatosoma	O
,	O
collected	O
from	O
30	O
sites	O
in	O
southern	O
California	O
from	O
2009	O
-	O
2012	O
,	O
were	O
processed	O
for	O
vertebrate	O
host	O
identification	O
by	O
nucleotide	O
sequencing	O
following	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
portions	O
of	O
the	O
cytochrome	B-FUNC
oxidase	O
I	O
and	O
cytochrome	B-FUNC
b	O
genes	O
of	O
vertebrate	O
animals	O
.	O

The	O
data	O
of	O
this	O
survey	O
also	O
provided	O
valuable	O
information	O
about	O
the	O
replication	O
of	O
IBD	O
vaccines	O
and	O
subsequent	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)	O
antibody	B-FUNC
responses	O
under	O
field	O
conditions	O
.	O

Detection	O
of	O
vaccine	O
virus	O
in	O
the	O
bursa	O
and	O
antibody	B-FUNC
response	O
to	O
the	O
IBD	O
vaccination	O
in	O
flocks	O
that	O
had	O
been	O
vaccinated	O
by	O
the	O
drinking	O
water	O
with	O
a	O
live	O
attenuated	O
vaccine	O
compared	O
to	O
a	O
vaccination	O
in	O
the	O
hatchery	O
using	O
an	O
immune	O
-	O
complex	O
vaccine	O
showed	O
a	O
delayed	O
replication	O
of	O
the	O
vaccines	O
that	O
had	O
been	O
applied	O
by	O
the	O
drinking	O
water	O
,	O
indicating	O
mistakes	O
in	O
the	O
timing	O
and	O
/	O
or	O
application	O
of	O
the	O
vaccines	O
.	O

TITLE	O
:	O
Treatments	O
for	O
Pulmonary	O
Ricin	B-FUNC
Intoxication	O
:	O
Current	O
Aspects	O
and	O
Future	O
Prospects	O
.	O

ABSTRACT	O
:	O
Ricin	B-FUNC
,	O
a	O
plant	O
-	O
derived	O
toxin	O
originating	O
from	O
the	O
seeds	O
of	O
Ricinus	O
communis	O
(	O
castor	O
beans	O
),	O
is	O
one	O
of	O
the	O
most	O
lethal	O
toxins	O
known	O
,	O
particularly	O
if	O
inhaled	O
.	O

Ricin	B-FUNC
is	O
considered	O
a	O
potential	O
biological	O
threat	O
agent	O
due	O
to	O
its	O
high	O
availability	O
and	O
ease	O
of	O
production	O
.	O

The	O
clinical	O
manifestation	O
of	O
pulmonary	O
ricin	B-FUNC
intoxication	O
in	O
animal	O
models	O
is	O
closely	O
related	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
involves	O
pulmonary	O
proinflammatory	O
cytokine	O
upregulation	O
,	O
massive	O
neutrophil	O
infiltration	O
and	O
severe	O
edema	O
.	O

The	O
efficacy	O
of	O
this	O
antitoxin	O
treatment	O
depends	O
on	O
antibody	B-FUNC
affinity	O
and	O
the	O
time	O
of	O
treatment	O
initiation	O
within	O
a	O
limited	O
therapeutic	O
time	O
window	O
.	O

This	O
review	O
focuses	O
on	O
the	O
current	O
treatment	O
options	O
for	O
pulmonary	O
ricin	B-FUNC
intoxication	O
using	O
anti	O
-	O
ricin	B-FUNC
antibodies	O
,	O
disease	O
-	O
modifying	O
countermeasures	O
,	O
anti	O
-	O
ricin	B-FUNC
small	O
molecules	O
and	O
their	O
various	O
combinations	O
.	O

The	O
inflammatory	O
cytokine	O
levels	O
,	O
including	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
were	O
examined	O
by	O
ELISA	O
assay	O
,	O
and	O
the	O
TLR4	O
and	O
NF	O
-	O
Bp65	O
expression	O
levels	O
were	O
evaluated	O
by	O
Real	O
time	O
-	O
PCR	O
and	O
western	O
blotting	O
.	O

ABSTRACT	O
:	O
The	O
folding	O
of	O
natural	O
proteins	O
typically	O
relies	O
on	O
hydrophobic	O
packing	O
,	O
metal	B-FUNC
binding	I-FUNC
,	O
or	O
disulfide	O
bond	O
formation	O
in	O
the	O
protein	O
core	O
.	O

Reverse	O
-	O
transcriptase	B-FUNC
quantitative	O
-	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
was	O
performed	O
on	O
all	O
samples	O
using	O
FCoV	O
-	O
specific	O
primers	O
,	O
followed	O
by	O
sequencing	O
of	O
a	O
section	O
of	O
the	O
S	O
gene	O
on	O
RT	O
-	O
qPCR	O
positive	O
samples	O
.	O

The	O
S	O
-	O
INDEL	O
-	O
inoculated	O
pigs	O
had	O
lower	O
ileal	O
IgA	O
antibody	B-FUNC
secreting	O
cells	O
,	O
serum	O
IgA	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
compared	O
with	O
PC21A	O
-	O
inoculated	O
pigs	O
.	O

TITLE	O
:	O
The	O
bulky	O
and	O
the	O
sweet	O
:	O
How	O
neutralizing	O
antibodies	O
and	O
glycan	O
receptors	O
compete	O
for	O
virus	O
binding	B-FUNC
.	O

ABSTRACT	O
:	O
Numerous	O
viruses	O
rely	O
on	O
glycan	O
receptor	B-FUNC
binding	I-FUNC
as	O
the	O
initial	O
step	O
in	O
host	O
cell	O
infection	O
.	O

Glycan	O
receptor	O
-	O
binding	B-FUNC
sites	O
are	O
typically	O
located	O
in	O
exposed	O
regions	O
on	O
viral	O
surfaces	O
-	O
sites	O
that	O
are	O
also	O
generally	O
prone	O
to	O
binding	B-FUNC
of	O
neutralizing	O
antibodies	O
that	O
directly	O
interfere	O
with	O
virus	O
-	O
glycan	O
receptor	O
interactions	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
locations	O
and	O
architecture	O
of	O
the	O
glycan	O
-	O
and	O
antibody	B-FUNC
-	O
binding	B-FUNC
sites	O
in	O
four	O
different	O
viruses	O
with	O
stalk	O
-	O
like	O
attachment	O
proteins	O
(	O
reovirus	O
,	O
influenza	O
virus	O
,	O
norovirus	O
,	O
and	O
coronavirus	O
)	O
and	O
investigate	O
the	O
mechanisms	O
by	O
which	O
antibodies	O
block	O
glycan	O
recognition	O
.	O

Those	O
viruses	O
exemplify	O
that	O
direct	O
molecular	O
mimicking	O
of	O
glycan	O
receptors	O
by	O
antibodies	O
is	O
rare	O
and	O
further	O
demonstrate	O
that	O
antibodies	O
often	O
partly	O
overlap	O
or	O
bind	B-FUNC
sufficiently	O
close	O
to	O
the	O
receptor	O
-	O
binding	B-FUNC
region	O
to	O
hinder	O
access	O
to	O
this	O
site	O
,	O
achieving	O
neutralization	O
partially	O
because	O
of	O
the	O
epitope	O
location	O
and	O
partly	O
due	O
to	O
their	O
sheer	O
size	O
.	O

The	O
N	O
-	O
terminus	O
of	O
S2	O
subunit	O
of	O
SARS	O
-	O
CoV	O
reported	O
to	O
be	O
active	O
in	O
cell	O
fusion	O
whereby	O
FPs	B-FUNC
have	O
been	O
identified	O
.	O

Atomic	O
-	O
resolution	O
structure	O
of	O
FPs	B-FUNC
derived	O
either	O
in	O
model	O
membranes	O
or	O
in	O
membrane	O
mimic	O
environment	O
would	O
glean	O
insights	O
toward	O
viral	O
cell	O
fusion	O
mechanism	O
.	O

TITLE	O
:	O
Characterization	O
of	O
novel	O
monoclonal	O
antibodies	O
against	O
the	O
MERS	O
-	O
coronavirus	O
spike	O
protein	O
and	O
their	O
application	O
in	O
species	O
-	O
independent	O
antibody	B-FUNC
detection	O
by	O
competitive	O
ELISA	O
.	O

ABSTRACT	O
:	O
Since	O
discovering	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
a	O
causative	O
agent	O
of	O
severe	O
respiratory	O
illness	O
in	O
the	O
Middle	O
East	O
in	O
2012	O
,	O
serological	O
testing	O
has	O
been	O
conducted	O
to	O
assess	O
antibody	B-FUNC
responses	O
in	O
patients	O
and	O
to	O
investigate	O
the	O
zoonotic	O
reservoir	O
of	O
the	O
virus	O
.	O

Competitive	O
ELISA	O
(	O
cELISA	O
),	O
in	O
which	O
a	O
labeled	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
competes	O
with	O
test	O
serum	O
antibodies	O
for	O
target	O
epitopes	O
,	O
may	O
be	O
a	O
suitable	O
alternative	O
because	O
it	O
detects	O
antibodies	O
in	O
a	O
species	O
-	O
independent	O
manner	O
.	O

The	O
cELISA	O
detected	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
in	O
sera	B-FUNC
from	O
MERS	O
-	O
CoV	O
-	O
infected	O
rats	O
and	O
rabbits	O
immunized	O
with	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
MAb	O
-	O
based	O
cELISA	O
was	O
validated	O
using	O
sera	B-FUNC
from	O
Ethiopian	O
dromedary	O
camels	O
.	O

For	O
the	O
PEDV	O
diagnosis	O
,	O
a	O
rapid	O
test	O
kit	B-FUNC
that	O
is	O
specific	O
and	O
sensitive	O
to	O
PEDV	O
is	O
critical	O
to	O
monitor	O
this	O
disease	O
at	O
pig	O
farms	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
response	O
to	O
equine	O
coronavirus	O
in	O
horses	O
inoculated	O
with	O
a	O
bovine	O
coronavirus	O
vaccine	O
.	O

This	O
study	O
investigated	O
antibody	B-FUNC
response	O
to	O
ECoV	O
in	O
horses	O
inoculated	O
with	O
BCoV	O
vaccine	O
.	O

Virus	O
neutralization	O
tests	O
showed	O
that	O
antibody	B-FUNC
titers	O
against	O
ECoV	O
increased	O
in	O
all	O
six	O
horses	O
tested	O
at	O
14	O
days	O
post	O
inoculation	O
,	O
although	O
the	O
antibody	B-FUNC
titers	O
were	O
lower	O
against	O
ECoV	O
than	O
against	O
BCoV	O
.	O
This	O
study	O
showed	O
that	O
BCoV	O
vaccine	O
provides	O
horses	O
with	O
antibodies	O
against	O
ECoV	O
to	O
some	O
extent	O
.	O

By	O
combining	O
a	O
bio	O
-	O
optical	O
sensor	O
,	O
that	O
transduces	O
the	O
presence	O
of	O
the	O
target	O
DNA	O
based	O
on	O
binding	B-FUNC
-	O
induced	O
changes	O
in	O
the	O
refractive	O
index	O
on	O
the	O
waveguide	O
surface	O
in	O
a	O
label	O
-	O
free	O
and	O
real	O
-	O
time	O
manner	O
,	O
with	O
isothermal	O
DNA	O
amplification	O
,	O
this	O
new	O
diagnostic	O
tool	O
offers	O
a	O
rapid	O
(<	O
20	O
min	O
),	O
1	O
-	O
step	O
DNA	O
amplification	O
/	O
detection	O
method	O
.	O

In	O
vivo	O
immunization	O
of	O
chickens	O
showed	O
that	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
/	O
IBV	O
NPs	O
or	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
-	O
IBV	O
NPs	O
intranasally	O
induced	O
higher	O
titers	O
of	O
IgG	O
and	O
IgA	O
antibodies	O
,	O
significantly	O
promoted	O
proliferation	O
of	O
lymphocytes	O
and	O
induced	O
higher	O
levels	O
of	O
interleukine	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
interferon	O
-	O
	O
(	O
IFN	O
-	O
	O
)	O
than	O
the	O
commercially	O
combined	O
attenuated	O
live	O
vaccine	O
did	O
.	O

The	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
and	O
the	O
placental	O
growth	O
factor	O
(	O
PlGF	O
)	O
are	O
vascular	O
permeability	O
factors	O
and	O
may	O
be	O
involved	O
in	O
the	O
disruption	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	O
,	O
leading	O
to	O
alveolar	O
edema	O
.	O

To	O
do	O
so	O
,	O
we	O
used	O
16S	O
ribosomal	B-FUNC
RNA	I-FUNC
gene	O
amplicon	O
sequencing	O
of	O
endotracheal	O
aspirate	O
samples	O
obtained	O
on	O
ICU	O
admission	O
(	O
n	O
=	O
74	O
)	O
and	O
at	O
48	O
hours	O
after	O
admission	O
(	O
n	O
=	O
30	O
).	O

In	O
this	O
study	O
,	O
several	O
nsps	O
encoded	O
by	O
avian	O
gammacoronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
screened	O
for	O
RNA	O
-	O
binding	B-FUNC
activity	O
and	O
interaction	O
with	O
its	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
nsp12	O
.	O

Nsp2	O
,	O
nsp5	O
,	O
nsp8	O
,	O
nsp9	O
and	O
nsp10	O
were	O
found	O
to	O
bind	B-FUNC
to	O
untranslated	O
regions	O
(	O
UTRs	O
),	O
while	O
nsp8	O
was	O
confirmed	O
to	O
interact	O
with	O
nsp12	O
.	O

TITLE	O
:	O
Murine	O
Hepatitis	O
Virus	O
nsp14	O
Exoribonuclease	B-FUNC
Activity	I-FUNC
Is	O
Required	O
for	O
Resistance	O
to	O
Innate	O
Immunity	O
.	O

CoV	O
nonstructural	O
protein	O
14	O
(	O
nsp14	O
)	O
encodes	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	B-FUNC
activity	I-FUNC
(	O
ExoN	O
),	O
which	O
performs	O
a	O
proofreading	O
function	O
and	O
is	O
required	O
for	O
high	O
-	O
fidelity	O
replication	O
.	O

Isothermal	O
titration	O
calorimetry	O
showed	O
a	O
direct	O
interaction	O
between	O
calcium	O
cations	O
and	O
both	O
FPs	B-FUNC
.	O

Within	O
a	O
cleft	O
formed	O
at	O
the	O
interface	O
of	O
these	O
two	O
domains	O
,	O
the	O
peptide	O
substrate	O
is	O
thought	O
to	O
bind	B-FUNC
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
retrospective	O
investigation	O
of	O
the	O
antibody	B-FUNC
response	O
in	O
plasma	O
samples	O
from	O
37	O
cases	O
of	O
hospitalized	O
patients	O
and	O
analysed	O
the	O
relationship	O
between	O
the	O
antibody	B-FUNC
response	O
and	O
the	O
clinical	O
outcomes	O
.	O

Our	O
results	O
showed	O
that	O
the	O
HA7	O
-	O
binding	B-FUNC
antibody	B-FUNC
was	O
generated	O
earlier	O
than	O
the	O
neutralizing	O
antibody	B-FUNC
.	O

TITLE	O
:	O
CD59	O
association	O
with	O
infectious	O
bronchitis	O
virus	O
particles	O
protects	O
against	O
antibody	B-FUNC
-	O
dependent	O
complement	O
-	O
mediated	O
lysis	O
.	O

PdCoV	O
S1	O
-	O
CTD	O
binds	B-FUNC
to	O
an	O
unidentified	O
receptor	O
on	O
host	O
cell	O
surfaces	O
.	O

In	O
the	O
spleen	O
,	O
and	O
in	O
the	O
combined	O
data	O
set	O
of	O
the	O
shell	O
gland	O
and	O
spleen	O
,	O
the	O
two	O
most	O
stable	O
and	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
were	O
TBP	O
and	O
YWHAZ	O
,	O
and	O
ribosomal	B-FUNC
protein	I-FUNC
L4	O
(	O
RPL4	O
)	O
and	O
ALB	O
,	O
respectively	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
a	O
novel	O
extracorporeal	O
cytokine	O
hemoadsorption	O
device	O
on	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
elimination	O
in	O
septic	O
patients	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

Primary	O
outcome	O
was	O
change	O
in	O
normalized	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
-	O
serum	O
concentrations	O
during	O
study	O
day	O
1	O
and	O
7	O
.	O

Significant	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
elimination	O
,	O
averaging	O
between	O
5	O
and	O
18	O
%	O
per	O
blood	O
pass	O
throughout	O
the	O
entire	O
treatment	O
period	O
was	O
recorded	O
.	O

In	O
this	O
patient	O
population	O
with	O
predominantly	O
septic	O
shock	O
and	O
multiple	O
organ	O
failure	O
,	O
hemoadsorption	O
removed	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
but	O
this	O
did	O
not	O
lead	O
to	O
lower	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
-	O
levels	O
.	O

Higher	O
expression	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IFN	O
-	O
	O
were	O
recorded	O
in	O
DCs	O
after	O
treatment	O
with	O
Zhejiang08	O
for	O
24	O
h	O
.	O
Furthermore	O
,	O
genome	O
sequencing	O
and	O
phylogenetic	O
analysis	O
revealed	O
high	O
homology	O
between	O
the	O
main	O
antigen	O
epitopes	O
of	O
Zhejiang08	O
and	O
PEDV	O
pandemic	O
isolates	O
following	O
2011	O
.	O

Specific	O
fluorescence	O
signal	O
was	O
detected	O
in	O
Vero	O
cells	O
infected	O
with	O
SeACoV	O
by	O
using	O
a	O
positive	O
sow	O
serum	O
collected	O
in	O
the	O
same	O
farm	O
,	O
but	O
not	O
by	O
using	O
TGEV	O
-,	O
PEDV	O
-	O
or	O
PDCoV	O
-	O
specific	O
antibody	B-FUNC
.	O

Here	O
we	O
show	O
that	O
V	O
-	O
set	O
immunoglobulin	B-FUNC
-	O
domain	O
-	O
containing	O
4	O
(	O
VSIG4	O
),	O
a	O
B7	O
family	O
-	O
related	O
protein	O
that	O
is	O
expressed	O
by	O
resting	O
macrophages	O
,	O
inhibits	O
macrophage	O
activation	O
in	O
response	O
to	O
lipopolysaccharide	O
.	O

With	O
the	O
emergence	O
of	O
novel	O
coronaviruses	O
such	O
as	O
SARS	O
and	O
MERS	O
,	O
the	O
need	O
for	O
fast	B-FUNC
genome	O
characterisation	O
is	O
ever	O
so	O
important	O
.	O

TITLE	O
:	O
Discrepancies	O
between	O
feline	O
coronavirus	O
antibody	B-FUNC
and	O
nucleic	O
acid	O
detection	O
in	O
effusions	O
of	O
cats	O
with	O
suspected	O
feline	O
infectious	O
peritonitis	O
.	O

Three	O
samples	O
with	O
high	O
antibody	B-FUNC
levels	O
tested	O
negative	O
by	O
qRT	O
-	O
PCR	O
,	O
whereas	O
18	O
qRT	O
-	O
PCR	O
positive	O
effusions	O
contained	O
no	O
or	O
low	O
-	O
titre	O
antibodies	O
.	O

qRT	O
-	O
PCR	O
positive	O
samples	O
with	O
low	O
antibody	B-FUNC
titres	O
mostly	O
contained	O
low	O
FCoV	O
RNA	O
loads	O
,	O
although	O
the	O
highest	O
antibody	B-FUNC
titres	O
were	O
detected	O
in	O
effusions	O
with	O
C	O

TITLE	O
:	O
Feline	O
coronavirus	O
antibody	B-FUNC
titer	O
in	O
cerebrospinal	O
fluid	O
from	O
cats	O
with	O
neurological	O
signs	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
utility	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
anti	O
-	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibody	B-FUNC
test	O
for	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
the	O
antibody	B-FUNC
titers	O
were	O
tested	O
in	O
CSF	O
and	O
sera	B-FUNC
from	O
271	O
FIP	O
-	O
suspected	O
neurological	O
cats	O
.	O

However	O
,	O
eight	O
domains	O
of	O
Nsp3	O
exist	O
in	O
all	O
known	O
CoVs	O
:	O
the	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
1	O
(	O
Ubl1	O
),	O
the	O
Glu	O
-	O
rich	O
acidic	O
domain	O
(	O
also	O
called	O
""""	O
hypervariable	O
region	O
"""),"	O
a	O
macrodomain	O
(	O
also	O
named	O
""""	O
X	O
domain	O
"""),"	O
the	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
the	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PL2	O

The	O
virus	O
binds	B-FUNC
to	O
target	O
cells	O
by	O
use	O
of	O
heparan	O
sulfate	O
proteoglycans	O
and	O
interacts	O
with	O
the	O
ACE2	O
protein	O
.	O

In	O
these	O
situations	O
,	O
establishing	O
an	O
extracorporeal	O
circuit	O
,	O
combining	O
a	O
centrifugal	O
pump	O
and	O
a	O
membrane	O
oxygenator	O
(	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
,	O
ECMO	O
),	O
can	O
ensure	O
total	O
pulmonary	O
assistance	O
and	O
allow	O
the	O
lungs	O
to	O
rest	B-FUNC
under	O
ultraprotective	O
mechanical	O
ventilation	O
.	O

However	O
,	O
the	O
use	O
of	O
MSCs	B-FUNC
,	O
their	O
specific	O
methods	O
and	O
risks	O
,	O
especially	O
on	O
the	O
risk	O
of	O
iatrogenic	O
tumor	O
formation	O
remains	O
unresolved	O
.	O

In	O
this	O
paper	O
,	O
we	O
reviewed	O
the	O
main	O
problems	O
in	O
the	O
application	O
of	O
MSCs	B-FUNC
in	O
the	O
treatment	O
of	O
ALI	O
and	O
the	O
main	O
problems	O
in	O
the	O
application	O
of	O
MSCs	B-FUNC
in	O
order	O
to	O
explore	O
the	O
feasibility	O
and	O
future	O
direction	O
of	O
MSCs	B-FUNC
in	O
the	O
treatment	O
of	O
ALI	O
.	O

Histological	O
examination	O
revealed	O
MERS	O
-	O
CoV	O
enteric	O
infection	O
in	O
all	O
inoculated	O
mice	O
,	O
as	O
shown	O
by	O
the	O
presence	O
of	O
virus	O
-	O
positive	O
cells	O
,	O
progressive	O
inflammation	O
,	O
and	O
epithelial	O
degeneration	O
in	O
small	O
intestines	O
,	O
which	O
were	O
exaggerated	O
in	O
the	O
mice	O
pretreated	O
with	O
the	O
proton	B-FUNC
pump	I-FUNC
inhibitor	O
pantoprazole	O
.	O

The	O
interleukin	O
(	O
IL	O
)-	O
36	O
cytokines	O
(	O
IL	O
-	O
36	O
,	O
IL	O
-	O
36	O
and	O
IL	O
-	O
36	O
)	O
are	O
newly	O
described	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
like	O
family	O
cytokines	O
that	O
promote	O
inflammatory	O
response	O
via	O
binding	B-FUNC
to	O
the	O
IL	O
-	O
36	O
receptor	O
(	O
IL	O
-	O
36R	O
).	O

GI	O
symptoms	O
were	O
more	O
likely	O
declared	O
in	O
case	O
of	O
laboratory	O
confirmed	O
-	O
enteric	O
infection	O
(	O
adjusted	O
odds	O
ratio	O
(	O
aOR	B-FUNC
)	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
[	O
1	O
.	O
2	O
-	O
9	O
.	O
9	O
];	O
p	O
=	O
0	O
.	O
02	O
)	O
or	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infection	O
(	O
aOR	B-FUNC
=	O
2	O
.	O
7	O
;	O
[	O
1	O
.	O
2	O
-	O
6	O
.	O
8	O
];	O
p	O
=	O
0	O
.	O
02	O
).	O

Consumption	O
of	O
antipyretic	O
medication	O
before	O
the	O
consultation	O
seemed	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
GI	O
symptoms	O
for	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
aOR	B-FUNC
=	O
0	O
.	O
3	O
;	O
[	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
];	O
p	O
=	O
0	O
.	O
002	O
).	O

The	O
detected	O
coronaviruses	O
shared	O
a	O
conserved	O
gene	O
sequences	O
in	O
S	O
and	O
RdRp	B-FUNC
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
cytosolic	O
phospholipase	B-FUNC
A	I-FUNC

Based	O
on	O
typical	O
clinical	O
features	O
,	O
and	O
on	O
positivity	O
for	O
serum	O
GD1b	O
-	O
IgM	O
antibodies	O
,	O
GBS	O
with	O
proximal	O
conduction	O
failure	O
at	O
multiple	O
radicular	O
levels	O
was	O
postulated	O
,	O
and	O
a	O
standard	O
regime	O
of	O
intravenous	O
immunoglobulin	B-FUNC
was	O
administered	O
.	O

Viral	O
titers	O
were	O
calculated	O
by	O
using	O
the	O
plaque	O
formation	O
assay	O
,	O
and	O
the	O
cytotoxicity	O
of	O
APS	O
was	O
tested	O
by	O
utilizing	O
a	O
Cell	O
Counting	O
Kit	B-FUNC
-	O
8	O
assay	O
.	O

The	O
expression	O
of	O
viral	O
mRNA	O
and	O
cytokine	O
(	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
	O
)	O
mRNA	O
transcripts	O
was	O
determined	O
by	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
).	O

We	O
also	O
found	O
that	O
the	O
decreased	O
viral	O
replication	O
after	O
APS	O
treatment	O
was	O
associated	O
with	O
reduced	O
mRNA	O
levels	O
of	O
the	O
cytokines	O
IL	O
-	O
1B	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNF	O
-	O
	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
loops	O
in	O
alphacoronavirus	O
adaptation	O
and	O
evolution	O
.	O

Here	O
we	O
report	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
229E	O
,	O
in	O
complex	O
with	O
the	O
ectodomain	O
of	O
its	O
receptor	O
,	O
aminopeptidase	O
N	O
(	O
APN	O
).	O

Three	O
extended	O
loops	O
are	O
solely	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
the	O
evolution	O
of	O
HCoV	O
-	O
229E	O
and	O
its	O
close	O
relatives	O
is	O
accompanied	O
by	O
changing	O
loop	O
-	O
receptor	O
interactions	O
.	O

These	O
RBD	O
classes	O
differ	O
in	O
their	O
affinity	O
for	O
APN	O
and	O
their	O
ability	O
to	O
bind	B-FUNC
an	O
HCoV	O
-	O
229E	O
neutralizing	O
antibody	B-FUNC
.	O

Together	O
,	O
our	O
results	O
provide	O
a	O
model	O
for	O
alphacoronavirus	O
adaptation	O
and	O
evolution	O
based	O
on	O
the	O
use	O
of	O
extended	O
loops	O
for	O
receptor	B-FUNC
binding	I-FUNC
.	O

These	O
viruses	O
can	O
interfere	O
with	O
the	O
specific	O
steps	O
of	O
viral	O
life	O
cycle	O
by	O
blocking	O
the	O
binding	B-FUNC
between	O
virus	O
and	O
host	O
cells	O
,	O
disrupting	O
viral	O
endocytosis	O
,	O
disturbing	O
membrane	O
fusion	O
,	O
and	O
interrupting	O
viral	O
RNA	O
replication	O
and	O
translation	O
,	O
thereby	O
demonstrating	O
potent	O
therapeutic	O
effect	O
against	O
various	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
.	O

We	O
suggest	O
to	O
consider	O
inflammation	O
in	O
ARDS	O
as	O
a	O
system	O
controlled	O
by	O
scale	O
-	O
free	O
networks	O
of	O
genome	O
-	O
wide	O
molecular	B-FUNC
interaction	I-FUNC
with	O
hubs	O
(	O
e	O
.	O
g	O
.	O
NFB	O
,	O
C	O
/	O
EBP	O
,	O
ATF3	O
),	O
exhibiting	O
nonlinear	O
emergence	O
and	O
the	O
ability	O
to	O
adapt	O
,	O
meaning	O
for	O
instance	O
that	O
mild	O
and	O
life	O
-	O
threatening	O
inflammation	O
in	O
ARDS	O
are	O
distinct	O
processes	O
.	O

The	O
results	O
showed	O
that	O
higher	O
anti	O
-	O
PEDV	O
serum	O
IgG	O
and	O
mucosal	O
SIgA	O
antibody	B-FUNC
responses	O
were	O
induced	O
in	O
mice	O
orally	O
immunized	O
with	O
strain	O
pPG	O
-	O
COE	O
-	O
Co1	O
/	O
L393	O
as	O
compared	O
to	O
the	O
mice	O
immunized	O
with	O
strain	O
L393	O
expressing	O
COE	O
alone	O
or	O
carrying	O
the	O
empty	O
plasmid	O
.	O

Furthermore	O
,	O
M	O
cell	O
-	O
targeting	O
peptide	O
ligand	B-FUNC
Co1	O
is	O
a	O
good	O
mucosal	O
adjuvant	O
.	O

RESULTS	O
:	O
BAL	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
as	O
well	O
as	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	O
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

Importantly	O
,	O
strains	O
with	O
high	O
genetic	O
similarity	O
to	O
SARS	O
-	O
CoV	O
in	O
the	O
hypervariable	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
and	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
S1	O
gene	O
,	O
the	O
ORF3	O
and	O
ORF8	O
region	O
,	O
respectively	O
,	O
were	O
all	O
discovered	O
in	O
this	O
cave	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
HR2P	O
peptide	O
and	O
anti	O
-	O
HR2P	O
antibody	B-FUNC
can	O
serve	O
as	O
a	O
tool	O
for	O
dissecting	O
the	O
fusion	O
mechanism	O
of	O
PEDV	O
,	O
guiding	O
the	O
search	O
for	O
potent	O
inhibitors	O
with	O
therapeutic	O
value	O
against	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
microRNA	O
-	O
4331	O
Promotes	O
Transmissible	O
Gastroenteritis	O
Virus	O
(	O
TGEV	O
)-	O
induced	O
Mitochondrial	O
Damage	O
Via	O
Targeting	O
RB1	O
,	O
Upregulating	O
Interleukin	O
-	O
1	O
Receptor	O
Accessory	O
Protein	O
(	O
IL1RAP	O
),	O
and	O
Activating	O
p38	B-FUNC
MAPK	B-FUNC
Pathway	O
ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
a	O
member	O
of	O
the	O
coronaviridae	O
family	O
,	O
could	O
cause	O
fatal	O
diarrhea	O
of	O
piglets	O
and	O
result	O
in	O
numerous	O
economic	O
losses	O
.	O

In	O
multivariable	O
models	O
,	O
a	O
combination	O
of	O
Stimulation	O
-	O
2	O
(	O
ST2	O
;	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
8	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
P	O
=	O
.	O
025	O
)	O
was	O
the	O
best	O
panel	O
for	O
distinguishing	O
IPS	O
at	O
diagnosis	O
from	O
unaffected	O
controls	O
,	O
whereas	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
1	O
(	O
TNFR1	O
;	O
OR	O
,	O
2	O
.	O
9	O
;	O
P	O
=	O
.	O
002	O
)	O
was	O
the	O
best	O
marker	O
when	O
comparing	O
patients	O
with	O
IPS	O
and	O
viral	O
pneumonia	O
.	O

Using	O
estimated	O
sensitivity	O
and	O
specificity	O
values	O
from	O
cutoffs	O
determined	O
with	O
the	O
ROC	O
analysis	O
(	O
cutoff	O
level	O
:	O
ST2	O
,	O
21	O
ng	O
/	O
mL	O
;	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
61	O
pg	O
/	O
mL	O
;	O
TNFR1	O
,	O
3421	O
pg	O
/	O
mL	O
),	O
we	O
calculated	O
positive	O
predictive	O
values	O
(	O
PPV	O
)	O
for	O
a	O
range	O
of	O
estimated	O
population	O
prevalence	O
values	O
of	O
IPS	O
.	O

In	O
addition	O
,	O
intestinal	O
IR	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
ex	O
-	O
vivo	O
lung	O
levels	O
of	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
VEGF	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
increase	O
in	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
CINC	O
-	O
1	O
,	O
uric	O
acid	O
and	O
circulating	O
,	O
but	O
not	O
bone	O
marrow	O
,	O
leukocyte	O
numbers	O
.	O

Among	O
them	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinases	O
(	O
JNK	B-FUNC
)	O
are	O
known	O
to	O
be	O
activated	O
by	O
various	O
environmental	O
stresses	O
including	O
virus	O
infections	O
.	O

Previously	O
,	O
activation	O
of	O
the	O
JNK	B-FUNC
pathway	O
has	O
been	O
detected	O
in	O
cells	O
infected	O
with	O
several	O
coronaviruses	O
.	O

Here	O
we	O
report	O
that	O
the	O
JNK	B-FUNC
pathway	O
was	O
activated	O
in	O
cells	O
infected	O
with	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Of	O
the	O
two	O
known	O
upstream	O
MAPK	B-FUNC
kinases	O
(	O
MKK	B-FUNC
),	O
MKK7	B-FUNC
,	O
but	O
not	O
MKK4	B-FUNC
,	O
was	O
shown	O
to	O
be	O
responsible	O
for	O
IBV	O
-	O
induced	O
JNK	B-FUNC
activation	O
.	O

Moreover	O
,	O
knockdown	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
JNK	B-FUNC
served	O
as	O
a	O
pro	O
-	O
apoptotic	O
protein	O
during	O
IBV	O
infection	O
.	O

Interestingly	O
,	O
pro	O
-	O
apoptotic	O
activity	O
of	O
JNK	B-FUNC
was	O
not	O
mediated	O
via	O
c	O
-	O
Jun	O
,	O
but	O
involved	O
modulation	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
B	O
-	O
cell	O
lymphoma	O
2	O
(	O
Bcl2	O
).	O

TITLE	O
:	O
A	O
recombinant	O
VSV	O
-	O
vectored	O
MERS	O
-	O
CoV	O
vaccine	O
induces	O
neutralizing	O
antibody	B-FUNC
and	O
T	O
cell	O
responses	O
in	O
rhesus	O
monkeys	O
after	O
single	O
dose	O
immunization	O
.	O

ABSTRACT	O
:	O
Cyclophilin	B-FUNC
A	O
(	O
CypA	O
)	O
is	O
an	O
important	O
host	O
factor	O
in	O
the	O
replication	O
of	O
a	O
variety	O
of	O
RNA	O
viruses	O
.	O

The	O
three	O
dimensional	O
macromolecular	O
structure	O
(	O
3DMMS	O
)	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
S	O
protein	O
was	O
predicted	O
by	O
sequence	O
-	O
homology	O
method	O
using	O
the	O
protein	O
data	O
bank	O
(	O
PDB	O
).	O

More	O
surveillance	O
studies	O
are	O
needed	O
to	O
better	O
investigate	O
the	O
potential	O
intermediate	O
hosts	O
that	O
may	O
play	O
a	O
role	O
in	O
the	O
interspecies	O
transmission	O
of	O
known	O
and	O
currently	O
unknown	O
coronaviruses	O
with	O
particular	O
attention	O
to	O
the	O
S	O
protein	O
and	O
the	O
receptor	O
specificity	O
and	O
binding	B-FUNC
affinity	O
.	O

All	O
microbiological	O
tests	O
were	O
negative	O
except	O
multiplex	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
using	O
respiratory	O
specimen	O
,	O
which	O
was	O
positive	O
for	O
human	O
adenovirus	O
.	O

TITLE	O
:	O
Prospective	O
Observational	O
Study	O
on	O
the	O
Association	O
Between	O
Serum	O
Mannose	O
-	O
Binding	B-FUNC
Lectin	O
Levels	O
and	O
Severe	O
Outcome	O
in	O
Critically	O
Ill	O
Patients	O
with	O
Pandemic	O
Influenza	O
Type	O
A	O
(	O
H1N1	O
)	O
Infection	O
.	O

ABSTRACT	O
:	O
Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
innate	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
a	O
frequent	O
cause	O
of	O
acute	O
lung	O
disease	O
in	O
children	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

ACS	B-FUNC
is	O
associated	O
with	O
prolonged	O
hospitalization	O
,	O
increased	O
risk	O
of	O
respiratory	O
failure	O
,	O
and	O
the	O
potential	O
for	O
developing	O
chronic	O
lung	O
disease	O
.	O

The	O
etiology	O
of	O
ACS	B-FUNC
is	O
often	O
multifactorial	O
.	O

Several	O
risk	O
factors	O
have	O
been	O
identified	O
in	O
children	O
to	O
be	O
associated	O
with	O
increased	O
incidence	O
of	O
ACS	B-FUNC
.	O

Within	O
the	O
lipoprotein	O
family	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
),	O
primarily	O
composed	O
of	O
apolipoprotein	B-FUNC
A1	O
(	O
apoA	O
-	O
I	O
)	O
and	O
phospholipids	O
,	O
measuring	O
a	O
mere	O
10	O
nm	O
,	O
is	O
the	O
smallest	O
and	O
densest	O
particle	O
.	O

The	O
latter	O
is	O
facilitated	O
by	O
HDL	O
'	O
s	O
intrinsic	O
ability	O
to	O
interact	O
with	O
the	O
ATP	O
-	O
binding	B-FUNC
cassette	O
receptor	O
A1	O
(	O
ABCA1	O
)	O
and	O
ABCG1	O
,	O
as	O
well	O
as	O
scavenger	O
receptor	O
type	O
B1	O
(	O
SR	O
-	O
BI	O
).	O

Making	O
use	O
of	O
recombinant	O
viruses	O
either	O
devoid	O
of	O
the	O
E	O
protein	O
or	O
harboring	O
mutations	O
either	O
in	O
putative	O
transmembrane	O
domain	O
or	O
PDZ	O
-	O
binding	B-FUNC
motif	O
,	O
we	O
demonstrated	O
that	O
a	O
fully	O
functional	O
HCoV	O
-	O
OC43	O
E	O
protein	O
is	O
first	O
needed	O
for	O
optimal	O
production	O
of	O
recombinant	O
infectious	O
viruses	O
.	O

In	O
brief	O
,	O
the	O
CSFIA	O
-	O
based	O
method	O
is	O
highly	O
efficient	O
and	O
inexpensive	O
with	O
a	O
simple	O
and	O
direct	O
operation	O
,	O
which	O
is	O
an	O
excellent	O
candidate	O
method	O
for	O
antigen	O
-	O
specific	O
positive	O
clone	O
isolation	O
in	O
a	O
monoclonal	O
antibody	B-FUNC
preparation	O
.	O

TITLE	O
:	O
Accessory	O
proteins	O
8b	O
and	O
8ab	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
suppress	O
the	O
interferon	O
signaling	O
pathway	O
by	O
mediating	O
ubiquitin	B-FUNC
-	O
dependent	O
rapid	O
degradation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
.	O

This	O
counteracting	O
effect	O
was	O
partially	O
mediated	O
by	O
protein	O
8b	O
/	O
8ab	O
-	O
induced	O
degradation	O
of	O
IRF3	O
in	O
a	O
ubiquitin	B-FUNC
-	O
proteasome	O
-	O
dependent	O
manner	O
.	O

We	O
previously	O
determined	O
the	O
immunogenicity	O
of	O
a	O
novel	O
dendritic	O
cell	O
(	O
DC	O
)-	O
targeted	O
PEDV	O
S1	O
protein	O
-	O
based	O
subunit	O
vaccine	O
in	O
weaned	O
piglets	O
in	O
which	O
the	O
PEDV	O
antigen	O
was	O
targeted	O
to	O
DCs	O
through	O
a	O
porcine	O
Langerin	O
-	O
specific	O
antibody	B-FUNC
.	O

After	O
the	O
binding	B-FUNC
,	O
CA	O
could	O
play	O
its	O
role	O
through	O
the	O
complicated	O
signal	O
way	O
.	O

Estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	B-FUNC
)	O
before	O
TDF	O
exposure	O
was	O
92	O
ml	O
/	O
min	O
/	O
1	O
.	O
73m	O

ABSTRACT	O
:	O
In	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
atelectatic	O
solid	O
-	O
like	O
lung	O
tissue	O
impairs	O
transmission	O
of	O
negative	O
swings	O
in	O
pleural	O
pressure	O
(	O
Ppl	B-FUNC
)	O
that	O
result	O
from	O
diaphragmatic	O
contraction	O
.	O

Regional	O
histology	O
(	O
rabbit	O
),	O
inflammation	O
(	O
positron	O
emission	O
tomography	O
;	O
pig	O
),	O
regional	O
inspiratory	O
Ppl	B-FUNC
(	O
intrabronchial	O
balloon	O
manometry	O
),	O
and	O
stretch	O
(	O
electrical	O
impedance	O
tomography	O
;	O
pig	O
)	O
were	O
measured	O
.	O

Stronger	O
effort	O
(	O
vs	O
.	O
muscle	O
paralysis	O
)	O
caused	O
local	O
overstretch	O
and	O
greater	O
tidal	O
recruitment	O
in	O
dependent	O
lung	O
,	O
where	O
more	O
negative	O
Ppl	B-FUNC
was	O
localized	O
and	O
greater	O
stretch	O
was	O
generated	O
.	O

Ventilatory	O
and	O
mechanical	O
parameters	O
,	O
arterial	O
blood	O
gases	O
,	O
diffuse	O
alveolar	O
damage	O
score	O
,	O
epithelial	O
integrity	O
measured	O
by	O
E	O
-	O
cadherin	O
tissue	O
expression	O
,	O
and	O
biological	O
markers	O
associated	O
with	O
inflammation	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
,	O
CINC	O
-	O
1	O
)	O
and	O
type	O
II	O
epithelial	O
cell	O
damage	O
(	O
surfactant	O
protein	O
-	O
B	O
)	O
were	O
evaluated	O
.	O

In	O
PSV	O
,	O
PEEP	O
=	O
5	O
cmH2O	O
compared	O
with	O
PEEP	O
=	O
2	O
cmH2O	O
was	O
associated	O
with	O
significantly	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
[	O
median	O
(	O
interquartile	O
range	O
),	O
11	O
(	O
8	O
.	O
5	O
to	O
13	O
.	O
5	O
)	O
vs	O
.	O
23	O
(	O
19	O
to	O
26	O
),	O
P	O
=	O
0	O
.	O
005	O
]	O
and	O
expressions	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
CINC	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
both	O
),	O
whereas	O
surfactant	O
protein	O
-	O
B	O
mRNA	O
expression	O
increased	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Peak	O
transpulmonary	O
pressure	O
correlated	O
positively	O
with	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
[	O
Spearman	O
'	O
s	O
rho	O
(	O
	O
)	O
=	O
0	O
.	O
62	O
,	O
P	O
=	O
0	O
.	O
0007	O
]	O
and	O
CINC	O
-	O
1	O
expressions	O
(	O
	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
E	O
-	O
cadherin	O
expression	O
(	O
	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
=	O
0	O
.	O
0002	O
).	O

Peak	O
transpulmonary	O
pressure	O
correlated	O
positively	O
with	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
[	O
Spearman	O
'	O
s	O
rho	O
(	O
	O
)	O
=	O
0	O
.	O
62	O
,	O
P	O
=	O
0	O
.	O
0007	O
]	O
and	O
CINC	O
-	O
1	O
expressions	O
(	O
	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
E	O
-	O
cadherin	O
expression	O
(	O
	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
=	O
0	O
.	O
0002	O
).	O

UTI	O
significantly	O
protected	O
animals	O
from	O
LPS	O
-	O
induced	O
ALI	O
,	O
decreasing	O
the	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
ALI	O
score	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
myeloperoxidase	B-FUNC
activity	I-FUNC
,	O
and	O
malondialdehyde	O
content	O
,	O
factors	O
associated	O
with	O
lung	O
histological	O
damage	O
.	O

Neutrophils	O
from	O
these	O
patients	O
showed	O
higher	O
capacity	O
to	O
release	O
MPO	B-FUNC
-	O
DNA	O
complex	O
in	O
response	O
to	O
interleukin	O
-	O
8	O
or	O
lipopolysaccharide	O
stimulation	O
.	O

This	O
regulation	O
is	O
carried	O
out	O
by	O
spike	O
'	O
s	O
major	O
functions	O
:	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
Safety	O
and	O
tolerability	O
of	O
a	O
novel	O
,	O
polyclonal	O
human	O
anti	O
-	O
MERS	O
coronavirus	O
antibody	B-FUNC
produced	O
from	O
transchromosomic	O
cattle	O
:	O
a	O
phase	O
1	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
single	O
-	O
dose	O
-	O
escalation	O
study	O
.	O

Human	O
immunoglobulin	B-FUNC
derived	O
from	O
transchromosomic	O
cattle	O
could	O
offer	O
a	O
new	O
platform	O
technology	O
to	O
produce	O
fully	O
human	O
polyclonal	O
IgG	O
antibodies	O
for	O
other	O
medical	O
conditions	O
.	O

However	O
,	O
broilers	O
supplemented	O
with	O
0	O
mg	O
/	O
kg	O
of	O
VE	O
had	O
lower	O
antibody	B-FUNC
titers	O
against	O
SRBC	O
than	O
those	O
fed	O
100	O
mg	O
/	O
kg	O
of	O
VE	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
24th	O
day	O
.	O

The	O
findings	O
of	O
our	O
study	O
suggest	O
that	O
dietary	O
RP	O
and	O
VE	O
additives	O
can	O
interact	O
and	O
modulate	O
the	O
humoral	O
immunity	O
of	O
broilers	O
,	O
but	O
not	O
sufficiently	O
to	O
improve	O
antibody	B-FUNC
titers	O
against	O
specific	O
virus	O
during	O
a	O
42	O
-	O
day	O
production	O
cycle	O
.	O

TITLE	O
:	O
Surfactant	O
protein	O
C	O
dampens	O
inflammation	O
by	O
decreasing	O
JAK	B-FUNC
/	O
STAT	O
activation	O
during	O
lung	O
repair	O
.	O

Consistent	O
with	O
a	O
proinflammatory	O
phenotype	O
,	O
immunofluorescence	O
revealed	O
increased	O
phosphorylated	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
3	O
(	O
pSTAT3	O
),	O
suggesting	O
enhanced	O
Janus	O
kinase	O
(	O
JAK	B-FUNC
)/	O
STAT	O
activation	O
in	O
inflammatory	O
and	O
AT2	O
cells	O
of	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
.	O

Our	O
findings	O
showing	O
a	O
novel	O
role	O
for	O
SPC	O
in	O
regulating	O
inflammation	O
via	O
JAK	B-FUNC
/	O
STAT	O
may	O
have	O
clinical	O
applications	O
.	O

TITLE	O
:	O
Receptor	O
Usage	O
of	O
a	O
Novel	O
Bat	O
Lineage	O
C	O
Betacoronavirus	O
Reveals	O
Evolution	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Related	O
Coronavirus	O
Spike	O
Proteins	O
for	O
Human	O
Dipeptidyl	O
Peptidase	O
4	O
Binding	B-FUNC
.	O

Because	O
Ty	O
-	O
BatCoV	O
HKU4	O
but	O
not	O
Pi	O
-	O
BatCoV	O
HKU5	O
can	O
use	O
the	O
MERS	O
-	O
CoV	O
receptor	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
hDPP4	O
)	O
for	O
cell	O
entry	O
,	O
we	O
tested	O
the	O
ability	O
of	O
Hp	O
-	O
BatCoV	O
HKU25	O
to	O
bind	B-FUNC
and	O
use	O
hDPP4	O
.	O

The	O
HKU25	O
-	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
can	O
bind	B-FUNC
to	O
hDPP4	O
protein	O
and	O
hDPP4	O
-	O
expressing	O
cells	O
,	O
but	O
it	O
does	O
so	O
with	O
lower	O
efficiency	O
than	O
that	O
of	O
MERS	O
-	O
RBD	O
.	O

Galectin	O
-	O
3	O
,	O
a	O
	O
-	O
galactoside	O
-	O
binding	B-FUNC
protein	O
widely	O
distributed	O
in	O
immune	O
and	O
epithelial	O
cells	O
,	O
regulates	O
various	O
immune	O
functions	O
and	O
modulates	O
microbial	O
infections	O
.	O

It	O
remains	O
unclear	O
whether	O
acute	O
or	O
chronic	O
EP	O
(	O
AEP	O
or	O
CEP	B-FUNC
)	O
represent	O
different	O
diseases	O
,	O
and	O
the	O
secondary	O
goal	O
of	O
this	O
review	O
is	O
to	O
determine	O
if	O
there	O
are	O
factors	O
that	O
may	O
help	O
distinguish	O
these	O
2	O
entities	O
.	O

Eosinophilia	O
in	O
the	O
blood	O
at	O
the	O
time	O
of	O
diagnosis	O
characterized	O
only	O
the	O
CEP	B-FUNC
patients	O
(	O
80	O
%	O
in	O
CEP	B-FUNC
vs	O
.	O
20	O
%	O
in	O
AEP	O
).	O

Most	O
patients	O
with	O
EP	O
were	O
treated	O
with	O
steroids	O
with	O
a	O
higher	O
rate	O
of	O
relapse	O
observed	O
in	O
patients	O
with	O
CEP	B-FUNC
.	O

However	O
,	O
there	O
is	O
significant	O
clinical	O
overlap	O
among	O
AEP	O
and	O
CEP	B-FUNC
that	O
are	O
associated	O
with	O
drug	O
toxicity	O
,	O
suggesting	O
the	O
possibility	O
that	O
AEP	O
and	O
CEP	B-FUNC
are	O
distinct	O
clinical	O
presentations	O
that	O
share	O
a	O
common	O
pathogenic	O
pathway	O
.	O

Most	O
patients	O
with	O
EP	O
were	O
treated	O
with	O
steroids	O
with	O
a	O
higher	O
rate	O
of	O
relapse	O
observed	O
in	O
patients	O
with	O
CEP	B-FUNC
.	O

CONCLUSIONS	O
:	O
AEP	O
is	O
a	O
much	O
more	O
fulminant	O
and	O
severe	O
disease	O
than	O
the	O
gradual	O
onset	O
and	O
slowly	O
progressive	O
nature	O
of	O
CEP	B-FUNC
.	O

In	O
particular	O
,	O
4b	O
had	O
a	O
strong	O
preference	O
for	O
binding	B-FUNC
karyopherin	O
-	O
4	O
(	O
KPNA4	O
),	O
which	O
is	O
known	O
to	O
translocate	O
the	O
NF	O
-	O
B	O
protein	O
complex	O
into	O
the	O
nucleus	O
.	O

Binding	B-FUNC
of	O
4b	O
to	O
KPNA4	O
during	O
infection	O
inhibited	O
its	O
interaction	O
with	O
NF	O
-	O
B	O
-	O
p65	O
subunit	O
.	O

Thereby	O
we	O
propose	O
a	O
model	O
where	O
4b	O
outcompetes	O
NF	O
-	O
B	O
for	O
KPNA4	O
binding	B-FUNC
and	O
translocation	O
into	O
the	O
nucleus	O
as	O
a	O
mechanism	O
of	O
interference	O
with	O
the	O
NF	O
-	O
B	O
-	O
mediated	O
innate	O
immune	O
response	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
-	O
Induced	O
Epidermal	B-FUNC
Growth	I-FUNC
Factor	I-FUNC
Receptor	O
Activation	O
Impairs	O
the	O
Antiviral	O
Activity	O
of	O
Type	O
I	O
Interferon	O
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
EGFR	B-FUNC
activation	O
affected	O
PEDV	O
infection	O
by	O
using	O
an	O
activator	O
or	O
overexpression	O
assay	O
.	O

We	O
also	O
found	O
that	O
specific	O
inhibition	O
of	O
EGFR	B-FUNC
by	O
either	O
inhibitors	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
led	O
to	O
a	O
decrease	O
in	O
virus	O
yields	O
.	O

Further	O
analysis	O
revealed	O
that	O
inhibition	O
of	O
EGFR	B-FUNC
produced	O
augmentation	O
of	O
type	O
I	O
interferon	O
genes	O
.	O

We	O
next	O
observed	O
that	O
the	O
EGFR	B-FUNC
downstream	O
cascade	O
STAT3	O
was	O
also	O
activated	O
upon	O
PEDV	O
infection	O
.	O

Similar	O
to	O
the	O
case	O
of	O
EGFR	B-FUNC
,	O
specific	O
inhibition	O
of	O
STAT3	O
by	O
either	O
inhibitor	O
or	O
siRNA	O
increased	O
the	O
antiviral	O
activity	O
of	O
interferon	O
and	O
resulted	O
in	O
decreased	O
PEDV	O
RNA	O
levels	O
,	O
and	O
vice	O
versa	O
.	O

The	O
data	O
on	O
STAT3	O
depletion	O
in	O
combination	O
with	O
EGFR	B-FUNC
activation	O
suggest	O
that	O
the	O
attenuation	O
of	O
antiviral	O
activity	O
by	O
EGFR	B-FUNC
activation	O
requires	O
activation	O
of	O
the	O
STAT3	O
signaling	O
pathway	O
.	O

Neutralizing	O
antibody	B-FUNC
titers	O
in	O
serum	O
and	O
milk	O
of	O
control	O
sow	O
was	O
negative	O
throughout	O
the	O
experimental	O
period	O
,	O
whereas	O
high	O
titers	O
were	O
observed	O
in	O
the	O
vaccinated	O
sows	O
.	O

TITLE	O
:	O
Dual	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
and	O
integrase	O
inhibitors	O
from	O
ABSTRACT	O
:	O
During	O
our	O
search	O
for	O
potential	O
templates	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
and	O
integrase	O
(	O
IN	O
)	O
dual	O
inhibitors	O
,	O
the	O
methanolic	O
extract	O
obtained	O
from	O
aerial	O
parts	O
of	O

The	O
molecular	O
mechanisms	O
of	O
ALI	O
and	O
ARDS	O
are	O
still	O
not	O
well	O
explored	O
,	O
but	O
available	O
reports	O
indicate	O
the	O
involvement	O
of	O
several	O
pro	O
-	O
inflammatory	O
mediators	O
including	O
cytokines	O
(	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
chemokines	O
[	O
like	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
and	O
macrophage	O
inhibitory	O
factor	O
(	O
MIF	O
)],	O
as	O
well	O
as	O
macrophage	O
polarization	O
regulating	O
the	O
migration	O
and	O
pulmonary	O
infiltration	O
of	O
neutrophils	O
into	O
the	O
pulmonary	O
interstitial	O
tissue	O
,	O
causing	O
injury	O
to	O
the	O
pulmonary	O
parenchyma	O
.	O

Although	O
most	O
of	O
the	O
IFN	O
-	O
regulatory	O
and	O
-	O
related	O
genes	O
evaluated	O
in	O
this	O
study	O
were	O
either	O
down	O
-	O
regulated	O
or	O
remained	O
unchanged	O
,	O
IL11	O
behaved	O
significantly	O
up	O
-	O
regulated	O
,	O
with	O
the	O
peak	O
at	O
16	O
hpi	B-FUNC
.	O

Fresh	O
tissue	O
samples	O
were	O
submitted	O
for	O
fluorescent	O
antibody	B-FUNC
testing	O
(	O
FAT	O
)	O
after	O
autopsy	O
in	O
17	O
cases	O
,	O
and	O
positive	O
results	O
were	O
found	O
in	O
only	O
7	O
cases	O
.	O

A	O
prominent	O
pro	O
-	O
inflammatory	O
Th1	O
and	O
Th17	O
response	O
was	O
clearly	O
seen	O
in	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	O
,	O
with	O
markedly	O
increased	O
concentrations	O
of	O
IFN	O
-	O
	O
,	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
compared	O
to	O
controls	O
.	O

No	O
changes	O
were	O
observed	O
in	O
the	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
5	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
,	O
and	O
TGF	O
-	O
	O
(	O
P	O
>	O
.	O
05	O
).	O

Decreasing	O
NETs	O
reduced	O
lung	O
injury	O
and	O
improved	O
survival	O
after	O
DNase	B-FUNC
I	I-FUNC
treatment	O
or	O
with	O
partial	O
protein	O
arginine	O
deiminase	O
4	O
deficiency	O
(	O
PAD4	O
+/-).	O

Lastly	O
,	O
we	O
observed	O
in	O
humans	O
that	O
increased	O
plasma	O
NETs	O
were	O
associated	O
with	O
ARDS	O
severity	O
and	O
mortality	O
,	O
and	O
lower	O
plasma	O
DNase	B-FUNC
I	I-FUNC
levels	O
were	O
associated	O
with	O
the	O
development	O
of	O
sepsis	O
-	O
induced	O
ARDS	O
.	O

Pulmonary	O
patients	O
are	O
typically	O
forced	O
to	O
maintain	O
bed	O
rest	B-FUNC
,	O
or	O
at	O
least	O
spend	O
most	O
of	O
their	O
waking	O
hours	O
dealing	O
with	O
mobility	O
limitations	O
,	O
due	O
to	O
various	O
pathological	O
conditions	O
including	O
dyspnea	O
,	O
fatigue	O
,	O
and	O
poor	O
tolerance	O
of	O
movements	O
.	O

After	O
immunization	O
,	O
significantly	O
higher	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
IgG	O
antibodies	O
with	O
PEDV	O
neutralizing	O
activity	O
in	O
the	O
sera	B-FUNC
and	O
mucosal	O
sIgA	O
antibodies	O
in	O
the	O
tractus	O
genitalis	O
,	O
intestinal	O
mucus	O
,	O
and	O
stools	O
were	O
detected	O
in	O
mice	O
orally	O
administered	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
,	O
which	O
expressed	O
DCpep	O
and	O
Col	O
targeting	O
ligands	O
fused	O
with	O
the	O
PEDV	O
COE	O
antigen	O
,	O
compared	O
to	O
mice	O
orally	O
immunized	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
/	O
L393	O
without	O
the	O
DCpep	O
and	O
Col	O
targeting	O
ligands	O
.	O

Moreover	O
,	O
in	O
response	O
to	O
restimulation	O
with	O
the	O
PEDV	O
COE	O
antigen	O
in	O
vitro	O
,	O
a	O
significant	O
difference	O
in	O
splenocyte	O
proliferation	O
response	O
and	O
Th2	O
-	O
associated	O
cytokine	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
level	O
was	O
observed	O
in	O
the	O
group	O
of	O
mice	O
orally	O
immunized	O
with	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
groups	O
of	O
mice	O
that	O
received	O
pPG	O
-	O
COE	O
-	O
Col	O
/	O
L393	O
and	O
pPG	O
-	O
COE	O
-	O
DCpep	O
/	O
L393	O
,	O
respectively	O
.	O

RESULTS	O
:	O
After	O
immunization	O
,	O
significantly	O
higher	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
IgG	O
antibodies	O
with	O
PEDV	O
neutralizing	O
activity	O
in	O
the	O
sera	B-FUNC
and	O
mucosal	O
sIgA	O
antibodies	O
in	O
the	O
tractus	O
genitalis	O
,	O
intestinal	O
mucus	O
,	O
and	O
stools	O
were	O
detected	O
in	O
mice	O
orally	O
administered	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
,	O
which	O
expressed	O
DCpep	O
and	O
Col	O
targeting	O
ligands	O
fused	O
with	O
the	O
PEDV	O
COE	O
antigen	O
,	O
compared	O
to	O
mice	O
orally	O
immunized	O
with	O
the	O
recombinant	O
strain	O
pPG	O
-	O
COE	O
/	O
L393	O
without	O
the	O
DCpep	O
and	O
Col	O
targeting	O
ligands	O
.	O

Specific	O
therapies	O
include	O
colloid	O
oncotic	O
support	O
,	O
antibiotics	O
,	O
hyperimmune	O
plasma	O
,	O
polymyxin	O
B	O
,	O
pentoxifylline	O
,	O
probiotics	O
,	O
binding	B-FUNC
agents	O
,	O
gastroprotectants	O
,	O
laminitis	O
prevention	O
,	O
and	O
coagulation	O
prophylaxis	O
.	O

It	O
is	O
produced	O
by	O
excess	O
nitrates	O
which	O
induce	O
the	O
haemoglobin	O
'	O
s	O
iron	O
oxidation	O
,	O
preventing	O
its	O
adequate	O
binding	B-FUNC
to	O
oxygen	O
.	O

ABSTRACT	O
:	O
Continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
is	O
an	O
effective	O
treatment	O
for	O
obstructive	O
sleep	O
apnoea	O
(	O
OSA	O
),	O
but	O
an	O
evaluation	O
of	O
CPAP	O
adherence	O
is	O
rarely	O
carried	O
out	O
among	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
).	O

The	O
goals	O
of	O
the	O
study	O
are	O
to	O
analyse	O
long	O
-	O
term	O
adherence	O
and	O
identify	O
the	O
predictors	O
of	O
non	O
-	O
compliance	O
with	O
CPAP	O
treatment	O
for	O
patients	O
with	O
non	O
-	O
sleepy	O
OSA	O
and	O
ACS	B-FUNC
.	O

It	O
also	O
showed	O
a	O
significant	O
interaction	O
between	O
ACS	B-FUNC
history	O
and	O
age	O
(	O
P	O
=	O
0	O
.	O
0131	O
),	O
such	O
that	O
young	O
patients	O
with	O
their	O
first	O
ACS	B-FUNC
showed	O
significantly	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
than	O
patients	O
with	O
recurrent	O
ACS	B-FUNC
and	O
significantly	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
were	O
associated	O
with	O
ageing	O
only	O
in	O
patients	O
with	O
recurrent	O
ACS	B-FUNC
.	O

Protective	O
factors	O
against	O
non	O
-	O
compliance	O
with	O
CPAP	O
treatment	O
in	O
non	O
-	O
sleepy	O
patients	O
with	O
ACS	B-FUNC
were	O
illness	O
severity	O
(	O
high	O
values	O
of	O
AHI	O
or	O
ICU	O
stay	O
length	O
)	O
or	O
smoking	O
amount	O
.	O

Patients	O
with	O
no	O
previous	O
history	O
of	O
ACS	B-FUNC
showed	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
than	O
patients	O
with	O
a	O
recurrent	O
ACS	B-FUNC
with	O
younger	O
age	O
.	O

ABSTRACT	O
:	O
Hyperventilation	O
syndrome	O
(	O
HVS	B-FUNC
)	O
sometimes	O
occurs	O
in	O
patients	O
under	O
stressful	O
conditions	O
and	O
may	O
provoke	O
severe	O
complications	O
such	O
as	O
myocardial	O
infarction	O
and	O
death	O
.	O

The	O
authors	O
report	O
a	O
case	O
of	O
HVS	B-FUNC
following	O
general	O
anesthesia	O
,	O
where	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
dexmedetomidine	O
was	O
effective	O
for	O
HVS	B-FUNC
.	O

An	O
arterial	O
blood	O
gas	O
determination	O
showed	O
pH	O
7	O
.	O
63	O
,	O
PaCO	O
HVS	B-FUNC
can	O
occur	O
after	O
emergence	O
from	O
general	O
anesthesia	O
,	O
and	O
dexmedetomidine	O
infusion	O
was	O
effective	O
for	O
HVS	B-FUNC
.	O

This	O
protein	O
is	O
composed	O
of	O
an	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
trans	O
-	O
membrane	O
fusion	O
domain	O
(	O
S2	O
).	O

The	O
recombinant	O
fusion	O
core	O
protein	O
was	O
crystallized	O
and	O
its	O
structure	O
was	O
solved	O
at	O
a	O
resolution	O
of	O
2	O
.	O
45	O
	O
.	O
Then	O
we	O
characterized	O
the	O
binding	B-FUNC
of	O
HR1s	O
and	O
HR2s	O
via	O
both	O
sequence	O
alignment	O
and	O
structural	O
analysis	O
.	O

A	O
promising	O
approach	O
for	O
prevention	O
are	O
live	O
attenuated	O
vaccines	O
(	O
LAVs	O
),	O
some	O
of	O
which	O
target	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
,	O
which	O
is	O
a	O
small	O
membrane	O
protein	O
that	O
forms	O
ion	B-FUNC
channels	I-FUNC
.	O

Some	O
but	O
not	O
all	O
of	O
the	O
Nidovirus	O
sg	O
mRNAs	O
also	O
have	O
a	O
common	O
5	O
'	O
leader	O
sequence	O
that	O
is	O
acquired	O
by	O
a	O
discontinuous	O
RNA	O
synthesis	O
mechanism	O
regulated	O
by	O
multiple	O
3	O
'	O
body	O
transcription	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
and	O
the	O
5	O
'	O
leader	O
TRS	B-FUNC
.	O

Initial	O
studies	O
detected	O
a	O
single	O
major	O
body	O
TRS	B-FUNC
for	O
each	O
3	O
'	O
sg	O
mRNA	O
with	O
a	O
few	O
alternative	O
functional	O
TRSs	O
reported	O
.	O

To	O
address	O
this	O
need	O
,	O
we	O
are	O
developing	O
a	O
subunit	O
recombinant	O
protein	O
vaccine	O
comprising	O
residues	O
377	O
-	O
588	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
),	O
which	O
,	O
when	O
formulated	O
with	O
the	O
AddaVax	O
adjuvant	O
,	O
it	O
induces	O
a	O
significant	O
neutralizing	O
antibody	B-FUNC
response	O
and	O
protection	O
against	O
MERS	O
-	O
CoV	O
challenge	O
in	O
vaccinated	O
animals	O
.	O

To	O
prepare	O
for	O
the	O
manufacture	O
and	O
first	O
-	O
in	O
-	O
human	O
testing	O
of	O
the	O
vaccine	O
,	O
we	O
have	O
developed	O
a	O
process	O
to	O
stably	O
produce	O
the	O
recombinant	O
MERS	O
S377	O
-	O
588	O
protein	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)	O
cells	O
.	O

To	O
accomplish	O
this	O
,	O
we	O
transfected	O
an	O
adherent	O
dihydrofolate	O
reductase	O
-	O
deficient	O
CHO	B-FUNC
cell	O
line	O
(	O
adCHO	O
)	O
with	O
a	O
plasmid	O
encoding	O
S377	O
-	O
588	O
fused	O
with	O
the	O
human	O
IgG	O
Fc	O
fragment	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
).	O

The	O
adCHO	O
-	O
expressed	O
S377	O
-	O
588	O
-	O
Fc	O
recombinant	O
protein	O
demonstrated	O
functionality	O
and	O
binding	B-FUNC
specificity	O
identical	O
to	O
those	O
of	O
the	O
protein	O
from	O
transiently	O
transfected	O
HEK293T	O
cells	O
.	O

TITLE	O
:	O
Intravenous	O
immunoglobulin	B-FUNC
fails	O
to	O
improve	O
ARDS	O
in	O
patients	O
undergoing	O
ECMO	O
therapy	O
.	O

To	O
support	O
the	O
immunological	O
response	O
in	O
this	O
patient	O
collective	O
,	O
we	O
used	O
intravenous	O
IgM	O
immunoglobulin	B-FUNC
therapy	O
to	O
enhance	O
the	O
likelihood	O
of	O
pulmonary	O
recovery	O
.	O

Using	O
a	O
panel	O
of	O
60	O
swine	O
biological	O
samples	O
(	O
feces	O
,	O
intestinal	O
contents	O
,	O
and	O
sera	B-FUNC
)	O
characterized	O
by	O
PEDV	O
,	O
PDCoV	O
and	O
transmissible	O
gastroenteritis	O
virus	O
-	O
specific	O
RT	O
-	O
PCR	O
assays	O
,	O
we	O
demonstrated	O
that	O
sensitivity	O
and	O
specificity	O
of	O
the	O
newly	O
established	O
panCoV	O
RT	O
-	O
PCR	O
assay	O
were	O
100	O
%.	O

We	O
found	O
that	O
nano	O
silicon	O
applied	O
with	O
inactivated	O
TGEV	O
vaccine	O
induced	O
high	O
antibody	B-FUNC
titers	O
,	O
increase	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
	O
and	O
IFN	O
-	O
	O
expression	O
,	O
and	O
stimulate	O
CD3	O
+	O
T	O
cell	O
proliferation	O
with	O
a	O
high	O
CD4	O
+/	O
CD8	O
+	O
T	O
lymphocyte	O
ratio	O
.	O

ABSTRACT	O
:	O
A	O
monkey	O
cell	O
line	O
Vero	O
(	O
ATCC	O
CCL	B-FUNC
-	O
81	O
)	O
is	O
commonly	O
used	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
propagation	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
we	O
developed	O
a	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
rapid	O
nucleocapsid	O
protein	O
detection	O
assay	O
for	O
diagnosis	O
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
humans	O
and	O
dromedary	O
camels	O
.	O

The	O
definitive	O
diagnosis	O
is	O
laboratorial	O
,	O
by	O
the	O
Fluorescent	O
Antibody	B-FUNC
Test	O
(	O
FAT	O
)	O
as	O
a	O
quick	O
test	O
and	O
Mouse	O
Inoculation	O
Test	O
(	O
MIT	O
)	O
as	O
a	O
confirmatory	O
test	O
(	O
gold	O
standard	O
).	O

There	O
are	O
no	O
vaccines	O
or	O
therapeutic	O
agents	O
currently	O
available	O
for	O
MERS	O
-	O
CoV	O
.	O
Using	O
a	O
probe	O
-	O
based	O
single	O
B	O
cell	O
cloning	O
strategy	O
,	O
we	O
have	O
identified	O
and	O
characterized	O
multiple	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
specifically	O
binding	B-FUNC
to	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
or	O
S1	O
(	O
non	O
-	O
RBD	O
)	O
regions	O
from	O
a	O
convalescent	O
MERS	O
-	O
CoV	O
-	O
infected	O
patient	O
and	O
from	O
immunized	O
rhesus	O
macaques	O
.	O

Six	O
RBD	O
-	O
specific	O
and	O
five	O
S1	O
-	O
specific	O
MAbs	O
could	O
be	O
sorted	O
into	O
four	O
RBD	O
and	O
three	O
non	O
-	O
RBD	O
distinct	O
binding	B-FUNC
patterns	O
,	O
based	O
on	O
competition	O
assays	O
,	O
mapping	O
neutralization	O
escape	O
variants	O
,	O
and	O
structural	O
analysis	O
.	O

We	O
determined	O
cocrystal	O
structures	O
for	O
two	O
MAbs	O
targeting	O
the	O
RBD	O
from	O
different	O
angles	O
and	O
show	O
they	O
can	O
bind	B-FUNC
the	O
RBD	O
only	O
in	O
the	O
""""	O
out	O
""""	O
position	O
.	O

Here	O
,	O
we	O
show	O
that	O
MHV	O
-	O
A59	O
S	O
protein	O
is	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
at	O
37	O
	O
C	O
to	O
induce	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
on	O
293T	O
cells	O
,	O
and	O
that	O
the	O
conformational	O
changes	O
in	O
S	O
proteins	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
are	O
very	O
similar	O
to	O
those	O
triggered	O
by	O
receptor	B-FUNC
binding	I-FUNC
.	O

Inflammatory	O
stress	O
and	O
immune	O
parameters	O
including	O
procalcitonin	O
(	O
PCT	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
),	O
and	O
CD4	O
Seventy	O
patients	O
with	O
severe	O
pneumonia	O
were	O
enrolled	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
serum	O
PCT	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
	O
or	O
CD4	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
have	O
the	O
ability	O
to	O
regulate	O
immune	O
responses	O
,	O
and	O
many	O
researches	O
showed	O
that	O
MSCs	B-FUNC
had	O
potential	O
therapeutic	O
effects	O
on	O
autoimmune	O
diseases	O
and	O
graft	O
versus	O
host	O
diseases	O
.	O

Recently	O
,	O
basic	O
researches	O
showed	O
that	O
MSCs	B-FUNC
could	O
treat	O
ARDS	O
and	O
many	O
scientists	O
paid	O
attention	O
to	O
the	O
therapeutic	O
use	O
of	O
MSC	O
in	O
the	O
treatment	O
of	O
ARDS	O
.	O

In	O
this	O
study	O
we	O
have	O
examined	O
the	O
subcellular	O
localization	O
and	O
other	O
functions	O
of	O
TGEV	O
nsp7	O
protein	O
through	O
analysis	O
of	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	O
cycle	O
progression	O
,	O
interleukin	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
expression	O
,	O
and	O
NF	O
-	O
B	O
activation	O
.	O

Our	O
results	O
showed	O
that	O
the	O
nsp7	O
protein	O
is	O
localized	O
in	O
the	O
cytoplasm	O
and	O
has	O
no	O
effect	O
on	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
growth	O
,	O
cell	O
cycle	O
,	O
and	O
cyclin	B-FUNC
A	O
expression	O
.	O

Interestingly	O
,	O
the	O
IECs	O
expressing	O
nsp7	O
protein	O
secreted	O
lower	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
than	O
control	O
cells	O
.	O

Patients	O
were	O
stratified	O
by	O
treatment	O
arm	O
(	O
12	O
versus	O
6	O
cm	O
A	O
total	O
of	O
446	O
(	O
49	O
%)	O
patients	O
had	O
complete	O
SP	O
-	O
D	O
,	O
VWF	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
measurements	O
on	O
study	O
enrollment	O
and	O
day	O
3	O
.	O

However	O
,	O
patients	O
with	O
a	O
P	O
/	O
F	O
ratio	O
of	O
greater	O
than	O
120	O
or	O
receiving	O
high	O
tidal	O
volume	O
ventilation	O
had	O
either	O
no	O
change	O
or	O
an	O
increase	O
in	O
SP	O
-	O
D	O
,	O
WVF	O
,	O
or	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
446	O
(	O
49	O
%)	O
patients	O
had	O
complete	O
SP	O
-	O
D	O
,	O
VWF	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
measurements	O
on	O
study	O
enrollment	O
and	O
day	O
3	O
.	O

However	O
,	O
patients	O
with	O
a	O
P	O
/	O
F	O
ratio	O
of	O
greater	O
than	O
120	O
or	O
receiving	O
high	O
tidal	O
volume	O
ventilation	O
had	O
either	O
no	O
change	O
or	O
an	O
increase	O
in	O
SP	O
-	O
D	O
,	O
WVF	O
,	O
or	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
.	O

Co	O
-	O
immunoprecipitation	O
(	O
CO	O
-	O
IP	O
)	O
results	O
clearly	O
demonstrated	O
that	O
PEDV	O
N	O
protein	O
could	O
bind	B-FUNC
to	O
human	O
hnRNP	O
A1	O
.	O

She	O
was	O
given	O
comprehensive	O
treatment	O
,	O
including	O
oseltamivir	O
,	O
methylprednisolone	O
,	O
immunoglobulin	B-FUNC
,	O
gastric	O
protection	O
,	O
and	O
noninvasive	O
mechanical	O
ventilation	O
.	O

However	O
,	O
some	O
symptoms	O
exacerbated	O
again	O
2	O
days	O
later	O
with	O
ground	O
-	O
glass	O
changes	O
appearing	O
in	O
upper	O
area	O
of	O
right	O
lung	O
and	O
the	O
titer	O
of	O
antibody	B-FUNC
to	O
Mycoplasma	O
pneumoniae	O
rising	O
from	O
1	O
:	O
80	O
to	O
1	O
:	O
640	O
.	O

All	O
cases	O
underwent	O
autopsy	O
,	O
histopathology	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
for	O
FCoV	O
.	O
Furthermore	O
,	O
a	O
genotype	O
-	O
discriminating	O
quantitative	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
was	O
performed	O
on	O
shavings	O
of	O
paraffin	O
-	O
embedded	O
tissues	O
to	O
discriminate	O
between	O
cats	O
with	O
FIP	O
and	O
controls	O
,	O
and	O
the	O
sensitivity	O
and	O
specificity	O
of	O
this	O
discriminating	O
RT	O
-	O
qPCR	O
were	O
calculated	O
using	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
).	O

The	O
mechanism	O
of	O
action	O
of	O
the	O
compounds	O
and	O
the	O
structural	O
determinants	O
associated	O
with	O
binding	B-FUNC
were	O
illuminated	O
using	O
X	O
-	O
ray	O
crystallography	O
.	O

This	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
bivalirudin	O
compared	O
with	O
UFH	O
with	O
or	O
without	O
GPIs	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
who	O
underwent	O
invasive	O
management	O
.	O

In	O
patients	O
with	O
ACS	B-FUNC
,	O
the	O
rates	O
of	O
MACEs	O
and	O
NACEs	O
were	O
not	O
significantly	O
lower	O
with	O
bivalirudin	O
than	O
with	O
UFH	O
,	O
irrespective	O
of	O
planned	O
GPI	O
use	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
)	O
causes	O
acute	O
enteric	O
disease	O
and	O
yellowish	O
watery	O
diarrhea	O
,	O
making	O
piglets	O
fast	B-FUNC
dehydration	O
to	O
death	O
.	O

Here	O
we	O
highlight	O
the	O
many	O
benefits	O
of	O
combining	O
immunisation	O
with	O
phage	O
display	O
in	O
combating	O
infectious	O
diseases	O
,	O
and	O
how	O
our	O
knowledge	O
of	O
antibody	B-FUNC
engineering	O
has	O
played	O
a	O
crucial	O
role	O
in	O
fully	O
exploiting	O
these	O
platforms	O
in	O
generating	O
therapeutic	O
and	O
diagnostic	O
biologics	O
towards	O
antigenic	O
targets	O
of	O
infectious	O
organisms	O
.	O

ABSTRACT	O
:	O
Clinical	O
samples	O
were	O
evaluated	O
with	O
the	O
Mobile	O
Analysis	O
Platform	O
(	O
MAP	O
)	O
to	O
determine	O
platform	O
performance	O
for	O
detecting	O
respiratory	O
viruses	O
in	O
samples	O
previously	O
characterized	O
using	O
clinical	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assays	O
.	O

TITLE	O
:	O
Coronavirus	O
S	O
protein	O
-	O
induced	O
fusion	O
is	O
blocked	O
prior	O
to	O
hemifusion	O
by	O
Abl	O
kinase	B-FUNC
inhibitors	I-FUNC
.	O

We	O
have	O
shown	O
previously	O
that	O
an	O
Abelson	O
(	O
Abl	O
)	O
kinase	B-FUNC
inhibitor	I-FUNC
,	O
imatinib	O
,	O
significantly	O
reduces	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
viral	O
titres	O
and	O
prevents	O
endosomal	O
entry	O
by	O
HIV	O
SARS	O
S	O
and	O
MERS	O
S	O
pseudotyped	O
virions	O
.	O

Here	O
,	O
we	O
use	O
IBV	O
,	O
a	O
BSL	O
-	O
2	O
virus	O
,	O
as	O
a	O
model	O
for	O
studying	O
the	O
role	O
of	O
Abl	O
kinase	B-FUNC
activity	I-FUNC
during	O
coronavirus	O
infection	O
.	O

Our	O
results	O
indicate	O
that	O
membrane	O
fusion	O
(	O
both	O
virus	O
-	O
cell	O
and	O
cell	O
-	O
cell	O
)	O
is	O
blocked	O
in	O
the	O
presence	O
of	O
Abl	O
kinase	B-FUNC
inhibitors	I-FUNC
.	O

Studying	O
the	O
effects	O
of	O
Abl	O
kinase	B-FUNC
inhibitors	I-FUNC
on	O
IBV	O
will	O
be	O
useful	O
in	O
identifying	O
the	O
host	O
cell	O
pathways	O
required	O
for	O
coronavirus	O
infection	O
.	O

Blood	O
serum	O
samples	O
were	O
tested	O
by	O
an	O
electrophoretic	O
method	O
for	O
the	O
assessment	O
of	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
concentration	O
,	O
whereas	O
fecal	O
samples	O
were	O
submitted	O
to	O
ELISA	O
test	O
for	O
positivity	O
to	O
Escherichia	O
coli	O
K99	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
Cryptosporidium	O
spp	O
.	O

ABSTRACT	O
:	O
By	O
means	O
of	O
structure	O
-	O
based	O
molecular	O
hybridization	O
strategy	O
,	O
a	O
series	O
of	O
novel	O
diarylpyri	O
(	O
mi	O
)	O
dine	O
derivatives	O
targeting	O
the	O
entrance	O
channel	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
were	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
as	O
potent	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
(	O
NNRTIs	O
).	O

As	O
the	O
number	O
of	O
vaccinations	O
increased	O
,	O
the	O
amounts	O
of	O
antibody	B-FUNC
in	O
serum	O
and	O
colostrum	O
,	O
and	O
neutralizing	O
activities	O
increased	O
.	O

TITLE	O
:	O
Exogenous	O
surfactant	O
as	O
a	O
bridge	O
to	O
prolonged	O
""""	O
total	O
lung	O
rest	B-FUNC
""""	O
in	O
severely	O
injured	O
patient	O
during	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Simultaneous	O
implementation	O
of	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
together	O
with	O
surfactant	O
application	O
allowed	O
prolonged	O
disconnection	O
of	O
patient	O
from	O
mechanical	O
ventilation	O
"("""	O
total	O
lung	O
rest	B-FUNC
""""	O
mode	O
).	O

Interestingly	O
,	O
plasma	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
EGF	B-FUNC
were	O
negatively	O
and	O
positively	O
correlated	O
with	O
sDPP4	O
concentrations	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
interstitial	O
pneumonia	O
associated	O
with	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-FUNC
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

Because	O
some	O
auto	O
-	O
antibodies	O
associated	O
with	O
acute	O
/	O
subacute	O
onset	O
IP	O
have	O
recently	O
become	O
available	O
in	O
clinic	O
,	O
we	O
examined	O
those	O
including	O
anti	O
-	O
aminoacyl	O
tRNA	B-FUNC
synthetase	O
(	O
ARS	O
)	O
antibodies	O
,	O
and	O
found	O
that	O
she	O
was	O
positive	O
for	O
anti	O
-	O
PL	O
-	O
7	O
antibody	B-FUNC
.	O

All	O
six	O
isolated	O
compounds	O
have	O
been	O
evaluated	O
firstly	O
for	O
the	O
inhibition	O
of	O
both	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Reverse	O
Transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
,	O
for	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
in	O
biochemical	O
assays	O
,	O
and	O
also	O
for	O
their	O
effect	O
on	O
viral	O
replication	O
.	O

In	O
addition	O
,	O
immune	O
responses	O
against	O
three	O
other	O
structural	O
proteins	O
,	O
the	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
,	O
were	O
also	O
detected	O
in	O
sera	B-FUNC
of	O
mice	O
that	O
received	O
IV	O
.	O

Quantitation	O
of	O
the	O
challenge	O
pathogens	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
determined	O
that	O
MGC	O
was	O
shed	O
in	O
much	O
higher	O
titers	O
from	O
the	O
trachea	O
than	O
MG	O
,	O
when	O
co	O
-	O
infected	O
with	O
IBV	O
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
have	O
attracted	O
attention	O
as	O
a	O
potential	O
therapy	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
).	O

To	O
date	O
,	O
early	O
clinical	O
trials	O
of	O
MSCs	B-FUNC
in	O
ARDS	O
have	O
excluded	O
patients	O
supported	O
by	O
ECMO	O
.	O

Six	O
strains	O
were	O
successfully	O
isolated	O
from	O
positive	O
samples	O
and	O
were	O
serially	O
passaged	O
40	O
times	O
in	O
Vero	O
cells	O
,	O
with	O
obvious	O
cytopathic	O
effects	O
observed	O
after	O
24	O
h	O
post	O
inoculation	O
(	O
hpi	B-FUNC
)	O
and	O
virus	O
titers	O
reaching	O
1	O
.	O
0	O
	O
10	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
can	O
be	O
utilized	O
for	O
severe	O
ACS	B-FUNC
in	O
adult	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

Prompt	O
initiation	O
of	O
this	O
modality	O
may	O
improve	O
outcomes	O
in	O
adult	O
patients	O
with	O
sickle	O
cell	O
disease	O
complicated	O
by	O
life	O
threatening	O
ACS	B-FUNC
.	O

R	O
-	O
848	O
enhanced	O
the	O
antigen	O
specific	O
humoral	O
and	O
cellular	O
immune	O
responses	O
when	O
co	O
-	O
administered	O
with	O
the	O
vaccines	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
antibody	B-FUNC
titre	O
in	O
ELISA	O
and	O
stimulation	O
index	O
in	O
lymphocyte	O
transformation	O
test	O
(	O
LTT	O
)	O
till	O
35	O
dpi	O
and	O
increased	O
proportion	O
of	O
CD4	O

However	O
,	O
treatment	O
with	O
APN	O
-	O
specific	O
antibody	B-FUNC
and	O
inhibitors	O
did	O
not	O
completely	O
block	O
PDCoV	O
infection	O
in	O
IPI	O
-	O
2I	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

Early	O
acute	O
respiratory	O
distress	O
syndrome	O
alveolar	O
environment	O
drives	O
an	O
anti	O
-	O
inflammatory	O
macrophage	O
polarization	O
favoring	O
epithelial	O
repair	O
through	O
activation	O
of	O
the	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
pathway	O
.	O

Previously	O
we	O
found	O
that	O
L	O
*	O
was	O
the	O
first	O
viral	O
protein	B-FUNC
binding	I-FUNC
directly	O
RNase	O
L	O
.	O
Our	O
current	O
data	O
show	O
that	O
L	O
*	O
binds	B-FUNC
the	O
ankyrin	O
repeats	O
R1	O
and	O
R2	O
of	O
RNase	O
L	O
and	O
inhibits	O
2	O
'-	O
5	O
'	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
)	O
binding	B-FUNC
to	O
RNase	O
L	O
.	O
Thereby	O
,	O
L	O
*	O
prevents	O
dimerization	O
and	O
oligomerization	O
of	O
RNase	O
L	O
in	O
response	O
to	O
2	O
-	O
5A	O
.	O

Interestingly	O
,	O
those	O
data	O
show	O
that	O
L	O
*	O
can	O
functionally	O
substitute	O
for	O
the	O
MHV	O
-	O
encoded	O
phosphodiesterase	B-FUNC
ns2	O
,	O
which	O
acts	O
upstream	O
of	O
L	O
*	O
in	O
the	O
OAS	O
/	O
RNase	O
L	O
pathway	O
,	O
by	O
degrading	O
2	O
-	O
5A	O
.	O

Analysis	O
of	O
cultured	O
patient	O
fibroblasts	O
demonstrated	O
deficient	O
pyruvate	O
dehydrogenase	O
(	O
PDH	B-FUNC
)	O
activity	O
and	O
reduced	O
quantity	O
of	O
protein	O
subunits	O
of	O
mitochondrial	O
complexes	O
I	O
and	O
II	O
,	O
consistent	O
with	O
BOLA3	O
dysfunction	O
.	O

A	O
sero	O
-	O
epidemiological	O
survey	O
was	O
performed	O
in	O
1	O
,	O
610	O
contacts	O
(	O
average	O
duration	O
from	O
exposure	O
to	O
test	O
,	O
4	O
.	O
8	O
months	O
),	O
and	O
the	O
collected	O
sera	B-FUNC
were	O
tested	O
using	O
an	O
enzyme	O
-	O
linked	O
immunespecific	O
assay	O
(	O
ELISA	O
),	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
and	O
plaque	O
reduction	O
neutralization	O
antibody	B-FUNC
test	O
(	O
PRNT	O
).	O

The	O
large	O
number	O
of	O
mutations	O
on	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
allowed	O
the	O
viruses	O
to	O
infect	O
the	O
new	O
host	O
,	O
posing	O
a	O
potential	O
threat	O
to	O
both	O
agriculture	O
and	O
public	O
health	O
.	O

The	O
blood	O
samples	O
for	O
the	O
levels	O
of	O
steroid	O
hormones	O
and	O
insulin	B-FUNC
-	I-FUNC
like	I-FUNC
growth	I-FUNC
factor	I-FUNC
I	O
(	O
IGF	O
-	O
I	O
)	O
were	O
assessed	O
using	O
immunoassays	O
and	O
the	O
levels	O
of	O
fatty	O
acids	O
were	O
assessed	O
using	O
gas	O
chromatography	O
.	O

However	O
,	O
the	O
mucosal	O
antibody	B-FUNC
response	O
to	O
many	O
respiratory	O
viruses	O
is	O
not	O
long	O
-	O
lasting	O
and	O
declines	O
with	O
age	O
.	O

Our	O
study	O
showed	O
that	O
complement	O
was	O
excessively	O
activated	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
hDPP4	O
-	O
Tg	O
mice	O
through	O
observations	O
of	O
increased	O
concentrations	O
of	O
the	O
C5a	O
and	O
C5b	O
-	O
9	O
complement	O
activation	O
products	O
in	O
sera	B-FUNC
and	O
lung	O
tissues	O
,	O
respectively	O
.	O

More	O
importantly	O
,	O
anti	O
-	O
C5aR	O
antibody	B-FUNC
treatment	O
led	O
to	O
decreased	O
viral	O
replication	O
in	O
lung	O
tissues	O
.	O

Substantial	O
saturation	O
of	O
the	O
binding	B-FUNC
resins	O
was	O
detected	O
within	O
the	O
first	O
treatment	O
hour	O
.	O

Finally	O
,	O
high	O
levels	O
of	O
exogenous	O
miR	O
-	O
146a	O
-	O
5p	O
in	O
HD11	O
cells	O
led	O
to	O
down	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
receptor	O
associated	O
kinase	O
-	O
2	O
(	O
IRAK2	O
)	O
and	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
receptor	O
superfamily	O
member	O
18	O
(	O
TNFRSF18	O
)	O
genes	O
.	O

Luciferase	O
reporter	O
assays	O
revealed	O
that	O
miR	O
-	O
146a	O
-	O
5p	O
could	O
bind	B-FUNC
to	O
the	O
3	O
'-	O
UTRs	O
of	O
IRAK2	O
and	O
TNFRSF18	O
.	O

Antibody	B-FUNC
responses	O
were	O
assessed	O
in	O
serum	O
,	O
colostrum	O
and	O
milk	O
of	O
immunized	O
gilts	O
,	O
and	O
passive	O
transfer	O
of	O
antibodies	O
was	O
evaluated	O
in	O
piglet	O
sera	B-FUNC
.	O

Patients	O
included	O
were	O
<	O
18	O
years	O
old	O
with	O
HMP	O
or	O
RSV	O
detected	O
from	O
nasopharyngeal	O
specimens	O
by	O
commercial	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
assay	O
admitted	O
to	O
a	O
study	O
site	O
.	O

Results	O
indicated	O
that	O
upregulation	O
of	O
proinflammatory	O
cytokines	O
(	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	O
-	O
1	O
)	O
and	O
lipopolysaccharide	O
-	O
induced	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
factor	O
(	O
LITAF	O
)	O
expression	O
is	O
induced	O
by	O
IBV	O
M41	O
in	O
the	O
trachea	O
and	O
by	O
IBV	O
885	O
and	O
QX	O
in	O
the	O
kidney	O
,	O
which	O
mainly	O
coincides	O
with	O
tracheal	O
and	O
renal	O
histopathological	O
lesions	O
respectively	O
caused	O
by	O
these	O
strains	O
.	O

TITLE	O
:	O
Porcine	O
Deltacoronavirus	O
Accessory	O
Protein	O
NS6	O
Antagonizes	O
Interferon	O
Beta	O
Production	O
by	O
Interfering	O
with	O
the	O
Binding	B-FUNC
of	O
RIG	O
-	O
I	O
/	O
MDA5	O
to	O
Double	O
-	O
Stranded	O
RNA	O
.	O

This	O
interaction	O
attenuates	O
the	O
binding	B-FUNC
of	O
double	O
-	O
stranded	O
RNA	O
by	O
RIG	O
-	O
I	O
/	O
MDA5	O
,	O
resulting	O
in	O
the	O
reduction	O
of	O
RLR	O
-	O
mediated	O
IFN	O
-	O
	O
production	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
ectopic	O
expression	O
of	O
NS6	O
antagonizes	O
IFN	O
-	O
	O
production	O
by	O
interfering	O
with	O
the	O
binding	B-FUNC
of	O
RIG	O
-	O
I	O
/	O
MDA5	O
to	O
double	O
-	O
stranded	O
RNA	O
,	O
revealing	O
a	O
new	O
strategy	O
employed	O
by	O
PDCoV	O
accessory	O
proteins	O
to	O
counteract	O
the	O
host	O
innate	O
antiviral	O
immune	O
response	O
.	O

TITLE	O
:	O
Health	O
benefits	O
of	O
orally	O
administered	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
antibody	B-FUNC
in	O
milk	O
-	O
fed	O
dairy	O
calves	O
.	O

ABSTRACT	O
:	O
The	O
primary	O
objective	O
of	O
this	O
randomized	O
controlled	O
trial	O
was	O
to	O
determine	O
whether	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
egg	O
yolk	O
antibodies	O
fed	O
upon	O
arrival	O
to	O
a	O
calf	O
ranch	O
would	O
lower	O
the	O
prevalence	O
of	O
Cryptosporidium	O
parvum	O
shedding	O
in	O
naturally	O
challenged	O
preweaned	O
dairy	O
calves	O
.	O

A	O
total	O
of	O
133	O
calves	O
,	O
enrolled	O
at	O
24	O
to	O
72	O
h	O
of	O
age	O
,	O
received	O
a	O
daily	O
dose	O
of	O
0	O
.	O
96	O
g	O
of	O
egg	O
yolk	O
powder	O
with	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
antibodies	O
(	O
MAB	O
,	O
n	O
=	O
71	O
)	O
or	O
without	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
antibodies	O
(	O
MEP	O
,	O
n	O
=	O
62	O
)	O
split	O
between	O
2	O
feedings	O
for	O
the	O
first	O
11	O
d	O
on	O
feed	O
at	O
a	O
calf	O
ranch	O
.	O

TITLE	O
:	O
Versatile	O
Electrochemiluminescence	O
Assays	O
for	O
PEDV	O
Antibody	B-FUNC
Based	O
on	O
Rolling	O
Circle	O
Amplification	O
and	O
Ru	O
-	O
DNA	O
Nanotags	O
.	O

ABSTRACT	O
:	O
The	O
sensitive	O
and	O
accurate	O
detection	O
methods	O
for	O
PEDV	O
antibody	B-FUNC
have	O
practical	O
significance	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
PEDV	O
.	O

In	O
this	O
work	O
,	O
a	O
new	O
multiple	O
pathways	O
signal	O
amplification	O
method	O
was	O
proposed	O
to	O
construct	O
a	O
sensitive	O
electrochemiluminescence	O
(	O
ECL	O
)	O
platform	O
for	O
the	O
detection	O
of	O
PEDV	O
antibody	B-FUNC
.	O

The	O
binding	B-FUNC
system	O
of	O
biotin	O
-	O
streptavidin	O
,	O
RCA	O
,	O
and	O
Ru	O
(	O
bpy	O
)	O

Additionally	O
,	O
proteins	O
3a	O
and	O
E	O
have	O
a	O
PDZ	O
-	O
binding	B-FUNC
motif	O
(	O
PBM	O
),	O
which	O
can	O
potentially	O
bind	B-FUNC
over	O
400	O
cellular	O
proteins	O
which	O
contain	O
a	O
PDZ	O
domain	O
,	O
making	O
them	O
potentially	O
important	O
for	O
the	O
control	O
of	O
cell	O
function	O
.	O

PEDV	O
infection	O
up	O
-	O
regulates	O
the	O
levels	O
of	O
p21	O
,	O
cdc2	O
,	O
cdk2	O
,	O
cdk4	O
,	O
Cyclin	B-FUNC
A	O
protein	O
and	O
down	O
-	O
regulates	O
Cyclin	B-FUNC
E	O
protein	O
.	O

Further	O
research	O
results	O
showed	O
that	O
inhibition	O
of	O
p53	O
signaling	O
pathway	O
can	O
reverse	O
the	O
cell	O
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
induced	O
by	O
PEDV	O
infection	O
and	O
cancel	O
out	O
the	O
up	O
-	O
regulation	O
of	O
p21	O
and	O
corresponding	O
Cyclin	B-FUNC
/	O
cdk	B-FUNC
mentioned	O
above	O
.	O

TITLE	O
:	O
Identification	O
and	O
application	O
of	O
self	O
-	O
binding	B-FUNC
zipper	O
-	O
like	O
sequences	O
in	O
SARS	O
-	O
CoV	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Self	O
-	O
binding	B-FUNC
peptides	O
containing	O
zipper	O
-	O
like	O
sequences	O
,	O
such	O
as	O
the	O
Leu	O
/	O
Ile	O
zipper	O
sequence	O
within	O
the	O
coiled	O
coil	O
regions	O
of	O
proteins	O
and	O
the	O
cross	O
-	O
	O
spine	O
steric	O
zippers	O
within	O
the	O
amyloid	O
-	O
like	O
fibrils	O
,	O
could	O
bind	B-FUNC
to	O
the	O
protein	O
-	O
of	O
-	O
origin	O
through	O
homophilic	O
sequence	O
-	O
specific	O
zipper	O
motifs	O
.	O

Peptide	O
array	O
scanning	O
of	O
overlapping	O
peptides	O
covering	O
the	O
entire	O
length	O
of	O
S	O
protein	O
identified	O
34	O
putative	O
self	O
-	O
binding	B-FUNC
peptides	O
of	O
six	O
clusters	O
,	O
five	O
of	O
which	O
contained	O
octapeptide	O
core	O
consensus	O
sequences	O
.	O

The	O
data	O
suggest	O
that	O
short	O
	O
-	O
zipper	O
-	O
like	O
self	O
-	O
binding	B-FUNC
peptides	O
within	O
the	O
S	O
protein	O
could	O
be	O
identified	O
through	O
combining	O
the	O
peptide	O
scanning	O
and	O
predictive	O
methods	O
,	O
and	O
could	O
be	O
exploited	O
as	O
biochemical	O
detection	O
reagents	O
for	O
viral	O
infection	O
.	O

We	O
then	O
assayed	O
the	O
purified	O
target	O
proteins	O
through	O
immunogenicity	O
tests	O
,	O
PEDV	O
binding	B-FUNC
interference	O
assays	O
,	O
circular	O
dichroism	O
(	O
CD	O
)	O
measurements	O
,	O
pAPN	O
activity	O
assay	O
and	O
structural	O
determination	O
,	O
demonstrating	O
that	O
they	O
were	O
biologically	O
functional	O
.	O

TITLE	O
:	O
CAR	O
T	O
cell	O
-	O
induced	O
cytokine	O
release	O
syndrome	O
is	O
mediated	O
by	O
macrophages	O
and	O
abated	O
by	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
blockade	O
.	O

TITLE	O
:	O
Ultrapotent	O
Human	O
Neutralizing	O
Antibody	B-FUNC
Repertoires	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
From	O
a	O
Recovered	O
Patient	O
.	O

Of	O
the	O
13	O
mAbs	O
displaying	O
strong	O
neutralizing	O
activity	O
against	O
MERS	O
-	O
CoV	O
,	O
two	O
with	O
the	O
immunoglobulin	B-FUNC
heavy	O
-	O
chain	O
variable	O
region	O
(	O
IGHV	O
)	O
1	O
-	O
69	O
-	O
derived	O
heavy	O
chain	O
(	O
named	O
MERS	O
-	O
GD27	O
and	O
MERS	O
-	O
GD33	O
)	O
showed	O
the	O
most	O
potent	O
neutralizing	O
activity	O
against	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
in	O
vitro	O
.	O

Mutagenesis	O
analysis	O
suggested	O
that	O
MERS	O
-	O
GD27	O
and	O
MERS	O
-	O
GD33	O
recognized	O
distinct	O
regions	O
in	O
S	O
glycoproteins	O
,	O
and	O
the	O
combination	O
of	O
2	O
mAbs	O
demonstrated	O
a	O
synergistic	O
effect	O
in	O
neutralization	O
against	O
pseudotyped	O
MERS	O
-	O
CoV	O
.	O
The	O
structural	O
basis	O
of	O
MERS	O
-	O
GD27	O
neutralization	O
and	O
recognition	O
revealed	O
that	O
its	O
epitope	O
almost	O
completely	O
overlapped	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
site	O
.	O

The	O
prevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	O
in	O
Israeli	O
camels	O
was	O
examined	O
in	O
71	O
camel	O
sera	B-FUNC
collected	O
from	O
four	O
farms	O
across	O
Israel	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
microneutralization	O
(	O
Mnt	O
)	O
assay	O
and	O
confirmed	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
immunofluorescence	O
assay	O
(	O
IFA	O
).	O

Although	O
this	O
study	O
cannot	O
rule	O
out	O
potential	O
antibody	B-FUNC
cross	O
-	O
reactivity	O
by	O
IFA	O
,	O
the	O
presence	O
of	O
bovine	O
coronavirus	O
-	O
specific	O
antibodies	O
do	O
not	O
appear	O
to	O
impact	O
detection	O
of	O
MERS	O
-	O
CoV	O
antibodies	O
by	O
Mnt	O
.	O

The	O
high	O
rate	O
of	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibody	B-FUNC
seropositivity	O
in	O
dromedary	O
camels	O
in	O
the	O
absence	O
of	O
any	O
reported	O
human	O
MERS	O
cases	O
suggests	O
that	O
there	O
is	O
still	O
much	O
to	O
be	O
learned	O
about	O
the	O
dynamics	O
of	O
camel	O
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Could	O
Heme	O
Oxygenase	B-FUNC
-	O
1	O
Be	O
a	O
New	O
Target	O
for	O
Therapeutic	O
Intervention	O
in	O
Malaria	O
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
?	O

Further	O
investigation	O
determined	O
that	O
the	O
ectopic	O
expression	O
of	O
Rab5	O
mutants	O
induces	O
aberrant	O
endosomal	O
accumulation	O
of	O
activated	O
pTrkA	O
,	O
proving	O
that	O
targeting	O
of	O
Ulk1	O
-	O
TrkA	O
-	O
NGF	O
signaling	O
to	O
the	O
retrograde	O
transport	O
route	O
in	O
the	O
neurodegenerative	O
process	O
that	O
underlies	O
PHEV	O
infection	O
is	O
dependent	O
on	O
Rab5	O
GTPase	B-FUNC
activity	I-FUNC
.	O

Besides	O
detecting	O
viruses	O
,	O
the	O
technique	O
also	O
allowed	O
the	O
characterisation	O
of	O
host	O
mitochondrial	O
DNA	O
present	O
and	O
thus	O
identifying	O
host	O
species	O
,	O
while	O
ribosomal	B-FUNC
RNA	I-FUNC
sequences	O
provided	O
insight	O
into	O
the	O
""""	O
ribosomal	O
activity	O
microbiome	O
""";"	O
of	O
gut	O
parasites	O
;	O
and	O
of	O
food	O
eaten	O
such	O
as	O
plants	O
or	O
insects	O
,	O
which	O
we	O
correlated	O
to	O
non	O
-	O
avian	O
host	O
associated	O
viruses	O
.	O

TITLE	O
:	O
Epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
is	O
a	O
co	O
-	O
factor	O
for	O
transmissible	O
gastroenteritis	O
virus	O
entry	O
.	O

This	O
study	O
discovered	O
that	O
the	O
extracellular	O
receptor	B-FUNC
binding	I-FUNC
domain	O
1	O
pertaining	O
to	O
epidermal	O
growth	O
receptor	O
(	O
EGFR	B-FUNC
)	O
interact	O
with	O
TGEV	O
spike	O
protein	O
.	O

APN	O
and	O
EGFR	B-FUNC
synergistically	O
promote	O
TGEV	O
invasion	O
.	O

TGEV	O
promotes	O
APN	O
and	O
EGFR	B-FUNC
clustering	O
early	O
in	O
infection	O
.	O

TGEV	O
binds	B-FUNC
with	O
EGFR	B-FUNC
,	O
and	O
subsequently	O
promotes	O
EGFR	B-FUNC
internalization	O
by	O
a	O
clathrin	O
-	O
mediated	O
endocytosis	O
pathway	O
.	O

These	O
results	O
show	O
that	O
EGFR	B-FUNC
is	O
a	O
co	O
-	O
factor	O
of	O
TGEV	O
,	O
and	O
that	O
it	O
plays	O
a	O
synergistic	O
role	O
with	O
APN	O
early	O
in	O
TGEV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
membrane	O
-	O
associated	O
78	O
-	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP78	O
)	O
as	O
an	O
additional	O
binding	B-FUNC
target	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
.	O

The	O
vaccination	O
not	O
only	O
enhanced	O
the	O
antibody	B-FUNC
responses	O
of	O
serum	O
IgG	O
/	O
IgA	O
,	O
mucosal	O
IgA	O
and	O
serum	O
neutralizing	O
antibody	B-FUNC
,	O
but	O
also	O
improved	O
the	O
production	O
of	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

The	O
improved	O
protective	O
efficiency	O
of	O
rSF	O
-	O
COE	O
-	O
3D	O
compared	O
with	O
COE	O
was	O
mostly	O
benefited	O
from	O
the	O
enhanced	O
production	O
of	O
serum	O
IgA	O
,	O
mucosal	O
IgA	O
in	O
feces	O
and	O
serum	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

The	O
strain	O
ZYYR	O
-	O
2014	O
also	O
presented	O
stronger	O
antibody	B-FUNC
responses	O
and	O
lower	O
viral	O
loads	O
in	O
tracheas	O
,	O
lungs	O
and	O
kidneys	O
.	O

MERS	O
-	O
CoV	O
antibodies	O
were	O
detected	O
in	O
13	O
of	O
24	O
(	O
54	O
%)	O
case	O
patients	O
with	O
available	O
sera	B-FUNC
,	O
including	O
1	O
severely	O
symptomatic	O
,	O
9	O
mildly	O
symptomatic	O
,	O
and	O
3	O
asymptomatic	O
case	O
patients	O
.	O

No	O
serologic	O
evidence	O
of	O
MERS	O
-	O
CoV	O
transmission	O
was	O
found	O
among	O
105	O
household	O
contacts	O
with	O
available	O
sera	B-FUNC
.	O

The	O
results	O
showed	O
that	O
TGEV	O
N	O
protein	O
localised	O
in	O
the	O
cytoplasm	O
,	O
inhibited	O
IEC	O
growth	O
,	O
prolonged	O
the	O
S	O
-	O
phase	O
cell	O
cycle	O
by	O
down	O
-	O
regulating	O
cell	O
cycle	O
protein	O
cyclin	B-FUNC
A	O
,	O
and	O
was	O
mainly	O
degraded	O
through	O
the	O
proteasome	O
pathway	O
.	O

Moreover	O
,	O
TGEV	O
N	O
protein	O
induced	O
ER	O
stress	O
and	O
activated	O
NF	O
-	O
B	O
,	O
which	O
was	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
Bcl	O
-	O
2	O
expression	O
.	O

To	O
be	O
specific	O
,	O
in	O
IEC	O
,	O
TGEV	O
N	O
protein	O
induces	O
cell	O
cycle	O
prolongation	O
at	O
the	O
S	O
-	O
phase	O
,	O
ER	O
stress	O
and	O
up	O
-	O
regulates	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
expression	O
.	O

A	O
total	O
of	O
411	O
camels	O
,	O
102	O
alpacas	O
and	O
19	O
llamas	O
'	O
sera	B-FUNC
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
to	O
MERS	O
-	O
CoV	O
.	O
Our	O
findings	O
indicate	O
a	O
lower	O
MERS	O
-	O
CoV	O
seropositivity	O
among	O
Israeli	O
dromedaries	O
than	O
in	O
the	O
surrounding	O
countries	O
,	O
and	O
for	O
the	O
first	O
time	O
naturally	O
infected	O
llamas	O
were	O
identified	O
.	O

Serological	O
activity	O
was	O
evaluated	O
with	O
anti	O
-	O
MERS	O
-	O
CoV	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
,	O
ELISA	O
IgA	O
,	O
immunofluorescence	O
assay	O
IgM	O
and	O
plaque	O
reduction	O
neutralization	O
test	O
(	O
PRNT	O
).	O

We	O
also	O
demonstrated	O
that	O
the	O
impact	O
of	O
TCs	O
on	O
VILI	O
repair	O
might	O
partially	O
due	O
to	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	B-FUNC
)	O
secreted	O
by	O
TCs	O
upon	O
VILI	O
stimulation	O
,	O
and	O
that	O
VEGF	B-FUNC
could	O
induce	O
the	O
proliferation	O
of	O
hemangioendothelioma	O
endothelial	O
cells	O
(	O
EOMA	O
).	O

TITLE	O
:	O
Dimerization	O
of	O
Coronavirus	O
nsp9	O
with	O
Diverse	O
Modes	O
Enhances	O
Its	O
Nucleic	B-FUNC
Acid	I-FUNC
Binding	I-FUNC
Affinity	O
.	O

Nonstructural	O
protein	O
9	O
(	O
nsp9	O
)	O
is	O
an	O
essential	O
RNA	B-FUNC
binding	I-FUNC
protein	O
for	O
coronavirus	O
replication	O
.	O

Our	O
results	O
show	O
that	O
the	O
diverse	O
dimerization	O
forms	O
of	O
coronavirus	O
nsp9	O
proteins	O
enhance	O
their	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
affinity	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
through	O
activation	O
of	O
the	O
cytochrome	B-FUNC
c	I-FUNC
-	O
mediated	O
intrinsic	O
mitochondrial	O
pathway	O
.	O

Experimental	O
data	O
indicated	O
that	O
PDCoV	O
infection	O
led	O
to	O
Bax	O
-	O
mediated	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
),	O
resulting	O
in	O
specific	O
relocation	O
of	O
the	O
mitochondrial	O
cytochrome	B-FUNC
c	I-FUNC
(	O
cyt	O
c	O
)	O
into	O
the	O
cytoplasm	O
.	O

The	O
amount	O
of	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
,	O
in	O
supernatants	O
of	O
co	O
-	O
infected	O
cell	O
cultures	O
,	O
was	O
determined	O
using	O
an	O
ELISA	O
assay	O
.	O

The	O
effects	O
of	O
dietary	O
yeast	O
nucleotides	O
supplementation	O
on	O
intestinal	O
development	O
,	O
expression	O
of	O
intestinal	O
barrier	O
-	O
related	O
genes	O
,	O
intestinal	O
microbiota	O
,	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antibody	B-FUNC
titer	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
were	O
investigated	O
.	O

At	O
day	O
10	O
,	O
17	O
,	O
24	O
,	O
31	O
,	O
38	O
,	O
and	O
45	O
,	O
the	O
serum	O
IBV	O
antibody	B-FUNC
titers	O
were	O
tested	O
.	O

In	O
conclusion	O
,	O
dietary	O
yeast	O
nucleotides	O
supplementation	O
can	O
help	O
birds	O
to	O
mount	O
a	O
faster	O
and	O
stronger	O
antibody	B-FUNC
response	O
to	O
IBV	O
vaccine	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
novel	O
neutralizing	O
Nb	O
(	O
NbMS10	O
)	O
and	O
its	O
human	O
-	O
Fc	O
-	O
fused	O
version	O
(	O
NbMS10	O
-	O
Fc	O
),	O
both	O
of	O
which	O
target	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
).	O

We	O
further	O
tested	O
their	O
receptor	O
-	O
binding	B-FUNC
affinity	O
,	O
recognizing	O
epitopes	O
,	O
cross	O
-	O
neutralizing	O
activity	O
,	O
half	O
-	O
life	O
,	O
and	O
efficacy	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

Both	O
Nbs	O
can	O
be	O
expressed	O
in	O
yeasts	O
with	O
high	O
yield	O
,	O
bind	B-FUNC
to	O
MERS	O
-	O
CoV	O
RBD	O
with	O
high	O
affinity	O
,	O
and	O
block	O
the	O
binding	B-FUNC
of	O
MERS	O
-	O
CoV	O
RBD	O
to	O
the	O
MERS	O
-	O
CoV	O
receptor	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
relationship	O
between	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
and	O
severity	O
of	O
acute	O
pancreatitis	O
(	O
AP	O
)	O
measured	O
by	O
the	O
revised	O
Atlanta	O
classification	O
(	O
RAC	O
)	O
and	O
determinant	O
-	O
based	O
classification	O
(	O
DBC	O
).	O

Secondary	O
objectives	O
were	O
to	O
assess	O
IAH	B-FUNC
as	O
a	O
predictor	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
ICU	O
.	O

IAH	B-FUNC
predicted	O
shock	O
(	O
area	O
under	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
(	O
AUC	O
)	O
0	O
	O
79	O
,	O
95	O
per	O
cent	O
c	O
.	O
i	O
.	O

IAH	B-FUNC
was	O
associated	O
with	O
severity	O
of	O
AP	O
classified	O
according	O
to	O
both	O
RAC	O
and	O
DBC	O
systems	O
.	O

The	O
IBV	O
-	O
specific	O
antibody	B-FUNC
levels	O
,	O
as	O
well	O
as	O
the	O
percentages	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
,	O
were	O
detected	O
within	O
28	O
days	O
post	O
-	O
vaccination	O
(	O
dpv	O
).	O

The	O
results	O
showed	O
that	O
the	O
IBV	O
-	O
specific	O
antibody	B-FUNC
levels	O
and	O
the	O
percentages	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
were	O
higher	O
in	O
the	O
rHBM	O
-	O
S1	O
-	O
N	O
vaccinated	O
birds	O
compared	O
to	O
birds	O
vaccinated	O
with	O
the	O
rHBM	O
-	O
S1	O
and	O
rHBM	O
-	O
N	O
vaccines	O
.	O

Based	O
on	O
binding	B-FUNC
energy	O
,	O
ADME	O
properties	O
,	O
and	O
toxicology	O
analysis	O
,	O
we	O
finally	O
selected	O
3	O
compounds	O
from	O
structure	O
-	O
based	O
virtual	O
screening	O
(	O
ZINC	O
ID	O
:	O
75121653	O
,	O
41131653	O
,	O
and	O
67266079	O
)	O
having	O
binding	B-FUNC
energy	O
-	O
7	O
.	O
12	O
,	O
-	O
7	O
.	O
1	O
and	O
-	O
7	O
.	O
08	O
Kcal	O
/	O
mol	O
,	O
respectively	O
and	O
5	O
compounds	O
from	O
ligandbased	O
virtual	O
screening	O
(	O
ZINC	O
ID	O
:	O
05576502	O
,	O
47654332	O
,	O
04829153	O
,	O
86434515	O
and	O
25626324	O
)	O
having	O
binding	B-FUNC
energy	O
-	O
49	O
.	O
8	O
,	O
-	O
54	O
.	O
9	O
,	O
-	O
65	O
.	O
6	O
,	O
-	O
61	O
.	O
1	O
and	O
-	O
66	O
.	O
7	O
Kcal	O
/	O
mol	O
respectively	O
.	O

All	O
the	O
compounds	O
showed	O
no	O
inhibition	O
of	O
cytochrome	B-FUNC
P450	I-FUNC
enzymes	O
,	O
no	O
blood	O
-	O
brain	O
barrier	O
permeability	O
and	O
no	O
toxic	O
structure	O
in	O
medicinal	O
chemistry	O
profile	O
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-FUNC
-	I-FUNC
glycoprotein	I-FUNC
.	O

RESULTS	O
:	O
Based	O
on	O
binding	B-FUNC
energy	O
,	O
ADME	O
properties	O
,	O
and	O
toxicology	O
analysis	O
,	O
we	O
finally	O
selected	O
3	O
compounds	O
from	O
structure	O
-	O
based	O
virtual	O
screening	O
(	O
ZINC	O
ID	O
:	O
75121653	O
,	O
41131653	O
,	O
and	O
67266079	O
)	O
having	O
binding	B-FUNC
energy	O
-	O
7	O
.	O
12	O
,	O
-	O
7	O
.	O
1	O
and	O
-	O
7	O
.	O
08	O
Kcal	O
/	O
mol	O
,	O
respectively	O
and	O
5	O
compounds	O
from	O
ligandbased	O
virtual	O
screening	O
(	O
ZINC	O
ID	O
:	O
05576502	O
,	O
47654332	O
,	O
04829153	O
,	O
86434515	O
and	O
25626324	O
)	O
having	O
binding	B-FUNC
energy	O
-	O
49	O
.	O
8	O
,	O
-	O
54	O
.	O
9	O
,	O
-	O
65	O
.	O
6	O
,	O
-	O
61	O
.	O
1	O
and	O
-	O
66	O
.	O
7	O
Kcal	O
/	O
mol	O
respectively	O
.	O

Their	O
clinical	O
phenotypes	O
including	O
laboratory	O
test	O
results	O
,	O
high	O
-	O
resolution	O
lung	O
computed	O
tomography	O
data	O
,	O
response	O
to	O
therapy	O
,	O
and	O
prognosis	O
were	O
compared	O
between	O
those	O
who	O
were	O
positive	O
and	O
negative	O
for	O
MAAs	O
,	O
such	O
as	O
antinuclear	O
antibody	B-FUNC
(	O
ANA	O
),	O
anti	O
-	O
cyclic	O
citrullinated	O
peptide	O
(	O
CCP	O
),	O
anti	O
-	O
SSA	O
,	O
and	O
anti	O
-	O
SSB	O
antibodies	O
.	O

One	O
hundred	O
and	O
seventy	O
(	O
45	O
.	O
33	O
%)	O
tested	O
samples	O
were	O
found	O
positive	O
by	O
the	O
commercially	O
-	O
available	O
ELISA	O
test	O
kit	B-FUNC
,	O
and	O
10	O
(	O
5	O
.	O
68	O
%)	O
of	O
these	O
170	O
samples	O
found	O
positive	O
were	O
positive	O
by	O
the	O
in	O
-	O
house	O
blocking	O
ELISA	O
.	O

Reasons	O
for	O
the	O
high	O
variance	O
in	O
the	O
results	O
obtained	O
remain	O
unclear	O
;	O
more	O
research	O
is	O
required	O
to	O
ensure	O
higher	O
sensitivity	O
and	O
specificity	O
in	O
terms	O
of	O
PEDV	O
antibody	B-FUNC
tests	O
and	O
other	O
PED	O
diagnostic	O
methods	O
.	O

As	O
compared	O
with	O
the	O
control	O
group	O
,	O
all	O
piglets	O
in	O
the	O
S	O
protein	O
-	O
LTB	O
immunized	O
(	O
IM	O
PEDV	O
S	O
-	O
LTB	O
)	O
group	O
generated	O
systemic	O
PEDV	O
S	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	B-FUNC
in	O
blood	O
but	O
a	O
low	O
level	O
of	O
fecal	O
PEDV	O
-	O
specific	O
IgA	O
and	O
limited	O
protection	O
against	O
challenge	O
of	O
PEDV	O
-	O
PT	O
strain	O
.	O

Antibody	B-FUNC
titers	O
against	O
Newcastle	O
disease	O
and	O
infectious	O
bronchitis	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
fed	O
groups	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

In	O
the	O
past	O
few	O
years	O
,	O
newly	O
recognized	O
infections	O
with	O
Zika	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
viruses	O
have	O
pushed	O
the	O
US	O
military	O
to	O
fund	O
research	O
and	O
fast	B-FUNC
track	O
clinical	O
trials	O
to	O
quickly	O
and	O
effectively	O
develop	O
vaccines	O
for	O
emerging	O
diseases	O
.	O

Finally	O
,	O
19	O
codons	O
are	O
defined	O
as	O
the	O
major	O
preference	O
codons	O
in	O
MERS	O
-	O
Co	O
V	O
.	O
The	O
results	O
have	O
a	O
certain	O
significance	O
for	O
MERS	O
-	O
Co	O
V	O
that	O
selecting	O
gene	O
expression	O
host	O
system	O
,	O
contributing	O
further	O
to	O
development	O
of	O
genetically	O
engineered	O
vaccine	O
and	O
therapeutic	O
antibody	B-FUNC
.	O

Compared	O
with	O
classical	O
vaccine	O
strains	O
,	O
a	O
series	O
of	O
deletions	O
and	O
frequently	O
occurring	O
mutations	O
were	O
observed	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domains	O
of	O
our	O
PEDV	O
strains	O
.	O

An	O
estimated	O
50	O
-	O
kDa	O
recombinant	O
protein	O
corresponding	O
to	O
the	O
expected	O
molecular	O
weight	O
of	O
IBV	O
N	O
including	O
the	O
6xHis	O
tag	O
was	O
detected	O
using	O
an	O
anti	O
-	O
His	O
monoclonal	O
antibody	B-FUNC
.	O

Specific	O
immunoreactivity	O
of	O
the	O
recombinant	O
protein	O
was	O
confirmed	O
by	O
Western	O
blot	O
using	O
antiserum	O
obtained	O
from	O
vaccinated	O
and	O
naturally	O
infected	O
chicken	O
from	O
Turkey	O
as	O
well	O
as	O
using	O
a	O
monoclonal	O
antibody	B-FUNC
raised	O
against	O
the	O
N	O
protein	O
of	O
the	O
IBV	O
Massachusetts	O
strain	O
.	O

We	O
observed	O
that	O
untreated	O
barrier	O
-	O
free	O
(	O
BF	O
)	O
mice	O
suffered	O
from	O
severe	O
antibody	B-FUNC
-	O
mediated	O
acute	O
lung	O
injury	O
,	O
whereas	O
the	O
more	O
sterile	O
housed	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
mice	O
and	O
gut	O
flora	O
-	O
depleted	O
BF	O
mice	O
were	O
both	O
protected	O
from	O
lung	O
injury	O
.	O

DNA	O
sequencing	O
of	O
amplicons	O
of	O
the	O
16S	O
ribosomal	B-FUNC
RNA	I-FUNC
gene	O
revealed	O
a	O
varying	O
gastrointestinal	O
bacterial	O
composition	O
between	O
BF	O
and	O
SPF	O
mice	O
.	O

Heatmap	O
cluster	O
analysis	O
showed	O
that	O
the	O
vast	O
majority	O
of	O
the	O
viral	O
groups	O
were	O
differentially	O
expressed	O
in	O
miRNA	O
compared	O
with	O
the	O
control	O
group	O
,	O
Go	O
analysis	O
showed	O
that	O
miRNAs	O
are	O
widely	O
involved	O
in	O
combination	O
,	O
binding	B-FUNC
protein	O
,	O
protein	B-FUNC
kinase	I-FUNC
activity	I-FUNC
,	O
transfer	O
enzyme	B-FUNC
activity	I-FUNC
,	O
phosphorus	O
containing	O
radicals	O
transfer	O
,	O
phosphotransferase	O
enzyme	B-FUNC
activity	I-FUNC
and	O
other	O
biological	O
effects	O
.	O

TITLE	O
:	O
Structural	O
Definition	O
of	O
a	O
Unique	O
Neutralization	O
Epitope	O
on	O
the	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
of	O
MERS	O
-	O
CoV	O
Spike	O
Glycoprotein	O
.	O

ABSTRACT	O
:	O
The	O
major	O
mechanism	O
of	O
antibody	B-FUNC
-	O
mediated	O
neutralization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
involves	O
competition	O
with	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
for	O
binding	B-FUNC
to	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

Here	O
,	O
we	O
report	O
a	O
unique	O
epitope	O
and	O
unusual	O
neutralizing	O
mechanism	O
of	O
the	O
isolated	O
human	O
antibody	B-FUNC
MERS	O
-	O
4	O
.	O

Structurally	O
,	O
MERS	O
-	O
4	O
approached	O
the	O
RBD	O
from	O
the	O
outside	O
of	O
the	O
RBD	O
-	O
DPP4	O
binding	B-FUNC
interface	O
.	O

Such	O
binding	B-FUNC
resulted	O
in	O
the	O
folding	O
of	O
the	O
5	O
-	O
6	O
loop	O
toward	O
a	O
shallow	O
groove	O
on	O
the	O
RBD	O
interface	O
critical	O
for	O
accommodating	O
DPP4	O
.	O

The	O
key	O
residues	O
for	O
binding	B-FUNC
are	O
identified	O
through	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Structural	O
modeling	O
revealed	O
that	O
MERS	O
-	O
4	O
binds	B-FUNC
to	O
RBD	O
only	O
in	O
the	O
""""	O
up	O
""""	O
position	O
in	O
the	O
S	O
trimer	O
.	O

TITLE	O
:	O
Heme	O
Oxygenase	B-FUNC
-	O
1	O
Reduces	O
Sepsis	O
-	O
Induced	O
Endoplasmic	O
Reticulum	O
Stress	O
and	O
Acute	O
Lung	O
Injury	O
.	O

Heme	O
oxygenase	B-FUNC
-	O
1	O
(	O
HO	O
-	O
1	O
),	O
an	O
ER	O
-	O
anchored	O
protein	O
,	O
exerts	O
antioxidant	O
and	O
protective	O
functions	O
under	O
ALI	O
.	O

Nasopharyngeal	O
samples	O
obtained	O
from	O
269	O
hospitalized	O
children	O
were	O
analyzed	O
for	O
viral	O
respiratory	O
pathogens	O
using	O
the	O
xTAG	O
Respiratory	O
Virus	O
Panel	O
Fast	B-FUNC
assay	O
,	O
and	O
the	O
data	O
were	O
correlated	O
with	O
the	O
clinical	O
and	O
demographic	O
information	O
available	O
for	O
these	O
patients	O
.	O

TITLE	O
:	O
Cyclophilins	O
and	O
cyclophilin	B-FUNC
inhibitors	O
in	O
nidovirus	O
replication	O
.	O

Also	O
the	O
involvement	O
of	O
the	O
FK	O
-	O
506	O
-	O
binding	B-FUNC
proteins	O
and	O
parvulins	O
is	O
discussed	O
.	O

A	O
previous	O
report	O
shows	O
that	O
furin	O
,	O
which	O
is	O
distributed	O
mainly	O
in	O
the	O
Golgi	O
apparatus	O
and	O
cycled	O
to	O
the	O
cell	O
surface	O
and	O
endosomes	O
,	O
proteolytically	O
activates	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
following	O
receptor	B-FUNC
binding	I-FUNC
to	O
mediate	O
fusion	O
between	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

Tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
-	O
3	O
(	O
TIMP	O
-	O
3	O
)	O
is	O
a	O
regulator	O
of	O
matrix	O
metalloproteinase	B-FUNC
activity	I-FUNC
,	O
inflammation	O
,	O
and	O
vascular	O
permeability	O
,	O
and	O
hence	O
has	O
plausibility	O
as	O
a	O
biomarker	O
for	O
the	O
systemic	O
response	O
to	O
TBI	O
.	O

Notably	O
,	O
we	O
discovered	O
calpain	O
-	O
5	O
(	O
CAPN5	O
)	O
and	O
the	O
ubiquitin	B-FUNC
ligase	O
Casitas	O
B	O
-	O
lineage	O
lymphoma	O
proto	O
-	O
oncogene	O
B	O
(	O
CBLB	O
)	O
to	O
form	O
a	O
complex	O
with	O
CD81	O
and	O
support	O
HCV	O
entry	O
.	O

Besides	O
siRNA	O
efficacy	O
,	O
we	O
paid	O
attention	O
to	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
,	O
obtained	O
by	O
analysing	O
all	O
known	O
Zika	O
genomes	O
,	O
and	O
siRNA	O
safety	O
,	O
by	O
excluding	O
siRNAs	O
that	O
could	O
potentially	O
provoke	O
an	O
immune	O
response	O
or	O
interfere	O
with	O
host	O
mRNAs	O
,	O
lncRNAs	O
,	O
circRNAs	O
and	O
RNA	B-FUNC
binding	I-FUNC
proteins	O
.	O

TITLE	O
:	O
Oh	O
,	O
SNAP	B-FUNC
!	O

Persistent	O
high	O
fever	O
was	O
resistant	O
to	O
intravenous	O
immunoglobulin	B-FUNC
and	O
pulse	O
steroid	O
therapy	O
.	O

RESULTS	O
:	O
The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
	O
promoter	O
,	O
and	O
NF	O
-	O
B	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	O
,	O
following	O
the	O
challenge	O
of	O
cells	O
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
	O
or	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
.	O

All	O
patients	O
with	O
influenza	O
>	O
18	O
-	O
years	O
-	O
old	O
hospitalized	O
to	O
the	O
ICU	O
department	O
of	O
Tunisian	O
University	O
hospital	O
of	O
Sousse	O
,	O
between	O
December	O
1	O
,	O
2009	O
and	O
March	O
31	O
,	O
2016	O
,	O
with	O
a	O
positive	O
influenza	O
A	O
/	O
H1N1	O
/	O
09	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
specimen	O
were	O
included	O
,	O
were	O
included	O
.	O

TITLE	O
:	O
Detection	O
,	O
sequence	O
analysis	O
,	O
and	O
antibody	B-FUNC
prevalence	O
of	O
porcine	O
deltacoronavirus	O
in	O
Taiwan	O
.	O

To	O
further	O
trace	O
PDCoV	O
in	O
the	O
period	O
of	O
2011	O
to	O
2015	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
detect	O
antibodies	O
against	O
PDCoV	O
.	O
The	O
results	O
showed	O
that	O
279	O
of	O
1	O
,	O
039	O
(	O
26	O
.	O
9	O
%)	O
sera	B-FUNC
were	O
positive	O
for	O
the	O
PDCoV	O
nucleocapsid	O
protein	O
,	O
implying	O
that	O
PDCoV	O
might	O
have	O
existed	O
in	O
Taiwan	O
before	O
2011	O
.	O

The	O
obtained	O
results	O
demonstrated	O
the	O
significant	O
effect	O
of	O
the	O
constructed	O
L	O
.	O
plantarum	O
expressing	O
S	O
-	O
DCpep	O
fusion	O
proteins	O
in	O
inducing	O
high	O
expression	O
levels	O
of	O
B7	O
molecules	O
on	O
DCs	O
,	O
as	O
well	O
as	O
high	O
levels	O
of	O
IgG	O
,	O
secretory	O
IgA	O
,	O
and	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
cytokines	O
compared	O
with	O
the	O
other	O
groups	O
.	O

In	O
this	O
review	O
,	O
we	O
illustrate	O
the	O
structure	O
and	O
function	O
of	O
S	O
protein	O
as	O
a	O
vaccine	O
target	O
,	O
describe	O
available	O
animal	O
models	O
for	O
evaluating	O
MERS	O
vaccines	O
,	O
and	O
summarize	O
recent	O
progress	O
on	O
MERS	O
-	O
CoV	O
S	O
-	O
based	O
vaccines	O
,	O
focusing	O
on	O
their	O
ability	O
to	O
elicit	O
antibody	B-FUNC
and	O
/	O
or	O
cellular	O
immune	O
responses	O
,	O
neutralizing	O
antibodies	O
,	O
and	O
protection	O
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
different	O
models	O
.	O

The	O
majority	O
of	O
MERS	O
vaccines	O
under	O
development	O
are	O
based	O
on	O
MERS	O
-	O
CoV	O
S	O
protein	O
,	O
including	O
full	O
-	O
length	O
S	O
,	O
S1	O
,	O
and	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
).	O

The	O
374	O
-	O
residue	O
protein	O
displayed	O
robust	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	B-FUNC
activity	I-FUNC
in	O
the	O
presence	O
of	O
Mg	O

At	O
the	O
convalescent	O
phase	O
,	O
disease	O
severity	O
-	O
dependent	O
antibody	B-FUNC
responses	O
emerged	O
and	O
antigen	O
-	O
reactive	O
cells	O
were	O
identified	O
in	O
both	O
T	O
-	O
cell	O
subsets	O
.	O

The	O
MERS	O
-	O
CoV	O
4a	O
accessory	O
protein	O
is	O
known	O
to	O
inhibit	O
SG	O
formation	O
in	O
cells	O
in	O
which	O
it	O
was	O
expressed	O
by	O
binding	B-FUNC
to	O
double	O
-	O
stranded	O
RNAs	O
and	O
inhibiting	O
protein	O
kinase	O
R	O
(	O
PKR	O
)-	O
mediated	O
phosphorylation	O
of	O
the	O
	O
subunit	O
of	O
eukaryotic	O
initiation	O
factor	O
2	O
(	O
eIF2	O
).	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
human	O
	O
-	O
defensin	O
(	O
HBD	O
)	O
2	O
to	O
promote	O
antiviral	O
immunity	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	O
(	O
Ag	O
).	O

When	O
HBD	O
2	O
-	O
conjugated	O
S	O
RBD	O
was	O
used	O
to	O
treat	O
THP	O
-	O
1	O
human	O
monocytic	O
cells	O
,	O
the	O
expression	O
levels	O
of	O
antiviral	O
(	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
MxA	O
,	O
PKR	O
,	O
and	O
RNaseL	O
)	O
and	O
primary	O
immune	O
-	O
inducing	O
(	O
NOD2	O
,	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
molecules	O
were	O
enhanced	O
compared	O
to	O
those	O
expressed	O
after	O
treatment	O
with	O
S	O
RBD	O
only	O
.	O

More	O
important	O
,	O
immunization	O
of	O
mice	O
with	O
HBD	O
2	O
-	O
conjugated	O
S	O
RBD	O
enhanced	O
the	O
immunogenicity	O
of	O
the	O
S	O
RBD	O
and	O
elicited	O
a	O
higher	O
S	O
RBD	O
-	O
specific	O
neutralizing	O
antibody	B-FUNC
response	O
than	O
S	O
RBD	O
alone	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
human	O
	O
-	O
defensin	O
(	O
HBD	O
)	O
2	O
to	O
promote	O
antiviral	O
immunity	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	O
(	O
Ag	O
).	O

More	O
important	O
,	O
immunization	O
of	O
mice	O
with	O
HBD	O
2	O
-	O
conjugated	O
S	O
RBD	O
enhanced	O
the	O
immunogenicity	O
of	O
the	O
S	O
RBD	O
and	O
elicited	O
a	O
higher	O
S	O
RBD	O
-	O
specific	O
neutralizing	O
antibody	B-FUNC
response	O
than	O
S	O
RBD	O
alone	O
.	O

These	O
derivatives	O
were	O
first	O
evaluated	O
for	O
their	O
inhibitory	O
effect	O
on	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
(	O
RT	O
)	O
enzyme	B-FUNC
activity	I-FUNC
.	O

Feed	O
was	O
then	O
analyzed	O
for	O
PEDV	O
RNA	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
semiquantitative	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
as	O
measured	O
by	O
cycle	O
threshold	O
(	O
Ct	O
)	O
and	O
for	O
infectivity	O
by	O
bioassay	O
.	O

These	O
strong	O
antibody	B-FUNC
responses	O
may	O
be	O
caused	O
by	O
affinity	O
maturation	O
as	O
a	O
result	O
of	O
repeated	O
exposure	O
to	O
the	O
virus	O
or	O
by	O
the	O
fact	O
that	O
dromedaries	O
-	O
apart	O
from	O
conventional	O
antibodies	O
-	O
have	O
relatively	O
unique	O
,	O
heavy	O
chain	O
-	O
only	O
antibodies	O
(	O
HCAbs	O
).	O

The	O
selected	O
VHHs	O
bind	B-FUNC
with	O
exceptionally	O
high	O
affinity	O
to	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
the	O
viral	O
spike	O
protein	O
.	O

The	O
complex	O
structure	O
shows	O
that	O
only	O
one	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
trimeric	O
S	O
glycoprotein	O
binds	B-FUNC
ACE2	O
and	O
adopts	O
a	O
protruding	O
""""	O
up	O
""""	O
conformation	O
.	O

However	O
,	O
binding	B-FUNC
to	O
the	O
receptor	O
opens	O
up	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
S1	O
,	O
which	O
could	O
promote	O
the	O
release	O
of	O
the	O
S1	O
-	O
ACE2	O
complex	O
and	O
S1	O
monomers	O
from	O
the	O
prefusion	O
spike	O
and	O
trigger	O
the	O
pre	O
-	O
to	O
postfusion	O
conformational	O
transition	O
.	O

ABSTRACT	O
:	O
Antisynthetase	O
syndrome	O
is	O
a	O
clinical	O
entity	O
characterized	O
by	O
specific	O
anti	O
-	O
aminoacyl	O
-	O
tRNA	B-FUNC
-	O
synthetase	O
antibodies	O
usually	O
associated	O
with	O
inflammatory	O
myopathy	O
and	O
interstitial	O
lung	O
disease	O
.	O

We	O
used	O
latent	O
class	O
analysis	O
to	O
identify	O
patients	O
with	O
distinct	O
MMP	O
profiles	O
and	O
then	O
associated	O
those	O
profiles	O
with	O
markers	O
of	O
inflammation	O
(	O
IL	B-FUNC
-	I-FUNC
1RA	I-FUNC
,	O
-	O
6	O
,	O
-	O
8	O
,	O
-	O
10	O
,	O
and	O
-	O
18	O
;	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
and	O
-	O
1	O
;	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
and	O
-	O
R2	O
),	O
endothelial	O
injury	O
(	O
angiopoietin	O
-	O
2	O
,	O
von	O
Willebrand	O
factor	O
,	O
soluble	O
thrombomodulin	O
),	O
impaired	O
oxygenation	O
(	O
Pa	O
In	O
geographically	O
distinct	O
derivation	O
and	O
validation	O
cohorts	O
,	O
approximately	O
one	O
-	O
third	O
of	O
patients	O
demonstrated	O
an	O
MMP	O
profile	O
characterized	O
by	O
elevated	O
MMP	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
7	O
,	O
and	O
-	O
8	O
and	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
and	O
-	O
2	O
;	O
and	O
depressed	O
active	O
and	O
total	O
MMP	O
-	O
9	O
.	O

In	O
this	O
study	O
,	O
the	O
aim	O
was	O
to	O
establish	O
two	O
ELISA	O
systems	O
for	O
detecting	O
antigens	O
and	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
Using	O
a	O
recombinant	O
full	O
-	O
length	O
S	O
protein	O
,	O
an	O
indirect	O
ELISA	O
was	O
developed	O
and	O
found	O
to	O
detect	O
MERS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
in	O
animal	O
sera	B-FUNC
and	O
sera	B-FUNC
of	O
patient	O
with	O
MERS	O
.	O

This	O
indirect	O
ELISA	O
was	O
compared	O
to	O
indirect	O
immunoinfluscent	O
assay	O
(	O
IFA	O
),	O
and	O
the	O
overall	O
coincidence	O
rate	O
was	O
96	O
.	O
74	O
%	O
based	O
on	O
testing	O
368	O
clinical	O
serum	O
samples	O
with	O
different	O
PEDV	O
antibody	B-FUNC
levels	O
.	O

The	O
survival	O
days	O
of	O
mice	O
,	O
and	O
the	O
serum	O
levels	O
of	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
were	O
examined	O
.	O

Balb	O
/	O
cJ	O
mice	O
died	O
in	O
3	O
to	O
6	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
with	O
severe	O
hepatic	O
necrosis	O
and	O
significant	O
augmentation	O
of	O
serum	O
ALT	B-FUNC
and	O
AST	O
levels	O
.	O

The	O
proportions	O
of	O
	O
T	O
cells	O
in	O
blood	O
,	O
spleen	O
and	O
liver	O
were	O
significantly	O
increased	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
while	O
those	O
of	O
the	O
early	O
activating	O
molecule	O
CD69	O
-	O
expressing	O
	O
T	O
cells	O
and	O
productions	O
of	O
cytokines	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
and	O
interferon	O
-	O
	O
(	O
IFN	O
-	O
	O
)	O
increased	O
remarkably	O
in	O
the	O
liver	O
.	O

Serine	O
substitution	O
of	O
residue	O
F285	O
,	O
which	O
harbors	O
an	O
aromatic	O
side	O
chain	O
that	O
disturbs	O
RNA	B-FUNC
binding	I-FUNC
compared	O
with	O
that	O
of	O
other	O
homologs	O
,	O
increases	O
catalytic	B-FUNC
activity	I-FUNC
.	O

In	O
contrast	O
,	O
mutant	O
D39A	O
exhibits	O
increased	O
activity	O
and	O
a	O
higher	O
substrate	O
binding	B-FUNC
capacity	O
.	O

The	O
Nsp7	O
/	O
Nsp8	O
complex	O
displays	O
a	O
higher	O
binding	B-FUNC
affinity	O
for	O
Nsp15	O
.	O

Moreover	O
,	O
the	O
infectivity	O
of	O
scIAV	O
-	O
S	O
was	O
associated	O
with	O
the	O
degree	O
of	O
cell	O
adaptation	O
of	O
PEDV	O
-	O
S	O
.	O
Intriguingly	O
,	O
scIAV	O
-	O
S	O
lacking	O
functional	O
neuraminidase	O
(	O
NA	O
)	O
exhibited	O
substantially	O
higher	O
infectivity	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
the	O
sialic	O
acid	O
in	O
the	O
binding	B-FUNC
/	O
entry	O
of	O
PEDV	O
.	O

TITLE	O
:	O
A	O
fast	B-FUNC
and	O
simple	O
one	O
-	O
step	O
duplex	O
PCR	O
assay	O
for	O
canine	O
distemper	O
virus	O
(	O
CDV	O
)	O
and	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
detection	O
.	O

ABSTRACT	O
:	O
Single	O
-	O
domain	O
antibody	B-FUNC
(	O
sdAb	O
)	O
or	O
nanobody	O
possesses	O
specific	O
features	O
non	O
-	O
accessible	O
for	O
conventional	O
antibodies	O
that	O
make	O
them	O
suitable	O
for	O
research	O
and	O
biotechnological	O
applications	O
.	O

The	O
functional	O
characteristics	O
analysis	O
revealed	O
that	O
the	O
recombinant	O
sdAb	O
-	O
Mcs	O
have	O
excellent	O
binding	B-FUNC
activity	O
and	O
specificity	O
to	O
M	O
protein	O
but	O
have	O
no	O
neutralizing	O
activity	O
to	O
PEDV	O
.	O

Quantitative	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
was	O
applied	O
on	O
the	O
collected	O
tracheal	O
swabs	O
for	O
detecting	O
RNA	O
copies	O
of	O
H9N2	O
AIV	O
.	O

Isolating	O
PEDV	O
neutralizing	O
antibodies	O
are	O
crucial	O
to	O
identifying	O
the	O
receptor	O
-	O
binding	B-FUNC
domains	O
of	O
the	O
viral	O
spike	O
and	O
elucidating	O
the	O
mechanism	O
of	O
protection	O
against	O
PEDV	O
infection	O
.	O

E	O
.	O
coli	O
prokaryotic	O
expression	O
system	O
and	O
Bac	O
-	O
to	O
-	O
Bac	O
expression	O
system	O
were	O
used	O
to	O
identify	O
the	O
target	O
protein	O
of	O
each	O
monoclonal	O
antibody	B-FUNC
.	O

The	O
data	O
suggested	O
that	O
PEDV	O
neutralizing	O
antibody	B-FUNC
inhibited	O
virus	O
infection	O
by	O
binding	B-FUNC
to	O
infectious	O
virions	O
,	O
which	O
could	O
work	O
as	O
a	O
tool	O
to	O
find	O
the	O
receptor	O
-	O
binding	B-FUNC
domains	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggested	O
that	O
PEDV	O
neutralizing	O
antibody	B-FUNC
inhibited	O
virus	O
infection	O
by	O
binding	B-FUNC
to	O
infectious	O
virions	O
,	O
which	O
could	O
work	O
as	O
a	O
tool	O
to	O
find	O
the	O
receptor	O
-	O
binding	B-FUNC
domains	O
.	O

Three	O
series	O
of	O
derivatives	O
bearing	O
two	O
lipophilic	O
groups	O
were	O
synthesized	O
by	O
attaching	O
bis	B-FUNC
-	O
alkylthio	O
maleimides	O
directly	O
or	O
through	O
linkers	O
of	O
different	O
lengths	O
to	O
the	O
glycopeptide	O
.	O

We	O
obtained	O
samples	O
with	O
nylon	O
swabs	O
from	O
the	O
glans	O
penis	O
,	O
corona	O
,	O
inner	O
layer	O
of	O
the	O
prepuce	O
and	O
penile	O
body	O
and	O
detected	O
different	O
types	O
of	O
HPV	O
infection	O
using	O
the	O
Hybribio	O
HPV	O
typing	O
kit	B-FUNC
,	O
PCR	O
and	O
membrane	O
hybridization	O
.	O

Both	O
viruses	O
establish	O
an	O
infection	O
in	O
porcine	O
enterocytes	O
in	O
the	O
small	O
intestine	O
,	O
and	O
their	O
spike	O
(	O
S	O
)	O
proteins	O
play	O
a	O
key	O
role	O
in	O
the	O
virus	O
-	O
cell	O
binding	B-FUNC
process	O
under	O
unfavorable	O
conditions	O
when	O
the	O
intestine	O
with	O
a	O
low	O
pH	O
is	O
filled	O
with	O
a	O
thick	O
layer	O
of	O
mucus	O
and	O
proteases	O
.	O

However	O
,	O
the	O
details	O
of	O
how	O
sialic	O
acid	O
and	O
low	O
pH	O
affect	O
virus	O
binding	B-FUNC
to	O
the	O
host	O
cell	O
are	O
not	O
determined	O
,	O
and	O
the	O
functions	O
of	O
the	O
proteases	O
are	O
unknown	O
.	O

LPS	O
induced	O
the	O
release	O
of	O
TNF	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
by	O
HLMVECs	O
that	O
were	O
inhibited	O
by	O
sitagliptin	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	O
elastase	O
mRNA	O
expression	O
and	O
myeloperoxidase	B-FUNC
activity	I-FUNC
in	O
the	O
lung	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	O
elastase	O
mRNA	O
expression	O
and	O
myeloperoxidase	B-FUNC
activity	I-FUNC
in	O
the	O
lung	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
chemical	O
clarification	O
of	O
oral	O
fluids	O
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
antibody	B-FUNC
responses	O
.	O

To	O
evaluate	O
both	O
the	O
immediate	O
and	O
residual	O
effects	O
of	O
treatment	O
on	O
antibody	B-FUNC
detection	O
,	O
samples	O
were	O
tested	O
immediately	O
post	O
-	O
treatment	O
,	O
then	O
stored	O
at	O
4	O
	O
C	O
and	O
retested	O
at	O
2	O
,	O
4	O
,	O
and	O
6	O
days	O
post	O
-	O
treatment	O
(	O
DPT	O
).	O

Therefore	O
,	O
chitosan	O
efficiently	O
clarified	O
OF	O
specimens	O
without	O
affecting	O
the	O
results	O
of	O
the	O
PEDV	O
IgG	O
and	O
IgA	O
antibody	B-FUNC
ELISAs	O
.	O

TITLE	O
:	O
Interplay	O
between	O
the	O
Poly	O
(	O
A	O
)	O
Tail	O
,	O
Poly	O
(	O
A	O
)-	O
Binding	B-FUNC
Protein	O
,	O
and	O
Coronavirus	O
Nucleocapsid	O
Protein	O
Regulates	O
Gene	O
Expression	O
of	O
Coronavirus	O
and	O
the	O
Host	O
Cell	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
interactions	O
among	O
the	O
poly	O
(	O
A	O
)	O
tail	O
,	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
and	O
poly	O
(	O
A	O
)-	O
binding	B-FUNC
protein	O
(	O
PABP	O
)	O
in	O
the	O
regulation	O
of	O
coronavirus	O
gene	O
expression	O
.	O

PCR	O
amplification	O
of	O
the	O
conserved	O
coronaviral	O
protein	O
RdRp	B-FUNC
detected	O
coronaviruses	O
in	O
26	O
.	O
65	O
%	O
of	O
bats	O
belonging	O
to	O
this	O
region	O
,	O
and	O
this	O
number	O
was	O
influenced	O
by	O
seasonal	O
changes	O
.	O

High	O
antibody	B-FUNC
responses	O
were	O
detected	O
in	O
chickens	O
immunized	O
with	O
IBV	O
-	O
Flagellin	O
-	O
SAPN	O
.	O

5	O
)	O
Natural	O
products	O
were	O
identified	O
to	O
allosterically	O
inhibit	O
Zika	O
and	O
Dengue	O
proteases	O
through	O
binding	B-FUNC
a	O
pocket	O
on	O
the	O
back	O
of	O
the	O
active	O
site	O
.	O

Two	O
microarray	O
assays	O
,	O
which	O
were	O
rapid	O
,	O
specific	O
,	O
sensitive	O
,	O
and	O
relatively	O
simple	O
,	O
were	O
developed	O
for	O
the	O
detection	O
of	O
an	O
antibody	B-FUNC
against	O
IBV	O
.	O

Our	O
investigation	O
proved	O
the	O
strong	O
regulatory	O
roles	O
of	O
CVC1303	O
on	O
PEDV	O
-	O
specific	O
IgG	O
and	O
IgG1	O
antibody	B-FUNC
and	O
cytokines	O
productions	O
,	O
and	O
the	O
significant	O
increased	O
CD3	O
+	O
CD4	O
+	O
T	O
cells	O
subpopulation	O
and	O
expressions	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
dendritic	O
cells	O
in	O
the	O
immunized	O
mice	O
.	O

Moreover	O
,	O
our	O
findings	O
verified	O
the	O
significantly	O
enhanced	O
PEDV	O
-	O
specific	O
IgA	O
antibody	B-FUNC
titers	O
in	O
small	O
intestinal	O
and	O
lung	O
in	O
the	O
mice	O
immunized	O
with	O
PEDV	O
vaccine	O
and	O
CVC1303	O
.	O

RESULTS	O
:	O
Our	O
investigation	O
proved	O
the	O
strong	O
regulatory	O
roles	O
of	O
CVC1303	O
on	O
PEDV	O
-	O
specific	O
IgG	O
and	O
IgG1	O
antibody	B-FUNC
and	O
cytokines	O
productions	O
,	O
and	O
the	O
significant	O
increased	O
CD3	O
+	O
CD4	O
+	O
T	O
cells	O
subpopulation	O
and	O
expressions	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
dendritic	O
cells	O
in	O
the	O
immunized	O
mice	O
.	O

TITLE	O
:	O
Caerin1	O
.	O
1	O
Suppresses	O
the	O
Growth	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
In	O
Vitro	O
via	O
Direct	O
Binding	B-FUNC
to	O
the	O
Virus	O
.	O

TGEV	O
infection	O
induced	O
activation	O
of	O
phospho	O
-	O
protein	O
kinase	O
C	O
	O
(	O
p	O
-	O
PKC	B-FUNC
	O
),	O
phospho	O
-	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
p	O
-	O
EGFR	B-FUNC
),	O
and	O
enhanced	O
the	O
expression	O
of	O
caveolin	O
-	O
1	O
,	O
all	O
of	O
which	O
appear	O
to	O
be	O
involved	O
in	O
down	O
-	O
regulating	O
arginine	O
uptake	O
and	O
CAT	O
-	O
1	O
expression	O
.	O

In	O
order	O
to	O
determine	O
if	O
the	O
nucleocapsid	O
protein	O
of	O
MERS	O
-	O
CoV	O
(	O
MERS	O
-	O
N	O
)	O
plays	O
a	O
role	O
in	O
viral	O
-	O
host	O
interactions	O
,	O
a	O
murine	O
monoclonal	O
antibody	B-FUNC
was	O
generated	O
so	O
as	O
to	O
allow	O
detection	O
of	O
the	O
protein	O
in	O
infected	O
cells	O
as	O
well	O
as	O
in	O
overexpression	O
system	O
.	O

Furthermore	O
,	O
cells	O
treated	O
with	O
the	O
inhibitors	O
of	O
ERK1	B-FUNC
/	O
2	O
(	O
PD98059	O
)	O
and	O
p38	B-FUNC
(	O
SB203580	O
)	O
mitigated	O
the	O
expression	O
of	O
cytokines	O
induced	O
by	O
LPS	O
,	O
thus	O
suggesting	O
that	O
ERK1	B-FUNC
/	O
2	O
and	O
p38	B-FUNC
activity	O
are	O
required	O
for	O
the	O
inflammatory	O
response	O
.	O

ABSTRACT	O
:	O
Cell	O
entry	O
by	O
coronaviruses	O
involves	O
two	O
principal	O
steps	O
,	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
;	O
the	O
latter	O
requires	O
activation	O
by	O
host	O
proteases	O
,	O
particularly	O
lysosomal	O
proteases	O
.	O

To	O
this	O
end	O
,	O
we	O
controlled	O
the	O
contributions	O
from	O
receptor	B-FUNC
binding	I-FUNC
and	O
other	O
host	O
proteases	O
,	O
thereby	O
attributing	O
coronavirus	O
entry	O
solely	O
or	O
mainly	O
to	O
the	O
efficiency	O
of	O
lysosomal	O
proteases	O
in	O
activating	O
coronavirus	O
spike	O
-	O
mediated	O
membrane	O
fusion	O
.	O

ORF	O
3a	O
is	O
predicted	O
to	O
contain	O
DNA	O
-	O
binding	B-FUNC
and	O
transcription	O
activator	O
domains	O
,	O
and	O
it	O
is	O
localised	O
in	O
the	O
nucleus	O
and	O
in	O
the	O
cytoplasm	O
.	O

TITLE	O
:	O
Detection	O
of	O
neutralizing	O
antibody	B-FUNC
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
subclinically	O
infected	O
finishing	O
pigs	O
.	O

Blood	O
samples	O
were	O
centrifuged	O
to	O
obtain	O
sera	B-FUNC
.	O

Moreover	O
,	O
inoculation	O
with	O
iPEDVPT	O
-	O
P96	O
elicited	O
comparable	O
levels	O
of	O
anti	O
-	O
PEDV	O
specific	O
plasma	O
IgG	O
and	O
fecal	O
/	O
salivary	O
IgA	O
,	O
neutralizing	O
antibody	B-FUNC
titers	O
,	O
and	O
similar	O
but	O
less	O
effective	O
immunoprotection	O
against	O
the	O
virulent	O
PEDVPT	O
-	O
P5	O
challenge	O
compared	O
to	O
the	O
parental	O
PEDVPT	O
-	O
P96	O
.	O

ABSTRACT	O
:	O
We	O
tested	O
sera	B-FUNC
of	O
24	O
free	O
-	O
ranging	O
European	O
brown	O
bears	O
(	O
Ursus	O
arctos	O
)	O
from	O
six	O
regions	O
of	O
Slovakia	O
for	O
antibodies	O
to	O
10	O
viral	O
agents	O
.	O

We	O
tested	O
sera	B-FUNC
by	O
an	O
indirect	O
fluorescence	O
antibody	B-FUNC
test	O
for	O
antibodies	O
to	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
coronavirus	O
(	O
CCV	O
),	O
canine	O
parvovirus	O
type	O
2	O
(	O
CPV	O
-	O
2	O
),	O
canine	O
adenovirus	O
,	O
canine	O
parainfluenza	O
virus	O
type	O
2	O
(	O
CPIV	O
-	O
2	O
),	O
and	O
canine	O
herpesvirus	O
type	O
1	O
(	O
CHV	O
-	O
1	O
).	O

In	O
early	O
2016	O
,	O
sera	B-FUNC
and	O
standardized	O
interviews	O
were	O
obtained	O
from	O
MERS	O
-	O
CoV	O
cases	O
and	O
their	O
contacts	O
.	O

Interviews	O
and	O
sera	B-FUNC
were	O
collected	O
from	O
2	O
surviving	O
cases	O
,	O
23	O
household	O
contacts	O
,	O
and	O
278	O
health	O
care	O
contacts	O
;	O
1	O
(	O
50	O
%)	O
case	O
,	O
2	O
(	O
9	O
%)	O
household	O
contacts	O
,	O
and	O
3	O
(	O
1	O
%)	O
health	O
care	O
contacts	O
tested	O
seropositive	O
.	O

Although	O
we	O
found	O
a	O
high	O
rate	O
of	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
positive	O
dromedaries	O
(	O
75	O
.	O
62	O
%)	O
in	O
Pakistan	O
,	O
no	O
neutralizing	O
antibodies	O
were	O
detected	O
in	O
humans	O
with	O
and	O
without	O
contact	O
to	O
camels	O
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
analysis	O
showed	O
differentially	O
expressed	O
mRNAs	O
were	O
linked	O
to	O
inflammation	O
-	O
related	O
pathways	O
,	O
including	O
NF	O
-	O
B	O
,	O
Toll	O
-	O
like	O
receptor	O
,	O
NOD	O
-	O
like	O
receptor	O
,	O
Jak	B-FUNC
-	O
STAT	O
,	O
TNF	O
,	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
pathways	O
.	O

TITLE	O
:	O
Influenza	O
-	O
mediated	O
reduction	O
of	O
lung	O
epithelial	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
leads	O
to	O
dysregulated	O
pulmonary	O
fluid	O
homeostasis	O
.	O

For	O
fast	B-FUNC
and	O
reliable	O
diagnosis	O
of	O
the	O
causative	O
agent	O
associated	O
with	O
viral	O
diarrhea	O
in	O
pigs	O
,	O
an	O
inexpensive	O
and	O
easy	O
to	O
perform	O
gel	O
-	O
based	O
multiplex	O
PCR	O
assay	O
was	O
developed	O
in	O
this	O
study	O
to	O
detect	O
and	O
differentiate	O
the	O
different	O
viruses	O
by	O
amplicon	O
size	O
.	O

Moreover	O
,	O
PHD2	O
knockdown	O
can	O
increase	O
hypoxia	O
-	O
inducible	O
factor	O
/	O
vascular	O
endothelial	O
protein	O
tyrosine	O
phosphatase	B-FUNC
signaling	O
and	O
reactive	O
oxygen	O
species	O
-	O
dependent	O
p38	B-FUNC
activation	O
,	O
leading	O
to	O
the	O
induction	O
of	O
vascular	O
endothelial	O
cadherin	O
.	O

The	O
phylogenetic	O
analysis	O
of	O
a	O
part	O
of	O
the	O
RdRp	B-FUNC
region	O
revealed	O
the	O
presence	O
of	O
all	O
five	O
lineages	O
of	O
PAstV	O
in	O
Slovakia	O
(	O
PAstV	O
-	O
1	O
-	O
PAstV	O
-	O
5	O
),	O
with	O
the	O
most	O
frequent	O
lineages	O
being	O
PAstV	O
-	O
2	O
and	O
PAstV	O
-	O
4	O
.	O

TITLE	O
:	O
Novel	O
natural	O
non	O
-	O
nucleoside	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
identified	O
by	O
shape	O
-	O
and	O
structure	O
-	O
based	O
virtual	O
screening	O
techniques	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
we	O
report	O
a	O
parallel	O
application	O
of	O
both	O
docking	O
-	O
and	O
shape	O
-	O
based	O
virtual	O
screening	O
(	O
VS	O
)	O
methods	O
,	O
followed	O
by	O
Molecular	O
Dynamics	O
simulations	O
(	O
MDs	O
),	O
for	O
discovering	O
new	O
compounds	O
able	O
to	O
inhibit	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)	O
RNA	B-FUNC
-	I-FUNC
dependent	I-FUNC
DNA	I-FUNC
polymerase	I-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Structure	O
-	O
Activity	O
Relationships	O
in	O
Metal	O
-	O
Binding	B-FUNC
Pharmacophores	O
for	O
Influenza	O
Endonuclease	O
.	O

A	O
limitation	O
to	O
the	O
early	O
development	O
of	O
metalloenzyme	O
inhibitors	O
has	O
been	O
the	O
lack	O
of	O
established	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
for	O
molecules	O
that	O
bind	B-FUNC
the	O
metal	O
ion	O
cofactor	O
(	O
s	O
)	O
of	O
a	O
metalloenzyme	O
.	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
targeting	O
the	O
spike	O
protein	O
using	O
a	O
synthetic	O
peptide	O
epitope	O
-	O
CpG	O
-	O
DNA	O
-	O
liposome	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
selected	O
two	O
epitope	O
peptide	O
sequences	O
within	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S	O
protein	O
.	O

As	O
SARS	O
-	O
CoV	O
enters	O
host	O
cells	O
,	O
the	O
viral	O
S	O
is	O
believed	O
to	O
undergo	O
a	O
number	O
of	O
conformational	O
transitions	O
as	O
it	O
is	O
cleaved	O
by	O
host	O
proteases	O
and	O
binds	B-FUNC
to	O
host	O
receptors	O
.	O

Neither	O
binding	B-FUNC
to	O
ACE2	O
nor	O
cleavage	O
by	O
trypsin	O
at	O
the	O
S1	O
/	O
S2	O
cleavage	O
site	O
impart	O
large	O
conformational	O
changes	O
within	O
stabilized	O
SARS	O
-	O
CoV	O
S	O
or	O
expose	O
the	O
secondary	O
cleavage	O
site	O
,	O
S2	O
'.	O

In	O
this	O
study	O
,	O
we	O
performed	O
qRT	O
-	O
PCR	O
and	O
viral	O
metagenomic	O
analysis	O
of	O
the	O
extraction	O
efficiency	O
of	O
four	O
commonly	O
used	O
Qiagen	O
extraction	O
kits	O
:	O
QIAamp	O
Viral	O
RNA	O
Mini	O
Kit	B-FUNC
(	O
VRMK	O
),	O
QIAamp	O
MinElute	O
Virus	O
Spin	O
Kit	B-FUNC
(	O
MVSK	O
),	O
RNeasy	O
Mini	O
Kit	B-FUNC
(	O
RMK	O
),	O
and	O
RNeasy	O
Plus	O
Micro	O
Kit	B-FUNC
(	O
RPMK	O
),	O
using	O
a	O
mixed	O
respiratory	O
clinical	O
sample	O
without	O
any	O
pre	O
-	O
treatment	O
.	O

Our	O
results	O
highlighted	O
the	O
importance	O
of	O
nucleic	O
acid	O
extraction	O
kit	B-FUNC
selection	O
,	O
which	O
has	O
a	O
major	O
impact	O
on	O
the	O
yield	O
and	O
number	O
of	O
viral	O
reads	O
by	O
NGS	O
analysis	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
performed	O
qRT	O
-	O
PCR	O
and	O
viral	O
metagenomic	O
analysis	O
of	O
the	O
extraction	O
efficiency	O
of	O
four	O
commonly	O
used	O
Qiagen	O
extraction	O
kits	O
:	O
QIAamp	O
Viral	O
RNA	O
Mini	O
Kit	B-FUNC
(	O
VRMK	O
),	O
QIAamp	O
MinElute	O
Virus	O
Spin	O
Kit	B-FUNC
(	O
MVSK	O
),	O
RNeasy	O
Mini	O
Kit	B-FUNC
(	O
RMK	O
),	O
and	O
RNeasy	O
Plus	O
Micro	O
Kit	B-FUNC
(	O
RPMK	O
),	O
using	O
a	O
mixed	O
respiratory	O
clinical	O
sample	O
without	O
any	O
pre	O
-	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
paper	O
focussed	O
on	O
a	O
step	O
-	O
by	O
-	O
step	O
structural	O
modification	O
of	O
a	O
cycloheptathiophene	O
-	O
3	O
-	O
carboxamide	O
derivative	O
recently	O
identified	O
by	O
us	O
as	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
inhibitor	O
.	O

The	O
presence	O
of	O
the	O
catechol	O
moiety	O
at	O
the	O
C	O
-	O
2	O
position	O
of	O
the	O
scaffold	O
emerged	O
as	O
critical	O
to	O
achieve	O
potent	O
anti	O
-	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
,	O
which	O
also	O
encompassed	O
anti	O
-	O
RNA	O
dependent	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
activity	O
for	O
the	O
tricyclic	O
derivatives	O
.	O

Furthermore	O
,	O
we	O
also	O
found	O
that	O
YQFM	O
significantly	O
inhibited	O
the	O
PM	O
-	O
induced	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
in	O
lung	O
tissues	O
,	O
decreased	O
the	O
PM	O
-	O
induced	O
inflammatory	O
cytokines	O
including	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
),	O
reduced	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
total	O
protein	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
),	O
and	O
effectively	O
attenuated	O
PM	O
-	O
induced	O
increases	O
lymphocytes	O
in	O
BALF	O
.	O

We	O
obtained	O
blood	O
samples	O
from	O
30	O
camel	O
herders	O
,	O
truck	O
drivers	O
,	O
and	O
handlers	O
with	O
well	O
-	O
documented	O
camel	O
exposure	O
and	O
from	O
healthy	O
donors	O
,	O
and	O
measured	O
MERS	O
-	O
CoV	O
-	O
specific	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
,	O
as	O
well	O
as	O
T	O
cell	O
responses	O
.	O

TITLE	O
:	O
Development	O
and	O
validation	O
of	O
a	O
monoclonal	O
antibody	B-FUNC
-	O
based	O
competitive	O
ELISA	O
for	O
detection	O
of	O
antibodies	O
against	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
).	O

The	O
diagnostic	O
performance	O
of	O
the	O
test	O
was	O
evaluated	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
using	O
a	O
panel	O
of	O
829	O
known	O
sera	B-FUNC
collected	O
from	O
different	O
commercial	O
pig	O
farms	O
,	O
with	O
or	O
without	O
a	O
history	O
of	O
PED	O
presence	O
and	O
from	O
experimentally	O
infected	O
pigs	O
.	O

ABSTRACT	O
:	O
Recent	O
years	O
have	O
seen	O
extremely	O
fast	B-FUNC
development	O
of	O
new	O
viral	O
nanovaccines	O
and	O
diagnostic	O
agents	O
using	O
nanostructures	O
prepared	O
by	O
biological	O
and	O
chemical	O
synthesis	O
.	O

The	O
literature	O
data	O
demonstrate	O
that	O
immunization	O
of	O
animals	O
with	O
the	O
TGEV	O
antigen	O
coupled	O
to	O
gold	O
nanoparticles	O
(	O
GNPs	O
)	O
not	O
only	O
activates	O
antigen	O
-	O
presenting	O
cells	O
but	O
also	O
increases	O
the	O
proliferative	O
activity	O
of	O
splenic	O
lymphoid	O
(	O
antibody	B-FUNC
-	O
forming	O
)	O
cells	O
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
Spike	O
Protein	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Transmitted	O
in	O
Korea	O
Increase	O
Resistance	O
to	O
Antibody	B-FUNC
-	O
Mediated	O
Neutralization	O
.	O

The	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
binds	B-FUNC
to	O
the	O
cellular	O
protein	O
DPP4	O
via	O
its	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
and	O
mediates	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

Counterintuitively	O
,	O
these	O
mutations	O
were	O
found	O
to	O
reduce	O
DPP4	O
binding	B-FUNC
and	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

Neither	O
mutation	O
modulated	O
S	O
protein	B-FUNC
binding	I-FUNC
to	O
sialic	O
acids	O
,	O
S	O
protein	O
activation	O
by	O
host	O
cell	O
proteases	O
,	O
or	O
inhibition	O
of	O
S	O
protein	O
-	O
driven	O
entry	O
by	O
interferon	O
-	O
induced	O
transmembrane	O
proteins	O
.	O

TITLE	O
:	O
Diagnosis	O
of	O
non	O
-	O
effusive	O
feline	O
infectious	O
peritonitis	O
by	O
reverse	O
transcriptase	B-FUNC
quantitative	O
PCR	O
from	O
mesenteric	O
lymph	O
node	O
fine	O
-	O
needle	O
aspirates	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
reverse	O
transcriptase	B-FUNC
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
on	O
fine	O
-	O
needle	O
aspirates	O
(	O
FNAs	O
)	O
from	O
mesenteric	O
lymph	O
nodes	O
(	O
MLNs	O
)	O
collected	O
in	O
sterile	O
saline	O
for	O
the	O
purpose	O
of	O
diagnosing	O
non	O
-	O
effusive	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
in	O
cats	O
.	O

TITLE	O
:	O
Elevated	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
promotes	O
expression	O
of	O
MMP2	O
and	O
MMP9	O
via	O
activating	O
STAT3	O
in	O
alveolar	O
macrophages	O
during	O
LPS	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Neutralizing	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
in	O
culture	O
medium	O
with	O
specific	O
antibodies	O
suppressed	O
the	O
expression	O
and	O
secretion	O
of	O
MMP2	O
and	O
MMP9	O
in	O
LPS	O
-	O
treated	O
alveolar	O
macrophages	O
.	O

Consistently	O
,	O
eliminating	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
decreased	O
the	O
levels	O
of	O
MMP2	O
and	O
MMP9	O
in	O
BALF	O
and	O
alleviated	O
lung	O
injury	O
in	O
ALI	O
rats	O
.	O

A	O
wide	O
range	O
of	O
cells	O
have	O
been	O
identified	O
as	O
potential	O
candidates	O
for	O
use	O
,	O
among	O
these	O
are	O
mesenchymal	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
),	O
which	O
are	O
adult	O
multi	O
-	O
lineage	O
cells	O
that	O
can	O
modulate	O
the	O
immune	O
response	O
and	O
enhance	O
repair	O
of	O
damaged	O
tissue	O
.	O

TITLE	O
:	O
Hormonal	O
Regulation	O
of	O
Physiology	O
,	O
Innate	O
Immunity	O
and	O
Antibody	B-FUNC
Response	O
to	O
H1N1	O
Influenza	O
Virus	O
Infection	O
During	O
Pregnancy	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
sequences	O
assigned	O
the	O
detected	O
CoV	O
to	O
clade	O
2b	O
within	O
betacoronaviruses	O
,	O
clustering	O
with	O
SARS	O
-	O
like	O
bat	O
CoVs	O
previously	O
reported	O
.	O

A	O
phylogenetic	O
analysis	O
of	O
23	O
nebovirus	O
RdRp	B-FUNC
fragments	O
showed	O
that	O
these	O
strains	O
were	O
closely	O
related	O
to	O
Nebraska	O
-	O
like	O
(	O
NB	O
-	O
like	O
)	O
strains	O
but	O
were	O
all	O
located	O
in	O
a	O
unique	O
large	O
branch	O
.	O

The	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
showed	O
the	O
correlation	O
of	O
the	O
Italian	O
strains	O
with	O
CoVs	O
that	O
was	O
only	O
detected	O
in	O
the	O
bat	O
Pipistrellus	O
genera	O
(	O
Pipistrellus	O
kuhlii	O
and	O
Pipistrellus	O
Pipistrellus	O
)	O
in	O
European	O
countries	O
.	O

ABSTRACT	O
:	O
Treatment	O
with	O
bone	O
-	O
marrow	O
-	O
derived	O
mesenchymal	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
)	O
has	O
shown	O
benefits	O
in	O
preclinical	O
models	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Safety	O
has	O
not	O
been	O
established	O
for	O
administration	O
of	O
MSCs	B-FUNC
in	O
critically	O
ill	O
patients	O
with	O
ARDS	O
.	O

We	O
did	O
a	O
phase	O
2a	O
trial	O
to	O
assess	O
safety	O
after	O
administration	O
of	O
MSCs	B-FUNC
to	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
.	O

We	O
did	O
a	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
multicentre	O
,	O
randomised	O
trial	O
to	O
assess	O
treatment	O
with	O
one	O
intravenous	O
dose	O
of	O
MSCs	B-FUNC
compared	O
with	O
placebo	O
.	O

TITLE	O
:	O
Design	O
of	O
novel	O
multi	O
-	O
epitope	O
vaccines	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
validated	O
through	O
multistage	O
molecular	B-FUNC
interaction	I-FUNC
and	O
dynamics	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
high	O
-	O
throughput	O
protein	B-FUNC
binding	I-FUNC
inhibition	O
assay	O
using	O
image	O
cytometry	O
.	O

The	O
image	O
cytometry	O
-	O
based	O
high	O
-	O
throughput	O
screening	O
method	O
was	O
developed	O
by	O
selecting	O
a	O
cell	O
type	O
with	O
high	O
DPP4	O
expression	O
and	O
defining	O
optimal	O
seeding	O
density	O
and	O
protein	B-FUNC
binding	I-FUNC
conditions	O
.	O

Binding	B-FUNC
inhibition	O
results	O
were	O
comparable	O
with	O
those	O
described	O
in	O
previous	O
literature	O
for	O
MERS	O
-	O
CoV	O
spike	O
monomer	O
and	O
showed	O
similar	O
patterns	O
as	O
neutralization	O
results	O
.	O

The	O
ability	O
to	O
rapidly	O
determine	O
direct	O
antibody	B-FUNC
binding	B-FUNC
to	O
host	O
cells	O
in	O
a	O
high	O
-	O
throughput	O
manner	O
can	O
be	O
applied	O
to	O
study	O
other	O
pathogen	O
-	O
antibody	B-FUNC
interactions	O
and	O
thus	O
can	O
impact	O
future	O
research	O
on	O
viral	O
pathogens	O
.	O

They	O
comprise	O
small	O
proportions	O
of	O
cultured	O
fibroblasts	O
and	O
MSCs	B-FUNC
and	O
can	O
be	O
isolated	O
from	O
these	O
populations	O
.	O

Administration	O
of	O
Muse	O
cell	O
through	O
the	O
left	O
pulmonary	O
artery	O
immediately	O
after	O
reperfusion	O
more	O
significantly	O
improved	O
lung	O
oxygenation	O
capacity	O
,	O
compliance	O
,	O
and	O
histological	O
damage	O
on	O
days	O
1	O
and	O
3	O
after	O
reperfusion	O
compared	O
with	O
MSCs	B-FUNC
,	O
and	O
this	O
was	O
associated	O
with	O
higher	O
expression	O
levels	O
of	O
proteins	O
related	O
with	O
anti	O
-	O
inflammation	O
and	O
tissue	O
repair	O
in	O
the	O
lung	O
.	O

There	O
is	O
no	O
specific	O
treatment	O
for	O
the	O
MERS	O
-	O
CoV	O
till	O
now	O
,	O
but	O
drugs	O
are	O
in	O
pipeline	O
which	O
bind	B-FUNC
with	O
the	O
spike	O
glycoprotein	O
and	O
inhibit	O
its	O
entrance	O
host	O
cells	O
.	O

Total	O
nucleic	O
acid	O
was	O
extracted	O
using	O
Pure	B-FUNC
Link	O
viral	O
RNA	O
/	O
DNA	O
mini	O
kit	B-FUNC
(	O
Invitrogen	O
),	O
and	O
multiplex	O
RT	O
-	O
PCR	O
assays	O
were	O
performed	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
current	O
advances	O
in	O
neutralizing	O
mAbs	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
is	O
a	O
major	O
target	O
,	O
and	O
mouse	O
,	O
camel	O
,	O
or	O
human	O
-	O
derived	O
neutralizing	O
mAbs	O
targeting	O
RBD	O
have	O
been	O
developed	O
.	O

ABSTRACT	O
:	O
In	O
an	O
initial	O
study	O
in	O
specified	O
pathogen	O
free	O
(	O
SPF	O
)	O
chickens	O
,	O
a	O
heterologous	O
virus	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-FUNC
response	O
to	O
IBV	O
variants	O
Q1	O
,	O
Variant	O
2	O
(	O
Var	O
2	O
),	O
D388	O
/	O
QX	O
(	O
D388	O
),	O
D274	O
and	O
Arkansas	O
(	O
DPI	O
)	O
was	O
observed	O
using	O
a	O
vaccination	O
programme	O
incorporating	O
two	O
different	O
live	O
-	O
attenuated	O
IBV	O
vaccines	O
,	O
followed	O
by	O
boosting	O
with	O
an	O
inactivated	O
vaccine	O
containing	O
IBV	O
Massachusetts	O
(	O
Mass	O
)	O
antigen	O
.	O

In	O
the	O
present	O
case	O
,	O
no	O
casual	O
genetic	O
mutations	O
known	O
to	O
be	O
involved	O
in	O
humans	O
with	O
PVOD	O
and	O
PAH	B-FUNC
were	O
found	O
.	O

The	O
test	O
detects	O
a	O
cooperative	O
interaction	O
between	O
a	O
gold	O
nanoparticle	O
and	O
arguably	O
the	O
three	O
most	O
important	O
proteins	O
involved	O
in	O
the	O
immune	O
system	O
:	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
),	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
and	O
at	O
least	O
one	O
complement	O
protein	O
,	O
C3	O
,	O
in	O
the	O
blood	O
serum	O
.	O

Suppressing	O
TRIM8	O
markedly	O
ameliorated	O
LPS	O
-	O
elicited	O
inflammatory	O
response	O
,	O
as	O
evidenced	O
by	O
the	O
down	O
-	O
regulated	O
mRNA	O
levels	O
of	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
)	O
in	O
cells	O
mainly	O
through	O
inactivating	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
signaling	O
pathway	O
;	O
however	O
,	O
over	O
-	O
expressing	O
TRIM8	O
markedly	O
promoted	O
inflammation	O
in	O
LPS	O
-	O
challenged	O
cells	O
.	O

Additionally	O
,	O
our	O
in	O
vivo	O
findings	O
suggested	O
that	O
TRIM8	O
knockdown	O
effectively	O
attenuated	O
LPS	O
-	O
induced	O
lung	O
injury	O
nu	O
decrease	O
of	O
lung	O
wet	O
/	O
dry	O
(	O
W	O
/	O
T	O
)	O
ratio	O
,	O
protein	O
concentrations	O
,	O
neutrophil	O
infiltration	O
,	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
and	O
superoxide	O
dismutase	O
(	O
SOD	B-FUNC
)	O
depletion	O
.	O

Meanwhile	O
,	O
the	O
loss	O
of	O
TRIM8	O
markedly	O
lessened	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
	O
expression	O
in	O
lung	O
tissues	O
of	O
LPS	O
-	O
challenged	O
mice	O
,	O
and	O
reduced	O
NF	O
-	O
B	O
phosphorylation	O
.	O

The	O
combination	O
of	O
persistent	O
hypernatremia	O
(	O
150	O
-	O
160	O
mmol	O
/	O
l	O
),	O
polyuria	O
(	O
8	O
.	O
4	O
ml	O
/	O
kg	O
/	O
hr	O
),	O
high	O
plasma	O
osmolality	O
(	O
323	O
mosm	O
/	O
kg	O
),	O
hyposthenuria	O
(	O
75	O
mosm	O
/	O
kg	O
)	O
and	O
an	O
undetectable	O
serum	O
ADH	B-FUNC
(<	O
0	O
.	O
8	O
pg	O
/	O
ml	O
)	O
confirmed	O
the	O
diagnosis	O
of	O
central	O
diabetes	O
insipidus	O
(	O
CDI	O
).	O

Serum	O
ADH	B-FUNC
levels	O
can	O
be	O
helpful	O
in	O
confirming	O
the	O
central	O
origin	O
of	O
DI	O
and	O
subcutaneous	O
desmopressin	O
can	O
be	O
an	O
effective	O
treatment	O
in	O
the	O
preterm	O
infant	O
.	O

Critical	O
residues	O
for	O
binding	B-FUNC
to	O
MERS	O
-	O
CoV	O
spike	O
protein	O
were	O
mostly	O
conserved	O
in	O
bat	O
DPP4	O
.	O

Tertiary	O
models	O
for	O
both	O
the	O
MEVs	O
were	O
generated	O
,	O
refined	O
,	O
and	O
further	O
studied	O
for	O
their	O
molecular	B-FUNC
interaction	I-FUNC
with	O
toll	O
-	O
like	O
receptor	O
3	O
.	O

Screened	O
CTL	O
and	O
HTL	O
epitopes	O
were	O
found	O
to	O
have	O
high	O
propensity	O
for	O
stable	O
molecular	B-FUNC
interaction	I-FUNC
with	O
HLA	O
alleles	O
molecules	O
.	O

CTL	O
epitopes	O
were	O
also	O
found	O
to	O
have	O
favorable	O
molecular	B-FUNC
interaction	I-FUNC
within	O
the	O
cavity	O
of	O
transporter	O
associated	O
with	O
antigen	O
processing	O
.	O

Both	O
the	O
CTL	O
and	O
HTL	O
MEVs	O
molecular	O
models	O
have	O
shown	O
to	O
have	O
stable	O
binding	B-FUNC
and	O
complex	O
formation	O
propensity	O
with	O
toll	O
-	O
like	O
receptor	O
3	O
.	O

A	O
total	O
of	O
389	O
sera	B-FUNC
were	O
tested	O
against	O
the	O
rN	O
in	O
ELISA	O
and	O
the	O
results	O
were	O
compared	O
with	O
those	O
of	O
the	O
commercial	O
IDEXX	O
IBV	O
Ab	O
test	O
.	O

WB	O
confirmed	O
all	O
false	O
negative	O
sera	B-FUNC
in	O
ELISA	O
-	O
rN	O
or	O
IDEXX	O
test	O
as	O
truly	O
positive	O
.	O

Positive	O
and	O
negative	O
sera	B-FUNC
for	O
IBV	O
were	O
used	O
as	O
controls	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
from	O
a	O
commercial	O
kit	B-FUNC
.	O

Serum	O
samples	O
scored	O
as	O
negative	O
with	O
the	O
commercial	O
kit	B-FUNC
but	O
as	O
positive	O
with	O
the	O
ELISA	O
-	O
rN	O
were	O
further	O
analysed	O
by	O
Western	O
blot	O
analyses	O
using	O
the	O
rN	O
protein	O
as	O
an	O
antigen	O
.	O

Out	O
of	O
244	O
sera	B-FUNC
that	O
scored	O
positive	O
in	O
the	O
commercial	O
ELISA	O
IDEXX	O
IBV	O
Ab	O
Test	O
,	O
220	O
were	O
also	O
positive	O
in	O
the	O
ELISA	O
-	O
rN	O
,	O
yielding	O
an	O
ELISA	O
-	O
rN	O
test	O
sensitivity	O
of	O
90	O
.	O
16	O
%.	O

Sera	B-FUNC
that	O
tested	O
negative	O
in	O
the	O
ELISA	O
-	O
rN	O
and	O
positive	O
in	O
the	O
commercial	O
test	O
also	O
reacted	O
with	O
the	O
rN	O
protein	O
in	O
Western	O
blot	O
.	O

PHEV	O
binds	B-FUNC
to	O
integrin	O
51	O
and	O
then	O
initiates	O
the	O
integrin	O
51	O
-	O
FAK	O
signaling	O
pathway	O
,	O
leading	O
to	O
virus	O
-	O
induced	O
early	O
cofilin	O
phosphorylation	O
and	O
F	O
-	O
actin	O
polymerization	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	B-FUNC
(	O
ANCA	O
)-	O
associated	O
vasculitis	O
(	O
AAV	O
)	O
is	O
a	O
systemic	O
vasculitis	O
resulting	O
in	O
severe	O
organ	O
injuries	O
.	O

ANCA	O
is	O
a	O
disease	O
-	O
labeled	O
antibody	B-FUNC
of	O
AAV	O
,	O
and	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
and	O
proteinase	B-FUNC
3	O
are	O
the	O
main	O
targeted	O
antigens	O
of	O
ANCA	O
.	O

A	O
78	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
presented	O
with	O
severe	O
renal	O
dysfunction	O
,	O
which	O
was	O
diagnosed	O
as	O
MPO	B-FUNC
-	O
ANCA	O
-	O
associated	O
systemic	O
vasculitis	O
.	O

Considering	O
the	O
present	O
case	O
and	O
the	O
previously	O
reported	O
coexisting	O
cases	O
of	O
takotsubo	O
syndrome	O
and	O
AAV	O
,	O
we	O
propose	O
that	O
female	O
sex	O
,	O
initiation	O
of	O
glucocorticoid	O
therapy	O
,	O
and	O
high	O
titer	O
of	O
MPO	B-FUNC
-	O
ANCA	O
are	O
potential	O
risk	O
factors	O
of	O
developing	O
takotsubo	O
syndrome	O
.	O

For	O
example	O
,	O
human	O
-	O
like	O
symptomology	O
and	O
acute	O
respiratory	O
syndrome	O
is	O
found	O
in	O
cynomolgus	O
macaques	O
infected	O
with	O
highly	O
pathogenic	O
avian	O
influenza	O
virus	O
,	O
antibody	B-FUNC
enhanced	O
dengue	O
disease	O
is	O
common	O
in	O
neotropical	O
primates	O
,	O
and	O
in	O
NHP	O
models	O
of	O
viral	O
hepatitis	O
cytokine	O
-	O
induced	O
inflammation	O
induces	O
severe	O
liver	O
damage	O
,	O
fibrosis	O
,	O
and	O
hepatocellular	O
carcinoma	O
recapitulates	O
human	O
disease	O
.	O

To	O
identify	O
the	O
cellular	O
proteins	O
that	O
interact	O
with	O
the	O
TGEV	O
M	O
protein	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
employed	O
,	O
and	O
seven	O
cellular	O
proteins	O
were	O
identified	O
M	O
-	O
binding	B-FUNC
partners	O
.	O

The	O
human	O
antibody	B-FUNC
response	O
to	O
EV	O
-	O
D68	O
needs	O
to	O
be	O
studied	O
further	O
to	O
clarify	O
the	O
role	O
of	O
antibodies	O
in	O
protection	O
versus	O
pathogenesis	O
,	O
which	O
might	O
differ	O
among	O
respiratory	O
and	O
neurologic	O
disease	O
phenotypes	O
.	O

Additionally	O
,	O
viral	O
replication	O
was	O
compared	O
in	O
Vero	O
and	O
IPEC	O
-	O
DQ	O
cells	O
at	O
the	O
presence	O
of	O
bovine	O
mucin	O
(	O
BM	O
),	O
porcine	O
gastric	O
mucin	O
(	O
PGM	B-FUNC
),	O
swine	O
bile	O
and	O
bile	O
acids	O
during	O
inoculation	O
.	O

Serum	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
levels	O
were	O
induced	O
drastically	O
in	O
orally	O
infected	O
pigs	O
at	O
7	O
dpi	O
and	O
then	O
gradually	O
declined	O
.	O

Serum	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
levels	O
followed	O
a	O
similar	O
pattern	O
while	O
the	O
fold	O
-	O
change	O
was	O
much	O
lower	O
.	O

Interestingly	O
,	O
erythrocytes	O
from	O
Casd1	O
-	O
deficient	O
mice	O
also	O
lost	O
reactivity	O
to	O
TER	O
-	O
119	O
,	O
a	O
rat	O
monoclonal	O
antibody	B-FUNC
that	O
is	O
widely	O
used	O
to	O
mark	O
the	O
murine	O
erythroid	O
lineage	O
.	O

Although	O
the	O
structure	O
of	O
the	O
sialoglycoconjugate	O
recognized	O
by	O
TER	O
-	O
119	O
was	O
not	O
chemically	O
demonstrated	O
,	O
its	O
selective	O
binding	B-FUNC
to	O
virolectins	O
suggests	O
that	O
it	O
may	O
be	O
comprised	O
of	O
a	O
7	O
,	O
9	O
-	O
di	O
-	O
O	O
-	O
acetyl	O
form	O
of	O
sialic	O
acid	O
.	O

Influenza	O
virus	O
primarily	O
binds	B-FUNC
to	O
the	O
epithelium	O
,	O
interfering	O
with	O
the	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
function	O
.	O

Hence	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
is	O
assumed	O
to	O
provide	O
a	O
target	O
for	O
a	O
broad	O
range	O
of	O
antiviral	O
agents	O
.	O

It	O
is	O
known	O
that	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
via	O
its	O
soluble	O
receptor	O
(	O
sIL	O
-	O
6R	O
),	O
initiates	O
a	O
pro	O
-	O
inflammatory	O
response	O
while	O
an	O
anti	O
-	O
inflammatory	O
response	O
is	O
triggered	O
by	O
the	O
membrane	O
-	O
bound	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
receptor	O
(	O
IL	B-FUNC
-	I-FUNC
6R	I-FUNC
).	O

Future	O
antivirals	O
should	O
thus	O
aim	O
to	O
target	O
the	O
mechanism	O
that	O
regulates	O
switching	O
between	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
trans	O
-	O
and	O
classical	O
-	O
signaling	O
.	O

In	O
this	O
review	O
,	O
we	O
propose	O
that	O
the	O
tumour	O
necrosis	O
factor	O
-	O
	O
converting	O
enzyme	O
ADAM	O
-	O
17	O
could	O
be	O
the	O
master	O
molecule	O
involved	O
in	O
regulating	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
class	O
switching	O
and	O
through	O
this	O
in	O
controlling	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
responses	O
to	O
viral	O
antigenic	O
stimuli	O
.	O

TITLE	O
:	O
Fine	O
Tuning	O
the	O
Cytokine	O
Storm	O
by	O
IFN	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
Following	O
Neurotropic	O
Coronavirus	O
Encephalomyelitis	O
.	O

Interestingly	O
,	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
limits	O
expansion	O
of	O
tissue	O
lesions	O
during	O
chronic	O
infection	O
without	O
affecting	O
viral	O
persistence	O
.	O

We	O
previously	O
identified	O
a	O
fusion	O
inhibitory	O
peptide	O
(	O
HR2P	O
-	O
M2	O
)	O
targeting	O
the	O
MERS	O
-	O
CoV	O
S2	O
protein	O
HR1	O
domain	O
and	O
a	O
highly	O
potent	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
m336	O
)	O
specific	O
to	O
the	O
S1	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
).	O

siRNA	O
-	O
silencing	O
of	O
each	O
RTC	O
-	O
proximal	O
host	O
factor	O
demonstrated	O
importance	O
of	O
vesicular	O
trafficking	O
pathways	O
,	O
ubiquitin	B-FUNC
-	O
dependent	O
and	O
autophagy	O
-	O
related	O
processes	O
,	O
and	O
translation	O
initiation	O
factors	O
.	O

We	O
developed	O
a	O
testing	O
algorithm	O
for	O
high	O
throughput	O
screening	O
of	O
livestock	O
sera	B-FUNC
with	O
ELISA	O
and	O
confirmation	O
with	O
recombinant	O
immunofluorescence	O
assay	O
testing	O
for	O
antibodies	O
against	O
HCoV	O
-	O
NL63	O
in	O
livestock	O
.	O

Compared	O
with	O
the	O
P120	O
group	O
,	O
P3	O
-	O
and	O
P100C4	O
-	O
inoculated	O
pigs	O
had	O
higher	O
serum	O
PEDV	O
-	O
specific	O
IgG	O
and	O
viral	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-FUNC
(	O
Ab	O
)	O
titers	O
at	O
14	O
dpi	O
.	O

P100C4	O
induced	O
higher	O
PEDV	O
-	O
specific	O
antibody	B-FUNC
responses	O
than	O
P120	O
post	O
inoculation	O
resulting	O
in	O
a	O
greater	O
anamnestic	O
response	O
post	O
challenge	O
.	O

Six	O
8	O
-	O
week	O
-	O
old	O
mice	O
were	O
immunized	O
with	O
the	O
recombinant	O
plasmid	O
pPI	O
-	O
2	O
.	O
EGFP	O
.	O
VP7	O
.	O
S	O
.	O
The	O
high	O
humoral	O
immune	O
responses	O
(	O
virus	O
specific	O
antibody	B-FUNC
)	O
and	O
cellular	O
immune	O
responses	O
(	O
IFN	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
and	O
spleen	O
lymphocyte	O
proliferation	O
)	O
were	O
evaluated	O
.	O

The	O
immune	O
-	O
enhancing	O
effect	O
of	O
IFN	O
-	O
	O
adjuvant	O
was	O
excellent	O
compared	O
with	O
pig	O
spleen	O
transfer	O
factor	O
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
adjuvant	O
.	O

These	O
results	O
demonstrated	O
that	O
pPI	O
-	O
2	O
.	O
EGFP	O
.	O
VP7	O
.	O
S	O
possess	O
the	O
immunological	O
functions	O
of	O
the	O
VP7	O
proteins	O
of	O
PoRV	O
and	O
S	O
proteins	O
of	O
PEDV	O
,	O
indicating	O
that	O
pPI	O
-	O
2	O
.	O
EGFP	O
.	O
VP7	O
.	O
S	O
is	O
a	O
candidate	O
vaccine	O
for	O
porcine	O
rotaviral	O
infection	O
(	O
PoR	B-FUNC
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
).	O

Point	O
mutations	O
observed	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
hypervariable	O
region	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
protein	O
likely	O
have	O
an	O
effect	O
on	O
these	O
differences	O
in	O
biological	O
characteristics	O
,	O
although	O
the	O
influence	O
of	O
other	O
factors	O
-	O
such	O
as	O
host	O
innate	O
-	O
immune	O
responses	O
and	O
changes	O
in	O
genomic	O
regions	O
beyond	O
the	O
S1	O
protein	O
-	O
might	O
also	O
be	O
responsible	O
for	O
such	O
changes	O
.	O

Ubiquitin	B-FUNC
-	O
like	O
interferon	O
-	O
stimulated	O
gene	O
product	O
15	O
(	O
ISG15	O
)	O
is	O
a	O
key	O
modulator	O
of	O
these	O
interferon	O
responses	O
.	O

Unlike	O
ubiquitin	B-FUNC
,	O
which	O
is	O
virtually	O
identical	O
across	O
all	O
animals	O
,	O
comparison	O
of	O
ISG15s	O
across	O
species	O
reveals	O
that	O
they	O
are	O
relatively	O
divergent	O
,	O
with	O
sequence	O
identity	O
dropping	O
to	O
as	O
low	O
as	O
	O
58	O
%	O
among	O
mammals	O
.	O

We	O
herein	O
reported	O
that	O
three	O
peptides	O
derived	O
from	O
the	O
HR2	O
region	O
in	O
spike	O
protein	O
of	O
BatCoV	O
HKU4	O
,	O
including	O
HKU4	O
-	O
HR2P1	O
,	O
HKU4	O
-	O
HR2P2	O
and	O
HKU4	O
-	O
HR2P3	O
,	O
could	O
bind	B-FUNC
the	O
MERS	O
-	O
CoV	O
HR1	O
-	O
derived	O
peptide	O
to	O
form	O
a	O
six	O
-	O
helix	O
bundle	O
(	O
6	O
-	O
HB	O
)	O
with	O
high	O
stability	O
.	O

TITLE	O
:	O
Advances	O
in	O
MERS	O
-	O
CoV	O
Vaccines	O
and	O
Therapeutics	O
Based	O
on	O
the	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
.	O

The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
S	O
protein	O
contains	O
a	O
critical	O
neutralizing	O
domain	O
and	O
is	O
an	O
important	O
target	O
for	O
development	O
of	O
MERS	O
vaccines	O
and	O
therapeutics	O
.	O

Furthermore	O
,	O
the	O
PEDV	O
N	O
protein	O
harbouring	O
truncations	O
of	O
amino	O
acids	O
(	O
aa	O
)	O
1	O
to	O
170	O
or	O
aa	O
125	O
to	O
301	O
was	O
demonstrated	O
to	O
cross	O
-	O
react	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
polyclonal	O
antibody	B-FUNC
(	O
PAb	B-FUNC
),	O
whereas	O
the	O
truncation	O
-	O
expressing	O
aa	O
302	O
to	O
401	O
resulted	O
in	O
a	O
specific	O
reaction	O
with	O
the	O
anti	O
-	O
PEDV	O
N	O
PAb	B-FUNC
but	O
not	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
PAb	B-FUNC
.	O

Results	O
indicated	O
that	O
the	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
of	O
the	O
new	O
ICA	O
was	O
0	O
.	O
47	O
g	O
/	O
mL	O
(	O
5	O
.	O
9	O
	O
10	O
A	O
new	O
ICA	O
based	O
on	O
mAbs	O
prepared	O
by	O
CSFIA	O
was	O
developed	O
in	O
this	O
study	O
.	O

Results	O
indicated	O
that	O
the	O
limit	O
of	O
detection	O
(	O
LOD	B-FUNC
)	O
of	O
the	O
new	O
ICA	O
was	O
0	O
.	O
47	O
g	O
/	O
mL	O
(	O
5	O
.	O
9	O
	O
10	O

Biomarkers	O
of	O
particular	O
interest	O
have	O
included	O
interleukins	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
interferon	O
gamma	O
(	O
IFN	O
-	O
	O
),	O
surfactant	O
proteins	O
(	O
SPD	O
and	O
SPB	O
),	O
von	O
Willebrand	O
factor	O
antigen	O
,	O
angiopoietin	O
1	O
/	O
2	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
).	O

TITLE	O
:	O
Human	O
coronaviruses	O
OC43	O
and	O
HKU1	O
bind	B-FUNC
to	O
9	O
-	O
ABSTRACT	O
:	O
Human	O
betacoronaviruses	O
OC43	O
and	O
HKU1	O
are	O
endemic	O
respiratory	O
pathogens	O
and	O
,	O
while	O
related	O
,	O
originated	O
from	O
independent	O
zoonotic	O
introductions	O
.	O

TITLE	O
:	O
Prophylactic	O
efficacy	O
of	O
a	O
human	O
monoclonal	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
in	O
the	O
common	O
marmoset	O
.	O

Expression	O
of	O
genes	O
encoding	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
,	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
	O
,	O
CXCL10	O
,	O
CCL8	O
,	O
interferon	O
(	O
IFN	O
)-	O
	O
,	O
IFN	O
-	O
	O
and	O
IFN	O
-	O
	O
,	O
was	O
higher	O
in	O
cats	O
with	O
FIP	O
,	O
consistent	O
with	O
inflammatory	O
pathway	O
activation	O
.	O

Serum	O
samples	O
from	O
453	O
domestic	O
pigs	O
and	O
42	O
vaccinated	O
pigs	O
were	O
analyzed	O
by	O
the	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
test	O
and	O
rS1	O
-	O
ELISA	O
.	O

This	O
rS1	O
-	O
ELISA	O
was	O
then	O
applied	O
to	O
antibody	B-FUNC
detection	O
in	O
inactivated	O
PEDV	O
vaccinated	O
pigs	O
.	O

The	O
antibody	B-FUNC
could	O
be	O
detected	O
2	O
-	O
4	O
weeks	O
after	O
the	O
first	O
inoculation	O
.	O

Although	O
the	O
two	O
antibodies	O
studied	O
blocked	O
attachment	O
to	O
the	O
host	O
cell	O
receptor	O
,	O
only	O
the	O
anti	O
-	O
SARS	O
-	O
CoV	O
S	O
antibody	B-FUNC
triggered	O
fusogenic	O
conformational	O
changes	O
via	O
receptor	O
functional	O
mimicry	O
.	O

It	O
is	O
a	O
variant	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
causing	O
an	O
abrupt	O
increase	O
in	O
intra	O
-	O
abdominal	O
pressure	O
.	O

We	O
present	O
a	O
case	O
of	O
pneumoperitoneum	O
,	O
after	O
an	O
endoscopic	O
mucosal	O
resection	O
with	O
the	O
development	O
of	O
ACS	B-FUNC
.	O

The	O
present	O
study	O
describes	O
development	O
and	O
evaluation	O
of	O
a	O
multiplexed	O
magnetic	O
microsphere	O
immunoassay	O
(	O
MMIA	O
)	O
to	O
simultaneously	O
detect	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
specific	O
for	O
recombinant	O
nucleocapsid	O
proteins	O
(	O
recN	O
)	O
from	O
hCoVs	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
MERS	O
-	O
CoV	O
.	O
We	O
used	O
paired	O
human	O
sera	B-FUNC
to	O
screen	O
for	O
IgG	O
with	O
reactivity	O
against	O
six	O
hCoVs	O
to	O
determine	O
assay	O
sensitivity	O
,	O
specificity	O
and	O
reproducibility	O
.	O

In	O
this	O
study	O
,	O
a	O
recombinant	O
scFv	O
antibody	B-FUNC
phage	O
display	O
library	O
was	O
constructed	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
piglets	O
infected	O
with	O
TGEV	O
.	O

The	O
3D8	O
single	O
chain	O
variable	O
fragment	O
(	O
scFv	O
)	O
protein	O
is	O
a	O
recombinant	O
antibody	B-FUNC
with	O
nuclease	B-FUNC
activity	I-FUNC
that	O
shows	O
antiviral	O
effects	O
against	O
various	O
DNA	O
and	O
RNA	O
viruses	O
in	O
mice	O
and	O
chickens	O
.	O

ABSTRACT	O
:	O
Nod	O
-	O
like	O
receptor	O
family	O
,	O
pyrin	O
domain	O
-	O
containing	O
3	O
(	O
NLRP3	O
)	O
regulates	O
the	O
secretion	O
of	O
proinflammatory	O
cytokines	O
interleukin	O
1	O
beta	O
(	O
IL	O
-	O
1	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

The	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
of	O
the	O
3a	O
protein	O
was	O
essential	O
for	O
3a	O
-	O
mediated	O
IL	O
-	O
1	O
secretion	O
.	O

So	O
,	O
significant	O
neutralizing	O
activity	O
was	O
not	O
demonstrated	O
in	O
any	O
sera	B-FUNC
of	O
three	O
patients	O
with	O
mild	O
pneumonia	O
>	O
1	O
year	O
after	O
being	O
successfully	O
treated	O
with	O
antiviral	O
agents	O
and	O
recovering	O
from	O
MERS	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
Enhanced	O
Ability	O
of	O
Oligomeric	O
Nanobodies	O
Targeting	O
MERS	O
Coronavirus	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
.	O

Nanobodies	O
(	O
Nbs	O
)	O
are	O
camelid	O
heavy	O
chain	O
variable	O
domains	O
with	O
properties	O
distinct	O
from	O
those	O
of	O
conventional	O
antibodies	O
and	O
antibody	B-FUNC
fragments	O
.	O

To	O
inhibit	O
glutamine	O
metabolism	O
,	O
we	O
administered	O
a	O
glutamine	O
analogue	O
,	O
6	O
-	O
diazo	O
-	O
5	O
-	O
oxo	O
-	O
L	O
-	O
norleucine	O
(	O
DON	O
)	O
that	O
binds	B-FUNC
to	O
glutamine	O
-	O
utilizing	O
enzymes	O
and	O
transporters	O
,	O
after	O
injury	O
was	O
well	O
established	O
.	O

ABSTRACT	O
:	O
Fusion	O
peptides	O
(	O
FPs	B-FUNC
)	O
in	O
spike	O
proteins	O
are	O
key	O
players	O
mediating	O
early	O
events	O
in	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
,	O
vital	O
for	O
intercellular	O
viral	O
spread	O
.	O

Moreover	O
,	O
results	O
suggested	O
that	O
pre	O
-	O
infection	O
with	O
CAV	O
directly	O
correlated	O
with	O
elevated	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IFN	O
.	O

The	O
presence	O
of	O
S	O
-	O
IgG	O
prior	O
to	O
viral	O
clearance	O
,	O
however	O
,	O
abrogated	O
wound	O
-	O
healing	O
responses	O
and	O
promoted	O
MCP1	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
production	O
and	O
proinflammatory	O
monocyte	O
/	O
macrophage	O
recruitment	O
and	O
accumulation	O
.	O

Their	O
sera	B-FUNC
enhanced	O
SARS	O
-	O
CoV	O
-	O
induced	O
MCP1	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
production	O
by	O
human	O
monocyte	O
-	O
derived	O
wound	O
-	O
healing	O
macrophages	O
,	O
whereas	O
blockade	O
of	O
FcR	O
reduced	O
such	O
effects	O
.	O

Protection	O
in	O
alpaca	O
correlates	O
with	O
high	O
serum	O
neutralizing	O
antibody	B-FUNC
titers	O
.	O

TITLE	O
:	O
Guinea	O
Fowl	O
Coronavirus	O
Diversity	O
Has	O
Phenotypic	O
Consequences	O
for	O
Glycan	O
and	O
Tissue	O
Binding	B-FUNC
.	O

The	O
biosensor	O
is	O
based	O
on	O
indirect	O
competition	O
between	O
free	O
virus	O
in	O
the	O
sample	O
and	O
immobilized	O
MERS	O
-	O
CoV	O
protein	O
for	O
a	O
fixed	O
concentration	O
of	O
antibody	B-FUNC
added	O
to	O
the	O
sample	O
.	O

Whereas	O
the	O
PEDV	O
nsp13	O
barely	O
regulates	O
type	O
I	O
IFN	O
,	O
inflammatory	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
a	O
)	O
and	O
MHCII	O
,	O
nsp16	O
and	O
nsp14	O
(	O
to	O
a	O
lesser	O
extent	O
)	O
down	O
-	O
regulate	O
these	O
antiviral	O
effectors	O
.	O

It	O
involves	O
the	O
installment	O
of	O
either	O
single	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
moieties	O
or	O
one	O
of	O
eight	O
different	O
polyUb	O
linkage	O
types	O
,	O
each	O
giving	O
a	O
distinct	O
cellular	O
outcome	O
.	O

The	O
Ub	O
system	O
displays	O
significant	O
crosstalk	O
with	O
structurally	O
homologous	O
ubiquitin	B-FUNC
-	O
like	O
proteins	O
(	O
Ubls	O
),	O
including	O
SUMO	O
,	O
Nedd8	O
,	O
and	O
ISG15	O
.	O

In	O
the	O
present	O
report	O
we	O
discuss	O
a	O
fatal	O
case	O
of	O
18	O
-	O
years	O
-	O
old	O
boy	O
,	O
who	O
had	O
smoked	O
SCs	B-FUNC
since	O
several	O
months	O
and	O
an	O
overuse	O
of	O
SCs	B-FUNC
during	O
last	O
48	O
h	O
of	O
his	O
life	O
has	O
been	O
apprised	O
.	O

In	O
addition	O
,	O
the	O
recombinant	O
L	O
.	O
lactis	O
vaccine	O
could	O
induce	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IFN	O
-	O
	O
in	O
immunized	O
mice	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Diagnosis	O
was	O
confirmed	O
by	O
the	O
detection	O
of	O
(	O
1	O
)	O
O	O
.	O
tsutsugamushi	O
-	O
specific	O
DNA	O
in	O
blood	O
or	O
eschar	O
samples	O
with	O
a	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
(	O
2	O
)	O
a	O
fourfold	O
rise	O
in	O
immunoglobulin	B-FUNC
M	O
(	O
IgM	O
)	O
titer	O
to	O
	O
1	O
:	O
3200	O
in	O
paired	O
plasma	O
samples	O
with	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IFA	O
),	O
or	O
(	O
3	O
)	O
a	O
single	O
IgM	O
titer	O
of	O
	O
1	O
:	O
3200	O
in	O
an	O
acute	O
plasma	O
sample	O
with	O
an	O
IFA	O
.	O

A	O
total	O
of	O
820	O
sera	B-FUNC
and	O
823	O
nasal	O
swabs	O
from	O
cattle	O
,	O
sheep	O
,	O
goats	O
,	O
donkeys	O
,	O
buffaloes	O
,	O
mules	O
,	O
and	O
horses	O
were	O
collected	O
.	O

Sera	B-FUNC
were	O
screened	O
using	O
virus	O
microneutralization	O
tests	O
and	O
positive	O
sera	B-FUNC
(	O
where	O
available	O
)	O
were	O
confirmed	O
using	O
plaque	O
reduction	O
neutralization	O
tests	O
(	O
PRNT	O
).	O

We	O
detected	O
90	O
%	O
PRNT	O
confirmed	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
in	O
35	O
(	O
55	O
.	O
6	O
%)	O
of	O
63	O
sera	B-FUNC
from	O
sheep	O
collected	O
from	O
Senegal	O
,	O
two	O
sheep	O
(	O
1	O
.	O
8	O
%)	O
of	O
114	O
in	O
Tunisia	O
and	O
a	O
goat	O
(	O
0	O
.	O
9	O
%)	O
of	O
107	O
in	O
Egypt	O
,	O
with	O
titres	O
ranging	O
from	O
1	O
:	O
80	O
to	O
	O
1	O
:	O
320	O
.	O

CoV	O
E	O
has	O
a	O
single	O
hydrophobic	O
domain	O
(	O
HD	O
),	O
is	O
targeted	O
to	O
Golgi	O
membranes	O
,	O
and	O
has	O
cation	B-FUNC
channel	I-FUNC
activity	I-FUNC

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
antibody	B-FUNC
and	O
cell	O
-	O
mediated	O
immune	O
(	O
CMI	O
)	O
responses	O
in	O
the	O
mucosal	O
and	O
systemic	O
compartments	O
and	O
protection	O
against	O
challenge	O
with	O
a	O
nephropathogenic	O
Brazilian	O
(	O
BR	O
-	O
I	O
)	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
chickens	O
submitted	O
to	O
a	O
vaccination	O
regime	O
comprising	O
a	O
priming	O
dose	O
of	O
heterologous	O
live	O
attenuated	O
Massachusetts	O
vaccine	O
followed	O
by	O
a	O
booster	O
dose	O
of	O
an	O
experimental	O
homologous	O
inactivated	O
vaccine	O
two	O
weeks	O
later	O
.	O

Additionally	O
,	O
vaccinated	O
and	O
challenged	O
chickens	O
showed	O
reduced	O
viral	O
loads	O
and	O
microscopic	O
lesion	O
counts	O
in	O
tracheal	O
and	O
kidney	O
tissues	O
,	O
and	O
their	O
antibody	B-FUNC
and	O
CMI	O
responses	O
were	O
negatively	O
correlated	O
with	O
viral	O
loads	O
in	O
the	O
trachea	O
and	O
kidney	O
.	O

Positive	O
samples	O
were	O
characterized	O
by	O
partial	O
sequencing	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
,	O
and	O
ensuing	O
phylogenetic	O
analysis	O
was	O
performed	O
to	O
investigate	O
the	O
association	O
between	O
virus	O
epidemiology	O
and	O
bird	O
migration	O
routes	O
.	O

In	O
this	O
paper	O
,	O
the	O
linear	O
epitope	O
of	O
the	O
3F10	O
non	O
-	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
that	O
was	O
previously	O
prepared	O
in	O
our	O
laboratory	O
was	O
identified	O
.	O

Identifying	O
the	O
epitope	O
recognized	O
by	O
an	O
antibody	B-FUNC
helps	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
antigen	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
shedding	O
and	O
antibody	B-FUNC
responses	O
are	O
not	O
fully	O
understood	O
,	O
particularly	O
in	O
relation	O
to	O
underlying	O
medical	O
conditions	O
,	O
clinical	O
manifestations	O
,	O
and	O
mortality	O
.	O

Among	O
case	O
-	O
patients	O
who	O
died	O
,	O
development	O
of	O
robust	O
neutralizing	O
serum	O
antibody	B-FUNC
responses	O
during	O
the	O
second	O
and	O
third	O
week	O
of	O
illness	O
was	O
not	O
sufficient	O
for	O
patient	O
recovery	O
or	O
virus	O
clearance	O
.	O

These	O
findings	O
should	O
be	O
considered	O
in	O
the	O
development	O
of	O
infection	O
control	O
policies	O
,	O
vaccines	O
,	O
and	O
antibody	B-FUNC
therapeutics	O
.	O

In	O
the	O
moderate	O
and	O
severe	O
groups	O
,	O
PAP	B-FUNC
was	O
significantly	O
higher	O
in	O
neonates	O
with	O
pulmonary	O
ALI	O
/	O
ADDS	O
(	O
ALI	O
/	O
ARDSp	O
)	O
than	O
in	O
neonates	O
with	O
extrapulmonary	O
ALI	O
/	O
ARDS	O
(	O
ALI	O
/	O
ARDSexp	O
)	O
(	O
62	O
.	O
5	O
	O
5	O
.	O
4	O
vs	O
68	O
.	O
0	O
	O
6	O
.	O
5	O
,	O
54	O
.	O
7	O
	O
5	O
.	O
9	O
vs	O
64	O
.	O
2	O
	O
4	O
.	O
9	O
;	O
t	O
=	O
3	O
.	O
264	O
,	O
3	O
.	O
123	O
;	O
P	O
=	O
.	O
004	O
,.	O
039	O
).	O

Furthermore	O
,	O
PAP	B-FUNC
was	O
higher	O
in	O
neonates	O
with	O
ALI	O
/	O
ADDSp	O
in	O
the	O
severe	O
group	O
,	O
compared	O
with	O
those	O
in	O
the	O
moderate	O
group	O
(	O
t	O
=	O
2	O
.	O
420	O
,	O
P	O
<	O
.	O
05	O
).	O

PAP	B-FUNC
was	O
positively	O
correlated	O
with	O
the	O
OSI	O
index	O
(	O
r	O
=	O
0	O
.	O
823	O
).	O

The	O
overall	O
dynamic	O
PAP	B-FUNC
monitoring	O
results	O
revealed	O
that	O
PAP	B-FUNC
was	O
higher	O
in	O
the	O
pulmonary	O
group	O
than	O
that	O
in	O
the	O
extrapulmonary	O
group	O
,	O
and	O
this	O
exhibited	O
a	O
gradually	O
decreasing	O
trend	O
as	O
the	O
condition	O
of	O
the	O
subject	O
improved	O
.	O

PAP	B-FUNC
was	O
significantly	O
higher	O
in	O
neonates	O
with	O
ALI	O
/	O
ADDSp	O
than	O
in	O
neonates	O
with	O
ALI	O
/	O
ADDSexp	O
.	O

To	O
identify	O
amino	O
acids	O
responsible	O
for	O
S	O
-	O
mediated	O
syncytium	O
formation	O
,	O
we	O
constructed	O
and	O
characterized	O
chimeric	O
S	O
proteins	O
of	O
the	O
cell	O
-	O
adapted	O
variant	O
,	O
YN144	O
,	O
in	O
which	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
and	O
S1	O
/	O
S2	O
cleavage	O
site	O
were	O
replaced	O
with	O
those	O
of	O
a	O
poorly	O
culturable	O
field	O
isolate	O
(	O
G2	O
).	O

Serology	O
was	O
performed	O
on	O
38	O
serum	O
samples	O
,	O
nested	O
reverse	O
transcriptase	B-FUNC
PCR	O
(	O
nRT	O
-	O
PCR	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
were	O
performed	O
on	O
39	O
blood	O
samples	O
and	O
on	O
17	O
semen	O
samples	O
,	O
and	O
histology	O
,	O
immunohistochemistry	O
and	O
nRT	O
-	O
PCR	O
were	O
performed	O
on	O
39	O
testicles	O
.	O

TITLE	O
:	O
Glycosylation	O
of	O
the	O
viral	O
attachment	O
protein	O
of	O
avian	O
coronavirus	O
is	O
essential	O
for	O
host	O
cell	O
and	O
receptor	B-FUNC
binding	I-FUNC
.	O

The	O
heavily	O
glycosylated	O
IBV	O
spike	O
protein	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
host	O
tissues	O
.	O

Initial	O
screening	O
using	O
anti	O
-	O
MERS	O
-	O
CoV	O
IgG	O
(	O
IgG	O
rS1	O
-	O
ELISA	O
kit	B-FUNC
)	O
revealed	O
ten	O
reactive	O
samples	O
from	O
BD	O
(	O
10	O
/	O
4719	O
,	O
0	O
.	O
21	O
%),	O
one	O
from	O
CC	O
(	O
1	O
/	O
135	O
,	O
0	O
.	O
74	O
%),	O
and	O
three	O
from	O
CP	O
(	O
3	O
/	O
4	O
,	O
75	O
%).	O

Immunization	O
of	O
hDPP4	O
Tg	O
+	O
mice	O
with	O
a	O
single	O
dose	O
of	O
rAd5	O
-	O
S1	O
/	O
F	O
/	O
CD40L	O
elicited	O
as	O
robust	O
and	O
significant	O
specific	O
immunoglobulin	B-FUNC
G	O
and	O
neutralizing	O
antibodies	O
as	O
those	O
induced	O
with	O
2	O
doses	O
of	O
rAd5	O
-	O
S1	O
.	O

Treatment	O
with	O
intravenous	O
immunoglobulin	B-FUNC
led	O
to	O
an	O
uneventful	O
clinical	O
course	O
with	O
partial	O
recovery	O
within	O
2	O
weeks	O
.	O

Early	O
intervention	O
with	O
intravenous	O
immunoglobulin	B-FUNC
may	O
benefit	O
these	O
patients	O
.	O

TITLE	O
:	O
Identification	O
and	O
Characterization	O
of	O
a	O
Human	O
Coronavirus	O
229E	O
Nonstructural	O
Protein	O
8	O
-	O
Associated	O
RNA	O
3	O
'-	O
Terminal	O
Adenylyltransferase	B-FUNC
Activity	I-FUNC
.	O

The	O
American	O
College	O
of	O
Surgeons	O
-	O
National	O
Surgical	O
Quality	O
Improvement	O
Program	O
(	O
ACS	B-FUNC
-	O
NSQIP	O
)	O
database	O
was	O
reviewed	O
retrospectively	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
adapt	O
our	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
lab	O
-	O
developed	O
test	O
(	O
LDT	B-FUNC
)	O
to	O
3	O
""""	O
Sample	O
to	O
Result	O
""""	O
(	O
S2R	O
)	O
systems	O
:	O
BD	O
MAX	O
(	O
BD	O
),	O
ELITe	O
InGenius	O
(	O
ELITechGroup	O
),	O
and	O
ARIES	O
(	O
Luminex	O
).	O

We	O
also	O
found	O
that	O
PDCoV	O
could	O
be	O
detected	O
in	O
sows	O
faeces	O
and	O
sera	B-FUNC
while	O
the	O
sows	O
showed	O
mild	O
,	O
self	O
-	O
limited	O
diarrhea	O
in	O
clinic	O
.	O

These	O
antibodies	O
belong	O
to	O
six	O
distinct	O
epitope	O
groups	O
and	O
interfere	O
with	O
the	O
three	O
critical	O
entry	O
functions	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
:	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
,	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
.	O

Furthermore	O
,	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
were	O
lower	O
,	O
which	O
was	O
second	O
to	O
mice	O
treated	O
with	O
the	O
rectal	O
administration	O
of	O
20	O
g	O
CpG	O
ODN	O
.	O

At	O
the	O
nadir	O
of	O
illness	O
,	O
the	O
most	O
frequent	O
diagnosis	O
in	O
H	O
.	O
influenzae	O
-	O
related	O
cases	O
was	O
""""	O
pure	B-FUNC
FS	O
""""	O
without	O
limb	O
weakness	O
or	O
central	O
nervous	O
system	O
involvement	O
(	O
71	O
%),	O
in	O
C	O
.	O
jejuni	O
-	O
related	O
cases	O
""""	O
incomplete	O
FS	O
""""	O
such	O
as	O
acute	O
ophthalmoparesis	O
with	O
or	O
without	O
ataxia	O
(	O
60	O
%),	O
and	O
in	O
CMV	O
-	O
related	O
cases	O
(	O
50	O
%)	O
advanced	O
conditions	O
such	O
as	O
GBS	O
overlap	O
and	O
Bickerstaff	O
brainstem	O
encephalitis	O
.	O

CMV	O
-	O
related	O
FS	O
appeared	O
to	O
be	O
similar	O
to	O
H	O
.	O
influenzae	O
-	O
and	O
C	O
.	O
jejuni	O
-	O
related	O
FS	O
regarding	O
anti	O
-	O
GQ1b	O
antibody	B-FUNC
-	O
mediated	O
pathogenesis	O
,	O
as	O
opposed	O
to	O
CMV	O
-	O
related	O
GBS	O
.	O

Interestingly	O
,	O
careful	O
literature	O
analysis	O
shows	O
that	O
viruses	O
indeed	O
bind	B-FUNC
to	O
the	O
cell	O
surface	O
via	O
sialic	O
acids	O
,	O
but	O
there	O
is	O
no	O
solid	O
data	O
that	O
these	O
moieties	O
mediate	O
virus	O
entry	O
.	O

In	O
our	O
study	O
,	O
using	O
a	O
number	O
of	O
techniques	O
,	O
we	O
showed	O
that	O
all	O
three	O
viruses	O
are	O
indeed	O
able	O
to	O
bind	B-FUNC
to	O
sialic	O
acids	O
to	O
a	O
different	O
extent	O
,	O
but	O
these	O
molecules	O
render	O
the	O
cells	O
permissive	O
only	O
for	O
the	O
clinical	O
strain	O
of	O
HCoV	O
-	O
OC43	O
,	O
while	O
for	O
others	O
they	O
serve	O
only	O
as	O
attachment	O
receptors	O
.	O

Based	O
on	O
the	O
reactivity	O
analysis	O
of	O
the	O
mAbs	O
with	O
two	O
prevalent	O
PEDV	O
strains	O
in	O
G2	O
type	O
and	O
the	O
attenuated	O
CV777	O
strain	O
in	O
G1	O
type	O
,	O
6	O
mAbs	O
were	O
selected	O
for	O
subsequent	O
identification	O
of	O
COE	O
mAb	O
-	O
binding	B-FUNC
epitopes	O
.	O

Updates	O
were	O
presented	O
on	O
several	O
influenza	O
antivirals	O
including	O
baloxavir	O
,	O
CC	O
-	O
42344	O
,	O
VIS410	O
,	O
immunoglobulin	B-FUNC
,	O
immune	O
plasma	O
,	O
MHAA4549A	O
,	O
pimodivir	O
(	O
JNJ	O
-	O
63623872	O
),	O
umifenovir	O
,	O
and	O
HA	O
minibinders	O
;	O
RSV	O
antivirals	O
including	O
presatovir	O
(	O
GS	O
-	O
5806	O
),	O
ziresovir	O
(	O
AK0529	O
),	O
lumicitabine	O
(	O
ALS	O
-	O
008176	O
),	O
JNJ	O
-	O
53718678	O
,	O
JNJ	O
-	O
64417184	O
,	O
and	O
EDP	O
-	O
938	O
;	O
broad	O
spectrum	O
antivirals	O
such	O
as	O
favipiravir	O
,	O
VH244	O
,	O
remdesivir	O
,	O
and	O
EIDD	O
-	O
1931	O
/	O
EIDD	O
-	O
2801	O
;	O
and	O
host	O
directed	O
strategies	O
including	O
nitazoxanide	O
,	O
eritoran	O
,	O
and	O
diltiazem	O
.	O

Trace	O
element	O
and	O
PAH	B-FUNC
analysis	O
demonstrated	O
the	O
almost	O
similar	O
chemical	O
composition	O
of	O
both	O
particle	O
fractions	O
.	O

Fatty	O
acid	O
-	O
binding	B-FUNC
protein	O
1	O
(	O
FABP1	O
)	O
and	O
fatty	O
acid	O
-	O
binding	B-FUNC
protein	O
3	O
(	O
FABP3	O
)	O
were	O
found	O
to	O
be	O
regulated	O
by	O
PDCoV	O
.	O
These	O
two	O
genes	O
not	O
only	O
mediate	O
fatty	O
acid	O
transportation	O
to	O
different	O
cell	O
organelles	O
such	O
as	O
mitochondria	O
,	O
peroxisome	O
,	O
endoplasmic	O
reticulum	O
and	O
nucleus	O
,	O
but	O
also	O
modulate	O
fatty	O
acid	O
metabolism	O
and	O
storage	O
as	O
a	O
signaling	O
molecule	O
outside	O
the	O
cell	O
.	O

Monocytes	O
of	O
QFS	O
patients	O
produced	O
significantly	O
less	O
TNF	O
-	O
	O
(	O
p	O
=	O
0	O
.	O
032	O
),	O
IL	O
-	O
1	O
(	O
0	O
.	O
004	O
,	O
0	O
.	O
024	O
,	O
and	O
0	O
.	O
008	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
0	O
.	O
043	O
),	O
RANTES	O
(	O
0	O
.	O
033	O
),	O
IP	O
-	O
10	O
(	O
0	O
.	O
049	O
),	O
MCP	B-FUNC
-	O
1	O
(	O
0	O
.	O
022	O
),	O
IL	O
-	O
13	O
(	O
0	O
.	O
029	O
),	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(	O
0	O
.	O
026	O
)	O
than	O
healthy	O
controls	O
when	O
stimulated	O
with	O
various	O
ligands	O
.	O

H3K4me3	O
expression	O
was	O
significantly	O
lower	O
in	O
QFS	O
patients	O
than	O
in	O
healthy	O
controls	O
on	O
the	O
promoter	O
regions	O
of	O
IL	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
MCP	B-FUNC
-	O
1	O
(<	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
001	O
),	O
IP	O
-	O
10	O
(<	O
0	O
.	O
001	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(	O
0	O
.	O
041	O
),	O
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
(<	O
0	O
.	O
001	O
,	O
<	O
0	O
.	O
001	O
,	O
and	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Pathogenesis	O
of	O
oral	O
type	O
I	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
infection	O
:	O
Antibody	B-FUNC
-	O
dependent	O
enhancement	O
infection	O
of	O
cats	O
with	O
type	O
I	O
FIPV	O
via	O
the	O
oral	O
route	O
.	O

In	O
this	O
study	O
,	O
when	O
cats	O
passively	O
immunized	O
with	O
anti	O
-	O
FIPV	O
-	O
I	O
KU	O
-	O
2	O
antibodies	O
were	O
orally	O
inoculated	O
with	O
FIPV	O
-	O
I	O
KU	O
-	O
2	O
,	O
FIP	O
was	O
caused	O
at	O
a	O
50	O
%	O
probability	O
,	O
i	O
.	O
e	O
.,	O
FIPV	O
not	O
causing	O
FIP	O
through	O
oral	O
infection	O
caused	O
FIP	O
by	O
inducing	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
VIP	O
inhibited	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
17R	I-FUNC
in	O
the	O
lungs	O
of	O
mice	O
with	O
ARDS	O
and	O
NIH3T3	O
cells	O
stimulated	O
with	O
LPS	O
,	O
which	O
was	O
partly	O
inhibited	O
by	O
antagonists	O
of	O
protein	O
kinase	O
A	O
and	O
protein	O
kinase	O
C	O
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
VIP	O
inhibited	O
the	O
activation	O
of	O
fibroblast	O
via	O
downregulation	O
of	O
IL	O
-	O
17RC	O
,	O
which	O
may	O
contribute	O
to	O
the	O
protective	O
effects	O
of	O
VIP	O
against	O
ARDS	O
in	O
mice	O
.	O

(	O
Gene	O
Ontology	O
)	O
GO	O
annotation	O
and	O
functional	O
enrichment	O
analysis	O
indicated	O
that	O
all	O
of	O
the	O
DEGs	O
(	O
differentially	O
expressed	O
genes	O
)	O
were	O
annotated	O
into	O
biological	O
process	O
,	O
cellular	O
component	O
and	O
molecular	B-FUNC
function	I-FUNC
.	O

Most	O
of	O
these	O
unigenes	O
are	O
annotated	O
in	O
cellular	O
processes	O
,	O
the	O
cell	O
and	O
binding	B-FUNC
.	O

Extracorporeal	O
life	O
support	O
can	O
provide	O
adequate	O
oxygenation	O
while	O
allowing	O
the	O
lungs	O
to	O
rest	B-FUNC
and	O
heal	O
,	O
which	O
might	O
be	O
an	O
ideal	O
therapy	O
in	O
this	O
patient	O
group	O
,	O
although	O
long	O
-	O
term	O
clinical	O
and	O
radiological	O
outcomes	O
are	O
not	O
known	O
.	O

However	O
,	O
treatment	O
with	O
the	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
SB203580	O
,	O
and	O
the	O
SAPK	B-FUNC
/	O
JNK	B-FUNC
inhibitor	O
SP600125	O
reversed	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

Activated	O
p38	B-FUNC
MAPK	B-FUNC
and	O
SAPK	B-FUNC
/	O
JNK	B-FUNC
exerted	O
no	O
influence	O
on	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

ORF3a	O
-	O
induced	O
elevation	O
of	O
IL	O
-	O
1	O
secretion	O
was	O
independent	O
of	O
its	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
or	O
absent	O
in	O
melanoma	O
2	O
but	O
required	O
NLRP3	O
,	O
ASC	O
,	O
and	O
TRAF3	O
.	O

The	O
level	O
of	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
greater	O
in	O
higher	O
CCI	O
score	O
(	O
4	O
)	O
group	O
compared	O
with	O
lower	O
CCI	O
score	O
(<	O
4	O
)	O
group	O
(	O
Patients	O
with	O
a	O
higher	O
CCI	O
score	O
had	O
more	O
severe	O
symptoms	O
,	O
functional	O
impairment	O
and	O
higher	O
level	O
of	O
inflammatory	O
factors	O
and	O
high	O
frequency	O
of	O
hospital	O
admission	O
due	O
to	O
acute	O
exacerbation	O
.	O

The	O
level	O
of	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
greater	O
in	O
higher	O
CCI	O
score	O
(	O
4	O
)	O
group	O
compared	O
with	O
lower	O
CCI	O
score	O
(<	O
4	O
)	O
group	O
(	O
CONCLUSIONS	O
:	O
Patients	O
with	O
a	O
higher	O
CCI	O
score	O
had	O
more	O
severe	O
symptoms	O
,	O
functional	O
impairment	O
and	O
higher	O
level	O
of	O
inflammatory	O
factors	O
and	O
high	O
frequency	O
of	O
hospital	O
admission	O
due	O
to	O
acute	O
exacerbation	O
.	O

The	O
expression	O
levels	O
of	O
citrate	O
synthase	O
(	O
CS	O
),	O
cytochrome	B-FUNC
C	I-FUNC
,	O
somatic	O
(	O
CYC	O
,	O
S	O
)	O
and	O
sodium	O
-	O
potassium	O
adenosine	O
triphosphatase	O
(	O
Na	O
It	O
was	O
concluded	O
that	O
IBV	O
T	O
strain	O
infection	O
in	O
laying	O
hens	O
reduced	O
mitochondrial	O
counts	O
only	O
in	O
the	O
shell	O
gland	O
region	O
of	O
the	O
oviduct	O
.	O

The	O
expression	O
levels	O
of	O
citrate	O
synthase	O
(	O
CS	O
),	O
cytochrome	B-FUNC
C	I-FUNC
,	O
somatic	O
(	O
CYC	O
,	O
S	O
)	O
and	O
sodium	O
-	O
potassium	O
adenosine	O
triphosphatase	O
(	O
Na	O

Peptide	O
4934	O
reacted	O
equally	O
with	O
positive	O
sera	B-FUNC
from	O
healthy	O
cats	O
and	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
while	O
peptide	O
16433	O
was	O
recognized	O
predominantly	O
by	O
FIP	O
-	O
affected	O
cats	O
.	O

The	O
value	O
of	O
antibody	B-FUNC
tests	O
based	O
on	O
these	O
peptides	O
in	O
differentiating	O
between	O
the	O
enteric	O
and	O
FIP	O
forms	O
of	O
feline	O
coronavirus	O
infection	O
remains	O
to	O
be	O
determined	O
.	O

To	O
evade	O
further	O
complications	O
,	O
identifying	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
and	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
),	O
in	O
critically	O
ill	O
individuals	O
and	O
hospitalised	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
is	O
obligated	O
.	O

Eighty	O
-	O
nine	O
patients	O
(	O
71	O
.	O
2	O
%)	O
showed	O
normal	O
intra	O
-	O
abdominal	O
pressure	O
since	O
31	O
patients	O
(	O
24	O
.	O
8	O
%),	O
and	O
5	O
patients	O
(	O
4	O
%)	O
developed	O
IAH	B-FUNC
and	O
ACS	B-FUNC
.	O

Intra	O
-	O
abdominal	O
pressure	O
test	O
,	O
as	O
a	O
valuable	O
prognosis	O
test	O
for	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
and	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
),	O
may	O
offer	O
better	O
results	O
when	O
added	O
to	O
the	O
routine	O
medical	O
checkup	O
of	O
ICU	O
patients	O
.	O

However	O
,	O
non	O
-	O
ST	O
elevation	O
myocardial	O
infarction	O
(	O
NSTEMI	O
)	O
had	O
not	O
yet	O
been	O
ruled	O
out	O
and	O
the	O
patient	O
was	O
started	O
on	O
started	O
on	O
a	O
heparin	O
infusion	O
per	O
the	O
ACS	B-FUNC
protocol	O
.	O

A	O
rapid	O
and	O
simple	O
immunochromatographic	O
strip	O
(	O
ICS	O
)	O
was	O
developed	O
in	O
this	O
study	O
by	O
employing	O
monoclonal	O
antibodies	O
against	O
spike	O
and	O
nucleocapsid	O
proteins	O
of	O
IBV	O
as	O
the	O
tracer	O
and	O
the	O
capture	O
antibody	B-FUNC
.	O

TITLE	O
:	O
The	O
ER	O
stress	O
sensor	O
IRE1	O
and	O
MAP	O
kinase	O
ERK	B-FUNC
modulate	O
autophagy	O
induction	O
in	O
cells	O
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Finally	O
,	O
the	O
anti	O
-	O
apoptotic	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	B-FUNC
/	O
2	O
)	O
also	O
contributed	O
to	O
IBV	O
-	O
induced	O
autophagy	O
.	O

Viral	O
RNA	O
was	O
extracted	O
from	O
pooled	O
tissue	O
samples	O
(	O
trachea	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
liver	O
)	O
and	O
tested	O
for	O
Avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
dihydroquinazoline	O
-	O
2	O
-	O
amines	O
as	O
potent	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
HIV	O
-	O
1	O
strains	O
.	O

To	O
test	O
applicability	O
of	O
in	O
vitro	O
results	O
to	O
real	O
life	O
,	O
virus	O
load	O
was	O
measured	O
in	O
two	O
households	O
in	O
a	O
double	O
crossover	O
study	O
of	O
four	O
Fuller	O
'	O
s	O
earth	O
-	O
based	O
cat	O
litters	O
by	O
testing	O
rectal	O
swabs	O
using	O
FCoV	O
reverse	O
transcriptase	B-FUNC
quantitative	O
PCR	O
.	O

The	O
gender	O
,	O
age	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
within	O
24	O
hours	O
of	O
admission	O
,	O
neutral	O
red	O
phagocytosis	O
and	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
of	O
macrophages	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
,	O
total	O
hospitalization	O
time	O
,	O
hospitalization	O
expenses	O
,	O
and	O
prognosis	O
were	O
recorded	O
.	O

Pearson	O
test	O
was	O
used	O
to	O
analyze	O
the	O
correlation	O
between	O
neutral	O
red	O
phagocytosis	O
function	O
of	O
macrophages	O
and	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
and	O
other	O
indicators	O
.	O

The	O
prognosis	O
was	O
analyzed	O
by	O
binary	O
Logistic	O
regression	O
combined	O
with	O
neutral	O
red	O
phagocytosis	O
and	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
in	O
patients	O
,	O
and	O
the	O
predictive	O
value	O
of	O
both	O
subjects	O
on	O
prognosis	O
was	O
analyzed	O
by	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O

The	O
neutral	O
red	O
phagocytosis	O
ability	O
of	O
alveolar	O
macrophages	O
in	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
328	O
,	O
-	O
0	O
.	O
572	O
,	O
-	O
0	O
.	O
809	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
);	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
and	O
hospitalization	O
expenses	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
334	O
,	O
-	O
0	O
.	O
583	O
,	O
-	O
0	O
.	O
470	O
,	O
-	O
0	O
.	O
517	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
AUC	O
of	O
alkaline	O
phosphatase	B-FUNC
for	O
the	O
prognosis	O
of	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
0	O
.	O
813	O
;	O
when	O
the	O
cut	O
-	O
off	O
value	O
was	O
19	O
.	O
72	O
mol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
75	O
.	O
0	O
%,	O
and	O
the	O
specificity	O
was	O
87	O
.	O
5	O
%.	O

The	O
AUC	O
of	O
alkaline	O
phosphatase	B-FUNC
for	O
the	O
prognosis	O
of	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
0	O
.	O
813	O
;	O
when	O
the	O
cut	O
-	O
off	O
value	O
was	O
19	O
.	O
72	O
mol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
75	O
.	O
0	O
%,	O
and	O
the	O
specificity	O
was	O
87	O
.	O
5	O
%.	O

Inflammatory	O
cytokines	O
such	O
as	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
have	O
been	O
documented	O
in	O
malaria	O
induced	O
thrombocytopaenia	O
.	O

Serial	O
blood	O
samples	O
for	O
measurement	O
of	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
titers	O
and	O
nasal	O
swabs	O
for	O
detection	O
of	O
BCV	O
and	O
other	O
common	O
viral	O
and	O
bacterial	O
BRD	O
pathogens	O
were	O
collected	O
from	O
all	O
calves	O
or	O
subsets	O
of	O
calves	O
at	O
predetermined	O
times	O
from	O
birth	O
through	O
weaning	O
.	O

Between	O
herd	O
analyses	O
revealed	O
anti	O
-	O
BCV	O
serum	O
antibody	B-FUNC
abundance	O
did	O
not	O
associate	O
with	O
the	O
incidence	O
of	O
BRD	O
or	O
BCV	O
shedding	O
,	O
though	O
these	O
measurements	O
may	O
have	O
been	O
hindered	O
by	O
the	O
long	O
periods	O
between	O
sample	O
collections	O
.	O

We	O
analyzed	O
the	O
mechanisms	O
by	O
which	O
HBD	O
2	O
primes	O
innate	O
antiviral	O
immunity	O
and	O
polarized	O
activation	O
of	O
macrophage	O
-	O
like	O
THP	O
-	O
1	O
cells	O
using	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
nucleocapsid	O
protein	O
antagonizes	O
IFN	O
-	O
	O
production	O
by	O
impairing	O
dsRNA	O
and	O
PACT	O
binding	B-FUNC
to	O
RIG	O
-	O
I	O
.	O
ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
an	O
emerging	O
swine	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
watery	O
diarrhea	O
,	O
vomiting	O
and	O
mortality	O
in	O
newborn	O
piglets	O
.	O

Furthermore	O
,	O
study	O
revealed	O
that	O
PDCoV	O
N	O
protein	O
interacted	O
with	O
RIG	O
-	O
I	O
and	O
MDA5	O
in	O
an	O
in	O
vitro	O
overexpression	O
system	O
and	O
evident	O
interactions	O
between	O
N	O
protein	O
and	O
RIG	O
-	O
I	O
could	O
be	O
detected	O
in	O
the	O
context	O
of	O
PDCoV	O
infection	O
,	O
which	O
interfered	O
with	O
the	O
binding	B-FUNC
of	O
dsRNA	O
and	O
protein	O
activator	O
of	O
protein	O
kinase	O
R	O
(	O
PACT	O
)	O
to	O
RIG	O
-	O
I	O
.	O
Together	O
,	O
our	O
results	O
demonstrate	O
that	O
PDCoV	O
N	O
protein	O
is	O
an	O
IFN	O
antagonist	O
and	O
utilizes	O
diverse	O
strategies	O
to	O
attenuate	O
RIG	O
-	O
I	O
recognition	O
and	O
activation	O
.	O

Single	O
intranasal	O
immunization	O
with	O
AdC68	O
-	O
S	O
induced	O
robust	O
and	O
sustained	O
neutralizing	O
antibody	B-FUNC
and	O
T	O
cell	O
responses	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

Passive	O
transfer	O
of	O
immune	O
sera	B-FUNC
to	O
nave	O
hDPP4	O
-	O
KI	O
mice	O
also	O
provided	O
survival	O
advantages	O
from	O
lethal	O
MERS	O
-	O
CoV	O
-	O
MA	O
challenge	O
.	O

In	O
728	O
of	O
834	O
(	O
87	O
.	O
3	O
%)	O
cases	O
nasopharyngeal	O
/	O
tracheal	O
swab	O
samples	O
and	O
in	O
106	O
(	O
12	O
.	O
7	O
%)	O
of	O
them	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
samples	O
were	O
studied	O
by	O
the	O
use	O
of	O
""""	O
FTD	O
Respiratory	O
21	O
(	O
Fast	B-FUNC
-	O
Tract	O
Diagnostics	O
Luxemburg	O
")"""	O
kit	B-FUNC
,	O
with	O
multiplex	O
Rt	O
-	O
PCR	O
method	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
),	O
SARS	O
-	O
Nsp12	O
,	O
can	O
enhance	O
the	O
helicase	B-FUNC
activity	I-FUNC
of	O
SARS	O
-	O
Nsp13	O
through	O
interacting	O
with	O
it	O
directly	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
viruses	O
bind	B-FUNC
amyloidogenic	O
peptides	O
in	O
their	O
corona	O
and	O
catalyze	O
amyloid	O
formation	O
via	O
surface	O
-	O
assisted	O
heterogeneous	O
nucleation	O
.	O

At	O
72	O
hours	O
post	O
-	O
PEDV	O
inoculation	O
(	O
hpi	B-FUNC
),	O
the	O
animals	O
either	O
deceased	O
or	O
euthanized	O
were	O
necropsied	O
and	O
intestines	O
were	O
sampled	O
.	O

I	O
,	O
all	O
6	O
WT	O
piglets	O
and	O
only	O
1	O
of	O
6	O
KO	O
piglets	O
died	O
at	O
72	O
hpi	B-FUNC
.	O

TITLE	O
:	O
Porcine	O
Deltacoronavirus	O
Nucleocapsid	O
Protein	O
Suppressed	O
IFN	O
-	O
	O
Production	O
by	O
Interfering	O
Porcine	O
RIG	O
-	O
I	O
dsRNA	O
-	O
Binding	B-FUNC
and	O
K63	O
-	O
Linked	O
Polyubiquitination	O
.	O

We	O
confirmed	O
that	O
PDCoV	O
N	O
antagonizes	O
IFN	O
-	O
	O
production	O
by	O
associating	O
with	O
pRIG	O
-	O
I	O
to	O
impede	O
it	O
from	O
binding	B-FUNC
double	O
-	O
stranded	O
RNA	O
.	O

Infections	O
are	O
initiated	O
by	O
the	O
transmembrane	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
which	O
binds	B-FUNC
to	O
host	O
receptors	O
and	O
fuses	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

The	O
receptor	O
-	O
interacting	O
site	O
is	O
conserved	O
in	O
all	O
coronavirus	O
S	O
glycoproteins	O
that	O
engage	O
9	O
-	O
O	O
-	O
acetyl	O
-	O
sialogycans	O
,	O
with	O
an	O
architecture	O
similar	O
to	O
those	O
of	O
the	O
ligand	B-FUNC
-	O
binding	B-FUNC
pockets	O
of	O
coronavirus	O
hemagglutinin	O
esterases	B-FUNC
and	O
influenza	O
virus	O
C	O
/	O
D	O
hemagglutinin	O
-	O
esterase	O
fusion	O
glycoproteins	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
-	O
mediated	O
protection	O
against	O
MERS	O
-	O
CoV	O
in	O
the	O
murine	O
model	O
.	O

ABSTRACT	O
:	O
Murine	O
antisera	O
with	O
neutralising	O
activity	O
for	O
the	O
coronavirus	O
causative	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
were	O
induced	O
by	O
immunisation	O
of	O
Balb	O
/	O
c	O
mice	O
with	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
Spike	O
protein	O
.	O

Subsequent	O
challenge	O
of	O
the	O
recipient	O
transduced	O
mice	O
by	O
the	O
intra	O
-	O
nasal	O
route	O
with	O
a	O
clinical	O
isolate	O
of	O
the	O
MERS	O
-	O
CoV	O
resulted	O
in	O
a	O
significantly	O
reduced	O
viral	O
load	O
in	O
their	O
lungs	O
,	O
compared	O
with	O
transduced	O
mice	O
receiving	O
a	O
negative	O
control	O
antibody	B-FUNC
.	O

Thus	O
,	O
antibody	B-FUNC
and	O
antigen	O
testing	O
may	O
be	O
dispensable	O
in	O
the	O
long	O
run	O
,	O
particularly	O
in	O
the	O
combination	O
of	O
NAT	O
testing	O
with	O
pathogen	O
reduction	O
.	O

Donor	O
screening	O
NAT	O
also	O
contributed	O
significantly	O
to	O
our	O
knowledge	O
on	O
how	O
fast	B-FUNC
viruses	O
replicate	O
,	O
and	O
on	O
the	O
respective	O
diagnostic	O
window	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
are	O
able	O
to	O
modulate	O
proliferation	O
,	O
activation	O
,	O
and	O
effector	O
function	O
of	O
all	O
immune	O
cells	O
that	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
and	O
chronic	O
inflammatory	O
lung	O
diseases	O
.	O

We	O
tested	O
16	O
different	O
respiratory	O
virus	O
infections	O
in	O
post	O
-	O
surgery	O
mild	O
symptomatic	O
PSP	O
group	O
and	O
asymptomatic	O
PSP	O
group	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
panel	O
.	O

Results	O
showed	O
that	O
GSLS	O
promoted	O
significantly	O
higher	O
NDV	O
-	O
and	O
IBV	O
-	O
specific	O
antibody	B-FUNC
responses	O
with	O
the	O
highest	O
antibody	B-FUNC
response	O
detected	O
in	O
GSLS	O
-	O
Se	O
group	O
.	O

In	O
addition	O
,	O
GSLS	O
-	O
Se	O
enhanced	O
lymphocyte	O
proliferation	O
and	O
production	O
of	O
IFN	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

More	O
importantly	O
GSLS	O
-	O
Se	O
was	O
found	O
to	O
promote	O
early	O
production	O
and	O
prolong	O
the	O
duration	O
of	O
the	O
antibody	B-FUNC
responses	O
.	O

In	O
ST	O
cells	O
,	O
caspase	B-FUNC
activity	I-FUNC
assay	O
showed	O
that	O
the	O
activity	O
of	O
caspase	O
3	O
,	O
caspase	O
8	O
and	O
caspase	O
9	O
increased	O
significantly	O
with	O
the	O
infection	O
of	O
PDCoV	O
,	O
but	O
not	O
observed	O
in	O
UV	O
irradiated	O
PDCoV	O
-	O
infected	O
cells	O
,	O
indicating	O
that	O
PDCoV	O
infection	O
activated	O
both	O
endogenous	O
and	O
exogenous	O
apoptotic	O
pathways	O
in	O
ST	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
depended	O
on	O
viral	O
replication	O
.	O

To	O
further	O
investigate	O
the	O
endogenous	O
apoptosis	O
induced	O
by	O
PDCoV	O
,	O
cytochrome	B-FUNC
C	I-FUNC
and	O
apoptosis	O
-	O
inducing	O
factors	O
in	O
cytoplasm	O
and	O
mitochondria	O
were	O
detected	O
.	O

Compared	O
with	O
normal	O
cells	O
,	O
the	O
amount	O
of	O
cytochrome	B-FUNC
C	I-FUNC
released	O
from	O
mitochondria	O
to	O
cytoplasm	O
increased	O
significantly	O
in	O
PDCoV	O
-	O
infected	O
cells	O
,	O
and	O
the	O
release	O
increased	O
with	O
the	O
prolongation	O
of	O
infection	O
,	O
while	O
the	O
apoptosis	O
-	O
inducing	O
factor	O
was	O
always	O
localized	O
to	O
mitochondria	O
,	O
suggesting	O
that	O
PDCoV	O
induced	O
apoptosis	O
was	O
initiated	O
through	O
caspase	O
-	O
dependent	O
mitochondrial	O
apoptosis	O
pathway	O
by	O
promoting	O
cytochrome	B-FUNC
C	I-FUNC
in	O
the	O
mitochondrial	O
membrane	O
gap	O
into	O
the	O
cytosol	O
.	O

Remdesivir	O
(	O
RDV	O
,	O
GS	O
-	O
5734	O
)	O
is	O
a	O
monophosphoramidate	O
prodrug	O
of	O
an	O
adenosine	O
analog	O
with	O
potent	O
activity	O
against	O
an	O
array	O
of	O
RNA	O
virus	O
families	O
including	O
Filoviridae	O
,	O
Paramyxoviridae	O
,	O
Pneumoviridae	O
,	O
and	O
Orthocoronavirinae	O
,	O
through	O
the	O
targeting	O
of	O
the	O
viral	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
).	O

However	O
AAV	O
-	O
Pck2	O
overexpression	O
reduced	O
TA	O
muscle	O
weights	O
(	O
p	O
=	O
0	O
.	O
0434	O
),	O
particularly	O
in	O
the	O
Control	O
(	O
vehicle	O
treated	O
)	O
mice	O
(	O
p	O
=	O
0	O
.	O
059	O
for	O
AAV	O
x	O
Clenbuterol	O
interaction	O
)	O
and	O
increased	O
the	O
expression	O
of	O
Seryl	O
-	O
tRNA	B-FUNC
Synthetase	O
(	O
Sars	O
)	O
mRNA	O
(	O
p	O
=	O
0	O
.	O
0477	O
).	O

TITLE	O
:	O
Avian	O
coronavirus	O
infection	O
induces	O
mannose	O
-	O
binding	B-FUNC
lectin	O
production	O
in	O
dendritic	O
cell	O
precursors	O
of	O
chicken	O
lymphoid	O
organs	O
.	O

The	O
aim	O
of	O
this	O
immunocytochemical	O
study	O
was	O
to	O
compare	O
mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
production	O
induced	O
by	O
avian	O
coronavirus	O
in	O
the	O
spleen	O
and	O
caecal	O
tonsil	O
(	O
CT	O
).	O

ABSTRACT	O
:	O
The	O
6	O
'-	O
fluorinated	O
aristeromycins	O
were	O
designed	O
as	O
dual	O
-	O
target	O
antiviral	O
compounds	O
aimed	O
at	O
inhibiting	O
both	O
the	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
the	O
host	O
cell	O

Results	O
show	O
that	O
vaccination	O
on	O
day	O
1	O
of	O
age	O
elicits	O
significantly	O
lower	O
systemic	O
and	O
mucosal	O
antibody	B-FUNC
responses	O
compared	O
with	O
vaccination	O
at	O
later	O
time	O
points	O
in	O
the	O
life	O
of	O
the	O
chicken	O
.	O

A	O
fully	O
human	O
polyclonal	O
IgG	O
antibody	B-FUNC
(	O
SAB	O
-	O
301	O
)	O
was	O
safe	O
and	O
well	O
tolerated	O
in	O
healthy	O
individuals	O
and	O
this	O
agent	O
may	O
deserve	O
further	O
testing	O
for	O
efficacy	O
.	O

DNA	O
/	O
RNA	O
was	O
extracted	O
using	O
the	O
EZ1	O
Virus	O
Mini	O
Kit	B-FUNC
v2	O
.	O
0	O
(	O
Qiagen	O
,	O
Belgium	O
)	O
with	O
the	O
EZ1	O
extraction	O
device	O
(	O
Qiagen	O
,	O
Belgium	O
).	O

The	O
primary	O
therapies	O
were	O
antibiotics	O
(	O
99	O
.	O
0	O
%),	O
immunoglobulin	B-FUNC
(	O
88	O
.	O
3	O
%),	O
mechanical	O
ventilation	O
(	O
78	O
.	O
4	O
%),	O
vasoactive	O
infusions	O
(	O
59	O
.	O
6	O
%),	O
and	O
corticosteroids	O
(	O
46	O
.	O
1	O
%).	O

ELISA	O
and	O
Western	O
blot	O
results	O
revealed	O
that	O
fraxin	O
might	O
inhibit	O
the	O
production	O
of	O
inflammatory	O
factors	O
,	O
namely	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
	O
,	O
and	O
IL	O
-	O
1	O
,	O
and	O
the	O
activation	O
of	O
NF	O
-	O
B	O
and	O
MAPK	B-FUNC
signaling	O
pathways	O
in	O
the	O
lungs	O
.	O

In	O
neutralizing	O
assays	O
,	O
Amibara	O
S	O
recombinants	O
were	O
neutralized	O
by	O
lower	O
concentrations	O
of	O
sera	B-FUNC
from	O
both	O
Ethiopian	O
dromedaries	O
and	O
EMC	O
isolate	O
(	O
wild	O
-	O
type	O
)-	O
immunized	O
mouse	O
sera	B-FUNC
,	O
relative	O
to	O
the	O
EMC	O
S	O
recombinants	O
,	O
indicating	O
that	O
viruses	O
coated	O
in	O
the	O
Amibara	O
S	O
protein	O
were	O
easier	O
to	O
neutralize	O
than	O
the	O
EMC	O
S	O
protein	O
.	O

It	O
has	O
been	O
detected	O
that	O
the	O
levels	O
of	O
PEDV	O
-	O
specific	O
antibodies	O
(	O
IgG	O
and	O
IgA	O
)	O
in	O
their	O
sera	B-FUNC
and	O
milks	O
were	O
higher	O
than	O
other	O
negative	O
groups	O
(	O
P	O
<	O
0	O
	O
001	O
or	O
P	O
<	O
0	O
	O
05	O
).	O

Via	O
mucin	O
-	O
binding	B-FUNC
assays	O
,	O
we	O
showed	O
that	O
HKU23	O
-	O
NTD	O
is	O
able	O
to	O
bind	B-FUNC
sugars	O
.	O

We	O
further	O
solved	O
the	O
structure	O
of	O
HKU23	O
-	O
NTD	O
,	O
performed	O
structure	O
-	O
guided	O
mutagenesis	O
and	O
successfully	O
located	O
the	O
potential	O
sugar	O
-	O
binding	B-FUNC
pockets	O
in	O
the	O
structure	O
.	O

Therefore	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
establish	O
fast	B-FUNC
and	O
economical	O
screening	O
methods	O
using	O
cell	O
-	O
based	O
models	O
to	O
screen	O
and	O
develop	O
novel	O
immunomodulatory	O
agents	O
.	O

Gene	O
Ontology	O
analysis	O
suggested	O
that	O
cellular	O
macromolecule	O
and	O
protein	O
location	O
(	O
GO	O
-	O
BP	O
)	O
and	O
transcription	B-FUNC
factor	I-FUNC
binding	I-FUNC
(	O
GO	O
-	O
MF	O
)	O
were	O
abundant	O
in	O
IBV	O
-	O
stimulated	O
avian	O
DCs	O
.	O

Further	O
analysis	O
showed	O
that	O
the	O
actin	O
cytoskeleton	O
and	O
MAPK	B-FUNC
signal	O
pathway	O
were	O
related	O
to	O
the	O
target	O
genes	O
of	O
IBV	O
-	O
stimulated	O
miRNAs	O
.	O

Here	O
,	O
we	O
showed	O
that	O
recombinant	O
staphylococcal	O
PI	O
-	O
PLC	O
possesses	O
enzyme	B-FUNC
activity	I-FUNC
that	O
causes	O
shedding	O
of	O
glycosylphosphatidylinositol	O
-	O
anchored	O
CD55	O
and	O
CD59	O
from	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
surfaces	O
and	O
triggers	O
cell	O
lysis	O
via	O
complement	O
activity	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
serum	O
SP	O
-	O
D	O
levels	O
were	O
analyzed	O
in	O
37	O
CDH	O
infants	O
and	O
5	O
control	O
infants	O
using	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	B-FUNC
.	O

ABSTRACT	O
:	O
Most	O
neutralizing	O
antibodies	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
target	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
glycoprotein	O
and	O
block	O
its	O
binding	B-FUNC
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

Structure	O
determination	O
and	O
mutagenesis	O
experiments	O
reveal	O
the	O
epitope	O
and	O
critical	O
residues	O
on	O
the	O
NTD	O
for	O
7D10	O
binding	B-FUNC
and	O
neutralization	O
.	O

The	O
role	O
of	O
various	O
biomarkers	O
,	O
such	O
as	O
Clara	O
cell	O
protein	O
16	O
,	O
von	O
Willebrand	O
factor	O
,	O
interleukin	O
-	O
6	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
,	O
and	O
angiopoietin	O
,	O
has	O
been	O
studied	O
in	O
trauma	O
-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
The	O
interaction	O
between	O
a	O
low	O
pathogenic	O
avian	O
influenza	O
virus	O
(	O
A	O
/	O
CK	O
/	O
TUN	O
/	O
145	O
/	O
2012	O
),	O
a	O
H9N2	O
Tunisian	O
isolate	O
,	O
and	O
a	O
vaccine	O
strain	O
(	O
H120	O
)	O
of	O
avian	O
infectious	O
bronchitis	O
,	O
administered	O
simultaneously	O
or	O
sequentially	O
three	O
days	O
apart	O
to	O
chicks	O
during	O
20	O
days	O
,	O
was	O
evaluated	O
using	O
ELISA	O
antibody	B-FUNC
levels	O
,	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
analyses	O
and	O
histopathology	O
examination	O
.	O

Second	O
,	O
we	O
have	O
determined	O
the	O
amount	O
of	O
specific	O
antibodies	O
in	O
sera	B-FUNC
of	O
chick	O
'	O
s	O
infected	O
with	O
AIV	O
alone	O
,	O
IBV	O
alone	O
,	O
mixed	O
AIV	O
+	O
IBV	O
,	O
IBV	O
then	O
AIV	O
or	O
AIV	O
IBV	O
3	O
days	O
later	O
using	O
an	O
ELISA	O
test	O
.	O

TITLE	O
:	O
Mechanism	O
of	O
Cxc	O
Chemokine	O
Ligand	B-FUNC
5	O
(	O
CXCL5	O
)/	O
Cxc	O
Chemokine	O
Receptor	O
2	O
(	O
CXCR2	O
)	O
Bio	O
-	O
Axis	O
in	O
Mice	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

In	O
addition	O
,	O
CXCL5	O
neutralizing	O
antibody	B-FUNC
effectively	O
alleviated	O
inflammatory	O
response	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
pulmonary	O
edema	O
,	O
and	O
decreased	O
the	O
expression	O
levels	O
of	O
MMP2	O
and	O
MMP9	O
compared	O
to	O
LPS	O
-	O
induced	O
ARDS	O
.	O

After	O
treatment	O
with	O
intravenous	O
immunoglobulin	B-FUNC
and	O
plasma	O
exchange	O
followed	O
by	O
antiviral	O
therapy	O
by	O
direct	O
-	O
acting	O
antiviral	O
agent	O
,	O
patient	O
showed	O
progressive	O
recovery	O
and	O
was	O
transferred	O
3	O
months	O
after	O
his	O
first	O
admission	O
to	O
a	O
rehabilitation	O
center	O
.	O

Here	O
,	O
we	O
examined	O
the	O
intermediate	O
conformation	O
of	O
the	O
murine	O
coronavirus	O
fusion	O
protein	O
,	O
called	O
the	O
spike	O
protein	O
,	O
which	O
must	O
be	O
cleaved	O
by	O
a	O
cellular	O
protease	O
following	O
receptor	B-FUNC
binding	I-FUNC
.	O

On	O
day	O
1	O
,	O
2	O
-	O
3	O
and	O
4	O
-	O
5	O
after	O
admission	O
the	O
following	O
pituitary	O
axes	O
were	O
assessed	O
:	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
,	O
hypothalamic	O
-	O
pituitary	O
-	O
thyroid	O
,	O
somatotroph	O
,	O
prolactin	B-FUNC
and	O
copeptin	O
.	O

Especially	O
,	O
rAd	O
/	O
Spike	O
induced	O
the	O
highest	O
neutralizing	O
antibody	B-FUNC
titer	O
and	O
the	O
strongest	O
cytokine	O
-	O
induced	O
T	O
cell	O
responses	O
among	O
the	O
three	O
candidate	O
vaccines	O
.	O

The	O
levels	O
of	O
IL	O
-	O
1	O
in	O
REC	O
group	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
C	O
-	O
RELAP	O
group	O
,	O
and	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
TNF	O
-	O
	O
in	O
C	O
-	O
PRO	O
group	O
were	O
diminished	O
in	O
the	O
brain	O
.	O

The	O
levels	O
of	O
TNF	O
-	O
	O
in	O
REC	O
group	O
and	O
INF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
TGF	O
-	O
	O
and	O
TNF	O
-	O
	O
in	O
the	O
C	O
-	O
PRO	O
group	O
were	O
also	O
diminished	O
in	O
the	O
urinary	O
bladder	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
nsp15	O
antagonizes	O
interferon	O
-	O
	O
production	O
independently	O
of	O
its	O
endoribonuclease	B-FUNC
activity	I-FUNC
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
PDCoV	O
nsp15	O
is	O
an	O
IFN	O
antagonist	O
and	O
it	O
inhibits	O
interferon	O
-	O
	O
production	O
via	O
an	O
endoribonuclease	B-FUNC
activity	I-FUNC
-	O
independent	O
mechanism	O
.	O

HLH	O
was	O
noted	O
in	O
7	O
(	O
32	O
%)	O
cases	O
at	O
a	O
median	O
(	O
IQR	O
)	O
hospital	O
stay	O
of	O
5	O
(	O
2	O
-	O
8	O
)	O
d	O
.	O
Children	O
with	O
HLH	O
had	O
significantly	O
higher	O
Pediatric	O
Index	O
of	O
Mortality	O
2	O
(	O
PIM	O
2	O
)	O
score	O
at	O
admission	O
and	O
higher	O
frequency	O
of	O
pain	O
abdomen	O
,	O
anemia	O
,	O
hypoalbuminemia	O
,	O
elevated	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
ARDS	O
.	O

It	O
is	O
observed	O
that	O
seven	O
putative	O
peptides	O
have	O
good	O
binding	B-FUNC
score	O
based	O
on	O
cluster	O
size	O
cutoff	O
of	O
208	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
the	O
prototypic	O
Arabian	O
MERS	O
-	O
CoV	O
strain	O
,	O
human	O
betacoronavirus	O
2c	O
EMC	O
/	O
2012	O
,	O
and	O
the	O
above	O
stated	O
African	O
MERS	O
-	O
CoV	O
variants	O
do	O
not	O
appreciably	O
differ	O
in	O
expression	O
,	O
DPP4	O
binding	B-FUNC
and	O
ability	O
to	O
drive	O
entry	O
into	O
target	O
cells	O
.	O

The	O
research	O
findings	O
showed	O
that	O
serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
-	O
	O
),	O
interleukin	O
-	O
1	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
diamine	O
oxidase	O
(	O
DAO	O
),	O
endotoxin	O
,	O
D	O
-	O
lactic	O
acid	O
levels	O
and	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
II	O
)	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
scores	O
of	O
group	O
B	O
were	O
lower	O
than	O
those	O
of	O
group	O
A	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
)	O
after	O
treatment	O
.	O

Furthermore	O
,	O
strong	O
antibody	B-FUNC
responses	O
to	O
PEDV	O
were	O
detected	O
in	O
the	O
sera	B-FUNC
and	O
colostrum	O
of	O
immunized	O
sows	O
and	O
in	O
the	O
sera	B-FUNC
of	O
their	O
offspring	O
.	O

It	O
is	O
unclear	O
whether	O
OSA	O
is	O
a	O
risk	O
factor	O
for	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-FUNC
)	O
and	O
might	O
affect	O
its	O
outcome	O
.	O

On	O
the	O
one	O
hand	O
,	O
OSA	O
in	O
patients	O
with	O
ACS	B-FUNC
may	O
worsen	O
prognosis	O
;	O
on	O
the	O
other	O
hand	O
,	O
OSA	O
-	O
related	O
hypoxaemia	O
could	O
favour	O
the	O
development	O
of	O
coronary	O
collaterals	O
,	O
thereby	O
exerting	O
a	O
protective	O
effect	O
.	O

It	O
is	O
unknown	O
whether	O
positive	O
airway	O
pressure	O
treatment	O
may	O
influence	O
adverse	O
events	O
and	O
consequences	O
of	O
ACS	B-FUNC
.	O

Fewer	O
data	O
are	O
available	O
in	O
subjects	O
with	O
ACS	B-FUNC
and	O
OSA	O
,	O
and	O
results	O
of	O
randomised	O
controlled	O
studies	O
on	O
the	O
effects	O
of	O
CPAP	O
are	O
expected	O
shortly	O
.	O

The	O
picture	O
is	O
still	O
incomplete	O
,	O
and	O
the	O
potential	O
role	O
of	O
OSA	O
in	O
patients	O
with	O
ACS	B-FUNC
awaits	O
confirmation	O
,	O
as	O
well	O
as	O
clear	O
definition	O
of	O
subgroups	O
with	O
different	O
degrees	O
of	O
risk	O
.	O

The	O
reported	O
isolate	O
was	O
identified	O
by	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
assay	O
targeting	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
,	O
further	O
characterized	O
by	O
full	O
-	O
length	O
spike	O
(	O
S1	O
)	O
gene	O
sequencing	O
.	O

However	O
,	O
their	O
contribution	O
to	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
has	O
not	O
been	O
fully	O
investigated	O
.	O

Here	O
we	O
analyzed	O
13	O
out	O
of	O
14	O
contact	O
residues	O
by	O
mutagenesis	O
and	O
identified	O
I22	O
as	O
being	O
essential	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
G29	O
was	O
critical	O
for	O
the	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
triggered	O
by	O
either	O
receptor	B-FUNC
binding	I-FUNC
or	O
high	O
pH	O
.	O
Replacement	O
of	O
G29	O
with	O
A	O
,	O
D	O
,	O
F	O
,	O
K	O
,	O
M	O
,	O
and	O
T	O
,	O
to	O
different	O
extents	O
,	O
caused	O
spontaneous	O
dissociation	O
of	O
S1	O
from	O
the	O
S	O
protein	O
,	O
resulting	O
in	O
an	O
enhancement	O
of	O
high	O
-	O
pH	O
-	O
triggered	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
in	O
HEK293T	O
cells	O
,	O
compared	O
to	O
the	O
wild	O
type	O
(	O
WT	O
).	O

We	O
found	O
that	O
the	O
PEDV	O
strain	O
BJ2011C	O
could	O
quickly	O
colonize	O
the	O
small	O
intestine	O
,	O
which	O
occurred	O
in	O
just	O
6	O
h	O
post	O
infection	O
,	O
with	O
virus	O
shedding	O
starting	O
at	O
6	O
hpi	B-FUNC
and	O
peaking	O
at	O
24	O
hpi	B-FUNC
.	O

In	O
vivo	O
,	O
miR	O
-	O
150	O
decreased	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
and	O
production	O
of	O
inflammatory	O
cytokines	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
)	O
as	O
well	O
as	O
levels	O
of	O
total	O
protein	O
,	O
albumin	O
and	O
IgM	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
in	O
LPS	O
-	O
induced	O
ALI	O
mice	O
.	O

In	O
addition	O
,	O
miR	O
-	O
150	O
or	O
si	O
-	O
AKT3	O
effectively	O
inhibited	O
the	O
phosphorylation	O
levels	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
)	O
and	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
)	O
(	O
p65	O
and	O
IB	O
).	O

In	O
conclusion	O
,	O
miR	O
-	O
150	O
alleviated	O
LPS	O
-	O
induced	O
acute	O
lung	O
injury	O
via	O
directly	O
targeting	O
AKT3	O
expression	O
or	O
regulating	O
JNK	B-FUNC
and	O
NF	O
-	O
B	O
pathways	O
,	O
which	O
may	O
be	O
a	O
promising	O
therapeutic	O
strategy	O
to	O
treat	O
ALI	O
/	O
ARDS	O
.	O

Furthermore	O
,	O
HY	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	O
in	O
CEK	O
cells	O
,	O
and	O
significantly	O
reduced	O
the	O
mRNA	O
expression	O
levels	O
of	O
Fas	O
,	O
FasL	O
,	O
JNK	B-FUNC
,	O
Bax	O
,	O
Caspase	O
3	O
,	O
and	O
Caspase	O
8	O
,	O
and	O
significantly	O
increased	O
Bcl	O
-	O
2	O
mRNA	O
expression	O
level	O
in	O
CEK	O
cells	O
.	O

Immunoglobulin	B-FUNC
levels	O
were	O
examined	O
and	O
immunophenotyping	O
was	O
performed	O
.	O

We	O
found	O
that	O
the	O
serum	O
immunoglobulin	B-FUNC
levels	O
were	O
in	O
the	O
normal	O
range	O
in	O
70	O
%	O
of	O
the	O
children	O
.	O

Coronavirus	O
can	O
cause	O
severe	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
).	O
Intracerebral	O
haemorrhage	O
is	O
an	O
uncommon	O
presentation	O
of	O
ITP	O
.	O
Intravenous	O
immunoglobulin	B-FUNC
and	O
steroids	O
are	O
very	O
effective	O
treatments	O
for	O
severe	O
ITP	O
.	O

In	O
total	O
137	O
cat	O
serum	O
samples	O
and	O
25	O
FCoV	O
type	O
1	O
or	O
type	O
2	O
-	O
specific	O
antisera	O
were	O
screened	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
the	O
S1	O
receptor	B-FUNC
binding	I-FUNC
subunit	O
of	O
the	O
CoV	O
spike	O
protein	O
,	O
which	O
is	O
immunogenic	O
and	O
possesses	O
low	O
amino	O
acid	O
sequence	O
identity	O
among	O
coronavirus	O
species	O
.	O

Seventy	O
-	O
eight	O
sera	B-FUNC
were	O
positive	O
for	O
antibodies	O
that	O
recognized	O
one	O
or	O
more	O
coronavirus	O
S1s	O
whereas	O
1	O
serum	O
exclusively	O
reacted	O
with	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
two	O
sera	B-FUNC
exclusively	O
reacted	O
with	O
porcine	O
delta	O
coronavirus	O
(	O
PDCoV	O
).	O

Domain	O
mapping	O
of	O
antibody	B-FUNC
epitopes	O
indicated	O
the	O
presence	O
of	O
conserved	O
epitope	O
(	O
s	O
)	O
particularly	O
in	O
the	O
CD	O
domains	O
of	O
S1	O
.	O

The	O
diagnostic	O
criteria	O
of	O
AMAN	O
refer	O
to	O
AIDP	O
,	O
of	O
which	O
the	O
feature	O
of	O
AMAN	O
suggests	O
a	O
pure	B-FUNC
motor	O
nerve	O
dysfunction	O
and	O
significant	O
damage	O
on	O
motor	O
axon	O
.	O

TITLE	O
:	O
Sensitive	O
and	O
Specific	O
Detection	O
of	O
Low	O
-	O
Level	O
Antibody	B-FUNC
Responses	O
in	O
Mild	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infections	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
-	O
Encoded	O
Accessory	O
Proteins	O
Impair	O
MDA5	O
-	O
and	O
TBK1	B-FUNC
-	O
Mediated	O
Activation	O
of	O
NF	O
-	O
B	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerging	O
coronavirus	O
which	O
is	O
zoonotic	O
from	O
bats	O
and	O
camels	O
.	O

The	O
binding	B-FUNC
of	O
the	O
four	O
flavonoids	O
was	O
also	O
confirmed	O
independently	O
using	O
a	O
tryptophan	O
-	O
based	O
fluorescence	O
method	O
.	O

The	O
systematic	O
comparison	O
of	O
the	O
binding	B-FUNC
affinity	O
of	O
flavonoids	O
made	O
it	O
possible	O
to	O
infer	O
their	O
scaffolds	O
and	O
functional	O
groups	O
required	O
to	O
bind	B-FUNC
with	O
MERS	O
-	O
CoV	O
3CLpro	O
.	O

The	O
experimental	O
and	O
computational	O
study	O
showed	O
that	O
flavonol	O
and	O
chalcone	O
are	O
favourite	O
scaffolds	O
to	O
bind	B-FUNC
with	O
the	O
catalytic	O
site	O
of	O
MERS	O
-	O
CoV	O
3CLpro	O
.	O

TITLE	O
:	O
Chromenone	O
derivatives	O
as	O
a	O
versatile	O
scaffold	O
with	O
dual	O
mode	O
of	O
inhibition	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
Ribonuclease	O
H	O
function	O
and	O
integrase	B-FUNC
activity	I-FUNC
.	O

The	O
modeling	O
studies	O
calculated	O
the	O
theoretical	O
binding	B-FUNC
affinity	O
of	O
the	O
synthesized	O
compounds	O
on	O
both	O
HIV	O
-	O
1	O
IN	O
and	O
RT	O
-	O
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
active	O
sites	O
,	O
which	O
was	O
confirmed	O
by	O
biological	O
assays	O
.	O

TITLE	O
:	O
A	O
Novel	O
Bacterium	O
-	O
Like	O
Particle	O
Vaccine	O
Displaying	O
the	O
MERS	O
-	O
CoV	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
Induces	O
Specific	O
Mucosal	O
and	O
Systemic	O
Immune	O
Responses	O
in	O
Mice	O
.	O

The	O
use	O
of	O
plasmapheresis	O
is	O
considered	O
useful	O
in	O
acute	O
anti	O
-	O
glomerular	O
basement	O
membrane	O
(	O
GBM	O
)	O
disease	O
(	O
Goodpasture	O
'	O
s	O
syndrome	O
)	O
or	O
catastrophic	O
antiphospholipid	O
antibody	B-FUNC
syndrome	O
(	O
APS	O
).	O

We	O
used	O
isolated	O
peptides	O
and	O
giant	O
unilamellar	O
vesicles	O
(	O
GUV	O
)	O
to	O
demonstrate	O
membrane	O
binding	B-FUNC
for	O
a	O
peptide	O
located	O
near	O
the	O
N	O
-	O
terminus	O
of	O
the	O
S2	O
domain	O
.	O

Mutations	O
preventing	O
membrane	O
binding	B-FUNC
in	O
vitro	O
also	O
abolished	O
S	O
-	O
mediated	O
syncytium	O
formation	O
consistent	O
with	O
the	O
identified	O
peptide	O
acting	O
as	O
the	O
fusion	O
peptide	O
for	O
the	O
S	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
During	O
the	O
last	O
three	O
decades	O
or	O
so	O
,	O
many	O
efforts	O
have	O
been	O
made	O
to	O
study	O
the	O
protein	O
cleavage	O
sites	O
by	O
some	O
disease	O
-	O
causing	O
enzyme	O
,	O
such	O
as	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
protease	O
and	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
coronavirus	O
main	O
proteinase	B-FUNC
.	O

To	O
further	O
understand	O
the	O
antiviral	O
immunity	O
of	O
bats	O
,	O
we	O
screened	O
and	O
identified	O
a	O
series	O
of	O
bat	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
I	O
Ptal	O
-	O
N	O
*	O
01	O
:	O
01	O
-	O
binding	B-FUNC
peptides	O
derived	O
from	O
four	O
different	O
bat	O
-	O
borne	O
viruses	O
,	O
i	O
.	O
e	O
.,	O
Hendra	O
virus	O
(	O
HeV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
H17N10	O
influenza	O
-	O
like	O
virus	O
.	O

The	O
structures	O
of	O
Ptal	O
-	O
N	O
*	O
01	O
:	O
01	O
display	O
unusual	O
peptide	O
presentation	O
features	O
in	O
that	O
the	O
bat	O
-	O
specific	O
3	O
-	O
amino	O
acid	O
(	O
aa	O
)	O
insertion	O
enables	O
the	O
tight	O
""""	O
surface	O
anchoring	B-FUNC
""""	O
of	O
the	O
P1	O
-	O
Asp	O
in	O
pocket	O
A	O
of	O
bat	O
MHC	O
I	O
.	O
As	O
the	O
classical	O
primary	O
anchoring	B-FUNC
positions	O
,	O
the	O
B	O
and	O
F	O
pockets	O
of	O
Ptal	O
-	O
N	O
*	O
01	O
:	O
01	O
also	O
show	O
unconventional	O
conformations	O
,	O
which	O
contribute	O
to	O
unusual	O
peptide	O
motifs	O
and	O
distinct	O
peptide	O
presentation	O
.	O

In	O
order	O
to	O
determine	O
and	O
compare	O
which	O
of	O
the	O
viral	O
proteins	O
may	O
be	O
useful	O
as	O
diagnostic	O
antigens	O
,	O
whole	O
virus	O
(	O
WV	O
)	O
particles	O
and	O
a	O
panel	O
of	O
structural	O
and	O
nonstructural	O
PEDV	O
proteins	O
[	O
spike	O
subunit	O
1	O
(	O
S1	O
),	O
the	O
C	O
-	O
terminal	O
part	O
of	O
ORF3	O
(	O
ORF3C	O
),	O
envelope	O
(	O
E	O
),	O
nonstructural	O
protein	O
1	O
(	O
Nsp1	O
),	O
Nsp2	O
,	O
Ac	O
(	O
acidic	O
domain	O
of	O
Nsp3	O
),	O
and	O
ADRP	O
(	O
ADP	O
-	O
ribose	O
-	O
1	O
-	O
monophosphatase	O
domain	O
of	O
Nsp3	O
),	O
expressed	O
individually	O
in	O
bacterial	O
and	O
/	O
or	O
mammalian	O
cells	O
]	O
were	O
tested	O
for	O
reactivity	O
with	O
sera	B-FUNC
from	O
PEDV	O
-	O
infected	O
pigs	O
by	O
ELISA	O
and	O
/	O
or	O
western	O
blot	O
analysis	O
.	O

The	O
earliest	O
IgG	O
antibody	B-FUNC
response	O
was	O
observed	O
in	O
the	O
one	O
-	O
week	O
-	O
old	O
piglets	O
,	O
with	O
similar	O
antibody	B-FUNC
ontogeny	O
and	O
patterns	O
of	O
seroconversion	O
for	O
S1	O
,	O
ORF3C	O
,	O
E	O
,	O
and	O
WV	O
antigens	O
.	O

In	O
addition	O
,	O
the	O
pattern	O
of	O
neutralizing	O
antibody	B-FUNC
was	O
more	O
similar	O
to	O
that	O
of	O
IgA	O
in	O
weaning	O
piglets	O
after	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
GTPase	O
-	O
activating	O
protein	O
-	O
binding	B-FUNC
protein	O
1	O
(	O
G3BP1	O
)	O
plays	O
an	O
antiviral	O
role	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

An	O
increase	O
in	O
the	O
levels	O
of	O
mRNAs	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
	O
(	O
TNF	O
-	O
	O
)	O
was	O
also	O
observed	O
in	O
PEDV	O
-	O
infected	O
G3BP1	O
depleted	O
cells	O
compared	O
to	O
PEDV	O
-	O
infected	O
control	O
cells	O
.	O

TITLE	O
:	O
Peptides	O
with	O
16R	O
in	O
S2	O
protein	O
showed	O
broad	O
reactions	O
with	O
sera	B-FUNC
against	O
different	O
types	O
of	O
infectious	O
bronchitis	O
viruses	O
.	O

S2	O
-	O
derived	O
peptides	O
with	O
16R	O
,	O
but	O
not	O
those	O
with	O
16	O
K	O
,	O
could	O
react	O
with	O
sera	B-FUNC
against	O
different	O
types	O
of	O
IBVs	O
.	O

Notably	O
,	O
a	O
commercial	O
ELISA	O
kit	B-FUNC
for	O
detection	O
of	O
antibodies	O
against	O
IBV	O
did	O
not	O
react	O
with	O
sera	B-FUNC
against	O
all	O
types	O
of	O
IBVs	O
.	O

Histological	O
analysis	O
was	O
performed	O
,	O
and	O
results	O
showed	O
increase	O
serum	O
aminotransferase	O
(	O
ALT	B-FUNC
and	O
AST	O
)	O
levels	O
and	O
evident	O
liver	O
injury	O
on	O
days	O
3	O
and	O
7	O
,	O
especially	O
on	O
day	O
5	O
post	O
infection	O
.	O

Acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
a	O
serious	O
complication	O
of	O
SCD	O
and	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
present	O
herein	O
the	O
case	O
of	O
a	O
young	O
female	O
adult	O
(	O
19	O
y	O
.	O
o	O
.)	O
with	O
SCD	O
who	O
developed	O
severe	O
respiratory	O
failure	O
due	O
to	O
ACS	B-FUNC
occurring	O
twice	O
within	O
15	O
months	O
and	O
treated	O
by	O
VV	O
-	O
ECMO	O
.	O

We	O
describe	O
the	O
management	O
of	O
ACS	B-FUNC
with	O
VV	O
-	O
ECMO	O
using	O
two	O
different	O
approaches	O
,	O
namely	O
with	O
and	O
without	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Epitope	O
mapping	O
and	O
cellular	O
localization	O
of	O
swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
using	O
a	O
novel	O
monoclonal	O
antibody	B-FUNC
.	O

We	O
generated	O
and	O
characterized	O
an	O
N	O
-	O
reactive	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
3E9	O
from	O
mice	O
immunized	O
with	O
recombinant	O
N	O
protein	O
.	O

A	O
similar	O
staining	O
was	O
obtained	O
by	O
two	O
other	O
mAbs	O
which	O
recognize	O
the	O
sialic	O
acid	O
-	O
binding	B-FUNC
domain	O
and	O
the	O
ectodomain	O
of	O
the	O
membrane	O
fusion	O
subunit	O
S2	O
,	O
respectively	O
.	O

It	O
is	O
imperative	O
to	O
continue	O
surveillance	O
for	O
the	O
spread	O
of	O
antimicrobial	O
resistance	O
and	O
occurrence	O
of	O
all	O
infectious	O
diseases	O
causing	O
outbreaks	O
across	O
the	O
globe	O
in	O
the	O
last	O
year	O
,	O
like	O
Zika	O
virus	O
,	O
MDR	B-FUNC
-	O
Typhoid	O
,	O
Nipah	O
,	O
Ebola	O
,	O
cholera	O
,	O
chikungunya	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

Here	O
,	O
we	O
report	O
the	O
cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
the	O
PEDV	O
S	O
protein	O
in	O
the	O
prefusion	O
conformation	O
at	O
a	O
resolution	O
of	O
3	O
.	O
1	O
	O
.	O
Our	O
studies	O
revealed	O
that	O
the	O
sialic	O
acid	O
-	O
binding	B-FUNC
domain	O
at	O
the	O
N	O
terminus	O
of	O
the	O
S1	O
subunit	O
has	O
an	O
orientation	O
that	O
is	O
substantially	O
different	O
from	O
that	O
observed	O
in	O
the	O
previously	O
determined	O
spike	O
structure	O
from	O
human	O
alphacoronavirus	O
NL63	O
.	O

We	O
also	O
observed	O
dissociated	O
S1	O
subunit	O
trimers	O
wherein	O
the	O
putative	O
receptor	O
-	O
binding	B-FUNC
domains	O
exist	O
in	O
a	O
conformation	O
differing	O
from	O
that	O
observed	O
in	O
the	O
intact	O
spike	O
proteins	O
,	O
suggesting	O
that	O
the	O
PEDV	O
receptor	O
-	O
binding	B-FUNC
domain	O
undergoes	O
conformational	O
rearrangements	O
akin	O
to	O
those	O
that	O
have	O
been	O
described	O
in	O
the	O
related	O
betacoronaviruses	O
.	O

During	O
reverse	O
transcription	O
,	O
the	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
degrades	O
the	O
viral	O
genomic	O
RNA	O
to	O
facilitate	O
the	O
synthesis	O
of	O
viral	O
double	O
-	O
stranded	O
DNA	O
.	O

Cell	O
-	O
surface	O
binding	B-FUNC
studies	O
and	O
in	O
vitro	O
competition	O
experiments	O
demonstrate	O
that	O
G2	O
strongly	O
disrupts	O
the	O
attachment	O
of	O
MERS	O
-	O
CoV	O
S	O
to	O
its	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
with	O
the	O
inhibition	O
requiring	O
the	O
native	O
trimeric	O
S	O
conformation	O
.	O

The	O
role	O
of	O
Mincle	O
for	O
MERS	O
-	O
CoV	O
-	O
triggered	O
cytokine	O
/	O
chemokine	O
induction	O
was	O
established	O
based	O
on	O
the	O
results	O
of	O
antibody	B-FUNC
blockage	O
,	O
siRNA	O
depletion	O
of	O
Mincle	O
and	O
its	O
adaptor	O
spleen	O
tyrosine	O
kinase	O
(	O
Syk	O
),	O
and	O
Syk	O
pharmacological	O
inhibition	O
.	O

Taking	O
into	O
account	O
the	O
fact	O
that	O
the	O
majority	O
of	O
emerging	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
highly	O
pathogenic	O
avian	O
influenza	O
[	O
HPAI	B-FUNC
],	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
Nipah	O
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
)	O
are	O
zoonotic	O
diseases	O
,	O
Egypt	O
has	O
established	O
a	O
national	O
One	O
Health	O
coordination	O
mechanism	O
.	O

Egypt	O
'	O
s	O
platform	O
will	O
involve	O
all	O
sectors	O
concerned	O
with	O
HPAI	B-FUNC
control	O
and	O
combine	O
all	O
stakeholders	O
in	O
an	O
integrated	O
,	O
holistic	O
approach	O
to	O
improve	O
the	O
detection	O
of	O
,	O
response	O
to	O
and	O
control	O
of	O
any	O
threats	O
at	O
the	O
human	O
-	O
animal	O
-	O
environment	O
interface	O
in	O
Egypt	O
.	O

A	O
total	O
of	O
3	O
,	O
762	O
and	O
560	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
screened	O
by	O
comparison	O
of	O
uninfected	O
PK	O
-	O
15	O
cells	O
and	O
infected	O
PK	O
-	O
15	O
cells	O
at	O
24	O
h	O
post	O
infection	O
(	O
hpi	B-FUNC
)	O
(	O
INF_24h	O
versus	O
NC	O
),	O
and	O
also	O
comparison	O
of	O
infected	O
PK	O
-	O
15	O
cells	O
between	O
24	O
and	O
36	O
hpi	B-FUNC
(	O
INF_36h	O
versus	O
INF_24h	O
),	O
which	O
included	O
156	O
and	O
23	O
porcine	O
innate	O
immune	O
-	O
related	O
genes	O
in	O
the	O
DEGs	O
of	O
INF_24h	O
versus	O
NC	O
and	O
INF_36h	O
versus	O
INF_24h	O
,	O
respectively	O
.	O

GHRH	O
antagonists	O
suppressed	O
the	O
activation	O
of	O
MLC2	O
,	O
ERK1	B-FUNC
/	O
2	O
,	O
JAK2	O
/	O
STAT3	O
pathway	O
and	O
increased	O
the	O
intracellular	O
P53	O
and	O
pAMPK	O
levels	O
.	O

We	O
did	O
this	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
phase	O
3	O
trial	O
at	O
41	O
US	O
medical	O
centres	O
to	O
assess	O
the	O
efficacy	O
of	O
high	O
-	O
titre	O
anti	O
-	O
influenza	O
plasma	O
(	O
haemagglutination	O
inhibition	O
antibody	B-FUNC
titre	O
	O
1	O
:	O
80	O
)	O
compared	O
with	O
low	O
-	O
titre	O
plasma	O
(	O
1	O
:	O
10	O
).	O

In	O
the	O
current	O
study	O
,	O
the	O
effect	O
of	O
overexpression	O
,	O
silencing	O
,	O
antibody	B-FUNC
inhibition	O
,	O
and	O
co	O
-	O
expression	O
with	O
porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
of	O
integrin	O
v3	O
on	O
PEDV	O
infection	O
was	O
investigated	O
and	O
analyzed	O
in	O
African	O
green	O
monkey	O
Vero	O
E6	O
cells	O
and	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
using	O
the	O
classical	O
strain	O
CV777	O
and	O
variant	O
strain	O
HM2017	O
of	O
PEDV	O
.	O

Silencing	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
promoted	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
and	O
inhibited	O
NF	O
-	O
B	O
pathway	O
.	O

The	O
data	O
revealed	O
that	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
was	O
regulated	O
via	O
two	O
pathways	O
:	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
HK2	B-FUNC
axis	O
and	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
/	O
NF	O
-	O
B	O
axis	O
.	O

The	O
abundant	O
IFI204	O
could	O
significantly	O
interact	O
with	O
IRF7	O
in	O
nucleus	O
by	O
its	O
HIN	O
domain	O
and	O
prevent	O
the	O
binding	B-FUNC
of	O
IRF7	O
with	O
its	O
corresponding	O
promoter	O
.	O

Furthermore	O
,	O
viral	O
protease	O
-	O
mediated	O
immune	O
evasion	O
and	O
viral	O
manipulation	O
of	O
the	O
ubiquitin	B-FUNC
system	O
will	O
be	O
addressed	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
Nebulizable	O
CDR	O
-	O
Modified	O
MERS	O
-	O
CoV	O
Neutralizing	O
Human	O
Antibody	B-FUNC
.	O

As	O
limited	O
therapeutic	O
antibody	B-FUNC
is	O
accumulated	O
in	O
lung	O
tissue	O
following	O
systemic	O
administration	O
,	O
inhalation	O
is	O
newly	O
recognized	O
as	O
an	O
alternative	O
,	O
possibly	O
better	O
,	O
route	O
of	O
therapeutic	O
antibody	B-FUNC
for	O
pulmonary	O
diseases	O
.	O

The	O
nebulization	O
process	O
,	O
however	O
,	O
generates	O
diverse	O
physiological	O
stresses	O
,	O
and	O
thus	O
,	O
the	O
therapeutic	O
antibody	B-FUNC
must	O
be	O
resistant	O
to	O
these	O
stresses	O
,	O
remain	O
stable	O
,	O
and	O
form	O
minimal	O
aggregates	O
.	O

We	O
first	O
isolated	O
a	O
MERS	O
-	O
CoV	O
neutralizing	O
antibody	B-FUNC
that	O
is	O
reactive	O
to	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

To	O
increase	O
stability	O
,	O
we	O
introduced	O
mutations	O
into	O
the	O
complementarity	O
-	O
determining	O
regions	O
(	O
CDRs	O
)	O
of	O
the	O
antibody	B-FUNC
.	O

In	O
summary	O
,	O
we	O
generated	O
a	O
MERS	O
-	O
CoV	O
neutralizing	O
human	O
antibody	B-FUNC
that	O
is	O
reactive	O
to	O
recombinant	O
MERS	O
-	O
CoV	O
S	O
RBD	O
protein	O
for	O
delivery	O
via	O
a	O
pulmonary	O
route	O
by	O
introducing	O
stabilizing	O
mutations	O
into	O
five	O
CDRs	O
.	O

TITLE	O
:	O
The	O
Role	O
of	O
EGFR	B-FUNC
in	O
Influenza	O
Pathogenicity	O
:	O
Multiple	O
Network	O
-	O
Based	O
Approaches	O
to	O
Identify	O
a	O
Key	O
Regulator	O
of	O
Non	O
-	O
lethal	O
Infections	O
.	O

The	O
role	O
of	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
)	O
in	O
influenza	O
pathogenesis	O
,	O
one	O
of	O
the	O
bottleneck	O
regulators	O
with	O
corroborating	O
signals	O
across	O
transcript	O
and	O
protein	O
expression	O
data	O
,	O
was	O
tested	O
and	O
validated	O
in	O
additional	O
mouse	O
infection	O
experiments	O
.	O

We	O
demonstrate	O
that	O
EGFR	B-FUNC
is	O
important	O
during	O
influenza	O
infection	O
,	O
but	O
the	O
role	O
it	O
plays	O
changes	O
for	O
lethal	O
versus	O
non	O
-	O
lethal	O
infections	O
.	O

Its	O
overall	O
goal	O
is	O
to	O
manage	O
respiratory	O
failure	O
-	O
induced	O
hypoxemia	O
and	O
hypercarbia	O
to	O
allow	O
""""	O
lung	O
rest	B-FUNC
""""	O
and	O
promote	O
recovery	O
.	O

Such	O
lung	O
-	O
protective	O
ventilation	O
seeks	O
to	O
avoid	O
barotrauma	O
(	O
by	O
monitoring	O
transpulmonary	O
pressure	O
),	O
volutrauma	O
(	O
by	O
reducing	O
excessive	O
tidal	O
volume	O
to	O
promote	O
lung	O
rest	B-FUNC
),	O
atelectotrauma	O
[	O
by	O
maintaining	O
adequate	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)],	O
and	O
oxygen	O
toxicity	O
(	O
by	O
decreasing	O
ventilator	O
oxygen	O
levels	O
when	O
PEEP	O
is	O
adequate	O
).	O

Upon	O
infection	O
,	O
cyclophilin	B-FUNC
A	O
stays	O
evenly	O
distributed	O
throughout	O
the	O
cell	O
,	O
whereas	O
cyclophilin	B-FUNC
B	O
concentrates	O
at	O
ER	O
-	O
bleb	O
-	O
like	O
structures	O
.	O

Out	O
of	O
45	O
necropscid	O
calves	O
,	O
three	O
(	O
6	O
.	O
66	O
%)	O
cases	O
were	O
positive	O
for	O
BRoV	O
and	O
four	O
(	O
8	O
.	O
88	O
%)	O
cases	O
were	O
found	O
positive	O
for	O
BCoV	O
,	O
screened	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Engagement	O
of	O
the	O
opiate	O
receptors	O
generates	O
a	O
series	O
of	O
intracellular	O
signals	O
,	O
including	O
inhibition	O
of	O
adenylate	O
cyclase	O
,	O
decreased	O
opening	O
of	O
calcium	O
channels	O
,	O
increased	O
potassium	O
currents	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	B-FUNC
).	O

The	O
aminopenicillins	O
,	O
like	O
the	O
natural	O
first	O
generation	O
penicillins	O
,	O
bind	B-FUNC
to	O
bacterial	O
proteins	O
and	O
inhibit	O
synthesis	O
of	O
the	O
bacterial	O
cell	O
wall	O
,	O
causing	O
cell	O
lysis	O
particularly	O
in	O
rapidly	O
growing	O
organisms	O
.	O

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
only	O
a	O
small	O
proportion	O
of	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
positive	O
(	O
RBD	O
)	O
of	O
spike	O
protein	O
positive	O
camel	O
sera	B-FUNC
in	O
Kenya	O
were	O
also	O
seropositive	O
to	O
MERS	O
-	O
CoV	O
nucleocapsid	O
(	O
NP	O
).	O

Furthermore	O
,	O
we	O
found	O
bat	O
HKU8r	O
-	O
CoV	O
NP	O
antibody	B-FUNC
in	O
73	O
(	O
12	O
.	O
5	O
%)	O
of	O
the	O
MERS	O
-	O
CoV	O
RBD	O
positive	O
and	O
NP	O
negative	O
samples	O
,	O
yet	O
found	O
only	O
3	O
(	O
0	O
.	O
43	O
%)	O
of	O
the	O
HKU8r	O
-	O
CoV	O
S1	O
antibody	B-FUNC
in	O
the	O
same	O
samples	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
S	O
-	O
protein	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
and	O
fusion	O
of	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

In	O
addition	O
,	O
PSN	O
decreased	O
the	O
content	O
of	O
TNF	O
-	O
	O
,	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
the	O
expression	O
of	O
iNOS	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
NO	O
in	O
HKMRSA	O
-	O
induced	O
bone	O
marrow	O
derived	O
macrophages	O
(	O
BMDMs	O
).	O

Furthermore	O
,	O
treatment	O
with	O
PSN	O
suppressed	O
the	O
activation	O
of	O
MAPKs	O
(	O
e	O
.	O
g	O
.	O
p38	B-FUNC
MAPK	B-FUNC
,	O
JNK	B-FUNC
and	O
ERK	B-FUNC
)	O
and	O
NF	O
-	O
B	O
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
that	O
PSN	O
ameliorates	O
gram	O
-	O
positive	O
bacteria	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibition	O
of	O
the	O
MAPK	B-FUNC
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
,	O
and	O
our	O
studies	O
suggest	O
that	O
PSN	O
might	O
be	O
a	O
novel	O
candidate	O
for	O
treating	O
ALI	O
/	O
ARDS	O
.	O

Many	O
differentially	O
expressed	O
lncRNAs	O
act	O
as	O
elements	O
to	O
competitively	O
attach	O
microRNAs	O
(	O
miRNAs	O
)	O
which	O
target	O
to	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
to	O
mediate	O
expression	O
of	O
genes	O
that	O
related	O
to	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
),	O
NOD	O
-	O
like	O
receptors	O
(	O
NLRs	O
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
),	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
pathways	O
.	O

Functional	O
analysis	O
of	O
the	O
binding	B-FUNC
proteins	O
and	O
the	O
up	O
/	O
down	O
-	O
stream	O
genes	O
of	O
the	O
differentially	O
expressed	O
lncRNAs	O
revealed	O
that	O
lncRNAs	O
were	O
principally	O
related	O
to	O
inflammatory	O
response	O
.	O

The	O
data	O
showed	O
that	O
differentially	O
expressed	O
lncRNAs	O
might	O
be	O
involved	O
in	O
inflammatory	O
response	O
induced	O
by	O
TGEV	O
through	O
acting	O
as	O
miRNA	O
sponges	O
,	O
regulating	O
their	O
up	O
/	O
down	O
-	O
stream	O
genes	O
,	O
or	O
directly	O
binding	B-FUNC
proteins	O
.	O

The	O
levels	O
of	O
inflammatory	O
factors	O
(	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CRP	O
)	O
and	O
immune	O
factors	O
(	O
CD3	O
The	O
incidences	O
of	O
ARDS	O
and	O
MODS	O
during	O
rescue	O
in	O
EFR	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
015	O
and	O
0	O
.	O
010	O
respectively	O
),	O
and	O
the	O
successful	O
rescue	O
rate	O
in	O
EFR	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
011	O
).	O

On	O
day	O
7	O
after	O
treatment	O
,	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CRP	O
and	O
CD8	O
CONCLUSIONS	O
:	O
EFR	O
can	O
effectively	O
eliminate	O
inflammatory	O
factors	O
,	O
improve	O
immune	O
function	O
,	O
maintain	O
the	O
stability	O
of	O
blood	O
components	O
,	O
reduce	O
the	O
incidences	O
of	O
ARDS	O
and	O
MODS	O
,	O
and	O
elevate	O
the	O
successful	O
rescue	O
rate	O
in	O
patients	O
with	O
SPF	O
.	O

The	O
results	O
were	O
similar	O
to	O
those	O
obtained	O
from	O
the	O
VN	O
test	O
using	O
live	O
MERS	O
-	O
CoV	O
and	O
were	O
more	O
sensitive	O
than	O
the	O
ELISA	O
performed	O
using	O
synthetic	O
MERS	O
S1	O
fragment	O
as	O
the	O
antigen	O
as	O
well	O
as	O
the	O
competitive	O
ELISA	O
performed	O
using	O
a	O
monoclonal	O
antibody	B-FUNC
against	O
MERS	O
-	O
CoV	O
.	O
According	O
to	O
the	O
comprehensive	O
results	O
of	O
the	O
four	O
types	O
of	O
serodiagnosis	O
methods	O
,	O
positive	O
antibodies	O
were	O
detected	O
only	O
in	O
dromedary	O
camels	O
and	O
the	O
remaining	O
herbivorous	O
animals	O
were	O
not	O
infected	O
with	O
the	O
virus	O
.	O

TITLE	O
:	O
A	O
New	O
Approach	O
of	O
Mitigating	O
CYP3A4	B-FUNC
Induction	O
Led	O
to	O
the	O
Discovery	O
of	O
Potent	O
Hepatitis	O
B	O
Virus	O
(	O
HBV	O
)	O
Capsid	O
Inhibitor	O
with	O
Optimal	O
ADMET	O
Profiles	O
.	O

This	O
eventually	O
led	O
to	O
the	O
discovery	O
of	O
a	O
new	O
capsid	O
inhibitor	O
with	O
significantly	O
reduced	O
CYP3A4	B-FUNC
induction	O
,	O
excellent	O
anti	O
-	O
HBV	O
activity	O
,	O
favorable	O
preclinical	O
PK	O
/	O
PD	O
profiles	O
,	O
and	O
no	O
early	O
safety	O
flags	O
.	O

However	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
there	O
has	O
been	O
no	O
reported	O
cases	O
of	O
effective	O
antiviral	O
antibody	B-FUNC
-	O
peptide	O
bispecific	O
fusion	O
proteins	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
coronavirus	O
,	O
which	O
binds	B-FUNC
to	O
cellular	O
receptors	O
and	O
mediates	O
membrane	O
fusion	O
for	O
cell	O
entry	O
,	O
is	O
a	O
candidate	O
vaccine	O
target	O
for	O
blocking	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
Three	O
Amino	O
Acid	O
Changes	O
in	O
Avian	O
Coronavirus	O
Spike	O
Protein	O
Allow	O
Binding	B-FUNC
to	O
Kidney	O
Tissue	O
.	O

Here	O
,	O
we	O
elucidate	O
the	O
determinants	O
for	O
kidney	O
tropism	O
by	O
studying	O
interactions	O
between	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
attachment	O
protein	O
spike	O
from	O
two	O
IBV	O
strains	O
with	O
different	O
tropisms	O
.	O

The	O
lack	O
of	O
binding	B-FUNC
of	O
QX	O
-	O
RBD	O
to	O
a	O
previously	O
identified	O
IBV	O
-	O
M41	O
receptor	O
was	O
confirmed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
demonstrating	O
that	O
tissue	O
binding	B-FUNC
of	O
QX	O
-	O
RBD	O
is	O
dependent	O
on	O
a	O
different	O
sialylated	O
glycan	O
receptor	O
.	O

Using	O
chimeric	O
RBD	O
proteins	O
,	O
we	O
discovered	O
that	O
the	O
region	O
encompassing	O
amino	O
acids	O
99	O
to	O
159	O
of	O
QX	O
-	O
RBD	O
was	O
required	O
to	O
establish	O
kidney	O
binding	B-FUNC
.	O

In	O
particular	O
,	O
QX	O
-	O
RBD	O
amino	O
acids	O
110	O
to	O
112	O
(	O
KIP	O
)	O
were	O
sufficient	O
to	O
render	O
IBV	O
-	O
M41	O
with	O
the	O
ability	O
to	O
bind	B-FUNC
to	O
kidney	O
,	O
while	O
the	O
reciprocal	O
mutations	O
in	O
IBV	O
-	O
QX	O
abolished	O
kidney	O
binding	B-FUNC
completely	O
.	O

Structural	O
analysis	O
of	O
both	O
RBDs	O
suggests	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
site	O
for	O
QX	O
is	O
located	O
at	O
a	O
different	O
location	O
on	O
the	O
spike	O
than	O
that	O
of	O
M41	O
.	O

This	O
infectious	O
single	O
-	O
stranded	O
,	O
positive	O
(+)	O
sense	O
RNA	O
virus	O
enters	O
the	O
host	O
by	O
binding	B-FUNC
to	O
dipeptidyl	O
-	O
peptide	O
receptors	O
.	O

Antibody	B-FUNC
responses	O
in	O
seropositive	O
camels	O
were	O
enhancedby	O
the	O
vaccine	O
;	O
these	O
camels	O
had	O
a	O
higher	O
average	O
age	O
than	O
seronegative	O
.	O

We	O
considered	O
an	O
alternative	O
diagnosis	O
of	O
Goodpasture	O
syndrome	O
or	O
anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	B-FUNC
(	O
ANCA	O
)	O
related	O
vasculitis	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
fusion	O
peptide	O
(	O
residues	O
770	O
-	O
788	O
)	O
of	O
an	O
S2	O
glycoprotein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
exposed	O
upon	O
receptor	B-FUNC
binding	I-FUNC
,	O
is	O
crucial	O
for	O
virus	O
entry	O
into	O
the	O
host	O
cell	O
.	O

We	O
have	O
used	O
depth	O
-	O
dependent	O
fluorescence	O
probes	O
,	O
1	O
,	O
6	O
-	O
diphenyl	O
-	O
1	O
,	O
3	O
,	O
5	O
-	O
hexatriene	O
(	O
DPH	O
)	O
and	O
its	O
trimethylammonium	O
derivative	O
(	O
TMA	O
-	O
DPH	O
),	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
peptide	B-FUNC
binding	I-FUNC
along	O
the	O
bilayer	O
normal	O
.	O

We	O
have	O
further	O
evaluated	O
the	O
effect	O
of	O
membrane	O
cholesterol	O
on	O
the	O
binding	B-FUNC
and	O
organization	O
of	O
the	O
peptide	O
and	O
the	O
impact	O
of	O
peptide	B-FUNC
binding	I-FUNC
on	O
the	O
depth	O
-	O
dependent	O
physical	O
properties	O
of	O
the	O
membrane	O
at	O
various	O
cholesterol	O
concentrations	O
.	O

Our	O
results	O
clearly	O
demonstrate	O
that	O
the	O
membrane	O
cholesterol	O
alters	O
the	O
oligomeric	O
status	O
of	O
the	O
membrane	O
-	O
bound	O
peptide	O
and	O
the	O
effect	O
of	O
peptide	B-FUNC
binding	I-FUNC
on	O
the	O
depth	O
-	O
dependent	O
membrane	O
organization	O
and	O
dynamics	O
.	O

PLpro	O
also	O
functions	O
as	O
both	O
a	O
deubiquitinating	O
(	O
DUB	O
)	O
and	O
deISGylating	O
(	O
deISG	O
)	O
enzyme	O
and	O
removes	O
ubiquitin	B-FUNC
(	O
Ub	O
)	O
and	O
interferon	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
from	O
cellular	O
proteins	O
.	O

TITLE	O
:	O
Repeated	O
and	O
progressive	O
rhabdomyolysis	O
due	O
to	O
a	O
novel	O
carnitine	B-FUNC
palmitoyltransferase	I-FUNC
II	I-FUNC
gene	O
variant	O
in	O
an	O
adult	O
male	O
:	O
A	O
case	O
report	O
.	O

Carnitine	O
palmitoyltransferase	O
(	O
CPT	B-FUNC
)	O
II	O
deficiency	O
could	O
be	O
a	O
rare	O
etiology	O
of	O
repetitive	O
nontraumatic	O
rhabdomyolysis	O
,	O
and	O
several	O
mutations	O
of	O
CPT	B-FUNC
II	O
have	O
been	O
reported	O
.	O

WES	O
conducted	O
in	O
the	O
patient	O
and	O
his	O
mother	O
revealed	O
2	O
novel	O
mutations	O
of	O
CPT	B-FUNC
II	O
(	O
c	O
.	O
482G	O
>	O
A	O
and	O
c	O
.	O
1493G	O
>	O
T	O
)	O
in	O
this	O
patient	O
.	O

Here	O
,	O
at	O
the	O
molecular	O
level	O
,	O
we	O
found	O
that	O
all	O
purified	O
bat	O
CD26s	O
(	O
bCD26s	O
)	O
from	O
a	O
diverse	O
range	O
of	O
species	O
interact	O
with	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
,	O
with	O
equilibrium	O
dissociation	O
constant	O
values	O
ranging	O
from	O
several	O
to	O
hundreds	O
at	O
the	O
micromolar	O
level	O
.	O

Further	O
structural	O
analysis	O
indicated	O
that	O
in	O
the	O
bat	O
receptor	O
,	O
compared	O
to	O
the	O
human	O
receptor	O
,	O
substitutions	O
of	O
key	O
residues	O
and	O
their	O
adjacent	O
amino	O
acids	O
leads	O
to	O
decreased	O
binding	B-FUNC
affinity	O
to	O
the	O
MERS	O
-	O
RBD	O
.	O

A	O
selective	O
N	O
protein	O
variant	O
carrying	O
point	O
mutations	O
in	O
these	O
two	O
regions	O
fails	O
to	O
bind	B-FUNC
nsp3	O

We	O
retrospectively	O
reviewed	O
data	O
from	O
60	O
children	O
(	O
median	O
age	O
of	O
6	O
.	O
2	O
months	O
,	O
range	O
0	O
.	O
6	O
-	O
70	O
.	O
9	O
)	O
hospitalized	O
for	O
acute	O
respiratory	O
symptoms	O
,	O
with	O
HBoV	O
detected	O
from	O
a	O
respiratory	O
sample	O
,	O
using	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
for	O
14	O
respiratory	O
viruses	O
(	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	O
virus	O
A	O
and	O
B	O
,	O
human	O
coronavirus	O
OC43	O
,	O
229E	O
,	O
NL	O
-	O
63	O
and	O
HUK1	O
,	O
adenovirus	O
,	O
rhinovirus	O
,	O
parainfluenza	O
virus1	O
-	O
3	O
,	O
and	O
human	O
metapneumovirus	O
).	O

Among	O
the	O
1084	O
horse	O
sera	B-FUNC
,	O
seropositivity	O
varied	O
from	O
25	O
.	O
9	O
%	O
(	O
young	O
horses	O
)	O
to	O
82	O
.	O
8	O
%	O
(	O
adult	O
horses	O
)	O
in	O
Dutch	O
horse	O
populations	O
.	O

Further	O
,	O
sera	B-FUNC
of	O
Icelandic	O
horses	O
were	O
included	O
in	O
this	O
study	O
and	O
a	O
significant	O
number	O
of	O
sera	B-FUNC
(	O
62	O
%)	O
were	O
found	O
to	O
be	O
positive	O
.	O

Using	O
receptor	O
-	O
blocking	O
antibodies	O
,	O
we	O
show	O
that	O
infection	O
with	O
the	O
PDF2180	O
spike	O
does	O
not	O
require	O
MERS	O
-	O
CoV	O
receptor	O
DPP4	O
and	O
antibodies	O
developed	O
against	O
the	O
MERS	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
S2	O
portion	O
are	O
ineffective	O
in	O
neutralizing	O
the	O
PDF2180	O
chimera	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
exogenous	O
trypsin	O
also	O
rescues	O
HKU5	O
-	O
CoV	O
,	O
a	O
second	O
bat	O
group	O
2c	O
CoV	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
proteolytic	O
cleavage	O
of	O
the	O
spike	O
,	O
not	O
receptor	B-FUNC
binding	I-FUNC
,	O
is	O
the	O
primary	O
infection	O
barrier	O
for	O
these	O
two	O
group	O
2c	O
CoVs	O
.	O

Coupled	O
with	O
receptor	B-FUNC
binding	I-FUNC
,	O
proteolytic	O
activation	O
offers	O
a	O
new	O
parameter	O
to	O
evaluate	O
the	O
emergence	O
potential	O
of	O
bat	O
CoVs	O
and	O
offers	O
a	O
means	O
to	O
recover	O
previously	O
unrecoverable	O
zoonotic	O
CoV	O
strains	O
.	O

TITLE	O
:	O
Discovery	O
of	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
derivatives	O
as	O
dual	O
allosteric	O
HIV	O
-	O
1	O
Integrase	O
and	O
Reverse	O
Transcriptase	B-FUNC
associated	O
Ribonuclease	O
H	O
inhibitors	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
5	O
,	O
6	O
-	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
(	O
DHICA	O
)	O
derivatives	O
on	O
both	O
HIV	O
-	O
1	O
Integrase	O
(	O
IN	O
)	O
and	O
Reverse	O
Transcriptase	B-FUNC
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
activities	O
.	O

TITLE	O
:	O
Molecular	O
Mechanism	O
for	O
Antibody	B-FUNC
-	O
Dependent	O
Enhancement	O
of	O
Coronavirus	O
Entry	O
.	O

ABSTRACT	O
:	O
Antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
viral	O
entry	O
has	O
been	O
a	O
major	O
concern	O
for	O
epidemiology	O
,	O
vaccine	O
development	O
,	O
and	O
antibody	B-FUNC
-	O
based	O
drug	O
therapy	O
.	O

Coronavirus	O
spike	O
protein	O
mediates	O
viral	O
entry	O
into	O
cells	O
by	O
first	O
binding	B-FUNC
to	O
a	O
receptor	O
on	O
the	O
host	O
cell	O
surface	O
and	O
then	O
fusing	O
viral	O
and	O
host	O
membranes	O
.	O

Our	O
results	O
showed	O
that	O
MAb	O
binds	B-FUNC
to	O
the	O
virus	O
surface	O
spike	O
,	O
allowing	O
it	O
to	O
undergo	O
conformational	O
changes	O
and	O
become	O
prone	O
to	O
proteolytic	O
activation	O
.	O

Meanwhile	O
,	O
MAb	O
binds	B-FUNC
to	O
cell	O
surface	O
IgG	O
Fc	O
receptor	O
,	O
guiding	O
viral	O
entry	O
through	O
canonical	O
viral	O
-	O
receptor	O
-	O
dependent	O
pathways	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
antibody	B-FUNC
/	O
Fc	O
-	O
receptor	O
complex	O
functionally	O
mimics	O
viral	O
receptor	O
in	O
mediating	O
viral	O
entry	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
molecular	O
mechanism	O
for	O
antibody	B-FUNC
-	O
enhanced	O
viral	O
entry	O
and	O
can	O
guide	O
future	O
vaccination	O
and	O
antiviral	O
strategies	O
.	O

Using	O
a	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
,	O
miR	O
-	O
142a	O
-	O
3p	O
was	O
found	O
to	O
bind	B-FUNC
directly	O
bound	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
Rab3a	O
mRNA	O
and	O
downregulate	O
its	O
expression	O
.	O

Both	O
organs	O
were	O
found	O
to	O
upregulate	O
mRNA	O
expression	O
of	O
the	O
inflammatory	O
triad	O
of	O
cytokines	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
TNF	O
-	O
	O
in	O
FIP	O
.	O

The	O
enantiomerically	O
pure	B-FUNC
6	O
'-	O
fluorinated	O
-	O
5	O
'-	O
homoaristeromycin	O
analogues	O
3a	O
-	O
e	O
were	O
synthesized	O
via	O
the	O
electrophilic	O
fluorination	O
of	O
the	O
silyl	O
enol	O
ether	O
with	O
Selectfluor	O
,	O
using	O
a	O
base	O
-	O
build	O
up	O
approach	O
as	O
the	O
key	O
steps	O
.	O

The	O
vaccine	O
elicited	O
a	O
specific	O
S1	O
-	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
response	O
,	O
which	O
was	O
detected	O
in	O
the	O
sera	B-FUNC
of	O
the	O
vaccinated	O
mice	O
at	O
weeks	O
4	O
and	O
6	O
from	O
the	O
onset	O
of	O
the	O
first	O
immunization	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
amount	O
of	O
Th1	O
-	O
related	O
cytokines	O
(	O
interferon	O
-	O
	O
and	O
interleukin	O
[	O
IL	O
]	O
12	O
),	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
Th2	O
-	O
related	O
cytokine	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
in	O
splenocyte	O
cell	O
culture	O
of	O
the	O
vaccinated	O
group	O
compared	O
with	O
the	O
control	O
groups	O
.	O

We	O
postulated	O
that	O
the	O
effect	O
of	O
these	O
residues	O
in	O
enteric	O
tropism	O
may	O
be	O
mediated	O
by	O
the	O
modification	O
of	O
both	O
glycosaminoglycan	B-FUNC
binding	I-FUNC
and	O
S	O
protein	O
structure	O
.	O

Furthermore	O
,	O
as	O
they	O
can	O
adapt	O
fast	B-FUNC
and	O
cross	O
the	O
species	O
barrier	O
,	O
some	O
of	O
these	O
pathogens	O
,	O
like	O
influenza	O
A	O
and	O
SARS	O
-	O
CoV	O
,	O
have	O
occasionally	O
caused	O
epidemics	O
or	O
pandemics	O
,	O
and	O
were	O
associated	O
with	O
more	O
serious	O
clinical	O
diseases	O
and	O
even	O
mortality	O
.	O

To	O
find	O
small	O
molecules	O
with	O
anti	O
-	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
properties	O
,	O
we	O
utilized	O
a	O
virtual	O
screening	O
technique	O
to	O
identify	O
the	O
active	O
site	O
on	O
the	O
viral	O
protease	O
for	O
the	O
binding	B-FUNC
of	O
the	O
available	O
natural	O
compounds	O
.	O

ABSTRACT	O
:	O
Interleukin	O
-	O
11	O
(	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
),	O
a	O
well	O
-	O
known	O
anti	O
-	O
inflammatory	O
factor	O
,	O
provides	O
protection	O
from	O
intestinal	O
epithelium	O
damage	O
caused	O
by	O
physical	O
or	O
chemical	O
factors	O
.	O

However	O
,	O
little	O
is	O
known	O
of	O
the	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
during	O
viral	O
infections	O
.	O

In	O
this	O
study	O
,	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
expression	O
at	O
mRNA	O
and	O
protein	O
levels	O
were	O
found	O
to	O
be	O
high	O
in	O
Vero	O
cells	O
and	O
the	O
jejunum	O
of	O
piglets	O
during	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
,	O
while	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
expression	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
viral	O
infection	O
.	O

Pretreatment	O
with	O
recombinant	O
porcine	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
(	O
pIL	O
-	O
11	O
)	O
was	O
found	O
to	O
suppress	O
PEDV	O
replication	O
in	O
Vero	O
E6	O
cells	O
,	O
while	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
knockdown	O
promoted	O
viral	O
infection	O
.	O

Furthermore	O
,	O
pIL	O
-	O
11	O
was	O
found	O
to	O
inhibit	O
viral	O
infection	O
by	O
preventing	O
PEDV	O
-	O
mediated	O
apoptosis	O
of	O
cells	O
by	O
activating	O
the	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
/	O
STAT3	O
signaling	O
pathway	O
.	O

The	O
potential	O
of	O
IL	B-FUNC
-	I-FUNC
11	I-FUNC
to	O
be	O
used	O
as	O
a	O
novel	O
therapeutic	O
against	O
devastating	O
viral	O
diarrhea	O
in	O
piglets	O
deserves	O
more	O
attention	O
and	O
study	O
.	O

MALAT1	O
interacted	O
with	O
miR	O
-	O
425	O
and	O
protected	O
phosphatase	B-FUNC
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
expression	O
in	O
A549	O
and	O
HFL	O
-	O
1	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
methods	O
for	O
in	O
vitro	O
serial	O
passaging	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
select	O
for	O
mutations	O
which	O
increase	O
replication	O
on	O
semi	O
-	O
permissive	O
cell	O
lines	O
as	O
described	O
in	O
Letko	O
et	O
al	O
.,	O
Cell	O
Rep	B-FUNC
24	O
,	O
1730	O
-	O
1737	O
,	O
2018	O
.	O

The	O
virus	O
can	O
bind	B-FUNC
host	O
-	O
cell	O
carbohydrates	O
as	O
well	O
as	O
proteinaceous	O
receptors	O
.	O

ABSTRACT	O
:	O
Three	O
-	O
dimensional	O
structures	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
bound	O
to	O
cellular	O
receptor	O
and	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
have	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
providing	O
structural	O
information	O
about	O
receptor	O
recognition	O
and	O
neutralizing	O
mechanisms	O
of	O
mAbs	O
at	O
the	O
atomic	O
level	O
.	O

Though	O
the	O
gold	O
standard	O
for	O
diagnosing	O
MERS	O
-	O
CoV	O
infection	O
in	O
humans	O
is	O
still	O
nucleic	O
acid	O
amplification	O
test	O
(	O
NAAT	B-FUNC
)	O
of	O
the	O
up	O
-	O
E	O
region	O
,	O
an	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
could	O
also	O
be	O
of	O
use	O
for	O
early	O
diagnosis	O
in	O
less	O
developed	O
locations	O
.	O

In	O
the	O
present	O
method	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
guide	O
to	O
perform	O
a	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
capture	O
ELISA	O
using	O
two	O
NP	O
-	O
specific	O
monoclonal	O
antibodies	O
is	O
provided	O
for	O
readers	O
to	O
develop	O
their	O
in	O
-	O
house	O
workflow	O
or	O
diagnostic	O
kit	B-FUNC
for	O
clinical	O
use	O
and	O
for	O
mass	O
-	O
screening	O
project	O
of	O
animals	O
(	O
e	O
.	O
g	O
.,	O
dromedaries	O
and	O
bats	O
)	O
to	O
better	O
understand	O
the	O
spread	O
and	O
evolution	O
of	O
the	O
virus	O
.	O

It	O
is	O
a	O
highly	O
specific	O
and	O
sensitive	O
assay	O
for	O
evaluating	O
virus	O
-	O
specific	O
neutralizing	O
antibodies	O
(	O
nAbs	O
)	O
in	O
human	O
and	O
animal	O
sera	B-FUNC
.	O

TITLE	O
:	O
Generation	O
of	O
MERS	O
-	O
CoV	O
Pseudotyped	O
Viral	O
Particles	O
for	O
the	O
Evaluation	O
of	O
Neutralizing	O
Antibodies	O
in	O
Mammalian	O
Sera	B-FUNC
.	O

This	O
platform	O
is	O
optimized	O
to	O
generate	O
high	O
titer	O
of	O
MERSpp	O
and	O
to	O
test	O
sera	B-FUNC
from	O
different	O
mammalian	O
species	O
.	O

ABSTRACT	O
:	O
Indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
enables	O
detection	O
and	O
quantification	O
of	O
antigen	O
-	O
specific	O
antibodies	O
in	O
biological	O
samples	O
such	O
as	O
human	O
or	O
animal	O
sera	B-FUNC
.	O

SADS	O
-	O
CoV	O
also	O
blocked	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
and	O
NF	O
-	O
B	O
.	O
Furthermore	O
,	O
SADS	O
-	O
CoV	O
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
IFN	O
-	O
	O
promoter	O
stimulated	O
by	O
IRF3	O
,	O
TBK1	B-FUNC
and	O
IKK	O
,	O
but	O
counteracted	O
its	O
activation	O
induced	O
by	O
IPS	O
-	O
1	O
and	O
RIG	O
-	O
I	O
.	O
Collectively	O
,	O
this	O
study	O
is	O
the	O
first	O
investigation	O
that	O
shows	O
interactions	O
between	O
SADS	O
-	O
CoV	O
and	O
the	O
host	O
innate	O
immunity	O
,	O
which	O
provides	O
information	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
SASD	O
-	O
CoV	O
infection	O
.	O

We	O
examined	O
the	O
pathogenic	O
effects	O
of	O
the	O
viruses	O
in	O
chicken	O
embryos	O
and	O
the	O
size	O
and	O
morphology	O
of	O
the	O
virus	O
particles	O
,	O
performed	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	O
gene	O
and	O
complete	O
genomic	O
sequences	O
,	O
and	O
examined	O
the	O
antibody	B-FUNC
responses	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
Structures	O
and	O
exoribonuclease	B-FUNC
activity	I-FUNC
fonctions	O
in	O
arenavirus	O
and	O
coronavirus	O
.	O

Indeed	O
,	O
the	O
exoribonuclease	B-FUNC
activity	I-FUNC
carried	O
by	O
the	O
arenavirus	O
nucleoprotein	O
seems	O
to	O
counteract	O
the	O
innate	O
immunity	O
antiviral	O
response	O
while	O
the	O
exoribonuclease	B-FUNC
activity	I-FUNC
carried	O
by	O
the	O
coronavirus	O
nsp14	O
protein	O
is	O
likely	O
involved	O
in	O
a	O
unique	O
RNA	O
repair	O
mechanism	O
.	O

TITLE	O
:	O
Isolation	O
and	O
Identification	O
of	O
Porcine	O
Deltacoronavirus	O
and	O
Alteration	O
of	O
Immunoglobulin	B-FUNC
Transport	O
Receptors	O
in	O
the	O
Intestinal	O
Mucosa	O
of	O
PDCoV	O
-	O
Infected	O
Piglets	O
.	O

The	O
neonatal	O
Fc	O
receptor	O
(	O
FcRn	O
)	O
and	O
polymeric	O
immunoglobulin	B-FUNC
receptor	O
(	O
pIgR	O
)	O
are	O
crucial	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
receptors	O
for	O
the	O
transcytosis	O
ofimmunoglobulin	O
G	O
(	O
IgG	O
),	O
IgA	O
,	O
or	O
IgM	O
.	O
Importantly	O
,	O
CHN	O
-	O
JS	O
-	O
2017	O
infected	O
five	O
-	O
day	O
-	O
old	O
piglets	O
could	O
significantly	O
down	O
-	O
regulate	O
the	O
expression	O
of	O
FcRn	O
,	O
pIgR	O
,	O
and	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
in	O
the	O
intestinal	O
mucosa	O
.	O

At	O
farm	O
A	O
,	O
20	O
calves	O
were	O
selected	O
and	O
sampled	O
weekly	O
for	O
12	O
weeks	O
(	O
184	O
samples	O
);	O
at	O
farm	O
B	O
,	O
10	O
calves	O
were	O
selected	O
and	O
sampled	O
for	O
five	O
weeks	O
(	O
50	O
samples	O
);	O
and	O
at	O
the	O
rest	B-FUNC
of	O
the	O
46	O
farms	O
,	O
88	O
calves	O
were	O
sampled	O
once	O
.	O

This	O
implies	O
that	O
the	O
mutation	O
in	O
residue	O
506	O
-	O
509	O
,	O
529	O
,	O
and	O
534	O
of	O
S	O
is	O
critical	O
to	O
generate	O
neutralization	O
escape	O
variants	O
of	O
MERS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
all	O
five	O
neutralizing	O
mAbs	O
have	O
binding	B-FUNC
affinity	O
to	O
RBD	O
,	O
although	O
most	O
mAbs	O
generated	O
by	O
RBD	O
did	O
not	O
have	O
neutralizing	O
activity	O
.	O

TITLE	O
:	O
Specificity	O
,	O
kinetics	O
and	O
longevity	O
of	O
antibody	B-FUNC
responses	O
to	O
avian	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
The	O
long	O
-	O
term	O
dynamics	O
of	O
antibody	B-FUNC
responses	O
in	O
patients	O
with	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
are	O
not	O
well	O
understood	O
.	O

A	O
(	O
H7N9	O
)	O
virus	O
-	O
specific	O
antibody	B-FUNC
responses	O
were	O
assessed	O
by	O
hemagglutination	O
inhibition	O
(	O
HAI	O
)	O
and	O
neutralization	O
(	O
NT	O
)	O
assays	O
.	O

A	O
random	O
intercept	O
model	O
was	O
used	O
to	O
fit	O
a	O
curve	O
to	O
HAI	O
antibody	B-FUNC
responses	O
over	O
time	O
.	O

HAI	O
antibody	B-FUNC
responses	O
were	O
compared	O
by	O
clinical	O
severity	O
.	O

HAI	O
antibody	B-FUNC
responses	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
experienced	O
severe	O
disease	O
,	O
including	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
compared	O
with	O
patients	O
who	O
experienced	O
less	O
severe	O
illness	O
.	O

Patients	O
with	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
who	O
survived	O
severe	O
disease	O
mounted	O
higher	O
antibody	B-FUNC
responses	O
that	O
persisted	O
for	O
longer	O
periods	O
compared	O
with	O
those	O
that	O
experienced	O
moderate	O
disease	O
.	O

RESULTS	O
:	O
Of	O
67	O
patients	O
with	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
,	O
HAI	O
antibody	B-FUNC
titers	O
reached	O
40	O
on	O
average	O
11	O
days	O
after	O
illness	O
onset	O
and	O
peaked	O
at	O
a	O
titer	O
of	O
290	O
after	O
three	O
months	O
,	O
and	O
average	O
titers	O
of	O
	O
80	O
and	O
	O
40	O
were	O
present	O
until	O
11	O
months	O
and	O
22	O
months	O
respectively	O
.	O

HAI	O
antibody	B-FUNC
responses	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
experienced	O
severe	O
disease	O
,	O
including	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
compared	O
with	O
patients	O
who	O
experienced	O
less	O
severe	O
illness	O
.	O

Herein	O
we	O
investigated	O
the	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
of	O
newly	O
synthesized	O
sixteen	O
halogenated	O
triazole	O
compounds	O
through	O
the	O
inhibition	O
of	O
helicase	B-FUNC
activity	I-FUNC
using	O
the	O
FRET	O
assay	O
.	O

The	O
antibody	B-FUNC
designated	O
4E88	O
had	O
highest	O
binding	B-FUNC
affinity	O
with	O
the	O
N	O
protein	O
and	O
was	O
chosen	O
for	O
in	O
-	O
depth	O
examination	O
.	O

Here	O
,	O
we	O
asked	O
whether	O
naturally	O
-	O
occurring	O
polymorphisms	O
in	O
DPP4	O
,	O
that	O
alter	O
amino	O
acid	O
residues	O
required	O
for	O
MERS	O
-	O
CoV	O
S	O
binding	B-FUNC
,	O
influence	O
cellular	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
By	O
screening	O
of	O
public	O
databases	O
,	O
we	O
identified	O
fourteen	O
such	O
polymorphisms	O
.	O

Four	O
polymorphisms	O
(	O
K267E	O
,	O
K267N	O
,	O
A291P	O
and	O
346	O
-	O
348	O
)	O
strongly	O
reduced	O
binding	B-FUNC
of	O
MERS	O
-	O
CoV	O
S	O
to	O
DPP4	O
and	O
S	O
protein	O
-	O
driven	O
host	O
cell	O
entry	O
,	O
as	O
determined	O
using	O
soluble	O
S	O
protein	O
and	O
S	O
protein	O
bearing	O
rhabdoviral	O
vectors	O
,	O
respectively	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
application	O
of	O
Gram	O
-	O
positive	O
enhancer	O
matrix	O
(	O
GEM	O
)	O
particles	O
as	O
a	O
bacterial	O
vector	O
displaying	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
is	O
a	O
very	O
promising	O
MERS	O
vaccine	O
candidate	O
that	O
is	O
capable	O
of	O
producing	O
potential	O
neutralization	O
antibodies	O
.	O

The	O
results	O
show	O
that	O
the	O
rabies	O
virus	O
vector	O
-	O
based	O
vaccine	O
can	O
induce	O
remarkably	O
earlier	O
antibody	B-FUNC
response	O
and	O
higher	O
levels	O
of	O
cellular	O
immunity	O
than	O
the	O
GEM	O
particles	O
vector	O
.	O

However	O
,	O
the	O
GEM	O
particles	O
vector	O
-	O
based	O
vaccine	O
candidate	O
can	O
induce	O
remarkably	O
higher	O
antibody	B-FUNC
response	O
,	O
even	O
at	O
a	O
very	O
low	O
dose	O
of	O
1	O
g	O
.	O

Previous	O
published	O
serological	O
studies	O
showed	O
that	O
sera	B-FUNC
of	O
Bactrian	O
camels	O
were	O
all	O
negative	O
for	O
MERS	O
-	O
CoV	O
antibodies	O
.	O

All	O
the	O
12	O
serum	O
samples	O
that	O
were	O
positive	O
with	O
the	O
neutralization	O
antibody	B-FUNC
test	O
were	O
also	O
positive	O
for	O
the	O
S	O
-	O
ELISA	O
.	O

All	O
the	O
6	O
serum	O
samples	O
that	O
were	O
positive	O
for	O
the	O
S	O
-	O
ELISA	O
were	O
also	O
positive	O
with	O
the	O
neutralization	O
antibody	B-FUNC
test	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
the	O
antibody	B-FUNC
levels	O
detected	O
by	O
S	O
-	O
ELISA	O
and	O
neutralizing	O
antibody	B-FUNC
titers	O
,	O
with	O
a	O
Spearman	O
coefficient	O
of	O
0	O
.	O
6262	O
(	O

This	O
is	O
the	O
first	O
study	O
demonstrating	O
that	O
miRNAs	O
regulate	O
IBV	O
replication	O
by	O
regulating	O
the	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
(	O
DUBs	O
).	O

Results	O
indicated	O
that	O
degree	O
of	O
intestinal	O
epithelial	O
damage	O
differed	O
among	O
calves	O
grouped	O
by	O
the	O
etiologic	O
agent	O
of	O
diarrhea	O
and	O
that	O
such	O
damage	O
might	O
have	O
been	O
more	O
severe	O
in	O
calves	O
with	O
diarrhea	O
caused	O
by	O
K99	O
RESULTS	O
:	O
Across	O
the	O
3	O
time	O
points	O
at	O
which	O
blood	O
samples	O
were	O
obtained	O
and	O
evaluated	O
,	O
the	O
groups	O
of	O
calves	O
with	O
diarrhea	O
generally	O
had	O
markedly	O
higher	O
mean	O
serum	O
concentrations	O
of	O
L	O
-	O
FABP	O
,	O
TFF	O
-	O
3	O
,	O
IAP	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
LP	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

However	O
,	O
the	O
external	O
subdomain	O
of	O
Spike	O
'	O
s	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
2019	O
-	O
nCoV	O
shares	O
only	O
40	O
%	O
amino	O
acid	O
identity	O
with	O
other	O
SARS	O
-	O
related	O
coronaviruses	O
.	O

Fast	B-FUNC
unconstrained	O
Bayesian	O
approximation	O
analysis	O
shows	O
that	O
the	O
nucleocapsid	O
and	O
the	O
spike	O
glycoprotein	O
have	O
some	O
sites	O
under	O
positive	O
pressure	O
,	O
whereas	O
homology	O
modeling	O
revealed	O
some	O
molecular	O
and	O
structural	O
differences	O
between	O
the	O
viruses	O
.	O

One	O
unique	O
amino	O
acid	O
mutation	O
at	O
I507	O
L	O
in	O
spike	O
protein	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
was	O
detected	O
,	O
which	O
segregated	O
this	O
subgenotype	O
C3	O
from	O
other	O
known	O
subgenotypes	O
.	O

Since	O
the	O
SARS	O
-	O
CoV	O
outbreak	O
in	O
2002	O
,	O
extensive	O
structural	O
analyses	O
have	O
revealed	O
key	O
atomic	O
-	O
level	O
interactions	O
between	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
and	O
its	O
host	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
regulate	O
both	O
the	O
cross	O
-	O
species	O
and	O
human	O
-	O
to	O
-	O
human	O
transmissions	O
of	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
analyzed	O
the	O
potential	O
receptor	O
usage	O
by	O
2019	O
-	O
nCoV	O
,	O
based	O
on	O
the	O
rich	O
knowledge	O
about	O
SARS	O
-	O
CoV	O
and	O
the	O
newly	O
released	O
sequence	O
of	O
2019	O
-	O
nCoV	O
.	O
First	O
,	O
the	O
sequence	O
of	O
2019	O
-	O
nCoV	O
RBD	O
,	O
including	O
its	O
receptor	O
-	O
binding	B-FUNC
motif	O
(	O
RBM	O
)	O
that	O
directly	O
contacts	O
ACE2	O
,	O
is	O
similar	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
strongly	O
suggesting	O
that	O
2019	O
-	O
nCoV	O
uses	O
ACE2	O
as	O
its	O
receptor	O
.	O

Third	O
,	O
several	O
other	O
critical	O
residues	O
in	O
2019	O
-	O
nCoV	O
RBM	O
(	O
particularly	O
Asn501	O
)	O
are	O
compatible	O
with	O
,	O
but	O
not	O
ideal	O
for	O
,	O
binding	B-FUNC
human	O
ACE2	O
,	O
suggesting	O
that	O
2019	O
-	O
nCoV	O
has	O
acquired	O
some	O
capacity	O
for	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
tentative	O
receptor	O
-	O
binding	B-FUNC
domain	O
resembles	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
indicating	O
that	O
these	O
viruses	O
might	O
use	O
the	O
same	O
receptor	O
.	O

Archived	O
human	O
sera	B-FUNC
(	O
7461	O
)	O
collected	O
between	O
2011	O
and	O
2016	O
from	O
healthy	O
adult	O
blood	O
donors	O
from	O
50	O
different	O
nationalities	O
in	O
the	O
western	O
part	O
of	O
Saudi	O
Arabia	O
were	O
obtained	O
for	O
MERS	O
-	O
CoV	O
seroprevalence	O
investigation	O
.	O

Out	O
of	O
7461	O
samples	O
,	O
174	O
sera	B-FUNC
from	O
individuals	O
with	O
18	O
different	O
nationalities	O
were	O
ELISA	O
positive	O
(	O
2	O
.	O
3	O
%,	O
95	O
%	O
CI	O
2	O
.	O
0	O
-	O
2	O
.	O
7	O
).	O

RESULTS	O
:	O
Out	O
of	O
7461	O
samples	O
,	O
174	O
sera	B-FUNC
from	O
individuals	O
with	O
18	O
different	O
nationalities	O
were	O
ELISA	O
positive	O
(	O
2	O
.	O
3	O
%,	O
95	O
%	O
CI	O
2	O
.	O
0	O
-	O
2	O
.	O
7	O
).	O

TITLE	O
:	O
Genomic	O
characterisation	O
and	O
epidemiology	O
of	O
2019	O
novel	O
coronavirus	O
:	O
implications	O
for	O
virus	O
origins	O
and	O
receptor	B-FUNC
binding	I-FUNC
.	O

Homology	O
modelling	O
was	O
done	O
to	O
explore	O
the	O
likely	O
receptor	O
-	O
binding	B-FUNC
properties	O
of	O
the	O
virus	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
2019	O
-	O
nCoV	O
fell	O
within	O
the	O
subgenus	O
Sarbecovirus	O
of	O
the	O
genus	O
Betacoronavirus	O
,	O
with	O
a	O
relatively	O
long	O
branch	O
length	O
to	O
its	O
closest	O
relatives	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
,	O
and	O
was	O
genetically	O
distinct	O
from	O
SARS	O
-	O
CoV	O
.	O
Notably	O
,	O
homology	O
modelling	O
revealed	O
that	O
2019	O
-	O
nCoV	O
had	O
a	O
similar	O
receptor	O
-	O
binding	B-FUNC
domain	O
structure	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
despite	O
amino	O
acid	O
variation	O
at	O
some	O
key	O
residues	O
.	O

Viral	O
activate	O
MCs	O
release	O
early	O
inflammatory	O
chemical	O
copounds	O
including	O
histamine	O
and	O
protease	O
;	O
while	O
late	O
activation	O
provoke	O
the	O
generation	O
of	O
pro	O
-	O
inflammatory	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
family	O
members	O
including	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
.	O

Here	O
,	O
we	O
propose	O
for	O
the	O
first	O
time	O
that	O
inflammation	O
by	O
coronavirus	O
maybe	O
inhibited	O
by	O
anti	O
-	O
inflammatory	O
cytokines	O
belonging	O
to	O
the	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
family	O
members	O
.	O

Here	O
,	O
we	O
focus	O
on	O
advances	O
in	O
research	O
and	O
development	O
of	O
fast	B-FUNC
diagnosis	O
methods	O
,	O
as	O
well	O
as	O
potential	O
prophylactics	O
and	O
therapeutics	O
to	O
prevent	O
or	O
treat	O
2019	O
-	O
nCoV	O
infection	O
.	O

Phylogenetic	O
analysis	O
indicates	O
that	O
2019	O
-	O
nCoV	O
is	O
close	O
to	O
coronaviruses	O
(	O
CoVs	O
)	O
circulating	O
in	O
Rhinolophus	O
(	O
Horseshoe	O
bats	O
),	O
such	O
as	O
98	O
.	O
7	O
%	O
nucleotide	O
identity	O
to	O
partial	O
RdRp	B-FUNC
gene	O
of	O
bat	O
coronavirus	O
strain	O
BtCoV	O
/	O
4991	O
(	O
GenBank	O
KP876546	O
,	O
370	O
nt	O
sequence	O
of	O
RdRp	B-FUNC
and	O
lack	O
of	O
other	O
genome	O
sequence	O
)	O
and	O
87	O
.	O
9	O
%	O
nucleotide	O
identity	O
to	O
bat	O
coronavirus	O
strain	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
.	O

Also	O
,	O
during	O
simulations	O
,	O
the	O
CTL	O
epitopes	O
were	O
observed	O
to	O
be	O
binding	B-FUNC
MHC	O
class	O
I	O
peptide	O
-	O
binding	B-FUNC
grooves	O
via	O
multiple	O
contacts	O
,	O
with	O
continuous	O
hydrogen	O
bonds	O
and	O
salt	O
bridge	O
anchors	O
,	O
indicating	O
their	O
potential	O
in	O
generating	O
immune	O
responses	O
.	O

Other	O
key	O
drug	O
targets	O
,	O
including	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
coronavirus	O
main	O
proteinase	B-FUNC
(	O
3CLpro	O
),	O
share	O
a	O
strikingly	O
high	O
(>	O
95	O
%)	O
homology	O
to	O
SARS	O
-	O
CoV	O
.	O
Herein	O
,	O
we	O
suggest	O
four	O
potential	O
drug	O
candidates	O
(	O
an	O
ACE2	O
-	O
based	O
peptide	O
,	O
remdesivir	O
,	O
3CLpro	O
-	O
1	O
and	O
a	O
novel	O
vinylsulfone	O
protease	O
inhibitor	O
)	O
that	O
could	O
be	O
used	O
to	O
treat	O
patients	O
suffering	O
with	O
the	O
2019	O
-	O
nCoV	O
.	O
We	O
also	O
summarize	O
previous	O
efforts	O
into	O
drugging	O
these	O
targets	O
and	O
hope	O
to	O
help	O
in	O
the	O
development	O
of	O
broad	O
-	O
spectrum	O
anti	O
-	O
coronaviral	O
agents	O
for	O
future	O
epidemics	O
.	O

GGO	O
with	O
consolidation	O
was	O
present	O
in	O
30	O
of	O
51	O
(	O
59	O
%)	O
patients	O
,	O
and	O
pure	B-FUNC
consolidation	O
was	O
present	O
in	O
28	O
of	O
51	O
(	O
55	O
%)	O
patients	O
.	O

His	O
background	O
immunological	O
status	O
was	O
complicated	O
because	O
AIHA	O
was	O
mixed	O
-	O
type	O
(	O
warm	O
and	O
cold	O
antibody	B-FUNC
type	O
).	O

The	O
anticomplement	O
antibody	B-FUNC
was	O
positive	O
and	O
his	O
cold	O
hemagglutinin	O
level	O
had	O
increased	O
.	O

Anticardiolipin	O
antibodies	O
were	O
negative	O
:	O
anticardiolipin	O
2GPI	O
antibody	B-FUNC
	O
1	O
.	O
2	O
U	O
/	O
mL	O
(<	O
3	O
.	O
5	O
),	O
anticardiolipin	O
immunoglobulin	B-FUNC
G	O
antibody	B-FUNC
	O
8	O
U	O
/	O
mL	O
(<	O
10	O
),	O
and	O
anticardiolipin	O
immunoglobulin	B-FUNC
M	O
antibody	B-FUNC
	O
5	O
U	O
/	O
mL	O
(<	O
8	O
).	O

Based	O
on	O
the	O
clinical	O
data	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
),	O
as	O
well	O
as	O
the	O
dada	O
from	O
previous	O
clinical	O
studies	O
and	O
the	O
recommendations	O
from	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
),	O
the	O
committee	O
board	O
of	O
the	O
Chinese	O
Society	O
of	O
Extracorporeal	O
Life	O
Support	O
(	O
CSECLS	O
)	O
made	O
this	O
recommendations	O
to	O
guide	O
clinical	O
ECMO	O
application	O
in	O
the	O
patients	O
with	O
NCP	B-FUNC
.	O

Griffithsin	O
(	O
GRFT	O
)	O
is	O
high	O
-	O
mannose	O
oligosaccharide	B-FUNC
binding	I-FUNC
lectin	O
that	O
has	O
shown	O
in	O
vivo	O
broad	O
-	O
spectrum	O
activity	O
against	O
viruses	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
human	O
immunodeficiency	O
virus	O
1	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
Japanese	O
encephalitis	O
virus	O
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
ER	O
Stress	O
Response	O
by	O
the	O
Ion	B-FUNC
Channel	I-FUNC
Activity	I-FUNC
of	O
the	O
Infectious	O
Bronchitis	O
Coronavirus	O
Envelope	O
Protein	O
Modulates	O
Virion	O
Release	O
,	O
Apoptosis	O
,	O
Viral	O
Fitness	O
,	O
and	O
Pathogenesis	O
.	O

First	O
,	O
using	O
small	O
interfering	O
RNAs	O
,	O
we	O
found	O
that	O
TGEV	O
up	O
-	O
regulated	O
FcRn	O
expression	O
via	O
TLR3	O
,	O
TLR9	O
and	O
RIG	O
-	O
I	O
.	O
Moreover	O
,	O
TGEV	O
induced	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
TGF	O
-	O
	O
,	O
and	O
TNF	O
-	O
	O
production	O
.	O

TGF	O
-	O
	O
-	O
stimulated	O
IPEC	O
-	O
J2	O
cells	O
highly	O
up	O
-	O
regulated	O
FcRn	O
expression	O
,	O
while	O
treatment	O
with	O
a	O
JNK	B-FUNC
-	O
specific	O
inhibitor	O
down	O
-	O
regulated	O
the	O
expression	O
.	O

MERS	O
-	O
CoV	O
infection	O
was	O
associated	O
with	O
age	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-FUNC
]	O
=	O
1	O
.	O
06	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
02	O
-	O
1	O
.	O
098	O
],	O
P	O
-	O
value	O
=	O
0	O
.	O
004	O
),	O
male	O
gender	O
(	O
AOR	B-FUNC
=	O
1	O
.	O
617	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
365	O
-	O
1	O
.	O
77	O
],	O
P	O
-	O
value	O
<	O
0	O
.	O
001	O
)	O
and	O
diabetes	O
(	O
AOR	B-FUNC
=	O
1	O
.	O
68	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
346	O
-	O
1	O
.	O
848	O
],	O
P	O
-	O
value	O
=	O
0	O
.	O
002	O
.	O

Immunoglobulin	B-FUNC
G	O
was	O
delivered	O
to	O
some	O
critically	O
ill	O
patients	O
according	O
to	O
their	O
conditions	O
.	O

CoV	O
infection	O
requires	O
spike	O
proteins	O
,	O
which	O
bind	B-FUNC
viruses	O
to	O
host	O
cell	O
receptors	O
and	O
catalyze	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

As	O
this	O
bivalent	O
binding	B-FUNC
may	O
enable	O
broad	O
zoonotic	O
CoV	O
infection	O
,	O
we	O
aimed	O
to	O
identify	O
roles	O
for	O
each	O
receptor	O
in	O
distinct	O
infection	O
stages	O
.	O

Focusing	O
on	O
two	O
betacoronaviruses	O
,	O
murine	O
JHM	O
-	O
CoV	O
and	O
human	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
we	O
found	O
that	O
virus	O
particle	O
binding	B-FUNC
to	O
cells	O
was	O
mediated	O
by	O
sialic	O
acids	O
;	O
however	O
,	O
the	O
transmembrane	O
protein	O
receptors	O
were	O
required	O
for	O
a	O
subsequent	O
virus	O
infection	O
.	O

How	O
to	O
effectively	O
prevent	O
and	O
control	O
NCP	B-FUNC
among	O
children	O
with	O
limited	O
resources	O
is	O
an	O
urgent	O
issue	O
to	O
be	O
explored	O
.	O

Under	O
the	O
unified	O
arrangement	O
of	O
the	O
Xiangya	O
Hospital	O
of	O
Central	O
South	O
University	O
,	O
the	O
Department	O
of	O
Pediatrics	O
has	O
formulated	O
an	O
action	O
plan	O
with	O
Xiangya	O
unique	O
model	O
to	O
prevent	O
and	O
control	O
NCP	B-FUNC
among	O
children	O
according	O
to	O
the	O
current	O
epidemic	O
situation	O
and	O
diagnostic	O
and	O
therapeutic	O
program	O
in	O
China	O
.	O

We	O
studied	O
44	O
mini	O
-	O
bronchoalveolar	O
lavage	O
samples	O
(	O
collected	O
with	O
a	O
double	O
catheter	O
,	O
Combicath	O
	O
kit	B-FUNC
)	O
from	O
patients	O
with	O
mean	O
age	O
in	O
the	O
seventh	O
decade	O
,	O
20	O
from	O
WORI	O
group	O
and	O
24	O
from	O
WRI	O
group	O
,	O
who	O
were	O
hospitalized	O
for	O
acute	O
respiratory	O
failure	O
in	O
Intensive	O
Care	O
Units	O
of	O
two	O
hospitals	O
in	O
the	O
Lisbon	O
area	O
.	O

We	O
here	O
share	O
the	O
therapeutic	O
experiences	O
of	O
NCP	B-FUNC
treatment	O
with	O
literature	O
review	O
.	O

Inappropriate	O
application	O
of	O
antibiotics	O
should	O
be	O
avoided	O
,	O
especially	O
the	O
combination	O
of	O
broad	O
-	O
spectrum	O
antibiotics	O
,	O
for	O
the	O
NCP	B-FUNC
is	O
not	O
often	O
complicated	O
with	O
bacterial	O
infection	O
.	O

ABSTRACT	O
:	O
During	O
a	O
short	O
period	O
of	O
time	O
,	O
the	O
outbreak	O
of	O
pneumonia	O
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
named	O
Novel	O
Coronavirus	O
Pneumonia	O
(	O
NCP	B-FUNC
),	O
was	O
first	O
reported	O
in	O
China	O
,	O
spreading	O
to	O
24	O
countries	O
and	O
regions	O
rapidly	O
.	O

This	O
paper	O
,	O
based	O
on	O
existing	O
guidelines	O
and	O
published	O
researches	O
pertinent	O
to	O
dental	O
infection	O
-	O
control	O
principles	O
and	O
practices	O
,	O
mainly	O
discusses	O
epidemiological	O
characteristics	O
of	O
NCP	B-FUNC
and	O
the	O
features	O
of	O
nosocomial	O
infection	O
in	O
oral	O
healthcare	O
settings	O
,	O
and	O
furthermore	O
provides	O
recommendations	O
on	O
patient	O
'	O
s	O
evaluation	O
,	O
and	O
infection	O
control	O
protocols	O
in	O
department	O
of	O
stomatology	O
under	O
current	O
circumstance	O
..	O

Most	O
NCP	B-FUNC
patients	O
were	O
clinically	O
mild	O
cases	O
.	O

Finally	O
,	O
we	O
drafted	O
the	O
prevention	O
and	O
control	O
strategies	O
and	O
recommendations	O
to	O
make	O
a	O
reference	O
for	O
medical	O
staff	O
of	O
general	O
surgery	O
to	O
fight	O
NCP	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
infected	O
patients	O
by	O
binding	B-FUNC
human	O
ACE2	O
,	O
leading	O
to	O
severe	O
pneumonia	O
and	O
highly	O
mortality	O
rate	O
in	O
patients	O
.	O

The	O
binding	B-FUNC
of	O
COVID	O
-	O
19	O
and	O
ACE2	O
resulted	O
in	O
the	O
exhaustion	O
of	O
ACE2	O
,	O
and	O
then	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	O
receptor	O
pathway	O
was	O
inhibited	O
.	O

The	O
first	O
patient	O
A	O
developed	O
on	O
January	O
22	O
,	O
2020	O
,	O
with	O
a	O
history	O
of	O
residence	O
in	O
Wuhan	O
,	O
and	O
confirmed	O
severe	O
cases	O
of	O
NCP	B-FUNC
on	O
January	O
24	O
,	O
2020	O
;	O
patient	O
B	O
,	O
on	O
January	O
23	O
,	O
2020	O
,	O
diagnosed	O
on	O
January	O
31	O
,	O
severe	O
cases	O
;	O
patient	O
C	O
,	O
asymptomatic	O
,	O
diagnosed	O
on	O
January	O
27	O
;	O
patient	O
D	O
,	O
asymptomatic	O
,	O
diagnosed	O
on	O
January	O
27	O
;	O
patient	O
E	O
,	O
on	O
January	O
24	O
,	O
diagnosed	O
on	O
January	O
28	O
;	O
patient	O
F	O
,	O
asymptomatic	O
,	O
diagnosed	O
on	O
January	O
31	O
;	O
Patient	O
G	O
was	O
asymptomatic	O
and	O
was	O
diagnosed	O
on	O
January	O
31	O
.	O

Except	O
for	O
the	O
discharged	O
cases	O
,	O
5	O
cases	O
were	O
positive	O
for	O
COVID	O
-	O
19	O
specific	O
IgM	O
antibody	B-FUNC
and	O
1	O
case	O
was	O
negative	O
.	O

TITLE	O
:	O
Potent	O
binding	B-FUNC
of	O
2019	O
novel	O
coronavirus	O
spike	O
protein	O
by	O
a	O
SARS	O
coronavirus	O
-	O
specific	O
human	O
monoclonal	O
antibody	B-FUNC
.	O

Considering	O
the	O
relatively	O
high	O
identity	O
of	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
2019	O
-	O
nCoV	O
and	O
SARS	O
-	O
CoV	O
,	O
it	O
is	O
urgent	O
to	O
assess	O
the	O
cross	O
-	O
reactivity	O
of	O
anti	O
-	O
SARS	O
CoV	O
antibodies	O
with	O
2019	O
-	O
nCoV	O
spike	O
protein	O
,	O
which	O
could	O
have	O
important	O
implications	O
for	O
rapid	O
development	O
of	O
vaccines	O
and	O
therapeutic	O
antibodies	O
against	O
2019	O
-	O
nCoV	O
.	O
Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
a	O
SARS	O
-	O
CoV	O
-	O
specific	O
human	O
monoclonal	O
antibody	B-FUNC
,	O
CR3022	O
,	O
could	O
bind	B-FUNC
potently	O
with	O
2019	O
-	O
nCoV	O
RBD	O
(	O
KD	O
of	O
6	O
.	O
3	O
nM	O
).	O

Interestingly	O
,	O
some	O
of	O
the	O
most	O
potent	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibodies	O
(	O
e	O
.	O
g	O
.	O
m396	O
,	O
CR3014	O
)	O
that	O
target	O
the	O
ACE2	O
binding	B-FUNC
site	O
of	O
SARS	O
-	O
CoV	O
failed	O
to	O
bind	B-FUNC
2019	O
-	O
nCoV	O
spike	O
protein	O
,	O
implying	O
that	O
the	O
difference	O
in	O
the	O
RBD	O
of	O
SARS	O
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
has	O
a	O
critical	O
impact	O
for	O
the	O
cross	O
-	O
reactivity	O
of	O
neutralizing	O
antibodies	O
,	O
and	O
that	O
it	O
is	O
still	O
necessary	O
to	O
develop	O
novel	O
monoclonal	O
antibodies	O
that	O
could	O
bind	B-FUNC
specifically	O
to	O
2019	O
-	O
nCoV	O
RBD	O
.	O

TITLE	O
:	O
Detection	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
using	O
high	O
-	O
throughput	O
imaging	O
cytometry	O
.	O

The	O
assessment	O
of	O
PEDV	O
-	O
neutralizing	O
antibody	B-FUNC
levels	O
provides	O
a	O
valuable	O
tool	O
to	O
assess	O
and	O
predict	O
herd	O
immunity	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
has	O
cost	O
a	O
great	O
loss	O
to	O
the	O
health	O
and	O
economic	O
property	O
of	O
Chines	O
people	O
.	O

Rapid	O
diagnosis	O
of	O
concomitant	O
NCP	B-FUNC
,	O
safe	O
and	O
effective	O
transportation	O
,	O
implementation	O
of	O
the	O
interventional	O
procedure	O
,	O
protection	O
of	O
vascular	O
surgical	O
team	O
and	O
postoperative	O
management	O
and	O
follow	O
-	O
up	O
of	O
such	O
patients	O
have	O
become	O
urgent	O
problems	O
for	O
us	O
.	O

It	O
also	O
hopes	O
to	O
inspire	O
the	O
national	O
vascular	O
surgeons	O
to	O
manage	O
critical	O
emergencies	O
in	O
vascular	O
surgery	O
and	O
even	O
routine	O
vascular	O
diseases	O
with	O
NCP	B-FUNC
,	O
as	O
a	O
final	O
point	O
to	O
limit	O
the	O
severe	O
epidemic	O
situation	O
,	O
and	O
minimize	O
the	O
damage	O
of	O
NCP	B-FUNC
.	O

The	O
activation	O
of	O
RIPK3	O
-	O
MLKL	O
by	O
tumour	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
and	O
TNFR1	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
required	O
catalytically	O
active	O
RIPK1	O
and	O
the	O
inhibition	O
of	O
Fas	O
-	O
associated	O
protein	O
with	O
death	O
domain	O
(	O
FADD	O
)/	O
caspase	O
-	O
8	O
catalytic	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
[	O
Health	O
protection	O
guideline	O
of	O
passenger	O
transport	O
stations	O
and	O
transportation	O
facilities	O
during	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
outbreak	O
].	O

ABSTRACT	O
:	O
During	O
the	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
outbreak	O
,	O
the	O
transportation	O
industries	O
are	O
faced	O
with	O
the	O
more	O
burdensome	O
tasks	O
of	O
outbreak	O
prevention	O
and	O
control	O
as	O
well	O
as	O
ensuring	O
smooth	O
transportation	O
.	O

From	O
the	O
perspective	O
of	O
health	O
,	O
this	O
guideline	O
puts	O
forward	O
technical	O
requirements	O
on	O
the	O
operation	O
management	O
,	O
personnel	O
requirements	O
and	O
health	O
protection	O
of	O
passenger	O
transportation	O
places	O
such	O
as	O
aviation	O
,	O
railway	O
,	O
subway	O
,	O
bus	O
,	O
taxi	O
,	O
ship	O
,	O
etc	O
.,	O
which	O
reduces	O
the	O
impact	O
of	O
the	O
NCP	B-FUNC
outbreak	O
on	O
the	O
transportation	O
industry	O
and	O
personal	O
health	O
risks	O
.	O

TITLE	O
:	O
Antibodies	O
to	O
coronaviruses	O
are	O
higher	O
in	O
older	O
compared	O
with	O
younger	O
adults	O
and	O
binding	B-FUNC
antibodies	O
are	O
more	O
sensitive	O
than	O
neutralizing	O
antibodies	O
in	O
identifying	O
coronavirus	O
-	O
associated	O
illnesses	O
.	O

Binding	B-FUNC
and	O
neutralizing	O
antibodies	O
were	O
higher	O
in	O
older	O
adults	O
.	O

Only	O
16	O
(	O
35	O
.	O
7	O
%)	O
of	O
RI	O
with	O
increases	O
in	O
binding	B-FUNC
antibodies	O
also	O
had	O
increases	O
in	O
neutralizing	O
antibodies	O
to	O
HCoV	O
.	O
Increases	O
in	O
binding	B-FUNC
antibodies	O
with	O
RI	O
were	O
more	O
frequent	O
than	O
increased	O
neutralizing	O
antibodies	O
and	O
virus	O
shedding	O
,	O
and	O
more	O
frequent	O
in	O
younger	O
compared	O
to	O
older	O
adults	O
.	O

ABSTRACT	O
:	O
In	O
the	O
recent	O
outbreak	O
of	O
novel	O
coronavirus	O
infection	O
in	O
Wuhan	O
,	O
China	O
,	O
significantly	O
abnormal	O
coagulation	O
parameters	O
in	O
severe	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
cases	O
were	O
a	O
concern	O
.	O

To	O
describe	O
the	O
coagulation	O
feature	O
of	O
patients	O
with	O
NCP	B-FUNC
.	O

Conventional	O
coagulation	O
results	O
and	O
outcomes	O
of	O
183	O
consecutive	O
patients	O
with	O
confirmed	O
NCP	B-FUNC
in	O
Tongji	O
hospital	O
were	O
retrospectively	O
analyzed	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
the	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
has	O
become	O
a	O
public	O
health	O
emergency	O
in	O
China	O
.	O

For	O
the	O
patients	O
with	O
gastrointestinal	O
tumors	O
,	O
pre	O
-	O
admission	O
screening	O
should	O
be	O
done	O
in	O
order	O
to	O
rule	O
out	O
NCP	B-FUNC
.	O

All	O
cases	O
with	O
suspicious	O
or	O
confirmed	O
with	O
NCP	B-FUNC
must	O
be	O
reported	O
to	O
the	O
local	O
CDC	O
department	O
.	O

Fever	O
after	O
surgery	O
must	O
be	O
carefully	O
differentiated	O
whether	O
it	O
'	O
s	O
caused	O
by	O
post	O
-	O
surgery	O
abdominal	O
infection	O
/	O
inflammation	O
or	O
NCP	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
caused	O
by	O
2019	O
novel	O
coronavirus	O
has	O
become	O
a	O
global	O
public	O
health	O
challenge	O
.	O

Here	O
we	O
analyzed	O
the	O
clinical	O
features	O
,	O
susceptible	O
population	O
,	O
potential	O
causes	O
and	O
therapeutic	O
strategies	O
of	O
NCP	B-FUNC
related	O
liver	O
injury	O
.	O

The	O
predominant	O
state	O
of	O
the	O
trimer	O
has	O
one	O
of	O
the	O
three	O
receptor	O
-	O
binding	B-FUNC
domains	O
(	O
RBDs	O
)	O
rotated	O
up	O
in	O
a	O
receptor	O
-	O
accessible	O
conformation	O
.	O

We	O
also	O
provide	O
biophysical	O
and	O
structural	O
evidence	O
that	O
the	O
2019	O
-	O
nCoV	O
S	O
protein	O
binds	B-FUNC
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
with	O
higher	O
affinity	O
than	O
does	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
S	O
.	O
Additionally	O
,	O
we	O
tested	O
several	O
published	O
SARS	O
-	O
CoV	O
RBD	O
-	O
specific	O
monoclonal	O
antibodies	O
and	O
found	O
that	O
they	O
do	O
not	O
have	O
appreciable	O
binding	B-FUNC
to	O
2019	O
-	O
nCoV	O
S	O
,	O
suggesting	O
that	O
antibody	B-FUNC
cross	O
-	O
reactivity	O
may	O
be	O
limited	O
between	O
the	O
two	O
RBDs	O
.	O

Those	O
recommendations	O
include	O
:	O
(	O
1	O
)	O
Standard	O
prevention	O
and	O
protection	O
,	O
and	O
patient	O
isolation	O
;	O
(	O
2	O
)	O
Patient	O
wearing	O
mask	O
during	O
HFNC	O
treatment	O
;	O
(	O
3	O
)	O
Using	O
dual	O
limb	O
ventilator	O
with	O
filters	O
placed	O
at	O
the	O
ventilator	O
outlets	O
,	O
or	O
using	O
heat	O
-	O
moisture	O
exchanger	B-FUNC
(	O
HME	B-FUNC
)	O
instead	O
of	O
heated	O
humidification	O
in	O
single	O
limb	O
ventilator	O
with	O
HME	B-FUNC
placed	O
between	O
exhalation	O
port	O
and	O
mask	O
;	O
avoid	O
using	O
mask	O
with	O
exhalation	O
port	O
on	O
the	O
mask	O
;	O
(	O
4	O
)	O
Placing	O
filter	O
between	O
resuscitator	O
and	O
mask	O
or	O
artificial	O
airway	O
;	O
(	O
5	O
)	O
For	O
spontaneous	O
breathing	O
patients	O
,	O
placing	O
mask	O
for	O
patients	O
during	O
bronchoscopy	O
examination	O
;	O
for	O
patients	O
receiving	O
noninvasive	O
ventilation	O
,	O
using	O
the	O
special	O
mask	O
with	O
bronchoscopy	O
port	O
to	O
perform	O
bronchoscopy	O
;	O
(	O
6	O
)	O
Using	O
sedation	O
and	O
paralytics	O
during	O
intubation	O
,	O
cuff	O
pressure	O
should	O
be	O
maintained	O
between	O
25	O
-	O
30	O
cmH	O
(	O
2	O
)	O
O	O
;	O
(	O
7	O
)	O
In	O
-	O
line	O
suction	O
catheter	O
is	O
recommended	O
and	O
it	O
can	O
be	O
used	O
for	O
one	O
week	O
;	O
(	O
8	O
)	O
Dual	O
-	O
limb	O
heated	O
wire	O
circuits	O
are	O
recommended	O
and	O
only	O
changed	O
with	O
visible	O
soiled	O
;	O
(	O
9	O
.	O

ABSTRACT	O
:	O
Novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
),	O
a	O
new	O
respiratory	O
infectious	O
disease	O
,	O
has	O
become	O
an	O
important	O
public	O
health	O
problem	O
.	O

Inappropriate	O
protection	O
and	O
disinfection	O
measures	O
are	O
potential	O
risk	O
factors	O
of	O
transmission	O
and	O
outbreak	O
of	O
NCP	B-FUNC
in	O
key	O
places	O
.	O

This	O
theme	O
issue	O
is	O
concerned	O
with	O
the	O
prevention	O
and	O
control	O
of	O
NCP	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
has	O
already	O
entered	O
a	O
key	O
period	O
.	O

The	O
patients	O
treated	O
in	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
are	O
susceptible	O
to	O
viral	O
infection	O
because	O
of	O
disease	O
,	O
age	O
and	O
other	O
factors	O
,	O
so	O
it	O
is	O
very	O
important	O
to	O
manage	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
during	O
the	O
prevention	O
and	O
control	O
of	O
NCP	B-FUNC
epidemic	O
.	O

Nanjing	O
Stomatological	O
Hospital	O
has	O
implemented	O
the	O
emergency	O
management	O
practices	O
for	O
the	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
),	O
mainly	O
focusing	O
on	O
the	O
implementation	O
of	O
prevention	O
and	O
control	O
training	O
programs	O
for	O
medical	O
staffs	O
and	O
the	O
infection	O
control	O
projects	O
on	O
the	O
hospital	O
environment	O
.	O

ABSTRACT	O
:	O
Novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
is	O
currently	O
raging	O
in	O
China	O
.	O

Referring	O
to	O
the	O
""""	O
Diagnosis	O
and	O
Treatment	O
Scheme	O
for	O
NCP	B-FUNC
(	O
Trial	O
Version	O
4	O
and	O
5	O
")"""	O
and	O
combining	O
the	O
actual	O
practice	O
situation	O
in	O
our	O
hospital	O
with	O
the	O
""""	O
Summary	O
of	O
New	O
Coronavirus	O
Files	O
of	O
Shanghai	O
Renji	O
Hospital	O
""","	O
we	O
summarize	O
how	O
to	O
carry	O
out	O
the	O
clinical	O
practice	O
of	O
colorectal	O
surgery	O
under	O
the	O
situation	O
of	O
the	O
prevention	O
and	O
control	O
of	O
the	O
NCP	B-FUNC
epidemiology	O
,	O
meanwhile	O
under	O
such	O
situation	O
aiming	O
the	O
procedure	O
of	O
diagnose	O
and	O
treatment	O
for	O
emergency	O
patients	O
with	O
colorectal	O
tumor	O
,	O
we	O
share	O
the	O
experiences	O
of	O
the	O
diagnosis	O
of	O
colorectal	O
tumor	O
,	O
the	O
management	O
of	O
patients	O
with	O
colorectal	O
cancer	O
who	O
are	O
scheduled	O
to	O
be	O
admitted	O
for	O
surgery	O
,	O
the	O
protection	O
of	O
wards	O
,	O
the	O
perioperative	O
management	O
.	O

(	O
3	O
)	O
The	O
colorectal	O
cancer	O
patients	O
with	O
suspected	O
or	O
confirmed	O
NCP	B-FUNC
should	O
be	O
placed	O
in	O
the	O
isolated	O
room	O
with	O
separate	O
medical	O
devices	O
,	O
and	O
the	O
operative	O
room	O
with	O
negative	O
pressure	O
(	O
under	O
-	O
5	O
Pa	O
)	O
must	O
be	O
separated	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
pneumonia	O
(	O
new	O
coronavirus	O
pneumonia	O
)	O
(	O
NCP	B-FUNC
)	O
has	O
been	O
prevalent	O
in	O
Wuhan	O
and	O
spread	O
rapidly	O
to	O
all	O
of	O
our	O
country	O
.	O

For	O
NCP	B-FUNC
patients	O
with	O
mechanical	O
ventilation	O
,	O
reasonable	O
sedation	O
and	O
analgesia	O
strategies	O
should	O
be	O
formulated	O
;	O
delirium	O
should	O
not	O
be	O
ignored	O
.	O

In	O
addition	O
,	O
there	O
is	O
up	O
regulation	O
of	O
inflammatory	O
factors	O
in	O
patients	O
with	O
severe	O
NCP	B-FUNC
,	O
but	O
the	O
effect	O
of	O
renal	O
replacement	O
therapy	O
needs	O
to	O
be	O
further	O
confirmed	O
by	O
clinical	O
research	O
.	O

We	O
also	O
present	O
data	O
on	O
the	O
use	O
of	O
in	O
silico	O
docking	O
in	O
gaining	O
insight	O
into	O
2019	O
-	O
nCoV	O
Spike	O
-	O
receptor	B-FUNC
binding	I-FUNC
to	O
aid	O
in	O
therapeutic	O
development	O
.	O

TITLE	O
:	O
Swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
-	O
induced	O
apoptosis	O
is	O
caspase	O
-	O
and	O
cyclophilin	B-FUNC
D	O
-	O
dependent	O
.	O

One	O
possible	O
answer	O
is	O
antibody	B-FUNC
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
due	O
to	O
prior	O
exposure	O
to	O
other	O
coronaviruses	O
.	O

RESULTS	O
:	O
Pretreatment	O
of	O
HNE	O
and	O
HTE	O
cells	O
with	O
glycopyrronium	O
or	O
formoterol	O
decreased	O
viral	O
RNA	O
levels	O
and	O
/	O
or	O
titers	O
,	O
the	O
expression	O
of	O
the	O
HCoV	O
-	O
229E	O
receptor	O
CD13	O
,	O
the	O
number	O
and	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
where	O
HCoV	O
-	O
229E	O
RNA	O
enters	O
the	O
cytoplasm	O
,	O
and	O
the	O
infection	O
-	O
induced	O
production	O
of	O
cytokines	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IFN	O
-	O
	O
.	O

Here	O
,	O
we	O
co	O
-	O
expressed	O
the	O
MERS	O
-	O
CoV	O
nonstructural	O
proteins	O
nsp5	O
,	O
nsp7	O
,	O
nsp8	O
,	O
and	O
nsp12	O
(	O
RdRp	B-FUNC
)	O
in	O
insect	O
cells	O
as	O
a	O
part	O
a	O
polyprotein	O
to	O
study	O
the	O
mechanism	O
of	O
inhibition	O
of	O
MERS	O
-	O
CoV	O
RdRp	B-FUNC
by	O
RDV	O
.	O

The	O
additional	O
three	O
nucleotides	O
may	O
protect	O
the	O
inhibitor	O
from	O
excision	O
by	O
the	O
viral	O
3	B-FUNC
'-	I-FUNC
5	I-FUNC
'	I-FUNC
exonuclease	I-FUNC
activity	I-FUNC
.	O

The	O
decreased	O
expression	O
of	O
inflammatory	O
factors	O
(	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
	O
)	O
by	O
Western	O
blotting	O
assay	O
and	O
ELISA	O
,	O
angiogenesis	O
protein	O
(	O
VEGF	O
)	O
by	O
Western	O
blotting	O
assay	O
and	O
other	O
related	O
proteins	O
(	O
BDNF	O
,	O
NF	O
-	O
B	O
,	O
iNOS	O
and	O
COX	O
-	O
2	O
)	O
by	O
Western	O
blotting	O
assay	O
in	O
peri	O
-	O
tumour	O
tissue	O
indicated	O
that	O
AVNP2	O
could	O
control	O
tumour	O
-	O
associated	O
inflammation	O
,	O
thus	O
efficiently	O
ameliorating	O
the	O
local	O
inflammatory	O
condition	O
and	O
,	O
to	O
some	O
extent	O
,	O
inhibiting	O
angiogenesis	O
in	O
C6	O
-	O
bearing	O
rats	O
.	O

The	O
lesions	O
were	O
typically	O
ill	O
-	O
defined	O
and	O
were	O
composed	O
of	O
mixed	O
ground	O
-	O
glass	O
opacities	O
and	O
consolidation	O
or	O
pure	B-FUNC
ground	O
-	O
glass	O
opacities	O
.	O

Patchy	O
to	O
confluent	O
lesions	O
were	O
primarily	O
distributed	O
in	O
the	O
lower	O
lobes	O
(	O
COVID	O
-	O
19	O
pneumonia	O
in	O
Korea	O
primarily	O
manifested	O
as	O
pure	B-FUNC
to	O
mixed	O
ground	O
-	O
glass	O
opacities	O
with	O
a	O
patchy	O
to	O
confluent	O
or	O
nodular	O
shape	O
in	O
the	O
bilateral	O
peripheral	O
posterior	O
lungs	O
.	O

Patchy	O
to	O
confluent	O
lesions	O
were	O
primarily	O
distributed	O
in	O
the	O
lower	O
lobes	O
(	O
CONCLUSIONS	O
:	O
COVID	O
-	O
19	O
pneumonia	O
in	O
Korea	O
primarily	O
manifested	O
as	O
pure	B-FUNC
to	O
mixed	O
ground	O
-	O
glass	O
opacities	O
with	O
a	O
patchy	O
to	O
confluent	O
or	O
nodular	O
shape	O
in	O
the	O
bilateral	O
peripheral	O
posterior	O
lungs	O
.	O

She	O
was	O
diagnosed	O
with	O
COVID	O
-	O
19	O
infection	O
confirmed	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

A	O
prospective	O
interventional	O
case	O
series	O
study	O
was	O
performed	O
,	O
and	O
30	O
confirmed	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
patients	O
were	O
selected	O
at	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhejiang	O
University	O
from	O
26	O
January	O
2020	O
to	O
9	O
February	O
2020	O
.	O

We	O
speculate	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
may	O
be	O
detected	O
in	O
the	O
tears	O
and	O
conjunctival	O
secretions	O
in	O
NCP	B-FUNC
patients	O
with	O
conjunctivitis	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
common	O
-	O
type	O
and	O
nine	O
severe	O
-	O
type	O
NCP	B-FUNC
patients	O
were	O
enrolled	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
systematic	O
comparison	O
and	O
analysis	O
to	O
predict	O
the	O
interaction	O
between	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
coronavirus	O
spike	O
protein	O
and	O
the	O
host	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

ABSTRACT	O
:	O
The	O
critical	O
period	O
for	O
the	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
in	O
China	O
,	O
in	O
response	O
to	O
requirements	O
for	O
accelerating	O
the	O
modernization	O
of	O
the	O
disease	O
prevention	O
and	O
control	O
system	O
,	O
we	O
analyzed	O
and	O
summarized	O
the	O
current	O
situation	O
,	O
existing	O
problems	O
,	O
and	O
deficiencies	O
in	O
China	O
'	O
s	O
modernization	O
of	O
disease	O
prevention	O
and	O
control	O
system	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
comprehensive	O
descriptions	O
on	O
data	O
deposition	O
,	O
management	O
,	O
release	O
and	O
utility	O
in	O
2019nCoVR	O
,	O
laying	O
important	O
foundations	O
in	O
aid	O
of	O
studies	O
on	O
virus	O
classification	O
and	O
origin	O
,	O
genome	O
variation	O
and	O
evolution	O
,	O
fast	B-FUNC
detection	O
,	O
drug	O
development	O
and	O
pneumonia	O
precision	O
prevention	O
and	O
therapy	O
.	O

With	O
this	O
test	O
kit	B-FUNC
,	O
we	O
carried	O
out	O
clinical	O
studies	O
to	O
validate	O
its	O
clinical	O
efficacy	O
uses	O
.	O

These	O
epitopes	O
are	O
usually	O
linked	O
to	O
specific	O
linkers	O
to	O
build	O
vaccine	O
components	O
and	O
molecularly	O
dock	O
on	O
toll	O
-	O
like	O
receptor	O
-	O
5	O
to	O
get	O
binding	B-FUNC
affinity	O
.	O

Therefore	O
,	O
to	O
provide	O
a	O
fast	B-FUNC
immunogenic	O
profile	O
of	O
these	O
epitopes	O
,	O
we	O
performed	O
immunoinformatics	O
analysis	O
so	O
that	O
the	O
rapid	O
development	O
of	O
the	O
vaccine	O
might	O
bring	O
this	O
disastrous	O
situation	O
to	O
the	O
end	O
earlier	O
.	O

Except	O
for	O
3	O
severe	O
patients	O
,	O
the	O
rest	B-FUNC
of	O
the	O
77	O
patients	O
exhibited	O
mild	O
or	O
moderate	O
symptoms	O
.	O

Fifty	O
patients	O
were	O
enrolled	O
,	O
including	O
mild	O
type	O
in	O
nine	O
,	O
common	O
in	O
28	O
,	O
severe	O
in	O
10	O
and	O
critically	O
severe	O
in	O
the	O
rest	B-FUNC
three	O
.	O

CT	O
imaging	O
presentations	O
of	O
NCP	B-FUNC
are	O
mostly	O
patchy	O
ground	O
glass	O
opacities	O
in	O
the	O
peripheral	O
areas	O
under	O
the	O
pleura	O
with	O
partial	O
consolidation	O
which	O
will	O
be	O
absorbed	O
with	O
formation	O
of	O
fibrotic	O
stripes	O
if	O
improved	O
.	O

CT	O
scanning	O
provides	O
important	O
bases	O
for	O
early	O
diagnosis	O
and	O
treatment	O
of	O
NCP	B-FUNC
.	O

RESULTS	O
:	O
Fifty	O
patients	O
were	O
enrolled	O
,	O
including	O
mild	O
type	O
in	O
nine	O
,	O
common	O
in	O
28	O
,	O
severe	O
in	O
10	O
and	O
critically	O
severe	O
in	O
the	O
rest	B-FUNC
three	O
.	O

CONCLUSIONS	O
:	O
CT	O
imaging	O
presentations	O
of	O
NCP	B-FUNC
are	O
mostly	O
patchy	O
ground	O
glass	O
opacities	O
in	O
the	O
peripheral	O
areas	O
under	O
the	O
pleura	O
with	O
partial	O
consolidation	O
which	O
will	O
be	O
absorbed	O
with	O
formation	O
of	O
fibrotic	O
stripes	O
if	O
improved	O
.	O

A	O
commercial	O
RT	O
-	O
PCR	O
kit	B-FUNC
developed	O
by	O
the	O
Beijing	O
Genomic	O
Institute	O
is	O
currently	O
widely	O
used	O
in	O
China	O
and	O
likely	O
in	O
Asia	O
.	O

Herein	O
,	O
we	O
reported	O
the	O
first	O
confirmed	O
case	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
imported	O
from	O
China	O
in	O
Taiwan	O
.	O

This	O
case	O
report	O
revealed	O
a	O
natural	O
course	O
of	O
NCP	B-FUNC
with	O
self	O
-	O
recovery	O
,	O
which	O
may	O
be	O
a	O
good	O
example	O
in	O
comparison	O
with	O
medical	O
treatments	O
.	O

At	O
present	O
,	O
some	O
therapies	O
such	O
as	O
interleukin	O
-	O
6	O
antibody	B-FUNC
blocker	O
,	O
stem	O
cell	O
therapy	O
,	O
and	O
transfusion	O
of	O
convalescent	O
plasma	O
have	O
been	O
applied	O
to	O
counteract	O
the	O
cytokine	O
storm	O
and	O
have	O
made	O
some	O
progress	O
.	O

I	O
consider	O
the	O
options	O
of	O
drug	O
repurposing	O
,	O
developing	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
therapy	O
,	O
and	O
an	O
oligonucleotide	O
strategy	O
targeting	O
the	O
viral	O
RNA	O
genome	O
,	O
emphasizing	O
the	O
promise	O
and	O
pitfalls	O
of	O
these	O
approaches	O
.	O

The	O
proposal	O
is	O
a	O
biologic	O
that	O
blocks	O
2019	O
-	O
nCoV	O
entry	O
using	O
a	O
soluble	O
version	O
of	O
the	O
viral	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
fused	O
to	O
an	O
immunoglobulin	B-FUNC
Fc	O
domain	O
,	O
providing	O
a	O
neutralizing	O
antibody	B-FUNC
with	O
maximal	O
breath	O
to	O
avoid	O
any	O
viral	O
escape	O
,	O
while	O
also	O
helping	O
to	O
recruit	O
the	O
immune	O
system	O
to	O
build	O
lasting	O
immunity	O
.	O

The	O
current	O
study	O
aims	O
to	O
test	O
anti	O
-	O
HCV	O
drugs	O
against	O
COVID	O
-	O
19	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
).	O

In	O
this	O
study	O
,	O
sequence	O
analysis	O
,	O
modeling	O
,	O
and	O
docking	O
are	O
used	O
to	O
build	O
a	O
model	O
for	O
Wuhan	O
COVID	O
-	O
19	O
RdRp	B-FUNC
.	O

Additionally	O
,	O
the	O
newly	O
emerged	O
Wuhan	O
HCoV	O
RdRp	B-FUNC
model	O
is	O
targeted	O
by	O
anti	O
-	O
polymerase	O
drugs	O
,	O
including	O
the	O
approved	O
drugs	O
Sofosbuvir	O
and	O
Ribavirin	O
.	O

The	O
present	O
study	O
presents	O
a	O
perfect	O
model	O
for	O
COVID	O
-	O
19	O
RdRp	B-FUNC
enabling	O
its	O
testing	O
in	O
silico	O
against	O
anti	O
-	O
polymerase	O
drugs	O
.	O

In	O
the	O
absence	O
of	O
a	O
proven	O
clinical	O
FcR	O
blocker	O
,	O
the	O
use	O
of	O
intravenous	O
immunoglobulin	B-FUNC
to	O
block	O
FcR	O
activation	O
may	O
be	O
a	O
viable	O
option	O
for	O
the	O
urgent	O
treatment	O
of	O
pulmonary	O
inflammation	O
to	O
prevent	O
severe	O
lung	O
injury	O
.	O

Results	O
from	O
the	O
current	O
study	O
showed	O
that	O
pretreatment	O
with	O
nafithromycin	O
significantly	O
reduced	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
MPO	B-FUNC
,	O
TNF	O
-	O
	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
in	O
BAL	O
fluid	O
compared	O
to	O
LPS	O
control	O
group	O
.	O

This	O
idea	O
is	O
based	O
on	O
observations	O
that	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
very	O
likely	O
serves	O
as	O
the	O
binding	B-FUNC
site	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
the	O
strain	O
implicated	O
in	O
the	O
current	O
COVID	O
-	O
19	O
epidemic	O
,	O
similarly	O
to	O
strain	O
SARS	O
-	O
CoV	O
implicated	O
in	O
the	O
2002	O
-	O
2003	O
SARS	O
epidemic	O
.	O

It	O
is	O
still	O
unclear	O
how	O
fast	B-FUNC
the	O
virus	O
evolved	O
and	O
how	O
the	O
virus	O
interacts	O
with	O
other	O
microorganisms	O
in	O
the	O
lung	O
.	O

TITLE	O
:	O
Perspectives	O
on	O
monoclonal	O
antibody	B-FUNC
therapy	O
as	O
potential	O
therapeutic	O
intervention	O
for	O
Coronavirus	O
disease	O
-	O
19	O
(	O
COVID	O
-	O
19	O
).	O

Cell	O
entry	O
of	O
coronaviruses	O
depends	O
on	O
binding	B-FUNC
of	O
the	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
to	O
cellular	O
receptors	O
and	O
on	O
S	O
protein	O
priming	O
by	O
host	O
cell	O
proteases	O
.	O

Sera	B-FUNC
of	O
sixty	O
-	O
three	O
dromedaries	O
and	O
twenty	O
-	O
eight	O
camel	O
traders	O
were	O
recruited	O
(	O
January	O
2015	O
-	O
December	O
2016	O
).	O

Having	O
specific	O
antibodies	O
among	O
the	O
examined	O
camel	O
sera	B-FUNC
was	O
significantly	O
different	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
relation	O
to	O
various	O
sampling	O
localities	O
,	O
gender	O
and	O
age	O
groups	O
.	O

These	O
7	O
cases	O
were	O
younger	O
(	O
median	O
age	O
:	O
14	O
.	O
0	O
years	O
;	O
P	O
=	O
0	O
.	O
012	O
)	O
than	O
the	O
rest	B-FUNC
.	O

In	O
addition	O
,	O
there	O
are	O
many	O
significantly	O
important	O
trials	O
with	O
positive	O
results	O
:	O
high	O
dose	O
vitamin	O
C	O
for	O
septic	O
shock	O
,	O
weaning	O
strategy	O
with	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
)	O
mode	O
,	O
tranexamic	O
acid	O
for	O
patients	O
with	O
acute	O
traumatic	O
brain	O
injury	O
,	O
and	O
new	O
monoclonal	O
antibody	B-FUNC
for	O
Ebola	O
virus	O
disease	O
.	O

A	O
60	O
-	O
year	O
-	O
old	O
nonalcoholic	O
man	O
,	O
with	O
normal	O
baseline	O
liver	O
function	O
tests	O
,	O
was	O
admitted	O
with	O
diffuse	O
abdominal	O
pain	O
and	O
AST	O
=	O
499	O
U	O
/	O
L	O
and	O
ALT	B-FUNC
=	O
539	O
U	O
/	O
L	O
,	O
six	O
days	O
after	O
completing	O
a	O
7	O
-	O
day	O
course	O
of	O
clarithromycin	O
500	O
mg	O
twice	O
daily	O
for	O
suspected	O
upper	O
respiratory	O
infection	O
.	O

AST	O
and	O
ALT	B-FUNC
each	O
rose	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
2	O
of	O
admission	O
,	O
and	O
rose	O
to	O
	O
6	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
3	O
,	O
with	O
development	O
of	O
severe	O
hepatic	O
encephalopathy	O
and	O
severe	O
coagulopathy	O
.	O

Rise	O
of	O
AST	O
/	O
ALT	B-FUNC
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
each	O
was	O
temporally	O
incompatible	O
with	O
shock	O
liver	O
because	O
this	O
rise	O
preceded	O
the	O
hemorrhagic	O
shock	O
,	O
but	O
the	O
subsequent	O
AST	O
/	O
ALT	B-FUNC
rise	O
to	O
	O
6	O
,	O
000	O
U	O
/	O
L	O
each	O
may	O
have	O
had	O
a	O
component	O
of	O
shock	O
liver	O
.	O

Review	O
of	O
6	O
previously	O
reported	O
and	O
current	O
case	O
of	O
clarithromycin	O
-	O
associated	O
ALF	O
revealed	O
that	O
patients	O
had	O
AST	O
and	O
ALT	B-FUNC
values	O
in	O
the	O
thousands	O
.	O

The	O
role	O
of	O
fibrinolytic	O
components	O
such	O
as	O
Urokinase	O
Plasminogen	O
activator	O
(	O
uPA	O
),	O
uPA	O
receptor	O
(	O
uPAR	B-FUNC
)	O
and	O
Plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
has	O
been	O
detailed	O
in	O
I	O
.	O
Curcumin	O
is	O
known	O
to	O
possess	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
effects	O
.	O

The	O
spike	O
protein	O
of	O
coronavirus	O
GX_P2V	O
shares	O
92	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
that	O
of	O
2019	O
-	O
nCoV	O
isolate	O
Wuhan	O
-	O
hu	O
-	O
1	O
,	O
and	O
uses	O
ACE2	O
as	O
the	O
receptor	O
for	O
infection	O
just	O
like	O
2019	O
-	O
nCoV	O
.	O
Three	O
drugs	O
-	O
cepharanthine	O
(	O
CEP	B-FUNC
),	O
selamectin	O
and	O
mefloquine	O
hydrochloride	O
exhibited	O
complete	O
inhibition	O
of	O
cytopathic	O
effects	O
in	O
cell	O
culture	O
at	O
10	O
mol	O
/	O
L	O
.	O
CEP	B-FUNC
demonstrated	O
the	O
most	O
potent	O
inhibition	O
of	O
GX_P2V	O
infection	O
,	O
with	O
a	O
concentration	O
for	O
50	O
%	O
of	O
maximal	O
effect	O
[	O
EC50	O
]	O
of	O
0	O
.	O
98	O
mol	O
/	O
L	O
.	O
The	O
viral	O
RNA	O
yield	O
in	O
cells	O
treated	O
with	O
10	O
mol	O
/	O
L	O
CEP	B-FUNC
was	O
15	O
,	O
393	O
-	O
fold	O
lower	O
than	O
in	O
cells	O
without	O
CEP	B-FUNC
treatment	O
([	O
6	O
.	O
48	O
	O
0	O
.	O
02	O
]	O
	O
10vs	O
.	O

Plaque	O
assays	O
found	O
no	O
production	O
of	O
live	O
viruses	O
in	O
media	O
containing	O
10	O
mol	O
/	O
L	O
CEP	B-FUNC
at	O
48	O
h	O
p	O
.	O
i	O
.	O

Furthermore	O
,	O
we	O
found	O
CEP	B-FUNC
has	O
potent	O
antiviral	O
activities	O
against	O
both	O
viral	O
entry	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
37	O
vs	O
.	O
0	O
.	O
46	O
	O
0	O
.	O
12	O
,	O
t	O
=	O
2	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
viral	O
replication	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
43	O
vs	O
.	O
[	O
6	O
.	O
18	O
	O
0	O
.	O
95	O
]	O
	O
10	O
,	O
t	O
=	O
3	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

CEP	B-FUNC
,	O
selamectin	O
and	O
mefloquine	O
hydrochloride	O
are	O
potential	O
drugs	O
for	O
treating	O
2019	O
-	O
nCoV	O
infection	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
CEP	B-FUNC
is	O
a	O
wide	O
-	O
spectrum	O
inhibitor	O
of	O
pan	O
-	O
betacoronavirus	O
,	O
and	O
clinical	O
trial	O
of	O
CEP	B-FUNC
for	O
treatment	O
of	O
2019	O
-	O
nCoV	O
infection	O
is	O
warranted	O
.	O

RESULTS	O
:	O
The	O
spike	O
protein	O
of	O
coronavirus	O
GX_P2V	O
shares	O
92	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
that	O
of	O
2019	O
-	O
nCoV	O
isolate	O
Wuhan	O
-	O
hu	O
-	O
1	O
,	O
and	O
uses	O
ACE2	O
as	O
the	O
receptor	O
for	O
infection	O
just	O
like	O
2019	O
-	O
nCoV	O
.	O
Three	O
drugs	O
-	O
cepharanthine	O
(	O
CEP	B-FUNC
),	O
selamectin	O
and	O
mefloquine	O
hydrochloride	O
exhibited	O
complete	O
inhibition	O
of	O
cytopathic	O
effects	O
in	O
cell	O
culture	O
at	O
10	O
mol	O
/	O
L	O
.	O
CEP	B-FUNC
demonstrated	O
the	O
most	O
potent	O
inhibition	O
of	O
GX_P2V	O
infection	O
,	O
with	O
a	O
concentration	O
for	O
50	O
%	O
of	O
maximal	O
effect	O
[	O
EC50	O
]	O
of	O
0	O
.	O
98	O
mol	O
/	O
L	O
.	O
The	O
viral	O
RNA	O
yield	O
in	O
cells	O
treated	O
with	O
10	O
mol	O
/	O
L	O
CEP	B-FUNC
was	O
15	O
,	O
393	O
-	O
fold	O
lower	O
than	O
in	O
cells	O
without	O
CEP	B-FUNC
treatment	O
([	O
6	O
.	O
48	O
	O
0	O
.	O
02	O
]	O
	O
10vs	O
.	O

Furthermore	O
,	O
we	O
found	O
CEP	B-FUNC
has	O
potent	O
antiviral	O
activities	O
against	O
both	O
viral	O
entry	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
37	O
vs	O
.	O
0	O
.	O
46	O
	O
0	O
.	O
12	O
,	O
t	O
=	O
2	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
viral	O
replication	O
(	O
1	O
.	O
00	O
	O
0	O
.	O
43	O
vs	O
.	O
[	O
6	O
.	O
18	O
	O
0	O
.	O
95	O
]	O
	O
10	O
,	O
t	O
=	O
3	O
.	O
98	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
We	O
developed	O
and	O
validated	O
2	O
species	O
-	O
independent	O
protein	O
-	O
based	O
assays	O
to	O
detect	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
functional	O
antibodies	O
that	O
can	O
block	O
virus	O
receptor	O
-	O
binding	B-FUNC
or	O
sialic	O
acid	O
-	O
attachment	O
.	O

Antibody	B-FUNC
levels	O
measured	O
in	O
both	O
assays	O
correlated	O
strongly	O
with	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
titers	O
,	O
proving	O
their	O
use	O
for	O
serologic	O
confirmatory	O
diagnosis	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

The	O
trimeric	O
spike	O
contains	O
three	O
receptor	O
-	O
binding	B-FUNC
S1	O
heads	O
sitting	O
on	O
top	O
of	O
a	O
trimeric	O
membrane	O
-	O
fusion	O
S2	O
stalk	O
.	O

Three	O
receptor	O
molecules	O
bind	B-FUNC
to	O
the	O
sides	O
of	O
the	O
spike	O
trimer	O
,	O
where	O
three	O
NTDs	O
are	O
located	O
.	O

Receptor	B-FUNC
binding	I-FUNC
induces	O
structural	O
changes	O
in	O
the	O
spike	O
,	O
weakening	O
the	O
interactions	O
between	O
S1	O
and	O
S2	O
.	O

Using	O
protease	O
sensitivity	O
and	O
negative	O
-	O
stain	O
EM	O
analyses	O
,	O
we	O
further	O
showed	O
that	O
after	O
protease	O
treatment	O
of	O
the	O
spike	O
,	O
receptor	B-FUNC
binding	I-FUNC
facilitated	O
the	O
dissociation	O
of	O
S1	O
from	O
S2	O
,	O
allowing	O
S2	O
to	O
transition	O
from	O
pre	O
-	O
fusion	O
to	O
post	O
-	O
fusion	O
conformation	O
.	O

In	O
this	O
context	O
,	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
),	O
which	O
is	O
one	O
of	O
the	O
few	O
HIV	O
-	O
1	O
encoded	O
enzymatic	O
function	O
still	O
not	O
targeted	O
by	O
any	O
current	O
drug	O
,	O
can	O
be	O
considered	O
as	O
an	O
appealing	O
target	O
.	O

We	O
show	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
uses	O
ACE2	O
to	O
enter	O
cells	O
and	O
that	O
the	O
receptor	O
-	O
binding	B-FUNC
domains	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
and	O
SARS	O
-	O
CoV	O
S	O
bind	B-FUNC
with	O
similar	O
affinities	O
to	O
human	O
ACE2	O
,	O
correlating	O
with	O
the	O
efficient	O
spread	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
among	O
humans	O
.	O

The	O
fully	O
automated	O
workflow	O
enables	O
high	O
-	O
throughput	O
testing	O
with	O
minimal	O
hands	O
-	O
on	O
time	O
,	O
while	O
offering	O
fast	B-FUNC
and	O
reliable	O
results	O
.	O

We	O
describe	O
our	O
laboratory	O
experiences	O
during	O
a	O
large	O
contact	O
tracing	O
investigation	O
,	O
comparing	O
previously	O
published	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
in	O
different	O
PCR	O
systems	O
and	O
a	O
commercial	O
kit	B-FUNC
.	O

Our	O
results	O
suggest	O
that	O
duplex	O
RNA	O
is	O
a	O
preferred	O
substrate	O
for	O
the	O
helicase	B-FUNC
activity	I-FUNC
of	O
nsP13	O
than	O
duplex	O
DNA	O
at	O
high	O
ATP	O
concentrations	O
.	O

Compared	O
to	O
NON	O
-	O
NCOVID	O
-	O
19	O
,	O
NCOVID	O
-	O
19	O
present	O
remarkably	O
more	O
abnormal	O
laboratory	O
tests	O
including	O
AST	O
,	O
ALT	B-FUNC
,	O
	O
-	O
GT	O
,	O
LDH	O
and	O
	O
-	O
HBDH	O
.	O

Compared	O
to	O
NON	O
-	O
NCOVID	O
-	O
19	O
,	O
NCOVID	O
-	O
19	O
present	O
remarkably	O
more	O
abnormal	O
laboratory	O
tests	O
including	O
AST	O
,	O
ALT	B-FUNC
,	O
	O
-	O
GT	O
,	O
LDH	O
and	O
	O
-	O
HBDH	O
.	O

We	O
studied	O
children	O
at	O
a	O
large	O
tertiary	O
-	O
care	O
hospital	O
in	O
China	O
,	O
during	O
the	O
period	O
from	O
28	O
January	O
2019	O
to	O
8	O
February	O
2020	O
,	O
who	O
had	O
positive	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
COVID	O
-	O
19	O
.	O

Recently	O
,	O
our	O
group	O
has	O
developed	O
a	O
novel	O
deep	O
learning	O
platform	O
-	O
Deep	O
Docking	O
(	O
DD	O
)	O
which	O
provides	O
fast	B-FUNC
prediction	O
of	O
docking	O
scores	O
of	O
Glide	O
(	O
or	O
any	O
other	O
docking	O
program	O
)	O
and	O
,	O
hence	O
,	O
enables	O
structure	O
-	O
based	O
virtual	O
screening	O
of	O
billions	O
of	O
purchasable	O
molecules	O
in	O
a	O
short	O
time	O
.	O

While	O
a	O
confirmed	O
and	O
fast	B-FUNC
ARTI	O
diagnosis	O
is	O
key	O
for	O
antibiotic	O
prescribing	O
,	O
empiric	O
antimicrobial	O
treatment	O
remains	O
common	O
,	O
because	O
viral	O
symptoms	O
are	O
often	O
clinically	O
similar	O
and	O
difficult	O
to	O
distinguish	O
from	O
those	O
caused	O
by	O
bacteria	O
.	O

ABSTRACT	O
:	O
The	O
new	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
),	O
also	O
named	O
as	O
COVID	O
-	O
19	O
by	O
WHO	O
on	O
Feb	O
11	O
2020	O
,	O
is	O
now	O
causing	O
a	O
severe	O
public	O
health	O
emergency	O
in	O
China	O
since	O
.	O

Combination	O
of	O
Ribavirin	O
and	O
interferon	O
-	O
	O
is	O
recommended	O
by	O
the	O
5	O
(	O
th	O
)	O
edition	O
National	O
Health	O
Commission	O
'	O
s	O
Regimen	O
(	O
Revised	O
Edition	O
)	O
because	O
of	O
the	O
effect	O
on	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
and	O
the	O
effectiveness	O
of	O
Lopinavir	O
/	O
Ritonavir	O
and	O
Remdisivir	O
needs	O
to	O
be	O
confirmed	O
by	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
),	O
given	O
the	O
situation	O
of	O
no	O
specific	O
antivirus	O
drug	O
on	O
NCP	B-FUNC
is	O
unavailable	O
.	O

He	O
developed	O
a	O
severe	O
acute	O
respiratory	O
failure	O
treated	O
with	O
a	O
ventilatory	O
support	O
by	O
means	O
of	O
a	O
continuous	O
positive	O
airway	O
pressure	O
(	O
C	O
-	O
PAP	B-FUNC
)	O
therapy	O
.	O

China	O
has	O
been	O
learning	O
from	O
practice	O
for	O
better	O
reporting	O
and	O
is	O
fast	B-FUNC
to	O
adapt	O
itself	O
.	O

Hemoadsorption	O
with	O
cartridge	O
column	O
(	O
Cytosorb	O
)	O
in	O
combination	O
with	O
continuous	O
renal	O
replacement	O
therapy	O
was	O
associated	O
to	O
the	O
anti	O
-	O
cytokine	O
therapy	O
(	O
tocilizumab	O
,	O
a	O
monoclonal	O
antibody	B-FUNC
targeting	O
interleukin	O
-	O
6	O
receptor	O
).	O

For	O
coronaviruses	O
,	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
is	O
an	O
important	O
protease	O
that	O
catalyzes	O
the	O
replication	O
of	O
RNA	O
from	O
RNA	O
template	O
and	O
is	O
an	O
attractive	O
therapeutic	O
target	O
.	O

We	O
found	O
that	O
theaflavin	O
has	O
a	O
lower	O
idock	O
score	O
in	O
the	O
catalytic	O
pocket	O
of	O
RdRp	B-FUNC
in	O
SARS	O
-	O
CoV	O
-	O
2	O
(-	O
9	O
.	O
11	O
kcal	O
/	O
mol	O
),	O
SARS	O
-	O
CoV	O
(-	O
8	O
.	O
03	O
kcal	O
/	O
mol	O
),	O
and	O
MERS	O
-	O
CoV	O
(-	O
8	O
.	O
26	O
kcal	O
/	O
mol	O
)	O
from	O
idock	O
.	O

To	O
confirm	O
the	O
result	O
,	O
we	O
discovered	O
that	O
theaflavin	O
has	O
lower	O
binding	B-FUNC
energy	O
of	O
-	O
8	O
.	O
8	O
kcal	O
/	O
mol	O
when	O
it	O
docks	O
in	O
the	O
catalytic	O
pocket	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
RdRp	B-FUNC
by	O
using	O
the	O
Blind	O
Docking	O
server	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
spike	O
-	O
host	O
cell	O
receptor	O
GRP78	O
binding	B-FUNC
site	O
prediction	O
.	O

In	O
this	O
study	O
,	O
the	O
COVID	O
-	O
19	O
spike	O
binding	B-FUNC
site	O
to	O
the	O
cell	O
-	O
surface	O
receptor	O
(	O
Glucose	O
Regulated	O
Protein	O
78	O
(	O
GRP78	O
))	O
is	O
predicted	O
using	O
combined	O
molecular	O
modeling	O
docking	O
and	O
structural	O
bioinformatics	O
.	O

Protein	O
-	O
protein	O
docking	O
was	O
performed	O
to	O
test	O
the	O
four	O
regions	O
of	O
the	O
spike	O
that	O
fit	O
tightly	O
in	O
the	O
GRP78	O
Substrate	O
Binding	B-FUNC
Domain	O
	O
(	O
SBD	O
).	O

The	O
docking	O
pose	O
revealed	O
the	O
involvement	O
of	O
the	O
SBD	O
of	O
GRP78	O
and	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
coronavirus	O
spike	O
protein	O
in	O
recognition	O
of	O
the	O
host	O
cell	O
receptor	O
.	O

We	O
reveal	O
that	O
the	O
binding	B-FUNC
is	O
more	O
favorable	O
between	O
regions	O
III	O
(	O
C391	O
-	O
C525	O
)	O
and	O
IV	O
(	O
C480	O
-	O
C488	O
)	O
of	O
the	O
spike	O
protein	O
model	O
and	O
GRP78	O
.	O

Region	O
IV	O
is	O
the	O
main	O
driving	O
force	O
for	O
GRP78	O
binding	B-FUNC
with	O
the	O
predicted	O
binding	B-FUNC
affinity	O
of	O
-	O
9	O
.	O
8	O
kcal	O
/	O
mol	O
.	O

The	O
docking	O
pose	O
revealed	O
the	O
involvement	O
of	O
the	O
SBD	O
of	O
GRP78	O
and	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
coronavirus	O
spike	O
protein	O
in	O
recognition	O
of	O
the	O
host	O
cell	O
receptor	O
.	O

TITLE	O
:	O
Induction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
and	O
lung	O
inflammation	O
by	O
Coronavirus	O
-	O
19	O
(	O
COVI	O
-	O
19	O
or	O
SARS	O
-	O
CoV	O
-	O
2	O
):	O
anti	O
-	O
inflammatory	O
strategies	O
.	O

When	O
COVI	O
-	O
19	O
infect	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
it	O
can	O
cause	O
mild	O
or	O
highly	O
acute	O
respiratory	O
syndrome	O
with	O
consequent	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

The	O
binding	B-FUNC
of	O
COVI	O
-	O
19	O
to	O
the	O
Toll	O
Like	O
Receptor	O
(	O
TLR	O
)	O
causes	O
the	O
release	O
of	O
pro	O
-	O
IL	O
-	O
1	O
which	O
is	O
cleaved	O
by	O
caspase	O
-	O
1	O
,	O
followed	O
by	O
inflammasome	O
activation	O
and	O
production	O
of	O
active	O
mature	O
IL	O
-	O
1	O
which	O
is	O
a	O
mediator	O
of	O
lung	O
inflammation	O
,	O
fever	O
and	O
fibrosis	O
.	O

Suppression	O
of	O
pro	O
-	O
inflammatory	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
family	O
members	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
have	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
in	O
many	O
inflammatory	O
diseases	O
,	O
including	O
viral	O
infections	O
.	O

This	O
cytokine	O
inhibits	O
class	O
II	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
molecules	O
and	O
inflammation	O
in	O
inflammatory	O
diseases	O
by	O
suppressing	O
MyD88	O
and	O
subsequently	O
IL	O
-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
and	O
CCL2	O
.	O

Another	O
inhibitory	O
cytokine	O
is	O
IL	O
-	O
38	O
,	O
the	O
newest	O
cytokine	O
of	O
the	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
family	O
members	O
,	O
produced	O
by	O
several	O
immune	O
cells	O
including	O
B	O
cells	O
and	O
macrophages	O
.	O

Pure	B-FUNC
ground	O
-	O
glass	O
opacity	O
(	O
GGO	O
)	O
was	O
the	O
predominant	O
presence	O
in	O
94	O
/	O
131	O
(	O
72	O
%)	O
lesions	O
for	O
the	O
non	O
-	O
pregnant	O
adults	O
.	O

The	O
median	O
duration	O
to	O
negative	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
tests	O
of	O
upper	O
respiratory	O
tract	O
samples	O
was	O
11	O
days	O
(	O
95	O
CIs	O
:	O
10	O
-	O
12	O
days	O
).	O

TITLE	O
:	O
False	O
-	O
Negative	O
Results	O
of	O
Real	O
-	O
Time	O
Reverse	O
-	O
Transcriptase	B-FUNC
Polymerase	O
Chain	O
Reaction	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
2	O
:	O
Role	O
of	O
Deep	O
-	O
Learning	O
-	O
Based	O
CT	O
Diagnosis	O
and	O
Insights	O
from	O
Two	O
Cases	O
.	O

Here	O
we	O
report	O
our	O
modelled	O
homo	O
-	O
trimer	O
structure	O
of	O
COVID	O
-	O
19	O
spike	O
glycoprotein	O
in	O
both	O
closed	O
(	O
ligand	B-FUNC
-	O
free	O
)	O
and	O
open	O
(	O
ligand	B-FUNC
-	O
bound	O
)	O
conformation	O
,	O
which	O
is	O
involved	O
in	O
host	O
cell	O
adhesion	O
.	O

GA	O
has	O
shown	O
pleiotropic	O
effects	O
in	O
vitro	O
,	O
including	O
:	O
antitumor	O
effects	O
through	O
inhibition	O
of	O
lipogenesis	O
;	O
decreased	O
expression	O
of	O
invasion	O
associated	O
proteins	O
through	O
AMPK	B-FUNC
activation	O
;	O
and	O
potential	O
rescue	O
of	O
amyloid	O
-	O
	O
(	O
A	O
)	O
induced	O
synaptic	O
impairment	O
.	O

Several	O
mechanisms	O
for	O
this	O
activity	O
have	O
been	O
suggested	O
including	O
:	O
SUMOylation	O
inhibition	O
;	O
blocking	O
formation	O
of	O
the	O
E1	O
-	O
SUMO	O
intermediate	O
;	O
inhibition	O
of	O
fatty	O
acid	O
synthase	O
;	O
non	O
-	O
specific	O
SIRT	O
inhibition	O
;	O
and	O
activation	O
of	O
protein	O
phosphatase	B-FUNC
type	O
-	O
2C	O
.	O

Comparison	O
of	O
the	O
haematological	O
parameters	O
between	O
the	O
mild	O
and	O
severe	O
groups	O
showed	O
significant	O
differences	O
in	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
D	O
-	O
Dimer	O
,	O
GLU	O
,	O
TT	O
,	O
FIB	O
and	O
CRP	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
area	O
under	O
the	O
ROC	O
curve	O
(	O
AUC	O
)	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
combined	O
with	O
D	O
-	O
Dimer	O
was	O
0	O
.	O
840	O
.	O

The	O
specificity	O
of	O
predicting	O
the	O
severity	O
of	O
COVID	O
-	O
19	O
during	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
D	O
-	O
Dimer	O
tandem	O
testing	O
was	O
up	O
to	O
93	O
.	O
3	O
%,	O
while	O
the	O
sensitivity	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
D	O
-	O
Dimer	O
by	O
parallel	O
test	O
in	O
the	O
severe	O
COVID	O
-	O
19	O
was	O
96	O
.	O
4	O
%.	O

IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
D	O
-	O
Dimer	O
were	O
closely	O
related	O
to	O
the	O
occurrence	O
of	O
severe	O
COVID	O
-	O
19	O
in	O
the	O
adult	O
patients	O
,	O
and	O
their	O
combined	O
detection	O
had	O
the	O
highest	O
specificity	O
and	O
sensitivity	O
for	O
early	O
prediction	O
of	O
the	O
severity	O
of	O
COVID	O
-	O
19	O
patients	O
,	O
which	O
has	O
important	O
clinical	O
value	O
.	O

ABSTRACT	O
:	O
Intravenous	O
infusions	O
of	O
angiotensin	O
-	O
converting	O
enzyme	B-FUNC
inhibitors	I-FUNC
(	O
ACEIs	O
)	O
and	O
angiotensin	O
receptor	O
blockers	O
(	O
ARBs	O
)	O
in	O
experimental	O
animals	O
increase	O
the	O
numbers	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptors	O
in	O
the	O
cardiopulmonary	O
circulation	O
.	O

ACE2	O
receptors	O
serve	O
as	O
binding	B-FUNC
sites	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
virions	O
in	O
the	O
lungs	O
.	O

The	O
more	O
oligonucleotide	O
probes	O
are	O
however	O
used	O
,	O
the	O
higher	O
are	O
potential	O
off	O
-	O
target	O
binding	B-FUNC
effects	O
that	O
create	O
background	O
noise	O
.	O

PLP2	O
acts	O
as	O
a	O
protease	O
that	O
cleaves	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
and	O
a	O
deubiquitinating	O
(	O
DUB	O
)	O
enzyme	O
which	O
removes	O
ubiquitin	B-FUNC
moieties	O
from	O
ubiquitin	B-FUNC
-	O
conjugated	O
proteins	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
host	O
transcriptional	O
response	O
to	O
infection	O
with	O
murine	O
coronaviruses	O
encoding	O
independent	O
mutations	O
in	O
one	O
of	O
two	O
different	O
viral	O
antagonists	O
:	O
the	O
deubiquitinase	B-FUNC
(	O
DUB	O
)	O
within	O
nonstructural	O
protein	O
3	O
or	O
the	O
endoribonuclease	O
(	O
EndoU	O
)	O
within	O
nonstructural	O
protein	O
15	O
.	O

Pure	B-FUNC
ground	O
-	O
glass	O
opacity	O
was	O
the	O
most	O
prevalent	O
sub	O
-	O
type	O
of	O
ground	O
-	O
glass	O
opacity	O
after	O
symptom	O
onset	O
(	O
20	O
/	O
50	O
[	O
40	O
%]	O
to	O
20	O
/	O
28	O
[	O
71	O
%]).	O

66	O
/	O
70	O
(	O
94	O
%)	O
patients	O
discharged	O
had	O
residual	O
disease	O
on	O
final	O
CT	O
scans	O
(	O
median	O
CT	O
scores	O
and	O
zones	O
involved	O
:	O
4	O
and	O
4	O
),	O
with	O
ground	O
-	O
glass	O
opacity	O
(	O
42	O
/	O
70	O
[	O
60	O
%])	O
and	O
pure	B-FUNC
ground	O
-	O
glass	O
opacity	O
(	O
31	O
/	O
42	O
[	O
74	O
%])	O
the	O
most	O
common	O
pattern	O
and	O
subtype	O
.	O

Awake	O
""""	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
maintains	O
oxygenation	O
,	O
improves	O
ventilation	O
,	O
adequately	O
allows	O
the	O
injured	O
lungs	O
to	O
rest	B-FUNC
,	O
and	O
avoids	O
complications	O
associated	O
with	O
sedation	O
,	O
intubation	O
,	O
and	O
mechanical	O
ventilation	O
.	O

Other	O
findings	O
included	O
decreased	O
CD16	O
+	O
CD56	O
(	O
4	O
/	O
8	O
)	O
and	O
Th	O
/	O
Ts	O
*(	O
1	O
/	O
8	O
),	O
increased	O
CD3	O
(	O
2	O
/	O
8	O
),	O
CD4	O
(	O
4	O
/	O
8	O
)	O
and	O
CD8	O
(	O
1	O
/	O
8	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
2	O
/	O
8	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(	O
5	O
/	O
8	O
)	O
and	O
IFN	O
-	O
	O
(	O
2	O
/	O
8	O
).	O

Elseways	O
,	O
the	O
recurrent	O
virus	O
exposure	O
over	O
a	O
short	O
time	O
-	O
lapse	O
might	O
result	O
in	O
the	O
Antibody	B-FUNC
Dependent	O
Enhancement	O
,	O
triggering	O
the	O
violent	O
immune	O
reaction	O
responsible	O
for	O
the	O
severe	O
clinical	O
outcomes	O
observed	O
in	O
the	O
Hubei	O
province	O
.	O

All	O
of	O
them	O
accepted	O
mechanical	O
ventilation	O
,	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
),	O
blood	O
transfusion	O
,	O
glucocorticoid	O
,	O
and	O
multi	O
-	O
anti	O
-	O
infectious	O
therapy	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	O
of	O
PRESCIENT	O
(	O
Platform	O
for	O
the	O
Rapid	O
Evaluation	O
of	O
antibody	B-FUNC
SucCess	O
using	O
Integrated	O
microfluidics	O
ENabled	O
Technology	O
),	O
a	O
droplet	O
microfluidic	O
system	O
that	O
can	O
enable	O
high	O
-	O
throughput	O
single	O
-	O
cell	O
resolution	O
identification	O
of	O
nAb	O
repertoires	O
elicited	O
in	O
response	O
to	O
viral	O
infection	O
.	O

Combined	O
with	O
the	O
published	O
literature	O
,	O
the	O
potential	O
pathogenesis	O
of	O
COVID	O
-	O
19	O
is	O
inferred	O
,	O
and	O
the	O
treatment	O
recommendations	O
for	O
giving	O
high	O
-	O
doses	O
intravenous	O
immunoglobulin	B-FUNC
and	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
anticoagulant	O
therapy	O
to	O
severe	O
type	O
patients	O
are	O
proposed	O
.	O

ABSTRACT	O
:	O
The	O
three	O
unprecedented	O
outbreaks	O
of	O
emerging	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infections	O
at	O
the	O
beginning	O
of	O
21st	O
century	O
have	O
highlighted	O
the	O
necessity	O
for	O
readily	O
available	O
,	O
accurate	O
and	O
fast	B-FUNC
diagnostic	O
testing	O
methods	O
.	O

Newer	O
laboratory	O
methods	O
are	O
fast	B-FUNC
,	O
highly	O
sensitive	O
and	O
specific	O
,	O
and	O
are	O
gradually	O
replacing	O
the	O
conventional	O
gold	O
standards	O
.	O

Several	O
integrated	O
,	O
random	O
-	O
access	O
,	O
point	O
-	O
of	O
-	O
care	O
molecular	O
devices	O
are	O
currently	O
under	O
development	O
for	O
fast	B-FUNC
and	O
accurate	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infections	O
.	O

These	O
assays	O
are	O
simple	O
,	O
fast	B-FUNC
and	O
safe	O
and	O
can	O
be	O
used	O
in	O
the	O
local	O
hospitals	O
and	O
clinics	O
bearing	O
the	O
burden	O
of	O
identifying	O
and	O
treating	O
patients	O
.	O

The	O
laboratory	O
results	O
showed	O
that	O
compared	O
to	O
the	O
normal	O
values	O
,	O
the	O
patients	O
'	O
lymphocytes	O
were	O
reduced	O
(	O
4	O
[	O
80	O
%]	O
patients	O
),	O
and	O
liver	O
function	O
ALT	B-FUNC
and	O
AST	O
(	O
2	O
[	O
40	O
%]	O
patients	O
,	O
2	O
[	O
40	O
%]	O
patients	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
4	O
[	O
80	O
%]	O
patients	O
)	O
were	O
increased	O
when	O
admitted	O
to	O
hospital	O
.	O

ABSTRACT	O
:	O
At	O
the	O
end	O
of	O
2019	O
,	O
the	O
novel	O
coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
),	O
a	O
fast	B-FUNC
-	O
spreading	O
respiratory	O
disease	O
caused	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
),	O
was	O
reported	O
in	O
Wuhan	O
,	O
China	O
and	O
has	O
now	O
affected	O
over	O
123	O
countries	O
globally	O
[...].	O

The	O
median	O
duration	O
of	O
IgM	O
and	O
IgA	O
antibody	B-FUNC
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	O
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

RESULTS	O
:	O
The	O
median	O
duration	O
of	O
IgM	O
and	O
IgA	O
antibody	B-FUNC
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	O
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

Clinical	O
data	O
and	O
CT	O
images	O
of	O
80	O
cases	O
of	O
NCP	B-FUNC
were	O
collected	O
.	O

The	O
chest	O
CT	O
of	O
NCP	B-FUNC
patients	O
is	O
characterised	O
by	O
the	O
onset	O
of	O
bilateral	O
ground	O
-	O
glass	O
lesions	O
located	O
in	O
the	O
subpleural	O
area	O
of	O
the	O
lung	O
,	O
and	O
progressive	O
lesions	O
that	O
result	O
in	O
consolidation	O
with	O
no	O
migratory	O
lesions	O
.	O

CONCLUSIONS	O
:	O
The	O
chest	O
CT	O
of	O
NCP	B-FUNC
patients	O
is	O
characterised	O
by	O
the	O
onset	O
of	O
bilateral	O
ground	O
-	O
glass	O
lesions	O
located	O
in	O
the	O
subpleural	O
area	O
of	O
the	O
lung	O
,	O
and	O
progressive	O
lesions	O
that	O
result	O
in	O
consolidation	O
with	O
no	O
migratory	O
lesions	O
.	O

TITLE	O
:	O
Membrane	O
binding	B-FUNC
proteins	O
of	O
coronaviruses	O
.	O

Membranes	O
represent	O
both	O
an	O
obstacle	O
and	O
aid	O
to	O
CoV	O
replication	O
-	O
and	O
in	O
consequence	O
-	O
virus	O
-	O
encoded	O
structural	O
and	O
nonstructural	O
proteins	O
have	O
membrane	O
-	O
binding	B-FUNC
properties	O
.	O

Here	O
,	O
the	O
role	O
of	O
each	O
protein	O
in	O
membrane	O
binding	B-FUNC
is	O
described	O
to	O
provide	O
a	O
comprehensive	O
picture	O
of	O
their	O
role	O
in	O
the	O
CoV	O
replication	O
cycle	O
.	O

Here	O
,	O
we	O
identified	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
protein	O
and	O
found	O
that	O
the	O
RBD	O
protein	O
bound	O
strongly	O
to	O
human	O
and	O
bat	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptors	O
.	O

LH	O
significantly	O
inhibited	O
SARS	O
-	O
CoV	O
-	O
2	O
replication	O
in	O
Vero	O
E6	O
cells	O
and	O
markedly	O
reduced	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CCL	B-FUNC
-	O
2	O
/	O
MCP	B-FUNC
-	O
1	O
and	O
CXCL	O
-	O
10	O
/	O
IP	O
-	O
10	O
)	O
production	O
at	O
the	O
mRNA	O
levels	O
.	O

As	O
a	O
result	O
,	O
we	O
identified	O
a	O
list	O
of	O
potential	O
temporin	O
AMPs	O
which	O
docked	O
to	O
the	O
antiviral	O
protein	O
(	O
MERS	O
-	O
CoV	O
),	O
it	O
shows	O
good	O
protein	O
-	O
peptide	B-FUNC
binding	I-FUNC
.	O

CoV	O
spike	O
(	O
S	O
)	O
protein	O
which	O
is	O
crucial	O
for	O
receptor	B-FUNC
binding	I-FUNC
,	O
membrane	O
fusion	O
via	O
conformational	O
changes	O
,	O
internalization	O
of	O
the	O
virus	O
,	O
host	O
tissue	O
tropism	O
and	O
comprises	O
crucial	O
targets	O
for	O
vaccine	O
development	O
,	O
remain	O
largely	O
uncharacterized	O
.	O

When	O
tested	O
against	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
pseudovirus	O
,	O
SARS	O
-	O
CoV	O
-	O
2	O
convalescent	O
patient	O
sera	B-FUNC
showed	O
high	O
neutralizing	O
potency	O
,	O
which	O
underscore	O
its	O
potential	O
as	O
therapeutics	O
.	O

Furthermore	O
,	O
he	O
observes	O
the	O
significant	O
abnormality	O
of	O
coagulation	O
function	O
and	O
proposes	O
that	O
the	O
early	O
intravenous	O
immunoglobulin	B-FUNC
and	O
low	O
molecular	O
weight	O
heparin	O
anticoagulation	O
therapy	O
are	O
very	O
important	O
.	O

The	O
optimal	O
feature	O
(	O
GGAP	O
,	O
g	O
=	O
3	O
)	O
performed	O
well	O
in	O
terms	O
of	O
predicting	O
infection	O
risk	O
and	O
could	O
be	O
used	O
to	O
explore	O
the	O
evolutionary	O
dynamic	O
in	O
a	O
simple	O
,	O
fast	B-FUNC
and	O
large	O
-	O
scale	O
manner	O
.	O

Neutralising	O
antibody	B-FUNC
response	O
appeared	O
within	O
9	O
days	O
along	O
with	O
specific	O
IgM	O
and	O
IgG	O
response	O
,	O
targeting	O
particularly	O
nucleocapsid	O
and	O
spike	O
proteins	O
.	O

Alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
(	O
22	O
.	O
00	O
[	O
15	O
.	O
00	O
,	O
34	O
.	O
00	O
]	O
U	O
/	O
L	O
vs	O
.	O
18	O
.	O
70	O
[	O
13	O
.	O
00	O
,	O
30	O
.	O
38	O
]	O
U	O
/	O
L	O
,	O
Z	O
=	O
2	O
.	O
592	O
,	O
P	O
=	O
0	O
.	O
010	O
),	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
(	O
34	O
.	O
00	O
[	O
27	O
.	O
00	O
,	O
47	O
.	O
00	O
]	O
U	O
/	O
L	O
vs	O
.	O
22	O
.	O
00	O
[	O
17	O
.	O
65	O
,	O
31	O
.	O
75	O
]	O
U	O
/	O
L	O
,	O
Z	O
=	O
7	O
.	O
308	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
creatinine	O
levels	O
(	O
89	O
.	O
00	O
[	O
72	O
.	O
00	O
,	O
133	O
.	O
50	O
]	O
mol	O
/	O
L	O
vs	O
.	O
65	O
.	O
00	O
[	O
54	O
.	O
60	O
,	O
78	O
.	O
75	O
]	O
mol	O
/	O
L	O
,	O
Z	O
=	O
6	O
.	O
478	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
significantly	O
higher	O
in	O
the	O
death	O
group	O
that	O
those	O
in	O
the	O
recovered	O
group	O
.	O

ABSTRACT	O
:	O
The	O
world	O
must	O
act	O
fast	B-FUNC
to	O
contain	O
wider	O
international	O
spread	O
of	O
the	O
epidemic	O
of	O
COVID	O
-	O
19	O
now	O
.	O

